PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wang, X; Hu, B; Weiss, RS; Wang, Y				Wang, X; Hu, B; Weiss, RS; Wang, Y			The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining	ONCOGENE			English	Article						Hus1; IR (ionizing radiation); DNA damage; DNA repair; NHEJ (nonhomologous end-joining); HRR (homologous recombination repair)	DNA-DAMAGE; GENOMIC INSTABILITY; MAMMALIAN-CELLS; MOUSE HUS1; HUMAN RAD9; CHECKPOINT; CHK1; PHOSPHORYLATION; ACTIVATION; RESPONSES	Mammalian Hus1 plays an important role in maintaining genomic integrity. Cells lacking mouse Hus1 are hypersensitive to DNA damage inducers including UV and camptothecin ( CPT). By using clonogenic assay, we show here that Hus1 deficient mouse cells are hypersensitive to ionizing radiation ( IR) compared with their Hus1-positive counterparts. However, these cells show similar induction levels and similar rejoining rates of DNA double strand breaks ( DSBs) following IR, indicating that the effect of Hus1 on cell radiosensitivity is independent of nonhomologous end-joining (NHEJ). By combining an I-SceI-induced-DNA DSBs system and a siRNA approach, we also show that knocking down Hus1 decreases the efficiency of homologous recombination repair ( HRR), which is associated with the cellular sensitivity to IR-induced killing. Together, these results indicate that the role of Hus1 affecting the sensitivity of cells to IR-induced killing is independent of NHEJ but might be linked to HRR.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; Beijing Inst Biotechnol, Beijing, Peoples R China	Jefferson University; Jefferson University; Cornell University	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Thompson Bldg Room B-1,1020 Sansom St, Philadelphia, PA 19107 USA.	ya.wang@mail.tju.edu			NCI NIH HHS [R01 CA108773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Hu BC, 2005, CANCER RES, V65, P8613, DOI 10.1158/0008-5472.CAN-05-1966; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Nickoloff Jac A, 2004, Methods Mol Biol, V262, P35; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Wang X, 2004, NUCLEIC ACIDS RES, V32, P767, DOI 10.1093/nar/gkh243; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1	18	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1980	1983		10.1038/sj.onc.1209212	http://dx.doi.org/10.1038/sj.onc.1209212			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278671	Green Submitted			2022-12-25	WOS:000236224800015
J	Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF				Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF			Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls	ONCOGENE			English	Article						epigenetic; DNA methylation; bladder cancer; urinalysis	DNA METHYLATION; HYPERMETHYLATION; URINE; GENE; NEOPLASIA	Tumour suppressor gene ( TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC). Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC. Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years. Methylation analysis was performed for eight gene promoters using quantitative methylation-specific PCR. Methylation was detected in urine DNA from all three patient groups. The highest frequencies were seen in UC patients. Significantly less methylation was present in control samples than UC cases for RASSF1a and APC ( P < 0.034). The 'methylation index' and level of methylation was highest in the UC group and lowest in the young control group. A marker panel of RASSF1a, E-cad and APC generated a sensitivity of 69%, a specificity of 60% and a diagnostic accuracy of 86%. TSG methylation is detectable in urine DNA from patients with and without bladder cancer. The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice.	Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Inst Canc Studies, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Catto, JWF (corresponding author), Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, K Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	J.Catto@sheffield.ac.uk		catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754				Ahuja N, 1998, CANCER RES, V58, P5489; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; HARNDEN SV, 2003, CLIN CANCER RES, V9, P370; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Maruyama R, 2001, CANCER RES, V61, P8659; Molinie V, 2001, ANN PATHOL, V21, P361; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Usadel H, 2002, CANCER RES, V62, P371	20	77	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1984	1988		10.1038/sj.onc.1209209	http://dx.doi.org/10.1038/sj.onc.1209209			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288222				2022-12-25	WOS:000236224800016
J	Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y				Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y			Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways	ONCOGENE			English	Article						breast tumors; laser microdissection; DNA microarray; gene profiling; estrogen receptor	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION PROFILES; CANCER CELLS; CAPTURE MICRODISSECTION; CDNA MICROARRAY; MESSENGER-RNA; EPH RECEPTORS; P-CADHERIN; IDENTIFICATION	About 70-80% of breast cancers express estrogen receptor alpha (ER-alpha), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size, and histological grade, ER status is considered as one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. To investigate genes and pathways that are associated with ER status and epithelial cells in breast tumor, we applied laser capture microdissection (LCM) technology to capture epithelial tumor cells from 28 lymph node-negative breast tumor samples, in which 17 patients had ER-alpha + tumors, and 11 patients have ER-alpha- tumors. Gene expression profiles were analysed on Affymetrix Hu133A GeneChip. Meanwhile, gene profiles using total RNA isolated from bulk tumors of the same 28 patients were also generated. In total, 146 ;genes and 112 genes with significant P-value and having significant differential expression between ER-alpha + and ER-alpha- tumors were identified from the LCM data set and bulk tissue data set, respectively. A total of 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathways may play roles related to ER. The gene pro. ling with LCM-captured tumor cells provides a unique approach to study epithelial tumor cells and to gain an insight into signaling pathways associated with ER.	Veridex LLC, Johnson & Johnson Co, San Diego, CA 92121 USA; Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands	Johnson & Johnson; Johnson & Johnson USA; Erasmus University Rotterdam; Erasmus MC	Jiang, Y (corresponding author), Veridex LLC, Johnson & Johnson Co, 3210 Merryfield Row, San Diego, CA 92121 USA.	jjiang2@vrxus.jnj.com						Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FOEKENS JA, 1989, CANCER RES, V49, P5823; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Gruvberger S, 2001, CANCER RES, V61, P5979; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Kamme F, 2004, METH MOLEC MED, P215; Khoo C, 1997, PROTEIN EXPRES PURIF, V9, P379, DOI 10.1006/prep.1996.0709; Kim H, 2001, BIOCHEM SOC T, V29, P216, DOI 10.1042/BST0290216; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Luzzi V, 2003, J MOL DIAGN, V5, P9, DOI 10.1016/S1525-1578(10)60445-X; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Matsui H, 2003, ANTICANCER RES, V23, P195; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Mokbel K, 2003, CURR MED RES OPIN, V19, P683, DOI 10.1185/030079903125002397; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nishidate T, 2004, INT J ONCOL, V25, P797; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Parl F.F., 2000, ESTROGENS ESTROGEN R; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polacek DC, 2003, PHYSIOL GENOMICS, V13, P147, DOI 10.1152/physiolgenomics.00173.2002; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Seth A, 2003, ANTICANCER RES, V23, P2043; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun JM, 2005, EXP CELL RES, V302, P96, DOI 10.1016/j.yexcr.2004.08.015; Tamini Y, 2004, INVEST OPHTH VIS SCI, V45, P3904, DOI 10.1167/iovs.04-0628; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Weisz A, 2004, J CELL PHYSIOL, V200, P440, DOI 10.1002/jcp.20039; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yim SH, 2003, TOXICOL PATHOL, V31, P295, DOI 10.1080/01926230309753	47	51	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1413	1419		10.1038/sj.onc.1209165	http://dx.doi.org/10.1038/sj.onc.1209165			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261164				2022-12-25	WOS:000235708200015
J	Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F				Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F			Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract	ONCOGENE			English	Article						upper urinary tract; urothelial cell carcinoma; renal pelvis; hereditary non-polyposis colorectal cancer; microsatellite instability; MSI phenotype	NONPOLYPOSIS COLORECTAL-CANCER; REPAIR-DEFICIENT CANCERS; MISMATCH-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; MRE11 EXPRESSION; TARGET GENES; TUMORS; HMLH1; LINES	A subset of upper urinary tract urothelial cell carcinomas (UUC), arising sporadically or as a manifestation of hereditary non-polyposis colorectal cancer, displays microsatellite instability (MSI). MSI tumours are characterized by defective mismatch repair and accumulation of frameshift mutations in numerous genes harbouring repeats in their coding sequences. We have evaluated the incidence of MSI in UUC and the intratumoral distribution of mutations in 13 candidate target genes. A total of 58 unselected UUC were screened for MSI using the panel of five mononucleotide markers recently recommended by the National Cancer Institute for a precise MSI assessment. Four tumours displayed MSI (7%), among which at least three had alterations in the genes MSH3, BAX, MRE11, RAD50. Mutations in genes involved in key cellular pathways (ATR, DNA-PKcs, MBD4, TCF-4, MSH6, and BLM) were further detected. BAX and MRE11 mutations tend to present homogeneously within the three MSI UUC. Immunohistochemistry (MLH1, MSH2, MSH6) showed that loss of mismatch repair protein expression occurred in all MSI UUC de. ning the gene defect and that MRE11 and RAD50 mutations were associated with their concomitant loss expression. In conclusion, MSI UUC represent a small proportion of UUC in which BAX and MRE11 mutations are frequent and may play a role early in UUC tumorigenesis.	Univ Paris 07, Hop St Louis, Dept Urol, Paris, France; CNRS, UPR 2169, Villejuif, France; Erasmus Med Ctr, Dept Pathol, Rotterdam, Netherlands; INSERM, Ctr Etud Polymorphisme Humain, U434, Paris, France; Hop St Louis, CNRS, UPR 9051, Dept Biochem, Paris, France; Erasmus Med Ctr, Dept Urol, Rotterdam, Netherlands; Hop St Louis, INSERM, U728, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mongiat-Artus, P (corresponding author), Hop St Louis, Dept Urol, 1 Ave Claude Vellefaux, F-75010 Paris, France.	pierre.mongiat-artus@sls.aphp.fr	PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020; miquel, catherine/B-5536-2013	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889; Van der Kwast, Theodorus/0000-0001-8640-5786				Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Aben KKH, 2002, INT J CANCER, V98, P274, DOI 10.1002/ijc.10191; Barnetson R, 2000, GENE CHROMOSOME CANC, V29, P130, DOI 10.1002/1098-2264(200010)29:2<130::AID-GCC1023>3.0.CO;2-Z; Blaszyk H, 2002, MODERN PATHOL, V15, P790, DOI 10.1097/01.MP.0000024263.25043.0C; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Buhard O, 2004, DIS MARKERS, V20, P251, DOI 10.1155/2004/159347; Catto JWF, 2003, ONCOGENE, V22, P8699, DOI 10.1038/sj.onc.1206964; Dietmaier W, 1997, CANCER RES, V57, P4749; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Ericson KM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-23; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hartmann A, 2003, HUM PATHOL, V34, P222, DOI 10.1053/hupa.2003.22; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacob S, 2005, NUCLEIC ACIDS RES, V33, P106, DOI 10.1093/nar/gki154; Kane MF, 1997, CANCER RES, V57, P808; Kim NG, 2001, CANCER RES, V61, P36; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Parc Y, 2004, GUT, V53, P371, DOI 10.1136/gut.2003.019190; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roupret M, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017871; Sijmons RH, 1998, J UROLOGY, V160, P466, DOI 10.1016/S0022-5347(01)62926-4; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Verma L, 1999, J MED GENET, V36, P678; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421	36	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					2113	2118		10.1038/sj.onc.1209229	http://dx.doi.org/10.1038/sj.onc.1209229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288216				2022-12-25	WOS:000236359700014
J	Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL				Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL			HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells	ONCOGENE			English	Article						FAK; HEF1; CAS; Crk-associated substrate; glioblastoma; migration	FOCAL ADHESION KINASE; SRC FAMILY KINASES; GROWTH-FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; ASTROCYTIC TUMORS; SIGNALING PATHWAY; COMPLEX-FORMATION; V-SRC	The highly invasive behavior of glioblastoma cells contributes to the morbidity and mortality associated with these tumors. The integrin-mediated adhesion and migration of glioblastoma cells on brain matrix proteins is enhanced by stimulation with growth factors, including platelet-derived growth factor (PDGF). As focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, has been shown to promote cell migration in various other cell types, we analysed its role in glioblastoma cell migration. Forced overexpression of FAK in serum-starved glioblastoma cells plated on recombinant (rec)osteopontin resulted in a twofold enhancement of basal migration and a ninefold enhancement of PDGF-BB-stimulated migration. Both expression of mutant FAK(397F) and the downregulation of FAK with small interfering(si) RNA inhibited basal and PDGF-stimulated migration. FAK overexpression and PDGF stimulation was found to increase the phosphorylation of the Crk-associated substrate (CAS) family member human enhancer of filamentation 1 (HEF1), but not p130CAS or Src-interacting protein (Sin)/Efs, although the levels of expression of these proteins was similar. Moreover downregulation of HEF1 with siRNA, but not p130CAS, inhibited basal and PDGF-stimulated migration. The phosphorylated HEF1 colocalized with vinculin and was associated almost exclusively with 0.1% Triton X-100 insoluble material, consistent with its signaling at focal adhesions. FAK overexpression promoted invasion through normal brain homogenate and siHEF1 inhibited this invasion. Results presented here suggest that HEF1 acts as a necessary and specific downstream effector of FAK in the invasive behavior of glioblastoma cells and may be an effective target for treatment of these tumors.	Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA; Univ Alabama, Dept Med, Div Hematol Oncol, Biostat Sect, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Fox Chase Cancer Center; Columbia University; University of Alabama System; University of Alabama Birmingham	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu		McFarland, Braden C./0000-0002-7517-9688; Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P50CA097247, R01CA109748, R01CA097110] Funding Source: NIH RePORTER; NCI NIH HHS [CA97247, CA97110, CA109748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 2003, IMMUNOL REV, V192, P181, DOI 10.1034/j.1600-065X.2003.00021.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200; Ding Q, 2002, CANCER RES, V62, P5336; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fashena SJ, 2002, J CELL SCI, V115, P99; ffrench-Constant C, 2004, TRENDS CELL BIOL, V14, P678, DOI 10.1016/j.tcb.2004.10.005; GLADSON CL, 1995, J CELL SCI, V108, P947; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; HERMANSON M, 1992, CANCER RES, V52, P3213; Ishino M, 1995, ONCOGENE, V11, P2331; Jones G, 2001, CANCER RES, V61, P4978; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MERLO A, 2004, SCI STKE, V229, P18; Merrill RA, 2004, DEV DYNAM, V231, P564, DOI 10.1002/dvdy.20159; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang DY, 2000, J CELL SCI, V113, P4221; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zagzag D, 2000, PEDIATR NEUROSURG, V33, P49, DOI 10.1159/000028975; Zrihan-Licht S, 2004, INT J ONCOL, V24, P153	50	156	164	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1721	1732		10.1038/sj.onc.1209199	http://dx.doi.org/10.1038/sj.onc.1209199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288224				2022-12-25	WOS:000236013700004
J	Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T				Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T			Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma	ONCOGENE			English	Article						methylation; HOXB13; renal cell carcinoma; RCC	HYPERMETHYLATION-ASSOCIATED INACTIVATION; PROSTATE-CANCER CELLS; CPG-ISLAND; DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; GASTRIC-CANCER; CLEAR-CELL; COLORECTAL-CANCER; SOMATIC MUTATIONS	Epigenetic alterations like DNA methylation and the resulting inactivation of cancer-related genes often contribute to the development of various cancers. To identify the genes that are silenced by aberrant methylation in renal cell carcinoma (RCC), we subjected two RCC lines to methylated CpG island amplification/representational difference analysis. This identified 27 CpG islands. Combined bisulfite restriction analysis of these CpG islands in primary RCC cases revealed that four were methylated in a tumor-specific manner. One of these was identified as the human homeo-box gene B13 (HOXB13) gene, but the remaining three CpG islands were not associated with known genes. The methylation frequencies of HOXB13 in primary RCC samples and lines were 30 and 73%, respectively. The methylation status of HOXB13 correlated with the loss of its expression both in RCC lines and primary tumors, and methyltransferase inhibitor treatment induced the recovery of its expression. Exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression suppressed colony formation and induced apoptotic features. Furthermore, HOXB13 methylation correlated positively with tumor grade and microvessel invasion. These results suggest that HOXB13 is a novel candidate tumor suppressor gene in RCC and that its inactivation may play an important role in both RCC tumorigenesis and progression.	Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Kochi Med Sch, Dept Ophthalmol, Nankoku, Kochi 7838505, Japan; Kochi Med Sch, Dept Tumor Pathol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido, Japan	Kochi University; Sapporo Medical University; Kochi University; Kochi University; Sapporo Medical University	Okuda, H (corresponding author), Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan.	okudah@med.kochi-u.ac.jp	Tokino, Takashi/AAI-9887-2021					Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; Esteller M, 2000, CANCER RES, V60, P129; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Japanese Urological Association the Japanese Society of Pathology and the Japan Radiological Society, 1999, GEN RUL CLIN PATH ST, V4th; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Mertens F, 1997, CANCER RES, V57, P2765; MORITA R, 1991, CANCER RES, V51, P820; Morrissey C, 2001, CANCER RES, V61, P7277; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Ogi K, 2002, CLIN CANCER RES, V8, P3164; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888; Satoh A, 2003, CANCER RES, V63, P8606; SHUIN T, 1994, CANCER RES, V54, P2852; Shuin T, 1999, Contrib Nephrol, V128, P1; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tokinaga K, 2004, ONCOL REP, V12, P805; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2001, CANCER RES, V61, P8540; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zeltser L, 1996, DEVELOPMENT, V122, P2475	46	67	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1733	1742		10.1038/sj.onc.1209200	http://dx.doi.org/10.1038/sj.onc.1209200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278676				2022-12-25	WOS:000236013700005
J	Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y				Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y			Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4	ONCOGENE			English	Article						TSLL2/IGSF4C; cell adhesion; tumor-suppressor gene; prostate cancer; TSLC1/IGSF4	CANCER AGGRESSIVENESS; PROMOTER METHYLATION; TSLC1 GENE; TUMORIGENICITY; IDENTIFICATION; INVOLVEMENT; LINKAGE; CLONING; TSLL2; LINE	The TSLL2/ IGSF4C encodes an immunoglobulin (Ig) superfamily molecule showing significant homology with a lung tumor suppressor, TSLC1. The TSLL2 protein of 55 kDa is mainly expressed in the kidney, bladder, and prostate in addition to the brain. Here, we report the biological signifance of TSLL2 in the urinary tissues. An immunohistochemical study reveals that TSLL2 is expressed at the cell-cell attachment sites in the renal tubules, the transitional epithelia of the bladder, and the glandular epithelia of the prostate. Confocal microscopy analysis demonstrates that TSLL2 is localized in the lateral membranes in polarized Mardin-Darby canine kidney (MDCK) cells. TSLL2 forms homo-dimers and its overexpression induces aggregation of suspended MDCK cells in a Ca2+/Mg2+ -independent manner, suggesting that it is involved in cell adhesion through homophilic trans-interaction. The TSLL2 gene is mapped on the chromosomal region 19q13.2, whose loss of heterozygosity has been frequently reported in prostate cancer. TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1. Introduction of TSLL2 into PPC-1 strongly suppresses subcutaneous tumor formation in nude mice. These results suggest that TSLL2 is a new member of the Ig superfamily cell adhesion molecules and is a tumor-suppressor candidate in prostate cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, GENE, V323, P11, DOI 10.1016/j.gene.2003.09.018; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Ito T, 2003, CANCER RES, V63, P6320; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Neville PJ, 2003, GENE CHROMOSOME CANC, V36, P332, DOI 10.1002/gcc.10165; Ozen M, 2000, ANTICANCER RES, V20, P1905; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7	27	43	49	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1446	1453		10.1038/sj.onc.1209192	http://dx.doi.org/10.1038/sj.onc.1209192			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261159				2022-12-25	WOS:000235890400002
J	Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA				Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA			Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells	ONCOGENE			English	Article						p53; phosphorylation; p53 resistance; apoptosis; tumor suppressor	INTERACTING PROTEIN KINASE-2; TRANSCRIPTIONAL ACTIVITY; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; POTENTIAL MEDIATOR; UV-RADIATION; IN-VIVO; ACTIVATION; PATHWAY	To investigate whether dysregulation of p53 phosphorylation confers tumor resistance to p53, we analysed the effects of wild-type p53 on oral squamous cell carcinoma (SCC) cell lines carrying various mutations of p53. Introduction of exogenous p53 neither induced apoptosis nor suppressed colony formation in HSC-3 cells lacking any detectable p53 and HSC-4 cells expressing mutant p53R248Q protein. Consistently, exogenous p53 did not induce proapoptotic p53-target genes in these p53-resistant cells. We found that phosphorylation of exogenous p53 on serine 46 (Ser46) was severely impaired in HSC-3 but not HSC-4 cells. A mutant mimicking Ser46-phosphorylation (p53S46D) enhanced proapoptotic Noxa promoter activity, and overcame the resistance to p53-mediated apoptosis and growth suppression in HSC-3 cells. Conversely, a mutant defective for Ser46-phosphorylation (p53S46A) failed to suppress the growth of p53-sensitive HSC-2 cells. In contrast to HSC-3 cells, p53S46D had no effect on HSC-4 cells, and inhibition of endogenous p53R248Q by siRNA restored p53-mediated apoptosis in HSC-4 cells, indicating a dominant-negative effect of p53R248Q protein on wild-type p53 function. These results demonstrate that the defect in Ser46 phosphorylation accounts for the p53 resistance of HSC-3 cells, and provide evidence for a mechanism underlying the acquisition of p53 resistance in oral SCC.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Sect Maxillofacial Surg, Tokyo, Japan; Chulalongkorn Univ, Fac Dent, Dept Anat, Bangkok, Thailand; Univ Indonesia, Fac Dent, Dept Oral Biol, Jakarta, Indonesia	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Chulalongkorn University; University of Indonesia	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	mikeda.emb@tmd.ac.jp	Auerkari, Elza Ibrahim/F-7406-2017; Ichwan, Solachuddin/E-6027-2016; ARIEF, SOLACHUDDIN JAUHARI/K-3011-2019	Auerkari, Elza Ibrahim/0000-0002-5680-7925; Ichwan, Solachuddin/0000-0002-2780-2455; 				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prives C, 1999, J PATHOL, V187, P112; Restle A, 2005, ONCOGENE, V24, P4380, DOI 10.1038/sj.onc.1208639; Rodicker F, 2003, CANCER RES, V63, P2737; SAKAI E, 1992, ONCOGENE, V7, P927; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Tamamori-Adachi M, 2003, CIRC RES, V92, pE12, DOI 10.1161/01.RES.0000049105.15329.1C; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	43	50	50	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1216	1224		10.1038/sj.onc.1209158	http://dx.doi.org/10.1038/sj.onc.1209158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247456				2022-12-25	WOS:000235537500009
J	Waugh, MG; Minogue, S; Chotai, D; Berditchevski, F; Hsuan, JJ				Waugh, MG; Minogue, S; Chotai, D; Berditchevski, F; Hsuan, JJ			Lipid and peptide control of phosphatidylinositol 4-kinase II alpha activity on Golgi-endosomal rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASP VENOM; SECRETORY GRANULES; RHO PROTEIN; MASTOPARAN; 4-KINASE; BINDING; KINASE; GTP; IDENTIFICATION; CALMODULIN	The most abundant and widely expressed mammalian phosphoinositide kinase activity is contributed by phosphatidylinositol 4-kinase II alpha (PI4KII alpha). In this study we demonstrate that PI4KII alpha is a novel GTP-independent target of the wasp venom tetradecapeptide mastoparan and that different mechanisms of activation occur in different subcellular membranes. Following cell membrane fractionation mastoparan specifically stimulated a high activity Golgi/endosomal pool of PI4KII alpha independently of exogenous guanine nucleotides. Conversely, GTP gamma S stimulated a low activity pool of PI4KII alpha in a separable dense membrane fraction and this response was further enhanced by mastoparan. Overexpression of PI4KII alpha increased the basal phosphatidylinositol 4-kinase activity of each membrane pool, as well as the mastoparan-dependent activities, thereby demonstrating that mastoparan specifically activates this isozyme. Both mastoparan and M7, at concentrations known to invoke secretion, stimulated PI4KII alpha with similar efficacies, resulting in an increase in the apparent V-max and decrease in K-m for exogenously added PI. Mastoparan also stimulated PI4KII alpha immunoprecipitated from the raft fraction, indicating that PI4KII alpha is a direct target of mastoparan. Finally we reveal a striking dependence of both basal and mastoparan-stimulated PI4KII alpha activity on endogenous cholesterol concentration and therefore conclude that changes in membrane environment can regulate PI4KII alpha activity.	UCL, Royal Free & Univ Coll Med Sch, Ctr Mol Cell Biol, Dept Med, London NW3 2PF, England; Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of London; University College London; Cancer Research UK; University of Birmingham	Hsuan, JJ (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Ctr Mol Cell Biol, Dept Med, Rowland Hill St, London NW3 2PF, England.	j.hsuan@medsch.ucl.ac.uk	Waugh, Mark/K-5232-2013; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Waugh, Mark/0000-0002-7241-3168	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; BARNETTE MS, 1983, BIOCHEM PHARMACOL, V32, P2929, DOI 10.1016/0006-2952(83)90398-2; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Barylko B, 2002, J BIOL CHEM, V277, P44366, DOI 10.1074/jbc.M203241200; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chahdi A, 2003, J BIOL CHEM, V278, P12039, DOI 10.1074/jbc.M212084200; Christian AE, 1997, J LIPID RES, V38, P2264; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Hirata Y, 2003, BIOCHEM J, V371, P81, DOI 10.1042/BJ20021844; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; HUSEBYE ES, 1988, BIOCHEM PHARMACOL, V37, P4149, DOI 10.1016/0006-2952(88)90109-8; KLINKER JF, 1994, BIOCHEM J, V304, P377, DOI 10.1042/bj3040377; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOCH G, 1992, BIOCHEM BIOPH RES CO, V186, P448, DOI 10.1016/S0006-291X(05)80828-9; Kowluru A, 2002, BIOCHEM PHARMACOL, V63, P2091, DOI 10.1016/S0006-2952(02)01025-0; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Panaretou C, 2002, BIOCHEM J, V363, P289, DOI 10.1042/0264-6021:3630289; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Tisch-Idelson D, 2001, BIOCHEM PHARMACOL, V61, P1063, DOI 10.1016/S0006-2952(01)00561-5; Vold RR, 1997, J BIOMOL NMR, V9, P329, DOI 10.1023/A:1018643312309; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Waugh MG, 2003, BIOCHEM J, V376, P497, DOI 10.1042/BJ20031212; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200	33	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3757	3763		10.1074/jbc.M506527200	http://dx.doi.org/10.1074/jbc.M506527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16249177	hybrid			2022-12-25	WOS:000235275300003
J	Henry, LK; Field, JR; Adkins, EM; Parnas, ML; Vaughan, RA; Zou, MF; Newman, AH; Blakely, RD				Henry, LK; Field, JR; Adkins, EM; Parnas, ML; Vaughan, RA; Zou, MF; Newman, AH; Blakely, RD			Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SCANNING MUTAGENESIS; DOPAMINE TRANSPORTER; DOMAIN-I; NEUROTRANSMITTER TRANSPORTERS; BINDING-SITE; CITALOPRAM; SUBSTRATE; ACID; ESCITALOPRAM; EXPRESSION	In previous studies examining the structural determinants of antidepressant and substrate recognition by serotonin transporters (SERTs), we identified Tyr-95 in transmembrane segment 1 (TM1) of human SERT as a major determinant of binding for several antagonists, including racemic citalopram ((RS)-CIT). Here we described a separate site in hSERT TM3 (Ile-172) that impacts (RS)-CIT recognition when switched to the corresponding Drosophila SERT residue (I172M). The hSERT I172M mutant displays a marked loss of inhibitor potency for multiple inhibitors such as (RS)-CIT, clomipramine, RTI-55, fluoxetine, cocaine, nisoxetine, mazindol, and nomifensine, whereas recognition of substrates, including serotonin and 3,4-methylenedioxymethamphetamine, is unaffected. Selectivity for antagonist interactions is evident with this substitution because the potencies of the antidepressants tianeptine and paroxetine are unchanged. Reduced cocaine analog recognition was verified in photoaffinity labeling studies using [I-125] MFZ 2-24. In contrast to the I172M substitution, other substitutions at this position significantly affected substrate recognition and/or transport activity. Additionally, the mouse mutation (mSERT I172M) exhibits similar selective changes in inhibitor potency. Unlike hSERT or mSERT, analogous substitutions in mouse dopamine transporter (V152M) or human norepinephrine transporter (V148M) result in transporters that bind substrate but are deficient in the subsequent translocation of the substrate. A double mutant hSERT Y95F/ I172M had a synergistic impact on ( RS)-CIT recognition (similar to 10,000-fold decrease in ( RS)-CIT potency) in the context of normal serotonin recognition. The less active enantiomer (R)-CIT responded to the I172M substitution like (S)-CIT but was relatively insensitive to the Y95F substitution and did not display a synergistic loss at Y95F/ I172M. An hSERT mutant with single cysteine substitutions in TM1 and TM3 resulted in formation of a high affinity cadmium metal coordination site, suggesting proximity of these domains in the tertiary structure of SERT. These studies provided evidence for distinct binding sites coordinating SERT antagonists and revealed a close interaction between TM1 and TM3 differentially targeted by stereoisomers of CIT.	Vanderbilt Univ, Ctr Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Utah, Ctr Med, Dept Pathol, Salt Lake City, UT 84112 USA; Univ N Dakota, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA	Vanderbilt University; Vanderbilt University; Utah System of Higher Education; University of Utah; University of North Dakota Grand Forks; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Blakely, RD (corresponding author), Vanderbilt Univ, Ctr Med, Ctr Mol Neurosci, Ste 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu			CENTER FOR INFORMATION TECHNOLOGY [Z01CT000259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015175, R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 15175, DA 07390] Funding Source: Medline	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; AKUNNE HC, 1992, NEUROCHEM RES, V17, P1275, DOI 10.1007/BF00968412; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BARKER EL, 1995, PSYCHOPHARMACOLOGY 4; Barker EL, 1998, METHOD ENZYMOL, V296, P475; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Gaffaney JD, 2004, MOL PHARMACOL, V65, P692, DOI 10.1124/mol.65.3.692; Hahn MK, 2003, J NEUROSCI, V23, P4470; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; Larsen MB, 2004, J BIOL CHEM, V279, P42147, DOI 10.1074/jbc.M405579200; Lee SH, 1998, BIOCHEM BIOPH RES CO, V246, P347, DOI 10.1006/bbrc.1998.8618; Lee SH, 2000, MOL PHARMACOL, V57, P883; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortensen OV, 2001, J NEUROCHEM, V79, P237, DOI 10.1046/j.1471-4159.2001.00587.x; Owens MJ, 2001, BIOL PSYCHIAT, V50, P345, DOI 10.1016/S0006-3223(01)01145-3; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramsey IS, 2002, J BIOL CHEM, V277, P14475, DOI 10.1074/jbc.M110783200; Ravna AW, 2003, J PHARMACOL EXP THER, V307, P34, DOI 10.1124/jpet.103.054593; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Sanchez C, 2004, PSYCHOPHARMACOLOGY, V174, P163, DOI 10.1007/s00213-004-1865-z; Sanchez C, 2003, PSYCHOPHARMACOLOGY, V167, P353, DOI 10.1007/s00213-002-1364-z; Schwartz JW, 2003, J BIOL CHEM, V278, P9768, DOI 10.1074/jbc.M209824200; Vaughan RA, 1996, J BIOL CHEM, V271, P21672, DOI 10.1074/jbc.271.35.21672; Vaughan RA, 2005, J NEUROSCI METH, V143, P33, DOI 10.1016/j.jneumeth.2004.09.022; Vaughan RA, 1999, J NEUROSCI, V19, P630; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zomot E, 2005, J BIOL CHEM, V280, P25512, DOI 10.1074/jbc.M503864200; Zou MF, 2001, J MED CHEM, V44, P4453, DOI 10.1021/jm0101904	36	144	148	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2012	2023		10.1074/jbc.M505055200	http://dx.doi.org/10.1074/jbc.M505055200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16272152	hybrid			2022-12-25	WOS:000234760400022
J	Biarnes, X; Nieto, J; Planas, A; Rovira, C				Biarnes, X; Nieto, J; Planas, A; Rovira, C			Substrate distortion in the michaelis complex of Bacillus 1,3-1,4-beta-glucanase - Insight from first principles molecular dynamics simulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-FUNCTIONAL THEORY; BETA-D-GLUCOPYRANOSE; AQUEOUS-SOLUTION; GLYCOSYL HYDROLASES; CATALYTIC MECHANISM; 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASES; CONFORMATIONAL ITINERARY; CELLOBIOHYDROLASE CEL6A; ANGSTROM RESOLUTION; AB-INITIO	The structure and dynamics of the enzyme-substrate complex of Bacillus 1,3-1,4-beta-glucanase, one of the most active glycoside hydrolases, is investigated by means of Car-Parrinello molecular dynamics simulations (CPMD) combined with force field molecular dynamics (QM/MM CPMD). It is found that the substrate sugar ring located at the -1 subsite adopts a distorted S-1(3) skew-boat conformation upon binding to the enzyme. With respect to the undistorted C-4(1) chair conformation, the S-1(3) skew-boat conformation is characterized by: (a) an increase of charge at the anomeric carbon (C1), (b) an increase of the distance between C1 and the leaving group, and (c) a decrease of the intraring O5-C1 distance. Therefore, our results clearly show that the distorted conformation resembles both structurally and electronically the transition state of the reaction in which the substrate acquires oxocarbenium ion character, and the glycosidic bond is partially broken. Together with analysis of the substrate conformational dynamics, it is concluded that the main determinants of substrate distortion have a structural origin. To fit into the binding pocket, it is necessary that the aglycon leaving group is oriented toward the beta region, and the skew-boat conformation naturally fulfills this premise. Only when the aglycon is removed from the calculation the substrate recovers the all-chair conformation, in agreement with the recent determination of the enzyme product structure. The QM/MM protocol developed here is able to predict the conformational distortion of substrate binding in glycoside hydrolases because it accounts for polarization and charge reorganization at the -1 sugar ring. It thus provides a powerful tool to model (ES)-S-. complexes for which experimental information is not yet available.	Ctr Especial Rec Quim Teor, Barcelona 08028, Spain; Univ Ramon Llull, Inst Quim Sarria, Biochem Lab, Barcelona 08017, Spain	Universitat Ramon Llull; Institut Quimic de Sarria	Rovira, C (corresponding author), Ctr Especial Rec Quim Teor, Parc Cient Barcelona,Josep Samitier 1-5, Barcelona 08028, Spain.	crovira@pcb.ub.es	Biarnés, Xevi/AAA-3107-2019; PLANAS, ANTONI/I-4803-2015; Rovira, Carme/K-5195-2014	Biarnés, Xevi/0000-0003-4121-9474; PLANAS, ANTONI/0000-0001-7073-3320; Rovira, Carme/0000-0003-1477-5010				Andre G, 2003, PROTEIN ENG, V16, P125, DOI 10.1093/proeng/gzg017; Appell M, 2004, CARBOHYD RES, V339, P537, DOI 10.1016/j.carres.2003.10.014; Ballone P, 2000, J PHYS CHEM B, V104, P6313, DOI [10.1021/jp994346b, 10.1021/jp00143b]; Berces A, 2001, J AM CHEM SOC, V123, P5460, DOI 10.1021/ja001194l; Brameld KA, 1998, J AM CHEM SOC, V120, P3571, DOI 10.1021/ja972282h; Canales A, 2005, J AM CHEM SOC, V127, P5778, DOI 10.1021/ja043363y; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; Carloni P, 2002, ACCOUNTS CHEM RES, V35, P455, DOI 10.1021/ar010018u; Corchado JC, 2004, J AM CHEM SOC, V126, P7311, DOI 10.1021/ja0398767; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coutinho P. M., 1999, RECENT ADV CARBOHYDR; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; Espinosa JF, 1998, J AM CHEM SOC, V120, P1309, DOI 10.1021/ja972291q; Faijes M, 2003, BIOCHEMISTRY-US, V42, P13304, DOI 10.1021/bi030131n; Fernandez-Alonso MD, 2005, CHEMPHYSCHEM, V6, P671, DOI 10.1002/cphc.200400495; GAISER OJ, 2005, IN PRESS J MOL BIOL; Garcia-Herrero A, 2002, J AM CHEM SOC, V124, P4804, DOI 10.1021/ja0122445; Golan G, 2004, J BIOL CHEM, V279, P3014, DOI 10.1074/jbc.M310098200; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; HAHN M, 1995, FEBS LETT, V374, P221, DOI 10.1016/0014-5793(95)01111-Q; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hurtley S, 2001, SCIENCE, V291, P2337, DOI 10.1126/science.291.5512.2337; Ireta J, 2004, J PHYS CHEM A, V108, P5692, DOI 10.1021/jp0377073; Kankainen M, 2004, PHYS CHEM CHEM PHYS, V6, P5074, DOI 10.1039/b409589h; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KIRBY AJ, 1984, ACCOUNTS CHEM RES, V17, P305, DOI 10.1021/ar00105a002; Klein CDP, 2003, J BIOL CHEM, V278, P47862, DOI 10.1074/jbc.M305325200; KOCH W, 2000, CHEM GUIDE DENSITY F, P41; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; Laio A, 2002, J CHEM PHYS, V116, P6941, DOI 10.1063/1.1462041; LARSSON A, 2005, 6 CARB BIOENG M BARC; Magistrato A, 2003, J PHYS CHEM B, V107, P4182, DOI 10.1021/jp027032o; Marx D., 2000, MODERN METHODS ALGOR, P301; Molteni C, 1998, J AM CHEM SOC, V120, P2168, DOI 10.1021/ja973008q; Mordasini T, 2003, J BIOL CHEM, V278, P4381, DOI 10.1074/jbc.C200664200; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Piana S, 2004, J PHYS CHEM B, V108, P11139, DOI 10.1021/jp037651c; Piotukh K, 1999, BIOCHEMISTRY-US, V38, P16092, DOI 10.1021/bi991690q; Planas A, 2003, BIOCATAL BIOTRANSFOR, V21, P223, DOI 10.1080/10242420310001618500; Planas N, 2000, BBA-PROTEIN STRUCT M, V1543, P361, DOI 10.1016/S0167-4838(00)00231-4; Rousseau R, 2004, ANGEW CHEM INT EDIT, V43, P4804, DOI 10.1002/anie.200453857; Rovira C, 2001, BIOPHYS J, V81, P435, DOI 10.1016/S0006-3495(01)75711-6; Stubbs JM, 2003, J AM CHEM SOC, V125, P10960, DOI 10.1021/ja035600n; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; Suzuki T, 2005, J PHYS CHEM B, V109, P12997, DOI 10.1021/jp050475i; Suzuki T, 2005, J PHYS CHEM B, V109, P12603, DOI 10.1021/jp050100x; Taylor EJ, 2005, J BIOL CHEM, V280, P32761, DOI 10.1074/jbc.M506580200; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Tvaroska I, 2000, J AM CHEM SOC, V122, P8762, DOI 10.1021/ja001525u; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; Varrot A, 2003, CHEM COMMUN, P946, DOI 10.1039/b301592k; Varrot A, 2002, ACTA CRYSTALLOGR D, V58, P2201, DOI 10.1107/S0907444902017006; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; White A, 1997, CURR OPIN STRUC BIOL, V7, P645, DOI 10.1016/S0959-440X(97)80073-5; WOODS RJ, 1995, J PHYS CHEM-US, V99, P3832, DOI 10.1021/j100011a061; Yip VLY, 2004, J AM CHEM SOC, V126, P8354, DOI 10.1021/ja047632w; Zhang YK, 1999, J CHEM PHYS, V110, P46, DOI 10.1063/1.478083; Zhou WL, 2004, BIOCHEMISTRY-US, V43, P9655, DOI 10.1021/bi049394n; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3	67	76	78	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1432	1441		10.1074/jbc.M507643200	http://dx.doi.org/10.1074/jbc.M507643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16260784	hybrid			2022-12-25	WOS:000234652000020
J	Espiau, B; Lemercier, G; Ambit, A; Bringaud, F; Merlin, G; Baltz, T; Bakalara, N				Espiau, B; Lemercier, G; Ambit, A; Bringaud, F; Merlin, G; Baltz, T; Bakalara, N			A soluble pyrophosphatase, a key enzyme for polyphosphate metabolism in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; TRYPANOSOMA-BRUCEI; ESCHERICHIA-COLI; DICTYOSTELIUM-DISCOIDEUM; SACCHAROMYCES-CEREVISIAE; CONTRACTILE VACUOLE; PARASITIC PROTOZOA; ACIDOCALCISOMES; EXOPOLYPHOSPHATASE; AMAZONENSIS	We report the functional characterization in Leishmania amazonensis of a soluble pyrophosphatase (LaVSP1) that localizes in acidocalcisomes, a vesicular acidic compartment. LaVSP1 is preferentially expressed in metacyclic forms. Experiments with dominant negative mutants show the requirement of LaVSP1 functional expression for metacyclogenesis and virulence in mice. Depending on the pH and the cofactors Mg2+ or Zn2+, both present in acidocalcisomes, LaVSP1 hydrolyzes either inorganic pyrophosphate (K-m = 92 mu M, k(cat) = 125 s(-1)), tripolyphosphate (K-m = 1153 mu M, k(cat) = 131 s(-1)), or polyphosphate of 28 residues (K-m = 123 mu M, k(cat) = 8 s(-1)). Predicted structural analysis suggests that the structural orientation of the residue Lys78 in LaVSP1 accounts for the observed increase in Km compared with the yeast pyrophosphatase and for the ability of trypanosomatid VSP1 enzymes to hydrolyze polyphosphate. These results make the VSP1 enzyme an attractive drug target against trypanosomatid parasites.	Univ Bordeaux 2, Lab Genom Fonct Trypanosomatides, CNRS, UMR 5162, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bakalara, N (corresponding author), Ecole Natl Super Chim Montpellier, 8 Rue Ecole Normale, F-34296 Montpellier, France.	norbert.bakalara@enscm.fr						AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; Arrais-Silva WW, 2005, EXP MOL PATHOL, V78, P49, DOI 10.1016/j.yexmp.2004.09.002; Avaeva SM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P373; Baykov AA, 1999, EUR J BIOCHEM, V260, P308, DOI 10.1046/j.1432-1327.1999.00181.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MRW, 2004, P NATL ACAD SCI USA, V101, P16085, DOI 10.1073/pnas.0406909101; Chaves CS, 2003, EXP PARASITOL, V103, P152, DOI 10.1016/S0014-4894(03)00098-5; Christensen ST, 1998, INT REV CYTOL, V177, P181; Colhone MC, 2004, J PARASITOL, V90, P510, DOI 10.1645/GE-3286; Cuvillier A, 2000, J CELL SCI, V113, P2065; de Souza W, 2003, MEM I OSWALDO CRUZ, V98, P151, DOI 10.1590/S0074-02762003000200001; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Gomez-Garcia MR, 2004, P NATL ACAD SCI USA, V101, P15876, DOI 10.1073/pnas.0406923101; Gomez-Garcia MR, 2004, FEBS LETT, V560, P158, DOI 10.1016/S0014-5793(04)00097-3; Halonen P, 2005, BIOCHEMISTRY-US, V44, P4004, DOI 10.1021/bi047926u; Hammarton Tansy C, 2003, Prog Cell Cycle Res, V5, P91; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; Kornberg A, 1999, Prog Mol Subcell Biol, V23, P1; Kotsikorou E, 2005, J MED CHEM, V48, P6128, DOI 10.1021/jm058220g; Kulaev I, 2000, ANNU REV MICROBIOL, V54, P709, DOI 10.1146/annurev.micro.54.1.709; Kulaev IS, 2000, BIOCHEMISTRY-MOSCOW+, V65, P271; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; Lemercier G, 2004, J BIOL CHEM, V279, P3420, DOI 10.1074/jbc.M309974200; Lemercier G, 2003, J CHROMATOGR B, V786, P305, DOI 10.1016/S1570-0232(02)00745-6; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; McGrath JW, 2005, RES MICROBIOL, V156, P485, DOI 10.1016/j.resmic.2004.12.006; Miranda K, 2004, HISTOCHEM CELL BIOL, V121, P407, DOI 10.1007/s00418-004-0646-4; Moreno B, 2002, FEBS LETT, V523, P207, DOI 10.1016/S0014-5793(02)02977-0; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Rao N N, 1999, Prog Mol Subcell Biol, V23, P183; Rodrigues CO, 2002, J BIOL CHEM, V277, P50899, DOI 10.1074/jbc.M208940200; Rohloff P, 2004, J BIOL CHEM, V279, P52270, DOI 10.1074/jbc.M410372200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SHATTON JB, 1983, ANAL BIOCHEM, V130, P114, DOI 10.1016/0003-2697(83)90657-7; Sivula T, 1999, FEBS LETT, V454, P75, DOI 10.1016/S0014-5793(99)00779-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5; Tuominen V, 1998, J MOL BIOL, V284, P1565, DOI 10.1006/jmbi.1998.2266; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; Yan SF, 2002, MOL BIOCHEM PARASIT, V119, P217, DOI 10.1016/S0166-6851(01)00418-2; Zhang HY, 2005, P NATL ACAD SCI USA, V102, P2731, DOI 10.1073/pnas.0500023102; Zhang HY, 2002, P NATL ACAD SCI USA, V99, P16678, DOI 10.1073/pnas.262655199; Zhang K, 2005, MOL MICROBIOL, V55, P1566, DOI 10.1111/j.1365-2958.2005.04493.x; Zhang K, 2003, EMBO J, V22, P6016, DOI 10.1093/emboj/cdg584; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zyryanov AB, 2002, BIOCHEM J, V367, P901, DOI 10.1042/BJ20020880	58	28	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1516	1523		10.1074/jbc.M506947200	http://dx.doi.org/10.1074/jbc.M506947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291745	hybrid			2022-12-25	WOS:000234652000029
J	Kashuba, EV; Gradin, K; Isaguliants, M; Szekely, L; Poellinger, L; Klein, G; Kazlauskas, A				Kashuba, EV; Gradin, K; Isaguliants, M; Szekely, L; Poellinger, L; Klein, G; Kazlauskas, A			Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBP-J-KAPPA; DIOXIN RECEPTOR; AH RECEPTOR; CELL-CYCLE; C-MYC; ASSOCIATION; MECHANISM; SUBUNIT; COMPLEX; BINDS	EBNA-3 is one of the Epstein-Barr virus (EBV)-encoded nuclear antigens that is indispensable for immunoblastic transformation and sustained proliferation of B-lymphocytes. The molecular mechanisms responsible for the function of EBNA-3 are poorly understood. We previously found that EBNA-3 interacts with an immunophilinlike protein XAP2/ARA9/AIP, which in mammalian cells is known to interact with the latent aryl hydrocarbon receptor (AhR). AhR is a ligand-inducible transcription factor that mediates cellular responses to environmental pollutants, such as 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD). In this study, we show that EBNA-3 interacts specifically with AhR. The stability of this interaction is determined by the activation state of AhR and its association with XAP2. We and others have demonstrated that XAP2 retains the nonactivated AhR in the cell cytoplasm. However, in the presence of TCDD, the effect of XAP2 on the intracellular localization of AhR was counter-acted by EBNA-3, resulting in nuclear translocation of the AhR. In addition, EBNA-3 enhanced transactivation function by the ligand-activated AhR in cells, as assessed by reporter gene assays. Our data suggested that EBNA-3 plays a role in facilitating the ligand-dependent AhR activation process. Following activation of the AhR, we also observed that EBNA-3 counteracted the inhibitory effect of TCDD on the growth of EBV-carrying lymphoblasts. Taken together, our studies revealed a novel interaction between EBV- and AhR-dependent cellular pathways that control cell proliferation and survival.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Integrat Recognit Immune Syst, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Inst Biotechnol, Dept Immunol, LT-02241 Vilnius, Lithuania	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Vilnius University	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Von Eulers Vag 3, S-17177 Stockholm, Sweden.	lorenz.poellinger@cmb.ki.se	, ISSAGOULIANTIS/AAI-3148-2021; Kashuba, Elena/O-5389-2015; Kashuba, Elena/Q-4739-2019; Szekely, Laszlo/B-1268-2009	, ISSAGOULIANTIS/0000-0001-9382-2254; Kashuba, Elena/0000-0001-7001-4035; Kashuba, Elena/0000-0001-7001-4035; Szekely, Laszlo/0000-0001-6144-6573				Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Cooper A, 2003, J VIROL, V77, P999, DOI 10.1128/JVI.77.2.999-1010.2003; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hickabottom M, 2002, J BIOL CHEM, V277, P47197, DOI 10.1074/jbc.M208116200; Isaguliants MG, 2000, AIDS RES HUM RETROV, V16, P1269, DOI 10.1089/08892220050117032; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Kashuba E, 2000, ONCOGENE, V19, P1801, DOI 10.1038/sj.onc.1203501; Kashuba E, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-23; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; Kuppers R, 2003, NAT REV IMMUNOL, V3, P801, DOI 10.1038/nri1201; Ma Q, 1997, J BIOL CHEM, V272, P8878; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maruo S, 2003, J VIROL, V77, P10437, DOI 10.1128/JVI.77.19.10437-10447.2003; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Murray P G, 2001, Expert Rev Mol Med, V3, P1, DOI 10.1017/S1462399401003842; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996	36	38	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1215	1223		10.1074/jbc.M509036200	http://dx.doi.org/10.1074/jbc.M509036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16257957	hybrid			2022-12-25	WOS:000234447200064
J	Peters-Libeu, CA; Newhouse, Y; Hatters, DM; Weisgraber, KH				Peters-Libeu, CA; Newhouse, Y; Hatters, DM; Weisgraber, KH			Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CARBOXYL-TERMINAL DOMAINS; ALZHEIMERS-DISEASE; A-I; E POLYMORPHISM; LIPID-BINDING; EPSILON-4; ALLELE; CONFORMATION; ASSOCIATION	Apolipoprotein (apo) E plays a critical role in cholesterol transport, through high affinity binding to the low density lipoprotein receptor. This interaction requires apoE to be associated with a lipoprotein particle. To determine the structure of biologically active apoE on a lipoprotein particle, we crystallized dipalmitoylphosphatidylcholine particles containing two apoE molecules and determined the molecular envelope of apoE at 10 angstrom resolution. On the basis of the molecular envelope and supporting biochemical evidence, we propose a model in which each apoE molecule is folded into a helical hairpin with the binding region for the low density lipoprotein receptor at its apex.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weisgraber, KH (corresponding author), Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA.	kweisgraber@gladstone.ucsf.edu		Hatters, Danny/0000-0002-9965-2847	NHLBI NIH HHS [HL-64963] Funding Source: Medline; NIA NIH HHS [AG-020235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Newhouse Y, 2005, ACTA CRYSTALLOGR F, V61, P981, DOI 10.1107/S1744309105032410; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; RAFFAI R, 1995, J LIPID RES, V36, P1905; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Raussens V, 2003, J BIOL CHEM, V278, P25998, DOI 10.1074/jbc.M301753200; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1992, J LIPID RES, V33, P141; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P512; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	40	70	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1073	1079		10.1074/jbc.M510851200	http://dx.doi.org/10.1074/jbc.M510851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278220	Green Submitted, hybrid			2022-12-25	WOS:000234447200048
J	Hake, SB; Garcia, BA; Duncan, EM; Kauer, M; Dellaire, G; Shabanowitz, J; Bazett-Jones, DP; Allis, CD; Hunt, DF				Hake, SB; Garcia, BA; Duncan, EM; Kauer, M; Dellaire, G; Shabanowitz, J; Bazett-Jones, DP; Allis, CD; Hunt, DF			Expression patterns and post-translational modifications associated with mammalian histone H3 variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; SEQUENCE-ANALYSIS; ACTIVE CHROMATIN; X-CHROMOSOME; METHYLATION; NUCLEOSOME; ACETYLATION; CORE; HETEROCHROMATIN; TRANSCRIPTION	Covalent histone modifications and the incorporation of histone variants bring about changes in chromatin structure that in turn alter gene expression. Interest in non-allelic histone variants has been renewed, in part because of recent work on H3 (and other) histone variants. However, only in mammals do three non-centromeric H3 variants (H3.1, H3.2, and H3.3) exist. Here, we show that mammalian cell lines can be separated into two different groups based on their expression of H3.1, H3.2, and H3.3 at both mRNA and protein levels. Additionally, the ratio of these variants changes slightly during neuronal differentiation of murine ES cells. This difference in H3 variant expression between cell lines could not be explained by changes in growth rate, cell cycle stages, or chromosomal ploidy, but rather suggests other possibilities, such as changes in H3 variant incorporation during differentiation and tissue- or species-specific H3 variant expression. Moreover, quantitative mass spectrometry analysis of human H3.1, H3.2, and H3.3 showed modification differences between these three H3 variants, suggesting that they may have different biological functions. Specifically, H3.3 contains marks associated with transcriptionally active chromatin, whereas H3.2, in contrast, contains mostly silencing modifications that have been associated with facultative heterochromatin. Interestingly, H3.1 is enriched in both active and repressive marks, although the latter marks are different from those observed in H3.2. Although the biological significance as to why mammalian cells differentially employ three highly similar H3 variants remains unclear, our results underscore potential functional differences between them and reinforce the general view that H3.1 and H3.2 in mammalian cells should not be treated as equivalent proteins.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA; Hosp Sick Children, Res Inst, Cell Biol Programme, Toronto, ON M5S 1X8, Canada	Rockefeller University; University of Virginia; University of Virginia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol, Box 78,1230 York Ave, New York, NY 10021 USA.	alliscd@rockefeller.edu; dfh@virginia.edu	Dellaire, Graham/L-9948-2014; Hunt, Donald F/I-6936-2012; Duncan, Elizabeth/AAJ-3351-2020	Dellaire, Graham/0000-0002-3466-6316; Hunt, Donald F/0000-0003-2815-6368; Duncan, Elizabeth/0000-0003-2003-6417	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37537, GM 40922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chow CM, 2005, EMBO REP, V6, P354, DOI 10.1038/sj.embor.7400366; Chow JC, 2003, CELL MOL LIFE SCI, V60, P2586, DOI 10.1007/s00018-003-3121-9; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Garcia BA, 2005, BIOCHEMISTRY-US, V44, P13202, DOI 10.1021/bi050906n; GROVE GW, 1984, BIOCHEMISTRY-US, V23, P4436, DOI 10.1021/bi00314a030; Hake SB, 2005, P NATL ACAD SCI USA, V102, P6344, DOI 10.1073/pnas.0502413102; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Johnson L, 2004, NUCLEIC ACIDS RES, V32, P6511, DOI 10.1093/nar/gkh992; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Pesavento JJ, 2004, J AM CHEM SOC, V126, P3386, DOI 10.1021/ja039748i; PINA B, 1987, DEV BIOL, V123, P51, DOI 10.1016/0012-1606(87)90426-X; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Smith MM, 2002, MOL CELL, V9, P1158, DOI 10.1016/S1097-2765(02)00552-X; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; URBAN MK, 1983, DEV BIOL, V95, P421, DOI 10.1016/0012-1606(83)90043-X; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	30	245	253	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					559	568		10.1074/jbc.M509266200	http://dx.doi.org/10.1074/jbc.M509266200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267050	hybrid			2022-12-25	WOS:000234307200068
J	Sorensen, S; Ranheim, T; Bakken, KS; Leren, TP; Kulseth, MA				Sorensen, S; Ranheim, T; Bakken, KS; Leren, TP; Kulseth, MA			Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; LDL RECEPTOR; QUALITY-CONTROL; FAMILIAL HYPERCHOLESTEROLEMIA; CHEMICAL CHAPERONES; MOLECULAR-GENETICS; DEGRADATION; ACTIVATION; DISORDERS; MUTATIONS	Familial hypercholesterolemia is an autosomal dominant disease caused by mutations in the gene encoding the low density lipoprotein receptor ( LDLR). More than 50% of these mutations lead to receptor proteins that are completely or partly retained in the endoplasmic reticulum ( ER). The mechanisms involved in the intracellular processing and retention of mutant LDLR are poorly understood. In the present study we show that the G544V mutant LDLR associates with the chaperones Grp78, Grp94, ERp72, and calnexin in the ER of transfected Chinese hamster ovary cells. Retention of the mutant LDLR was shown to cause ER stress and activation of the unfolded protein response. We observed a marked increase in the activity of two ER stress sensors, IRE1 and PERK. These results show that retention of mutant LDLR in ER induces cellular responses, which might be important for the clinical outcome of familial hypercholesterolemia.	Univ Hosp, Rikshosp, Dept Med Genet, Med Genet Lab, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Kulseth, MA (corresponding author), Univ Hosp, Rikshosp, Dept Med Genet, Med Genet Lab, N-0027 Oslo, Norway.	mari.ann.kulseth@rikshospitalet.no	Longo, Kenneth A/A-5631-2010					Araki E, 2003, EXP BIOL MED, V228, P1213, DOI 10.1177/153537020322801018; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN EV, 2004, SEMIN VASC MED, V4, P31; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ESSER V, 1988, J BIOL CHEM, V263, P13276; Gent J, 2004, CELL MOL LIFE SCI, V61, P2461, DOI 10.1007/s00018-004-4090-3; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Jansen ACM, 2005, ARTERIOSCL THROM VAS, V25, P1475, DOI 10.1161/01.ATV.0000168909.44877.a7; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Ji C, 2004, WORLD J GASTROENTERO, V10, P1699; Jorgensen MM, 2000, J BIOL CHEM, V275, P33861, DOI 10.1074/jbc.M004663200; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Knorre A, 2002, BIOL CHEM, V383, P271, DOI 10.1515/BC.2002.029; Kolter T, 2003, CHEMBIOCHEM, V4, P260, DOI 10.1002/cbic.200390045; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Leren TP, 1997, J INTERN MED, V241, P185, DOI 10.1046/j.1365-2796.1997.78119000.x; Li YH, 2004, J LIPID RES, V45, P1084, DOI 10.1194/jlr.M300482-JLR200; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Ma YJ, 2002, CELL STRESS CHAPERON, V7, P222, DOI 10.1379/1466-1268(2002)007<0222:TMERAA>2.0.CO;2; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Williams RR, 1996, GENETIC APPROACHES TO NONCOMMUNICABLE DISEASES, P35; Yasuda Y, 2002, BIOCHEM BIOPH RES CO, V296, P313, DOI 10.1016/S0006-291X(02)00859-8; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	49	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					468	476		10.1074/jbc.M507071200	http://dx.doi.org/10.1074/jbc.M507071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16257961	hybrid			2022-12-25	WOS:000234307200058
J	Blonska, M; Shambharkar, PB; Kobayashi, M; Zhang, DY; Sakurai, H; Su, B; Lin, X				Blonska, M; Shambharkar, PB; Kobayashi, M; Zhang, DY; Sakurai, H; Su, B; Lin, X			TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE KINASE KINASE; PROTEIN; IL-1; TAB2; RIP; PHOSPHORYLATION; DIMERIZATION; DOMAIN; ROLES	Receptor-interacting protein (RIP) plays a critical role in tumor necrosis factor-alpha (TNF-alpha)-induced I kappa B kinase (IKK) activation and subsequent activation of transcription factor NF-kappa B. However, the molecular mechanism by which RIP mediates TNF-alpha-induced NF-kappa B activation is not completely defined. In this study, we have found that TAK1 is recruited to the TNF-alpha receptor complex in a RIP-dependent manner following the stimulation of TNF-alpha receptor 1 (TNF-R1). Moreover, a forced recruitment of TAK1 to TNF-R1 in the absence of RIP is sufficient to mediate TNF-alpha-induced NF-kappa B activation, indicating that the major function of RIP is to recruit its downstream kinases to the TNF-R1 complex. Interestingly, we also find that TAK1 and MEKK3 form a functional complex, in which TAK1 regulates autophosphorylation of MEKK3. The TAK1-mediated regulation of MEKK3 phosphorylation is dependent on the kinase activity of TAK1. Although TAK1-MEKK3 interaction is not affected by overexpressed TAB1, TAB1 is required for TAK1 activation and subsequent MEKK3 phosphorylation. Together, we conclude that TAK1 is recruited to the TNF-R1 complex via RIP and likely cooperates with MEKK3 to activate NF-kappa B in TNF-alpha signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; SUNY Buffalo, Grad Program Microbiol & Immunol, Buffalo, NY 14214 USA; Toyama Med & Pharmaceut Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Toyama	Lin, X (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	xllin@mdanderson.org	Sakurai, Hiroaki/AAE-4294-2019; Blonska, Marzenna/U-7751-2019	Blonska, Marzenna/0000-0001-5237-8732; Sakurai, Hiroaki/0000-0003-0657-9570	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050848] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070225] Funding Source: Medline; NIAID NIH HHS [AI050848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cheng J, 2005, MOL CELL BIOL, V25, P5955, DOI 10.1128/MCB.25.14.5955-5964.2005; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 2002, BIOCHEM BIOPH RES CO, V297, P1277, DOI 10.1016/S0006-291X(02)02379-3; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; ZHANG D, 2005, IN PRESS EMBO J; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	32	106	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43056	43063		10.1074/jbc.M507807200	http://dx.doi.org/10.1074/jbc.M507807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260783	hybrid			2022-12-25	WOS:000234200800071
J	Panov, A; Dikalov, S; Shalbuyeva, N; Taylor, G; Sherer, T; Greenamyre, T				Panov, A; Dikalov, S; Shalbuyeva, N; Taylor, G; Sherer, T; Greenamyre, T			Rotenone model of Parkinson disease - Multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; INDUCED OXIDATIVE STRESS; RAT-LIVER MITOCHONDRIA; INDUCED ANIMAL-MODELS; COMPLEX-I; PERMEABILITY TRANSITION; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISEASES; HEART MITOCHONDRIA; RESPIRATORY-CHAIN	Chronic infusion of rotenone (Rot) to Lewis rats reproduces many features of Parkinson disease. Rot (3 mg/kg/day) was infused subcutaneously to male Lewis rats for 6 days using Alzet minipumps. Control rats received the vehicle only. Presence of 0.1% bovine serum albumin during the isolation procedure completely removed rotenone bound to the mitochondria. Therefore all functional changes observed were aftereffects of rotenone toxicity in vivo. In Rot rat brain mitochondria (Rot-RBM) there was a 30-40% inhibition of respiration in State 3 and State 3U with Complex I (Co-I) substrates and succinate. Rot did not affect the State 4 Delta Psi of RBM and rat liver mitochondria (RLM). However, Rot-RBM required two times less Ca2+ to initiate permeability transition (mPT). There was a 2-fold increase in O-2(-) or H2O2 generation in Rot-RBM oxidizing glutamate. Rot infusion affected RLM little. Our results show that in RBM, the major site of reactive oxygen species generation with glutamate or succinate is Co-I. We also found that Co-II generates substantial amounts of reactive oxygen species that increased 2-fold in the Rot-RBM. Our data suggest that the primary mechanism of the Rot toxic effect on RBM consists in a significant increase of O-2(-) generation that causes damage to Co-I and Co-II, presumably at the level of 4Fe-4S clusters. Decreased respiratory activity diminishes resistance of RBM to Ca2+ and thus increases probability of mPT and apoptotic cell death. We suggest that the damage to Co-I and Co-II shifts O2. generation from the CoQ(10) sites to more proximal sites, such as flavines, and makes it independent of the RBM functional state.	Carolinas Med Ctr, Carolinas Neuromuscular ALS MDA Ctr, Charlotte, NC 28203 USA; Emory Univ, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Div Cardiol, Atlanta, GA 30322 USA	Carolinas Medical Center; Emory University; Emory University	Panov, A (corresponding author), 1000 Blythe Blvd, Charlotte, NC 28203 USA.	alexander.panov@carolinashealthcare.org	Greenamyre, J. Timothy/B-4049-2011	Sherer, Todd/0000-0001-9667-6600; Greenamyre, J. Timothy/0000-0003-3468-7878; Dikalov, Sergey/0000-0003-2976-6184	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES012068] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREEVA L, 1994, EUR J BIOCHEM, V221, P261, DOI 10.1111/j.1432-1033.1994.tb18737.x; Bashkatova V, 2004, EXP NEUROL, V186, P235, DOI 10.1016/j.expneurol.2003.12.005; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; Borlongan CV, 1997, NEUROSCI RES, V28, P185, DOI 10.1016/S0168-0102(97)00045-X; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Dikalov SI, 2002, ARCH BIOCHEM BIOPHYS, V402, P218, DOI 10.1016/S0003-9861(02)00064-4; Echaniz-Laguna A, 2002, ANN NEUROL, V52, P623, DOI 10.1002/ana.10357; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GREENAMYRE JT, 1992, J NEUROCHEM, V59, P746, DOI 10.1111/j.1471-4159.1992.tb09431.x; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; GREENE JG, 1995, J NEUROCHEM, V64, P2332; Hoglinger GU, 2003, J NEUROCHEM, V84, P491, DOI 10.1046/j.1471-4159.2003.01533.x; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V288, pC1440, DOI 10.1152/ajpcell.00607.2004; LANOUE KF, 1986, BIOCHEMISTRY-US, V25, P7667, DOI 10.1021/bi00371a058; Lapointe N, 2004, FASEB J, V18, P717, DOI 10.1096/fj.03-0677fje; LEE CP, 1967, METHOD ENZYMOL, P543; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Ohnishi ST, 2005, J BIOENERG BIOMEMBR, V37, P1, DOI 10.1007/s10863-005-4117-y; Panov A, 1996, BIOCHEMISTRY-US, V35, P12849, DOI 10.1021/bi960139f; Panov AV, 2004, ARCH BIOCHEM BIOPHYS, V424, P44, DOI 10.1016/j.abb.2004.01.013; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Panov AV, 1996, AM J PHYSIOL-HEART C, V270, pH1398, DOI 10.1152/ajpheart.1996.270.4.H1398; Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Santos MS, 2001, DIABETES-METAB RES, V17, P223, DOI 10.1002/dmrr.200; Schober A, 2004, CELL TISSUE RES, V318, P215, DOI 10.1007/s00441-004-0938-y; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Sherer TB, 2003, NEUROSCI LETT, V341, P87, DOI 10.1016/S0304-3940(03)00172-1; Sherer TB, 2002, J NEUROSCI, V22, P7006; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Uversky VN, 2004, CELL TISSUE RES, V318, P225, DOI 10.1007/s00441-004-0937-z; Vanacore N, 2002, NEUROL SCI, V23, pS119, DOI 10.1007/s100720200098; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x	54	201	206	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42026	42035		10.1074/jbc.M508628200	http://dx.doi.org/10.1074/jbc.M508628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16243845	hybrid			2022-12-25	WOS:000233992700028
J	Opaleye, O; Rose, RS; Whittaker, MM; Woo, EJ; Whittaker, JW; Pickersgill, RW				Opaleye, O; Rose, RS; Whittaker, MM; Woo, EJ; Whittaker, JW; Pickersgill, RW			Structural and spectroscopic studies shed light on the mechanism of oxalate oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BARLEY; GERMIN; PURIFICATION; MOLSCRIPT; PROTEINS; DATABASE; ENZYMES; PROGRAM	Oxalate oxidase (EC 1.2.3.4) catalyzes the conversion of oxalate and dioxygen to hydrogen peroxide and carbon dioxide. In this study, glycolate was used as a structural analogue of oxalate to investigate substrate binding in the crystalline enzyme. The observed monodentate binding of glycolate to the active site manganese ion of oxalate oxidase is consistent with a mechanism involving C - C bond cleavage driven by superoxide anion attack on a monodentate coordinated substrate. In this mechanism, the metal serves two functions: to organize the substrates ( oxalate and dioxygen) and to transiently reduce dioxygen. The observed structure further implies important roles for specific active site residues ( two asparagines and one glutamine) in correctly orientating the substrates and reaction intermediates for catalysis. Combined spectroscopic, biochemical, and structural analyses of mutants confirms the importance of the asparagine residues in organizing a functional active site complex.	OHSU, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA; Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England	Oregon Health & Science University; University of London; Queen Mary University London	Whittaker, JW (corresponding author), OHSU, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	jim@ebs.ogi.edu; richard.pickersgill@qmul.ac.uk	Rose, Ruth/AAW-3844-2020	Rose, Ruth/0000-0001-6406-137X; Woo, Eui-Jeon/0000-0001-6983-0270	Biotechnology and Biological Sciences Research Council [BBS/B/07896] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aguilar C, 1999, ARCH BIOCHEM BIOPHYS, V366, P275, DOI 10.1006/abbi.1999.1216; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; DUMAS B, 1993, CR ACAD SCI III-VIE, V316, P793; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; ELLISON RD, 1971, ACTA CRYSTALL B-STRU, VB 27, P333, DOI 10.1107/S0567740871002188; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P743; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANE BG, 1993, J BIOL CHEM, V268, P12239; LANE BG, 1994, FASEB J, V8, P294, DOI 10.1096/fasebj.8.3.8143935; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; LIS T, 1980, ACTA CRYSTALLOGR B, V36, P701, DOI 10.1107/S0567740880004190; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIETTA PG, 1982, PREP BIOCHEM, V12, P341, DOI 10.1080/00327488208065681; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Schwarzenbacher R, 2004, PROTEINS, V56, P392, DOI 10.1002/prot.20016; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; Svedruzic D, 2005, ARCH BIOCHEM BIOPHYS, V433, P176, DOI 10.1016/j.abb.2004.08.032; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; Woo EJ, 1998, FEBS LETT, V437, P87, DOI 10.1016/S0014-5793(98)01203-4; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; Zhou FS, 1998, PLANT PHYSIOL, V117, P33, DOI 10.1104/pp.117.1.33	30	61	63	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6428	6433		10.1074/jbc.M510256200	http://dx.doi.org/10.1074/jbc.M510256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16291738	hybrid			2022-12-25	WOS:000236030800036
J	Oka, S; Kato, J; Moss, J				Oka, S; Kato, J; Moss, J			Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					NHLBI, PCCMB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Yodoi, Junji/F-6189-2011	Yodoi, Junji/0000-0001-6849-4914; Masutani, Hiroshi/0000-0001-7633-2827; Hirata, Hiromi/0000-0002-3769-7441					0	98	101	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 6	2006	20	4	1				A45	A45		10.1096/fj.05-4439fje	http://dx.doi.org/10.1096/fj.05-4439fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	024OW	16254043				2022-12-25	WOS:000236206500217
J	Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH				Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH			ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO	ONCOGENE			English	Article						acute myeloid leukemia; neutrophil elastase; gene regulation; AML1-ETO	ACUTE MYELOID-LEUKEMIA; ENCODING NEUTROPHIL ELASTASE; T(8/21) FUSION PROTEIN; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; TARGET GENE; C-MYB; N-COR; ETO; T(8-21)	A 117 bp fragment of the human ELA2 promoter has been characterized that can act as a minimal promoter for the expression of neutrophil elastase. Chromatin immunoprecipitation and siRNAs revealed that expression of ELA2 is regulated by the acute myeloid human leukemia 1 protein (AML1), C/EBP alpha, PU.1 and c-Myb transcription factors. ELA2 has also been investigated as a possible target of the leukemic fusion protein AML1-ETO resulting from the t(8;21) chromosomal translocation. AML1-ETO, like AML1, binds the ELA2 promoter in the myeloid cell lines Kasumi-1 and U937, but unexpectedly fails to significantly alter expression of ELA2. Although AML1-ETO downregulates the expression of C/EBP alpha, changes in C/EBP alpha expression do not correlate with changes in the expression of ELA2. Our observations indicate that AML1-ETO may not be a constitutive repressor of gene expression in every case in which it can associate with DNA, either on its own or in conjunction with C/EBP alpha. Since neither ETO nor AML1-ETO are typically expressed in hematopoietic progenitors, we hypothesize that it is the interactions between AML1-ETO and regulatory cofactors in disease-state cells that alter gene expression programs during hematopoiesis. These protein-protein interactions may not require simultaneous DNA binding by AML1-ETO for the deleterious effects of the fusion protein to be realized.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Univ Freiburg, Ctr Med, Div Hematol & Oncol, Dept Med, Freiburg, Germany	Rockefeller University; University of Freiburg	Werner, MH (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave,Box 42, New York, NY 10021 USA.	mwerner@portugal.rockefeller.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ancliff PJ, 2001, BLOOD, V98, P2645, DOI 10.1182/blood.V98.9.2645; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; Lane AA, 2005, MOL CELL BIOL, V25, P23, DOI 10.1128/MCB.25.1.23-33.2005; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Shimada H, 2000, BLOOD, V96, P655; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wildonger J, 2005, DEVELOPMENT, V132, P2263, DOI 10.1242/dev.01824; YAN M, 2004, P NATL ACAD SCI USA, V49, P17186; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	48	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1349	1357		10.1038/sj.onc.1209181	http://dx.doi.org/10.1038/sj.onc.1209181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247445				2022-12-25	WOS:000235708200008
J	Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK				Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK			K-ras activation generates an inflammatory response in lung tumors	ONCOGENE			English	Article						K-ras; inflammation; lung cancer; macrophages; neutrophils	PEPTIDE ENA-78; CANCER; INTERLEUKIN-8; EXPRESSION; CELL; IDENTIFICATION; TUMORIGENESIS; ANGIOGENESIS; INDUCTION; GROWTH	Activating mutations in K-ras are one of the most common genetic alterations in human lung cancer. To dissect the role of K-ras activation in bronchial epithelial cells during lung tumorigenesis, we created a model of lung adenocarcinoma by generating a conditional mutant mouse with both Clara cell secretory protein (CC10)-Cre recombinase and the Lox-Stop-Lox K-ras(G12D) alleles. The activation of K-ras mutant allele in CC10 positive cells resulted in a progressive phenotype characterized by cellular atypia, adenoma and ultimately adenocarcinoma. Surprisingly, K-ras activation in the bronchiolar epithelium is associated with a robust inflammatory response characterized by an abundant infiltration of alveolar macrophages and neutrophils. These mice displayed early mortality in the setting of this pulmonary inflammatory response with a median survival of 8 weeks. Bronchoalveolar lavage fluid from these mutant mice contained the MIP-2, KC, MCP-1 and LIX chemokines that increased significantly with age. Cell lines derived from these tumors directly produced MIP-2, LIX and KC. This model demonstrates that K-ras activation in the lung induces the elaboration of inflammatory chemokines and provides an excellent means to further study the complex interactions between inflammatory cells, chemokines and tumor progression.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Wong, KK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, 44 Binney St,M413, Boston, MA 02115 USA.	kwong1@partners.org	Tonon, Giovanni/J-9804-2018; Maser, Richard/B-2970-2012	Tonon, Giovanni/0000-0003-2973-5038; 	NHLBI NIH HHS [R01 HL70321] Funding Source: Medline; NIA NIH HHS [K08AG 2400401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, CHEST, V105, pS95, DOI 10.1378/chest.105.3_Supplement.95S; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Karp JE, 2001, CURR OPIN ONCOL, V13, P470, DOI 10.1097/00001622-200111000-00009; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Linnoila RI, 2000, ANN NY ACAD SCI, V923, P249; LUKACS NW, 1995, AM J PHYSIOL-LUNG C, V268, pL856, DOI 10.1152/ajplung.1995.268.5.L856; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Ono M, 1999, CANCER CHEMOTH PHARM, V43, pS69, DOI 10.1007/s002800051101; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Poznansky MC, 2002, J CLIN INVEST, V109, P1101, DOI 10.1172/JCI200213853; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WATNICK RS, 2003, CANCER CELL, V6, P447	34	209	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2105	2112		10.1038/sj.onc.1209237	http://dx.doi.org/10.1038/sj.onc.1209237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288213				2022-12-25	WOS:000236359700013
J	Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S				Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S			Id proteins: Novel targets of activin action, which regulate epidermal homeostasis	ONCOGENE			English	Article						epidermis; skin; TGF-beta; wound	BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; KERATINOCYTE CELL-LINE; LOOP-HELIX PROTEINS; WOUND REPAIR; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; BINDING PROTEINS; EPITHELIAL-CELLS	Activin is a member of the transforming growth factor beta (TGF-beta) family, which plays a crucial role in skin morphogenesis and wound healing. To gain insight into the underlying mechanisms of action, we searched for activin-regulated genes in cultured keratinocytes. One of the identified target genes encodes Id1, a negative regulator of helix-loop-helix transcription factors. We show that Id1, Id2, and Id3 are strongly downregulated by activin in keratinocytes in vitro and in vivo. To determine the role of Id1 in keratinocyte biology, we generated stable HaCaT keratinocyte cell lines overexpressing this protein. Our results revealed that enhanced levels of Id1 do not affect proliferation of keratinocytes in monoculture under exponential culture conditions or in response to activin or TGF-beta 1. However, in three-dimensional organotypic cultures, Id1-overexpressing HaCaT cells formed a hyperthickened and disorganized epithelium that was characterized by enhanced keratinocyte proliferation, abnormal differentiation, and an increased rate of apoptosis. These results identify an important function of Id1 in the regulation of epidermal homeostasis.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, HPM D42, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Bamberger C, 2005, AM J PATHOL, V167, P733, DOI 10.1016/S0002-9440(10)62047-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bjorntorp E, 2003, ACTA DERM-VENEREOL, V83, P403, DOI 10.1080/00015550310015806; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chaturvedi V, 2003, EXP DERMATOL, V12, P255, DOI 10.1034/j.1600-0625.2003.00066.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cruise BA, 2004, DEV BIOL, V271, P1, DOI 10.1016/j.ydbio.2004.04.003; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; HARA E, 1994, J BIOL CHEM, V269, P2139; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lin CQ, 1999, ENDOCR-RELAT CANCER, V6, P49, DOI 10.1677/erc.0.0060049; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, RECEPTOR, V3, P173; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; Schaefer BM, 2001, EXP CELL RES, V266, P250, DOI 10.1006/excr.2001.5215; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamashita S, 2004, J AM SOC NEPHROL, V15, P91, DOI 10.1097/01.ASN.0000103225.68136.E6; Zhang L, 2005, MOL CELL BIOL, V25, P60, DOI 10.1128/MCB.25.1.60-65.2005	50	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2070	2081		10.1038/sj.onc.1209230	http://dx.doi.org/10.1038/sj.onc.1209230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288215				2022-12-25	WOS:000236359700010
J	de Jong, RN; Ab, E; Diercks, T; Truffault, V; Daniels, M; Kaptein, R; Folkers, GE				de Jong, RN; Ab, E; Diercks, T; Truffault, V; Daniels, M; Kaptein, R; Folkers, GE			Solution structure of the human ubiquitin-specific protease 15 DUSP domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINDAU TUMOR-SUPPRESSOR; NF-KAPPA-B; DEUBIQUITINATING ENZYME; PROTEIN STRUCTURES; COP9 SIGNALOSOME; FUNCTIONAL-CHARACTERIZATION; DEUBIQUITYLATING ENZYME; ASSIGNMENT; NMR; IDENTIFICATION	Ubiquitin-specific proteases ( USPs) can remove covalently attached ubiquitin moieties from target proteins and regulate both the stability and ubiquitin-signaling state of their substrates. All USPs contain a conserved catalytic domain surrounded by one or more subdomains, some of which contribute to target recognition. One such specific subdomain, the DUSP domain ( domain present in ubiquitin-specific proteases), is present in at least seven different human USPs that regulate the stability of or interact with the hypoxia-inducible transcription factor HIF1-alpha, the Von Hippel-Lindau protein ( pVHL), cullin E3 ligases, and BRCA2. We describe the NMR solution structure of the DUSP domain of human USP15, recently implicated in COP9 ( constitutive photomorphogenic gene 9) -signalosome regulation. Its tripod-like structure consists of a 3-fold alpha-helical bundle supporting a triple-stranded anti-parallel alpha-sheet. The DUSP domain displays a novel fold, an alpha/beta tripod ( AB3). DUSP domain surface properties and previously described work suggest a potential role in protein/protein interaction or substrate recognition.	Univ Utrecht, Bijvoet Ctr Biomol Res, Dept NMR Spect, NL-3584 CH Utrecht, Netherlands	Utrecht University	Folkers, GE (corresponding author), Univ Utrecht, Bijvoet Ctr Biomol Res, Dept NMR Spect, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	g.folkers@chem.uu.nl	Folkers, Gert E/C-2863-2009; Diercks, Tammo/AAT-3731-2021; AB, Eiso/H-8177-2012; Diercks, Tammo/G-1167-2011	Folkers, Gert E/0000-0003-1070-0505; Diercks, Tammo/0000-0002-5200-0905; Diercks, Tammo/0000-0002-5200-0905; de Jong, Rob N./0000-0002-9300-6633; AB, Eiso/0000-0002-5758-0435				Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Angelats C, 2003, MAMM GENOME, V14, P31, DOI 10.1007/s00335-002-3035-0; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Curcio-Morelli C, 2003, J CLIN INVEST, V112, P189, DOI 10.1172/JCI200318348; Czyzyk-Krzeska MF, 2004, TRENDS MOL MED, V10, P146, DOI 10.1016/j.molmed.2004.02.004; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; Folkers G. E., 2004, Journal of Structural and Functional Genomics, V5, P119, DOI 10.1023/B:JSFG.0000029200.66197.0c; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hetfeld BKJ, 2005, CURR BIOL, V15, P1217, DOI 10.1016/j.cub.2005.05.059; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Ingvarsdottir K, 2005, MOL CELL BIOL, V25, P1162, DOI 10.1128/MCB.25.3.1162-1172.2005; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Leutner M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Ovaa H, 2004, P NATL ACAD SCI USA, V101, P2253, DOI 10.1073/pnas.0308411100; Park KC, 2000, BIOCHEM J, V349, P443, DOI 10.1042/0264-6021:3490443; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Saito K, 2004, STRUCTURE, V12, P1719, DOI 10.1016/j.str.2004.07.012; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Schwechheimer C, 2004, BBA-MOL CELL RES, V1695, P45, DOI 10.1016/j.bbamcr.2004.09.023; Soboleva TA, 2005, J BIOL CHEM, V280, P745, DOI 10.1074/jbc.M401394200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wee S, 2005, NAT CELL BIOL, V7, P387, DOI 10.1038/ncb1241; Whitehead B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	45	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5026	5031		10.1074/jbc.M510993200	http://dx.doi.org/10.1074/jbc.M510993200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16298993	Green Published, hybrid			2022-12-25	WOS:000235426200055
J	Sgarra, R; Lee, J; Tessari, MA; Altamura, S; Spolaore, B; Giancotti, V; Bedford, MT; Manfioletti, G				Sgarra, R; Lee, J; Tessari, MA; Altamura, S; Spolaore, B; Giancotti, V; Bedford, MT; Manfioletti, G			The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA ENHANCEOSOME; IN-VIVO MODIFICATIONS; SUBSTRATE-SPECIFICITY; HMGA1A PROTEIN; CDC2 KINASE; HMGI-C; POSTTRANSLATIONAL MODIFICATIONS; SYMMETRIC DIMETHYLARGININE; N-METHYLTRANSFERASE; MASS-SPECTROMETRY	The HMGA1a protein belongs to the high mobility group A ( HMGA) family of architectural nuclear factors, a group of proteins that plays an important role in chromatin dynamics. HMGA proteins are multifunctional factors that associate both with DNA and nuclear proteins that have been involved in several nuclear processes, such as transcriptional regulation, viral integration, DNA repair, RNA processing, and chromatin remodeling. The activity of HMGA proteins is finely modulated by a variety of post-translational modifications. Arginine methylation was recently demonstrated to occur on HMGA1a protein, and it correlates with the apoptotic process and neoplastic progression. Methyltransferases responsible for these modifications are unknown. Here we show that the protein arginine methyltransferase PRMT6 specifically methylates HMGA1a protein both in vitro and in vivo. By mass spectrometry, the sites of methylation were unambiguously mapped to Arg(57) and Arg(59), two residues which are embedded in the second AT-hook, a region critical for both protein-DNA and protein-protein interactions and whose modification may cause profound alterations in the HMGA network. The in vivo association of HMGA and PRMT6 place this yet functionally uncharacterized methyltransferase in the well established functional context of the chromatin structure organization.	Univ Trieste, Dipartimento Biochim, I-34127 Trieste, Italy; Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Padua, CRIBI, Ctr Biotechnol, I-35131 Padua, Italy	University of Trieste; University of Texas System; UTMD Anderson Cancer Center; University of Padua	Manfioletti, G (corresponding author), Univ Trieste, Dipartimento Biochim, Via L Giorgieri 1, I-34127 Trieste, Italy.	manfiole@units.it	Bedford, Mark T/E-7856-2011	MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Sgarra, Riccardo/0000-0002-4496-2856; Altamura, Sandro/0000-0002-6781-1073				Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Boulanger MC, 2005, J VIROL, V79, P124, DOI 10.1128/JVI.79.1.124-131.2005; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; Diana F, 2001, J BIOL CHEM, V276, P11354, DOI 10.1074/jbc.M009521200; Edberg DD, 2005, J BIOL CHEM, V280, P8961, DOI 10.1074/jbc.M407348200; Edberg DD, 2004, BIOCHEMISTRY-US, V43, P11500, DOI 10.1021/bi049833i; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Hung CM, 2004, GENE, V340, P179, DOI 10.1016/j.gene.2004.07.039; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lee Jaeho, 2004, Methods Mol Biol, V284, P195; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; Miranda TB, 2005, BIOCHEM BIOPH RES CO, V336, P831, DOI 10.1016/j.bbrc.2005.08.179; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Sgarra R, 2005, PROTEOMICS, V5, P1494, DOI 10.1002/pmic.200401028; Sgarra R, 2004, FEBS LETT, V574, P1, DOI 10.1016/j.febslet.2004.08.013; Sgarra R, 2003, CELL DEATH DIFFER, V10, P386, DOI 10.1038/sj.cdd.4401184; Sgarra R, 2003, BIOCHEMISTRY-US, V42, P3575, DOI 10.1021/bi027338l; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zou Y, 2005, BIOCHEMISTRY-US, V44, P6293, DOI 10.1021/bi0475525	47	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3764	3772		10.1074/jbc.M510231200	http://dx.doi.org/10.1074/jbc.M510231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16293633	hybrid			2022-12-25	WOS:000235275300004
J	Mauro, C; Crescenzi, E; De Mattia, R; Pacifico, F; Mellone, S; Salzano, S; de Luca, C; D'Adamio, L; Palumbo, G; Formisano, S; Vito, P; Leonardi, A				Mauro, C; Crescenzi, E; De Mattia, R; Pacifico, F; Mellone, S; Salzano, S; de Luca, C; D'Adamio, L; Palumbo, G; Formisano, S; Vito, P; Leonardi, A			Central role of the scaffold protein tumor necrosis factor receptor- associated factor 2 in regulating endoplasmic reticulum stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA B ACTIVATION; CELL-DEATH; OXIDATIVE STRESS; MAMMALIAN-CELLS; JNK ACTIVATION; CYTOCHROME-C; ER; KINASE; TRANSDUCERS; SUPPRESSION	The endoplasmic reticulum represents the quality control site of the cell for folding and assembly of cargo proteins. A variety of conditions can alter the ability of the endoplasmic reticulum ( ER) to properly fold proteins, thus resulting in ER stress. Cells respond to ER stress by activating different signal transduction pathways leading to increased transcription of chaperone genes, decreased protein synthesis, and eventually to apoptosis. In the present paper we analyzed the role that the adaptor protein tumor necrosis factor-receptor associated factor 2 ( TRAF2) plays in regulating cellular responses to apoptotic stimuli from the endoplasmic reticulum. Mouse embryonic fibroblasts derived from TRAF2(-/-) mice were more susceptible to apoptosis induced by ER stress than the wild type counterpart. This increased susceptibility to ER stress-induced apoptosis was because of an increased accumulation of reactive oxygen species following ER stress, and was abolished by the use of antioxidant. In addition, we demonstrated that the NF-kappa B pathway protects cells from ER stress-induced apoptosis, controlling ROS accumulation. Our results underscore the involvement of TRAF2 in regulating ER stress responses and the role of NF-kappa B in protecting cells from ER stress-induced apoptosis.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Sannio; Yeshiva University; Albert Einstein College of Medicine	Leonardi, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	vito, pasquale/ABF-5505-2020; Pacifico, Francesco/AAX-3958-2020; leonardi, antonio/A-2887-2009; Mauro, Claudio/AAN-1848-2021; Palumbo, Giuseppe/N-3136-2016	Pacifico, Francesco/0000-0001-9563-3596; leonardi, antonio/0000-0001-8636-9623; Mauro, Claudio/0000-0002-3736-0099; D'Adamio, Luciano/0000-0002-2204-9441; vito, pasquale/0000-0002-5721-7716; CRESCENZI, ELVIRA/0000-0002-9258-8053; Palumbo, Giuseppe/0000-0001-9380-8436; D'Adamio, Luciano/0000-0002-9820-4882				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bray TM, 1999, P SOC EXP BIOL MED, V222, P195, DOI 10.1046/j.1525-1373.1999.d01-135.x; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Chung JY, 2002, J CELL SCI, V115, P679; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonardi A, 2002, ENDOCRINOLOGY, V143, P2169, DOI 10.1210/en.143.6.2169; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	35	51	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2631	2638		10.1074/jbc.M502181200	http://dx.doi.org/10.1074/jbc.M502181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16299380	hybrid, Green Published			2022-12-25	WOS:000234931800027
J	Kim, MS; Day, CJ; Selinger, CI; Magno, CL; Stephens, SRJ; Morrison, NA				Kim, MS; Day, CJ; Selinger, CI; Magno, CL; Stephens, SRJ; Morrison, NA			MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NF kappa B ligand for bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; NUCLEAR-FACTOR; DIFFERENTIATION; EXPRESSION; INHIBITION; PRECURSORS; MARKERS	MCP-1 (monocyte chemotactic protein-1) is a CC chemokine that is induced by receptor activator of NF kappa B ligand (RANKL) in human osteoclasts. In the absence of RANKL, treatment of human peripheral blood mononuclear cells with macrophage colony-stimulating factor and MCP-1 resulted in tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells that are positive for calcitonin receptor (CTR) and a number of other osteoclast markers, including nuclear factor of activated t cells, cytoplasmic, calcineurin-dependent 1 (NFATc1). Although NFATc1 was strongly induced by MCP-1 and was observed in the nucleus, MCP-1 did not permit the formation of bone-resorbing osteoclasts, although these cells had the typical TRAP(+)/CTR+ multinuclear phenotype of osteoclasts. Despite a similar appearance to osteoclasts, RANKL treatment was required in order for TRAP(+)/CTR+ multinuclear cells to develop bone resorption activity. The lack of bone resorption was correlated with a deficiency in expression of certain genes related to bone resorption, such as cathepsin K and MMP9. Furthermore, calcitonin blocked the MCP-1-induced formation of TRAP(+)/CTR+ multinuclear cells as well as blocking osteoclast bone resorption activity, indicating that calcitonin acts at two stages of osteoclast differentiation. Ablation of NFATc1 in mature osteoclasts did not prevent bone resorption activity, suggesting NFATc1 is involved in cell fusion events and not bone resorption. We propose that the MCP-1-induced TRAP(+)/CTR+ multinuclear cells represent an arrested stage in osteoclast differentiation, after NFATc1 induction and cellular fusion but prior to the development of bone resorption activity.				N.Morrison@griffith.edu.au	Morrison, Nigel A/F-4082-2012; Eltis, Lindsay D/J-8272-2015	Morrison, Nigel A/0000-0003-4774-3808; Eltis, Lindsay D/0000-0002-6774-8158; Day, Christopher/0000-0001-7953-4408				Aitken CJ, 2004, J BONE MINER RES, V19, P2057, DOI 10.1359/JBMR.040913; Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P153; Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; KIM MS, 2005, IN PRESS J CELL BIOC; Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444; KURIHARA N, 1990, ENDOCRINOLOGY, V127, P3215, DOI 10.1210/endo-127-6-3215; Lean J, 2004, BIOCHEM BIOPH RES CO, V321, P845, DOI 10.1016/j.bbrc.2004.07.035; Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004-1021; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Nakamura I, 1996, CELL TISSUE RES, V286, P507, DOI 10.1007/s004410050720; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; Sakiyama H, 2001, J BONE MINER METAB, V19, P220, DOI 10.1007/s007740170024; Selinger CI, 2005, J CELL BIOCHEM, V96, P996, DOI 10.1002/jcb.20575; Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600-0765.2005.00814.x; Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050; Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190	28	116	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1274	1285		10.1074/jbc.M510156200	http://dx.doi.org/10.1074/jbc.M510156200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16280328	hybrid			2022-12-25	WOS:000234447200070
J	Rhee, M; Davis, P				Rhee, M; Davis, P			Mechanism of uptake of C105Y, a novel cell-penetrating peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME COMPLEX RECEPTOR; GENE-TRANSFER; PROTEIN TRANSDUCTION; HEPATOMA-CELLS; DRUG-DELIVERY; IN-VIVO; TECHNOLOGY; DOMAIN; MACROPINOCYTOSIS; EXPRESSION	C105Y, a synthetic peptide (CSIPPEVKFNKPFVYLI) based on the amino acid sequence corresponding to residues 359-374 of alpha 1-antitrypsin, enhances gene expression from DNA nanoparticles. To investigate how this enhancement occurs, C105Y was fluorescently labeled to study its uptake and intracellular trafficking. When human hepatoma cells (HuH7) were incubated with fluorescently labeled C105Y for as little as 3min, C105Y displayed nuclear and cytoplasmic staining with enrichment of fluorescent signal in the nucleus and nucleolus. Uptake and nucleolar localization were observed with the short sequence PFVYLI, but not with SIPPEVK-FNK, and the D-isomer was readily taken up into cells but not into the nucleus. We found that the C105Y peptide is routed to the nucleolus very rapidly in an energy-dependent fashion, whereas membrane translocation and nuclear localization are energy-independent. When we tested the involvement of known endocytosis pathways in uptake and trafficking of this peptide, we demonstrated that C105Y peptide is internalized by a clathrin-and caveolin-independent pathway, although lipid raft-mediated endocytosis may play a role in peptide intracellular trafficking. Efficient energy-independent cell entry with rapid nuclear localization probably accounts for enhancement of gene expression from inclusion of C105Y into DNA nanoparticles.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Davis, P (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, Rm BRB 831,2109 Adelbert Rd, Cleveland, OH 44106 USA.	pbd@case.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK058318] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK58318, P30 DK27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Bhatnagar A, 2004, J BIOL CHEM, V279, P34614, DOI 10.1074/jbc.M404673200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Drin G, 2002, BBA-BIOMEMBRANES, V1559, P160, DOI 10.1016/S0005-2736(01)00447-3; Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x; Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Patel S, 2001, J GENE MED, V3, P271, DOI 10.1002/jgm.180; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; Prochiantz A, 2005, ADV DRUG DELIVER REV, V57, P491, DOI 10.1016/j.addr.2004.11.002; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Swedlow JR, 2002, P NATL ACAD SCI USA, V99, P2014, DOI 10.1073/pnas.022554999; SYMTHE E, 1991, EUR J BIOCHEM, V202, P689; Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Yoshida T, 2004, BIOCHEM BIOPH RES CO, V321, P961, DOI 10.1016/j.bbrc.2004.07.054; Ziady AG, 1998, GENE THER, V5, P1685, DOI 10.1038/sj.gt.3300777; Ziady AG, 2004, GENE THER, V11, P1378, DOI 10.1038/sj.gt.3302299; Ziady AG, 1999, J BIOL CHEM, V274, P4908, DOI 10.1074/jbc.274.8.4908; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545; Ziady AG, 2002, MOL THER, V5, P413, DOI 10.1006/mthe.2002.0556	36	103	111	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1233	1240		10.1074/jbc.M509813200	http://dx.doi.org/10.1074/jbc.M509813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272160	hybrid			2022-12-25	WOS:000234447200066
J	Ciszak, EM; Makal, A; Hong, YS; Vettaikkorumakankauv, AK; Korotchkina, LG; Patel, MS				Ciszak, EM; Makal, A; Hong, YS; Vettaikkorumakankauv, AK; Korotchkina, LG; Patel, MS			How dihydrolipoamide dehydrogenase-binding protein binds dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; LIPOAMIDE DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; MULTIENZYME COMPLEX; ACETYLTRANSFERASE COMPONENT; BACILLUS-STEAROTHERMOPHILUS; E1-ALPHA SUBUNIT; STRUCTURAL BASIS; LIPOYL DOMAIN; CDNA-CLONES	The dihydrolipoamide dehydrogenase-binding protein (E3BP) and the dihydrolipoamide acetyltransferase (E2) component enzyme form the structural core of the human pyruvate dehydrogenase complex by providing the binding sites for two other component proteins, dihydrolipoamide dehydrogenase (E3) and pyruvate dehydrogenase (E1), as well as pyruvate dehydrogenase kinases and phosphatases. Despite a high similarity between the primary structures of E3BP and E2, the E3-binding domain of human E3BP is highly specific to human E3, whereas the E1-binding domain of human E2 is highly specific to human E1. In this study, we characterized binding of human E3 to the E3-binding domain of E3BP by x-ray crystallography at 2.6-angstrom resolution, and we used this structural information to interpret the specificity for selective binding. Two subunits of E3 form a single recognition site for the E3-binding domain of E3BP through their hydrophobic interface. The hydrophobic residues Pro(133), Pro(154), and Ile(157) in the E3-binding domain of E3BP insert themselves into the surface of both E3 polypeptide chains. Numerous ionic and hydrogen bonds between the residues of three interacting polypeptide chains adjacent to the central hydrophobic patch add to the stability of the subcomplex. The specificity of pairing for human E3BP with E3 is interpreted from its subcomplex structure to be most likely due to conformational rigidity of the binding fragment of the E3-binding domain of E3BP and its exquisite amino acid match with the E3 target interface.	Univ Alabama, Natl Space Sci & Technol Ctr, Struct Biol Lab, Huntsville, AL 35805 USA; NASA, George C Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35805 USA; SUNY Buffalo, Dept Biochem, Sch Med & Biochem Sci, Buffalo, NY 14214 USA	University of Alabama System; University of Alabama Huntsville; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ciszak, EM (corresponding author), Univ Alabama, Natl Space Sci & Technol Ctr, Struct Biol Lab, 320 Sparkman Dr, Huntsville, AL 35805 USA.	ciszakE@uah.edu	Makal, Anna M/X-5306-2018	Makal, Anna M/0000-0001-9357-2670	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042885] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42885] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MD, 2005, FEBS J, V272, P259, DOI 10.1111/j.1432-1033.2004.04405.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; delaSierra IL, 1997, J MOL BIOL, V269, P129, DOI 10.1006/jmbi.1997.1009; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; HO L, 1988, BIOCHEM BIOPH RES CO, V150, P904, DOI 10.1016/0006-291X(88)90714-0; Howard MJ, 1998, GASTROENTEROLOGY, V115, P139, DOI 10.1016/S0016-5085(98)70375-0; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Izard T, 1999, P NATL ACAD SCI USA, V96, P1240, DOI 10.1073/pnas.96.4.1240; Jones DD, 2000, BIOCHEMISTRY-US, V39, P8448, DOI 10.1021/bi992978i; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; Lawson JE, 1997, J BIOL CHEM, V272, P31625, DOI 10.1074/jbc.272.50.31625; Liu TC, 1999, PROTEIN EXPRES PURIF, V16, P27, DOI 10.1006/prep.1999.1047; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NEAGLE J, 1989, FEBS LETT, V253, P11, DOI 10.1016/0014-5793(89)80919-6; NEAGLE JC, 1991, BIOCHEM J, V278, P423, DOI 10.1042/bj2780423; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; Toyoda T, 1998, ACTA CRYSTALLOGR D, V54, P982, DOI 10.1107/S090744499800033X; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361	49	50	57	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					648	655		10.1074/jbc.M507850200	http://dx.doi.org/10.1074/jbc.M507850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263718	hybrid			2022-12-25	WOS:000234307200077
J	Grimm, DH; Karihaloo, A; Cai, YQ; Somlo, S; Cantley, LG; Caplan, MJ				Grimm, DH; Karihaloo, A; Cai, YQ; Somlo, S; Cantley, LG; Caplan, MJ			Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; GENE-PRODUCT; CATION CHANNEL; DISEASE ADPKD; G-PROTEINS; PKD2; ACTIVATION; GROWTH; EXPRESSION; APOPTOSIS	Autosomal dominant polycystic kidney disease ( ADPKD) is characterized by the formation of multiple fluid- filled cysts that expand over time and destroy the renal architecture. Loss or mutation of polycystin- 1 or polycystin- 2, the respective proteins encoded by the ADPKD genes PKD1 and PKD2, is associated with most cases of ADPKD. Thus, the polycystin proteins likely play a role in cell proliferation and morphogenesis. Recent studies indicate that polycystin1 is involved in these processes, but little is known about the role played by polycystin- 2. To address this question, we created a number of related cell lines variable in their expression of polycystin- 2. We show that the basal and epidermal growth factor- stimulated rate of cell proliferation is higher in cells that do not express polycystin-2 versus those that do, indicating that polycystin- 2 acts as a negative regulator of cell growth. In addition, cells not expressing polycystin- 2 exhibit significantly more branching morphogenesis and multicellular tubule formation under basal and hepatocyte growth factor- stimulated conditions than their polycystin- 2- expressing counterparts, suggesting that polycystin- 2 may also play an important role in the regulation of tubulogenesis. Cells expressing a channel mutant of polycystin- 2 proliferated faster than those expressing the wild- type protein, but exhibited blunted tubule formation. Thus, the channel activity of polycystin- 2 may be an important component of its regulatory machinery. Finally, we show that polycystin- 2 regulation of cell proliferation appears to be dependent on its ability to prevent phosphorylated extracellular- related kinase from entering the nucleus. Our results indicate that polycystin-2 is necessary for the proper growth and differentiation of kidney epithelial cells and suggest a possible mechanism for the cyst formation seen in ADPKD2.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Nephrol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Caplan, MJ (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, POB 208026, New Haven, CT 06520 USA.	michael.caplan@yale.edu		Caplan, Michael/0000-0001-5768-4405	NIDDK NIH HHS [DK57328, DK 065109, DK 064258] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, P50DK057328, K01DK064258] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguiari G, 2004, FASEB J, V18, P884, DOI 10.1096/fj.03-0687fje; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Berridge MV, 1996, J IMMUNOL, V156, P4092; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002-9440(10)64919-X; Chou RC, 2003, BRAIN RES PROTOC, V11, P162, DOI 10.1016/S1385-299X(03)00043-6; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; DU J, 1995, AM J PHYSIOL-CELL PH, V269, pC487, DOI 10.1152/ajpcell.1995.269.2.C487; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fishman DD, 1998, INT J ONCOL, V12, P181; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gallagher AR, 2002, CELL MOL LIFE SCI, V59, P682, DOI 10.1007/s00018-002-8457-z; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GOTTARDI CJ, 1993, J CELL SCI, P13; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; GRANTHAM JJ, 1993, ADV INTERNAL MED, V38, P409; Grimm DH, 2003, J BIOL CHEM, V278, P36786, DOI 10.1074/jbc.M306536200; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Karihaloo A, 2005, MOL CELL BIOL, V25, P7441, DOI 10.1128/MCB.25.17.7441-7448.2005; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kim H, 2004, EUR J HUM GENET, V12, P433, DOI 10.1038/sj.ejhg.5201136; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lanoix J, 1996, ONCOGENE, V13, P1153; Lu WN, 1999, NAT GENET, V21, P160, DOI 10.1038/5944; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Markovska RP, 1999, ADSORPT SCI TECHNOL, V17, P25, DOI 10.1177/026361749901700103; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Ong ACM, 2000, EXP NEPHROL, V8, P208; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Rubinfeld Hadara, 2004, Methods Mol Biol, V250, P1; Takacs-Jarrett M, 1998, AM J PHYSIOL-RENAL, V275, pF802, DOI 10.1152/ajprenal.1998.275.5.F802; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Wilson P D, 1995, Curr Top Pathol, V88, P1; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	51	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					137	144		10.1074/jbc.M507845200	http://dx.doi.org/10.1074/jbc.M507845200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16278216	hybrid			2022-12-25	WOS:000234307200020
J	Zhao, P; Caretti, G; Mitchell, S; McKeehan, WL; Boskey, AL; Pachman, LM; Sartorelli, V; Hoffman, EP				Zhao, P; Caretti, G; Mitchell, S; McKeehan, WL; Boskey, AL; Pachman, LM; Sartorelli, V; Hoffman, EP			Fgfr4 is required for effective muscle regeneration in vivo - Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT BINDING-FACTOR; GROWTH-FACTOR RECEPTOR-4; BILE-ACID SYNTHESIS; ENHANCER FACTOR-I; HEAVY-CHAIN GENE; SKELETAL-MUSCLE; DNA-BINDING; EXPRESSION; MUTATIONS; PROTEIN	Fgfr4 has been shown to be important for appropriate muscle development in chick limb buds; however, Fgfr4 null mice show no phenotype. Here, we show that staged induction of muscle regeneration in Fgfr4 null mice becomes highly abnormal at the time point when Fgfr4 is normally expressed. By 7 days of regeneration, differentiation of myotubes became poorly coordinated and delayed by both histology and embryonic myosin heavy chain staining. By 14 days much of the muscle was replaced by fat and calcifications. To begin to dissect the molecular pathways involving Fgfr4, we queried the promoter sequences for transcriptional factor binding sites and tested candidate regulators in a 27-time point regeneration series. The Fgfr4 promoter region contained a Tead protein binding site (M-CAT 5'-CATTCCT-3'), and Tead2 showed induction during regeneration commensurate with Fgfr4 regulation. Co-transfection of Tead2 and Fgfr4 promoter reporter constructs into C2C12 myotubes showed Tead2 to activate Fgfr4, and mutation of the M-CAT motif in the Fgfr4 promoter abolished these effects. Immunostaining for Tead2 showed timed expression in myotube nuclei consistent with the mRNA data. Query of the expression timing and genomic sequences of Tead2 suggested direct regulation by MyoD, and consistent with this, MyoD directly bound to two strong E-boxes in the first intron of Tead2 by chromatin immunoprecipitation assay. Moreover, co-transfection of MyoD and Tead2 intron reporter constructs into 10T1/2 cells activated reporter activity in a dose-dependent manner. This activation was greatly reduced when the two E-boxes were mutated. Our data suggest a novel MyoD-Tead2-Fgfr4 pathway important for effective muscle regeneration.	Childrens Natl Med Ctr, Res Ctr Genet Med, Washington, DC 20010 USA; NIAMS, NIH, Muscle Gene Express Grp, Lab Muscle Biol, Bethesda, MD 20892 USA; Texas A&M Univ, Ctr Canc Biol & Nutr, Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Hosp Special Surg, Mineralized Tissues Lab, New York, NY 10021 USA; Childrens Mem Res Ctr, Mol & Cellular Pathobiol Program, Chicago, IL 60614 USA	Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Hoffman, EP (corresponding author), Childrens Natl Med Ctr, Res Ctr Genet Med, 111 Michigan Ave NW, Washington, DC 20010 USA.	ehoffman@cnmcresearch.org	Pachman, Lauren/AAZ-6061-2021	Pachman, Lauren/0000-0001-8117-574X; Hoffman, Eric/0000-0001-6470-5139; Sartorelli, Vittorio/0000-0002-9284-3675; Boskey, Adele/0000-0002-6181-2219	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR006009] Funding Source: Medline; NIDDK NIH HHS [DK35310, R01 DK035310] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; Armand AS, 2003, BBA-MOL CELL RES, V1642, P97, DOI 10.1016/S0167-4889(03)00103-4; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Boskey A, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1922927; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Cool SM, 2002, HISTOCHEM J, V34, P291, DOI 10.1023/A:1023326524562; Coulier Francois, 1994, Progress in Growth Factor Research, V5, P1, DOI 10.1016/0955-2235(94)90014-0; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; Delfini MC, 2004, DEVELOPMENT, V131, P713, DOI 10.1242/dev.00967; Dusterhoft S, 1999, DIFFERENTIATION, V65, P161, DOI 10.1046/j.1432-0436.1999.6530161.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; Huang J, 1996, MOL CELL BIOL, V16, P3893; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Kaneko KJ, 1997, DEVELOPMENT, V124, P1963; Karasseva N, 2003, MOL CELL BIOL, V23, P5143, DOI 10.1128/MCB.23.15.5143-5164.2003; Kastner S, 2000, J HISTOCHEM CYTOCHEM, V48, P1079, DOI 10.1177/002215540004800805; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Marics I, 2002, DEVELOPMENT, V129, P4559; Mendelsohn R, 1999, J BIOMED OPT, V4, P14, DOI 10.1117/1.429916; Mielcarek M, 2002, MECH DEVELOP, V119, pS269, DOI 10.1016/S0925-4773(03)00127-8; Milewski RC, 2004, DEVELOPMENT, V131, P829, DOI 10.1242/dev.00975; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Ohno K, 2003, HUM MOL GENET, V12, P739, DOI 10.1093/hmg/ddg089; Pizette S, 1996, EXP CELL RES, V224, P143, DOI 10.1006/excr.1996.0122; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sheehan SM, 1999, J CELL PHYSIOL, V181, P499, DOI 10.1002/(SICI)1097-4652(199912)181:3<499::AID-JCP14>3.0.CO;2-1; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; Weinstein M, 1998, DEVELOPMENT, V125, P3615; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V228, P365, DOI 10.1006/bbrc.1996.1667; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Yu CD, 2002, AM J PATHOL, V161, P2003, DOI 10.1016/S0002-9440(10)64478-1; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Yu SJ, 2004, LAB INVEST, V84, P1571, DOI 10.1038/labinvest.3700187; Yu SJ, 2004, CLIN CANCER RES, V10, P6750, DOI 10.1158/1078-0432.CCR-04-0223; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457; Zhao P, 2003, CR BIOL, V326, P1049, DOI 10.1016/j.crvi.2003.09.035; Zhao P, 2002, J BIOL CHEM, V277, P30091, DOI 10.1074/jbc.M202668200; ZHOU JH, 1994, J BIOL CHEM, V269, P18563	58	69	76	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					429	438		10.1074/jbc.M507440200	http://dx.doi.org/10.1074/jbc.M507440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267055	Green Accepted, hybrid			2022-12-25	WOS:000234307200053
J	Knauth, K; Bex, C; Jemth, P; Buchberger, A				Knauth, K; Bex, C; Jemth, P; Buchberger, A			Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1 alpha interactions	ONCOGENE			English	Article						VHL; RCC; HIF-1 alpha	TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLATION/; LIGASE ACTIVITY; REGULATE HIF; VHL DISEASE; IN-VIVO; MUTATIONS; BINDING; COMPLEX; GENE	The von Hippel-Lindau (VHL) tumor suppressor protein is the substrate binding subunit of the CBCVHL E3 ubiquitin ligase complex. Mutations in the VHL gene cause a variety of tumors with complex genotype/ phenotype correlations. Type 2A and type 2B VHL disease are characterized by a low or high risk of renal cell carcinoma, respectively. To investigate the molecular basis underlying the difference between disease types 2A and 2B, we performed a detailed biochemical analysis of the two most frequent type 2A mutations, Y98H and Y112 H, in comparison to type 2B mutations in the same residues, Y98N and Y112N. While none of these mutations affected the assembly of CBCVHL complexes, the type 2A mutant proteins exhibited higher stabilities at physiological temperature. Moreover, the type 2A mutant proteins possessed higher binding affinities for the key cellular substrate, hypoxia-inducible transcription factor 1 (HIF-1 alpha). Consistent with these results, type 2A but not type 2B mutant VHL proteins retained significant ubiquitin ligase activity towards HIF-1 alpha in vitro. We propose that this residual ubiquitin ligase activity is sufficient to suppress renal cell carcinogenesis in vivo.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; MRC, Ctr Prot Engn, Cambridge, England	Max Planck Society; University of Cambridge	Buchberger, A (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	buchberg@biochem.mpg.de	Buchberger, Alexander/AAF-4728-2019; Buchberger, Alexander/J-4070-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Pfander, Claudia/0000-0002-9574-9553				Allen DL, 1998, PROTEIN SCI, V7, P1262, DOI 10.1002/pro.5560070524; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buchberger A, 1999, J BIOL CHEM, V274, P38017, DOI 10.1074/jbc.274.53.38017; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Killenberg-Jabs M, 2002, BIOPHYS CHEM, V96, P259, DOI 10.1016/S0301-4622(02)00017-0; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Li ZB, 2003, EMBO J, V22, P1857, DOI 10.1093/emboj/cdg173; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657	41	55	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					370	377		10.1038/sj.onc.1209062	http://dx.doi.org/10.1038/sj.onc.1209062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16261165				2022-12-25	WOS:000234714100005
J	Moore, HPH; Silver, RB; Mottillo, EP; Bernlohr, DA; Granneman, JG				Moore, HPH; Silver, RB; Mottillo, EP; Bernlohr, DA; Granneman, JG			Perilipin targets a novel pool of lipid droplets for lipolytic attack by hormone-sensitive lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAT ADIPOCYTES; PERMEABILIZED ADIPOCYTES; ADENYLATE-CYCLASE; TRANSLOCATION; STIMULATION; STORAGE; METABOLISM; MODULATION; BINDING	Adipocytes serve as the principal energy reservoir of the body; however, the subcellular organization of the machinery regulating lipid trafficking and metabolism is poorly understood. Mobilization of stored triglyceride is thought be controlled by interactions among intracellular lipases and proteins that coat lipid storage droplets. A major limitation of previous studies of hormone-mediated lipolysis, however, is the use of cultured model adipocytes whose three-dimensional architectures do not resemble those in real adipose tissue. To address this limitation, we investigated the intracellular targeting of perilipin, a major lipid coat protein, and hormone-sensitive lipase in three preparations that exhibit more appropriate morphologies: 3T3-L1 adipocytes grown in three-dimensional matrix, dissociated mature adipocytes from mouse adipose tissue, and adipocytes within intact fat pads. High resolution imaging of native and fluorescently tagged proteins indicate that: 1) perilipin preferentially targets a special class of peripheral lipid storage droplets, but not the major or central lipid storage droplets, 2) the peripheral droplets are the sites of attack by hormone-sensitive lipase, and 3) perilipin and hormone-sensitive lipase are continuously colocalized following lipolytic activation. These results indicate that in white adipose tissue, lipolysis takes place in a specialized subcellular domain that is distinct from the major lipid storage site and is defined by perilipin.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol Physiol Radiol & Biomed Engn, Detroit, MI 48201 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Technol Univ, Coll Arts & Sci, Southfield, MI 48075 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	Wayne State University; Wayne State University; University of California System; University of California Berkeley; University of Minnesota System; University of Minnesota Twin Cities	Granneman, JG (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Ctr Integrat Metab & Endocrine Res, 550 E Canfield, Detroit, MI 48201 USA.	jgranne@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062292, R01DK053189, R56DK053189, R21DK066505, R56DK062292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22454] Funding Source: Medline; NCRR NIH HHS [R24RR14891] Funding Source: Medline; NIDDK NIH HHS [R01 DK076629, DK 062292, DK 066505, DK 053189] Funding Source: Medline; NIEHS NIH HHS [P30ES06639] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Chaudhry A, 1999, AM J PHYSIOL-REG I, V277, pR147, DOI 10.1152/ajpregu.1999.277.1.R147; Clifford GM, 2001, METABOLISM, V50, P1264, DOI 10.1053/meta.2001.27216; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; D'Eon TM, 2005, J BIOL CHEM, V280, P35983, DOI 10.1074/jbc.M507339200; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Granneman JG, 2004, AM J PHYSIOL-ENDOC M, V287, pE574, DOI 10.1152/ajpendo.00567.2003; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; IZAWA T, 1991, J APPL PHYSIOL, V71, P23, DOI 10.1152/jappl.1991.71.1.23; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; LONDOS C, 1985, ADV CYCLIC NUCL PROT, V19, P221; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Marchesan D, 2003, J BIOL CHEM, V278, P27293, DOI 10.1074/jbc.M301430200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; MOONEY RA, 1983, EUR J BIOCHEM, V136, P603, DOI 10.1111/j.1432-1033.1983.tb07783.x; MOONEY RA, 1988, METHOD ENZYMOL, V159, P193; Morimoto C, 2001, J LIPID RES, V42, P120; Muller G, 2003, BIOCHIMIE, V85, P1245, DOI 10.1016/j.biochi.2003.10.004; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; RODBELL M, 1964, J BIOL CHEM, V239, P375; Smith AJ, 2004, J BIOL CHEM, V279, P52399, DOI 10.1074/jbc.M410301200; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	40	96	99	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43109	43120		10.1074/jbc.M506336200	http://dx.doi.org/10.1074/jbc.M506336200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16243839	hybrid			2022-12-25	WOS:000234200800077
J	Jiang, HD; Liu, XY; Zhang, G; Li, Y				Jiang, HD; Liu, XY; Zhang, G; Li, Y			Kinetics and template nucleation of self-assembled hydroxyapatite nanocrystallites by chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOMINERALIZATION; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; DESIGN; PRINCIPLES	Biomineralization is an important process, which is often assisted by biomolecules. In this paper, the effect of chondroitin sulfate on the crystallization of hydroxyapatite was examined quantitatively based on a generic heterogeneous nucleation model. It is found that chondroitin sulfate can suppress the supersaturation-driven interfacial structure mismatch between the hydroxyapatite crystal and the substrate and promote the formation of ordered hydroxyapatite nanocrystallite assemblies. The nucleation mechanism of self-aligned hydroxyapatite nanocrystallites was examined from the viewpoints of kinetics and interfacial structure and properties, which contributes to an understanding of the fundamentals of biomineralization of self-assembled structures. The results obtained from this study will provide a basic principle to design and fabricate highly orderly organic-inorganic hybrid materials.	Natl Univ Singapore, Dept Phys, Singapore 117542, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	National University of Singapore; National University of Singapore	Liu, XY (corresponding author), Natl Univ Singapore, Dept Phys, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Liu, XY/E-5090-2010; Zhou, Weiqian/B-8991-2011; Li, Jingliang/A-6039-2011	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246; Zhang, Gang/0000-0001-7697-7203; Liu, Xiang-Yang/0000-0002-5592-6885				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; Bauerlein E, 2003, ANGEW CHEM INT EDIT, V42, P614, DOI 10.1002/anie.200390176; Colfen H, 2003, ANGEW CHEM INT EDIT, V42, P2350, DOI 10.1002/anie.200200562; Elliott J.C., 1994, STRUCTURE CHEM APATI, P9; Embery G, 2001, CRIT REV ORAL BIOL M, V12, P331, DOI 10.1177/10454411010120040401; Goldberg M, 2003, CONNECT TISSUE RES, V44, P184, DOI 10.1080/03008200390152304; GREENFIELD EM, 1984, AM ZOOL, V24, P925; HALL R, 1995, CALCIFIED TISSUE INT, V56, P236, DOI 10.1007/BF00298617; HUNTER GK, 1989, J THEOR BIOL, V138, P195, DOI 10.1016/S0022-5193(89)80139-0; Jiang HD, 2004, J BIOL CHEM, V279, P41286, DOI 10.1074/jbc.M314027200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRAMPITZ G, 1988, ANGEW CHEM INT EDIT, V27, P1145, DOI 10.1002/anie.198811451; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 2003, J AM CHEM SOC, V125, P888, DOI 10.1021/ja020355d; Liu XY, 2000, J CHEM PHYS, V112, P9949, DOI 10.1063/1.481644; Liu XY, 2000, LANGMUIR, V16, P7337, DOI 10.1021/la991333g; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MILLANE RP, 1983, J MOL BIOL, V169, P903, DOI 10.1016/S0022-2836(83)80142-9; MOSS M, 1965, ORAL SURG ORAL MED O, V20, P795, DOI 10.1016/0030-4220(65)90143-X; MUTAFTSCHIEV B, 1993, HDB CRYSTAL GROWTH, P187; PAROLI E, 1991, DRUG EXP CLIN RES, V17, P9; RAJAMANI L, 2003, P NATL ACAD SCI USA, V99, P5155; Rees SG, 2002, BIOMATERIALS, V23, P481, DOI 10.1016/S0142-9612(01)00130-2; Rodriguez-Carvajal MA, 2003, BIOPOLYMERS, V69, P15, DOI 10.1002/bip.10304; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Snead ML, 2003, CONNECT TISSUE RES, V44, P47, DOI 10.1080/03008200390152089; Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242; Veis A., 1989, P189; Weiner S, 1997, J MATER CHEM, V7, P689, DOI 10.1039/a604512j; Weiner S, 2000, MAT SCI ENG C-BIO S, V11, P1, DOI 10.1016/S0928-4931(00)00141-7; Wilt FH, 2003, DIFFERENTIATION, V71, P237, DOI 10.1046/j.1432-0436.2003.7104501.x; ZETTLEMOYER AC, 1969, NUCLEATION, P225	35	57	60	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42061	42066		10.1074/jbc.M412280200	http://dx.doi.org/10.1074/jbc.M412280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251185	hybrid			2022-12-25	WOS:000233992700032
J	Kushiyama, A; Shojima, N; Ogihara, T; Inukai, K; Sakoda, H; Fujishiro, M; Fukushima, Y; Anai, M; Ono, H; Horike, N; Viana, AYI; Uchijima, Y; Nishiyama, K; Shimosawa, T; Fujita, T; Katagiri, H; Oka, Y; Kurihara, H; Asano, T				Kushiyama, A; Shojima, N; Ogihara, T; Inukai, K; Sakoda, H; Fujishiro, M; Fukushima, Y; Anai, M; Ono, H; Horike, N; Viana, AYI; Uchijima, Y; Nishiyama, K; Shimosawa, T; Fujita, T; Katagiri, H; Oka, Y; Kurihara, H; Asano, T			Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-UPTAKE; RECEPTOR EXPRESSION; REGULATED KINASE; SKELETAL-MUSCLE; TISSUE; CELLS; HYPERINSULINEMIA; OVEREXPRESSION; POLYPEPTIDE	Resistin and resistin-like molecules (RELMs) are a family of proteins reportedly related to insulin resistance and inflammation. Because the serum concentration and intestinal expression level of RELM beta were elevated in insulin-resistant rodent models, in this study we investigated the effect of RELM beta on insulin signaling and metabolism using transgenic mice and primary cultured hepatocytes. First, transgenic mice with hepatic RELM beta overexpression were shown to exhibit significant hyperglycemia, hyperlipidemia, fatty liver, and pancreatic islet enlargement when fed a high fat diet. Hyperinsulinemic glucose clamp showed a decreased glucose infusion rate due to increased hepatic glucose production. In addition, the expression levels of IRS-1 and IRS-2 proteins as well as the degrees of insulin-induced phosphatidylinositol 3-kinase and Akt activations were attenuated in RELM beta transgenic mice. Similar down-regulations of IRS-1 and IRS-2 proteins were observed in primary cultured hepatocytes chronically treated (for 24 h) with RELM beta, suggesting the insulin resistance-inducing effect of RELM beta to be direct. Furthermore, it was shown that RELM beta acutely and markedly activates ERK and p38, while weakly activating JNK, in primary cultured hepatocytes. This increased basal p38 phosphorylation level was also observed in the livers of RELM beta transgenic mice. In conclusion, RELM beta, a gut-derived hormone, impairs insulin signaling probably via the activations of classic MAPKs, and increased expression of RELM beta may be involved in the pathogenesis of glucose intolerance and hyperlipidemia in some insulin-resistant models. Thus, RELM beta is a potentially useful marker for assessing insulin resistance and may also be a target for future novel anti-diabetic agents.	Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Tohoku Univ, Grad Sch Med, Div Adv Therapeut Metab Dis, Ctr Translat & Adv Ainm Res Human Dis, Sendai, Miyagi 9808574, Japan; Saitama Med Sch, Dept Med, Div Endocrinol & Metab, Iruma, Saitama 3500495, Japan; Asahi Life Fdn, Inst Adult Dis, Dept Internal Med, Chiyoda Ku, Tokyo 1000005, Japan	University of Tokyo; University of Tokyo; Tohoku University; Saitama Medical University; Asahi Life Foundation	Asano, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	asano-tky@umin.ac.jp	Kushiyama, Akifumi/W-5988-2019; Nishiyama, Koichi/H-4275-2014; Shimosawa, Tatsuo/A-2920-2015; Kushiyama, Akifumi/A-6386-2011	Kushiyama, Akifumi/0000-0003-1385-7487; Nishiyama, Koichi/0000-0003-0529-4207; Shimosawa, Tatsuo/0000-0002-8742-5129; Kushiyama, Akifumi/0000-0003-1385-7487; Kurihara, Hiroki/0000-0002-6476-5593				Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; BERGMEYER HU, 1984, METHOD ENZYMAT AN, P11; Calabro P, 2004, CIRCULATION, V110, P3335, DOI 10.1161/01.CIR.0000147825.97879.E7; Chumakov AM, 2004, ONCOGENE, V23, P3414, DOI 10.1038/sj.onc.1207126; Fehmann HC, 2002, HORM METAB RES, V34, P671, DOI 10.1055/s-2002-38241; Fisher SJ, 2003, J CLIN INVEST, V111, P463, DOI 10.1172/JCI16426; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fueger PT, 2004, DIABETES, V53, P306, DOI 10.2337/diabetes.53.2.306; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; Kapoor GS, 2002, MOL CELL BIOCHEM, V236, P13, DOI 10.1023/A:1016185928871; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lee JH, 2003, J CLIN ENDOCR METAB, V88, P4848, DOI 10.1210/jc.2003-030519; Mehta KD, 1999, TRENDS CARDIOVAS MED, V9, P201, DOI 10.1016/S1050-1738(00)00021-9; Miles PDG, 2003, AM J PHYSIOL-ENDOC M, V284, pE618, DOI 10.1152/ajpendo.00312.2002; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Mooney MH, 2002, BBA-GEN SUBJECTS, V1569, P75, DOI 10.1016/S0304-4165(01)00237-9; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Ogihara T, 2004, DIABETOLOGIA, V47, P794, DOI 10.1007/s00125-004-1391-x; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rangwala SM, 2004, DIABETES, V53, P1937, DOI 10.2337/diabetes.53.8.1937; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Sakoda H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1239, DOI 10.1152/ajpendo.00455.2001; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Satoh H, 2004, J CLIN INVEST, V114, P224, DOI 10.1172/JCI200420785; Shojima N, 2005, DIABETOLOGIA, V48, P984, DOI 10.1007/s00125-005-1735-1; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Tomimoto S, 2004, J PHARMACOL EXP THER, V309, P796, DOI 10.1124/jpet.103.062919	36	56	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42016	42025		10.1074/jbc.M503065200	http://dx.doi.org/10.1074/jbc.M503065200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16243841	hybrid			2022-12-25	WOS:000233992700027
J	Zhao, B; Guengerich, FP; Voehler, M; Waterman, MR				Zhao, B; Guengerich, FP; Voehler, M; Waterman, MR			Role of active site water molecules and substrate hydroxyl groups in oxygen activation by cytochrome P450 158A2 - A new mechanism of proton transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-LIMITING STEPS; POLYKETIDE SYNTHASE; P450CAM; CRYSTALLOGRAPHY; BIOSYNTHESIS; OXIDATION; REDUCTION; CATALYSIS	From the x-ray crystal structure of CYP158A2 ( Zhao, B., Guengerich, F. P., Bellamine, A., Lamb, D. C., Izumikawa, M., Lei, L., Podust, L. M., Sundaramoorthy, M., Reddy, L. M., Kelly, S. L., Kalaitzis, J. A., Stec, D., Voehler, M., Falck, J. R., Moore, B. S., Shimada, T., and Waterman, M. R. ( 2005) J. Biol. Chem. 280, 11599 - 11607), one of 18 cytochrome P450 ( CYP) genes in the actinomycete Streptomyces coelicolor, ordered active site water molecules ( WAT505, WAT600, and WAT640), and hydroxyl groups of the substrate flaviolin were proposed to participate in proton transfer and oxygen cleavage in this monooxygenase. To probe their roles in catalysis, we have studied the crystal structures of a substrate analogue ( 2-hydroxy-1,4-naphthoquinone) complex with ferric CYP158A2 ( 2.15A) and the flaviolin ferrous dioxygen-bound CYP158A2 complex ( 1.8 (A) over circle). Catalytic activity toward 2-hydroxy-1,4-naphthoquinone was similar to 70-fold less than with flaviolin. In the ferrous dioxygen-bound flaviolin complex, the three water molecules in the ferric flaviolin complex still occupy the same positions and form hydrogen bonds to the distal dioxygen atom. These findings suggest that CYP158A2 utilizes substrate hydroxyl groups to stabilize active site water and further assist in the iron-linked dioxygen activation. A continuous hydrogen-bonded water network connecting the active site to the protein surface ( bulk solvent) not present in the other two ferrous dioxygen-bound P450 structures ( CYP101A1/P450(cam) and CYP107A1/P450(eryF)) is proposed to participate in the proton-delivery cascade, leading to dioxygen bond scission. This ferrous-dioxygen structure suggests two classes of P450s based on the pathway of proton transfer, one using the highly conserved threonine in the I-helix ( CYP101A1) and the other requiring hydroxyl groups of the substrate molecules either directly transferring protons ( CYP107A1) or stabilizing a water pathway for proton transfer ( CYP158A2).	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Struct Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Zhao, B (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 864 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	bin.zhao@vanderbilt.edu			NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM69970, GM37942] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069970, R01GM037942, R37GM037942] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caffrey P, 2001, CHEM BIOL, V8, P713, DOI 10.1016/S1074-5521(01)00046-1; Cortes J, 2002, MOL MICROBIOL, V44, P1213, DOI 10.1046/j.1365-2958.2002.02975.x; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Davydov R, 2005, J AM CHEM SOC, V127, P1403, DOI 10.1021/ja045351i; DEMONTELLANO PRO, 2005, CYTOCHROME P450 STRU, P323; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Funa N, 2005, J BIOL CHEM, V280, P14514, DOI 10.1074/jbc.M500190200; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Graziani EI, 1998, BIOORG MED CHEM LETT, V8, P3117, DOI 10.1016/S0960-894X(98)00553-8; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; Guengerich FP, 2002, BIOL CHEM, V383, P1553, DOI 10.1515/BC.2002.175; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P243; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Nagano S, 2005, J BIOL CHEM, V280, P22102, DOI 10.1074/jbc.M501732200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; OHAVER TC, 1976, ANAL CHEM, V48, P312, DOI 10.1021/ac60366a016; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SEVRIOUKOVA IF, 1995, ARCH BIOCHEM BIOPHYS, V317, P397, DOI 10.1006/abbi.1995.1180; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; Walsh C., 1979, ENZYMATIC REACTION M, P121; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhao B, 2005, J BIOL CHEM, V280, P11599, DOI 10.1074/jbc.M410933200	41	65	68	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42188	42197		10.1074/jbc.M509220200	http://dx.doi.org/10.1074/jbc.M509220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239228	hybrid			2022-12-25	WOS:000233992700047
J	Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ				Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ			AP2 alpha alters the transcriptional activity and stability of p53	ONCOGENE			English	Article						AP2 alpha; AP-2; p53; transcription; stability; p21	INVASIVE BREAST-CANCER; APOPTOTIC CELL-DEATH; FACTOR AP-2; GENE PROMOTER; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; EPITHELIAL-CELLS; DOWN-REGULATION; RETINOIC ACID; BINDING-SITE	AP2 alpha and p53 form nuclear complexes that establish a functional partnership, which regulates the expression of certain genes involved in cell growth and metastasis. The growth effects of AP2 alpha are mediated through p21(WAF1/CIP1) and the ability for AP2 alpha to coactivate p21 requires p53. Herein, we have localized the AP2-binding region of p53 to amino acids 305-375. Analysis of 26 distinct p53 alleles established a correlation between AP2a binding and transcriptional coactivation. The L350P point mutation was the only nonbinding allele that retained normal transcriptional activity by reporter assay. Although both wild-type and L350P alleles facilitated binding of AP2 alpha to the p21 promoter, the L350P allele was significantly reduced in its ability to induce the endogenous p21 gene, demonstrating a striking difference in activity comparing reporter assays with activation of endogenous p53 target genes. Interestingly, expression of AP2 in the absence of radiation repressed p53-mediated induction of p21 and this effect was explained by a reduction in p53 stability induced by AP2 alpha overexpression. We conclude that AP2 alpha has competing effects on p53 activity through coactivation and decreased stability. These findings may provide a mechanism to account for the discrepancies reported for the association between AP2 and p21 expression in tumor tissue.	Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,Room 1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu		Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila MA, 2000, BRIT J CANCER, V82, P1974; ASTROM A, 1992, J BIOL CHEM, V267, P25251; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Brokx RD, 2003, J BIOL CHEM, V278, P2327, DOI 10.1074/jbc.M208528200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Katsel PL, 2001, J BIOL CHEM, V276, P752, DOI 10.1074/jbc.M007553200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim HS, 2001, J NEUROCHEM, V76, P280, DOI 10.1046/j.1471-4159.2001.00044.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leung KM, 2002, CANCER RES, V62, P4890; Lipponen P, 2000, EUR UROL, V37, P573, DOI 10.1159/000020195; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; REN Y, 2001, J BIOL CHEM, V13, P13; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Terui T, 2003, CANCER RES, V63, P8948; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	54	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2148	2159		10.1038/sj.onc.1209250	http://dx.doi.org/10.1038/sj.onc.1209250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288208				2022-12-25	WOS:000236581200002
J	Maeda, T; Desouky, J; Friedl, A				Maeda, T; Desouky, J; Friedl, A			Syndecan-1 expression by stromal. broblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis	ONCOGENE			English	Article						tumor stroma; breast carcinoma; syndecan-1; epithelial-stromal interactions; angiogenesis	HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; EPITHELIAL MESENCHYMAL INTERACTIONS; MULTIPLE-MYELOMA; BINDING; CANCER; RECEPTORS; MATRIX; FGF	The induction of the cell surface heparan sulfate proteoglycan syndecan-1 (Sdc1) in stromal fibroblasts is observed in more than 70% of human breast carcinomas. Using a coculture model, we have recently shown that stromal cell-derived Sdc1 stimulates carcinoma cell proliferation in vitro, and that this activity requires Sdc1 glycanation. In the present study, we investigated the effect of stromal cell Sdc1 on breast carcinoma growth in vivo. MDA-MB-231 human breast carcinoma cells were inoculated into the flanks of athymic nude mice either alone, or as mixed suspensions with Sdc1-transfected or mock-transfected 3T3 mouse fibroblasts. The mixed tumors showed an intimate association between carcinoma cells and stromal fibroblasts and histologically closely resembled poorly differentiated human breast carcinomas. The presence of fibroblasts led to significantly accelerated tumor growth, which was further augmented (88% increase) by forced expression of stromal Sdc1. The hyperemic macroscopic appearance of tumors containing Sdc1-positive stromal cells contrasted with pale tumors developing in the presence of mock-transfected fibroblasts, which prompted us to examine tumor microvessels. Stromal Sdc1 expression was associated with a significantly elevated microvessel density (36% increase) and a larger vessel area (153% increase). To evaluate the relevance of this finding in human breast cancer, the relationship between stromal Sdc1 and tumor vascularity was also examined in a tissue array containing 207 human breast carcinoma samples. Similar to the xenografts, stromal Sdc1 expression correlated with both vessel density (P = 0.013) and total vessel area (P = 0.0026). In conclusion, stromal fibroblast-derived Sdc1 stimulates breast carcinoma growth and angiogenesis in vivo.	Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA.	afriedl@wisc.edu			NATIONAL CANCER INSTITUTE [P30CA014520, R01CA107012] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA107012, CA14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Burbach BJ, 2004, EXP CELL RES, V300, P234, DOI 10.1016/j.yexcr.2004.07.001; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Friedl A, 2001, Methods Mol Biol, V171, P535; Ito Y, 2003, HISTOPATHOLOGY, V43, P157, DOI 10.1046/j.1365-2559.2003.01656.x; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Mukunyadzi P, 2003, MODERN PATHOL, V16, P796, DOI 10.1097/01.MP.0000081731.17549.53; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Radisky D, 2002, CANCER INVEST, V20, P139, DOI 10.1081/CNV-120000374; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Weaver VM, 2004, J CELL SCI, V117, P1287, DOI 10.1242/jcs.01137; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610	29	115	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1408	1412		10.1038/sj.onc.1209168	http://dx.doi.org/10.1038/sj.onc.1209168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247452				2022-12-25	WOS:000235708200014
J	de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T				de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T			Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer?	ONCOGENE			English	Article						LOH; HNPCC; MMR	MISMATCH REPAIR DEFICIENCY; HMLH1 PROMOTER; MICROSATELLITE INSTABILITY; COLON-CANCER; GERMLINE MUTATIONS; CELL-LINES; TUMORS; HYPERMETHYLATION; MLH1; INACTIVATION	hMLH1 and hMSH2 can be considered tumor suppressor genes, as both alleles must be inactivated in order to lose the mismatch repair (MMR) function. In this regard, it has been proposed that LOH at MMR loci is a common Knudson's second-hit mechanism in HNPCC patients. However, experimental evidence supporting this view is scarcely found in the literature. We have performed a comprehensive analysis of LOH in 45 HNPCC tumors carrying a germline alteration in MMR loci. Overall, we have detected LOH at MMR loci in 56% of the cases. However, up to 40% of the LOH events targeted the mutant allele, arguing against a second-hit role in these tumors. Interestingly, the age at diagnosis was significantly older in these patients. To explain this and previous data, we propose a dual role for LOH at MMR loci in HNPCC.	Hosp Clin San Carlos, Oncol Mol Lab, E-28040 Madrid, Spain; Leiden Univ Ctr, Dept Pathol, Leiden, Netherlands; Hosp Clin San Carlos, Dept Clin Oncol, Madrid, Spain	Hospital Clinico San Carlos; Leiden University; Leiden University - Excl LUMC; Hospital Clinico San Carlos	Caldes, T (corresponding author), Hosp Clin San Carlos, Oncol Mol Lab, Martin Lagos S-N, E-28040 Madrid, Spain.	tcaldes@hcsc.es	de la Hoya, MIguel/Z-2911-2019; Godino, Javier/M-3753-2018	Godino, Javier/0000-0002-5653-2722; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Ahuja N, 1998, CANCER RES, V58, P5489; Caldes T, 2002, INT J CANCER, V98, P774, DOI 10.1002/ijc.10240; Cunningham JM, 1998, CANCER RES, V58, P3455; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; de la Hoya M, 1999, CLIN CHEM, V45, P2028; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 1999, J MED GENET, V36, P801; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Osorio A, 2002, INT J CANCER, V99, P305, DOI 10.1002/ijc.10337; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	24	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2124	2130		10.1038/sj.onc.1209233	http://dx.doi.org/10.1038/sj.onc.1209233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288214				2022-12-25	WOS:000236359700016
J	Radhakrishnan, SK; Gierut, J; Gartel, AL				Radhakrishnan, SK; Gierut, J; Gartel, AL			Multiple alternate p21 transcripts are regulated by p53 in human cells	ONCOGENE			English	Article						p21; alternate transcript; p53; basal transcription	CANCER CELLS; EXPRESSION; PUMA; P21(WAF1/CIP1); APOPTOSIS; STABILITY; MEDIATOR; PROMOTER; BINDING; GENE	The p53 tumor-suppressor is a transcription factor that is stabilized in response to cellular stress leading to growth arrest or apoptosis. p21(WAF1/CIP1) is a major transcriptional target of p53 and it plays a critical role in p53-dependent cell cycle arrest. In this study, we identified multiple alternate human p21 transcripts that have their transcriptional start sites in the direct proximity of the distal p53 response element. These transcripts are upregulated as a result of DNA damage-induced p53 activation. Furthermore, the basal expression of these alternate transcripts is strongly regulated by p53 and they are undetectable in p53-knocked down cells. This is in contrast to classical p21 transcripts, which have reduced, albeit detectable expression levels in the absence of p53. The existence of the alternate transcripts underscores the complexity of the human p21 genomic locus and opens up new avenues for further investigation.	Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498	NCI NIH HHS [CA91146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Chen B, 2000, CANCER RES, V60, P3290; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 2004, ONCOGENE, V23, P8154, DOI 10.1038/sj.onc.1207820; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	23	32	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1812	1815		10.1038/sj.onc.1209195	http://dx.doi.org/10.1038/sj.onc.1209195			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261158				2022-12-25	WOS:000236013700013
J	Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK				Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK			Merlin facilitates ubiquitination and degradation of transactivation-responsive RNA-binding protein	ONCOGENE			English	Article						Nf2; merlin; tarbp2; TRBP; ubiquitination; degradation	NF2 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GROWTH SUPPRESSION; UNITED-KINGDOM; ERM PROTEINS; GENE-PRODUCT; KINASE PKR; PHOSPHORYLATION; DOMAIN; TRBP	The Nf2 tumor suppressor codes for merlin, a protein whose function is largely unknown. We have previously demonstrated a novel interaction between merlin and TRBP, which inhibits the oncogenic activity of TRBP. In spite of the significance of their functional interaction, its molecular mechanism still remains to be elucidated. In this report, we investigated how merlin inhibits the oncogenic activity of TRBP in association with cell growth conditions. In the human embryonic kidney 293 cell line, the level of endogenous merlin increased, whereas that of endogenous TRBP significantly decreased along with the increase in cell confluence. We demonstrated that the carboxyl-terminal region of TRBP was responsible for this phenomenon using stable cell lines expressing deletion mutants of TRBP. The overexpression of merlin decreased the protein level of TRBP, and the ubiquitin-like subdomain of merlin's FERM domain was important for this activity. We also demonstrated that TRBP is ubiquitinylated and the ubiquitinylated forms of TRBP are accumulated by ectopically expressed merlin or cell confluence in the presence of MG132, a proteasome inhibitor. Furthermore, we showed that the regulation of TRBP in response to cell confluence was abolished upon knockdown of merlin expression by specific small interfering RNA. Finally, we showed that ectopically expressed merlin restored cell-cell contact inhibition in cells stably expressing TRBP but not in TRBP Delta c. These results suggest that merlin is involved in the regulation of TRBP protein level by facilitating its ubiquitination in response to such cues as cell-cell contacts.	Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul, South Korea; Catholic Univ Korea, Dept Biomed Sci, Seoul, South Korea; Catholic Univ Korea, Dept Orthoped Surg, Seoul, South Korea; Catholic Univ Korea, Dept Psychiat, Seoul, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul, South Korea; Duke Univ, Durham, NC USA; Catholic Univ Korea, Dept Neurosurg, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Duke University; Catholic University of Korea	Kim, YH (corresponding author), Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, 4011,505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr		Chun, Heung Jae/0000-0002-0446-9901				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee RB, 1996, IEEE MICRO, V16, P6, DOI 10.1109/MM.1996.526920; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	35	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1143	1152		10.1038/sj.onc.1209150	http://dx.doi.org/10.1038/sj.onc.1209150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247459				2022-12-25	WOS:000235537500002
J	Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M				Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M			Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3 '-untranslated region interacting with a cellular protein in human chondrosarcoma cells	ONCOGENE			English	Article						hypoxia; connective tissue growth factor; CCN family; mRNA stability; 3 '-UTR; post-transcriptional regulation	VASCULAR ENDOTHELIAL-CELLS; INDUCIBLE FACTOR-I; GENE-EXPRESSION; CTGF/HCS24 GENE; RICH SEQUENCE; BINDING; ANGIOGENESIS; IDENTIFICATION; ELEMENT; VITRO	Connective tissue growth factor (CTGF/CCN2) can be induced by various forms of stress such as exposure to high glucose, mechanical load, or hypoxia. Here, we investigated the molecular mechanism involved in the induction of ctgf/ccn2 by hypoxia in a human chondrosarcoma cell line, HCS-2/8. Hypoxia increased the ctgf/ccn2 mRNA level by altering the 3'-untranslated region (UTR)-mediated mRNA stability without requiring de novo protein synthesis. After a series of extensive analyses, we eventually found that the cis-repressive element of 84 bases within the 3'-UTR specifically bound to a cytoplasmic/nuclear protein. By conducting a UV crosslinking assay, we found the cytoplasmic/nuclear protein to be a 35 kDa molecule that bound to the cis-element in a hypoxia-inducible manner. These results suggest that a cis-element in the 3'-UTR of ctgf/ccn2 mRNA and trans-factor counterpart(s) play an important role in the post-transcriptional regulation by determining the stability of ctgf/ccn2 mRNA.	Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Oral & Maxillofacial Reconstruct Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Nichirei Corp, Biosci Business Div, Chuo Ku, Tokyo, Japan	Okayama University; Okayama University; Nichirei Corporation	Takigawa, M (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	takigawa@md.okayama-u.ac.jp	Kondo, Seiji/ABD-3982-2020; Kondo, Seiji/I-4332-2017; Mukudai, Yoshiki/L-4459-2019	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Mukudai, Yoshiki/0000-0002-9600-4430				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eguchi T, 2001, J BIOCHEM, V130, P79, DOI 10.1093/oxfordjournals.jbchem.a002965; FAN XC, 1998, P NATL ACAD SCI US, V95; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kubota S, 2000, ONCOGENE, V19, P4773, DOI 10.1038/sj.onc.1203835; Kubota S, 2005, FEBS LETT, V579, P3751, DOI 10.1016/j.febslet.2005.05.068; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kubota S, 2003, BONE, V33, P694, DOI 10.1016/S8756-3282(03)00227-8; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Kunz M, 2003, J BIOL CHEM, V278, P45651, DOI 10.1074/jbc.M301373200; KUNZ M, 2003, MOL CANCER, V2, P1, DOI DOI 10.1186/1476-4598-2-1.PUBMED:12537587; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Mukudai Y, 2005, J BIOL CHEM, V280, P3166, DOI 10.1074/jbc.M411632200; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Shih SC, 1998, INT J EXP PATHOL, V79, P347, DOI 10.1046/j.1365-2613.1998.00088.x; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; TAKIGAWA M, 1989, CANCER RES, V49, P3996; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1099	1110		10.1038/sj.onc.1209129	http://dx.doi.org/10.1038/sj.onc.1209129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247469				2022-12-25	WOS:000235361000014
J	Heimlich, G; Cidlowski, JA				Heimlich, G; Cidlowski, JA			Selective role of intracellular chloride in the regulation of the intrinsic but not extrinsic pathway of apoptosis in Jurkat T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-INDUCED APOPTOSIS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; VOLUME DECREASE; JNK ACTIVATION; JUN KINASE; CL-CHANNEL; DEATH; K+; POTASSIUM	Apoptosis is a genetic program for the removal of unwanted cells from an organism, which is distinct from necrosis by its characteristic volume loss or apoptotic volume decrease. This cell shrinkage is the result of ion redistribution that is crucial for both the activation and execution of apoptosis. Here we report that UV-C but not Fas ligand treatment results in a significant decrease in intracellular chloride that can be abolished by modulation of chloride flux using either the chloride channel inhibitor SITS or medium with a reduced chloride concentration. Accordingly, downstream events are diminished during UV-C-induced apoptosis following chloride flux modulation, whereas Fas ligand-induced apoptotic characteristics are not affected. Moreover, the activation of the mitogen-activated protein kinase signal transduction pathway early in the apoptotic signaling cascade was affected by chloride flux in Jurkat T-cells. Thus, an alteration of intracellular chloride plays an important role in the activation of signaling molecules upstream of the mitochondria, specifically impairing the intrinsic but not extrinsic apoptotic pathway.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlows1@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090057, ZIAES090079, Z01ES090079, Z01ES090057] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; AULL F, 1979, BIOCHIM BIOPHYS ACTA, V554, P538, DOI 10.1016/0005-2736(79)90390-0; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; Bortner CD, 2003, J BIOL CHEM, V278, P39176, DOI 10.1074/jbc.M303516200; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BUTT AG, 1994, J MEMBRANE BIOL, V142, P9; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; FINE DM, 1995, J MEMBRANE BIOL, V145, P129; Fujita H, 1999, CELL BIOL INT, V23, P241, DOI 10.1006/cbir.1999.0342; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gao J, 2004, EXP CELL RES, V297, P461, DOI 10.1016/j.yexcr.2004.03.047; Gomez-Angelats M, 2002, TOXICOL PATHOL, V30, P541, DOI 10.1080/01926230290105820; Hughes FM, 1999, ADV ENZYME REGUL, V39, P157, DOI 10.1016/S0065-2571(98)00010-7; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inglefield JR, 1999, METHODS, V18, P197, DOI 10.1006/meth.1999.0772; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAMBERT A, 1978, J PHYSIOL-LONDON, V275, P51, DOI 10.1113/jphysiol.1978.sp012177; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; MACVINISH LJ, 1993, BRIT J PHARMACOL, V108, P469, DOI 10.1111/j.1476-5381.1993.tb12827.x; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Nietsch HH, 2000, J BIOL CHEM, V275, P20556, DOI 10.1074/jbc.M002535200; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Pilas B, 1997, CYTOMETRY, V28, P316, DOI 10.1002/(SICI)1097-0320(19970801)28:4<316::AID-CYTO7>3.3.CO;2-J; Porcelli AM, 2004, CELL DEATH DIFFER, V11, P655, DOI 10.1038/sj.cdd.4401396; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Scoltock AB, 2004, EXP CELL RES, V297, P212, DOI 10.1016/j.yexcr.2004.03.025; Shimizu T, 2004, P NATL ACAD SCI USA, V101, P6770, DOI 10.1073/pnas.0401604101; Small DL, 2002, NEUROSCI LETT, V334, P95, DOI 10.1016/S0304-3940(02)01107-2; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Takeuchi S, 1997, HEARING RES, V113, P99, DOI 10.1016/S0378-5955(97)00134-2; Tanabe S, 2005, FEBS LETT, V579, P517, DOI 10.1016/j.febslet.2004.12.020; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Vu CCQ, 2001, J BIOL CHEM, V276, P37602, DOI 10.1074/jbc.M104810200; Woll E, 1996, PFLUG ARCH EUR J PHY, V432, P486, DOI 10.1007/s004240050160; Zhou JG, 2005, J BIOL CHEM, V280, P7301, DOI 10.1074/jbc.M412813200	45	53	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2232	2241		10.1074/jbc.M507367200	http://dx.doi.org/10.1074/jbc.M507367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16299378	hybrid			2022-12-25	WOS:000234760400047
J	Furuki, S; Tamura, S; Matsumoto, N; Miyata, N; Moser, A; Moser, HW; Fujiki, Y				Furuki, S; Tamura, S; Matsumoto, N; Miyata, N; Moser, A; Moser, HW; Fujiki, Y			Mutations in the peroxin Pex26p responsible for peroxisome biogenesis disorders of complementation group 8 impair its stability, peroxisomal localization, and interaction with the Pex1p center dot Pex6p complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE ZELLWEGER-SYNDROME; CELL MUTANTS; FUNCTIONAL COMPLEMENTATION; PTS1 RECEPTOR; HUMAN PEX1; GENE; PHENOTYPES; SPECTRUM; IMPORT	Peroxisome biogenesis disorders (PBDs) are fatal autosomal recessive diseases and are caused by impaired peroxisome biogenesis. PBDs are genetically heterogeneous and classified into 13 complementation groups (CGs). CG8 is one of the most common groups and has three clinical phenotypes, including Zellweger syndrome (ZS), neonatal adrenoleukodystrophy, and infantile Refsum disease (IRD). We recently isolated PEX26 as the pathogenic gene for PBD of CG8. Pex26p functions in recruiting to peroxisomes the complexes of the AAA ATPase peroxins, Pex1p and Pex6p. In the present work, we identified four distinct mutations in PEX26 from five patients of CG8 PBD including 2 with ZS and 3 with IRD, in addition to 7 mutant alleles in 8 patients in the first report describing the pathogenic PEX26 gene for CG8 PBD. Phenotype-genotype analyses revealed that temperature-sensitive (ts) peroxisome assembly gave rise to a milder IRD in contrast to the non-ts phenotype of the cells from ZS patients. Furthermore, we present several lines of evidence that show that the instability, insufficient binding to Pex1p(.)Pex6p complexes, or mislocalization of patient-derived Pex26p mutants is most likely responsible for the CG8 PBDs.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, Fukuoka 8128581, Japan; Johns Hopkins Univ, Kennedy Krieger Inst, Dept Neurol & Pediat, Baltimore, MD 21205 USA; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Johns Hopkins University; Kennedy Krieger Institute; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp	Matsumoto, Naomi/AAD-3468-2022; Matsumoto, Naomi/AFL-4833-2022		NCRR NIH HHS [RR 00052] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Crane DI, 2005, HUM MUTAT, V26, P167, DOI 10.1002/humu.20211; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Ghaedi K, 2000, AM J HUM GENET, V67, P976, DOI 10.1086/303086; Ghaedi K, 1999, EXP CELL RES, V248, P482, DOI 10.1006/excr.1999.4412; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Matsumoto N, 2003, AM J HUM GENET, V73, P233, DOI 10.1086/377004; Matsumoto N, 2001, J HUM GENET, V46, P273, DOI 10.1007/s100380170078; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 2004, HUM MUTAT, V23, P552, DOI 10.1002/humu.20032; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; Steinberg S, 2004, MOL GENET METAB, V83, P252, DOI 10.1016/j.ymgme.2004.08.008; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tamura S, 2001, BIOCHEM J, V357, P417, DOI 10.1042/0264-6021:3570417; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Walter C, 2001, AM J HUM GENET, V69, P35, DOI 10.1086/321265; Weller S, 2005, AM J HUM GENET, V76, P987, DOI 10.1086/430637; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	25	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1317	1323		10.1074/jbc.M510044200	http://dx.doi.org/10.1074/jbc.M510044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16257970	hybrid			2022-12-25	WOS:000234652000005
J	Giorgione, JR; Lin, JH; McCammon, JA; Newton, AC				Giorgione, JR; Lin, JH; McCammon, JA; Newton, AC			Increased membrane affinity of the C1 domain of protein kinase C delta compensates for the lack of involvement of its C2 domain in membrane recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; TARGETING MODULES; INDUCED APOPTOSIS; OXIDATIVE STRESS; PHORBOL ESTERS; BINDING; ACTIVATION; PHOSPHATIDYLSERINE; PHOSPHORYLATION; TRANSLOCATION	Protein kinase C (PKC) family members are allosterically activated following membrane recruitment by specific membrane-targeting modules. Conventional PKC isozymes are recruited to membranes by two such modules: a C1 domain, which binds diacylglycerol (DAG), and a C2 domain, which is a Ca2+-triggered phospholipid-binding module. In contrast, novel PKC isozymes respond only to DAG, despite the presence of a C2 domain. Here, we address the molecular mechanism of membrane recruitment of the novel isozyme PKC delta. We show that PKC delta and a conventional isozyme, PKC beta II, bind membranes with comparable affinities. However, dissection of the contribution of individual domains to this binding revealed that, although the C2 domain is a major determinant in driving the interaction of PKC beta II with membranes, the C2 domain of PKC delta does not bind membranes. Instead, the C1B domain is the determinant that drives the interaction of PKC delta with membranes. The C2 domain also does not play any detectable role in the activity or subcellular location of PKC delta in cells; in vivo imaging studies revealed that deletion of the C2 domain does not affect the stimulus-dependent translocation or activity of PKC delta. Thus, the increased affinity of the C1 domain of PKC delta allows this isozyme to respond to DAG alone, whereas conventional PKC isozymes require the coordinated action of Ca2+ binding to the C2 domain and DAG binding to the C1 domain for activation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, Leichtag 282,9500 Gilman Dr, La Jolla, CA 92093 USA.	anewton@ucsd.edu	Lin, Jung-Hsin/T-7390-2019; Lin, Jung-Hsin/B-7512-2012; McCammon, J. Andrew/AAG-1832-2021	Lin, Jung-Hsin/0000-0002-6712-4994; 	NIGMS NIH HHS [R37 GM043154, R01 GM043154-11, GM 43154, R01 GM043154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Braun DC, 2005, MOL CANCER THER, V4, P141; Corbalan-Garcia S, 2003, BIOCHEMISTRY-US, V42, P11661, DOI 10.1021/bi034850d; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Giorgione J, 2003, BIOCHEMISTRY-US, V42, P11194, DOI 10.1021/bi0350046; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Hurley JH, 1997, PROTEIN SCI, V6, P477; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lin JH, 2004, BIOPHYS J, V86, p371A; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rybin VO, 2004, J BIOL CHEM, V279, P19350, DOI 10.1074/jbc.M311096200; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang QMJ, 2004, MOL CANCER RES, V2, P129; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	43	89	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1660	1669		10.1074/jbc.M510251200	http://dx.doi.org/10.1074/jbc.M510251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293612	Green Accepted, hybrid			2022-12-25	WOS:000234652000046
J	Mortier, E; Quemener, A; Vusio, P; Lorenzen, I; Boublik, Y; Grotzinger, J; Plet, A; Jacques, Y				Mortier, E; Quemener, A; Vusio, P; Lorenzen, I; Boublik, Y; Grotzinger, J; Plet, A; Jacques, Y			Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma - Hyperagonist IL-15 center dot IL-15R alpha fusion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ALPHA-CHAIN; NATURAL-KILLER-CELLS; GAMMA-CHAIN; BETA-CHAIN; T-CELLS; INTERLEUKIN (IL)-15; GROWTH-FACTOR; FORM; CYTOKINE; IL-15R-ALPHA	Interleukin-15 (IL-15) is crucial for the generation of multiple lymphocyte subsets (natural killer (NK), NK-T cells, and memory CD8 T cells), and transpresentation of IL-15 by monocytes and dendritic cells has been suggested to be the dominant activating process of these lymphocytes. We have previously shown that a natural soluble form of IL-15R alpha chain corresponding to the entire extracellular domain of IL-15R alpha behaves as a high affinity IL-15 antagonist. In sharp contrast with this finding, we demonstrate in this report that a recombinant, soluble sushi domain of IL-15R alpha, which bears most of the binding affinity for IL-15, behaves as a potent IL-15 agonist by enhancing its binding and biological effects (proliferation and protection from apoptosis) through the IL-15R beta/gamma heterodimer, whereas it does not affect IL-15 binding and function of the tripartite IL-15R alpha/beta/gamma membrane receptor. Our results suggest that, if naturally produced, such soluble sushi domains might be involved in the IL-15 transpresentation mechanism. Fusion proteins (RLI and ILR), in which IL-15 and IL-15R alpha-sushi are attached by a flexible linker, are even more potent than the combination of IL-15 plus sIL-15R alpha-sushi. After binding to IL-15R beta/gamma, RLI is internalized and induces a biological response very similar to the IL-15 high affinity response. Such hyper-IL-15 fusion proteins appear to constitute potent adjuvants for the expansion of lymphocyte subsets.	INSERM, Grp Rech Cytokines & Recepteurs, Inst Biol, U601, F-44093 Nantes 01, France; Univ Nantes, Inst Biol, Unite Format & Rech Med, IFR 26, F-44093 Nantes, France; Univ Kiel, D-24098 Kiel, Germany; CNRS, Ctr Rech Biochim Macromol, FRE 2593, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; University of Kiel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Jacques, Y (corresponding author), INSERM, Grp Rech Cytokines & Recepteurs, Inst Biol, U601, 9 Quai Moncousu, F-44093 Nantes 01, France.	yjacques@nantes.inserm.fr	Mortier, Erwan/AAH-7925-2021; Mortier, Erwan/B-2189-2009; QUEMENER, Agnès/R-9489-2019	QUEMENER, Agnès/0000-0002-4026-8496; Mortier, Erwan/0000-0002-6321-6488				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200; Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045; Burkett PR, 2003, P NATL ACAD SCI USA, V100, P4724, DOI 10.1073/pnas.0737048100; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Farner NL, 1997, CYTOKINE, V9, P316, DOI 10.1006/cyto.1996.0171; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Giron-Michel J, 2005, BLOOD, V106, P2302, DOI 10.1182/blood-2005-01-0064; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; HORI T, 1987, BLOOD, V70, P1069; Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kobayashi H, 2005, BLOOD, V105, P721, DOI 10.1182/blood-2003-12-4187; Koka R, 2003, J EXP MED, V197, P977, DOI 10.1084/jem.20021836; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253; Lodolce JP, 2001, J EXP MED, V194, P1187, DOI 10.1084/jem.194.8.1187; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Matsumoto M, 2003, PROTEIN EXPRES PURIF, V31, P64, DOI 10.1016/S1046-5928(03)00143-8; Meazza R, 1998, INT J CANCER, V78, P189, DOI 10.1002/(SICI)1097-0215(19981005)78:2<189::AID-IJC12>3.0.CO;2-6; Meissner U, 2001, BLOOD, V97, P183; Mortier E, 2004, J IMMUNOL, V173, P1681, DOI 10.4049/jimmunol.173.3.1681; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Pflanz S, 1999, FEBS LETT, V450, P117, DOI 10.1016/S0014-5793(99)00477-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Ruchatz H, 1998, J IMMUNOL, V160, P5654; Sandau MM, 2004, J IMMUNOL, V173, P6537, DOI 10.4049/jimmunol.173.11.6537; Schluns KS, 2004, P NATL ACAD SCI USA, V101, P5616, DOI 10.1073/pnas.0307442101; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sheu BC, 2001, CANCER RES, V61, P237; Smith XG, 2000, J IMMUNOL, V165, P3444, DOI 10.4049/jimmunol.165.6.3444; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255	41	210	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1612	1619		10.1074/jbc.M508624200	http://dx.doi.org/10.1074/jbc.M508624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16284400	hybrid			2022-12-25	WOS:000234652000040
J	Hermans, PWM; Adrian, PV; Albert, C; Estevao, S; Hoogenboezem, T; Luijendijk, IHT; Kamphausen, T; Hammerschmidt, S				Hermans, PWM; Adrian, PV; Albert, C; Estevao, S; Hoogenboezem, T; Luijendijk, IHT; Kamphausen, T; Hammerschmidt, S			The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION PROTEIN-A; MIP-LIKE PROTEIN; SURFACE PROTEIN; LEGIONELLA-PNEUMOPHILA; CHLAMYDIA-TRACHOMATIS; BACILLUS-SUBTILIS; EPITHELIAL-CELLS; BINDING PROTEIN; ALPHA-ENOLASE; INTRACELLULAR INFECTION	Streptococcus pneumoniae expresses two surface-exposed lipoproteins, PpmA and SlrA, which share homology with distinct families of peptidyl-prolyl isomerases (PPIases). In this study, we demonstrated for the first time that the lipoprotein cyclophilin, SlrA, can catalyze the cis-trans isomerization of proline containing tetrapeptides and that SlrA contributes to pneumococcal colonization. The substrate specificity of SlrA is typical for prokaryotic and eukaryotic cyclophilins, with Suc-Ala-Ala-Pro- Phe-p-nitroanilide (pNA) being the most rapidly catalyzed substrate. In a mouse pneumonia model the slrA knock-out D39 Delta slrA did not cause significant differences in the survival times of mice compared with the isogenic wild-type strain. In contrast, a detailed analysis of bacterial outgrowth over time in the nasopharynx, airways, lungs, blood, and spleen showed a rapid elimination of slrA mutants from the upper airways but did not reveal significant differences in the lungs, blood, and spleen. These results suggested that SlrA is involved in colonization but does not contribute significantly to invasive pneumococcal disease. In cell culture infection experiments, the absence of SlrA impaired adherence to pneumococcal disease-specific epithelial and endothelial non-professional cell lines. Adherence of the slrA mutant could not be restored by exogenously added SlrA. Strikingly, deficiency in SlrA did not reduce binding activity to host target proteins, but resulted in enhanced uptake by professional phagocytes. In conclusion, SlrA is a functional, cyclophilin-type PPIase and contributes to pneumococcal virulence in the first stage of infection, namely, colonization of the upper airways, most likely by modulating the biological function of important virulence proteins.	Univ Med Ctr St Radboud, Lab Pediat Infect Dis, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat, NL-3000 DR Rotterdam, Netherlands; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle Saale, Germany	Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; University of Wurzburg; Max Planck Society	Hermans, PWM (corresponding author), Univ Med Ctr St Radboud, Lab Pediat Infect Dis, Dept Pediat, POB 9101,Internal Post 184, NL-6500 HB Nijmegen, Netherlands.	p.hermans@cukz.umcn.nl	Hermans, Peter W.M./H-8042-2014; Hermans, Peter P.W.M./F-4655-2010; Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681				Adrian PV, 2004, VACCINE, V22, P2737, DOI 10.1016/j.vaccine.2004.01.042; Adrian PV, 2000, ANTIMICROB AGENTS CH, V44, P355, DOI 10.1128/AAC.44.2.355-361.2000; ALEXANDER JE, 1994, INFECT IMMUN, V62, P5683, DOI 10.1128/IAI.62.12.5683-5688.1994; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; Benton KA, 1997, MICROB PATHOGENESIS, V23, P201, DOI 10.1006/mpat.1997.0150; Bergmann S, 2005, THROMB HAEMOSTASIS, V94, P304, DOI 10.1160/TH05-05-0369; Bergmann S, 2004, INFECT IMMUN, V72, P2416, DOI 10.1128/IAI.72.4.2416-2419.2004; Bergmann S, 2003, MOL MICROBIOL, V49, P411, DOI 10.1046/j.1365-2958.2003.03557.x; Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Cavarec L, 2002, J BIOL CHEM, V277, P41171, DOI 10.1074/jbc.M203757200; CIANCIOTTO NP, 1995, CURR MICROBIOL, V30, P247, DOI 10.1007/BF00293641; CIANCIOTTO NP, 1989, INFECT IMMUN, V57, P1255, DOI 10.1128/IAI.57.4.1255-1262.1989; CIANCIOTTO NP, 1992, P NATL ACAD SCI USA, V89, P5188, DOI 10.1073/pnas.89.11.5188; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; Drouault S, 2002, APPL ENVIRON MICROB, V68, P3932, DOI 10.1128/AEM.68.8.3932-3942.2002; Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002; Eberhard T, 1999, MICROB PATHOGENESIS, V26, P175, DOI 10.1006/mpat.1998.0262; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Hammerschmidt S, 1999, INFECT IMMUN, V67, P1683; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Holmes AR, 2001, MOL MICROBIOL, V41, P1395, DOI 10.1046/j.1365-2958.2001.02610.x; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; Iannelli F, 2004, INFECT IMMUN, V72, P3077, DOI 10.1128/IAI.72.5.3077-3080.2004; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; Kerr AR, 2002, INFECT IMMUN, V70, P1547, DOI 10.1128/IAI.70.3.1547-1557.2002; Kohler R, 2003, INFECT IMMUN, V71, P4389, DOI 10.1128/IAI.71.8.4389-4397.2003; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KONTINEN VP, 1991, MOL MICROBIOL, V5, P1273, DOI 10.1111/j.1365-2958.1991.tb01901.x; KOSTRZYNSKA M, 1992, ZBL BAKT-INT J MED M, V277, P80; LUNDEMOSE AG, 1992, MOL MICROBIOL, V6, P2539; LUNDEMOSE AG, 1993, MOL MICROBIOL, V7, P777, DOI 10.1111/j.1365-2958.1993.tb01168.x; Lyon WR, 1998, EMBO J, V17, P6263, DOI 10.1093/emboj/17.21.6263; Manteca A, 2004, FEBS LETT, V572, P19, DOI 10.1016/j.febslet.2004.06.091; Marra A, 2002, MICROBIOL-SGM, V148, P1483, DOI 10.1099/00221287-148-5-1483; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; MO YY, 1995, MICROBIOL-SGM, V141, P2861, DOI 10.1099/13500872-141-11-2861; MORO A, 1995, EMBO J, V14, P2483, DOI 10.1002/j.1460-2075.1995.tb07245.x; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; Overweg K, 2000, INFECT IMMUN, V68, P4180, DOI 10.1128/IAI.68.7.4180-4188.2000; Overweg K, 2000, INFECT IMMUN, V68, P4604, DOI 10.1128/IAI.68.8.4604-4610.2000; Pracht D, 2005, INFECT IMMUN, V73, P2680, DOI 10.1128/IAI.73.5.2680-2689.2005; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Rockey DD, 1996, MICROBIOL-UK, V142, P945, DOI 10.1099/00221287-142-4-945; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Shaper M, 2004, INFECT IMMUN, V72, P5031, DOI 10.1128/IAI.72.9.5031-5040.2004; TRIEUCUOT P, 1990, NUCLEIC ACIDS RES, V18, P3660, DOI 10.1093/nar/18.12.3660; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; VANDERFLIER M, 1995, INFECT IMMUN, V63, P4317, DOI 10.1128/IAI.63.11.4317-4322.1995; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WINTERMEYER E, 1995, INFECT IMMUN, V63, P4576, DOI 10.1128/IAI.63.12.4576-4583.1995; Wu HY, 1997, MICROB PATHOGENESIS, V23, P127, DOI 10.1006/mpat.1997.0142; YOTHER J, 1992, J BACTERIOL, V174, P601, DOI 10.1128/jb.174.2.601-609.1992; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	71	92	100	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					968	976		10.1074/jbc.M510014200	http://dx.doi.org/10.1074/jbc.M510014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16260779	hybrid, Green Published			2022-12-25	WOS:000234447200036
J	Arulanantham, H; Kershaw, NJ; Hewitson, KS; Hughes, CE; Thirkettle, JE; Schofield, CJ				Arulanantham, H; Kershaw, NJ; Hewitson, KS; Hughes, CE; Thirkettle, JE; Schofield, CJ			ORF17 from the clavulanic acid biosynthesis gene cluster catalyzes the ATP-dependent formation of N-glycyl-clavaminic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM SYNTHETASE; CARBAMOYL-PHOSPHATE SYNTHETASE; RAY CRYSTAL-STRUCTURE; D-ALANYL PHOSPHATE; STREPTOMYCES-CLAVULIGERUS; FUNCTIONAL-ANALYSIS; D-ALANINE; ORNITHINE ACETYLTRANSFERASE; AMIDINO HYDROLASE; BINDING-SITE	(3R,5R)-Clavulanic acid, a clinically used inhibitor of serine beta-lactamases, is produced by fermentation of Streptomyces clavuligerus. The early steps in clavulanic acid biosynthesis leading to the bicyclic beta-lactam intermediate (3S,5S)-clavaminic acid have been defined. However, the mechanism by which (3S,5S)-clavaminic acid is converted to the penultimate intermediate (3R,5R)-clavaldehyde is unclear. Disruption of orf15 or orf16, of the clavulanic acid biosynthesis gene cluster, blocks clavulanic acid production and leads to the accumulation of N-acetyl-glycyl-clavaminic acid and N-glycylclavaminic acid, suggesting that these compounds are intermediates in the pathway. Two alternative start codons have been proposed for orf17 to encode for two possible polypeptides, one of which has 92 N-terminal residues less then the other. The shorter version of orf17 was successfully expressed in Escherichia coli and purified as a monomeric protein. Sequence analyses predicting the ORF17 protein to be a member of the ATP-grasp fold superfamily were supported by soft ionization mass spectrometric analyses that demonstrated binding of ATP to the ORF17 protein. Semisynthetic clavaminic acid, prepared by in vitro reconstitution of the biosynthetic pathway from the synthetically accessible intermediate proclavaminic acid, was shown by mass spectrometric analyses to be converted to N-glycyl-clavaminic acid in the presence of ORF17, ATP, and glycine. Under the same conditions N-acetyl-glycine and clavaminic acid were not converted to N-acetyl-glycyl-clavaminic acid. The specificity of ORF17 as an N-glycyl-clavaminic acid synthetase, together with the reported accumulation of N-glycyl-clavaminic acid in orf15 and orf16 disruption mutants, suggested that N-glycyl-clavaminic acid is an intermediate in clavulanic acid biosynthesis.	Univ Oxford, Dept Chem, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England; GlaxoSmithKline Pharmaceut, Worthing BN14 8QH, W Sussex, England	University of Oxford; University of Oxford; GlaxoSmithKline	Schofield, CJ (corresponding author), Univ Oxford, Dept Chem, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chem.ox.ac.uk	Kershaw, Nadia/G-5770-2014	Schofield, Christopher/0000-0002-0290-6565; Kershaw, Nadia/0000-0002-3554-2622				AIDOO KA, 1994, GENE, V147, P41, DOI 10.1016/0378-1119(94)90036-1; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; Baggaley KH, 1997, NAT PROD REP, V14, P309, DOI 10.1039/np9971400309; BALDWIN JE, 1991, TETRAHEDRON, V47, P4089, DOI 10.1016/S0040-4020(01)86446-2; BALDWIN JE, 1990, J CHEM SOC CHEM COMM, P617, DOI 10.1039/c39900000617; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; BROWN AG, 1976, J ANTIBIOT, V29, P668, DOI 10.7164/antibiotics.29.668; BUSBY RW, 1995, J BIOL CHEM, V270, P4262, DOI 10.1074/jbc.270.9.4262; Caines MEC, 2004, J BIOL CHEM, V279, P5685, DOI 10.1074/jbc.M310803200; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; Cooper R. A., 1969, METHOD ENZYMOL, V13, P309; DeLano WL, 2005, DRUG DISCOV TODAY, V10, P213, DOI 10.1016/S1359-6446(04)03363-X; Egan LA, 1997, J AM CHEM SOC, V119, P2348, DOI 10.1021/ja963107o; Elkins JM, 2005, BIOCHEM J, V385, P565, DOI 10.1042/BJ20040814; Elkins JM, 2002, BIOCHEM J, V366, P423, DOI 10.1042/BJ20020125; ELSON SW, 1987, J CHEM SOC CHEM COMM, P1736, DOI 10.1039/c39870001736; ELSON SW, 1993, J CHEM SOC CHEM COMM, P1212, DOI 10.1039/c39930001212; ELSON SW, 1988, J CHEM SOC CHEM COMM, P979, DOI 10.1039/c39880000979; Fan C, 1997, BIOCHEMISTRY-US, V36, P2531, DOI 10.1021/bi962431t; FOULSTONE M, 1982, ANTIMICROB AGENTS CH, V22, P753, DOI 10.1128/AAC.22.5.753; Fulston M, 2001, J CHEM SOC PERK T 1, P1122, DOI 10.1039/b007009m; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Healy VL, 2000, CHEM BIOL, V7, P505, DOI 10.1016/S1074-5521(00)00135-6; HODGSON JE, 1995, GENE, V166, P49, DOI 10.1016/0378-1119(95)00560-9; JENSEN SE, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P169; Jensen SE, 2004, ANTIMICROB AGENTS CH, V48, P514, DOI 10.1128/AAC.48.2.514-520.2004; Jensen SE, 2004, ANTIMICROB AGENTS CH, V48, P192, DOI 10.1128/AAC.48.1.192-202.2004; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kershaw NJ, 2002, EUR J BIOCHEM, V269, P2052, DOI 10.1046/j.1432-1033.2002.02853.x; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; Kuzin AP, 2000, STRUCT FOLD DES, V8, P463, DOI 10.1016/S0969-2126(00)00129-5; Lessard IAD, 1999, BIOCHEMISTRY-US, V38, P14006, DOI 10.1021/bi991384c; Li RF, 2000, J BACTERIOL, V182, P4087, DOI 10.1128/JB.182.14.4087-4095.2000; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; LUSTY CJ, 1978, J BIOL CHEM, V253, P4270; MARSH EN, 1992, BIOCHEMISTRY-US, V31, P12648, DOI 10.1021/bi00165a015; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Mellado E, 2002, MICROBIOL-SGM, V148, P1427, DOI 10.1099/00221287-148-5-1427; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; Mosher RH, 1999, ANTIMICROB AGENTS CH, V43, P1215, DOI 10.1128/AAC.43.5.1215; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; NOVY T, 2001, INNOVATIOINS, V12, P1; PARADKAR AS, 1995, J BACTERIOL, V177, P1307, DOI 10.1128/jb.177.5.1307-1314.1995; Penefsky HS, 1983, METHOD ENZYMAT AN, V4, P324; Pierrat OA, 2002, ARCH BIOCHEM BIOPHYS, V400, P34, DOI 10.1006/abbi.2002.2767; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALOWE SP, 1990, BIOCHEMISTRY-US, V29, P6499, DOI 10.1021/bi00479a023; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Tahlan K, 2004, ANTIMICROB AGENTS CH, V48, P930, DOI 10.1128/AAC.48.3.930-939.2004; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Townsend CA, 2002, CURR OPIN CHEM BIOL, V6, P583, DOI 10.1016/S1367-5931(02)00392-7; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; WU TK, 1995, J BACTERIOL, V177, P3714, DOI 10.1128/jb.177.13.3714-3720.1995; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	62	34	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					279	287		10.1074/jbc.M507711200	http://dx.doi.org/10.1074/jbc.M507711200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16251194	hybrid			2022-12-25	WOS:000234307200036
J	Benlloch, M; Mena, S; Ferrer, P; Obrador, E; Asensi, M; Pellicer, JA; Carretero, J; Ortega, A; Estrela, JM				Benlloch, M; Mena, S; Ferrer, P; Obrador, E; Asensi, M; Pellicer, JA; Carretero, J; Ortega, A; Estrela, JM			Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; GLUTATHIONE DEPLETION; METASTATIC ACTIVITY; ENDOTHELIAL-CELLS; FAMILY PROTEINS; TNF-ALPHA; APOPTOSIS; INHIBITION; GROWTH; METABOLISM	(1)Mitochondrial glutathione ( mtGSH) depletion increases sensitivity of Bcl- 2- overexpressing B16 melanoma ( B16M)- F10 cells ( high metastatic potential) to tumor necrosis factor- alpha( TNF- alpha)- induced oxidative stress and death in vitro. In vivo, mtGSH depletion in B16M- F10 cells was achieved by feeding mice ( where the B16M-F10 grew as a solid tumor in the footpad) with an L- glutamine ( L- Gln)- enriched diet, which promoted in the tumor cells an increase in glutaminase activity, accumulation of cytosolic L- glutamate, and competitive inhibition of GSH transport into mitochondria. L- Gln- adapted B16M- F10 cells, isolated using anti- Met- 72 monoclonal antibodies and flow cytometry- coupled cell sorting, were injected into the portal vein to produce hepatic metastases. In L- Gln- adapted invasive ( iB16M- Gln(+)) cells, isolated from the liver by the same methodology and treated with TNF- alpha and an antisense Bcl- 2 oligodeoxynucleotide, viability decreased to similar to 12%. iB16M-Gln (+) cell death associated with increased generation of O-2(center dot). and H2O2, opening of the mitochondrial permeability transition pore complex, and release of proapoptotic molecular signals. Activation of cell death mechanisms was prevented by GSH ester- induced mtGSH replenishment. The oxidative stress- resistant survivors showed an adaptive response that includes overexpression of manganese-containing superoxide dismutase ( Mn- SOD) and catalase activities. By treating iB16M- Gln (+) cells with a double anti- antisense therapy ( Bcl- 2 and SOD2 antisense oligodeoxynucleotides) and TNF- alpha, metastatic cell survival decreased to similar to 1%. Chemotherapy ( taxol plus daunorubicin) easily removed this minimum percentage of survivors. This contribution identifies critical molecules that can be sequentially targeted to facilitate elimination of highly resistant metastatic cells.	Univ Valencia, Fac Med, Dept Physiol, Valencia 46010, Spain	University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Fac Med, Dept Physiol, Av Blasco Ibanez 17, Valencia 46010, Spain.	jose.m.estrela@uv.es	MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mena, Salvador/L-8780-2014; Carretero, Julian/N-5214-2014; Mena, Salvador/F-6696-2016; Estrela, Jose/H-4449-2015; Ortega, Angel L./A-4113-2014; Miralles, Miguel A Asensi/I-2756-2015; OBRADOR, ELENA/H-4069-2015	Mena, Salvador/0000-0002-6423-4741; Carretero, Julian/0000-0001-7269-8506; Estrela, Jose/0000-0002-2540-9190; Ortega, Angel L./0000-0002-9901-3383; Miralles, Miguel A Asensi/0000-0003-1922-7777; OBRADOR, ELENA/0000-0002-5934-5543				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akerboom T P, 1981, Methods Enzymol, V77, P373; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; Anderson GM, 2004, CURR OPIN PHARMACOL, V4, P314, DOI 10.1016/j.coph.2004.04.004; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Benlloch M, 2005, J BIOL CHEM, V280, P6950, DOI 10.1074/jbc.M408531200; Bergmeyer H.U., 1985, METHODS ENZYMATIC AN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosnan JT, 2003, J NUTR, V133, p2068S, DOI 10.1093/jn/133.6.2068S; Buzaid AC, 2004, ONCOLOGY-NY, V18, P1443; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Carretero J, 2000, FREE RADICAL BIO MED, V29, P913, DOI 10.1016/S0891-5849(00)00392-0; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CHEN MK, 1993, ANN SURG, V217, P655, DOI 10.1097/00000658-199306000-00007; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fischer CP, 1998, ANN SURG, V227, P627, DOI 10.1097/00000658-199805000-00003; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; HALESTRAP A, 2000, BIOCHEMIST, V22, P19; Hamilton KL, 2004, FREE RADICAL BIO MED, V37, P1360, DOI 10.1016/j.freeradbiomed.2004.07.025; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; Hochwald SN, 1996, J NATL CANCER I, V88, P193, DOI 10.1093/jnci/88.3-4.193; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KIMURA AK, 1986, JNCI-J NATL CANCER I, V76, P1247; Kinnula VL, 2004, FREE RADICAL BIO MED, V36, P718, DOI 10.1016/j.freeradbiomed.2003.12.010; Klimberg VS, 1996, AM J SURG, V172, P418; KLIMBERG VS, 1990, CANCER-AM CANCER SOC, V66, P62, DOI 10.1002/1097-0142(19900701)66:1<62::AID-CNCR2820660113>3.0.CO;2-E; Labow BI, 2000, WORLD J SURG, V24, P1503, DOI 10.1007/s002680010269; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; LINDERHOROWITZ M, 1969, CANCER RES, V29, P1195; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MATSUDA Y, 1973, J BIOCHEM, V73, P291; MATSUNO T, 1985, INT J BIOCHEM, V17, P1369, DOI 10.1016/0020-711X(85)90062-X; Medina MA, 2001, J NUTR, V131, p2539S, DOI 10.1093/jn/131.9.2539S; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Melis GC, 2004, CURR OPIN CLIN NUTR, V7, P59, DOI 10.1097/00075197-200401000-00011; Miyake H, 1999, CANCER RES, V59, P4030; Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Obrador E., 2001, Current Pharmaceutical Biotechnology, V2, P119; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Rodriguez-Bigas MA, 2003, HOLLAND FREI CANC ME; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Savarese DMF, 2003, CANCER TREAT REV, V29, P501, DOI 10.1016/S0305-7372(03)00133-6; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; SOUBA WW, 1993, ANN SURG, V218, P715, DOI 10.1097/00000658-199312000-00004; Stevenson D, 2002, TOXICOL IN VITRO, V16, P609, DOI 10.1016/S0887-2333(02)00042-5; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sun W, 2001, Curr Treat Options Oncol, V2, P193, DOI 10.1007/s11864-001-0033-5; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Tsan MF, 2001, INT J MOL MED, V7, P13; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; Ueta E, 2001, INT J CANCER, V94, P545, DOI 10.1002/ijc.1513; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Verrier F, 2003, ANN NY ACAD SCI, V1010, P126, DOI 10.1196/annals.1299.022; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, pS137, DOI 10.1177/0148607190014004201; Ziegler TR, 2001, J NUTR, V131, p2578S, DOI 10.1093/jn/131.9.2578S	81	40	42	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					69	79		10.1074/jbc.M507471200	http://dx.doi.org/10.1074/jbc.M507471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263711	hybrid			2022-12-25	WOS:000234307200012
J	Jacobs, M; Hayakawa, K; Swenson, L; Bellon, S; Fleming, M; Taslimi, P; Doran, J				Jacobs, M; Hayakawa, K; Swenson, L; Bellon, S; Fleming, M; Taslimi, P; Doran, J			The structure of dimeric ROCK I reveals the mechanism for ligand selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; FORMING PROTEIN-KINASE; FASUDIL HYDROCHLORIDE; CEREBRAL VASOSPASM; CATALYTIC-ACTIVITY; ROK-ALPHA; INHIBITOR; PHOSPHORYLATION; MYOSIN; DOMAIN	ROCK or Rho-associated kinase, a serine/threonine kinase, is an effector of Rho-dependent signaling and is involved in actin-cytoskeleton assembly and cell motility and contraction. The ROCK protein consists of several domains: an N-terminal region, a kinase catalytic domain, a coiled-coil domain containing a RhoA binding site, and a pleckstrin homology domain. The C-terminal region of ROCK binds to and inhibits the kinase catalytic domains, and this inhibition is reversed by binding RhoA, a small GTPase. Here we present the structure of the N-terminal region and the kinase domain. In our structure, two N-terminal regions interact to form a dimerization domain linking two kinase domains together. This spatial arrangement presents the kinase active sites and regulatory sequences on a common face affording the possibility of both kinases simultaneously interacting with a dimeric inhibitory domain or with a dimeric substrate. The kinase domain adopts a catalytically competent conformation; however, no phosphorylation of active site residues is observed in the structure. We also determined the structures of ROCK bound to four different ATP-competitive small molecule inhibitors (Y-27632, fasudil, hydroxyfasudil, and H-1152P). Each of these compounds binds with reduced affinity to cAMP-dependent kinase (PKA), a highly homologous kinase. Subtle differences exist between the ROCK-and PKA- bound conformations of the inhibitors that suggest that interactions with a single amino acid of the active site (Ala(215) in ROCK and Thr(183) in PKA) determine the relative selectivity of these compounds. Hydroxyfasudil, a metabolite of fasudil, may be selective for ROCK over PKA through a reversed binding orientation.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Jacobs, M (corresponding author), 130 Waverly St, Cambridge, MA 02139 USA.	marc_jacobs@vrtx.com						Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEAK P, 1972, TETRAHEDRON, V28, P5507, DOI 10.1016/S0040-4020(01)93615-4; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; Breitenlechner C, 2004, ONCOL RES, V14, P267; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chambers SP, 2004, PROTEIN EXPRES PURIF, V36, P40, DOI 10.1016/j.pep.2004.03.003; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Doran JD, 2004, BIOCHEM J, V384, P255, DOI 10.1042/BJ20040344; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; HIDAKA H, Patent No. 4678783; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ikeda F, 2003, J SURG RES, V109, P155, DOI 10.1016/S0022-4804(02)00081-1; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Masaoka H, 2001, ACT NEUR S, V77, P209; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; NAGATA K, 1993, CLIN NEUROPHARMACOL, V16, P501, DOI 10.1097/00002826-199312000-00003; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Ohki S, 2001, J HEART LUNG TRANSPL, V20, P956, DOI 10.1016/S1053-2498(01)00292-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Pierce AC, 2002, PROTEINS, V49, P567, DOI 10.1002/prot.10259; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shibuya M, 2001, ACTA NEUROCHIR SUPPL, V77, P201; SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahlstrom JL, 2003, J BIOL CHEM, V278, P5123, DOI 10.1074/jbc.M206963200; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zhang RX, 2003, FEBS LETT, V546, P281, DOI 10.1016/S0014-5793(03)00601-X; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	57	186	217	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					260	268		10.1074/jbc.M508847200	http://dx.doi.org/10.1074/jbc.M508847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249185	hybrid			2022-12-25	WOS:000234307200034
J	Lane, MC; O'Toole, PW; Moore, SA				Lane, MC; O'Toole, PW; Moore, SA			Molecular basis of the interaction between the flagellar export proteins FliI and FliH from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE; COMPONENTS; SEQUENCE; APPARATUS; SYSTEM; GENE; IDENTIFICATION; INFECTION; MOTILITY; ULCER	Bacterial flagellar protein export requires an ATPase, FliI, and presumptive inhibitor, FliH. We have explored the molecular basis for FliI/ FliH interaction in the human gastric pathogen Helicobacter pylori. By using bioinformatic and biochemical analyses, we showed that residues 1-18 of FliI very likely form an amphipathic alpha-helix upon interaction with FliH, and that residues 21-91 of FliI resemble the N-terminal oligomerization domain of the F-1-ATPase catalytic subunits. A truncated FliI-(2- 91) protein was shown to be folded, although the N-terminal 18 residues were likely unstructured. Deletion and scanning mutagenesis showed that residues 1-18 of FliI were essential for the FliI/ FliH interaction. Scanning mutation of amino acids in the N-terminal 10 residues of FliI indicated that a cluster of hydrophobic residues in this segment was critical for the interaction with FliH. The interaction between FliI and FliH has similarities to the interaction between the N-terminal alpha-helix of the F-1-ATPase alpha-subunit and the globular domain of the F-1-ATPase delta-subunit, respectively. This similarity suggests that FliH may function as a molecular stator.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Coll Cork, Dept Microbiol, Cork, Ireland; Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand	University of Saskatchewan; University College Cork; University College Cork; Massey University	Moore, SA (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	stan.moore@usask.ca	O'Toole, Paul W/G-1593-2012	O'Toole, Paul W/0000-0001-5377-0824				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Akeda Y, 2004, J BACTERIOL, V186, P2402, DOI 10.1128/JB.186.8.2402-2412.2004; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Auvray F, 2002, J MOL BIOL, V318, P941, DOI 10.1016/S0022-2836(02)00172-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Claret L, 2003, MOL MICROBIOL, V48, P1349, DOI 10.1046/j.1365-2958.2003.03506.x; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; EICHELBERG K, 1994, J BACTERIOL, V176, P4501, DOI 10.1128/JB.176.15.4501-4510.1994; EUROGAST, 1993, LANCET, V341, P16681; FORMAN D, 1993, LANCET, V341, P1359; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Ge YG, 1996, GENE, V168, P73, DOI 10.1016/0378-1119(95)00743-1; Gonzalez-Pedrajo B, 2002, MOL MICROBIOL, V45, P967, DOI 10.1046/j.1365-2958.2002.03047.x; Jackson MW, 2000, FEMS MICROBIOL LETT, V186, P85, DOI 10.1111/j.1574-6968.2000.tb09086.x; Kavermann H, 2003, J EXP MED, V197, P813, DOI 10.1084/jem.20021531; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minamino T, 2000, MOL MICROBIOL, V37, P1494, DOI 10.1046/j.1365-2958.2000.02106.x; Minamino T, 2001, J MOL BIOL, V312, P1027, DOI 10.1006/jmbi.2001.5000; Minamino T, 2000, MOL MICROBIOL, V35, P1052, DOI 10.1046/j.1365-2958.2000.01771.x; Minamino T, 2002, J MOL BIOL, V322, P281, DOI 10.1016/S0022-2836(02)00754-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niehus E, 2004, MOL MICROBIOL, V52, P947, DOI 10.1111/j.1365-2958.2004.04006.x; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; O'Toole PW, 2000, MICROBES INFECT, V2, P1207, DOI 10.1016/S1286-4579(00)01274-0; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Porwollik S, 1999, INFECT IMMUN, V67, P2060, DOI 10.1128/IAI.67.5.2060-2070.1999; Pozidis C, 2003, J BIOL CHEM, V278, P25816, DOI 10.1074/jbc.M301903200; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROUSSEL A, 1991, TURBO FRODO SILICON; Ryan KA, 2005, J BACTERIOL, V187, P5742, DOI 10.1128/JB.187.16.5742-5750.2005; Ryan KA, 2005, FEMS MICROBIOL LETT, V248, P47, DOI 10.1016/j.femsle.2005.05.022; Sambrook J., 2001, MOL CLONING LAB MANU; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stephens C, 1997, J BACTERIOL, V179, P5355, DOI 10.1128/jb.179.17.5355-5365.1997; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VANGIJSEGEM F, 1995, MOL MICROBIOL, V15, P1095, DOI 10.1111/j.1365-2958.1995.tb02284.x; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P177; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991; Weber J, 2004, J BIOL CHEM, V279, P25673, DOI 10.1074/jbc.M402738200	48	37	38	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					508	517		10.1074/jbc.M507238200	http://dx.doi.org/10.1074/jbc.M507238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260786	hybrid			2022-12-25	WOS:000234307200063
J	Sheng, T; Chi, SM; Zhang, XL; Xie, JW				Sheng, T; Chi, SM; Zhang, XL; Xie, JW			Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BASAL-CELL CARCINOMAS; CUBITUS-INTERRUPTUS; HEDGEHOG SIGNAL; SONIC HEDGEHOG; DROSOPHILA; ACTIVATION; CANCER; PHOSPHORYLATION; COMPLEX	The hedgehog ( Hh) pathway plays a critical role during development of embryos and cancer. Although the molecular basis by which protein kinase A ( PKA) regulates the stability of hedgehog downstream transcription factor cubitus interruptus, the Drosophila homologue of vertebrate Gli molecules, is well documented, the mechanism by which PKA inhibits the functions of Gli molecules in vertebrates remains elusive. Here, we report that activation of PKA retains Gli1 in the cytoplasm. Conversely, inhibition of PKA activity promotes nuclear accumulation of Gli1. Mutation analysis identifies Thr(374) as a major PKA site determining Gli1 protein localization. In the three- dimensional structure, Thr(374) resides adjacent to the basic residue cluster of the nuclear localization signal ( NLS). Phosphorylation of this Thr residue is predicted to alter the local charge and consequently the NLS function. Indeed, mutation of this residue to Asp ( Gli1/ T374D) results in more cytoplasmic Gli1 whereas a mutation to Lys ( Gli1/ T374K) leads to more nuclear Gli1. Disruption of the NLS causes Gli1/ T374K to be more cytoplasmic. We find that the change of Gli1 localization is correlated with the change of its transcriptional activity. These data provide evidence to support a model that PKA regulates Gli1 localization and its transcriptional activity, in part, through modulating the NLS function.	Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Xie, JW (corresponding author), Sealy Ctr Canc Cell Biol, MRB 9-104,UTMB,301 Univ Blvd, Galveston, TX 77555 USA.	jinxie@utmb.edu			NCI NIH HHS [R01CA94160] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200; He NG, 2005, MOL CARCINOGEN, V42, P18, DOI 10.1002/mc.20063; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Jia JH, 2003, GENE DEV, V17, P2709, DOI 10.1101/gad.1136603; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kiger JA, 2001, GENETICS, V158, P1157; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Ma XL, 2005, CARCINOGENESIS, V26, P1698, DOI 10.1093/carcin/bgi130; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stecca B, 2005, TRENDS MOL MED, V11, P199, DOI 10.1016/j.molmed.2005.03.004; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 1999, DEVELOPMENT, V126, P5097; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101; Zhu YH, 2004, CANCER LETT, V207, P205, DOI 10.1016/j.canlet.2003.10.025	43	101	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					9	12		10.1074/jbc.C500300200	http://dx.doi.org/10.1074/jbc.C500300200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16293631	hybrid			2022-12-25	WOS:000234307200003
J	Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS				Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS			Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a	ONCOGENE			English	Article						Brn-3a; HPV-16; cervical cancer; URR; E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; ELEVATED EXPRESSION; BINDING-SITES; CANCER CELLS; FACTOR PLAYS; YOUNG-WOMEN; TYPE-16; PROMOTER; INFECTION	The Brn-3a POU family transcription factor is over-expressed in human cervical carcinoma biopsies and is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulatory region ( URR), which drives the expression of the E6 and E7 oncoproteins. Inhibition of Brn-3a expression in human cervical cancer cells inhibits HPV gene expression and reduces cellular growth and anchorage independence in vitro as well as the ability to form tumours in vivo. Here, we show that Brn-3a differentially regulates different HPV-16 variants that have previously been shown to be associated with different risks of progression to cervical carcinoma. In human cervical material, Brn-3a levels correlate directly with HPV E6 levels in individuals infected with a high risk variant of HPV-16, whereas this is not the case for a low-risk variant. Moreover, the URRs of high- and intermediate-risk variants are activated by Brn-3a in transfection assays, whereas the URR of a low-risk variant is not. The change of one or two bases in a low-risk variant URR to their equivalent in a higher-risk URR can render the URR responsive to Brn-3a and vice versa. These results help explain why the specific interplay between viral and cellular factors necessary for the progression to cervical carcinoma only occurs in a minority of those infected with HPV-16.	UCL, Inst Child Hlth, Med Mol Biol Unit, London, England; Whittington Hosp, Dept Womens & Childrens Hlth, London N19 5NF, England; Kings Coll London, Sch Med, Richard Dimbelby Lab Canc Virol, GKT, London SE5 9PJ, England; Univ London Birkbeck Coll, London WC1E 7HX, England	University of London; University College London; University of London; University College London; University of London; King's College London; University of London; Birkbeck University London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London, England.	d.latchman@ich.ucl.ac.uk						Bible JM, 2000, J GEN VIROL, V81, P1517, DOI 10.1099/0022-1317-81-6-1517; BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Gascoyne DM, 2004, ONCOGENE, V23, P3830, DOI 10.1038/sj.onc.1207497; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hudson CD, 2004, J NEUROSCI RES, V78, P803, DOI 10.1002/jnr.20299; Kammer C, 2000, J GEN VIROL, V81, P1975, DOI 10.1099/0022-1317-81-8-1975; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Miller AB, 2001, LANCET, V357, P1816, DOI 10.1016/S0140-6736(00)05008-X; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NAKSHATRI H, 1990, VIROLOGY, V178, P92, DOI 10.1016/0042-6822(90)90382-2; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisang D, 2001, ONCOGENE, V20, P4899, DOI 10.1038/sj.onc.1204634; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Ripley BJM, 2005, ARTHRITIS RHEUM-US, V52, P1171, DOI 10.1002/art.21000; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Sindos M, 2003, GYNECOL ONCOL, V90, P366, DOI 10.1016/S0090-8258(03)00261-0; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	33	9	11	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					51	60		10.1038/sj.onc.1209006	http://dx.doi.org/10.1038/sj.onc.1209006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247485	Green Accepted			2022-12-25	WOS:000234406400006
J	Chen, JH; Avci, FY; Munoz, EM; McDowell, LM; Chen, M; Pedersen, LC; Zhang, LJ; Linhardt, RJ; Liu, J				Chen, JH; Avci, FY; Munoz, EM; McDowell, LM; Chen, M; Pedersen, LC; Zhang, LJ; Linhardt, RJ; Liu, J			Enzymatic redesigning of biologically active heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; ENTRY RECEPTOR; BIOSYNTHESIS; BINDING; OLIGOSACCHARIDES; PROTEOGLYCANS; SPECIFICITY; MIMETICS; SEQUENCE; REVEALS	Heparan sulfate carries a wide range of biological activities, regulating blood coagulation, cell differentiation, and inflammatory responses. The sulfation patterns of the polysaccharide are essential for the biological activities. In this study, we report an enzymatic method for the sulfation of multimilligram amounts of heparan sulfate with specific functions using immobilized sulfotransferases combined with a 3'-phosphoadenosine 5'-phosphosulfate regeneration system. By selecting appropriate enzymatic modification steps, an inactive precursor has been converted to the heparan sulfate having three distinct biological activities, associated with binding to antithrombin, fibroblast growth factor-2, and herpes simplex virus envelope glycoprotein D. Because the recombinant sulfotransferases are expressed in bacteria, and the method uses a low cost sulfo donor, it can be readily utilized to synthesize large quantities of anticoagulant heparin drug or other biologically active heparan sulfates.	Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Chapel Hill, NC 27599 USA; Rensselaer Polytech Inst, Dept Chem & Chem Biol, Troy, NY 12180 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; Rensselaer Polytechnic Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liu, J (corresponding author), Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Rm 309,Beard Hall, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Pedersen, Lars/C-6173-2019	Pedersen, Lars/0000-0002-4488-4077; Avci, Fikri/0000-0002-1902-7532	NHLBI NIH HHS [HL52622, R01 HL052622, R01 HL062244, R01 HL062244-05A1] Funding Source: Medline; NIAID NIH HHS [AI50050, R01 AI050050] Funding Source: Medline; NIGMS NIH HHS [R01 GM069968, GM069968, R01 GM038060-17, R01 GM038060, R01 GM038060-16A2, GM38060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069968, R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; Avci FY, 2003, CURR PHARM DESIGN, V9, P2323, DOI 10.2174/1381612033453929; BJORNSSON S, 1993, ANAL BIOCHEM, V210, P282, DOI 10.1006/abio.1993.1197; Burkart MD, 2000, J ORG CHEM, V65, P5565, DOI 10.1021/jo000266o; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Duncan MB, 2004, BBA-GEN SUBJECTS, V1671, P34, DOI 10.1016/j.bbagen.2003.12.010; Edavettal SC, 2004, J BIOL CHEM, V279, P25789, DOI 10.1074/jbc.M401089200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; Kuberan B, 2003, J BIOL CHEM, V278, P52613, DOI 10.1074/jbc.M305029200; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Kuberan B, 2003, J AM CHEM SOC, V125, P12424, DOI 10.1021/ja036737g; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Lindahl U, 2005, J MED CHEM, V48, P349, DOI 10.1021/jm049812m; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Moon AF, 2004, J BIOL CHEM, V279, P45185, DOI 10.1074/jbc.M405013200; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Saribas AS, 2004, GLYCOBIOLOGY, V14, P1217, DOI 10.1093/glycob/cwh129; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sheng JJ, 2004, DRUG METAB DISPOS, V32, P559, DOI 10.1124/dmd.32.5.559; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	46	95	104	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42817	42825		10.1074/jbc.M504338200	http://dx.doi.org/10.1074/jbc.M504338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260789	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000234200800043
J	Colina, AR; Young, D				Colina, AR; Young, D			Raf60, a novel component of the Rpd3 histone deacetylase complex required for Rpd3 activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX; TRANSCRIPTIONAL REPRESSION; INTEGRAL COMPONENT; YEAST; UME6; IDENTIFICATION; ACETYLATION; COREPRESSOR; SUPPRESSOR; GROWTH	The Rpd3 histone deacetylase complex contains several previously characterized proteins, including Rpd3, Sin3, Sds3, Sap30, and Pho23. We purified the Rdp3 complex to near homogeneity using the tandem affinity purification method. Mass spectrometric analysis revealed the presence of a novel component, which we named Raf60. We showed that Myc-Raf60 co-fractionated with Rpd3-TAP by gel filtration chromatography, and both Myc-Rpd3 and Sin3 co-immunoprecipitated with HA-Raf60. In addition, HA-Raf60 immunoprecipitates displayed Rpd3-dependent histone deacetylase activity, and raf60 deletion resulted in loss of Rpd3 complex activity, as measured by in vitro assays. Furthermore, we found that raf60 Delta cells exhibited phenotypes similar to those of rpd3 Delta cells, including derepression of secreted acid phosphatase (Pho5), hypersensitivity to cycloheximide, and hypersensitivity to heat shock. Also, we found by reverse transcription-PCR that raf60 Delta cells, similar to rpd3 Delta cells, displayed elevated levels of PHO5 and INO1 mRNA. Our results demonstrate that Raf60 is a component of the Rpd3 histone deacetylase complex and that it is required for normal Rpd3 complex activity and repression of gene expression.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Young, D (corresponding author), 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	young@ucalgary.ca						Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Aparicio JG, 2004, MOL CELL BIOL, V24, P4769, DOI 10.1128/MCB.24.11.4769-4780.2004; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hubberstey A, 1996, J CELL BIOCHEM, V61, P459, DOI 10.1002/(SICI)1097-4644(19960601)61:3<459::AID-JCB13>3.0.CO;2-E; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jiang JC, 2002, EXP GERONTOL, V37, P1023, DOI 10.1016/S0531-5565(02)00064-5; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Messenguy F, 2000, J BACTERIOL, V182, P3158, DOI 10.1128/JB.182.11.3158-3164.2000; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Puig S, 2004, J BIOL CHEM, V279, P30298, DOI 10.1074/jbc.M313463200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sabet N, 2004, MOL CELL BIOL, V24, P8823, DOI 10.1128/MCB.24.20.8823-8833.2004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; van Ingen H, 2004, BIOCHEMISTRY-US, V43, P46, DOI 10.1021/bi0355645; Vannier D, 1996, GENETICS, V144, P1343; VIDAL M, 1990, GENETICS, V125, P313; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Washburn BK, 2001, MOL CELL BIOL, V21, P2057, DOI 10.1128/MCB.21.6.2057-2069.2001; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	13	14	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42552	42556		10.1074/jbc.M511561200	http://dx.doi.org/10.1074/jbc.M511561200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16275642	hybrid			2022-12-25	WOS:000234200800011
J	Piruat, JI; Lopez-Barneo, J				Piruat, JI; Lopez-Barneo, J			Oxygen tension regulates mitochondrial DNA-encoded complex I gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; INDUCIBLE FACTOR-ALPHA; MOUSE CEREBRAL-CORTEX; NADH-DEHYDROGENASE; CHRONIC HYPOXIA; HIF-ALPHA; CELLULAR RESPIRATION; ERYTHROPOIETIN GENE; TRANSCRIPTION; PROTEIN	Oxygen is a major regulator of nuclear gene expression. However, although mitochondria consume almost all of the O-2 available to the cells, little is known about how O-2 tension influences the expression of the mitochondrial genome. We show in O-2-sensitive excitable rat PC12 cells that, among the mtDNA- encoded genes, hypoxia produced a specific down-regulation of the transcripts encoding mitochondrial complex I NADH dehydrogenase (ND) subunits, particularly ND4 and ND5 mRNAs and a stable mRNA precursor containing the ND5 and cytochrome b genes. This unprecedented effect of hypoxia was fast (developed in < 30 min) and fairly reversible and occurred at moderate levels of hypoxia (O-2 tensions in the range of 20 - 70 mm Hg). Hypoxic down-regulation of the mitochondrial complex I genes was paralleled by the reduction of complex I activity and was retarded by iron chelation, suggesting that an iron-dependent post- transcriptional mechanism could regulate mitochondrial mRNA stability. It is known that cell respiration is under tight control by the amount of proteins in mitochondrial complexes of the electron transport chain. Therefore, regulation of the expression of the mitochondrial (mtDNA)-encoded complex I subunits could be part of an adaptive mechanism to adjust respiration rate to the availability of O-2 and to induce fast adaptive changes in hypoxic cells.	Univ Seville, Hosp Univ Virgen Rocio, E-41013 Seville, Spain; Univ Seville, Lab Invest Biomed, Dept Fisiol, E-41013 Seville, Spain	University of Sevilla; Virgen del Rocio University Hospital; University of Sevilla	Lopez-Barneo, J (corresponding author), Hosp Univ Virgen Rocio, Lab Invest Biomed, Edificio Labs,2A Planta,Ave Manuel Siurot S-N, E-41013 Seville, Spain.	Jose.L.Barneo.sspa@juntadeandalucia.es	IBIS, NEUROBIOLOGIA/O-9922-2015					Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; AMALRIC F, 1978, J MOL BIOL, V118, P1, DOI 10.1016/0022-2836(78)90241-3; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BHAT KS, 1985, BIOCHEMISTRY-US, V24, P5818, DOI 10.1021/bi00342a020; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Caceda R, 2001, NEUROSCI LETT, V301, P171, DOI 10.1016/S0304-3940(01)01630-5; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHAVEZ JC, 1995, NEUROSCI LETT, V193, P169, DOI 10.1016/0304-3940(95)11692-P; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Del Toro R, 2003, J BIOL CHEM, V278, P22316, DOI 10.1074/jbc.M212576200; Eads BD, 2003, J EXP BIOL, V206, P3681, DOI 10.1242/jeb.00595; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gagliardi D, 2004, TRENDS GENET, V20, P260, DOI 10.1016/j.tig.2004.04.006; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KADOWAKI T, 1991, EXP CELL RES, V192, P243, DOI 10.1016/0014-4827(91)90182-T; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Montoya J, 1997, MOL CELL BIOCHEM, V174, P227, DOI 10.1023/A:1006812625445; NARDELLI M, 1994, FEBS LETT, V344, P10, DOI 10.1016/0014-5793(94)00342-4; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Peers C, 2004, CELL CALCIUM, V36, P341, DOI 10.1016/j.ceca.2004.02.005; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; Ryan CM, 2003, J BIOL CHEM, V278, P32753, DOI 10.1074/jbc.M303552200; SBISA E, 1992, FEBS LETT, V296, P311, DOI 10.1016/0014-5793(92)80311-4; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Selwood SP, 2001, FEBS LETT, V494, P186, DOI 10.1016/S0014-5793(01)02345-6; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Taylor SC, 1999, J PHYSIOL-LONDON, V514, P483, DOI 10.1111/j.1469-7793.1999.483ae.x; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TULLO A, 1994, FEBS LETT, V354, P30, DOI 10.1016/0014-5793(94)01080-3; VANITALLIE CM, 1993, AM J PHYSIOL, V265, pC712, DOI 10.1152/ajpcell.1993.265.3.C712; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WANG GL, 1993, BLOOD, V82, P3610; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WILSON DF, 1988, J BIOL CHEM, V263, P2712; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	67	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42676	42684		10.1074/jbc.M507044200	http://dx.doi.org/10.1074/jbc.M507044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16257962	hybrid			2022-12-25	WOS:000234200800025
J	Zhao, KW; Li, D; Zhao, Q; Huang, Y; Silverman, RH; Sims, PJ; Chen, GQ				Zhao, KW; Li, D; Zhao, Q; Huang, Y; Silverman, RH; Sims, PJ; Chen, GQ			Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase C delta and JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID SCRAMBLASE-1; GROWTH-FACTOR RECEPTOR; TRANSBILAYER MOVEMENT; I INTERFERONS; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNALING PATHWAYS; GENE-EXPRESSION; LEUKEMIA-CELLS	Phospholipid scramblase 1 (PLSCR1), a calcium-binding protein that either inserts into the plasma membrane or binds to genomic DNA in the nucleus, has been shown to contribute to the cell proliferation, differentiation, and apoptosis as well as antiviral activity of interferon (IFN). The expression of PLSCR1 protein is also known to be markedly increased in response to IFN and to some differentiation inducing agents such as all-trans retinoic acid, but the precise mechanisms of this response remain to be investigated. In this study, we show that the protein kinase C delta (PKC delta)-specific inhibitor rottlerin and the dominant negative mutant of PKC delta significantly antagonized IFN-induced PLSCR1 expression. The influence of PKC delta on IFN-mediated induction of PLSCR1 was dependent upon the phosphorylation of STAT1 at Ser-727. Furthermore, PKC delta-mediated activation of STAT1 required the activation of JNK, as the inhibition of JNK activity by its specific inhibitor or transfection of its dominant negative mutant suppressed both serine phosphorylation of STAT1 and PLSCR1 expression but not the activation of PKC delta. In conclusion, our results suggest that the induction of PLSCR1 transcription through STAT1 depends upon sequential activation of PKC delta and JNK.	Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol,Key Lab Cell Differentiat & Apo, Rui Jin Hosp,Chinese Minist Educ, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci, Inst Hlth Sci, Chinese Acad Sci, Shanghai 200025, Peoples R China; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Cleveland Clinic Foundation; Scripps Research Institute	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol,Key Lab Cell Differentiat & Apo, Rui Jin Hosp,Chinese Minist Educ, 280 Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn	Li, Dong/C-7344-2011		NCI NIH HHS [R01CA089132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Ham YM, 2003, J BIOL CHEM, V278, P50330, DOI 10.1074/jbc.M302997200; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kaur S, 2005, EXP HEMATOL, V33, P550, DOI 10.1016/j.exphem.2005.01.014; Leitges M, 2001, LAB INVEST, V81, P1087, DOI 10.1038/labinvest.3780321; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	42	45	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42707	42714		10.1074/jbc.M506178200	http://dx.doi.org/10.1074/jbc.M506178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260419	hybrid			2022-12-25	WOS:000234200800029
J	Huang, K; Dong, J; Phillips, NB; Carey, PR; Weiss, MA				Huang, K; Dong, J; Phillips, NB; Carey, PR; Weiss, MA			Proinsulin is refractory to protein fibrillation - Topological protection of a precursor protein from cross-beta assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SOLID-STATE NMR; INSULIN AMYLOID FIBRILS; AKITA DIABETIC MOUSE; CIRCULAR-DICHROISM; LINEAR POLYMERIZATION; ENDOPLASMIC-RETICULUM; STRUCTURAL-PROPERTIES; RAMAN-SPECTROSCOPY; CRYSTAL-STRUCTURE	Insulin is susceptible to fibrillation, a misfolding process leading to well ordered cross-beta assembly. Protection from fibrillation in beta cells is provided by sequestration of the susceptible monomer within zinc hexamers. We demonstrate that proinsulin is refractory to fibrillation under conditions that promote the rapid fibrillation of zinc-free insulin. Proinsulin fibrils, as probed by Raman microscopy, are nonetheless similar in structure to insulin fibrils. The connecting peptide, although not well ordered in native proinsulin, participates in a fibril-specific beta-sheet. Native insulin and proinsulin exhibit similar free energies of unfolding as inferred from guanidine denaturation studies: relative amyloidogenicities are thus not correlated with global stability. Strikingly, the susceptibility of proinsulin to fibrillation is increased by scission of the connecting peptide at single sites. We thus propose that the connecting peptide constrains a large scale conformational change in the misfolded protein. A tethering mechanism is proposed based on a model of an insulin protofilament derived from electron-microscopic image reconstruction. The proposed relationship between cross-beta assembly and protein topology is supported by studies of single-chain analogs (mini- proinsulin and insulin-like growth factor I) in which foreshortened connecting peptides further retard fibrillation. In addition to its classic function to facilitate disulfide pairing, the connecting peptide may protect beta cells from toxic protein misfolding in the endoplasmic reticulum.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	maw21@case.edu	Huang, Kun/H-4427-2012		NIDDK NIH HHS [DK0697674] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Altose MD, 2001, P NATL ACAD SCI USA, V98, P3006, DOI 10.1073/pnas.061029598; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Brange J, 1997, J PHARM SCI, V86, P517, DOI 10.1021/js960297s; Brange J, 1997, PROTEINS, V27, P507, DOI 10.1002/(SICI)1097-0134(199704)27:4<507::AID-PROT4>3.3.CO;2-H; BREMS DN, 1990, BIOCHEMISTRY-US, V29, P9289, DOI 10.1021/bi00491a026; Brunger A. T, 1993, XPLOR MANUAL VERSION; Brzozowski AM, 2002, BIOCHEMISTRY-US, V41, P9389, DOI 10.1021/bi020084j; Canet D, 1999, BIOCHEMISTRY-US, V38, P6419, DOI 10.1021/bi983037t; Cao AE, 2004, PROTEIN SCI, V13, P319, DOI 10.1110/ps.03183404; Carey P. R., 1982, BIOCH APPLICATIONS R, P89; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CLARK JL, 1969, BIOCHEM BIOPH RES CO, V35, P456, DOI 10.1016/0006-291X(69)90367-2; Cohen Alan S., 1994, Current Opinion in Rheumatology, V6, P55, DOI 10.1097/00002281-199401000-00010; Cohen FE, 2000, MOL MED TODAY, V6, P292, DOI 10.1016/S1357-4310(00)01740-8; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Dong J, 2003, J MOL BIOL, V330, P431, DOI 10.1016/S0022-2836(03)00536-9; Dong J, 1998, APPL SPECTROSC, V52, P1117; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FRANK BH, 1972, DIABETES, V21, P486, DOI 10.2337/diab.21.2.S486; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Goers J, 2002, BIOCHEMISTRY-US, V41, P12546, DOI 10.1021/bi0262698; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; HELLMAN U, 1990, BIOCHEM BIOPH RES CO, V169, P571, DOI 10.1016/0006-291X(90)90369-X; Hua QX, 2004, J BIOL CHEM, V279, P21449, DOI 10.1074/jbc.M314141200; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Krebs MRH, 2005, J STRUCT BIOL, V149, P30, DOI 10.1016/j.jsb.2004.08.002; Lachmann HJ, 2003, BRIT J HAEMATOL, V122, P78, DOI 10.1046/j.1365-2141.2003.04433.x; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Lindquist S, 1998, BIOCHEM SOC T, V26, P486, DOI 10.1042/bst0260486; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; LU Z X, 1963, Sci Sin, V12, P83; LU ZX, 1964, SCI SINICA, V13, P1951; Lynn DG, 2000, J STRUCT BIOL, V130, P153, DOI 10.1006/jsbi.2000.4287; Maiti NC, 2004, J AM CHEM SOC, V126, P2399, DOI 10.1021/ja0356176; MARKUSSEN J, 1975, INT J PEPT PROT RES, V7, P47; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; NAITHANI VK, 1975, H-S Z PHYSIOL CHEM, V356, P1305, DOI 10.1515/bchm2.1975.356.2.1305; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; NISHI M, 1990, MOL ENDOCRINOL, V4, P1192, DOI 10.1210/mend-4-8-1192; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Pace CN, 2000, PROTEINS, P1; PENG CM, 1963, SCI SINICA, V12, P213; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2004, J MOL BIOL, V335, P247, DOI 10.1016/j.jmb.2003.10.044; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; RHODES CJ, 1994, DIABETES, V43, P511, DOI 10.2337/diabetes.43.4.511; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Schaffer ML, 2003, BIOCHEMISTRY-US, V42, P9324, DOI 10.1021/bi034386c; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; Tycko R, 2003, J AM CHEM SOC, V125, P6606, DOI 10.1021/ja0342042; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Vajdos FF, 2001, BIOCHEMISTRY-US, V40, P11022, DOI 10.1021/bi0109111; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WAUGH DF, 1946, J AM CHEM SOC, V68, P247, DOI 10.1021/ja01206a030; Waugh DF, 1944, J AM CHEM SOC, V66, P663, DOI 10.1021/ja01232a516; WAUGH DF, 1953, J AM CHEM SOC, V75, P2592, DOI 10.1021/ja01107a013; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; Whittingham JL, 2002, J MOL BIOL, V318, P479, DOI 10.1016/S0022-2836(02)00021-9; Williams AD, 2005, P NATL ACAD SCI USA, V102, P7115, DOI 10.1073/pnas.0408582102; YU NT, 1972, J MOL BIOL, V70, P117, DOI 10.1016/0022-2836(72)90167-2; YUNT, 1972, J AM CHEM SOC, V94, P3250, DOI 10.1021/ja00764a068	82	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42345	42355		10.1074/jbc.M507110200	http://dx.doi.org/10.1074/jbc.M507110200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239223	hybrid			2022-12-25	WOS:000233992700064
J	Kanda, T; Wakino, S; Homma, K; Yoshioka, K; Tatematsu, S; Hasegawa, K; Takamatsu, I; Sugano, N; Hayashi, K; Saruta, T				Kanda, T; Wakino, S; Homma, K; Yoshioka, K; Tatematsu, S; Hasegawa, K; Takamatsu, I; Sugano, N; Hayashi, K; Saruta, T			Rho-kinase as a molecular target for insulin resistance and hypertension	FASEB JOURNAL			English	Article						obesity; skeletal muscle; IRS-1	NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; DIABETIC DB/DB MICE; OBESE ZUCKER RATS; SKELETAL-MUSCLE; TNF-ALPHA; RECEPTOR SUBSTRATE-1; DISTINCT PATHWAYS; PROTEIN-KINASE; GLUCOSE-UPTAKE	Rho-kinase plays an important role in hypertension and is reported to interfere with insulin signaling through serine phosphorylation of insulin receptor substrate-1 (IRS-1) in cultured vascular smooth muscle cells. We therefore examined the role of Rho-kinase in the development of insulin resistance in Zucker obese rats. In skeletal muscles and aortic tissues of Zucker obese rats, activation of RhoA/Rho-kinase was observed. Long-term Rho-kinase inhibition by 4 wk treatment with fasudil (a Rho-kinase inhibitor) not only reduced blood pressure but corrected glucose and lipid metabolism, with improvement in serine phosphorylation of IRS-1 and insulin signaling in skeletal muscles. Direct visualization of skeletal muscle arterioles with an intravital CCD videomicroscope demonstrated that both acetylcholine- and sodium nitroprusside-induced vasodilations were blunted, which were restored by the fasudil treatment. Furthermore, both fasudil and Y-27632 prevented the serine phosphorylation of IRS-1 induced by insulin and/or tumor necrosis factor-alpha in skeletal muscle cells. Collectively, Rho-kinase is responsible for the impairment of insulin signaling and may constitute a critical mediator linking between metabolic and hemodynamic abnormalities in insulin resistance.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Hayashi, K (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	khayashi@sc.itc.keio.ac.jp	Homma, Koichiro/J-3146-2015					Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; Cheung AT, 1998, ENDOCRINOLOGY, V139, P4928, DOI 10.1210/en.139.12.4928; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; de Jongh RT, 2004, CIRCULATION, V109, P2529, DOI 10.1161/01.CIR.0000129772.26647.6F; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Del Aguila LF, 1999, AM J PHYSIOL-ENDOC M, V276, pE849, DOI 10.1152/ajpendo.1999.276.5.E849; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; Emilsson V, 1998, BIOCHEM BIOPH RES CO, V252, P450, DOI 10.1006/bbrc.1998.9667; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Fujiwara K, 1999, HYPERTENSION, V33, P1470, DOI 10.1161/01.HYP.33.6.1470; Gong MC, 1997, J BIOL CHEM, V272, P10704; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; HAYASHI K, 1989, CIRC RES, V65, P1475, DOI 10.1161/01.RES.65.6.1475; Hori H, 2002, DIABETES, V51, P2387, DOI 10.2337/diabetes.51.8.2387; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; LEVIN BE, 1980, PHARMACOL BIOCHEM BE, V13, P107, DOI 10.1016/0091-3057(80)90128-8; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 2000, AM J PHYSIOL-REG I, V279, pR1305, DOI 10.1152/ajpregu.2000.279.4.R1305; Matsuda H, 1999, J AM SOC NEPHROL, V10, P2272; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Plante GE, 2003, CARDIOVASC RES, V59, P963, DOI 10.1016/S0008-6363(03)00521-2; Rask-Madsen C, 2003, CIRCULATION, V108, P1815, DOI 10.1161/01.CIR.0000091406.72832.11; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sandu OA, 2000, DIABETES, V49, P2178, DOI 10.2337/diabetes.49.12.2178; Shimokawa H, 1999, CARDIOVASC RES, V43, P1029, DOI 10.1016/S0008-6363(99)00144-3; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Valverde AM, 2003, J BIOL CHEM, V278, P10221, DOI 10.1074/jbc.M209363200; Wakino S, 2004, CIRC RES, V95, pE45, DOI 10.1161/01.RES.0000142313.68389.92; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; Yamamoto T, 2001, KIDNEY INT, V60, P364, DOI 10.1046/j.1523-1755.2001.00808.x; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539; Zick Y, 2003, INT J OBESITY, V27, pS56, DOI 10.1038/sj.ijo.0802503	47	88	91	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					169	+		10.1096/fj.05-4197fje	http://dx.doi.org/10.1096/fj.05-4197fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16267124				2022-12-25	WOS:000234053100021
J	Schild, L; Jaroscakova, I; Lendeckel, U; Wolf, G; Keilhoff, G				Schild, L; Jaroscakova, I; Lendeckel, U; Wolf, G; Keilhoff, G			Neuronal nitric oxide synthase controls enzyme activity pattern of mitochondria and lipid metabolism	FASEB JOURNAL			English	Article						endogenous nitric oxide; citrate synthase; respiratory chain	CYTOCHROME-C; INHIBITION; COMPLEXES; MECHANISM; OXYGEN; CELLS; DNA	Mitochondria are affected by endogenous nitric oxide ( NO). Besides effects of NO on mitochondrial enzymes and the stimulation of mitochondrial H2O2 production, a NO-dependent increase in mitochondrial biogenesis in several tissues has been reported. It is still obscure whether NO generated by one specific or different NO synthase ( NOS) isoenzymes determine such effects. Therefore, we analyzed the amount of mitochondria, respiratory chain enzyme complexes, and citrate synthase in the brain, muscle, heart, kidney, and liver by comparing wildtype (WT) mice and mice lacking the neuronal nitric oxide synthase isoform (nNOS-KO). Our results show that the activities of NADH: cytochrome c oxidoreductase and succinate cytochrome c oxidoreductase differ between WT and nNOS-KO mice. However, similar quantities of mitochondria were found in the homogenates of tissues in WT and nNOS-KO animals. Most impressive, higher activities and protein of citrate synthase were found in the brain, muscle, heart, kidney, and liver of nNOS-KO mice. Additionally, higher contents of fatty acid synthase and lipids were determined in the livers of nNOS-KO mice but not in the heart and brain. Furthermore, liver mitochondria from nNOS-KO mice consumed pyruvate at a higher rate and released more citric acid. Our data document a previously unrecognized role of endogenous NO in the regulation of lipid metabolism.	Otto Von Guericke Univ, Fak Med, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Fak Med, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Fak Med, Inst Expt Innere Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Otto Von Guericke Univ, Fak Med, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	Lorenz.Schild@Medizin.Uni-Magdeburg.de	Lendeckel, Uwe/Q-6922-2016	Lendeckel, Uwe/0000-0002-0684-9959				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Brennan PA, 2002, ANN ROY COLL SURG, V84, P75; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Galli S, 2003, CANCER RES, V63, P6370; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Haynes V, 2003, IUBMB LIFE, V55, P599, DOI 10.1080/15216540310001628681; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Kim MM, 2004, CLIN CANCER RES, V10, P8512, DOI 10.1158/1078-0432.CCR-04-0734; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Ramachandran A, 2004, P NATL ACAD SCI USA, V101, P384, DOI 10.1073/pnas.0304653101; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Roediger WE, 2004, IUBMB LIFE, V56, P35, DOI 10.1080/15216540310001649822; Sarti P, 2003, IUBMB LIFE, V55, P605, DOI 10.1080/15216540310001628726; Schild L, 1996, ACTA OPHTHALMOL SCAN, V74, P354; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; Shiva S, 2004, BIOCHEM J, V379, P359, DOI 10.1042/BJ20031758; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1	36	38	38	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					145	+		10.1096/fj.05-3898fje	http://dx.doi.org/10.1096/fj.05-3898fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16246868				2022-12-25	WOS:000232991100009
J	Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J				Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J			A novel Bcl-x splice product, Bcl-x(AK), triggers apoptosis in human melanoma cells without BH3 domain	ONCOGENE			English	Article						Bcl-x; apoptosis; alternative splicing; melanoma; chemotherapeutics	HUMAN MALIGNANT-MELANOMA; CANCER-CELLS; CONDITIONAL EXPRESSION; ANTIAPOPTOTIC PROTEIN; FAMILY PROTEINS; MESSENGER-RNA; IN-VITRO; DEATH; BAX; LINES	Pro- and antiapoptotic proteins of the large Bcl-2 family are critical regulators of apoptosis via the mitochondrial pathway. Whereas antiapoptotic proteins of the family share all four Bcl-2 homology domains (BH1-BH4), proapoptotic members may lack some of these domains, but all so far described proapoptotic Bcl-2 proteins enclose BH3. The bcl-x gene gives rise to several alternative splice products resulting in proteins with distinct functions as the antiapoptotic Bcl-x(L) and proapoptotic Bcl-x(S). Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-x(AK) (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. Weak endogenous expression of Bcl-x(AK) was seen in melanoma and other tumor cells. Interestingly, its overexpression by applying a tetracycline-inducible expression system-resulted in significant induction of apoptosis in melanoma cells, which occurred in synergism with drug-induced apoptosis. After exogenous overexpression, Bcl-x(AK) was localized both in mitochondrial and in cytosolic cell fractions. By these findings, a completely new class of Bcl-2-related proteins is introduced, which promotes apoptosis independently from the BH3 domain and implies additional, new mechanisms for apoptosis regulation in melanoma cells.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, D-12203 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, Campus Benjamin Franklin,Fabeckstr 60-62, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BEAN MA, 1975, CANCER RES, V35, P2902; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DEL PL, 1997, SCIENCE, V278, P687; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fecker LF, 2002, J INVEST DERMATOL, V118, P1019, DOI 10.1046/j.1523-1747.2002.01744.x; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; HOLZMANN B, 1988, INT J CANCER, V41, P542; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; HOSSINI AM, 2003, ARCH DERMATOL RES, V294, P499; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LIAO SK, 1975, J NATL CANCER I, V54, P1037; Lindenboim L, 2000, ONCOGENE, V19, P1783, DOI 10.1038/sj.onc.1203495; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ogata Y, 2003, DRUG NEWS PERSPECT, V16, P446, DOI 10.1358/dnp.2003.16.7.829356; OPPERMANN M, 2005, ONCOGENE; Oxford SME, 2004, CURR MED CHEM, V11, P1031, DOI 10.2174/0929867043455486; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Renshaw SA, 2004, J BIOL CHEM, V279, P2846, DOI 10.1074/jbc.M309769200; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Schmitt E, 2004, ONCOGENE, V23, P3915, DOI 10.1038/sj.onc.1207554; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	62	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2160	2169		10.1038/sj.onc.1209253	http://dx.doi.org/10.1038/sj.onc.1209253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288206				2022-12-25	WOS:000236581200003
J	Huang, M; Kamasani, U; Prendergast, GC				Huang, M; Kamasani, U; Prendergast, GC			RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3	ONCOGENE			English	Article						Ras; Rho; Akt; cancer	FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; PROTEIN-KINASE; PHOSPHORYLATION; TRANSFORMATION; GROWTH; CANCER; DEGRADATION; SUPPRESSION; EXPRESSION	The small GTPase RhoB suppresses cancer in part by limiting cell proliferation. However, the mechanisms it uses to achieve this are poorly understood. Recent studies link RhoB to trafficking of Akt, which through its regulation of glycogen synthase kinase-3 (GSK-3) has an important role in controlling the stability of the c-Myc oncoprotein. c-Myc stabilization may be a root feature of human tumorigenesis as it phenocopies an essential contribution of SV40 small T antigen in human cell transformation. In this study we show that RhoB directs efficient turnover of c-Myc in established or transformed mouse fibroblasts and that the attenuation of RhoB which occurs commonly in human cancer is a sufficient cause to elevate c-Myc levels. Increased levels of c-Myc elicited by RhoB deletion increased the proliferation of nullizygous cells, whereas restoring RhoB in null cells decreased the stability of c-Myc and restrained cell proliferation. Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc. RhoB deletion restricted nuclear localization of GSK-3, reduced T58 phosphorylation, and stabilized c-Myc. These effects were not associated with changes in phosphorylation or localization of Akt, however, differences were observed in phosphorylation and localization of the GSK-3 regulatory Akt-related kinase, serum- and glucocorticoid-inducible protein kinase (SGK). The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells.	Lankenau Inst Med Res, Canc Cell Signaling Lab, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Sch Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, Canc Cell Signaling Lab, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NCI NIH HHS [CA82222, R01 CA100123, CA100123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100123, R01CA082222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, MOL CELL BIOL, V19, P1831; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; WANG S, 2004, NOVART FDN SYMP, V259, P245; WANG S, 2004, NOVART FDN SYMP, V259, P285; Wang Shaowen, 2004, Novartis Found Symp, V259, P238; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wherlock M, 2004, J CELL SCI, V117, P3221, DOI 10.1242/jcs.01193; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zeng PY, 2003, ONCOGENE, V22, P1124, DOI 10.1038/sj.onc.1206181	48	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1281	1289		10.1038/sj.onc.1209174	http://dx.doi.org/10.1038/sj.onc.1209174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247449				2022-12-25	WOS:000235708200001
J	Jean, D; Rousselet, N; Frade, R				Jean, D; Rousselet, N; Frade, R			Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms	ONCOGENE			English	Article						gene amplification; DNA methylation; transcription regulation; mRNA stability	HUMAN-MELANOMA CELLS; CHAIN VARIABLE FRAGMENT; CLEAVES HUMAN C3; 3RD COMPONENT; CYSTEINE PROTEINASE; PROCATHEPSIN-L; L GENE; METASTATIC PROPERTIES; COMPLEMENT; PROMOTER	Cathepsin L, a cysteine protease, is overexpressed in human tumor cells and plays a major role in melanoma progression. Our aim was herein to identify molecular mechanisms, which contribute to its overexpression. We found that cathepsin L protein expression correlated with mRNA level in tumor cells. Therefore, we focused on mechanisms involved in cathepsin L mRNA regulation. CpG island was localized in the 5' region of cathepsin L gene that encompassed regulatory regions identified as essential for promoter activity. CpG dinucleotides, not methylated in any melanoma cells analysed, were methylated in a B lymphoma cell line, which poorly express cathepsin L. Our data demonstrate that in lymphoma cells, cathepsin L silencing was methylation-dependent. Furthermore, gene amplification was involved in cathepsin L overexpression in one melanoma cell line, while transcriptional mechanisms but not mRNA stability are responsible of cathepsin L overexpression in others melanoma cells. In addition, NF-Y, Sp1, Sp2 and Sp3 transcription factors, essential to basal cathepsin L transcription, are not directly involved in overexpression. Thus, our data provides the first demonstration that cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.	INSERM, U 672, U 354, F-91030 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Jean, D (corresponding author), INSERM, U 672, U 354, Batiment G8,Campus 1,5 Rue Henri Desbrueres,Genop, F-91030 Evry, France.	jean354@genopole.evry.inserm.fr	Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404				Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Charron M, 2003, BIOL REPROD, V68, P1649, DOI 10.1095/biolreprod.102.012328; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; Frade R, 1999, IMMUNOPHARMACOLOGY, V42, P39, DOI 10.1016/S0162-3109(99)00028-4; Frade R, 2000, CANCER RES, V60, P6585; Frade R, 1998, CANCER RES, V58, P2733; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Guillaume-Rousselet N, 2002, BIOCHEM J, V367, P219, DOI 10.1042/BJ20020350; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Ishidoh K, 1997, BIOCHEM BIOPH RES CO, V238, P665, DOI 10.1006/bbrc.1997.7349; Jean D, 1996, CANCER RES, V56, P254; Jean D, 1997, IMMUNOL LETT, V58, P107, DOI 10.1016/S0165-2478(97)00030-8; Jean D, 2002, BIOCHEM J, V361, P173, DOI 10.1042/0264-6021:3610173; Jean D, 1995, BIOCHEM J, V312, P961, DOI 10.1042/bj3120961; KAMBOJ RC, 1993, BIOCHIMIE, V75, P873, DOI 10.1016/0300-9084(93)90042-Q; Kawada A, 1997, ARCH DERMATOL RES, V289, P87, DOI 10.1007/s004030050160; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mao X, 2000, CANCER GENET CYTOGEN, V122, P87, DOI 10.1016/S0165-4608(00)00278-8; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; Sriraman V, 2004, ENDOCRINOLOGY, V145, P582, DOI 10.1210/en.2003-0963; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6	33	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1474	1484		10.1038/sj.onc.1209196	http://dx.doi.org/10.1038/sj.onc.1209196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261157				2022-12-25	WOS:000235890400005
J	Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM				Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM			Molecular determinants of Akt-induced keratinocyte transformation	ONCOGENE			English	Article						Akt; myc; CycD; keratinocyte; HNSCC; Wnt pathway	SQUAMOUS-CELL CARCINOMA; GLYCOGEN-SYNTHASE KINASE; MOUSE SKIN CARCINOGENESIS; INTEGRIN-LINKED KINASE; BETA-CATENIN; CYCLIN D1; C-MYC; DEREGULATED EXPRESSION; MAMMALIAN TARGET; TUMOR-SUPPRESSOR	The PI3K/PTEN/Akt signaling pathway has emerged in recent years as a main player in human cancers, increasing proliferation and decreasing apoptosis of transformed cells, and thus becoming a potential target for therapeutic intervention. Our previous data have demonstrated that Akt-mediated signaling is of a key relevance in the mouse skin carcinogenesis system, one of the best-known models of experimental carcinogenesis. Here, we investigated the involvement of several pathways as mediators of Akt-induced increased proliferation and tumorigenesis in keratinocytes. Tumors produced by subcutaneous injection of Akt-transformed keratinocytes showed increased Foxo3a phosphorylation, but no major alterations in p21(Cip1/WAF1), p27(Kip1) or mdm2 expression and/or localization. In contrast, we found increased expression and nuclear localization of Delta Np63, beta-catenin and Lef1. Concomitantly, we also found increased expression of c-myc and CycD1, targets of the beta-catenin/Tcf pathway. Such increase is associated with increased phosphorylation and stabilization of c-myc protein as well as increased translation of c-myc and CycD1 due to mTOR activation. Using immunohistochemistry approaches in samples of oral dysplasias and human head and neck squamous cell carcinomas, we confirmed that increased Akt activation significantly correlates with increased Delta Np63 and CycD expression, c-myc phosphorylation and nuclear accumulation of beta-catenin. Collectively, these results demonstrate that Akt is able to transform keratinocytes by specific mechanisms involving transcriptional and post-transcriptional processes.	CIEMAT, Dept Cell & Mol Biol, E-28040 Madrid, Spain; Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Hospital Universitario 12 de Octubre	Paramio, JM (corresponding author), CIEMAT, Dept Cell & Mol Biol, Ave Complutense 22, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Santos, Mirentxu/AAA-1727-2020; Segrelles, Carmen/E-3655-2016; Garcia-Escudero, Ramon/A-2735-2012; Paramio, Jesus M/M-8482-2014; Martinez, Jesus/M-3791-2014; Cabanás, María Lara/AAH-3621-2019; Ruiz, Sergio/G-1561-2016	Segrelles, Carmen/0000-0001-9340-2102; Garcia-Escudero, Ramon/0000-0001-5640-6542; Paramio, Jesus M/0000-0001-7520-3177; Martinez, Jesus/0000-0002-9521-8744; Ruiz, Sergio/0000-0002-0177-6965				Ambrosch P, 2000, ANTICANCER RES, V20, P3151; Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Balz V, 2005, ADV OTO-RHINO-LARYNG, V62, P58; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bhatia N, 2005, MOL CARCINOGEN, V42, P213, DOI 10.1002/mc.20077; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Brown J, 2003, CARCINOGENESIS, V24, P171, DOI 10.1093/carcin/24.2.171; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Casanova ML, 2002, CANCER RES, V62, P3402; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Segrelles C, 2004, CARCINOGENESIS, V25, P1137, DOI 10.1093/carcin/bgh132; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Suzuki A, 2003, CANCER RES, V63, P674; Thurfjell N, 2005, ADV OTO-RHINO-LARYNG, V62, P49; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Warnakulasuriya KAAS, 1998, J ORAL PATHOL MED, V27, P376; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	75	79	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1174	1185		10.1038/sj.onc.1209155	http://dx.doi.org/10.1038/sj.onc.1209155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247457				2022-12-25	WOS:000235537500005
J	Radtke, S; Jorissen, A; Schmitz-Van de Leur, H; Heinrich, PC; Behrmann, I				Radtke, S; Jorissen, A; Schmitz-Van de Leur, H; Heinrich, PC; Behrmann, I			Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient expression in the absence of an associated Janus kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; INHIBITORY FACTOR-RECEPTOR; GROWTH-HORMONE RECEPTOR; CELL-SURFACE EXPRESSION; CYTOKINE RECEPTOR; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; CYTOPLASMIC TAIL; FERM DOMAIN; IN-VITRO	The oncostatinMreceptor (OSMR) is part of receptor complexes for oncostatin M and interleukin-31. Signaling events are triggered by Jaks (Janus kinases) that constitutively bind to membrane-proximal receptor regions. Besides their established role in signaling, Jaks are involved in the regulation of the surface expression of several cytokine receptors. Here, we analyzed the structural requirements within the human OSMR that underlie its limited surface expression in the absence of associated Jaks. We identified three dileucine-like motifs within the Jak-binding region of the OSMR that control receptor surface and overall expression. A receptor mutant in which all three motifs were mutated to alanine displayed markedly increased surface expression. Although the surface half-life of this mutant was increased compared with that of the wildtype receptor, no difference in the internalization rate was detectable, implying that these receptors differ in their post-endocytic fate. The protein stability of the wild-type receptor was markedly lower than that of mutant receptors, but could be strongly increased in the presence of the lysosomal inhibitor chloroquine. Our data are consistent with the dileucine motifs being involved in destabilization of receptors devoid of associated Jaks as part of a quality control ensuring signaling competence of OSMRs.	Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52074 Aachen, Germany	University of Luxembourg; RWTH Aachen University; RWTH Aachen University Hospital	Behrmann, I (corresponding author), Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	iris.behrmann@uni.lu		Behrmann, Iris/0000-0003-3688-3645				Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Derouet D, 2004, P NATL ACAD SCI USA, V101, P4827, DOI 10.1073/pnas.0306178101; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fujita H, 1999, BIOCHEM BIOPH RES CO, V255, P54, DOI 10.1006/bbrc.1998.0140; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; He K, 2005, ENDOCRINOLOGY, V146, P4755, DOI 10.1210/en.2005-0514; He K, 2003, MOL ENDOCRINOL, V17, P2211, DOI 10.1210/me.2003-0256; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OGATA S, 1994, J BIOL CHEM, V269, P5210; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Radtke S, 2005, J BIOL CHEM, V280, P25760, DOI 10.1074/jbc.M500822200; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Royer Y, 2005, J BIOL CHEM, V280, P27251, DOI 10.1074/jbc.M501376200; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	46	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4024	4034		10.1074/jbc.M511779200	http://dx.doi.org/10.1074/jbc.M511779200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16286453	hybrid			2022-12-25	WOS:000235275300031
J	Ghogomu, SM; van Venrooy, S; Ritthaler, M; Wedlich, D; Gradl, D				Ghogomu, SM; van Venrooy, S; Ritthaler, M; Wedlich, D; Gradl, D			HIC-5 is a novel repressor of lymphoid enhancer factor/T-cell factor-driven transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-ALPHA ENHANCER; BETA-CATENIN; ANDROGEN RECEPTOR; GLUCOCORTICOID-RECEPTOR; ACTIVATION DOMAIN; LIM DOMAINS; PROTEIN; WNT; LEF-1; COACTIVATOR	Activation of Wnt/beta-catenin target genes is regulated by a heterodimer of beta-catenin and the high mobility group box transcription factors of the lymphoid enhancer factor (LEF)/T-cell factor (TCF) family. In vertebrates, four LEF/TCF family members have been identified. They all contain a conserved beta-catenin-binding motif at the N terminus and a highly conserved high mobility group box for DNA binding. The core sequence between these motifs is less conserved and contributes to the specific properties of the individual family members. To identify interacting proteins that allocate specific functions to the individual LEF/TCF transcription factors, we performed a yeast two-hybrid screen using the less conserved core sequence as bait. We isolated the murine LIM protein HIC-5 ((h) under bar ydrogen peroxide-(i) under bar nduced (c) under bar lone (5) under bar; also termed ARA-55 ((a) under bar ndrogen (r) under bar eceptor (a) under bar ctivator of (55) under bar kDa)) and cloned the highly conserved Xenopus homolog. In addition, we report that the LIM domain-containing C-terminal half of HIC-5 binds to a conserved alternatively spliced exon in LEF/TCF transcription factors. Our functional analyses revealed that HIC-5 acts as negative regulator of a subset of LEF/TCF family members, which have been characterized as activators in reporter gene analyses and in the Xenopus axis induction assay. In addition, we observed a repressive interference of LEF/TCF family members with HIC-5-mediated activation of glucocorticoid-driven transcription, which again could be allocated to specific LEF/TCF subtypes. With the characterization of HIC-5 as a binding partner of the alternatively spliced exon in LEF/TCF transcription factors, we identified a novel molecular mechanism in the dialog of steroid and canonical Wnt signaling that is LEF/TCF subtype-dependent.	Univ Karlsruhe, Tech Hsch, Inst Zool 2, D-76131 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Gradl, D (corresponding author), Univ Karlsruhe, Tech Hsch, Inst Zool 2, Kaiserstr 12, D-76131 Karlsruhe, Germany.	dietmar.gradl@zi2.uni-karlsruhe.de	Ghogomu, Stephen/AAF-6825-2020					Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Gradl D, 2002, J BIOL CHEM, V277, P14159, DOI 10.1074/jbc.M107055200; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pukrop T, 2001, J BIOL CHEM, V276, P8968, DOI 10.1074/jbc.M007533200; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007	42	39	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1755	1764		10.1074/jbc.M505869200	http://dx.doi.org/10.1074/jbc.M505869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291758	hybrid			2022-12-25	WOS:000234652000056
J	Hua, B; Tamamori-Adachi, M; Luo, Y; Tamura, K; Morioka, M; Fukuda, M; Tanaka, Y; Kitajima, S				Hua, B; Tamamori-Adachi, M; Luo, Y; Tamura, K; Morioka, M; Fukuda, M; Tanaka, Y; Kitajima, S			A splice variant of stress response gene ATF3 counteracts NF-kappa B-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; C-JUN; REPRESSOR ATF3; MESSENGER-RNA; EXPRESSION; PROMOTER; INDUCTION; SUBUNIT	Activating transcription factor (ATF) 3 plays a role in determining cell fate and generates a variety of alternatively spliced isoforms in stress response. We have reported previously that splice variant ATF3 Delta Zip2, which lacks the leucine zipper region, is induced in response to various stress stimuli. However, its biological function has not been elucidated. By using cells treated with tumor necrosis factor-alpha and actinomycin D or cells overexpressing ATF3 Delta Zip2, we showed that ATF3 Delta Zip2 sensitizes cells to apoptotic cell death in response to tumor necrosis factor-alpha, at least in part through suppressing nuclear factor (NF)-kappa B-dependent transcription of antiapoptotic genes such as cIAP2 and XIAP. ATF3 Delta Zip2 interacts with a p65 (RelA)-cofactor complex containing CBP/p300 and HDAC1 at NF-kappa B sites of the proximal promoter region of the cIAP2 gene in vivo and down-regulates the recruitment of CBP/p300. Our study revealed that ATF3 Delta Zip2 counteracts anti-apoptotic activity of NF-kappa B, at least in part, by displacing positive cofactor CBP/p300 and provides insight into the mechanism by which ATF3 regulates cell fate through alternative splicing in stress response.	Tokyo Med & Dent Univ, Dept Biochem Genet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Lab Genome Struct & Regulat, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Dept Biochem Genet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp						Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hai T, 1999, GENE EXPRESSION, V7, P321; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 2003, J BIOL CHEM, V278, P32899, DOI 10.1074/jbc.M305456200; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	49	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1620	1629		10.1074/jbc.M508471200	http://dx.doi.org/10.1074/jbc.M508471200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291753	hybrid			2022-12-25	WOS:000234652000041
J	Horzempa, J; Comer, JE; Davis, SA; Castric, P				Horzempa, J; Comer, JE; Davis, SA; Castric, P			Glycosylation substrate specificity of Pseudomonas aeruginosa 1244 pilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA PILI; C-TERMINAL REGION; PROTEIN GLYCOSYLATION; MONOCLONAL-ANTIBODIES; CAMPYLOBACTER-JEJUNI; GLYCOPROTEINS; GLYCAN; IDENTIFICATION; PATHOGENS; ADHERENCE	The beta-carbon of the Pseudomonas aeruginosa 1244 pilin C-terminal Ser is a site of glycosylation. The present study was conducted to determine the pilin structures necessary for glycosylation. It was found that although Thr could be tolerated at the pilin C terminus, the blocking of the Ser carboxyl group with the addition of an Ala prevented glycosylation. Pilin from strain PA103 was not glycosylated by P. aeruginosa 1244, even when the C-terminal residue was converted to Ser. Substituting the disulfide loop region of strain PA103 pilin with that of strain 1244 allowed glycosylation to take place. Neither conversion of 1244 pilin disulfide loop Cys residues to Ala nor the deletion of segments of this structure prevented glycosylation. It was noted that the PA103 pilin disulfide loop environment was electronegative, whereas that of strain 1244 pilin had an overall positive charge. Insertion of a positive charge into the PA103 pilin disulfide loop of a mutant containing Ser at the C terminus allowed glycosylation to take place. Extending the "tail" region of the PA103 mutant pilin containing Ser at its terminus resulted in robust glycosylation. These results suggest that the terminal Ser is the major pilin glycosylation recognition feature and that this residue cannot be substituted at its carboxyl group. Although no other specific recognition features are present, the pilin surface must be compatible with the reaction apparatus for glycosylation to occur.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	Duquesne University	Castric, P (corresponding author), Duquesne Univ, Dept Biol Sci, 600 Forbes Ave, Pittsburgh, PA 15282 USA.	castric@duq.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054929] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054929-03, AI054929, R01 AI054929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Bolivar F, 1979, Methods Enzymol, V68, P245; CASTRIC P, 1995, MICROBIOL-UK, V141, P1247, DOI 10.1099/13500872-141-5-1247; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; CASTRIC PA, 1994, INFECT IMMUN, V62, P371, DOI 10.1128/IAI.62.2.371-376.1994; CASTRIC PA, 1989, MOL GEN GENET, V216, P75, DOI 10.1007/BF00332233; Chia JS, 2001, INFECT IMMUN, V69, P6987, DOI 10.1128/IAI.69.11.6987-6998.2001; Comer JE, 2002, INFECT IMMUN, V70, P2837, DOI 10.1128/IAI.70.6.2837-2845.2002; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; DiGiandomenico A, 2002, MOL MICROBIOL, V46, P519, DOI 10.1046/j.1365-2958.2002.03171.x; Feldman MF, 2005, P NATL ACAD SCI USA, V102, P3016, DOI 10.1073/pnas.0500044102; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; HATANO K, 1994, INFECT IMMUN, V62, P3608, DOI 10.1128/IAI.62.9.3608-3616.1994; HUNT JD, 1994, VACCINE, V12, P457, DOI 10.1016/0264-410X(94)90125-2; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kus JV, 2004, MICROBIOL-SGM, V150, P1315, DOI 10.1099/mic.0.26822-0; LEE KK, 1989, MOL MICROBIOL, V3, P1493, DOI 10.1111/j.1365-2958.1989.tb00135.x; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; LIU PV, 1973, J INFECT DIS, V128, P506, DOI 10.1093/infdis/128.4.506; Mattick JS, 2002, ANNU REV MICROBIOL, V56, P289, DOI 10.1146/annurev.micro.56.012302.160938; MESCHER MF, 1974, J BACTERIOL, V120, P945, DOI 10.1128/JB.120.2.945-954.1974; OMEARA TJ, 1993, IMMUNOL CELL BIOL, V71, P473, DOI 10.1038/icb.1993.53; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PETERS J, 1992, BIOL CHEM H-S, V373, P171, DOI 10.1515/bchm3.1992.373.1.171; RAMPHAL R, 1984, INFECT IMMUN, V44, P38, DOI 10.1128/IAI.44.1.38-40.1984; RAMPHAL R, 1991, INFECT IMMUN, V59, P1307, DOI 10.1128/IAI.59.4.1307-1311.1991; RUVKUN GB, 1981, NATURE, V289, P85, DOI 10.1038/289085a0; SAIMAN L, 1989, INFECT IMMUN, V57, P2764, DOI 10.1128/IAI.57.9.2764-2770.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; SHETH HB, 1994, MOL MICROBIOL, V11; SIDBERRY H, 1985, J IMMUNOL METHODS, V76, P299, DOI 10.1016/0022-1759(85)90307-2; Silipigni-Fusco J, 1987, THESIS U PITTSBURGH; Smedley JG, 2005, INFECT IMMUN, V73, P7922, DOI 10.1128/IAI.73.12.7922-7931.2005; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; WEST SEH, 1994, GENE, V128, P81; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	44	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1128	1136		10.1074/jbc.M510975200	http://dx.doi.org/10.1074/jbc.M510975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286455	Green Accepted, hybrid			2022-12-25	WOS:000234447200054
J	Komenda, J; Barker, M; Kuvikova, S; de Vries, R; Mullineaux, CW; Tichy, M; Nixon, PJ				Komenda, J; Barker, M; Kuvikova, S; de Vries, R; Mullineaux, CW; Tichy, M; Nixon, PJ			The FtsH protease slr0228 is important for quality control of photosystem II in the thylakoid membrane of Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-CENTER COMPLEX; SP PCC 6803; D1 PROTEIN; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; CORE COMPLEX; GENE; HOMOLOG	The cyanobacterium Synechocystis sp. PCC 6803 contains four members of the FtsH protease family. One of these, FtsH (slr0228), has been implicated recently in the repair of photodamaged photosystem II (PSII) complexes. We have demonstrated here, using a combination of blue native PAGE, radiolabeling, and immunoblotting, that FtsH (slr0228) is required for selective replacement of the D1 reaction center subunit in both wild type PSII complexes and in PSII subcomplexes lacking the PSII chlorophyll alpha-binding subunit CP43. To test whether FtsH (slr0228) has a more general role in protein quality control in vivo, we have studied the synthesis and degradation of PSII subunits in wild type and in defined insertion and missense mutants incapable of proper assembly of the PSII holoenzyme. We discovered that, when the gene encoding FtsH (slr0228) was disrupted in these strains, the overall level of assembly intermediates and unassembled PSII proteins markedly increased. Pulse-chase experiments showed that this was due to reduced rates of degradation in vivo. Importantly, analysis of epitope-tagged and green fluorescent protein-tagged strains revealed that slr0228 was present in the thylakoid and not the cytoplasmic membrane. Overall, our results show that FtsH (slr0228) plays an important role in controlling the removal of PSII subunits from the thylakoid membrane and is not restricted to selective D1 turnover.	Acad Sci, Inst Microbiol, Trebon 37981, Czech Republic; Univ S Bohemia, Inst Phys Biol, Nove Hrady 37333, Czech Republic; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Biol, London SW7 2AZ, England; Univ London, Sch Biol Sci, London E1 4NS, England	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Imperial College London; University of London	Komenda, J (corresponding author), Acad Sci, Inst Microbiol, Opatovicky Mlyn, Trebon 37981, Czech Republic.	komenda@alga.cz	Tichy, Martin/B-6545-2008; Komenda, Josef/H-4083-2014	Tichy, Martin/0000-0003-2814-1959; Komenda, Josef/0000-0003-4588-0382; Nixon, Peter/0000-0003-1952-6937				Adam Z, 2005, PHYSIOL PLANTARUM, V123, P386, DOI 10.1111/j.1399-3054.2004.00436.x; Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bailey S, 2002, J BIOL CHEM, V277, P2006, DOI 10.1074/jbc.M105878200; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Chiba S, 2002, J BACTERIOL, V184, P4775, DOI 10.1128/JB.184.17.4775-4782.2002; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; Jansen T, 2002, J PLANT PHYSIOL, V159, P1205, DOI 10.1078/0176-1617-00829; KALTWASSER M, 2002, APPL ENVIRON MICROB, V268, P624; Keren N, 2005, J BIOL CHEM, V280, P6548, DOI 10.1074/jbc.M410218200; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; Norling B, 1998, FEBS LETT, V436, P189, DOI 10.1016/S0014-5793(98)01123-5; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; ROGNER M, 1991, BIOCHEMISTRY-US, V30, P5387; Sakamoto W, 2002, GENES CELLS, V7, P769, DOI 10.1046/j.1365-2443.2002.00558.x; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; SMITH D, 1993, FEMS MICROBIOL LETT, V110, P341, DOI 10.1016/0378-1097(93)90126-M; Spence E, 2003, MOL MICROBIOL, V48, P1481, DOI 10.1046/j.1365-2958.2003.03519.x; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yu F, 2004, PLANT J, V37, P864, DOI 10.1111/j.1365-313X.2003.02014.x; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zhang LX, 2001, J BIOL CHEM, V276, P37809; Zhang PP, 2004, PLANT CELL, V16, P3326, DOI 10.1105/tpc.104.026526; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	39	117	122	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1145	1151		10.1074/jbc.M503852200	http://dx.doi.org/10.1074/jbc.M503852200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286465	hybrid			2022-12-25	WOS:000234447200056
J	Los, AP; Vinke, FP; de Widt, J; Topham, MK; van Blitterswijk, WJ; Divecha, N				Los, AP; Vinke, FP; de Widt, J; Topham, MK; van Blitterswijk, WJ; Divecha, N			The retinoblastoma family proteins bind to and activate diacylglycerol kinase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHOLIPASE-C BETA(1); CELL-CYCLE PROGRESSION; NUCLEAR DIACYLGLYCEROL; DNA-DAMAGE; PHOSPHATIDIC-ACID; SWISS 3T3-CELLS; ZETA; LOCALIZATION; ALPHA	The retinoblastoma protein (pRB) is a tumor suppressor and key regulator of the cell cycle. We have previously shown that pRB interacts with phosphatidylinositol-4-phosphate 5-kinases, lipid kinases that can regulate phosphatidylinositol 4,5-bisphosphate levels in the nucleus. Here, we investigated pRB binding to another lipid kinase in the phosphoinositide cycle, diacylglycerol kinase (DGK) that phosphorylates the second messenger diacylglycerol to yield phosphatidic acid. We found that DGK xi, but not DGK alpha or DGK beta, interacts with pRB in vitro and in vivo. Binding of DGK xi to pRB is dependent on the phosphorylation status of pRB, since only hypophosphorylated pRB interacts with DGK xi. DGK xi also binds to the pRB-related pocket proteins p107 and p130 in vitro and in cells. Although DGK xi did not affect the ability of pRB to regulate E2F-mediated transcription, we found that pRB, p107, and p130 potently stimulate DGK xi activity in vitro. Finally, overexpression of DGK xi in pRB-null fibroblasts reconstitutes a cell cycle arrest induced by gamma-irradiation. These results suggest that DGK xi may act in vivo as a downstream effector of pRB to regulate nuclear levels of diacylglycerol and phosphatidic acid.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Netherlands Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Divecha, N (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.v.blitterswijk@nki.nl; n.divecha@nki.nl		divecha, nullin/0000-0001-9695-6039				BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; Brose N, 2004, CURR OPIN NEUROBIOL, V14, P328, DOI 10.1016/j.conb.2004.05.006; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; D'Santos CS, 1999, CURR BIOL, V9, P437, DOI 10.1016/S0960-9822(99)80193-6; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Divecha N, 2002, CURR BIOL, V12, P582, DOI 10.1016/S0960-9822(02)00769-8; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hozumi Y, 2003, EUR J NEUROSCI, V18, P1448, DOI 10.1046/j.1460-9568.2003.02871.x; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Luo B, 2004, CELL SIGNAL, V16, P983, DOI 10.1016/j.cellsig.2004.03.016; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Manzoli L, 1997, CANCER RES, V57, P2137; Martelli AM, 2000, CANCER RES, V60, P815; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Matteucci A, 1998, CANCER RES, V58, P5057; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; VANBLITTERSWIJK WJ, 1994, CURRENT TOPICS MEMBR; Xia XM, 2003, MOL CELL BIOL, V23, P1717, DOI 10.1128/MCB.23.5.1717-1725.2003; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001	41	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					858	866		10.1074/jbc.M502693200	http://dx.doi.org/10.1074/jbc.M502693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286473	hybrid			2022-12-25	WOS:000234447200024
J	Giannattasio, S; Liu, ZC; Thornton, J; Butow, RA				Giannattasio, S; Liu, ZC; Thornton, J; Butow, RA			Retrograde response to mitochondrial dysfunction is separable from TOR1/2 regulation of retrograde gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RTG-DEPENDENT MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; SIGNALING PATHWAY; CELL-GROWTH; GLUTAMINE-SYNTHETASE; AMMONIA METABOLISM; PROTEIN COMPLEXES	Retrograde (RTG) signaling senses mitochondrial dysfunction and initiates readjustments of carbohydrate and nitrogen metabolism through nuclear accumulation of the heterodimeric transcription factors, Rtg1/3p. The RTG pathway is also linked to target of rapamycin (TOR) signaling, among whose activities is transcriptional control of nitrogen catabolite repression (NCR)-sensitive genes. To investigate the connections between these two signaling pathways, we have analyzed rapamycin sensitivity of the expression of the RTG target gene CIT2 and of two NCR-sensitive genes, GLN1 and DAL5, in respiratory-competent (p(+)) and -incompetent (p(0)) yeast cells. Here we have presented evidence that retrograde gene expression is separable from TOR regulation of RTG- and NCR-responsive genes. We showed that expression of these two classes of genes is differentially regulated by glutamate starvation whether in response to mitochondrial dysfunction or induced by rapamycin treatment, as well by glutamine or histidine starvation. We also showed that Lst8p, a component of the TOR1/2 complexes and a negative regulator of the RTG pathway, has multiple roles in the regulation of RTG- and NCR-sensitive genes. Lst8p negatively regulates CIT2 and GLN1 expression, whereas DAL5 expression is independent of Lst8p function. DAL5 expression depends on the GATA transcription factors Gln3p and Gat1p. Gat1p is translocated to the nucleus only upon TOR inhibition by rapamycin. Altogether, these data show that Rtg1/3p, Gln3p, and Gat1p can be differentially regulated through different nutrient-sensing pathways, such as TOR and retrograde signaling, and by multiple factors, such as Lst8p, which is suggested to have a role in connecting the RTG and TOR pathways.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; CNR, Ist Biomembrane & Bioenerget, I-70126 Bari, Italy	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR)	Butow, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ronald.Butow@UTSouthwestern.edu		Giannattasio, Sergio/0000-0001-5559-5556; Thornton, Janet/0000-0003-0824-4096	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chelstowska A, 1999, YEAST, V15, P1377, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1377::AID-YEA473>3.0.CO;2-0; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Crespo JL, 2004, J BIOL CHEM, V279, P37512, DOI 10.1074/jbc.M407372200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cunningham TS, 2000, J BACTERIOL, V182, P6584, DOI 10.1128/JB.182.23.6584-6591.2000; Dilova I, 2004, J BIOL CHEM, V279, P46527, DOI 10.1074/jbc.M409012200; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Forsberg H, 2001, MOL MICROBIOL, V42, P215, DOI 10.1046/j.1365-2958.2001.02627.x; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; MacAlpine DM, 2000, EMBO J, V19, P767, DOI 10.1093/emboj/19.4.767; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MANNING JM, 1969, BIOCHEMISTRY-US, V8, P2681, DOI 10.1021/bi00834a066; MINEHART PL, 1992, J BACTERIOL, V174, P1828, DOI 10.1128/jb.174.6.1828-1836.1992; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Rai R, 2004, FEMS YEAST RES, V5, P29, DOI 10.1016/j.femsyr.2004.06.004; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; Wang HM, 2003, MOL CELL BIOL, V23, P3116, DOI 10.1128/MCB.23.9.3116-3125.2003; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; WULLSCHLEGER S, 2005, J BIOL CHEM	54	67	69	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42528	42535		10.1074/jbc.M509187200	http://dx.doi.org/10.1074/jbc.M509187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16253991	hybrid			2022-12-25	WOS:000234200800008
J	Kumbrink, J; Gerlinger, M; Johnson, JP				Kumbrink, J; Gerlinger, M; Johnson, JP			Egr-1 induces the expression of its corepressor Nab2 by activation of the Nab2 promoter thereby establishing a negative feedback loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ENDOTHELIAL-CELLS; CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENT; PROSTATE-CANCER; SP1; PROTEINS; BINDING; TRANSACTIVATION	The transcription factor Egr-1 regulates the expression of numerous genes involved in differentiation, growth, and in response to environmental signals. Egr-1 activity is modulated in part through the binding of corepressors Nab1 and Nab2. Nab2 appears crucial for controlling Egr-1-mediated transactivation because it is a delayed early response gene, induced by the same stimuli that induce the immediate early gene Egr-1. To identify important elements regulating Nab2 expression, we cloned the human Nab2 gene and investigated the 5'- region. The TATA- and initiator-less Nab2 promoter, located from -679 to -74 bp, contains a total of 11 Egr binding sites, including a cluster of multiple overlapping Egr/Sp1 sites between -329 and -260 bp. This region is critical for basal promoter activity as well as for maximum induction by phorbol esters. Electromobility shifts show that Sp1 binds to this region in normal and stimulated cells, whereas stimulation induces binding of Egr-1. In addition Egr-1 activates the Nab2 promoter in a pattern similar to phorbol esters, suggesting that Egr-1 is a major inducer of protein kinase C-mediated Nab2 induction. Depletion of Egr-1 by each of two distinct Egr-1 short-interfering RNAs reduces Nab2 expression and inducibility, confirming that Egr-1 is an important regulator of Nab2 expression. Transfection experiments show that Egr-1-induced Nab2 promoter activity is itself repressed by Nab2. These results indicate that Egr-1 mediates the induction of its own repressor, thereby preventing a permanent transactivation of Egr-1 target genes and a damaging overreaction in response to environmental signals.	Univ Munich, Inst Immunol, D-80336 Munich, Germany	University of Munich	Johnson, JP (corresponding author), Univ Munich, Inst Immunol, Goethestr 31, D-80336 Munich, Germany.	johnson@med.uni-muenchen.de		Gerlinger, Marco/0000-0003-2719-299X				Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Eid MA, 1998, CANCER RES, V58, P2461; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Jimenez SK, 2004, CARDIOVASC RES, V62, P548, DOI 10.1016/j.cardiores.2004.01.032; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kirsch KH, 1996, ONCOGENE, V12, P963; Krikun G, 2000, MOL ENDOCRINOL, V14, P393, DOI 10.1210/me.14.3.393; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEUNG S, 1993, ONCOGENE, V8, P989; Lucerna M, 2003, J BIOL CHEM, V278, P11433, DOI 10.1074/jbc.M204937200; Mechta-Grigoriou F, 2000, DEVELOPMENT, V127, P119; Midgley VC, 2004, J BIOL CHEM, V279, P40289, DOI 10.1074/jbc.M406063200; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Neef R, 2002, CANCER RES, V62, P5920; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raychowdhury R, 2001, GASTROENTEROLOGY, V120, pA305; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Venken K, 2002, NEUROGENETICS, V4, P37, DOI 10.1007/s10048-001-0124-2; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Yang WS, 1998, J LIPID RES, V39, P2054	32	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42785	42793		10.1074/jbc.M511079200	http://dx.doi.org/10.1074/jbc.M511079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260776	hybrid			2022-12-25	WOS:000234200800039
J	Burguiere, A; Hitchen, PG; Dover, LG; Kremer, L; Ridell, M; Alexander, DC; Liu, J; Morris, HR; Minnikin, DE; Dell, A; Besra, GS				Burguiere, A; Hitchen, PG; Dover, LG; Kremer, L; Ridell, M; Alexander, DC; Liu, J; Morris, HR; Minnikin, DE; Dell, A; Besra, GS			LosA, a key glycosyltransferase involved in the biosynthesis of a novel family of glycosylated acyltrehalose lipooligosaccharides from Mycobacterium marinum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREHALOSE-CONTAINING LIPOOLIGOSACCHARIDES; PHOSPHATIDYLINOSITOL MANNOSIDE; TUBERCULOSIS COMPLEX; ANTIGENS; MANNOSYLTRANSFERASE; LIPOARABINOMANNAN; GENE; DEFINITION; KANSASII; GASTRI	Members of the genus Mycobacterium are characterized by cell envelopes rich in unusual free lipids, interacting with a covalently anchored mycolyl-arabinogalactan matrix. Previous studies have shown that Mycobacterium marinum produces large amounts of a diacylglycosylphenolphthiocerol, "phenolic" glycolipid. When cultivated on liquid Sauton medium, traces of a polar lipooligosaccharide ( LOS) glycolipid antigen were also previously indicated. In this study, it was found that growth of the type strain of M. marinum on solid Sauton or Middlebrook 7H10 agar gave substantial, but different, amounts of a family of four major trehalose-based LOSs. The core pentasaccharide LOS-I was a rhamnosyl diglucosyl-acylated trehalose. The heptasaccharide, LOS-II, was derived from LOS-I by adding xylose accompanied by a novel sugar ( X); repeated addition of this sugar unit X gave the octasaccharide LOS-III. LOS-IV has a decasaccharide component with two additional unusual sugar units, YZ. In a recent study ( Alexander, D. C., Jones, J. R., Tan, T., Chen, J. M., and Liu, J. ( 2004) J. Biol. Chem. 279, 18824 - 18833), chromatographically similar glycolipids were assigned to the family of phosphatidylinositol mannosides ( PIMs) and a "PimF" ( Rv1500) glycosyltransferase implicated in the conversion of a supposed "PIM5" to a "PIM7. " The present study indicates that these putative PIMs are in fact members of the phosphorus-free LOS family of glycolipids and that the protein product of Rv1500, which we have now termed LosA, is a glycosyltransferase involved in transferring sugars to LOS-III to form LOS-IV of M. marinum.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Mol Biosci, London SW7 2AZ, England; Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Mol Interact Membranaires, F-34095 Montpellier, France; Univ Gothenburg, Dept Immunol & Med Microbiol, S-40530 Gothenburg, Sweden; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; M SCAN Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	University of Birmingham; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Gothenburg; University of Toronto	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Kremer, Laurent/M-4935-2017; Dover, Lynn George/Q-6778-2019; Liu, Jun/AAC-9209-2019; Dover, Lynn G/F-3021-2010	Kremer, Laurent/0000-0002-6604-4458; Dover, Lynn George/0000-0002-4776-2665; Liu, Jun/0000-0002-0522-6733; Dover, Lynn G/0000-0002-4776-2665; Besra, Gurdyal/0000-0002-5605-0395	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander DC, 2004, J BIOL CHEM, V279, P18824, DOI 10.1074/jbc.M400791200; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BESRA GS, 1994, ACS SYM SER, V541, P203; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P12705, DOI 10.1021/bi00210a020; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; BRENNAN PJ, 1984, MICROBIOLOGY 1984, P366; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; DELL A, 1994, METHOD ENZYMOL, V203, P108; DOBSON G, 1990, BIOCHIM BIOPHYS ACTA, V1042, P176, DOI 10.1016/0005-2760(90)90004-H; Dobson G., 1985, CHEM METHODS BACTERI, P237; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; GILLERON M, 1995, GLYCOCONJUGATE J, V12, P298, DOI 10.1007/BF00731333; GILLERON M, 1993, J BIOL CHEM, V268, P3168; Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; HUNTER SW, 1985, BIOCHEMISTRY-US, V24, P2798, DOI 10.1021/bi00332a030; HUNTER SW, 1988, BIOCHEMISTRY-US, V27, P1549, DOI 10.1021/bi00405a023; HUNTER SW, 1983, J BIOL CHEM, V258, P481; JANTZEN E, 1989, APMIS, V97, P1037, DOI 10.1111/j.1699-0463.1989.tb00515.x; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; MCNEIL M, 1987, J BACTERIOL, V169, P3312, DOI 10.1128/jb.169.7.3312-3320.1987; Minnikin D E, 1989, Acta Leprol, V7 Suppl 1, P51; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; MINNIKIN DE, 1990, FEMS MICROBIOL LETT, V67, P55; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Papa F, 1989, Acta Leprol, V7 Suppl 1, P98; PREHM P, 1980, CARBOHYD RES, V78, P372, DOI 10.1016/0008-6215(80)90018-X; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Stamm LA, 2004, MICROBES INFECT, V6, P1418, DOI 10.1016/j.micinf.2004.10.003; Tonjum T, 1998, J CLIN MICROBIOL, V36, P918; Wallace PA, 1996, CHEM PHYS LIPIDS, V82, P141, DOI 10.1016/0009-3084(96)02570-4	40	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42124	42133		10.1074/jbc.M507500200	http://dx.doi.org/10.1074/jbc.M507500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257960	hybrid			2022-12-25	WOS:000233992700039
J	Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M				Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M			Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1dependent	ONCOGENE			English	Article						Apaf-1; apoptin; apoptosis; caspases; Bcl-2; Bcl-xL	CHICKEN ANEMIA VIRUS; TUMOR-CELLS; INDUCED APOPTOSIS; PROTEIN APOPTIN; NUCLEAR-LOCALIZATION; CASPASE ACTIVATION; BH3-ONLY PROTEINS; CANCER; INDUCTION; SIGNAL	Apoptin, a chicken anemia virus-derived protein, selectively induces apoptosis in transformed but not in normal cells, thus making it a promising candidate as a novel anticancer therapeutic. The mechanism of apoptin-induced apoptosis is largely unknown. Here, we report that contrary to previous assumptions, Bcl-2 and Bcl-x(L) inhibit apoptin-induced cell death in several tumor cell lines. In contrast, deficiency of Bax conferred resistance, whereas Bax expression sensitized cells to apoptin-induced death. Cell death induction by apoptin was associated with cytochrome c release from mitochondria as well as with caspase-3 and -7 activation. Benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone, a broad spectrum caspase inhibitor, was highly protective against apoptin-induced cell death. Apoptosis induced by apoptin required Apaf-1, as immortalized Apaf-1-deficient fibroblasts as well as tumor cells devoid of Apaf-1 were strongly protected. Thus, our data indicate that apoptin-induced apoptosis is not only Bcl-2- and caspase dependent, but also engages an Apaf-1 apoptosome-mediated mitochondrial death pathway.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, Munster, Germany; Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada	Heinrich Heine University Dusseldorf; University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Manitoba	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Burek, Malgorzata/AAF-3283-2021; Schulze-Osthoff, Klaus/N-9025-2013	Burek, Malgorzata/0000-0001-6148-2195; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411	Canadian Institutes of Health Research [81237] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; ALMAZAN G, 1992, BRAIN RES, V579, P234, DOI 10.1016/0006-8993(92)90056-F; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Bouillet P, 2002, J CELL SCI, V115, P1567; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Danen-Van Oorschot AAAM, 1999, ADV EXP MED BIOL, V457, P245; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Everett H, 2001, VIROLOGY, V288, P1, DOI 10.1006/viro.2001.1081; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Ghavami S, 2004, J LEUKOCYTE BIOL, V76, P169, DOI 10.1189/jlb.0903435; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JAATTELA M, 1995, ONCOGENE, V10, P2297; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; LAMKANFI M, 2002, CASPASES THEIR ROLE; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Somai S, 2003, INT J CANCER, V105, P607, DOI 10.1002/ijc.11147; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Wadia JS, 2004, J VIROL, V78, P6077, DOI 10.1128/JVI.78.11.6077-6078.2004; Zhang YH, 2003, EXP CELL RES, V289, P36, DOI 10.1016/S0014-4827(03)00188-5; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	52	62	73	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2213	2222		10.1038/sj.onc.1209258	http://dx.doi.org/10.1038/sj.onc.1209258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288204	Green Accepted, Green Published			2022-12-25	WOS:000236581200008
J	Shaw, RW; Kim, SK; Kim, KM; Cottenoir, M; Sims, CL; Peng, J; Fisher, AJ				Shaw, RW; Kim, SK; Kim, KM; Cottenoir, M; Sims, CL; Peng, J; Fisher, AJ			Novel DNA and RNA inhibitors of metallo-beta-lactamase	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					Texas Tech Univ, Lubbock, TX 79409 USA; Univ Calif Davis, Davis, CA 95616 USA	Texas Tech University System; Texas Tech University; University of California System; University of California Davis									0	41	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2006	20	5	2				A898	A898		10.1096/fj.05-4055fje	http://dx.doi.org/10.1096/fj.05-4055fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	026GA	16293708				2022-12-25	WOS:000236326200376
J	Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R				Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R			The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1	ONCOGENE			English	Article						phosphoinositol 3-kinase; LY294002; multidrug resistance-associated protein MRP1; colon cancer; doxorubicin	BREAST-CANCER CELLS; MULTIDRUG-RESISTANCE; INDUCED APOPTOSIS; ADENOCARCINOMA CELLS; SIGNALING PATHWAY; ACTIVATION LEADS; ERK ACTIVATION; RAS ONCOGENES; EXPRESSION; 3-KINASE	Multidrug resistance may be achieved by the activation of membrane transporters, detoxification, alterations in DNA repair or failure in apoptotic pathways. Recent data have suggested an involvement of mitogenic signalling pathways mediated by Ras and phosphoinositol-3-kinase (PI3K/Akt) in controlling multidrug resistance. Since these pathways are important targets for therapeutic interference, we sought to investigate whether blocking effectors kinases by specific inhibitors would result in a sensitization toward cytotoxic drugs. We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect. This suggested that the PI3K-pathways controls cell survival and drug resistance in these cells. Besides blocking Akt phosphorylation, the PI3K-inibitor increased the intracellular doxorubicin concentration threefold. LY294002 inhibits drug export in a competitive manner as revealed by measuring drug efflux in the presence and the absence of inhibitor. The efficacy of drug efflux inhibition by LY294002 was similar to that achieved by the MRP1 inhibitors MK571 and genistein. We conclude that the PI3K inhibitor LY294002 may have therapeutic potential when combined with doxorubicin in the treatment of MRP1-mediated drug resistance.	Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Gyorffy, Balazs/AAA-9135-2021; Serra, Violeta/AAG-8328-2019; Schäfer, Reinhold/AAB-5110-2021	Gyorffy, Balazs/0000-0002-5772-3766; Jurchott, Karsten/0000-0003-1589-0037; Serra, Violeta/0000-0001-6620-1065				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; BERG J, 2002, BIOCH ENYZMES BASIC; BOS JL, 1989, CANCER RES, V49, P4682; Brognard J, 2001, CANCER RES, V61, P3986; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; Chang FM, 2003, INT J ONCOL, V22, P469; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chen ZH, 2003, MOL CANCER THER, V2, P543; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Clark AS, 2002, MOL CANCER THER, V1, P707; Ding S, 2001, BRIT J CANCER, V85, P1175, DOI 10.1054/bjoc.2001.2044; DiSimone D, 1997, ANTICANCER RES, V17, P3587; Filipeanu CM, 2000, FEBS LETT, V474, P107, DOI 10.1016/S0014-5793(00)01585-4; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GYORFFY B, 2005, IN PRESS ONCOGENE; Han JW, 1997, CANCER RES, V57, P176; Hu LM, 2002, CANCER RES, V62, P1087; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; KOPNIN BP, 1995, ONCOL RES, V7, P299; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054/bjoc.2001.2107; Mizutani H, 2005, LIFE SCI, V76, P1439, DOI 10.1016/j.lfs.2004.05.040; Nakashio A, 2000, CANCER RES, V60, P5303; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Ng SSW, 2000, CANCER RES, V60, P5451; Plasschaert SLA, 2003, CLIN CANCER RES, V9, P5171; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; van Zanden JJ, 2004, BIOCHEM PHARMACOL, V67, P1607, DOI 10.1016/j.bcp.2003.12.032; van Zuylen L, 2000, INVEST NEW DRUG, V18, P205, DOI 10.1023/A:1006487003814; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang QD, 2002, CLIN CANCER RES, V8, P1940; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yu DH, 1996, ONCOGENE, V13, P1359; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	94	108	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1743	1752		10.1038/sj.onc.1209201	http://dx.doi.org/10.1038/sj.onc.1209201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288223				2022-12-25	WOS:000236013700006
J	Worrillow, LJ; Allan, JM				Worrillow, LJ; Allan, JM			Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia	ONCOGENE			English	Article						therapy-related AML; DNA mismatch repair; homologous recombination repair; alkylating agents; embryonic stem cells; clones	ACUTE MYELOID-LEUKEMIA; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; P53 MUTATIONS; HUMAN RAD51; MSH2 GENE; MECHANISMS; RESISTANCE; EXPRESSION	Chemotherapeutic regimes involving alkylating agents, such as methylators and cross linking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2-proficient and -defficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMR-competent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.	Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England	University of York - UK	Allan, JM (corresponding author), Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England.	jim.allan@egu.york.ac.uk	Allan, James/B-4448-2009	Allan, James/0000-0002-7580-5087				Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BenYehuda D, 1996, BLOOD, V88, P4296; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Boulton E, 2003, BLOOD, V101, P2349, DOI 10.1182/blood-2002-08-2394; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Clark DJ, 1996, GENE CHROMOSOME CANC, V16, P238, DOI 10.1002/(SICI)1098-2264(199608)16:4<238::AID-GCC3>3.3.CO;2-L; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Davies SM, 2001, MED PEDIATR ONCOL, V36, P536, DOI 10.1002/mpo.1126; Delwail V, 2002, BRIT J HAEMATOL, V118, P189, DOI 10.1046/j.1365-2141.2002.03564.x; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Gaymes TJ, 2002, CANCER RES, V62, P2791; Giot L, 1997, GENETICS, V146, P1239; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hatch SB, 2005, CLIN CANCER RES, V11, P2180, DOI 10.1158/1078-0432.CCR-04-0234; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Loeb LA, 2001, CANCER RES, V61, P3230; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Mohammad H, 2002, BRIT J HAEMATOL, V117, P359, DOI 10.1046/j.1365-2141.2002.03458.x; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pedersen-Bjergaard J, 2002, BLOOD, V99, P1909, DOI 10.1182/blood.V99.6.1909; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; Qin XS, 2000, CARCINOGENESIS, V21, P833, DOI 10.1093/carcin/21.4.833; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Thirman MJ, 1996, HEMATOL ONCOL CLIN N, V10, P293, DOI 10.1016/S0889-8588(05)70340-3; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang ZM, 2001, J NATL CANCER I, V93, P1473, DOI 10.1093/jnci/93.19.1473; Worrillow LJ, 2003, CLIN CANCER RES, V9, P3012; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	47	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1709	1720		10.1038/sj.onc.1209208	http://dx.doi.org/10.1038/sj.onc.1209208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278672				2022-12-25	WOS:000236013700003
J	Joyce, J; Cook, J; Chabot, D; Hepler, R; Shoop, W; Xu, QW; Stambaugh, T; Aste-Amezaga, M; Wang, S; Indrawati, L; Bruner, M; Friedlander, A; Keller, P; Caulfield, M				Joyce, J; Cook, J; Chabot, D; Hepler, R; Shoop, W; Xu, QW; Stambaugh, T; Aste-Amezaga, M; Wang, S; Indrawati, L; Bruner, M; Friedlander, A; Keller, P; Caulfield, M			Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; VACCINE; POLYSACCHARIDE; SAFETY; PEPTIDE; IMMUNIZATION; ANTIBODIES; PLASMID	The capsular polypeptide of Bacillus anthracis is composed of a unique polyglutamic acid polymer in which D-glutamate monomers are joined by gamma-peptidyl bonds. The capsule is poorly immunogenic, and efforts at exploiting the polymer for vaccine development have focused on increasing its inherent immunogenicity through chemical coupling to immune-stimulating protein carriers. The usual strategy has employed carbodiimide-based condensing reagents for activation of free alpha-carboxyl groups, despite reports that this chemistry may lead to chain scission. We have purified the high molecular mass capsule to > 95% homogeneity and have demonstrated that the polymer contains > 99% poly-gamma-D-glutamic acid. The predominant structure of the polymer as assessed by circular dichroism and multiangle laser light scattering was unordered at near-neutral pH. We investigated the effects of various activation chemistries, and we demonstrated that carbodiimide treatment under aqueous conditions results in significant cleavage of the alpha-peptidyl bond, whereas scission is significantly reduced in nonaqueous polar solvents, although undesired side chain modification was still observed. An activation chemistry was developed using the triazine-based reagent 4-(4,6-dimethoxy (1,3,5) triazin-2-yl)-4-methylmorpholinium chloride, which allowed for controlled and reproducible derivatization of alpha-carbonyls. In a two-pot reaction scheme, activated capsule was derivatized with a sulfhydryl-reactive heterobifunctional moiety and was subsequently coupled to thiolated carrier protein. This conjugate elicited very high capsule-specific immune titers in mice. More importantly, mice immunized with conjugated capsule exhibited good protection against lethal challenge from a virulent B. anthracis strain in two models of infection. We also showed, for the first time, that treatment of capsule with carbodiimide significantly reduced recognition by capsule-specific antisera concurrent with the reagent-induced reduction of polymer mass. The data suggested that for vaccine development, maintenance of the high mass of the polymer may be important.	Merck Res Labs, Dept Vaccine Res, Lab Sci & Investigat Toxicol & Bioproc & Bioanaly, West Point, PA 19486 USA; Merck Res Labs, Dept Biol Res, Lab Sci & Investigat Toxicol & Bioproc & Bioanaly, West Point, PA 19486 USA; USA, Med Res Inst Infect Dis, Frederick, MD 21701 USA; Merck Res Labs, Dept Human & Anim Infect Dis Res, Rahway, NJ 07065 USA; Lockheed Martin, Edison, NJ 08837 USA	Merck & Company; Merck & Company; Merck & Company; Lockheed Martin	Joyce, J (corresponding author), Merck Res Labs, Dept Vaccine & Biol Res, POB 4, West Point, PA 19486 USA.	joseph_joyce@merck.com	Hepler, Robert/A-9664-2008	Hepler, Robert/0000-0003-4344-8203; Chabot, Donald/0000-0003-4925-5779				BALASUBRAMANIAN D, 1973, BIOPOLYMERS, V12, P1089, DOI 10.1002/bip.1973.360120513; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; Bhatnagar R, 2001, CRIT REV MICROBIOL, V27, P167, DOI 10.1080/20014091096738; CAULFIELD MJ, 1984, J IMMUNOL METHODS, V74, P205, DOI 10.1016/0022-1759(84)90288-6; Chabot DJ, 2004, VACCINE, V23, P43, DOI 10.1016/j.vaccine.2004.05.029; Crescenzi V, 1996, ACS SYM SER, V627, P233; Demicheli V, 1998, VACCINE, V16, P880, DOI 10.1016/S0264-410X(98)00023-1; DONNELLY JJ, 1990, J IMMUNOL, V145, P3071; Drysdale M, 2005, EMBO J, V24, P221, DOI 10.1038/sj.emboj.7600495; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FATTOM A, 1995, VACCINE, V13, P1288, DOI 10.1016/0264-410X(95)00052-3; FATTOM A, 1990, INFECT IMMUN, V58, P2309, DOI 10.1128/IAI.58.7.2309-2312.1990; FRANZBLAU C, 1963, BIOPOLYMERS, V1, P79, DOI 10.1002/bip.360010109; Friedlander AM, 1999, JAMA-J AM MED ASSOC, V282, P2104, DOI 10.1001/jama.282.22.2104; GAST K, 1992, LASER LIGHT SCATTERI, P209; Goldblatt D, 1998, J MED MICROBIOL, V47, P563, DOI 10.1099/00222615-47-7-563; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; IVINS BE, 1986, INFECT IMMUN, V52, P454, DOI 10.1128/IAI.52.2.454-458.1986; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; Joyce JG, 2003, CARBOHYD RES, V338, P903, DOI 10.1016/S0008-6215(03)00045-4; Kimura T, 2002, J AM CHEM SOC, V124, P11596, DOI 10.1021/ja026639f; Kniskern P J, 1995, Pharm Biotechnol, V6, P673; Kozel TR, 2004, P NATL ACAD SCI USA, V101, P5042, DOI 10.1073/pnas.0401351101; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; LIFELY MR, 1987, VACCINE, V5, P11, DOI 10.1016/0264-410X(87)90004-1; Lindberg AA, 1999, VACCINE, V17, pS28, DOI 10.1016/S0264-410X(99)00232-7; MACKENZIE SL, 1974, J CHROMATOGR, V97, P19, DOI 10.1016/S0021-9673(01)97579-X; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARLBOROUGH DI, 1973, BIOPOLYMERS, V12, P1083, DOI 10.1002/bip.1973.360120512; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; MIKESELL P, 1983, INFECT IMMUN, V39, P371, DOI 10.1128/IAI.39.1.371-376.1983; Mirlashari Mohammad Reza, 2003, Med Sci Monit, V9, pBR316; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; MULHOLLAND EK, 1993, PEDIATR INFECT DIS J, V12, P632, DOI 10.1097/00006454-199308000-00002; NAKAJIMA N, 1995, BIOCONJUGATE CHEM, V6, P123, DOI 10.1021/bc00031a015; PATERSON Y, 1980, BIOCHEM BIOPH RES CO, V95, P1722, DOI 10.1016/S0006-291X(80)80097-0; Pawlowski A, 2000, VACCINE, V18, P1873, DOI 10.1016/S0264-410X(99)00336-9; Perez-Camero G, 1999, BIOTECHNOL BIOENG, V63, P110, DOI 10.1002/(SICI)1097-0290(19990405)63:1<110::AID-BIT11>3.0.CO;2-T; Perez-Melgosa M, 2001, EUR J IMMUNOL, V31, P2373, DOI 10.1002/1521-4141(200108)31:8<2373::AID-IMMU2373>3.0.CO;2-G; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; Rhie GE, 2003, P NATL ACAD SCI USA, V100, P10925, DOI 10.1073/pnas.1834478100; ROELANTS GE, 1969, J IMMUNOL, V103, P937; Schneerson R, 2003, P NATL ACAD SCI USA, V100, P8945, DOI 10.1073/pnas.1633512100; Sever JL, 2004, PHARMACOEPIDEM DR S, V13, P825, DOI 10.1002/pds.936; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; Wang TT, 2004, INFECT IMMUN, V72, P5460, DOI 10.1128/IAI.72.9.5460-5463.2004; Wang TT, 2004, FEMS IMMUNOL MED MIC, V40, P231, DOI 10.1016/S0928-8244(03)00366-3; WESSELS MR, 1987, P NATL ACAD SCI USA, V84, P9170, DOI 10.1073/pnas.84.24.9170; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Zanuy D, 1998, INT J BIOL MACROMOL, V23, P175, DOI 10.1016/S0141-8130(98)00047-6; Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200	52	60	63	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4831	4843		10.1074/jbc.M509432200	http://dx.doi.org/10.1074/jbc.M509432200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16293624	hybrid			2022-12-25	WOS:000235426200034
J	Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I				Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I			Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity	ONCOGENE			English	Article						15-lipoxygenase-1; PPAR-gamma; PPAR-delta; colon cancer	PROLIFERATOR-ACTIVATED RECEPTOR; COLORECTAL-CANCER CELLS; ADIPOCYTE DIFFERENTIATION; COLON CARCINOGENESIS; NUCLEAR RECEPTORS; DELTA; APOPTOSIS; LIGANDS; 15-LIPOXYGENASE-1; EXPRESSION	Peroxisome proliferator-activated receptors (PPARs) are transcription factors that strongly influence molecular events in normal and cancer cells. PPAR-beta/delta (PPAR-b/d) overexpression suppresses the activity of PPAR-gamma (PPAR-g) and PPAR-alpha. This interaction has been questioned, however, by studies with synthetic ligands of PPARs in PPAR-b/d-null cells, and it is not known whether an interaction between PPAR-b/d and PPAR-g exists, especially in relation to the signaling by natural PPAR ligands. Oxidative metabolites of linoleic and arachidonic acids are natural ligands of PPARs. 13-S-hydroxyoctadecadienoic acid (13-S-HODE), the main product of 15-lipoxygenase-1 (15-LOX-1) metabolism of linoleic acid, downregulates PPAR-b/d. We tested (a) whether PPAR-b/d expression modulates PPAR-g activity in experimental models of the loss and gain of PPAR-b/d function in colon cancer cells and (b) whether 15-LOX-1 formation of 13-S-HODE influences the interaction between PPAR-b/d and PPAR-g. We found that (a) 15-LOX-1 formation of 13-S-HODE promoted PPAR-gactivity, (b) PPAR-b/d expression suppressed PPAR-gactivity in models of both loss and gain of PPAR-b/d function, (c) 15-LOX-1 activated PPAR-g by downregulating PPAR-b/d, and (d) 15-LOX-1 expression induced apoptosis in colon cancer cells via modulating PPAR-b/d suppression of PPAR-g. These findings elucidate a novel mechanism of the signaling by natural ligands of PPARs, which involves modulating the interaction between PPAR-b/d and PPAR-g.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77230 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX USA; GlaxoSmithKline Inc, Dept Screening & Cmpd Profiling, Res Triangle Pk, NC USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360,1515 Holcombe Blvd, Houston, TX 77230 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Zuo, Xiangsheng/0000-0002-8593-1132; Shureiqi, Imad/0000-0003-2019-938X	NATIONAL CANCER INSTITUTE [R01CA104278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104278] Funding Source: Medline; NIEHS NIH HHS [ES07784, P30 ES007784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bull AW, 2003, CARCINOGENESIS, V24, P1717, DOI 10.1093/carcin/bgg131; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Matsusue K, 2004, FASEB J, V18, P1477, DOI 10.1096/fj.04-1944fje; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Nixon JB, 2003, PROSTAG LEUKOTR ESS, V68, P323, DOI 10.1016/S0952-3278(03)00023-1; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rusinol AE, 2000, J BIOL CHEM, V275, P7296, DOI 10.1074/jbc.275.10.7296; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Yu JS, 2003, CANCER RES, V63, P6170	36	84	87	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 23	2006	25	8					1225	1241		10.1038/sj.onc.1209160	http://dx.doi.org/10.1038/sj.onc.1209160			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16288226	Green Accepted			2022-12-25	WOS:000235537500010
J	Chen, AP; Weber, IT; Harrison, RW; Leis, J				Chen, AP; Weber, IT; Harrison, RW; Leis, J			Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; MOLECULAR-MECHANICS CALCULATIONS; ELECTRON-DENSITY MAPS; FULL-SITE INTEGRATION; VIRAL-DNA BINDING; IN-VITRO; TYPE-1 INTEGRASE; CRYSTAL-STRUCTURE; PREINTEGRATION COMPLEXES; CONCERTED INTEGRATION	A tetramer model for HIV-1 integrase ( IN) with DNA representing 20 bp of the U3 and U5 long terminal repeats (LTR) termini was assembled using structural and biochemical data and molecular dynamics simulations. It predicted amino acid residues on the enzyme surface that can interact with the LTR termini. A separate structural alignment of HIV-1, simian sarcoma virus (SIV), and avian sarcoma virus (ASV) INs predicted which of these residues were unique. To determine whether these residues were responsible for specific recognition of the LTR termini, the amino acids from ASV IN were substituted into the structurally equivalent positions of HIV-1 IN, and the ability of the chimeras to 3' process U5 HIV-1 or ASV duplex oligos was determined. This analysis demonstrated that there are multiple amino acid contacts with the LTRs and that substitution of ASV IN amino acids at many of the analogous positions in HIV-1 IN conferred partial ability to cleave ASV substrates with a concomitant loss in the ability to cleave the homologous HIV-1 substrate. HIV-1 IN residues that changed specificity include Val(72), Ser(153), Lys(160)-Ile(161), Gly(163)-Val(165), and His(171)-Leu(172). Because a chimera that combines several of these substitutions showed a specificity of cleavage of the U5 ASV substrate closer to wild type ASV IN compared with chimeras with individual amino acid substitutions, it appears that the sum of the IN interactions with the LTRs determines the specificity. Finally, residues Ser153 and Val72 in HIV-1 IN are among those that change in enzymes that develop resistance to naphthyridine carboxamide- and diketo acid-related inhibitors in cells. Thus, amino acid residues involved in recognition of the LTRs are among these positions that change in development of drug resistance.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; Georgia State Univ, Dept Comp Sci, Atlanta, GA 30303 USA	Northwestern University; Feinberg School of Medicine; University System of Georgia; Georgia State University; University System of Georgia; Georgia State University	Leis, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-leis@northwestern.edu		Harrison, Robert/0000-0003-2449-1214	NCI NIH HHS [R01 CA052047-14, CA52047, R01 CA052047] Funding Source: Medline; NIGMS NIH HHS [P20 GM065762, U01 GM062920, R01 GM062920, GM62920, GM065762, R01 GM062920-07A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM065762, R01GM062920, U01GM062920] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Bagossi P, 1999, J MOL MODEL, V5, P143, DOI 10.1007/s008940050114; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brin E, 2002, J BIOL CHEM, V277, P18357, DOI 10.1074/jbc.M201354200; Brin E, 2002, J BIOL CHEM, V277, P10938, DOI 10.1074/jbc.M108116200; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DOUGLAS RD, 1999, J BIOL CHEM, V274, P11904; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Fikkert V, 2003, J VIROL, V77, P11459, DOI 10.1128/JVI.77.21.11459-11470.2003; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; GRAIG NL, 1995, SCIENCE, V270, P253; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; Harrison RW, 1999, J MATH CHEM, V26, P125, DOI 10.1023/A:1019181811090; Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 2001, J VIROL, V75, P1132, DOI 10.1128/JVI.75.3.1132-1141.2001; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; JOHNSON M, 2004, BMC BIOL 2004, P8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalpana GV, 1999, VIROLOGY, V259, P274, DOI 10.1006/viro.1999.9767; Karki RG, 2004, J COMPUT AID MOL DES, V18, P739, DOI 10.1007/s10822-005-0365-5; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1994, PHARMACOL THERAPEUT, V61, P185, DOI 10.1016/0163-7258(94)90062-0; Lee DJ, 2004, J VIROL, V78, P5835, DOI 10.1128/JVI.78.11.5835-5847.2004; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; McCord M, 1999, VIROLOGY, V259, P392, DOI 10.1006/viro.1999.9782; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Podtelezhnikov AA, 2003, BIOPOLYMERS, V68, P110, DOI 10.1002/bip.10217; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; Ridky TW, 1998, BIOCHEMISTRY-US, V37, P13835, DOI 10.1021/bi980612k; Sayasith K, 2000, MOL CELLS, V10, P525, DOI 10.1007/s10059-000-0525-3; Snasel J, 2005, FEBS J, V272, P203, DOI 10.1111/j.1432-1033.2004.04386.x; Suzuki Y, 2002, J VIROL, V76, P12376, DOI 10.1128/JVI.76.23.12376-12380.2002; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Weber IT, 1996, PROTEIN ENG, V9, P679, DOI 10.1093/protein/9.8.679; Weber IT, 1997, PROTEIN SCI, V6, P2365; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	69	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4173	4182		10.1074/jbc.M510628200	http://dx.doi.org/10.1074/jbc.M510628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16298997	Green Accepted, hybrid			2022-12-25	WOS:000235275300049
J	Dusek, RL; Getsios, S; Chen, F; Park, JK; Amargo, EV; Cryns, VL; Green, KJ				Dusek, RL; Getsios, S; Chen, F; Park, JK; Amargo, EV; Cryns, VL; Green, KJ			The differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 target that regulates apoptosis in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENTS; BETA-CATENIN; PLAKOGLOBIN-BINDING; BULLOUS IMPETIGO; VE-CADHERIN; CLEAVAGE; DESMOPLAKIN; PROTEIN; IDENTIFICATION; EXPRESSION	Although a number of cell adhesion proteins have been identified as caspase substrates, the potential role of differentiation-specific desmosomal cadherins during apoptosis has not been examined. Here, we demonstrate that UV-induced caspase cleavage of the human desmoglein 1 cytoplasmic tail results in distinct 17- and 140-kDa products, whereas metalloproteinase-dependent shedding of the extracellular adhesion domain generates a 75-kDa product. In vitro studies identify caspase-3 as the preferred enzyme that cleaves desmoglein 1 within its unique repeating unit domain at aspartic acid 888, part of a consensus sequence not conserved among the other desmosomal cadherins. Apoptotic processing leads to decreased cell surface expression of desmoglein 1 and re-localization of its C terminus diffusely throughout the cytoplasm over a time course comparable with the processing of other desmosomal proteins and cytoplasmic keratins. Importantly, whereas classic cadherins have been reported to promote cell survival, short hairpin RNA-mediated suppression of desmoglein 1 in differentiated keratinocytes protected cells from UV-induced apoptosis. Collectively, our results identify desmoglein 1 as a novel caspase and metalloproteinase substrate whose cleavage likely contributes to the dismantling of desmosomes during keratinocyte apoptosis and also reveal desmoglein 1 as a previously unrecognized regulator of apoptosis in keratinocytes.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Cell Death Regulat Lab, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Green, KJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu			NCI NIH HHS [T32 CA09560] Funding Source: Medline; NIAMS NIH HHS [R01AR41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aho S, 2004, EXP DERMATOL, V13, P700, DOI 10.1111/j.0906-6705.2004.00217.x; Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; Amagai M, 2002, J INVEST DERMATOL, V118, P845, DOI 10.1046/j.1523-1747.2002.01751.x; ANGST BD, 1990, J CELL SCI, V97, P247; Angst BD, 2001, J CELL SCI, V114, P629; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DANIELS F, 1961, J INVEST DERMATOL, V37, P351, DOI 10.1038/jid.1961.131; Denning MF, 1998, EXP CELL RES, V239, P50, DOI 10.1006/excr.1997.3890; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, DIFFERENTIATION, V72, P419, DOI 10.1111/j.1432-0436.2004.07208008.x; GILCHREST BA, 1981, J AM ACAD DERMATOL, V5, P411, DOI 10.1016/S0190-9622(81)70103-8; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hanakawa Y, 2002, J CLIN INVEST, V110, P53, DOI 10.1172/JCI200215766; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Kalinin AE, 2005, J INVEST DERMATOL, V124, P46, DOI 10.1111/j.0022-202X.2004.23507.x; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kljuic A, 2003, CELL, V113, P249, DOI 10.1016/S0092-8674(03)00273-3; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MATHUR M, 1994, J BIOL CHEM, V118, P703; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Noe V, 2001, J CELL SCI, V114, P111; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Norvell SM, 1998, J CELL SCI, V111, P1305; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schmeiser K, 1998, FEBS LETT, V433, P51, DOI 10.1016/S0014-5793(98)00850-3; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sheehan JM, 2002, PHOTOCH PHOTOBIO SCI, V1, P365, DOI 10.1039/b108291d; SHEEHEN JM, 1972, NATURE-NEW BIOL, V235, P147; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Takahashi T, 1998, J INVEST DERMATOL, V111, P367, DOI 10.1046/j.1523-1747.1998.00295.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Whittock NV, 2003, J INVEST DERMATOL, V120, P523, DOI 10.1046/j.1523-1747.2003.12113.x; Whittock NV, 2003, CLIN EXP DERMATOL, V28, P410, DOI 10.1046/j.1365-2230.2003.01311.x; Zhuang LH, 2000, J INTERF CYTOK RES, V20, P445, DOI 10.1089/10799900050023852	74	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3614	3624		10.1074/jbc.M508258200	http://dx.doi.org/10.1074/jbc.M508258200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16286477	hybrid			2022-12-25	WOS:000235128200073
J	Shen, R; Chen, M; Wang, YJ; Kaneki, H; Xing, LP; O'Keefe, RJ; Chen, D				Shen, R; Chen, M; Wang, YJ; Kaneki, H; Xing, LP; O'Keefe, RJ; Chen, D			Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CBFA1; BONE-FORMATION; CHONDROCYTE DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; NEGATIVE REGULATION; SMURF1; LIGASE; EXPRESSION; RECEPTOR	Runx2 is a bone-specific transcription factor that plays a critical role in bone development, postnatal bone formation, and chondrocyte maturation. The protein levels of Runx2 are regulated by the ubiquitin- proteasome pathway. In previous studies we discovered that E3 ubiquitin ligase Smad ubiquitin regulatory factor 1 (Smurf1) induces Runx2 degradation in a ubiquitin- proteasome-dependent manner, and Smurf1 plays an important role in osteoblast function and bone formation. In the present studies we investigated the molecular mechanism of Smurf1- induced Runx2 degradation. Smurf1 interacts with the PY motif of substrate proteins, and a PY motif has been identified in the C terminus of the Runx2 protein. To determine whether Smurf1 induces Runx2 degradation through the interaction with the PY motif of Runx2, we created amutant Runx2 with a PY motif deletion and found that Smurf1 retained some of its ability to induce the degradation of the mutant Runx2, suggesting that Smurf1 could induce Runx2 degradation through an indirect mechanism. Smurf1 has been shown to interact with Smads 1, 5, 6, and 7, and Smads 1 and 5 also interact with Runx2. In the present studies we found that Smads 1 and 5 had no effect on Smurf1- induced Runx2 degradation. Although Smads 6 and 7 bind Smurf1, it is not known if Smads 6 or 7 interacts with Runx2 and mediate Runx2 degradation. We performed immunoprecipitation assays and found that Smad6 but not Smad7 interacts with Runx2. Smad6 enhances Smurf1-induced Runx2 degradation in an ubiquitin-proteasome-dependent manner. These results demonstrate that in addition to its interaction with the PY motif of Runx2, Smurf1 induces Runx2 degradation in a Smad6- dependent manner. Smurf1-induced Runx2 degradation serves as a negative	Univ Rochester, Med Ctr, Dept Orthopaed, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol, Ctr Musculoskeletal Res, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Chen, D (corresponding author), Univ Rochester, Med Ctr, Dept Orthopaed, Ctr Musculoskeletal Res, Box 665,601 Elmwood Ave, Rochester, NY 14642 USA.	di_chen@urmc.rochester.edu	Chen, Mo/E-8234-2010		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR048920, R01AR051189] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR051189-01, R01 AR051189, R03 AR048920-01A1, R03 AR048920-02, AR048920, R01 AR051189-02, R03 AR048920, AR051189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	40	124	134	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3569	3576		10.1074/jbc.M506761200	http://dx.doi.org/10.1074/jbc.M506761200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16299379	hybrid, Green Accepted			2022-12-25	WOS:000235128200068
J	Basile, V; Mantovani, R; Imbriano, C				Basile, V; Mantovani, R; Imbriano, C			DNA damage promotes histone deacetylase 4 nuclear localization and repression of G(2)/M promoters, via p53 C-terminal lysines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; HUMAN-PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; FACTOR NF-Y; CYCLIN B2; IN-VIVO; E6 ONCOPROTEIN; PROTEIN SIR2	Repression of G(2)/M promoters after DNA damage is an active mechanism that requires the p53 tumor suppressor. We have recently found that histone deacetylase 4 (HDAC4) is recruited on NF-Y-dependent repressed promoters. In this report, we describe the relationship between p53 and HDAC4 recruitment following DNA damage using immunofluorescence, chromatin immunoprecipitation, and transfection experiments. HDAC4 shuttles from the cytoplasm into the nucleus, following DNA damage, independently of the activation of p53 and becomes associated with promoters through a p53-dependent mechanism. The C-terminal lysines of p53, which are acetylated and methylated, are required for HDAC4 recruitment and transcriptional repression. Trichostatin treatment, but not HDAC4 functional inactivation, relieves the adriamycin-mediated repression of G(2)/M promoters. Our results indicate that HDAC4 is a component of the DNA damage response and that post-translational modifications of p53 are important for repression of G(2)/M genes.	Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy	Universita di Modena e Reggio Emilia; University of Milan	Imbriano, C (corresponding author), Univ Modena & Reggio Emilia, Dipartimento Biol Anim, Via Campi 213-D, I-41100 Modena, Italy.	cimbriano@unimo.it	Imbriano, Carol/ABD-8204-2021; Imbriano, Carol/C-9376-2015; Basile, Valentina/S-3828-2016	Imbriano, Carol/0000-0003-2864-4820; Imbriano, Carol/0000-0003-2864-4820; Basile, Valentina/0000-0003-3151-1228				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Bakin RE, 2004, J BIOL CHEM, V279, P51218, DOI 10.1074/jbc.M409271200; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Borghi S, 2001, J CELL SCI, V114, P4477; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Frontini M, 2004, CELL CYCLE, V3, P217; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; GU W, 1997, CELL, V90, P605; Han AD, 2005, J MOL BIOL, V345, P91, DOI 10.1016/j.jmb.2004.10.033; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kahle J, 2005, MOL CELL BIOL, V25, P5339, DOI 10.1128/MCB.25.13.5339-5354.2005; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kim MS, 2003, CANCER RES, V63, P7291; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lomonte P, 2004, J VIROL, V78, P6744, DOI 10.1128/JVI.78.13.6744-6757.2004; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Takahashi Y, 2000, GENE DEV, V14, P804; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WELLS J, 2000, MOL CELL BIOL, V23, P1025; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	73	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2347	2357		10.1074/jbc.M507712200	http://dx.doi.org/10.1074/jbc.M507712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16293626	hybrid			2022-12-25	WOS:000234760400060
J	Clement, MJ; Fortune, A; Phalipon, A; Marcel-Peyre, V; Simenel, C; Imberty, A; Delepierre, M; Mulard, LA				Clement, MJ; Fortune, A; Phalipon, A; Marcel-Peyre, V; Simenel, C; Imberty, A; Delepierre, M; Mulard, LA			Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides - The example of Shigella flexneri 5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; CELL-WALL POLYSACCHARIDE; CAPSULAR POLYSACCHARIDE; CRYPTOCOCCUS-NEOFORMANS; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSE; 3-DIMENSIONAL STRUCTURES; CRYSTAL-STRUCTURE; RATIONAL DESIGN; COMBINING SITES	Protein conjugates of oligosaccharides or peptides that mimic complex bacterial polysaccharide antigens represent alternatives to the classical polysaccharide-based conjugate vaccines developed so far. Hence, a better understanding of the molecular basis ensuring appropriate mimicry is required in order to design efficient carbohydrate mimic-based vaccines. This study focuses on the following two unrelated sets of mimics of the Shigella flexneri 5a O-specific polysaccharide (O-SP): (i) a synthetic branched pentasaccharide known to mimic the average solution conformation of S. flexneri 5a O-SP, and (ii) three nonapeptides selected upon screening of phage-displayed peptide libraries with two protective murine monoclonal antibodies (mAbs) of the A isotype specific for S. flexneri 5a O-SP. By inducing anti-O-SP antibodies upon immunization in mice when appropriately presented to the immune system, the pentasaccharide and peptides p100c and p115, but not peptide p22, were qualified as mimotopes of the native antigen. NMR studies based on transferred NOE (trNOE) experiments revealed that both kinds of mimotopes had an average conformation when bound to the mAbs that was close to that of their free form. Most interestingly, saturation transfer difference (STD) experiments showed that the characteristic turn conformations adopted by the major conformers of p100c and p115, as well as of p22, are clearly involved in mAb binding. These latter experiments also showed that the branched glucose residue of the pentasaccharide was a key part of the determinant recognized by the protective mAbs. Finally, by using NMR-derived pentasaccharide and peptide conformations coupled to STD information, models of antigen-antibody interaction were obtained. Most interestingly, only one model was found compatible with experimental data when large O-SP fragments were docked into one of the mIgA-binding sites. This newly made available system provides a new contribution to the understanding of the molecular mimicry of complex polysaccharides by peptides and short oligosaccharides.	Inst Pasteur, Unite RMN Biomol, CNRS, URA 2185, F-75724 Paris 15, France; Inst Pasteur, Unite Chim Organ, CNRS, URA 2128, F-75724 Paris 15, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France; UJF, CNRS, UMR 5063, DPM, F-38240 Meylan, France; Univ Grenoble 1, CNRS, CERMAV, F-38041 Grenoble 09, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Delepierre, M (corresponding author), Inst Pasteur, Unite RMN Biomol, CNRS, URA 2185, 25 Rue Dr Roux, F-75724 Paris 15, France.	murield@pasteur.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashkenazi S, 1999, J INFECT DIS, V179, P1565, DOI 10.1086/314759; BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; Belot F, 2005, CHEM-EUR J, V11, P1625, DOI 10.1002/chem.200400903; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernardi A, 2004, CHEM-EUR J, V10, P4395, DOI 10.1002/chem.200400084; Bernardi A, 2002, CHEM-EUR J, V8, P4598; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; BOCK K, 1982, J CHEM SOC PERK T 2, P59, DOI 10.1039/p29820000059; Buchwald UK, 2005, INFECT IMMUN, V73, P325, DOI 10.1128/IAI.73.1.325-333.2005; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5172, DOI 10.1021/bi00183a022; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Clement MJ, 2003, J BIOL CHEM, V278, P47928, DOI 10.1074/jbc.M308259200; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Cunto-Amesty G, 2001, VACCINE, V19, P2361, DOI 10.1016/S0264-410X(00)00527-2; Cunto-Amesty G, 2001, J BIOL CHEM, V276, P30490, DOI 10.1074/jbc.M103257200; Dinglasan RR, 2005, VACCINE, V23, P2717, DOI 10.1016/j.vaccine.2004.11.063; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Fleuridor R, 2001, J IMMUNOL, V166, P1087, DOI 10.4049/jimmunol.166.2.1087; GOEBEL HH, 1981, ACTA NEUROPATHOL, V55, P247, DOI 10.1007/BF00691325; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; Herfurth L, 2000, ANGEW CHEM INT EDIT, V39, P2097, DOI 10.1002/1521-3773(20000616)39:12<2097::AID-ANIE2097>3.0.CO;2-9; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Jimenez-Barbero J., 2002, NMR SPECTROSCOPY GLY, P289; Johnson MA, 2004, CARBOHYD RES, V339, P907, DOI 10.1016/j.carres.2003.12.028; Johnson MA, 2004, BIOORGAN MED CHEM, V12, P295, DOI 10.1016/j.bmc.2003.09.041; Johnson MA, 2002, BIOCHEMISTRY-US, V41, P2149, DOI 10.1021/bi011927u; Johnson MA, 2003, J BIOL CHEM, V278, P24740, DOI 10.1074/jbc.M301846200; Johnson MA, 2003, BIOORGAN MED CHEM, V11, P781, DOI 10.1016/S0968-0896(02)00449-2; Johnson MA, 2002, J AM CHEM SOC, V124, P15368, DOI 10.1021/ja020983v; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; Kreis UC, 1997, J MOL STRUC-THEOCHEM, V395, P389, DOI 10.1016/S0166-1280(96)04541-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauvrak V, 2004, SCAND J IMMUNOL, V59, P373, DOI 10.1111/j.1365-3083.2004.01400.x; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; LINDBLAD B, 1991, J VASC SURG, V13, P231, DOI 10.1016/0741-5214(91)90215-G; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; Maitta RW, 2004, INFECT IMMUN, V72, P196, DOI 10.1128/IAI.72.1.196-208.2004; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mer G, 1998, J MOL BIOL, V281, P235, DOI 10.1006/jmbi.1998.1939; Monfardini C, 1996, P ASSOC AM PHYSICIAN, V108, P420; Monzavi-Karbassi B, 2003, VACCINE, V21, P753, DOI 10.1016/S0264-410X(02)00703-X; Monzavi-Karbassi B, 2002, TRENDS BIOTECHNOL, V20, P207, DOI 10.1016/S0167-7799(02)01940-6; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mulard LA, 2002, TETRAHEDRON, V58, P2593, DOI 10.1016/S0040-4020(02)00148-5; Mulard LA, 2000, J CARBOHYD CHEM, V19, P193, DOI 10.1080/07328300008544074; OOMEN RP, 1991, PROTEIN ENG, V4, P427, DOI 10.1093/protein/4.4.427; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PEETERS CCAM, 1992, INFECT IMMUN, V60, P1826, DOI 10.1128/IAI.60.5.1826-1833.1992; Phalipon A, 2003, CRIT REV IMMUNOL, V23, P371, DOI 10.1615/CritRevImmunol.v23.i56.20; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; Pincus S H, 2001, Int Rev Immunol, V20, P221, DOI 10.3109/08830180109043035; Pincus SH, 1998, J IMMUNOL, V160, P293; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pirofski LA, 2001, TRENDS MICROBIOL, V9, P445, DOI 10.1016/S0966-842X(01)02134-5; Pitner JB, 2000, CARBOHYD RES, V324, P17, DOI 10.1016/S0008-6215(99)00279-7; POKKULURI PR, 1994, J MOL BIOL, V243, P283, DOI 10.1006/jmbi.1994.1654; Pozsgay V, 1999, P NATL ACAD SCI USA, V96, P5194, DOI 10.1073/pnas.96.9.5194; Prinz DM, 2004, J IMMUNOL METHODS, V285, P1, DOI 10.1016/j.jim.2003.08.005; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Romesberg FE, 1998, SCIENCE, V279, P1929, DOI 10.1126/science.279.5358.1929; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROY R, 2004, TECHNOLOGIES, V1, P327; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEIN H, 1984, LANCET, V2, P71; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; Valadon P, 1998, J IMMUNOL, V161, P1829; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209; Vyas NK, 2003, P NATL ACAD SCI USA, V100, P15023, DOI 10.1073/pnas.2431286100; Vyas NK, 2002, BIOCHEMISTRY-US, V41, P13575, DOI 10.1021/bi0261387; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wright K, 2004, ORG BIOMOL CHEM, V2, P1518, DOI 10.1039/b400986J; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407	92	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2317	2332		10.1074/jbc.M510172200	http://dx.doi.org/10.1074/jbc.M510172200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16251186	hybrid			2022-12-25	WOS:000234760400057
J	Boncela, J; Smolarczyk, K; Wyroba, E; Cierniewski, CS				Boncela, J; Smolarczyk, K; Wyroba, E; Cierniewski, CS			Binding of PAI-1 to endothelial cells stimulated by thymosin beta 4 and modulation of their fibrinolytic potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BETA-4; EXPRESSION	Our previous studies showed that thymosin beta 4 (T beta 4) induced the synthesis of plasminogen activator inhibitor-1 (PAI-1) in cultured human umbilical vein endothelial cells (HUVECs) via the AP-1 dependent mechanism and its enhanced secretion. In this work we provide evidence that the released PAI-1 is accumulated on the surface of HUVECs, exclusively in its active form, in a complex with alpha 1-acid glycoprotein (AGP) that is also up-regulated and released from the cells. This mechanism is supported by several lines of experiments, in which expression of both proteins was analyzed by flow cytometry and their colocalization supported by confocal microscopy. PAI-1 did not bind to quiescent cells but only to the T beta 4-activated endothelial cells. In contrast, significant amounts of AGP were found to be associated with the cells overexpressing enhanced green fluorescent protein (EGFP)-alpha 1-acid glycoprotein (AGP) without T beta 4 treatment. The AGP center dot PAI-1 complex was accumulated essentially at the basal surface of endothelial cells, and such cells showed (a) morphology characteristic for strongly adhered and spread cells and (b) significantly reduced plasmin formation. Taken together, these results provide the evidence supporting a novel mechanism by which active PAI-1 can be bound to the T beta 4-activated endothelial cells, thus influencing their adhesive properties as well as their ability to generate plasmin.	Polish Acad Sci, Ctr Med Biol, PL-93232 Lodz, Poland; Polish Acad Sci, M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Med Univ Lodz, Dept Mol & Med Biophys, PL-92215 Lodz, Poland	Polish Academy of Sciences; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Medical University Lodz	Cierniewski, CS (corresponding author), Polish Acad Sci, Ctr Med Biol, PL-93232 Lodz, Poland.	cciern@zdn.am.lodz.pl	Boncela, Joanna/AAU-4481-2020; Wyroba, Elzbieta/P-4434-2019; Wyroba, Elzbieta/R-7525-2016	Boncela, Joanna/0000-0001-8419-7012; 				Al-Nedawi KNI, 2004, BLOOD, V103, P1319, DOI 10.1182/blood-2003-04-1015; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Boncela J, 2001, J BIOL CHEM, V276, P35305, DOI 10.1074/jbc.M104028200; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; BU GJ, 1994, BLOOD, V83, P3427; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cieslak M, 2002, J BIOL CHEM, V277, P6779, DOI 10.1074/jbc.M102325200; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; EMEIS JJ, 1988, BLOOD, V71, P1669; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; Huang WQ, 2001, EXP HEMATOL, V29, P12, DOI 10.1016/S0301-472X(00)00634-2; JAFFE EA, 1976, J EXP MED, V144, P209, DOI 10.1084/jem.144.1.209; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; SMOLARCZYK K, 2005, BIOCHEMISTRY-US, V44, P12834; Sorensson J, 1999, AM J PHYSIOL-HEART C, V276, pH530, DOI 10.1152/ajpheart.1999.276.2.H530; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	26	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1066	1072		10.1074/jbc.M506303200	http://dx.doi.org/10.1074/jbc.M506303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272158	hybrid			2022-12-25	WOS:000234447200047
J	Khlistunova, I; Biernat, J; Wang, YP; Pickhardt, M; von Bergen, M; Gazova, Z; Mandelkow, E; Mandelkow, M				Khlistunova, I; Biernat, J; Wang, YP; Pickhardt, M; von Bergen, M; Gazova, Z; Mandelkow, E; Mandelkow, M			Inducible expression of tau repeat domain in cell models of tauopathy - Aggregation is toxic to cells but can be reversed by inhibitor drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; MICROTUBULE-ASSOCIATED PROTEINS; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PHOSPHORYLATED TAU; CASPASE-CLEAVAGE; IN-VITRO; BETA; MUTATIONS; MECHANISM	We generated several cell models of tauopathy in order to study the mechanisms of neurodegeneration in diseases involving abnormal changes of tau protein. N2a neuroblastoma cell lines were created that inducibly express different variants of the repeat domain of tau (tau(RD)) when exposed to doxycycline (Tet-On system). The following three constructs were chosen: (i) the repeat domain of tau that coincides with the core of Alzheimer paired helical filaments; (ii) the repeat domain with the deletion mutation Delta K280 known from frontotemporal dementia and highly prone to spontaneous aggregation; and (iii) the repeat domain with Delta K280 and two proline point mutations that inhibit aggregation. The comparison of wild-type, pro-aggregation, and anti-aggregation mutants shows the following. (a) Aggregation of tauRD is toxic to cells. (b) The degree of aggregation and toxicity depends on the propensity for beta-structure. (c) Soluble mutants of tauRD that cannot aggregate are not toxic. (d) Aggregation is preceded by fragmentation. (e) Fragmentation of tauRD in cells is initially due to a thrombin-like protease activity. (f) Phosphorylation of tau(RD) (at KXGS motifs) precedes aggregation but is not correlated with the degree of aggregation. (g) Aggregates of tauRD disappear when the expression is silenced, showing that aggregation is reversible. (h) Aggregation can be prevented by drugs and even pre-formed aggregates can be dissolved again by drugs. Thus, the cell models open up new insights into the relationship between the structure, expression, phosphorylation, aggregation, and toxicity of tauRD that can be used to test current hypotheses on tauopathy and to develop drugs that prevent the aggregation and degeneration of cells.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Mandelkow, M (corresponding author), DESY, Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.	mandelkow@mpasmb.desy.de	von Bergen, Martin/D-7960-2011; Gazova, Zuzana/L-6685-2019; Gazova, Zuzana/T-4146-2019	von Bergen, Martin/0000-0003-2732-2977; Gazova, Zuzana/0000-0002-0670-3431; 				Arai T, 2005, J BIOL CHEM, V280, P5145, DOI 10.1074/jbc.M409234200; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brown MR, 2005, J ALZHEIMERS DIS, V7, P15; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Delobel P, 2005, FEBS LETT, V579, P1, DOI 10.1016/j.febslet.2004.11.018; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; FEICK RG, 1990, ANAL BIOCHEM, V187, P205, DOI 10.1016/0003-2697(90)90445-F; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; JOHNSON GV, 2005, BIOCHIM BIOPHYS ACTA, V1739, P280; Kosik KS, 2005, BBA-MOL BASIS DIS, V1739, P298, DOI 10.1016/j.bbadis.2004.10.011; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Mukrasch MD, 2005, J BIOL CHEM, V280, P24978, DOI 10.1074/jbc.M501565200; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; Pickhardt M, 2005, J BIOL CHEM, V280, P3628, DOI 10.1074/jbc.M410984200; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Rosso SM, 2002, CURR OPIN NEUROL, V15, P423, DOI 10.1097/00019052-200208000-00004; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Watanabe A, 2004, J NEUROCHEM, V90, P1302, DOI 10.1111/j.1471-4159.2004.02611.x; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102	57	274	285	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1205	1214		10.1074/jbc.M507753200	http://dx.doi.org/10.1074/jbc.M507753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16246844	hybrid			2022-12-25	WOS:000234447200063
J	Xie, B; Tassi, E; Swift, MR; McDonnell, K; Bowden, ET; Wang, SM; Ueda, Y; Tomita, Y; Riegel, AT; Wellstein, A				Xie, B; Tassi, E; Swift, MR; McDonnell, K; Bowden, ET; Wang, SM; Ueda, Y; Tomita, Y; Riegel, AT; Wellstein, A			Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SPINAL-CORD-INJURY; SKIN CARCINOGENESIS; MOLECULAR-CLONING; PEPTIDE LIGANDS; UP-REGULATION; KAZAL TYPE; HEPARIN; EXPRESSION; RECEPTOR	Fibroblast growth factor-binding proteins (FGF-BP) are secreted carrier proteins that release fibroblast growth factors (FGFs) from the extracellular matrix storage and thus enhance FGF activity. Here we have mapped the interaction domain between human FGF-BP1 and FGF-2. For this, we generated T7 phage display libraries of N-terminally and C-terminally truncated FGF-BP1 fragments that were then panned against immobilized FGF-2. From this panning, a C-terminal fragment of FGF-BP1 (amino acids 193-234) was identified as the minimum binding domain for FGF. As a recombinant protein, this C-terminal fragment binds to FGF-2 and enhances FGF-2-induced signaling in NIH-3T3 fibroblasts and GM7373 endothelial cells, as well as mitogenesis and chemotaxis of NIH-3T3 cells. The FGF interaction domain in FGF-BP1 is distinct from the heparin-binding domain (amino acids 110-143), and homology modeling supports the notion of a distinct domain in the C terminus that is conserved across different species. This domain also contains conserved positioning of cysteine residues with the Cys-214/Cys-222 positions in the human protein predicted to participate in disulfide bridge formation. Phage display of a C214A mutation of FGF-BP1 reduced binding to FGF-2, indicating the functional significance of this disulfide bond. We concluded that the FGF interaction domain is contained in the C terminus of FGF-BP1.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; Univ Michigan, Dept Med, Ann Arbor, MI 49109 USA	Georgetown University; University of Michigan System; University of Michigan	Wellstein, A (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Res Bldg E311,3970 Reservoir Rd, Washington, DC 20057 USA.	wellstea@georgetown.edu	Tassi, Enrico/AAJ-9661-2020; Tassi, Enrico/K-3958-2015	Tassi, Enrico/0000-0002-3335-6500; Wang, Shaomeng/0000-0002-8782-6950; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71508-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; Fan HK, 2000, IUBMB LIFE, V49, P545; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2000, J BIOL CHEM, V275, P39801; Kagan BL, 2003, CANCER RES, V63, P1696; Krause R, 1998, DIFFERENTIATION, V63, P285, DOI 10.1046/j.1432-0436.1998.6350285.x; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; Le Stunff H, 2004, J BIOL CHEM, V279, P34290, DOI 10.1074/jbc.M404907200; LIEPINSH E, 1994, J MOL BIOL, V239, P137, DOI 10.1006/jmbi.1994.1356; Liu XH, 2001, KIDNEY INT, V59, P1717, DOI 10.1046/j.1523-1755.2001.0590051717.x; McDonnell K, 2005, LAB INVEST, V85, P747, DOI 10.1038/labinvest.3700269; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; *NOV INC, 2000, T7SEL SYST MAN; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; RAY PE, 2006, IN PRESS AM J PHYSL, V290; Ray R, 2003, CANCER RES, V63, P8085; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; TASSI E, 2006, IN PRESS CANC RES, V66; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Wang XC, 1998, BIOCHEM MOL BIOL INT, V46, P81; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201; Zozulya S, 1999, NAT BIOTECHNOL, V17, P1193, DOI 10.1038/70736	48	27	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1137	1144		10.1074/jbc.M510754200	http://dx.doi.org/10.1074/jbc.M510754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16257968	hybrid			2022-12-25	WOS:000234447200055
J	Chu, PJ; Rivera, JF; Arnold, DB				Chu, PJ; Rivera, JF; Arnold, DB			A role for Kif17 in transport of Kv4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN SUPERFAMILY MOTOR; HIPPOCAMPAL-NEURONS; AXONAL-TRANSPORT; AMPA RECEPTORS; PROTEIN; CHANNEL; DENDRITES; MOTIF; SHAL; LOCALIZATION	Although kinesins are known to transport neuronal proteins, it is not known what role they play in the targeting of their cargos to specific subcellular compartments in neurons. Here we present evidence that the K+ channel Kv4.2, which is a major regulator of dendritic excitability, is transported to dendrites by the kinesin isoform Kif17. We show that a dominant negative construct against Kif17 dramatically inhibits localization to dendrites of both introduced and endogenous Kv4.2, but those against other kinesins found in dendrites do not. Kv4.2 colocalizes with Kif17 but not with other kinesin isoforms in dendrites of cortical neurons. Native Kv4.2 and Kif17 coimmunoprecipitate from brain lysate, and introduced, tagged versions of the two proteins coimmunoprecipitate from COS cell lysate, indicating that the two proteins interact, either directly or indirectly. The interaction between Kif17 and Kv4.2 appears to occur through the extreme C terminus of Kv4.2 and not through the dileucine motif. Thus, the dileucine motif does not determine the localization of Kv4.2 by causing the channel to interact with a specific motor protein. In support of this conclusion, we found that the dileucine motif mediates dendritic targeting of CD8 independent of Kif17. Together our data show that Kif17 is probably the motor that transports Kv4.2 to dendrites but suggest that this motor does not, by itself, specify dendritic localization of the channel.	Univ So Calif, Dept Biol, Los Angeles, CA 90089 USA; Univ So Calif, Program Mol & Computat Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Arnold, DB (corresponding author), Univ So Calif, Dept Biol, 1050 Childs Way,MCB 204B, Los Angeles, CA 90089 USA.	darnold@usc.edu			NINDS NIH HHS [R01 NS-41963] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041963] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Aridor M, 2004, J NEUROSCI, V24, P3770, DOI 10.1523/JNEUROSCI.4775-03.2004; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Baro DJ, 2001, NEUROSCIENCE, V106, P419, DOI 10.1016/S0306-4522(01)00261-5; Baro DJ, 2000, J NEUROSCI, V20, P6619, DOI 10.1523/JNEUROSCI.20-17-06619.2000; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Cheng CL, 2002, J NEUROSCI, V22, P10643; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Francesconi A, 2002, J NEUROSCI, V22, P2196, DOI 10.1523/JNEUROSCI.22-06-02196.2002; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; Guillaud L, 2003, J NEUROSCI, V23, P131; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; Horton AC, 2003, J NEUROSCI, V23, P6188; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Johnston D, 1999, CURR OPIN NEUROBIOL, V9, P288, DOI 10.1016/S0959-4388(99)80042-7; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; Ren XM, 2005, MOL CELL NEUROSCI, V29, P320, DOI 10.1016/j.mcn.2005.02.003; Rivera JF, 2003, NAT NEUROSCI, V6, P243, DOI 10.1038/nn1020; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Stricker NL, 2003, NEUROPHARMACOLOGY, V45, P837, DOI 10.1016/S0028-3908(03)00275-2; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; White E.L., 1989, CORTICAL CIRCUITS, DOI [10.1007/978-1-4684-8721-3, DOI 10.1007/978-1-4684-8721-3]; Yoshimura Y, 2004, J NEUROCHEM, V88, P759, DOI 10.1046/j.1471-4159.2003.02136.x	31	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					365	373		10.1074/jbc.M508897200	http://dx.doi.org/10.1074/jbc.M508897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16257958	hybrid			2022-12-25	WOS:000234307200046
J	Haigis, K; Sage, J; Glickman, J; Shafer, S; Jacks, T				Haigis, K; Sage, J; Glickman, J; Shafer, S; Jacks, T			The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; HYPERPLASTIC POLYPS; TRANSGENIC MICE; HOMEOBOX GENE; ADIPOCYTE DIFFERENTIATION; REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; SERRATED ADENOMAS; TUMOR-SUPPRESSOR; NERVOUS-SYSTEM	pRb, p107, and p130 are related proteins that play a central role in the regulation of cell cycle progression and terminal differentiation in mammalian cells. Nevertheless, it is still largely unclear how these proteins achieve this regulation in vivo. The intestinal epithelium is an ideal in vivo system in which to study the molecular pathways that regulate proliferation and differentiation because it exists in a constant state of development throughout an animal's lifetime. We studied the phenotypic effects on the intestinal epithelium of mutating Rb and p107 or p130. Although mutating these genes singly had little or no effect, loss of pRb and p107 or p130 together produced chronic hyperplasia and dysplasia of the small intestinal and colonic epithelium. In Rb/p130 double mutants this hyperplasia was associated with defects in terminal differentiation of specific cell types and was dependent on the increased proliferation seen in the epithelium of mutant animals. At the molecular level, dysregulation of the Rb pathway led to an increase in the expression of Math1, Cdx1, Cdx2, transcription factors that regulate proliferation and differentiation in the intestinal epithelium. The absence of Cdx1 function in Rb/p130 double mutant mice partially reverted the histologic phenotype by suppressing ectopic mitosis in the epithelium. These studies implicate the Rb pathway as a regulator of epithelial homeostasis in the intestine.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Chevy Chase, MD 20185 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Jacks, T (corresponding author), MA Inst Technol, E17-517A,77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu						ALI AA, 1993, FASEB J, V7, P931, DOI 10.1096/fasebj.7.10.8344490; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Caputi M, 2002, CLIN CANCER RES, V8, P3850; Chan TL, 2003, CANCER RES, V63, P4878; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HAYASHI T, 1974, GASTROENTEROLOGY, V66, P347; Helms AW, 2001, MOL CELL NEUROSCI, V17, P671, DOI 10.1006/mcne.2000.0969; Huang CS, 2004, AM J GASTROENTEROL, V99, P2242, DOI 10.1111/j.1572-0241.2004.40131.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shackney SE, 1997, CYTOMETRY, V29, P1; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Tamai Y, 1999, CANCER RES, V59, P2965; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Wong NACS, 2004, P NATL ACAD SCI USA, V101, P574, DOI 10.1073/pnas.0307190101; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	53	61	61	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					638	647		10.1074/jbc.M509053200	http://dx.doi.org/10.1074/jbc.M509053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16258171	hybrid			2022-12-25	WOS:000234307200076
J	Martin, OJ; Lee, A; McGraw, TE				Martin, OJ; Lee, A; McGraw, TE			GLUT4 distribution between the plasma membrane and the intracellular compartments is maintained by an insulin-modulated bipartite dynamic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; ISOLATED RAT ADIPOCYTES; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; RECYCLING COMPARTMENT; REGULATED TRANSPORT; MUSCLE-CELLS; TRAFFICKING; ENDOCYTOSIS; INTERNALIZATION	The GLUT4 glucose transporter is predominantly retained inside basal fat and muscle cells, and it is rapidly recruited to the plasma membrane with insulin stimulation. There is controversy regarding the mechanism of basal GLUT4 retention. One model is that GLUT4 retention is dynamic, based on slow exocytosis and rapid internalization of the entire pool of GLUT4 (Karylowski, O., Zeigerer, A., Cohen, A., and McGraw, T. E. ( 2004) Mol. Biol. Cell 15, 870 - 882). In this model, insulin increases GLUT4 in the plasma membrane by modulating GLUT4 exocytosis and endocytosis. The second model is that GLUT4 retention is static, with similar to 90% of GLUT4 stored in compartments that are not in equilibrium with the cell surface in basal conditions (Govers, R., Coster, A. C., and James, D. E. ( 2004) Mol. Cell Biol. 24, 6456 - 6466). In this model, insulin increases GLUT4 in the plasma membrane by releasing it from the static storage compartment. Here we show that under all experimental conditions examined, basal GLUT4 retention is by a bipartite dynamic mechanism involving slow efflux and rapid internalization. To establish that the dynamic model developed in studies of the extreme conditions of > 100 nM insulin and no insulin also describes GLUT4 behavior at more physiological insulin concentrations, we characterized GLUT4 trafficking in 0.5 nM insulin. This submaximal insulin concentration promotes an intermediate effect on both GLUT4 exocytosis and endocytosis, resulting in an intermediate degree of redistribution to the plasma membrane. These data establish that changes in the steady-state surface/ total distributions of GLUT4 are the result of gradated, insulin-induced changes in GLUT4 exocytosis and endocytosis rates.	Weill Cornell Med Coll, Dept Biochem, New York, NY 10013 USA; Weill Cornell Med Coll, Training Program Chem Biol, New York, NY 10013 USA	Cornell University; Cornell University	McGraw, TE (corresponding author), Weill Cornell Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10013 USA.	temcgraw@med.cornell.edu		Lee, Adrian/0000-0001-9917-514X	NIDDK NIH HHS [DK52582] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiray EM, 2004, METABOLISM, V53, P1558, DOI 10.1016/j.metabol.2004.06.024; Al-Hasani H, 1999, FEBS LETT, V460, P338, DOI 10.1016/S0014-5793(99)01369-1; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Corvera S, 1994, J Cell Biol, V126, P1625, DOI 10.1083/jcb.126.6.1625; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GIBBS EM, 1984, J CELL PHYSIOL, V121, P569, DOI 10.1002/jcp.1041210316; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lampson MA, 2000, J CELL SCI, V113, P4065; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sannerud R, 2003, CURR OPIN CELL BIOL, V15, P438, DOI 10.1016/S0955-0674(03)00077-2; Sara Y, 2005, NEURON, V45, P563, DOI 10.1016/j.neuron.2004.12.056; Satoh H, 2005, DIABETES, V54, P1304, DOI 10.2337/diabetes.54.5.1304; Sedaghat AR, 2002, AM J PHYSIOL-ENDOC M, V283, pE1084, DOI 10.1152/ajpendo.00571.2001; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	36	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					484	490		10.1074/jbc.M505944200	http://dx.doi.org/10.1074/jbc.M505944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16269413	hybrid			2022-12-25	WOS:000234307200060
J	Morita-Ishihara, T; Ogawa, M; Sagara, H; Yoshida, M; Katayama, E; Sasakawa, C				Morita-Ishihara, T; Ogawa, M; Sagara, H; Yoshida, M; Katayama, E; Sasakawa, C			Shigella Spa33 is an essential C-ring component of type III secretion machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEEDLE COMPLEX; SALMONELLA-TYPHIMURIUM; SUPRAMOLECULAR STRUCTURE; BACTERIAL FLAGELLA; IPA PROTEINS; FLEXNERI; LENGTH; SYSTEM; PATHWAY; HOOK	Type III secretion machinery (TTSM), composed of a needle, a basal body, and a C-ring compartment, delivers a subset of effectors into host cells. Here, we show that Shigella Spa33 is an essential component of the C-ring compartment involved in mediating the transit of various TTSM-associated translocated proteins. Electron microscopic analysis and pull-down assay revealed Spa33 to be localized beneath the TTSM via interaction with MxiG and MxiJ (basal body components). Spa33 is also capable of interacting with Spa47 (TTSM ATPase), MxiK, MxiN (required for the transit of MxiH, the needle component), Spa32 (required for determining needle length), and several effectors. Genetic and functional analyses of the Spa33 C-terminal region, which is highly conserved in the SpaO-YscQ-HrcQB-FliN family, indicate that some of the conserved residues are crucial for needle formation via interactions with MxiN. Thus, Spa33 plays a central role as the C-ring component in recruiting/ exporting TTSM-associated proteins.	Univ Tokyo, Int Res Ctr Infect Dis, Dept Microbiol & Immunol, Tokyo 1088639, Japan; Univ Tokyo, Int Res Ctr Infect Dis, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Int Res Ctr Infect Dis, Dept Basic Med Sci, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Int Res Ctr Infect Dis, Dept Infect Dis Control, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Juntendo Univ, Grad Sch Med, Biomed Res Ctr, Div Ultrastruct Res,Bunkyo Ku, Tokyo 1138421, Japan; CREST, Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Juntendo University; Japan Science & Technology Agency (JST)	Sasakawa, C (corresponding author), Univ Tokyo, Int Res Ctr Infect Dis, Dept Microbiol & Immunol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Sagara, Hiroshi/GRX-7740-2022	Sagara, Hiroshi/0000-0001-8456-8362				Aizawa S, 2001, FEMS MICROBIOL LETT, V202, P157, DOI 10.1111/j.1574-6968.2001.tb10797.x; Alfano JR, 1997, J BACTERIOL, V179, P5655, DOI 10.1128/jb.179.18.5655-5662.1997; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Fadouloglou VE, 2004, P NATL ACAD SCI USA, V101, P70, DOI 10.1073/pnas.0304579101; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; He SY, 2004, BBA-MOL CELL RES, V1694, P181, DOI 10.1016/j.bbamcr.2004.03.011; Hirano T, 2005, MOL MICROBIOL, V56, P346, DOI 10.1111/j.1365-2958.2005.04615.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jouihri N, 2003, MOL MICROBIOL, V49, P755, DOI 10.1046/j.1365-2958.2003.03590.x; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Kimbrough TG, 2002, MICROBES INFECT, V4, P75, DOI 10.1016/S1286-4579(01)01512-X; KUBORI T, 1992, J MOL BIOL, V226, P433, DOI 10.1016/0022-2836(92)90958-M; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; Makishima S, 2001, SCIENCE, V291, P2411, DOI 10.1126/science.1058366; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; MENARD R, 1993, J BACTERIOL, V175, P5899; Minamino T, 2005, MOL MICROBIOL, V56, P303, DOI 10.1111/j.1365-2958.2005.04611.x; Plano GV, 2001, MOL MICROBIOL, V40, P284, DOI 10.1046/j.1365-2958.2001.02354.x; Russmann H, 2002, MOL MICROBIOL, V46, P769, DOI 10.1046/j.1365-2958.2002.03196.x; Schuch R, 2001, INFECT IMMUN, V69, P2180, DOI 10.1128/IAI.69.4.2180-2189.2001; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Tamano K, 2002, METHOD ENZYMOL, V358, P385; Tamano K, 2002, J BACTERIOL, V184, P1244, DOI 10.1128/JB.184.5.1244-1252.2002; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tampakaki AP, 2004, CELL MICROBIOL, V6, P805, DOI 10.1111/j.1462-5822.2004.00432.x; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; Yip CK, 2005, NATURE, V435, P702, DOI 10.1038/nature03554; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452	37	85	91	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					599	607		10.1074/jbc.M509644200	http://dx.doi.org/10.1074/jbc.M509644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16246841	hybrid			2022-12-25	WOS:000234307200072
J	Valton, J; Fontecave, M; Douki, T; Kendrew, SG; Niviere, V				Valton, J; Fontecave, M; Douki, T; Kendrew, SG; Niviere, V			An aromatic hydroxylation reaction catalyzed by a two-component FMN-dependent monooxygenase - The ActVA-ActVB system from streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN REDUCTASE ACTVB; ESCHERICHIA-COLI; GENE-CLUSTER; NAD(P)H-FLAVIN OXIDOREDUCTASE; ANTIBIOTIC ACTINORHODIN; 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE; CHLOROPHENOL 4-MONOOXYGENASE; FUNCTIONAL-ANALYSIS; PRISTINAMYCIN-IIB; BIOSYNTHESIS	The ActVA- ActVB system from Streptomyces coelicolor is a two-component flavin- dependent monooxygenase that belongs to an emerging class of enzymes involved in various oxidation reactions in microorganisms. The ActVB component is a NADH: flavin oxidoreductase that provides a reduced FMN to the second component, ActVA the proper monooxygenase. In this work, we demonstrate that the ActVA- ActVB system catalyzes the aromatic monohydroxylation of dihydrokalafungin by molecular oxygen. In the presence of reduced FMN and molecular oxygen, the ActVA active site accommodates and stabilizes an electrophilic flavin FMN- OOH hydroperoxide intermediate species as the oxidant. Surprisingly, we demonstrate that the quinone form of dihydrokalafungin is not oxidized by the ActVA- ActVB system, whereas the corresponding hydroquinone is an excellent substrate. The enantiomer of dihydrokalafungin, nanaomycin A, as well as the enantiomer of kalafungin, nanaomycin D, are also substrates in their hydroquinone forms. The previously postulated product of the ActVA- ActVB system, the antibiotic actinorhodin, was not found to be formed during the oxidation reaction.	UJF, CEA, UMR E3, Lab Les Acides Nucl,DRFMC,SCIB, F-38054 Grenoble 9, France; Biotica Technol Ltd, Saffron Walden CB10 1XL, Essex, England	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS, Lab Chim & Biochim, CEA,Ctr Redox Biol,DRDC, 17 Ave Martyrs, F-38054 Grenoble 9, France.	mfontecave@cea.fr; vniviere@cea.fr	Thierry, Douki/H-2108-2018	Thierry, Douki/0000-0002-5022-071X; Niviere, Vincent/0000-0002-5132-457X; Valton, Julien/0000-0003-0826-5401				Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232, DOI 10.1128/AEM.63.6.2232-2239.1997; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; Bohuslavek J, 2001, APPL ENVIRON MICROB, V67, P688, DOI 10.1128/AEM.67.2.688-695.2001; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Filisetti L, 2005, FEBS LETT, V579, P2817, DOI 10.1016/j.febslet.2005.04.019; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; GAUDU P, 1994, J BIOL CHEM, V269, P8182; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; Jeffers CE, 2003, BIOCHEMISTRY-US, V42, P529, DOI 10.1021/bi026877n; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Khan MS, 2005, SPECTROCHIM ACTA A, V61, P777, DOI 10.1016/j.saa.2004.04.027; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; TANAKA H, 1982, J ANTIBIOT, V35, P1565, DOI 10.7164/antibiotics.35.1565; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; Valton J, 2004, J BIOL CHEM, V279, P44362, DOI 10.1074/jbc.M407722200; van den Heuvel RHH, 2004, J BIOL CHEM, V279, P12860, DOI 10.1074/jbc.M313765200; Xi L, 1997, BIOCHEM BIOPH RES CO, V230, P73, DOI 10.1006/bbrc.1996.5878; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; Xun LY, 2004, J BIOL CHEM, V279, P6696, DOI 10.1074/jbc.M312072200; Xun LY, 1996, J BACTERIOL, V178, P2645, DOI 10.1128/jb.178.9.2645-2649.1996; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	32	36	37	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					27	35		10.1074/jbc.M506146200	http://dx.doi.org/10.1074/jbc.M506146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267053	hybrid			2022-12-25	WOS:000234307200007
J	Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ				Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ			p53 tumor suppressor protein regulates the levels of huntingtin gene expression	ONCOGENE			English	Article						p53; hungtingtin; Huntington's disease; p53-responsive element; transcription regulation; gene expression	MONOZYGOTIC TWINS	The p53 protein is a transcription factor that integrates various cellular stress signals. The accumulation of the mutant huntingtin protein with an expanded polyglutamine tract plays a central role in the pathology of human Huntington's disease. We found that the huntingtin gene contains multiple putative p53-responsive elements and p53 binds to these elements both in vivo and in vitro. p53 activation in cultured human cells, either by a temperature-sensitive mutant p53 protein or by gamma-irradiation (gamma-irradiation), increases huntingtin mRNA and protein expression. Similarly, murine huntingtin also contains multiple putative p53-responsive elements and its expression is induced by p53 activation in cultured cells. Moreover, gamma-irradiation, which activates p53, increases huntingtin gene expression in the striatum and cortex of mouse brain, the major pathological sites for Huntington's disease, in p53+/+ but not the isogenic p53 -/- mice. These results demonstrate that p53 protein can regulate huntingtin expression at transcriptional level, and suggest that a p53 stress response could be a modulator of the process of Huntington's disease.	Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Dept Pharmacol, Piscataway, NJ 08854 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Cold Spring Harbor Labs, Cold Spring Harbor, NY USA; Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Yale University; Cold Spring Harbor Laboratory; Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu						Anca MH, 2004, AM J MED GENET A, V124A, P89, DOI 10.1002/ajmg.a.20328; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dixon KT, 2003, GENE EXPRESSION, V11, P221, DOI 10.3727/000000003783992234; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Georgiou N, 1999, MOVEMENT DISORD, V14, P320, DOI 10.1002/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Jin SK, 2001, J CELL SCI, V114, P4139; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	20	77	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					1	7		10.1038/sj.onc.1209021	http://dx.doi.org/10.1038/sj.onc.1209021			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278683				2022-12-25	WOS:000234406400001
J	Ko, M; Zou, K; Minagawa, H; Yu, WX; Gong, JS; Yanagisawa, K; Michikawa, M				Ko, M; Zou, K; Minagawa, H; Yu, WX; Gong, JS; Yanagisawa, K; Michikawa, M			Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LIPID COMPLEXES; ALZHEIMERS-DISEASE; DEPENDENT MODULATION; CULTURED NEURONS; PHOSPHORYLATION; KINASE; GROWTH; RAFTS; TAU; SRC	The acquisition of neuronal type-specific morphogenesis is a central feature of neuronal differentiation and has important consequences for region-specific nervous system functions. Here, we report that the cell type-specific cholesterol profile determines the differential modulation of axon and dendrite outgrowths in hippocampal and cerebral cortical neurons in culture. The extent of axon and dendrite outgrowths is greater and the polarity formation occurs earlier in cortical neurons than in hippocampal neurons. The cholesterol concentrations in total homogenate and the lipid rafts from hippocampal neurons are significantly higher than those from cortical neurons. Cholesterol depletion by beta-cyclodextrin markedly enhanced the neurite outgrowth and accelerated the establishment of neuronal polarity in hippocampal neurons, which were similarly observed in nontreated cortical neurons, whereas cholesterol loading had no effects. In contrast, both depletion and loading of cholesterol decreased the neurite outgrowths in cortical neurons. The stimulation of neurite outgrowth and polarity formation induced by cholesterol depletion was accompanied by an enhanced localization of Fyn, a Src kinase, in the lipid rafts of hippocampal neurons. A concomitant treatment with beta-cyclodextrin and a Src family kinase inhibitor, PP2, specifically blocked axon outgrowth but not dendrite outgrowth ( both of which were enhanced by beta-cyclodextrin) in hippocampal neurons, suggesting that axon outgrowth modulated by cholesterol is induced in a Fyn-dependent manner. These results suggest that cellular cholesterol modulates axon and dendrite outgrowths and neuronal polarization under culture conditions and also that the difference in cholesterol profile between hippocampal and cortical neurons underlies the difference in neurite outgrowth between these two types of neurons.	Natl Inst Longev Sci, Dept Alzheimers Dis Res, Aichi 4748522, Japan		Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Alzheimers Dis Res, 36-3 Gengo, Aichi 4748522, Japan.	michi@nils.go.jp						Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Bu BT, 2002, J NEUROSCI, V22, P6515; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Fan QW, 2002, J NEUROCHEM, V80, P178, DOI 10.1046/j.0022-3042.2001.00686.x; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Goodrum JF, 2000, J NEUROPATH EXP NEUR, V59, P1002, DOI 10.1093/jnen/59.11.1002; Hayashi H, 2004, J BIOL CHEM, V279, P14009, DOI 10.1074/jbc.M313828200; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; Katsuno T, 2005, NEUROLOGY, V64, P687, DOI 10.1212/01.WNL.0000151958.79884.86; Koudinov AR, 2001, FASEB J, V15, P1858, DOI 10.1096/fj.00-0815fje; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Meriane M, 2004, J CELL BIOL, V167, P687, DOI 10.1083/jcb.200405053; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2004, J BIOL CHEM, V279, P11984, DOI 10.1074/jbc.M309832200; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; Yu WX, 2005, J BIOL CHEM, V280, P11731, DOI 10.1074/jbc.M412898200	30	67	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42759	42765		10.1074/jbc.M509164200	http://dx.doi.org/10.1074/jbc.M509164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16267051	hybrid			2022-12-25	WOS:000234200800036
J	Yuan, LP; Yu, WM; Xu, M; Qu, CK				Yuan, LP; Yu, WM; Xu, M; Qu, CK			SHP-2 phosphatase regulates DNA damage-induced apoptosis and G(2)/M arrest in catalytically dependent and independent manners, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; HEMATOPOIETIC-CELL DEVELOPMENT; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; C-ABL; PHOSPHOTYROSINE PHOSPHATASE; TRANSFORMING ACTIVITY; GENE; P53; MUTATIONS	SHP-2, a tyrosine phosphatase implicated in diverse signaling pathways induced by growth factors and cytokines, is also involved in DNA damage-triggered signaling and cellular responses. We previously demonstrated that SHP-2 played an important role in DNA damage-induced apoptosis and G(2)/M cell cycle checkpoint. In the present studies, we have provided evidence that SHP-2 functions in DNA damage apoptosis and G(2)/M arrest in catalytically dependent and independent manners, respectively. Mutant embryonic fibroblasts with the Exon 3 deletion mutation in SHP-2 showed decreased apoptosis and diminished G(2)/M arrest in response to cisplatin treatment. Wild type (WT), but not catalytically inactive mutant SHP-2 (SHP-2 C459S), rescued the apoptotic response of the mutant cells. Interestingly, both WT and SHP-2 C459S efficiently restored the G(2)/M arrest response. Furthermore, inhibition of the catalytic activity of endogenous SHP-2 in WT cells by overexpression of SHP-2 C459S greatly decreased cell death but not G(2)/M arrest induced by cisplatin. Biochemical analyses revealed that activation of c-Abl kinase was decreased in SHP-2 C459S-over-expressing cells. However, DNA damage-induced translocation of Cdc25C from the nucleus to the cytoplasm was fully restored in both WT and SHP-2 C459S "rescued" cells. Additionally, we demonstrated that the role of SHP-2 in DNA damage-induced cellular responses was independent of the tumor suppressor p53. Embryonic stem cells with the SHP-2 deletion mutation showed markedly decreased sensitivity to cisplatin-induced apoptosis, attributed to impaired induction of p73 but not p53. In agreement with these results, DNA damage-induced apoptosis and G(2)/M arrest were also decreased in SHP-2/p53 double mutant embryonic fibroblasts. Collectively, these studies have further defined the mechanisms by which SHP-2 phosphatase regulates DNA damage responses.	Case Western Reserve Univ, Dept Med, Div Hematol Oncol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Maryland, Sch Med, Dept Pathol, Rockville, MD 20855 USA	Case Western Reserve University	Qu, CK (corresponding author), Case Western Reserve Univ, Dept Med, Div Hematol Oncol, Case Comprehens Canc Ctr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cxq6@case.edu			NHLBI NIH HHS [R01 HL68212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agami R, 1999, NATURE, V399, P809; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gong JG, 1999, NATURE, V399, P806; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Yuan LP, 2003, J BIOL CHEM, V278, P42812, DOI 10.1074/jbc.M305075200; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	46	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42701	42706		10.1074/jbc.M506768200	http://dx.doi.org/10.1074/jbc.M506768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260787	hybrid			2022-12-25	WOS:000234200800028
J	Ma, YY; Temkin, V; Liu, HT; Pope, RM				Ma, YY; Temkin, V; Liu, HT; Pope, RM			NF-kappa B protects macrophages from lipopolysaccharide-induced cell death - The role of caspase 8 and receptor-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; DOMAIN KINASE RIP; BACTERIA-FACED MACROPHAGES; INDUCED APOPTOSIS; TNF-ALPHA; RHEUMATOID-ARTHRITIS; MURINE MACROPHAGES; MEDIATED APOPTOSIS; DENDRITIC CELLS; ACTIVATION	Macrophages play a pivotal role in the pathogenesis of a variety of diseases. These studies were performed to characterize the mechanisms by which Toll-like receptor 4 (TLR4)-mediated NF-kappa B activation promotes resistance to cell death in macrophages. When NF-kappa B activation was inhibited by a super-repressor, I kappa B alpha, the TLR4 ligand lipopolysaccharide induced the activation of caspase 8, the loss of mitochondrial transmembrane potential (Delta Psi(m)), and apoptotic cell death in macrophages. The inhibition of caspase 8 activation suppressed DNA fragmentation but failed to protect macrophages against the loss of Delta Psi(m) and resulted in necrotic cell death. In contrast, the reduction of receptor-interacting protein 1 suppressed the loss of Delta Psi(m) and inhibited apoptotic cell death. Further, when caspase 8 activation was suppressed, the knock down of receptor-interacting protein inhibited the loss of Delta Psi(m) and necrotic cell death. These observations demonstrate that following TLR4 ligation by lipopolysaccharide, NF-kappa B is a critical determinant of macrophage life or death, whereas caspase 8 determines the pathway employed.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Pope, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, 240 E Huron St,Suite M300, Chicago, IL 60611 USA.	rmp158@northwestern.edu		Pope, Richard M./0000-0003-2416-8660	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049217, R01AR048269] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR048269, R01AR049217] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barcia RN, 2003, CELL IMMUNOL, V226, P78, DOI 10.1016/j.cellimm.2003.11.006; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Cusson N, 2002, J EXP MED, V196, P15, DOI 10.1084/jem.20011470; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; GRIFFITHS MM, 1981, J RHEUMATOL, V8, P647; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Haase R, 2003, J IMMUNOL, V171, P4294, DOI 10.4049/jimmunol.171.8.4294; Han KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Jobin C, 1998, J IMMUNOL, V160, P410; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KARLSSONPARRA A, 1990, SCAND J IMMUNOL, V31, P283, DOI 10.1111/j.1365-3083.1990.tb02770.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kitamura M, 1999, EUR J IMMUNOL, V29, P1647; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lakics V, 1998, J IMMUNOL, V161, P2490; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu HT, 2004, J IMMUNOL, V172, P1907, DOI 10.4049/jimmunol.172.3.1907; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Ruckdeschel K, 2002, J IMMUNOL, V168, P4601, DOI 10.4049/jimmunol.168.9.4601; Ruckdeschel K, 2004, J IMMUNOL, V173, P3320, DOI 10.4049/jimmunol.173.5.3320; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SCHENCK P, 1995, J RHEUMATOL, V22, P400; Suzuki T, 2004, INFECT IMMUN, V72, P1856, DOI 10.1128/IAI.72.4.1856-1865.2004; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Xaus J, 2000, BLOOD, V95, P3823	51	71	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41827	41834		10.1074/jbc.M510849200	http://dx.doi.org/10.1074/jbc.M510849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16246838	hybrid			2022-12-25	WOS:000233992700008
J	Almeida, M; Han, L; Bellido, T; Manolagas, SC; Kousteni, S				Almeida, M; Han, L; Bellido, T; Manolagas, SC; Kousteni, S			Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; HIGH-BONE-MASS; CELL-CYCLE; OSTEOGENIC DIFFERENTIATION; ACTIN CYTOSKELETON; INHIBITS APOPTOSIS; NEGATIVE REGULATOR; PATHWAY; KINASE; TRANSCRIPTION	Genetic studies in humans and mice have revealed an important role of the Wnt signaling pathway in the regulation of bone mass, resulting from potent effects on the control of osteoblast progenitor proliferation, commitment, differentiation, and perhaps osteoblast apoptosis. To establish the linkage between Wnts and osteoblast survival and to elucidate the molecular pathways that link the two, we have utilized three cell models: the uncommitted bipotential C2C12 cells, the preosteoblastic cell line MC3T3-E1, and bone marrow-derived OB-6 osteoblasts. Serum withdrawal-induced apoptosis was prevented by the canonical Wnts(Wnt3a and Wnt1) and the noncanonical Wnt5a in all cell types. Wnt3a induced LRP5-independent transient phosphorylation and nuclear accumulation of ERKs and phosphorylation of Src and Akt. The anti-apoptotic effect of Wnt3a was abrogated by inhibitors of canonical Wnt signaling, as well as by inhibitors of MEK, Src, phosphatidylinositol 3-kinase(PI3K), or Akt kinases, or by the addition of cycloheximide to the culture medium. Wnt3a-induced phosphorylation of GSK-3 beta and downstream activation of beta-catenin-mediated transcription required ERK, PI3K, and Akt signaling. Wnt3a increased the expression of the anti-apoptotic protein Bcl-2 in an ERK-dependent manner. beta-Catenin-mediated transcription was permissive for the anti-apoptotic actions of Wnt1 and Wnt3a but was dispensable for the anti- apoptotic action of Wnt5a. However, Src, ERKs, PI3K, and Akt kinases were required for the anti- apoptotic effects of Wnt5a. These results demonstrate for the first time that Wnt proteins, irrespective of their ability to stimulate canonical Wnt signaling, prolong the survival of osteoblasts and uncommitted osteoblast progenitors via activation of the Src/ERK and PI3K/Akt signaling cascades.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Kousteni, S (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Slot 587,4301 W Markham St, Little Rock, AR 72205 USA.	koustenistavroula@uams.edu		Almeida, Maria/0000-0002-6722-9200	NIAMS NIH HHS [K01-AR02127, R01-AR51187-01] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127, R01AR051187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Almeida M, 2003, J BONE MINER RES, V18, pS77; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; CHEYETTE BN, 2004, SCI STKE, pE54; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Graham NA, 2004, J BIOL CHEM, V279, P23517, DOI 10.1074/jbc.M314055200; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kousteni S, 2004, J BONE MINER RES, V19, pS31; Kousteni S, 2003, J BONE MINER RES, V18, pS28; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang YF, 2003, BIOESSAYS, V25, P317, DOI 10.1002/bies.10255; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026; You L, 2004, CANCER RES, V64, P3474, DOI 10.1158/0008-5472.CAN-04-0115; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	74	332	369	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41342	41351		10.1074/jbc.M502168200	http://dx.doi.org/10.1074/jbc.M502168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16251184	hybrid			2022-12-25	WOS:000233866900029
J	Lee, JH; Skalnik, DG				Lee, JH; Skalnik, DG			CpG-binding protein (CXXC finger protein 1) is a component of the mammalian set1 histone H3-Lys(4) methyltransferase complex, the analogue of the yeast Set1/COMPASS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; DNA METHYLATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; DROSOPHILA-TRITHORAX; LYSINE-4 METHYLATION; NEUROSPORA-CRASSA; GENE-EXPRESSION; ACUTE LEUKEMIAS; PHD FINGER	CpG-binding protein (CXXC finger protein 1 (CFP1)) binds to DNA containing unmethylated CpG motifs and is required for mammalian embryogenesis, normal cytosine methylation, and cellular differentiation. Studies were performed to identify proteins that interact with CFP1 to gain insight into the molecular function of this protein. Immunoprecipitation and mass spectrometry reveal that human CFP1 associates with a similar to 450-kDa complex that contains the mammalian homologues of six of the seven components of the Set1/COMPASS complex, the sole histone H3-Lys(4) methyltransferase in yeast. In vitro assays demonstrate that the human Set1/CFP1 complex is a histone methyltransferase that produces mono-, di-, and trimethylated histone H3 at Lys(4). Confocal microscopy reveals that CFP1 and Set1 co-localize to nuclear speckles associated with euchromatin. A Set1 complex of reduced mass persists in murine embryonic stem cells lacking CFP1. These cells carry elevated levels of methylated histone H3-Lys(4) and reduced levels of methylated histone H3-Lys(9). Together with the previous finding of reduced levels of cytosine methylation, these data indicate that cells lacking CFP1 contain reduced levels of heterochromatin. Furthermore, ES cells lacking CFP1 exhibit a 4-fold excess of histone H3-Lys(4) methylation following induction of differentiation, indicating that CFP1 restricts the activity of the Set1 histone methyltransferase complex. These results reveal amammalian counterpart to the yeast Set1/COMPASS complex. The presence of CFP1 in this complex implicates this protein as a critical epigenetic regulator of histone modification in addition to cytosine methylation and reveals one mechanism by which this protein intersects with the epigenetic machinery.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol,Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol,Dept Pediat, Canc Res Bldg,Rm 327,1044 W Walnut St, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Amente S, 2005, FEBS LETT, V579, P683, DOI 10.1016/j.febslet.2004.12.045; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; Carlone DL, 2005, MOL CELL BIOL, V25, P4881, DOI 10.1128/MCB.25.12.4881-4891.2005; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; Lee JH, 2001, J BIOL CHEM, V276, P44669, DOI 10.1074/jbc.M107179200; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; Ono R, 2002, CANCER RES, V62, P4075; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Roguev A, 2003, J BIOL CHEM, V278, P8487, DOI 10.1074/jbc.M209562200; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yanagida M, 2004, J BIOL CHEM, V279, P1607, DOI 10.1074/jbc.M305604200; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	55	237	252	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41725	41731		10.1074/jbc.M508312200	http://dx.doi.org/10.1074/jbc.M508312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16253997	hybrid			2022-12-25	WOS:000233866900074
J	Misenheimer, TM; Mosher, DF				Misenheimer, TM; Mosher, DF			Biophysical characterization of the signature domains of thrombospondin-4 and thrombospondin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; C-TERMINAL REGION; MYOCARDIAL-INFARCTION; A387P POLYMORPHISM; TYPE-3 REPEATS; CALCIUM; BINDING; EXPRESSION; PSEUDOACHONDROPLASIA; IDENTIFICATION	The signature domain of thrombospondins consists of tandem epidermal growth factor-like modules, 13 calcium-binding repeats, and a lectin-like module. Although very similar, the signature domains of thrombospondin-1 and -2 differ in several potentially important ways from the domains of thrombospondin-3, -4, and -5. We have compared matching recombinant segments representing the signature domains of thrombospondin-2 and -4. In the presence of 2 mM CaCl2, the far UV circular dichroism spectra of thrombospondin-2 and -4 constructs contain a strong negative band at 202 nm, but only the thrombospondin-2 construct has a band at 216 nm. Chelation of calcium shifted the negative bands to lower magnitudes. Titrations of the spectra demonstrated lower cooperativity and affinity for binding of calcium to thrombospondin-4 compared with thrombospondin-2. Atomic absorption spectroscopy demonstrated that the thrombospondin-4 constructs bind seven less calcium than the thrombospondin-2 construct at 0.6 mM CaCl2. In 2 mM CaCl2, the near UV circular dichroism spectra of thrombospondin-2, but not thrombospondin-4, contain a positive band at 292 nm that disappears upon calcium chelation. Intrinsic fluorescence spectra for both proteins were also sensitive to calcium, but the changes were simpler and more marked for thrombospondin-2 than for thrombospondin-4. In differential scanning calorimetry, the thrombospondin-2 construct melted in two distinct transitions at 53.5 and 81.8 degrees C, whereas the first transition for thrombospondin-4 constructs was observed at 63.5 degrees C. Thus, the studies revealed significant differences between the signature domains of thrombospondin-2 and thrombospondin-4 in calcium binding, fine structure, and inter-modular interactions.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Misenheimer, TM (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.	tmmisenh@wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR13790, S10 RR013790] Funding Source: Medline; NHLBI NIH HHS [HL54462, R01 HL054462] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J. C., 1995, THROMBOSPONDIN GENE; ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; Adams JC, 2004, INT J BIOCHEM CELL B, V36, P1102, DOI 10.1016/j.biocel.2004.01.022; Adams JC, 2003, J MOL BIOL, V328, P479, DOI 10.1016/S0022-2836(03)00248-1; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CREIGHTON TE, 1997, PROTEIN STRUCTURE PR, P287; Cui JX, 2004, ARTERIOSCL THROM VAS, V24, pE183, DOI 10.1161/01.ATV.0000147304.67100.ee; Hannah BLA, 2004, J BIOL CHEM, V279, P51915, DOI 10.1074/jbc.M409632200; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1983, J BIOL CHEM, V258, P2098; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Misenheimer TM, 2003, BIOCHEMISTRY-US, V42, P5125, DOI 10.1021/bi026983p; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Narouz-Ott L, 2000, J BIOL CHEM, V275, P37110, DOI 10.1074/jbc.M007223200; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Stenina OI, 2005, FASEB J, V19, P1893, DOI 10.1096/fj.05-3712fje; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Wessel J, 2004, AM HEART J, V147, P905, DOI 10.1016/j.ahj.2003.12.013; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957	28	19	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41229	41235		10.1074/JBC.M504696200	http://dx.doi.org/10.1074/JBC.M504696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16246837	Green Accepted, hybrid			2022-12-25	WOS:000233866900016
J	Krishnan, M; Park, JM; Cao, F; Wang, DX; Paulmurugan, R; Tseng, JR; Gonzalgo, ML; Gambhir, SS; Wu, JC				Krishnan, M; Park, JM; Cao, F; Wang, DX; Paulmurugan, R; Tseng, JR; Gonzalgo, ML; Gambhir, SS; Wu, JC			Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging	FASEB JOURNAL			English	Article						gene silencing; molecular imaging; stem cell transplant	POSITRON-EMISSION-TOMOGRAPHY; MYOBLAST TRANSFER THERAPY; TRANSGENE EXPRESSION; DNA METHYLATION; LIVING MICE; IN-VITRO; CANCER; TRANSPLANTATION; REACTIVATION; VECTOR	Tracking stem cell localization, survival, differentiation, and proliferation after transplantation in living subjects is essential for understanding stem cell biology and physiology. In this study, we investigated the long-term stability of reporter gene expression in an embryonic rat cardiomyoblast cell line and the role of epigenetic modulation on reversing reporter gene silencing. Cells were stably transfected with plasmids carrying cytomegalovirus promoter driving firefly luciferase reporter gene (CMV-Fluc) and passaged repeatedly for 3-8 months. Within the highest expressor clone, the firefly luciferase activity decreased progressively from passage 1 ( 843 +/- 28) to passage 20 ( 250 +/- 10) to passage 40 ( 44 +/- 3) to passage 60 ( 3 +/- 1 RLU/mu g; P < 0.05 vs. passage 1). Firefly luciferase activity was maximally rescued by treatment with 5-azacytidine ( DNA methyltransferase inhibitor) compared with trichostatin A ( histone deacetylase inhibitor) and retinoic acid ( transcriptional activator; P < 0.05). Increasing dosages of 5-azacytidine treatment led to higher levels of firefly luciferase mRNA ( RT-PCR) and protein ( Western blots) and inversely lower levels of methylation in the CMV promoter ( DNA nucleotide sequence). These in vitro results were extended to in vivo bioluminescence imaging (BLI) of cell transplant in living animals. Cells treated with 5-azacytidine were monitored for 2 wk compared with 1 wk for untreated cells ( P < 0.05). These findings should have important implications for reporter gene-based imaging of stem cell transplantation.	Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Palo Alto, CA 94304 USA; Stanford Univ, BioX Program, Palo Alto, CA 94304 USA; Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA; Stanford Univ, Dept Bioengn, Palo Alto, CA 94304 USA; Stanford Univ, Dept Med, Div Cardiol, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Johns Hopkins University; Johns Hopkins Medicine; Stanford University; Stanford University	Wu, JC (corresponding author), Stanford Univ, Sch Med, Edwards Bldg,R354, Stanford, CA 94305 USA.	joewu@stanford.edu	; Wu, Joseph/H-1067-2013	Paulmurugan, Ramasamy/0000-0001-7155-4738; Park, MD, PhD, FACR, Jinha M./0000-0002-0849-3482; Wu, Joseph/0000-0002-6068-8041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074883] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL074883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Adonai N, 2002, P NATL ACAD SCI USA, V99, P3030, DOI 10.1073/pnas.052709599; Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blasberg RG, 2003, J CLIN INVEST, V111, P1620, DOI 10.1172/JCI200318855; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Fan Y, 1996, MUSCLE NERVE, V19, P853, DOI 10.1002/(SICI)1097-4598(199607)19:7<853::AID-MUS7>3.0.CO;2-8; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gaetano C, 2000, GENE THER, V7, P1624, DOI 10.1038/sj.gt.3301296; Jacobs A, 2001, LANCET, V358, P727, DOI 10.1016/S0140-6736(01)05904-9; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim YH, 2005, J NUCL MED, V46, P305; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Lee-Pullen TF, 2004, TRANSPLANTATION, V78, P1172, DOI 10.1097/01.TP.0000137936.75203.B4; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Loser P, 1998, J VIROL, V72, P180; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Marsee DK, 2004, CANCER GENE THER, V11, P121, DOI 10.1038/sj.cgt.7700661; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Meier JL, 2001, J VIROL, V75, P1581, DOI 10.1128/JVI.75.4.1581-1593.2001; Muller-Ehmsen J, 2002, CIRCULATION, V105, P1720, DOI 10.1161/01.CIR.0000013782.76324.92; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rasmussen Theodore P, 2003, Reprod Biol Endocrinol, V1, P100, DOI 10.1186/1477-7827-1-100; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P251, DOI 10.1006/jmcc.2001.1494; Rosenqvist N, 2002, J GENE MED, V4, P248, DOI 10.1002/jgm.268; Skuk D, 2003, J NEUROPATH EXP NEUR, V62, P951, DOI 10.1093/jnen/62.9.951; Smythe GM, 2001, J CELL MOL MED, V5, P33, DOI 10.1111/j.1582-4934.2001.tb00136.x; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Wu JC, 2004, J NUCL CARDIOL, V11, P491, DOI 10.1016/j.nuclcard.2004.04.004; Wu JC, 2002, CIRCULATION, V106, P180, DOI 10.1161/01.CIR.0000023620.59633.53; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Yamazaki S, 2003, J HEPATOL, V38, P107, DOI 10.1016/S0168-8278(03)80630-X	43	104	110	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					106	+		10.1096/fj.05-4551fje	http://dx.doi.org/10.1096/fj.05-4551fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16246867	Green Accepted			2022-12-25	WOS:000232991100011
J	Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M				Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M			Prevention of lung cancer progression by bexarotene in mouse models	ONCOGENE			English	Article						chemoprevention; bexarotene; lung cancer; mouse models	RETINOID-X-RECEPTOR; SELECTIVE LIGAND LGD1069; MAMMARY-CARCINOMA; TARGRETIN; TUMORS; TAMOXIFEN; EFFICACY; MUTATION; KRAS2; TRIAL	Bexarotene (Targretin((R)), Ligand Pharmaceuticals Inc.) is a synthetic high-affinity RXR receptor agonist with limited affinity for RAR receptors. Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers. However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer models. In this study, we have investigated the ability of bexarotene to inhibit lung tumor progression in the mutant A/J mouse models with genetic alterations in p53 or K-ras, two of the most commonly altered genes in human lung tumorigenesis. Mice were administered vinyl carbamate ( VC), a carcinogen, by a single intraperitoneal injection (i.p.) at 6 weeks of age. Bexarotene was given by gavage starting at 16 weeks after VC and was continued for 12 weeks. Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice. Bexarotene inhibited both tumor multiplicity and tumor volume in mice of all three genotypes. Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by similar to 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice. Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; Chemoprevent Agent Dev Res Grp, NCI, Rockville, MD USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN25104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Bischoff ED, 1998, CANCER RES, V58, P479; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; Gottardis MM, 1996, CANCER RES, V56, P5566; Herzog CR, 1997, J CELL BIOCHEM, P49; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; Konopleva M, 2002, CURR OPIN HEMATOL, V9, P294, DOI 10.1097/00062752-200207000-00006; Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033; Li J, 2003, ONCOGENE, V22, P1243, DOI 10.1038/sj.onc.1206192; Lubet RA, 2005, CARCINOGENESIS, V26, P441, DOI 10.1093/carcin/bgh338; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; NASONBURCHENAL K, 1999, HANDB EXP PHARM, V139, P301; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sherman SI, 1999, NEW ENGL J MED, V340, P1075, DOI 10.1056/NEJM199904083401404; STONER GD, 1991, EXP LUNG RES, V17, P405, DOI 10.3109/01902149109064428; Tong LZ, 1996, CANCER, V78, P1004, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6; Wang Y, 2003, CANCER RES, V63, P4389; Wu KD, 2002, CANCER RES, V62, P6376; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2004, ONCOGENE, V23, P3841, DOI 10.1038/sj.onc.1207496; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2000, CANCER RES, V60, P901	32	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1320	1329		10.1038/sj.onc.1209180	http://dx.doi.org/10.1038/sj.onc.1209180			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247446				2022-12-25	WOS:000235708200005
J	Liou, B; Kazimierczuk, A; Zhang, M; Scott, CR; Hegde, RS; Grabowski, GA				Liou, B; Kazimierczuk, A; Zhang, M; Scott, CR; Hegde, RS; Grabowski, GA			Analyses of variant acid beta-glucosidases - Effects of Gaucher disease mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY-STRUCTURE; SAPOSIN-C; HUMAN GLUCOCEREBROSIDASE; HETEROLOGOUS EXPRESSION; LYSOSOMAL GLUCOCEREBROSIDASE; GENETIC-HETEROGENEITY; CATALYTIC-ACTIVITY; MUTANT ALLELES; TYPE-1	Acid beta-glucosidase (GCase) is a 497-amino acid, membrane-associated lysosomal exo-beta-glucosidase whose defective activity leads to the Gaucher disease phenotypes. To move toward a structure/function map for disease mutations, 52 selected single amino acid substitutions were introduced into GCase, expressed in an insect cell system, purified, and characterized for basic kinetic, stability, and activator response properties. The variant GCases from Gaucher disease patients and selected variant GCases from the mouse had decreased relative k(cat) and differential effects on active site binding and/or attachment of mechanism-based covalent (conduritol B epoxide) or reversible (deoxynojirimycin derivatives) inhibitors. A defect in negatively charged phospholipid activation was present in the majority of variant GCases but was increased in two, N370S and V394L. Deficits in saposin C enhancement of kcat were present in variant GCases involving residues 48-122, whereas similar to 2-fold increases were obtained with the L264I GCase. About 50% of variant GCases each had wild-type or increased sensitivity to in vitro cathepsin D digestion. Mapping of these properties onto the crystal structures of GCase indicated wide dispersion of functional properties that can affect catalytic function and stability. Site-directed mutagenesis of cysteine residues showed that the disulfide bonds, Cys(4)-Cys(16) and Cys(18)-Cys(23), and a free Cys(342) were essential for activity; the free Cys(126) and Cys(248) were not. Relative kcat was highly sensitive to a His substitution at Arg(496) but not at Arg(495). These studies and high phylogenetic conservation indicate localized and general structural effects of Gaucher disease mutations that were not obvious from the nature of the amino acid substitution, including those predicted to be nondisruptive (e.g. Val -> Leu). These results provide initial studies for the engineering of variant GCases and, potentially, molecular chaperones for therapeutic use.	Childrens Hosp, Res Fdn, Div Program Human Genet, Cincinnati, OH 45229 USA; Childrens Hosp, Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Washington; University of Washington Seattle	Grabowski, GA (corresponding author), Childrens Hosp, Res Fdn, Div Program Human Genet, 3333 Burnet Ave,ML C4006, Cincinnati, OH 45229 USA.	greg.grabowski@cchmc.org			NEI NIH HHS [EY014648] Funding Source: Medline; NIDDK NIH HHS [DK36729] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfonso P, 2004, BLOOD CELL MOL DIS, V32, P218, DOI 10.1016/j.bcmd.2003.10.010; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BERGMANN JE, 1989, AM J HUM GENET, V44, P741; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Bodamer OAF, 2002, AM J MED GENET, V109, P328, DOI 10.1002/ajmg.10385; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; Brautbar A, 2003, BLOOD CELL MOL DIS, V31, P187, DOI 10.1016/S1079-9796(03)00126-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; EYAL N, 1991, HUM GENET, V87, P328; FABBRO D, 1987, AM J HUM GENET, V40, P15; Fabrega SL, 2000, GLYCOBIOLOGY, V10, P1217, DOI 10.1093/glycob/10.11.1217; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; Grace ME, 1997, J CLIN INVEST, V99, P2530, DOI 10.1172/JCI119437; GRACE ME, 1994, J BIOL CHEM, V269, P2283; GRACE ME, 1991, AM J HUM GENET, V49, P646; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GRAY GM, 1975, J LIPID RES, V16, P434; Hawkins CA, 2005, J MOL BIOL, V346, P1381, DOI 10.1016/j.jmb.2004.12.045; He Guo-Shun, 1992, Human Mutation, V1, P423, DOI 10.1002/humu.1380010513; Horowitz M, 1998, HUM MUTAT, V12, P240, DOI 10.1002/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Kim JW, 1996, HUM MUTAT, V7, P214, DOI 10.1002/(SICI)1098-1004(1996)7:3<214::AID-HUMU5>3.0.CO;2-A; Koprivica V, 2000, AM J HUM GENET, V66, P1777, DOI 10.1086/302925; Leonova T, 2000, MOL GENET METAB, V70, P281, DOI 10.1006/mgme.2000.3035; Liou B., 1996, THESIS U CINCINNATI; MIAO SC, 1994, J BIOL CHEM, V269, P10975; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paal K, 2004, BIOCHEM J, V378, P141, DOI 10.1042/BJ20031028; Pampols T, 1999, ACTA NEUROPATHOL, V97, P91, DOI 10.1007/s004010050960; Park JK, 2003, PEDIATR RES, V53, P387, DOI 10.1203/01.PDR.0000049515.79882.94; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Qi XY, 1999, BIOCHEMISTRY-US, V38, P6284, DOI 10.1021/bi990079o; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; Ron I, 2005, HUM MOL GENET, V14, P2387, DOI 10.1093/hmg/ddi240; Schmitz M, 2005, INT J BIOCHEM CELL B, V37, P2310, DOI 10.1016/j.biocel.2005.05.008; Seeman PJV, 1996, NEUROLOGY, V46, P1102, DOI 10.1212/WNL.46.4.1102; Shamseddine A, 2004, AM J MED GENET A, V125A, P257, DOI 10.1002/ajmg.a.20518; Sidransky E, 2004, MOL GENET METAB, V83, P6, DOI 10.1016/j.ymgme.2004.08.015; Stone DL, 2000, HUM MUTAT, V15, P181, DOI 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.3.CO;2-J; STRASBERG PM, 1994, BIOCHEM MED METAB B, V53, P16, DOI 10.1006/bmmb.1994.1052; Sun Y, 2003, J BIOL CHEM, V278, P31918, DOI 10.1074/jbc.M302752200; Tayebi N, 1996, BIOCHEM MOL MED, V57, P149, DOI 10.1006/bmme.1996.0021; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1986, J BIOL CHEM, V261, P50; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; Uchida Y, 2000, J LIPID RES, V41, P2071; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; Verghese J, 2000, ARCH NEUROL-CHICAGO, V57, P389, DOI 10.1001/archneur.57.3.389; WERTZ PW, 1989, COMP BIOCHEM PHYS B, V93, P265, DOI 10.1016/0305-0491(89)90080-1; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; Xu YH, 2003, AM J PATHOL, V163, P2093, DOI 10.1016/S0002-9440(10)63566-3; Xu YH, 2000, MOL GENET METAB, V70, P106, DOI 10.1006/mgme.2000.3010; Zhao H, 2003, CLIN GENET, V64, P57, DOI 10.1034/j.1399-0004.2003.00100.x; Zhao HQ, 2003, AM J MED GENET A, V116A, P52, DOI 10.1002/ajmg.a.10029	65	92	109	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4242	4253		10.1074/jbc.M511110200	http://dx.doi.org/10.1074/jbc.M511110200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16293621	hybrid			2022-12-25	WOS:000235275300057
J	Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA				Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA			Loss of one HuD allele on chromosome # 1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein; chromosome 1p deletion; gene amplification	PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN; RESISTANT CHINESE-HAMSTER; RNA-BINDING PROTEIN; GENE AMPLIFICATION; SHORT ARM; EXPRESSION; ELAV; LINES; HETEROZYGOSITY; HYBRIDIZATION	In human neuroblastoma tumors, amplification of the N-myc proto-oncogene and loss of all or part of the short arm of chromosome #1 are both associated with a poor prognosis. Accruing evidence indicates that it is the absence of one allele of the HuD (ELAVL4) gene, encoding the neuronal-specific RNA-binding protein HuD and localized to 1p34, that is linked to amplification. In 12 human neuroblastoma cell lines, N-myc amplification correlates with loss of one HuD allele and decreased HuD expression. Transfection experiments demonstrate that modulating HuD expression affects N-myc gene copy number as well as expression. Introduction of a sense HuD construct into two N-myc amplified cell lines considerably increases N-myc expression whereas gene copy number decreases. Conversely, expression of antisense HuD in N-myc nonamplified SH-SY5Y cells reduces HuD and N-myc mRNA levels even as cells show amplification of the N-myc gene. Thus, N-myc gene copy number is modulated by alteration of HuD expression. We propose that haploinsufficiency of HuD due to chromosome #1p deletion in neuroblastoma selects for cells that amplify N-myc genes. Application of these findings could lead to more effective therapies in the treatment of those patients with the worst prognosis.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Rd, Bronx, NY 10458 USA.	rross@fordham.edu			NCI NIH HHS [CA77593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; Ball NS, 1997, CLIN CANCER RES, V3, P1859; BELLO MJ, 1995, CANCER GENET CYTOGEN, V83, P160, DOI 10.1016/0165-4608(95)00064-V; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1979, PROGR CANC RES THERP, V12, P881; BIEDLER JL, 1983, RATIONAL BASIS CHEMO, P71; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; FOLEY J, 1991, CANCER RES, V51, P6338; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Han J, 1996, GENOMICS, V36, P189, DOI 10.1006/geno.1996.0444; Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; ISCN, 1995, INT SYST HUM CYT NOM; Izbicki T, 2003, ANTICANCER RES, V23, P755; KING PH, 1994, J NEUROSCI, V14, P1943; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lutz W, 1996, ONCOGENE, V13, P803; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; Mora J, 2001, ONCOLOGIST, V6, P263, DOI 10.1634/theoncologist.6-3-263; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MURESU R, 1994, CYTOGENET CELL GENET, V65, P177, DOI 10.1159/000133626; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Sivak LE, 1999, MOL CELL BIOL, V19, P155; Spengler BA, 1997, ONCOL RES, V9, P467; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	47	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					706	712		10.1038/sj.onc.1209095	http://dx.doi.org/10.1038/sj.onc.1209095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16278682				2022-12-25	WOS:000235068800006
J	Dodson, GE; Tibbetts, RS				Dodson, GE; Tibbetts, RS			DNA replication stress-induced phosphorylation of cyclic AMP response element-binding protein mediated by ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TELANGIECTASIA-RELATED PROTEIN; DAMAGE-INDUCED PHOSPHORYLATION; EARLY EMBRYONIC LETHALITY; GENOME-WIDE ANALYSIS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; GENOTOXIC STRESS; DEPENDENT PHOSPHORYLATION; CHECKPOINT ACTIVATION	The DNA damage-response regulators ATM (ataxia-telangiectasia-mutated) and ATR (ATM-Rad3-related) are structurally and functionally related protein kinases that exhibit nearly identical substrate specificities in vitro. Current paradigms hold that the relative contributions of ATM and ATR to nuclear substrate phosphorylation are dictated by the type of initiating DNA lesion; ATM-dependent substrate phosphorylation is principally activated by DNA double strand breaks, whereas ATR-dependent substrate phosphorylation is induced by UV light and other forms of DNA replication stress. In this report, we employed the cyclic AMP-response element-binding (CREB) protein to provide evidence for substrate discrimination by ATM and ATR in cellulo. ATM and ATR phosphorylate CREB in vitro, and CREB is phosphorylated on Ser-121 in intact cells in response to ionizing radiation (IR), UV light, and hydroxyurea. The UV light- and hydroxyurea-induced phosphorylation of CREB was delayed in comparison to the canonical ATR substrate CHK1, suggesting potentially different mechanisms of phosphorylation. UV light- induced CREB phosphorylation temporally correlated with ATM autophosphorylation on Ser-1981, and an ATM-specific small interfering RNA suppressed CREB phosphorylation in response to this stimulus. UV light- induced CREB phosphorylation was absent in ATM-deficient cells, confirming that ATM is required for CREB phosphorylation in UV irradiation-damaged cells. Interestingly, RNA interference-mediated suppression of ATR partially inhibited CREB phosphorylation in response to UV light, which correlated with reduced phosphorylation of ATM on Ser-1981. These findings suggest that ATM is the major genotoxin-induced CREB kinase in mammalian cells and that ATR lies upstream of ATM in a UV light- induced signaling pathway.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NIGMS NIH HHS [GM067868-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen JJ, 2000, CANCER RES, V60, P5037; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1692	1697		10.1074/jbc.M509577200	http://dx.doi.org/10.1074/jbc.M509577200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293623	hybrid			2022-12-25	WOS:000234652000049
J	Gardiner, DL; Trenholme, KR; Adams, TSS; Stack, CM; Dalton, JP				Gardiner, DL; Trenholme, KR; Adams, TSS; Stack, CM; Dalton, JP			Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites - Target for the antimalarial activity of bestatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; HEMOGLOBIN DEGRADATION; CHABAUDI CHABAUDI; AMINO-ACIDS; M1 FAMILY; CYSTEINE; PROTEASES; INHIBITION; HYDROLYSIS; PROTEINS	Malaria aminopeptidases are important in the generation and regulation of free amino acids that are used in protein anabolism and for maintaining osmotic stability within the infected erythrocyte. The intraerythrocytic development of malaria parasites is blocked when the activity of aminopeptidases is specifically inhibited by reagents such as bestatin. One of the major aminopeptidases of malaria parasites is a leucyl aminopeptidase of the M17 family. We reasoned that, when this enzyme was the target of bestatin inhibition, its overexpression in malaria cells would lead to a reduced sensitivity to the inhibitor. To address this supposition, transgenic Plasmodium falciparum parasites overexpressing the leucyl aminopeptidase were generated by transfection with a plasmid that housed the full-length gene. Transgenic parasites expressed a 65-kDa protein close to the predicted molecule size of 67.831 kDa for the introduced leucyl aminopeptidase, and immunofluorescence studies localized the protein to the cytosol, the location of the native enzyme. The product of the transgene was shown to be functionally active with cytosolic extracts of transgenic parasites exhibiting twice the leucyl aminopeptidase activity compared with wildtype parasites. In vitro inhibitor sensitivity assays demonstrated that the transgenic parasites were more resistant to bestatin (EC50 64 mu M) compared with the parent parasites (EC50 25 mu M). Overexpression of genes in malaria parasites would have general application in the identification and validation of targets for antimalarial drugs.	Univ Technol Sydney, Inst Biotechnol Infect Dis, Sydney, NSW 2065, Australia; Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, Malaria Biol Lab, Brisbane, Qld 4029, Australia	University of Technology Sydney; QIMR Berghofer Medical Research Institute	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Westbourne St,Gore Hill, Sydney, NSW 2065, Australia.	john.dalton@uts.edu.au	Gardiner, Don/G-4717-2010; Trenholme, Katharine/C-9244-2013; Skinner-Adams, Tina S/A-9798-2012; Dalton, John/K-4457-2014; Stack, Colin M/D-4601-2009	Skinner-Adams, Tina S/0000-0001-7011-3850; Stack, Colin/0000-0002-7539-7677				Allary M, 2002, PARASITOLOGY, V125, P1, DOI 10.1017/S0031182002001828; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; CHARET P, 1980, ANN PARASIT HUM COMP, V55, P359, DOI 10.1051/parasite/1980554359; CURLEY GP, 1994, J EUKARYOT MICROBIOL, V41, P119, DOI 10.1111/j.1550-7408.1994.tb01483.x; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Gavigan CS, 2001, ANTIMICROB AGENTS CH, V45, P3175, DOI 10.1128/AAC.45.11.3175-3181.2001; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GYANG FN, 1982, MOL BIOCHEM PARASIT, V5, P263, DOI 10.1016/0166-6851(82)90034-2; Hawthorne PL, 2004, MOL BIOCHEM PARASIT, V136, P181, DOI 10.1016/j.molbiopara.2004.03.013; HUBER W, 1993, ACTA TROP, V55, P257, DOI 10.1016/0001-706X(93)90083-N; Ichinose Y, 2003, JNCI-J NATL CANCER I, V95, P605, DOI 10.1093/jnci/95.8.605; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lew VL, 2004, BLOOD CELL MOL DIS, V32, P353, DOI 10.1016/j.bcmd.2004.01.006; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; Nankya-Kitaka MF, 1998, PARASITOL RES, V84, P552, DOI 10.1007/s004360050447; ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033; Rosenthal PJ, 2004, INT J PARASITOL, V34, P1489, DOI 10.1016/j.ijpara.2004.10.003; Rosenthal PJ, 2003, J EXP BIOL, V206, P3735, DOI 10.1242/jeb.00589; Rosenthal PJ, 2002, CURR OPIN HEMATOL, V9, P140, DOI 10.1097/00062752-200203000-00010; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; SHERMAN IW, 1969, MIL MED, V134, P954; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P8721, DOI 10.1073/pnas.0402738101; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Skinner-Adams T, 1999, ANTIMICROB AGENTS CH, V43, P1304, DOI 10.1128/AAC.43.5.1304; Skinner-Adams TS, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-19; STRATER N, 2004, HDB PROTEOLYTIC ENZY, P896; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Turner AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P289; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; VANDERJAGT DL, 1984, MOL BIOCHEM PARASIT, V10, P45, DOI 10.1016/0166-6851(84)90017-3	39	56	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1741	1745		10.1074/jbc.M508955200	http://dx.doi.org/10.1074/jbc.M508955200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16286469	hybrid			2022-12-25	WOS:000234652000054
J	Hayashi, H; Matsuzaki, O; Muramatsu, S; Tsuchiya, Y; Harada, T; Suzuki, Y; Sugano, S; Matsuda, A; Nishida, E				Hayashi, H; Matsuzaki, O; Muramatsu, S; Tsuchiya, Y; Harada, T; Suzuki, Y; Sugano, S; Matsuda, A; Nishida, E			Centaurin-alpha(1) is a phosphatidylinositol 3-kinase-dependent activator of ERK1/2 mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,4,5-TRISPHOSPHATE-BINDING PROTEIN; IDENTIFICATION; EXPRESSION; P42(IP4); CLONING; ARF6	Centaurin-alpha(1) is known to be a phosphatidylinositol 3,4,5triphosphate (PIP3)-binding protein that has two pleckstrin homology domains and a putative ADP ribosylation factor GTPase-activating protein domain. However, the physiological function of centaurin-alpha(1) is still not understood. Here we have shown that transient expression of centaurin-alpha(1) in COS-7 cells results in specific activation of ERK, and the activation is inhibited by co-expression of a dominant negative form of Ras. We have also found that a mutant form of centaurin-alpha(1) that is unable to bind PIP3 fails to induce ERK activation and that a phosphatidylinositol 3-kinase inhibitor LY294002 inhibits centaurin-alpha(1)-dependent ERK activation. Furthermore, transient knockdown of centaurin-alpha(1) by small interfering RNAs results in reduced ERK activation after epidermal growth factor stimulation in T-REx 293 cells. These results suggest that centaurin-alpha(1) contributes to ERK activation in growth factor signaling, linking the PI3K pathway to the ERK mitogen-activated protein kinase pathway through its ability to interact with PIP3.	Asahi Kasei Pharma Corp, Pharmaceut R&D Planning Grp, Chiyoda Ku, Tokyo 1018481, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Asahi Kasei Pharma Corp, Life Sci Res Inst, Biol Lab, Fuji, Shizuoka 4168501, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Struct Anal,Minato Ku, Tokyo 1088639, Japan	Asahi Kasei Pharma Corporation; Kyoto University; Asahi Kasei Pharma Corporation; University of Tokyo	Matsuzaki, O (corresponding author), Asahi Kasei Pharma Corp, Pharmaceut R&D Planning Grp, Chiyoda Ku, 9-1 Kanda Mitoshirocho, Tokyo 1018481, Japan.	matsuzaki.ob@om.asahi-kasei.co.jp						Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campbell M, 2004, CIRC RES, V95, P380, DOI 10.1161/01.RES.0000138019.82184.5d; Chanda SK, 2003, P NATL ACAD SCI USA, V100, P12153, DOI 10.1073/pnas.1934839100; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Harada T, 2003, GENES CELLS, V8, P493, DOI 10.1046/j.1365-2443.2003.00650.x; Langford D, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-8; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Reiser G, 2004, NEUROREPORT, V15, P147, DOI 10.1097/00001756-200401190-00028; Reiser G, 2002, NEUROREPORT, V13, P2417, DOI 10.1097/00001756-200212200-00008; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sedehizade F, 2002, MOL BRAIN RES, V99, P1, DOI 10.1016/S0169-328X(01)00335-7; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Thacker E, 2004, EUR J CELL BIOL, V83, P541, DOI 10.1078/0171-9335-00416; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Venkateswarlu K, 2004, J BIOL CHEM, V279, P6205, DOI 10.1074/jbc.C300482200; Venkateswarlu K, 1999, BIOCHEM BIOPH RES CO, V262, P237, DOI 10.1006/bbrc.1999.1065; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359	25	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1332	1337		10.1074/jbc.M505905200	http://dx.doi.org/10.1074/jbc.M505905200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16287813	hybrid			2022-12-25	WOS:000234652000007
J	Wines, BD; Willoughby, N; Fraser, JD; Hogarth, PM				Wines, BD; Willoughby, N; Fraser, JD; Hogarth, PM			A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alpha RI, is revealed by SSL7 binding at the C alpha 2/C alpha 3 interface of IgA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS PROTEIN; CRYSTAL-STRUCTURES; LIGAND-BINDING; DOMAIN; IDENTIFICATION; CD89; SUPERANTIGENS; EXPRESSION; RESPONSES; RESIDUES	Leukocyte recruitment and effector functions like phagocytosis and respiratory burst are key elements of immunity to infection. Pathogen survival is dependent upon the ability to overwhelm, evade or inhibit the immune system. Pathogenic group A and group B streptococci are well known to produce virulence factors that block the binding of IgA to the leukocyte IgA receptor, Fc alpha RI, thereby inhibiting IgA-mediated immunity. Recently we found Staphylococcus aureus also interferes with IgA-mediated effector functions as the putative virulence factor SSL7 also binds IgA and blocks binding to Fc alpha RI. Herein we report that SSL7 and Fc alpha RI bind many of the same key residues in the Fc region of human IgA. Residues Leu-257 and Leu-258 in domain C alpha 2 and residues 440-443 PLAF in C alpha 3 of IgA lie at the C alpha 2/C alpha 3 interface and make major contributions to the binding of both the leukocyte receptor Fc alpha RI and SSL7. It is remarkable this S. aureus IgA binding factor and unrelated factors from streptococci are functionally convergent, all targeting a number of the same residues in the IgA Fc, which comprise the binding site for the leukocyte IgA receptor, Fc alpha RI.	Austin Hlth, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Heidelberg, Vic 3084, Australia; Univ Auckland, Sch Med Sci, Auckland 1020, New Zealand	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Auckland	Wines, BD (corresponding author), Austin Hlth, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	b.wines@ari.unimelb.edu.au		Hogarth, Mark/0000-0002-0360-7890				Al-Shangiti AM, 2004, INFECT IMMUN, V72, P4261, DOI 10.1128/IAI.72.7.4261-4270.2004; Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; Arcus VL, 2002, J BIOL CHEM, V277, P32274, DOI 10.1074/jbc.M203914200; Areschoug T, 2002, J BIOL CHEM, V277, P12642, DOI 10.1074/jbc.M112072200; ARESCHOUG T, 2004, VACCINE S1, V22, P9; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; Johnsson E, 1999, J BIOL CHEM, V274, P14521, DOI 10.1074/jbc.274.21.14521; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Langley R, 2005, J IMMUNOL, V174, P2926, DOI 10.4049/jimmunol.174.5.2926; Lee LYL, 2004, J INFECT DIS, V190, P571, DOI 10.1086/422259; Lina G, 2004, J INFECT DIS, V189, P2334, DOI 10.1086/420852; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Nashev D, 2004, FEMS MICROBIOL LETT, V233, P45, DOI 10.1016/j.femsle.2004.01.032; Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000; Pleass RJ, 1997, BIOCHEM SOC T, V25, pS328, DOI 10.1042/bst025328s; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Pleass RJ, 2001, J BIOL CHEM, V276, P8197, DOI 10.1074/jbc.M009396200; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Stabila PF, 1998, NAT BIOTECHNOL, V16, P1357, DOI 10.1038/4339; STEINITZ M, 1980, J IMMUNOL, V125, P194; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; Williams RJ, 2000, INFECT IMMUN, V68, P4407, DOI 10.1128/IAI.68.8.4407-4415.2000; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2003, IMMUNOLOGY, V109, P246, DOI 10.1046/j.1365-2567.2003.01652.x; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266; Woof JM, 2002, BIOCHEM SOC T, V30, P491, DOI 10.1042/bst0300491	33	35	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1389	1393		10.1074/jbc.M509334200	http://dx.doi.org/10.1074/jbc.M509334200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293625	hybrid			2022-12-25	WOS:000234652000014
J	Lee, TH; Perrem, K; Harper, JW; Lu, KP; Zhou, XZ				Lee, TH; Perrem, K; Harper, JW; Lu, KP; Zhou, XZ			The F-box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; PIN1-DEPENDENT PROLYL ISOMERIZATION; LENGTH REGULATOR; TRF1; PHOSPHORYLATION; IDENTIFICATION; PROTEOLYSIS; ELONGATION; EXPRESSION; TANKYRASE	Pin2/TRF1 was identified previously as both a protein (TRF1) that binds to telomeric DNA repeats and as a protein (Pin2) that associates with the kinase NIMA and suppresses its mitosis inducing activity. Pin2/TRF1 negatively regulates telomere length and also plays a critical role in cell cycle checkpoint control. Pin2/TRF1 is down-regulated in many human cancers and may be degraded by the ubiquitin-proteasome pathway, but components of the pathway involved in Pin2/TRF1 turnover have not been elucidated. By using the two-hybrid system, we recently identified Pin2/TRF1-interacting proteins, PinX1-4, and we demonstrated that PinX1 is a conserved telomerase inhibitor and a putative tumor suppressor. Here we report the characterization of PinX3. PinX3 was later found to be identical to Fbx4, a member of the F-box family of proteins, which function as substrate-specific adaptors of Cul 1-based ubiquitin ligases. Fbx4 interacts with both Pin2 and TRF1 isoforms and promotes their ubiquitination in vitro and in vivo. Moreover, overexpression of Fbx4 reduces endogenous Pin2/TRF1 protein levels and causes progressive telomere elongation in human cells. In contrast, inhibition of Fbx4 by RNA interference stabilizes Pin2/TRF1 and promotes telomere shortening, thereby impairing cell growth. These results demonstrate that Fbx4 is a central regulator of Pin2/TRF1 protein abundance and that alterations in the stability of Pin2/TRF1 can have a dramatic impact on telomere length. Thus, Fbx4 may play a critical role in telomere maintenance.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Zhou, XZ (corresponding author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02215 USA.	klu@bidmc.harvard.edu; xzhou@bidmc.harvard.edu	Lee, Tae Ho/AAT-1721-2020	Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [R21CA022082] Funding Source: Medline; NIA NIH HHS [R01AG11085, R01 AG011085] Funding Source: Medline; NIGMS NIH HHS [R01GM56230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; den Engelsman J, 2004, EUR J BIOCHEM, V271, P4195, DOI 10.1111/j.1432-1033.2004.04359.x; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Katayama S, 2002, MOL BIOL CELL, V13, P211, DOI 10.1091/mbc.01-07-0333; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kishi S, 2002, J BIOL CHEM, V277, P7420, DOI 10.1074/jbc.M111365200; Kishi S, 2001, ONCOGENE, V20, P1497, DOI 10.1038/sj.onc.1204229; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lin J, 2004, GENE DEV, V18, P387, DOI 10.1101/gad.1171804; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Nakamura M, 2002, FEBS LETT, V514, P193, DOI 10.1016/S0014-5793(02)02363-3; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ohyashiki JH, 2001, INT J ONCOL, V18, P593; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; Zhou XZ, 2003, J CELL BIOCHEM, V89, P19, DOI 10.1002/jcb.10496; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	56	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					759	768		10.1074/jbc.M509855200	http://dx.doi.org/10.1074/jbc.M509855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16275645	hybrid, Green Published			2022-12-25	WOS:000234447200012
J	Diel, S; Klass, K; Wittig, B; Kleuss, C				Diel, S; Klass, K; Wittig, B; Kleuss, C			G beta gamma activation site in adenylyl cyclase type II Adenylyl cyclase type III is inhibited by G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; G(S ALPHA); G-PROTEINS; SUBUNITS; PURIFICATION; STIMULATION; REGIONS	The G beta gamma complex of heterotrimeric G proteins is the most outstanding example for the divergent regulation of mammalian adenylyl cyclases. The heterodimeric G beta gamma complex inhibits some isoforms, e. g. ACI, and stimulates the isoforms ACII, -IV, and -VII. Although former studies identified the QEHA region located in the C-2 domain of ACII as an important interaction site for G beta gamma, the determinant of the stimulatory effect of G beta gamma has not been detected. Here, we identified the C-1b domain as the stimulatory region using full-length adenylyl cyclase. The relevant G beta gamma signal transfer motif in IIC1b was determined as MTRYLESWGAAKPFAHL (amino acids 493-509). Amino acids of this PFAHL motif were absolutely necessary for ACII to be stimulated by G beta gamma, whereas they were dispensable for G alpha(s) or forskolin stimulation. The PFAHL motif is present in all three adenylyl cyclase isoforms that are activated by G beta gamma but is absent in other adenylyl cyclase isoforms as well as other known effectors of G beta gamma. The emerging concept of two contact sites on different molecule halves for effective regulation of adenylyl cyclase is discussed.	Univ Med Berlin, Inst Pharmakol, Charite, D-14195 Berlin, Germany; Univ Med Berlin, Inst Mol Biol & Bioinformat, Charite, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kleuss, C (corresponding author), Univ Med Berlin, Inst Pharmakol, Charite, Thielallee 67-73, D-14195 Berlin, Germany.	ckleuss@zedat.fu-berlin.de						Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Beeler JA, 2004, BIOCHEMISTRY-US, V43, P15463, DOI 10.1021/bi049088+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Linder JU, 2003, CELL SIGNAL, V15, P1081, DOI 10.1016/S0898-6568(03)00130-X; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Steiner D, 2006, CELL SIGNAL, V18, P62, DOI 10.1016/j.cellsig.2005.03.014; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tsu RC, 1996, J NEUROSCI, V16, P1317; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; Weitmann S, 2001, BIOCHEMISTRY-US, V40, P10853, DOI 10.1021/bi011176w; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	34	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					288	294		10.1074/jbc.M511045200	http://dx.doi.org/10.1074/jbc.M511045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16275644	hybrid			2022-12-25	WOS:000234307200037
J	Lu, JZQ; Fujiwara, T; Komatsuzawa, H; Sugai, M; Sakon, J				Lu, JZQ; Fujiwara, T; Komatsuzawa, H; Sugai, M; Sakon, J			Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; SH3 DOMAINS; MOLECULAR CHARACTERIZATION; BACTERIOLYTIC AGENT; ENZYMATIC APPROACH; ELECTRON-DENSITY; LYSOSTAPHIN; SIMULANS; GENE; EPR	ALE-1, a homologue of lysostaphin, is a peptidoglycan hydrolase that specifically lyses Staphylococcus aureus cell walls by cleaving the pentaglycine linkage between the peptidoglycan chains. Binding of ALE-1 to S. aureus cells through its C-terminal 92 residues, known as the targeting domain, is functionally important for staphylolytic activity. The ALE-1-targeting domain belongs to the SH3b domain family, the prokaryotic counterpart of the eukaryotic SH3 domains. The 1.75 angstrom crystal structure of the targeting domain shows an all-beta fold similar to typical SH3s but with unique features. The structure reveals patches of conserved residues among orthologous targeting domains, forming surface regions that can potentially interact with some common features of the Gram-positive cell wall. ALE-1-targeting domain binding studies employing various bacterial peptidoglycans demonstrate that the length of the interpeptide bridge, as well as the amino acid composition of the peptide, confers the maximum binding of the targeting domain to the staphylococcal peptidoglycan. Truncation of the highly conserved first 9 N-terminal residues results in loss of specificity to S. aureus cell wall-targeting, suggesting that these residues confer specificity to S. aureus cell wall.	Hiroshima Univ, Dept Bacteriol, Grad Sch Biomed Sci, Hiroshima 7348553, Japan; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Hiroshima University; University of Arkansas System; University of Arkansas Fayetteville	Sugai, M (corresponding author), Hiroshima Univ, Dept Bacteriol, Grad Sch Biomed Sci, Hiroshima 7348553, Japan.	sugai@hiroshima-u.ac.jp; jsakon@uark.edu	Komatsuzawa, Hitoshi/AAC-7731-2019; Sakon, Joshua/N-2289-2014	Sakon, Joshua/0000-0002-8373-969X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR-1556901, P20 RR015569, P20 RR015569-086768] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baba T, 1996, EMBO J, V15, P4789, DOI 10.1002/j.1460-2075.1996.tb00859.x; Baba T, 1998, EMBO J, V17, P4639, DOI 10.1093/emboj/17.16.4639; BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P383, DOI 10.1016/0006-291X(65)90473-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Climo MW, 1998, ANTIMICROB AGENTS CH, V42, P1355, DOI 10.1128/AAC.42.6.1355; Ehlert K, 1997, J BACTERIOL, V179, P7573, DOI 10.1128/jb.179.23.7573-7576.1997; Ehlert K, 2000, J BACTERIOL, V182, P2635, DOI 10.1128/JB.182.9.2635-2638.2000; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Kerr DE, 2001, NAT BIOTECHNOL, V19, P66, DOI 10.1038/83540; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KOMATSUZAWA H, 1994, J ANTIMICROB CHEMOTH, V34, P885, DOI 10.1093/jac/34.6.885; Lai ACY, 2002, FEMS MICROBIOL LETT, V215, P133, DOI 10.1016/S0378-1097(02)00919-9; Mayer BJ, 2001, J CELL SCI, V114, P1253; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; POXTON IR, 1978, BIOCHEM J, V175, P1033, DOI 10.1042/bj1751033; RECSEI PA, 1987, P NATL ACAD SCI USA, V84, P1127, DOI 10.1073/pnas.84.5.1127; SCHAFFNE.W, 1967, YALE J BIOL MED, V39, P215; SCHAFFNER W, 1967, YALE J BIOL MED, V39, P230; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SLOAN GL, 1982, INT J SYST BACTERIOL, V32, P170, DOI 10.1099/00207713-32-2-170; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; Sugai M, 1997, J BACTERIOL, V179, P1193, DOI 10.1128/jb.179.4.1193-1202.1997; Sugai M, 1997, J BACTERIOL, V179, P4311, DOI 10.1128/jb.179.13.4311-4318.1997; Sugai M, 1998, GENE, V224, P67, DOI 10.1016/S0378-1119(98)00508-3; Thumm G, 1997, MOL MICROBIOL, V23, P1251, DOI 10.1046/j.1365-2958.1997.2911657.x; TRAYER HR, 1970, J BIOL CHEM, V245, P4842; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	35	103	107	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					549	558		10.1074/jbc.M509691200	http://dx.doi.org/10.1074/jbc.M509691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16257954	hybrid			2022-12-25	WOS:000234307200067
J	Metz, J; Wachter, A; Schmidt, B; Bujnicki, JM; Schwappach, B				Metz, J; Wachter, A; Schmidt, B; Bujnicki, JM; Schwappach, B			The yeast Arr4p ATPase binds the chloride transporter Gef1p when copper is available in the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; MEMBRANE-PROTEIN; CHANNEL GENE; CBS DOMAINS; IRON; METAL; CHAPERONE; DISEASE; DETOXIFICATION; MUTATIONS	Cellular ion homeostasis involves communication between the cytosol and the luminal compartment of organelles. This is particularly critical for metal ions because of their toxic potential. We have identified the yeast homologue of the prokaryotic ArsA protein, the homodimeric ATPase Arr4p, as a protein that binds to the yeast intracellularCLCchloride-transport protein, Gef1p. We show that binding of Arr4p to the C terminus of Gef1p requires the presence of yeast cytosol and is sensitive to a highly specific copper chelator in vitro and in vivo. Copper alone can substitute for cytosol to support the interaction of Arr4p with the C terminus of Gef1p. The migration behavior of Arr4p in nonreducing gel electrophoresis correlates with cellular copper deficiency, repletion, or stress. Our homology model of Arr4p shows that the antimony ( arsenic) metal binding site of ArsA is not conserved in Arr4p. The model suggests that a pair of cysteines, Cys(285) and Cys(288), is located in the interface of the Arr4p dimer. These residues are required for Arr4p homodimerization and for binding to the C terminus of Gef1p. Whereas both proteins are required for normal growth under iron-limiting conditions, they play opposite roles when copper and heat stress are combined in an alkaline environment. Under these conditions, Delta gef1 cells grow much better than wild type yeast, whereas Delta arr4 cells are unable to grow. Comparison of the Delta arr4 with the Delta arr4 Delta gef1 strain suggests that Arr4p antagonizes the function of Gef1p.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Int Inst Mol & Cell Biol, Lab Bioinformat & Prot Engn, PL-02109 Warsaw, Poland	Ruprecht Karls University Heidelberg; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Schwappach, B (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	b.schwappach@zmbh.uni-heidelberg.de		Schwappach, Blanche/0000-0003-0225-6432				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Blair D., 1961, TALANTA LONDON, V7, P163; Brett CL, 2005, MOL BIOL CELL, V16, P1396, DOI 10.1091/mbc.E04-11-0999; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; James P, 1996, GENETICS, V144, P1425; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kosinski J, 2003, PROTEINS, V53, P369, DOI 10.1002/prot.10545; Kurdi-Haidar B, 1998, J BIOL CHEM, V273, P22173, DOI 10.1074/jbc.273.35.22173; Kuroda M, 1997, J BIOL CHEM, V272, P326; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mingot JM, 2004, EMBO J, V23, P3227, DOI 10.1038/sj.emboj.7600338; MOHINDRU A, 1983, NATURE, V303, P64, DOI 10.1038/303064a0; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Shen J, 2003, BIOMETALS, V16, P369, DOI 10.1023/A:1022504311669; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Wachter A, 2005, FEBS LETT, V579, P1149, DOI 10.1016/j.febslet.2005.01.011; Wang T, 2004, GASTROENTEROLOGY, V126, P1157, DOI 10.1053/j.gastro.2004.01.015; Yamada K, 1998, BIOTECHNIQUES, V24, P596, DOI 10.2144/98244bm19; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; Zhu XD, 2003, MOL MICROBIOL, V50, P1271, DOI 10.1046/j.1365-2958.2003.03752.x	48	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					410	417		10.1074/jbc.M507481200	http://dx.doi.org/10.1074/jbc.M507481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260785	hybrid			2022-12-25	WOS:000234307200051
J	Soldovieri, MV; Castaldo, P; Iodice, L; Miceli, F; Barrese, V; Bellini, G; del Giudice, EM; Pascotto, A; Bonatti, S; Annunziato, L; Taglialatela, M				Soldovieri, MV; Castaldo, P; Iodice, L; Miceli, F; Barrese, V; Bellini, G; del Giudice, EM; Pascotto, A; Bonatti, S; Annunziato, L; Taglialatela, M			Decreased subunit stability as a novel mechanism for potassium current impairment by a KCNQ2 C terminus mutation causing benign familial neonatal convulsions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC GENERALIZED EPILEPSY; KCNQ2/KCNQ3 K+ CHANNELS; ENDOPLASMIC-RETICULUM; VOLTAGE SENSOR; GENE; DEGRADATION; TRAFFICKING; EXPRESSION; CELLS; BRAIN	KCNQ2 and KCNQ3 K+ channel subunits underlie the muscarinicregulated K+ current (I-KM), a widespread regulator of neuronal excitability. Mutations in KCNQ2- or KCNQ3- encoding genes cause benign familiar neonatal convulsions (BFNCs), a rare autosomal-dominant idiopathic epilepsy of the newborn. In the present study, we have investigated, by means of electrophysiological, biochemical, and immunocytochemical techniques in transiently transfected cells, the consequences prompted by a BFNC-causing 1-bp deletion (2043 Delta T) in the KCNQ2 gene; this frameshift mutation caused the substitution of the last 163 amino acids of the KCNQ2 C terminus and the extension of the subunit by additional 56 residues. The 2043 Delta T mutation abolished voltage-gated K+ currents produced upon homomeric expression of KCNQ2 subunits, dramatically reduced the steady-state cellular levels of KCNQ2 subunits, and prevented their delivery to the plasma membrane. Metabolic labeling experiments revealed that mutant KCNQ2 subunits underwent faster degradation; 10-h treatment with the proteasomal inhibitor MG132 (20 mu M) at least partially reversed such enhanced degradation. Co-expression with KCNQ3 subunits reduced the degradation rate of mutant KCNQ2 subunits and led to their expression on the plasma membrane. Finally, co-expression of KCNQ2 2043 Delta T together with KCNQ3 subunits generated functional voltage-gated K+ currents having pharmacological and biophysical properties of heteromeric channels. Collectively, the present results suggest that mutation-induced reduced stability of KCNQ2 subunits may cause epilepsy in neonates.	Univ Naples Federico II, Div Pharmacol, Dept Neurosci, I-80131 Naples, Italy; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy; Univ Naples 2, Chair Child Neuropsychiat, I-80131 Naples, Italy; Univ Naples 2, Dept Pediat, I-80131 Naples, Italy; Univ Molise, Dept Hlth Sci, I-86100 Campobasso, Italy; Univ Ancona, Dept Neurosci, I-60121 Ancona, Italy	University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Molise; Marche Polytechnic University	Taglialatela, M (corresponding author), Univ Naples Federico II, Div Pharmacol, Dept Neurosci, I-80131 Naples, Italy.	mtaglial@unina.it	del Giudice, Emanuele Muraglia/AAC-2824-2019; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/A-2062-2019; Miceli, Francesco/H-3767-2013; Taglialatela, Maurizio/K-1840-2013; Soldovieri, Maria Virginia/ADZ-5219-2022; Taglialatela, Maurizio/AAB-8621-2022	Miceli, Francesco/0000-0002-5393-1402; Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; ANNUNZIATO, LUCIO/0000-0002-8534-8270; Barrese, Vincenzo/0000-0001-8721-8843; Soldovieri, Maria Virginia/0000-0002-3601-9374	Telethon [GGP030209] Funding Source: Medline	Telethon(Fondazione Telethon)		Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BONATTI S, 1989, J BIOL CHEM, V264, P12590; Borgatti R, 2004, NEUROLOGY, V63, P57, DOI 10.1212/01.WNL.0000132979.08394.6D; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Castaldo P, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0003.2002; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Cooper EC, 2000, P NATL ACAD SCI USA, V97, P4914, DOI 10.1073/pnas.090092797; Coppola G, 2003, NEUROLOGY, V61, P131, DOI 10.1212/01.WNL.0000069465.53698.BD; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Dedek K, 2001, P NATL ACAD SCI USA, V98, P12272, DOI 10.1073/pnas.211431298; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Etxeberria A, 2004, J NEUROSCI, V24, P9146, DOI 10.1523/JNEUROSCI.3194-04.2004; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Haug K, 2000, EPILEPSY RES, V42, P57, DOI 10.1016/S0920-1211(00)00164-9; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Jones HM, 2004, J BIOL CHEM, V279, P15531, DOI 10.1074/jbc.M400069200; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lerche C, 2000, J BIOL CHEM, V275, P22395, DOI 10.1074/jbc.M002378200; Lerche H, 1999, ANN NEUROL, V46, P305, DOI 10.1002/1531-8249(199909)46:3<305::AID-ANA5>3.0.CO;2-5; Li Y, 2004, J NEUROSCI, V24, P5079, DOI 10.1523/JNEUROSCI.0882-04.2004; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Maljevic S, 2003, J PHYSIOL-LONDON, V548, P353, DOI 10.1113/jphysiol.2003.040980; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; Myers MP, 2004, FEBS LETT, V568, P110, DOI 10.1016/j.febslet.2004.05.023; Peretz A, 2005, MOL PHARMACOL, V67, P1053, DOI 10.1124/mol.104.007112; Rogawski MA, 2000, TRENDS NEUROSCI, V23, P393, DOI 10.1016/S0166-2236(00)01629-5; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Selyanko AA, 2001, J PHYSIOL-LONDON, V534, P15, DOI 10.1111/j.1469-7793.2001.00015.x; Shah MM, 2002, J PHYSIOL-LONDON, V544, P29, DOI 10.1113/jphysiol.2002.028571; Shieh CC, 2000, PHARMACOL REV, V52, P557; Singh NA, 2003, BRAIN, V126, P2726, DOI 10.1093/brain/awg286; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Steinlein OK, 1999, NEUROREPORT, V10, P1163, DOI 10.1097/00001756-199904260-00001; Steinlein OK, 1998, CLIN GENET, V54, P169; Tang BS, 2004, J NEUROL SCI, V221, P31, DOI 10.1016/j.jns.2004.03.001; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	47	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					418	428		10.1074/jbc.M510980200	http://dx.doi.org/10.1074/jbc.M510980200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260777	hybrid			2022-12-25	WOS:000234307200052
J	Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression ofVDAC1	ONCOGENE			English	Article						apoptosis; Ca2+; CD45; myeloma; ROS; VDAC1	DEPENDENT ANION CHANNEL; TYROSINE PROTEIN-KINASE; PLASMA-CELLS; CYTOCHROME-C; BONE-MARROW; ACTIVATION; BCL-2; SRC; PROLIFERATION; FAMILY	Expression of CD45 is quite variable in human myeloma cells and cell lines, such as U266, and CD45(+) U266 proliferates in response to a growth factor, interleukin-6. Here, we show that CD45(+) myeloma cell lines were more sensitive to various apoptotic stimuli, such as oxidative stress and endoplasmic reticulum ( ER)-stress, than CD45(-) cells. Reactive oxygen species and calcium ion seemed to be involved in the susceptibility to apoptosis of CD45(+) U266. The activation of the src family kinases associated with CD45 phosphatase played an important role in the augmented apoptosis in CD45(+) U266 by oxidative stress. These results indicate that the CD45- expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45(+) myeloma cells dependently upon the circumstantial stimuli. Furthermore, voltage-dependent anion channel ( VDAC) 1 was identified as a gene highly expressed in CD45(+) U266 by cDNA subtraction. The increased expression of VDAC1 seemed to augment the sensitivity to the ER-stress because the VDAC1-transfected U266 was more susceptible to the thapsigargininduced apoptosis. Thus, CD45 expression accompanied by the increased VDAC1 expression sensitizes myeloma cells to the various extracellular stimuli that trigger apoptosis via the mitochondrial pathways.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, Ube, Yamaguchi 755, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Decaudin D, 1997, CANCER RES, V57, P62; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Joshua D, 1996, BRIT J HAEMATOL, V94, P76, DOI 10.1046/j.1365-2141.1996.d01-1784.x; Justement L B, 2001, Int Rev Immunol, V20, P713, DOI 10.3109/08830180109045587; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KAWANO MM, 1995, BLOOD, V85, P487; KAWANO MM, 1993, BLOOD, V82, P564; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Schneider U, 1997, BRIT J HAEMATOL, V97, P56, DOI 10.1046/j.1365-2141.1997.d01-2115.x; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU S, 1993, LEUKEMIA, V7, P274; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	43	28	30	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					419	429		10.1038/sj.onc.1208982	http://dx.doi.org/10.1038/sj.onc.1208982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247487				2022-12-25	WOS:000234714100010
J	Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ				Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ			GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing	ONCOGENE			English	Article						renal cell carcinoma; cell surface engineering; FAS apoptosis; TIMP-1; GPI anchor	TUMOR-INFILTRATING LYMPHOCYTES; TISSUE INHIBITOR; IN-VIVO; MATRIX METALLOPROTEINASES; PANCREATIC-CANCER; EPITHELIAL-CELLS; MEDIATED LYSIS; DEATH; CYTOTOXICITY; APOPTOSIS	The resistance of tumours to immune-mediated lysis has been linked to the biology of matrix metalloproteinases (MMPs), and specically to the cell surface expression of MMPs by the tumour cell. The endogenous tissue inhibitors of metalloproteinases (TIMPs) exhibit diverse physiological/biological functions including the moderation of tumour growth, metastasis and apoptosis. These biologic activities are mediated in part by the stoichiometry of TIMP/MMP/cell surface protein interactions. A glycosylphosphatidylinositol (GPI) anchor was fused to TIMP-1 to focus defined concentrations of this inhibitory protein on the surface of three renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53 and A498) independently of cell surface protein-protein interactions. Exogenously added TIMP-1-GPI efficiently inserted into the RCC cell membrane and dramatically altered the association of MMPs with the cell surface. TIMP-1-GPI treatment inhibited RCC proliferation and rendered the normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis but did not alter perforin-mediated lysis by cytotoxic effector cells. The increased sensitivity to FAS-mediated apoptosis correlated with an alteration in the balance of pro- and antiapoptotic BCL-2-family proteins. By interfering with the proliferative capacity and inducing sensitivity to immune effector mechanisms GPI-anchored TIMP-1 may represent a more effective version of the TIMP-1 protein for therapeutic strategies.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF Inst Mol Immunol, Munich, Germany; Univ Munich, Inst Immunol, D-80336 Munich, Germany; Tech Univ Munich, Childrens Hosp, Med Ctr, D-8000 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	peter.nelson@med.uni-muenchen.de						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BARNSTABLE CJ, 1978, BRIT MED BULL, V34, P241, DOI 10.1093/oxfordjournals.bmb.a071504; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Brand Karsten, 2002, Current Gene Therapy, V2, P255, DOI 10.2174/1566523024605564; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown O, 2000, GENE THER, V7, P1947, DOI 10.1038/sj.gt.3301325; Djafarzadeh R, 2004, BIOL CHEM, V385, P655, DOI 10.1515/BC.2004.081; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Frost P, 2003, INT J ONCOL, V22, P431; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GONG JH, 1994, LEUKEMIA, V8, P652; Hemmerlein B, 2004, INT J ONCOL, V24, P1069; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; JOHNSON JP, 1988, IMMUNOBIOLOGY, V178, P275, DOI 10.1016/S0171-2985(88)80071-8; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KIRBY AC, 1995, BIOCHEM BIOPH RES CO, V214, P200, DOI 10.1006/bbrc.1995.2275; Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173; Lang R, 2004, J MOL BIOL, V336, P213, DOI 10.1016/j.jmb.2003.12.022; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Schendel DJ, 2000, GENE THER, V7, P2007, DOI 10.1038/sj.gt.3301349; Schendel DJ, 1997, J MOL MED-JMM, V75, P400, DOI 10.1007/s001090050125; SCHENDEL DJ, 1993, J IMMUNOL, V151, P4209; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Span PN, 2004, J PATHOL, V202, P395, DOI 10.1002/path.1528; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Zacchigna S, 2004, CANCER GENE THER, V11, P73, DOI 10.1038/sj.cgt.7700657	44	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1496	1508		10.1038/sj.onc.1209188	http://dx.doi.org/10.1038/sj.onc.1209188			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261161				2022-12-25	WOS:000235890400007
J	Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK				Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK			Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells	ONCOGENE			English	Article						polyamines; ornithine decarboxylase; invasion; Raf/ERK; Akt	MOUSE EPIDERMAL-CELLS; BINDING PROTEIN RHO; EPITHELIAL-CELLS; RAS TRANSFORMATION; TRANSGENIC MICE; ONCOGENIC RAS; ALPHA-DIFLUOROMETHYLORNITHINE; SIGNALING PATHWAYS; TUMOR PROMOTION; HUMAN CANCER	Ornithine decarboxylase (ODC) overexpression coupled with activated Ras is fully sufficient to oncogenically transform primary keratinocytes. To determine the Ras effector pathways that represent the minimal essential contribution to full oncogenic transformation in this context, we evaluated the cooperativity of different Ras effector mutants with overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasiveness. Primary keratinocytes, isolated from either K6/ODC transgenic mouse skin (expressing increased ODC) or from normal littermate skin were infected with retrovirus producing an activated RasV12 or partial loss-of-function effector mutants of RasV12 that selectively induce only the Raf/ERK, RalGDS, or the PI3-kinase signaling pathway. Whereas keratinocytes expressing a fully activated RasV12 are not invasive in tracheal xenotransplants, ODC-overexpressing keratinocytes acquire an invasive phenotype with additional expression of either RasV12 or activation of the Raf/ERK pathway. Independent of a mutated ras, elevated levels of ODC activate the Akt/mTOR signaling pathway as well as the Rho/Rac pathway in primary keratinocytes. Thus, Raf/ERK signaling is sufficient to cooperate with increased ODC activity in the conversion of normal keratinocytes to invasive cells. In order to promote invasiveness in keratinocytes, elevated levels of ODC may cooperate with Raf/ERK via activation of the Akt and Rho/Rac signaling pathway.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA	Lankenau Medical Center; Lankenau Institute for Medical Research	Gilmour, SK (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	gilmours@mlhs.org			NCI NIH HHS [CA070739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; Feith DJ, 2001, CANCER RES, V61, P6073; Feith DJ, 2005, CANCER RES, V65, P572; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Gilmour SK, 2001, J INVEST DERMATOL, V117, P1674, DOI 10.1046/j.0022-202x.2001.01597.x; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jaffer ZM, 2004, J BIOL CHEM, V279, P35123, DOI 10.1074/jbc.R400010200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lan L, 2000, CANCER RES, V60, P5696; Lan L, 2005, J INVEST DERMATOL, V124, P602, DOI 10.1111/j.0022-202X.2005.23620.x; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MEGOSH L, 1995, CANCER RES, V55, P4205; OBrien TG, 1997, CANCER RES, V57, P2630; OBRIEN TG, 1975, CANCER RES, V35, P1662; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PEGG AE, 1988, CANCER RES, V48, P759; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Ray RM, 2003, J BIOL CHEM, V278, P13039, DOI 10.1074/jbc.M208741200; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Smith MK, 1997, CANCER RES, V57, P2104; STRUGILL TW, 1988, NATURE, V334, P715; Sturge J, 2002, J CELL SCI, V115, P699; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKIGAWA M, 1983, CANCER RES, V43, P3732; Tang XW, 2004, J CLIN INVEST, V113, P867, DOI 10.1172/JCI200420732; Tarutani M, 2003, CANCER RES, V63, P319; Ulku AS, 2003, MOL CANCER RES, V1, P1077; VAN AL, 1997, GENE DEV, V11, P2295; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	68	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1543	1553		10.1038/sj.onc.1209198	http://dx.doi.org/10.1038/sj.onc.1209198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278677				2022-12-25	WOS:000235890400011
J	Zhang, Y; Gilquin, B; Khochbin, S; Matthias, P				Zhang, Y; Gilquin, B; Khochbin, S; Matthias, P			Two catalytic domains are required for protein deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-DEACETYLASE; IN-VIVO; ACETYLTRANSFERASE; MICROTUBULES	Histone deacetylase ( HDAC)-6 was recently identified as a dual substrate, possibly multisubstrate, deacetylase that can act both on acetylated histone tails and on alpha-tubulin acetylated on Lys(40). HDAC-6 is unique among deacetylases in having two hdac domains, and we have used this enzyme as a useful model to dissect the structural requirements for the deacetylation reaction. In this report, we show that both hdac domains are required for the intact deacetylase activity of HDAC-6 in vitro and in vivo. The spatial arrangement of these two domains in HDAC-6 is essential and alteration of the linker region between the two domains severely affects the catalytic activity. Artificial chimeric HDACs, made by replacing the hdac domains in HDAC-6 with corresponding domains from other class II HDACs, show de novo deacetylase activity. Taken together, our results demonstrate for the first time that the spatial arrangement of hdac domains is critical for in vivo deacetylation reaction and may provide a useful model for the development of novel HDAC inhibitors.	Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; INSERM, U309, Inst Albert Bonniot, Fac Med, F-38706 La Tronche, France	Friedrich Miescher Institute for Biomedical Research; Novartis; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Matthias, P (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, POB 2543,Maulbeerstr 66, CH-4058 Basel, Switzerland.	patrick.matthias@fmi.ch	Khochbin, Saadi/M-8090-2013; GILQUIN, Benoit/A-6234-2014	Khochbin, Saadi/0000-0002-0455-0857; GILQUIN, benoit/0000-0001-8138-7021				Adachi N, 2002, J BIOL CHEM, V277, P35688, DOI 10.1074/jbc.M204640200; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Mottus R, 2000, GENETICS, V154, P657; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	13	120	134	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2401	2404		10.1074/jbc.C500241200	http://dx.doi.org/10.1074/jbc.C500241200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16272578	hybrid			2022-12-25	WOS:000234931800002
J	Vergnes, A; Pommier, J; Toci, R; Blasco, F; Giordano, G; Magalon, A				Vergnes, A; Pommier, J; Toci, R; Blasco, F; Giordano, G; Magalon, A			NarJ chaperone binds on two distinct sites of the aponitrate reductase of Escherichia coli to coordinate molybdenum cofactor insertion and assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-OXIDE REDUCTASE; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; HYDROGENASE 3; CYTOPLASMIC MEMBRANE; ANGSTROM RESOLUTION; XANTHINE-OXIDASE; GENE-PRODUCTS; BETA-SUBUNIT; MOLYBDOPTERIN	Understanding when and how metal cofactor insertion occurs into a multisubunit metalloenzyme is of fundamental importance. Molybdenum cofactor insertion is a tightly controlled process that involves specific interactions between the proteins that promote cofactor delivery, enzyme-specific chaperones, and the apoenzyme. In the assembly pathway of the multisubunit molybdoenzyme, membrane-bound nitrate reductase A from Escherichia coli, a NarJ-assisted molybdenum cofactor (Moco) insertion step, must precede membrane anchoring of the apoenzyme. Here, we have shown that the NarJ chaperone interacts at two distinct binding sites of the apoenzyme, one interfering with its membrane anchoring and another one being involved in molybdenum cofactor insertion. The presence of the two NarJ-binding sites within NarG is required to ensure productive formation of active nitrate reductase. Our findings supported the view that enzyme-specific chaperones play a central role in the biogenesis of multisubunit molybdoenzymes by coordinating subunits assembly and molybdenum cofactor insertion.	CNRS, Chim Bacterienne Lab, IBSM, F-13402 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS)	Magalon, A (corresponding author), CNRS, Chim Bacterienne Lab, IBSM, 31,Chemin Joseph Aiguier, F-13402 Marseille 09, France.	magalon@ibsm.cnrs-mrs.fr	Vergnes, Alexandra/AAM-2842-2020	Magalon, Axel/0000-0002-3375-738X				Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; Blasco F, 2001, CELL MOL LIFE SCI, V58, P179, DOI 10.1007/PL00000846; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; Blokesch M, 2002, BIOCHEM SOC T, V30, P674, DOI 10.1042/BST0300674; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Drapal N, 1998, BIOCHEMISTRY-US, V37, P2941, DOI 10.1021/bi9720078; GRAHAM A, 1980, FEBS LETT, V113, P15, DOI 10.1016/0014-5793(80)80484-4; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; Magalon A, 2000, FEBS LETT, V473, P254, DOI 10.1016/S0014-5793(00)01542-8; Magalon A, 2000, J BIOL CHEM, V275, P21114, DOI 10.1074/jbc.M000987200; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Nichols JD, 2005, J BIOL CHEM, V280, P7817, DOI 10.1074/jbc.M413783200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rothery RA, 2001, J MOL MICROB BIOTECH, V3, P273; Rothery RA, 2004, BIOCHEMISTRY-US, V43, P5324, DOI 10.1021/bi049938l; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; Wu LF, 2000, ARCH MICROBIOL, V173, P319, DOI 10.1007/s002030000144; Zafra O, 2005, J BACTERIOL, V187, P3990, DOI 10.1128/JB.187.12.3990-3996.2005	43	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2170	2176		10.1074/jbc.M505902200	http://dx.doi.org/10.1074/jbc.M505902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16286471	hybrid			2022-12-25	WOS:000234760400040
J	Lee, JWM; Chu, JJH; Ng, ML				Lee, JWM; Chu, JJH; Ng, ML			Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alpha V beta 3 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; GLYCOPROTEIN; SURFACE; CELLS; ENTRY	A previous study has illustrated that the alpha V beta 3 integrin served as the functional receptor for West Nile virus (WNV) entry into cells. Domain III (DIII) of WNV envelope protein (E) was postulated to mediate virus binding to the cellular receptor. In this study, the specificity and affinity binding of WNV E DIII protein to alpha V beta 3 integrin was confirmed with co-immunoprecipitation and receptor competition assay. Binding of WNVEDIII protein to alpha V beta 3 integrin induced the phosphorylation of focal adhesion kinase that is required to mediate ligand-receptor internalization into cells. A novel platform was then developed using the atomic force microscopy to measure this specific binding force between WNV E DIII protein and the cellular receptor, alpha V beta 3 integrin. The single protein pair-interacting force measured was in the range of 45 +/- 5 pico-newtons. This interacting force was highly specific as minimal force was measured in the WNV E DIII protein interaction with alpha V beta 5 integrin molecules and heparan sulfate. These experiments provided an insight to quantitate virus-receptor interaction. Force measurement using atomic force microscopy can serve to quantitatively analyze the effect of candidate drugs that modulate virus-host receptor affinity.	Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, Singapore 117597, Singapore	National University of Singapore	Ng, ML (corresponding author), Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, 5 Sci Dr 2, Singapore 117597, Singapore.	micngml@nus.edu.sg	Chu, Justin Jang Hann/ABA-8297-2021; Ng, Mei Li/Q-3704-2016	Chu, Justin Jang Hann/0000-0002-1673-6819; Ng, Mei Li/0000-0001-9917-4534				Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z; Allen S, 1999, BIOCHEM J, V341, P173, DOI 10.1042/0264-6021:3410173; Anderson R, 2003, ADV VIRUS RES, V59, P229, DOI 10.1016/S0065-3527(03)59007-8; Andreev IA, 2004, J MOL BIOL, V339, P1041, DOI 10.1016/j.jmb.2004.04.013; Berge T, 2003, J STRUCT BIOL, V142, P241, DOI 10.1016/S1047-8477(03)00015-7; Braet F, 1998, J MICROSC-OXFORD, V190, P328, DOI 10.1046/j.1365-2818.1998.00333.x; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1071; Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0; Chu JJH, 2004, J BIOL CHEM, V279, P54533, DOI 10.1074/jbc.M410208200; Chu JJH, 2003, VIROLOGY, V312, P458, DOI 10.1016/S0042-6822(03)00261-7; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; Edwardson JM, 2004, DRUG DISCOV TODAY, V9, P64, DOI 10.1016/S1359-6446(03)02905-2; Kakoulides EP, 1998, J CONTROL RELEASE, V52, P291, DOI 10.1016/S0168-3659(98)00005-4; Krautbauer R, 2002, FEBS LETT, V510, P154, DOI 10.1016/S0014-5793(01)03257-4; Kuznetsov YG, 1997, J STRUCT BIOL, V120, P180, DOI 10.1006/jsbi.1997.3936; Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003; Lee Jason WM, 2004, J Nanobiotechnology, V2, P6, DOI 10.1186/1477-3155-2-6; Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005; Nakanishi M, 2001, ADV DRUG DELIVER REV, V52, P197, DOI 10.1016/S0169-409X(01)00207-1; Negishi A, 2004, GLYCOBIOLOGY, V14, P969, DOI 10.1093/glycob/cwh118; Ng ML, 2004, EMERG INFECT DIS, V10, P1907, DOI 10.3201/eid1011.040195; Ni HL, 2000, J VIROL, V74, P2903, DOI 10.1128/JVI.74.6.2903-2906.2000; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rotsch C, 1997, CELL BIOL INT, V21, P685, DOI 10.1006/cbir.1997.0213	26	68	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1352	1360		10.1074/jbc.M506614200	http://dx.doi.org/10.1074/jbc.M506614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16275649	hybrid			2022-12-25	WOS:000234652000010
J	Gobbi, M; Colombo, L; Morbin, M; Mazzoleni, G; Accardo, E; Vanoni, M; Del Favero, E; Cantu, L; Kirschner, DA; Manzoni, C; Beeg, M; Ceci, P; Ubezio, P; Forloni, G; Tagliavini, F; Salmona, M				Gobbi, M; Colombo, L; Morbin, M; Mazzoleni, G; Accardo, E; Vanoni, M; Del Favero, E; Cantu, L; Kirschner, DA; Manzoni, C; Beeg, M; Ceci, P; Ubezio, P; Forloni, G; Tagliavini, F; Salmona, M			Gerstmann-Strarussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PRION-PROTEIN; IN-VITRO; FIBRIL ELONGATION; CROSS-LINKING; PRP PEPTIDES; FRAGMENT; BINDING; CONFORMATION; BARRIER	Prion protein (PrP) amyloid formation is a central feature of genetic and acquired prion diseases such as Gerstmann-Straussler-Scheinker disease (GSS) and variant Creutzfeldt-Jakob disease. The major component of GSS amyloid is a PrP fragment spanning residues -82-146, which when synthesized as a peptide, readily forms fibrils featuring GSS amyloid. The present study employed surface plasmon resonance (SPR) to characterize the binding events underlying PrP82-146 oligomerization at the first stages of fibrillization, according to evidence suggesting a pathogenic role of prefibrillar oligomers rather than mature amyloid fibrils. We followed in real time the binding reactions occurring during short term (seconds) addition of PrP82-146 small oligomers (1-5-mers, flowing species) onto soluble prefibrillar PrP82-146 aggregates immobilized on the sensor surface. SPR data confirmed very efficient aggregation/ elongation, consistent with the hypothesis of nucleation-dependent polymerization process. Much lower binding was observed when PrP82-146 flowed onto the scrambled sequence of PrP82-146 or onto prefibrillar A beta 42 aggregates. As previously found with A beta 40, SPR data could be adequately fitted by equations modeling the "dock-and-lock" mechanism, in which the "locking" step is due to sequential conformational changes, each increasing the affinity of the monomer for the fibril until a condition of irreversible binding is reached. However, these conformational changes (i.e. the locking steps) appear to be faster and easier with PrP82-146 than with A beta 40. Such differences suggest that PrP82-146 has a greater propensity to polymerize and greater stability of the aggregates.	Mario Negri Inst Pharmacol Res, I-20100 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20100 Milan, Italy; Univ Milan, Dipartimento Biotecnol & Biosci, I-20100 Milan, Italy; Univ Milan, Dipartimento Chim Biochim & Biotecnol Med, I-20100 Milan, Italy; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta; University of Milan; University of Milan; Boston College	Gobbi, M (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	Gobbi@marionegri.it	Gobbi, Marco/J-2638-2016; Beeg, Marten/AAA-9269-2020; manzoni, claudia/F-4831-2014; colombo, laura/AAA-6716-2020; salmona, mario/ABI-4066-2020; Tagliavini, Fabrizio/AAO-7891-2021; ubezio, paolo/AAA-6704-2020; Forloni, Gianluigi/AAB-2115-2020; DEL FAVERO, ELENA/AAR-3567-2020; DEL FAVERO, ELENA/R-4991-2017; Ubezio, Paolo/AAA-6455-2020; salmona, mario/AAA-7116-2020	Gobbi, Marco/0000-0003-1014-6225; Beeg, Marten/0000-0001-7201-6704; colombo, laura/0000-0002-3243-0270; Tagliavini, Fabrizio/0000-0003-1039-7315; Forloni, Gianluigi/0000-0001-5374-3914; DEL FAVERO, ELENA/0000-0002-6584-1869; DEL FAVERO, ELENA/0000-0002-6584-1869; Ubezio, Paolo/0000-0003-0412-9891; salmona, mario/0000-0002-9098-9873; Kirschner, Daniel/0000-0003-3498-1452; VANONI, MARCO ERCOLE/0000-0002-8690-2587; Morbin, Michela/0000-0001-8034-3123				Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Cannon MJ, 2004, ANAL BIOCHEM, V328, P67, DOI 10.1016/j.ab.2004.01.014; CANTU L, 1994, J PHYS II, V4, P1585, DOI 10.1051/jp2:1994219; Critchley P, 2004, BIOCHEM BIOPH RES CO, V313, P559, DOI 10.1016/j.bbrc.2003.12.004; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Epple G, 2004, J THROMB HAEMOST, V2, P962, DOI 10.1111/j.1538-7836.2004.00675.x; Epple G, 2004, THROMB HAEMOSTASIS, V91, P465, DOI 10.1160/TH03-06-0382; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Hachiya NS, 2004, BIOCHEM BIOPH RES CO, V323, P339, DOI 10.1016/j.bbrc.2004.08.098; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hashimoto Setsuko, 2000, P23; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kazlauskaite J, 2005, BIOCHEM BIOPH RES CO, V328, P292, DOI 10.1016/j.bbrc.2004.12.172; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; Meggio F, 2000, BIOCHEM J, V352, P191, DOI 10.1042/0264-6021:3520191; Murakami-Kubo I, 2004, J VIROL, V78, P1281, DOI 10.1128/JVI.78.3.1281-1288.2004; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Myszka DG, 1999, METHOD ENZYMOL, V309, P386; Pierce MM, 2005, BIOCHEMISTRY-US, V44, P321, DOI 10.1021/bi047964d; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Salmona M, 2003, J BIOL CHEM, V278, P48146, DOI 10.1074/jbc.M307295200; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840	35	31	34	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					843	849		10.1074/jbc.M506164200	http://dx.doi.org/10.1074/jbc.M506164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286452	hybrid			2022-12-25	WOS:000234447200022
J	Yakubovskaya, E; Chen, ZX; Carrodeguas, JA; Kisker, C; Bogenhagen, DF				Yakubovskaya, E; Chen, ZX; Carrodeguas, JA; Kisker, C; Bogenhagen, DF			Functional human mitochondrial DNA polymerase gamma forms a heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; ACCESSORY SUBUNIT; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PROCESSIVITY FACTOR; IDENTIFICATION; PURIFICATION; MUTATIONS; RESIDUES; BINDING	Mitochondrial DNA polymerase gamma(pol gamma) is responsible for replication and repair of mtDNA and is mutated in individuals with genetic disorders such as chronic external ophthalmoplegia and Alpers syndrome. pol gamma is also an adventitious target for toxic side effects of several antiviral compounds, and mutation of its proofreading exonuclease leads to accelerated aging in mouse models. We have used a variety of physical and functional approaches to study the interaction of the human pol gamma catalytic subunit with both the wild-type accessory factor, pol gamma B, and a deletion derivative that is unable to dimerize and consequently is impaired in its ability to stimulate processive DNA synthesis. Our studies clearly showed that the functional human holoenzyme contains two subunits of the processivity factor and one catalytic subunit, thereby forming a heterotrimer. The structure of pol gamma seems to be variable, ranging from a single catalytic subunit in yeast to a heterodimer in Drosophila and a heterotrimer in mammals.	SUNY Stony Brook, Dept Pharmaceut Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmaceut Sci, Stony Brook, NY 11794 USA.	dan@pharm.sunysb.edu	Carrodeguas, Jose/L-7334-2014; Kisker, Caroline/T-1724-2019	Carrodeguas, Jose/0000-0003-0062-1029; Kisker, Caroline/0000-0002-0216-6026	NIGMS NIH HHS [R01-GM029681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAY H, 1992, J BIOL CHEM, V267, P5835; Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Loregian A, 2004, J VIROL, V78, P158, DOI 10.1128/JVI.78.1.158-167.2004; Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; Wolf YI, 2001, TRENDS GENET, V17, P431, DOI 10.1016/S0168-9525(01)02370-8; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	31	120	124	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					374	382		10.1074/jbc.M509730200	http://dx.doi.org/10.1074/jbc.M509730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263719	hybrid			2022-12-25	WOS:000234307200047
J	Du, Y; Bock, BC; Schachter, KA; Chao, M; Gallo, KA				Du, Y; Bock, BC; Schachter, KA; Chao, M; Gallo, KA			Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE; B-RAF ACTIVATION; T-CELL-RECEPTOR; PROTEIN-KINASE; PLASMA-MEMBRANE; SRC-HOMOLOGY-3 DOMAIN; PROGENITOR KINASE-1; NEGATIVE REGULATION; NEURONAL APOPTOSIS; SIGNALING PATHWAY	Mixed lineage kinase 3 (MLK3) functions as a mitogen-activated protein kinase kinase kinase to activate multiple mitogen-activated protein kinase pathways. Our current studies demonstrate that lack of MLK3 blocks signaling of activated Cdc42 to c-Jun N-terminal kinase, giving strong support for the idea that Cdc42 is a physiological activator of MLK3. We show herein that Cdc42, in a prenylation dependent manner, targets MLK3 from a perinuclear region to membranes, including the plasma membrane. Cdc42-induced membrane targeting of MLK3 is independent of MLK3 catalytic activity but depends upon an intact Cdc42/Rac-interactive binding motif, consistent with MLK3 membrane translocation being mediated through direct binding of Cdc42. Phosphorylation of the activation loop of MLK3 requires MLK3 catalytic activity and is induced by Cdc42 in a prenylation-independent manner, arguing that Cdc42 binding is sufficient for activation loop autophosphorylation of MLK3. However, membrane targeting is necessary for full activation of MLK3 and maximal signaling to JNK. We previously reported that MLK3 is autoinhibited through an interaction between its N-terminal SH3 domain and a proline-containing sequence found between the leucine zipper and the CRIB motif of MLK3. Thus we propose a model in which GTP-bound Cdc42/Rac binds MLK3 and disrupts SH3-mediated autoinhibition leading to dimerization and activation loop autophosphorylation. Targeting of this partially active MLK3 to membranes likely results in additional phosphorylation events that fully activate MLK3 and its ability to maximally signal through the JNK pathway.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 4180 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	gallok@msu.edu						Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Cha H, 2004, J CELL SCI, V117, P751, DOI 10.1242/jcs.00897; Chadee DN, 2004, CELL CYCLE, V3, P1227, DOI 10.4161/cc.3.10.1187; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Hartkamp J, 1999, CANCER RES, V59, P2195; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mineo C, 1997, J BIOL CHEM, V272, P10345; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Nomura K, 2004, J BIOL CHEM, V279, P22664, DOI 10.1074/jbc.M314169200; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Peyker A, 2005, CHEMBIOCHEM, V6, P78, DOI 10.1002/cbic.200400280; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Swenson KI, 2003, MOL BIOL CELL, V14, P156, DOI 10.1091/mbc.E02-02-0115; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	70	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42984	42993		10.1074/jbc.M502671200	http://dx.doi.org/10.1074/jbc.M502671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16253996	hybrid			2022-12-25	WOS:000234200800062
J	Kiselyov, K; Chen, J; Rbaibi, Y; Oberdick, D; Tjon-Kon-Sang, S; Shcheynikov, N; Muallem, S; Soyombo, A				Kiselyov, K; Chen, J; Rbaibi, Y; Oberdick, D; Tjon-Kon-Sang, S; Shcheynikov, N; Muallem, S; Soyombo, A			TRP-ML1 is a lysosomal monovalent cation channel that undergoes proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOLIPIDOSIS TYPE-IV; IDENTIFICATION; MUTATIONS; EXPRESSION; PROTEINS; CLONING	Mutations in the gene MCOLN1 coding for the TRP (transient receptor potential) family ion channel TRP-ML1 lead to the lipid storage disorder mucolipidosis type IV (MLIV). The function and role of TRP-ML1 are not well understood. We report here that TRPML1 is a lysosomal monovalent cation channel. Both native and recombinant TRP-ML1 are cleaved resulting in two products. Recombinant TRP-ML1 is detected as the full-length form and as short N- and C-terminal forms, whereas in native cells mainly the cleaved N and C termini are detected. The N- and C-terminal fragments of TRP-ML1 were co-immunoprecipitated from cell lysates and co-eluted from a Ni2+ column. TRP-ML1 undergoes proteolytic cleavage that is inhibited by inhibitors of cathepsin B (CatB) and is altered when TRP-ML1 is expressed in CatB(-/-) cells. N- terminal sequencing of purified C-terminal fragment of TRP-ML1 expressed in Sf9 cells indicates a cleavage site at Arg(200) down arrow Pro(201). Consequently, the conserved R200H mutation changed the cleavage pattern of TRP-ML1. The cleavage inhibited TRP-ML1 channel activity. This work provides the first example of inactivation by cleavage of a TRP channel. The significance of the cleavage to the function of TRP-ML1 is under investigation.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu		Soyombo, Abigail/0000-0003-0850-2593; Kiselyov, Kirill/0000-0001-6683-2895	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bach G, 2001, MOL GENET METAB, V73, P197, DOI 10.1006/mgme.2001.3195; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Bargal R, 2002, NEUROPEDIATRICS, V33, P199, DOI 10.1055/s-2002-34496; Bargal R, 2001, HUM MUTAT, V17, P397, DOI 10.1002/humu.1115; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; Bonavita S, 2003, J CHILD NEUROL, V18, P443, DOI 10.1177/08830738030180070701; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; CHITAYAT D, 1991, AM J MED GENET, V41, P313, DOI 10.1002/ajmg.1320410310; Duncan LM, 1998, CANCER RES, V58, P1515; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Frei KP, 1998, NEUROLOGY, V51, P565, DOI 10.1212/WNL.51.2.565; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Sever N, 2002, BIOL CHEM, V383, P839, DOI 10.1515/BC.2002.088; Slaugenhaupt Susan A., 2002, Current Molecular Medicine (Hilversum), V2, P445, DOI 10.2174/1566524023362276; Smith JA, 2002, OPHTHALMOLOGY, V109, P588, DOI 10.1016/S0161-6420(01)00968-X; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200	23	116	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43218	43223		10.1074/jbc.M508210200	http://dx.doi.org/10.1074/jbc.M508210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16257972	hybrid			2022-12-25	WOS:000234200800088
J	Pears, MR; Cooper, JD; Mitchison, HM; Mortishire-Smith, RJ; Pearce, DA; Griffin, JL				Pears, MR; Cooper, JD; Mitchison, HM; Mortishire-Smith, RJ; Pearce, DA; Griffin, JL			High resolution H-1 NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSES; MAGNETIC-RESONANCE-SPECTROSCOPY; ACETYL-L-ASPARTATE; GLUTAMIC-ACID DECARBOXYLASE; BRAIN N-ACETYLASPARTATE; ALZHEIMERS-DISEASE; PATTERN-RECOGNITION; HUNTINGTONS-DISEASE; GENE-EXPRESSION; IN-VIVO	The neuronal ceroid lipofuscinoses (NCLs) constitute a range of progressive neurological disorders primarily affecting children. Although six of the causative genes have been characterized, the underlying disease pathogenesis for this family of disorders is unknown. Using a metabolomics approach based on high resolution H-1 NMR spectroscopy of the cortex, cerebellum, and remaining regions of the brain in conjunction with statistical pattern recognition, we report metabolic deficits associated with juvenile NCL in a Cln3 knock-out mouse model. Tissue from Cln3 null mutant mice aged 1-6 months was characterized by an increased glutamate concentration and a decrease in gamma-amino butyric acid (GABA) concentration in aqueous extracts from the three regions of the brain. These changes are consistent with the reported altered expression of genes involved in glutamate metabolism in older mice and imply a change in neurotransmitter cycling between glutamate/glutamine and the production of GABA. Further variations in myo-inositol, creatine, and N-acetyl-aspartate were also identified. These metabolic changes were distinct from the normal aging/developmental process. Together, these changes represent the first documented pre-symptomatic symptoms of the Cln3 mouse at 1 month of age and demonstrate the versatility of H-1 NMR spectroscopy as a tool for phenotyping mouse models of disease.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Kings Coll London, Pediat Storage Disorders Lab, Dept Neurosci,Inst Psychiat, Med Res Council Social Genet & Dev Psychiat Ctr, London SE5 8AF, England; UCL Royal Free & Univ Coll Med Sch, Dept Paediat & Child Hlth, London WC1 6JJ, England; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Aab Inst Biomed Sci,Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Cambridge; University of London; King's College London; University of London; University College London; UCL Medical School; Merck & Company; University of Rochester; University of Rochester	Pears, MR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.	jlg40@mole.bio.cam.ac.uk	Mitchison, Hannah M./C-1891-2008; Cooper, Jonathan/C-8117-2009; Cooper, Jonathan/V-9962-2019	Cooper, Jonathan/0000-0003-1339-4750; Cooper, Jonathan/0000-0003-1339-4750; Mitchison, Hannah/0000-0002-3163-6293	NIDDK NIH HHS [R21DK070288-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE P, 1992, AM J MED GENET, V42, P549, DOI 10.1002/ajmg.1320420426; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; Bhakoo KK, 2000, J NEUROCHEM, V74, P254, DOI 10.1046/j.1471-4159.2000.0740254.x; Bluml S, 1998, J NEUROCHEM, V71, P1564; Bothwell JH, 2001, J NEUROCHEM, V77, P1632, DOI 10.1046/j.1471-4159.2001.00403.x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks AI, 2003, MOL GENET METAB, V78, P17, DOI 10.1016/S1096-7192(02)00201-9; Burbaeva GS, 2003, PROG NEURO-PSYCHOPH, V27, P675, DOI 10.1016/S0278-5846(03)00078-2; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Chattopadhyay S, 2002, HUM MOL GENET, V11, P1421, DOI 10.1093/hmg/11.12.1421; Cooper JD, 2003, CURR OPIN NEUROL, V16, P121, DOI 10.1097/00019052-200304000-00001; DUNLOP DS, 1992, BRAIN RES, V580, P44, DOI 10.1016/0006-8993(92)90925-Y; Elshatory Y, 2003, FEBS LETT, V538, P207, DOI 10.1016/S0014-5793(03)00162-5; Eriksson L., 1999, INTRO MULTI MEGAVARI, P69; Gardiner RM, 2002, ADV NEUROL, V89, P211; Goebel HH, 1998, BRAIN PATHOL, V8, P151; Griffin JL, 2002, PHYSIOL GENOMICS, V11, P195, DOI 10.1152/physiolgenomics.00100.2002; Hofmann Sandra L., 2002, Current Molecular Medicine (Hilversum), V2, P423, DOI 10.2174/1566524023362294; Holmes E, 1998, NMR BIOMED, V11, P235, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<235::AID-NBM507>3.0.CO;2-V; ISAACKS RE, 1994, NEUROCHEM RES, V19, P331, DOI 10.1007/BF00971582; Kash SF, 1997, P NATL ACAD SCI USA, V94, P14060, DOI 10.1073/pnas.94.25.14060; Kim Y, 2005, EUKARYOT CELL, V4, P281, DOI 10.1128/EC.4.2.281-288.2005; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; KLUNK WE, 1992, NEUROLOGY, V42, P1578, DOI 10.1212/WNL.42.8.1578; Kopra O, 2004, HUM MOL GENET, V13, P2893, DOI 10.1093/hmg/ddh312; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lundbom N, 2001, EPILEPSIA, V42, P1507, DOI 10.1046/j.1528-1157.2001.15301.x; MANN DMA, 1978, J NEUROL SCI, V37, P83, DOI 10.1016/0022-510X(78)90229-0; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MEYERHOFF DJ, 1993, NEUROLOGY, V43, P509, DOI 10.1212/WNL.43.3_Part_1.509; Mitchison HM, 2004, BRAIN PATHOL, V14, P86, DOI 10.1111/j.1750-3639.2004.tb00502.x; Mitchison HM, 1999, NEUROBIOL DIS, V6, P321, DOI 10.1006/nbdi.1999.0267; Mitchison HM, 2001, CURR OPIN NEUROL, V14, P795, DOI 10.1097/00019052-200112000-00019; Mole S E, 1991, Int J Neurol, V25-26, P52; Mole SE, 2004, BRAIN PATHOL, V14, P70, DOI 10.1111/j.1750-3639.2004.tb00500.x; OCALLAGHAN JP, 1994, PSYCHOPHARMACOL BULL, V30, P549; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; Pontikis CC, 2004, BRAIN RES, V1023, P231, DOI 10.1016/j.brainres.2004.07.030; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Ross B, 2001, ANAT RECORD, V265, P54, DOI 10.1002/ar.1058; SCHOUSBOE A, 1993, DEV NEUROSCI-BASEL, V15, P359, DOI 10.1159/000111356; SEKHON SS, 1974, J NEUROCYTOL, V3, P59, DOI 10.1007/BF01111932; SPRAUL M, 1994, J PHARMACEUT BIOMED, V12, P1215, DOI 10.1016/0731-7085(94)00073-5; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Wisniewski KE, 2001, NEUROLOGY, V57, P576, DOI 10.1212/WNL.57.4.576; WOLFE LS, 1987, CHEM SCRIPTA, V27, P79	49	125	127	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42508	42514		10.1074/jbc.M507380200	http://dx.doi.org/10.1074/jbc.M507380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16239221	hybrid			2022-12-25	WOS:000234200800006
J	Brandhorst, TT; Gauthier, GM; Stein, RA; Klein, BS				Brandhorst, TT; Gauthier, GM; Stein, RA; Klein, BS			Calcium binding by the essential virulence factor BAD-1 of Blastomyces dermatitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOPLASMA-CAPSULATUM; CONFORMATIONAL-CHANGES; ALPHA PRODUCTION; CATION-BINDING; CA2+ BINDING; PROTEINS; SURFACE; ADHESIN; WI-1; YEASTS	BAD-1 ( Blastomyces adhesin 1), a 120-kDa protein of Blastomyces dermatitidis, functions as an adhesin, immune modulator, and essential virulence factor. Structurally, BAD-1 is composed of a short N-terminal region, a core of 30 tandem repeats critical for virulence, and a C-terminal epidermal growth factor domain that binds the protein to yeast cell surface chitin. Each of the 30 acidic residue-rich tandem repeats contains a sequence that resembles the calcium-binding loop of the EF-hand domain found in many calcium-binding proteins. Here, we investigated the binding of calcium by BAD-1 and its biological significance. Yeast washed with double distilled H2O released surface-bound BAD-1, but EGTA washes were an order of magnitude more efficient, suggesting an interaction between BAD-1 and calcium. Immobilized BAD-1 was stained with ruthenium red dye, an indicator of calcium-binding proteins. In equilibrium dialysis, BAD-1 bound Ca-45(2+) with an affinity of 0.41 x 10(-5) M and a capacity of 27 calcium/mol. Mass spectrometry confirmed this capacity. Elevated [ Ca2+] diminished BAD-1 solubility. Upon deletion of its C-terminal epidermal growth factor-like domain, BAD-1 resisted aggregation by elevated [ Ca2+] but retained its affinity and capacity for calcium. Removing 20 copies of the tandem repeat, however, sharply reduced the capacity of BAD-1 for calcium. Growth of the bad-1 null yeast was inhibited by 5 mM EGTA, and re-expression of BAD-1 in trans or the addition of exogenous purified BAD-1 restored growth. Thus, BAD-1 is a high capacity calcium-binding protein. This property contributes to the structure and function of BAD-1, as well as to B. dermatitidis acquisition of calcium from the environment.	Univ Wisconsin, Sch Med, Dept Pediat, Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Internal Med, Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Microbiol & Immunol, Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Klein, BS (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Univ Wisconsin Hosp & Clin, 600 Highland Ave,K4-434, Madison, WI 53792 USA.	bsklein@wisc.edu			NCRR NIH HHS [RR13790] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Audet R, 1997, PROTEIN EXPRES PURIF, V11, P219, DOI 10.1006/prep.1997.0783; Brandhorst T, 2000, J BIOL CHEM, V275, P7925, DOI 10.1074/jbc.275.11.7925; Brandhorst T, 2003, MOL MICROBIOL, V48, P53, DOI 10.1046/j.1365-2958.2003.03415.x; Brandhorst TT, 2004, J IMMUNOL, V173, P7444, DOI 10.4049/jimmunol.173.12.7444; Brandhorst TT, 1999, J EXP MED, V189, P1207, DOI 10.1084/jem.189.8.1207; Brown DM, 2004, AM J PHYSIOL-LUNG C, V286, pL344, DOI 10.1152/ajplung.00139.2003; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COX JA, 1994, J BIOL CHEM, V269, P32807; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; Eylar E H, 1978, Adv Exp Med Biol, V100, P307; Finkel-Jimenez B, 2002, J IMMUNOL, V168, P5746, DOI 10.4049/jimmunol.168.11.5746; Finkel-Jimenez B, 2001, J IMMUNOL, V166, P2665, DOI 10.4049/jimmunol.166.4.2665; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; GREEN JH, 1982, 82 ANN M AM SOC MICR; Hannah BLA, 2004, J BIOL CHEM, V279, P51915, DOI 10.1074/jbc.M409632200; HE ZP, 1993, J BIOL CHEM, V268, P24635; Hogan LH, 1995, J BIOL CHEM, V270, P30725, DOI 10.1074/jbc.270.51.30725; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Johnson WC, 1997, BBA-PROTEIN STRUCT M, V1342, P164, DOI 10.1016/S0167-4838(97)00091-5; Jordan PA, 2001, BIOCHEMISTRY-US, V40, P8387, DOI 10.1021/bi010238f; KLEIN BS, 1994, INFECT IMMUN, V62, P3890, DOI 10.1128/IAI.62.9.3890-3900.1994; KLOTZ SA, 1993, MICROB PATHOGENESIS, V14, P133, DOI 10.1006/mpat.1993.1014; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; NEWMAN SL, 1995, J IMMUNOL, V154, P753; Nickel R, 2000, FEBS LETT, V486, P112, DOI 10.1016/S0014-5793(00)02245-6; Sebghati TS, 2000, SCIENCE, V290, P1368, DOI 10.1126/science.290.5495.1368; SIBLEY LD, 1986, J CELL BIOL, V103, P867, DOI 10.1083/jcb.103.3.867; Soman J, 1999, PROTEINS, V37, P510, DOI 10.1002/(SICI)1097-0134(19991201)37:4<510::AID-PROT2>3.0.CO;2-T; Subramanian L, 2004, BIOCHEMISTRY-US, V43, P11175, DOI 10.1021/bi048848d; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527; VOGEL H, METHODS MOL BIOL, V172, P4; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137; YANG LY, 1992, J BACTERIOL, V174, P1258, DOI 10.1128/jb.174.4.1258-1267.1992	39	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42156	42163		10.1074/jbc.M507188200	http://dx.doi.org/10.1074/jbc.M507188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16243837	hybrid			2022-12-25	WOS:000233992700043
J	Matheu, A; Klatt, P; Serrano, M				Matheu, A; Klatt, P; Serrano, M			Regulation of the INK4a/ARF locus by histone deacetylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; SODIUM-BUTYRATE; TRANSCRIPTIONAL REPRESSION; GENE; EXPRESSION; CANCER; CYCLE; P53; SENESCENCE; PROMOTER	Despite the importance of the INK4a/ARF locus in tumor suppression, its modulation by histone deacetylase inhibitors (HDACis) remains to be characterized. Here, we have shown that the levels of p16(INK4a) are decreased in human and murine fibroblasts upon exposure to relatively high concentrations of trichostatin A and sodium butyrate. Interestingly, the levels of p19(ARF) are strongly upregulated in murine cells even at low concentrations of HDACis. Using ARF-deficient cells, we have demonstrated that p19ARF plays an active role in HDACi-triggered cytostasis and the contribution of p19ARF to this arrest is of higher magnitude than that of the well established HDACi target p21(Waf1/Cip). Moreover, chemically induced fibrosarcomas in ARF-null mice are more resistant to the therapeutic effect of HDACis than similar tumors in wild type or p21(Waf1/Cip)-null mice. Together, our results have established the tumor suppressor ARF as a relevant target for HDACi chemotherapy.	CNIO, Mol Oncol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), CNIO, Mol Oncol Program, Melchor Fernandez Almagro St 3, Madrid 28029, Spain.	mserrano@cnio.es	matheu, ander/G-9906-2014; Serrano, Manuel/H-2634-2015	matheu, ander/0000-0002-1848-0781; Serrano, Manuel/0000-0001-7177-9312				Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Choi CH, 2004, CELL CYCLE, V3, P114; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Glaser KB, 2003, MOL CANCER THER, V2, P151; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hara E, 1996, MOL CELL BIOL, V16, P859; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lindemann RK, 2004, CELL CYCLE, V3, P779; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Munro J, 2004, EXP CELL RES, V295, P525, DOI 10.1016/j.yexcr.2004.01.017; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 2001, EXP GERONTOL, V36, P1289, DOI 10.1016/S0531-5565(01)00104-8; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Xue LX, 2004, FEBS LETT, V564, P199, DOI 10.1016/S0014-5793(04)00352-7; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101	55	32	33	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42433	42441		10.1074/jbc.M508270200	http://dx.doi.org/10.1074/jbc.M508270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251190	hybrid			2022-12-25	WOS:000233992700074
J	Baufreton, J; Zhu, ZT; Garret, M; Bioulac, B; Johnson, SW; Taupignon, AI				Baufreton, J; Zhu, ZT; Garret, M; Bioulac, B; Johnson, SW; Taupignon, AI			Dopamine receptors set the pattern of activity generated in subthalamic neurons	FASEB JOURNAL			English	Article						subthalamic nucleus; slow-wave sleep; burst-firing; basal ganglia	ACTION-POTENTIAL GENERATION; IN-VITRO; PARKINSONS-DISEASE; NUCLEUS NEURONS; BASAL GANGLIA; FUNCTIONAL-ANATOMY; CYTOPLASMIC TAIL; GLOBUS-PALLIDUS; FIRING RATES; C-FOS	Information processing in the brain requires adequate background neuronal activity. As Parkinson's disease progresses, patients typically become akinetic; the death of dopaminergic neurons leads to a dopamine-depleted state, which disrupts information processing related to movement in a brain area called the basal ganglia. Using agonists of dopamine receptors in the D1 and D2 families on rat brain slices, we show that dopamine receptors in these two families govern the firing pattern of neurons in the subthalamic nucleus, a crucial part of the basal ganglia. We propose a conceptual frame, based on specific properties of dopamine receptors, to account for the dominance of different background firing patterns in normal and dopamine-depleted states.	Univ Victor Segalen, UMR 5543, F-33076 Bordeaux, France; Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; Oregon Hlth Sci Univ, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pharmacol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA	UDICE-French Research Universities; Universite de Bordeaux; Northwestern University; Feinberg School of Medicine; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Taupignon, AI (corresponding author), Univ Victor Segalen, UMR 5543, 146 Rue Saignat, F-33076 Bordeaux, France.	anne.taupignon@umr5543.u-bordeaux2.fr		Taupignon, Anne/0000-0002-4662-7971; Baufreton, Jerome/0000-0002-2623-6375	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038715] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38715] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Awad H, 2000, J NEUROSCI, V20, P7871; Baufreton J, 2001, J NEUROPHYSIOL, V86, P75, DOI 10.1152/jn.2001.86.1.75; Baufreton J, 2003, J NEUROSCI, V23, P816; Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Bevan MD, 2002, J NEUROPHYSIOL, V87, P1348, DOI 10.1152/jn.00582.2001; Bevan MD, 2000, J NEUROPHYSIOL, V83, P3169, DOI 10.1152/jn.2000.83.5.3169; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BROWN LL, 1979, SCIENCE, V206, P1416, DOI 10.1126/science.505015; Cragg SJ, 2004, EUR J NEUROSCI, V20, P1788, DOI 10.1111/j.1460-9568.2004.03629.x; CROSSMAN AR, 1990, MOVEMENT DISORD, V5, P100, DOI 10.1002/mds.870050203; Demchyshyn LL, 2000, J BIOL CHEM, V275, P23446, DOI 10.1074/jbc.M000157200; Do MTH, 2003, NEURON, V39, P109, DOI 10.1016/S0896-6273(03)00360-X; Eggermont JJ, 1998, NEUROSCI BIOBEHAV R, V22, P355, DOI 10.1016/S0149-7634(97)00021-3; Feger J, 1997, ADV NEUROL, V74, P31; Francois C, 2000, J COMP NEUROL, V425, P121, DOI 10.1002/1096-9861(20000911)425:1<121::AID-CNE10>3.0.CO;2-G; Hallworth NE, 2003, J NEUROSCI, V23, P7525; Hartings JA, 2003, J NEUROSCI, V23, P5264; Hassani OK, 1999, NEUROSCIENCE, V92, P533, DOI 10.1016/S0306-4522(98)00765-9; Hassani OK, 1997, BRAIN RES, V749, P88, DOI 10.1016/S0006-8993(96)01167-5; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hutchison WD, 2004, J NEUROSCI, V24, P9240, DOI 10.1523/JNEUROSCI.3366-04.2004; Jackson A, 2000, FEBS LETT, V470, P183, DOI 10.1016/S0014-5793(00)01315-6; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Krahe R, 2004, NAT REV NEUROSCI, V5, P13, DOI 10.1038/nrn1296; Kreiss DS, 1996, NEUROSCIENCE, V72, P863, DOI 10.1016/0306-4522(95)00583-8; Kreiss DS, 1997, J NEUROSCI, V17, P6807; Levy R, 2002, J NEUROSCI, V22, P2855, DOI 10.1523/JNEUROSCI.22-07-02855.2002; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; Magill PJ, 2001, NEUROSCIENCE, V106, P313, DOI 10.1016/S0306-4522(01)00281-0; Marino MJ, 2002, NEUROPHARMACOLOGY, V43, P147, DOI 10.1016/S0028-3908(02)00097-7; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; Mehta A, 2000, SYNAPSE, V37, P298, DOI 10.1002/1098-2396(20000915)37:4<298::AID-SYN7>3.0.CO;2-A; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAKANISHI H, 1987, BRAIN RES, V437, P35, DOI 10.1016/0006-8993(87)91524-1; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Nutt JG, 2001, NEUROLOGY, V57, P1835, DOI 10.1212/WNL.57.10.1835; Otsuka T, 2001, J NEUROPHYSIOL, V86, P1816, DOI 10.1152/jn.2001.86.4.1816; OVERTON PG, 1995, J NEURAL TRANSM-PARK, V10, P41, DOI 10.1007/BF02256628; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8; Song WJ, 2000, J NEUROPHYSIOL, V84, P2630, DOI 10.1152/jn.2000.84.5.2630; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Steriade M, 2001, NAT NEUROSCI, V4, P671, DOI 10.1038/89434; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Svenningsson P, 2002, EUR J NEUROSCI, V15, P133, DOI 10.1046/j.0953-816x.2001.01840.x; TIBERI M, 1994, J BIOL CHEM, V269, P27925; Tumova K, 2003, J BIOL CHEM, V278, P8146, DOI 10.1074/jbc.M208059200; Urbain N, 2002, J NEUROSCI, V22, P8665; Urbain N, 2004, EUR J NEUROSCI, V20, P392, DOI 10.1111/j.1460-9568.2004.03488.x; Wichmann T, 2003, ANN NY ACAD SCI, V991, P199, DOI 10.1111/j.1749-6632.2003.tb07477.x; Zhu ZT, 2002, NEUROPHARMACOLOGY, V42, P772, DOI 10.1016/S0028-3908(02)00035-7; Zhu ZT, 2004, EUR J NEUROSCI, V19, P1296, DOI 10.1111/j.1460-9568.2004.03240.x	56	47	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1771	1777		10.1096/fj.04-3401hyp	http://dx.doi.org/10.1096/fj.04-3401hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260646				2022-12-25	WOS:000234053100028
J	Kitamura, S; Yamasaki, Y; Kinomura, M; Sugaya, T; Sugiyama, H; Maeshima, Y; Makino, H				Kitamura, S; Yamasaki, Y; Kinomura, M; Sugaya, T; Sugiyama, H; Maeshima, Y; Makino, H			Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney	FASEB JOURNAL			English	Article						S3 segment of proximal tubules; renal tubular epithelial cells; renal progenitor-like cell	HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; REGENERATION; EXPRESSION; PROLIFERATION; DIFFERENTIATE; CONTRIBUTE; ISCHEMIA; MARKERS	Kidney is thought to be a regenerative organ in terms of repair from acute tubular injury. It is unknown whether cell population contributes to repair disordered kidney. We attempted to identify and isolate highly proliferative cells from a single cell. We dissected a single nephron from adult rat kidney. Isolated nephrons were separated into segments and cultured. Outgrowing cells were replated after limiting dilution so that each well contained a single cell. One of cell line which was the most potent to grow was designated as rKS56. rKS56 cells showed cobblestone appearance and expressed immature cell markers relating to kidney development and mature tubular cell markers. rKS56 cells grew exponentially and could be maintained for 300 days without transformation. In different culture conditions, rKS56 cells differentiated into mature tubular cells defined by aquaporin-1, 2 expression, and responsiveness to parathyroid hormone or vasopressin. Engrafted to kidney in rat ischemic reperfusion model, rKS56 cells replaced in injured tubules in part after implantation and improved renal function. These results suggest rKS56 cells possess character such as self-renewal, multi-plasticity and capability of tissue repair. rKS56 may possibly contribute to the future development of cell therapy for renal regeneration.	Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, Okayama 7008558, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Tokyo Dent Coll, Corneal Transplant Ctr, Chiba, Japan	Okayama University; University of Tsukuba; Tokyo Dental College	Makino, H (corresponding author), Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	makino@md.okayama-u.ac.jp	Sugiyama, Hitoshi/B-2252-2011	Sugiyama, Hitoshi/0000-0002-4127-6471				Al-Awqati Q, 2002, KIDNEY INT, V61, P387, DOI 10.1046/j.1523-1755.2002.00164.x; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Cha JH, 2001, J AM SOC NEPHROL, V12, P1410, DOI 10.1681/ASN.V1271410; Clarke RB, 2003, CELL PROLIFERAT, V36, P1, DOI 10.1046/j.1365-2184.36.s.1.1.x; Cornacchia F, 2001, J CLIN INVEST, V108, P1649; Dekel B, 2003, NAT MED, V9, P53, DOI 10.1038/nm812; Disashi T, 1997, HYPERTENSION, V30, P1591, DOI 10.1161/01.HYP.30.6.1591; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lin FM, 2003, J AM SOC NEPHROL, V14, P1188, DOI 10.1097/01.ASN.0000061595.28546.A0; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X; Nakauchi Hiromitsu, 2004, Cornea, V23, pS2, DOI 10.1097/01.ico.0000136664.18129.4f; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Oliver JA, 2002, AM J PHYSIOL-RENAL, V283, pF799, DOI 10.1152/ajprenal.00375.2001; Oliver JA, 2004, J CLIN INVEST, V114, P795, DOI 10.1172/JCI200420921; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Sherley James L, 2002, ScientificWorldJournal, V2, P1906; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Valerius MT, 2002, P NATL ACAD SCI USA, V99, P8090, DOI 10.1073/pnas.122229199; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	41	145	165	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1789	1797		10.1096/fj.05-3942com	http://dx.doi.org/10.1096/fj.05-3942com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260649				2022-12-25	WOS:000234053100031
J	Tanneur, V; Duranton, C; Brand, VB; Sandu, CD; Akkaya, C; Kasinathan, RS; Gachet, C; Sluyter, R; Barden, JA; Wiley, JS; Lang, F; Huber, SM				Tanneur, V; Duranton, C; Brand, VB; Sandu, CD; Akkaya, C; Kasinathan, RS; Gachet, C; Sluyter, R; Barden, JA; Wiley, JS; Lang, F; Huber, SM			Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes	FASEB JOURNAL			English	Article						purinergic receptors; ATP release; oxidative stress; new permeability pathways; red blood cells	RED-BLOOD-CELLS; ANION CHANNEL; P2Y(1) RECEPTORS; ATP RELEASE; PLASMODIUM; PATHWAYS; PARASITE; MEMBRANE; MECHANISM; DEFORMATION	In human erythrocytes, infection by the malaria parasite Plasmodium falciparum or oxidative stress induces a new organic osmolyte and anion permeability. To examine a role for autocrine purinoceptor signaling during this induction process, erythrocytic purinoceptor expression, and ATP release were determined. Furthermore, using pharmacological and genetic approaches the dependence on purinoceptor signaling of osmolyte permeability and Plasmodium development, both in vitro and in vivo, were assessed. Extracellular ATP did not induce an osmolyte permeability in non-infected or non-oxidized erythrocytes. ATP and other purinoceptor agonists increased the induction of osmolyte permeability during infection or oxidation as measured by isosmotic hemolysis and patch-clamp recording. Purinoceptor antagonists and apyrase decreased the induced permeability. The observed pharmacology suggested the involvement of P2Y purinoceptors. Accordingly, human erythrocytes expressed P2Y(1) protein. Moreover, P2Y(1)-deficient mouse erythrocytes exhibited a delayed appearance of the osmolyte permeability during P. berghei infection-or oxidation compared with wild-type erythrocytes. Furthermore, the nonspecific purinoceptor antagonist suramin decreased in vitro growth and DNA/RNA amplification of P. falciparum in human erythrocytes and decreased in vivo growth of P. berghei. P. berghei developed slower in P2Y(1)-deficient mice in vivo compared with wild-type animals. In conclusion, induction of the osmolyte permeability in Plasmodium-infected erythrocytes involves autocrine purinoceptor signaling.	Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; INSERM, U 311, Strasbourg, France; Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	Eberhard Karls University of Tubingen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Nepean Hospital; University of Sydney; University of Sydney	Huber, SM (corresponding author), Univ Tubingen, Dept Physiol 1, Gmelinstr 5, D-72076 Tubingen, Germany.	stephan.huber@uni-tuebingen.de	Kasinathan, Ravi/B-7657-2013; DURANTON, CHRISTOPHE/E-9582-2019; Gachet, Christian/H-9156-2016; Sluyter, Ronald/B-5798-2009	DURANTON, CHRISTOPHE/0000-0003-1127-2346; Sluyter, Ronald/0000-0003-4909-686X; Wiley, James/0000-0001-9421-4154; Huber, Stephan/0000-0002-9430-8334				Alkhalil A, 2004, BLOOD, V104, P4279, DOI 10.1182/blood-2004-05-2047; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BREUER WV, 1987, J CELL PHYSIOL, V133, P55, DOI 10.1002/jcp.1041330107; Brugnara C, 1997, Curr Opin Hematol, V4, P122; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Desai SA, 2005, J BIOL CHEM, V280, P16861, DOI 10.1074/jbc.M414629200; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Duranton C, 2004, J GEN PHYSIOL, V123, P417, DOI 10.1085/jgp.200308919; Duranton C, 2003, CELL PHYSIOL BIOCHEM, V13, P189, DOI 10.1159/000072421; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; Fleck SL, 2003, J BIOL CHEM, V278, P47670, DOI 10.1074/jbc.M306603200; Fong AY, 2002, NEUROSCIENCE, V113, P809, DOI 10.1016/S0306-4522(02)00237-3; Ginsburg H, 2004, J MEMBRANE BIOL, V197, P113, DOI 10.1007/s00232-003-0646-7; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; Hoffman JF, 2004, P NATL ACAD SCI USA, V101, P12370, DOI 10.1073/pnas.0404228101; Huber SM, 2005, INT REV CYTOL, V246, P59, DOI 10.1016/S0074-7696(05)46003-9; Huber SM, 2004, J BIOL CHEM, V279, P41444, DOI 10.1074/jbc.M407618200; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; Kisilevsky R, 2002, ANTIMICROB AGENTS CH, V46, P2619, DOI 10.1128/AAC.46.8.2619-2626.2002; Knofler R, 1997, AM J HEMATOL, V56, P259, DOI 10.1002/(SICI)1096-8652(199712)56:4<259::AID-AJH11>3.0.CO;2-4; Lambert IH, 2004, NEUROCHEM RES, V29, P27, DOI 10.1023/B:NERE.0000010433.08577.96; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Light DB, 2001, J MEMBRANE BIOL, V182, P193, DOI 10.1007/s0023201-0043-z; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Olearczyk J J, 2001, Med Sci Monit, V7, P669; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; Pedersen S, 1999, BBA-BIOMEMBRANES, V1416, P271, DOI 10.1016/S0005-2736(98)00228-4; Pitt SJ, 2005, MOL PHARMACOL, V67, P1705, DOI 10.1124/mol.104.009902; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rubino A, 1999, EUR J PHARMACOL, V370, P139, DOI 10.1016/S0014-2999(99)00150-8; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sherman IW, 2004, CELL MOL BIOL, V50, P159; Sluyter R, 2004, J BIOL CHEM, V279, P44749, DOI 10.1074/jbc.M405631200; Sprague RS, 2001, AM J PHYSIOL-CELL PH, V281, pC1158, DOI 10.1152/ajpcell.2001.281.4.C1158; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Staines HM, 2003, J PHYSIOL-LONDON, V552, P177, DOI 10.1113/jphysiol.2003.051169; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; UHLEMANN AC, 2000, MACS MORE, V4, P7; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281	48	62	63	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					133	+		10.1096/fj.04-3371fje	http://dx.doi.org/10.1096/fj.04-3371fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16267125				2022-12-25	WOS:000234053100019
J	Riley, JK; Carayannopoulos, MO; Wyman, AH; Chi, M; Moley, KH				Riley, JK; Carayannopoulos, MO; Wyman, AH; Chi, M; Moley, KH			Phosphatidylinositol 3-kinase activity is critical for glucose metabolism and embryo survival in murine Blastocysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INDUCED APOPTOSIS; CELL-PROLIFERATION; BOVINE BLASTOCYST; FACTOR-ALPHA; IGF-I; INSULIN; EXPRESSION; KINASE; PATHWAY	The phosphatidylinositol 3-kinase (PI3K) signal transduction pathway is a well known mediator of cell growth, proliferation, and survival signals. Whereas the expression and function of this pathway has been documented during mammalian development, evidence demonstrating the physiologic importance of this pathway in murine preimplantation embryos is beginning to emerge. This study demonstrates that inhibition of the PI3K pathway leads to the induction of apoptosis in both murine blastocysts and trophoblast stem cells. The apoptosis induced in both model systems correlates with a decrease in the expression of the glucose transporter GLUT1 at the plasma membrane. In addition, blastocysts cultured in the presence of the PI3K inhibitor LY-294002 display a decrease in both 2-deoxyglucose uptake and hexokinase activity as compared with control blastocysts. To determine the impact of PI3K inhibition on pregnancy outcome, embryo transfer experiments were performed. Blastocysts cultured in the presence of LY-294002 demonstrate a dramatic increase in fetal resorptions as compared with control embryos. Finally, we demonstrate that impairment of glucose metabolism via iodoacetate, a glyceraldehyde-3-phosphate dehydrogenase inhibitor, is sufficient to induce apoptosis in both blastocysts and trophoblast stem cells. Moreover, blastocysts treated with iodoacetate result in poor pregnancy outcome as determined by embryo transfer experiments. Taken together these data demonstrate the critical importance of the PI3K pathway in preimplantation embryo survival and pregnancy outcome and further emphasize the importance of glucose utilization and metabolism in cell survival pathways.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Moley, KH (corresponding author), Box 8064,4911 Barnes Jewish Hosp Plaza, St Louis, MO 63110 USA.	moleyk@wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK070351] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 40390, R01 HD040390] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341, DK 0070351, P30 DK056341-06] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Augustin R, 2003, REPRODUCTION, V126, P91, DOI 10.1530/rep.0.1260091; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Birnbaum MJ, 2004, DEV CELL, V7, P781, DOI 10.1016/j.devcel.2004.11.016; Brison DR, 1997, BIOL REPROD, V56, P1088, DOI 10.1095/biolreprod56.5.1088; Byrne AT, 2002, MOL REPROD DEV, V62, P489, DOI 10.1002/mrd.10153; Byrne AT, 2002, REPROD FERT DEVELOP, V14, P79, DOI 10.1071/RD01015; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHI MMY, 1993, ANAL BIOCHEM, V209, P335, DOI 10.1006/abio.1993.1130; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Danshina PV, 2001, IUBMB LIFE, V51, P309; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ecker DJ, 2004, P NATL ACAD SCI USA, V101, P1595, DOI 10.1073/pnas.0306846101; Fabian D, 2004, THERIOGENOLOGY, V61, P745, DOI 10.1016/S0093-691X(03)00254-1; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross VS, 2005, MOL REPROD DEV, V70, P324, DOI 10.1002/mrd.20212; Heilig CW, 2003, P NATL ACAD SCI USA, V100, P15613, DOI 10.1073/pnas.2536196100; Herrler A, 1998, BIOL REPROD, V59, P1302, DOI 10.1095/biolreprod59.6.1302; Hill MM, 1999, MOL CELL BIOL, V19, P7771; JANERO DR, 1994, AM J PHYSIOL, V266, pC179, DOI 10.1152/ajpcell.1994.266.1.C179; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawamura K, 2005, BIOL REPROD, V73, P1094, DOI 10.1095/biolreprod.105.042754; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lane M, 2005, REPROD FERT DEVELOP, V17, P371, DOI 10.1071/RD04102; Lane M, 2003, BIOL REPROD, V69, P1109, DOI 10.1095/biolreprod.103.018093; Lelievre E, 2005, BLOOD, V105, P3935, DOI 10.1182/blood-2004-10-3955; Lighten AD, 1997, MOL REPROD DEV, V47, P134, DOI 10.1002/(SICI)1098-2795(199706)47:2<134::AID-MRD2>3.0.CO;2-N; Lowry, 1993, ENZYMATIC ANAL; Lu DP, 2004, J CELL SCI, V117, P1567, DOI 10.1242/jcs.00991; Makarevich AV, 2002, BIOL REPROD, V66, P386, DOI 10.1095/biolreprod66.2.386; Matsui M, 1995, J VET MED SCI, V57, P1109, DOI 10.1292/jvms.57.1109; Moley KH, 1998, AM J PHYSIOL-ENDOC M, V275, pE38, DOI 10.1152/ajpendo.1998.275.1.E38; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; Nagy A., 2003, MANIPULATING MOUSE E; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P3795, DOI 10.1073/pnas.94.8.3795; Pinto AB, 2002, HUM REPROD, V17, P457, DOI 10.1093/humrep/17.2.457; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Riley JK, 2005, DEV BIOL, V284, P377, DOI 10.1016/j.ydbio.2005.05.033; Sirisathien S, 2003, ANIM REPROD SCI, V77, P21, DOI 10.1016/S0378-4320(02)00272-5; Smotrich DB, 1996, HUM REPROD, V11, P184; Spanos S, 2000, BIOL REPROD, V63, P1413, DOI 10.1095/biolreprod63.5.1413; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wentzel P, 2003, DIABETES, V52, P1222, DOI 10.2337/diabetes.52.5.1222; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763	58	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6010	6019		10.1074/jbc.M506982200	http://dx.doi.org/10.1074/jbc.M506982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16272157	hybrid			2022-12-25	WOS:000235568900082
J	Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F				Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F			CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis	ONCOGENE			English	Article						mammary gland; development; ductal morphogenesis; puberty; CITED1; amphiregulin	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; NUCLEAR-PROTEIN; TGF-BETA; EXPRESSION; GLAND; GENES	Expression microarray analysis identified CITED1 among a group of genes specifically upregulated in the pubertal mouse mammary gland. At puberty, CITED1 localizes to the luminal epithelial cell population of the mammary ducts and the body cells of the terminal end buds. Generation of CITED1 gene knockout mice showed that homozygous null mutants exhibit retarded mammary ductal growth at puberty and, in addition, dilated ductal structures with a lack of spatial restriction of the subtending branches. Analysis of CITED1 homozygous null and heterozygous null mammary gland gene expression using microarrays suggested that the mammary specific phenotype seen in the homozygous null females is due to a disturbance in the transcription of a number of key mediators of pubertal ductal morphogenesis. These include estrogen and TGF beta responsive genes, such as the EGFR/ErbB2 ligand, amphiregulin, whose transcription we suggest is directly or indirectly regulated by CITED1.	Univ Coll Dublin, Conway Inst, Dublin 4, Ireland; Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 4, Ireland; Massachusetts Gen Hosp, Ctr Canc, Lab Tumour Biol, Charlestown, MA USA	University College Dublin; University College Dublin; Harvard University; Massachusetts General Hospital	Martin, F (corresponding author), Univ Coll Dublin, Conway Inst, Dublin 4, Ireland.	finian.martin@ucd.ie	Lambe, Teresa/E-5733-2016; Howlin, Jill/G-9665-2011	Lambe, Teresa/0000-0001-7711-897X; Howlin, Jill/0000-0002-2766-3002; McBryan, Jean/0000-0002-7568-2208	NCI NIH HHS [CA082230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Berking C, 2001, CANCER RES, V61, P8306; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073; Daniel CW, 1996, J MAMMARY GLAND BIOL, V1, P331, DOI 10.1007/BF02017389; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Ewan KBR, 2005, AM J PATHOL, V167, P409, DOI 10.1016/S0002-9440(10)62985-9; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gallagher J, 2003, FEBS LETT, V551, P8, DOI 10.1016/S0014-5793(03)00823-8; Humphreys RC, 1999, J MAMMARY GLAND BIOL, V4, P213, DOI 10.1023/A:1018733426625; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Morse DL, 2005, ANAL BIOCHEM, V342, P69, DOI 10.1016/j.ab.2005.03.034; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; Nair SS, 2001, PIGM CELL RES, V14, P206, DOI 10.1034/j.1600-0749.2001.140311.x; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Connell FC, 2000, CELL DEATH DIFFER, V7, P360, DOI 10.1038/sj.cdd.4400647; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Prasad ML, 2004, THYROID, V14, P169, DOI 10.1089/105072504773297830; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Sid B, 2004, CRIT REV ONCOL HEMAT, V49, P245, DOI 10.1016/j.critrevonc.2003.09.009; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stewart HJS, 1995, GLIA, V15, P419, DOI 10.1002/glia.440150406; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	48	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1532	1542		10.1038/sj.onc.1209183	http://dx.doi.org/10.1038/sj.onc.1209183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278680				2022-12-25	WOS:000235890400010
J	Holla, VR; Mann, JR; Shi, Q; DuBois, RN				Holla, VR; Mann, JR; Shi, Q; DuBois, RN			Prostaglandin E-2 regulates the nuclear receptor NR4A2 in colorectal cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; CYCLOOXYGENASE-2 COX-2; HORMONE RECEPTORS; GENE-EXPRESSION; CELL-CYCLE; NGFI-B; NURR1; APOPTOSIS; GROWTH; DISEASE	Many lines of research implicate cyclooxygenase 2-derived prostaglandins in tumor growth and metastasis. More specifically, we have shown that prostaglandin E-2 (PGE(2)) promotes cell proliferation and invasion through transactivation of the epidermal growth factor receptor, initiates immune evasion through induction of decay accelerating factor, and transactivates peroxisome proliferator-activated receptor sigma, leading to increased polyp size and multiplicity. We continue to identify novel PGE(2) target genes in colorectal carcinoma cells and report here that an immediate early gene, nuclear factor NR4A2 (Nurr1), is induced by PGE(2) that in turn regulates cell death. Originally described as a critical dopaminergic neuron growth factor receptor, NR4A2 expression is rapidly but transiently induced by PGE(2) in a cAMP/protein kinase A-dependent manner. NR4A2 binds to the cognate NBRE response element and enhances transcription of a reporter construct in colorectal carcinoma cells. Furthermore, NR4A2 expression is elevated in Apc(-/+) mouse adenomas and its levels were further increased following PGE(2) treatment. Human colorectal cancers relative to matched normal mucosa showed increased NR4A2 expression. Although not previously described in epithelial tissues, NR4A2 protein localizes to proliferating crypts of Apc(-/+) mouse intestine. Finally, functional studies reveal that PGE(2)-mediated protection from apoptosis is completely inhibited by a dominant-negative NR4A2 construct. Building on previous reports from our group on the peroxisome proliferator-activated receptor family of nuclear receptors, these most recent data suggest that NR4A2, a member of another family of nuclear receptors can stimulate progression of colorectal cancer downstream from cyclooxygenase 2-derived PGE(2).	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	DuBois, RN (corresponding author), 691 Preston Bldg,2300 Pierce Ave, Nashville, TN 37232 USA.	raymond.dubois@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297] Funding Source: NIH RePORTER; NCI NIH HHS [P0-CA-77839] Funding Source: Medline; NIDDK NIH HHS [R0-DK-62112, R37-DK47297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; Cha YI, 2005, DEV BIOL, V282, P274, DOI 10.1016/j.ydbio.2005.03.014; Chen YH, 2001, AM J MED GENET, V105, P753, DOI 10.1002/ajmg.10036; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Denkert C, 2003, CANCER-AM CANCER SOC, V97, P2978, DOI 10.1002/cncr.11437; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Gupta RA, 2003, CANCER RES, V63, P906; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Holla VR, 2005, J BIOL CHEM, V280, P476, DOI 10.1074/jbc.M407403200; Huang M, 1998, CANCER RES, V58, P1208; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kim KS, 2003, J NEUROCHEM, V85, P622, DOI 10.1046/j.1471-4159.2003.01671.x; Ladetto M, 2005, BLOOD, V105, P4784, DOI 10.1182/blood-2004-11-4201; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Newman SJ, 2000, BRAIN RES, V857, P131, DOI 10.1016/S0006-8993(99)02417-8; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Pirih FQ, 2004, J BIOL CHEM, V279, P53167, DOI 10.1074/jbc.M405677200; Raspollini MR, 2005, INT J GYNECOL CANCER, V15, P255, DOI 10.1111/j.1525-1438.2005.15212.x; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Ristimaki A, 2004, NOVART FDN SYMP, V256, P259; Ristimaki Ari, 2004, Novartis Found Symp, V256, P215; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Sakamoto A, 2004, BRIT J CANCER, V91, P633, DOI 10.1038/sj.bjc.6602009; Sharma S, 2003, CLIN CANCER RES, V9, P961; Sheng HM, 1998, CANCER RES, V58, P362; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; Thun Michael J, 2004, Novartis Found Symp, V256, P6; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Thun MJ, 2004, NOVART FDN SYMP, V256, P22; THUN MJ, 2004, NOVART FDN SYMP, V256, P49; THUN MJ, 2004, NOVART FDN SYMP, V256, P22; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zweifel BS, 2002, CANCER RES, V62, P6706	55	92	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2676	2682		10.1074/jbc.M507752200	http://dx.doi.org/10.1074/jbc.M507752200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16293616	hybrid			2022-12-25	WOS:000234931800033
J	Palmqvist, P; Lundberg, P; Persson, E; Johansson, A; Lundgren, I; Lie, A; Conaway, HH; Lerner, UH				Palmqvist, P; Lundberg, P; Persson, E; Johansson, A; Lundgren, I; Lie, A; Conaway, HH; Lerner, UH			Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROINFLAMMATORY CYTOKINES; MATURE OSTEOCLASTS; RECEPTOR ACTIVATOR; RESORBING ACTIVITY; MOUSE CALVARIAE; NUCLEAR-FACTOR; GENE-THERAPY; LIGAND; CELLS	Interleukin (IL)-4 and IL-13 are cytokines that inhibit bone resorption. Data showing an inhibitory effect of IL-4 and IL-13 on RANK mRNA in mouse calvariae were first reported at the 22nd American Society for Bone and Mineral Research Meeting (Lerner, U. H., and Conaway, H. H. 2000) J. Bone Min. Res. 15, Suppl. 1, Abstr. SU 230). In the present study, release of Ca-45 from cultured mouse calvarial bones stimulated by different cytokines, peptides, and steroid hormones was inhibited by IL-4 and IL-13. IL-4 and IL- 13 decreased receptor activator of nuclear factor-kappa B ligand (RANKL) and RANK mRNA and increased osteoprotegerin (OPG) mRNA in calvariae. Additionally, the cytokines decreased RANKL protein and increased OPG protein in calvarial bones. In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D-3 were reversed by IL-4 and IL-13. IL-4 and IL-13 decreased the number of tartrate-resistant acid phosphatase positive multinucleated cells and the mRNA expression of calcitonin receptor, tartrate-resistant acid phosphatase, and cathepsin K in mouse spleen cells and bone marrow macrophages (BMM) treated with macrophage colony-stimulating factor and RANKL. Inhibition of mRNA for RANK and the transcription factor NFAT2 was also noted in spleen cell and BMM cultures treated with IL-4 and IL-13. In addition, RANK mRNA and RANK protein were decreased by IL-4 and IL-13 in RAW 264.7 cells. Osteoblasts, spleen cells, and BMM expressed mRNA for the four proteins making up the IL-4 and IL- 13 receptors. No effects by IL-4 on bone resorption and osteoclast formation or on RANKL and RANK mRNA expression were seen in Stat6(-/-) mice. The data indicate that IL-4 and IL-13, via a STAT6-dependent pathway, inhibit osteoclast differentiation and bone resorption by activating receptors on osteoblasts and osteoclasts that affect the RANKL/RANK/OPG system.	Umea Univ, Dept Oral Cell Biol, S-90187 Umea, Sweden; Umea Univ, Dept Periodont, S-90187 Umea, Sweden; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	Umea University; Umea University; University of Arkansas System; University of Arkansas Medical Sciences	Lerner, UH (corresponding author), Umea Univ, Dept Oral Cell Biol, S-90187 Umea, Sweden.	ulf.lerner@odont.umu.se		Lerner, Ulf/0000-0002-3579-1960				Abu-Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530; Ahlen J, 2002, BONE, V31, P242, DOI 10.1016/S8756-3282(02)00784-6; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196; Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198; BOONEKAMP PM, 1984, P K NED AKAD B PHYS, V87, P371; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DEWHIRST FE, 1985, J IMMUNOL, V135, P2562; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; HOROWITZ J, 2002, PRINCIPLES BONE BIOL, P961; HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793; Joosten LAB, 1999, ARTHRITIS RES, V1, P81, DOI 10.1186/ar14; KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169-6009(08)80229-2; Kawaguchi H, 1996, J BONE MINER RES, V11, P358; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lee CK, 2004, ARTHRITIS RHEUM-US, V50, P3831, DOI 10.1002/art.20637; Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945-053X(00)00052-4; Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202; LERNER UH, 1987, J BONE MINER RES, V2, P375; LERNER UH, 2002, PRINCIPLES BONE BIOL, P961; Lerner UH, 1997, KININ SYSTEM, P219; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; LJUNGGREN O, 1991, J BONE MINER RES, V6, P543; Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739; Mangashetti LS, 2005, J IMMUNOL, V175, P917, DOI 10.4049/jimmunol.175.2.917; Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10; MIOSSEC P, 1994, ARTHRITIS RHEUM, V37, P1715, DOI 10.1002/art.1780371202; Mirosavljevic D, 2003, J BONE MINER RES, V18, P984, DOI 10.1359/jbmr.2003.18.6.984; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mohamed SGK, 2005, BIOCHEM BIOPH RES CO, V329, P839, DOI 10.1016/j.bbrc.2005.02.049; Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood-2002-11-3437; NAGASAKI K, 1991, BIOCHEM BIOPH RES CO, V178, P694, DOI 10.1016/0006-291X(91)90163-2; NAKANO Y, 1994, J BONE MINER RES, V9, P1533, DOI 10.1002/jbmr.5650091005; Okada Y, 1998, BONE, V22, P361, DOI 10.1016/S8756-3282(97)00296-2; Onoe Y, 1996, J IMMUNOL, V156, P758; Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353; RIANCHO JA, 1993, J BONE MINER RES, V8, P1337; SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313; TAKAHASHI N, 2002, PRINCIPLES BONE BIOL, P109; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006-291X(90)91550-C; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	53	94	104	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2414	2429		10.1074/jbc.M510160200	http://dx.doi.org/10.1074/jbc.M510160200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16251181	hybrid			2022-12-25	WOS:000234931800004
J	Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA				Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA			Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatitis B X antigen; E-cadherin; migration; hepatocellular carcinoma; beta-catenin	BETA-CATENIN; HBX PROTEIN; CELL-LINES; EXPRESSION; GENE; METHYLATION; ADHESION; LIVER; P53; PROGRESSION	Hepatitis B virus (HBV)-encoded X antigen (HBxAg) contributes to the development of hepatocellular carcinoma (HCC). A frequent characteristic of HCC is reduced or absent expression of the cell adhesion protein, E-cadherin, although it is not known whether HBxAg plays a role. To address this, the levels of E-cadherin were determined in HBxAg-positive and - negative HepG2 cells in culture, and in tumor and surrounding nontumor liver from a panel of HBV carriers. The results showed an inverse relationship between HBxAg and E-cadherin expression both in tissue culture and in vivo. In HBxAg-positive cells, E-cadherin was suppressed at both the mRNA and protein levels. This was associated with hypermethylation of the E-cadherin promoter. Depressed E-cadherin correlated with HBxAg trans-activation function, as did the migration of HepG2 cells in vitro. Decreased expression of E-cadherin was also associated with the accumulation of beta-catenin in the cytoplasm and/or nuclei in tissues and cell lines, which is characteristic of activated beta-catenin. Additional work showed that HBxAg-activated beta-catenin. Together, these results suggest that the HBxAg is associated with decreased expression of E-cadherin, accumulation of beta-catenin in the cytoplasm and nucleus, and increased cell migration, which may contribute importantly to hepatocarcinogenesis.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Dept Digest Dis, Xian 710032, Shaanxi, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; Second Mil Med Univ, Shanghai Eastern Hosp, Shanghai, Peoples R China; Second Mil Med Univ, Inst Hepatobil Surg, Shanghai, Peoples R China; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, ZA-2001 Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Air Force Military Medical University; Chinese University of Hong Kong; Naval Medical University; Naval Medical University; University of Witwatersrand; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Mark.Feitelson@jefferson.edu	Han, Shuang/AAE-6982-2020; Arbuthnot, Patrick Brian/B-8163-2009; Lian, Zhaorui/AAW-2379-2020; Wang, Hongyang/B-1340-2010; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008	韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917	NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656, R01CA066971] Funding Source: NIH RePORTER; NCI NIH HHS [CA66971, CA48656] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SH, 2002, KOREAN J HEPATOL, V8, P297; Calvisi DF, 2004, LAB INVEST, V84, P1137, DOI 10.1038/labinvest.3700147; CASELMANN WH, 1995, J HEPATOL, V22, P34; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feitelson MA, 1999, FALK SYMP, V103C, P156; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inayoshi J, 2003, J GASTROEN HEPATOL, V18, P673, DOI 10.1046/j.1440-1746.2003.03021.x; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Kanai Y, 1997, INT J CANCER, V71, P355; Kondoh N, 2001, INT J ONCOL, V18, P1271; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5; Lian ZR, 2003, NEOPLASIA, V5, P229, DOI 10.1016/S1476-5586(03)80055-6; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liu J, 2004, METH MOLEC MED, V95, P71; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593	43	87	100	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1008	1017		10.1038/sj.onc.1209138	http://dx.doi.org/10.1038/sj.onc.1209138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247464				2022-12-25	WOS:000235361000006
J	Malta, E; Moolenaar, GF; Goosen, N				Malta, E; Moolenaar, GF; Goosen, N			Base flipping in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RECOGNITION; C-TERMINAL REGION; CRYSTAL-STRUCTURE; UVRB PROTEIN; 2-AMINOPURINE FLUORESCENCE; THERMUS-THERMOPHILUS; UVRABC ENDONUCLEASE; PREINCISION COMPLEX; STRUCTURAL BASIS; CATALYTIC SITE	UvrB, the ultimate damage-binding protein in bacterial nucleotide excision repair is capable of binding a vast array of structurally unrelated lesions. A beta-hairpin structure in the protein plays an important role in damage-specific binding. In this paper we have monitored DNA conformational alterations in the UvrB-DNA complex, using the fluorescent adenine analogue 2-aminopurine. We show that binding of UvrB to a DNA fragment with cholesterol damage moves the base adjacent to the lesion at the 3' side into an extrahelical position. This extrahelical base is not accessible for acrylamide quenching, suggesting that it inserts into a pocket of the UvrB protein. Also the base opposite this flipped base is extruded from the DNA helix. The degree of solvent exposure of both residues varies with the type of cofactor (ADP/ATP) bound by UvrB. Fluorescence of the base adjacent to the damage is higher when UvrB is in the ADP-bound configuration, but concomitantly this UvrB-DNA complex is less stable. In the ATP-bound form the UvrB-DNA complex is very stable and in this configuration the base in the non-damaged strand is more exposed. Hairpin residue Tyr-95 is specifically involved in base flipping in the non-damaged strand. We present evidence that this conformational change in the non-damaged strand is important for 3' incision by UvrC.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, Mol Genet Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Goosen, N (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, Mol Genet Lab, Einsteinweg 55, NL-2300 RA Leiden, Netherlands.	N.Goosen@chem.leidenuniv.nl						Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Christine KS, 2002, J BIOL CHEM, V277, P38339, DOI 10.1074/jbc.M206531200; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goosen N, 2001, RES MICROBIOL, V152, P401, DOI 10.1016/S0923-2508(01)01211-6; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; LIN JJ, 1992, J BIOL CHEM, V267, P17688; Ma HX, 2004, BIOCHEMISTRY-US, V43, P4206, DOI 10.1021/bi0359933; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Moolenaar GF, 2005, DNA REPAIR, V4, P699, DOI 10.1016/j.dnarep.2005.03.001; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2002, P NATL ACAD SCI USA, V99, P1467, DOI 10.1073/pnas.032584099; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; Skorvaga M, 2004, J BIOL CHEM, V279, P51574, DOI 10.1074/jbc.M409266200; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; Van Houten B, 2005, MUTAT RES-FUND MOL M, V577, P92, DOI 10.1016/j.mrfmmm.2005.03.013; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; Verhoeven EEA, 2002, EMBO J, V21, P4196, DOI 10.1093/emboj/cdf396; Verhoeven EEA, 2002, NUCLEIC ACIDS RES, V30, P2492, DOI 10.1093/nar/30.11.2492; Verhoeven EEA, 2001, EMBO J, V20, P601, DOI 10.1093/emboj/20.3.601; VISSE R, 1992, J BIOL CHEM, V267, P6736; WARD DC, 1969, J BIOL CHEM, V244, P1228; Zou Y, 2004, BIOCHEMISTRY-US, V43, P4196, DOI 10.1021/bi035992a	41	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2184	2194		10.1074/jbc.M508901200	http://dx.doi.org/10.1074/jbc.M508901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16282327	Green Published, hybrid			2022-12-25	WOS:000234760400042
J	Wu, LM; Nakano, H; Wu, ZG				Wu, LM; Nakano, H; Wu, ZG			The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappa B through TRAF6 and TAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; LYMPHOCYTE GROWTH TRANSFORMATION; RECEPTOR-ASSOCIATED FACTORS; NASOPHARYNGEAL CARCINOMA; SIGNAL-TRANSDUCTION; BINDING-SITE; HONG-KONG; MEDIATES ACTIVATION; NF-KAPPA-B2 P100; KINASE PATHWAY	Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) is oncogenic and indispensable for EBV-mediated B cell transformation. LMP1 is capable of activating several intracellular signaling pathways including the NF-kappa B pathway, which contributes to the EBV-mediated cell transformation. Two regions in the cytoplasmic carboxyl tail of LMP1, namely C-terminal activating regions 1 and 2 (CTAR1 and CTAR2), are responsible for NF-kappa B activation, with CTAR2 being the main NF-kappa B activator. Although the CTAR1-mediated NF-kappa B activation was previously shown to be TRAF3-dependent, we showed here that the CTAR2-mediated NF-kappa B activation is mainly TRAF6-dependent but TRAF2/5-independent. In contrast to the interleukin-1 receptor/toll-like receptor-mediated NF-kappa B pathways, the CTAR2-mediated NF-kappa B pathway does not require MyD88, IRAK1, or IRAK4 for TRAF6 engagement. Furthermore, we showed that TAK1 is required for NF-kappa B activation by LMP1. Thus, LMP1 utilizes two distinct pathways to activate NF-kappa B: a major one through CTAR2/TRAF6/TAK1/IKK beta (canonical pathway) and a minor one through CTAR1/TRAF3/NIK/IKK alpha (noncanonical pathway).	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan	Hong Kong University of Science & Technology; Juntendo University	Wu, ZG (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, ClearWater Bay, Kowloon, Hong Kong, Peoples R China.	bczgwu@ust.hk	Wu, liming/AAH-5415-2019; Wu, Liming/C-4004-2011	Wu, Zhenguo/0000-0003-3049-8324; Nakano, Hiroyasu/0000-0003-4843-1427				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Chan BCL, 2002, INT J CANCER, V102, P492, DOI 10.1002/ijc.10773; Cheung ST, 1998, INT J CANCER, V76, P399, DOI 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6; Chung JY, 2002, J CELL SCI, V115, P679; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; HUEN DS, 1995, ONCOGENE, V10, P549; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee AWM, 2003, INT J CANCER, V103, P680, DOI 10.1002/ijc.10894; Li XX, 1999, MOL CELL BIOL, V19, P4643; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Moss DJ, 1996, ADV CANCER RES, V69, P213, DOI 10.1016/S0065-230X(08)60864-7; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xie P, 2004, J IMMUNOL, V173, P5546, DOI 10.4049/jimmunol.173.9.5546; Xie P, 2004, J EXP MED, V199, P661, DOI 10.1084/jem.20031255; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	58	56	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2162	2169		10.1074/jbc.M505903200	http://dx.doi.org/10.1074/jbc.M505903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16280329	hybrid			2022-12-25	WOS:000234760400039
J	Moeller, ML; Shi, Y; Reichardt, LF; Ethell, IM				Moeller, ML; Shi, Y; Reichardt, LF; Ethell, IM			EphB receptors regulate dendritic spine morphogenesis through the recruitment/phosphorylation of focal adhesion kinase and RhoA activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; SMALL GTPASES; EPHRINS; PROTEIN; GROWTH; FAK; PHOSPHORYLATION; MECHANISMS; PAXILLIN; ROLES	Dendritic filopodia are small protrusions on the surface of neuronal dendrites that transform into dendritic spines upon synaptic contact with axon terminals. The formation of dendritic spines is a critical aspect of synaptic development. Dendritic spine morphogenesis is characterized by filopodia shortening followed by the formation of mature mushroom-shaped spines. Here we show that activation of the EphB receptor tyrosine kinases in cultured hippocampal neurons by their ephrinB ligands induces morphogenesis of dendritic filopodia into dendritic spines. This appears to occur through assembly of an EphB-associated protein complex that includes focal adhesion kinase (FAK), Src, Grb2, and paxillin and the subsequent activations of FAK, Src, paxillin, and RhoA. Furthermore, Cre- mediated knock- out of loxP-flanked fak or RhoA inhibition blocks EphB-mediated morphogenesis of dendritic filopodia. Finally, EphB-mediated RhoA activation is disrupted by FAK knock- down. These data suggest that EphB receptors are upstream regulators of FAK in dendritic filopodia and that FAK-mediated RhoA activation contributes to assembly of actin filaments in dendritic spines.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California Riverside; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ethell, IM (corresponding author), Univ Calif Riverside, Div Biomed Sci, B601 Stat Rd, Riverside, CA 92521 USA.	iryna.ethell@ucr.edu		Ethell, Iryna/0000-0002-1324-6611	NIMH NIH HHS [MH67121, R01 MH067121-04] Funding Source: Medline; NINDS NIH HHS [NS19090] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Govek EE, 2004, NAT NEUROSCI, V7, P364, DOI 10.1038/nn1210; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henkemeyer M, 2003, J CELL BIOL, V163, P1313, DOI 10.1083/jcb.200306033; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Li WQ, 2004, NAT NEUROSCI, V7, P1213, DOI 10.1038/nn1329; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Meriane M, 2004, J CELL BIOL, V167, P687, DOI 10.1083/jcb.200405053; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nikolopoulos SN, 2005, CELL CYCLE, V4, P429, DOI 10.4161/cc.4.3.1547; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Rossner M, 2004, J CELL BIOL, V166, P11, DOI 10.1083/jcb.200406019; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Tashiro A, 2004, MOL CELL NEUROSCI, V26, P429, DOI 10.1016/j.mcn.2004.04.001; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515	41	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1587	1598		10.1074/jbc.M511756200	http://dx.doi.org/10.1074/jbc.M511756200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16298995	hybrid			2022-12-25	WOS:000234652000037
J	Ogino, K; Masai, H				Ogino, K; Masai, H			Rad3-Cds1 mediates coupling of initiation of meiotic recombination with DNA replication - Mei4-dependent transcription as a potential target of meiotic checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; MEIOSIS; GENES; ENCODES; BREAKS; SEGREGATION; CHROMOSOME; EXPRESSION; MUTANTS	Premeiotic S-phase and meiotic recombination are known to be strictly coupled in Saccharomyces cerevisiae. However, the checkpoint pathway regulating this coupling has been largely unknown. In fission yeast, Rad3 is known to play an essential role in coordination of DNA replication and cell division during both mitotic growth and meiosis. Here we have examined whether the Rad3 pathway also regulates the coupling of DNA synthesis and recombination. Inhibition of premeiotic S-phase with hydroxyurea completely abrogates the progression of meiosis, including the formation of DNA double-strand breaks (DSBs). DSB formation is restored in rad3 mutant even in the presence of hydroxyurea, although repair of DSBs does not take place or is significantly delayed, indicating that the subsequent recombination steps may be still inhibited. Examination of the roles of downstream checkpoint kinases reveals that Cds1, but not Chk1 or Mek1, is required for suppression of DSB in the presence of hydroxyurea. Transcriptional induction of some rec(+) genes essential for DSB occurs at a normal timing and to a normal level in the absence of DNA synthesis in both the wild-type and cds1 Delta cells. On the other hand, the transcriptional induction of the mei4(+) transcription factor and cdc25(+) phosphatase, which is significantly suppressed by hydroxyurea in the wild-type cells, occurs almost to a normal level in cds1 Delta cells even in the presence of hydroxyurea. These results show that the Rad3-Cds1 checkpoint pathway coordinates initiation of meiotic recombination and meiotic cell divisions with premeiotic DNA synthesis. Because mei4(+) is known to be required for DSB formation and cdc25(+) is required for activation of meiotic cell divisions, we propose an intriguing possibility that the Rad3-Cds1 meiotic checkpoint pathway may target transcription of these factors.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						Abe H, 2000, GENETICS, V154, P1497; Borde V, 2000, SCIENCE, V290, P806, DOI 10.1126/science.290.5492.806; Cervantes MD, 2000, MOL CELL, V5, P883, DOI 10.1016/S1097-2765(00)80328-7; Davis L, 2001, P NATL ACAD SCI USA, V98, P8395, DOI 10.1073/pnas.121005598; Gregan J, 2005, CURR BIOL, V15, P1663, DOI 10.1016/j.cub.2005.07.059; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1995, GENETICS, V140, P1235; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; ISSHIKI T, 1992, GENE DEV, V6, P2455, DOI 10.1101/gad.6.12b.2455; LIN YK, 1994, GENETICS, V136, P769; Mizuno K, 1997, GENE DEV, V11, P876, DOI 10.1101/gad.11.7.876; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; Murakami H, 2003, NUCLEIC ACIDS RES, V31, P4085, DOI 10.1093/nar/gkg441; Murakami H, 2001, NAT GENET, V28, P290, DOI 10.1038/90142; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; Perez-Hidalgo L, 2003, J CELL SCI, V116, P259, DOI 10.1242/jcs.00232; Shimada M, 2002, EMBO J, V21, P2807, DOI 10.1093/emboj/21.11.2807; Smith KN, 2001, CURR BIOL, V11, P88, DOI 10.1016/S0960-9822(01)00026-4; Steiner WW, 2002, MOL CELL, V9, P847, DOI 10.1016/S1097-2765(02)00489-6; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Tonami Y, 2005, P NATL ACAD SCI USA, V102, P5797, DOI 10.1073/pnas.0407236102; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; Young JA, 2004, GENETICS, V167, P593, DOI 10.1534/genetics.103.023762	26	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1338	1344		10.1074/jbc.M505767200	http://dx.doi.org/10.1074/jbc.M505767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16286472	hybrid			2022-12-25	WOS:000234652000008
J	Brazzolotto, X; Rubach, JK; Gaillard, J; Gambarelli, S; Atta, M; Fontecave, M				Brazzolotto, X; Rubach, JK; Gaillard, J; Gambarelli, S; Atta, M; Fontecave, M			The [Fe-Fe]-hydrogenase maturation protein HydF from Thermotoga maritima is a GTPase with an iron-sulfur cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE HYDROGENASE HMD; FE ACTIVE-SITE; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; CARBON-MONOXIDE; INFRARED-SPECTROSCOPY; LIGHT-INACTIVATION; RADICAL SAM; ENZYMES; INSERTION	The active site of [Fe-Fe]-hydrogenases is composed of a di-iron complex, where the two metal atoms are bridged together by a putative di(thiomethyl) amine molecule and are also ligated by di-nuclear ligands, namely carbon monoxide and cyanide. Biosynthesis of this metal site is thought to require specific protein machinery coded by the hydE, hydF, and hydG genes. The HydF protein has been cloned from the thermophilic organism Thermotoga maritima, purified, and characterized. The enzyme possesses specific amino acid signatures for GTP binding and is able to hydrolyze GTP. The anaerobically reconstituted TmHydF protein binds a [4Fe-4S] cluster with peculiar EPR characteristics: an S = 1/2 signal presenting a high field shifted g-value together with a S = 3/2 signal, similar to those observed for [4Fe-4S] clusters ligated by only three cysteines. HYSCORE spectroscopy experiments were carried out to determine the nature of the fourth ligand of the cluster, and its exchangeability was demonstrated with the formation of a [4Fe-4S]imidazole complex.	Univ Grenoble 1, UMR, Lab Chim & Biochim,Dept Reponses,Dynam Cellulaire, Ctr Redox Biol,UMR,CNRS,Commissariat Energie Atom, F-38054 Grenoble 9, France; Univ Grenoble 1, Lab Chim Inorgan & Biol, UMR E 3,Dept Rech Fondamentale Mat Condensee, Commissariat Energie Atom,Cea Grenoble, F-38054 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, UMR, Lab Chim & Biochim,Dept Reponses,Dynam Cellulaire, Ctr Redox Biol,UMR,CNRS,Commissariat Energie Atom, 5047,17 Rue Des Martyrs, F-38054 Grenoble 9, France.	mfontecave@cea.fr	Brazzolotto, Xavier/GXG-3805-2022	Brazzolotto, Xavier/0000-0001-9219-1032				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Blokesch M, 2002, BIOCHEM SOC T, V30, P674, DOI 10.1042/BST0300674; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Dikanov SA, 1996, J AM CHEM SOC, V118, P8408, DOI 10.1021/ja960781x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLINT DH, 1993, J BIOL CHEM, V268, P14732; Fontecave M, 2003, CHEM REV, V103, P2149, DOI 10.1021/cr020427j; Fontecave M, 2002, PROG NUCLEIC ACID RE, V72, P95, DOI 10.1016/S0079-6603(02)72068-0; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Guigliarelli B, 1999, ADV INORG CHEM, V47, P421, DOI 10.1016/S0898-8838(08)60084-7; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Jeon WB, 2001, J BIOL CHEM, V276, P38602, DOI 10.1074/jbc.M104945200; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Lyon EJ, 2004, J AM CHEM SOC, V126, P14239, DOI 10.1021/ja046818s; Maryasov AG, 2004, J PHYS CHEM B, V108, P9412, DOI 10.1021/jp034912+; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; Nicolet Y, 2002, J INORG BIOCHEM, V91, P1, DOI 10.1016/S0162-0134(02)00392-6; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Pierik AJ, 1998, EUR J BIOCHEM, V258, P572, DOI 10.1046/j.1432-1327.1998.2580572.x; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Posewitz MC, 2004, J BIOL CHEM, V279, P25711, DOI 10.1074/jbc.M403206200; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Roseboom W, 2005, FEBS LETT, V579, P469, DOI 10.1016/j.febslet.2004.12.013; Rubach JK, 2005, FEBS LETT, V579, P5055, DOI 10.1016/j.febslet.2005.07.092; Rubio LM, 2005, J BACTERIOL, V187, P405, DOI 10.1128/JB.187.2.405-414.2005; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; Schweiger A., 2001, PRINCIPLES PULSE ELE; Shima S, 2005, J AM CHEM SOC, V127, P10430, DOI 10.1021/ja051895o; Shima S, 2004, ANGEW CHEM INT EDIT, V43, P2547, DOI 10.1002/anie.200353763; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tyryshkin AM, 1999, J AM CHEM SOC, V121, P3396, DOI 10.1021/ja982085y; VanderSpek TM, 1996, EUR J BIOCHEM, V237, P629; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0	44	108	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					769	774		10.1074/jbc.M510310200	http://dx.doi.org/10.1074/jbc.M510310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278209	Green Submitted, hybrid			2022-12-25	WOS:000234447200013
J	de Almeida, RA; Heuser, T; Blaschke, R; Bartram, CR; Janssen, JWG				de Almeida, RA; Heuser, T; Blaschke, R; Bartram, CR; Janssen, JWG			Control of MYEOV protein synthesis by upstream open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL RIBOSOME ENTRY; SQUAMOUS-CELL CARCINOMAS; TRANS-ACTING FACTORS; HUMAN BREAST-CANCER; DNA AMPLIFICATION; GENE-EXPRESSION; RNA TRANSLATION; POLIOVIRUS RNA; CYCLIN D1; INITIATION	The myeov gene has been isolated by the tumorigenicity assay and is localized at chromosome 11q13, a frequent site for chromosomal rearrangements in various carcinomas and B-cell neoplasms. In addition, myeov is coamplified with cyclin D1 and overexpressed in carcinomas of various organs. The mechanisms of myeov regulation remain enigmatic. The 5'-untranslated region (5'-UTR) of the myeov gene is long, encompasses several upstream AUGs, and is predicted to fold in a strong secondary structure, suggesting that its translation might be regulated by an internal ribosomal entry site. Here we show that initial experiments using monocistronic and dicistronic reporter constructs supported this assumption. However, the application of in vitro transcription/translation assays, Northern blot analysis, and promoterless dicistronic constructs revealed promoter activity of the myeov 5'-UTR. DNA transfection of dicistronic DNA constructs, normal and mutated forms of myeov cDNA fragments cloned in a eukaryotic expression vector, and direct RNA transfection analysis revealed that upstream AUG triplets in the 5'-UTR of the myeov transcript abrogate translation. Alternative splicing mechanisms in specific cell types and/or developmental stage may evade this translation control. Control experiments suggest that the 5'-UTR from encephalomyocarditis virus, when inserted at the midpoint of a dicistronic vector, is also able to function as a cryptic promoter.	Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Janssen, JWG (corresponding author), Univ Heidelberg, Inst Human Genet, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	hans_janssen@med.uniheidelberg.de						Blaschke RJ, 2003, J BIOL CHEM, V278, P47820, DOI 10.1074/jbc.M306685200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hernandez-Sanchez C, 2003, EMBO J, V22, P5582, DOI 10.1093/emboj/cdg515; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Janssen JWG, 2000, BLOOD, V95, P2691; Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Noti JD, 1996, BIOTECHNIQUES, V20, P174; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	36	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					695	704		10.1074/jbc.M511467200	http://dx.doi.org/10.1074/jbc.M511467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16275643	hybrid			2022-12-25	WOS:000234447200005
J	Feng, WK; Benz, FW; Cai, J; Pierce, WM; Kang, YJ				Feng, WK; Benz, FW; Cai, J; Pierce, WM; Kang, YJ			Metallothionein disulfides are present in metallothionein-overexpressing transgenic mouse heart and increase under conditions of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOXORUBICIN CARDIOTOXICITY; ZINC-METALLOTHIONEIN; INHIBITION; CLUSTERS; RELEASE; HOMEOSTASIS; RADICALS; KINETICS; PROTEIN; SITES	Metallothionein (MT) releases zinc under oxidative stress conditions in cultured cells. The change in the MT molecule after zinc release in vivo is unknown although in vitro studies have identified MT disulfide bond formation. The present study was undertaken to test the hypothesis that MT disulfide bond formation occurs in vivo. A cardiac-specific MT-overexpressing transgenic mouse model was used. Mice were administered saline as a control or doxorubicin ( 20 mg/kg), which is an effective anticancer drug but with severe cardiac toxicity at least partially because of the generation of reactive oxygen species. A differential alkylation of cysteine residues in MT of the heart extracts was performed. Free and metal-bound cysteines were first trapped by N-ethylmaleimide and the disulfide bonds were reduced by dithiothreitol followed by alkylation with radiolabeled iodoacetamide. Analyses of the differentially alkylated MTs in the heart extract by high preformance liquid chromatography, SDS-PAGE, Western blot, and mass spectrometry revealed that disulfide bonds were present in MT in vivo under both physiological and oxidative stress conditions. More disulfide bonds were found in MT under the oxidative stress conditions. The MT disulfide bonds were likely intramolecular and both alpha- and beta-domains were involved in the disulfide bond formation, although the alpha-domain appeared to be more easily oxidized than the beta-domain. The results suggest that under physiological conditions, the formation of MT disulfide bonds is involved in the regulation of zinc homeostasis. Additional zinc release from MT under oxidative stress conditions is accompanied by more MT disulfide bond formation.	Univ Louisville, Dept Med, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Kang, YJ (corresponding author), Univ Louisville, Dept Med, Louisville, KY 40292 USA.	yjkang01@louisville.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063760, R01HL059225] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59225, HL63760] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; Cai L, 2000, J BIOL CHEM, V275, P38957, DOI 10.1074/jbc.C000593200; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; Hathout Y, 2002, J INORG BIOCHEM, V88, P119, DOI 10.1016/S0162-0134(01)00375-0; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Jimenez I, 1997, TOXICOLOGY, V120, P37, DOI 10.1016/S0300-483X(97)03638-X; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Kang YJ, 2003, AM J PATHOL, V163, P1579, DOI 10.1016/S0002-9440(10)63514-6; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KLEIN D, 1994, ANAL BIOCHEM, V221, P405, DOI 10.1006/abio.1994.1434; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; Romero-Isart N, 2002, J INORG BIOCHEM, V88, P388, DOI 10.1016/S0162-0134(01)00347-6; Roschitzki B, 2003, BIOCHEMISTRY-US, V42, P9822, DOI 10.1021/bi034816z; SAVAS MM, 1993, J INORG BIOCHEM, V52, P235, DOI 10.1016/0162-0134(93)80028-8; Shaw CF, 1997, J BIOL INORG CHEM, V2, P65, DOI 10.1007/s007750050107; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; St Croix CM, 2002, AM J PHYSIOL-LUNG C, V282, pL185, DOI 10.1152/ajplung.00267.2001; STILLMAN MJ, 1995, COORDIN CHEM REV, V144, P461, DOI 10.1016/0010-8545(95)01173-M; Sun XH, 2002, EXP BIOL MED, V227, P652, DOI 10.1177/153537020222700815; Sun XH, 2001, CANCER RES, V61, P3382; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Vaher M, 2001, J INORG BIOCHEM, V83, P1, DOI 10.1016/S0162-0134(00)00183-5; VASAK M, 1983, MET IONS BIOL SYST, P218; Zangger K, 2001, BIOCHEM J, V359, P353, DOI 10.1042/0264-6021:3590353; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje	31	87	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					681	687		10.1074/jbc.M506956200	http://dx.doi.org/10.1074/jbc.M506956200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16243847	hybrid			2022-12-25	WOS:000234447200003
J	Kawamori, D; Kaneto, H; Nakatani, Y; Matsuoka, T; Matsuhisa, M; Hori, M; Yamasaki, Y				Kawamori, D; Kaneto, H; Nakatani, Y; Matsuoka, T; Matsuhisa, M; Hori, M; Yamasaki, Y			The forkhead transcription factor foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; INSULIN GENE-TRANSCRIPTION; NUCLEAR-LOCALIZATION SIGNAL; JUN NH2-TERMINAL KINASE; OXIDATIVE STRESS; GLUCOSE TOXICITY; MEDIATED SUPPRESSION; HIT-T15 CELLS; GK RATS; EXPRESSION	It has been shown that oxidative stress and activation of the c-Jun N-terminal kinase (JNK) pathway induce the nucleocytoplasmic translocation of the pancreatic transcription factor PDX-1, which leads to pancreatic beta-cell dysfunction. In this study, we have shown that the forkhead transcription factor Foxo1/FKHR plays a role as a mediator between the JNK pathway and PDX-1. Under oxidative stress conditions, Foxo1 changed its intracellular localization from the cytoplasm to the nucleus in the pancreatic beta-cell line HIT-T15. The overexpression of JNK also induced the nuclear localization of Foxo1, but in contrast, suppression of JNK reduced the oxidative stress-induced nuclear localization of Foxo1, suggesting the involvement of the JNK pathway in Foxo1 translocation. In addition, oxidative stress or activation of the JNK pathway decreased the activity of Akt in HIT cells, leading to the decreased phosphorylation of Foxo1 following nuclear localization. Furthermore, adenovirus-mediated Foxo1 overexpression reduced the nuclear expression of PDX-1, whereas repression of Foxo1 by Foxo1-specific small interfering RNA retained the nuclear expression of PDX-1 under oxidative stress conditions. Taken together, Foxo1 is involved in the nucleocytoplasmic translocation of PDX-1 by oxidative stress and the JNK pathway.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut A8, Suita, Osaka 5650871, Japan	Osaka University	Kaneto, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut A8, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneto@medone.med.osaka-u.ac.jp						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Gorogawa S, 2002, DIABETES RES CLIN PR, V57, P1, DOI 10.1016/S0168-8227(02)00005-0; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hessabi B, 1999, EUR J BIOCHEM, V263, P170, DOI 10.1046/j.1432-1327.1999.00481.x; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Ihara Y, 2000, FEBS LETT, V473, P24, DOI 10.1016/S0014-5793(00)01489-7; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Kahn C Ronald, 2003, Exp Diabesity Res, V4, P169, DOI 10.1155/EDR.2003.169; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Offield MF, 1996, DEVELOPMENT, V122, P983; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Okamoto H, 2003, J BIOL CHEM, V278, P28359, DOI 10.1074/jbc.R300009200; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	59	197	211	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1091	1098		10.1074/jbc.M508510200	http://dx.doi.org/10.1074/jbc.M508510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282329	hybrid			2022-12-25	WOS:000234447200050
J	Oh, MC; Derkach, VA; Guire, ES; Soderling, TR				Oh, MC; Derkach, VA; Guire, ES; Soderling, TR			Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; BIDIRECTIONAL SYNAPTIC PLASTICITY; 2 DISTINCT MECHANISMS; HIPPOCAMPAL-NEURONS; LATERAL MOVEMENTS; PYRAMIDAL NEURONS; SUBUNIT; SYNAPSES; DEPRESSION; LTP	Enhancement of synaptic transmission, as occurs in long-term potentiation (LTP), can result from several mechanisms that are regulated by phosphorylation of the AMPA-type glutamate receptor (AMPAR). Using a quantitative assay of net serine 845 (Ser-845) phosphorylation in the GluR1 subunit of AMPARs, we investigated the relationship between phospho-Ser-845, GluR1 surface expression, and synaptic strength in hippocampal neurons. About 15% of surface AMPARs in cultured neurons were phosphorylated at Ser845 basally, whereas chemical potentiation (forskolin/rolipram treatment) persistently increased this to 60% and chemical depression (N-methyl-D-aspartate treatment) decreased it to 10%. These changes in Ser-845 phosphorylation were paralleled by corresponding changes in the surface expression of AMPARs in both cultured neurons and hippocampal slices. For every 1% increase in net phos-pho-Ser-845, there was 0.75% increase in the surface fraction of GluR1. Phosphorylation of Ser-845 correlated with a selective delivery of AMPARs to extrasynaptic sites, and their synaptic localization required coincident synaptic activity. Furthermore, increasing the extrasynaptic pool of AMPA receptors resulted in stronger theta burst LTP. Our results support a two-step model for delivery of GluR1-containing AMPARs to synapses during activity-dependent LTP, where Ser-845 phosphorylation can traffic AMPARs to extrasynaptic sites for subsequent delivery to synapses during LTP.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Oregon Health & Science University	Soderling, TR (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	soderlit@ohsu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037, F30NS047773] Funding Source: NIH RePORTER; NINDS NIH HHS [NS47773, NS27037] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrasfalvy BK, 2004, J PHYSIOL-LONDON, V559, P543, DOI 10.1113/jphysiol.2004.065219; Andrasfalvy BK, 2003, J PHYSIOL-LONDON, V552, P35, DOI 10.1113/jphysiol.2003.045575; Ashby MC, 2004, J NEUROSCI, V24, P5172, DOI 10.1523/JNEUROSCI.1042-04.2004; Atkins CM, 2005, J NEUROSCI, V25, P5604, DOI 10.1523/JNEUROSCI.5051-04.2005; Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Derkach VA, 2003, BIOPHYS J, V84, P1701, DOI 10.1016/S0006-3495(03)74978-9; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Otmakhov N, 2004, J NEUROSCI, V24, P9324, DOI 10.1523/JNEUROSCI.2350-04.2004; Otmakhov N, 2004, J NEUROPHYSIOL, V91, P1955, DOI 10.1152/jn.00941.2003; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Snyder EM, 2005, J BIOL CHEM; Stein V, 2003, J NEUROSCI, V23, P5503; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Thomas-Crusells J, 2003, J NEUROSCI METH, V125, P159, DOI 10.1016/S0165-0270(03)00050-5; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2005, NEURON, V45, P269, DOI 10.1016/j.neuron.2005.01.009; Triller A, 2005, TRENDS NEUROSCI, V28, P133, DOI 10.1016/j.tins.2005.01.001; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005	40	363	373	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					752	758		10.1074/jbc.M509677200	http://dx.doi.org/10.1074/jbc.M509677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272153	hybrid			2022-12-25	WOS:000234447200011
J	Pardo, B; Contreras, L; Serrano, A; Ramos, M; Kobayashi, K; Iijima, M; Saheki, T; Satrustegui, J				Pardo, B; Contreras, L; Serrano, A; Ramos, M; Kobayashi, K; Iijima, M; Saheki, T; Satrustegui, J			Essential role of aralar in the transduction of small Ca2+ signals to neuronal mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART MITOCHONDRIA; ISLET BETA-CELLS; OXIDATIVE-PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; GLUTAMATE CARRIER; CALCIUM; NADH; METABOLISM; DEHYDROGENASE	Aralar, the neuronal Ca2+-binding mitochondrial aspartate-glutamate carrier, has Ca2+ binding domains facing the extramitochondrial space and functions in the malate-aspartate NADH shuttle (MAS). Here we showed that MAS activity in brain mitochondria is stimulated by extramitochondrial Ca2+ with an S-0.5 of 324 nM. By employing primary neuronal cultures from control and aralar-deficient mice and NAD(P) H imaging with two-photon excitation microscopy, we showed that lactate utilization involves a substantial transfer of NAD(P) H to mitochondria in control but not aralar-deficient neurons, in agreement with the lack of MAS activity associated with aralar deficiency. The increase in mitochondrial NAD(P) H was greatly potentiated by large [Ca2+](i) signals both in control and aralar-deficient neurons, showing that these large signals activate the Ca2+ uniporter and mitochondrial dehydrogenases but not MAS activity. On the other hand, small [Ca2+](i) signals potentiate the increase in mitochondrial NAD(P) H only in control but not in aralar-deficient neurons. We concluded that neuronal MAS activity is selectively activated by small Ca2+ signals that fall below the activation range of the Ca2+ uniporter and plays an essential role in mitochondrial Ca2+ signaling.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Kagoshima Univ, Grad Sc Med & Dent Sci, Dept Mol Metab & Biochem Genet, Kagoshima 8908544, Japan	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Kagoshima University	Satrustegui, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain.	jsatrustegui@cbm.uam.es	Contreras, Laura/ABG-7620-2021; Satrustegui, Jorgina/R-6732-2019; Contreras, Laura/A-2296-2015	Contreras, Laura/0000-0003-1157-4942; Serrano, Antonio/0000-0003-1993-640X; Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; RAMOS GOMEZ, MILAGROS/0000-0001-5798-9508				AVIDOR Y, 1962, J BIOL CHEM, V237, P2377; Basheer R, 2002, J NEUROSCI, V22, P7680; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bliss TM, 2004, J NEUROSCI, V24, P6202, DOI 10.1523/JNEUROSCI.0805-04.2004; Brandes R, 1999, BIOPHYS J, V77, P1666, DOI 10.1016/S0006-3495(99)77014-1; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; CHANCE B, 1958, J BIOL CHEM, V233, P736; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hayakawa Y, 2005, CELL CALCIUM, V37, P359, DOI 10.1016/j.ceca.2004.11.005; He XP, 2000, J CELL BIOL, V149, P783, DOI 10.1083/jcb.149.4.783; Jalil MA, 2005, J BIOL CHEM, V280, P31333, DOI 10.1074/jbc.M505286200; Kann O, 2003, NEUROSCIENCE, V119, P87, DOI 10.1016/S0306-4522(03)00026-5; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Lalo U, 1998, DEV BRAIN RES, V111, P43, DOI 10.1016/S0165-3806(98)00120-5; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Li Z, 1999, NEUROSCIENCE, V93, P667, DOI 10.1016/S0306-4522(99)00168-2; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; MCCORMACK JG, 1988, BIOCHIM BIOPHYS ACTA, V934, P282, DOI 10.1016/0005-2728(88)90088-6; Mironov SL, 2001, J PHYSIOL-LONDON, V533, P227, DOI 10.1111/j.1469-7793.2001.0227b.x; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nguyen NHT, 2003, J NEUROCHEM, V85, P831, DOI 10.1046/j.1471-4159.2003.01762.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; O'Donnell JM, 2004, AM J PHYSIOL-HEART C, V286, pH2237, DOI 10.1152/ajpheart.01113.2003; O'Donnell JM, 1998, AM J PHYSIOL-HEART C, V274, pH467, DOI 10.1152/ajpheart.1998.274.2.H467; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PASSONNEAU JV, 1974, METHOD ENZYMAT AN, P1452; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Pellerin L, 2004, SCIENCE, V305, P50, DOI 10.1126/science.1100428; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pitter JG, 2005, CELL CALCIUM, V37, P35, DOI 10.1016/j.ceca.2004.06.004; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Ramos M, 2003, DEV BRAIN RES, V143, P33, DOI 10.1016/S0165-3806(03)00097-X; Ramoz N, 2004, AM J PSYCHIAT, V161, P662, DOI 10.1176/appi.ajp.161.4.662; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rocheleau JV, 2002, J BIOL CHEM, V277, P30914, DOI 10.1074/jbc.M202314200; Roesch K, 2004, HUM MOL GENET, V13, P2101, DOI 10.1093/hmg/ddh217; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Ruiz F, 1998, NEUROREPORT, V9, P1277; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Sinasac DS, 2004, MOL CELL BIOL, V24, P527, DOI 10.1128/MCB.24.2.527-536.2004; SLUSE FE, 1973, EUR J BIOCHEM, V32, P283, DOI 10.1111/j.1432-1033.1973.tb02609.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Tretter L, 2000, J NEUROSCI, V20, P8972; VICARIO C, 1991, J NEUROCHEM, V57, P1700, DOI 10.1111/j.1471-4159.1991.tb06370.x; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134	66	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1039	1047		10.1074/jbc.M507270200	http://dx.doi.org/10.1074/jbc.M507270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16269409	hybrid			2022-12-25	WOS:000234447200044
J	Schulz, TJ; Thierbach, R; Voigt, A; Drewes, G; Mietzner, B; Steinberg, P; Pfeiffer, AFH; Ristow, M				Schulz, TJ; Thierbach, R; Voigt, A; Drewes, G; Mietzner, B; Steinberg, P; Pfeiffer, AFH; Ristow, M			Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth - Otto Warburg revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FRIEDREICH-ATAXIA; IN-VIVO; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; GLYCEMIC LOAD; IRON; LIVER; DEFICIENCY; FRUCTOSE	More than 80 years ago Otto Warburg suggested that cancer might be caused by a decrease in mitochondrial energy metabolism paralleled by an increase in glycolytic flux. In later years, it was shown that cancer cells exhibit multiple alterations in mitochondrial content, structure, function, and activity. We have stably overexpressed the Friedreich ataxia-associated protein frataxin in several colon cancer cell lines. These cells have increased oxidative metabolism, as shown by concurrent increases in aconitase activity, mitochondrial membrane potential, cellular respiration, and ATP content. Consistent with Warburg's hypothesis, we found that frataxin-overexpressing cells also have decreased growth rates and increased population doubling times, show inhibited colony formation capacity in soft agar assays, and exhibit a reduced capacity for tumor formation when injected into nude mice. Furthermore, overexpression of frataxin leads to an increased phosphorylation of the tumor suppressor p38 mitogen-activated protein kinase, as well as decreased phosphorylation of extracellular signal-regulated kinase. Taken together, these results support the view that an increase in oxidative metabolism induced by mitochondrial frataxin may inhibit cancer growth in mammals.	Univ Jena, Inst Nutr, Dept Human Nutr, D-07743 Jena, Germany; Univ Potsdam, Inst Nutr, Dept Nutr Toxicol, D-14558 Nuthetal, Germany; German Inst Human Nutr Potsdam Rehbrucke, D-14558 Nuthetal, Germany; Charite, D-12203 Berlin, Germany	Friedrich Schiller University of Jena; University of Potsdam; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ristow, M (corresponding author), Univ Jena, Inst Nutr, Dept Human Nutr, 29 Dornburger St, D-07743 Jena, Germany.	michael.ristow@mristow.org	Pfeiffer, Andreas F.H./AAJ-2311-2020; Ristow, Michael/O-9858-2014; Schulz, Tim/F-4842-2013	Pfeiffer, Andreas F.H./0000-0002-6887-0016; Ristow, Michael/0000-0003-2109-2453; Schulz, Tim/0000-0002-8413-3972				Ausubel F, 1997, SHORT PROTOCOLS MOL; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; CHAMBERLAIN S, 1982, J NEUROL NEUROSUR PS, V45, P1136, DOI 10.1136/jnnp.45.12.1136; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Cuezva JM, 2002, CANCER RES, V62, P6674; ENZMANN H, 1989, CARCINOGENESIS, V10, P1247, DOI 10.1093/carcin/10.7.1247; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; Higginbotham S, 2004, JNCI-J NATL CANCER I, V96, P229, DOI 10.1093/jnci/djh020; Isaya G, 2004, ACTA PAEDIATR, V93, P68, DOI 10.0180/08035320310021318; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jiralerspong S, 1997, NEUROBIOL DIS, V4, P103, DOI 10.1006/nbdi.1997.0139; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; MAENPAA PH, 1968, SCIENCE, V161, P1253, DOI 10.1126/science.161.3847.1253; Michaud DS, 2002, J NATL CANCER I, V94, P1293, DOI 10.1093/jnci/94.17.1293; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mori Mitsuru, 2000, Asian Pac J Cancer Prev, V1, P269; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Piemonte F, 2001, EUR J CLIN INVEST, V31, P1007, DOI 10.1046/j.1365-2362.2001.00922.x; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1; Ristow M, 2003, J CLIN INVEST, V112, P527, DOI 10.1172/JCI200318107; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Scheers I, 2005, J PEDIATR-US, V146, P414, DOI 10.1016/j.jpeds.2004.10.023; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; TERRIER F, 1989, RADIOLOGY, V171, P557, DOI 10.1148/radiology.171.2.2704824; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	48	150	156	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					977	981		10.1074/jbc.M511064200	http://dx.doi.org/10.1074/jbc.M511064200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16263703	hybrid			2022-12-25	WOS:000234447200037
J	Xu, ZQ; O'Rourke, BA; Skurray, RA; Brown, MH				Xu, ZQ; O'Rourke, BA; Skurray, RA; Brown, MH			Role of transmembrane segment 10 in efflux mediated by the staphylococcal multidrug transport protein QacA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; CYSTEINE-SCANNING MUTAGENESIS; DIRECTED CHEMICAL-MODIFICATION; POLYTOPIC MEMBRANE-PROTEINS; WATER-FILLED CHANNEL; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; LACTOSE PERMEASE; HELIX ASSOCIATION; GXXXG MOTIF	The staphylococcal multidrug exporter QacA confers resistance to a wide range of structurally dissimilar monovalent and bivalent cationic antimicrobial compounds. To understand the functional importance of transmembrane segment 10, which is thought to be involved in substrate binding, cysteine-scanning mutagenesis was performed in which 35 amino acid residues in the putative transmembrane helix and its flanking regions were replaced in turn with cysteine. Solvent accessibility analysis of the introduced cysteine residues using fluorescein maleimide indicated that transmembrane segment 10 of QacA contains a 20-amino-acid hydrophobic core and may extend from Pro-309 to Ala-334. Phenotypic analysis and fluorimetric transport assays of these mutants showed that Gly-313 is important for the efflux of both monovalent and bivalent cationic substrates, whereas Asp-323 is only important for the efflux of bivalent substrates and probably forms part of the bivalent substrate-binding site(s) together with Met-319. Furthermore, the effects of N-ethyl-maleimide treatment on ethidium and 4', 6-diamidino2-phenylindole export mediated by the QacA mutants suggest that the face of transmembrane segment 10 that contains Asp-323 may also be close to the monovalent substrate-binding site(s), making this helix an integral component of the QacA multidrug-binding pocket.	Elizabeth MacArthur Agr Inst, Camden, NSW 2570, Australia; Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Brown, MH (corresponding author), Elizabeth MacArthur Agr Inst, Private Mail Bag 8, Camden, NSW 2570, Australia.	mbrown@bio.usyd.edu.au	O'Rourke, Brendon/W-6589-2019; Brown, Melissa/V-2296-2017	O'Rourke, Brendon/0000-0001-6959-9398; Brown, Melissa/0000-0001-6461-7550; Xu, Zhi-Qiang/0000-0002-5884-0569				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Adler J, 2005, J BIOL CHEM, V280, P2721, DOI 10.1074/jbc.M412332200; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Frillingos S, 1997, PROTEIN SCI, V6, P438; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Hohn B, 1979, Methods Enzymol, V68, P299; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iwaki S, 2000, J BIOL CHEM, V275, P22704, DOI 10.1074/jbc.M910354199; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Klyachko KA, 1997, J BACTERIOL, V179, P2189, DOI 10.1128/jb.179.7.2189-2193.1997; LEELAPORN A, 1994, J MED MICROBIOL, V40, P214, DOI 10.1099/00222615-40-3-214; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mitchell BA, 1999, J BIOL CHEM, V274, P3541, DOI 10.1074/jbc.274.6.3541; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; Pazdernik NJ, 2000, J MEMBRANE BIOL, V174, P31, DOI 10.1007/s002320001029; Poelarends GJ, 2002, J BIOL CHEM, V277, P42891, DOI 10.1074/jbc.M206508200; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Yohannan S, 2004, P NATL ACAD SCI USA, V101, P959, DOI 10.1073/pnas.0306077101	46	26	29	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					792	799		10.1074/jbc.M508676200	http://dx.doi.org/10.1074/jbc.M508676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282328	hybrid			2022-12-25	WOS:000234447200016
J	Matsuzono, Y; Fujiki, Y				Matsuzono, Y; Fujiki, Y			In vitro transport of membrane proteins to peroxisomes by shuttling receptor Pex19p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT ZELLWEGER-SYNDROME; TARGETING SIGNAL RECEPTOR; OVARY CELL MUTANTS; FUNCTIONAL COMPLEMENTATION; MUTATION ANALYSIS; POTENTIAL ROLE; CDNA CLONING; BIOGENESIS; INTERACTS; PEX5P	The peroxin Pex19p comprising 299 amino acids functions in peroxisomal membrane assembly. We here developed a cell- free system for transport of membrane proteins to peroxisomes. Pex19p interacts with multiple membrane peroxins, including other membrane biogenesis peroxins, Pex16p and Pex26p, involved in matrix protein import. Cell- free synthesized, S-35- labeled Pex19p was targeted to subcellular fractions containing peroxisomes from Chinese hamster ovary- K1 cells as well as peroxisomes isolated from rat liver in an ATP- dependent manner. Such translocation was also reproduced with in vitro synthesized S-35- Pex16p with two transmembrane segments and C- tail anchor- type S-35- Pex26p, upon incubation with S-35- Pex19p in the reaction mixtures containing isolated peroxisomes. The transported S-35- Pex16p and S-35- Pex26p were integrated into membranes as assessed by the sodium carbonate extraction method. Peroxisome- associated and partly Na2CO3- resistant S-35- Pex19p was released to the cytosolic fraction upon incubation in the absence of ATP, whereas S-35- Pex16p and S-35- Pex26p remained in the membranes. Furthermore, not only 35S- Pex19p but also 35S- Pex19p complexes each with S-35- Pex16p and S-35- Pex26p were bound to S-35- Pex3p in vitro. Together, these results strongly suggested that Pex19p translocates the membrane peroxins from the cytosol to peroxisomes in an ATP- and Pex3p- dependent manner and then shuttles back to the cytosol.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp						Birschmann I, 2005, FEBS J, V272, P47, DOI 10.1111/j.1432-1033.2004.04393.x; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Fransen M, 2005, J MOL BIOL, V346, P1275, DOI 10.1016/j.jmb.2005.01.013; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gotte K, 1998, MOL CELL BIOL, V18, P616; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; JAMES GL, 1994, J BIOL CHEM, V269, P14182; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIURA S, 1992, J BIOL CHEM, V267, P14405; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0	42	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					36	42		10.1074/jbc.M509819200	http://dx.doi.org/10.1074/jbc.M509819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16280322	hybrid			2022-12-25	WOS:000234307200008
J	Wang, Q; Zhou, Y; Wang, X; Evers, BM				Wang, Q; Zhou, Y; Wang, X; Evers, BM			Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase	ONCOGENE			English	Article						GSK-3; MAPK; ERK; PKC delta; siRNA; colon cancer cells	NF-KAPPA-B; INTESTINAL-CELL DIFFERENTIATION; ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; COLON-CANCER CELLS; C-DELTA; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; DOWN-REGULATION	Glycogen-synthase kinase-3 (GSK- 3) and extracellular signal-regulated kinase (ERK) are critical downstream signaling proteins for the PI3-kinase/ Akt and Ras/Raf/ MEK-1 pathway, respectively, and regulate diverse cellular processes including embryonic development, cell differentiation and apoptosis. Here, we show that inhibition of GSK-3 using GSK- 3 inhibitors or RNA interference (RNAi) signifi. cantly induced the phosphorylation of ERK1/2 in human colon cancer cell lines HT29 and Caco-2. Pretreatment with the PKC delta-selective inhibitor rottlerin or transfection with PKC delta siRNA attenuated the phosphorylation of ERK1/2 induced by the GSK-3 inhibitor SB-216763 and, furthermore, treatment with SB-216763 or transfection with GSK-3 delta and GSK-3 beta siRNA increased PKCd activity, thus identifying a role for PKCd in the induction of ERK1/2 phosphorylation by GSK-3 inhibition. Treatment with SB-216763 increased expression of cyclooxygenase-2 (COX-2) and IL-8, which are downstream targets of ERK1/2 activation; this induction was abolished by MEK/ERK inhibition, suggesting GSK-3 inhibition induced COX-2 and IL-8 through ERK1/2 activation. The transcriptional induction of COX-2 and IL-8 by GSK- 3 inhibition was further demonstrated by the increased COX-2 and IL-8 promoter activity after SB-216763 treatment or transfection with GSK-3 alpha or GSK- 3b siRNA. Importantly, our. findings identify GSK-3, acting through PKCd, as a negative regulator of ERK1/2, thus revealing a novel crosstalk mechanism between these critical signaling pathways.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu			NIA NIH HHS [R37 AG010885, R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [R01 DK048498, P01 DK35608, P01 DK035608, R01 DK48498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK048498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen BC, 2004, J BIOL CHEM, V279, P20889, DOI 10.1074/jbc.M311279200; Choi JH, 2004, J BIOL CHEM, V279, P49430, DOI 10.1074/jbc.M402088200; Claria J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takahashi-Yanaga F, 2004, BIOCHEM BIOPH RES CO, V316, P411, DOI 10.1016/j.bbrc.2004.02.061; Tang QB, 2001, CANCER RES, V61, P4329; Tominaga K, 2004, ALIMENT PHARM THER, V20, P143, DOI 10.1111/j.1365-2036.2004.01986.x; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	60	97	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					43	50		10.1038/sj.onc.1209004	http://dx.doi.org/10.1038/sj.onc.1209004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278684	Green Accepted			2022-12-25	WOS:000234406400005
J	Cao, WH; Collins, QF; Becker, TC; Robidoux, J; Lupo, EG; Xiong, Y; Daniel, KW; Floering, L; Collins, S				Cao, WH; Collins, QF; Becker, TC; Robidoux, J; Lupo, EG; Xiong, Y; Daniel, KW; Floering, L; Collins, S			p38 mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR-2; INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; MAP KINASE; DEPENDENT TRANSCRIPTION; COACTIVATOR PGC-1; BINDING-PROTEIN; GENE-EXPRESSION; IMMUNE-SYSTEM	Hepatic gluconeogenesis is essential for maintaining blood glucose levels during fasting and is the major contributor to postprandial and fasting hyperglycemia in diabetes. Gluconeogenesis is a classic cAMP/protein kinase A-dependent process initiated by glucagon, which is elevated in the blood during fasting and in diabetes. In this study, we have shown that p38 mitogen-activated protein kinase (p38) was activated in liver by fasting and in primary hepatocytes by glucagon or forskolin. Fasting plasma glucose levels were reduced upon blockade of p38 with either a chemical inhibitor or small interference RNA in mice. In examining the mechanism, inhibition of p38 suppressed gluconeogenesis in liver, along with expression of key gluconeogenic genes, including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Peroxisome proliferator-activated receptor gamma coactivator 1 alpha and cAMP-response element-binding protein have been shown to be important mediators of hepatic gluconeogenesis. We have shown that inhibition of p38 prevented transcription of the PPAR gamma coactivator 1 alpha gene as well as phosphorylation of cAMP-response element-binding protein. Together, our results from in vitro and in vivo studies define a model in which cAMP-dependent activation of genes involved in gluconeogenesis is dependent upon the p38 pathway, thus adding a new player to our evolving understanding of this physiology.	CIIT Ctr Hlth Res, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Sarah W Stedman Ctr Nutr & Metab, Durham, NC 27708 USA; Duke Univ, Med Ctr, Div Endocrinol, Dept Med, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Cao, WH (corresponding author), CIIT Ctr Hlth Res, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@ciit.org		Robidoux, JAcques/0000-0002-4809-4734	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053092] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Beck-Nielsen Henning, 2002, Curr Diab Rep, V2, P231; BERG J, 2001, BIOCHEMISTRY-US, P845; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Borst SE, 2004, ENDOCRINE, V23, P177, DOI 10.1385/ENDO:23:2-3:177; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Crook M, 2004, DIABETIC MED, V21, P203, DOI 10.1046/j.1464-5491.2003.01030.x; Desfaits AC, 1998, DIABETES CARE, V21, P487, DOI 10.2337/diacare.21.4.487; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hohmeier HE, 2003, INT J OBESITY, V27, pS12, DOI 10.1038/sj.ijo.0802493; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Ju HS, 2003, J PHARMACOL EXP THER, V307, P932, DOI 10.1124/jpet.103.057422; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lee MY, 2002, DIABETES, V51, P3400; Lerin C, 2003, DIABETES, V52, P2221, DOI 10.2337/diabetes.52.9.2221; Levi Z, 2003, DIABETES OBES METAB, V5, P45, DOI 10.1046/j.1463-1326.2003.00240.x; LIU ZQ, 1993, METABOLISM, V42, P1546, DOI 10.1016/0026-0495(93)90149-I; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Mittelman SD, 1997, J CLIN INVEST, V100, P3121, DOI 10.1172/JCI119867; Mizuno K, 2002, BRIT J PHARMACOL, V135, P951, DOI 10.1038/sj.bjp.0704537; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ohanian J, 2001, ARTERIOSCL THROM VAS, V21, P1921, DOI 10.1161/hq1201.100264; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Roden M, 2001, RECENT PROG HORM RES, V56, P219, DOI 10.1210/rp.56.1.219; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; Salituro FG, 1999, CURR MED CHEM, V6, P807; Schulte G, 2003, EXP CELL RES, V290, P168, DOI 10.1016/S0014-4827(03)00324-0; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Tataranni PA, 2005, DIABETES, V54, P917, DOI 10.2337/diabetes.54.4.917; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	53	109	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42731	42737		10.1074/jbc.M506223200	http://dx.doi.org/10.1074/jbc.M506223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16272151	hybrid			2022-12-25	WOS:000234200800032
J	Seong, HA; Jung, H; Choi, HS; Kim, KT; Ha, HJ				Seong, HA; Jung, H; Choi, HS; Kim, KT; Ha, HJ			Regulation of transforming growth factor-beta signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; IN-VIVO; IDENTIFICATION; APOPTOSIS; CELLS; INVOLVEMENT; INHIBITION; MIGRATION; ACTIVATOR	To gain more insights about the biological roles of PDK1, we have used the yeast two-hybrid system and in vivo binding assay to identify interacting molecules that associate with PDK1. As a result, serine-threonine kinase receptor-associated protein (STRAP), a transforming growth factor-beta (TGF-beta) receptor-interacting protein, was identified as an interacting partner of PDK1. STRAP was found to form in vivo complexes with PDK1 in intact cells. Mapping analysis revealed that this binding was only mediated by the catalytic domain of PDK1 and not by the pleckstrin homology domain. Insulin enhanced a physical association between PDK1 and STRAP in intact cells, but this insulin-induced association was prevented by wortmannin, a phosphatidylinositol 3-kinase inhibitor. In addition, the association between PDK1 and STRAP was decreased by TGF-beta treatment. Analysis of the activities of the interacting proteins showed that PDK1 kinase activity was significantly increased by coexpression of STRAP, probably through the inhibition of the binding of 14-3-3, a negative regulator, to PDK1. Consistently, knockdown of the endogenous STRAP by the transfection of the small interfering RNA resulted in the decrease of PDK1 kinase activity. PDK1 also exhibited an inhibition of TGF-beta signaling with STRAP by contributing to the stable association between TGF-beta receptor and Smad7. Moreover, confocal microscopic study and immunostaining results demonstrated that PDK1 prevented the nuclear translocation of Smad3 in response to TGF-beta. Knockdown of endogenous PDK1 with small interfering RNA has an opposite effect. Taken together, these results suggested that STRAP acts as an intermediate signaling molecule linking between the phosphatidylinositol 3-kinase/PDK1 and the TGF-beta signaling pathways.	Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Chonnam National University; Pohang University of Science & Technology (POSTECH)	Ha, HJ (corresponding author), Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Buenemann CL, 2001, CARCINOGENESIS, V22, P447, DOI 10.1093/carcin/22.3.447; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; DEL PL, 1997, SCIENCE, V278, P687; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Engel ME, 1998, J CELL BIOCHEM, P111; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Tanaka S, 1996, CANCER RES, V56, P3391; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x	39	49	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42897	42908		10.1074/jbc.M507539200	http://dx.doi.org/10.1074/jbc.M507539200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16251192	hybrid			2022-12-25	WOS:000234200800052
J	Ferris, HU; Furukawa, Y; Minamino, T; Kroetz, MB; Kihara, M; Namba, K; Macnab, RM				Ferris, HU; Furukawa, Y; Minamino, T; Kroetz, MB; Kihara, M; Namba, K; Macnab, RM			FlhB regulates ordered export of flagellar components via autocleavage mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; PROTEIN EXPORT; SUBSTRATE-SPECIFICITY; III SECRETION; MOLECULAR CHARACTERIZATION; ANGSTROM RESOLUTION; APPARATUS; COMPLEX; DEGRADATION; CLEAVAGE	The bacterial flagellum is a predominantly cell-external supermacromolecular construction whose structural components are exported by a flagellum-specific export apparatus. One of the export apparatus proteins, FlhB, regulates the substrate specificity of the entire apparatus; i.e. it has a role in the ordered export of the two main groups of flagellar structural proteins such that the cell-proximal components (rod-/hook-type proteins) are exported before the cell-distal components (filament-type proteins). The controlled switch between these two export states is believed to be mediated by conformational changes in the structure of the C-terminal cytoplasmic domain of FlhB (FlhB(C)), which is consistently and specifically cleaved into two subdomains (FlhB(CN) and FlhB(CC)) that remain tightly associated with each other. The cleavage event has been shown to be physiologically significant for the switch. In this study, the mechanism of FlhB cleavage has been more directly analyzed. We demonstrate that cleavage occurs in a heterologous host, Saccharomyces cerevisiae, deficient in vacuolar proteinases A and B. In addition, we find that cleavage of a slow-cleaving variant, FlhB(C)(P270A), is stimulated in vitro at alkaline pH. We also show by analytical gel-filtration chromatography and analytical ultracentrifugation experiments that both FlhBC and FlhBC( P270A) are monomeric in solution, and therefore self-proteolysis is unlikely. Finally, we provide evidence via peptide analysis and FlhB cleavage variants that the tertiary structure of FlhB plays a significant role in cleavage. Based on these results, we propose that FlhB cleavage is an autocatalytic process.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Osaka Univ, Japan Sci & Technol Corp, Dynam NanoMachine Project, Int Cooperat Res Project, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Yale University; Japan Science & Technology Agency (JST); Osaka University; Osaka University	Ferris, HU (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.	hedda.ferris@yale.edu	Namba, Keiichi/A-9406-2016		NIAID NIH HHS [AI12202, T32 AI007640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASWAD DW, 1995, DEAMIDATION ISOASPAR; BRENNAN TV, 1993, BIOCHEM BIOPH RES CO, V193, P1031, DOI 10.1006/bbrc.1993.1728; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Edqvist PJ, 2003, J BACTERIOL, V185, P2259, DOI 10.1128/JB.185.7.2259-2266.2003; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; Fan F, 1996, J BIOL CHEM, V271, P31981, DOI 10.1074/jbc.271.50.31981; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; Fraser GM, 2003, MOL MICROBIOL, V48, P1043, DOI 10.1046/j.1365-2958.2003.03487.x; Fraser GM, 2003, J BACTERIOL, V185, P5546, DOI 10.1128/JB.185.18.5546-5554.2003; Gonzalez-Pedrajo B, 2002, MOL MICROBIOL, V45, P967, DOI 10.1046/j.1365-2958.2002.03047.x; HIRANO T, 1994, J BACTERIOL, V176, P5439, DOI 10.1128/JB.176.17.5439-5449.1994; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; KUTSUKAKE K, 1994, J BACTERIOL, V176, P7625, DOI 10.1128/JB.176.24.7625-7629.1994; Lavander M, 2002, J BACTERIOL, V184, P4500, DOI 10.1128/JB.184.16.4500-4509.2002; Macnab RM, 2004, BBA-MOL CELL RES, V1694, P207, DOI 10.1016/j.bbamcr.2004.04.005; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Macnab RM, 1999, J BACTERIOL, V181, P7149, DOI 10.1128/JB.181.23.7149-7153.1999; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; Minamino T, 1999, J BACTERIOL, V181, P1388, DOI 10.1128/JB.181.5.1388-1394.1999; Minamino T, 2000, J BACTERIOL, V182, P4906, DOI 10.1128/JB.182.17.4906-4914.2000; Minamino T, 2001, J MOL BIOL, V312, P1027, DOI 10.1006/jmbi.2001.5000; Minamino T, 2000, J BACTERIOL, V182, P4207, DOI 10.1128/JB.182.15.4207-4215.2000; MINAMINO T, 1994, J BACTERIOL, V176, P7630, DOI 10.1128/JB.176.24.7630-7637.1994; Minamino T, 2002, J MOL BIOL, V322, P281, DOI 10.1016/S0022-2836(02)00754-4; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Ohnishi K, 1997, J BACTERIOL, V179, P6092, DOI 10.1128/jb.179.19.6092-6099.1997; Pallen MJ, 2005, TRENDS MICROBIOL, V13, P143, DOI 10.1016/j.tim.2005.02.008; PATTERSO.J, 1973, ARCH MIKROBIOL, V90, P107, DOI 10.1007/BF00414513; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Radkiewicz JL, 2001, J AM CHEM SOC, V123, P3499, DOI 10.1021/ja0026814; Sherman F., 1986, METHODS YEAST GENETI; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Suzuki H, 1998, J STRUCT BIOL, V124, P104, DOI 10.1006/jsbi.1998.4048; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tamano K, 2002, J BACTERIOL, V184, P1244, DOI 10.1128/JB.184.5.1244-1252.2002; Taylor DJ, 2002, J VIROL, V76, P9972, DOI 10.1128/JVI.76.19.9972-9980.2002; Toker AS, 1996, J BACTERIOL, V178, P7069, DOI 10.1128/jb.178.24.7069-7079.1996; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; Williams AW, 1996, J BACTERIOL, V178, P2960, DOI 10.1128/jb.178.10.2960-2970.1996; YAMAGUCHI S, 1984, J GEN MICROBIOL, V130, P255	44	107	108	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41236	41242		10.1074/jbc.M509438200	http://dx.doi.org/10.1074/jbc.M509438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16246842	hybrid			2022-12-25	WOS:000233866900017
J	Wu, M; Wallace, MR; Muir, D				Wu, M; Wallace, MR; Muir, D			Nf1 haploinsufficiency augments angiogenesis	ONCOGENE			English	Article						neurofibromatosis; vasculature; Nf1 haploinsufficiency; endothelial cell; inflammatory cells	DEFICIENT SCHWANN-CELLS; NEUROFIBROMATOSIS 1; FACTOR MIDKINE; MAST-CELLS; EXPRESSION; MOUSE; COMPLICATION; ENCODES; CULTURE	Mutations in the NF1 tumor-suppressor gene underlie neuro. bromatosis type 1 (NF1), in which patients are predisposed to certain tumors such as neuro. bromas and may associate with vascular disorder. Plexiform neuro. bromas are slow growing benign tumors that are highly vascular and can progress to malignancy. The development of neuro. bromas requires loss of both Nf1 alleles in Schwann cells destined to become neoplastic and may be exacerbated by Nf1 heterozygosity in other non-neoplastic cells. This study tested the hypothesis that Nf1 heterozygosity exaggerates angiogenesis. We found that Nf1 heterozygous mice showed increased neovascularization in both the retina and cornea in response to hypoxia and bFGF, respectively, compared to their wild-type litter-mates. The increase in corneal neovascularization was associated with heightened endothelial cell proliferation and migration, and increased infiltration of inflammatory cells. In addition, Nf1 heterozygous endothelial cell cultures showed an exaggerated proliferative response to angiogenic factors, particularly to bFGF. These findings support the conclusion that Nf1 heterozygosity in endothelial cells and perhaps inflammatory cells augments angiogenesis, which may promote neurofibroma formation in NF1.	Univ Florida, Dept Pediat, Div Neurol, Gainesville, FL 32610 USA; Univ Florida, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, M (corresponding author), Univ Florida, Coll Med, Dept Pediat Neuro, Box 100296, Gainesville, FL 32610 USA.	wumin@ufl.edu						Arbiser JL, 1998, J AM ACAD DERMATOL, V38, P950, DOI 10.1016/S0190-9622(98)70158-6; Bajenaru ML, 2003, CANCER RES, V63, P8573; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DUPREZ K, 1991, MICROSURG, V12, P1, DOI 10.1002/micr.1920120102; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Hamilton SJ, 2001, AM J MED GENET, V100, P95, DOI 10.1002/1096-8628(20010422)100:2<95::AID-AJMG1235>3.0.CO;2-T; Hamilton SJ, 2000, CLIN GENET, V58, P341, DOI 10.1034/j.1399-0004.2000.580501.x; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JOHNSON MD, 1989, ARCH PATHOL LAB MED, V113, P1263; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; Morello F, 2001, J VASC INTERV RADIOL, V12, P773, DOI 10.1016/S1051-0443(07)61454-7; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MUIR D, 1990, ANAL BIOCHEM, V185, P377, DOI 10.1016/0003-2697(90)90310-6; Ozerdem Ugur, 2004, Angiogenesis, V7, P307, DOI 10.1007/s10456-004-6643-3; Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; RICCARDI VM, 1981, BIRTH DEFECTS-ORIG, V17, P129; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIDE L, 1998, NEUROFIBROMATOSIS TY; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Song L, 2003, IN VITRO CELL DEV-AN, V39, P313; Wolkenstein P, 2001, ARCH DERMATOL, V137, P233; Wu M, 2005, J NEUROSCI RES, V82, P357, DOI 10.1002/jnr.20646; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	36	39	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2297	2303		10.1038/sj.onc.1209264	http://dx.doi.org/10.1038/sj.onc.1209264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16288202				2022-12-25	WOS:000236764300002
J	Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N				Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N			RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells	ONCOGENE			English	Article						RAR alpha; RAR beta 2; Cyp26a1; epigenetic regulation; embryocarcinoma	RETINOIC ACID; DIFFERENTIATION; EXPRESSION; ALPHA; FEEDBACK; GENE	Retinoic acid (RA) is a signaling molecule that plays a pivotal role in major cellular processes and vertebrate development. RA action is mediated by specialized transcription factors, the nuclear RA receptors (RARs), which regulate the transcription of genes containing a RA-responsive element (RARE). Here we demonstrate that the genes for the RA-receptor RAR beta 2 and the cytochrome P450 RA-specific hydrolase Cyp26a1 involved in RA catabolism are coordinately regulated by RA. We found that both RAR beta 2 and Cyp26a1 genes are epigenetically silenced in the absence of DNA methylation in RAC65, a P19 embryocarcinoma cell line derivative carrying a dominant-negative RAR alpha mutant and resistant to the growth-inhibitory and differentiation effects of RA. In response to RA, RAR beta 2 transcription is epigenetically regulated by RAR alpha. Similarly, we found that Cyp26a1 transcription is epigenetically regulated by RAR beta 2. Knocking down RAR beta 2 transcription by RNA interference in wild-type P19 cells, with an intact RAR alpha, induced Cyp26a1 transcriptional repression in the absence of DNA methylation. Concomitantly, cells developed RA resistance and did not undergo RA-induced neuron differentiation. Apparently, RAR alpha, RAR beta 2 and Cyp26a1 are components of a RA-regulated gene network. Factors affecting an upstream gene of the network can trigger repressive chromatin changes-which are propagated in a domino fashion-at downstream genes of the network. This study also shows that chromatin inactivity, and consequent transcriptional silencing, can be achieved in the absence of DNA methylation.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sacchi, N (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,C&V Bldg,Rm 226, Buffalo, NY 14263 USA.	nicoletta.sacchi@roswellpark.org						Arney KL, 2004, J CELL SCI, V117, P4355, DOI 10.1242/jcs.01390; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dobbs-McAuliffe B, 2004, MECH DEVELOP, V121, P339, DOI 10.1016/j.mod.2004.02.008; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LAUDET V, 2002, NUCL RECEPTOR FACTS, P6; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200	25	28	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1400	1407		10.1038/sj.onc.1209173	http://dx.doi.org/10.1038/sj.onc.1209173			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261163				2022-12-25	WOS:000235708200013
J	Chu, YS; Eder, O; Thomas, WA; Simcha, I; Pincet, F; Ben-Ze'ev, A; Perez, E; Thiery, JP; Dufour, S				Chu, YS; Eder, O; Thomas, WA; Simcha, I; Pincet, F; Ben-Ze'ev, A; Perez, E; Thiery, JP; Dufour, S			Prototypical type I E-cadherin and type II cadherin-7 mediate very distinct adhesiveness through their extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; BETA-CATENIN; DIFFERENTIAL EXPRESSION; FORCE MEASUREMENTS; CLASSIC CADHERINS; N-CADHERIN; IDENTIFICATION; MOLECULES; SPECIFICITY; ASSOCIATION	Using a dual pipette assay that measures the force required to separate adherent cell doublets, we have quantitatively compared intercellular adhesiveness mediated by Type I (E- or N- cadherin) or Type II (cadherin-7 or -11) cadherins. At similar cadherin expression levels, cells expressing Type I cadherins adhered much more rapidly and strongly than cells expressing Type II cadherins. Using chimeric cadherins, we found that the extracellular domain exerts by far the dominant effect on cell adhesivity, that of E- cadherin conferring high adhesivity, and that of cadherin-7 conferring low adhesivity. Type I cadherins were incorporated to a greater extent into detergent-insoluble cytoskeletal complexes, and their cytoplasmic tails were much more effective in disrupting strong adherent junctions, suggesting that Type II cadherins form less stable complexes with beta-catenin. The present study demonstrates compellingly, for the first time, that cadherins are dramatically different in their ability to promote intercellular adhesiveness, a finding that has profound implications for the regulation of tissue morphogenesis.	Inst Curie, CNRS, UMR 144, F-75248 Paris, France; Colby Sawyer Coll, Dept Nat Sci, New London, NH 03257 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; ENS, CNRS, UMR 8550, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Universite Paris Cite	Dufour, S (corresponding author), Inst Curie, CNRS, UMR 144, F-75248 Paris, France.	Sylvie.Dufour@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; ben-ze'ev, avri/0000-0001-6113-3921; PINCET, FREDERIC/0000-0002-4243-2157				Ahrens T, 2003, J MOL BIOL, V325, P733, DOI 10.1016/S0022-2836(02)01286-X; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Borchers A, 2001, DEVELOPMENT, V128, P3049; BOYER B, 1992, EXP CELL RES, V201, P347, DOI 10.1016/0014-4827(92)90283-E; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chen HY, 1997, J CELL SCI, V110, P345; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; Chu YS, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.028102; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; DUBAND JL, 1988, DEVELOPMENT, V103, P325; Dufour S, 1999, J CELL BIOL, V146, P501, DOI 10.1083/jcb.146.2.501; Duguay D, 2003, DEV BIOL, V253, P309, DOI 10.1016/S0012-1606(02)00016-7; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hoben G, 2002, ANN BIOMED ENG, V30, P703, DOI 10.1114/1.1484218; Huber O, 1999, J CELL SCI, V112, P4415; Kawaguchi J, 1999, J BONE MINER RES, V14, P764, DOI 10.1359/jbmr.1999.14.5.764; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Le Douarin NM, 1999, NEURAL CREST, V2; Martinez-Rico C, 2005, J BIOL CHEM, V280, P4753, DOI 10.1074/jbc.M412544200; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Patel SD, 2003, CURR OPIN STRUC BIOL, V13, P690, DOI 10.1016/j.sbi.2003.10.007; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Pishvaian MJ, 1999, CANCER RES, V59, P947; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; Shimoyama Y, 2000, BIOCHEM J, V349, P159, DOI 10.1042/0264-6021:3490159; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; SIMONNEAU L, 1995, CELL ADHES COMMUN, V3, P115, DOI 10.3109/15419069509081281; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Stewart DB, 2000, J BIOL CHEM, V275, P20707, DOI 10.1074/jbc.M000467200; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Thoumine O, 1996, CELL MOTIL CYTOSKEL, V33, P276; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; Troyanovsky SM, 1999, CURR OPIN CELL BIOL, V11, P561, DOI 10.1016/S0955-0674(99)00021-6; Vallin J, 1998, MECH DEVELOP, V75, P171, DOI 10.1016/S0925-4773(98)00099-9; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wu CC, 2005, BIOCHEM BIOPH RES CO, V329, P256, DOI 10.1016/j.bbrc.2005.01.126; Yagi T, 2000, GENE DEV, V14, P1169; Yamamoto A, 1998, BIOMATERIALS, V19, P871, DOI 10.1016/S0142-9612(97)00248-2; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Zhu B, 2003, BIOPHYS J, V84, P4033, DOI 10.1016/S0006-3495(03)75129-7	62	93	96	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2901	2910		10.1074/jbc.M506185200	http://dx.doi.org/10.1074/jbc.M506185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16253998	hybrid			2022-12-25	WOS:000234931800059
J	Gross, AW; Lodish, HF				Gross, AW; Lodish, HF			Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; RECEPTOR; ACTIVATION; PHARMACOKINETICS; PROLIFERATION; INTERLEUKIN-3; ESTABLISHMENT; PROTEASOMES; EXPRESSION; POTENCY	Erythropoietin (Epo) is essential for the production of mature red blood cells, and recombinant Epo is commonly used to treat anemia, but how Epo is degraded and cleared from the body is not understood. Glycosylation of Epo is required for its in vivo bioactivity, although not for invitro receptor binding or stimulation of Epo-dependent celllines; Epoglycosylation actually reduces the affinity of Epo for the Epo receptor (EpoR). Interestingly, a hyperglycosylated analog of Epo, called novel erythropoiesis-stimulating protein (NESP), has a lower affinity than Epo for the EpoR but has greater in vivo activity and a longer serum half-life than Epo. We hypothesize that a major mechanism for degradation of Epo in the body occurs in cells expressing the Eporeceptor, through receptor-mediated endocytosis of Epo followed by degradation in lysosomes, and therefore investigated the trafficking and degradation of Epo and NESP by EpoR-expressing cells. We show that Epo and NESP are degraded only by cultured cells that express the EpoR, and their receptor binding, dissociation, and trafficking properties determine their rates of intracellular degradation. Epo binds surface EpoR faster than NESP (k(on) approximate to 5.0 x 10(8) M-1 min(-1) versus 1.1 x 10(8) M-1 min(-1)) but dissociates slower (koff = 0.029 min(-1) versus 0.042 min(-1)). Surface-bound Epo and NESP are internalized at the same rate (k(in) = 0.06 min(-1)), and after internalization 60% of each ligand is resecreted intact and 40% degraded. Our kinetic model of Epo and NESP receptor binding, intracellular trafficking, and degradation explains why Epo is degraded faster than NESP at the cellular level.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NHLBI NIH HHS [HL 32262, 5F32 HL 077036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL077036, P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; Egrie JC, 2001, NEPHROL DIAL TRANSPL, V16, P3, DOI 10.1093/ndt/16.suppl_3.3; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; Elliott S, 2003, NAT BIOTECHNOL, V21, P414, DOI 10.1038/nbt799; Elliott S, 2004, EXP HEMATOL, V32, P1146, DOI 10.1016/j.exphem.2004.08.004; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fallon EM, 2000, J BIOL CHEM, V275, P6790, DOI 10.1074/jbc.275.10.6790; FLAHARTY KK, 1990, CLIN PHARMACOL THER, V47, P557, DOI 10.1038/clpt.1990.76; Jelkmann W, 2002, EUR J HAEMATOL, V69, P265, DOI 10.1034/j.1600-0609.2002.02813.x; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Macdougall IC, 2002, NEPHROL DIAL TRANSPL, V17, P66, DOI 10.1093/ndt/17.suppl_5.66; Macdougall IC, 1999, J AM SOC NEPHROL, V10, P2392; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MISAIZU T, 1995, BLOOD, V86, P4097, DOI 10.1182/blood.V86.11.4097.bloodjournal86114097; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; Sugawa M, 2002, NEUROSCI RES, V44, P391, DOI 10.1016/S0168-0102(02)00161-X; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Walrafen P, 2005, BLOOD, V105, P600, DOI 10.1182/blood-2004-03-1216; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	30	107	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2024	2032		10.1074/jbc.M510493200	http://dx.doi.org/10.1074/jbc.M510493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16286456	hybrid			2022-12-25	WOS:000234760400023
J	Dooley, S; Said, HM; Gressner, AM; Floege, JRR; En-Nia, A; Mertens, PR				Dooley, S; Said, HM; Gressner, AM; Floege, JRR; En-Nia, A; Mertens, PR			Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; COLLAGEN GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; DNA-BINDING PROTEINS; TGF-BETA RESPONSE; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; PROXIMAL PROMOTER; MAMMALIAN-CELLS; YB-1	Y-box protein-1 (YB-1) is a known negative regulator of collagen (Col) expression by two different mechanisms, acting directly through binding to an interferon-gamma response element within the col1A2 promoter and/or by physically interacting with p300/Smad3, thereby abrogating the stimulatory effect of transforming growth factor-beta (TGF-beta). Here, we report that YB-1 activation via the Jak1 signaling pathway is required and sufficient to confer interferon-gamma- dependent activation of the smad7 gene. By binding to a bona fide recognition site within the smad7 promoter, YB-1 up-regulates smad7 transcription, which was additively enhanced by autoinhibitory TGF-beta signaling. Importantly, the anti-TGF-beta effect was not only supplied by induced Smad7 expression but was recapitulated in the context of the col1A2 promoter, where YB-1 overexpression abolished the trans-stimulatory TGF-beta effect in a dominant fashion. In conclusion, YB-1 is the main target of interferon-gamma signaling via Jak1 that exerts antifibrotic action by both interference with TGF-beta signaling and direct down-regulation of collagen expression.	Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Clin Chem & Pathobiochem, D-52057 Aachen, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Dept Nephrol & Immunol, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Dooley, S (corresponding author), Univ Mannheim Hosp, Med Clin 2, Mol Alcohol Res Gastroenterol & Hepatol, D-68167 Mannheim, Germany.	steven.dooley@med.ma.uni-heidelberg.de	Said, Harun Muayad/AAZ-7299-2021; Dooley, Steven/T-6491-2018; Mertens, Peter/AAI-7310-2020	Dooley, Steven/0000-0002-4840-6240; Said, Harun M./0000-0002-7032-2668				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ashizuka M, 2002, MOL CELL BIOL, V22, P6375, DOI 10.1128/MCB.22.18.6375-6383.2002; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BERGVELD HJ, 2002, PHIL RES, V1, P1; Bitzer M, 2000, GENE DEV, V14, P187; Capowski EE, 2001, J IMMUNOL, V167, P5970, DOI 10.4049/jimmunol.167.10.5970; Chen CY, 2000, GENE DEV, V14, P1236; Cheng SF, 2002, BIOCHEM J, V366, P807, DOI 10.1042/BJ20020202; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Fukada T, 2003, EMBO J, V22, P479, DOI 10.1093/emboj/cdg067; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GREENWEL P, 1993, LAB INVEST, V69, P210; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Inagaki Y, 2005, GASTROENTEROLOGY, V129, P259, DOI 10.1053/j.gastro.2005.03.088; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Monteleone G, 2005, GASTROENTEROLOGY, V128, P687, DOI 10.1053/j.gastro.2004.12.042; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; SABATH DE, 1990, J BIOL CHEM, V265, P12671; SAKURA H, 1988, GENE, V73, P499; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Tahashi Y, 2002, HEPATOLOGY, V35, P49, DOI 10.1053/jhep.2002.30083; TERADA Y, 2002, KIDNEY INT S1, V61, P94, DOI DOI 10.1046/J.1523-1755.2002.0610S1094.X; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	57	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1784	1795		10.1074/jbc.M510215200	http://dx.doi.org/10.1074/jbc.M510215200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16278212	hybrid			2022-12-25	WOS:000234652000060
J	Kida, Y; Morimoto, F; Mihara, K; Sakaguchi, M				Kida, Y; Morimoto, F; Mihara, K; Sakaguchi, M			Function of positive charges following signal-anchor sequences during translocation of the N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INTEGRATION; ENDOPLASMIC-RETICULUM; SYNAPTOTAGMIN-II; ORIENTATION; RECOGNITION; TOPOGENESIS; MUTAGENESIS; REGIONS; SEC61P	In topogenesis of membrane proteins on the endoplasmic reticulum, the orientation of the hydrophobic transmembrane (TM) segment is influenced by the charge of the flanking amino acid residues. We assessed the function of the positive charges downstream of the hydrophobic segment using synaptotagmin II. The positive charges were systematically replaced with non-charged residues. Although the original TM segment translocated the N terminus, the topology was inverted, depending on the mutations. Orientation was affected in mutants in which 6 Lys were shifted downstream, even when the 6 Lys were 25 residues from the hydrophobic segment. The Lys was functionally replaced by Arg, but not by Asp or Glu. The timing of action during polypeptide elongation indicated that the Lys functions at the ribosome exit sites. We suggest that the commitment of the TM segment to a particular orientation is influenced by far downstream parts of the polypeptide chain and that the positive charges are decoded after exiting the ribosome.	Univ Hyogo, Grad Sch Life Sci, Ako, Hyogo 6781297, Japan; Kyushu Univ, Grad Sch Med Sci, Fukuoka 8128582, Japan; Univ Hyogo, CREST, Japan Sci & Technol Agcy, Ako, Hyogo 6781297, Japan	University of Hyogo; Kyushu University; Japan Science & Technology Agency (JST); University of Hyogo	Sakaguchi, M (corresponding author), Univ Hyogo, Grad Sch Life Sci, Ako, Hyogo 6781297, Japan.	sakag@sci.u-hyogo.ac.jp						ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Goder V, 2004, MOL BIOL CELL, V15, P1470, DOI 10.1091/mbc.E03-08-0599; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; HIGH S, 1993, J BIOL CHEM, V268, P26745; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Kanki T, 2002, BIOCHEMISTRY-US, V41, P13973, DOI 10.1021/bi026619q; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; Kida Y, 2005, EMBO J, V24, P3202, DOI 10.1038/sj.emboj.7600788; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SAKAGUCHI M, 1997, MOL B INT U, P135; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6	28	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1152	1158		10.1074/jbc.M506613200	http://dx.doi.org/10.1074/jbc.M506613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16291756	hybrid			2022-12-25	WOS:000234447200057
J	Cipriano, DJ; Dunn, SD				Cipriano, DJ; Dunn, SD			The role of the is an element of subunit in the Escherichia coli ATP synthase - The C-terminal domain is required for efficient energy coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNIT; GAMMA-SUBUNIT; CROSS-LINKING; PROTON SLIP; RHODOBACTER-CAPSULATUS; MONOCLONAL-ANTIBODIES; STRUCTURAL FEATURES; F-1-ATPASE; F-1; LOCATION	The role of the C-domain of the epsilon subunit of ATP synthase was investigated by fusing either the 20-kDa flavodoxin ( Fd) or the 5-kDa chitin binding domain (CBD) to the N termini of both full-length epsilon and a truncation mutant epsilon(88-stop). All mutant epsilon proteins were stable in cells and supported F1F0 assembly. Cells expressing the Fd-epsilon or Fd-epsilon(88-stop) mutants were unable to grow on acetate minimal medium, indicating their inability to carry out oxidative phosphorylation because of steric blockage of rotation. The other forms of epsilon supported growth on acetate. Membrane vesicles containing Fd-epsilon showed 23% of the wild type ATPase activity but no proton pumping, suggesting that the ATP synthase is intrinsically partially uncoupled. Vesicles containing CBD-epsilon were indistinguishable from the wild type in ATPase activity and proton pumping, indicating that the N-terminal fusions alone do not promote uncoupling. Fd-epsilon(88-stop) caused higher rates of uncoupled ATP hydrolysis than Fd-epsilon, and epsilon(88-stop) showed an increased rate of membrane-bound ATP hydrolysis but decreased proton pumping relative to the wild type. Both results demonstrate the role of the C-domain in coupling. Analysis of the wild type and epsilon(88-stop) mutant membrane ATPase activities at concentrations of ATP from 50 mu M to 8 mM showed no significant dependence of the ratio of bound/released ATPase activity on ATP concentration. These results support the hypothesis that the main function of the C- domain in the Escherichia coli epsilon subunit is to reduce uncoupled ATPase activity, rather than to regulate coupled activity.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@uwo.ca	Dunn, Stanley/D-3418-2013					AGGELER R, 1992, ARCH BIOCHEM BIOPHYS, V296, P685, DOI 10.1016/0003-9861(92)90627-9; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Dunn S. D., 2004, HDB ATPASES, P311; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; EVRON Y, 1990, BIOCHIM BIOPHYS ACTA, V1019, P115, DOI 10.1016/0005-2728(90)90131-M; Feniouk BA, 1999, FEBS LETT, V445, P409, DOI 10.1016/S0014-5793(99)00160-X; Feniouk BA, 2005, BBA-BIOENERGETICS, V1706, P184, DOI 10.1016/j.bbabio.2004.10.010; Futai M., 2004, HDB ATPASES BIOCH CE, P237; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GRABER P, 1981, FEBS LETT, V136, P25, DOI 10.1016/0014-5793(81)81207-0; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUKI M, 1988, J BIOL CHEM, V263, P17437; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1971, P NATL ACAD SCI USA, V68, P2522, DOI 10.1073/pnas.68.10.2522; Nowak KF, 2004, BIOCHEMISTRY-US, V43, P3273, DOI 10.1021/bi035820d; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Turina P, 2004, BIOCHEMISTRY-US, V43, P11126, DOI 10.1021/bi048975+; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER JE, 2000, BIOCHIM BIOPHYS ACTA, V1458, P221; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i	47	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					501	507		10.1074/jbc.M509986200	http://dx.doi.org/10.1074/jbc.M509986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267041	hybrid			2022-12-25	WOS:000234307200062
J	Forbes, KP; Addepalli, B; Hunt, AG				Forbes, KP; Addepalli, B; Hunt, AG			An Arabidopsis Fip1 homolog interacts with RNA and provides conceptual links with a number of other polyadenylation factor subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNAS; CLEAVAGE FACTOR-I; POLY(A) SITE RECOGNITION; 3' END FORMATION; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; 3'-END FORMATION; KDA SUBUNIT; MAMMALIAN CLEAVAGE	The protein Fip1 is an important subunit of the eukaryotic polyadenylation apparatus, since it provides a bridge of sorts between poly(A) polymerase, other subunits of the polyadenylation apparatus, and the substrate RNA. In this study, a previously unreported Arabidopsis Fip1 homolog is characterized. The gene for this protein resides on chromosome V and encodes a 1196-amino acid polypeptide. Yeast two-hybrid and in vitro assays indicate that the N-terminal 137 amino acids of the Arabidopsis Fip1 protein interact with poly(A) polymerase (PAP). This domain also stimulates the activity of the PAP. Interestingly, this part of the Arabidopsis Fip1 interacts with Arabidopsis homologs of CstF77, CPSF30, CFIm-25, and PabN1. The interactions with CstF77, CPSF30, and CFIm-25 are reminiscent in various respects of similar interactions seen in yeast and mammals, although the part of the Arabidopsis Fip1 protein that participates in these interactions has no apparent counterpart in other eukaryotic Fip1 proteins. Interactions between Fip1 and PabN1 have not been reported in other systems; this may represent plant-specific associations. The C-terminal 789 amino acids of the Arabidopsis Fip1 protein were found to contain an RNA-binding domain; this domain correlated with an intact arginine-rich region and had a marked preference for poly(G) among the four homopolymers studied. These results indicate that the Arabidopsis Fip1, like its human counterpart, is an RNA-binding protein. Moreover, they provide conceptual links between PAP and several other Arabidopsis polyadenylation factor subunit homologs.	Univ Kentucky, Dept Plant & Soil Sci, Program Mol Biol, Lexington, KY 40546 USA	University of Kentucky	Hunt, AG (corresponding author), Univ Kentucky, Dept Plant & Soil Sci, Program Mol Biol, 301A Plant Sci Bldg,1405 Vet Dr, Lexington, KY 40546 USA.	aghunt00@uky.edu	Hunt, Arthur/A-8040-2009	Addepalli, Balasubrahmanyam/0000-0001-6257-7700; Hunt, Arthur/0000-0002-0008-4158				Addepalli B, 2004, BBA-GENE STRUCT EXPR, V1679, P117, DOI 10.1016/j.bbaexp.2004.06.001; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Barabino SML, 2000, EMBO J, V19, P3778, DOI 10.1093/emboj/19.14.3778; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DASGUPTA J, 1995, PLANT SCI, V110, P215; Dichtl B, 2002, EMBO J, V21, P4125, DOI 10.1093/emboj/cdf390; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Elliott BJ, 2003, PLANT MOL BIOL, V51, P373, DOI 10.1023/A:1022035219500; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; Gross S, 2001, P NATL ACAD SCI USA, V98, P6080, DOI 10.1073/pnas.101046598; Gross S, 2001, MOL CELL BIOL, V21, P8045, DOI 10.1128/MCB.21.23.8045-8055.2001; Helming S, 2001, MOL CELL BIOL, V21, P2026, DOI 10.1128/MCB.21.6.2026-2037.2001; Hirose Y, 2000, GENE DEV, V14, P1415; Hunt AG, 2000, BIOCHEM BIOPH RES CO, V272, P174, DOI 10.1006/bbrc.2000.2755; HUNT AG, 1994, ANNU REV PLANT PHYS, V45, P47, DOI 10.1146/annurev.pp.45.060194.000403; James P, 1996, GENETICS, V144, P1425; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; Kaufmann I, 2004, EMBO J, V23, P616, DOI 10.1038/sj.emboj.7600070; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; Kerwitz Y, 2003, EMBO J, V22, P3705, DOI 10.1093/emboj/cdg347; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meinke DW, 2003, PLANT PHYSIOL, V131, P409, DOI 10.1104/pp.014134; MOGEN BD, 1992, MOL CELL BIOL, V12, P5406, DOI 10.1128/MCB.12.12.5406; MOGEN BD, 1990, PLANT CELL, V2, P1261; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Proudfoot N, 2002, CURR BIOL, V12, pR855, DOI 10.1016/S0960-9822(02)01353-2; ROTHNIE HM, 1994, EMBO J, V13, P2200, DOI 10.1002/j.1460-2075.1994.tb06497.x; Rothnie HM, 1996, PLANT MOL BIOL, V32, P43, DOI 10.1007/BF00039376; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; SANFACON H, 1991, GENE DEV, V5, P141, DOI 10.1101/gad.5.1.141; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Venkataraman K, 2005, GENE DEV, V19, P1315, DOI 10.1101/gad.1298605; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; Xu RQ, 2004, GENE, V324, P35, DOI 10.1016/j.gene.2003.09.025; Yao YL, 2002, J EXP BOT, V53, P2277, DOI 10.1093/jxb/erf073; Zhelkovsky A, 1998, MOL CELL BIOL, V18, P5942, DOI 10.1128/MCB.18.10.5942; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	52	38	47	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					176	186		10.1074/jbc.M510964200	http://dx.doi.org/10.1074/jbc.M510964200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16282318	hybrid			2022-12-25	WOS:000234307200025
J	Malliri, A; Rygiel, TP; van der Kammen, RA; Song, JY; Engers, R; Hurlstone, AFL; Clevers, H; Collard, JG				Malliri, A; Rygiel, TP; van der Kammen, RA; Song, JY; Engers, R; Hurlstone, AFL; Clevers, H; Collard, JG			The Rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR TIAM1; BETA-CATENIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; MICE LACKING; COLON-CANCER; PPAR-DELTA; APC; EXPRESSION; RHO	Mutations in the canonical Wnt signaling pathway leading to its activation are known to cause the majority of intestinal tumors. However, few genes targeted by this pathway have been demonstrated to affect tumor development in vivo. Here we show that Tiam1, a selective Rac GTPase activator, is a Wnt-responsive gene expressed in the base of intestinal crypts and up-regulated in mouse intestinal tumors and human colon adenomas. Moreover, by comparing tumor development in APC mutant Min (multiple intestinal neoplasia) mice expressing or lacking Tiam1, we found that Tiam1 deficiency significantly reduces the formation and growth of polyps in vivo. However, invasion of malignant intestinal tumors is enhanced by a lack of Tiam1. In line with this, knock- down of Tiam1 reduced the growth potential of human colorectal cancer cells and their ability to form E-cadherin-based adhesions, a prerequisite for local invasion of tumor cells. Our data indicate a novel cross- talk between Tiam1-Rac and canonical Wnt-signaling pathways that influences intestinal tumor formation and progression.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Netherlands Inst Dev Biol, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Netherlands Cancer Institute; Heinrich Heine University Dusseldorf; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.collard@nki.nl		Malliri, Angeliki/0000-0001-6848-090X; Rygiel, Tomasz/0000-0003-4746-6505; Hurlstone, Adam/0000-0001-5260-9457				Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Fujita M, 2001, CANCER RES, V61, P7722; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Minard ME, 2005, ONCOGENE, V24, P2568, DOI 10.1038/sj.onc.1208503; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Stappenbeck TS, 2001, DEVELOPMENT, V128, P2603; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	37	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					543	548		10.1074/jbc.M507582200	http://dx.doi.org/10.1074/jbc.M507582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249175	hybrid			2022-12-25	WOS:000234307200066
J	Meli, AC; Hodak, H; Clantin, B; Locht, C; Molle, G; Jacob-Dubuisson, F; Saint, N				Meli, AC; Hodak, H; Clantin, B; Locht, C; Molle, G; Jacob-Dubuisson, F; Saint, N			Channel properties of TpsB transporter FhaC point to two functional domains with a C-terminal protein-conducting pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS FILAMENTOUS HEMAGGLUTININ; CHLOROPLASTIC ENVELOPE MEMBRANES; CONSERVED BACTERIAL PROTEIN; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; IMPORT CHANNEL; ESCHERICHIA-COLI; SERRATIA-MARCESCENS; LIPID-BILAYER; SECRETION	Integral outer membrane transporters of the Omp85/TpsB superfamily mediate the translocation of proteins across, or their integration into, the outer membranes of Gram-negative bacteria, chloroplasts, and mitochondria. The Bordetella pertussis FhaC/FHA couple serves as a model for the two-partner secretion pathway in Gram-negative bacteria, with the TpsB protein, FhaC, being the specific transporter of its TpsA partner, FHA, across the outer membrane. In this work, we have investigated the structure/function relationship of FhaC by analyzing the ion channel properties of the wild type protein and a collection of mutants with varied FHA secretion activities. We demonstrated that the channel is formed by the C-terminal two-thirds of FhaC most likely folding into a beta-barrel domain predicted to be conserved throughout the family. A C-proximal motif that represents the family signature appears essential for pore function. The N-terminal 200 residues of FhaC constitute a functionally distinct domain that modulates the pore properties and may participate in FHA recognition.	INSERM, UMR 5048, CNRS, U554,Ctr Biochim Struct, F-34090 Montpellier, France; Inst Pasteur, Inst Biol, INSERM, U629, F-59019 Lille, France; Inst Pasteur, Inst Biol, UMR 8525, CNRS, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Jacob-Dubuisson, F (corresponding author), INSERM, UMR 5048, CNRS, U554,Ctr Biochim Struct, 29 Rue Navacelles, F-34090 Montpellier, France.	francoise.jacob@ibl.fr	Saint, Nathalie/S-5286-2016; Meli, Albano C./O-7647-2018; Jacob-Dubuisson, Françoise/F-1610-2018; Locht, Camille/L-3516-2018	Saint, Nathalie/0000-0001-5219-9486; Meli, Albano C./0000-0002-1727-3027; Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Hodak, Helene/0000-0003-3318-9834				Alder NN, 2003, TRENDS BIOCHEM SCI, V28, P442, DOI 10.1016/S0968-0004(03)00167-1; Andersen C, 2002, J MEMBRANE BIOL, V185, P83, DOI 10.1007/s00232-001-0113-2; Andersen C, 1999, MOL MICROBIOL, V32, P851, DOI 10.1046/j.1365-2958.1999.01406.x; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; Coutte L, 2001, EMBO J, V20, P5040, DOI 10.1093/emboj/20.18.5040; Danelon C, 2003, J BIOL CHEM, V278, P35542, DOI 10.1074/jbc.M305434200; Eckart K, 2002, EMBO REP, V3, P557, DOI 10.1093/embo-reports/kvf110; Ertel F, 2005, J BIOL CHEM, V280, P28281, DOI 10.1074/jbc.M503035200; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Guedin S, 1998, MOL MICROBIOL, V29, P763, DOI 10.1046/j.1365-2958.1998.00970.x; Guedin S, 2000, J BIOL CHEM, V275, P30202, DOI 10.1074/jbc.M005515200; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Jacob-Dubuisson F, 2004, BBA-MOL CELL RES, V1694, P235, DOI 10.1016/j.bbamcr.2004.03.008; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; JacobDubuisson F, 1996, MOL MICROBIOL, V19, P65, DOI 10.1046/j.1365-2958.1996.349883.x; Johnson AE, 2004, NAT STRUCT MOL BIOL, V11, P113, DOI 10.1038/nsmb0204-113; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Moslavac S, 2005, FEBS J, V272, P1367, DOI 10.1111/j.1742-4658.2005.04569.x; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; Reumann S, 1999, TRENDS PLANT SCI, V4, P302, DOI 10.1016/S1360-1385(99)01449-1; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Sanchez-Pulido L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/j.tibs.2003.08.003; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Thanassi DG, 2000, CURR OPIN CELL BIOL, V12, P420, DOI 10.1016/S0955-0674(00)00111-3; Voulhoux R, 2004, RES MICROBIOL, V155, P129, DOI 10.1016/j.resmic.2003.11.007; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yang FL, 2000, INT J MED MICROBIOL, V290, P529; Yen MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0	43	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					158	166		10.1074/jbc.M508524200	http://dx.doi.org/10.1074/jbc.M508524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16284399	hybrid			2022-12-25	WOS:000234307200023
J	Lee, SR; Collins, K				Lee, SR; Collins, K			Starvation-induced cleavage of the tRNA anticodon loop in Tetrahymena thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III-TRANSCRIBED RNA; CODON USAGE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENOMIC SEQUENCE; GENE-EXPRESSION; DEGRADATION; NUCLEOTIDYLTRANSFERASE; GROWTH; YEAST	Amino acid deprivation triggers dramatic physiological responses in all organisms, altering both the synthesis and destruction of RNA and protein. Here we describe, using the ciliate Tetrahymena thermophila, a previously unidentified response to amino acid deprivation in which mature transfer RNA (tRNA) is cleaved in the anticodon loop. We observed that anticodon loop cleavage affects a small fraction of most or all tRNA sequences. Accumulation of cleaved tRNA is temporally coordinated with the morphological and metabolic changes of adaptation to starvation. The starvation-induced endonucleolytic cleavage activity targets tRNAs that have undergone maturation by 5' and 3' end processing and base modification. Curiously, the majority of cleaved tRNAs lack the 3' terminal CCA nucleotides required for aminoacylation. Starvation-induced tRNA cleavage is inhibited in the presence of essential amino acids, independent of the persistence of other starvation-induced responses. Our findings suggest that anticodon loop cleavage may reduce the accumulation of uncharged tRNAs as part of a specific response induced by amino acid starvation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	kcollins@berkeley.edu		Lee, Suzanne/0000-0003-1608-2576				Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Auffinger P, 1998, MODIFICATION EDITING, P569; CAMPBELL JM, 1980, J BIOL CHEM, V255, P4691; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; Collins K, 2005, CURR BIOL, V15, pR317, DOI 10.1016/j.cub.2005.04.039; CSANK C, 1992, J BIOL CHEM, V267, P4592; Deutscher MP, 2003, J BIOL CHEM, V278, P45041, DOI 10.1074/jbc.R300031200; Dever TE, 2005, MOL CELL, V18, P141, DOI 10.1016/j.molcel.2005.03.023; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Frankel J, 2000, METHOD CELL BIOL, V62, P27; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; HALLBERG EM, 1992, NUCLEIC ACIDS RES, V20, P912, DOI 10.1093/nar/20.4.912; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hopper AK, 2003, GENE DEV, V17, P162, DOI 10.1101/gad.1049103; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Kanaya S, 1999, GENE, V238, P143, DOI 10.1016/S0378-1119(99)00225-5; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Larsen LK, 1999, CELL BIOL INT, V23, P551, DOI 10.1006/cbir.1999.0419; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; Masaki H, 2002, BIOCHIMIE, V84, P433, DOI 10.1016/S0300-9084(02)01425-6; Miller MC, 2000, MOL CELL, V6, P827, DOI 10.1016/S1097-2765(05)00078-X; NELSEN EM, 1978, DEV BIOL, V66, P17, DOI 10.1016/0012-1606(78)90270-1; Percudani R, 1997, J MOL BIOL, V268, P322, DOI 10.1006/jmbi.1997.0942; PFEFFER S, 2005, CURRENT PROTOCOLS MO; Soll D., 1993, RNA WORLD, P157; SUTTON CA, 1979, J CELL PHYSIOL, V101, P349, DOI 10.1002/jcp.1041010214; SZABLEWSKI L, 1991, J PROTOZOOL, V38, P62, DOI 10.1111/j.1550-7408.1991.tb04802.x; Vanacova S, 2005, PLOS BIOL, V3, P986, DOI 10.1371/journal.pbio.0030189; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WELLNITZ WR, 1979, EXP CELL RES, V119, P175, DOI 10.1016/0014-4827(79)90346-X; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7; Witkin KL, 2004, GENE DEV, V18, P1107, DOI 10.1101/gad.1201704; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; Wuitschick JD, 1999, J EUKARYOT MICROBIOL, V46, P239, DOI 10.1111/j.1550-7408.1999.tb05120.x; Wuitschick Jeffrey D., 2000, Methods in Cell Biology, V62, P565; Yoshihisa T, 2003, MOL BIOL CELL, V14, P3266, DOI 10.1091/mbc.E02-11-0757; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	46	158	168	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42744	42749		10.1074/jbc.M510356200	http://dx.doi.org/10.1074/jbc.M510356200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16272149	hybrid			2022-12-25	WOS:000234200800034
J	Thompsett, AR; Abdelraheim, SR; Daniels, M; Brown, DR				Thompsett, AR; Abdelraheim, SR; Daniels, M; Brown, DR			High affinity binding between copper and full-length prion protein identified by two different techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SERUM-ALBUMIN; C-TERMINAL DOMAIN; SUPEROXIDE-DISMUTASE; OCTAREPEAT DOMAIN; OXIDATIVE STRESS; CU(II) BINDING; METAL-BINDING; ION-BINDING; EXPRESSION; SITES	The cellular prion protein is known to be a copper-binding protein. Despite the wide range of studies on the copper binding of PrP, there have been no studies to determine the affinity of the protein on both full-length prion protein and under physiological conditions. We have used two techniques, isothermal titration calorimetry and competitive metal capture analysis, to determine the affinity of copper for wild type mouse PrP and a series of mutants. High affinity copper binding by wild type PrP has been confirmed by the independent techniques indicating the presence of specific tight copper binding sites up to femtomolar affinity. Altogether, four high affinity binding sites of between femto- and nanomolar affinities are located within the octameric repeat region of the protein at physiological pH. A fifth copper binding site of lower affinity than those of the octameric repeat region has been detected in full-length protein. Binding to this site is modulated by the histidine at residue 111. Removal of the octameric repeats leads to the enhancement of affinity of this fifth site and a second binding site outside of the repeat region undetected in the wild type protein. High affinity copper binding allows PrP to compete effectively for copper in the extracellular milieu. The copper binding affinities of PrP have been compared with those of proteins of known function and are of magnitudes compatible with an extracellular copper buffer or an enzymatic function such as superoxide dismutase like activity.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Bath; University of Cambridge	Brown, DR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	bssdrb@bath.ac.uk	Brown, David/A-4083-2008	Rogers, Jack/0000-0003-1262-8578				Abajian C, 2004, J BIOL CHEM, V279, P53584, DOI 10.1074/jbc.M408099200; Arnesano F, 2002, STRUCTURE, V10, P1337, DOI 10.1016/S0969-2126(02)00858-4; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 2001, J NEUROCHEM, V76, P69, DOI 10.1046/j.1471-4159.2001.00009.x; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 1999, J NEUROSCI RES, V58, P717; Brown DR, 2003, J NEUROCHEM, V87, P377, DOI 10.1046/j.1471-4159.2003.02046.x; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Brown DR, 2004, J INORG BIOCHEM, V98, P133, DOI 10.1016/j.jinorgbio.2003.09.006; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Chattopadhyay M, 2005, J AM CHEM SOC, V127, P12647, DOI 10.1021/ja053254z; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; Cui T, 2003, EUR J BIOCHEM, V270, P3368, DOI 10.1046/j.1432-1033.2003.03717.x; Daniels M, 2002, METHOD ENZYMOL, V349, P258, DOI 10.1016/S0076-6879(02)49340-8; Dawson R. M. C., 1986, DATA BIOCH RES, P409; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Gusman H, 2001, BBA-PROTEIN STRUCT M, V1545, P86, DOI 10.1016/S0167-4838(00)00265-X; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; HIROSE J, 1988, CHEM PHARM BULL, V36, P2103; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Jones CE, 2005, J MOL BIOL, V346, P1393, DOI 10.1016/j.jmb.2004.12.043; Jones CE, 2004, J BIOL CHEM, V279, P32018, DOI 10.1074/jbc.M403467200; KELNER MJ, 1989, FREE RADICAL BIO MED, V6, P355, DOI 10.1016/0891-5849(89)90079-8; Kodama Hiroko, 2001, Expert Opin Ther Targets, V5, P625, DOI 10.1517/14728222.5.5.625; Kornblatt JA, 2004, CELL MOL BIOL, V50, P387; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; La Mendola D, 2005, J BIOL INORG CHEM, V10, P463, DOI 10.1007/s00775-005-0659-z; Levin J, 2005, BIOCHEM BIOPH RES CO, V329, P1200, DOI 10.1016/j.bbrc.2005.02.094; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; *MICR CORP, 1998, ITC DAT AN OR TUT GU, P67; Nielsen AD, 2003, ANAL BIOCHEM, V314, P227, DOI 10.1016/S0003-2697(02)00655-3; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Thackray AM, 2002, BIOCHEM J, V362, P253, DOI 10.1042/0264-6021:3620253; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; WEISS KC, 1985, AM J PHYSIOL, V249, P77; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2000, BIOCHEM BIOPH RES CO, V276, P1217, DOI 10.1006/bbrc.2000.3604; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; ZGIRSKI A, 1990, J INORG BIOCHEM, V39, P137, DOI 10.1016/0162-0134(90)80022-P; Zhang Y, 2000, INORG CHEM, V39, P3057, DOI 10.1021/ic000036s	59	130	131	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42750	42758		10.1074/jbc.M506521200	http://dx.doi.org/10.1074/jbc.M506521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16258172	hybrid			2022-12-25	WOS:000234200800035
J	Adam, E; Hansen, KK; Astudillo, OF; Coulon, L; Bex, F; Duhant, X; Jaumotte, E; Hollenberg, MD; Jacquet, A				Adam, E; Hansen, KK; Astudillo, OF; Coulon, L; Bex, F; Duhant, X; Jaumotte, E; Hollenberg, MD; Jacquet, A			The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CYSTEINE PROTEASE ACTIVITY; INDUCE CYTOKINE RELEASE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; TIGHT JUNCTIONS; GM-CSF; RECEPTOR-2	We investigated and compared the mechanisms by which two dust mite proteolytic allergens, Der p 1 and Der p 3, and a peptide agonist of proteinase-activated receptor 2 (PAR(2)AP) trigger interleukin (IL)-8 release from human pulmonary epithelial cells (A549). Although all three stimuli tested induced the up-regulation of IL-8 ( mRNA and protein), the Der p 1-mediated signaling events did not exactly match those induced by PAR(2)AP and Der p 3. First, Der p 1 was less effective in stimulating IL-8 gene transcriptional activity than PAR(2)AP and Der p 3. Second, Der p 1-mediated IL-8 expression was mainly dependent on NF-kappa B, whereas Der p 3 and PAR(2)AP regulated IL-8 expression through the activation of both NF-kappa B and AP-1. Third, although all three MAP kinases, ERK1/2, p38, and JNK, were activated, Der p 1 induced IL-8 release exclusively via the ERK1/2 signaling pathway, whereas PAR(2)AP and Der p 3 also involved the other kinases. Fourth, in HeLa cells, Der p 1 was able to up-regulate IL-8 secretion independent of PAR(2) expression, and in contrast with PAR(2)AP and Der p 3, Der p 1 was unable to affect calcium signaling via PAR(2) in PAR(2)-expressing KNRK cells. Finally, cleavage by Der p 1 of a synthetic peptide representing the N-terminal activation-cleavage site of PAR(2) did not release a high potency activator of PAR(2) as does Der p 3. We conclude that Der p 1 ( but not Der p 3)-induced IL-8 production in A549 epithelial cells is independent of PAR(2) activation.	Univ Libre Bruxelles, Inst Biol & Med Mol, Dept Appl Genet, B-6041 Gosselies, Belgium; Univ Calgary, Dept Pharmacol & Therapeut, Canadian Inst Hlth Res Prot & Inflammat Network, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med, Canadian Inst Hlth Res Prot & Inflammat Network, Calgary, AB T2N 4N1, Canada; Univ Libre Bruxelles, Inst CERIA, Microbiol Lab, B-1060 Brussels, Belgium; Univ Libre Bruxelles, Erasme Hosp, Dept Immunol, Sch Med,Inst Interdisciplinary Res, B-1060 Brussels, Belgium	Universite Libre de Bruxelles; University of Calgary; University of Calgary; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Jacquet, A (corresponding author), Univ Libre Bruxelles, Inst Biol & Med Mol, Dept Appl Genet, B-6041 Gosselies, Belgium.	alain.jacquet@ulb.ac.be	Jacquet, Alain/GQI-0546-2022; Jacquet, Alain/T-8611-2019; Hollenberg, Morley/AFV-6966-2022	Jacquet, Alain/0000-0002-0980-9741; Jacquet, Alain/0000-0002-0980-9741; 				Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Al-Ani B, 2003, J PHARMACOL EXP THER, V304, P1120, DOI 10.1124/jpet.102.043844; Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Bretschneider E, 1999, BRIT J PHARMACOL, V126, P1735, DOI 10.1038/sj.bjp.0702509; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Davies DE, 2001, CURR OPIN ALLERGY CL, V1, P67, DOI 10.1097/00130832-200102000-00012; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P728, DOI 10.1046/j.1365-2222.2002.01374.x; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; HOSHI H, 1995, CLIN EXP ALLERGY, V25, P720, DOI 10.1111/j.1365-2222.1995.tb00009.x; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; King C, 1998, J IMMUNOL, V161, P3645; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Massaer M, 2001, INT ARCH ALLERGY IMM, V125, P32, DOI 10.1159/000053794; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; MINTA A, 1989, J BIOL CHEM, V264, P8171; Mori N, 1999, INFECT IMMUN, V67, P3872, DOI 10.1128/IAI.67.8.3872-3878.1999; Mukaida N, 2000, INT J HEMATOL, V72, P391; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Simeonova PP, 1996, AM J RESP CELL MOL, V15, P787, DOI 10.1165/ajrcmb.15.6.8969274; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Tancharoen S, 2005, J IMMUNOL, V174, P5796, DOI 10.4049/jimmunol.174.9.5796; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang XL, 2002, J BIOL CHEM, V277, P23620, DOI 10.1074/jbc.M202242200; Wardlaw AJ, 2002, CLIN SCI, V103, P201; Winton HL, 1998, CLIN EXP ALLERGY, V28, P1273, DOI 10.1046/j.1365-2222.1998.00354.x; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	67	127	134	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6910	6923		10.1074/jbc.M507140200	http://dx.doi.org/10.1074/jbc.M507140200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16293628	hybrid			2022-12-25	WOS:000236030900003
J	Torres, E; Rosen, MK				Torres, E; Rosen, MK			Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; N-WASP; ARP2/3 COMPLEX; ACTIN POLYMERIZATION; INITIAL-CHARACTERIZATION; FILOPODIUM FORMATION; CDC42; BINDING; NUCLEATION; MOTIF	Protein- tyrosine kinases and Rho GTPases regulate many cellular processes, including the reorganization and dynamics of the actin cytoskeleton. The Wiskott- Aldrich syndrome protein ( WASP) and its homolog neuronal WASP ( N- WASP) are effectors of the Rho GTPase Cdc42 and provide a direct link between activated membrane receptors and the actin cytoskeleton. WASP and N- WASP are also regulated by a large number of other activators, including protein- tyrosine kinases, phosphoinositides, and Src homology 3- containing adaptor proteins, and can therefore serve as signal integrators inside cells. Here we show that Cdc42 and the Src family kinase Lck cooperate at two levels to enhance WASP activation. First, autoinhibition in N- WASP decreases the efficiency ( k(cat)/ K-m) of phosphorylation and dephosphorylation of the GTPase binding domain by 30- and 40- fold, respectively, and this effect is largely reversed by Cdc42. Second, Cdc42 and the Src homology 3- Src homology 2 module of Lck cooperatively stimulate the activity of phosphorylated WASP, with coupling energy of similar to 2.4 kcal/ mol between the two activators. These combined effects provide mechanisms for high specificity in WASP activation by coincident GTPase and kinase signals.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosen, MK (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mrosen@biochem.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM056322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Buck M, 2004, J MOL BIOL, V338, P271, DOI 10.1016/j.jmb.2004.02.036; Campellone KG, 2004, DEV CELL, V7, P217, DOI 10.1016/j.devcel.2004.07.004; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; EDISON AM, 1995, J BIOL CHEM, V270, P27112, DOI 10.1074/jbc.270.45.27112; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Fuller CL, 2003, IMMUNOL REV, V191, P220, DOI 10.1034/j.1600-065X.2003.00004.x; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung DW, 2005, P NATL ACAD SCI USA, V102, P5685, DOI 10.1073/pnas.0406472102; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; WATTS JD, 1992, J BIOL CHEM, V267, P901; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Wuchty S, 2003, NAT GENET, V35, P176, DOI 10.1038/ng1242	44	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3513	3520		10.1074/jbc.M509416200	http://dx.doi.org/10.1074/jbc.M509416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16293614	hybrid			2022-12-25	WOS:000235128200061
J	Kumar, RN; Shore, SK; Dhanasekaran, N				Kumar, RN; Shore, SK; Dhanasekaran, N			Neoplastic transformation by the gep oncogene, G alpha(12), involves signaling by STAT3	ONCOGENE			English	Article						gep; G alpha(12); STAT3; transformation; JAK3; PDGFR alpha	N-TERMINAL KINASE; PROTEIN-KINASE; CONSTITUTIVE ACTIVATION; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; ALPHA-SUBUNIT; HUMAN OVARIAN; C-DELTA; SRC; GROWTH	G alpha(12), the alpha-subunit of G12, which has been referred to as the gep oncogene, stimulates mitogenic pathways in different cell types and readily induces neoplastic transformation of. fibroblast cell lines. Recently, we have shown that the oncogenic pathway activated by G alpha(12) involves the receptor tyrosine kinase platelet derived growth factor receptor-alpha ( PDGFR alpha) and JAK3. In the present study, we demonstrate that the GTPase-deficient activated mutant of G alpha(12) activates signal transducer and activator of transcription 3 (STAT3) via PDGFRa as well as JAK3. Here we show that G alpha(12) stimulates the phosphorylation of STAT3 at both Tyrosine-705 and Serine-727 residues. Studies to delineate the mechanism by which G alpha(12) stimulates STAT3 have indicated that the Tyrosine-705-phosphorylation of STAT3 involves the tyrosine kinases, Janus Kinase-3 as well as Src kinase, whereas the Serine-727 phosphorylation of STAT3 occurs via the receptor tyrosine kinase, PDGFRa and phosphatidylinositol 3-OH kinase pathway. Our results also indicate that the coexpression of the dominant negative, DNA binding mutant of STAT3 (STAT3DB) inhibits the foci formation as well as anchorage- independent growth of G alpha(12)QL-transfectants, thereby establishing the critical role of STAT3 in G alpha(12)QL-mediated neoplastic cell growth. The results presented here demonstrate, for the. rst time, the ability of G alpha(12) to recruit multiple receptor-, nonreceptor-, and Ser/Thr kinases to stimulate STAT3-signaling to promote neoplastic transformation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,556 AHB, Philadelphia, PA 19140 USA.	danny001@temple.edu			NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berclaz G, 2001, INT J ONCOL, V19, P1155; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Kumar RN, 2004, CELL BIOCHEM BIOPHYS, V41, P63, DOI 10.1385/CBB:41:1:063; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Sambrook J, 2001, MOL CLONING LAB MANU; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; SHORE SK, 1989, ONCOGENE, V4, P1411; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200	47	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					899	906		10.1038/sj.onc.1209132	http://dx.doi.org/10.1038/sj.onc.1209132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247467				2022-12-25	WOS:000235212700009
J	Shenoy, SK; Drake, MT; Nelson, CD; Houtz, DA; Xiao, KH; Madabushi, S; Reiter, E; Premont, RT; Lichtarge, O; Lefkowitz, RJ				Shenoy, SK; Drake, MT; Nelson, CD; Houtz, DA; Xiao, KH; Madabushi, S; Reiter, E; Premont, RT; Lichtarge, O; Lefkowitz, RJ			beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta 2 adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; ANGIOTENSIN-II RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTOR; GAMMA-SUBUNITS; CONSTITUTIVE ACTIVATION; EVOLUTIONARY TRACE; PHOSPHORYLATION; BETA-ARRESTIN-2; AGONIST	Physiological effects of beta adrenergic receptor (beta 2AR) stimulation have been classically shown to result from G(s)-dependent adenylyl cyclase activation. Here we demonstrate a novel signaling mechanism wherein beta-arrestins mediate beta 2AR signaling to extracellular-signal regulated kinases 1/2 (ERK 1/2) independent of G protein activation. Activation of ERK1/2 by the beta 2AR expressed in HEK-293 cells was resolved into two components dependent, respectively, on G(s)-G(i)/protein kinase A (PKA) or beta-arrestins. G protein-dependent activity was rapid, peaking within 2-5 min, was quite transient, was blocked by pertussis toxin (G(i) inhibitor) and H-89 (PKA inhibitor), and was insensitive to depletion of endogenous beta-arrestins by siRNA. beta-Arrestin-dependent activation was slower in onset (peak 5-10 min), less robust, but more sustained and showed little decrement over 30 min. It was insensitive to pertussis toxin and H-89 and sensitive to depletion of either beta-arrestin1 or -2 by small interfering RNA. In G(s) knock-out mouse embryonic fibroblasts, wild-type beta 2AR recruited beta-arrestin2-green fluorescent protein and activated pertussis toxin-insensitive ERK1/2. Furthermore, a novel beta 2AR mutant (beta 2AR(T68F,Y132G,Y219A) or beta 2AR(TYY)), rationally designed based on Evolutionary Trace analysis, was incapable of G protein activation but could recruit beta-arrestins, undergo beta-arrestin-dependent internalization, and activate beta-arrestin-dependent ERK. Interestingly, overexpression of GRK5 or -6 increased mutant receptor phosphorylation and beta-arrestin recruitment, led to the formation of stable receptor-beta-arrestin complexes on endosomes, and increased agonist-stimulated phospho-ERK1/2. In contrast, GRK2, membrane translocation of which requires G beta gamma release upon G protein activation, was ineffective unless it was constitutively targeted to the plasma membrane by a prenylation signal (CAAX). These findings demonstrate that the beta 2AR can signal to ERK via a GRK5/6-beta-arrestin-dependent pathway, which is independent of G protein coupling.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Dept Biochem, Med Ctr, Durham, NC 27710 USA; INRA, F-37380 Nouzilly, France; Baylor Coll Med, Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA	Duke University; Howard Hughes Medical Institute; Duke University; INRAE; Baylor College of Medicine; Baylor College of Medicine	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Shenoy, Sudha/AAN-4075-2021; soler, martha maricel m gomez/L-6025-2014; Lefkowitz, Robert/AAW-2649-2021; Xiao, Kunhong/AAG-4275-2020	Shenoy, Sudha/0000-0002-2565-4663; soler, martha maricel m gomez/0000-0002-4412-8108; Xiao, Kunhong/0000-0002-1069-1226; Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL70631, HL16037] Funding Source: Medline; NIDDK NIH HHS [T32-DK-00701] Funding Source: Medline; NIGMS NIH HHS [GM66099] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037, R01HL070631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bastepe M, 2002, MOL ENDOCRINOL, V16, P1912, DOI 10.1210/me.2002-0054; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Friedman J, 2002, MOL PHARMACOL, V62, P1094, DOI 10.1124/mol.62.5.1094; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gaudin P, 1999, BIOCHEM BIOPH RES CO, V254, P15, DOI 10.1006/bbrc.1998.9883; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Gesty-Palmer D, 2005, J BIOL CHEM, V280, P32157, DOI 10.1074/jbc.M507460200; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Haga T, 2002, METHOD ENZYMOL, V343, P559; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, J BIOL CHEM, V268, P15412; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Stalheim L, 2005, MOL PHARMACOL, V67, P78, DOI 10.1124/mol.104.006072; Thomas WG, 2003, TRENDS ENDOCRIN MET, V14, P130, DOI 10.1016/S1043-2760(03)00023-7; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; Xiao R P, 2001, Sci STKE, V2001, pre15, DOI 10.1126/stke.2001.104.re15; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	53	590	606	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1261	1273		10.1074/jbc.M506576200	http://dx.doi.org/10.1074/jbc.M506576200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16280323	Green Published, hybrid			2022-12-25	WOS:000234447200069
J	Shivaprasad, S; Wetzel, R				Shivaprasad, S; Wetzel, R			Scanning cysteine mutagenesis analysis of A beta-(1-40) amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN FIBRILLOGENESIS; PROTOFIBRILS; SHEET; MECHANISM; PARALLEL; CORE; ANTIPARALLEL; MICROSCOPY; RESISTANT; PEPTIDE	We describe here the use of cysteine substitution mutants in the Alzheimer disease amyloid plaque peptide A beta-(1-40) to probe amyloid fibril structure and stabilization. In one approach, amyloid fibrils were grown from Cys mutant peptides under reducing conditions and then challenged with an alkylating agent to probe solvent accessibility of different residues in the fibril. In another approach, monomeric Cys mutants, either in the thiol form or modified with iodoacetic acid or methyl iodide, were grown into amyloid fibrils, and the equilibrium position at the end of the amyloid formation reaction was quantified by determining the concentration of monomeric A beta. The Delta G values of fibril elongation obtained were then compared in order to provide information on the environment of each residue side chain in the fibril. In general, Cys residues in the N and C termini of A beta-(1-40) were not only accessible to alkylation in the fibril state but also, when modified in the monomeric state, did not greatly impact fibril stability; these observations were consistent with previous indications that these portions of the peptide are not part of the amyloid core. In contrast, residues 16-19 and 31-34 were not only uniformly inaccessible to alkylation in the fibril state, but their modification with the negatively charged carboxymethyl group in monomeric A beta also destabilized fibril elongation, confirming other data showing that these segments are likely packed into a hydrophobic amyloid core. Residues 20, 30, and 35, flanking these implicated beta-sandwich regions, are accessible to alkylation in the fibril indicating a location in solvent exposed structure.	Univ Tennessee, Grad Sch Med, Knoxville, TN 37920 USA	University of Tennessee System; University of Tennessee Health Science Center	Wetzel, R (corresponding author), Univ Tennessee, Grad Sch Med, 1924 Alcoa Highway, Knoxville, TN 37920 USA.	rwetzel@mc.utmck.edu	Wetzel, Ronald/G-7453-2011		NATIONAL INSTITUTE ON AGING [R01AG018416] Funding Source: NIH RePORTER; NIA NIH HHS [AG 18416] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Cannon MJ, 2004, ANAL BIOCHEM, V328, P67, DOI 10.1016/j.ab.2004.01.014; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chen SM, 2001, PROTEIN SCI, V10, P887, DOI 10.1110/ps.42301; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P265; DELMAR C, 2005, P NATL ACAD SCI USA, P102; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Iwata K, 2001, J AM CHEM SOC, V123, P6728, DOI 10.1021/ja015735y; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Kane J F, 1991, Bioprocess Technol, V12, P121; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2003, BIOCHEMISTRY-US, V42, P14092, DOI 10.1021/bi0357816; Kheterpal I, 2003, PROTEIN SCI, V12, P635, DOI 10.1110/ps.0225703; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Means GE, 1971, CHEM MODIFICATION PR, P105; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; ONUALLAIN B, 2002, BIOCHEMISTRY-US, V4, P12709; ONUALLAIN B, 2006, IN PRESS METHODS ENZ; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2004, J MOL BIOL, V335, P247, DOI 10.1016/j.jmb.2003.10.044; Petrucelli L, 2004, ANN MED, V36, P315, DOI 10.1080/07853890410031948; Shivaprasad S, 2004, BIOCHEMISTRY-US, V43, P15310, DOI 10.1021/bi048019s; SHIVAPRASAD S, 2003, IN PRESS METHODS ENZ; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Vigouroux S, 2004, MOL NEUROBIOL, V30, P201, DOI 10.1385/MN:30:2:201; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WETZEL R, 1983, PEPTIDES ANAL SYNTHE, V5, P1; WETZEL R, 1992, STABILITY PROTEIN PH, P43; Whittemore NA, 2005, BIOCHEMISTRY-US, V44, P4434, DOI 10.1021/bi048292u; Williams AD, 2005, P NATL ACAD SCI USA, V102, P7115, DOI 10.1073/pnas.0408582102; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008	53	65	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					993	1000		10.1074/jbc.M505091200	http://dx.doi.org/10.1074/jbc.M505091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16263715	hybrid			2022-12-25	WOS:000234447200039
J	Kuwahara, T; Koyama, A; Gengyo-Ando, K; Masuda, M; Kowa, H; Tsunoda, M; Mitani, S; Iwatsubo, T				Kuwahara, T; Koyama, A; Gengyo-Ando, K; Masuda, M; Kowa, H; Tsunoda, M; Mitani, S; Iwatsubo, T			Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA MODEL; C-ELEGANS; INCLUSION FORMATION; LEWY BODIES; DISEASE; MUTATION; MICE; AGGREGATION; E46K; NEUROTOXICITY	Mutations in alpha-synuclein gene cause familial form of Parkinson disease, and deposition of wild-type alpha-synuclein as Lewy bodies occurs as a hallmark lesion of sporadic Parkinson disease and dementia with Lewy bodies, implicating alpha-synuclein in the pathogenesis of Parkinson disease and related neurodegenerative diseases. Dopamine neurons in substantia nigra are the major site of neurodegeneration associated with alpha-synuclein deposition in Parkinson disease. Here we establish transgenic Caenorhabditis elegans (TG worms) that overexpresses wild-type or familial Parkinson mutant human alpha-synuclein in dopamine neurons. The TG worms exhibit accumulation of alpha-synuclein in the cell bodies and neurites of dopamine neurons, and EGFP labeling of dendrites is often diminished in TG worms expressing familial Parkinson disease-linked A30P or A53T mutant alpha-synuclein, without overt loss of neuronal cell bodies. Notably, TG worms expressing A30P or A53T mutant alpha-synuclein show failure in modulation of locomotory rate in response to food, which has been attributed to the function of dopamine neurons. This behavioral abnormality was accompanied by a reduction in neuronal dopamine content and was treatable by administration of dopamine. These phenotypes were not seen upon expression of alpha-synuclein. The present TG worms exhibit dopamine neuron- specific dysfunction caused by accumulation of alpha-synuclein, which would be relevant to the genetic and compound screenings aiming at the elucidation of pathological cascade and therapeutic strategies for Parkinson disease.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Bioanalyt Chem, Tokyo 1130033, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan	University of Tokyo; University of Tokyo; Tokyo Women's Medical University	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019; Tsunoda, Makoto/AFI-6623-2022; Kuwahara, Tomoki/AAX-2459-2020; Kuwahara, Tomoki/AAT-7119-2021	Tsunoda, Makoto/0000-0001-9596-5988; Kuwahara, Tomoki/0000-0003-1788-7018				Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; BRENNER S, 1974, GENETICS, V77, P71; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Gomez-Isla T, 2003, NEUROBIOL AGING, V24, P245, DOI 10.1016/S0197-4580(02)00091-X; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Kahle PJ, 2002, EMBO REP, V3, P583, DOI 10.1093/embo-reports/kvf109; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kowa H, 2004, AM J PATHOL, V165, P273, DOI 10.1016/S0002-9440(10)63295-6; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lakso M, 2003, J NEUROCHEM, V86, P165, DOI 10.1046/j.1471-4159.2003.01809.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuoka Y, 2001, NEUROBIOL DIS, V8, P535, DOI 10.1006/nbdi.2001.0392; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITANI S, 1995, DEV GROWTH DIFFER, V37, P551; Nass R, 2002, P NATL ACAD SCI USA, V99, P3264, DOI 10.1073/pnas.042497999; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SVENDSEN PC, 1995, DEVELOPMENT, V121, P1253; Tsunoda M, 1999, ANAL BIOCHEM, V269, P386, DOI 10.1006/abio.1999.4043; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	42	134	144	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					334	340		10.1074/jbc.M504860200	http://dx.doi.org/10.1074/jbc.M504860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260788	hybrid			2022-12-25	WOS:000234307200042
J	Sepulveda, MR; Berrocal-Carrillo, MB; Gasset, M; Mata, AM				Sepulveda, MR; Berrocal-Carrillo, MB; Gasset, M; Mata, AM			The plasma membrane Ca2+-ATPase isoform 4 is localized in lipid rafts of cerebellum synaptic plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-INSOLUBLE COMPLEXES; CALCIUM-PUMP; SCRAPIE ISOFORM; PRION PROTEIN; CA2+ PUMP; DOMAINS; CAVEOLAE; PALMITOYLATION; CHOLESTEROL; BRAIN	Here we describe the association of the synaptosomal plasma membrane Ca2+-ATPase (PMCA) from pig cerebellum with cholesterol/ sphingomyelin-rich membrane domains ( rafts). The PMCA4 was localized exclusively in rafts prepared by floatation in Nycodenz density gradients of ice- cold Brij 96 extracts. This was corroborated by its colocalization with the raft markers cholesterol, ganglioside GM1, and PrPC. The remaining PMCA isoforms were found in the detergent-soluble fractions, with the majority of the membrane proteins. Activity assays confirmed the bimodal distribution of the PMCA isoforms in the density gradient, with a lower activity for PMCA4 and greater stimulation by calmodulin than for the other isoforms. By providing an ordered membrane microenvironment, lipid rafts may contribute to the interaction of PMCA4 with proteins involved in Ca2+ signaling at discrete functional positions on the synaptic nerve terminals.	Univ Extremadura, Dept Bioquim & Biol Mol & Genet, Fac Ciencia, E-06071 Badajoz, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	Universidad de Extremadura; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Mata, AM (corresponding author), Univ Extremadura, Dept Bioquim & Biol Mol & Genet, Fac Ciencia, Avda Elvas S-N, E-06071 Badajoz, Spain.	anam@unex.es	Sepulveda, M. Rosario/L-4907-2014; Berrocal Carrillo, María/H-1527-2018; Gasset, Maria/I-2050-2014; Gasset, Maria/K-4339-2012; Mata, Ana M./J-8460-2014	Sepulveda, M. Rosario/0000-0002-2375-5866; Berrocal Carrillo, María/0000-0003-0684-3853; Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055; Mata, Ana M./0000-0002-2887-7854				Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Balbis A, 2004, J BIOL CHEM, V279, P39348, DOI 10.1074/jbc.M404280200; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gubitosi-Klug RA, 2005, P NATL ACAD SCI USA, V102, P5964, DOI 10.1073/pnas.0501999102; Hering H, 2003, J NEUROSCI, V23, P3262; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Legname G, 2002, P NATL ACAD SCI USA, V99, P16285, DOI 10.1073/pnas.242611999; Ma L, 2003, J NEUROSCI, V23, P3164; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Molander-Melin M, 2005, J NEUROCHEM, V92, P171, DOI 10.1111/j.1471-4159.2004.02849.x; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Padanyi R, 2003, J BIOL CHEM, V278, P35798, DOI 10.1074/jbc.M305794200; Pang YH, 2005, FEBS LETT, V579, P2397, DOI 10.1016/j.febslet.2005.03.038; Parkin ET, 1999, J NEUROCHEM, V72, P1534, DOI 10.1046/j.1471-4159.1999.721534.x; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Radeva G, 2004, BIOCHEM J, V380, P219, DOI 10.1042/BJ20031348; Salvador JM, 1996, BIOCHEM J, V315, P183, DOI 10.1042/bj3150183; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Sepulveda MR, 2004, EUR J NEUROSCI, V19, P542, DOI 10.1111/j.0953-816X.2003.03156.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhao YF, 2004, ARCH BIOCHEM BIOPHYS, V427, P204, DOI 10.1016/j.abb.2004.04.009; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486	49	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					447	453		10.1074/jbc.M506950200	http://dx.doi.org/10.1074/jbc.M506950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249176	Green Published, hybrid			2022-12-25	WOS:000234307200055
J	Wang, CH; Liu, JH; Lee, SC; Hsiao, CD; Wu, WG				Wang, CH; Liu, JH; Lee, SC; Hsiao, CD; Wu, WG			Glycosphingolipid-facilitated membrane insertion and internalization of cobra cardiotoxin - The sulfatide center dot cardiotoxin complex structure in a membrane-like environment suggests a lipid-dependent cell-penetrating mechanism for membrane binding polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; CHOLERA-TOXIN; MASS-SPECTROMETRY; DELTA-LYSIN; PEPTIDES; ENDOCYTOSIS; PROTEIN; MITOCHONDRIA	Cobra cardiotoxins, a family of basic polypeptides having lipid- and heparin-binding capacities similar to the cell-penetrating peptides, induce severe tissue necrosis and systolic heart arrest in snakebite victims. Whereas cardiotoxins are specifically retained on the cell surface via heparan sulfate-mediated processes, their lipid binding ability appears to be responsible, at least in part, for cardiotoxin-induced membrane leakage and cell death. Although the exact role of lipids involved in toxin-mediated cytotoxicity remains largely unknown, monoclonal anti-sulfatide antibody O4 has recently been shown to inhibit the action of CTX A3, the major cardiotoxin from Taiwan cobra venom, on cardiomyocytes by preventing cardiotoxin-induced membrane leakage and CTX A3 internalization into mitochondria. Here, we show that anti-sulfatide acts by blocking the binding of CTX A3 to the sulfatides in the plasma membrane to prevent sulfatide-dependent CTX A3 membrane pore formation and internalization. We also describe the crystal structure of a CTX A3-sulfatide complex in a membrane-like environment at 2.3 angstrom resolution. The unexpected orientation of the sulfatide fatty chains in the structure allows prediction of the mode of toxin insertion into the plasma membrane. CTXA3 recognizes both the headgroup and the ceramide interfacial region of sulfatide to induce a lipid conformational change that may play a key role in CTX A3 oligomerization and cellular internalization. This proposed lipid-mediated toxin translocation mechanism may also shed light on the cellular uptake mechanism of the amphiphilic cell-penetrating peptides known to involve multiple internalization pathways.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30013, Taiwan; Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30013, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University; National Tsing Hua University	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	hsiao@gate.sinica.edu.tw; wgwu@life.nthu.edu.tw	Liu, Jyung-Hurng/C-1340-2010; Hsiao, Chwan-Deng/D-7327-2013; Hsiao, Chwan-Deng/AAZ-8869-2021	Liu, Jyung-Hurng/0000-0002-7173-0372; Hsiao, Chwan-Deng/0000-0002-7012-1532				Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; BOUGIS PE, 1989, BIOCHEMISTRY-US, V28, P3037, DOI 10.1021/bi00433a045; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DUFTON MJ, 1991, SNAKE TOXINS; Esteve E, 2005, J BIOL CHEM, V280, P12833, DOI 10.1074/jbc.M412521200; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Forouhar F, 2003, J BIOL CHEM, V278, P21980, DOI 10.1074/jbc.M208650200; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Huang WN, 2003, BIOCHEMISTRY-US, V42, P7457, DOI 10.1021/bi0344477; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kolter T, 2005, ANNU REV CELL DEV BI, V21, P81, DOI 10.1146/annurev.cellbio.21.122303.120013; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SC, 2005, J BIOL CHEM, V280, P9567, DOI 10.1074/jbc.M412398200; Lencer WI, 2003, TRENDS BIOCHEM SCI, V28, P639, DOI 10.1016/j.tibs.2003.10.002; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; LORIES V, 1989, J BIOL CHEM, V264, P7009; MACALA LJ, 1983, J LIPID RES, V24, P1243; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Marbois BN, 2000, BBA-MOL CELL BIOL L, V1484, P59, DOI 10.1016/S1388-1981(99)00201-2; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; McCann JA, 1997, BIOCHEMISTRY-US, V36, P9169, DOI 10.1021/bi962996p; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Menikh A, 1997, BIOCHEMISTRY-US, V36, P3438, DOI 10.1021/bi961869q; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Morales A, 2004, GLYCOCONJUGATE J, V20, P579; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NYHOLM PG, 1990, CHEM PHYS LIPIDS, V52, P1, DOI 10.1016/0009-3084(90)90002-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; Pokorny A, 2005, BIOCHEMISTRY-US, V44, P9538, DOI 10.1021/bi0506371; Pokorny A, 2004, BIOCHEMISTRY-US, V43, P8846, DOI 10.1021/bi0497087; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Rostand KS, 1997, INFECT IMMUN, V65, P1; SAITO M, 1985, ANAL BIOCHEM, V148, P54, DOI 10.1016/0003-2697(85)90627-X; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Subasinghe S, 2003, J NEUROCHEM, V84, P471, DOI 10.1046/j.1471-4159.2003.01552.x; Sue SC, 2002, J BIOL CHEM, V277, P2666, DOI 10.1074/jbc.M104887200; Sue SC, 2001, BIOCHEMISTRY-US, V40, P10436, DOI 10.1021/bi010847n; Tettamanti G, 2003, GLYCOCONJUGATE J, V20, P301, DOI 10.1023/B:GLYC.0000033627.02765.cc; Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049; Wang CH, 2005, TOXICON, V46, P430, DOI 10.1016/j.toxicon.2005.06.012; Wang CH, 2005, FEBS LETT, V579, P3169, DOI 10.1016/j.febslet.2005.05.006; Watanabe R, 1999, J NEUROCHEM, V73, P1375, DOI 10.1046/j.1471-4159.1999.0731375.x; Whitfield PD, 2001, MOL GENET METAB, V73, P30, DOI 10.1006/mgme.2001.3165; Williams SJ, 2001, TRENDS BIOTECHNOL, V19, P356, DOI 10.1016/S0167-7799(01)01699-7; Yang SH, 2005, CLIN EXP PHARMACOL P, V32, P515, DOI 10.1111/j.1440-1681.2005.04223.x; Zajonc DM, 2005, IMMUNITY, V22, P209, DOI 10.1016/j.immuni.2004.12.009; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	70	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					656	667		10.1074/jbc.M507880200	http://dx.doi.org/10.1074/jbc.M507880200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263708	hybrid			2022-12-25	WOS:000234307200078
J	Matsumoto, S; Ogino, K; Noguchi, E; Russell, P; Masai, H				Matsumoto, S; Ogino, K; Noguchi, E; Russell, P; Masai, H			Hsk1-Dfp1/Him1, the Cdc7-Dbf4 kinase in Schizosaccharomyces pombe, associates with Swi1, a component of the replication fork protection complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; FISSION YEAST; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; ALKYLATION DAMAGE; PROTEIN-KINASE; HSK1 KINASE; CELL-CYCLE; GENE; INITIATION	The protein kinase Hsk1 is essential for DNA replication in Schizosaccharomyces pombe. It associates with Dfp1/Him1 to form an active complex equivalent to the Cdc7-Dbf4 protein kinase in Saccharomyces cerevisiae. Swi1 and Swi3 are subunits of the replication fork protection complex in S. pombe that is homologous to the Tof1-Csm3complex in S. cerevisiae. The fork protection complex helps to preserve the integrity of stalled replication forks and is important for activation of the checkpoint protein kinase Cds1 in response to fork arrest. Here we describe physical and genetic interactions involving Swi1 and Hsk1-Dfp1/Him1.Dfp1/Him1 was identified in a yeast two-hybrid screen with Swi1. Hsk1 and Dfp1/Him1 both co-immunoprecipitate with Swi1. Swi1 is required for growth of a temperature-sensitive hsk1 (hsk1ts) mutant at its semi-permissive temperature. Hsk1(ts) cells accumulate Rad22 (Rad52 homologue) DNA repair foci at the permissive temperature, as previously observed in swi1 Delta cells, indicating that abnormal single-stranded DNA regions form near the replication fork in hsk1(ts) cells. hsk1(ts) cells were also unable to properly delay S-phase progression in the presence of a DNA alkylating agent and were partially defective in mating type switching. These data suggest that Hsk1-Dfp1/Him1 and Swi1-Swi3 complexes have interrelated roles in stabilization of arrested replication forks.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan; Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Tokyo Metropolitan Institute of Medical Science; Drexel University; Scripps Research Institute; Scripps Research Institute	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp	Noguchi, Eishi/E-7283-2013; Noguchi, Eishi/AAF-3986-2021	Noguchi, Eishi/0000-0001-5470-5127; 				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Alfa C., 1993, EXPT FISSION YEAST; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Du LL, 2003, MOL CELL BIOL, V23, P6150, DOI 10.1128/MCB.23.17.6150-6158.2003; Fung AD, 2002, MOL CELL BIOL, V22, P4477, DOI 10.1128/MCB.22.13.4477-4490.2002; Grewal SIS, 1997, GENETICS, V146, P1221; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nedelcheva MN, 2005, J MOL BIOL, V347, P509, DOI 10.1016/j.jmb.2005.01.041; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Sclafani RA, 2000, J CELL SCI, V113, P2111; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966	25	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42536	42542		10.1074/jbc.M510575200	http://dx.doi.org/10.1074/jbc.M510575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263721	hybrid			2022-12-25	WOS:000234200800009
J	Varin, A; Decrion, AZ; Sabbah, E; Quivy, V; Sire, J; Van Lint, C; Roques, BP; Aggarwal, BB; Herbein, G				Varin, A; Decrion, AZ; Sabbah, E; Quivy, V; Sire, J; Van Lint, C; Roques, BP; Aggarwal, BB; Herbein, G			Synthetic vpr protein activates activator protein-1, c-jun N-terminal kinase, and NF-kappa B and stimulates HIV-1 transcription in promonocytic cells and primary macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VPR; NUCLEAR-LOCALIZATION; CYCLE ARREST; REGULATORY PROTEIN; T-CELLS; GLUCOCORTICOID-RECEPTOR; MUTATIONAL ANALYSIS; GENE-EXPRESSION; NMR STRUCTURE	The human immunodeficiency virus (HIV) Vpr protein plays a critical role in AIDS pathogenesis, especially by allowing viral replication within nondividing cells such as mononuclear phagocytes. Most of the data obtained so far have been in experiments with endogenous Vpr protein; therefore the effects of extracellular Vpr protein remain largely unknown. We used synthetic Vpr protein to activate nuclear transcription factors activator protein-1 (AP-1) and NF-kappa B in the promonocytic cell line U937 and in primary macrophages. Synthetic HIV-1 Vpr protein activated AP-1, c-Jun N-terminal kinase, and MKK7 in both U937 cells and primary macrophages. Synthetic Vpr activated NF-kappa B in primary macrophages and to a lesser extent in U937 cells. Because synthetic Vpr activated AP-1 and NF-kappa B, which bind to the HIV-1 long terminal repeat, we investigated the effect of synthetic Vpr on HIV-1 replication. We observed that synthetic Vpr stimulated HIV-1 long terminal repeat in U937 cells and enhanced viral replication in chronically infected U1 promonocytic cells. Similarly, synthetic Vpr stimulated HIV-1 replication in acutely infected primary macrophages. Activation of transcription factors and enhancement of viral replication in U937 cells and primary macrophages were mediated by both the N-terminal and the C-terminal moieties of synthetic Vpr. Therefore, our results suggest that extracellular Vpr could fuel the progression of AIDS via stimulation of HIV-1 provirus present in such cellular reservoirs as mononuclear phagocytes in HIV-infected patients.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Franche Comte, Dept Virol, EA3186, IFR133, F-25030 Besancon, France; INSERM, U372, F-13276 Marseille, France; Univ Libre Bruxelles, Lab Virol Mol, Serv Chim Biol, Inst Biol & Med Mol, B-6041 Gosselies, Belgium; INSERM, Dept Pharmacochim Mol & Struct, U266, CNRS,UMR 8600, F-75270 Paris, France	University of Texas System; UTMD Anderson Cancer Center; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Herbein, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org; gherbein@chu-besancon.fr	Aggarwal, Bharat B/G-3388-2013	Varin, Audrey/0000-0002-9182-9193				Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905; Asin S, 2001, J VIROL, V75, P11408, DOI 10.1128/JVI.75.23.11408-11416.2001; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen MZ, 1999, J VIROL, V73, P3236, DOI 10.1128/JVI.73.4.3236-3245.1999; Coeytaux E, 2003, J BIOL CHEM, V278, P18110, DOI 10.1074/jbc.M300248200; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Conti L, 2000, J IMMUNOL, V165, P3293, DOI 10.4049/jimmunol.165.6.3293; de Rocquigny H, 2000, EUR J BIOCHEM, V267, P3654, DOI 10.1046/j.1432-1327.2000.01397.x; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS TM, 1988, J IMMUNOL, V140, P1117; Forget J, 1998, J MOL BIOL, V284, P915, DOI 10.1006/jmbi.1998.2206; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gummuluru S, 1999, J VIROL, V73, P5422, DOI 10.1128/JVI.73.7.5422-5430.1999; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Herbein G, 1997, J VIROL, V71, P4150, DOI 10.1128/JVI.71.5.4150-4156.1997; Herbein G, 1996, J VIROL, V70, P7388, DOI 10.1128/JVI.70.11.7388-7397.1996; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; Iordanskiy S, 2004, BLOOD, V104, P1867, DOI 10.1182/blood-2004-01-0081; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jacque JM, 1996, J VIROL, V70, P2930; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kamata M, 2000, J VIROL, V74, P7179, DOI 10.1128/JVI.74.15.7179-7186.2000; Karni O, 1998, FEBS LETT, V429, P421, DOI 10.1016/S0014-5793(98)00645-0; Kichler A, 2000, J VIROL, V74, P5424, DOI 10.1128/JVI.74.12.5424-5431.2000; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kumar A, 1998, J IMMUNOL, V161, P776; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Lum JJ, 2003, J CLIN INVEST, V111, P1547, DOI 10.1172/JCI200316233; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; Mahlknecht U, 2004, J IMMUNOL, V173, P3979, DOI 10.4049/jimmunol.173.6.3979; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; Muthumani K, 2004, DNA CELL BIOL, V23, P239, DOI 10.1089/104454904773819824; Muthumani K, 2002, J BIOL CHEM, V277, P37820, DOI 10.1074/jbc.M205313200; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; Richardson MW, 2003, BIOMED PHARMACOTHER, V57, P4, DOI 10.1016/S0753-3322(02)00327-X; Roumier T, 2002, CELL DEATH DIFFER, V9, P1212, DOI 10.1038/sj.cdd.4401089; Roux P, 2000, J VIROL, V74, P4658, DOI 10.1128/JVI.74.10.4658-4665.2000; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 2000, J VIROL, V74, P4877, DOI 10.1128/JVI.74.10.4877-4881.2000; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2003, J VIROL, V77, P7582, DOI 10.1128/JVI.77.13.7582-7589.2003; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Thotala D, 2004, VIROLOGY, V328, P89, DOI 10.1016/j.virol.2004.07.013; Vanitharani R, 2001, VIROLOGY, V289, P334, DOI 10.1006/viro.2001.1153; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; Varin A, 2003, J BIOL CHEM, V278, P2219, DOI 10.1074/jbc.M209622200; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Waldhuber MG, 2003, VIROLOGY, V313, P91, DOI 10.1016/S0042-6822(03)00258-7; Wang B, 1996, VIROLOGY, V223, P224, DOI 10.1006/viro.1996.0471; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zander K, 2003, J BIOL CHEM, V278, P43202, DOI 10.1074/jbc.M305414200; Zhu Y, 2003, APOPTOSIS, V8, P71, DOI 10.1023/A:1021653119934	84	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42557	42567		10.1074/jbc.M502211200	http://dx.doi.org/10.1074/jbc.M502211200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16243842	hybrid			2022-12-25	WOS:000234200800012
J	Sun, W; Xu, WF; Snyder, M; He, W; Ho, H; Ivashkiv, LB; Zhang, JJ				Sun, W; Xu, WF; Snyder, M; He, W; Ho, H; Ivashkiv, LB; Zhang, JJ			The conserved Leu-724 residue is required for both serine phosphorylation and co-activator recruitment for Stat1-mediated transcription activation in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; IFN-GAMMA; TRANSACTIVATION DOMAINS; TARGETED DISRUPTION; SIGNALING PATHWAY; GENE-EXPRESSION; INNATE IMMUNITY; MAP KINASE; STAT1; PROTEIN	The signal transducer and activator of transcription (STAT) proteins, a family of latent cytoplasmic transcription factors, become activated in response to extracellular ligand binding to cell surface receptors through tyrosine phosphorylation. Concurrently, a serine phosphorylation event in the transcription activation domain (serine 727 for Stat1) occurs. This serine phosphorylation is essential for the maximal transcription activity of Stat1. Here we show that, in addition to the Ser-727 residue and its phosphorylation, the conserved Leu-724 residue is also essential for gene activation mediated by Stat1. When Leu-724 is mutated to Ala, phosphorylation of Stat1 Ser-727 is defective both in vivo and in vitro. Surprisingly, we found a StatL724I mutant that lacks transcription activity despite normal Ser-727 phosphorylation. Further analyses show that Leu-724, as well as the phospho-Ser-727, are essential for the recruitment of the transcription co-activator CBP/p300 to the promoters of Stat1 target genes. Our results demonstrate that the conserved Leu-724 residue is a key residue that controls the maximal transcription activities of Stat1 in IFN-gamma signaling.	Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Hosp Special Surg, Arthritis & Tissue Degenerat Program, New York, NY 10021 USA; Hosp Special Surg, Program Immunol, New York, NY 10021 USA	Cornell University	Zhang, JJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10021 USA.	jjz2002@med.cornell.edu			NIGMS NIH HHS [GM61652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FONG YL, 1989, J BIOL CHEM, V264, P16759; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu BF, 1997, J IMMUNOL, V159, P1255; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Morinobu A, 2002, P NATL ACAD SCI USA, V99, P12281, DOI 10.1073/pnas.182618999; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tassiulas I, 2004, NAT IMMUNOL, V5, P1181, DOI 10.1038/ni1126; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang E, 2003, J BIOL CHEM, V278, P15794, DOI 10.1074/jbc.M213073200; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	41	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41844	41851		10.1074/jbc.M505797200	http://dx.doi.org/10.1074/jbc.M505797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257975	hybrid			2022-12-25	WOS:000233992700010
J	McColl, SR; St-Onge, M; Dussault, AA; Laflamme, C; Bouchard, L; Boulanger, J; Pouliot, M				McColl, SR; St-Onge, M; Dussault, AA; Laflamme, C; Bouchard, L; Boulanger, J; Pouliot, M			Immunomodulatory impact of the A(2A) adenosine receptor on the profile of chemokines produced by neutrophils	FASEB JOURNAL			English	Article						polymorphonuclear leukocytes; experimental animal models; resolution of inflammation	MACROPHAGE INFLAMMATORY PROTEIN-1; NECROSIS-FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; DOWN-REGULATION; EXPRESSION; MECHANISM; CYCLOOXYGENASE-2; RECRUITMENT; RELEASE; SITES	In LPS-stimulated human neutrophils, engagement of the adenosine A(2A) receptor selectively prevented the expression and release of TNF-alpha, MIP-1 alpha/CCL3, MIP-1 beta/CCL4, MIP-2 alpha/CXCL2, and MIP-3 alpha/CCL20. In mice lacking the A(2A) receptor, granulocytes that migrated into the air pouch 4 h after LPS injection expressed higher mRNA levels of TNF-alpha, MIP-1 alpha, and MIP-1 beta than PMNs from wild-type mice. In mononuclear cells present in the air pouch 72 h after LPS injection, expression of IL-1 beta, TNF-alpha, IL- 6, and MCP-2/CCL6 was higher in A(2A)R knockout mice. In addition to highlighting neutrophils as an early and pivotal target for mediating adenosine anti-inflammatory activities, these results identify TNF-alpha and the MIP chemokine family as gene products whose expression is pivotally affected by activation of A(2A)R in LPS-activated PMNs. Modulation by A(2A)R in the production of inflammatory signals by PMNs may thus influence the evolution of an inflammatory response by reducing the activation status of inflammatory cells.	CHUL, Ctr Rech Rhumatol & Immunol, CHUQ, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Anat Physiol, Fac Med, Quebec City, PQ G1K 7P4, Canada; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Laval University; Laval University; University of Adelaide	Pouliot, M (corresponding author), CHUL, Ctr Rech Rhumatol & Immunol, CHUQ, 2705 Laurier Blvd,Off T1-49, Ste Foy, PQ G1V 4G2, Canada.	Marc.Pouliot@crchul.ulaval.ca	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424	Canadian Institutes of Health Research [64315, 72200] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; Cadieux JS, 2005, J CELL SCI, V118, P1437, DOI 10.1242/jcs.01737; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; FANTONE JC, 1985, HUM PATHOL, V16, P973, DOI 10.1016/S0046-8177(85)80273-2; FANTONE JC, 1981, PROSTAG LEUKOTR ESS, V7, P195, DOI 10.1016/0161-4630(81)90062-8; Flamand N, 2000, AM J RESP CRIT CARE, V161, pS88, DOI 10.1164/ajrccm.161.supplement_1.ltta-18; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; Hachicha M, 1998, J IMMUNOL, V160, P449; Kuraishi Y, 2001, Nihon Yakurigaku Zasshi, V117, P248; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; MCCOLL SR, 1992, J EXP MED, V176, P593, DOI 10.1084/jem.176.2.593; Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615; OFLAHERTY JT, 1979, PROSTAGLANDINS, V17, P201, DOI 10.1016/0090-6980(79)90039-X; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Parker LC, 2005, J LEUKOCYTE BIOL, V77, P886, DOI 10.1189/jlb.1104636; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; Pouliot M, 2002, J IMMUNOL, V169, P5279, DOI 10.4049/jimmunol.169.9.5279; Sawyer D W, 1989, Rev Infect Dis, V11 Suppl 7, pS1532; Scapini P, 2001, EUR J IMMUNOL, V31, P1981, DOI 10.1002/1521-4141(200107)31:7<1981::AID-IMMU1981>3.0.CO;2-X; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Thiel M, 2003, MICROBES INFECT, V5, P515, DOI 10.1016/S1286-4579(03)00068-6; THIEL M, 1995, J LAB CLIN MED, V126, P275	29	79	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					187	+		10.1096/fj.05-4804fje	http://dx.doi.org/10.1096/fj.05-4804fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16280366	Green Accepted			2022-12-25	WOS:000234053100015
J	Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A				Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A			Cell context reveals a dual role for Maf in oncogenesis	ONCOGENE			English	Article						AP-1; Jun; transformation; differentiation; tumor suppressor; multiple myeloma	TISSUE-SPECIFIC EXPRESSION; CRYSTALLIN GENE-REGULATION; FACTOR C-MAF; TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; LENS DIFFERENTIATION; TUMOR-SUPPRESSOR; DISTINCT ROLES; GROWTH-FACTOR; INSULIN GENE	Maf b-Zip transcription factors are involved in both terminal differentiation and oncogenesis. To investigate this apparent contradiction, we used two different primary cell types and performed an extensive analysis of transformation parameters induced by Maf proteins. We show that MafA and c-Maf are potent oncogenes in chicken embryo fibroblasts, while MafB appears weaker. We also provide the first evidence that MafA can confer growth factor independence and promote cell division at low density. Moreover, using MafA as a model, we identified several parameters that are critical for Maf transforming activities. Indeed, MafA ability to induce anchorage-independent cell growth was sensitive to culture conditions. In addition, the transforming activity of MafA was dependent on its phosphorylation state, since mutation on Ser65 impaired its ability to induce growth at low density and anchorage-independent growth. We next examined transforming activity of large Maf proteins in embryonic neuroretina cells, where they are known to induce differentiation. Unlike v-Jun, MafA, MafB and c-Maf did not show oncogenic activity in these cells. Moreover, they counteracted transformation induced by constitutive activation of the Ras/Raf/MEK pathway. Taken together, our results show that Maf proteins could display antagonistic functions in oncogenesis depending on the cellular context, and support a dual role for Maf as both oncogenes and tumor suppressor-like proteins.	Ctr Univ, CNRS, Inst Curie Rech, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pouponnot, C (corresponding author), Ctr Univ, CNRS, Inst Curie Rech, UMR 146, Lab 110, F-91405 Orsay, France.	Celio.Pouponnot@curie.u-psud.fr; Alain.Eychene@curie.u-psud.fr	Hmitou, Isabelle/H-8341-2017; Eychene, Alain/M-8838-2017; DRUILLENNEC, Sabine/B-2572-2019	Hmitou, Isabelle/0000-0001-7320-6075; DRUILLENNEC, Sabine/0000-0003-0237-1465; LECOIN, Laure/0000-0001-5259-4339; Karine, SII FELICE/0000-0002-8695-8652; EYCHENE, Alain/0000-0002-6818-7225				Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Blanchi B, 2003, NAT NEUROSCI, V6, P1091, DOI 10.1038/nn1129; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; GOLDE A, 1961, VIROLOGY, V15, P36, DOI 10.1016/0042-6822(61)90074-5; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Lecoin L, 2004, GENE EXPR PATTERNS, V4, P35, DOI 10.1016/S1567-133X(03)00152-2; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Manzanares M, 1999, DEVELOPMENT, V126, P759; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; OSTRER H, 1981, DEV BIOL, V86, P403, DOI 10.1016/0012-1606(81)90198-6; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ring BZ, 2000, DEVELOPMENT, V127, P307; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sii-Felice K, 2005, FEBS LETT, V579, P3547, DOI 10.1016/j.febslet.2005.04.086; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Yoshida K, 2001, CURR EYE RES, V23, P116, DOI 10.1076/ceyr.23.2.116.5479; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	55	38	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1299	1310		10.1038/sj.onc.1209171	http://dx.doi.org/10.1038/sj.onc.1209171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247450				2022-12-25	WOS:000235708200003
J	Watts, AG; Oppezzo, P; Withers, SG; Alzari, PM; Buschiazzo, A				Watts, AG; Oppezzo, P; Withers, SG; Alzari, PM; Buschiazzo, A			Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on Trypanosoma rangeli sialidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANS-SIALIDASE; CELL-ADHESION; MUTAGENESIS; MECHANISM; TYROSINE	Trypanosoma rangeli sialidase is a glycoside hydrolase ( family GH33) that catalyzes the cleavage of alpha-2 -> 3-linked sialic acid residues from sialoglycoconjugates with overall retention of anomeric configuration. Retaining glycosidases usually operate through a ping-pong mechanism, wherein a covalent intermediate is formed between the carbohydrate and an active site carboxylic acid of the enzyme. Sialidases, instead, appear to use a tyrosine as the catalytic nucleophile, leaving the possibility of an essentially different catalytic mechanism. Indeed, a direct nucleophilic role for a tyrosine was shown for the homologous trans- sialidase from Trypanosoma cruzi, although itself not a typical sialidase. Here we present the three-dimensional structures of the covalent glycosyl-enzyme complexes formed by the T. rangeli sialidase with two different mechanism-based inactivators at 1.9 and 1.7 A resolution. To our knowledge, these are the first reported structures of enzymatically competent covalent intermediates for a strictly hydrolytic sialidase. Kinetic analyses have been carried out on the formation and turnover of both intermediates, showing that structural modifications to these inactivators can be used to modify the lifetimes of covalent intermediates. These results provide further evidence that all siali-dases likely operate through a similar mechanism involving the transient formation of a covalently sialylated enzyme. Furthermore, we believe that the ability to "tune" the inactivation and reactivation rates of mechanism- based inactivators toward specific enzymes represents an important step toward developing this class of inactivators into therapeutically useful compounds.	Inst Pasteur, Unite Biochim Struct, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2185, F-75724 Paris 15, France; Univ British Columbia, Dept Chem, Vancouver, BC V6T 121, Canada	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of British Columbia	Buschiazzo, A (corresponding author), Inst Pasteur, Unite Biochim Struct, 25 Rue Dr Roux, F-75724 Paris 15, France.	alebus@pasteur.fr	Buschiazzo, Alejandro/W-1095-2018; Watts, Andrew/D-2802-2014	Buschiazzo, Alejandro/0000-0002-2509-6526; Alzari, Pedro/0000-0002-4233-1903; Oppezzo, Pablo/0000-0003-4194-246X; Watts, Andrew/0000-0003-4299-2717				Amaya MF, 2003, J MOL BIOL, V325, P773, DOI 10.1016/S0022-2836(02)01306-2; Amaya MF, 2004, STRUCTURE, V12, P775, DOI 10.1016/j.str.2004.02.036; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brooks MJ, 2004, CURR OPIN PULM MED, V10, P197, DOI 10.1097/00063198-200405000-00009; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; Dreitlein WB, 2001, CLIN THER, V23, P327, DOI 10.1016/S0149-2918(01)80042-4; Franz CK, 2005, J NEUROSCI, V25, P2081, DOI 10.1523/JNEUROSCI.4880-04.2005; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Howard S, 1998, J BIOL CHEM, V273, P2067, DOI 10.1074/jbc.273.4.2067; JEFFREY GA, 1990, ACTA CRYSTALLOGR B, V46, P89, DOI 10.1107/S0108768189012449; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R. J., 2001, GRAFIT VERSION 5 0; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; McKimm-Breschkin Jennifer L, 2002, Expert Opin Pharmacother, V3, P103, DOI 10.1517/14656566.3.2.103; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newstead S, 2005, BIOCHEMISTRY-US, V44, P9117, DOI 10.1021/bi050517t; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Watson JN, 2005, CHEMBIOCHEM, V6, P1999, DOI 10.1002/cbic.200500114; Watson JN, 2003, BIOCHEMISTRY-US, V42, P12682, DOI 10.1021/bi035396g; Watts AG, 2004, CAN J CHEM, V82, P1581, DOI 10.1139/V04-125; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; Wicki J, 2002, METHOD ENZYMOL, V354, P84; Zechel DL, 2001, CURR OPIN CHEM BIOL, V5, P643, DOI 10.1016/S1367-5931(01)00260-5	33	73	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4149	4155		10.1074/jbc.M510677200	http://dx.doi.org/10.1074/jbc.M510677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16298994	hybrid			2022-12-25	WOS:000235275300046
J	Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG				Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG			c-FLIP inhibits chemotherapy-induced colorectal cancer cell death	ONCOGENE			English	Article						c-FLIP; 5-fluorouracil; oxaliplatin; irinotecan; apoptosis	LIGAND-INDEPENDENT ACTIVATION; MULTICENTER RANDOMIZED-TRIAL; RECEPTOR-INDUCED APOPTOSIS; UP-REGULATION; 1ST-LINE TREATMENT; CARCINOMA-CELLS; FAS; 5-FLUOROURACIL; FLUOROURACIL; RESISTANCE	FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors such as Fas and DR5. We studied the effect of c-FLIP on the apoptotic response to chemotherapies used in colorectal cancer (CRC) (5-fluorouracil, oxaliplatin and irinotecan). Simultaneous downregulation of both c-FLIP splice forms c-FLIPL and c-FLIPS with siRNA synergistically enhanced chemotherapy-induced apoptosis in p53 wild-type (HCT116p53(+/+), RKO), null (HCT116p53(-/-)) and mutant (H630) CRC cell lines. Furthermore, overexpression of c-FLIPL, but not c-FLIPS, potently inhibited apoptosis induced by chemotherapy in HCT116p53(-/-) cells, suggesting that c-FLIPL was the more important splice form in mediating chemoresistance. In support of this, siRNA specifically targeted against c-FLIPL synergistically enhanced chemotherapy-induced apoptosis in a manner similar to the siRNA targeted against both splice forms. Inhibition of caspase 8 blocked the enhanced apoptosis induced by c-FLIP-targeted (FT) siRNA and chemotherapy. Furthermore, we found that downregulating cell surface DR5, but not Fas, also inhibited apoptosis induced by FT siRNA and chemotherapy. Interestingly, these effects were not dependent on activation of DR5 by its ligand TRAIL. These results indicate that c-FLIP inhibits TRAIL-independent, DR5- and caspase 8-dependent apoptosis in response to chemotherapy in CRC cells. Moreover, targeting c-FLIP in combination with existing chemotherapies may have therapeutic potential for the treatment of CRC.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Belfast BT9 7AB, Antrim, North Ireland	Queens University Belfast	Longley, DB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.longley@qub.ac.uk	Wilson, Timothy R/F-8210-2012; McEwan, Miranda V/A-6900-2012	McDermott, Ultan/0000-0001-9032-4700	Medical Research Council [G0400302] Funding Source: Medline; MRC [G0400302] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHINNAIYAN AM, 1995, CELL, V81, P512; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Conticello C, 2004, J IMMUNOL, V172, P5467, DOI 10.4049/jimmunol.172.9.5467; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fulda S, 2000, CANCER RES, V60, P3947; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Iordanov MS, 2005, APOPTOSIS, V10, P167, DOI 10.1007/s10495-005-6071-x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Matta H, 2002, CANCER BIOL THER, V1, P652, DOI 10.4161/cbt.315; Maxwell PJ, 2003, CANCER RES, V63, P4602; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Santiago B, 2004, J IMMUNOL, V172, P560, DOI 10.4049/jimmunol.172.1.560; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	39	163	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	6					838	848		10.1038/sj.onc.1209122	http://dx.doi.org/10.1038/sj.onc.1209122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247474				2022-12-25	WOS:000235212700003
J	Naylor, K; Ingerman, E; Okreglak, V; Marino, M; Hinshaw, JE; Jodi, N				Naylor, K; Ingerman, E; Okreglak, V; Marino, M; Hinshaw, JE; Jodi, N			Mdv1 interacts with assembled Dnm1 to promote mitochondrial division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; RED FLUORESCENT PROTEIN; WD REPEAT PROTEIN; SACCHAROMYCES-CEREVISIAE; FISSION; YEAST; FUSION; SEGREGATION; MORPHOLOGY; LIBRARIES	The dynamin-related GTPase, Dnm1, self-assembles into punctate structures that are targeted to the outer mitochondrial membrane where they mediate mitochondrial division. Post-targeting, Dnm1-dependent division is controlled by the actions of the WD repeat protein, Mdv1, and the mitochondrial tetratricopeptide repeat-like outer membrane protein, Fis1. Our previous studies suggest a model where at this step Mdv1 functions as an adaptor linking Fis1 with Dnm1. To gain insight into the exact role of the Fis1 center dot Mdv1 center dot Dnm1 complex in mitochondrial division, we performed a structure-function analysis of the Mdv1 adaptor. Our analysis suggests that dynamic interactions between Mdv1 and Dnm1 play a key role in division by regulating Dnm1 self-assembly.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Jodi, N (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	jmnunnari@ucdavis.edu			NEI NIH HHS [1R01 EY 015294] Funding Source: Medline; NIGMS NIH HHS [5R01 GM 062942] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060100, ZIADK060100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062942] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Chen HC, 2004, CURR TOP DEV BIOL, V59, P119, DOI 10.1016/S0070-2153(04)59005-1; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; James P, 1996, GENETICS, V144, P1425; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Legesse-Miller A, 2003, MOL BIOL CELL, V14, P1953, DOI 10.1091/mbc.E02-10-0657; MANIATIS T, 1983, MOL CLONING LAB MANU; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Miyazaki K, 2002, BIOTECHNIQUES, V33, P1033, DOI 10.2144/02335st03; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Suzuki M, 2005, J BIOL CHEM, V280, P21444, DOI 10.1074/jbc.M414092200; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Youle RJ, 2005, DEV CELL, V8, P298, DOI 10.1016/j.devcel.2005.02.003	33	112	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2177	2183		10.1074/jbc.M507943200	http://dx.doi.org/10.1074/jbc.M507943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16272155	hybrid			2022-12-25	WOS:000234760400041
J	Vermeer, PD; Panko, L; Welsh, MJ; Zabner, J				Vermeer, PD; Panko, L; Welsh, MJ; Zabner, J			erbB1 Functions as a sensor of airway epithelial integrity by regulation of protein phosphatase 2A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE FER; TIGHT JUNCTION; BETA-CATENIN; N-CADHERIN; IN-VITRO; PHOSPHORYLATION; INVOLVEMENT; OCCLUDIN	Two enzymes, protein phosphatase 2A and atypical protein kinase C, are associated with the tight junction and regulate its function. For example, phosphorylation of the tight junction protein occludin is required for its incorporation into the junction. The association of a kinase and phosphatase with the tight junction suggests that a balance between their activities exists and is required for normal tight junction function. This hypothesis predicts that loss of epithelial integrity may disrupt this balance in such a way as to facilitate restoration of epithelial integrity. Our previous data have shown that apically localized growth factors segregate from their basolaterally localized erbB receptors. Loss of epithelial integrity allows ligand access to the basolateral membrane where it immediately binds to and activates erbB receptors. We found that activation of erbB1 leads to phosphorylation of protein phosphatase 2A, inhibiting its activity. Importantly, this phosphorylation event was dependent on factors in the overlying airway surface liquid; washing away this liquid prevented phosphorylation. erbB1-mediated inhibition of phosphatase activity would shift the balance in favor of the kinase such that tight junction proteins would regain their phosphorylation, allowing for their incorporation into the junction complex. This mechanism provides a rapid means of sensing the loss of epithelial integrity and subsequently restoring barrier function.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Nebraska, Program Forens Sci, Lincoln, NE 68588 USA	University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Nebraska System; University of Nebraska Lincoln	Zabner, J (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, 440 EMRB, Iowa City, IA 52242 USA.	joseph-zabner@uiowa.edu	Vermeer, Paola D/O-2572-2013	Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060113] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL075276-01A1] Funding Source: Medline; NIDDK NIH HHS [K01 DK60113-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chen YM, 2003, BIOL REPROD, V69, P656, DOI 10.1095/biolreprod.103.016881; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Meyer TN, 2001, J BIOL CHEM, V276, P22048, DOI 10.1074/jbc.M011477200; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Simonovic I, 2000, CELL MICROBIOL, V2, P305, DOI 10.1046/j.1462-5822.2000.00055.x; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tobey NA, 2004, AM J PHYSIOL-GASTR L, V286, pG1042, DOI 10.1152/ajpgi.00387.2003; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Xu G, 2002, J BIOL CHEM, V277, P49989, DOI 10.1074/jbc.M206454200; Yamagata T, 2002, EXP LUNG RES, V28, P543, DOI 10.1080/01902140290103062; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Zabner J, 1996, GENE THER, V3, P458	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1725	1730		10.1074/jbc.M506933200	http://dx.doi.org/10.1074/jbc.M506933200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293617	hybrid			2022-12-25	WOS:000234652000052
J	Ammoun, S; Lindholm, D; Wootz, H; Akerman, KEO; Kukkonen, JP				Ammoun, S; Lindholm, D; Wootz, H; Akerman, KEO; Kukkonen, JP			G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 Mitogen-/Stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; TUMOR-SUPPRESSOR; UV-RADIATION; P53 PROTEIN; MUTANT P53; APOPTOSIS; PATHWAYS; GROWTH; PHOSPHORYLATION; INHIBITION	We have investigated the signaling of OX1 receptors to cell death using Chinese hamster ovary cells as a model system. OX1 receptor stimulation with orexin-A caused a delayed cell death independently of cytosolic Ca2+ elevation. The classical mitogen-activated protein kinase (MAPK) pathways, ERK and p38, were strongly activated by orexin-A. p38 was essential for induction of cell death, whereas the ERK pathway appeared protective. A pathway often implicated in the p38-mediated cell death, activation of p53, did not mediate the cell death, as there was no stabilization of p53 or increase in p53-dependent transcriptional activity, and dominant-negative p53 constructs did not inhibit cell demise. Under basal conditions, orexin-A-induced cell death was associated with compact chromatin condensation and it required de novo gene transcription and protein synthesis, the classical hallmarks of programmed (apoptotic) cell death. However, though the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-(O-methyl) fluoromethyl ketone (Z-VAD-fmk) fully inhibited the caspase activity, it did not rescue the cells from orexin-A-induced death. In the presence of Z-VAD-fmk, orexin-A-induced cell death was still dependent on p38 and de novo protein synthesis, but it no longer required gene transcription. Thus, caspase inhibition causes activation of alternative, gene transcription-independent death pathway. In summary, the present study points out mechanisms for orexin receptor-mediated cell death and adds to our general understanding of the role of G-protein-coupled receptor signaling in cell death by suggesting a pathway from G-protein-coupled receptors to cell death via p38 mitogen-/stress-activated protein kinase independent of p53 and caspase activation.	Uppsala Univ, Dept Neurosci, Unit Physiol, SE-75123 Uppsala, Sweden; Uppsala Univ, Neurobiol Unit, Dept Neurosci, SE-75123 Uppsala, Sweden; Minerva Fdn, Med Res Inst, FIN-00290 Helsinki, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70210 Kuopio, Finland	Uppsala University; Uppsala University; University of Eastern Finland	Kukkonen, JP (corresponding author), Uppsala Univ, Dept Neurosci, Unit Physiol, BMC,POB 572, SE-75123 Uppsala, Sweden.	jyrki.kukkonen@neuro.uu.se	Lindholm, Dan/B-3777-2014	Kukkonen, Jyrki/0000-0002-6989-1564				Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Ammoun S, 2006, MOL ENDOCRINOL, V20, P80, DOI 10.1210/me.2004-0389; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Gutkind J.S, 2000, SCI STKE; Hilairet S, 2003, J BIOL CHEM, V278, P23731, DOI 10.1074/jbc.M212369200; Holmqvist T, 2005, J BIOL CHEM, V280, P6570, DOI 10.1074/jbc.M407397200; Holmqvist T, 2002, FEBS LETT, V526, P11, DOI 10.1016/S0014-5793(02)03101-0; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jung YS, 2004, JPN J PHYSIOL, V54, P23, DOI 10.2170/jjphysiol.54.23; Kansra V, 2001, J BIOL CHEM, V276, P31831, DOI 10.1074/jbc.M009374200; Karteris E, 2005, AM J PHYSIOL-ENDOC M, V288, pE1089, DOI 10.1152/ajpendo.00351.2004; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Kukkonen JP, 2005, HYPOCRETINS: INTEGRATORS OF PHYSIOLOGICAL FUNCTIONS, P221, DOI 10.1007/0-387-25446-3_14; Kukkonen JP, 2002, AM J PHYSIOL-CELL PH, V283, pC1567, DOI 10.1152/ajpcell.00055.2002; Kukkonen JP, 2001, NEUROREPORT, V12, P2017, DOI 10.1097/00001756-200107030-00046; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; Ma MC, 2005, J BIOL CHEM, V280, P16208, DOI 10.1074/jbc.M408055200; Mullins DE, 2002, REGUL PEPTIDES, V105, P65, DOI 10.1016/S0167-0115(01)00388-3; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Randeva HS, 2001, J CLIN ENDOCR METAB, V86, P4808, DOI 10.1210/jc.86.10.4808; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; Rouet-Benzineb P, 2004, J BIOL CHEM, V279, P45875, DOI 10.1074/jbc.M404136200; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Selbach O, 2004, NEUROSCIENCE, V127, P519, DOI 10.1016/j.neuroscience.2004.05.012; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	49	65	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					834	842		10.1074/jbc.M508603200	http://dx.doi.org/10.1074/jbc.M508603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282319	hybrid			2022-12-25	WOS:000234447200021
J	Ceresa, BP; Bahr, SJ				Ceresa, BP; Bahr, SJ			rab7 activity affects epidermal growth factor: Epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION; PROTEIN; CELLS; ACCUMULATION; ACTIVATION; EXPRESSION; FAMILY	The epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase family. Ligand (epidermal growth factor or EGF) binding to the EGFR results in the coordinated activation and integration of biochemical signaling events to mediate cell growth, migration, and differentiation. One mechanism the cell utilizes to orchestrate these events is ligand-mediated endocytosis through the canonical clathrin-mediated endocytic pathway. Identification of proteins that regulate the intracellular movement of the EGF center dot EGFR complex is an important first step in dissecting how specificity of EGFR signaling is conferred. We examined the role of the small molecular weight guanine nucleotide-binding protein (G-protein) rab7 as a regulator of the distal stages of the endocytic pathway. Through the transient expression of activating and inactivating mutants of rab7 in HeLa cells, we have determined that rab7 activity directly correlates with the rate of radiolabeled EGF and EGFR degradation. Furthermore, when inhibitory mutants of rab7 are expressed, the internalized EGF center dot EGFR complex accumulates in high-density endosomes that are characteristic of the late endocytic pathway. Thus, we conclude that rab7 regulates the endocytic trafficking of the EGF center dot EGFR complex by regulating its lysosomal degradation.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Ceresa, BP (corresponding author), POB 26901, Oklahoma City, OK 73190 USA.	brian-ceresa@ouhsc.edu						Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Clague MJ, 2001, J CELL SCI, V114, P3075; Cullis DN, 2002, J BIOL CHEM, V277, P49158, DOI 10.1074/jbc.M206316200; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; Dinneen JL, 2004, TRAFFIC, V5, P606, DOI 10.1111/j.1398-9219.2004.00204.x; Dinneen JL, 2004, EXP CELL RES, V294, P509, DOI 10.1016/j.yexcr.2003.12.006; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KING AC, 1984, BIOCHEM BIOPH RES CO, V124, P585, DOI 10.1016/0006-291X(84)91594-8; KORC M, 1985, P NATL ACAD SCI USA, V82, P6172, DOI 10.1073/pnas.82.18.6172; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Rodman JS, 2000, J CELL SCI, V113, P183; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	42	106	110	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1099	1106		10.1074/jbc.M504175200	http://dx.doi.org/10.1074/jbc.M504175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282324	hybrid			2022-12-25	WOS:000234447200051
J	Choi, HJ; Huber, AH; Weis, WI				Choi, HJ; Huber, AH; Weis, WI			Thermodynamics of beta-catenin-ligand interactions - The roles of the N- and C-terminal tails in modulating binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; CRYSTAL-STRUCTURE; E-CADHERIN; TRANSCRIPTION FACTORS; COMPLEX REVEALS; MECHANISM; PROTEIN; TCF4; APC; PHOSPHORYLATION	beta-Catenin is a structural component of adherens junctions, where it binds to the cytoplasmic domain of cadherin cell adhesion molecules. beta-Catenin is also a transcriptional coactivator in the Wnt signaling pathway, where it binds to Tcf/Lef family transcription factors. In the absence of a Wnt signal, nonjunctional beta-catenin is present in a multiprotein complex containing the proteins axin and adenomatous polyposis coli (APC), both of which bind directly to beta-catenin. The thermodynamics of beta-catenin binding to E-cadherin, Lef-1, APC, axin, and the transcriptional inhibitor ICAT have been determined by isothermal titration calorimetry. Most of the interactions showed large, unfavorable entropy changes, consistent with these ligands being natively unstructured in the absence of beta-catenin. Phosphorylation of serine residues present in a sequence motif common to cadherins and APC increased the affinity for beta-catenin 300-700-fold, and surface plasmon resonance measurements revealed that phosphorylation of E-cadherin both enhanced its on rate and decreased its off rate. The effects of the N- and C-terminal "tails" that flank the beta-catenin armadillo repeat domain on ligand binding have also been investigated using constructs lacking one or both tails. Contrary to earlier studies that employed less direct binding assays, the tails did not affect the affinity of beta-catenin for tight ligands such as E-cadherin, Lef-1, and phosphorylated APC. However, the beta-catenin C-terminal tail was found to decrease the affinity for the weaker ligands APC and axin, suggesting that this region may have a regulatory role in beta-catenin degradation.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Choi, Hee-Jung/0000-0002-1167-1526	NIGMS NIH HHS [R01 GM56169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fasolini M, 2003, J BIOL CHEM, V278, P21092, DOI 10.1074/jbc.M301781200; Gail R, 2005, J BIOL CHEM, V280, P7107, DOI 10.1074/jbc.M410215200; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Solanas G, 2004, J BIOL CHEM, V279, P49849, DOI 10.1074/jbc.M408685200; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Tago K, 2000, GENE DEV, V14, P1741; Tickenbrock L, 2003, J MOL BIOL, V327, P359, DOI 10.1016/S0022-2836(03)00144-X; Wahl JK, 2000, J CELL SCI, V113, P1737; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020	42	121	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1027	1038		10.1074/jbc.M511338200	http://dx.doi.org/10.1074/jbc.M511338200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16293619	hybrid			2022-12-25	WOS:000234447200043
J	Man, WC; Miyazaki, M; Chu, K; Ntambi, JM				Man, WC; Miyazaki, M; Chu, K; Ntambi, JM			Membrane topology of mouse stearoyl-CoA desaturase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DESATURASE; HEMAGGLUTININ EPITOPE INSERTION; POLYUNSATURATED FATTY-ACIDS; INDUCED GENE-EXPRESSION; REDUCED FOLATE CARRIER; N-TERMINAL DOMAIN; TRANSMEMBRANE ORGANIZATION; 3T3-L1 PREADIPOCYTES; ALKANE HYDROXYLASE; P-GLYCOPROTEIN	Stearoyl-CoA desaturase (SCD) is an integral membrane protein anchored in the endoplasmic reticulum. It catalyzes the biosynthesis of monounsaturated fatty acids that are required for the synthesis of triglycerides, cholesteryl esters, and phospholipids. Four mouse isoforms of SCD (SCD1-4) and two human isoforms have been characterized. In the current study, we characterize the topology of the mouse SCD1 isoform. Hydropathy analysis of the 355-amino acid mouse SCD1 protein predicts that the protein contains four transmembrane domains (TMDs) and three loops connecting the membrane-spanning domains. To define the topology of the protein, recombinant SCD1 constructs containing epitope tags were transiently expressed in HeLa cells and analyzed by indirect immunofluorescence and cysteine derivatization. Our data provide evidence that the N and C termini of SCD1 are oriented toward the cytosol with four transmembrane domains separated by two very short hydrophilic loops in the ER lumen and one large hydrophilic loop in the cytosol. In addition, based on the previous observation that SCD is a thiol enzyme, we sought to investigate whether the cysteine residues were essential for enzyme activity through mutagenesis studies, and our data suggest that the cysteines in SCD are not catalytically essential.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062388] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK-62388] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; Chen Chien Peter, 2002, Appl Bioinformatics, V1, P21; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; Diaz AR, 2002, J BIOL CHEM, V277, P48099, DOI 10.1074/jbc.M208960200; ENOCH HG, 1978, BIOCHEMISTRY-US, V17, P4927, DOI 10.1021/bi00616a011; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; HOLLOWAY PW, 1963, BIOCHEM BIOPH RES CO, V12, P300, DOI 10.1016/0006-291X(63)90300-0; JAMES AT, 1968, EUR J BIOCHEM, V3, P318, DOI 10.1111/j.1432-1033.1968.tb19532.x; Jones BH, 1998, BIOCHEM J, V335, P405, DOI 10.1042/bj3350405; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Landau JM, 1997, BBA-LIPID LIPID MET, V1345, P349, DOI 10.1016/S0005-2760(97)00010-6; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Liu HY, 2005, J BIOL CHEM, V280, P4524, DOI 10.1074/jbc.M400893200; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Mziaut H, 2000, P NATL ACAD SCI USA, V97, P8883, DOI 10.1073/pnas.97.16.8883; Ntambi JM, 1996, BIOCHEM BIOPH RES CO, V220, P990, DOI 10.1006/bbrc.1996.0520; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Ott CM, 2002, J CELL SCI, V115, P2003; Pottekat A, 2004, J BIOL CHEM, V279, P15743, DOI 10.1074/jbc.M313537200; PRASAD R, 1980, J BIOL CHEM, V255, P5834; RAJU PK, 1972, J BIOL CHEM, V247, P3700; RAJU PK, 1967, J BIOL CHEM, V242, P379; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Waters KM, 1996, LIPIDS, V31, pS33, DOI 10.1007/BF02637047; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	52	72	82	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1251	1260		10.1074/jbc.M508733200	http://dx.doi.org/10.1074/jbc.M508733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16275639	hybrid			2022-12-25	WOS:000234447200068
J	Qi, XJ; Wildey, GM; Howe, PH				Qi, XJ; Wildey, GM; Howe, PH			Evidence that Ser(87) of Bim(EL) is phosphorylated by Akt and regulates BimEL apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBER; CYTOCHROME-C RELEASE; BAX-DEPENDENT APOPTOSIS; BETA-INDUCED APOPTOSIS; CELL-SURVIVAL; BH3-ONLY PROTEIN; PROAPOPTOTIC ACTIVITY; SIGNALING PATHWAY	Bim, the Bcl-2 interacting mediator of cell death, is a member of the BH3-only family of pro-apoptotic proteins. Recent studies have demonstrated that the apoptotic activity of Bim can be regulated through a post-translational mechanism whereby ERK phosphorylation serves as a signal for Bim ubiquitination and proteasomal degradation. In this report, we investigated the signaling pathways leading to Bim phosphorylation in Ba/F3 cells, an interleukin-3 (IL3)-dependent B-cell line. IL-3 stimulation induced phosphorylation of Bim(EL), one of the predominant isoforms of Bim expressed in cells, at multiple sites, as evidenced by the formation of at least three to four bands by Western blotting that were sensitive to phosphatase digestion. The appearance of multiple, phosphorylated species of BimEL correlated with Akt, and not ERK, activation. The PI3K inhibitor, LY294002, blocked IL-3-stimulated Akt activity and partially blocked BimEL phosphorylation. In vitro kinase assays showed that recombinant Akt could directly phosphorylate a GST-Bim(EL) fusion protein and identified the Akt phosphorylation site in the Bim(EL) domain as Ser(87). Further, we demonstrated that cytokine stimulation promotes BimEL binding to 14-3-3 proteins. Finally, we show that mutation of Ser(87) dramatically increases the apoptotic potency of Bim(EL). We propose that Ser(87) of Bim(EL) is an important regulatory site that is targeted by Akt to attenuate the pro-apoptotic function of Bim(EL), thereby promoting cell survival.	Cleveland Clin Fdn, Cleveland Clin, Lerner Coll Med, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Cleveland Clin, Lerner Coll Med, Dept Cell Biol, NC-1, Cleveland, OH 44195 USA.	howep@ccf.org		Wildey, Gary/0000-0001-7105-1313	NCI NIH HHS [CA55536, CA80095] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536, R01CA080095] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHUANG LY, 1994, ANTICANCER RES, V14, P147; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, J BIOL CHEM, V280, P17657, DOI 10.1074/jbc.M412342200; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Liu JW, 2002, CANCER RES, V62, P2976; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MARANI M, 2003, ONCOGENE, V23, P1; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	56	185	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					813	823		10.1074/jbc.M505546200	http://dx.doi.org/10.1074/jbc.M505546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282323	hybrid			2022-12-25	WOS:000234447200019
J	Geng, CD; Vedeckis, WV				Geng, CD; Vedeckis, WV			c-Myb and members of the c-Ets family of transcription factors act as molecular switches to mediate opposite steroid regulation of the human glucocorticoid receptor 1A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SPI-B; INDUCED APOPTOSIS; LYMPHOMA-CELLS; FACTOR-BINDING; T-CELLS; PU.1; GENE; MECHANISMS; EXPRESSION	Steroid auto-regulation of the human glucocorticoid receptor (hGR) 1A promoter in lymphoblast cells resides largely in two DNA elements (footprints 11 and 12). We show here that c-Myb and c-Ets family members (Ets-1/2, PU. 1, and Spi-B) control hGR 1A promoter regulation in T- and B-lymphoblast cells. Two T- lymphoblast lines, CEM-C7 and Jurkat, contain high levels of c-Myb and low levels of PU. 1, whereas the opposite is true in IM-9 B-lymphoblasts. In Jurkat cells, overexpression of c-Ets-1, c-Ets-2, or PU. 1 effectively represses dexamethasone-mediated up-regulation of an hGR 1A promoter-luciferase reporter gene, as do dominant negative c-Myb (c-Myb DNA-binding domain) or Ets proteins (Ets-2 DNA-binding domain). Overexpression of c-Myb in IM-9 cells confers hormone-dependent up-regulation to the hGR 1A promoter reporter gene. Chromatin immunoprecipitation assays show that hormone treatment causes the recruitment of hGR and c-Myb to the hGR 1A promoter in CEM-C7 cells, whereas hGR and PU. 1 are recruited to this promoter in IM-9 cells. These observations suggest that the specific transcription factor that binds to footprint 12, when hGR binds to the adjacent footprint 11, determines the direction of hGR 1A promoter auto-regulation. This leads to a "molecular switch" model for auto-regulation of the hGR 1A promoter.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Vedeckis, WV (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 533 Bolivar St, New Orleans, LA 70112 USA.	wvedec@suhsc.edu						Anderson MK, 1999, DEVELOPMENT, V126, P3131; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BLOOMFIELD CD, 1980, LANCET, V1, P952; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BRESLIN M, 1998, 80 ANN M END SOC NEW, P133; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; Breslin MB, 1996, ENDOCRINE, V5, P15, DOI 10.1007/BF02738651; COSTLOW ME, 1982, CANCER RES, V42, P4801; Dahl R, 2002, EMBO J, V21, P2220, DOI 10.1093/emboj/21.9.2220; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; EISEN LP, 1988, J BIOL CHEM, V263, P12044; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GALILI U, 1983, J STEROID BIOCHEM, V19, P483, DOI 10.1016/0022-4731(83)90207-8; Garrett-Sinha LA, 2001, BLOOD, V97, P2908, DOI 10.1182/blood.V97.9.2908; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GAYNON PS, 1995, J PEDIAT HEMATOL ONC, V17, P1, DOI 10.1097/00043426-199502000-00001; GEHRING U, 1984, MOL CELL ENDOCRINOL, V36, P107, DOI 10.1016/0303-7207(84)90089-3; Geley S, 1996, CANCER RES, V56, P5033; Geng CD, 2004, MOL ENDOCRINOL, V18, P912, DOI 10.1210/me.2003-0157; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOMI M, 1990, CANCER RES, V50, P1873; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HOMODELARCHE F, 1984, CANCER RES, V44, P431; HONGO T, 1990, CANCER-AM CANCER SOC, V65, P1263, DOI 10.1002/1097-0142(19900315)65:6<1263::AID-CNCR2820650602>3.0.CO;2-S; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; KATO GJ, 1993, BLOOD, V82, P2304; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; LEVENTHAL BG, 1981, CANCER RES, V41, P4861; LEVINE EG, 1985, LEUKEMIA RES, V9, P993, DOI 10.1016/0145-2126(85)90069-4; LITTLEFIELD BA, 1989, CANCER RES, V46, P3945; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nunez BS, 2002, MOL CELL ENDOCRINOL, V189, P191, DOI 10.1016/S0303-7207(01)00676-1; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pedersen KB, 2004, BIOCHEMISTRY-US, V43, P10851, DOI 10.1021/bi049458u; Pedersen KB, 2003, BIOCHEMISTRY-US, V42, P10978, DOI 10.1021/bi034651u; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Ramdas J, 1999, CANCER RES, V59, P1378; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tanno B, 2002, J BIOL CHEM, V277, P23172, DOI 10.1074/jbc.M200141200; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427	60	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43264	43271		10.1074/jbc.M508245200	http://dx.doi.org/10.1074/jbc.M508245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263717	hybrid			2022-12-25	WOS:000234200800093
J	Thomassin, L; Werneck, CC; Broekelmann, TJ; Gleyzal, C; Hornstra, IK; Mecham, RP; Sommer, P				Thomassin, L; Werneck, CC; Broekelmann, TJ; Gleyzal, C; Hornstra, IK; Mecham, RP; Sommer, P			The pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; IN-VITRO; PROTEIN; TROPOELASTIN; LOX; EXPRESSION; CULTURES; INVITRO; CELLS; CDNA	These studies were undertaken to determine how lysyl oxidase (LOX) and lysyl oxidase like-1 (LOXL) enzymes are targeted to their substrates in the extracellular matrix. Full-length LOX/LOXL and constructs containing just the pro-regions of each enzyme localized to elastic fibers when expressed in cultured cells. However, the LOXL catalytic domain without the pro-region was secreted into the medium but did not associate with matrix. Ligand blot and mammalian two-hybrid assays confirmed an interaction between tropoelastin and the pro-regions of both LOX and LOXL. Immunofluorescence studies localized both enzymes to elastin at the earliest stages of elastic fiber assembly. Our results showed that the pro-regions of LOX and LOXL play a significant role in directing the deposition of both enzymes onto elastic fibers by mediating interactions with tropoelastin. These findings confirmed that an important element of substrate recognition lies in the pro-domain region of the molecule and that the pro-form of the enzyme is what initially interacts with the matrix substrate. These results have raised the interesting possibility that sequence differences between the pro-domain of LOX and LOXL account for some of the functional differences observed for the two enzymes.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Univ Lyon 1, CNRS, Inst Biol & Chim Prot, UMR 5086, F-69367 Lyon 07, France	Washington University (WUSTL); Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, CampusBox 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	bmecham@cellbiology.wustl.edu	Thomassin, Laetitita/AAZ-4072-2020; Werneck, Claudio C/C-7568-2012	Thomassin, Laetitita/0000-0002-2354-9085; Werneck, Claudio C/0000-0002-9413-0572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053325, R37HL053325, P50HL061006, R01HL062295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62295, HL53325, HL61006] Funding Source: Medline; NIAMS NIH HHS [AR047713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; Chen LJ, 2005, TOXICOL SCI, V83, P372, DOI 10.1093/toxsci/kfi019; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Hayashi K, 2004, J MOL HISTOL, V35, P845, DOI 10.1007/s10735-004-2340-1; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; Jung ST, 2003, PROTEIN EXPRES PURIF, V31, P240, DOI 10.1016/S1046-5928(03)00217-1; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1986, J CELL BIOL, V103, P1121, DOI 10.1083/jcb.103.3.1121; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KEELEY FW, 1991, LAB INVEST, V64, P499; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; Kozel BA, 2004, MATRIX BIOL, V23, P23, DOI 10.1016/j.matbio.2004.02.004; Kozel BA, 2003, J BIOL CHEM, V278, P18491, DOI 10.1074/jbc.M212715200; KOZEL BA, 2005, IN PRESS J CELL PHYS; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Mithieux SM, 2005, J STRUCT BIOL, V149, P282, DOI 10.1016/j.jsb.2004.11.005; MORRIS SM, 1986, ANAT REC, V215, P134, DOI 10.1002/ar.1092150207; NARAYANAN AS, 1976, J BIOL CHEM, V251, P1125; Noblesse E, 2004, J INVEST DERMATOL, V122, P621, DOI 10.1111/j.0022-202X.2004.22330.x; PARK PW, 1991, J BIOL CHEM, V266, P23399; RAJU K, 1987, J BIOL CHEM, V262, P5755; Seve S, 2002, CONNECT TISSUE RES, V43, P613, DOI 10.1080/03008200290001348; SIEGEL RC, 1976, J BIOL CHEM, V251, P5786; TOSELLI P, 1981, CONNECT TISSUE RES, V8, P231, DOI 10.3109/03008208109152381; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200	29	110	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42848	42855		10.1074/jbc.M506832200	http://dx.doi.org/10.1074/jbc.M506832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16251195	hybrid			2022-12-25	WOS:000234200800047
J	Weinhold, B; Seidenfaden, R; Rockle, I; Muhlenhoff, M; Schertzinger, F; Conzelmann, S; Marth, JD; Gerardy-Schahn, R; Hildebrandt, H				Weinhold, B; Seidenfaden, R; Rockle, I; Muhlenhoff, M; Schertzinger, F; Conzelmann, S; Marth, JD; Gerardy-Schahn, R; Hildebrandt, H			Genetic ablation of polysialic acid causes severe neurodevelopmental defects rescued by deletion of the neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; L1 KNOCKOUT MICE; SYNAPTIC PLASTICITY; PSA-NCAM; BRAIN-DEVELOPMENT; MOUSE; POLYSIALYLTRANSFERASES; MUTATION; GLYCOSYLATION; ABNORMALITIES	Poly-alpha 2,8-sialic acid (polySia) is a unique modification of the neural cell adhesion molecule, NCAM, tightly associated with neural development and plasticity. However, the vital role attributed to this carbohydrate polymer has been challenged by the mild phenotype of mice lacking polySia due to NCAM-deficiency. To dissect polySia and NCAM functions, we generated polySia-negative but NCAM-positive mice by simultaneous deletion of the two polysialyltransferase genes, St8sia-II and St8sia-IV. Beyond features shared with NCAM-null animals, a severe phenotype with specific brain wiring defects, progressive hydrocephalus, postnatal growth retardation, and precocious death was observed. These drastic defects were selectively rescued by additional deletion of NCAM, demonstrating that they originate from a gain of NCAM functions because of polySia deficiency. The data presented in this study reveal that the essential role of polySia resides in the control and coordination of NCAM interactions during mouse brain development. Moreover, this first demonstration in vivo that a highly specific glycan structure is more important than the glycoconjugate as a whole provides a novel view on the relevance of protein glycosylation for the complex process of building the vertebrate brain.	Hannover Med Sch, Zentrum Biochem, D-30625 Hannover, Germany; Univ Hohenheim, Inst Zool, D-70593 Stuttgart, Germany; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Hannover Medical School; University Hohenheim; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Gerardy-schahn.rita@mh-hannover.de	Hildebrandt, Herbert/A-7873-2010	Hildebrandt, Herbert/0000-0002-1044-0881; Rockle, Iris/0000-0003-2621-2223				Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Chazal G, 2000, J NEUROSCI, V20, P1446; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 1997, MOL CELL NEUROSCI, V8, P323, DOI 10.1006/mcne.1996.0588; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Dityatev A, 2004, J NEUROSCI, V24, P9372, DOI 10.1523/JNEUROSCI.1702-04.2004; Durbec P, 2001, MOL NEUROBIOL, V24, P53; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; Itoh K, 2004, J CELL BIOL, V165, P145, DOI 10.1083/jcb.200312107; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Johnson CP, 2005, BIOCHEMISTRY-US, V44, P546, DOI 10.1021/bi048263j; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Marx M, 2001, DEVELOPMENT, V128, P4949; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pillai-Nair N, 2005, J NEUROSCI, V25, P4659, DOI 10.1523/JNEUROSCI.0565-05.2005; Rabinowitz JE, 1996, P NATL ACAD SCI USA, V93, P6421, DOI 10.1073/pnas.93.13.6421; Rolf B, 2002, J NEUROSCI, V22, P8357; Rolf B, 2001, BRAIN RES, V891, P247, DOI 10.1016/S0006-8993(00)03219-4; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1998, J NEUROSCI, V18, P3757; Shen HM, 1997, J NEUROSCI, V17, P5221; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Vaithianathan T, 2004, J BIOL CHEM, V279, P47975, DOI 10.1074/jbc.M407138200; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Walmod PS, 2004, NEUROCHEM RES, V29, P2015, DOI 10.1007/s11064-004-6875-z; Wood GK, 1998, NEUROREPORT, V9, P461, DOI 10.1097/00001756-199802160-00019	46	228	230	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42971	42977		10.1074/jbc.M511097200	http://dx.doi.org/10.1074/jbc.M511097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16267048	hybrid			2022-12-25	WOS:000234200800060
J	Lee, WM; Elliott, JE; Brownsey, RW				Lee, WM; Elliott, JE; Brownsey, RW			Inhibition of acetyl-CoA carboxylase isoforms by pyridoxal phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; DEPENDENT PROTEIN-KINASE; MALONYL-COA; MOLECULAR-CLONING; SKELETAL-MUSCLE; ADIPOSE-TISSUE; RAT-LIVER; PHOSPHORYLATION; CITRATE	Mammalian isoforms of acetyl-CoA carboxylase (ACC-1 and ACC-2) play important roles in synthesis, elongation, and oxidation of long-chain fatty acids, and the possible significance of ACC in the development of obesity has led to interest in the development of inhibitors. Here, we demonstrate that pyridoxal phosphate (PLP) is a linear and reversible inhibitor of ACC-1 and ACC-2. ACC from rat liver and white adipose tissue (largely ACC-1) exhibited an IC50 of similar to 200 mu M, whereas ACC-2 from heart or skeletal muscle exhibited an IC50 exceeding 500 mu M. ACC from rat liver was equally sensitive to PLP following extensive purification by avidin affinity chromatography. When added before citrate, PLP inhibited ACC with a K-i of similar to 100 mu M, reducing maximal activity > 90% and increasing the K-a for citrate similar to 5-fold but having little effect on substrate K-m values. Pre-treatment with citrate increased the apparent K-i for ACC inhibition by PLP by similar to 4-fold. Inhibition of ACC was reversed by removal of PLP, either by washing or by reaction with hydroxylamine or amino-oxyacetate. ACC was irreversibly inhibited and radiolabeled, to a stoichiometry of similar to 0.4 mol[H]/mol subunit, in the presence of PLP plus [H-3]borohydride. Studies with structurally related compounds demonstrated that the reactive aldehyde and negatively charged substituents of PLP contribute importantly to ACC inhibition. The studies reported here suggest a rationale to develop ACC inhibitors that are not structurally related to the substrates or products of the reaction and an approach to probe the citrate-binding site of the enzyme.	Univ British Columbia, Dept Biochem, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Mol Biol & Life Sci Inst, Diabet Res Grp, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Brownsey, RW (corresponding author), Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	rogerb@interchange.ubc.ca						Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Barber MC, 1998, BIOCHEM J, V333, P17, DOI 10.1042/bj3330017; Barber MC, 2005, BBA-MOL CELL BIOL L, V1733, P1, DOI 10.1016/j.bbalip.2004.12.001; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Boone AN, 1999, BIOCHEM J, V341, P347, DOI 10.1042/0264-6021:3410347; BORTHWICK AC, 1987, BIOCHEM J, V241, P773, DOI 10.1042/bj2410773; BOSRON WF, 1978, J BIOL CHEM, V253, P1488; BRADY RO, 1952, J BIOL CHEM, V199, P421; BROPHY PJ, 1975, BIOCHEM J, V152, P495, DOI 10.1042/bj1520495; BROWNSEY RW, 1982, BIOCHEM J, V202, P77, DOI 10.1042/bj2020077; BROWNSEY RW, 1979, BIOCHEM J, V184, P23, DOI 10.1042/bj1840023; Brownsey RW, 1997, BIOCHEM SOC T, V25, P1232, DOI 10.1042/bst0251232; BROWNSEY RW, ENZYMES, V18, P123; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; COLOMBO G, 1976, BIOCHEMISTRY-US, V15, P1774, DOI 10.1021/bi00653a028; GATEHOUSE PW, 1979, J BIOL CHEM, V243, P2319; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GREGOLIN C, 1968, J BIOL CHEM, V243, P4227; GREGOLIN C, 1966, P NATL ACAD SCI USA, V56, P148, DOI 10.1073/pnas.56.1.148; GREMSE DA, 1995, ARCH BIOCHEM BIOPHYS, V316, P215, DOI 10.1006/abbi.1995.1030; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HALESTRAP AP, 1974, BIOCHEM J, V142, P365, DOI 10.1042/bj1420365; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HASHIMOTO T, 1971, EUR J BIOCHEM, V24, P128, DOI 10.1111/j.1432-1033.1971.tb19663.x; HEYWOOD HJ, 2003, J BIOL CHEM, V278, P37099; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; KEMP RG, 1987, BIOCHEMISTRY-US, V26, P3443, DOI 10.1021/bi00386a029; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; KLEINSCH.AK, 1969, SCIENCE, V166, P1276, DOI 10.1126/science.166.3910.1276; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane M D, 1974, Curr Top Cell Regul, V8, P139; Levert KL, 2002, J BIOL CHEM, V277, P16347, DOI 10.1074/jbc.C200113200; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MILLER AL, 1969, J BIOL CHEM, V244, P2334; Natuzzi D, 1999, J BIOENERG BIOMEMBR, V31, P535, DOI 10.1023/A:1026414826457; Numa S, 1974, Curr Top Cell Regul, V8, P197; Saha AK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1030, DOI 10.1152/ajpendo.1999.276.6.E1030; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; TAKAI T, 1988, J BIOL CHEM, V263, P2651; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TRUMBLE GE, 1995, EUR J BIOCHEM, V231, P192, DOI 10.1111/j.1432-1033.1995.tb20686.x; UYEDA K, 1969, BIOCHEMISTRY-US, V8, P2366, DOI 10.1021/bi00834a017; VAGELOS PR, 1963, J BIOL CHEM, V238, P533; WAITE M, 1962, J BIOL CHEM, V237, P2750; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1960, BIOCHIM BIOPHYS ACTA, V41, P122, DOI 10.1016/0006-3002(60)90377-2; WAKIL SJ, 1957, BIOCHIM BIOPHYS ACTA, V24, P453, DOI 10.1016/0006-3002(57)90233-0; WINZ R, 1994, J BIOL CHEM, V269, P14438; WU JY, 1973, J BIOL CHEM, V248, P3029	61	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41835	41843		10.1074/jbc.M510728200	http://dx.doi.org/10.1074/jbc.M510728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16249179	hybrid, Green Published			2022-12-25	WOS:000233992700009
J	Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C				Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C			beta 1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury	ONCOGENE			English	Article						beta 1-integrin; ECM; Akt; PI3K; p130Cas; ionizing radiation	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; HUMAN-TUMOR; INTEGRINS; GROWTH; FAK; EXPRESSION; PROTEINS; MICROENVIRONMENT	Integrin-mediated adhesion to extracellular matrix proteins confers resistance to radiation- or drug-induced genotoxic injury. To analyse the underlying mechanisms specific for beta 1-integrins, wild-type beta 1A-integrin-expressing GD25 beta 1A cells were compared to GD25 beta 1B cells, which express signaling-incompetent beta 1B variants. Cells grown on fibronectin, collagen-III, beta 1-integrin-IgG or poly-l-lysine were exposed to 0-6 Gy X-rays in presence or depletion of growth factors and phosphatidylinositol-3 kinase (PI3K) inhibitors (LY294002, wortmannin). In order to test the relevance of these findings in tumor cells, human A-172 glioma cells were examined under the same conditions after siRNA-mediated silencing of beta 1-integrins. We found that beta 1A-integrin-mediated adhesion to fibronectin, collagen-III or beta 1-IgG was essential for cell survival after radiation- induced genotoxic injury. Mediated by PI3K, pro-survival beta 1A-integrin/Akt signaling was critically involved in this process. Additionally, the beta 1-integrin downstream targets p130Cas and paxillin-impaired survival-regulating PI3K-dependent JNK. In A-172 glioma cells, beta 1-integrin knockdown and PI3K inhibition confirmed the central role of beta 1-integrins in Akt- and p130Cas/paxillin-mediated prosurvival signaling. These findings suggest beta 1-integrins as critical regulators of cell survival after radiation- induced genotoxic injury. Elucidation of the molecular circuitry of prosurvival beta 1-integrin-mediated signaling in tumor cells may promote the development of innovative molecular-targeted therapeutic antitumor strategies.	Tech Univ Dresden, Med Fac, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Tech Univ, Klinikum Isar, Dept Radiat Oncol, Munich, Germany; Max Planck Inst Biochem, Dept Mol Med, Martinsried, Germany	Technische Universitat Dresden; Technical University of Munich; Max Planck Society	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac, Fetscherstr 74-PF 86, D-01307 Dresden, Germany.	Nils.Cordes@mailbox.tu-dresden.de		Cordes, Nils/0000-0001-5684-629X; Brakebusch, Cord/0000-0002-9342-1634				Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Armulik A, 2000, EXP CELL RES, V254, P55, DOI 10.1006/excr.1999.4722; Armulik A, 2002, FRONT BIOSCI-LANDMRK, V7, pD219, DOI 10.2741/armulik; Barcellos-Hoff MH, 2001, J MAMMARY GLAND BIOL, V6, P213, DOI 10.1023/A:1011317009329; Beinke C, 2003, INT J RADIAT BIOL, V79, P721, DOI 10.1080/09553000310001610231; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cook JA, 2004, SEMIN RADIAT ONCOL, V14, P259, DOI 10.1016/j.semradonc.2004.04.001; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Oguey D, 2000, GENE THER, V7, P1292, DOI 10.1038/sj.gt.3301236; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Unger Meredith, 2003, Methods Mol Biol, V223, P315; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	46	130	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1378	1390		10.1038/sj.onc.1209164	http://dx.doi.org/10.1038/sj.onc.1209164			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247454				2022-12-25	WOS:000235708200011
J	He, YY; Huang, JL; Chignell, CF				He, YY; Huang, JL; Chignell, CF			Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization	ONCOGENE			English	Article						EGFR; caspase; apoptosis; internalization	DOWN-REGULATION; HUMAN KERATINOCYTES; KINASE-ACTIVITY; CELL-DEATH; ACTIVATION; CANCER; UVA; CHOLESTEROL	Epidermal growth factor receptor ( EGFR) plays a critical role in cell proliferation, differentiation, and transformation. EGFR downregulation attenuates its signaling intensity and duration to maintain cellular homeostasis. Here, we report that during apoptosis EGFR is cleaved by activated caspase-3 or related proteases at its C-terminus domain. EGFR downregulation by activation of caspases is neither stimulus- nor cell type-specific. EGFR internalization during apoptosis required dynamin and cholesterol since dominant-negative dynamin (K44A) or cholesterol depletion by methyl-beta-cyclodextrin prevented EGFR internalization. However, EGFR downregulation did not require its internalization. The EGFR cleavage fragment was detected in the membrane blebs in addition to the cell pellets. Mutations at the consensus sequence (DXXD) at the C-terminus domain revealed that DVVD1012 and to a lesser extent DNPD1172 may be target sites for active recombinant caspase-3 in vitro and activated caspase-3 or related proteases in vivo. We have detected the N-terminus and C-terminus fragments in vitro and in vivo. A cleavage-deficient EGFR mutant delayed apoptosis process. We conclude that the evolutionarily conserved C-terminus domain of EGFR is the target of caspases and subjected to degradation during apoptosis to shut down its signaling.	NIEHS, Chem Pharmacol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Chem Pharmacol Lab, NIH, MD F0-06,111 Alexander Dr,PO 12233, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050046, Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akunda JK, 2004, FASEB J, V18, P185, DOI 10.1096/fj.02-1192fje; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HELDIN CH, 1979, NATURE, V282, P419, DOI 10.1038/282419a0; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Nusbaum P, 2005, J BIOL CHEM, V280, P5843, DOI 10.1074/jbc.M413405200; Park IC, 2000, INT J ONCOL, V16, P1243; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	29	43	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1521	1531		10.1038/sj.onc.1209184	http://dx.doi.org/10.1038/sj.onc.1209184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247443				2022-12-25	WOS:000235890400009
J	Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D				Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D			Hair cycle and wound healing in mice with a keratinocyte-restricted deletion of FAK	ONCOGENE			English	Article						FAK; wound healing; hair; migration; proliferation; keratinocytes; stem cells	FOCAL ADHESION KINASE; STEM-CELLS; GROWTH-FACTOR; IN-VITRO; EXPRESSION; DIFFERENTIATION; ACTIVATION; MIGRATION; SKIN; BETA-1-INTEGRINS	Focal adhesion kinase (FAK) is a critical component in transducing signals downstream of both integrins and growth factor receptors. To determine how the loss of FAK affects the epidermis in vivo, we have generated a mouse model with a keratinocyte-restricted deletion of fak (FAK(K5 KO) mice). FAKK5 KO mice displayed three major phenotypes-irregularities of hair cycle, sebaceous glands hypoplasia, and a thinner epidermis-pointing to defects in the proliferative capacity of multipotent stem cells found in the bulge. FAK-null keratinocytes in conventional primary culture undergo massive apoptosis hindering further analyses, whereas the defects observed in vivo do not shorten the mouse lifespan. These results suggest that the structure and the signaling environment of the native tissue may overcome the lack of signaling through FAK. Our findings point to the importance of in vivo and three-dimensional in vitro models in analyses of cell migration, proliferation, and survival. Surprisingly, the difference between FAK(loxP/+) and FAK(K5) (KO) mice in wound closure was not statistically significant, suggesting that in vivo loss of FAK does not affect migration/proliferation of basal keratinocytes in the same way as it affects multipotent stem cells of the skin.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pulm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; CIEMAT, Dept Epithelial Damage, Repair & Tissue Engn Program, E-28040 Madrid, Spain; Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ilic, D (corresponding author), StemLifeLine Inc, 1300 Ind Rd,13, San Carlos, CA 94070 USA.	dilic@stemlifeline.com	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; ILIC, DUSKO/0000-0003-1647-0026	NCI NIH HHS [CA87652, K01 CA087652] Funding Source: Medline; NCRR NIH HHS [C06 RR016490, C06RR16490] Funding Source: Medline; NINDS NIH HHS [R01 NS019090-25, R01 NS019090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Cary LA, 1996, J CELL SCI, V109, P1787; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Cui CY, 2003, HUM MOL GENET, V12, P2931, DOI 10.1093/hmg/ddg325; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; Grose R, 2002, DEVELOPMENT, V129, P2303; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2001, CANCER RES, V61, P7079; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Ma DR, 2004, ANN ACAD MED SINGAP, V33, P784; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morasso MI, 2005, BIOL CELL, V97, P173; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	46	47	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1081	1089		10.1038/sj.onc.1209130	http://dx.doi.org/10.1038/sj.onc.1209130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247468	Green Accepted			2022-12-25	WOS:000235361000012
J	Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L				Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L			RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF	ONCOGENE			English	Article						ELF; PRAJA; TGF-beta; ubiquitination; half-life	LIVER DEVELOPMENT; LIGASE ACTIVITY; PARTIAL-HEPATECTOMY; SIGNALING PATHWAY; CELL-MEMBRANE; I RECEPTOR; DEGRADATION; GROWTH; PROTEIN; CANCER	In gastrointestinal cells, biological signals for transforming growth factor-beta (TGF-beta) are transduced through transmembrane serine/threonine kinase receptors that signal to Smad proteins. Smad4, a tumor suppressor, is often mutated in human gastrointestinal cancers. The mechanism of Smad4 inactivation, however, remains uncertain and could be through E3-mediated ubiquitination of Smad4/adaptor protein complexes. Disruption of ELF (embryonic liver fodrin), a Smad4 adaptor protein, modulates TGF-beta signaling. We have found that PRAJA, a RING-H2 protein, interacts with ELF in a TGF-beta-dependent manner, with a fivefold increase of PRAJA expression and a subsequent decrease in ELF and Smad4 expression, in gastrointestinal cancer cell lines (P < 0.05). Strikingly, PRAJA manifests substantial E3-dependent ubiquitination of ELF and Smad3, but not Smad4. Delta-PRAJA, which has a deleted RING finger domain at the C terminus, abolishes ubiquitination of ELF. A stable cell line that overexpresses PRAJA exhibits low levels of ELF in comparison to a D-PRAJA stable cell line, where ELF expression is high compared to normal controls. The alteration of ELF and/or Smad4 expression and/or function in the TGF-b signaling pathway may be induced by enhancement of ELF degradation, which is mediated by a high-level expression of PRAJA in gastrointestinal cancers. In hepatocytes, half-life (t(1/2)) and rate constant for degradation (k(D)) of ELF is 1.91 hand 21.72 min(-1) when coupled with ectopic expression of PRAJA in cells stimulated by TGF-beta, compared to PRAJA-transfected unstimulated cells (t(1/2) = 4.33 hand k(D) 9.6 min(-1)). These studies reveal a mechanism for tumorigenesis whereby defects in adaptor proteins for Smads, such as ELF, can undergo degradation by PRAJA, through the ubiquitin-mediated pathway.	Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20007 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA; Georgetown Univ, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Dept Pathol, Washington, DC 20007 USA; Dept Vet Affairs Med Ctr, Washington, DC USA	Georgetown University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Georgetown University; Georgetown University	Mishra, B (corresponding author), Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Med Dent Bldg,Rooms NW210-213,3900 Reservoir Rd,N, Washington, DC 20007 USA.	bm72@georgetown.edu; lm229@georgetown.edu	Volpe, Eugene A./D-2000-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106614-01A2] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bhanumathy CD, 2002, DEV DYNAM, V223, P59, DOI 10.1002/dvdy.1235; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Janse DM, 2004, J BIOL CHEM, V279, P21415, DOI 10.1074/jbc.M402954200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moser MJ, 2001, DIGEST DIS SCI, V46, P907, DOI 10.1023/A:1010791915733; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pan Y, 1999, CANCER RES, V59, P2064; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Wieser R, 2001, CURR OPIN ONCOL, V13, P70, DOI 10.1097/00001622-200101000-00014; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	61	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					693	705		10.1038/sj.onc.1209123	http://dx.doi.org/10.1038/sj.onc.1209123			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247473				2022-12-25	WOS:000235068800005
J	Robinson, CJ; Mulloy, B; Gallagher, JT; Stringer, SE				Robinson, CJ; Mulloy, B; Gallagher, JT; Stringer, SE			VEGF(165)-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VEGF RECEPTOR; EXTRACELLULAR DOMAIN; STRUCTURAL FEATURES; BINDING SEQUENCE; ACID FORM; CELLS; IDENTIFICATION; NEUROPILIN-1; GROWTH-FACTOR-165	The vascular endothelial growth factor (VEGF) family of proteins controls the formation and growth of blood vessels. The most potent and widely expressed isoform, VEGF(165), is secreted as a disulfide-linked homodimer with two identical heparin-binding sites. Interactions with heparan sulfate (HS) regulate the diffusion, half-life, and affinity of VEGF(165) for its signaling receptors. We have determined a number of key HS structural features that mediate the specific binding of the VEGF(165) dimer. Carboxylate groups and 2-O-, 6-O-, and N-sulfation of HS contributed to the strength of the VEGF(165) interaction; however, 6-O-sulfates appeared to be particularly important. Cleavage of HS by heparinase, heparitinase, or heparanase severely reduced VEGF(165) binding. In contrast, K5 lyase-cleaved HS retained significant VEGF(165) affinity, suggesting that binding sites for the growth factor are present within extended stretches of sulfation. Binding studies and molecular modeling demonstrated that an oligosaccharide 6 or 7 residues long was sufficient to fully occupy the heparin-binding site of a VEGF(165) monomer. The data presented are consistent with a model whereby the two heparin-binding sites of the VEGF(165) dimer interact simultaneously with highly sulfated S-domain regions of the HS chain that can be linked through a stretch of transition sequence.	Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Univ Manchester, Cardiovasc Grp, Manchester M13 9PT, Lancs, England	Cancer Research UK; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; National Institute for Biological Standards & Control; University of Manchester	Robinson, CJ (corresponding author), Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Christopher.Robinson@manchester.ac.uk		Robinson, Christopher/0000-0001-6146-566X				Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Hamma-Kourbali Y, 2001, J BIOL CHEM, V276, P39748, DOI 10.1074/jbc.M101117200; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Robinson CJ, 2001, J CELL SCI, V114, P853; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Stringer SE, 2002, BLOOD, V100, P1543, DOI 10.1182/blood.V100.5.1543.h81702001543_1543_1550; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310	53	135	137	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1731	1740		10.1074/jbc.M510760200	http://dx.doi.org/10.1074/jbc.M510760200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16258170	hybrid			2022-12-25	WOS:000234652000053
J	Todisco, S; Agrimi, G; Castegna, A; Palmieri, F				Todisco, S; Agrimi, G; Castegna, A; Palmieri, F			Identification of the mitochondrial NAD(+) transporter in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; 2 HUMAN ISOFORMS; FUNCTIONAL-CHARACTERIZATION; BACTERIAL EXPRESSION; TISSUE DISTRIBUTION; BOVINE MITOCHONDRIA; PLANT-MITOCHONDRIA; YEAST MITOCHONDRIA; LIFE-SPAN; RECONSTITUTION	The mitochondrial carriers are a family of transport proteins that shuttle metabolites, nucleotides, and cofactors across the inner mitochondrial membrane. In Saccharomyces cerevisiae, NAD(+) is synthesized outside the mitochondria and must be imported across the permeability barrier of the inner mitochondrial membrane. However, no protein responsible for this transport activity has ever been isolated or identified. In this report, the identification and functional characterization of the mitochondrial NAD(+) carrier protein (Ndt1p) is described. The NDT1 gene was overexpressed in bacteria. The purified protein was reconstituted into liposomes, and its transport properties and kinetic parameters were characterized. It transported NAD(+) and, to a lesser extent, (d) AMP and (d)GMP but virtually not alpha-NAD(+), NADH, NADP(+), or NADPH. Transport was saturable with an apparent Km of 0.38mM for NAD(+). The Ndt1p-GFP was found to be targeted to mitochondria. Consistently with Ndt1p localization and its function as a NAD(+) transporter, cells lacking NDT1 had reduced levels of NAD(+) and NADH in their mitochondria and reduced activity of mitochondrial NAD(+) requiring enzymes. Similar results were also found in the mitochondria of cells lacking NDT2 that encodes a protein (Ndt2p) displaying 70% homology with Ndt1p. The Delta ndt1 Delta ndt2 double mutant exhibited lower mitochondrial NAD(+) and NADH levels than the single deletants and a more pronounced delay in growth on nonfermentable carbon sources. The main role of Ndt1p and Ndt2p is to import NAD(+) into mitochondria by unidirectional transport or by exchange with intramitochondrially generated (d) AMP and (d) GMP.	Univ Bari, Biochem & Mol Biol Lab, Dept Pharmacobiol, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Bari, Biochem & Mol Biol Lab, Dept Pharmacobiol, Via E Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	castegna, alessandra/M-5106-2013; Todisco, Simona/AAU-2091-2021; castegna, alessandra/AAH-6668-2020; Agrimi, Gennaro/D-4001-2018	Agrimi, Gennaro/0000-0002-5219-4412; CASTEGNA, Alessandra/0000-0003-0235-6847				Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; Bedhomme M, 2005, J BIOL CHEM, V280, P34823, DOI 10.1074/jbc.M506045200; BOSTIAN KA, 1978, BIOCHEM J, V173, P773, DOI 10.1042/bj1730773; Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1327.2001.02418.x; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Fiermonte G, 2004, J BIOL CHEM, V279, P30722, DOI 10.1074/jbc.M400445200; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Flikweert MT, 1997, APPL ENVIRON MICROB, V63, P3399, DOI 10.1128/AEM.63.9.3399-3404.1997; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Haferkamp I, 2004, NATURE, V432, P622, DOI 10.1038/nature03131; Herrero-Yraola A, 2001, EMBO J, V20, P2404, DOI 10.1093/emboj/20.10.2404; Hildyard JCW, 2003, BIOCHEM J, V374, P607, DOI 10.1042/BJ20030995; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Marobbio CMT, 2006, BIOCHEM J, V393, P441, DOI 10.1042/BJ20051284; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; NOACK H, 1992, ANAL BIOCHEM, V202, P162, DOI 10.1016/0003-2697(92)90222-S; ONISHI T, 1967, EUR J BIOCHEM, V1, P301, DOI 10.1111/j.1432-1033.1967.tb00074.x; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SRERE PA, 1969, METHOD ENZYMOL, V13, P1; Suda Y, 2003, YEAST, V20, P995, DOI 10.1002/yea.1008; TOBIN A, 1980, PLANT PHYSIOL, V66, P225, DOI 10.1104/pp.66.2.225; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; TZAGOLOFF A, 1982, MITOCHONDRIA, P1; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; ZALKIN H, 1985, METHOD ENZYMOL, V113, P297; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang XJ, 2003, J BIOL CHEM, V278, P13503, DOI 10.1074/jbc.M300073200	50	175	184	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1524	1531		10.1074/jbc.M510425200	http://dx.doi.org/10.1074/jbc.M510425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291748	hybrid, Green Published			2022-12-25	WOS:000234652000030
J	van Nierop, P; Bertrand, S; Munno, DW; Gouwenberg, Y; van Minnen, J; Spafford, JD; Syed, NI; Bertrand, D; Smit, AB				van Nierop, P; Bertrand, S; Munno, DW; Gouwenberg, Y; van Minnen, J; Spafford, JD; Syed, NI; Bertrand, D; Smit, AB			Identification and functional expression of a family of nicotinic acetylcholine receptor subunits in the central nervous system of the mollusc Lymnaea stagnalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-TRANSMISSION; GENE FAMILY; ALPHA-BUNGAROTOXIN; ABDOMINAL GANGLION; DOPAMINE RELEASE; EXCITATORY SYNAPTOGENESIS; IONIC MECHANISMS; BINDING PROTEIN; XENOPUS-OOCYTES; POND SNAIL	We described a family of nicotinic acetylcholine receptor (nAChR) subunits underlying cholinergic transmission in the central nervous system (CNS) of the mollusc Lymnaea stagnalis. By using degenerate PCR cloning, we identified 12 subunits that display a high sequence similarity to nAChR subunits, of which 10 are of the alpha-type, 1 is of the alpha-type, and 1 was not classified because of insufficient sequence information. Heterologous expression of identified subunits confirms their capacity to form functional receptors responding to acetylcholine. The alpha-type subunits can be divided into groups that appear to underlie cation-conducting (excitatory) and anion-conducting (inhibitory) channels involved in synaptic cholinergic transmission. The expression of the Lymnaea nAChR subunits, assessed by real time quantitative PCR and in situ hybridization, indicates that it is localized to neurons and widespread in the CNS, with the number and localization of expressing neurons differing considerably between subunit types. At least 10% of the CNS neurons showed detectable nAChR subunit expression. In addition, cholinergic neurons, as indicated by the expression of the vesicular ACh transporter, comprise similar to 10% of the neurons in all ganglia. Together, our data suggested a prominent role for fast cholinergic transmission in the Lymnaea CNS by using a number of neuronal nAChR subtypes comparable with vertebrate species but with a functional complexity that may be much higher.	Free Univ Amsterdam, Dept Mol Cellular Neurobiol, Ctr Neurogenom Cognit Res, Fac Earth Life Sci, NL-1081 HV Amsterdam, Netherlands; Univ Geneva, Ctr Med, Dept Neurosci, CH-1211 Geneva, Switzerland; Univ Calgary, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada; Univ Calgary, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	Vrije Universiteit Amsterdam; University of Geneva; University of Calgary; University of Calgary	Smit, AB (corresponding author), Free Univ Amsterdam, Dept Mol Cellular Neurobiol, Ctr Neurogenom Cognit Res, Fac Earth Life Sci, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	guus.smit@falw.vu.nl	Smit, August B/E-8410-2011					Alkondon M, 1998, BRAIN RES, V810, P257, DOI 10.1016/S0006-8993(98)00880-4; Arvidsson U, 1997, J COMP NEUROL, V378, P454; BERTRAND D, 1994, EUR J NEUROSCI, V6, P869, DOI 10.1111/j.1460-9568.1994.tb00997.x; BERTRAND D, 1990, P NATL ACAD SCI USA, V87, P1993, DOI 10.1073/pnas.87.5.1993; BLANKENSHIP JE, 1971, J NEUROPHYSIOL, V34, P76, DOI 10.1152/jn.1971.34.1.76; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BRUSSAARD AB, 1990, NEUROSCIENCE, V39, P479, DOI 10.1016/0306-4522(90)90284-B; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CHEMERIS NK, 1982, J PHYSIOL-LONDON, V323, P1; CHIARANDINI DJ, 1967, SCIENCE, V156, P1597, DOI 10.1126/science.156.3782.1597; CHIARANDINI DJ, 1967, SCIENCE, V156, P1595, DOI 10.1126/science.156.3782.1595; Clarke PBS, 1996, BRIT J PHARMACOL, V117, P595, DOI 10.1111/j.1476-5381.1996.tb15232.x; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DeLange RPJ, 1997, NEUROSCIENCE, V78, P289, DOI 10.1016/S0306-4522(96)00576-3; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; GILLER E, 1968, SCIENCE, V161, P908, DOI 10.1126/science.161.3844.908; Grady SR, 2001, J NEUROCHEM, V76, P258, DOI 10.1046/j.1471-4159.2001.00019.x; Hamakawa T, 1999, J NEUROSCI, V19, P9306; HARVEY RJ, 1991, EMBO J, V10, P3239, DOI 10.1002/j.1460-2075.1991.tb04887.x; HUTTON ML, 1993, FEBS LETT, V326, P112, DOI 10.1016/0014-5793(93)81773-S; Jones AK, 2005, GENOMICS, V85, P176, DOI 10.1016/j.ygeno.2004.09.001; Jones AK, 2004, BIOESSAYS, V26, P39, DOI 10.1002/bies.10377; Jones AK, 2003, GENOMICS, V82, P441, DOI 10.1016/S0888-7543(03)00153-8; Kaiser S, 2000, MOL PHARMACOL, V58, P312, DOI 10.1124/mol.58.2.312; KANDEL ER, 1969, J NEUROPHYSIOL, V32, P496, DOI 10.1152/jn.1969.32.4.496; Koert CE, 2001, J NEUROSCI, V21, P5597, DOI 10.1523/JNEUROSCI.21-15-05597.2001; Lansdell SJ, 2004, J NEUROCHEM, V90, P479, DOI 10.1111/j.1471-4159.2004.02499.x; Le Novere N, 2001, NUCLEIC ACIDS RES, V29, P294, DOI 10.1093/nar/29.1.294; Meems R, 2003, J NEUROPHYSIOL, V89, P2611, DOI 10.1152/jn.00898.2002; MEESTER I, 1992, CELL TISSUE RES, V269, P183, DOI 10.1007/BF00384739; PENG X, 1994, MOL PHARMACOL, V45, P546; Reuben M, 2000, NEUROPHARMACOLOGY, V39, P290, DOI 10.1016/S0028-3908(99)00147-1; Sattelle DB, 2005, BIOESSAYS, V27, P366, DOI 10.1002/bies.20207; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schulz R, 1998, J NEUROCHEM, V71, P853; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SMIT AB, 1993, CELL MOL NEUROBIOL, V13, P263, DOI 10.1007/BF00733754; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; TAUC L, 1961, NATURE, V192, P366, DOI 10.1038/192366a0; TAUC L, 1962, J NEUROPHYSIOL, V25, P236, DOI 10.1152/jn.1962.25.2.236; TERMAAT A, 1980, COMP BIOCHEM PHYS C, V66, P115, DOI 10.1016/0306-4492(80)90082-9; TERMAAT A, 1983, J NEUROPHYSIOL, V49, P1392, DOI 10.1152/jn.1983.49.6.1392; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Der Steen W. J., 1969, NETH J ZOOL, V19, P131, DOI DOI 10.1163/002829669X00170; van Diepen MT, 2005, MOL CELL NEUROSCI, V29, P74, DOI 10.1016/j.mcn.2005.01.005; van Nierop P, 2005, J NEUROSCI, V25, P10617, DOI 10.1523/JNEUROSCI.2015-05.2005; VANMINNEN J, 1999, MODERN TECHNIQUES NE, P57; Vulfius CA, 2005, NEUROSCI LETT, V373, P232, DOI 10.1016/j.neulet.2004.10.010; VULFIUS EA, 1967, NATURE, V216, P400, DOI 10.1038/216400a0; WACHTEL H, 1967, SCIENCE, V158, P1206, DOI 10.1126/science.158.3805.1206; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200; Wonnacott S, 2000, EUR J PHARMACOL, V393, P51, DOI 10.1016/S0014-2999(00)00005-4; Woodin MA, 2002, J NEUROSCI, V22, P505, DOI 10.1523/JNEUROSCI.22-02-00505.2002; YEOMAN MS, 1993, J NEUROPHYSIOL, V70, P37, DOI 10.1152/jn.1993.70.1.37; ZEIMAL EV, 1967, NEUROBIOLOGY INVERTE, P255	57	48	49	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1680	1691		10.1074/jbc.M508571200	http://dx.doi.org/10.1074/jbc.M508571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16286458	hybrid, Green Published			2022-12-25	WOS:000234652000048
J	Yeh, PY; Kuo, SH; Yeh, KH; Chuang, SE; Hsu, CH; Chang, WC; Lin, HI; Gao, M; Cheng, AL				Yeh, PY; Kuo, SH; Yeh, KH; Chuang, SE; Hsu, CH; Chang, WC; Lin, HI; Gao, M; Cheng, AL			A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation - Bcl10 is up-regulated by NF-kappa b and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; MALT LYMPHOMA; CELL LYMPHOMA; KINASE-B; ACTIVATION; EXPRESSION; PROTEIN; TRANSCRIPTION; BINDING; CANCER	Bcl10 overexpression and nuclear translocation were originally identified in mucosa-associated lymphoid tissue lymphoma with t(1;14)(p32;q32) chromosome translocation. DNA amplification of Bcl10 was also found in other solid tumors. We have recently shown that nuclear translocation of Bcl10 is a specific molecular determinant of Helicobacter pylori-independent mucosa-associated lymphoid tissue lymphoma (Kuo, S.-H., Chen, L.T., Yeh, K.-H., Wu, M.S., Hsu, H.C., Yeh, P.Y., Mao, T.L., Chen, C.L., Doong, S.L., Lin, J.T., and Cheng, A.-L. (2004) J. Clin. Oncol. 22, 3491-3497). However, the molecular mechanism of Bcl10 nuclear translocation remains unknown. In this study, we observed that tumor necrosis factor-alpha (TNF alpha) up-regulates the expression of Bcl10 and induces a fraction of Bcl10 nuclear translocation in human breast carcinoma MCF7 cells. Chromatin immunoprecipitation assays and electrophoretic mobility shift assays indicated that an NF-kappa B-binding site resides in the Bcl10 5'-untranslated region. This study also demonstrates that Akt1, activated by TNF alpha, phosphorylates Bcl10 at Ser(218) and Ser(231) and that phosphorylated Bcl10 subsequently complexes with Bcl3 to enter the nucleus. Either inhibition of Akt1 or depletion of Bcl3 blocks Bcl10 nuclear translocation. In summary, these findings characterize a molecular linkage that directs Bcl10 nuclear translocation in response to TNF alpha treatment.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan; Natl Taiwan Univ, Inst Toxicol, Coll Med, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Hlth Res Inst, Div Canc Res, New York, NY 10016 USA	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Chuang, Shuang-En/D-2080-2010					Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CUNL S, 2004, LEUKEMIA BASINGSTOKE, V18, P1391; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Ge BS, 2003, J IMMUNOL, V171, P4210, DOI 10.4049/jimmunol.171.8.4210; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Kuo SH, 2004, J CLIN ONCOL, V22, P3491, DOI 10.1200/JCO.2004.10.087; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Liu YL, 2004, BIOCHEM BIOPH RES CO, V320, P1, DOI 10.1016/j.bbrc.2004.05.112; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Mitchell TC, 2002, ANN NY ACAD SCI, V975, P132, DOI 10.1111/j.1749-6632.2002.tb05947.x; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shen L, 2003, LEUKEMIA, V17, P2240, DOI 10.1038/sj.leu.2403128; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Thornburg NJ, 2003, CANCER RES, V63, P8293; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Yui D, 2001, ONCOGENE, V20, P4317, DOI 10.1038/sj.onc.1204576; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	43	38	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					167	175		10.1074/jbc.M511014200	http://dx.doi.org/10.1074/jbc.M511014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16280327	hybrid			2022-12-25	WOS:000234307200024
J	Fontana, L; Chen, Y; Prijateli, P; Sakai, T; Fassler, R; Sakai, LY; Rifkin, DB				Fontana, L; Chen, Y; Prijateli, P; Sakai, T; Fassler, R; Sakai, LY; Rifkin, DB			Fibronectin is required for integrin alpha v beta 6-mediated activation of latent TGF-beta complexes containing LTBP-1	FASEB JOURNAL			English	Article						LTBP; TGF-beta; fibronectin null cells	GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; ALPHA-5-BETA-1 INTEGRIN; CULTURED FIBROBLASTS; IN-VITRO; CELLS; EXPRESSION; TGF-BETA-1	Transforming growth factor-beta s (TGF-beta) are secreted as latent complexes consisting of the TGF-beta dimer, the TGF-beta propeptide dimer, and the latent TGF-beta binding protein ( LTBP). Although the bonds between TGF-beta and its propeptide are cleaved intracellulary, the propeptide associates with TGF-beta by electrostatic interactions, thereby conferring latency to the complex. We reported that a specific sequence of LTBP-1 is required for latent TGF-beta activation by the integrin alpha v beta 6. Here we describe a 24 amino acid sequence from the hinge domain required for activation. The LTBP-1 polypeptide rL1N, which includes the hinge, associates with fibronectin in binding assays. We present evidence that fibronectin null cells minimally activate latent TGF-beta and poorly incorporate the active hinge sequence into their matrix. In addition, cells missing the fibronectin receptor alpha 5 beta 1 exhibit defective activation of latent TGF-beta by alpha v beta 6 and decreased matrix incorporation. The results indicate specificity for integrin-mediated latent TGF-beta activation that include unique sequences in LTBP-1 and an appropriate matrix molecule.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Dept Mol Med, Martinsried, Germany	New York University; New York University; Oregon Health & Science University; Oregon Health & Science University; Max Planck Society	Rifkin, DB (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	rifkid01@med.nyu.edu			NATIONAL CANCER INSTITUTE [R01CA078422, R01CA034282] Funding Source: NIH RePORTER; NCI NIH HHS [CA78422, CA34282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; Collo G, 1999, J CELL SCI, V112, P569; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Koli K, 2001, MICROSC RES TECHNIQ, V52, P354, DOI 10.1002/1097-0029(20010215)52:4<354::AID-JEMT1020>3.0.CO;2-G; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; LYON M, 1994, J BIOL CHEM, V269, P11216; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mazzieri R, 2000, METH MOL B, V142, P13; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Unsold C, 2001, J CELL SCI, V114, P187; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; WU CY, 1993, J BIOL CHEM, V268, P21883; Yu Q, 2000, GENE DEV, V14, P163	57	132	137	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1798	1808		10.1096/fj.05-4134com	http://dx.doi.org/10.1096/fj.05-4134com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260650				2022-12-25	WOS:000234053100032
J	Segarra, M; Vilardell, C; Matsumoto, K; Esparza, J; Lozano, E; Serra-Pages, C; Urbano-Marquez, A; Yamada, KM; Cid, MC				Segarra, M; Vilardell, C; Matsumoto, K; Esparza, J; Lozano, E; Serra-Pages, C; Urbano-Marquez, A; Yamada, KM; Cid, MC			Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells	FASEB JOURNAL			English	Article						matrix metalloproteinases; lymphocytes; fibronectin	PROTEIN-TYROSINE KINASE; GTPASE-ACTIVATING PROTEIN; GELATINASE-A MMP-2; N-TERMINAL KINASE; MATRIX METALLOPROTEINASES; B MMP-9; V-SRC; EXPRESSION; FAK; MOTILITY	Integrin engagement induces matrix metalloproteinase (MMP) production by lymphocytes, allowing their progression into tissues. Focal adhesion kinase (FAK) is a key component of integrin-mediated signaling pathways regulating cell migration. We explored the role of FAK in integrin-induced gelatinase production by Jurkat T cells. Elevation of FAK expression by transient transfection increased cell invasiveness and gelatinase production and release driven by fibronectin. FAK point mutants revealed that gelatinase release was not dependent on FAK kinase activity but did require Y397, a binding site for Src-type tyrosine kinases. Requirement of Src kinases was further demonstrated by transfection with Src kinase-deficient mutants and treatment with a Src inhibitor. Transfection of truncated forms demonstrated dual functional elements in the FAK molecule. The FRNK fragment decreased gelatinase release, whereas the FAT subfragment enhanced it. FRNK inhibitory signals were transduced through Src-dependent pCAS phosphorylation and subsequent ERK1/2 activation. In contrast, FAT stimulated gelatinase secretion, which was also dependent on Src-kinase activity, was associated with a decreased ERK1/2 phosphorylation. This dual function of FAK in gelatinase secretion is then associated with changes in ERK1/2 activation status, a pathway coordinating cycles of adhesion/ release required for cell migration and defines a novel regulatory step in the complex control of MMP function.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Immunol, E-08036 Barcelona, Spain; Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Cid, MC (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, Villarroel 170, E-08036 Barcelona, Spain.	mccid@clinic.ub.es	Cid, Maria C./J-4553-2016; Segarra, Marta/ABE-2312-2020; Lozano, Ester/H-2215-2014	Cid, Maria C./0000-0002-4730-0938; Lozano, Ester/0000-0002-6307-9807; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Alexandropoulos K, 2003, IMMUNOL REV, V192, P181, DOI 10.1034/j.1600-065X.2003.00021.x; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Fukata M, 1999, J CELL SCI, V112, P4491; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ILLC D, 1995, NATURE, V377, P539; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; Johnatty RN, 1997, J IMMUNOL, V158, P2327; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Kim MH, 2001, ANTICANCER RES, V21, P45; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Liu SC, 2000, J CELL SCI, V113, P3563; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; Oktay MH, 2003, HUM PATHOL, V34, P240, DOI 10.1053/hupa.2003.40; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Owen JL, 2003, J IMMUNOL, V171, P4340, DOI 10.4049/jimmunol.171.8.4340; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schnaeker EM, 2004, CANCER RES, V64, P8924, DOI 10.1158/0008-5472.CAN-04-0324; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Tran H, 2002, J CELL SCI, V115, P2031; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wahlgren J, 2001, J PATHOL, V194, P217, DOI 10.1002/path.854; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xia MH, 1996, J IMMUNOL, V156, P160; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002	71	52	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1875	+		10.1096/fj.04-3574fje	http://dx.doi.org/10.1096/fj.04-3574fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16260653				2022-12-25	WOS:000232315700009
J	Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW				Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW			P53 promotes adenoviral replication and increases late viral gene expression	ONCOGENE			English	Article						p53; adenovirus; E1b55kDa; oncology	CARCINOMA CELL-LINES; MAJOR LATE PROMOTER; PHASE-II TRIAL; TUMOR-CELLS; 55-KILODALTON PROTEIN; NUCLEAR-LOCALIZATION; DELETED ADENOVIRUS; BINDING PROTEIN; NECK-CANCER; ONYX-015	The tumor suppressor protein, p53, plays a critical role in viro-oncology. However, the role of p53 in adenoviral replication is still poorly understood. In this paper, we have explored further the effect of p53 on adenoviral replicative lysis. Using well-characterized cells expressing a functional p53 (A549, K1neo, RKO) and isogenic derivatives that do not (K1scx, RKOp53.13), we show that virus replication, late virus protein expression and both wtAd5 and ONYX-015 virus-induced cell death are impaired in cells deficient in functional p53. Conversely, by transfecting p53 into these and other cells (IIICF/c, HeLa), we increase late virus protein expression and virus yield. We also show, using reporter assays in IIICF/c, HeLa and K1scx cells, that p53 can cooperate with E1a to enhance transcription from the major late promoter of the virus. Late viral protein production is enhanced by exogenous p53. Taken together, our data suggest that functional p53 can promote the adenovirus (Ad) lytic cycle. These results have implications for the use of Ad mutants that are defective in p53 degradation, such as ONYX-015, as agents for the treatment of cancers.	Univ Otago, Dept Pathol, Dunedin 9001, New Zealand; Univ Otago, Dept Microbiol, Dunedin 9001, New Zealand; Univ Cardiff Wales, Coll Med, Dept Pathol, Cardiff, Wales	University of Otago; University of Otago; Cardiff University	Royds, JA (corresponding author), Univ Otago, Dept Pathol, POB 913, Dunedin 9001, New Zealand.	janice.royds@stonebow.otago.ac.nz						BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1981, J VIROL, V39, P331, DOI 10.1128/JVI.39.2.331-340.1981; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Dix BR, 2000, CANCER RES, V60, P2666; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; Edwards SJ, 2002, J VIROL, V76, P12483, DOI 10.1128/JVI.76.24.12483-12490.2002; Geoerger B, 2002, CANCER RES, V62, P764; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Koch P, 2001, CANCER RES, V61, P5941; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KRUIJER W, 1981, NUCLEIC ACIDS RES, V9, P4439, DOI 10.1093/nar/9.18.4439; Lee H, 2000, INT J CANCER, V88, P454, DOI 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T; LEHMAN TA, 1991, CANCER RES, V51, P4090; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rauen KA, 2002, CANCER RES, V62, P3812; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Rogulski KR, 2000, CANCER RES, V60, P1193; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENK T, 1996, VIROLOGY, V2, P2111; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WEYER U, 1985, EMBO J, V4, P3015, DOI 10.1002/j.1460-2075.1985.tb04037.x; WILLIAMS JF, 1974, COLD SPRING HARB SYM, V39, P427, DOI 10.1101/SQB.1974.039.01.055; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	53	34	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1509	1520		10.1038/sj.onc.1209185	http://dx.doi.org/10.1038/sj.onc.1209185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247442				2022-12-25	WOS:000235890400008
J	Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D				Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D			Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells	ONCOGENE			English	Article						ras; HSF1; HSP70b	HEAT-SHOCK FACTOR-1; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; DNA-BINDING ACTIVITY; FACTOR-I; NEURONAL DIFFERENTIATION; MOLECULAR CHAPERONES; PC12 CELLS; PROGNOSTIC IMPLICATIONS; INCREASING COMPLEXITY	Heat shock proteins (Hsps) are overexpressed in many tumors, but are downregulated in some tumors. To check for a direct effect of Ha-Ras(va112) on HSP70 transcription, we transiently expressed the oncoprotein in Rat1 fibro-blasts and monitored its effect on HSP70b promoter-driven reporter gene. We show that expression of Ha-Ras(va112) induced this promoter. Promoter analysis via systematic deletions and point mutations revealed that Ha-Ras(va112) induces HSP70b transcription via heat shock elements (HSEs). Also, Ha-Ras(va112) induction of HSE-mediated transcription was dramatically reduced in HSF1 -/- cells. Yet, residual effect of Ha-Ras(va112) that was still measured in HSF1 -/- cells suggests that some of the Ha-Ras(va112) effect is Hsf1-independent. When HSF1 -/- cells, stably expressing Ha-Ras(va112), were grown on soft agar only small colonies were formed suggesting a role for heat shock factor 1 (Hsf1) in Ha-Ras(va112)-mediated transformation. Although Ha-ras(Val12) seems to be an inducer of HSP70's expression, we found that in Ha-ras(Va112-)transformed fibroblasts expression of this gene is suppressed. This suppression is correlated with higher sensitivity of Ha-ras(va112)-transformed cells to heat shock. We suggest that Ha-ras(Va112) is involved in Hsf1 activation, thereby inducing the cellular protective response. Cells that repress this response are perhaps those that acquire the capability to further proliferate and become transformed clones.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Chaim Sheba Med Ctr, Dept Funct Genom, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, GI Oncol Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Gastroenterol, IL-69978 Tel Aviv, Israel; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	Engelber@mail.ls.huji.ac.il	Hendel, Ayal/GMW-7991-2022	Arber, Nadir/0000-0001-5283-6991; Kaminski, Naftali/0000-0001-5917-4601; Hendel, Ayal/0000-0002-3388-6202				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brown JM, 1999, CANCER RES, V59, P1391; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Dwyer DS, 1996, NEUROCHEM RES, V21, P659, DOI 10.1007/BF02527722; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Han SI, 2002, FEBS LETT, V515, P141, DOI 10.1016/S0014-5793(02)02459-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatayama T, 1997, J BIOCHEM-TOKYO, V122, P904; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MIVECHI NF, 1995, CANCER RES, V55, P5512; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Myung Jae-Kyung, 2004, Proteome Sci, V2, P8, DOI 10.1186/1477-5956-2-8; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Santarosa M, 1997, EUR J CANCER, V33, P873, DOI 10.1016/S0959-8049(97)00002-6; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TETU B, 1992, CANCER RES, V52, P2325; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Voellmy R, 2004, PROG NUCLEIC ACID RE, V78, P143, DOI 10.1016/S0079-6603(04)78004-6; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	79	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1485	1495		10.1038/sj.onc.1209193	http://dx.doi.org/10.1038/sj.onc.1209193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278678				2022-12-25	WOS:000235890400006
J	Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM				Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM			Accelerated onsets of gastric hamartomas and hepatic adenomas/carcinomas in Lkb1(+/-)p53(-/-) compound mutant mice	ONCOGENE			English	Article						LKB1; p53; Peutz-Jeghers syndrome; hamartoma; HCC	PEUTZ-JEGHERS-SYNDROME; CELL-CYCLE ARREST; INTESTINAL METAPLASIA; KNOCKOUT MICE; LKB1 GENE; CANCER; MUTATIONS; KINASE; P53; CARCINOMA	Germline mutations in the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), which is characterized by gastrointestinal hamartomas and increasing risk of cancer. Mice with Lkb1(-/+) mutation develop gastric hamartomas after > 20 weeks of age, and hepatocellular adenomas and carcinomas > 30 weeks. It has been reported that, in PJS patients, carcinomas progressed from hamartomas contain p53 mutations, and that LKB1 regulates p53-dependent apoptosis. To investigate the roles of LKB1 and p53 mutations in tumorigenesis, we constructed compound mutant mice of Lkb1 and p53 genes. In the Lkb1(+/-) p53(-/-) mice, formation of gastric hamartomas and hepatic tumors was accelerated. However, histopathology of hamartomas was similar between Lkb1(+/-) p53(-/-) and Lkb1(+/-) mice, and Lkb1 genotype remained heterozygous, suggesting that the p53 mutation affected hamartoma initiation. Contrary to the heterozygous hamartomas in the stomach and duodenum, the hepatic adenomas in Lkb1(+/-) p53(-/-) mice showed loss of Lkb1 heterozygosity (LOH), suggesting that lack of p53 stimulated Lkb1 LOH and tumor initiation in the liver. Taken together, these results indicate that lack of p53 causes earlier onsets of gastric hamartomas and hepatic tumors in Lkb1(-/-) p53(-/-) mice.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bronner MP, 2003, MODERN PATHOL, V16, P359, DOI 10.1097/01.MP.0000062992.54036.E4; Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Miyaki M, 2000, CANCER RES, V60, P6311; Miyoshi H, 2002, CANCER RES, V62, P2261; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Nakau M, 2002, CANCER RES, V62, P4549; Papageorgiou T, 2002, INT J GYNECOL CANCER, V12, P337, DOI 10.1046/j.1525-1438.2002.01147.x; Seno H, 2002, INT J ONCOL, V21, P769; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Takahashi M, 2004, J GASTROENTEROL, V39, P1210, DOI 10.1007/s00535-004-1474-y; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	23	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1816	1820		10.1038/sj.onc.1209207	http://dx.doi.org/10.1038/sj.onc.1209207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278673	Green Submitted			2022-12-25	WOS:000236013700014
J	Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY				Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY			Clusterin plays an important role in hepatocellular carcinoma metastasis	ONCOGENE			English	Article						clusterin; hepatocellular carcinoma; metastasis; YKL-40; microarray	SMOOTH-MUSCLE-CELLS; SERUM YKL-40; PROSTATE-CANCER; MIGRATION; MARKER; GENE; OVEREXPRESSION; MICROARRAY; EXPRESSION; PROTEIN	To identify genes associated with tumor metastasis in hepatocellular carcinoma (HCC), gene expression profiles between a pair of primary HCC (H2-P) and their matched metastatic HCC (H2-M) were compared. Overexpression of clusterin (CLU) was found in H2-M cells. To determine the roles CLU played in HCC metastasis, CLU was transfected into H2-P cells. Overexpression of CLU in H2-P cells increased cell migration by twofold in vitro and formation of metastatic tumor nodules in liver by eightfold in vivo. To evaluate the correlation of CLU expression with HCC metastasis, the expression levels of CLU in HCCs were investigated using a tissue microarray (TMA) containing 104 pairs of primary HCCs and their matched metastases. The frequency of CLU overexpression increased significantly in metastatic HCCs (59.1%) compared with that in primary tumors (32.6%, P < 0.001). To gain additional insight into the function of CLU, the expression pro. le of H2P-CLU was compared with vector-transfected H2-P cells by cDNA microarray. A total of 35 upregulated and 14 downregulated genes were detected in H2P-CLU. One of the upregulated genes known as YKL-40, which is implicated in matrix-remodeling and metastasis, was further studied using TMA. A significant correlation (P < 0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China; Sun Yat Sen Univ, Dept Pathol, Guangzhou, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; City University of Hong Kong; Naval Medical University; Sun Yat Sen University; University of Hong Kong	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Estate Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Lau, George/AAQ-2085-2021; Yang, Mengsu/I-5750-2015; Yang, Mo/C-4455-2009; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017				BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Dehn H, 2003, ACTA OBSTET GYN SCAN, V82, P287, DOI 10.1034/j.1600-0412.2003.00010.x; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hu L, 2004, CANCER GENET CYTOGEN, V148, P80, DOI 10.1016/S0165-4608(03)00206-1; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Lau SH, 2005, ACTA PHARMACOL SIN, V26, P659, DOI 10.1111/j.1745-7254.2005.00126.x; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Millis AJT, 2001, J CELL PHYSIOL, V186, P210, DOI 10.1002/1097-4652(200102)186:2<210::AID-JCP1019>3.0.CO;2-N; Mitsunobu M, 1996, CLIN EXP METASTAS, V14, P520, DOI 10.1007/BF00115112; Miyake H, 2002, J UROLOGY, V167, P2203, DOI 10.1016/S0022-5347(05)65129-4; Miyata M, 2001, CIRCULATION, V104, P1407, DOI 10.1161/hc3701.095583; NAGAO T, 1990, ANN SURG, V211, P28, DOI 10.1097/00000658-199001000-00005; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tanwar MK, 2002, CANCER RES, V62, P4364; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Xie D, 2005, CANCER-AM CANCER SOC, V103, P277, DOI 10.1002/cncr.20765	29	124	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1242	1250		10.1038/sj.onc.1209141	http://dx.doi.org/10.1038/sj.onc.1209141			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247463				2022-12-25	WOS:000235537500011
J	Lingappa, JR; Dooher, JE; Newman, MA; Kiser, PK; Klein, KC				Lingappa, JR; Dooher, JE; Newman, MA; Kiser, PK; Klein, KC			Basic residues in the nucleocapsid domain of gag are required for interaction of HIV-1 Gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNASE-L INHIBITOR; MURINE LEUKEMIA-VIRUS; 2-5A/RNASE L PATHWAY; ROUS-SARCOMA-VIRUS; IN-VITRO; PRIMATE LENTIVIRUSES; RIBOSOME BIOGENESIS; ESCHERICHIA-COLI; FREE SYSTEMS	During human immunodeficiency virus, type 1 (HIV-1) assembly, Gag polypeptides multimerize into immature HIV-1 capsids. The cellular ATP-binding protein ABCE1 (also called HP68 or RNase L inhibitor) appears to be critical for proper assembly of the HIV-1 capsid. In primate cells, ABCE1 associates with Gag polypeptides present in immature capsid assembly intermediates. Here we demonstrate that the NC domain of Gag is critical for interaction with endogenous primate ABCE1, whereas other domains in Gag can be deleted without eliminating the association of Gag with ABCE1. NC contains two Cys-His boxes that form zinc finger motifs and are responsible for encapsidation of HIV-1 genomic RNA. In addition, NC contains basic residues known to play a critical role in nonspecific RNA binding, Gag-Gag interactions, and particle formation. We demonstrate that basic residues in NC are needed for the Gag-ABCE1 interaction, whereas the cysteine and histidine residues in the zinc fingers are dispensable. Constructs that fail to interact with primate ABCE1 or interact poorly also fail to form capsids and are arrested at an early point in the immature capsid assembly pathway. Whereas others have shown that basic residues in NC bind nonspecifically to RNA, which in turn scaffolds or nucleates assembly, our data demonstrate that the same basic residues in NC act either directly or indirectly to recruit a cellular protein that also promotes capsid formation. Thus, in cells, basic residues in NC appear to act by two mechanisms, recruiting both RNA and a cellular ATPase in order to facilitate efficient assembly of HIV-1 capsids.	Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lingappa, JR (corresponding author), Univ Washington, Dept Pathobiol, Box 357238,1959 NE Pacific St, Seattle, WA 98195 USA.	jais@u.washington.edu	Lingappa, Jairam/N-7760-2017		NCI NIH HHS [T32 CA09229] Funding Source: Medline; NIAID NIH HHS [P30 AI027757, R01 AI048389, T32 AI007509-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007509, R01AI048389, P30AI027757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Bowzard JB, 1998, J VIROL, V72, P9034, DOI 10.1128/JVI.72.11.9034-9044.1998; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Cimarelli A, 2000, J VIROL, V74, P3046, DOI 10.1128/JVI.74.7.3046-3057.2000; Dawson L, 1998, VIROLOGY, V251, P141, DOI 10.1006/viro.1998.9374; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Dooher JE, 2004, J MED PRIMATOL, V33, P272, DOI 10.1111/j.1600-0684.2004.00075.x; Dooher JE, 2004, J MED PRIMATOL, V33, P262, DOI 10.1111/j.1600-0684.2004.00074.x; Dooher JE, 2004, J VIROL, V78, P1645, DOI 10.1128/JVI.78.4.1645-1656.2004; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; El Hage A, 2001, MOL GEN GENET, V264, P796; Estevez AM, 2004, MOL BIOCHEM PARASIT, V133, P137, DOI 10.1016/j.molbiopara.2003.09.009; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; Hage AE, 2004, MOL MICROBIOL, V51, P189, DOI 10.1046/j.1365-2958.2003.03813.x; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; KUSHNER DJ, 1969, BACTERIOL REV, V33, P302, DOI 10.1128/MMBR.33.2.302-345.1969; Le Roy F, 2000, J INTERF CYTOK RES, V20, P635, DOI 10.1089/107999000414817; Lee EG, 2003, J VIROL, V77, P2010, DOI 10.1128/JVI.77.3.2010-2020.2003; LEWIS N, 1990, J VIROL, V64, P1690, DOI 10.1128/JVI.64.4.1690-1697.1990; Lingappa JR, 2005, VIROLOGY, V333, P114, DOI 10.1016/j.virol.2004.12.024; Lingappa VR, 2005, MT SINAI J MED, V72, P141; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Martinand C, 1998, J INTERF CYTOK RES, V18, P1031, DOI 10.1089/jir.1998.18.1031; MERIC C, 1989, J VIROL, V63, P1558; Muriaux D, 2004, J VIROL, V78, P12378, DOI 10.1128/JVI.78.22.12378-12385.2004; Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Sandefur S, 2000, J VIROL, V74, P7238, DOI 10.1128/JVI.74.16.7238-7249.2000; Sandefur S, 1998, J VIROL, V72, P2723, DOI 10.1128/JVI.72.4.2723-2732.1998; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Singh AR, 2001, VIROLOGY, V279, P257, DOI 10.1006/viro.2000.0706; SMITH AJ, 1990, J VIROL, V64, P2743, DOI 10.1128/JVI.64.6.2743-2750.1990; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang YQ, 1997, J VIROL, V71, P6765, DOI 10.1128/JVI.71.9.6765-6776.1997; ZHANG YQ, 1995, J VIROL, V69, P5716, DOI 10.1128/JVI.69.9.5716-5722.1995; Zhao ZY, 2004, BIOCHEM BIOPH RES CO, V323, P104, DOI 10.1016/j.bbrc.2004.08.068; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	53	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3773	3784		10.1074/jbc.M507255200	http://dx.doi.org/10.1074/jbc.M507255200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16275648				2022-12-25	WOS:000235275300005
J	Hickey, FB; Cotter, TG				Hickey, FB; Cotter, TG			BCR-ABL regulates phosphatidylinositol 3-kinase-p110 gamma transcription and activation and is required for proliferation and drug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; G-BETA-GAMMA; POSITIVE PHILADELPHIA-CHROMOSOME; CHRONIC MYELOGENOUS LEUKEMIA; MESSENGER-RNA STABILITY; PHOSPHOINOSITIDE 3-KINASE; CELL-LINE; CONSTITUTIVE ACTIVATION; LYSOPHOSPHATIDIC ACID; HEMATOPOIETIC-CELLS	The BCR-ABL oncogene is the hallmark of chronic myeloid leukemia, a clonal hematopoietic stem cell disorder. BCR-ABL displays constitutive tyrosine kinase activity, required for its transformation ability. Although the molecular mechanisms behind this malignancy are not fully understood, a role for phosphatidylinositol ( PI) 3-kinase has been repeatedly described. Here we report the specific up-regulation of the class I-B catalytic subunit of PI3-kinase (p110 gamma) in response to BCR-ABL expression. We demonstrate that this upregulation is due to increased transcription and is dependent on both PI3-kinase and MEK activity. We performed in vitro kinase activity assays and show that BCR-ABL also leads to increased p110 gamma activity and that this activation requires both G protein-coupled receptor and Ras signaling. In addition, by transfection of cells with dominant negative p110 gamma, we determined that this specific PI 3-kinase isoform is involved in both proliferation and the apoptosis resistance associated with chronic myeloid leukemia. The data presented here define for the first time the ability of BCR-ABL to alter the expression levels of PI3-kinase isoforms and also demonstrate a previously unreported link between BCR-ABL and p110 gamma.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Biosci Inst, Cork, Ireland	University College Cork	Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Biosci Inst, Cork, Ireland.	t.cotter@ucc.ie	Hickey, Fionnuala/F-2616-2013	Hickey, Fionnuala/0000-0002-5855-8010; Cotter, Thomas/0000-0003-4626-5613	NATIONAL CANCER INSTITUTE [R01CA097022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068487] Funding Source: NIH RePORTER; NCI NIH HHS [CA097022] Funding Source: Medline; NIGMS NIH HHS [GM068487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; AKITA Y, 1990, J BIOL CHEM, V265, P354; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bondev A, 1999, BIOL CHEM, V380, P1337, DOI 10.1515/BC.1999.171; Brennan FM, 2002, ARTHRITIS RHEUM, V46, P31, DOI 10.1002/1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5; Brewer G, 2003, J INTERF CYTOK RES, V23, P553, DOI 10.1089/107999003322485053; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chai SK, 1997, J IMMUNOL, V159, P4720; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Douthwaite JA, 2003, BIOCHEM PHARMACOL, V66, P589, DOI 10.1016/S0006-2952(03)00336-8; Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Jain SK, 1996, BLOOD, V88, P1542; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Liu Y, 2004, J BIOL CHEM, V279, P45556, DOI 10.1074/jbc.M407701200; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MacDonald PE, 2004, ENDOCRINOLOGY, V145, P4078, DOI 10.1210/en.2004-0028; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; Nienaber JJ, 2003, J CLIN INVEST, V112, P1067, DOI 10.1172/JCI200318213; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Qiu Q, 2004, MOL HUM REPROD, V10, P677, DOI 10.1093/molehr/gah088; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROWLEY JD, 1978, VIRCHOWS ARCH B, V29, P57; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Setalo G, 2005, NEUROCHEM RES, V30, P779, DOI 10.1007/s11064-005-6871-y; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WENSHENG W, 2005, IN PRESS CANC LETT; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200	66	54	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2441	2450		10.1074/jbc.M511173200	http://dx.doi.org/10.1074/jbc.M511173200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16291747	hybrid			2022-12-25	WOS:000234931800006
J	Shang, LM; Tomasi, TB				Shang, LM; Tomasi, TB			The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MHC CLASS-I; IFN-GAMMA; TRANSACTIVATOR CIITA; GENE-EXPRESSION; HSP90; ACTIVATION; STAT1; CELLS	Interferon signaling pathways are critical to both innate and adaptive immunity. We have demonstrated here that the inhibition of heat shock protein 90 (Hsp90) functions by small interfering RNAs or chemical inhibitors blocking interferon-induced gene expression. Hsp90 was required for signal transducers and activators of transcription 1 phosphorylation, and in its absence, Janus kinase (JAK) 1/2 were degraded by the proteosome. JAK1 interacts with Hsp90 and the CDC37 co-chaperone, and both interactions are destabilized by Hsp90 inhibitors. The biological consequences were suggested by experiments showing that T cell activation by interferon-gamma- primed macrophages and the antiviral response of interferons required Hsp90. We conclude that JAK1/2 are client proteins of Hsp90 and that Hsp90 and CDC37 play a critical role in types I and II interferon pathways.	Roswell Pk Canc Inst, Dept Immunol, Mol Med Lab, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Tomasi, TB (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Mol Med Lab, Elm & Carlton Sts, Buffalo, NY 14263 USA.	thomas.tomasi@roswellpark.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017013] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NICHD NIH HHS [HD 17013, R01 HD017013] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Baechler EC, 2004, CURR OPIN IMMUNOL, V16, P801, DOI 10.1016/j.coi.2004.09.014; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; CHOU S, 2005, IN PRESS INT IMMUNOL; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Gibson G, 2000, BIOESSAYS, V22, P372, DOI 10.1002/(SICI)1521-1878(200004)22:4<372::AID-BIES7>3.0.CO;2-J; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Luft T, 1998, J IMMUNOL, V161, P1947; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Pai RK, 2002, J IMMUNOL, V169, P1326, DOI 10.4049/jimmunol.169.3.1326; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sato Y, 1999, J RHEUMATOL, V26, P294; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yamano T, 2002, J EXP MED, V196, P185, DOI 10.1084/jem.20011922; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253	50	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1876	1884		10.1074/jbc.M509901200	http://dx.doi.org/10.1074/jbc.M509901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16280321	hybrid			2022-12-25	WOS:000234760400005
J	Gasch, A; Wiesner, S; Martin-Malpartida, P; Ramirez-Espain, X; Ruiz, L; Macias, MJ				Gasch, A; Wiesner, S; Martin-Malpartida, P; Ramirez-Espain, X; Ruiz, L; Macias, MJ			The structure of Prp40 FF1 domain and its interaction with the crn-TPR1 motif of Clf1 gives a new insight into the binding mode of FF domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; SPLICING FACTOR; TRANSCRIPTION ELONGATION; NMR EXPERIMENTS; CA150 BIND; PROTEIN; RECOGNITION; PHOSPHORYLATION; ASSIGNMENT	The yeast splicing factor Prp40 (pre- mRNA processing protein 40) consists of a pair of WW domains followed by several FF domains. The region comprising the FF domains has been shown to associate with the 5' end of U1 small nuclear RNA and to interact directly with two proteins, the Clf1 ( Crooked neck-like factor 1) and the phosphorylated repeats of the C-terminal domain of RNA polymerase II (CTD-RNAPII). In this work we reported the solution structure of the first FF domain of Prp40 and the identification of a novel ligand-binding site in FF domains. By using chemical shift assays, we found a binding site for the N-terminal crooked neck tetratricopeptide repeat of Clf1 that is distinct and structurally separate from the previously identified CTD-RNAPII binding pocket of the FBP11 (formin-binding protein 11) FF1 domain. Nointeraction, however, was observed between the Prp40 FF1 domain and three different peptides derived from the CTD- RNAPII protein. Indeed, the equivalent CTD-RNAPII-binding site in the Prp40 FF1 domain is predominantly negatively charged and thus unfavorable for an interaction with phosphorylated peptide sequences. Sequence alignments and phylogenetic tree reconstructions using the FF domains of three functionally related proteins, Prp40, FBP11, and CA150, revealed that Prp40 and FBP11 are not orthologous proteins and supported the different ligand specificities shown by their respective FF1 domains. Our results also revealed that not all FF domains in Prp40 are functionally equivalent. We proposed that at least two different interaction surfaces exist in FF domains that have evolved to recognize distinct binding motifs.	Inst Catalana Reserca & Estudis Avancats, E-08028 Barcelona, Spain; Biomed Res Inst Barcelona, E-08028 Barcelona, Spain; EMBL Heidelberg, Struct Biol Program, D-69117 Heidelberg, Germany	ICREA; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; European Molecular Biology Laboratory (EMBL)	Macias, MJ (corresponding author), Inst Catalana Reserca & Estudis Avancats, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	mmacias@pcb.ub.es	Macias, Maria J/K-3898-2014; Martin-Malpartida, Pau/L-1809-2014	Macias, Maria J/0000-0002-6915-963X; Martin-Malpartida, Pau/0000-0001-5867-5535; Ruiz Sainz, Lidia/0000-0002-8918-9158; Wiesner, Silke/0000-0003-0015-0167	ICREA Funding Source: Custom	ICREA(ICREA)		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Allen M, 2002, J MOL BIOL, V323, P411, DOI 10.1016/S0022-2836(02)00968-3; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bedford MT, 1999, TRENDS BIOCHEM SCI, V24, P264, DOI 10.1016/S0968-0004(99)01417-6; Ben-Yehuda S, 2000, GENETICS, V156, P1503; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Burge CB, 1999, RNA WORLD, P525; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Chung SY, 1999, RNA, V5, P1042, DOI 10.1017/S1355838299990635; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Noble CG, 2005, NAT STRUCT MOL BIOL, V12, P144, DOI 10.1038/nsmb887; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Smith MJ, 2004, MOL CELL BIOL, V24, P9274, DOI 10.1128/MCB.24.21.9274-9285.2004; Sun X, 2004, CHROMOSOMA, V113, P244, DOI 10.1007/s00412-004-0314-4; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Vincent K, 2003, GENETICS, V164, P895; Wang Q, 2003, J BIOL CHEM, V278, P7875, DOI 10.1074/jbc.M210839200; Wei J, 2005, MOL CELL, V17, P23, DOI 10.1016/j.molcel.2004.11.024; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099	46	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					356	364		10.1074/jbc.M508047200	http://dx.doi.org/10.1074/jbc.M508047200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16253993	hybrid			2022-12-25	WOS:000234307200045
J	Kurat, CF; Natter, K; Petschnigg, J; Wolinski, H; Scheuringer, K; Scholz, H; Zimmermann, R; Leber, R; Zechner, R; Kohlwein, SD				Kurat, CF; Natter, K; Petschnigg, J; Wolinski, H; Scheuringer, K; Scholz, H; Zimmermann, R; Leber, R; Zechner, R; Kohlwein, SD			Obese yeast: Triglyceride lipolysis is functionally conserved from mammals to yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; FATTY-ACID-METABOLISM; SACCHAROMYCES-CEREVISIAE; LIPID PARTICLES; DIACYLGLYCEROL ACYLTRANSFERASE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ADIPOSE-TISSUE; TRIACYLGLYCEROL; LIPASE	Storage and degradation of triglycerides are essential processes to ensure energy homeostasis and availability of precursors for membrane lipid synthesis. Recent evidence suggests that an emerging class of enzymes containing a conserved patatin domain are centrally important players in lipid degradation. Here we describe the identification and characterization of a major triglyceride lipase of the adipose triglyceride lipase/ Brummer family, Tgl4, in the yeast Saccharomyces cerevisiae. Elimination of Tgl4 in a tgl3 background led to fat yeast, rendering growing cells unable to degrade triglycerides. Tgl4 and Tgl3 lipases localized to lipid droplets, independent of each other. Serine 315 in the GXSXG lipase active site consensus sequence of the patatin domain of Tgl4 is essential for catalytic activity. Mouse adipose triglyceride lipase ( which also contains a patatin domain but is otherwise highly divergent in primary structure from any yeast protein) localized to lipid droplets when expressed in yeast, and significantly restored triglyceride breakdown in tgl4 mutants in vivo. Our data identify yeast Tgl4 as a functional ortholog of mammalian adipose triglyceride lipase.	Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria	University of Graz	Kohlwein, SD (corresponding author), Graz Univ, Inst Mol Biosci, Schubertstr 1, A-8010 Graz, Austria.	Sepp.kohlwein@uni-graz.at		Zimmermann, Robert/0000-0002-7354-870X; Kohlwein, Sepp Dieter/0000-0002-1030-0598; Leber, Regina/0000-0001-5306-5834; Kurat, Christoph/0000-0003-0962-3258; Zechner, Rudolf/0000-0001-5483-1182; Wolinski, Heimo/0000-0002-1583-6092	Austrian Science Fund (FWF) [W 901] Funding Source: researchfish; Austrian Science Fund FWF [W 901] Funding Source: Medline	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF))		Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bell CG, 2005, NAT REV GENET, V6, P221, DOI 10.1038/nrg1556; Brachmann CB, 1998, YEAST, V14, P115; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Fernandez JP, 2005, J BIOL CHEM, V280, P8544, DOI 10.1074/jbc.M413999200; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Gray JV, 2004, MICROBIOL MOL BIOL R, V68, P187, DOI 10.1128/MMBR.68.2.187-206.2004; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Gronke S, 2005, CELL METAB, V1, P323, DOI 10.1016/j.cmet.2005.04.003; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; HONIGBERG SM, 1992, GENETICS, V130, P703; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jandrositz A, 2005, BBA-MOL CELL BIOL L, V1735, P50, DOI 10.1016/j.bbalip.2005.04.005; Kals M, 2005, YEAST, V22, P213, DOI 10.1002/yea.1204; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Kohlwein SD, 2000, MICROSC RES TECHNIQ, V51, P511, DOI 10.1002/1097-0029(20001215)51:6<511::AID-JEMT3>3.3.CO;2-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinez MJ, 2004, MOL BIOL CELL, V15, P5295, DOI 10.1091/mbc.E03-11-0856; Mullner H, 2005, J BIOL CHEM, V280, P13321, DOI 10.1074/jbc.M409914200; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Natter K, 2005, MOL CELL PROTEOMICS, V4, P662, DOI 10.1074/mcp.M400123-MCP200; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Subramanian V, 2004, J LIPID RES, V45, P1983, DOI 10.1194/jlr.M400291-JLR200; Trotter PJ, 2001, ANNU REV NUTR, V21, P97, DOI 10.1146/annurev.nutr.21.1.97; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Roermund CWT, 2003, CELL MOL LIFE SCI, V60, P1838, DOI 10.1007/s00018-003-3076-x; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WHO Consultation, 2000, WHO TECH REP SER, V894, P1; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	57	232	245	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					491	500		10.1074/jbc.M508414200	http://dx.doi.org/10.1074/jbc.M508414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267052	hybrid			2022-12-25	WOS:000234307200061
J	Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H				Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H			SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines	ONCOGENE			English	Article						SWI/SNF complex; nonsmall cell lung carcinoma; NRSF; neuronal differentiation; histone deacetylation	RESTRICTIVE SILENCER FACTOR; SWI-SNF COMPLEX; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL LEVEL; REMODELING COMPLEXES; HISTONE DEACETYLASE; BRM GENES; EXPRESSION; CANCER	Mammalian chromatin remodelingfact or, SWI/ SNF complex contains a single molecule of either Brm or BRG1 as the ATPase catalytic subunit. Here, we show that the SWI/ SNF complex forms a larger complex with neuron-restrictive silencer factor (NRSF) and its corepressors, mSin3A and CoREST, in human nonsmall cell lung carcinoma cell lines. We also demonstrate that the strong transcriptional suppression of such neuron-specific genes as synaptophysin and SCG10 by NRSF in these non-neural cells requires the functional SWI/ SNF complex; these neuronal genes were elevated in cell lines deficient in both Brm and BRG1, whereas retrovirus vectors expressing siRNAs targeting integral components of SWI/ SNF complex (Brm/BRG1 or Ini1) induced expression of these neuronal genes in SWI/ SNF-competent cell lines. In cell lines deficient in both Brm and BRG1, exogenous Brm or BRG1 suppressed expression of these neuronal genes in an ATP-dependent manner and induced efficient and specific deacetylation of histone H4 around the NRSF binding site present in the synaptophysin gene by a large complex containing the recruited functional SWI/ SNF complex. Patients with Brm/BRG1 deficient lung carcinoma have been reported to carry poor prognosis; derepression of NRSF-regulated genes including these neuron-specific genes could contribute to enhance tumorigenicity and also would provide selective markers for Brm/BRG1-deficient tumors.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Nagasaki Univ, Sch Med, Dept Anat & Neurobiol, Nagasaki 852, Japan; Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan	University of Tokyo; Nagasaki University; Akita University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Watanabe, Hirotaka/GZA-8002-2022					Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 2000, CANCER RES, V60, P1840; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Furumai R, 2002, CANCER RES, V62, P4916; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Linnoila RI, 1996, J CELL BIOCHEM, P92; LINNOILA RI, 1995, LUNG CANCER, P73; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tabuchi A, 2002, BIOCHEM BIOPH RES CO, V290, P415, DOI 10.1006/bbrc.2001.6194; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Van Lommel A, 1999, ARCH HISTOL CYTOL, V62, P1, DOI 10.1679/aohc.62.1; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	51	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					470	479		10.1038/sj.onc.1209068	http://dx.doi.org/10.1038/sj.onc.1209068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247481				2022-12-25	WOS:000234714100015
J	Adams, DG; Coffee, RL; Zhang, H; Pelech, S; Strack, S; Wadzinski, BE				Adams, DG; Coffee, RL; Zhang, H; Pelech, S; Strack, S; Wadzinski, BE			Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAY; KAPPA-B KINASE; OKADAIC ACID; CALYCULIN-A; S6 KINASE; SUBUNIT; ACTIVATION; DEPHOSPHORYLATION; FAMILY; RAF-1	Protein serine/threonine phosphatase 2A (PP2A) regulates a wide variety of cellular signal transduction pathways. The predominant form of PP2A in cells is a heterotrimeric holoenzyme consisting of a scaffolding (A) subunit, a regulatory (B) subunit, and a catalytic (C) subunit. Although PP2A is known to regulate Raf1-MEK1/2-ERK1/2 signaling at multiple steps in this pathway, the specific PP2A holoenzymes involved remain unclear. To address this question, we established tetracycline-inducible human embryonic kidney 293 cell lines for overexpression of FLAG-tagged B alpha/delta regulatory subunits by similar to 3-fold or knock-down of B alpha by greater than 70% compared with endogenous levels. The expression of functional epitope-tagged B subunits was confirmed by the detection of A and C subunits as well as phosphatase activity in FLAG immune complexes from extracts of cells overexpressing the FLAG-B alpha/delta subunit. Western analysis of the cell extracts using phosphospecific antibodies for MEK1/2 and ERK1/2 demonstrated that activation of these kinases in response to epidermal growth factor was markedly diminished in B alpha knock- down cells but elevated in B alpha- and B alpha- overexpressing cells as compared with control cells. In parallel with the activation of MEK1/2 and ERK1/2, the inhibitory phosphorylation site of Raf1 (Ser-259) was dephosphorylated in cells overexpressing B alpha or B alpha. Pharmacological inhibitor studies as well as reporter assays for ERK-dependent activation of the transcription factor Elk1 revealed that the PP2A holoenzymes AB alpha C and AB delta C act downstream of Ras and upstream of MEK1 to promote activation of this MAPK signaling cascade. Furthermore both PP2A holoenzymes were found to associate with Raf1 and catalyze dephosphorylation of inhibitory phospho-Ser-259. Together these findings indicate that PP2A AB alpha C and AB delta C holoenzymes function as positive regulators of Raf1-MEK1/2-ERK1/2 signaling by targeting Raf1.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Univ British Columbia, Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	Vanderbilt University; University of British Columbia; University of British Columbia; University of Iowa	Wadzinski, BE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu		Strack, Stefan/0000-0002-6175-7280; Coffee, Lane/0000-0003-0059-0461	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM062265, R01GM051366] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, 5T32DK07563] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson KA, 2004, J BIOL CHEM, V279, P31708, DOI 10.1074/jbc.M404523200; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Garcia L, 2002, FEBS LETT, V523, P90, DOI 10.1016/S0014-5793(02)02950-2; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; JAKES S, 1988, BIOCHIM BIOPHYS ACTA, V967, P11, DOI 10.1016/0304-4165(88)90182-1; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pelech Steven, 2003, Methods Mol Biol, V218, P99; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	57	108	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42644	42654		10.1074/jbc.M502464200	http://dx.doi.org/10.1074/jbc.M502464200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16239230	hybrid			2022-12-25	WOS:000234200800022
J	Arnold, LA; Estebanez-Perpina, E; Togashi, M; Jouravel, N; Shelat, A; McReynolds, AC; Mar, E; Nguyen, P; Baxter, JD; Fletterick, RJ; Webb, P; Guy, RK				Arnold, LA; Estebanez-Perpina, E; Togashi, M; Jouravel, N; Shelat, A; McReynolds, AC; Mar, E; Nguyen, P; Baxter, JD; Fletterick, RJ; Webb, P; Guy, RK			Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BETA-SELECTIVE AGONIST; ESTROGEN-RECEPTOR; BINDING DOMAIN; MANNICH-BASES; COACTIVATOR; LIGAND; GC-1; TRIIODOTHYRONINE; MECHANISM	Thyroid hormone (3,5,3'-triiodo-L-thyronine, T3) is an endocrine hormone that exerts homeostatic regulation of basal metabolic rate, heart rate and contractility, fat deposition, and other phenomena (1, 2). T3 binds to the thyroid hormone receptors (TRs) and controls their regulation of transcription of target genes. The binding of TRs to thyroid hormone induces a conformational change in TRs that regulates the composition of the transcriptional regulatory complex. Recruitment of the correct coregulators (CoR) is important for successful gene regulation. In principle, inhibition of the TR-CoR interaction can have a direct influence on gene transcription in the presence of thyroid hormones. Herein we report a high throughput screen for small molecules capable of inhibiting TR coactivator interactions. One class of inhibitors identified in this screen was aromatic beta-aminoketones, which exhibited IC50 values of similar to 2 mu M. These compounds can undergo a deamination, generating unsaturated ketones capable of reacting with nucleophilic amino acids. Several experiments confirm the hypothesis that these inhibitors are covalently bound to TR. Optimization of these compounds produced leads that inhibited the TR-CoR interaction in vitro with potency of similar to 0.6 mu M and thyroid signaling in cellular systems. These are the first small molecules irreversibly inhibiting the coactivator binding of a nuclear receptor and suppressing its transcriptional activity.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Guy, RK (corresponding author), St Jude Childrens Res Hosp, Dept Chem Biol Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USA.	kip.guy@stjude.org	Estebanez-Perpina, Eva/L-4021-2014; Shelat, Anang/J-4995-2013; Guy, Rodney/J-7107-2013	Shelat, Anang/0000-0002-6266-2910; Guy, Rodney/0000-0002-9638-2060; Togashi, Marie/0000-0002-0886-8766; Arnold, Leggy/0000-0003-1411-1572; Estebanez-Perpina, Eva/0000-0003-2687-5801	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK058080, R01DK058080] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61648, R01 DK058080-05, R01 DK058080, DK58080] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arend M, 1998, ANGEW CHEM INT EDIT, V37, P1044, DOI 10.1002/(SICI)1521-3773(19980504)37:8<1044::AID-ANIE1044>3.0.CO;2-E; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Berg T, 2003, ANGEW CHEM INT EDIT, V42, P2462, DOI 10.1002/anie.200200558; Briel D, 1999, J MED CHEM, V42, P1849, DOI 10.1021/jm980288r; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Davioud-Charvet E, 2003, BIOCHEMISTRY-US, V42, P13319, DOI 10.1021/bi0353629; DIETRICH SW, 1977, J MED CHEM, V20, P863, DOI 10.1021/jm00217a001; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Freitas FRS, 2003, AM J PHYSIOL-ENDOC M, V285, pE1135, DOI 10.1152/ajpendo.00506.2002; Galande AK, 2004, J PEPT RES, V63, P297, DOI 10.1111/j.1399-3011.2004.00152.x; Geistlinger TR, 2003, J AM CHEM SOC, V125, P6852, DOI 10.1021/ja0348391; Geistlinger TR, 2001, J AM CHEM SOC, V123, P1525, DOI 10.1021/ja005549c; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Gul HI, 2003, BIOL PHARM BULL, V26, P631; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Leduc AM, 2003, P NATL ACAD SCI USA, V100, P11273, DOI 10.1073/pnas.1934759100; Malm J, 2004, CURR PHARM DESIGN, V10, P3525, DOI 10.2174/1381612043382873; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Manzano J, 2003, ENDOCRINOLOGY, V144, P5480, DOI 10.1210/en.2003-0633; Mishra MK, 2004, J COMP PHYSIOL B, V174, P471, DOI 10.1007/s00360-004-0433-5; Moore JMR, 2005, MOL CELL PROTEOMICS, V4, P475, DOI 10.1074/mcp.R500001-MCP200; Moore JMR, 2004, J BIOL CHEM, V279, P27584, DOI 10.1074/jbc.M403453200; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodriguez AL, 2004, J MED CHEM, V47, P600, DOI 10.1021/jm030404c; Roehrl MHA, 2004, BIOCHEMISTRY-US, V43, P16056, DOI 10.1021/bi048233g; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Stanton JL, 2000, BIOORG MED CHEM LETT, V10, P1661, DOI 10.1016/S0960-894X(00)00309-7; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Webb P, 2002, J STEROID BIOCHEM, V83, P59, DOI 10.1016/S0960-0760(02)00270-4; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Ye L, 2003, J MED CHEM, V46, P1580, DOI 10.1021/jm021080f; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	49	83	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43048	43055		10.1074/jbc.M506693200	http://dx.doi.org/10.1074/jbc.M506693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263725	Green Published, hybrid			2022-12-25	WOS:000234200800070
J	Li, JL; Liu, DW; Ke, HZ; Duncan, RL; Turner, CH				Li, JL; Liu, DW; Ke, HZ; Duncan, RL; Turner, CH			The P2X(7) nucleotide receptor mediates skeletal mechanotransduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; EXTRACELLULAR NUCLEOTIDES; OSTEOCLAST FORMATION; ATP RELEASE; ACTIVATION; CELLS; OSTEOBLASTS; MODULATION; INHIBITION; PROSTAGLANDINS	The P2X(7) nucleotide receptor (P2X(7)R) is an ATP-gated ion channel expressed in many cell types including osteoblasts and osteocytes. Mice with a null mutation of P2X(7)R have osteopenia in load bearing bones, suggesting that the P2X(7)R may be involved in the skeletal response to mechanical loading. We found the skeletal sensitivity to mechanical loading was reduced by up to 73% in P2X(7)R null (knock-out ( KO)) mice. Release of ATP in the primary calvarial osteoblasts occurred within 1 min of onset of fluid shear stress (FSS). After 30 min of FSS, P2X(7)R-mediated pore formation was observed in wild type (WT) cells but not in KO cells. FSS increased prostaglandin ( PG) E-2 release in WT cells but did not alter PGE(2) release in KO cells. Studies using MC3T3-E1 osteoblasts and MLO-Y4 osteocytes confirmed that PGE2 release was suppressed by P2X(7)R blockade, whereas the P2X(7)R agonist BzATP enhanced PGE(2) release. We conclude that ATP signaling through P2X(7)R is necessary for mechanically induced release of prostaglandins by bone cells and subsequent osteogenesis.	Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA; Indiana Univ Purdue Univ, Dept Biomed Engn, Biomech & Biomat Res Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Pfizer; Indiana University System; Indiana University-Purdue University Indianapolis	Turner, CH (corresponding author), Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.	turnerch@iupui.edu	Duncan, Randall/AAK-3888-2020	Duncan, Randall/0000-0001-5733-6603	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045218, R01AR043222] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01AR046530, R01AR43222, P01AR045218] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bakker AD, 2003, BIOCHEM BIOPH RES CO, V305, P677, DOI 10.1016/S0006-291X(03)00831-3; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756-3282(01)00430-6; Brambilla R, 2001, ANN NY ACAD SCI, V939, P54; Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02-0940com; Cario-Toumaniantz C, 1998, J PHYSIOL-LONDON, V508, P659, DOI 10.1111/j.1469-7793.1998.659bp.x; Chambers TJ, 1997, ADV EXP MED BIOL, V433, P295; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; Chow J W, 2000, Exerc Sport Sci Rev, V28, P185; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Fortes FSA, 2004, J CELL SCI, V117, P4717, DOI 10.1242/jcs.01345; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Gartland A, 2003, CRIT REV EUKAR GENE, V13, P237; Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223-002-2098-y; Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Hiken JF, 2004, AM J PHYSIOL-CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003; HILLAM RA, 1995, J BONE MINER RES, V10, P683; Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756-3282(97)00147-6; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Ke HZ, 1998, BONE, V23, P249, DOI 10.1016/S8756-3282(98)00102-1; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; KleinNulend J, 1996, J CELL PHYSIOL, V168, P1, DOI 10.1002/(SICI)1097-4652(199607)168:1<1::AID-JCP1>3.0.CO;2-T; Koolpe M, 1999, ARTHRITIS RHEUM, V42, P258, DOI 10.1002/1529-0131(199902)42:2<258::AID-ANR7>3.0.CO;2-O; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Panupinthu N, 2005, J BONE MINER RES, V20, pS248; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; PERRONE CE, 1995, J BIOL CHEM, V270, P2099, DOI 10.1074/jbc.270.5.2099; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124; Saunders MM, 2003, BONE, V32, P350, DOI 10.1016/S8756-3282(03)00025-5; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; SUZUKI A, 1993, CELL ADHES COMMUN, V1, P113, DOI 10.3109/15419069309095687; UHTHOFF HK, 1978, J BONE JOINT SURG BR, V60, P420, DOI 10.1302/0301-620X.60B3.681422; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wiley JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140-6736(02)08156-4; Yamamoto K, 2003, AM J PHYSIOL-HEART C, V285, pH793, DOI 10.1152/ajpheart.01155.2002; You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200	53	199	208	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42952	42959		10.1074/jbc.M506415200	http://dx.doi.org/10.1074/jbc.M506415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16269410	hybrid			2022-12-25	WOS:000234200800058
J	Maddali, KK; Korzick, DH; Tharp, DL; Bowles, DK				Maddali, KK; Korzick, DH; Tharp, DL; Bowles, DK			PKC delta mediates testosterone-induced increases in coronary smooth muscle Ca(v)1.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ANDROGEN RECEPTOR EXPRESSION; CA2+ CHANNELS; HEART-DISEASE; UP-REGULATION; CELLS; AROMATASE; ATHEROSCLEROSIS; CONTRACTION; CONVERSION	Sex hormones have emerged as important modulators of cardiovascular physiology and pathophysiology. Our previous studies demonstrated that testosterone increases expression and activity of L-type, voltage-gated calcium channels (Ca(v)1.2) in coronary arteries of males. The purpose of the present study was to determine whether testosterone (T) alters coronary protein kinase C delta(PKC delta) expression and whether PKC delta plays a role in coronary Ca(v)1.2 expression. For in vitro studies, porcine right coronary arteries (RCA) and post-confluent (passages 3-6) 5-day, serum-restricted coronary smooth muscle cell cultures (CSMC) were incubated in the presence and absence of T or dihydrotestosterone (10 and 100 nM) for 18 h at 37 degrees C in a humidified chamber. For sex and endogenous testosterone-dependent effects, RCA were obtained from intact males, castrated males, castrated males with T replacement, and intact females. In vitro T and dihydrotestosterone caused an similar to 2-3-fold increase in PKC delta protein levels, similar to 1.5-2-fold increase in PKC delta kinase activity, and localization of PKC delta toward the plasma membrane and nuclear envelope. PKC delta protein levels were higher in coronary arteries of intact males compared with intact females. Elimination of endogenous testosterone by castration reduced RCA PKC delta protein levels, an effect partially (similar to 45%) reversed by exogenous T ( castrated males with T replacement). In CSMC, PKC inhibition with either the general PKC inhibitor, cheylerythrine, or the putative PKC delta inhibitor, rottlerin, completely inhibited the T-mediated increase in coronary Ca(v)1.2 protein levels. Conversely, Go6976, a conventional PKC isoform inhibitor, failed to inhibit T-induced increases in coronary Ca(v)1.2 protein levels. PKC delta short interference RNA completely blocked T-induced increases in Ca(v)1.2 protein levels in CSMC. These results demonstrate for the first time that 1) endogenous T is a primary modulator of coronary PKC delta protein and activity in males and 2) T increases Ca(v)1.2 protein expression in a PKC delta-dependent manner.	Univ Missouri, Dept Biomed Sci, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA; Univ Missouri, Natl Ctr Gender Physiol, Columbia, MO 65211 USA; Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; Penn State Univ, Program Physiol, University Pk, PA 16802 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bowles, DK (corresponding author), Univ Missouri, Dept Biomed Sci, E102 Vet Med, Columbia, MO 65211 USA.	BowlesD@missouri.edu		Bowles, Doug/0000-0003-2043-7368	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL071574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandersen P, 1996, ATHEROSCLEROSIS, V125, P1, DOI 10.1016/0021-9150(96)05864-9; American Heart Association, 2003, HEART DIS STROK STAT; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BALTHAZART J, 1993, J STEROID BIOCHEM, V44, P521, DOI 10.1016/0960-0760(93)90256-V; BARRETTCONNOR E, 1988, CIRCULATION, V78, P539, DOI 10.1161/01.CIR.78.3.539; Bowles DK, 2004, AM J PHYSIOL-HEART C, V287, pH2091, DOI 10.1152/ajpheart.00258.2004; Bowles DK, 2001, J APPL PHYSIOL, V91, P2503, DOI 10.1152/jappl.2001.91.6.2503; Dunajska K, 2004, Aging Male, V7, P197; Fukui M, 2003, DIABETES CARE, V26, P1869, DOI 10.2337/diacare.26.6.1869; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; Hanke H, 2001, CIRCULATION, V103, P1382, DOI 10.1161/01.CIR.103.10.1382; Harada N, 1999, CIRC RES, V84, P1285, DOI 10.1161/01.RES.84.11.1285; HELLER RF, 1981, BRIT MED J, V282, P438, DOI 10.1136/bmj.282.6262.438; Higashiura K, 1997, J CARDIOVASC PHARM, V29, P311, DOI 10.1097/00005344-199703000-00002; Hill BJF, 2000, J PHARMACOL EXP THER, V295, P484; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; IOTH H, 2001, AM J PHYSIOL, V281, pH359; Kanashiro CA, 2001, AM J PHYSIOL-CELL PH, V280, pC34, DOI 10.1152/ajpcell.2001.280.1.C34; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; Korzick DH, 2005, MED SCI SPORT EXER, V37, P381, DOI 10.1249/01.MSS.0000155698.76417.4C; Leitges M, 2001, J CLIN INVEST, V108, P1505; LITTEN RZ, 1987, EUR J PHARMACOL, V144, P185, DOI 10.1016/0014-2999(87)90518-8; Liu L, 2000, AM J PHYSIOL-HEART C, V278, pH1153, DOI 10.1152/ajpheart.2000.278.4.H1153; Ma R, 2005, HORM RES, V63, P6, DOI 10.1159/000082339; Maddali KK, 2005, VASC PHARMACOL, V42, P153, DOI 10.1016/j.vph.2004.11.008; Mayr M, 2004, CIRC RES, V94, pE87, DOI 10.1161/01.RES.0000131496.49135.1d; Mukherjee TK, 2002, P NATL ACAD SCI USA, V99, P4055, DOI 10.1073/pnas.052703199; Nathan L, 2001, P NATL ACAD SCI USA, V98, P3589, DOI 10.1073/pnas.051003698; Nelson MT, 1990, AM J PHYSIOL, V259, P3; Obejero-Paz CA, 1998, AM J PHYSIOL-CELL PH, V275, pC535, DOI 10.1152/ajpcell.1998.275.2.C535; Sieminska Lucyna, 2003, Med Sci Monit, V9, pCR162; Walter HJ, 2000, J BIOL CHEM, V275, P25717, DOI 10.1074/jbc.M910282199; Wamhoff BR, 2004, CIRC RES, V95, P406, DOI 10.1161/01.RES.0000138582.36921.9e	34	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43024	43029		10.1074/jbc.M509147200	http://dx.doi.org/10.1074/jbc.M509147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16243844	hybrid			2022-12-25	WOS:000234200800067
J	Huang, J; Imamura, T; Babendure, JL; Lu, JC; Olefsky, JM				Huang, J; Imamura, T; Babendure, JL; Lu, JC; Olefsky, JM			Disruption of microtubules ablates the specificity of insulin signaling to GLUT4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; RAT ADIPOCYTES; PROTEIN; ACTIN; RECEPTOR; KINESIN; REARRANGEMENT; LOCALIZATION	Although the cytoskeletal network is important for insulin-induced glucose uptake, several studies have assessed the effects of microtubule disruption on glucose transport with divergent results. Here, we investigated the effects of microtubule-depolymerizing reagent, nocodazole and colchicine, on GLUT4 translocation in 3T3-L1 adipocytes. After nocodazole treatment to disrupt microtubules, GLUT4 vesicles were dispersed from the perinuclear region in the basal state, and insulin-induced GLUT4 translocation was partially inhibited by 20-30%, consistent with other reports. We found that platelet-derived growth factor (PDGF), which did not stimulate GLUT4 translocation in intact cells, was surprisingly able to enhance GLUT4 translocation to similar to 50% of the maximal insulin response, in nocodazole-treated cells with disrupted microtubules. This effect of PDGF was blocked by pretreatment with wortmannin and attenuated in cells pretreated with cytochalasin D. Using confocal microscopy, we found an increased co-localization of GLUT4 and F-actin in nocodazole-treated cells upon PDGF stimulation compared with control cells. Furthermore, microinjection of small interfering RNA targeting the actin-based motor Myo1c, but not the microtubule-based motor KIF3, significantly inhibited both insulin-and PDGF-stimulated GLUT4 translocation after nocodazole treatment. In summary, our data suggest that 1) proper perinuclear localization of GLUT4 vesicles is a requirement for insulin-specific stimulation of GLUT4 translocation, and 2) nocodazole treatment disperses GLUT4 vesicles from the perinuclear region allowing them to engage insulin and PDGF-sensitive actin filaments, which can participate in GLUT4 translocation in a phosphatidylinositol 3-kinase-dependent manner.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Lu, Juu-Chin/ABB-3198-2020	Lu, Juu-Chin/0000-0001-8523-6992	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai H, 2003, AM J PHYSIOL-ENDOC M, V285, pE836, DOI 10.1152/ajpendo.00238.2002; Asahi Yoshihiko, 1999, Journal of Medical Investigation, V46, P192; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Khayat ZA, 2000, J CELL SCI, V113, P279; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Olefsky JM, 1999, J BIOL CHEM, V274, P1863, DOI 10.1074/jbc.274.4.1863; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Shigematsu S, 2001, J BIOL CHEM, V276, P15292, DOI 10.1074/jbc.M009684200; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Usui I, 2004, EMBO J, V23, P2821, DOI 10.1038/sj.emboj.7600297; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Whiteman EL, 2003, ENDOCRINOLOGY, V144, P3811, DOI 10.1210/en.2003-0480	36	43	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42300	42306		10.1074/jbc.M510920200	http://dx.doi.org/10.1074/jbc.M510920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239226	hybrid			2022-12-25	WOS:000233992700059
J	Rossi, D; Brambilla, L; Valori, CF; Crugnola, A; Giaccone, G; Capobianco, R; Mangieri, M; Kingston, AE; Bloc, A; Bezzi, P; Volterra, A				Rossi, D; Brambilla, L; Valori, CF; Crugnola, A; Giaccone, G; Capobianco, R; Mangieri, M; Kingston, AE; Bloc, A; Bezzi, P; Volterra, A			Defective tumor necrosis factor-alpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; IN-SITU; SYNAPTIC-TRANSMISSION; NEURONAL-ACTIVITY; CALCIUM OSCILLATIONS; HIPPOCAMPAL-NEURONS; CNS SYNAPTOGENESIS; ENTORHINAL CORTEX; AMPA RECEPTOR; BETA PROTEIN	The cytokine tumor necrosis factor-alpha ( TNF alpha) induces Ca2+-dependent glutamate release from astrocytes via the downstream action of prostaglandin ( PG) E-2. By this process, astrocytes may participate in intercellular communication and neuromodulation. Acute inflammation in vitro, induced by adding reactive microglia to astrocyte cultures, enhances TNF alpha production and amplifies glutamate release, switching the pathway into a neurodamaging cascade ( Bezzi, P., Domercq, M., Brambilla, L., Galli, R., Schols, D., De Clercq, E., Vescovi, A., Bagetta, G., Kollias, G., Meldolesi, J., and Volterra, A. ( 2001) Nat. Neurosci. 4,702 - 710). Because glial inflammation is a component of Alzheimer disease ( AD) and TNF alpha is overexpressed in AD brains, we investigated possible alterations of the cytokine-dependent pathway in PDAPP mice, a transgenic model of AD. Glutamate release was measured in acute hippocampal and cerebellar slices from mice at early ( 4-month-old) and late ( 12-month-old) disease stages in comparison with age-matched controls. Surprisingly, TNF alpha-evoked glutamate release, normal in 4-month-old PDAPP mice, was dramatically reduced in the hippo campus of 12-month-old animals. This defect correlated with the presence of numerous beta-amyloid deposits and hypertrophic astrocytes. In contrast, release was normal in cerebellum, a region devoid of beta-amyloid deposition and astrocytosis. The Ca2+-dependent process by which TNF alpha evokes glutamate release in acute slices is distinct from synaptic release and displays properties identical to those observed in cultured astrocytes, notably PG dependence. However, prostaglandin E2 induced normal glutamate release responses in 12-month-old PDAPP mice, suggesting that the pathology-associated defect involves the TNF alpha-dependent control of secretion rather than the secretory process itself. Reduced expression of DENN/MADD, a mediator of TNF alpha-PG coupling, might account for the defect. Alteration of this neuromodulatory astrocytic pathway is described here for the first time in relation to Alzheimer disease.	Univ Milan, Dept Pharmacol Sci, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Lausanne, Dept Morfol & Biol Celular, CH-1005 Lausanne, Switzerland; Natl Neurol Inst Carlo Besta, I-20133 Milan, Italy; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Milan; University of Lausanne; IRCCS Istituto Neurologico Besta; Eli Lilly	Volterra, A (corresponding author), Univ Milan, Dept Pharmacol Sci, Ctr Excellence Neurodegenerat Dis, Via Balzaretti,9, I-20133 Milan, Italy.	Andrea.Volterra@unil.ch	Giaccone, Giorgio/J-6212-2012; giaccone, giorgio/AAB-9978-2019; Brambilla, Liliana/AAA-3303-2021; Bezzi, Paola/AAP-2440-2020; Rossi, Daniela Maria/AAA-3401-2021; Valori, C./E-7012-2010	giaccone, giorgio/0000-0002-4803-0802; Brambilla, Liliana/0000-0001-5714-3625; Rossi, Daniela Maria/0000-0002-3346-1327; Volterra, Andrea/0000-0003-1069-1602	Telethon [GGP05244, GGP02052] Funding Source: Medline	Telethon(Fondazione Telethon)		Aguado F, 2002, J NEUROSCI, V22, P9430; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; ARANGUEZ I, 1995, GLIA, V13, P185, DOI 10.1002/glia.440130305; Araque A, 2002, J NEUROSCI, V22, P2443, DOI 10.1523/JNEUROSCI.22-07-02443.2002; Auld DS, 2003, NEURON, V40, P389, DOI 10.1016/S0896-6273(03)00607-X; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; DICKSON DW, 1988, AM J PATHOL, V132, P86; Dodart JC, 2000, NEUROBIOL DIS, V7, P71, DOI 10.1006/nbdi.1999.0278; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Irizarry MC, 1997, J NEUROSCI, V17, P7053; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; JOURDAIN P, 2004, SOC NEUR 34 ANN M SA; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Masliah E, 1996, J NEUROSCI, V16, P5795; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Pasti L, 1997, J NEUROSCI, V17, P7817; Perea G, 2005, J NEUROSCI, V25, P2192, DOI 10.1523/JNEUROSCI.3965-04.2005; Porter JT, 1996, J NEUROSCI, V16, P5073; Reilly JF, 2003, P NATL ACAD SCI USA, V100, P4837, DOI 10.1073/pnas.0330745100; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Su Y, 1998, J NEUROSCI RES, V53, P177, DOI 10.1002/(SICI)1097-4547(19980715)53:2<177::AID-JNR6>3.0.CO;2-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Volterra A., 2002, TRIPARTITE SYNAPSE G, P164; WISNIEWSKI HM, 1991, NEUROBIOL AGING, V12, P593, DOI 10.1016/0197-4580(91)90091-W; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zhao M, 2003, NEUROCHEM RES, V28, P307, DOI 10.1023/A:1022337519035; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	64	45	49	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42088	42096		10.1074/jbc.M504124200	http://dx.doi.org/10.1074/jbc.M504124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16253995	hybrid			2022-12-25	WOS:000233992700035
J	Pleskova, M; Beck, KF; Behrens, MH; Huwiler, A; Fichtlscherer, B; Wingerter, O; Brandes, RP; Mulsch, A; Pfeilschifter, J				Pleskova, M; Beck, KF; Behrens, MH; Huwiler, A; Fichtlscherer, B; Wingerter, O; Brandes, RP; Mulsch, A; Pfeilschifter, J			Nitric oxide down-regulates the expression of the catalytic NADPH oxidase subunit Nox1 in rat renal mesangial cells	FASEB JOURNAL			English	Article						kidney; siRNA; promoter; reactive oxygen species	SOLUBLE GUANYLYL CYCLASE; SUPEROXIDE-DISMUTASE; MESSENGER-RNA; SYNTHASE EXPRESSION; GENE-EXPRESSION; REACTIVE OXYGEN; IDENTIFICATION; ACTIVATION; COMPONENTS; AMPLIFICATION	Glomerular mesangial cells can produce high amounts of nitric oxide ( NO) and reactive oxygen species (ROS). Here we analyzed the impact of NO on the ROS-generating system, particularly on the NADPH oxidase Nox1. Nox1 mRNA and protein levels were markedly decreased by treatment of mesangial cells with the NO-releasing compound DETA-NO in a concentration- and time-dependent fashion. By altering the cGMP signaling system with different inhibitors or activators, we revealed that the effect of NO on Nox1 expression is at least in part mediated by cGMP. Analysis of a reporter construct comprising the 2547 bp of the nox1 promoter region revealed that a stimulatory effect of IL-1 beta on nox1 transcription is counteracted by an inhibitory effect of IL-1 beta-evoked endogenous NO formation. Moreover, pretreatment of mesangial cells with DETA-NO attenuated platelet-derived growth factor ( PDGF)-BB or serum stimulated production of superoxide as assessed by real-time EPR spectroscopy and dichlorofluorescein formation. Transfection of mesangial cells with siRNAs directed against Nox1 and Nox4 revealed that inhibition of Nox1, but not Nox4 expression, is responsible for the reduced ROS formation by NO. Obviously, there exists a fine-tuned crosstalk between NO and ROS generating systems in the course of inflammatory diseases.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Theodor Stern Kai,7, D-60590 Frankfurt, Germany.	pfeilschifter@em.uni-frankfurt.de	Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Babior B M, 1995, Curr Opin Hematol, V2, P55; BAUD L, 1993, BRIT MED BULL, V49, P621, DOI 10.1093/oxfordjournals.bmb.a072635; Beck KF, 1998, FEBS LETT, V435, P35, DOI 10.1016/S0014-5793(98)01035-7; Beck KF, 1999, J EXP BIOL, V202, P645; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cattell V, 2002, KIDNEY INT, V61, P816, DOI 10.1046/j.1523-1755.2002.00226.x; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Frank S, 1999, FASEB J, V13, P869, DOI 10.1096/fasebj.13.8.869; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; Fukai T, 2000, J CLIN INVEST, V105, P1631, DOI 10.1172/JCI9551; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Hruby Z, 1997, CLIN EXP IMMUNOL, V107, P76, DOI 10.1046/j.1365-2249.1997.d01-906.x; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keller T, 2003, NITRIC OXIDE-BIOL CH, V9, P183, DOI 10.1016/j.niox.2004.01.003; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; MARTYN KD, 2005, CELL SIGNAL; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 2002, KIDNEY INT, V61, P809, DOI 10.1046/j.1523-1755.2002.00225.x; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sandau K, 1997, J IMMUNOL, V158, P4938; Sano H, 1997, IMMUNOLOGY, V92, P118, DOI 10.1046/j.1365-2567.1997.00322.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHULTZ PJ, 1991, AM J PHYSIOL, V261, pF600, DOI 10.1152/ajprenal.1991.261.4.F600; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4	49	54	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					139	+		10.1096/fj.05-3791fje	http://dx.doi.org/10.1096/fj.05-3791fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16254042				2022-12-25	WOS:000232991100002
J	Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD				Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD			RNAi-based screening of the human kinome identies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors	ONCOGENE			English	Article						siRNA; Akt; kinome; multitargeted inhibitors	INOSITOL PHOSPHATE MULTIKINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; INTERFERING RNAS; MAMMALIAN-CELLS; CANCER-THERAPY; HUMAN HOMOLOG; DNA-PK; PATHWAY; EXPRESSION	Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.	Abbott Labs, Canc Res, Abbott Pk, IL 60064 USA; Abbott Labs, Adv Technol, Abbott Pk, IL USA	Abbott Laboratories; Abbott Laboratories	Leverson, JD (corresponding author), Abbott Labs, Canc Res, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	joel.leverson@abbott.com		Schurdak, Mark/0000-0002-1146-3268				Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Deininger MWN, 2004, CANCER CELL, V6, P108, DOI 10.1016/j.ccr.2004.08.006; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Kusuda J, 1998, CYTOGENET CELL GENET, V83, P101, DOI 10.1159/000015143; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Melnikova I, 2004, NAT REV DRUG DISCOV, V3, P993, DOI 10.1038/nrd1600; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mouritzen P, 2004, BIOTECHNIQUES, V37, P492, DOI 10.2144/04373AF02; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Piccolo E, 2004, ONCOGENE, V23, P1754, DOI 10.1038/sj.onc.1207296; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	48	50	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1340	1348		10.1038/sj.onc.1209169	http://dx.doi.org/10.1038/sj.onc.1209169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247451				2022-12-25	WOS:000235708200007
J	Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K				Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K			Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo	ONCOGENE			English	Article						RNA interference; cyclin B1; inhibition in vivo; apoptosis; taxol	CLINICAL-SIGNIFICANCE; NUCLEAR-LOCALIZATION; CANCER; OVEREXPRESSION; INHIBITION; EXPRESSION; PHOSPHORYLATION; ACTIVATION; KINASE; PROLIFERATION	Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibit ion of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL USA; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Goethe University Frankfurt	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de; Strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Korenaga D, 2002, SURGERY, V131, pS114, DOI 10.1067/msy.2002.119362; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Matthess Y, 2005, ONCOGENE, V24, P2973, DOI 10.1038/sj.onc.1208472; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Park M, 2000, CANCER RES, V60, P542; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Soria JC, 2000, CANCER RES, V60, P4000; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Viallard JF, 1999, EXP CELL RES, V247, P208, DOI 10.1006/excr.1998.4352; Walsh S, 2003, MOL CANCER RES, V1, P280; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yasuda M, 2002, J CANCER RES CLIN, V128, P412, DOI 10.1007/s00432-002-0359-9; Yin XY, 2001, CANCER RES, V61, P6487; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; Yuan J, 2005, LETT DRUG DES DISCOV, V2, P274, DOI 10.2174/1570180054038378; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	45	101	113	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1753	1762		10.1038/sj.onc.1209202	http://dx.doi.org/10.1038/sj.onc.1209202			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278675				2022-12-25	WOS:000236013700007
J	Chelu, MG; Goonasekera, SA; Durham, WJ; Tang, W; Lueck, JD; Riehl, J; Pessah, IN; Zhang, PM; Bhattacharjee, MB; Dirksen, RT; Hamilton, SL				Chelu, Mihail G.; Goonasekera, Sanjeewa A.; Durham, William J.; Tang, Wei; Lueck, John D.; Riehl, Joyce; Pessah, Isaac N.; Zhang, Pumin; Bhattacharjee, Meenakshi B.; Dirksen, Robert T.; Hamilton, Susan L.			Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse	FASEB JOURNAL			English	Article									[Chelu, Mihail G.; Durham, William J.; Tang, Wei; Zhang, Pumin; Hamilton, Susan L.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Bhattacharjee, Meenakshi B.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Goonasekera, Sanjeewa A.; Lueck, John D.; Dirksen, Robert T.] Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Dept VM Mol Biosci, Davis, CA 95616 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA	Baylor College of Medicine; Baylor College of Medicine; University of Rochester; University of California System; University of California Davis; University of California System; University of California Davis	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	susanh@bcm.tmc.edu	Pessah, Isaac N/K-7985-2017; Chelu, Mihail/AAM-7426-2020	Pessah, Isaac N/0000-0002-8149-588X; Chelu, Mihail/0000-0001-9688-1604; Hamilton, Susan/0000-0003-0241-9369; Lueck, John/0000-0002-1820-711X	NIAMS NIH HHS [AR44864, AR46513, AR41802, AR44657] Funding Source: Medline; NIEHS NIH HHS [ES11269] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044864, R01AR041802, R01AR046513, R01AR044657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))			0	129	132	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					329	330		10.1096/fj.05-4497fje	http://dx.doi.org/10.1096/fj.05-4497fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16284304				2022-12-25	WOS:000207915000010
J	Arniges, M; Fernandez-Fernandez, JM; Albrecht, N; Schaefer, M; Valverde, MA				Arniges, M; Fernandez-Fernandez, JM; Albrecht, N; Schaefer, M; Valverde, MA			Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-EVOKED ACTIVATION; CA2+ ENTRY; SUBUNIT STOICHIOMETRY; VANILLOID RECEPTOR-1; ENDOTHELIAL-CELLS; CATION CHANNEL; ION-CHANNEL; VR-OAC; PROTEIN; KIDNEY	The TRPV4 cation channel exhibits a topology consisting of six predicted transmembrane domains (TM) with a putative pore loop between TM5 and TM6 and intracellular N- and C-tails, the former containing at least three ankyrin domains. Functional transient receptor potential (TRP) channels are supposed to result following the assembly of four subunits. However, the rules governing subunit assembly and protein domains implied in this process are only starting to emerge. The ankyrin, TM, and the C-tail domains have been identified as important determinants of the oligomerization process. We now describe the maturation and oligomerization of five splice variants of the TRPV4 channel. The already known TRPV4-A and TRPV4-B (Delta 384-444) variants and the new TRPV4-C (Delta 237-284), TRPV4-D (Delta 27-61), and TRPV4-E (Delta 237-284 and Delta 384-444) variants. All alternative spliced variants involved deletions in the cytoplasmic N- terminal region, affecting (except for TRPV4-D) the ankyrin domains. Subcellular localization, fluorescence resonance energy transfer, co-immunoprecipitation, glycosylation profile, and functional analysis of these variants permitted us to group them into two classes: group I (TRPV4-A and TRPV4-D) and group II (TRPV4-B, TRPV4-C, and TRPV4-E). Group I, unlike group II variants, were correctly processed, homo- and heteromultimerized in the endoplasmic reticulum, and were targeted to the plasma membrane where they responded to typical TRPV4 stimuli. Our results suggest that: 1) TRPV4 biogenesis involves core glycosylation and oligomerization in the endoplasmic reticulum followed by transfer to the Golgi apparatus for subsequent maturation; 2) ankyrin domains are necessary for oligomerization of TRPV4; and 3) lack of TRPV4 oligomerization determines its accumulation in the endoplasmic reticulum.	Univ Pompeu Fabra, Grp Canalopaties, Unitat Senyalitzacio Cellular, Barcelona 08003, Spain; Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Pompeu Fabra University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Valverde, MA (corresponding author), C Dr Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@upf.edu	Fernández-Fernández, José Manuel M/M-8157-2015	Fernández-Fernández, José Manuel M/0000-0003-2330-8449; Valverde, Miguel A./0000-0002-6961-3361				Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; Andrade YN, 2005, J CELL BIOL, V168, P869, DOI 10.1083/jcb.200409070; Arniges M, 2004, J BIOL CHEM, V279, P54062, DOI 10.1074/jbc.M409708200; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Cohen DM, 2005, PFLUG ARCH EUR J PHY, V451, P168, DOI 10.1007/s00424-005-1456-9; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Guler AD, 2002, J NEUROSCI, V22, P6408; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hermosilla R, 2001, MOL PHARMACOL, V60, P1031, DOI 10.1124/mol.60.5.1031; Hoenderop JGJ, 2003, PFLUG ARCH EUR J PHY, V446, P304, DOI 10.1007/s00424-003-1045-8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jaskolski F, 2005, J BIOL CHEM, V280, P22968, DOI 10.1074/jbc.M413166200; Jia YL, 2004, AM J PHYSIOL-LUNG C, V287, pL272, DOI 10.1152/ajplung.00393.2003; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Niemeyer BA, 2005, N-S ARCH PHARMACOL, V371, P285, DOI 10.1007/s00210-005-1053-7; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Oberwinkler J, 2005, J BIOL CHEM, V280, P22540, DOI 10.1074/jbc.M503092200; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; Wang CB, 2004, J BIOL CHEM, V279, P37423, DOI 10.1074/jbc.M407205200; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu F, 2003, BRIT J PHARMACOL, V140, P413, DOI 10.1038/sj.bjp.0705443; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	56	135	144	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1580	1586		10.1074/jbc.M511456200	http://dx.doi.org/10.1074/jbc.M511456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293632	hybrid			2022-12-25	WOS:000234652000036
J	Eliopoulos, AG; Das, S; Tsichlis, PN				Eliopoulos, AG; Das, S; Tsichlis, PN			The tyrosine kinase Syk regulates TPL2 activation signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELL LINES; PROTEIN-KINASE; DEATH-DOMAIN; TNF RECEPTOR; NUCLEAR-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE INHIBITOR; HUMAN NEUTROPHILS; NF-KAPPA-B1 P105	Tpl2/Cot is a serine/threonine kinase that plays a key physiological role in the regulation of immune responses to pro-inflammatory stimuli, including tumor necrosis factor-alpha (TNF-alpha). TNF-alpha stimulates the JNK, ERK, and p38 mitogen-activated protein kinases and the NF-kappa B pathway by recruiting RIP1 and TRAF2 to the TNF receptor 1. Here we showed that Tpl2 activation by TNF-alpha signals depends on the integrity of the Tpl2-interacting proteins RIP1 and TRAF2, which are required for the engagement of the ERK mitogen-activated protein kinase pathway. However, neither RIP1 nor TRAF2 overexpression was sufficient to activate Tpl2 and ERK. We also showed that Tpl2 activation by TNF-alpha depends on a tyrosine kinase activity that is detected in TNF-alpha-stimulated cells. Based on both genetic and biochemical evidence, we concluded that in a variety of cell types, Syk is the tyrosine kinase that plays an important role in the activation of Tpl2 upstream of ERK. These data therefore dissect the TNF receptor 1 proximal events that regulate Tpl2 and ERK and highlight a role for RIP1, TRAF2, and Syk in this pathway.	Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Crete, Greece; Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	University of Crete; Cancer Research UK; University of Birmingham; Tufts Medical Center; Tufts University	Eliopoulos, AG (corresponding author), Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Crete, Greece.	eliopag@med.uoc.gr	ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	NCI NIH HHS [R01 CA38047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABULAWI KI, 1995, CELL MOL BIOL RES, V41, P49; Arndt PG, 2004, J BIOL CHEM, V279, P10883, DOI 10.1074/jbc.M309901200; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; Caivano M, 2003, J BIOL CHEM, V278, P52124, DOI 10.1074/jbc.M306583200; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dang O, 2004, SHOCK, V21, P470, DOI 10.1097/00024382-200405000-00012; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Funakoshi-Tago M, 2003, J BIOL CHEM, V278, P29359, DOI 10.1074/jbc.M213115200; Gandara ML, 2003, MOL CELL BIOL, V23, P7377, DOI 10.1128/MCB.23.20.7377-7390.2003; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MAKRIS A, 1993, J VIROL, V67, P1286, DOI 10.1128/JVI.67.3.1286-1291.1993; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Renedo MA, 2001, EUR J IMMUNOL, V31, P1361, DOI 10.1002/1521-4141(200105)31:5<1361::AID-IMMU1361>3.0.CO;2-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Yamada T, 2001, J IMMUNOL, V167, P283, DOI 10.4049/jimmunol.167.1.283; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	63	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1371	1380		10.1074/jbc.M506790200	http://dx.doi.org/10.1074/jbc.M506790200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291755	hybrid			2022-12-25	WOS:000234652000012
J	Datta, S; Wang, L; Moore, DD; Osborne, TF				Datta, S; Wang, L; Moore, DD; Osborne, TF			Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase promoter by nuclear receptors liver receptor homologue-1 and small heterodimer partner - A mechanism for differential regulation of cholesterol synthesis and uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; NEGATIVE FEEDBACK-REGULATION; BILE-ACID SYNTHESIS; STEROL REGULATION; COA REDUCTASE; GENE; SHP; TRANSCRIPTION; REPRESSION; SREBP-1A	Cholesterol homeostasis in mammals involves pathways for biosynthesis, cellular uptake, and hepatic conversion to bile acids. Key genes for all three pathways are regulated by negative feedback control. Uptake and biosynthesis are directly regulated by cholesterol through its inhibition of the proteolytic activation of the sterol regulatory element binding proteins. The conversion of cholesterol into bile acids in the liver is regulated through the bile acid-dependent induction of the negatively acting small heterodimer partner nuclear receptor. In this report, we have shown that the small heterodimer partner also directly regulates cholesterol biosynthesis through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase but has no effect on low density lipoprotein receptor expression. This has significant metabolic significance, as it provides both a mechanism to independently regulate cholesterol synthesis from uptake (an essential regulatory feature known to occur in vivo) and a pathway for direct regulation of cholesterol biosynthesis by bile acids. This latter feature ensures that the early phase of bile acid synthesis (pre-cholesterol) is in metabolic communication with the later stages of the pathway to properly regulate whole pathway flux. This highlights an important regulatory feature that is shared with other key branched, multienzyme pathways, such as glycolysis, where pathway outflow through pyruvate kinase is regulated by the concentration of a key early intermediate, fructose 1,6-bisphosphate.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pharmacol, Kansas City, KS 66160 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	University of California System; University of California Irvine; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Baylor College of Medicine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3244 McGaugh Hall, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MILLINDERVALLET.S, 1996, J BIOL CHEM, V271, P12247; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; Rosenfeld JM, 1998, J BIOL CHEM, V273, P16112, DOI 10.1074/jbc.273.26.16112; RUSSELL DW, 2003, ANN REV BIOCH; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHEFER S, 1973, J LIPID RES, V14, P573; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SPADY DK, 1985, J LIPID RES, V26, P465; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025	23	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					807	812		10.1074/jbc.M511050200	http://dx.doi.org/10.1074/jbc.M511050200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282330	hybrid			2022-12-25	WOS:000234447200018
J	Schoenhofen, IC; McNally, DJ; Vinogradov, E; Whitfield, D; Young, NM; Dick, S; Wakarchuk, WW; Brisson, JR; Logan, SM				Schoenhofen, IC; McNally, DJ; Vinogradov, E; Whitfield, D; Young, NM; Dick, S; Wakarchuk, WW; Brisson, JR; Logan, SM			Functional characterization of dehydratase/aminotransferase pairs from helicobacter and campylobacter - Enzymes distinguishing the pseudaminic acid and bacillosamine biosynthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; PROTEIN GLYCOSYLATION; C-6 DEHYDRATASE; LIPOPOLYSACCHARIDE BIOSYNTHESIS; STAPHYLOCOCCUS-AUREUS; GENOME SEQUENCE; O-ANTIGEN; JEJUNI; PYLORI; IDENTIFICATION	Helicobacter pylori and Campylobacter jejuni have been shown to modify their flagellins with pseudaminic acid (Pse), via O-linkage, while C. jejuni also possesses a general protein glycosylation pathway (Pgl) responsible for the N-linked modification of at least 30 proteins with a heptasaccharide containing 2,4-diacetamido-2,4,6-trideoxy-alpha-D-glucopyranose, a derivative of bacillosamine. To further define the Pse and bacillosamine biosynthetic pathways, we have undertaken functional characterization of UDP-alpha-D-GlcNAc modifying dehydratase/aminotransferase pairs, in particular the H. pylori and C. jejuni flagellar pairs HP0840/HP0366 and Cj1293/Cj1294, as well as the C. jejuni Pgl pair Cj1120c/Cj1121c using His(6)-tagged purified derivatives. The metabolites produced by these enzymes were identified using NMR spectroscopy at 500 and/or 600 MHz with a cryogenically cooled probe for optimal sensitivity. The metabolites of Cj1293 (PseB) and HP0840 (FlaA1) were found to be labile and could only be characterized by NMR analysis directly in aqueous reaction buffer. The Cj1293 and HP0840 enzymes exhibited C6 dehydratase as well as a newly identified C5 epimerase activity that resulted in the production of both UDP-2-acetamido2,6-dideoxy-beta-L-arabino-4-hexulose and UDP-2-acetamido-2,6-dideoxy-alpha-D-xylo-4-hexulose. In contrast, the Pgl dehydratase Cj1120c (PglF) was found to possess only C6 dehydratase activity generating UDP-2-acetamido-2,6-dideoxy-alpha-D-xylo-4-hexulose. Substrate-specificity studies demonstrated that the flagellar aminotransferases HP0366 and Cj1294 utilize only UDP-2-acetamido2,6-dideoxy- beta-L-arabino-4-hexulose as substrate producing UDP-4-amino-4,6-dideoxy-beta-L-AltNAc, a precursor in the Pse biosynthetic pathway. In contrast, the Pgl aminotransferase Cj1121c (PglE) utilizes only UDP-2-acetamido-2,6-dideoxy-beta-D-xylo-4-hexulose producing UDP-4-amino-4,6-dideoxy-alpha-D-GlcNAc (UDP-2-acetamido-4-amino- 2,4,6-trideoxy-alpha-D-glucopyranose), a precursor used in the production of the Pgl glycan component 2,4-diacetamido-2,4,6-trideoxy-alpha- D-glucopyranose.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Logan, SM (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	susan.logan@nrc-cnrc.gc.ca	Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Vinogradov, Evgeny/0000-0002-5364-1376				Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Berces A, 2001, TETRAHEDRON, V57, P477, DOI 10.1016/S0040-4020(00)01019-X; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Burrows LL, 2000, INFECT IMMUN, V68, P931, DOI 10.1128/IAI.68.2.931-936.2000; BUTZLER JP, 1979, CLIN GASTROENTEROL, V8, P737; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Fouts DE, 2005, PLOS BIOL, V3, P72, DOI 10.1371/journal.pbio.0030015; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Immel S, 1999, PROCEEDINGS OF THE 9TH INTERNATIONAL SYMPOSIUM ON CYCLODEXTRINS, P41; Ionescu AR, 2005, J PHYS CHEM A, V109, P8096, DOI 10.1021/jp052197t; Karlyshev AV, 2005, FEMS MICROBIOL REV, V29, P377, DOI 10.1016/j.femsre.2005.01.003; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; KNIREL YA, 1986, EUR J BIOCHEM, V155, P659, DOI 10.1111/j.1432-1033.1986.tb09537.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; MacLean LL, 2001, EUR J BIOCHEM, V268, P2710, DOI 10.1046/j.1432-1327.2001.02163.x; Merkx-Jacques A, 2004, J BACTERIOL, V186, P2253, DOI 10.1128/JB.186.8.2253-2265.2004; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; Obhi RK, 2005, J BIOL CHEM, V280, P20902, DOI 10.1074/jbc.M413832200; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sau S, 1996, J BACTERIOL, V178, P2118, DOI 10.1128/jb.178.7.2118-2126.1996; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	38	143	156	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					723	732		10.1074/jbc.M511021200	http://dx.doi.org/10.1074/jbc.M511021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286454	hybrid			2022-12-25	WOS:000234447200008
J	Bao, SZ; Bohrer, A; Ramanadham, S; Jin, W; Zhang, S; Turk, J				Bao, SZ; Bohrer, A; Ramanadham, S; Jin, W; Zhang, S; Turk, J			Effects of stable suppression of group VIA phospholipase A(2) expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TANDEM MASS-SPECTROMETRY; ARACHIDONIC-ACID RELEASE; ISLET BETA-CELLS; MECHANISM-BASED DISCRIMINATION; STIMULATED PANCREATIC-ISLETS; VASCULAR SMOOTH-MUSCLE; SMALL INTERFERING RNA; HAMSTER OVARY CELLS; ELECTROSPRAY-IONIZATION; P388D(1) MACROPHAGES	Studies involving pharmacologic inhibition or transient reduction of Group VIA phospholipase A(2) (iPLA(2)beta) expression have suggested that it is a housekeeping enzyme that regulates cell 2-lysophosphatidylcholine (LPC) levels, rates of arachidonate incorporation into phospholipids, and degradation of excess phosphatidylcholine (PC). In insulin-secreting islet beta-cells and some other cells, in contrast, iPLA(2)beta signaling functions have been proposed. Using retroviral vectors, we prepared clonal INS-1 beta-cell lines in which iPLA(2)beta expression is stably suppressed by small interfering RNA. Two such iPLA(2)beta knockdown (iPLA(2)beta-KD) cell lines express less than 20% of the iPLA(2)beta of control INS-1 cell lines. The iPLA(2)beta-KD INS-1 cells exhibit impaired insulin secretory responses and reduced proliferation rates. Electrospray ionization mass spectrometric analyses of PC and LPC species that accumulate in INS-1 cells cultured with arachidonic acid suggest that 18:0/20:4-glycerophosphocholine (GPC) synthesis involves sn-2 remodeling to yield 16:0/20:4-GPC and then sn-1 remodeling via a 1-lyso/20:4-GPC intermediate. Electrospray ionization mass spectrometric analyses also indicate that the PC and LPC content and composition of iPLA(2)beta-KD and control INS-1 cells are nearly identical, as are the rates of arachidonate incorporation into PC and the composition and remodeling of other phospholipid classes. These findings indicate that iPLA(2)beta plays signaling or effector roles in beta-cell secretion and proliferation but that stable suppression of its expression does not affect beta-cell GPC lipid content or composition even under conditions in which LPC is being actively consumed by conversion to PC. This calls into question the generality of proposed housekeeping functions for iPLA(2)beta in PC homeostasis and remodeling.	Washington Univ, Sch Med, Med Dept Mass Spectrometry Facil, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Metabol & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Med Dept Mass Spectrometry Facil, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	jturk@wustl.edu		Bao, Shunzhong/0000-0002-3427-3678	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, R37DK034388, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR000954, P41-RR00954, P41 RR000954-30] Funding Source: Medline; NHLBI NIH HHS [P01 HL057278, P01-HL57278] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, P60 DK020579, R37 DK034388-23, P60 DK020579-269005, P30-DK56341, P30 DK056341, P30 DK056341-069003, P60-DK20579, R37 DK034388, P30 DK056341-05S2, R37-DK34388] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline; PHS HHS [R01-69455] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akiba S, 2004, BIOL PHARM BULL, V27, P1174, DOI 10.1248/bpb.27.1174; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; Bao SZ, 2004, DIABETES, V53, pS186, DOI 10.2337/diabetes.53.2007.S186; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Chiu CH, 2001, BIOCHEM BIOPH RES CO, V287, P600, DOI 10.1006/bbrc.2001.5632; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GUNSTONE FD, 1994, LIPID HDB, P382; Guo ZH, 2003, J BIOL CHEM, V278, P1856, DOI 10.1074/jbc.M211075200; HALLBERG A, 1984, BIOCHIM BIOPHYS ACTA, V796, P328, DOI 10.1016/0005-2760(84)90134-6; Hawker JR, 2003, J IMMUNOL METHODS, V274, P77, DOI 10.1016/S0022-1759(02)00437-4; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P892, DOI 10.1016/S1044-0305(00)00159-8; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Hsu FF, 2001, J AM SOC MASS SPECTR, V12, P1036, DOI 10.1016/S1044-0305(01)00285-9; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P986, DOI 10.1016/S1044-0305(00)00172-0; Hsu FF, 2003, J AM SOC MASS SPECTR, V14, P352, DOI 10.1016/S1044-0305(03)00064-3; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; LANDS WEM, 1997, ENZYMES BIOL MEMBRAN, V2; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 2001, LIPIDS, V36, P689, DOI 10.1007/s11745-001-0774-9; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Manguikian AD, 2004, J BIOL CHEM, V279, P52881, DOI 10.1074/jbc.M410659200; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; MURPHY RC, 1990, METHOD ENZYMOL, V187, P90; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Owada S, 1999, J BIOL CHEM, V274, P2000, DOI 10.1074/jbc.274.4.2000; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; Ramanadham S, 2002, BBA-MOL CELL BIOL L, V1580, P40, DOI 10.1016/S1388-1981(01)00189-5; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; Ramanadham S, 2000, BBA-MOL CELL BIOL L, V1484, P251, DOI 10.1016/S1388-1981(00)00022-6; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Seashols SJ, 2004, BBA-MOL CELL BIOL L, V1684, P29, DOI 10.1016/j.bbalip.2004.05.003; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Shirai Y, 2005, BBA-MOL CELL BIOL L, V1735, P119, DOI 10.1016/j.bbalip.2005.05.005; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TURK J, 1992, BIOCHIM BIOPHYS ACTA, V1125, P280, DOI 10.1016/0005-2760(92)90057-3; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VACHER P, 1989, AM J PHYSIOL, V257, pE203, DOI 10.1152/ajpendo.1989.257.2.E203; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; WOLF BA, 1986, J BIOL CHEM, V261, P6284; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200	102	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					187	198		10.1074/jbc.M509105200	http://dx.doi.org/10.1074/jbc.M509105200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16286468	hybrid, Green Accepted			2022-12-25	WOS:000234307200026
J	Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M				Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M			The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1	ONCOGENE			English	Article						HBV; HBx; AP-1; Jab1; HCC	STABLE RNA INTERFERENCE; COP9 SIGNALOSOME; HBX PROTEIN; C-JUN; TRANSCRIPTION FACTORS; BINDING PROTEIN; GENE-EXPRESSION; CELL-CYCLE; COMPLEX; KINASES	Hepatitis B virus X protein (HBx) has many cellular functions and is a major factor in hepatitis and hepatocellular carcinoma caused by HBV infection. A proteomic approach was used to search for HBx-interacting proteins in order to elucidate the molecular mechanism of hepatocarcinogenesis. HBx was attached to myc and flag tags (MEF tags) and expressed in 293T cells; the protein complex formed within the cells was purified and characterized by mass spectrometry. COP9 signalosome (CSN) subunits 3 and 4 were subsequently identified as HBx-interacting proteins. In addition, CSN subunit 5, Jun activation domain-binding protein 1 (Jab1), was shown to be a novel cellular target of HBx. In vivo and in vitro interactions between HBx and Jab1 were confirmed by standard immunoprecipitation and GST pull-down assays. An analysis of HBx deletion constructs showed that amino acids 30-125 of HBx were responsible for binding to Jab1. Confocal laser microscopy demonstrated that HBx was mainly localized in the cytoplasm, while Jab1 was found mainly in the nucleus and partially in the cytoplasm, and that the two proteins colocalized in the cytoplasm. The cotransfection of HBx and Jab1 resulted in substantial activator protein 1 (AP-1) activation and knockdown of endogenous Jab1 attenuated AP-1 activation caused by HBx. In addition, the coexpression of HBx and Jab1 potentiated phosphorylation of JNK, leading to the subsequent phosphorylation of c-Jun, whereas the level of c-Jun and JNK phosphorylation induced by HBx was decreased in Jab1 knockdown cells. These results suggest that the interaction between HBx and Jab1 enhances HBx-mediated AP-1 activation.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 113, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Hachioji, Tokyo 19203, Japan	University of Tokyo; University of Tokyo; Tokyo Metropolitan University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Isobe, Toshiaki/Q-9279-2017; IJICHI, Hideaki/AGZ-2874-2022; Ijichi, Hideaki/AAE-6692-2022; Asaoka, Yoshinari/ABC-5412-2021	IJICHI, Hideaki/0000-0002-2379-7986; Ijichi, Hideaki/0000-0002-2379-7986; Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chopra S, 2002, J BIOL CHEM, V277, P32413, DOI 10.1074/jbc.C200311200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Nijhara R, 2001, FEBS LETT, V504, P59, DOI 10.1016/S0014-5793(01)02773-9; Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209; Oron E, 2002, DEVELOPMENT, V129, P4399; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Zhang SM, 2005, ARCH VIROL, V150, P1579, DOI 10.1007/s00705-005-0521-1; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	54	77	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					633	642		10.1038/sj.onc.1209093	http://dx.doi.org/10.1038/sj.onc.1209093			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247477				2022-12-25	WOS:000234897400014
J	Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N				Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N			LMP1 signaling and activation of NF-kappa B in LMP1 transgenic mice	ONCOGENE			English	Article						NF-kappa B; Epstein-Barr virus; LMP1	EPSTEIN-BARR-VIRUS; LATENT INFECTION MEMBRANE-PROTEIN-1; RECEPTOR-ASSOCIATED FACTOR-1; GROWTH-FACTOR RECEPTOR; REED-STERNBERG CELLS; PROTEIN 1 ENGAGES; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; P53 GENE; EXPRESSION	Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice. In vitro, LMP1 activates numerous signaling pathways including p38, c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K)/Akt, and NF-kappa B through interactions with tumor necrosis receptor-associated factors (TRAFs). These pathways are frequently activated in EBV-associated malignancies, although their activation cannot be definitively linked to LMP1 expression in vivo. In this study, interactions between LMP1 and TRAFs and the activation of PI3K/Akt, JNK, p38, and NF-kappa B were examined in LMP1 transgenic mice. LMP1 co-immunoprecipitated with TRAFs 1, 2, and 3. Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas. Multiple forms of NF-kappa B were activated in healthy splenocytes from LMP1 transgenic mice, in contrast to healthy splenocytes from LMP1-negative mice. However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappa B c-Rel, was specifically activated. Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene. These data indicate that NF-kappa B is activated in LMP1-positive healthy splenocytes; however, NF-kappa B c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice. The LMP1-mediated activation of NF-kappa B may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, CB 7295,Room 102,Mason Farm Rd, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu		Shair, Kathy Ho Yen/0000-0002-9556-1745; Thornburg, Natalie/0000-0003-3523-3616	NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NCI NIH HHS [CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BALLERINI P, 1993, BLOOD, V81, P166; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; EDWARDS RH, 1994, J VIROL, V68, P1309, DOI 10.1128/JVI.68.3.1309-1315.1994; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liebowitz D, 1998, NEW ENGL J MED, V338, P1413, DOI 10.1056/NEJM199805143382003; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pai S, 2002, J VIROL, V76, P1914, DOI 10.1128/JVI.76.4.1914-1921.2002; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Panagopoulos D, 2004, J VIROL, V78, P13253, DOI 10.1128/JVI.78.23.13253-13261.2004; Stunz LL, 2004, IMMUNITY, V21, P255, DOI 10.1016/j.immuni.2004.07.008; Thornburg NJ, 2003, CANCER RES, V63, P8293; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9	47	73	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					288	297		10.1038/sj.onc.1209023	http://dx.doi.org/10.1038/sj.onc.1209023			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16247482				2022-12-25	WOS:000234583600013
J	Zou, GM; Chen, JJ; Ni, J				Zou, GM; Chen, JJ; Ni, J			LIGHT induces differentiation of mouse embryonic stem cells associated with activation of ERK5	ONCOGENE			English	Article						LIGHT; ES cells; ERK5; MKP-3; differentiation	TNF SUPERFAMILY; DENDRITIC CELLS; SIGNAL; ALPHA; PROLIFERATION; PHOSPHORYLATION; PLURIPOTENCY; ANGIOGENESIS; EXPRESSION; MATURATION	LT-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells ( LIGHT) is a recently cloned type II transmembrane protein belonging to the TNF family that was originally identified as a weak inducer of apoptosis. This cytokine has been extensively defined in its role on T-cell regulation and dendritic cell maturation. However, whether this cytokine regulates stem cell proliferation and/or differentiation remains unknown. In this study, we transduced exogenous LIGHT into embryonic stem cells (ES cells) and found it induced their differentiation. The expression of phospho-STAT3, Nanog and Oct-4 was reduced in LIGHT-transduced ES cells compared with wild-type ES cells. LIGHT-transduced ES cells exhibit a low level of SSEA-1 surface antigen and alkaline phosphatase staining compared with wild-type cells. Introduction of LIGHT into ES cells results in the dephosphorylation of MKP-3 and activation of extracellular signal-regulated kinase (ERK)5. When ERK5 was inhibited by the specific inhibitor PD184352 or knocked down by ERK5 siRNA, reduction of Oct-4 and SSEA-1 expression was rescued. We conclude that LIGHT overrides leukemia inhibitory factor to induce ES cell differentiation associated with activation of ERK5.	Univ Iowa, Sch Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Shanghai Fuchun Zhongnan Biotech Co Ltd, Shanghai, Peoples R China	University of Iowa; University of Chicago; University of Chicago Medical Center	Zou, GM (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, 1044 W Walnut St,Rm402, Indianapolis, IN 46202 USA.	gzou@iupui.edu	Zou, Gang-Ming/F-1085-2016					Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen Y, 2003, FASEB J, V17, P2231, DOI 10.1096/fj.03-0030com; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fandrich F, 2002, NAT MED, V8, P171, DOI 10.1038/nm0202-171; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Morel Y, 2001, J IMMUNOL, V167, P2479, DOI 10.4049/jimmunol.167.5.2479; Nakaoka Y, 2003, CIRC RES, V93, P221, DOI 10.1161/01.RES.0000085562.48906.4A; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Sato M, 2001, INTERNAL MED, V40, P195, DOI 10.2169/internalmedicine.40.195; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Tamada K, 2000, NAT MED, V6, P283; Wang YC, 2004, DEV DYNAM, V231, P72, DOI 10.1002/dvdy.20114; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wu DY, 2005, CELL RES, V15, P317, DOI 10.1038/sj.cr.7290300; Wuu YD, 1998, BIOL REPROD, V58, P1416, DOI 10.1095/biolreprod58.6.1416; Zou GM, 2005, J CELL PHYSIOL, V205, P437, DOI 10.1002/jcp.20420; Zou GM, 2000, AM J REPROD IMMUNOL, V43, P240, DOI 10.1111/j.8755-8920.2000.430409.x; Zou GM, 2004, CANCER IMMUNOL IMMUN, V53, P681, DOI 10.1007/s00262-004-0518-8; Zou GM, 2003, TRANSPL P, V35, P2827, DOI 10.1016/j.transproceed.2003.09.044; Zou GM, 2003, BIOL CELL, V95, P365, DOI 10.1016/S0248-4900(03)00079-0	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					463	469		10.1038/sj.onc.1208987	http://dx.doi.org/10.1038/sj.onc.1208987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247486				2022-12-25	WOS:000234714100014
J	Canguilhem, B; Pradines, A; Baudouin, C; Boby, C; Lajoie-Mazenc, I; Charveron, M; Favre, G				Canguilhem, B; Pradines, A; Baudouin, C; Boby, C; Lajoie-Mazenc, I; Charveron, M; Favre, G			RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; GENE-EXPRESSION; EXCHANGE-FACTOR; GTPASE RHOB; CELL-DEATH; RAS; CANCER; TRANSFORMATION; LIGHT; ACTIVATION	Exposure of the skin to UVB light results in the formation of DNA photolesions that can give rise to cell death, mutations, and the onset of carcinogenic events. Specific proteins are activated by UVB and then trigger signal transduction pathways that lead to cellular responses. An alteration of these signaling molecules is thought to be a fundamental event in tumor promotion by UVB irradiation. RhoB, encoding a small GTPase has been identified as a DNA damage-inducible gene. RhoB is involved in epidermal growth factor (EGF) receptor trafficking, cytoskeletal organization, cell transformation, and survival. We have analyzed the regulation of RhoB and elucidated its role in the cellular response of HaCaT keratinocytes to relevant environmental UVB irradiation. We report here that the activated GTP-bound form of RhoB is increased rapidly within 5 min of exposure to UVB, and then RhoB protein levels increased concomitantly with EGF receptor ( EGFR) activation. Inhibition of UVB-induced EGFR activation prevents RhoB protein expression and AKT phosphorylation but not the early activation of RhoB. Blocking UVB-induced RhoB expression with specific small interfering RNAs inhibits AKT and glycogen synthase kinase-3 beta phosphorylation through inhibition of EGFR expression. Moreover, down-regulation of RhoB potentiates UVB-induced cell apoptosis. In contrast, RhoB overexpression protects keratinocytes against UVB-induced apoptosis. These results indicated that RhoB is regulated upon UVB exposure by a two-step process consisting of an early EGFR-independent RhoB activation followed by an EGFR-dependent induction of RhoB expression. Moreover, we have demonstrated that RhoB is essential in regulating keratinocyte cell survival after UVB exposure, suggesting its potential role in photocarcinogenesis.	Univ Toulouse 3, INSERM, U563, Dept innovat Therapeut & Oncol Mol,Inst Claudius, F-31052 Toulouse, France; Inst Rech Pierre Fabre, Biol Cellulaire Lab, F-31025 Toulouse 3, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Favre, G (corresponding author), Univ Toulouse 3, INSERM, U563, Dept innovat Therapeut & Oncol Mol,Inst Claudius, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	favre@icr.fnclcc.fr	Pradines, Anne/M-3935-2014; FAVRE, Gilles/K-9189-2014; Lajoie-Mazenc, Isabelle/M-4636-2014	Pradines, Anne/0000-0002-2449-678X; FAVRE, Gilles/0000-0002-2344-1883; BOBY, Celine/0000-0002-4420-7033				Ader I, 2003, ONCOGENE, V22, P8861, DOI 10.1038/sj.onc.1207095; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Gampel A, 2002, BIOCHEM J, V366, P393, DOI 10.1042/BJ20020844; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gonzales M, 2002, ONCOGENE, V21, P2721, DOI 10.1038/sj.onc.1205366; He ZW, 2005, J BIOL CHEM, V280, P2446, DOI 10.1074/jbc.M402053200; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mazieres J, 2005, EXP CELL RES, V304, P354, DOI 10.1016/j.yexcr.2004.10.019; Milia J, 2005, CELL DEATH DIFFER, V12, P492, DOI 10.1038/sj.cdd.4401586; MILLER CC, 1994, J BIOL CHEM, V269, P3529; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Tovar D, 2003, GENOMICS, V81, P525, DOI 10.1016/S0888-7543(03)00044-2; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Walker PR, 1997, BIOCHEM CELL BIOL, V75, P287, DOI 10.1139/bcb-75-4-287; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Westmark CJ, 2005, ONCOGENE, V24, P502, DOI 10.1038/sj.onc.1208224	45	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43257	43263		10.1074/jbc.M508650200	http://dx.doi.org/10.1074/jbc.M508650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16278215	hybrid			2022-12-25	WOS:000234200800092
J	Richter, S; Bruser, T				Richter, S; Bruser, T			Targeting of unfolded PhoA to the TAT translocon of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWIN-ARGININE TRANSLOCASE; SIGNAL PEPTIDE; PROTEIN TRANSLOCATION; PATHWAY; MEMBRANE; TRANSPORT; EXPORT; LOCALIZATION; COMPLEXES; SEQUENCE	In Escherichia coli, the Tat system does not translocate Tat signal sequence fused PhoA (RR-PhoA), as it requires disulfide formation for folding. Here we show that such a RR-PhoA construct can be efficiently targeted to the Tat translocon, but the transport is not completed. RR-PhoA is detectable in a 580-kDa TatBC-containing complex, which is the first substrate-bound TatBC complex detected in a bacterial system so far. A second TatBC complex near 440 kDa comprises most of the TatB and TatC but is devoid of RR-PhoA. The targeting of PhoA to the Tat translocon depends on the twin-arginine motif and results in severe growth defects. This physiological effect is likely to be due to proton leakage at the cytoplasmic membrane. The results point to mechanistic incompatibilities of the Tat system with unfolded proteins such as RR-PhoA. There does not exist an intrinsic quality control at the TatBC complex itself, although correct folding is inevitable for Tat-dependent translocation.	Univ Halle Wittenberg, Inst Microbiol, D-06120 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Bruser, T (corresponding author), Univ Halle Wittenberg, Inst Microbiol, Kurt Mothes Str 3, D-06120 Halle An Der Saale, Germany.	t.brueser@mikrobiologie.uni-halle.de		Bruser, Thomas/0000-0002-5889-8306				Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Barrett CML, 2005, FEBS J, V272, P2261, DOI 10.1111/j.1742-4658.2005.04654.x; Behrendt J, 2004, FEMS MICROBIOL LETT, V234, P303, DOI 10.1016/j.femsle.2004.03.048; Berghofer J, 1999, FEBS LETT, V460, P328, DOI 10.1016/S0014-5793(99)01365-4; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Bruser T, 1998, FEMS MICROBIOL LETT, V164, P329; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; Buchanan G, 2001, ARCH MICROBIOL, V177, P107, DOI 10.1007/s00203-001-0366-2; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; DeLisa MP, 2003, P NATL ACAD SCI USA, V100, P6115, DOI 10.1073/pnas.0937838100; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAXIXANTHIS K, 2003, MOL MICROBIOL, V49, P1377; Ize B, 2003, MOL MICROBIOL, V48, P1183, DOI 10.1046/j.1365-2958.2003.03504.x; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Jeong KJ, 2004, J MOL BIOL, V341, P901, DOI 10.1016/j.jmb.2004.05.078; Kipping M, 2003, FEBS LETT, V550, P18, DOI 10.1016/S0014-5793(03)00804-4; Kumagai H, 1997, BIOCHEMISTRY-US, V36, P5509, DOI 10.1021/bi970014q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, J BIOL CHEM, V269, P28822; LEE HC, 1978, BIOCHIM BIOPHYS ACTA, V508, P339, DOI 10.1016/0005-2736(78)90336-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sanders C, 2001, MOL MICROBIOL, V41, P241, DOI 10.1046/j.1365-2958.2001.02514.x; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SILVESTRO A, 1989, BIOCHIM BIOPHYS ACTA, V999, P208, DOI 10.1016/0167-4838(89)90220-3; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x	37	79	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42723	42730		10.1074/jbc.M509570200	http://dx.doi.org/10.1074/jbc.M509570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263723	hybrid			2022-12-25	WOS:000234200800031
J	Surks, HK; Riddick, N; Ohtani, K				Surks, HK; Riddick, N; Ohtani, K			M-RIP targets myosin phosphatase to stress fibers to regulate myosin light chain phosphorylation in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY SPASM; RHO-KINASE; NEOINTIMAL FORMATION; INTERACTING PROTEIN; BINDING SUBUNIT; INHIBITION; LOCALIZATION; ACTIVATION; P116(RIP); IDENTIFICATION	Vascular smooth muscle cell contraction and relaxation are directly related to the phosphorylation state of the regulatory myosin light chain. Myosin light chains are dephosphorylated by myosin phosphatase, leading to vascular smooth muscle relaxation. Myosin phosphatase is localized not only at actin-myosin stress fibers where it dephosphorylates myosin light chains, but also in the cytoplasm and at the cell membrane. The mechanisms by which myosin phosphatase is targeted to these loci are incompletely understood. We recently identified myosin phosphatase-Rho interacting protein as a member of the myosin phosphatase complex that directly binds both the myosin binding subunit of myosin phosphatase and RhoA and is localized to actin-myosin stress fibers. We hypothesized that myosin phosphatase-Rho interacting protein targets myosin phosphatase to the contractile apparatus to dephosphorylate myosin light chains. We used RNA interference to silence the expression of myosin phosphatase-Rho interacting protein in human vascular smooth muscle cells. Myosin phosphatase-Rho interacting protein silencing reduced the localization of the myosin binding subunit to stress fibers. This reduction in stress fiber myosin phosphatase-Rho interacting protein and myosin binding subunit increased basal and lysophosphatidic acid-stimulated myosin light chain phosphorylation. Neither cellular myosin phosphatase, myosin light chain kinase, nor RhoA activities were changed by myosin phosphatase-Rho interacting protein silencing. Furthermore, myosin phosphatase-Rho interacting protein silencing resulted in marked phenotypic changes in vascular smooth muscle cells, including increased numbers of stress fibers, increased cell area, and reduced stress fiber inhibition in response to a Rho-kinase inhibitor. These data support the importance of myosin phosphatase-Rho interacting protein-dependent targeting of myosin phosphatase to stress fibers for regulating myosin light chain phosphorylation state and morphology in human vascular smooth muscle cells.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Med, Div Cardiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Surks, HK (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	Hsurks@tufts-nemc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL074069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Endo A, 2004, J BIOL CHEM, V279, P42055, DOI 10.1074/jbc.M403676200; Eto Y, 2000, AM J PHYSIOL-HEART C, V278, pH1744, DOI 10.1152/ajpheart.2000.278.6.H1744; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOLDBERG ID, 1979, SCIENCE, V205, P920, DOI 10.1126/science.472713; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; IKEBE M, 1985, J BIOL CHEM, V260, P27; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kandabashi T, 2000, CIRCULATION, V101, P1319, DOI 10.1161/01.CIR.101.11.1319; Kandabashi T, 2002, ARTERIOSCL THROM VAS, V22, P243, DOI 10.1161/hq0202.104274; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Koga Y, 2005, J BIOL CHEM, V280, P4983, DOI 10.1074/jbc.M410909200; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Masumoto A, 2002, CIRCULATION, V105, P1545, DOI 10.1161/hc1002.105938; Mohri M, 2003, J AM COLL CARDIOL, V41, P15, DOI 10.1016/S0735-1097(02)02632-3; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; Mulder J, 2004, MOL BIOL CELL, V15, P5516, DOI 10.1091/mbc.E04-04-0275; Mulder J, 2003, J BIOL CHEM, V278, P27216, DOI 10.1074/jbc.M302399200; Murata K, 1997, MOL BIOL CELL, V8, P663, DOI 10.1091/mbc.8.4.663; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SHEPHERD JT, 1985, MAYO CLIN PROC, V60, P33, DOI 10.1016/S0025-6196(12)65280-X; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Shimokawa H, 1999, CARDIOVASC RES, V43, P1029, DOI 10.1016/S0008-6363(99)00144-3; Shin HM, 2002, CIRC RES, V90, P546, DOI 10.1161/01.RES.0000012822.23273.EC; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; VELASCO G, 2002, FEBS LETT, V101, P527; Wang ZQ, 2003, AM J RESP CELL MOL, V29, P465, DOI 10.1165/rcmb.2002-0157OC; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Xia DL, 2005, EXP CELL RES, V304, P506, DOI 10.1016/j.yexcr.2004.11.025; Zhang Y, 1997, BBA-PROTEIN STRUCT M, V1343, P51, DOI 10.1016/S0167-4838(97)00120-9	52	47	49	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42543	42551		10.1074/jbc.M506863200	http://dx.doi.org/10.1074/jbc.M506863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16257966	hybrid			2022-12-25	WOS:000234200800010
J	Golubkov, VS; Chekanov, AV; Doxsey, SJ; Strongin, AY				Golubkov, VS; Chekanov, AV; Doxsey, SJ; Strongin, AY			Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice - Potential implications for tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MT1-MMP; ANEUPLOIDY; INVASION; GROWTH; ORGANIZATION; ASSOCIATION; ACTIVATION; COMPLEX; CANCER; ENZYME	Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits distinctive and important pericellular cleavage functions. Recently, we determined that MT1-MMP was trafficked to the centrosomes in the course of endocytosis. Our data suggested that the functionally important, integral, centrosomal protein, pericentrin-2, was a cleavage target of MT1-MMP in human and in canine cells and that the sequence of the cleavage sites were ALRRLLG(1156) down arrow L(1157)FG and ALRRLLS(2068) down arrow L(2069)FG, respectively. The presence of Asp-948 at the P1 position inactivated the corresponding site (ALRRLLD(948)-L(949)FGD) in murine pericentrin. To confirm that MT1-MMP itself cleaves pericentrin directly, rather than indirectly, we analyzed the cleavage of the peptides that span the MT1-MMP cleavage site. In addition, we analyzed glioma U251 cells, which co-expressed MT1-MMP with the wild type murine pericentrin and the D948G mutant. We determined that the D948G mutant that exhibited the cleavage sequence of human pericentrin was sensitive to MT1-MMP, whereas unmodified murine pericentrin was resistant to proteolysis. Taken together, our results confirm that MT1-MMP cleaves pericentrin-2 in humans but not in mice and that mouse models of cancer probably cannot be used to critically examine MT1-MMP functionality.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Massachusetts, Sch Med, Worcester, MA 01605 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Massachusetts System; University of Massachusetts Worcester	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Golubkov, Vladislav/L-6828-2017	Strongin, Alex/0000-0003-3765-3016; 	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NCRR NIH HHS [RR028043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 1998, CANCER RES, V58, P3743; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing A, 2005, BIOCHEM BIOPH RES CO, V331, P694, DOI 10.1016/j.bbrc.2005.03.157; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Golubkov VS, 2005, J BIOL CHEM, V280, P25079, DOI 10.1074/jbc.M502779200; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2004, TRENDS BIOCHEM SCI, V29, P285, DOI 10.1016/j.tibs.2004.04.001; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jurczyk A, 2004, J CELL BIOL, V166, P637, DOI 10.1083/jcb.200405023; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Remacle AG, 2005, J CELL SCI, V118, P4975, DOI 10.1242/jcs.02610; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Soulie P, 2005, ONCOGENE, V24, P1689, DOI 10.1038/sj.onc.1208360; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	48	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42237	42241		10.1074/jbc.M510139200	http://dx.doi.org/10.1074/jbc.M510139200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251193	hybrid			2022-12-25	WOS:000233992700052
J	Kim, JH; Lee, JA; Song, YM; Park, CH; Hwang, SJ; Kim, YS; Kaang, BK; Son, H				Kim, JH; Lee, JA; Song, YM; Park, CH; Hwang, SJ; Kim, YS; Kaang, BK; Son, H			Overexpression of calbindin-D-28K in hippocampal progenitor cells increases neuronal differentiation and neurite outgrowth	FASEB JOURNAL			English	Article						hippocampus; CaMK; NeuroD	CALCIUM-BINDING PROTEINS; PYRAMIDAL NEURONS; GRANULE CELLS; PHENOTYPE; NEUROTROPHIN-3; INACTIVATION; FACILITATION; STIMULATION; CHANNELS; CURRENTS	Excitatory stimuli are known to be a potent regulator for induction of neuronal differentiation. Calbindin-D-28K buffers intracellular Ca2+ and modifies synaptic functions in neurons. However, the effects of calbindin-D-28K on the regulation of activity-induced neuronal differentiation and related biochemical modifications remain unsolved. In the present study, by a gain-of-function study with retroviral vector system and dicer-generated small interfering RNA (d-siRNA) to effectively knock down the expression of calbindin-D-28K, we demonstrated that calbindin-D-28K at a physiologically relevant level promoted neuronal differentiation and neurite outgrowth. Increase of neuronal differentiation by calbindin-D-28K overexpression was concurrent with the expression of basic helix-loop-helix ( bHLH) transcriptional factors, phosphorylation of calcium and calmodulin-dependent protein kinase II (CaMKII) and NeuroD at Ser(336). KN-62, a highly specific CaMKII inhibitor, blocked the up-regulation of proneural bHLH genes, p-CaMKII, and pSer(336)NeuroD. Calbindin-D-28K appeared to facilitate neuronal differentiation of both fetal and adult hippocampal progenitor cells. Together, these findings establish the novel calbindin-regulated function of CaMKII and NeuroD in control of neuronal differentiation and neurite outgrowth.	Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Anat & Cell Biol, Seoul 133791, South Korea; Seoul Natl Univ, Natl Res Lab Neurobiol, Inst Mol Biol & Genet, Sch Biol Sci,Coll Nat Sci, Seoul 151742, South Korea; Seoul Natl Univ Hosp & Coll Med, Dept Neurol, Seoul 110799, South Korea	Hanyang University; Hanyang University; Hanyang University; Seoul National University (SNU); Seoul National University (SNU)	Son, H (corresponding author), Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, 17 Haengdang Dong, Seoul 133791, South Korea.	hyeonson@hanyang.ac.kr						Alexianu ME, 1998, J NEUROSCI RES, V51, P58, DOI 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Blatow M, 2003, NEURON, V38, P79, DOI 10.1016/S0896-6273(03)00196-X; Boukhaddaoui H, 2000, EUR J NEUROSCI, V12, P2068, DOI 10.1046/j.1460-9568.2000.00105.x; Boukhaddaoui H, 2001, J NEUROSCI, V21, P8789, DOI 10.1523/JNEUROSCI.21-22-08789.2001; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DAILEY ME, 1994, J NEUROBIOL, V25, P243, DOI 10.1002/neu.480250305; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Dumas TC, 2004, HIPPOCAMPUS, V14, P701, DOI 10.1002/hipo.10210; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Kim JH, 2005, J NEUROCHEM, V94, P417, DOI 10.1111/j.1471-4159.2005.03208.x; Kim JS, 2004, J NEUROCHEM, V89, P324, DOI 10.1046/j.1471-4159.2004.02329.x; KOHR G, 1991, EXP BRAIN RES, V85, P543; Lee JA, 2001, LEARN MEMORY, V8, P220, DOI 10.1101/lm.40201; Marty S, 1996, NEURON, V16, P565, DOI 10.1016/S0896-6273(00)80075-6; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Molinari S, 1996, P NATL ACAD SCI USA, V93, P8028, DOI 10.1073/pnas.93.15.8028; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Nagerl UV, 1998, J PHYSIOL-LONDON, V509, P39, DOI 10.1111/j.1469-7793.1998.039bo.x; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Shin MH, 2002, EXP MOL MED, V34, P401, DOI 10.1038/emm.2002.57; SUTHERLAND MK, 1992, MOL BRAIN RES, V13, P239; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TILLOTSON D, 1979, P NATL ACAD SCI USA, V76, P1497, DOI 10.1073/pnas.76.3.1497; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015	30	26	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					109	+		10.1096/fj.05-4826fje	http://dx.doi.org/10.1096/fj.05-4826fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16278289				2022-12-25	WOS:000234053100018
J	Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP			DLK1: increased expression in gliomas and associated with oncogenic activities	ONCOGENE			English	Article						DLK1; expression; oncogenic activities; glioma	EPIDERMAL-GROWTH-FACTOR; EGF-LIKE REPEATS; PROTEIN DLK; DELTA-LIKE; CELL-LINE; ADIPOCYTE DIFFERENTIATION; FETAL ANTIGEN-1; HUMAN HOMOLOG; GENE; PREF-1	DLK1 ( delta-like) is a transmembrane and secreted protein in the epidermal growth factor- like homeotic family. Although expressed widely during embryonic development, only a few tissues retain the expression in adults. Neuroendocrine tumors often highly express this protein; therefore, we hypothesized that brain tumors might also express it. This study found that the expression of DLK1 in gliomas was higher than that in normal brain (P < 0.05). After stable transfection of a DLK1 cDNA expression vector into GBM cell lines, their proliferation was increased. Furthermore, they lost contact inhibition, had enhanced anchorage-independent growth in soft agar, and had significantly greater capacity to migrate. Western blot studies showed that expression of cyclin D1, CDK2, and E2F4 were increased, and Rb levels were decreased in these cells. DLK1 was found on the cell surface and secreted in the medium from the transfected GBM cells. DLK1-enriched condition medium stimulated the growth of glioblastoma multiforme cell lines and explants. DLK1 antibody blocked cell growth stimulated by DLK1. In summary, these results suggest that DLK1 may play a role in the formation or progression of gliomas.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Chinese Acad Sci, Inst Nutr Sci, SIBS, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Boney CM, 1996, ENDOCRINOLOGY, V137, P2923, DOI 10.1210/en.137.7.2923; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Edwards PAW, 1999, CANCER METAST REV, V18, P175, DOI 10.1023/A:1006304821464; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Floridon C, 2000, DIFFERENTIATION, V66, P49, DOI 10.1046/j.1432-0436.2000.066001049.x; GAETANO C, 1992, CANCER RES, V52, P4402; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Samulewicz SJ, 2002, WOUND REPAIR REGEN, V10, P215, DOI 10.1046/j.1524-475X.2002.10404.x; Schmidt JV, 2000, GENE DEV, V14, P1997; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Tornehave D, 1996, HISTOCHEM CELL BIOL, V106, P535; TORNEHAVE D, 1993, ANAT EMBRYOL, V187, P335; van Limpt V, 2000, MED PEDIATR ONCOL, V35, P554, DOI 10.1002/1096-911X(20001201)35:6<554::AID-MPO13>3.0.CO;2-R; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	44	69	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2006	25	13					1852	1861		10.1038/sj.onc.1209219	http://dx.doi.org/10.1038/sj.onc.1209219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288219				2022-12-25	WOS:000236224800002
J	Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C				Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C			The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells	ONCOGENE			English	Article						retinoic acid receptors; PI3K; Akt; p85 alpha; F9 cells	PROTEIN-KINASE; SIGNALING PATHWAY; DEPENDENT MECHANISM; LEUKEMIA-CELLS; BREAST-CANCER; RAR-GAMMA; ACTIVATION; PHOSPHORYLATION; PKB/AKT; BETA	Retinoic acid ( RA) induces cell growth arrest and differentiation through two families of nuclear receptors, the RARs and the RXRs. The phosphoinositide 3-kinase (PI3K)/Akt pathway also plays key roles in these processes, that is, cell cycle progression, cell differentiation and cell survival. We report that, in mouse embryocarcinoma cells (F9 cells), RA induces an early activation of PI3K and Akt via an increase in the expression of the p85 alpha regulatory subunit. This effect is followed by an inhibition of Akt. Both effects require the integrity of the RA pathway as they are not observed in RA-resistant RAR gamma null cells. We propose a model through which RA induces a biphasic regulation of Akt with an activation participitating to the differentiation process, followed by an inhibition, which has been correlated to the RA-induced growth arrest.	CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, F-67404 Illkirch Graffenstaden, France; CHU Purpan, CPTP, Unite INSERM 563, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Rochette-Egly, C (corresponding author), CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr		, Bernard/0000-0002-8693-0190				Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cabane C, 2004, CELL SIGNAL, V16, P1405, DOI 10.1016/j.cellsig.2004.05.003; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carter CA, 2003, EXP MOL PATHOL, V75, P34, DOI 10.1016/S0014-4800(03)00033-9; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ishida S, 2004, BIOCHEM PHARMACOL, V68, P2177, DOI 10.1016/j.bcp.2004.08.017; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kocki J, 2003, J APPL GENET, V44, P553; Lal L, 2005, BLOOD, V105, P1669, DOI 10.1182/blood-2004-06-2078; Laudet V, 2002, NUCL RECEPTOR FACTSB; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Neri LM, 2003, MOL CANCER RES, V1, P234; Oridate N, 1996, ONCOGENE, V12, P2019; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Puscheck EE, 1998, MOL REPROD DEV, V49, P386, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;386::AID-MRD5&gt;3.0.CO;2-J; Rieusset J, 2001, FEBS LETT, V502, P98, DOI 10.1016/S0014-5793(01)02674-6; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarker KP, 2004, ONCOGENE, V23, P6064, DOI 10.1038/sj.onc.1207819; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	42	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2040	2047		10.1038/sj.onc.1209241	http://dx.doi.org/10.1038/sj.onc.1209241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288212				2022-12-25	WOS:000236359700007
J	Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA				Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA			Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma	ONCOGENE			English	Article						CDK4; cyclin D1; mantle cell lymphoma; apoptosis	TUMOR-SUPPRESSOR PATHWAY; EARLY PRE-B; C-MYC; DEPENDENT KINASE; TRANSGENIC MICE; CDK INHIBITORS; P53 MUTATIONS; T-CELLS; TRANSFORMATION; APOPTOSIS	Mantle cell lymphoma (MCL) is a B- cell lymphoma characterized by overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. While expression of cyclin D1 correlates with MCL development, expression of wild- type (WT) cyclin D1 transgene in murine lymphocytes is unable to drive B- cell lymphoma. As cyclin D1 mutants that are refractory to nuclear export display heighten oncogenicity in vitro compared with WT D1, we generated mice expressing FLAG-D1/T286A, a constitutively nuclear mutant, under the control of the immunoglobulin enhancer, E mu. D1/T286A transgenic mice universally develop a mature B- cell lymphoma. Expression of D1/T286A in B lymphocytes results in S phase entry in resting lymphocytes and increased apoptosis in spleens of young premalignant mice. Lymphoma onset correlates with perturbations in p53/MDM2/p19(Arf) expression and with BcL-2 overexpression suggesting that alterations in one or both of these pathways may contribute to lymphoma development. Our results describe a cyclin D1-driven model of B-cell lymphomagenesis and provide evidence that nuclear-retention of cyclin D1 is oncogenic in vivo.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Ctr Canc, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [R01 CA093237, R01 CA093237-05, R01 CA089194, CA93237, CA89194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089194, R01CA093237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKIYAMA N, 1994, CANCER RES, V54, P377; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; Chen WG, 1996, LAB INVEST, V75, P519; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Howe D, 2001, HAEMATOLOGICA, V86, P563; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lai R, 2002, LEUKEMIA RES, V26, P849, DOI 10.1016/S0145-2126(02)00013-9; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; Martinez N, 2003, CANCER RES, V63, P8226; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SETO M, 1992, ONCOGENE, V7, P1401; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; STRASSER A, 1993, ONCOGENE, V8, P1; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	102	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					998	1007		10.1038/sj.onc.1209147	http://dx.doi.org/10.1038/sj.onc.1209147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247460	Green Accepted			2022-12-25	WOS:000235361000005
J	Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K				Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K			Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors	ONCOGENE			English	Article						hypoxia; ER stress; apoptosis; Mcl-1; metastasis	CANCER-CELLS; REGULATED PROTEIN; UP-REGULATION; RESISTANCE; PROGRESSION; EXPRESSION; MITOCHONDRIAL; INDUCTION; BNIP3; DEATH	Low oxygen tension (hypoxia) is a common feature of solid tumors and stimulates the expressions of a variety of genes including those related to angiogenesis, apoptosis and endoplasmic reticulum (ER) stress response. Here we show a close correlation between metastatic potential and the resistance to hypoxia- and ER stress-induced apoptosis among the cell lines with differing metastatic potential derived from Lewis lung carcinoma. An apoptosis-specific expression pro. ling and immunoblot analyses revealed that the expression of antiapoptotic Mcl-1 increased as the resistance to apoptosis increased. Downregulation of the Mcl-1 expression in the high-metastatic cells by Mcl-1 small interfering RNA increased the sensitivity to hypoxia-induced apoptosis and decreased the metastatic ability. The hypoxia-induced apoptosis was not associated with p53 accumulation, although at present it is not possible to conclude that apoptosis-induced apoptosis is p53-independent. There was no correlation between the expression levels of ER stress-response proteins GADD153, GRP78 and ORP150 and the resistance to hypoxia or ER stresses. In vitro, small numbers of the high-metastatic cells overtook the low-metastatic cells after exposure to several rounds of hypoxia and reoxygenation. In solid tumors initially established from equal mixtures, the proportion of the high-metastatic cells to low-metastatic cells was significantly higher in hypoxic areas. Moreover, the high-metastatic cells were overtaking the low-metastatic cells in some of the tumors. Thus, tumor hypoxia and ER stress may provide a physiological selective pressure for the expansion of the high-metastatic cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors.	Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, Chiba 2608717, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center	Takenaga, K (corresponding author), Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	keizo@chiba-cc.jp						Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Brown JM, 1998, CANCER RES, V58, P1408; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; BUFALO DD, 1997, FASEB J, V11, P947; Cairns RA, 2001, CANCER RES, V61, P8903; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Dachs GU, 1998, SEMIN RADIAT ONCOL, V8, P208, DOI 10.1016/S1053-4296(98)80046-5; Durand RE, 1998, INT J RADIAT ONCOL, V42, P711, DOI 10.1016/S0360-3016(98)00305-8; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Friedman AD, 1996, CANCER RES, V56, P3250; Glinsky GV, 1997, CRIT REV ONCOL HEMAT, V25, P175, DOI 10.1016/S1040-8428(97)00234-5; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 1996, CANCER RES, V56, P4509; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kim CY, 1997, CANCER RES, V57, P4200; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LORD EM, 1993, CANCER RES, V53, P5721; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maeta Yoshihiko, 2004, Gastric Cancer, V7, P78; McConkey DJ, 1996, CANCER RES, V56, P5594; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RUSSO CA, 1995, CANCER RES, V55, P1122; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wong CW, 2001, CANCER RES, V61, P333; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					917	928		10.1038/sj.onc.1209128	http://dx.doi.org/10.1038/sj.onc.1209128			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247470				2022-12-25	WOS:000235212700011
J	Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L				Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L			The cytoskeletal network controls c-Jun translation in a UTR-dependent manner	ONCOGENE			English	Article						c-Jun; translation control; UTRs; cytoskeletal network; cell density	ACTIVATED PROTEIN-KINASES; MAMMALIAN UV RESPONSE; NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; BINDING PROTEIN; MESSENGER-RNAS; GROWTH-FACTORS; CELL LIFE; INDUCTION; AGENTS	The cytoskeleton is a dynamic network that undergoes restructuring during various cellular events, influencing cell proliferation, differentiation, and apoptosis. Here, we report that accumulation of c-Jun, a member of the AP1 family of transcription factors that play a key role in normal and aberrant cell growth, dramatically increases upon depolymerization of the cytoskeleton, and that, unexpectedly, this increase is controlled translationally. Depolymerization of the actin or microtubule network induces an increase in c-Jun accumulation with no corresponding increase in c-Jun mRNA or in the half-life of the c-Jun protein, but rather in the translatability of its transcript. This increase is mediated by the untranslated regions (UTRs) of c-Jun mRNA, and is not dependent on activated mitogen-activated protein kinase pathways. This novel mechanism of c-Jun regulation might be relevant to physiological conditions in which c-Jun plays a pivotal role.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Vardimon, L (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	vardi@post.tau.ac.il		Polak, Pazit/0000-0001-8363-0734				Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oren A, 1999, MOL CELL BIOL, V19, P1742; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; REISFELD S, 1994, MOL ENDOCRINOL, V8, P1224, DOI 10.1210/me.8.9.1224; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sehgal A, 2000, ONCOGENE, V19, P2836, DOI 10.1038/sj.onc.1203601; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Xiao DH, 2003, CANCER RES, V63, P6825; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	43	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					665	676		10.1038/sj.onc.1209114	http://dx.doi.org/10.1038/sj.onc.1209114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247475				2022-12-25	WOS:000235068800002
J	Shemon, AN; Sluyter, R; Fernando, SL; Clarke, AL; Dao-Ung, LP; Skarratt, KK; Saunders, BM; Tan, KS; Gu, BJ; Fuller, SJ; Britton, WJ; Petrou, S; Wiley, JS				Shemon, AN; Sluyter, R; Fernando, SL; Clarke, AL; Dao-Ung, LP; Skarratt, KK; Saunders, BM; Tan, KS; Gu, BJ; Fuller, SJ; Britton, WJ; Petrou, S; Wiley, JS			A Thr(357) to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X(7) function and impairs ATP-induced mycobacterial killing by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; PURINERGIC RECEPTORS; HUMAN-LYMPHOCYTES; PORE FORMATION; OF-FUNCTION; L-SELECTIN; GENE; EXPRESSION; TUBERCULOSIS; INHIBITION	The P2X(7) receptor is a ligand-gated cation channel that is highly expressed on mononuclear leukocytes and that mediates ATP-induced apoptosis and killing of intracellular pathogens. There is a wide variation in P2X(7) receptor function between subjects, explained in part by four loss-of-function polymorphisms (R307Q, E496A, I568N, and a 5'-intronic splice site polymorphism), as well as rare mutations. In this study, we report the allele frequencies of 11 non-synonymous P2X(7) polymorphisms and describe a fifth loss-of-function polymorphism in the gene (1096C -> G), which changes Thr(357) to Ser (T357S) with an allele frequency of 0.08 in the Caucasian population. P2X(7) function was measured by ATP-induced ethidium(+) influx into peripheral blood lymphocytes and monocytes and, when compared with wild-type subjects, was reduced to 10-65% in heterozygotes, 1-18% in homozygotes, and 0-10% in compound heterozygotes carrying T357S and a second loss-of-function polymorphism. Overexpression of the T357S mutant P2X(7) in either HEK-293 cells or Xenopus oocytes gave P2X(7) function of similar to 50% that of wild-type constructs. Differentiation of monocytes to macrophages, which also up-regulates P2X(7), restored P2X(7) function to near normal in cells heterozygous for T357S and to a value 50-65% of wild-type in cells homozygous for T357S or compound heterozygous for T357S/E496A. However, macrophages from subjects that are compound heterozygous for either T357S/R307Q or T357S/stop codon had near-to-absent P2X(7) function. These functional deficits induced by T357S were paralleled by impaired ATP-induced apoptosis and mycobacteria killing in macrophages from these subjects. Lymphocytes, monocytes, and macrophages from subjects homozygous for T357S or compound heterozygous for T357S and a second loss-of-function allele have reduced or absent P2X(7) receptor function.	Univ Sydney, Dept Med, Nepean Hosp, Penrith, NSW 2750, Australia; Centenary Inst Canc Med & Cell Biol, Camperdown, NSW 2042, Australia; Univ Sydney, Cent Clin Sch, Discipline Med, Sydney, NSW 2006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia	Nepean Hospital; University of Sydney; University of Sydney; Centenary Institute; University of Sydney; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Wiley, JS (corresponding author), Univ Sydney, Dept Med, Nepean Hosp, Level 5,Spurrett Bldg, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Skarratt, Kristy/AAN-1479-2020; Fuller, Stephen/W-6646-2019; Petrou, Steven/M-8332-2013; Sluyter, Ronald/B-5798-2009	Fuller, Stephen/0000-0003-4637-7391; Sluyter, Ronald/0000-0003-4909-686X; Skarratt, Kristy/0000-0003-4971-2773; Britton, Warwick/0000-0001-6721-9646; Petrou, Steven/0000-0002-4960-6375; Gu, Ben/0000-0001-5500-4453; Saunders, Bernadette/0000-0003-0540-4445; Wiley, James/0000-0001-9421-4154				Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Buell GN, 1998, RECEPTOR CHANNEL, V5, P347; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Dao-Ung LP, 2004, BRIT J HAEMATOL, V125, P815, DOI 10.1111/j.1365-2141.2004.04976.x; Denlinger LC, 2005, J IMMUNOL, V174, P4424, DOI 10.4049/jimmunol.174.7.4424; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Feng YH, 2005, AM J PHYSIOL-CELL PH, V288, pC1342, DOI 10.1152/ajpcell.00315.2004; Fernando SL, 2005, J INFECT DIS, V192, P149, DOI 10.1086/430622; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Georgiou JG, 2005, J INVEST DERMATOL, V125, P482, DOI 10.1111/j.0022-202X.2005.23835.x; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; Jiang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC1295, DOI 10.1152/ajpcell.00253.2005; KAHK BS, 2001, NAT REV NEUROSCI, V2, P165; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Kuzmenkin A, 2003, PFLUG ARCH EUR J PHY, V447, P71, DOI 10.1007/s00424-003-1137-5; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Le Stunff H, 2004, J BIOL CHEM, V279, P16918, DOI 10.1074/jbc.M313064200; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Shemon AN, 2004, BRIT J PHARMACOL, V142, P1015, DOI 10.1038/sj.bjp.0705868; Skarratt KK, 2005, FEBS LETT, V579, P2675, DOI 10.1016/j.febslet.2005.03.091; Sluyter R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/sj.gene.6364127; Sluyter R, 2004, J BIOL CHEM, V279, P44749, DOI 10.1074/jbc.M405631200; Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Smart ML, 2002, AM J PHYSIOL-CELL PH, V283, pC77, DOI 10.1152/ajpcell.00456.2001; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Triccas JA, 1999, MICROBIOL-SGM, V145, P2923, DOI 10.1099/00221287-145-10-2923; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Wiley JS, 2001, DRUG DEVELOP RES, V53, P72, DOI 10.1002/ddr.1173; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7	52	138	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2079	2086		10.1074/jbc.M507816200	http://dx.doi.org/10.1074/jbc.M507816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16263709	hybrid			2022-12-25	WOS:000234760400029
J	Evans, GJO; Barclay, JW; Prescott, GR; Jo, SR; Burgoyne, RD; Birnbaum, MJ; Morgan, A				Evans, GJO; Barclay, JW; Prescott, GR; Jo, SR; Burgoyne, RD; Birnbaum, MJ; Morgan, A			Protein kinase B/Akt is a novel cysteine string protein kinase that regulates exocytosis release kinetics and quantal size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; STIMULATED GLUT4 TRANSLOCATION; SYNAPTIC VESICLE PROTEIN; GRANULE EXOCYTOSIS; 3T3-L1 ADIPOCYTES; GLUCOSE-UPTAKE; DEPENDENT PHOSPHORYLATION; WORTMANNIN INHIBITION; INSULIN STIMULATION; TRANSMITTER RELEASE	Protein kinase B/Akt has been implicated in the insulin-dependent exocytosis of GLUT4-containing vesicles, and, more recently, insulin secretion. To determine if Akt also regulates insulin-independent exocytosis, we used adrenal chromaffin cells, a popular neuronal model. Akt1 was the predominant isoform expressed in chromaffin cells, although lower levels of Akt2 and Akt3 were also found. Secretory stimuli in both intact and permeabilized cells induced Akt phosphorylation on serine 473, and the time course of Ca2+-induced Akt phosphorylation was similar to that of exocytosis in permeabilized cells. To determine if Akt modulated exocytosis, we transfected chromaffin cells with Akt constructs and monitored catecholamine release by amperometry. Wild-type Akt had no effect on the overall number of exocytotic events, but slowed the kinetics of catecholamine release from individual vesicles, resulting in an increased quantal size. This effect was due to phosphorylation by Akt, because it was not seen in cells transfected with kinase-dead mutant Akt. As overexpression of cysteine string protein (CSP) results in a similar alteration in release kinetics and quantal size, we determined if CSP was an Akt substrate. In vitro P-32-phosphorylation studies revealed that Akt phosphorylates CSP on serine 10. Using phospho-Ser10-specific antisera, we found that both transfected and endogenous cellular CSP is phosphorylated by Akt on this residue. Taken together, these findings reveal a novel role for Akt phosphorylation in regulating the late stages of exocytosis and suggest that this is achieved via the phosphorylation of CSP on serine 10.	Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Univ Penn, Sch Med, Dept Med, Howard Hughes Med Inst,Cox Inst, Philadelphia, PA 19104 USA	University of Liverpool; Howard Hughes Medical Institute; University of Pennsylvania	Morgan, A (corresponding author), Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England.	amorgan@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008; Morgan, Alan/AAI-8875-2020	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Barclay, Jeff W/0000-0003-4320-2094; Evans, Gareth John Owen/0000-0003-2573-7001; Morgan, Alan/0000-0002-0346-1289; Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK56886, R01 DK056886] Funding Source: Medline; Wellcome Trust [072504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Burgoyne RD, 2001, TRENDS CELL BIOL, V11, P404, DOI 10.1016/S0962-8924(01)02089-X; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 2001, J CELL SCI, V114, P445; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; Chavis P, 1998, NEURON, V20, P773, DOI 10.1016/S0896-6273(00)81015-6; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; Ciufo LF, 2005, MOL BIOL CELL, V16, P470, DOI 10.1091/mbc.E04-08-0685; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cousin MA, 2000, J NEUROCHEM, V75, P1645, DOI 10.1046/j.1471-4159.2000.0751645.x; DAHMER MK, 1990, J NEUROCHEM, V54, P931, DOI 10.1111/j.1471-4159.1990.tb02340.x; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Evans GJO, 2005, EUR J NEUROSCI, V21, P2671, DOI 10.1111/j.1460-9568.2005.04118.x; Evans GJO, 2002, BIOCHEM J, V364, P343, DOI 10.1042/BJ20020123; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2004, J BIOL CHEM, V279, P32751, DOI 10.1074/jbc.M400827200; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hilfiker S, 2001, J PHYSIOL-LONDON, V531, P141, DOI 10.1111/j.1469-7793.2001.0141j.x; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hille B, 1999, J PHYSIOL-LONDON, V520, P23, DOI 10.1111/j.1469-7793.1999.00023.x; James DJ, 2004, J BIOL CHEM, V279, P20567, DOI 10.1074/jbc.C400096200; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUMAKURA K, 1994, J NEUROSCI, V14, P7695; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; Lonart G, 2003, CELL, V115, P49, DOI 10.1016/S0092-8674(03)00727-X; Machado JD, 2001, MOL PHARMACOL, V60, P514; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; Morgan A, 1995, ESSAYS BIOCHEM, V30, P77; Mori Y, 2004, CELL STRUCT FUNCT, V29, P101, DOI 10.1247/csf.29.101; Nagy G, 2004, NEURON, V41, P417, DOI 10.1016/S0896-6273(04)00038-8; Nagy G, 2002, J NEUROSCI, V22, P9278; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; Shimaya A, 2004, J BIOL CHEM, V279, P55277, DOI 10.1074/jbc.M411540200; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zakharenko SS, 2002, NEURON, V35, P1099, DOI 10.1016/S0896-6273(02)00898-X; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345	62	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1564	1572		10.1074/jbc.M503628200	http://dx.doi.org/10.1074/jbc.M503628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16243840	Green Accepted, hybrid			2022-12-25	WOS:000234652000034
J	Arevolo, JC; Pereira, DB; Yano, H; Teng, KK; Chao, MV				Arevolo, JC; Pereira, DB; Yano, H; Teng, KK; Chao, MV			Identification of a switch in neurotrophin signaling by selective tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ADAPTER PROTEIN; EARLY ENDOSOMES; RECEPTOR; TRKB; DISRUPTION; ACTIVATION; FAMILY; REQUIREMENTS; TRANSDUCTION	Neurotrophins, such as nerve growth factor and brain-derived neurotrophic factor, activate Trk receptor tyrosine kinases through receptor dimerization at the cell surface followed by autophosphorylation and recruitment of intracellular signaling molecules. The intracellular pathways used by neurotrophins share many common protein substrates that are used by other receptor tyrosine kinases (RTK), such as Shc, Grb2, FRS2, and phospholipase C-gamma. Here we describe a novel RTK mechanism that involves a 220-kilodalton membrane tetraspanning protein, ARMS/Kidins220, which is rapidly tyrosine phosphorylated in primary neurons after neurotrophin treatment. ARMS/Kidins220 undergoes multiple tyrosine phosphorylation events and also serine phosphorylation by protein kinase D. We have identified a single tyrosine (Tyr1096) phosphorylation event in ARMS/Kidins220 that plays a critical role in neurotrophin signaling. A reassembled complex of ARMS/Kidins220 and CrkL, an upstream component of the C3G-Rap1-MAP kinase cascade, is SH3-dependent. However, Tyr1096 phosphorylation enables ARMS/Kidins220 to recruit CrkL through its SH2 domain, thereby freeing the CrkL SH3 domain to engage C3G for MAP kinase activation in a neurotrophin dependent manner. Accordingly, mutation of Tyr1096 abolished CrkL interaction and sustained MAPK kinase activity, a response that is not normally observed in other RTKs. Therefore, Trk receptor signaling involves an inducible switch mechanism through an unconventional substrate that distinguishes neurotrophin action from other growth factor receptors.	NYU, Sch Med, Skirball Inst Biomol Med, Dept Cell Biol,Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Dept Physiol,Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Dept Neurosci,Mol Neurobiol Program, New York, NY 10016 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	New York University; New York University; New York University; Cornell University	Chao, MV (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dept Cell Biol,Mol Neurobiol Program, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu	Pereira, Daniela/AAZ-5285-2021; Arévalo, Juan Carlos/J-8154-2014	Arévalo, Juan Carlos/0000-0003-1994-3095; B. Pereira, Daniela/0000-0003-4872-5505; Chao, Moses/0000-0002-6969-3744; Teng, Kenneth/0000-0002-9392-2172	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravind L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r30; Arevalo JC, 2004, EMBO J, V23, P2358, DOI 10.1038/sj.emboj.7600253; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cabrera-Poch N, 2004, J BIOL CHEM, V279, P28592, DOI 10.1074/jbc.M312242200; Chang MS, 2004, J NEUROSCI RES, V78, P186, DOI 10.1002/jnr.20262; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Luo S, 2005, J CELL BIOL, V169, P813, DOI 10.1083/jcb.200412008; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; Suzuki S, 2004, J CELL BIOL, V167, P1205, DOI 10.1083/jcb.200404106; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yano H, 2005, NEUROCHEM RES, V30, P767, DOI 10.1007/s11064-005-6870-z; Yano H, 2004, J NEUROBIOL, V58, P244, DOI 10.1002/neu.10321; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6	38	55	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1001	1007		10.1074/jbc.M504163200	http://dx.doi.org/10.1074/jbc.M504163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16284401	hybrid			2022-12-25	WOS:000234447200040
J	Ramsperger, A; Augustin, M; Schott, AK; Gerhardt, S; Krojer, T; Eisenreich, W; Illarionov, B; Cushman, M; Bacher, A; Huber, R; Fischer, M				Ramsperger, A; Augustin, M; Schott, AK; Gerhardt, S; Krojer, T; Eisenreich, W; Illarionov, B; Cushman, M; Bacher, A; Huber, R; Fischer, M			Crystal structure of an archaeal pentameric riboflavin synthase in complex with a substrate analog inhibitor - Stereochemical implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT CAPSIDS; BACILLUS-SUBTILIS; LUMAZINE SYNTHASE; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; ANGSTROM RESOLUTION; DEUTERIUM EXCHANGE; DIFFRACTION DATA; BINDING MODE; XYLENE RING; BIOSYNTHESIS	Whereas eubacterial and eukaryotic riboflavin synthases form homotrimers, archaeal riboflavin synthases from Methanocaldococcus jannaschii and Methanothermobacter thermoautrophicus are homopentamers with sequence similarity to the 6,7-dimethyl-8-ribityllumazine synthase catalyzing the penultimate step in riboflavin biosynthesis. Recently it could be shown that the complex dismutation reaction catalyzed by the pentameric M. jannaschii riboflavin synthase generates riboflavin with the same regiochemistry as observed for trimeric riboflavin synthases. Here we present crystal structures of the pentameric riboflavin synthase from M. jannaschii and its complex with the substrate analog inhibitor, 6,7-dioxo-8-ribityllumazine. The complex structure shows five active sites located between adjacent monomers of the pentamer. Each active site can accommodate two substrate analog molecules in anti-parallel orientation. The topology of the two bound ligands at the active site is well in line with the known stereochemistry of a pentacyclic adduct of 6,7-dimethyl-8-ribityllumazine that has been shown to serve as a kinetically competent intermediate. The pentacyclic intermediates of trimeric and pentameric riboflavin synthases are diastereomers.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Purdue Univ, Dept Med Chem & Pharmacol, W Lafayette, IN 47907 USA	Max Planck Society; Technical University of Munich; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Ramsperger, A (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18, D-82152 Martinsried, Germany.	ramsperg@biochem.mpg.de	Eisenreich, Wolfgang/A-1258-2013; Fischer, Markus J./G-9477-2012; Fischer, Markus/H-2870-2012; Fischer, Markus/AFT-1856-2022; Krojer, Tobias/ABE-3829-2021	Eisenreich, Wolfgang/0000-0002-9832-8279; Fischer, Markus/0000-0001-7243-4199; Krojer, Tobias/0000-0003-0661-0814; Gerhardt, Stefan/0000-0002-9098-8475	NATIONAL CANCER INSTITUTE [U01CA089566] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA89566] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHER A, 1980, J BIOL CHEM, V255, P632; Bacher A, 2001, VITAM HORM, V61, P1; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; BACHER A, 1978, J BACTERIOL, V134, P476, DOI 10.1128/JB.134.2.476-482.1978; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEACH RL, 1971, J ORG CHEM, V36, P3937, DOI 10.1021/jo00824a020; BEACH RL, 1970, J AM CHEM SOC, V92, P2913, DOI 10.1021/ja00712a052; BEACH RL, 1970, BIOCHEMISTRY-US, V9, P760, DOI 10.1021/bi00806a009; BOWN DH, 1986, J ORG CHEM, V51, P2461, DOI 10.1021/jo00363a011; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JH, 2005, ANAL BIOCHEM, V338, P124, DOI 10.1016/j.ab.2004.11.033; DeLano W, 2002, PYMOL 0 99; Echt S, 2004, J MOL BIOL, V341, P1085, DOI 10.1016/j.jmb.2004.06.053; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fischer M, 2005, NAT PROD REP, V22, P324, DOI 10.1039/b210142b; Fischer M, 2005, BIOCHEM SOC T, V33, P780, DOI 10.1042/BST0330780; Fischer M, 2004, J MOL BIOL, V343, P267, DOI 10.1016/j.jmb.2004.08.016; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; Gerhardt S, 2002, STRUCTURE, V10, P1371, DOI 10.1016/S0969-2126(02)00864-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Illarionov B, 2005, J BIOL CHEM, V280, P28541, DOI 10.1074/jbc.M503093200; Illarionov B, 2001, P NATL ACAD SCI USA, V98, P7224, DOI 10.1073/pnas.131610698; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; Kis K, 2001, J ORG CHEM, V66, P2555, DOI 10.1021/jo001120s; Koch M, 2004, EUR J BIOCHEM, V271, P3208, DOI 10.1111/j.1432-1033.2004.04253.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADENSTEIN R, 1994, EUR J BIOCHEM, V223, P1007, DOI 10.1111/j.1432-1033.1994.tb19079.x; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Morgunova E, 2005, BIOCHEMISTRY-US, V44, P2746, DOI 10.1021/bi047848a; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATERSON T, 1969, J CHEM SOC CHEM COMM, P290, DOI 10.1039/c29690000290; Persson K, 1999, PROTEIN SCI, V8, P2355; PFLEIDERER W, 1971, CHEM BER-RECL, V104, P2273, DOI 10.1002/cber.19711040731; PFLEIDERER W, 1973, CHEM BER-RECL, V106, P3149, DOI 10.1002/cber.19731061007; Plaut G. W. E., 1976, FLAVINS FLAVOPROTEIN, P737; PLAUT GWE, 1963, J BIOL CHEM, V238, P2225; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; ROWAN T, 1963, P CHEM SOC LONDON, P21; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIPOS L, 1998, SYBYL MOL MODELING S; TRUFFAULT V, 2002, THESIS TU MUNCHEN GA; TURK D, 1992, THESIS TU MUNCHEN GA; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; WACKER H, 1964, J BIOL CHEM, V239, P3493; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	53	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1224	1232		10.1074/jbc.M509440200	http://dx.doi.org/10.1074/jbc.M509440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272154	hybrid			2022-12-25	WOS:000234447200065
J	Vukicevic, M; Weder, G; Boillat, A; Boesch, A; Kellenberger, S				Vukicevic, M; Weder, G; Boillat, A; Boesch, A; Kellenberger, S			Trypsin cleaves acid-sensing ion channel 1a in a domain that is critical for channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; CONFORMATIONAL-CHANGE; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; CELL-SURFACE; BRAIN; ENAC; EXPRESSION; ASIC1; ION-CHANNEL-1	Acid-sensing ion channels (ASICs) are neuronal Na+ channels that are members of the epithelial Na+ channel/degenerin family and are transiently activated by extracellular acidification. ASICs in the central nervous system have amodulatory role in synaptic transmission and are involved in cell injury induced by acidosis. We have recently demonstrated that ASIC function is regulated by serine proteases. We provide here evidence that this regulation of ASIC function is tightly linked to channel cleavage. Trypsin cleaves ASIC1a with a similar time course as it changes ASIC1a function, whereas ASIC1b, whose function is not modified by trypsin, is not cleaved. Trypsin cleaves ASIC1a at Arg-145, in the N-terminal part of the extracellular loop, between a highly conserved sequence and a sequence that is critical for ASIC1a inhibition by the venom of the tarantula Psalmopoeus cambridgei. This channel domain controls the inactivation kinetics and co-determines the pH dependence of ASIC gating. It undergoes a conformational change during inactivation, which renders the cleavage site inaccessible to trypsin in inactivated channels.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland	University of Lausanne	Kellenberger, S (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland.	Stephan.Kellenberger@unil.ch		Weder, Gilles/0000-0002-0321-8756; Kellenberger, Stephan/0000-0003-1755-6198; Boesch, Anne/0000-0003-3376-3111				Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Coric T, 2005, J PHYSIOL-LONDON, V568, P725, DOI 10.1113/jphysiol.2005.087734; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Neaga E, 2005, J NEUROSCI METH, V144, P241, DOI 10.1016/j.jneumeth.2004.11.012; Poirot O, 2004, J BIOL CHEM, V279, P38448, DOI 10.1074/jbc.M407381200; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Vukicevic M, 2004, AM J PHYSIOL-CELL PH, V287, pC682, DOI 10.1152/ajpcell.00127.2004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yousef GM, 2003, CLIN CHIM ACTA, V329, P1, DOI 10.1016/S0009-8981(03)00004-4	38	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					714	722		10.1074/jbc.M510472200	http://dx.doi.org/10.1074/jbc.M510472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282326	hybrid			2022-12-25	WOS:000234447200007
J	Li, CM; Crambert, G; Thuillard, D; Roy, S; Schaer, D; Geering, K				Li, CM; Crambert, G; Thuillard, D; Roy, S; Schaer, D; Geering, K			Role of the transmembrane domain of FXYD7 in structural and functional interactions with Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; GAMMA-SUBUNIT; BETA-SUBUNIT; SODIUM-PUMP; SCANNING MUTAGENESIS; MODULATION; TERMINUS; ISOFORMS; FEATURES; SITES	Members of the FXYD family are tissue-specific regulators of the Na, K-ATPase. Here, we have investigated the contribution of amino acids in the transmembrane (TM) domain of FXYD7 to the interaction with Na, K-ATPase. Twenty amino acids of the TM domain were replaced individually by tryptophan, and combined mutations and alanine insertion mutants were constructed. Wild type and mutant FXYD7 were expressed in Xenopus oocytes with Na, K-ATPase. Mutational effects on the stable association with Na, K-ATPase and on the functional regulation of Na, K-ATPase were determined by co-immunoprecipitation and two-electrode voltage clamp techniques, respectively. Most residues important for the structural and functional interaction of FXYD7 are clustered in a face of the TM helix containing the two conserved glycine residues, but others are scattered over two-thirds of the FXYD TM helix. Ile-35, Ile-43, and Ile-44 are only involved in the stable association with Na, K-ATPase. Glu-26, Met-30, and Ile-44 are important for the functional effect and/or the efficient association of FXYD7 with Na, K-ATPase, consistent with the prediction that these amino acids contact TM domain 9 of the alpha subunit (Li, C., Grosdidier, A., Crambert, G., Horisberger, J.-D., Michielin, O., and Geering, K. (2004) J. Biol. Chem. 279, 38895-38902). Several amino acids that are not implicated in the efficient association of FXYD7 with the Na, K-ATPase are specifically involved in the functional effect of FXYD7. Leu-32 and Phe-37 influence the apparent affinity for external K+, whereas Val-28 and Ile-42 are implicated in the apparent affinity for both external K+ and external Na+. These amino acids act in a synergistic way. These results highlight the important structural and functional role of the TM domain of FXYD7 and delineate the determinants that mediate the complex interactions of FXYD7 with Na, K-ATPase.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@unil.ch		Crambert, Gilles/0000-0001-7065-9124				Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; Crambert G, 2004, J BIOL CHEM, V279, P30888, DOI 10.1074/jbc.M313494200; CRAMBERT G, 2003, SCI STKE, V166, pRE1; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Horisberger JD, 2002, J PHYSIOL-LONDON, V539, P669, DOI 10.1113/jphysiol.2001.013201; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Li CM, 2005, P NATL ACAD SCI USA, V102, P12706, DOI 10.1073/pnas.0505980102; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SHARP LL, 1995, P NATL ACAD SCI USA, V92, P7946, DOI 10.1073/pnas.92.17.7946; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	22	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42738	42743		10.1074/jbc.M508451200	http://dx.doi.org/10.1074/jbc.M508451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16269407	hybrid			2022-12-25	WOS:000234200800033
J	Stuhlmeier, KM; Pollaschek, C				Stuhlmeier, KM; Pollaschek, C			Adenovirus-mediated gene transfer of mutated I kappa B kinase and I kappa B alpha reveal NF-kappa B-dependent as well as NF-kappa B-independent pathways of HAS1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA TGF-BETA; RHEUMATOID-ARTHRITIS; HYALURONAN SYNTHASE; TRANSFORMING GROWTH-FACTOR-BETA-1; SYNOVIAL TISSUES; EXPRESSION; CELLS; SKIN; STIMULATION; FIBROBLASTS	It has become increasingly clear that hyaluronan is more than the simple matrix molecule it was once thought to be but instead takes part in a multitude of biological functions. Three genes encode for hyaluronan synthases (HAS). We demonstrated earlier that HAS2 and HAS3 are constitutively activated in type-B synoviocytes (fibro-blast-like synoviocytes) and, furthermore, that the only gene that readily responds to stimulation with a series of proinflammatory cytokines is HAS1. Here we probe the involvement of the transcription factor NF-kappa B in induced and noninduced HAS activation. Transforming growth factor (TGF) beta 1 as well as interleukin (IL)-1 beta are both strong inducers of HAS1 transcription. Stimulation of fibroblast-like synoviocytes with IL-1 beta resulted in rapid degradation of I kappa B alpha, an event that was preceded by I kappa B alpha phosphorylation. Interestingly, TGF beta 1 neither affected I kappa B alpha levels, nor did it cause phosphorylation of I kappa B alpha. In addition, TGF beta 1 had no effect on I kappa B alpha and I kappa B alpha levels. Electrophorectic mobility shift assays demonstrate that IL-1 beta is a potent inducer of NF-kappa B translocation; however, TGF beta 1 treatment did not result in shifting bands. Two adenovirus constructs were used to further clarify differences in TGF beta 1- and IL-1 beta-induced HAS1 activation. Overexpressing I kappa B alpha completely abolished the IL-1 beta effect on HAS1 but did not interfere with TGF beta 1-induced HAS1 mRNA accumulation. Identical results were obtained when a dominant negative IKK was overexpressed. Interestingly, neither overexpression of I kappa B alpha nor of IKK had any effect on HAS2 and HAS3 mRNA levels. Taken together, HAS1 can be activated by distinct pathways; IL-1 beta utilizes NF-kappa B, and TGF beta 1 does not. Furthermore, HAS2 and HAS3 are activated without the involvement of NF-kappa B.	Ludwig Boltzmann Inst Rheumatol & Balneol, A-1100 Vienna, Austria	Ludwig Boltzmann Institute	Stuhlmeier, KM (corresponding author), Ludwig Boltzmann Inst Rheumatol & Balneol, Kurbadstr 10, A-1100 Vienna, Austria.	karlms@excite.com						Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Andreakos E, 2003, ARTHRITIS RHEUM, V48, P1901, DOI 10.1002/art.11044; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bacher S, 2004, CURR PHARM DESIGN, V10, P2827, DOI 10.2174/1381612043383584; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Bondeson J, 1999, J IMMUNOL, V162, P2939; Bondeson J, 1999, P NATL ACAD SCI USA, V96, P5668, DOI 10.1073/pnas.96.10.5668; Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365-2249.2002.01785.x; Dayer JM, 2002, ARTHRITIS RHEUM, V46, P574, DOI 10.1002/art.10168; deMartin R, 1997, GENE THER, V4, P493, DOI 10.1038/sj.gt.3300408; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ellis IR, 1996, EXP CELL RES, V228, P326, DOI 10.1006/excr.1996.0332; Emlen W, 1996, J RHEUMATOL, V23, P974; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Hascall VC, 2000, GLYCOCONJUGATE J, V17, P607, DOI 10.1023/A:1011082728155; HAUBECK HD, 1995, ARTHRITIS RHEUM-US, V38, P669, DOI 10.1002/art.1780380515; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Itokazu M, 1998, CLIN RHEUMATOL, V17, P261, DOI 10.1007/BF01451063; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Kawakami M, 1998, ANN RHEUM DIS, V57, P602, DOI 10.1136/ard.57.10.602; KAY J, 2004, RHEUMATOLOGY S3, V43, pR2; Kiningham KK, 2004, BIOCHEM J, V384, P543, DOI 10.1042/BJ20040714; Kumar Sanjay, 2001, Current Opinion in Pharmacology, V1, P307, DOI 10.1016/S1471-4892(01)00054-6; Maliekal TT, 2004, J BIOL CHEM, V279, P36287, DOI 10.1074/jbc.M404568200; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; McDonald J, 2002, J BIOL CHEM, V277, P4575, DOI 10.1074/jbc.R100064200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Oguchi T, 2004, CONNECT TISSUE RES, V45, P197, DOI 10.1080/03008200490523031; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9; Roche JK, 2000, INFECT IMMUN, V68, P5635, DOI 10.1128/IAI.68.10.5635-5644.2000; Schoenfelder M, 2003, BIOL REPROD, V69, P269, DOI 10.1095/biolreprod.102.011577; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Spicer Andrew P, 2004, Birth Defects Res C Embryo Today, V72, P89, DOI 10.1002/bdrc.20006; STUHLMEIER KM, 1994, EUR J IMMUNOL, V24, P2186, DOI 10.1002/eji.1830240938; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TAKETAZU F, 1994, LAB INVEST, V70, P620; Toole BP, 2000, J CLIN INVEST, V106, P335, DOI 10.1172/JCI10706; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WESTERGRENTHORSSON G, 1990, EXP CELL RES, V186, P192, DOI 10.1016/0014-4827(90)90227-2; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Yoshida M, 2004, ARTHRITIS RES THER, V6, pR514, DOI 10.1186/ar1223	53	18	18	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42766	42773		10.1074/jbc.M503374200	http://dx.doi.org/10.1074/jbc.M503374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16258173	hybrid			2022-12-25	WOS:000234200800037
J	Tran, HJ; Heroven, AK; Winkler, L; Spreter, T; Beatrix, B; Dersch, P				Tran, HJ; Heroven, AK; Winkler, L; Spreter, T; Beatrix, B; Dersch, P			Analysis of RovA, a transcriptional regulator of Yersinia pseudotuberculosis virulence that acts through antirepression and direct transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; CRYSTAL-STRUCTURE; SALMONELLA-TYPHIMURIUM; ALPHA-SUBUNIT; M-CELLS; SLYA; EXPRESSION; GENE; ENTEROCOLITICA	The transcription factor RovA of Yersinia pseudotuberculosis and analogous proteins in other Enterobacteriaceae activate the expression of virulence genes that play a crucial role in stress adaptation and pathogenesis. In this study, we demonstrate that the RovA protein forms dimers independent of DNA binding, stimulates RNA polymerase, most likely via its C-terminal domain, and counteracts transcriptional repression by the histone-like protein H-NS. As the molecular function of the RovA family is largely uncharacterized, random mutagenesis and terminal deletions were used to identify functionally important domains. Our analysis showed that a winged-helix motif in the center of the molecule is essential and directly involved in DNA binding. Terminal deletions and amino acid changes within both termini also abrogate RovA activation and DNA-binding functions, most likely due to their implication in dimer formation. Finally, we show that the last four amino acids of RovA are crucial for activation of gene transcription. Successive deletions of these residues result in a continuous loss of RovA activity. Their removal reduced the capacity of RovA to activate RNA polymerase and abolished transcription of RovA-activated promoters in the presence of H-NS, although dimerization and DNA binding functions were retained. Our structural model implies that the final amino acids of RovA play a role in protein-protein interactions, adjusting RovA activity.	Robert Koch Inst, Jr Res Grp 6, D-13353 Berlin, Germany; Free Univ Berlin, D-14195 Berlin, Germany	Robert Koch Institute; Free University of Berlin	Dersch, P (corresponding author), Robert Koch Inst, Jr Res Grp 6, Nordufer 20, D-13353 Berlin, Germany.	derschp@rki.de	Winkler, Lars/D-1949-2012; Winkler, Lars/M-6134-2014	Winkler, Lars/0000-0003-3350-1189; Dersch, Petra/0000-0001-8177-3280				Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 1999, J BACTERIOL, V181, P4669, DOI 10.1128/JB.181.15.4669-4672.1999; Barnard A, 2004, CURR OPIN MICROBIOL, V7, P102, DOI 10.1016/j.mib.2004.02.011; Bottone EJ, 1997, CLIN MICROBIOL REV, V10, P257, DOI 10.1128/CMR.10.2.257; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Daniels JJD, 1996, INFECT IMMUN, V64, P5075, DOI 10.1128/IAI.64.12.5075-5084.1996; DELCASTILLO I, 1990, J BACTERIOL, V172, P437, DOI 10.1128/JB.172.1.437-445.1990; Dube PH, 2001, P NATL ACAD SCI USA, V98, P10880, DOI 10.1073/pnas.191214498; Ferrandiz MJ, 2005, INFECT IMMUN, V73, P1684, DOI 10.1128/IAI.73.3.1684-1694.2005; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Griffith KL, 2002, BIOCHEM BIOPH RES CO, V291, P979, DOI 10.1006/bbrc.2002.6559; GRUTZKAU A, 1990, GUT, V31, P1011, DOI 10.1136/gut.31.9.1011; Heroven AK, 2002, TRENDS MICROBIOL, V10, P267, DOI 10.1016/S0966-842X(02)02374-0; Heroven AK, 2004, MOL MICROBIOL, V53, P871, DOI 10.1111/j.1365-2958.2004.04162.x; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Li RG, 2003, J BACTERIOL, V185, P4219, DOI 10.1128/JB.185.14.4219-4225.2003; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Marra A, 1997, INFECT IMMUN, V65, P3412, DOI 10.1128/IAI.65.8.3412-3421.1997; Martin RG, 2002, MOL MICROBIOL, V43, P355, DOI 10.1046/j.1365-2958.2002.02748.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; Porter ME, 2004, MOL MICROBIOL, V54, P1117, DOI 10.1111/j.1365-2958.2004.04333.x; Revell PA, 2000, MOL MICROBIOL, V35, P677, DOI 10.1046/j.1365-2958.2000.01740.x; Sambrook J, 2001, MOL CLONING LAB MANU; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smego RA, 1999, EUR J CLIN MICROBIOL, V18, P1, DOI 10.1007/s100960050219; Spory A, 2002, J BACTERIOL, V184, P3549, DOI 10.1128/JB.184.13.3549-3559.2002; Thomson NR, 1997, MOL MICROBIOL, V26, P531, DOI 10.1046/j.1365-2958.1997.5981976.x; Wu RY, 2003, J BIOL CHEM, V278, P20240, DOI 10.1074/jbc.M300292200; Yu RR, 2002, MOL MICROBIOL, V43, P119, DOI 10.1046/j.1365-2958.2002.02721.x	40	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42423	42432		10.1074/jbc.M504464200	http://dx.doi.org/10.1074/jbc.M504464200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257976	hybrid			2022-12-25	WOS:000233992700073
J	Weinhofer, I; Kunze, M; Rampler, H; Bookout, AL; Petter, SF; Berger, J				Weinhofer, I; Kunze, M; Rampler, H; Bookout, AL; Petter, SF; Berger, J			Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression - Novel cross-talk in gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ADRENOLEUKODYSTROPHY; CHOLESTEROL-METABOLISM; ACID-METABOLISM; PPAR-ALPHA; LXR-ALPHA; MOUSE; MICE; INDUCTION; PROMOTER; THERAPY	The peroxisomal ATP binding cassette (ABC) transporter adrenoleukodystrophy-related protein, encoded by ABCD2, displays functional redundancy with the X-linked adrenoleukodystrophy-associated protein, making ABCD2 up-regulation of therapeutic value. Cholesterol lowering activates human ABCD2 in cultured cells. To investigate in vivo regulation by sterols, we first characterized a sterol regulatory element (SRE) in the murine Abcd2 promoter that is directly bound by SRE-binding proteins (SREBPs). Intriguingly, this element overlaps with a direct repeat 4, which serves as binding site for liver X receptor (LXR)/retinoid X receptor heterodimers, suggesting novel cross-talk between SREBP and LXR/retinoid X receptor in gene regulation. Using fasting-refeeding and cholesterol loading, SREBP accessibility to the SRE/direct repeat 4 was tested. Results suggest that adipose Abcd2 is induced by SREBP1c, whereas hepatic Abcd2 expression is down-regulated by concurrent activation of LXR alpha and SREBP1c. In cell culture, SREBP1c-mediated Abcd2 induction is counteracted by ligand-activated LXR alpha. Finally, hepatic Abcd2 expression in LXR alpha,beta-deficient mice is inducible to levels vastly exceeding wild type. Together, we identify LXR alpha as negative modulator of Abcd2, acting through a novel regulatory mechanism involving overlapping SREBP and LXR alpha binding sites.	Med Univ Vienna, Ctr Brain Res, A-1090 Vienna, Austria; Univ Texas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, Dept Pharmacol, Dallas, TX 75390 USA	Medical University of Vienna; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Berger, J (corresponding author), Med Univ Vienna, Ctr Brain Res, Spitalgasse 4, A-1090 Vienna, Austria.	johannes.berger@meduniwien.ac.at	Berger, Johannes/A-9122-2014	Berger, Johannes/0000-0003-0182-2658				Berger J, 1999, EUR J BIOCHEM, V265, P719, DOI 10.1046/j.1432-1327.1999.00772.x; BOOKOUT AL, 2003, NURSA E J, V1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; Fourcade S, 2003, MOL PHARMACOL, V63, P1296, DOI 10.1124/mol.63.6.1296; Fourcade S, 2001, EUR J BIOCHEM, V268, P3490, DOI 10.1046/j.1432-1327.2001.02249.x; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Houck KA, 2004, MOL GENET METAB, V83, P184, DOI 10.1016/j.ymgme.2004.07.007; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; MIAO B, 2004, J LIPID RES; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; Nakamura MT, 2002, BIOCHEM SOC T, V30, P1076, DOI 10.1042/BST0301076; Netik A, 1999, HUM MOL GENET, V8, P907, DOI 10.1093/hmg/8.5.907; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pujol A, 2004, HUM MOL GENET, V13, P2997, DOI 10.1093/hmg/ddh323; Pujol A, 2000, GENOMICS, V70, P131, DOI 10.1006/geno.2000.6367; Quack M, 2002, J CELL BIOCHEM, V86, P601, DOI 10.1002/jcb.10247; Rampler H, 2003, MOL GENET METAB, V80, P398, DOI 10.1016/j.ymgme.2003.09.002; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Shenoy SD, 2004, DRUG METAB DISPOS, V32, P66, DOI 10.1124/dmd.32.1.66; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; Stulnig TM, 2002, DIABETES, V51, P2426, DOI 10.2337/diabetes.51.8.2426; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Weinhofer I, 2002, HUM MOL GENET, V11, P2701, DOI 10.1093/hmg/11.22.2701; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Yuan, 2002, Mol Interv, V2, P78, DOI 10.1124/mi.2.2.78	34	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41243	41251		10.1074/jbc.M509450200	http://dx.doi.org/10.1074/jbc.M509450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16249184	hybrid			2022-12-25	WOS:000233866900018
J	Ethier, MF; Madison, JM				Ethier, MF; Madison, JM			IL-4 inhibits calcium transients in bovine trachealis cells by a ryanodine receptor dependent mechanism	FASEB JOURNAL			English	Article						interleukin (IL)-13; airway smooth muscle; ionomycin; caffeine; carbachol; cyclic ADP-ribose	AIRWAY SMOOTH-MUSCLE; CYCLIC-ADP-RIBOSE; CYCLOPIAZONIC ACID; EOTAXIN RELEASE; CYTOSOLIC CA2+; INTERLEUKIN-4; CHANNEL; MODULATION; EXPRESSION; CYTOKINES	IL-4 and IL-13 have important roles in the pathogenesis of asthma. A novel finding was that brief exposure of airway smooth muscle cells to IL-4 inhibited carbachol-stimulated calcium transients. We hypothesized that IL-4 inhibits transients by decreasing calcium store content and tested this by measuring the effects of IL-4 on transients induced by a nonspecific ionophore. Bovine trachealis cells were loaded with fura 2-AM, and cytosolic calcium concentrations ([Ca2+]i) were measured in single cells by digital microscopy. Stimulation (S1) with carbachol (10 mu M) caused rapid, transient increases in [Ca2+](i) to 1299 +/- 355 nM (n= 5). After recovery of calcium stores, stimulation (S2) of the same cells with ionomycin (10 mu M), in the absence of extracellular calcium, also increased [Ca2+](i) to give S2/S1 ratio of 1.03 +/- 0.29. However, after 20 min of IL-4 (50 ng/ml), but not IL-13, ionomycin transients were decreased to 0.50 +/- 0.16 (S2/S1, P=0.02, n= 6). IL-4 did not inhibit transients with ryanodine receptor calcium release channels (RyR) blocked by ryanodine (200 mu M) (S2/S1= 1.01 +/- 0.11) but still did in the presence of 8-bromo cyclic ADP-ribose, an antagonist of cyclic ADP-ribose (cADPR) signaling at RyR (S2/S1= 0.48 +/- 0.13). Together, findings suggest that IL-4 decreases intracellular calcium stores by mechanisms dependent on RyR, but not on cADPR signaling.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Madison, JM (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB 319,364 Plantat St, Worcester, MA 01605 USA.	Mark.Madison@umassmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054143] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054143, R01 HL054143-10, R01 HL054143-06, HL-54143, R01 HL054143-07A1, R01 HL054143-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; BIZZARRI C, 1994, J BIOL CHEM, V269, P13817; Deshpande DA, 2005, AM J PHYSIOL-LUNG C, V288, pL773, DOI 10.1152/ajplung.00217.2004; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Ethier MF, 2005, J PHARMACOL EXP THER, V313, P127, DOI 10.1124/jpet.104.079343; Ethier MF, 2001, AM J PHYSIOL-LUNG C, V281, pL126, DOI 10.1152/ajplung.2001.281.1.L126; Faffe DS, 2005, J ALLERGY CLIN IMMUN, V115, P514, DOI 10.1016/j.jaci.2004.11.033; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; JANSSEN LJ, 1993, AM J PHYSIOL, V265, pC877, DOI 10.1152/ajpcell.1993.265.4.C877; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; KAJITA J, 1993, AM J PHYSIOL, V264, pL496, DOI 10.1152/ajplung.1993.264.5.L496; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Laporte R, 2004, PHARMACOL REV, V56, P439, DOI 10.1124/pr.56.4.1; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Liu XB, 1996, J PHARMACOL EXP THER, V277, P789; Madison JM, 2001, AM J RESP CELL MOL, V25, P239, DOI 10.1165/ajrcmb.25.2.4286; Madison JM, 1998, AM J PHYSIOL-LUNG C, V275, pL852, DOI 10.1152/ajplung.1998.275.5.L852; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mitchell RW, 2000, AM J PHYSIOL-LUNG C, V278, pL1091, DOI 10.1152/ajplung.2000.278.5.L1091; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; OCONNELL RJ, 2005, P AM THORACIC SOC, V2, pA238; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White RA, 2003, FASEB J, V17, P482, DOI 10.1096/fj.02-0622fje; YAMAKURA T, 1995, LONG TERM ECOLOGICAL, V2, P2; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049	39	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					154	+		10.1096/fj.05-4031fje	http://dx.doi.org/10.1096/fj.05-4031fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16280365	Green Accepted			2022-12-25	WOS:000234053100014
J	Schreiner, B; Voss, J; Wischhusen, JR; Dombrowski, Y; Steinle, A; Lochmuller, H; Dalakas, M; Melms, A; Wiendl, H				Schreiner, B; Voss, J; Wischhusen, JR; Dombrowski, Y; Steinle, A; Lochmuller, H; Dalakas, M; Melms, A; Wiendl, H			Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release, and up-regulation of NKG2D-ligands	FASEB JOURNAL			English	Article						immunobiology of muscle; TLR; myositis; myoblasts	DOUBLE-STRANDED-RNA; INCLUSION-BODY MYOSITIS; NF-KAPPA-B; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODY; CYTOKINE EXPRESSION; ADHESION MOLECULES; DUCHENNE DYSTROPHY; ENDOTHELIAL-CELLS	The particular microenvironment of the skeletal muscle can be the site of complex immune reactions. Toll-like receptors (TLRs) mediate inflammatory stimuli from pathogens and endogenous danger signals and link the innate and adaptive immune system. We investigated innate immune responses in human muscle. Analyzing TLR1-9 mRNA in cultured myoblasts and rhabdomyosarcoma cells, we found constitutive expression of TLR3. The TLR3 ligand Poly (I:C), a synthetic analog of dsRNA, and IFN-gamma increased TLR3 levels. TLR3 was mainly localized intracellularly and regulated at the protein level. Poly (I:C) challenge 1) activated nuclear factor-kappa B (NF-kappa B), 2) increased IL-8 release, and 3) up-regulated NKG2D ligands and NK-cell-mediated lysis of muscle cells. We examined muscle biopsy specimens of 6 HIV patients with inclusion body myositis/polymyositis (IBM/ PM), 7 cases of sporadic IBM and 9 nonmyopathic controls for TLR3 expression. TLR3 mRNA levels were elevated in biopsy specimens from patients with IBM and HIV-myopathies. Muscle fibers in inflammatory myopathies expressed TLR3 in close proximity of infiltrating mononuclear cells. Taken together, our study suggests an important role of TLR3 in the immunobiology of muscle, and has substantial implications for the understanding of the pathogenesis of inflammatory myopathies or therapeutic interventions like vaccinations or gene transfer.	Univ Tubingen, Dept Gen Neurol, Hertie Inst Clin Brain Res, Tubingen, Germany; NINDS, NIH, Bethesda, MD 20892 USA; Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany; Univ Munich, Genzentrum, Friedrich Baur Inst, Munich, Germany; Univ Munich, Dept Neurol, Munich, Germany; Univ Wurzburg, Dept Neurol & Gynecol, Wurzburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Eberhard Karls University of Tubingen; University of Munich; University of Munich; University of Wurzburg	Wiendl, H (corresponding author), Julius Maximilians Univ Wurzburg, Clin Res Grp Multiple Sclerosis & Neuroimmunol, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	heinz.wiendl@klinik.uni-wuerzburg.de	Wiendl, Heinz/AAX-6041-2021; Dombrowski, Yvonne/N-7020-2019; Voss, Joachim/AAA-1277-2020; Steinle, Alexander/E-6131-2012	Dombrowski, Yvonne/0000-0003-1732-6288; Steinle, Alexander/0000-0001-5081-8503; Wiendl, Heinz/0000-0003-4310-3432; Voss, Joachim/0000-0002-8072-6244; Lochmuller, Hanns/0000-0003-2324-8001	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [K22NR008672] Funding Source: NIH RePORTER; NINR NIH HHS [K22 NR008672] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Banwell BL, 2000, NEUROLOGY, V54, P1033, DOI 10.1212/WNL.54.5.1033; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Choi YC, 2000, NEUROLOGY, V54, P65, DOI 10.1212/WNL.54.1.65; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; De Bleecker JL, 2002, NEUROLOGY, V58, P1779, DOI 10.1212/WNL.58.12.1779; De Paepe B, 2004, NEUROMUSCULAR DISORD, V14, P265, DOI 10.1016/j.nmd.2004.01.001; DEBLEECKER JL, 1994, J NEUROPATH EXP NEUR, V53, P369, DOI 10.1097/00005072-199407000-00008; Dunn C, 2003, J EXP MED, V197, P1427, DOI 10.1084/jem.20022059; Farina C, 2005, J NEUROIMMUNOL, V159, P12, DOI 10.1016/j.jneuroim.2004.09.009; Friese MA, 2003, CANCER RES, V63, P8996; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; GOEBELS N, 1992, J IMMUNOL, V149, P661; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; Hohlfeld Reinhard, 1997, Current Opinion in Rheumatology, V9, P520, DOI 10.1097/00002281-199711000-00007; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kaiser WJ, 2004, J IMMUNOL, V172, P1699, DOI 10.4049/jimmunol.172.3.1699; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kieseier BC, 2001, BRAIN, V124, P341, DOI 10.1093/brain/124.2.341; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Maaser C, 2004, J IMMUNOL, V172, P5056, DOI 10.4049/jimmunol.172.8.5056; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Raju R, 2003, J NEUROIMMUNOL, V141, P125, DOI 10.1016/S0165-5728(03)00218-2; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Schmidt KN, 2004, J IMMUNOL, V172, P138, DOI 10.4049/jimmunol.172.1.138; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Sugiura T, 2000, J IMMUNOL, V164, P6593, DOI 10.4049/jimmunol.164.12.6593; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tews DS, 1996, J NEUROPATH EXP NEUR, V55, P342, DOI 10.1097/00005072-199603000-00009; TEWS DS, 1995, J NEUROIMMUNOL, V59, P185, DOI 10.1016/0165-5728(95)00045-4; VALIANTE NM, 1992, CELL IMMUNOL, V145, P187, DOI 10.1016/0008-8749(92)90322-G; Welte SA, 2003, EUR J IMMUNOL, V33, P194, DOI 10.1002/immu.200390022; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, HUM IMMUNOL, V64, P1050, DOI 10.1016/j.humimm.2003.07.001; Wiendl H, 2003, FASEB J, V17, P1892, DOI 10.1096/fj.03-0039fje; Wiendl H, 2003, BRAIN, V126, P1026, DOI 10.1093/brain/awg114	57	70	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					118	+		10.1096/fj.05-4342fje	http://dx.doi.org/10.1096/fj.05-4342fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16293707				2022-12-25	WOS:000234053100009
J	Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S				Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S			IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1	ONCOGENE			English	Article						SYT-SSX1; IGF2; apoptosis; synovial sarcoma	FACTOR-II GENE; CTCF-BINDING SITES; GROWTH-FACTORS; HUMAN CANCER; WILMS-TUMOR; SSX GENES; COLORECTAL-CANCER; TARGET GENE; SYT; EXPRESSION	Synovial sarcoma is an aggressive soft tissue tumor characterized by a specific chromosomal translocation between chromosome 18 and X. This translocation can generate a fusion transcript encoding SYT-SSX1, a transforming oncoprotein. We present evidence that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells. SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synthesis protects cells from anoikis and is required for tumor formation in vivo. We also found a loss of imprinting ( LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleotides critical for maintaining imprinting. These findings suggest that inhibition of the IGF2/IGF1-R signaling pathway may represent a significant therapeutic modality for treating synovial sarcoma.	Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Sch Med & Dent, Rochester, NY USA; Huntsman Canc Inst, Salt Lake City, UT USA; Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan	University of Rochester; University of Rochester; Huntsman Cancer Institute; Hokkaido University	Sun, Y (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	yin_sun@urmc.rochester.edu	Gao, Dingcheng/P-5889-2019; Tanaka, Shinya/D-3586-2011					Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cui HM, 2002, CANCER RES, V62, P6442; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu QQ, 1996, CIRC RES, V79, P716, DOI 10.1161/01.RES.79.4.716; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; NIELSEN FC, 1994, CANCER, V73, P1312, DOI 10.1002/1097-0142(19940215)73:4<1312::AID-CNCR2820730429>3.0.CO;2-D; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Stadnick MP, 1999, DEV GENES EVOL, V209, P239, DOI 10.1007/s004270050248; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Xie YT, 1999, CANCER RES, V59, P3588; Xie YT, 2003, ONCOGENE, V22, P7628, DOI 10.1038/sj.onc.1207153; Zhang LJ, 1996, CANCER RES, V56, P1367	53	65	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1042	1052		10.1038/sj.onc.1209143	http://dx.doi.org/10.1038/sj.onc.1209143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247461				2022-12-25	WOS:000235361000009
J	Grudzien, E; Kalek, M; Jemielity, J; Darzynkiewicz, E; Rhoads, RE				Grudzien, E; Kalek, M; Jemielity, J; Darzynkiewicz, E; Rhoads, RE			Differential inhibition of mRNA degradation pathways by novel cap analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; IN-VITRO; POLY(A)-BINDING PROTEIN; INITIATION-FACTORS; EUKARYOTIC TRANSLATION; MAMMALIAN EXOSOME; YEAST; DEADENYLATION; COMPLEX; DECAY	mRNA degradation predominantly proceeds through two alternative routes: the 5' -> 3' pathway, which requires deadenylation followed by decapping and 5' -> 3' -> hydrolysis; and the 3' -> 5' pathway, which involves deadenylation followed by 3' -> 3' hydrolysis and finally decapping. The mechanisms and relative contributions of each pathway are not fully understood. We investigated the effects of different cap structure (Gp(3)G, m(7)Gp(3)G, or m(2) (7,3- O)Gp(3)G) and 3' termini (A(31), A(60), or G(16)) on both translation and mRNA degradation in mammalian cells. The results indicated that cap structures that bind eIF4E with higher affinity stabilize mRNA to degradation in vivo. mRNA stability depends on the ability of the 5' terminus to bind eIF4E, not merely the presence of a blocking group at the 5'- end. Introducing a stem-loop in the 5'-UTR that dramatically reduces translation, but keeping the cap structure the same, does not alter the rate of mRNA degradation. To test the relative contributions of the 5' -> 3' versus 3' -> 5' pathways, we designed and synthesized two new cap analogs, in which a methylene group was substituted between the alpha- and beta- phosphate moieties, m(2) (7,3-O)GppCH(2)pG and m(2) (7,3-O)GpCH(2)ppG, that are predicted to be resistant to cleavage by Dcp1/Dcp2 and DcpS, respectively. These cap analogs were recognized by eIF4E and conferred cap-dependent translation to mRNA both in vitro and in vivo. Oligonucleotides capped with m(2) (7,3-O)GppCH(2)pG were resistant to hydrolysis by recombinant human Dcp2 in vitro. mRNAs capped with m(2) (7,3-O)GppCH(2)pG, but not m(2)(7,3-O)GpCH(2)ppG, were more stable in vivo, indicating that the 5'-> 3' pathway makes a major contribution to overall degradation. Luciferase mRNA containing a 5'-terminal m(2) (7,3-O)GppCH(2)pG and 3'- terminal poly(G) had the greatest stability of all mRNAs tested.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Warsaw, Dept Biophys, PL-02089 Warsaw, Poland	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Warsaw	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu	Jemielity, Jacek/E-2635-2013; Kalek, Marcin/B-6298-2013	Jemielity, Jacek/0000-0001-7633-788X; Kalek, Marcin/0000-0002-1595-9818	FOGARTY INTERNATIONAL CENTER [R03TW006446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020818] Funding Source: NIH RePORTER; FIC NIH HHS [1R03 TW 006446-01] Funding Source: Medline; NIGMS NIH HHS [2R01 GM 20818] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BENNE R, 1978, J BIOL CHEM, V253, P3078; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; DARNBROUGH C, 1973, J MOL BIOL, V76, P379; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1987, BIOCHEMISTRY-US, V26, P4372, DOI 10.1021/bi00388a028; DARZYNKIEWICZ E, 1990, NUCLEOS NUCLEOT, V9, P599, DOI 10.1080/07328319008045191; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Grudzien E, 2004, RNA, V10, P1479, DOI 10.1261/rna.7380904; HELLMANN GM, 1982, J BIOL CHEM, V257, P4056; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Kalek M, 2005, NUCLEOS NUCLEOT NUCL, V24, P615, DOI 10.1081/NCN-200060091; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; Korner CG, 1997, J BIOL CHEM, V272, P10448; LaGrandeur T, 1999, RNA, V5, P420, DOI 10.1017/S1355838299981748; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; LONDON IM, 1976, FED PROC, V35, P2218; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; Niepel M, 1999, FEBS LETT, V462, P79, DOI 10.1016/S0014-5793(99)01514-8; Pasquinelli AE, 1995, RNA, V1, P957; Piccirillo C, 2003, RNA, V9, P1138, DOI 10.1261/rna.5690503; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rodgers ND, 2002, RNA, V8, P1526, DOI 10.1017/S1355838202029035; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SAFER B, 1978, J BIOL CHEM, V253, P3384; Schwartz DC, 2000, MOL CELL BIOL, V20, P7933, DOI 10.1128/MCB.20.21.7933-7942.2000; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Stepinski J, 2001, RNA, V7, P1486; STEPINSKI J, 1995, NUCLEOS NUCLEOT, V14, P717; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; van Dijk E, 2003, P NATL ACAD SCI USA, V100, P12081, DOI 10.1073/pnas.1635192100; Vilela C, 2000, EMBO J, V19, P4372, DOI 10.1093/emboj/19.16.4372; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Wakiyama M, 2000, CURR BIOL, V10, P1147, DOI 10.1016/S0960-9822(00)00701-6; Walther TN, 1998, RNA, V4, P1034, DOI 10.1017/S1355838298971771; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wilusz CJ, 2001, RNA, V7, P1416; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	73	66	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1857	1867		10.1074/jbc.M509121200	http://dx.doi.org/10.1074/jbc.M509121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16257956	hybrid			2022-12-25	WOS:000234760400003
J	Madrid, M; Soto, T; Khong, HK; Franco, A; Vicente, J; Perez, P; Gacto, M; Cansado, J				Madrid, M; Soto, T; Khong, HK; Franco, A; Vicente, J; Perez, P; Gacto, M; Cansado, J			Stress-induced response, localization, and regulation of the Pmk1 cell integrity pathway in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FISSION-YEAST-CELL; MAP KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; OXIDATIVE STRESS; WALL INTEGRITY; NUCLEAR EXPORT; BUDDING YEAST	Mitogen-activated protein kinase ( MAPK) signaling pathways are critical for the sensing and response of eukaryotic cells to extracellular changes. In Schizosaccharomyces pombe, MAPK Pmk1/Spm1 has been involved in cell wall construction, morphogenesis, cytokinesis, and ion homeostasis, as part of the so-called cell integrity pathway together with MAPK kinase kinase Mkh1 and MAPK kinase Pek1. We show that Pmk1 is activated in multiple stress situations, including hyper- or hypotonic stress, glucose deprivation, presence of cell wall-damaging compounds, and oxidative stress induced by hydrogen peroxide or pro-oxidants. The stress-induced activation of Pmk1 was completely dependent on Mkh1 and Pek1 function, supporting a nonbranched pathway in the regulation of MAPK activation. Fluorescence microscopy revealed that Mkh1, Pek1, and Pmp1 ( a protein phosphatase that inactivates Pmk1) are cytoplasmic proteins. Mkh1 and Pek1 were also found at the septum, whereas Pmk1 localized in both cytoplasm and nucleus as well as in the mitotic spindle and septum during cytokinesis. Interestingly, Pmk1 subcellular localization was unaffected by stress or the absence of Mkh1 and Pek1, suggesting that its activation by the Mkh1-Pek1 cascade takes place at the cytoplasm and/or septum and that the active and inactive forms of this kinase cross the nuclear membrane. Cdc42 GTPase and its effectors, p21-activated kinases Pak2 and Pak1, are not upstream elements controlling the basal level or the stress-induced activation of Pmk1. However, Sty1 MAPK was essential for proper Pmk1 deactivation after hypertonic stress in a process regulated by Atf1 transcription factor. These results provide the first evidence for the existence of cross-talk between two MAPK cascades during the stress response in fission yeast.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain; Univ Salamanca, CSIC, Dept Microbiol & Genet, Inst Microbiol & Bioquim, Salamanca 37007, Spain	University of Murcia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Gacto, M (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, Campus Univ Espinardo, E-30071 Murcia, Spain.	maga@um.es	Madrid, Marisa/K-7755-2014; Pino, Teresa Soto/AAC-6096-2020; Vicente-Soler, Jerónima/ABF-6293-2020; Perez, Pilar/B-4948-2010; Cansado, Jose/ABC-6872-2020; Cansado, Jose/K-5212-2014; Franco, Alejandro/ABG-6823-2020; Khong, Hou Keat/Q-2205-2018; Madrid, Marisa/AAV-2154-2020	Madrid, Marisa/0000-0002-7970-2587; Pino, Teresa Soto/0000-0003-2965-318X; Vicente-Soler, Jerónima/0000-0001-8759-6545; Perez, Pilar/0000-0003-3557-2247; Cansado, Jose/0000-0002-2342-8152; Franco, Alejandro/0000-0001-7461-3414; Madrid, Marisa/0000-0002-7970-2587				Alfa C, 1993, EXPT FISSION YEAST L; Alonso-Nunez ML, 2005, MOL BIOL CELL, V16, P2003, DOI 10.1091/mbc.E04-06-0442; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Degols G, 1996, MOL CELL BIOL, V16, P2870; Dekker N, 2004, MOL BIOL CELL, V15, P3903, DOI 10.1091/mbc.E04-04-0319; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; HUANG KN, 1995, GENETICS, V141, P1275; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Le Goff X, 1999, MOL GEN GENET, V262, P163; Loewith R, 2000, J CELL SCI, V113, P153; Madrid M, 2004, J BIOL CHEM, V279, P41594, DOI 10.1074/jbc.M405509200; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; Martin-Cuadrado AB, 2003, J CELL SCI, V116, P1689, DOI 10.1242/jcs.00377; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; Merla A, 2001, CURR GENET, V39, P205, DOI 10.1007/s002940100210; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nguyen AN, 2002, MOL BIOL CELL, V13, P2651, DOI 10.1091/mbc.02-03-0043; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Paredes V, 2004, YEAST, V21, P593, DOI 10.1002/yea.1128; Perez P, 2004, METHODS, V33, P245, DOI 10.1016/j.ymeth.2003.11.020; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sells MA, 1998, J BIOL CHEM, V273, P18490, DOI 10.1074/jbc.273.29.18490; Sengar AS, 1997, MOL CELL BIOL, V17, P3508, DOI 10.1128/MCB.17.7.3508; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Soto T, 2002, EUR J BIOCHEM, V269, P1; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toda T, 1996, MOL CELL BIOL, V16, P6752; van Drogen F, 2002, CURR BIOL, V12, P1698, DOI 10.1016/S0960-9822(02)01186-7; Vilella F, 2005, J BIOL CHEM, V280, P9149, DOI 10.1074/jbc.M411062200; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Yang PR, 1998, J BIOL CHEM, V273, P18481, DOI 10.1074/jbc.273.29.18481; ZaitsevskayaCarter T, 1997, EMBO J, V16, P1318, DOI 10.1093/emboj/16.6.1318; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690	47	75	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2033	2043		10.1074/jbc.M506467200	http://dx.doi.org/10.1074/jbc.M506467200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16291757	hybrid			2022-12-25	WOS:000234760400024
J	Church, JE; Fulton, D				Church, JE; Fulton, D			Differences in eNOS activity because of subcellular localization are dictated by phosphorylation state rather than the local calcium environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+; ENDOTHELIUM; NO; ACTIVATION; CALMODULIN; CELLS; STORE	Nitric oxide ( NO) produced in the endothelium via the enzyme endothelial nitric-oxide synthase ( eNOS) is an important vasoactive compound. Wild-type (WT) eNOS is localized to the plasma membrane and perinuclear/Golgi region by virtue of N-terminal myristoylation and palmitoylation. Acylation-deficient mutants (G2AeNOS) remain cytosolic and release less NO in response to Ca2+-elevating agonists; a disparity that we hypothesized was attributed to the greater distance between G2AeNOS and plasma membrane Ca2+ influx channels. The reduced activity of G2AeNOS versus WT was reversed upon disruption of cellular integrity with detergents or sonication. NO production from both constructs relied almost exclusively on the influx of extracellular Ca2+, and elevating intracellular Ca2+ to saturating levels with 10 mu M ionomycin in the presence of 10 mM extracellular Ca2+ equalized NO production. To identify the contribution of calcium to the differences in activity between these enzymes, we created Ca2+/CaM-independent eNOS mutants by deleting the two putative autoinhibitory domains of eNOS. There was no difference in NO production between WT and G2A-targeted Ca2+-independent eNOS, suggesting that Ca2+ was the factor responsible. When eNOS constructs were fused in-frame to the bioluminescent probe aequorin, membranebound probes were exposed to higher [Ca2+] in unstimulated cells but upon ionomycin stimulation, the probes experienced equal amounts of Ca2+. The WT and G2A enzymes displayed significant differences in the phosphorylation state of Ser(617), Ser(635), and Ser(1179), and mutating all three sites to alanine or restoring phosphorylation with the phosphatase inhibitor calyculin abolished the differences in activity. We therefore conclude that the disparity in NO production between WTeNOS and G2AeNOS is not caused by different localized [Ca2+] upon stimulation with ionomycin, but rather differences in phosphorylation state between the two constructs.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Fulton, D (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	dfulton@mcg.edu		Church, Jarrod/0000-0001-8266-4043	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL74279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basset O, 2004, J BIOL CHEM, V279, P47092, DOI 10.1074/jbc.M405054200; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; BLINKS JR, 1976, PHARMACOL REV, V28, P1; Boo YC, 2003, FREE RADICAL BIO MED, V35, P729, DOI 10.1016/S0891-5849(03)00397-6; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen PF, 2003, J BIOL CHEM, V278, P52392, DOI 10.1074/jbc.M305469200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Harris MB, 2004, AM J PHYSIOL-HEART C, V287, pH560, DOI 10.1152/ajpheart.00214.2004; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; JAGNANDAN D, 2005, AM J PHYSIOL-CELL PH, V25, P25; Jobin CM, 2003, BIOCHEMISTRY-US, V42, P11716, DOI 10.1021/bi035066w; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; Padua RA, 1998, AM J PHYSIOL-CELL PH, V274, pC615, DOI 10.1152/ajpcell.1998.274.3.C615; PANZA JA, 1995, CIRCULATION, V91, P1732, DOI 10.1161/01.CIR.91.6.1732; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Taniguchi H, 1999, N-S ARCH PHARMACOL, V360, P69, DOI 10.1007/s002109900033; Taniguchi H, 1999, J PHARM PHARMACOL, V51, P831, DOI 10.1211/0022357991773032; Tran QK, 2000, CARDIOVASC RES, V48, P13, DOI 10.1016/S0008-6363(00)00172-3; Yi FX, 2002, AM J PHYSIOL-HEART C, V283, pH2725, DOI 10.1152/ajpheart.00428.2002	44	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1477	1488		10.1074/jbc.M505968200	http://dx.doi.org/10.1074/jbc.M505968200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16257964	hybrid			2022-12-25	WOS:000234652000025
J	Kay, CWM; Mennenga, B; Gorisch, H; Bittl, R				Kay, CWM; Mennenga, B; Gorisch, H; Bittl, R			Structure of the pyrroloquinoline quinone radical in quinoprotein ethanol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOHEMOPROTEIN ALCOHOL-DEHYDROGENASE; ELECTRON-PARAMAGNETIC-RESONANCE; 1.9 ANGSTROM RESOLUTION; METHANOL DEHYDROGENASE; PSEUDOMONAS-AERUGINOSA; HYPHOMICROBIUM-X; PROSTHETIC GROUP; ACTIVE-SITE; METHYLOBACTERIUM-EXTORQUENS; GLUCOSE-DEHYDROGENASE	Quinoprotein alcohol dehydrogenases use the pyrroloquinoline quinone (PQQ) cofactor to catalyze the oxidation of alcohols. The catalytic cycle is thought to involve a hydride transfer from the alcohol to the oxidized PQQ, resulting in the generation of aldehyde and reduced PQQ. Reoxidation of the cofactor by cytochrome proceeds in two sequential steps via the PQQ radical. We have used a combination of electron nuclear double resonance and density functional theory to show that the PQQ radical is not protonated at either O-4 or O-5, a result that is at variance with the general presumption of a singly protonated radical. The quantum mechanical calculations also show that reduced PQQ is unlikely to be protonated at O-5; rather, it is either singly protonated at O-4 or not protonated at either O-4 or O-5, a result that also challenges the common assumption of a reduced PQQ protonated at both O-4 and O-5. The reaction cycle of PQQ-dependent alcohol dehydrogenases is revised in light of these findings.	Free Univ Berlin, Inst Expt Phys, Fachbereich Phys, D-14195 Berlin, Germany; Tech Univ Berlin, Inst Biotechnol, Fachgebiet Tech Biochem, D-13353 Berlin, Germany	Free University of Berlin; Technical University of Berlin	Kay, CWM (corresponding author), Free Univ Berlin, Inst Expt Phys, Fachbereich Phys, Arnimallee 14, D-14195 Berlin, Germany.	chris.kay@physik.fu-berlin.de	Kay, Christopher William Michael/C-2467-2008; Bittl, Robert/I-8149-2013	Kay, Christopher William Michael/0000-0002-5200-6004; Bittl, Robert/0000-0003-4103-3768				Afolabi PR, 2001, BIOCHEMISTRY-US, V40, P9799, DOI 10.1021/bi002932l; Anthony C, 2004, ARCH BIOCHEM BIOPHYS, V428, P2, DOI 10.1016/j.abb.2004.03.038; Anthony C, 1996, BIOCHEM J, V320, P697, DOI 10.1042/bj3200697; Anthony C, 2003, BBA-PROTEINS PROTEOM, V1647, P18, DOI 10.1016/S1570-9639(03)00042-6; AVEZOUX A, 1995, BIOCHEM J, V307, P735, DOI 10.1042/bj3070735; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; Buttner T, 2005, SCIENCE, V307, P235, DOI 10.1126/science.1106070; Chen ZW, 2002, STRUCTURE, V10, P837, DOI 10.1016/S0969-2126(02)00774-8; Davidson VL, 2004, ARCH BIOCHEM BIOPHYS, V428, P32, DOI 10.1016/j.abb.2004.03.022; de Beer R., 1979, Journal of Chemical Physics, V70, P4491, DOI 10.1063/1.437286; DEBEER R, 1980, BIOCHIM BIOPHYS ACTA, V622, P370, DOI 10.1016/0005-2795(80)90050-1; DEJONG GAH, 1995, EUR J BIOCHEM, V230, P899; DIJKSTRA M, 1989, BIOCHEM J, V257, P87, DOI 10.1042/bj2570087; Duine JA, 1999, J BIOSCI BIOENG, V88, P231, DOI 10.1016/S1389-1723(00)80002-X; DUINE JA, 1978, BIOCHIM BIOPHYS ACTA, V524, P277, DOI 10.1016/0005-2744(78)90164-X; DUINE JA, 1984, ARCH BIOCHEM BIOPHYS, V233, P708, DOI 10.1016/0003-9861(84)90497-1; DUINE JA, 1980, BIOCHEM J, V187, P221, DOI 10.1042/bj1870221; Felton LM, 2005, NATURE, V433, pE10, DOI 10.1038/nature03322; FRANK J, 1988, EUR J BIOCHEM, V174, P331, DOI 10.1111/j.1432-1033.1988.tb14102.x; FRISCH MJ, GAUSSIAN 03 REV B 04; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; HAUGE JG, 1964, J BIOL CHEM, V239, P3630; Jongejan A, 2001, J COMPUT CHEM, V22, P1732, DOI 10.1002/jcc.1128; KANO K, 1990, BIOELECTROCH BIOENER, V24, P193, DOI 10.1016/0302-4598(90)85021-9; Kasahara T, 2003, NATURE, V422, P832, DOI 10.1038/422832a; Kay CWM, 2005, J AM CHEM SOC, V127, P7974, DOI 10.1021/ja050972c; Kay CWM, 2004, FEBS LETT, V564, P69, DOI 10.1016/S0014-5793(04)00317-5; Keitel T, 2000, J MOL BIOL, V297, P961, DOI 10.1006/jmbi.2000.3603; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MUTZEL A, 1991, AGR BIOL CHEM TOKYO, V55, P1721, DOI 10.1080/00021369.1991.10870854; Oubrie A, 1999, EMBO J, V18, P5187, DOI 10.1093/emboj/18.19.5187; Oubrie A, 2002, J BIOL CHEM, V277, P3727, DOI 10.1074/jbc.M109403200; Oubrie A, 2003, BBA-PROTEINS PROTEOM, V1647, P143, DOI 10.1016/S1570-9639(03)00087-6; Oubrie A, 2000, PROTEIN SCI, V9, P1265, DOI 10.1110/ps.9.7.1265; Reddy SY, 2004, P NATL ACAD SCI USA, V101, P15887, DOI 10.1073/pnas.0407209101; Reddy SY, 2003, J AM CHEM SOC, V125, P8141, DOI 10.1021/ja034406y; Rucker R, 2005, NATURE, V433, pE10, DOI 10.1038/nature03323; RUPP M, 1988, BIOL CHEM H-S, V369, P431, DOI 10.1515/bchm3.1988.369.1.431; Sato A, 2001, BIOCHEM J, V357, P893, DOI 10.1042/0264-6021:3570893; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; WESTERLING J, 1979, BIOCHEM BIOPH RES CO, V87, P719, DOI 10.1016/0006-291X(79)92018-7; WHITE S, 1993, BIOCHEMISTRY-US, V32, P12955, DOI 10.1021/bi00211a002; Williams PA, 2005, ACTA CRYSTALLOGR D, V61, P75, DOI 10.1107/S0907444904026964; Xia ZX, 1999, BIOCHEMISTRY-US, V38, P1214, DOI 10.1021/bi9822574; XIA ZX, 1992, J BIOL CHEM, V267, P22289; Xia ZX, 1996, J MOL BIOL, V259, P480, DOI 10.1006/jmbi.1996.0334; Zheng YJ, 1997, P NATL ACAD SCI USA, V94, P11881, DOI 10.1073/pnas.94.22.11881; Zheng YJ, 2001, P NATL ACAD SCI USA, V98, P432, DOI 10.1073/pnas.021547498	49	19	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1470	1476		10.1074/jbc.M511132200	http://dx.doi.org/10.1074/jbc.M511132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16267040	hybrid			2022-12-25	WOS:000234652000024
J	Nitsche, DP; Johansson, HM; Frick, IM; Morgelin, M				Nitsche, DP; Johansson, HM; Frick, IM; Morgelin, M			Streptococcal protein FOG, a novel matrix adhesin interacting with collagen I in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-BINDING PROTEIN; GROUP-A STREPTOCOCCI; LIPOTEICHOIC ACID; RHEUMATIC-FEVER; PYOGENES; ENTRY; IDENTIFICATION; COLONIZATION; BACTEREMIA; INVASION	Group G streptococcus (GGS) is a human pathogen of emerging clinical significance. It causes skin and soft tissue infections, occasionally resulting in life-threatening conditions such as sepsis and necrotizing fasciitis. We recently identified FOG, a novel surface protein of GGS with fibrinogen binding and immune evasion properties. Here we investigated the role of FOG in streptococcal primary adhesion to host tissue. A FOG-expressing clinical isolate adhered more efficiently to human skin biopsies ex vivo and to the murine dermis in vivo than a FOG-deficient strain. Scanning and transmission electron microscopy of skin specimens exhibited that this property was assigned to the ability of FOG to interact with collagen I, a major interstitial component of the dermis. Overlay experiments with human skin extracts and radiolabeled FOG followed by matrix-assisted laser desorption/ionization time of flight mass spectrometry analysis identified both the alpha 1- and alpha 2-chains of collagen I as targets for FOG. Transmission electron microscopy of the molecular complexes revealed thread-like FOG molecules binding via their NH2 termini to distinct sites on collagen I monomers and fibrils. The results demonstrate that FOG is important for GGS adhesion in vivo, implying a pathogenic role for this surface protein.	Lund Univ, Ctr Biomed, Sect Clin & Expt Infect Med, Dept Clin Sci, S-22184 Lund, Sweden	Lund University	Frick, IM (corresponding author), Lund Univ, Ctr Biomed, Sect Clin & Expt Infect Med, Dept Clin Sci, S-22184 Lund, Sweden.	inga-maria.frick@med.lu.se; matthias.morgelin@med.lu.se		Linge, Helena/0000-0002-8919-0300				AUCKENTHALER R, 1983, REV INFECT DIS, V5, P196; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BEACHEY EH, 1976, J EXP MED, V143, P759, DOI 10.1084/jem.143.4.759; BJORCK L, 1984, J IMMUNOL, V133, P969; COURTNEY HS, 1992, MICROB PATHOGENESIS, V12, P199, DOI 10.1016/0882-4010(92)90054-R; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dinkla K, 2003, J CLIN INVEST, V111, P1905, DOI 10.1172/JCI200317247; Dinkla K, 2003, MOL MICROBIOL, V47, P861, DOI 10.1046/j.1365-2958.2003.03352.x; Fluckiger U, 1998, INFECT IMMUN, V66, P974, DOI 10.1128/IAI.66.3.974-979.1998; Frick IM, 2000, MOL MICROBIOL, V37, P1232, DOI 10.1046/j.1365-2958.2000.02084.x; Haidan A, 2000, LANCET, V356, P1167, DOI 10.1016/S0140-6736(00)02765-3; HASTY DL, 1992, INFECT IMMUN, V60, P2147, DOI 10.1128/IAI.60.6.2147-2152.1992; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Johansson HM, 2004, MICROBIOL-SGM, V150, P4211, DOI 10.1099/mic.0.27269-0; Kadler KE, 1996, BIOCHEM J, V316, P1; Kline JB, 1996, INFECT IMMUN, V64, P2122, DOI 10.1128/IAI.64.6.2122-2129.1996; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; NOHLGARD C, 1992, ACTA DERM-VENEREOL, V72, P128; Oster HR, 2000, GRAM-POSITIVE PATHOGENS, P184; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Sylvetsky N, 2002, AM J MED, V112, P622, DOI 10.1016/S0002-9343(02)01117-8; Xu Y, 2004, J INFECT DIS, V189, P2323, DOI 10.1086/420851; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	28	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1670	1679		10.1074/jbc.M506776200	http://dx.doi.org/10.1074/jbc.M506776200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16278217	Green Submitted, hybrid			2022-12-25	WOS:000234652000047
J	Zhang, ZY; Lin, SY; Neel, BG; Haimovich, B				Zhang, ZY; Lin, SY; Neel, BG; Haimovich, B			Phosphorylated alpha-actinin and protein-tyrosine phosphatase 1B coregulate the disassembly of the focal adhesion kinase center dot Src complex and promote cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FAMILY KINASES; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; LEADING-EDGE; C-SRC; INTEGRIN; PAXILLIN; BINDING; FIBROBLASTS	The focal adhesion kinase (FAK) is a key regulator of cell migration. Phosphorylation at Tyr-397 activates FAK and creates a binding site for Src family kinases. FAK phosphorylates the cytoskeletal protein alpha-actinin at Tyr-12. Here we report that protein-tyrosine phosphatase 1B (PTP 1B) is an alpha-actinin phosphatase. PTP 1B-dependent dephosphorylation of alpha-actinin was seen in COS-7 cells and PTP 1B-null fibroblasts reconstituted with PTP 1B. Furthermore, we show that coexpression of wild-type alpha-actinin and PTP 1B causes dephosphorylation at Tyr-397 in FAK. No dephosphorylation was observed in cells coexpressing the alpha-actinin phosphorylation mutant Y12F and PTP 1B. Furthermore, the phosphorylation at four other sites in FAK was not altered by PTP 1B. In addition, we found that phosphorylated alpha-actinin bound to Src and reduced the binding of FAK to Src. The dephosphorylation at Tyr-397 in FAK triggered by wild-type alpha-actinin and PTP 1B caused a significant increase in cell migration. We propose that phosphorylated alpha-actinin disrupts the FAK center dot Src complex exposing Tyr-397 in FAK to PTP 1B. These findings uncover a novel feedback loop involving phosphorylated alpha-actinin and PTP 1B that regulates FAK center dot Src interaction and cell migration.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Harvard Univ, Sch Med, Canc Biol Program, Div Hematol oncol,Dept Med,Beth Israel Deaconess, Boston, MA 02215 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Haimovich, B (corresponding author), Clin Acad Bldg,Rm 7018,125 Paterson St, New Brunswick, NJ 08903 USA.	haimovic@umdnj.edu		zhang, zhiyong/0000-0003-4061-7374; ZHANG, ZHIYONG/0000-0001-8576-1607	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054104, R29HL054104] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arias-Salgado EG, 2005, J CELL BIOL, V170, P837, DOI 10.1083/jcb.200503125; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILLC D, 1995, NATURE, V377, P539; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Lin SY, 2004, J BIOL CHEM, V279, P25755, DOI 10.1074/jbc.M314175200; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rigacci S, 2002, J BIOL CHEM, V277, P41631, DOI 10.1074/jbc.M201709200; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	67	40	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1746	1754		10.1074/jbc.M509590200	http://dx.doi.org/10.1074/jbc.M509590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291744	hybrid			2022-12-25	WOS:000234652000055
J	Elliman, SJ; Wu, I; Kemp, DM				Elliman, SJ; Wu, I; Kemp, DM			Adult tissue-specific expression of a Dppa(3)-derived retrogene represents a postnatal transcript of pluripotent cell origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSED PSEUDOGENES; GENES; EVOLUTION; PROTEIN; RETROTRANSPOSON; EMBRYOS; NANOG	Processed pseudogenes emerge by reverse transcription of spliced mRNAs followed by incorporation of the resultant cDNA into the genome. Their genesis requires that retrotransposition occurs within the germ line, a provision that significantly limits random distribution of source genes. We previously identified embryonic stem cell- specific genes as an enriched source of retropseudogene origin. Nanog, Oct4, and Dppa3 ( Stella/ PGC7) presented as source genes for > 30 processed pseudogenes within the human genome. In the current study, we extended our previous analysis and focused on the pluripotent cell- specific Dppa gene family. Of the five Dppa genes characterized, four were associated with putative retropseudogenes as determined by nucleotide BLAST ( basic local alignment sequence tool) searches of the respective mRNA transcripts against the human genome. A subset of the 11 Dppa3- derived hits were then screened against a human adult tissue cDNA panel for evidence of transcriptional activity. One of the putative Dppa3- derived retropseudogenes, Dppa3( d), located on human chromosome 16p13, tested positive for mRNA transcript in bone marrow, peripheral blood, pancreas, adrenal gland, and thyroid gland. Specificity against the source Dppa3 gene expression was sequence verified, and independent human tissue samples were obtained to confirm Dppa3( d) expression. These data substantiate the existence of human adult tissue- specific transcripts that originate via retrotransposition of the pluripotent cell- specific gene, Dppa3. Further studies may reveal an evolutionary role for this example of genetic diversity, but in the short term our observations serve a cautionary purpose regarding the use of Dppa3 transcripts in adult tissue- derived cells as a potential marker of pluripotency.	Novartis Inst Biomed Res, Diabet & Metab Dis Area, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Novartis; Massachusetts Institute of Technology (MIT)	Kemp, DM (corresponding author), Novartis Inst Biomed Res, Diabet & Metab Dis Area, 100 Technol Sq, Cambridge, MA 02139 USA.	daniel.kemp@novartis.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Balakirev ES, 2003, ANNU REV GENET, V37, P123, DOI 10.1146/annurev.genet.37.040103.103949; Bellingham J, 2003, J EXP ZOOL PART B, V297B, P1, DOI 10.1002/jez.b.00018; Bortvin A, 2003, DEVELOPMENT, V130, P1673, DOI 10.1242/dev.00366; Bortvin Alex, 2004, BMC Dev Biol, V4, P2, DOI 10.1186/1471-213X-4-2; Boschan C, 2002, GENOMICS, V79, P387, DOI 10.1006/geno.2001.6715; Bowles J, 2003, CYTOGENET GENOME RES, V101, P261, DOI 10.1159/000074346; Brandt J, 2005, GENE, V345, P101, DOI 10.1016/j.gene.2004.11.022; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Conlon JM, 2005, GEN COMP ENDOCR, V142, P53, DOI 10.1016/j.ygcen.2004.11.016; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Devor EJ, 2003, HUM BIOL, V75, P661, DOI 10.1353/hub.2003.0075; Goncalves I, 2000, GENOME RES, V10, P672, DOI 10.1101/gr.10.5.672; Harrison PM, 2005, NUCLEIC ACIDS RES, V33, P2374, DOI 10.1093/nar/gki531; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Johnson J, 2005, CELL, V122, P303, DOI 10.1016/j.cell.2005.06.031; Korneev SA, 1999, J NEUROSCI, V19, P7711; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Pain D, 2005, J BIOL CHEM, V280, P6265, DOI 10.1074/jbc.C400587200; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Uechi T, 2002, NUCLEIC ACIDS RES, V30, P5369, DOI 10.1093/nar/gkf696; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; Zhang ZL, 2004, CURR OPIN GENET DEV, V14, P328, DOI 10.1016/j.gde.2004.06.003	25	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					16	19		10.1074/jbc.C500415200	http://dx.doi.org/10.1074/jbc.C500415200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16291741	hybrid			2022-12-25	WOS:000234307200005
J	Kosuga, S; Tashiro, E; Kajioka, T; Ueki, M; Shimizu, Y; Imoto, M				Kosuga, S; Tashiro, E; Kajioka, T; Ueki, M; Shimizu, Y; Imoto, M			GSK-3 beta directly phosphorylates and activates MARK2/PAR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-I; GLYCOGEN-SYNTHASE KINASE-3-BETA; MICROTUBULE-ASSOCIATED PROTEINS; ALZHEIMERS-DISEASE BRAIN; PEUTZ-JEGHERS-SYNDROME; TAU-PROTEIN; INDUCED NEUROTOXICITY; HIPPOCAMPAL-NEURONS; NEURITE OUTGROWTH; PRO MOTIFS	In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3 beta(GSK-3 beta), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3 beta in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3 beta indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3 beta phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3 beta or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3 beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3 beta-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp	Tashiro, Etsu/C-4903-2014	Tashiro, Etsu/0000-0003-4533-623X				Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Cho JH, 2001, J NEUROCHEM, V77, P103, DOI 10.1046/j.1471-4159.2001.t01-1-00230.x; Cox DN, 2001, CURR BIOL, V11, P75, DOI 10.1016/S0960-9822(01)00027-6; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Drewes G, 2004, TRENDS BIOCHEM SCI, V29, P548, DOI 10.1016/j.tibs.2004.08.001; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; FAN SF, 1993, BRAIN RES, V605, P214, DOI 10.1016/0006-8993(93)91743-C; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Ikura Y, 1998, NEUROREPORT, V9, P2375, DOI 10.1097/00001756-199807130-00041; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JOACHIM CL, 1987, J NEUROPATH EXP NEUR, V46, P611, DOI 10.1097/00005072-198711000-00001; JOACHIM CL, 1987, ANN NEUROL, V22, P514, DOI 10.1002/ana.410220411; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kishi M, 2005, SCIENCE, V307, P929, DOI 10.1126/science.1107403; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Liu TB, 2004, J NEUROCHEM, V88, P554, DOI 10.1046/j.1471-4159.2003.02196.x; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; POLLARD CE, 1993, BRAIN RES, V614, P178, DOI 10.1016/0006-8993(93)91032-N; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Ryder J, 2004, CELL SIGNAL, V16, P187, DOI 10.1016/j.cellsig.2003.07.004; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sang HC, 2001, NEUROSCI LETT, V312, P141, DOI 10.1016/S0304-3940(01)02206-6; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SONG JS, 1995, J PROTEIN CHEM, V14, P95, DOI 10.1007/BF01888367; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; TAKASHIMA A, 1995, NEUROSCI LETT, V198, P83, DOI 10.1016/0304-3940(95)11964-X; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tashiro E, 2003, CANCER RES, V63, P424; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Williams R, 2004, BIOCHEM SOC T, V32, P799, DOI 10.1042/BST0320799; YAMADA M, 1988, ACTA NEUROPATHOL, V77, P136	47	44	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42715	42722		10.1074/jbc.M507941200	http://dx.doi.org/10.1074/jbc.M507941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16257959	hybrid			2022-12-25	WOS:000234200800030
J	Liu, W; Wang, SQ; Wei, S; Sun, L; Feng, X				Liu, W; Wang, SQ; Wei, S; Sun, L; Feng, X			Receptor activator of NF-kappa B (RANK) cytoplasmic motif, (369)PFQEP(373), plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; FORK-HEAD; TRANSCRIPTION FACTORS; INHIBITORY FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; OSTEOPROTEGERIN LIGAND; CAENORHABDITIS-ELEGANS; MATURE OSTEOCLASTS; BONE-RESORPTION	Receptor activator of NF-kappa B ligand (RANKL) plays a crucial role in osteoclast differentiation, function, and survival. RANKL exerts its effect by activating its receptor RANK (receptor activator of NF-kappa B), which recruits various intracellular signaling molecules via specific motifs in its cytoplasmic tail. Previously, we identified three RANK cytoplasmic motifs (Motif 1, (369)PFQEP(373); Motif 2, (559)PVQEET(564); and Motif 3, (604)PVQEQG(609)) mediating osteoclast formation and function. Here, we investigated RANK cytoplasmic motifs involved in osteoclast survival. Motif 1, in contrast to its minimal role in osteoclast formation and function, plays a predominant role in promoting osteoclast survival. Moreover, whereas Motif 2 and Motif 3 are highly potent in osteoclast formation and function, they exert a moderate effect on osteoclast survival. We also investigated the role of these motifs in activating Akt/protein kinase B (PKB), which has been implicated in RANKL-induced osteoclast survival. Motif 1, but not Motif 2 or Motif 3, is able to stimulate Akt/PKB activation. Because Akt/PKB has been shown to utilize distinct downstream effectors (glycogen synthase kinase-3 beta, FKHR/FOXO1a, BAD, and AFX/FOXO4) to regulate cell survival, we next determined which downstream effector(s) is activated by Akt/PKB to promote osteoclast survival. Our data revealed that RANKL only stimulates AFX/FOXO4 phosphorylation, indicating that AFX/FOXO4 is a key downstream target activated by Akt/PKB to modulate osteoclast survival. Taken together, we conclude that Motif 1 plays a predominant role in mediating osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Mt Sinai Sch Med, Dept Med Endocrinol, New York, NY 10029 USA; First Municipal Peoples Hosp, Dept Hematol, Guangzhou 510180, Guangdong, Peoples R China	University of Alabama System; University of Alabama Birmingham; Icahn School of Medicine at Mount Sinai; South China University of Technology	Feng, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,VH G046B, Birmingham, AL 35294 USA.	xfeng@path.uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047830, P30AR046031] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30AR46031, AR 47830] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akatsu T, 1998, BIOCHEM BIOPH RES CO, V250, P229, DOI 10.1006/bbrc.1998.9294; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	45	26	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43064	43072		10.1074/jbc.M509006200	http://dx.doi.org/10.1074/jbc.M509006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16260781	hybrid			2022-12-25	WOS:000234200800072
J	Rangarajan, ES; Li, YG; Ajamian, E; Iannuzzi, P; Kernaghan, SD; Fraser, ME; Cygler, M; Matte, A				Rangarajan, ES; Li, YG; Ajamian, E; Iannuzzi, P; Kernaghan, SD; Fraser, ME; Cygler, M; Matte, A			Crystallographic trapping of the glutamyl-CoA thioester intermediate of Family ICoA transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-TRANSFERASE; ESCHERICHIA-COLI; ACIDAMINOCOCCUS-FERMENTANS; PIG-HEART; ACTIVE-SITE; CATALYTIC RESIDUE; ENZYME-COENZYME; CLONING; IDENTIFICATION; PROTEINS	Coenzyme A transferases are involved in a broad range of biochemical processes in both prokaryotes and eukaryotes, and exhibit a diverse range of substrate specificities. The YdiF protein from Escherichia coli O157:H7 is an acyl-CoA transferase of unknown physiological function, and belongs to a large sequence family of CoA transferases, present in bacteria to humans, which utilize oxoacids as acceptors. In vitro measurements showed that YdiF displays enzymatic activity with short-chain acyl-CoAs. The crystal structures of YdiF and its complex with CoA, the first co-crystal structure for any Family I CoA transferase, have been determined and refined at 1.9 and 2.0 angstrom resolution, respectively. YdiF is organized into tetramers, with each monomer having an open alpha/beta structure characteristic of Family I CoA transferases. Co-crystallization of YdiF with a variety of CoA thioesters in the absence of acceptor carboxylic acid resulted in trapping a covalent gamma-glutamyl-CoA thioester intermediate. The CoA binds within a well defined pocket at the N- and C-terminal domain interface, but makes contact only with the C-terminal domain. The structure of the YdiF complex provides a basis for understanding the different catalytic steps in the reaction of Family I CoA transferases.	McGill Univ, Dept Biochem, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	McGill University; National Research Council Canada; University of Calgary	Cygler, M (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H4P 2R2, Canada.	mirek.cygler@nrc-cnrc.gc.ca; allan.matte@nrc-cnrc.gc.ca		Fraser, Marie/0000-0001-8501-1494				Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bateman KS, 2002, BIOCHEMISTRY-US, V41, P14455, DOI 10.1021/bi020568f; Berry GT, 2001, J INHERIT METAB DIS, V24, P587, DOI 10.1023/A:1012419911789; BUCKEL W, 1981, EUR J BIOCHEM, V118, P315, DOI 10.1111/j.1432-1033.1981.tb06404.x; CARY JW, 1990, APPL ENVIRON MICROB, V56, P1576, DOI 10.1128/AEM.56.6.1576-1583.1990; Coros AM, 2004, ACTA CRYSTALLOGR D, V60, P1717, DOI 10.1107/S0907444904017974; CorthesyTheulaz IE, 1997, J BIOL CHEM, V272, P25659, DOI 10.1074/jbc.272.41.25659; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; FIERKE CA, 1986, J BIOL CHEM, V261, P7603; Fukao T, 2000, GENOMICS, V68, P144, DOI 10.1006/geno.2000.6282; Gobel M, 2002, J BACTERIOL, V184, P216, DOI 10.1128/JB.184.1.216-223.2002; Heider J, 2001, FEBS LETT, V509, P345, DOI 10.1016/S0014-5793(01)03178-7; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HERSH LB, 1967, J BIOL CHEM, V242, P3468; HERSH LB, 1967, J BIOL CHEM, V242, P339; HERSH LB, 1967, J BIOL CHEM, V242, P3481; Jacob U, 1997, STRUCTURE, V5, P415, DOI 10.1016/S0969-2126(97)00198-6; JENKINS LS, 1987, J BACTERIOL, V169, P42, DOI 10.1128/jb.169.1.42-52.1987; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson S, 2004, J BIOL CHEM, V279, P36003, DOI 10.1074/jbc.M404873200; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; Korolev S, 2002, ACTA CRYSTALLOGR D, V58, P2116, DOI 10.1107/S0907444902017055; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN TW, 1992, J BIOL CHEM, V267, P975; Lloyd AJ, 2001, BIOCHEMISTRY-US, V40, P2455, DOI 10.1021/bi002169v; MACK M, 1995, FEBS LETT, V357, P145, DOI 10.1016/0014-5793(94)01351-Z; MACK M, 1994, EUR J BIOCHEM, V226, P41, DOI 10.1111/j.1432-1033.1994.tb20024.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mishra PK, 2000, CHEM REV, V100, P3283, DOI 10.1021/cr990010m; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; Nunn WD, 1996, ESCHERICHIA COLI SAL, P285; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARALES RE, 1992, J BACTERIOL, V174, P4657, DOI 10.1128/JB.174.14.4657-4666.1992; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Ricagno S, 2003, EMBO J, V22, P3210, DOI 10.1093/emboj/cdg333; ROCHET JC, 1994, PROTEIN SCI, V3, P975; Selmer T, 1999, J BIOL CHEM, V274, P20772, DOI 10.1074/jbc.274.30.20772; Selmer T, 2002, EUR J BIOCHEM, V269, P372, DOI 10.1046/j.0014-2956.2001.02659.x; SOLOMON F, 1969, J BIOL CHEM, V244, P1079; SRAMEK SJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P14, DOI 10.1016/0003-9861(75)90002-8; Steinmann D, 1997, ARCH MICROBIOL, V168, P441, DOI 10.1007/s002030050520; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; WHITE H, 1976, J BIOL CHEM, V251, P1688; WHITE H, 1976, J BIOL CHEM, V251, P1700; WHITTY A, 1995, BIOCHEMISTRY-US, V34, P11678, DOI 10.1021/bi00037a005	49	27	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42919	42928		10.1074/jbc.M510522200	http://dx.doi.org/10.1074/jbc.M510522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16253988	hybrid			2022-12-25	WOS:000234200800054
J	Goulimari, P; Kitzing, TM; Knieling, H; Brandt, DT; Offermanns, S; Grosse, R				Goulimari, P; Kitzing, TM; Knieling, H; Brandt, DT; Offermanns, S; Grosse, R			G alpha(12/13) is essential for directed cell migration and localized Rho-Dia1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHOA ACTIVATION; SELECTIVE STABILIZATION; LYSOPHOSPHATIDIC ACID; G-PROTEINS; POLARITY; GTPASES; MICROTUBULES; INVOLVEMENT; PROTRUSION; MECHANISMS	Scratch-wound assays are frequently used to study directed cell migration, a process critical for embryogenesis, invasion, and tissue repair. The function and identity of trimeric G-proteins in cell behavior during wound healing is not known. Here we show that G alpha(12/13), but not G alpha(q/11) or G alpha(i), is indispensable for coordinated and cell migration. In mouse embryonic fibroblasts endogenous Rho activity is present at the rear of migrating cells but also at the leading edge, whereas it is undetectable at the cell front of G alpha(12/13)-deficient mouse embryonic fibroblasts. Spatial activation of Rho at the wound edge can be stimulated by lysophosphatidic acid. Active Rho colocalizes with the diaphanous- related formin Dia1 at the cell front. G alpha(12/13)-deficient cells lack Dia1 localization to the wound edge and are unable to form orientated, stable microtubules during wound healing. Knock down of Dia1 reveals its requirement for microtubule stabilization as well as polarized cell migration. Thus, we identified G alpha(12/13)-proteins as essential components linking extracellular signals to localized Rho-Dia1 function during directed cell movement.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Grosse, R (corresponding author), Univ Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	Robert.Grosse@urz.uni-heidelberg.de	Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805; Grosse, Robert/0000-0002-3380-5273				Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Berdeaux RL, 2004, J CELL BIOL, V166, P317, DOI 10.1083/jcb.200312168; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Dormann D, 2003, CURR OPIN GENET DEV, V13, P358, DOI 10.1016/S0959-437X(03)00087-X; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Magdalena J, 2003, J CELL SCI, V116, P743, DOI 10.1242/jcs.00288; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	40	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42242	42251		10.1074/jbc.M508690200	http://dx.doi.org/10.1074/jbc.M508690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251183	hybrid			2022-12-25	WOS:000233992700053
J	Ichijo, T; Voutetakis, A; Cotrim, AP; Bhattachryya, N; Fujii, M; Chrousos, GP; Kino, T				Ichijo, T; Voutetakis, A; Cotrim, AP; Bhattachryya, N; Fujii, M; Chrousos, GP; Kino, T			The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor - Potential clinical implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR; SMAD PROTEINS; STRESS HORMONES; COREPRESSOR; BONE; ACETYLATION; ACTIVATION; PROMOTER; BINDING	Glucocorticoids play pivotal roles in the maintenance of homeostasis but, when dysregulated, may also have deleterious effects. Smad6, one of the transforming growth factor beta ( TGF beta) family downstream transcription factors, interacts with the N-terminal domain of the glucocorticoid receptor ( GR) through its Mad homology 2 domain and suppresses GR-mediated transcriptional activity in vitro. Adenovirus-mediated Smad6 overexpression inhibits glucocorticoid action in rat liver in vivo, preventing dexamethasone-induced elevation of blood glucose levels and hepatic mRNA expression of phosphoenolpyruvate carboxykinase, a well known rate-limiting enzyme of liver gluconeogenesis. Smad6 suppresses GR-induced transactivation by attracting histone deacetylase 3 to DNA-bound GR and by antagonizing acetylation of histone H3 and H4 induced by p160 histone acetyltransferase. These results indicate that Smad6 regulates glucocorticoid actions as a corepressor of the GR. From our results and known cross-talks between glucocorticoids and TGF beta family molecules, it appears that the anti-glucocorticoid actions of Smad6 may contribute to the neuroprotective, anticatabolic and pro-wound healing properties of the TGF beta family of proteins.	NICHD, Reprod Biol & Med Branch, Pediat Endocrinol Sect, NIH,Clin Res Ctr, Bethesda, MD 20892 USA; NIDCR, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Growth & Dev Sect, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Athens, Sch Med, Dept Pediat 1, GR-11527 Athens, Greece	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Athens Medical School; National & Kapodistrian University of Athens	Kino, T (corresponding author), NICHD, Reprod Biol & Med Branch, Pediat Endocrinol Sect, NIH,Clin Res Ctr, Bldg 10,Rm 1-3140,10 Ctr Dr MSC 1109, Bethesda, MD 20892 USA.	kinot@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618, ZIAHD008732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000618, Z01HD008732] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Charmandari E, 2005, J CLIN ENDOCR METAB, V90, P3696, DOI 10.1210/jc.2004-1920; Charmandari E, 2004, ANN NY ACAD SCI, V1024, P168, DOI 10.1196/annals.1321.014; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Chrousos G.P., 2001, ENDOCRINOLOGY METABO, V4th ed., P609; Chrousos GP, 2004, AM J MED, V117, P204, DOI 10.1016/j.amjmed.2004.05.006; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; Franchimont D, 2002, NEUROIMMUNOMODULAT, V10, P247, DOI 10.1159/000069969; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall AK, 2004, J NEUROSCI RES, V76, P1, DOI 10.1002/jnr.20019; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Kino T, 2005, J CELL BIOL, V169, P885, DOI 10.1083/jcb.200409150; Kino T, 2005, J VIROL, V79, P2780, DOI 10.1128/JVI.79.5.2780-2787.2005; Kino T, 2004, ESSAYS BIOCHEM, V40, P137, DOI 10.1042/bse0400137; Kino T, 2003, J STEROID BIOCHEM, V85, P457, DOI 10.1016/S0960-0760(03)00218-8; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; KINO T, 2004, HDB STRESS BRAIN 1, P295; Kintscher U, 2002, CIRC RES, V91, pE35, DOI 10.1161/01.RES.0000046017.96083.34; Knight PG, 1996, FRONT NEUROENDOCRIN, V17, P476, DOI 10.1006/frne.1996.0013; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; Leal AMO, 2003, NEUROENDOCRINOLOGY, V77, P298, DOI 10.1159/000070896; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Liu YS, 2004, BONE, V35, P673, DOI 10.1016/j.bone.2004.04.017; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mirani M, 2002, J IMMUNOL, V169, P6361, DOI 10.4049/jimmunol.169.11.6361; Miyazono K, 2000, J CELL SCI, V113, P1101; Nowak G, 1996, AM J PHYSIOL-RENAL, V271, pF689, DOI 10.1152/ajprenal.1996.271.3.F689; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Sanyal S, 2004, NEURON, V41, P845, DOI 10.1016/S0896-6273(04)00152-7; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shimasaki S, 2003, REPRODUCTION, P323; Shukla A, 1999, WOUND REPAIR REGEN, V7, P133, DOI 10.1046/j.1524-475X.1999.00133.x; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Wang Q, 2004, MOL ENDOCRINOL, V18, P1376, DOI 10.1210/me.2003-0421; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	61	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42067	42077		10.1074/jbc.M509338200	http://dx.doi.org/10.1074/jbc.M509338200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16249187	hybrid			2022-12-25	WOS:000233992700033
J	Sims, RJ; Chen, CF; Santos-Rosa, H; Kouzarides, T; Patel, SS; Reinberg, D				Sims, RJ; Chen, CF; Santos-Rosa, H; Kouzarides, T; Patel, SS; Reinberg, D			Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTORS; DNA-BINDING; CHROMATIN; DOMAIN; TAIL; METHYLTRANSFERASE; TRANSCRIPTION; ASSOCIATION; INTERACTS; PATTERNS	Defining the protein factors that directly recognize post-translational, covalent histone modifications is essential toward understanding the impact of these chromatin "marks" on gene regulation. In the current study, we identify human CHD1, an ATP-dependent chromatin remodeling protein, as a factor that directly and selectively recognizes histone H3 methylated on lysine 4. In vitro binding studies identified that CHD1 recognizes di- and trimethyl H3K4 with a dissociation constant (K-d) of similar to 5 mu M, whereas monomethyl H3K4 binds CHD1 with a 3-fold lower affinity. Surprisingly, human CHD1 binds to methylated H3K4 in a manner that requires both of its tandem chromodomains. In vitro analyses demonstrate that unlike human CHD1, yeast Chd1 does not bind methylated H3K4. Our findings indicate that yeast and human CHD1 have diverged in their ability to discriminate covalently modified histones and link histone modification-recognition and non-covalent chromatin remodeling activities within a single human protein.	Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem, Piscataway, NJ 08854 USA; Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids Enzymol, Piscataway, NJ 08854 USA; Univ Cambridge, Dept Pathol, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Cambridge	Reinberg, D (corresponding author), Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem, 683 Hoes Lane, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Kouzarides, Tony/0000-0002-8918-4162; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071166, R01GM037120, R01GM051966, R37GM037120, R37GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM037120, GM-51966, F32 GM071166-02, R01 GM037120, F32 GM071166, GM-71166, GM-37120, R01 GM051966, R37 GM051966, F32 GM071166-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Kelley DE, 1999, CHROMOSOMA, V108, P10, DOI 10.1007/s004120050347; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	24	291	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41789	41792		10.1074/jbc.C500395200	http://dx.doi.org/10.1074/jbc.C500395200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16263726	hybrid, Green Accepted			2022-12-25	WOS:000233992700003
J	Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L				Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L			Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas	ONCOGENE			English	Article						T-cell lymphoma; gene expression profiling; microarray	DNA MICROARRAYS; KAPPA-B; CLASSIFICATION; PREDICTION; SURVIVAL; PROTEIN; DISTINCT; LINES; OVEREXPRESSION; CHEMOTHERAPY	The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate. To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL). The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL. In contrast, cases belonging to the broad category of 'PTCL, unspecified' (PTCL-U) did not share a single molecular pro. le. Using a multiclass predictor, we could separate PTCL-U into three molecular subgroups called U1, U2 and U3. The U1 gene expression signature included genes known to be associated with poor outcome in other tumors, such as CCND2. The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2. The U3 subgroup was mainly defined by overexpression of genes involved in the IFN/JAK/STAT pathway. It comprised a majority of histiocyte-rich PTCL samples. Gene Ontology annotations revealed different functional pro. le for each subgroup. These results suggest the existence of distinct subtypes of PTCL-U with specific molecular profiles, and thus provide a basis to improve their classification and to develop new therapeutic targets.	Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France; INSERM, TAGC, ERM206, Marseille, France; Univ Mediterranee, Marseille, France; CHU St Louis, Dept Hematopathol, Paris, France; Hop St Louis, Inst Hematol, Grp Etud Lymphomes Adulte, F-75010 Paris, France; Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; CHU Purpan, Dept Pathol, F-31052 Toulouse, France; CHU Lyon, Dept Pathol, Lyon, France; CHU Lyon, Dept Hematol, Lyon, France; Hop Henri Mondor, Dept Pathol, INSERM U 617, AP HP, F-94010 Creteil, France	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); CHU de Toulouse; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Xerri, L (corresponding author), Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France.	xerril@marseille.fnclcc.fr	Salles, Gilles/Z-2336-2019; Doucet, Gaelle/H-9367-2019; loriod, beatrice/L-2948-2016; Ballester, Benoit/N-6127-2016	Salles, Gilles/0000-0002-9541-8666; Doucet, Gaelle/0000-0003-4120-0474; gaulard, philippe/0000-0002-4243-905X; loriod, beatrice/0000-0001-5801-2264; Ballester, Benoit/0000-0002-0834-7135				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan WC, 1997, BLOOD, V89, P3909; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Dogan A, 2003, BRIT J HAEMATOL, V121, P681, DOI 10.1046/j.1365-2141.2003.04335.x; Fillmore GC, 2002, FEBS LETT, V522, P183, DOI 10.1016/S0014-5793(02)02914-9; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Gisselbrecht C, 1998, BLOOD, V92, P76; HARRIS NL, 1994, BLOOD, V84, P1361; Hiroi M, 2003, BIOCHEM J, V376, P393, DOI 10.1042/BJ20030842; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hisaoka M, 2004, CANCER GENET CYTOGEN, V152, P101, DOI 10.1016/j.cancergencyto.2003.11.011; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kagami Y, 1999, AM J SURG PATHOL, V23, P1184, DOI 10.1097/00000478-199910000-00003; Kari L, 2003, J EXP MED, V197, P1477, DOI 10.1084/jem.20021726; Li SY, 2001, AM J PATHOL, V158, P1231, DOI 10.1016/S0002-9440(10)64073-4; Lopez F, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-38; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Martinez-Delgado B, 2004, CLIN CANCER RES, V10, P4971, DOI 10.1158/1078-0432.CCR-04-0269; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Petit B, 2001, HUM PATHOL, V32, P196, DOI 10.1053/hupa.2001.21569; Pinet F, 2004, FASEB J, V18, P585, DOI 10.1096/fj.03-0939fje; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Rassidakis GZ, 2003, J PATHOL, V200, P240, DOI 10.1002/path.1346; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160; Tracey L, 2003, BLOOD, V102, P1042, DOI 10.1182/blood-2002-11-3574; Tsuchiya T, 2004, BLOOD, V103, P236, DOI 10.1182/blood-2002-05-1352; Villalva C, 2002, BRIT J HAEMATOL, V118, P791, DOI 10.1046/j.1365-2141.2002.03671.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	95	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1560	1570		10.1038/sj.onc.1209178	http://dx.doi.org/10.1038/sj.onc.1209178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16288225				2022-12-25	WOS:000235890400013
J	Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M				Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M			Chromosomal instability at a mutational hotspot in polyoma middle T-antigen affects its ability to activate the ARF-p53 tumor suppressor pathway	ONCOGENE			English	Article						ARF; p53; polyoma virus middle T-antigen; REF52 cells; chromosomal instability; hot spot mutations	FRAMESHIFT MUTATION; REF52 CELLS; P53; TRANSFORMATION; ONCOGENES; GROWTH; MECHANISMS; PROTEINS; MUTANTS; ARREST	We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activate the ARF-p53 pathway based on their inability to block REF52 cell division. The REF52 cells containing these mutants have a. at untransformed morphological phenotype and do not express the ARF protein. The PyMT mutations in the different cell isolates so far analysed occur at a mutational hotspot in the PyMT sequence between nucleotides 1241 and 1249, which contains nine consecutive cytosines. In one set of mutants a single cytosine was deleted, while in another mutant set an additional cytosine was inserted. Both these mutations result in frameshifts, generating altered PyMT proteins containing amino-acid sequences derived from each of the two other alternative reading frames of the polyoma virus early region. Both types of mutations result in the loss of the C-terminal PyMT region containing the membrane-binding hydrophobic region and result is mislocalization of the PyMT mutant proteins. Revertant wild-type PyMT ( containing nine cytosines) was easily detected in transformants generated after infection of REF52 cells expressing high amounts of dominant negative p53 with retroviruses containing either mutation. We demonstrate that wild-type PyMT revertants are derived from mutations in the hotspot sequence of the integrated mutant PyMT sequences.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Fried, M (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.	fried@cc.ucsf.edu		Moule, Madeleine/0000-0002-9612-4563	NCI NIH HHS [CA92454, CA101967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101967, R01CA092454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; KOHL NE, 1987, ONCOGENE, V2, P41; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCLURE DB, 1984, EFFECT SY40 TRANSFOR; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; RAGOZZINO MM, 1991, ENVIRON HEALTH PERSP, V93, P97, DOI 10.1289/ehp.919397; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Steele RJC, 1998, BRIT J SURG, V85, P1460; Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6; STREISINGER G, 1985, GENETICS, V109, P633; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; WILSON JB, 1986, CELL, V44, P477, DOI 10.1016/0092-8674(86)90469-1	30	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1454	1462		10.1038/sj.onc.1209197	http://dx.doi.org/10.1038/sj.onc.1209197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261156				2022-12-25	WOS:000235890400003
J	Bettenbrock, K; Fischer, S; Kremling, A; Jahreis, K; Sauter, T; Gilles, ED				Bettenbrock, K; Fischer, S; Kremling, A; Jahreis, K; Sauter, T; Gilles, ED			A quantitative approach to catabolite repression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE-DEPENDENT PHOSPHOTRANSFERASE; METABOLIC REACTION NETWORKS; CAMP RECEPTOR PROTEIN; GLUCOSE-TRANSPORTER; INDUCER EXCLUSION; SIGNAL-TRANSDUCTION; DIAUXIC GROWTH; MAJOR GLUCOSE; PTS; MLC	A dynamic mathematical model was developed to describe the uptake of various carbohydrates ( glucose, lactose, glycerol, sucrose, and galactose) in Escherichia coli. For validation a number of isogenic strains with defined mutations were used. By considering metabolic reactions as well as signal transduction processes influencing the relevant pathways, we were able to describe quantitatively the phenomenon of catabolite repression in E. coli. We verified model predictions by measuring time courses of several extra-and intracellular components such as glycolytic intermediates, EII-A(Crr) phosphorylation level, both LacZ and PtsG concentrations, and total cAMP concentrations under various growth conditions. The entire data base consists of 18 experiments performed with nine different strains. The model describes the expression of 17 key enzymes, 38 enzymatic reactions, and the dynamic behavior of more than 50 metabolites. The different phenomena affecting the phosphorylation level of EIIA(Crr), the key regulation molecule for inducer exclusion and catabolite repression in enteric bacteria, can now be explained quantitatively.	Max Planck Inst Dynam Komplexer Tech Syst, Syst Biol Grp, D-39106 Magdeburg, Germany; Univ Osnabruck, AG Genet, D-49069 Osnabruck, Germany	Max Planck Society; University Osnabruck	Bettenbrock, K (corresponding author), Max Planck Inst Dynam Komplexer Tech Syst, Syst Biol Grp, Sandtorstr 1, D-39106 Magdeburg, Germany.	bettenbrock@mpi-magdeburg.mpg.de	Bettenbrock, Katja/AAN-5812-2020	Sauter, Thomas/0000-0001-8225-2954				BERGMEYER HV, 1979, METHODEN ENZYMATISCH; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; BUHR A, 1992, J BIOL CHEM, V267, P3847; Chassagnole C, 2002, BIOTECHNOL BIOENG, V79, P53, DOI 10.1002/bit.10288; Covert MW, 2002, J BIOL CHEM, V277, P28058, DOI 10.1074/jbc.M201691200; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; Ginkel M, 2003, BIOINFORMATICS, V19, P1169, DOI 10.1093/bioinformatics/btg128; Hochhut B, 1997, J BACTERIOL, V179, P2097, DOI 10.1128/jb.179.7.2097-2102.1997; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; Holtman CK, 2001, J BACTERIOL, V183, P3336, DOI 10.1128/JB.183.11.3336-3344.2001; Inada T, 1996, GENES CELLS, V1, P293, DOI 10.1046/j.1365-2443.1996.24025.x; Inada T, 1996, MOL GEN GENET, V253, P198, DOI 10.1007/s004380050313; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kremling A, 2004, BIOSYSTEMS, V73, P57, DOI 10.1016/j.biosystems.2003.09.001; Kremling A, 2001, METAB ENG, V3, P362, DOI 10.1006/mben.2001.0199; Kremling A, 2001, METAB ENG, V3, P138, DOI 10.1006/mben.2000.0175; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PARDEE AB, 1961, BIOCHIM BIOPHYS ACTA, V49, P77, DOI 10.1016/0006-3002(61)90871-X; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REPHAELI AW, 1980, J BACTERIOL, V141, P658, DOI 10.1128/JB.141.2.658-663.1980; ROEHL RA, 1980, J BACTERIOL, V142, P120, DOI 10.1128/JB.142.1.120-130.1980; Rohwer JM, 1998, MOL MICROBIOL, V29, P641, DOI 10.1046/j.1365-2958.1998.00963.x; Sauter T, 2004, J BIOTECHNOL, V110, P181, DOI 10.1016/j.jbiotec.2004.02.002; SCHMID K, 1988, MOL MICROBIOL, V2, P1, DOI 10.1111/j.1365-2958.1988.tb00001.x; Seitz S, 2003, J BIOL CHEM, V278, P10744, DOI 10.1074/jbc.M212066200; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Wong P, 1997, BIOTECHNOL PROGR, V13, P132, DOI 10.1021/bp970003o; Zeppenfeld T, 2000, J BACTERIOL, V182, P4443, DOI 10.1128/JB.182.16.4443-4452.2000	41	105	106	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2578	2584		10.1074/jbc.M508090200	http://dx.doi.org/10.1074/jbc.M508090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16263707	hybrid			2022-12-25	WOS:000234931800021
J	Banci, L; Bertini, I; Cantini, F; D'Amelio, N; Gaggelli, E				Banci, L; Bertini, I; Cantini, F; D'Amelio, N; Gaggelli, E			Human SOD1 before harboring the catalytic metal - Solution structure of copper-depleted, disulfide-reduced form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC SUPEROXIDE-DISMUTASE; TORSION ANGLE DYNAMICS; RECOMBINANT HUMAN; PROTEIN NMR; MUTANTS; CHAPERONE; APO	SOD1 has to undergo several post-translational modifications before reaching its mature form. The protein requires insertion of zinc and copper atoms, followed by the formation of a conserved S-S bond between Cys-57 and Cys-146 (human numbering), which makes the protein fully active. In this report an NMR structural investigation of the reduced SH-SH form of thermostable E, Zn-as-SOD1 (E is empty; as is C6A, C111S) is reported, characterizing the protein just before the last step leading to the mature form. The structure is compared with that of the oxidized S-S form as well as with that of the yeast SOD1 complexed with its copper chaperone, CCS. Local conformational rearrangements upon disulfide bridge reduction are localized in the region near Cys-57 that is completely exposed to the solvent in the present structure, at variance with the oxidized forms. There is a local disorder around Cys-57 that may serve for protein-protein recognition and may possibly be involved in intermolecular S-S bonds in familial amyotrophic lateral sclerosis-related SOD1 mutants. The structure allows us to further discuss the copper loading mechanism in SOD1.	Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy	University of Florence; University of Florence; University of Siena	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via Luigi Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Cantini, Francesca/O-1220-2015; D'Amelio, Nicola/AAJ-4369-2021	Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774; D'Amelio, Nicola/0000-0002-4400-2222				Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Banci L, 1999, J BIOL INORG CHEM, V4, P795, DOI 10.1007/s007750050353; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2005, J BIOL CHEM, V280, P35815, DOI 10.1074/jbc.M506637200; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; BANCI L, 1992, J AM CHEM SOC, V114, P6994, DOI 10.1021/ja00044a007; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Banci L, 1999, BIOSPECTROSCOPY, V5, pS33, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S33::AID-BSPY4>3.0.CO;2-E; BANCI L, 1988, J AM CHEM SOC, V110, P3629, DOI 10.1021/ja00219a043; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hart PJ, 1998, PROTEIN SCI, V7, P545; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Keller R., 2004, COMPUTER AIDED RESON, V1; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Pearlman DA, 1997, AMBER 5 0; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; VALENTINE JS, 2004, ANN REV BIOCH; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197	44	66	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2333	2337		10.1074/jbc.M506497200	http://dx.doi.org/10.1074/jbc.M506497200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16291742	hybrid			2022-12-25	WOS:000234760400058
J	Lin, YW; Yang, JL				Lin, YW; Yang, JL			Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; DUAL-SPECIFICITY PHOSPHATASE; MAP KINASE; UBIQUITIN LIGASE; CELL-CYCLE; TRANSDUCTION PATHWAYS; CATALYTIC ACTIVATION; TYROSINE-PHOSPHATASE; SUSTAINED ACTIVATION	The dual-specificity MAPK phosphatase MKP-1/CL100/DUSP1 is an inducible nuclear protein controlled by p44/42 MAPK (ERK1/2) in a negative feedback mechanism to inhibit kinase activity. Here, we report on the molecular basis for a novel positive feedback mechanism to sustain ERK activation by triggering MKP-1 proteolysis. Active ERK2 docking to the DEF motif (FXFP, residues 339-342) of N-terminally truncated MKP-1 in vitro initiated phosphorylation at the Ser(296)/Ser(323) domain, which was not affected by substituting Ala for Ser at Ser(359)/Ser(364). The DEF and Ser(296)/Ser(323) sites were essential for ubiquitin-mediated MKP-1 proteolysis stimulated by MKK1-ERK signaling in H293 cells, whereas the N-terminal domain and Ser(359)/Ser(364) sites were dispensable. ERK activation by serum increased the endogenous level of ubiquitinated phospho- Ser(296) MKP-1 and the degradation of MKP-1. Intriguingly, active ERK-promoted phospho-Ser(296) MKP-1 bound to SCFSkp2 ubiquitin ligase in vivo and in vitro. Forced expression of Skp2 enhanced MKP-1 polyubiquitination and proteolysis upon ERK activation, whereas depletion of endogenous Skp2 suppressed such events. The kinetics of ERK signaling stimulated by serum correlated with the endogenous MKP-1 degradation rate in a Skp2-dependent manner. Thus, MKP-1 proteolysis can be achieved via ERK and SCFSkp2 cooperation, thereby sustaining ERK activation.	Natl Tsing Hua Univ, Inst Biotechnol, Mol Carcinogenesis Lab, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Tsing Hua University; National Tsing Hua University	Yang, JL (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Mol Carcinogenesis Lab, Hsinchu 300, Taiwan.	jlyang@life.nthu.edu.tw						Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1992, ONCOGENE, V7, P187; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Gioeli D, 1999, CANCER RES, V59, P279; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hutter D, 2002, MOL CELL BIOCHEM, V233, P107, DOI 10.1023/A:1015502226940; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin YW, 2003, J BIOL CHEM, V278, P21534, DOI 10.1074/jbc.M301854200; Lin YW, 2003, CARCINOGENESIS, V24, P53, DOI 10.1093/carcin/24.1.53; Manzano RG, 2002, ONCOGENE, V21, P4435, DOI 10.1038/sj.onc.1205542; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Muda M, 1996, J BIOL CHEM, V271, P4319; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	52	112	113	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					915	926		10.1074/jbc.M508720200	http://dx.doi.org/10.1074/jbc.M508720200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286470	hybrid			2022-12-25	WOS:000234447200030
J	Shibata, T; Iio, K; Kawai, Y; Shibata, N; Kawaguchi, M; Toi, S; Kobayashi, M; Kobayashi, M; Yamamoto, K; Uchida, K				Shibata, T; Iio, K; Kawai, Y; Shibata, N; Kawaguchi, M; Toi, S; Kobayashi, M; Kobayashi, M; Yamamoto, K; Uchida, K			Identification of a lipid peroxidation product as a potential trigger of the p53 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR-SUPPRESSOR; C-MYC; INDUCED APOPTOSIS; PROTEIN; ATM; 2'-DEOXYCYTIDINE; EXPRESSION; MUTATIONS; INDUCTION	The tumor suppressor and transcription factor p53 is a key modulator of cellular stress responses, and activation of p53 can trigger apoptosis in many cell types, including neurons. We found that this nuclear protein was significantly phosphorylated when human neuroblastoma SH-SY5Y cells were exposed to in vitro oxidized polyunsaturated fatty acids. To identify an oxidized lipid that induces p53 phosphorylation, we conducted a screening of lipid peroxidation products in human neuroblastoma SH-SY5Y cells and identified 4-oxo-2-nonenal (ONE), a recently identified aldehyde originating from the peroxidation of omega 6 polyunsaturated fatty acids, as a potential inducer of the p53 phosphorylation. We also found that ONE induced the phosphorylation of ataxia telangiectasia-mutated, which plays an essential role in transmitting DNA damage signals by the phosphorylation of p53. In addition, exposure of the cells to ONE resulted in an accumulation of ubiquitinated proteins and in a significant inhibition of proteasome activities, suggesting that ONE acted on the ubiquitin-proteasome pathway, a regulatory mechanism of p53 turnover. In addition, the observation that the ONE-induced p53 response was associated with the induction of apoptosis suggested that ONE activated the p53-dependent apoptosis mechanism via activation of the p53 signaling pathway and down-regulation of the p53 turnover. Finally, we observed that the ONE-2'-deoxyguanosine adduct, 7-(2-oxo-heptyl)-substituted 1,N-2-etheno-2'-deoxyguanosine, was accumulated in the spinal cord motor neurons of patients with sporadic amyotrophic lateral sclerosis. These data may suggest the potential critical role for ONE in the induction of a neuronal apoptosis program during oxidative processes.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Univ Tokushima, Grad Sch Nutr & Biosci, Tokushima 7708503, Japan; Tokyo Womens Med Univ, Neurol Inst, Tokyo 1628666, Japan; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan	Nagoya University; Tokushima University; Tokyo Women's Medical University; Kanazawa University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	Kawai, Yoshichika/G-3231-2011; Shibata, Takahiro/I-6872-2014	Shibata, Takahiro/0000-0003-3194-607X; Uchida, Koji/0000-0003-3894-5299				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Brown JM, 1999, CANCER RES, V59, P1391; BUNZ F, 1976, J BIOL CHEM, V251, P6550; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; de la Monte SM, 1998, LAB INVEST, V78, P401; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EL DW, 1993, CELL, V75, P817; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; HECHT SS, 1992, CHEM RES TOXICOL, V5, P706, DOI 10.1021/tx00029a018; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Kamada K, 2004, FREE RADICAL BIO MED, V37, P1875, DOI 10.1016/j.freeradbiomed.2004.09.002; Kawai Y, 2004, J BIOL CHEM, V279, P51241, DOI 10.1074/jbc.M408210200; Kawai Y, 2004, FREE RADICAL BIO MED, V36, P529, DOI 10.1016/j.freeradbiomed.2003.12.006; Kawai Y, 2002, CARCINOGENESIS, V23, P485, DOI 10.1093/carcin/23.3.485; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; Lin D, 2005, CHEM RES TOXICOL, V18, P1219, DOI 10.1021/tx050080q; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Morrison RS, 1996, J NEUROSCI, V16, P1337; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VOGAN K, 1993, CANCER RES, V53, P5269; West JD, 2004, CHEM RES TOXICOL, V17, P453, DOI 10.1021/tx034248o	51	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1196	1204		10.1074/jbc.M509065200	http://dx.doi.org/10.1074/jbc.M509065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16251187	hybrid			2022-12-25	WOS:000234447200062
J	Amsen, EM; Pham, N; Pak, Y; Rotin, D				Amsen, EM; Pham, N; Pak, Y; Rotin, D			The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; CYCLIC-AMP; HUMAN MELANOCYTES; ACTIVATES RAS; CAMP; MICROPHTHALMIA; APOPTOSIS; RAP1; DIFFERENTIATION; GENERATION	cAMP- dependent Ras activation has been demonstrated in numerous cell types, particularly of neuronal ( including melanoma cells) and endocrine origin, but the Ras activator involved has not been identified. In B16 melanoma cells, cAMPactivates the Ras/ Erk pathway, leading initially to stimulation but subsequently to long term (> 24- h) inhibition of melanogenesis ( dendrite extension and melanin production). Here we identify CNrasGEF as the Ras guanine nucleotide exchange factor ( GEF) involved. We demonstrate that CNrasGEF is expressed endogenously in B16 melanoma cells and that cAMP- mediated activation of Ras and Erk1/ 2 in these cells can be augmented by CNrasGEF overexpression and reduced by its knockdown by RNA interference. Moreover, we show that CNrasGEF participates in the regulation of melanogenesis. Knockdown of CNrasGEF leads to increased dendrite extension and melanin production observed similar to 50 h after forskolin/ isobutylmethylxanthine treatment, suggesting that CNrasGEF inhibits melanogenesis in the long term. Independently, we find that overexpression of CNrasGEF leads to apoptosis, whereas its knockdown by RNAi enhances cell proliferation, independent of cAMP. Collectively, these results suggest that CNrasGEF regulates melanogenesis but that it also has a distinct role in regulating cell proliferation/ apoptosis.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.ca		Amsen, Eva/0000-0003-0920-415X				Ando H, 1999, J LIPID RES, V40, P1312; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; BUSCA R, 2002, MECH SUNTANNING, P169; Cheng GJ, 2003, MOL ENDOCRINOL, V17, P450, DOI 10.1210/me.2002-0344; CILLO C, 1987, CANCER RES, V47, P2604; Cullen KA, 2004, AM J PHYSIOL-GASTR L, V287, pG334, DOI 10.1152/ajpgi.00517.2003; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DROOIJ J, 1997, ONCOGENE, V14, P623; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HILL RP, 1984, SCIENCE, V224, P998, DOI 10.1126/science.6719130; HILL SE, 1990, CLIN EXP METASTAS, V8, P475, DOI 10.1007/BF00058157; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1994, J CELL SCI, V107, P205; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Motulsky H., 1995, INTUITIVE BIOSTATIST, P11; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Saavedra AP, 2002, ONCOGENE, V21, P778, DOI 10.1038/sj.onc.1205123; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Stinchcombe J, 2004, SCIENCE, V305, P55, DOI 10.1126/science.1095291; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803	35	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					121	128		10.1074/jbc.M507595200	http://dx.doi.org/10.1074/jbc.M507595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16272156	hybrid			2022-12-25	WOS:000234307200018
J	Papanikou, E; Karamanou, S; Baud, C; Frank, M; Sianidis, G; Keramisanou, D; Kalodimos, CG; Kuhn, A; Economou, A				Papanikou, E; Karamanou, S; Baud, C; Frank, M; Sianidis, G; Keramisanou, D; Kalodimos, CG; Kuhn, A; Economou, A			Identification of the preprotein binding domain of SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA HELICASE ACTIVITY; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; SIGNAL-SEQUENCE; PRESECRETORY PROTEINS; CYTOPLASMIC MEMBRANE; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURES; MATURE SEQUENCE	SecA, the preprotein translocase ATPase, has a helicase DEAD motor. To catalyze protein translocation, SecA possesses two additional flexible domains absent from other helicases. Here we demonstrate that one of these "specificity domains" is a preprotein binding domain (PBD). PBD is essential for viability and protein translocation. PBD mutations do not abrogate the basal enzymatic properties of SecA ( nucleotide binding and hydrolysis), nor do they prevent SecA binding to the SecYEG protein conducting channel. However, SecA PBD mutants fail to load preproteins onto SecYEG, and their translocation ATPase activity does not become stimulated by preproteins. Bulb and Stem, the two sterically proximal PBD substructures, are physically separable and have distinct roles. Stem binds signal peptides, whereas the Bulb binds mature preprotein regions as short as 25 amino acids. Binding of signal or mature region peptides or full-length preproteins causes distinct conformational changes to PBD and to the DEAD motor. We propose that (a) PBD is a preprotein receptor and a physical bridge connecting bound preproteins to the DEAD motor, and (b) preproteins control the ATPase cycle via PBD.	FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece; Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA; Univ Hohenheim, Inst Microbiol & Mol Biol, D-70593 Stuttgart, Germany	Foundation for Research & Technology - Hellas (FORTH); University of Crete; Rutgers State University Newark; Rutgers State University New Brunswick; University Hohenheim	Economou, A (corresponding author), FORTH, Inst Mol Biol & Biotechnol, POB 1527, GR-71110 Iraklion, Crete, Greece.	aeconomo@imbb.forth.gr	Economou, Anastassios/P-8292-2017; Kalodimos, Charalampos/Q-9846-2018; Kalodimos, Charalampos/C-5380-2008; Karamanou, Spyridoula/H-7485-2018	Economou, Anastassios/0000-0002-1770-507X; Kalodimos, Charalampos/0000-0001-6354-2796; Karamanou, Spyridoula/0000-0002-8803-1404; Baud, Catherine/0000-0002-0816-9092				ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; Baud C, 2005, PROTEIN EXPRES PURIF, V40, P336, DOI 10.1016/j.pep.2004.12.009; Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chou YT, 2005, J BIOL CHEM, V280, P32753, DOI 10.1074/jbc.M507532200; Chou YT, 2002, J BIOL CHEM, V277, P50985, DOI 10.1074/jbc.M209237200; de Keyzer J, 2003, J BIOL CHEM, V278, P29581, DOI 10.1074/jbc.M303490200; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Fak JJ, 2004, BIOCHEMISTRY-US, V43, P7307, DOI 10.1021/BI0357208; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JAROSIK GP, 1991, J BACTERIOL, V173, P860, DOI 10.1128/jb.173.2.860-868.1991; Kajava AV, 2000, J BACTERIOL, V182, P2163, DOI 10.1128/JB.182.8.2163-2169.2000; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Khatib K, 2002, GENETICS, V162, P1031; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Matsumoto G, 2000, GENES CELLS, V5, P991, DOI 10.1046/j.1365-2443.2000.00388.x; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; Millman JS, 1999, J BIOL CHEM, V274, P33227, DOI 10.1074/jbc.274.47.33227; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; Papanikou E, 2004, EMBO REP, V5, P807, DOI 10.1038/sj.embor.7400206; Park SK, 1997, BIOCHEM BIOPH RES CO, V235, P593, DOI 10.1006/bbrc.1997.6834; Randall LL, 2004, PROTEIN SCI, V13, P1124, DOI 10.1110/ps.03410104; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Roos T, 2001, J BIOL CHEM, V276, P37909; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Vrontou E, 2004, J BIOL CHEM, V279, P22490, DOI 10.1074/jbc.M401008200; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	55	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43209	43217		10.1074/jbc.M509990200	http://dx.doi.org/10.1074/jbc.M509990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16243836	hybrid			2022-12-25	WOS:000234200800087
J	Bauerova-Zabranska, H; Stokrova, J; Strisovsky, K; Hunter, E; Ruml, T; Pichova, I				Bauerova-Zabranska, H; Stokrova, J; Strisovsky, K; Hunter, E; Ruml, T; Pichova, I			The RNA binding G-patch domain in retroviral protease is important for infectivity and D-type morphogenesis of Mason-Pfizer monkey virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING-RETENTION SIGNAL; 3 ACTIVE FORMS; ENDOGENOUS RETROVIRUS; ASPARTIC PROTEINASE; MAMMARY-TUMOR; IN-VITRO; GAG; REGION; IDENTIFICATION; POLYPEPTIDES	Retroviral proteases ( PRs) cleave the viral polyprotein precursors into functional mature proteins late during particle release and are essential for viral replication. Unlike most retroviruses, beta-retroviruses, including Mason-Pfizer monkey virus ( M-PMV), assemble immature capsids within the cytoplasm of the cell. The activation of beta-retroviral proteases must be highly regulated, because processing of the Gag-related polyprotein precursors occurs only after transport of immature capsids to the plasma membrane and budding. Several beta-retroviral proteases have unique C-terminal extension sequences, containing a glycine-rich motif ( G-patch), which specifically binds in vitro to single-stranded nucleic acids. In M-PMV PR the G-patch is removed in vitro as well as in vivo by autoproteolytic processing to yield truncated active forms of PR. To investigate the role of the G-patch domain on the virus life cycle, we introduced mutations within the C-terminal domain of protease. We found that the G-patch domain of M-PMV PR is not required for the processing of viral polyproteins, but it significantly influences the infectivity of M-PMV, the activity of reverse transcriptase, and assembly of immature capsid within the cells. These results demonstrate for the first time that the G-patch domain of M-PMV PR is critical for the life cycle of beta-retroviruses, and its evolutionary conservation within members of this genus suggests its importance for retroviruses that display D-type morphology.	Acad Sci Czech Republ, Inst Organ Chem & Biochem, Dept Prot Biochem, CR-16610 Prague, Czech Republic; Acad Sci Czech Republ, Ctr New Antivirals & Antineoplast, CR-16610 Prague, Czech Republic; Acad Sci Czech Republ, Inst Mol Genet, CR-16610 Prague, Czech Republic; Emory Univ, Emory Vaccine Ctr, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Inst Chem Technol, Dept Biochem & Microbiol, Prague 6, Czech Republic	Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Emory University; University of Chemistry & Technology, Prague	Pichova, I (corresponding author), Acad Sci Czech Republ, Inst Organ Chem & Biochem, Dept Prot Biochem, Flemingovo Nam 2, CR-16610 Prague, Czech Republic.	iva.pichova@uochb.cas.cz	Pichova, Iva/G-7917-2014; Strisovsky, Kvido/H-6284-2014; Zabranska, Helena/G-6218-2014; Ruml, Tomas/R-2543-2017	Strisovsky, Kvido/0000-0003-3677-0907; Ruml, Tomas/0000-0002-5698-4366				ANDREANSKY M, 1994, BIOTECHNIQUES, V16, P626; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; BRADAC JA, 1986, VIROLOGY, V150, P503, DOI 10.1016/0042-6822(86)90314-4; Choi G, 1999, J VIROL, V73, P5431, DOI 10.1128/JVI.73.7.5431-5437.1999; CHOPRA HC, 1970, CANCER RES, V30, P2081; Entin-Meer M, 2003, VIROLOGY, V310, P157, DOI 10.1016/S0042-6822(03)00113-2; Gifford R, 2005, J VIROL, V79, P6478, DOI 10.1128/JVI.79.10.6478-6486.2005; Guglielmi B, 2002, J BIOL CHEM, V277, P35712, DOI 10.1074/jbc.M205526200; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; Pichova I, 1998, ADV EXP MED BIOL, V436, P105; RHEE SS, 1990, CELL, V63, P77, DOI 10.1016/0092-8674(90)90289-Q; Sambrook J, 2001, MOL CLONING LAB MANU; Sfakianos JN, 2003, TRAFFIC, V4, P660, DOI 10.1034/j.1600-0854.2003.00125.x; Sfakianos JN, 2003, TRAFFIC, V4, P671, DOI 10.1034/j.1600-0854.2003.00126.x; Silverman EJ, 2004, MOL CELL BIOL, V24, P10101, DOI 10.1128/MCB.24.23.10101-10110.2004; Song CS, 2003, J VIROL, V77, P7779, DOI 10.1128/JVI.77.14.7779-7785.2003; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; Strisovsky K, 2002, ARCH BIOCHEM BIOPHYS, V398, P261, DOI 10.1006/abbi.2001.2728; Svec M, 2004, FEBS LETT, V576, P271, DOI 10.1016/j.febslet.2004.09.010; Towler EM, 1998, BIOCHEMISTRY-US, V37, P17137, DOI 10.1021/bi9818927; Veverka V, 2003, J MOL BIOL, V333, P771, DOI 10.1016/j.jmb.2003.08.049; Voisset C, 2003, J GEN VIROL, V84, P215, DOI 10.1099/vir.0.18670-0; Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8; Zabransky A, 1998, VIROLOGY, V245, P250, DOI 10.1006/viro.1998.9173; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	25	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42106	42112		10.1074/jbc.M508031200	http://dx.doi.org/10.1074/jbc.M508031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257973	hybrid			2022-12-25	WOS:000233992700037
J	Chanvorachote, P; Nimmannit, U; Wang, LY; Stehlik, C; Lu, B; Azad, N; Rojanasakul, Y				Chanvorachote, P; Nimmannit, U; Wang, LY; Stehlik, C; Lu, B; Azad, N; Rojanasakul, Y			Nitric oxide negatively regulates Fas CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; CELLULAR FLIP; SIGNALING PATHWAYS; WILD-TYPE; T-CELLS; DEATH; ACTIVATION; EXPRESSION	Stimulation of cell surface Fas ( CD95) results in recruitment of cytoplasmic proteins and activation of caspase-8, which in turn activates downstream effector caspases leading to programmed cell death. Nitric oxide ( NO) plays a key role in the regulation of apoptosis, but its role in Fas-induced cell death and the underlying mechanism are largely unknown. Here we show that stimulation of the Fas receptor by its ligand ( FasL) results in rapid generation of NO and concomitant decrease in cellular FLICE inhibitory protein ( FLIP) expression without significant effect on Fas and Fas-associated death domain ( FADD) adapter protein levels. FLIP down-regulation as well as caspase-8 activation and apoptosis induced by FasL were all inhibited by the NO-liberating agent sodium nitroprusside and dipropylenetriamine NONOate, whereas the NO synthase inhibitor aminoguanidine and NO scavenger 2-(4-carboxyphenyl)4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide ( PTIO) had opposite effects, indicating an anti-apoptotic role of NO in the Fas signaling process. FasL-induced down-regulation of FLIP is mediated by a ubiquitin-proteasome pathway that is negatively regulated by NO. S-nitrosylation of FLIP is an important mechanism rendering FLIP resistant to ubiquitination and proteasomal degradation by FasL. Deletion analysis shows that the caspase-like domain of FLIP is a key target for S-nitrosylation by NO, and mutations of its cysteine 254 and cysteine 259 residues completely inhibit S-nitrosylation, leading to increased ubiquitination and proteasomal degradation of FLIP. These findings indicate a novel pathway for NO regulation of FLIP that provides a key mechanism for apoptosis regulation and a potential new target for intervention in death receptor-associated diseases.	Chulalongkorn Univ, Pharmaceut Technol Int Program, Bangkok 10330, Thailand; W Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA	Chulalongkorn University; West Virginia University; West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Nimmannit, U (corresponding author), Chulalongkorn Univ, Pharmaceut Technol Int Program, Bangkok 10330, Thailand.	ubonthip.n@chula.ac.th; yrojanasakul@hsc.wvu.edu	Stehlik, Christian/AAG-2132-2021	Stehlik, Christian/0000-0002-3782-2484; Rojanasakul, Yon/0000-0002-8839-6462; chanvorachote, pithi/0000-0002-3103-3249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL071545] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL071545] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Borutaite V, 2003, FREE RADICAL BIO MED, V35, P1457, DOI 10.1016/j.freeradbiomed.2003.08.003; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen QM, 2005, ENDOCRINOLOGY, V146, P808, DOI 10.1210/en.2004-0579; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; De Paepe ME, 2000, AM J PHYSIOL-LUNG C, V279, pL967, DOI 10.1152/ajplung.2000.279.5.L967; Dimmeler S, 1997, CIRC RES, V81, P970; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Estevez AG, 1998, J NEUROSCI, V18, P3708; Fine A, 1997, AM J PHYSIOL-LUNG C, V273, pL64, DOI 10.1152/ajplung.1997.273.1.L64; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; Hagimoto N, 1999, AM J RESP CELL MOL, V21, P436, DOI 10.1165/ajrcmb.21.3.3397; Hamann KJ, 1998, AM J RESP CELL MOL, V19, P537, DOI 10.1165/ajrcmb.19.4.3100; Heigold S, 2002, CARCINOGENESIS, V23, P929, DOI 10.1093/carcin/23.6.929; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Hsu HC, 2001, J CLIN IMMUNOL, V21, P1, DOI 10.1023/A:1006730112726; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jee BC, 2003, GYNECOL OBSTET INVES, V56, P143, DOI 10.1159/000073773; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Kolb JP, 2001, LEUKEMIA LYMPHOMA, V40, P243, DOI 10.3109/10428190109057923; Korkolopoulou P, 2004, UROLOGY, V63, P1198, DOI 10.1016/j.urology.2004.01.007; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Li CQ, 2004, CANCER RES, V64, P3022, DOI 10.1158/0008-5472.CAN-03-1880; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Lievremont JP, 1999, J BIOL CHEM, V274, P15466, DOI 10.1074/jbc.274.22.15466; Lu B, 2002, AM J PHYSIOL-CELL PH, V283, pC831, DOI 10.1152/ajpcell.00045.2002; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pae HO, 2004, MOL PHARMACOL, V66, P122, DOI 10.1124/mol.66.1.122; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka T, 2002, EUR RESPIR J, V20, P359, DOI 10.1183/09031936.02.00252602; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87; Yoon SJ, 2002, MOL REPROD DEV, V61, P504, DOI 10.1002/mrd.10033	63	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42044	42050		10.1074/jbc.M510080200	http://dx.doi.org/10.1074/jbc.M510080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16246840	hybrid, Green Submitted			2022-12-25	WOS:000233992700030
J	Zvara, A; Bencsik, P; Fodor, G; Csont, TS; Hackler, L; Dux, MR; Furst, S; Jancso, G; Puskas, LG; Ferdinandy, P				Zvara, A; Bencsik, P; Fodor, G; Csont, TS; Hackler, L; Dux, MR; Furst, S; Jancso, G; Puskas, LG; Ferdinandy, P			Capsaicin-sensitive sensory neurons regulate myocardial function and gene expression pattern of rat hearts: a DNA microarray study	FASEB JOURNAL			English	Article						transient receptor potential vanilloid receptor-1; matrix metalloproteinase-13; cytochrome P450; farnesyl-transferase; ApoB; GABA receptor	SYNTHASE-CONTAINING NEURONS; VANILLOID RECEPTOR TRPV1; NITRIC-OXIDE; SUBSTANCE-P; GUINEA-PIG; INDUCED DEPLETION; PEPTIDE; CHANNELS; NERVES; PEROXYNITRITE	We have previously shown that capsaicin-sensitive sensory nerves contribute to the regulation of normal cardiac function and to the development of cardiac adaptation to ischemic stress; however, the underlying molecular mechanisms remain unknown. Therefore, here we assessed cardiac functional alterations and relative gene expression changes by DNA microarray analysis of 6400 genes in rat hearts 7 days after the end of systemic capsaicin treatment protocol leading to selective sensory chemodenervation. Capsaicin pretreatment resulted in a cardiac dysfunction characterized by elevation of left ventricular end-diastolic pressure and led to altered expression of 80 genes of known function or homology to known sequences. Forty-seven genes exhibited significant up-regulation and 33 genes were down-regulated (changes ranged from -3.9 to +4.8fold). The expression changes of 10 selected genes were verified, and an additional 11 genes were examined by real-time quantitative PCR. This is the first demonstration that gene expression changes in the heart due to capsaicin pretreatment included vanilloid receptor-1 (capsaicin receptor), transient receptor potential protein, GABA receptor rho-3 subunit, 5-hydroxytryptamine 3 receptor B, neurokinin receptor 2, endothelial nitric oxide synthase, matrix metalloproteinase-13, cytochrome P450, farnesyl-transferase, ApoB, and leptin. None of the genes have been previously shown to be involved in the mechanism of the cardiac functional effects of sensory chemodenervation by capsaicin. We conclude that capsaicin-sensitive sensory nerves play a significant role in the regulation of a variety of neuronal and non-neuronal genes in the heart and possibly in other tissues as well.	Univ Szeged, Cardiovasc Res Grp, Dept Biochem, H-6720 Szeged, Hungary; Hungarian Acad Sci, Lab Funct Genom, Biol Res Ctr, Szeged, Hungary; Hungarian Acad Sci, Neuro Psychopharmacol Res Grp, Szeged, Hungary; Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, Budapest, Hungary; Univ Szeged, Dept Physiol, Szeged, Hungary	Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Academy of Sciences; Semmelweis University; Szeged University	Ferdinandy, P (corresponding author), Univ Szeged, Cardiovasc Res Grp, Dept Biochem, Dom Ter 9, H-6720 Szeged, Hungary.	peter@bioch.szote.u-szeged.hu	Ferdinandy, Péter/H-9181-2019	Bencsik, Peter/0000-0003-1936-6232				Benson CJ, 1999, CIRC RES, V84, P921; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cortright DN, 2004, EUR J BIOCHEM, V271, P1814, DOI 10.1111/j.1432-1033.2004.04082.x; Csonka C, 1999, CIRCULATION, V100, P2260, DOI 10.1161/01.CIR.100.22.2260; Csont T, 2003, EUR J PHARMACOL, V476, P107, DOI 10.1016/S0014-2999(03)02117-4; Csont T, 2002, AM J PHYSIOL-HEART C, V283, pH69, DOI 10.1152/ajpheart.00817.2001; Dvorakova M, 2001, HISTOCHEM CELL BIOL, V116, P223, DOI 10.1007/s004180100308; Ferdinandy P, 2000, CIRC RES, V87, P241, DOI 10.1161/01.RES.87.3.241; Ferdinandy P, 1997, N-S ARCH PHARMACOL, V356, P356, DOI 10.1007/PL00005062; Ferrer-Montiel A, 2004, EUR J BIOCHEM, V271, P1820, DOI 10.1111/j.1432-1033.2004.04083.x; FRANCOCERECEDA A, 1988, ACTA PHYSIOL SCAND, V133, P1; FRANCOCERECEDA A, 1987, PEPTIDES, V8, P399, DOI 10.1016/0196-9781(87)90117-3; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Hamashima H, 2001, NEUROSCI RES, V39, P133, DOI 10.1016/S0168-0102(00)00208-X; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hoover DB, 2000, JPN J PHARMACOL, V84, P367, DOI 10.1254/jjp.84.367; JANCSO G, 1992, EXP PHYSIOL, V77, P405, DOI 10.1113/expphysiol.1992.sp003603; JANCSO G, 1987, ACTA PHYSIOL HUNG, V69, P295; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; JANCSO G, 1985, NEUROSCI LETT, V59, P209, DOI 10.1016/0304-3940(85)90201-0; JANCSO N, 1968, PHARM PAIN, P33; Kadowaki K, 2004, MOL BRAIN RES, V125, P105, DOI 10.1016/j.molbrainres.2004.03.021; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Katona M, 2004, N-S ARCH PHARMACOL, V370, P436, DOI 10.1007/s00210-004-0985-7; KRUGER L, 1989, J COMP NEUROL, V280, P291, DOI 10.1002/cne.902800210; Labrakakis C, 2003, J PHYSIOL-LONDON, V549, P131, DOI 10.1113/jphysiol.2002.031963; Li YJ, 1996, EUR J PHARMACOL, V311, P163, DOI 10.1016/0014-2999(96)00426-8; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Loffler S, 2004, REGUL PEPTIDES, V122, P131, DOI 10.1016/j.regpep.2004.06.009; MAGGI CA, 1989, BRIT J PHARMACOL, V97, P103, DOI 10.1111/j.1476-5381.1989.tb11929.x; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nishio H, 2002, JPN J PHARMACOL, V89, P242, DOI 10.1254/jjp.89.242; Onody A, 2003, FEBS LETT, V536, P35, DOI 10.1016/S0014-5793(03)00006-1; Palotas A, 2004, NEUROCHEM RES, V29, P1563, DOI 10.1023/B:NERE.0000029570.57903.74; PAPKA RE, 1984, NEUROSCIENCE, V12, P1277, DOI 10.1016/0306-4522(84)90021-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; Puskas LG, 2002, BIOTECHNIQUES, V33, P898, DOI 10.2144/02334mt03; RANKIN AJ, 1990, REGUL PEPTIDES, V30, P65, DOI 10.1016/0167-0115(90)90048-2; REN K, 1995, NEUROSCIENCE, V65, P505, DOI 10.1016/0306-4522(94)00510-C; RITTER S, 1992, J COMP NEUROL, V318, P103, DOI 10.1002/cne.903180108; Robbins J, 2001, PHARMACOL THERAPEUT, V90, P1, DOI 10.1016/S0163-7258(01)00116-4; Slavikova J, 1997, NEUROCHEM RES, V22, P1013, DOI 10.1023/A:1022431011019; Sosunov AA, 1996, CELL TISSUE RES, V284, P19, DOI 10.1007/s004410050563; Szallasi A, 1995, BRAIN RES, V703, P175, DOI 10.1016/0006-8993(95)01094-7; Szallasi A, 2004, J MED CHEM, V47, P2717, DOI 10.1021/jm030560j; Szallasi A, 2002, LANCET NEUROL, V1, P167, DOI 10.1016/S1474-4422(02)00072-8; Tokuoka H, 2003, NEURON, V38, P521, DOI 10.1016/S0896-6273(03)00290-3; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Yamaguchi F, 2001, MOL BRAIN RES, V86, P189, DOI 10.1016/S0169-328X(00)00213-8; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zahner MR, 2003, J PHYSIOL-LONDON, V551, P515, DOI 10.1113/jphysiol.2003.048207	55	44	51	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					160	+		10.1096/fj.05-4060fje	http://dx.doi.org/10.1096/fj.05-4060fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16278290				2022-12-25	WOS:000234053100016
J	Zabell, APR; Schroff, AD; Bain, BE; Van Etten, RL; Wiest, O; Stauffacher, CV				Zabell, APR; Schroff, AD; Bain, BE; Van Etten, RL; Wiest, O; Stauffacher, CV			Crystal structure of the human B-form low molecular weight phosphotyrosyl phosphatase at 1.6-A resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACID-PHOSPHATASE; SUBSTRATE-SPECIFICITY; LIVER; PURIFICATION; ACTIVATION; ISOENZYMES; EXPRESSION; COMPLEXES; RESIDUES	The crystal structure of HPTP-B, a human isoenzyme of the low molecular weight phosphotyrosyl phosphatase (LMW PTPase) is reported here at a resolution of 1.6 angstrom. This high resolution structure of the second human LMW PTPase isoenzyme provides the opportunity to examine the structural basis of different substrate and inhibitor/activator responses. The crystal packing of HPTP-B positions a normally surface-exposed arginine in a position equivalent to the tyrosyl substrate. A comparison of all deposited crystallographic coordinates of these PTPases reveals three atomic positions within the active site cavity occupied by hydrogen bond donor or acceptor atoms on bound molecules, suggesting useful design elements for synthetic inhibitors. A selection of inhibitor and activator molecules as well as small molecule and peptide substrates were tested against each human isoenzyme. These results along with the crystal packing seen in HPTP-B suggest relevant sequence elements in the currently unknown target sequence.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Notre Dame; University of Notre Dame; Walther Cancer Institute	Stauffacher, CV (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	cstauffa@purdue.edu			NCI NIH HHS [CA23568, CA82673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BAXTER JH, 1985, ARCH BIOCHEM BIOPHYS, V239, P29, DOI 10.1016/0003-9861(85)90808-2; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CIRRI P, 1995, BBA-GEN SUBJECTS, V1243, P129, DOI 10.1016/0304-4165(94)00055-3; Dahlke MH, 2004, LEUKEMIA LYMPHOMA, V45, P229, DOI 10.1080/1042819031000151932; DAVIS JP, 1994, BIOCHEMISTRY-US, V33, P1278, DOI 10.1021/bi00171a031; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DISSING J, 1993, BIOCHIM BIOPHYS ACTA, V1162, P275, DOI 10.1016/0167-4838(93)90291-X; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FISHER DK, 1994, PHARMACEUT RES, V11, P759, DOI 10.1023/A:1018996817529; FUJIMOTO S, 1988, CHEM PHARM BULL, V36, P3020; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kishiyama A, 2000, ANAL CHEM, V72, P5431, DOI 10.1021/ac000547w; KLEBE G, 1993, PHILOS T R SOC A, V345, P37, DOI 10.1098/rsta.1993.0115; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN D, 2000, THESIS PURDUE U; Madhurantakam C, 2005, J BACTERIOL, V187, P2175, DOI 10.1128/JB.187.6.2175-2181.2005; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Miller DT, 2000, GENE, V243, P1, DOI 10.1016/S0378-1119(99)00553-3; MODESTI A, 1995, FEBS LETT, V375, P235, DOI 10.1016/0014-5793(95)01220-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; OSTANIN K, 1995, J BIOL CHEM, V270, P18491, DOI 10.1074/jbc.270.31.18491; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park EK, 2002, MOL CELL BIOL, V22, P3404, DOI 10.1128/MCB.22.10.3404-3414.2002; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Saeed A, 1999, J CHEM SOC PAKISTAN, V21, P311; SEGALAS I, 1995, FEBS LETT, V371, P171, DOI 10.1016/0014-5793(95)00844-Y; Stauffacher CV, 2000, PRINCIPLES OF MOLECULAR REGULATION, P323; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; Tabernero L, 1999, BIOCHEMISTRY-US, V38, P11651, DOI 10.1021/bi990381x; Thomas CL, 2002, BIOCHEMISTRY-US, V41, P15601, DOI 10.1021/bi0203740; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tsuzuki S, 2000, J AM CHEM SOC, V122, P11450, DOI 10.1021/ja001901a; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; Wang S, 2000, BIOCHEMISTRY-US, V39, P1234, DOI 10.1021/bi991515+; WO YYP, 1992, J BIOL CHEM, V267, P10856; Zabell APR, 2004, BIOORGAN MED CHEM, V12, P1867, DOI 10.1016/j.bmc.2004.01.042; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; Zhang ZY, 2003, ACCOUNTS CHEM RES, V36, P385, DOI 10.1021/ar020122r; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	60	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6520	6527		10.1074/jbc.M506285200	http://dx.doi.org/10.1074/jbc.M506285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16253994	hybrid			2022-12-25	WOS:000236030800047
J	Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH				Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH			The JAK2 V617F mutation in de novo acute myelogenous leukemias	ONCOGENE			English	Article						JAK2; acute myelogenous leukemia; mutation; cancer	TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; INHIBITOR	A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction - single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs)(2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Arteaga CL, 2002, SEMIN ONCOL, V29, P4, DOI 10.1053/sonc.2002.34047; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; DIEZMARTIN JL, 1991, MAYO CLIN PROC, V66, P287, DOI 10.1016/S0025-6196(12)61011-8; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Pallis M, 2003, LEUKEMIA RES, V27, P803, DOI 10.1016/S0145-2126(03)00012-2; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Steensma DP, 2005, BLOOD; SWOLIN B, 1988, BLOOD, V72, P386; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Wakeling AE, 2002, CANCER RES, V62, P5749	15	119	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1434	1436		10.1038/sj.onc.1209163	http://dx.doi.org/10.1038/sj.onc.1209163			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247455				2022-12-25	WOS:000235708200018
J	Talukder, AH; Meng, Q; Kumar, R				Talukder, AH; Meng, Q; Kumar, R			CRIPak, a novel endogenous Pak1 inhibitor	ONCOGENE			English	Article						Pak1; negative regulation; ER	P21-ACTIVATED-KINASE-1 PHOSPHORYLATES; CYCLIN D1; KINASE; ACTIVATION; EXPRESSION; ALPHA; INTERACTS; CELLS	p21-activated protein kinase 1 (Pak1) plays an important role in several cellular processes, including cytoskeleton reorganization, promotion of the cell survival, and the estrogen receptor ( ER) signaling. Pak1 expression and activity is deregulated in a number of cancers. Pak1 is activated by a variety of physiological signals; however, less is known about the negative regulators of Pak1. Here, we report a negative regulator of Pak1. By performing a yeast two-hybrid screen of a mammary gland library, we identified cysteine-rich inhibitor of Pak1 (CRIPak) as a novel Pak1-interacting protein. We found that CRIPak is an intronless gene that localized to chromosome 4p16.3. It contains 13 zinc-finger domains and has three trypsin inhibitor-like, cysteine-rich domains and is widely expressed in a number of human cells and tissues. We further found that CRIPak interacted with Pak1 through the N-terminal regulatory domain and inhibited Pak1 kinase in both in vitro and in vivo assays. CRIPak inhibited Pak1-mediated LIM kinase activation and enhancement of ER transactivation. Conversely, selective inhibition of the endogenous CRIPak resulted in an increased Pak1 activity, and consequently, increased cytoskeleton remodeling and Pak1-mediated ER transactivation activity. The hormonal stimulation of cells enhanced CRIPak expression and promoted its colocalization with ER in the nuclear compartment. Our findings suggest that CRIPak is a novel negative regulator of the Pak1 and has a role in the modulation of Pak1-mediated ER transactivation in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA98823, CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Shivapurkar N, 1999, CANCER RES, V59, P3576; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298	27	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1311	1319		10.1038/sj.onc.1209172	http://dx.doi.org/10.1038/sj.onc.1209172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16278681				2022-12-25	WOS:000235708200004
J	Miles, G; Jayasinghe, L; Bayley, H				Miles, G; Jayasinghe, L; Bayley, H			Assembly of the bi-component leukocidin pore examined by truncation mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; GAMMA-HEMOLYSIN; CRYSTAL-STRUCTURE; AUREUS; LUKF; COMPONENT; TOXIN; OLIGOMERIZATION; 2-COMPONENT; INFECTIONS	Staphylococcal leukocidin (Luk) and alpha-hemolysin (alpha HL) are members of the same family of beta barrel pore-forming toxins (beta PFTs). Although the alpha HL pore is a homoheptamer, the Luk pore is formed by the co-assembly of four copies each of the two distantly related polypeptides, LukF and LukS, to form an octamer. Here, we examine N- and C-terminal truncation mutants of LukF and LukS. LukF subunits missing up to nineteen N- terminal amino acids are capable of producing stable, functional hetero-oligomers with WT LukS. LukS subunits missing up to fourteen N- terminal amino acids perform similarly in combination with WT LukF. Further, the simultaneous truncation of both LukF and LukS is tolerated. Both Luk subunits are vulnerable to short deletions at the C terminus. Interestingly, the N terminus of the LukS polypeptide becomes resistant to proteolytic digestion in the fully assembled Luk pore while the N terminus of LukF remains in an exposed conformation. The results from this work and related experiments on alpha HL suggest that, although the N termini of beta PFTs may undergo reorganization during assembly, they are dispensable for the formation of functional pores.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	University of Oxford; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Bayley, H (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	hagan.bayley@chem.ox.ac.uk		Bayley, Hagan/0000-0003-2499-6116				ALOUF JE, 1999, COMPREHENSIVE SOURCE, P402; Bayley H, 2005, NAT STRUCT MOL BIOL, V12, P385, DOI 10.1038/nsmb0505-385; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; Cheley S, 1999, PROTEIN SCI, V8, P1257, DOI 10.1110/ps.8.6.1257; Diep BA, 2004, J CLIN MICROBIOL, V42, P2080, DOI 10.1128/JCM.42.5.2080-2084.2004; Ferreras M, 1998, BBA-BIOMEMBRANES, V1414, P108, DOI 10.1016/S0005-2736(98)00160-6; Gouaux E, 1997, PROTEIN SCI, V6, P2631; Guillet V, 2004, J BIOL CHEM, V279, P41028, DOI 10.1074/jbc.M406904200; Howorka S, 1998, BIOTECHNIQUES, V25, P764, DOI 10.2144/98255bm03; Jayasinghe L, 2006, J BIOL CHEM, V281, P2195, DOI 10.1074/jbc.M510841200; Jayasinghe L, 2005, PROTEIN SCI, V14, P2550, DOI 10.1110/ps.051648505; Jones Douglas H., 1995, P591; KAMIO Y, 1993, FEBS LETT, V321, P15, DOI 10.1016/0014-5793(93)80611-W; Kaneko J, 1998, BIOSCI BIOTECH BIOCH, V62, P1465, DOI 10.1271/bbb.62.1465; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Miles G, 2002, PROTEIN SCI, V11, P894, DOI 10.1110/ps.4360102; Miles G, 2001, BIOCHEMISTRY-US, V40, P8514, DOI 10.1021/bi010454o; MILES G, 2005, THESIS TEXAS A M U C, P28; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Prevost G, 2003, CEL MOL MEC TOX ACT, V5, P3; Prevost G, 2001, CURR TOP MICROBIOL, V257, P53; PREVOST G, 1995, INFECT IMMUN, V63, P4121; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sugawara N, 1997, FEBS LETT, V410, P333, DOI 10.1016/S0014-5793(97)00618-2; Sugawara N, 1999, BIOSCI BIOTECH BIOCH, V63, P884, DOI 10.1271/bbb.63.884; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1	36	12	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2205	2214		10.1074/jbc.M510842200	http://dx.doi.org/10.1074/jbc.M510842200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16269405	hybrid			2022-12-25	WOS:000234760400044
J	El Omari, K; Ren, J; Bird, LE; Bona, MK; Klarmann, G; LeGrice, SFJ; Stammers, DK				El Omari, K; Ren, J; Bird, LE; Bona, MK; Klarmann, G; LeGrice, SFJ; Stammers, DK			Molecular architecture and ligand recognition determinants for T4 RNA ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 ANTICODON NUCLEASE; ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; DNA-LIGASE; NUCLEOTIDYL TRANSFER; CAPPING ENZYME; PROTEIN; MECHANISM; PURIFICATION; SUPERFAMILY	RNA ligase type 1 from bacteriophage T4 ( Rnl1) is involved in countering a host defense mechanism by repairing 5'-PO4 and 3'-OH groups in tRNALys. Rnl1 is widely used as a reagent in molecular biology. Although many structures for DNA ligases are available, only fragments of RNA ligases such as Rnl2 are known. We report the first crystal structure of a complete RNA ligase, Rnl1, in complex with adenosine 5'-(alpha,beta-methylenetriphosphate) (AMPcPP). The N- terminal domain is related to the equivalent region of DNA ligases and Rnl2 and binds AMPcPP but with further interactions from the additional N- terminal 70 amino acids in Rnl1 (via Tyr37 and Arg54) and the C-terminal domain (Gly269 and Asp272). The active site contains two metal ions, consistent with the two-magnesium ion catalytic mechanism. The C-terminal domain represents a new all alpha-helical fold and has a charge distribution and architecture for helix-nucleic acid groove interaction compatible with tRNA binding.	Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Sci Appl Int Co, Frederick, MD 21702 USA; NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	University of Oxford; Wellcome Centre for Human Genetics; Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stammers, DK (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England.	daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Bird, Louise/0000-0002-9846-5716; El Omari, Kamel/0000-0003-3506-6045	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Blondal T, 2005, NUCLEIC ACIDS RES, V33, P135, DOI 10.1093/nar/gki149; Blondal T, 2003, NUCLEIC ACIDS RES, V31, P7247, DOI 10.1093/nar/gkg914; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN D, 1988, J MOL BIOL, V199, P373, DOI 10.1016/0022-2836(88)90320-8; Cherepanov AV, 2002, J BIOL CHEM, V277, P1695, DOI 10.1074/jbc.M109616200; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Deng JP, 2004, J MOL BIOL, V343, P601, DOI 10.1016/j.jmb.2004.08.041; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jiang Y, 2001, J MOL BIOL, V305, P377, DOI 10.1006/jmbi.2000.4282; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; LEVITZ R, 1990, EMBO J, V9, P1383, DOI 10.1002/j.1460-2075.1990.tb08253.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 2003, NUCLEIC ACIDS RES, V31, P5090, DOI 10.1093/nar/gkg665; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; SNOPEK TJ, 1977, P NATL ACAD SCI USA, V74, P3355, DOI 10.1073/pnas.74.8.3355; SUGINO A, 1977, J BIOL CHEM, V252, P1732; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; WOOD WB, 1978, J BIOL CHEM, V253, P2437; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	32	52	54	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1573	1579		10.1074/jbc.M509658200	http://dx.doi.org/10.1074/jbc.M509658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16263720	hybrid			2022-12-25	WOS:000234652000035
J	Liu, L; D'Mello, SR				Liu, L; D'Mello, SR			Phosphorylation of I kappa B-beta is necessary for neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; ABL TYROSINE KINASE; BCR-ABL; DNA-BINDING; C-ABL; APOPTOSIS; CELLS; PROTEIN; POTASSIUM; ALPHA	Cerebellar granule neurons undergo apoptosis when switched from culture medium containing depolarizing levels of potassium ( high potassium or HK) to nondepolarizing medium ( low potassium or LK). We showed that in healthy neurons maintained in HK medium, I kappa B-beta is phosphorylated at a novel site, Tyr-161. LK-induced neuronal apoptosis is accompanied by a decrease in the extent of I kappa B-beta phosphorylation at this residue. Tyr-161 shares similarity to the consensus sequence for phosphorylation by the nonreceptor tyrosine kinases Abl and Arg. Arg phosphorylates Tyr161 differentially in vitro, and LK treatment does cause a down-regulation of Arg activity. Moreover, treatment of neurons with two structurally distinct and highly selective Abl inhibitors, PD173955 and Gleevec, blocks HK-induced phosphorylation of I kappa B-beta at Tyr161 and induces neuronal apoptosis. Overexpression of wild- type I kappa B-beta blocks LK-induced apoptosis, but this effect is abolished when Arg is pharmacologically inhibited. On the other hand, forced overexpression of I kappa B-beta in which Tyr-161 is mutated inhibits survival in HK demonstrating the importance of this residue to neuronal survival. Phosphorylation of I kappa B-beta enhances its association with p65/RelA causing an increase in NF-kappa B DNA binding activity. Our results identified I kappa B-beta phosphorylation as a key event in neuronal survival and provided a mechanism by which this is mediated.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	D'Mello, SR (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75083 USA.	dmello@utdallas.edu	D'Mello, Santosh/AAM-3644-2020; D'Mello, Santosh/AAO-7192-2020	D'Mello, Santosh/0000-0002-7652-1334	NINDS NIH HHS [NS40408] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040408] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATES PW, 2004, SCI STKE, pPE48, DOI DOI 10.1126/STKE.2542004PE48; Borodezt K, 1998, J NEUROSCI RES, V53, P531, DOI 10.1002/(SICI)1097-4547(19980901)53:5<531::AID-JNR3>3.3.CO;2-0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Finn AJ, 2003, NAT NEUROSCI, V6, P717, DOI 10.1038/nn1071; GALLI C, 1995, J NEUROSCI, V15, P1172; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Kovacs AD, 2004, EUR J NEUROSCI, V20, P345, DOI 10.1111/j.1460-9568.2004.03493.x; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Moresco EMY, 2003, J NEUROPHYSIOL, V89, P1678, DOI 10.1152/jn.00892.2002; Nardi N, 1997, J NEUROCHEM, V68, P750; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Schulz JB, 1996, J NEUROSCI, V16, P4696; SCHWARZ EM, 1996, MOL CELL BIOL, V16, P3654; Strife A, 2003, MOL CANCER RES, V1, P176; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Wills Z, 2002, NEURON, V36, P611, DOI 10.1016/S0896-6273(02)01022-X; Wisniewski D, 2002, CANCER RES, V62, P4244; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yalcin A, 2003, J NEUROCHEM, V84, P397, DOI 10.1046/j.1471-4159.2003.01540.x; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	34	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1506	1515		10.1074/jbc.M510402200	http://dx.doi.org/10.1074/jbc.M510402200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16286457	hybrid			2022-12-25	WOS:000234652000028
J	Oka, S; Kato, J; Moss, J				Oka, S; Kato, J; Moss, J			Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLARGININE HYDROLASES; NUCLEOTIDE-BINDING PROTEIN; MODIFICATION SITE; DIPHTHERIA-TOXIN; SKELETAL-MUSCLE; RIBOSYLTRANSFERASE; RIBOSYLATION; ARGININE; RIBOSE; CLONING	ADP-ribosylation is a post-translational modification resulting from transfer of the ADP-ribose moiety of NAD to protein. Mammalian cells contain mono-ADP-ribosyltransferases that catalyze the formation of ADP-ribose-(arginine) protein, which can be cleaved by a 39-kDa ADP-ribose-( arginine) protein hydrolase (ARH1), resulting in release of free ADP- ribose and regeneration of unmodified protein. Enzymes involved in poly( ADP- ribosylation) participate in several critical physiological processes, including DNA repair, cellular differentiation, and carcinogenesis. Multiple poly( ADP- ribose) polymerases have been identified in the human genome, but there is only one known poly( ADP- ribose) glycohydrolase (PARG), a 111-kDa protein that degrades the ( ADP- ribose) polymer to ADP- ribose. We report here the identification of an ARH1-like protein, termed poly( ADP- ribose) hydrolase or ARH3, which exhibited PARG activity, generating ADP- ribose from poly( ADP- ribose), but did not hydrolyze ADP-ribose- arginine, -cysteine, -diphthamide, or -asparagine bonds. The 39-kDa ARH3 shares amino acid sequence identity with both ARH1 and the catalytic domain of PARG. ARH3 activity, like that of ARH1, was enhanced by Mg2+. Critical vicinal acidic amino acids in ARH3, identified by mutagenesis (Asp(77) and Asp(78)), are located in a region similar to that required for activity in ARH1 but different from the location of the critical vicinal glutamates in the PARG catalytic site. All findings are consistent with the conclusion that ARH3 has PARG activity but is structurally unrelated to PARG.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Moss, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 6D05,Bldg 10,MSC 1590, Bethesda, MD 20892 USA.	mossj@nhlbi.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; Glowacki G, 2002, PROTEIN SCI, V11, P1657, DOI 10.1110/ps.0200602; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Konczalik P, 1999, J BIOL CHEM, V274, P16736, DOI 10.1074/jbc.274.24.16736; KRUEGER KM, 1995, CLIN MICROBIOL REV, V8, P34, DOI 10.1128/CMR.8.1.34; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; Liu ZX, 1999, J BIOL CHEM, V274, P17399, DOI 10.1074/jbc.274.25.17399; LOWERY RG, 1990, ADP RIBOSYLATING TOX, P459; Masutani M, 2005, CELL MOL LIFE SCI, V62, P769, DOI 10.1007/s00018-004-4509-x; Meyer RG, 2003, GENE, V314, P181, DOI 10.1016/S0378-1119(03)00738-8; Meyer-Ficca ML, 2004, EXP CELL RES, V297, P521, DOI 10.1016/j.yexcr.2004.03.050; MORII N, 1988, J BIOL CHEM, V263, P12420; Moss J, 1999, MOL CELL BIOCHEM, V193, P109, DOI 10.1023/A:1006924514074; MOSS J, 1977, J BIOL CHEM, V252, P2455; Moss J, 1997, ADV EXP MED BIOL, V419, P25; MOSS J, 1992, J BIOL CHEM, V267, P10481; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; Moss J, 1990, ADP RIBOSYLATING TOX; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OGATA N, 1981, J BIOL CHEM, V256, P4135; OGATA N, 1980, J BIOL CHEM, V255, P7610; OGATA N, 1980, J BIOL CHEM, V255, P7616; OHNO T, 1995, ANAL BIOCHEM, V231, P115, DOI 10.1006/abio.1995.1510; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; Padilla PI, 2004, P NATL ACAD SCI USA, V101, P2752, DOI 10.1073/pnas.0307345101; Patel CN, 2005, BIOCHEM J, V388, P493, DOI 10.1042/BJ20040942; Ribeiro JM, 2001, BBA-GEN SUBJECTS, V1526, P86, DOI 10.1016/S0304-4165(01)00113-1; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKADA T, 1993, J BIOL CHEM, V268, P17837; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; VANNESS BG, 1980, J BIOL CHEM, V255, P710; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; WEST RE, 1985, J BIOL CHEM, V260, P4428; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	47	212	219	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					705	713		10.1074/jbc.M510290200	http://dx.doi.org/10.1074/jbc.M510290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278211	hybrid			2022-12-25	WOS:000234447200006
J	Patre, M; Tabbert, A; Hermann, D; Walczak, H; Rackwitz, HR; Cordes, VC; Ferrando-May, E				Patre, M; Tabbert, A; Hermann, D; Walczak, H; Rackwitz, HR; Cordes, VC; Ferrando-May, E			Caspases target only two architectural components within the core structure of the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; NUCLEOPORIN NUP153; IN-VITRO; INTRANUCLEAR FILAMENTS; INDUCED APOPTOSIS; PROTEIN IMPORT; IDENTIFICATION; NUP98; BINDING	Caspases were recently implicated in the functional impairment of the nuclear pore complex during apoptosis, affecting its dual activity as nucleocytoplasmic transport channel and permeability barrier. Concurrently, electron microscopic data indicated that nuclear pore morphology is not overtly altered in apoptotic cells, raising the question of how caspases may deactivate nuclear pore function while leaving its overall structure largely intact. To clarify this issue we have analyzed the fate of all known nuclear pore proteins during apoptotic cell death. Our results show that only two of more than 20 nuclear pore core structure components, namely Nup93 and Nup96, are caspase targets. Both proteins are cleaved near their N terminus, disrupting the domains required for interaction with other nucleoporins actively involved in transport and providing the permeability barrier but dispensable for maintaining the nuclear pore scaffold. Caspase-mediated proteolysis of only few nuclear pore complex components may exemplify a general strategy of apoptotic cells to efficiently disable huge macromolecular machines.	Univ Konstanz, Fac Biol, Mol Toxicol Grp, D-78457 Constance, Germany; German Canc Res Ctr, Tumor Immunol Program, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; Peptide Specialty Labs GmbH, D-69118 Heidelberg, Germany; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	University of Konstanz; Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet; Ruprecht Karls University Heidelberg	Ferrando-May, E (corresponding author), Univ Konstanz, Fac Biol, Mol Toxicol Grp, POB X911, D-78457 Constance, Germany.	elisa.may@uni-konstanz.de	Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591				Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Buendia B, 1999, J CELL SCI, V112, P1743; CHOW KC, 1987, MOL CELL BIOL, V7, P3119, DOI 10.1128/MCB.7.9.3119; CORDES V, 1991, EUR J CELL BIOL, V55, P31; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FALCIERI E, 1994, HISTOCHEM J, V26, P754, DOI 10.1007/BF00158206; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Forler D, 2004, MOL CELL BIOL, V24, P1155, DOI 10.1128/MCB.24.3.1155-1167.2004; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Galy V, 2004, CELL, V116, P63, DOI 10.1016/S0092-8674(03)01026-2; Galy V, 2003, MOL BIOL CELL, V14, P5104, DOI 10.1091/mbc.E03-04-0237; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; Harel A, 2003, MOL CELL, V11, P853, DOI 10.1016/S1097-2765(03)00116-3; Hase ME, 2003, MOL BIOL CELL, V14, P1923, DOI 10.1091/mbc.E02-09-0620; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kihlmark M, 2004, EXP CELL RES, V293, P346, DOI 10.1016/j.yexcr.2003.10.019; Kihlmark M, 2001, J CELL SCI, V114, P3643; KITA K, 1993, J BIOCHEM-TOKYO, V113, P377, DOI 10.1093/oxfordjournals.jbchem.a124054; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Krull S, 2004, MOL BIOL CELL, V15, P4261, DOI 10.1091/mbc.E04-03-0165; Kuersten S, 2002, MOL CELL BIOL, V22, P5708, DOI 10.1128/MCB.22.16.5708-5720.2002; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Le Rouzic E, 2002, J BIOL CHEM, V277, P45091, DOI 10.1074/jbc.M207439200; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Loiodice I, 2004, MOL BIOL CELL, V15, P3333, DOI 10.1091/mbc.E03-12-0878; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Miller BR, 2000, MOL BIOL CELL, V11, P3381, DOI 10.1091/mbc.11.10.3381; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1993, J CELL BIOL, V121, P1, DOI 10.1083/jcb.121.1.1; RIS H, 1991, EMSA B, V21, P54; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Roehrig S, 2003, ANAL BIOCHEM, V318, P244, DOI 10.1016/S0003-2697(03)00242-2; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Schlaich NL, 1997, MOL BIOL CELL, V8, P33, DOI 10.1091/mbc.8.1.33; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Shibata S, 2002, GENES CELLS, V7, P421, DOI 10.1046/j.1365-2443.2002.00525.x; Strawn LA, 2004, NAT CELL BIOL, V6, P197, DOI 10.1038/ncb1097; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Trichet V, 1999, CYTOGENET CELL GENET, V85, P221, DOI 10.1159/000015297; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; vanDeursen J, 1996, EMBO J, V15, P5574, DOI 10.1002/j.1460-2075.1996.tb00942.x; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Walther TC, 2002, J CELL BIOL, V158, P63, DOI 10.1083/jcb.200202088; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zeitler B, 2004, J CELL BIOL, V167, P583, DOI 10.1083/jcb.200407156	78	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1296	1304		10.1074/jbc.M511717200	http://dx.doi.org/10.1074/jbc.M511717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286466	Green Submitted, hybrid, Green Published			2022-12-25	WOS:000234447200072
J	Suzuki, H; Furusho, Y; Higashi, T; Ohnishi, Y; Horinouchi, S				Suzuki, H; Furusho, Y; Higashi, T; Ohnishi, Y; Horinouchi, S			A novel o-aminophenol oxidase responsible for formation of the phenoxazinone chromophore of grixazone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ANTIBIOTICUS; MUSHROOM TYROSINASE; NUCLEOTIDE-SEQUENCE; COMPLEX-FORMATION; A-FACTOR; GENE; EXPRESSION; CLONING; METABOLISM; MECHANISM	Grixazone contains a phenoxazinone chromophore and is a secondary metabolite produced by Streptomyces griseus. In the grixazone biosynthesis gene cluster, griF (encoding a tyrosinase homolog) and griE (encoding a protein similar to copper chaperons for tyrosinases) are encoded. An expression study of GriE and GriF in Escherichia coli showed that GriE activated GriF by transferring copper ions to GriF, as has been observed for a Streptomyces melanogenesis system in which the MelC1 copper chaperon transfers copper ions to MelC2 tyrosinase. In contrast with tyrosinases, GriF showed no monophenolase activity, although it oxidized various o-aminophenols as preferable substrates rather than catechol-type substrates. Deletion of the griEF locus on the chromosome resulted in accumulation of 3-amino-4-hydroxybenzaldehyde (3,4-AHBAL) and its acetylated compound, 3-acetylamino-4-hydroxybenzaldehyde. GriF oxidized 3,4-AHBAL to yield an o-quinone imine derivative, which was then non-enzymatically coupled with another molecule of the o-quinone imine to form a phenoxazinone. The coexistence of N-acetylcysteine in the in vitro oxidation of 3,4-AHBAL by GriF resulted in the formation of grixazone A, suggesting that the -SH group of N-acetylcysteine is conjugated to the o-quinone imine formed from 3,4-AHBAL and that the conjugate is presumably coupled with another molecule of the o-quinone imine. GriF is thus a novel o-aminophenol oxidase that is responsible for the formation of the phenoxazinone chromophore in the grixazone biosynthetic pathway.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp	Suzuki, Hirokazu/AAG-2285-2020	Suzuki, Hirokazu/0000-0002-9507-6467; Ohnishi, Yasuo/0000-0001-7633-9236				ARISON BH, 1970, BIOCHEMISTRY-US, V9, P3976, DOI 10.1021/bi00822a016; AXEL Z, 1988, Patent No. 260486; BARRY CE, 1989, BIOCHEMISTRY-US, V28, P6323, DOI 10.1021/bi00441a026; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; Fenoll LG, 2004, BIOCHEM J, V380, P643, DOI 10.1042/BJ20040136; Fenoll LG, 2004, INT J BIOCHEM CELL B, V36, P235, DOI 10.1016/S1357-2725(03)00234-6; Gasowska B, 2004, BBA-GEN SUBJECTS, V1673, P170, DOI 10.1016/j.bbagen.2004.04.013; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; GERBER NN, 1983, J ANTIBIOT, V36, P688, DOI 10.7164/antibiotics.36.688; Gould SJ, 1996, J AM CHEM SOC, V118, P9228, DOI 10.1021/ja9524356; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; Hopwood D. A., 1985, GENETIC MANIPULATION; Horinouchi S, 2002, FRONT BIOSCI-LANDMRK, V7, pD2045, DOI 10.2741/horinouc; HSIEH CJ, 1995, J BACTERIOL, V177, P5740, DOI 10.1128/jb.177.20.5740-5747.1995; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; Hughes MA, 2002, APPL ENVIRON MICROB, V68, P4965, DOI 10.1128/AEM.68.10.4965-4970.2002; Ikeda K, 1996, APPL MICROBIOL BIOT, V45, P80, DOI 10.1007/s002530050652; IMAI S, 1990, J ANTIBIOT, V43, P1606, DOI 10.7164/antibiotics.43.1606; JOLLEY RL, 1969, J BIOL CHEM, V244, P1593; Jones GH, 2000, ANTIMICROB AGENTS CH, V44, P1322, DOI 10.1128/AAC.44.5.1322-1327.2000; KAWAMOTO S, 1993, J FERMENT BIOENG, V76, P345, DOI 10.1016/0922-338X(93)90020-9; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Kohashi PY, 2004, PROTEIN EXPRES PURIF, V34, P202, DOI 10.1016/j.pep.2003.11.015; Kunigami T, 1996, J ANTIBIOT, V49, P312, DOI 10.7164/antibiotics.49.312; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; Maniatis T., 1982, MOL CLONING LAB MANU; Moridani MY, 2001, CHEM RES TOXICOL, V14, P841, DOI 10.1021/tx000235o; Ohnishi Y, 2004, J ANTIBIOT, V57, P218, DOI 10.7164/antibiotics.57.218; OHNISHI Y, 2004, BIOFILMS, V1, P319; Schaerlaekens K, 2001, J BACTERIOL, V183, P6727, DOI 10.1128/JB.183.23.6727-6732.2001; Siegbahn PEM, 2004, J BIOL INORG CHEM, V9, P577, DOI 10.1007/s00775-004-0551-2; Simandi TM, 2004, DALTON T, P1056, DOI 10.1039/b316543d; Tepper AWJW, 2005, J AM CHEM SOC, V127, P567, DOI 10.1021/ja0454687; Wichers HJ, 2003, APPL MICROBIOL BIOT, V61, P336, DOI 10.1007/s00253-002-1194-2; WOLF G, 1975, ARCH MICROBIOL, V106, P245, DOI 10.1007/BF00446530	37	16	20	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					824	833		10.1074/jbc.M505806200	http://dx.doi.org/10.1074/jbc.M505806200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282322	hybrid			2022-12-25	WOS:000234447200020
J	Gallant, M; Rak, M; Szeghalmi, A; Del Bigio, MR; Westaway, D; Yang, J; Julian, R; Gough, KM				Gallant, M; Rak, M; Szeghalmi, A; Del Bigio, MR; Westaway, D; Yang, J; Julian, R; Gough, KM			Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; KINASE BB; METABOLISM; MICROSPECTROSCOPY; SUPPLEMENTATION; HIPPOCAMPAL; NEURONS; ENERGY	The creatine/ phosphocreatine system, regulated by creatine kinase, plays an important role in maintaining energy balance in the brain. Energy metabolism and the function of creatine kinase are known to be affected in Alzheimer diseased brain and in cells exposed to the beta- amyloid peptide. We used infrared microspectroscopy to examine hippocampal, cortical, and caudal tissue from 21 - 89- week- old transgenic mice expressing doubly mutant ( K670N/ M671L and V717F) amyloid precursor protein and displaying robust pathology from an early age. Microcrystalline deposits of creatine, suggestive of perturbed energetic status, were detected by infrared microspectroscopy in all animals with advanced plaque pathology. Relatively large creatine deposits were also found in hippocampal sections from post- mortem Alzheimer diseased human brain, compared with hippocampus from non- demented brain. We therefore speculate that this molecule is a marker of the disease process.	Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Pathol, Winnipeg, MB R3E 0W3, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Wisconsin, Ctr Synchrotron Radiat, Stoughton, WI 53589 USA	University of Manitoba; University of Manitoba; University of Toronto; University of Toronto; University of Wisconsin System	Gough, KM (corresponding author), Univ Manitoba, Dept Chem, 350 Parker Bldg, Winnipeg, MB R3T 2N2, Canada.	kmgough@ms.umanitoba.ca	Szeghalmi, Adriana/AAS-2884-2020	Szeghalmi, Adriana/0000-0003-2055-2825; Del Bigio, Marc/0000-0001-8366-0394				Aksenov M, 2000, J NEUROCHEM, V74, P2520, DOI 10.1046/j.1471-4159.2000.0742520.x; Aksenov MY, 1998, J MOL NEUROSCI, V10, P181, DOI 10.1007/BF02761773; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Blass JP, 2002, J ALZHEIMERS DIS, V4, P225, DOI 10.3233/JAD-2002-4312; BUTTERFIELD DA, 2003, APPL GENOMICS PROTEO, V2, P67; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Choo LP, 1996, BIOPHYS J, V71, P1672, DOI 10.1016/S0006-3495(96)79411-0; David S, 1998, MOL BRAIN RES, V54, P276, DOI 10.1016/S0169-328X(97)00343-4; Dringen R, 1998, J NEUROCHEM, V70, P835; Gibson GE, 2002, FREE RADICAL BIO MED, V32, P1061, DOI 10.1016/S0891-5849(02)00802-X; Gough K, 2005, VIB SPECTROSC, V38, P133, DOI 10.1016/j.vibspec.2005.02.027; Gough KM, 2003, ANAL BIOCHEM, V316, P232, DOI 10.1016/S0003-2697(03)00039-3; Huang W, 2001, NEUROLOGY, V57, P626, DOI 10.1212/WNL.57.4.626; Ipsiroglu OS, 2001, LIFE SCI, V69, P1805, DOI 10.1016/S0024-3205(01)01268-1; Lasch P, 2004, BBA-MOL BASIS DIS, V1688, P176, DOI 10.1016/j.bbadis.2003.12.006; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mohanakrishnan P, 1997, J GERONTOL A-BIOL, V52, pB111, DOI 10.1093/gerona/52A.2.B111; Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069; Pfefferbaum A, 1999, ARCH GEN PSYCHIAT, V56, P185, DOI 10.1001/archpsyc.56.2.185; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Stoppe G, 2000, ALZ DIS ASSOC DIS, V14, P112, DOI 10.1097/00002093-200004000-00009; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Valenzuela MJ, 2001, NEUROLOGY, V56, P592, DOI 10.1212/WNL.56.5.592; Wyss M, 2002, NEUROSCIENCE, V112, P243, DOI 10.1016/S0306-4522(02)00088-X; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107	30	55	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					5	8		10.1074/jbc.C500244200	http://dx.doi.org/10.1074/jbc.C500244200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267054	hybrid			2022-12-25	WOS:000234307200002
J	Liu, X; Clements, A; Zhao, KH; Marmorstein, R				Liu, X; Clements, A; Zhao, KH; Marmorstein, R			Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; HPV E7; CERVICAL-CANCER; BINDING-SITE; RB FUNCTION; PROTEIN; TYPE-16; E2F; DOMAIN; TRANSFORMATION	The E7 oncoprotein from human Papillomavirus (HPV) mediates cell transformation in part by binding to the human pRb tumor suppressor protein and E2F transcription factors, resulting in the dissociation of pRb from E2F transcription factors and the premature cell progression into the S-phase of the cell cycle. This activity is mediated by the LXCXE motif and the CR3 zinc binding domain of the E7 protein. In this study we report the x-ray crystal structure of the CR3 region of HPVE7 and a structure-based mutational analysis to investigate its mode of pRb and E2F binding and E2F displacement from pRb. The structure reveals a novel zinc-bound E7-CR3 obligate homodimer that contains two surface patches of sequence conservation. Mutation of residues within these patches reveals that one patch is required for pRb binding, whereas the other is required for E2F binding. We also show that both E7-mediated interactions are required to disrupt pRb(.)E2F complexes. Based on these studies we present a mechanistic model for how E7 displaces E2F from pRb. Because the CR3 region of HPV E7 has no detectable homology to other human proteins, the structure-function studies presented here provide an avenue for developing small molecule compounds that inhibit HPV-E7-mediated cell transformation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St,Rm 327, Philadelphia, PA 19104 USA.	marmor@wistar.upenn.edu						Alonso LG, 2004, BIOCHEMISTRY-US, V43, P3310, DOI 10.1021/bi036037o; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; Bernat A, 2003, ONCOGENE, V22, P7871, DOI 10.1038/sj.onc.1206896; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Longworth MS, 2004, J VIROL, V78, P3533, DOI 10.1128/JVI.78.7.3533-3541.2004; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MEYERS G, 1995, HUMAN PAPILLOMAVIRUS; MUNGER K, 1989, J VIROL, V63, P4417; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAH KV, 1996, FIELDS VIROLOGY, P2045; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	48	171	193	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					578	586		10.1074/jbc.M508455200	http://dx.doi.org/10.1074/jbc.M508455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249186	hybrid			2022-12-25	WOS:000234307200070
J	Remus, TP; Zima, AV; Bossuyt, J; Bare, DJ; Martin, JL; Blatter, LA; Bers, DM; Mignery, GA				Remus, TP; Zima, AV; Bossuyt, J; Bare, DJ; Martin, JL; Blatter, LA; Bers, DM; Mignery, GA			Biosensors to measure inositol 1,4,5-trisphosphate concentration in living cells with spatiotemporal resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL FUNCTION; ATRIAL MYOCYTES; RECEPTOR; PHOSPHATES; CA2+; ARRHYTHMIAS; CONTRACTION; RECOGNITION; EXPRESSION; MECHANISM	Phosphoinositides participate in many signaling cascades via phospholipase C stimulation, which hydrolyzes phosphatidylinositol 4,5-bisphosphate, producing second messengers diacylglycerol and inositol 1,4,5-trisphosphate (InsP(3)). Destructive chemical approaches required to measure [InsP(3)] limit spatiotemporal understanding of subcellular InsP(3) signaling. We constructed novel fluorescence resonance energy transfer-based InsP(3) biosensors called FIRE (fluorescent InsP(3)-responsive element) by fusing plasmids encoding the InsP(3)- binding domain of InsP(3) receptors (types 1-3) between cyan fluorescent protein and yellow fluorescent protein sequences. FIRE was expressed and characterized in COS-1 cells, cultured neonatal cardiac myocytes, and incorporated into an adenoviral vector for expression in adult cardiac ventricular myocytes. FIRE-1 exhibits an similar to 11% increase in the fluorescence ratio (F-530/F-480) at saturating [InsP(3)] (apparent K-d = 31.3 +/- 6.7 nM InsP(3)). In COS-1 cells, neonatal rat cardiac myocytes and adult cat ventricular myocytes FIRE-1 exhibited comparable dynamic range and a 10% increase in donor (cyan fluorescent protein) fluorescence upon bleach of yellow fluorescent protein, indicative of fluorescence resonance energy transfer. In FIRE-1 expressing ventricular myocytes endothelin-1, phenylephrine, and angiotensin II all produced rapid and spatially resolved increases in [InsP(3)] using confocal microscopy (with free [InsP(3)] rising to similar to 30 nM). Local entry of intracellular InsP(3) via membrane rupture by a patch pipette (containing InsP(3)) in myocytes expressing FIRE-1 allowed detailed spatiotemporal monitoring of intracellular InsP(3) diffusion. Both endothelin-1-induced and direct InsP(3) application ( via pipette rupture) revealed that InsP(3) diffusion into the nucleus occurs with a delay and blunted rise of [InsP(3)] versus cytosolic [InsP(3)]. These new biosensors allow studying InsP(3) dynamics at high temporal and spatial resolution that will be powerful in under-standing InsP(3) signaling in intact cells.	Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Dept Med, Maywood, IL 60153 USA; Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	gmigner@lumc.edu	Bers, Donald M/C-4507-2012; Blatter, Lothar/AAC-8431-2020	Bers, Donald/0000-0002-2237-9483; Bossuyt, Julie/0000-0001-8874-4765	NHLBI NIH HHS [HL30077, HL64724, HL62231] Funding Source: Medline; NIMH NIH HHS [MH53367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030077, R01HL030077, R01HL062231, R01HL064724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053367, R01MH053367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bare DJ, 2005, J BIOL CHEM, V280, P15912, DOI 10.1074/jbc.M414212200; Bartlett PJ, 2005, J BIOL CHEM, V280, P21837, DOI 10.1074/jbc.M411843200; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bers D.M., 2001, EXCITATION CONTRACTI, V2nd ed.; Blatter LA, 2003, J PHYSIOL-LONDON, V546, P19, DOI 10.1113/jphysiol.2002.025239; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; COBBOLD P, 1988, HORM CELL REGUL, V165, P135; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; FABIATO A, 1986, BIOPHYS J, V49, P190; Griffin TM, 2004, AM J PHYSIOL-HEART C, V287, pH1081, DOI 10.1152/ajpheart.00921.2003; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; HOKIN LE, 1958, J BIOL CHEM, V233, P805; HOKIN MR, 1953, J BIOL CHEM, V203, P967; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; Mackenzie L, 2004, J CELL SCI, V117, P6327, DOI 10.1242/jcs.01559; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nahorski SR, 2003, TRENDS NEUROSCI, V26, P444, DOI 10.1016/S0166-2236(03)00178-4; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NOSEK TM, 1986, AM J PHYSIOL, V250, P807; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; RUBENSTEIN DS, 1995, CIRCULATION, V91, P201, DOI 10.1161/01.CIR.91.1.201; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugimoto K, 2004, CHEM BIOL, V11, P475, DOI 10.1016/j.chembiol.2004.03.019; Tanimura A, 2004, J BIOL CHEM, V279, P38095, DOI 10.1074/jbc.C400312200; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; WILCOX RA, 1993, MOL PHARMACOL, V44, P810; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; WILLCOCKS AL, 1989, BIOCHEM J, V257, P297, DOI 10.1042/bj2570297; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; Wu X, 2004, CIRCULATION, V110, P285; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; Zima AV, 2004, J PHYSIOL-LONDON, V555, P607, DOI 10.1113/jphysiol.2003.058529	44	81	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					608	616		10.1074/jbc.M509645200	http://dx.doi.org/10.1074/jbc.M509645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249182	hybrid			2022-12-25	WOS:000234307200073
J	Suorsa, M; Sirpio, S; Allahverdiyeva, Y; Paakkarinen, V; Mamedov, F; Styring, S; Aro, EM				Suorsa, M; Sirpio, S; Allahverdiyeva, Y; Paakkarinen, V; Mamedov, F; Styring, S; Aro, EM			PsbR, a missing link in the assembly of the oxygen-evolving complex of plant photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MASS SUBUNITS; SYNECHOCYSTIS SP PCC-6803; EXTRINSIC PROTEINS; THYLAKOID MEMBRANES; GROWTH IRRADIANCES; PROTEOMIC ANALYSIS; POLYPEPTIDES; PHOTOINHIBITION; CHLOROPLASTS; ACCUMULATION	The oxygen- evolving complex of eukaryotic photosystem II ( PSII) consists of three extrinsic nuclear- encoded subunits, PsbO ( 33 kDa), PsbP ( 23 kDa), and PsbQ ( 17 kDa). Additionally, the 10- kDa PsbR protein has been found in plant PSII and anticipated to play a role in water oxidation, yet the physiological significance of PsbR has remained obscure. Using the Arabidopsis psbR mutant, we showed that the light- saturated rate of oxygen evolution is strongly reduced in the absence of PsbR, particularly in low light- grown plants. Lack of PsbR also induced a reduction in the content of both the PsbP and the PsbQ proteins, and a near depletion of these proteins was observed under steady state low light conditions. This regulation occurred post- transcriptionally and likely involves a proteolytic degradation of the PsbP and PsbQ proteins in the absence of an assembly partner, proposed to be the PsbR protein. Stable assembly of PsbR in the PSII core complex was, in turn, shown to require a chloroplast- encoded intrinsic low molecular mass PSII subunit PsbJ. Our results provided evidence that PsbR is an important link in the PSII core complex for stable assembly of the oxygen- evolving complex protein PsbP, whereas the effects on the assembly of PsbQ are probably indirect. The physiological role of the PsbR, PsbP, and PsbQ proteins is discussed in light of their peculiar expression in response to growth light conditions.	Univ Turku, Dept Biol, FI-20014 Turku, Finland; Uppsala Univ, Dept Mol Biomimet, S-75236 Uppsala, Sweden	University of Turku; Uppsala University	Aro, EM (corresponding author), Univ Turku, Dept Biol, FI-20014 Turku, Finland.	evaaro@utu.fi	Aro, Eva-Mari/Q-8664-2017; Mamedov, Fikret/A-1761-2016; Allahverdiyeva, Yagut/I-5652-2013; Styring, Stenbjörn/L-8414-2016	Aro, Eva-Mari/0000-0002-2922-1435; Mamedov, Fikret/0000-0002-6218-3039; Allahverdiyeva, Yagut/0000-0002-9262-1757; Styring, Stenbjörn/0000-0002-2803-9244; Suorsa, Marjaana/0000-0002-3821-0607				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ANDERSON JM, 1994, PHOTOSYNTH RES, V41, P315, DOI 10.1007/BF00019409; ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; Baena-Gonzalez E, 2002, PHILOS T R SOC B, V357, P1451, DOI 10.1098/rstb.2002.1141; Danielsson R, 2004, BBA-BIOENERGETICS, V1608, P53, DOI 10.1016/j.bbabio.2003.10.005; De Las Rivas J, 2004, TRENDS PLANT SCI, V9, P18, DOI 10.1016/j.tplants.2003.11.007; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Hager M, 2002, J BIOL CHEM, V277, P14031, DOI 10.1074/jbc.M112053200; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Hashimoto A, 1997, PLANT CELL, V9, P441, DOI 10.1105/tpc.9.3.441; Hashimoto A, 1996, FEBS LETT, V391, P29; Ishikawa Y, 2005, PHOTOSYNTH RES, V84, P257, DOI 10.1007/s11120-005-0477-8; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND LK, 1993, J BIOL CHEM, V268, P1575; LJUNGBERG U, 1984, BIOCHIM BIOPHYS ACTA, V767, P145, DOI 10.1016/0005-2728(84)90089-6; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; LUZIKOV VN, 1996, FEBS LETT, V200, P259; MEIERHOFF K, 1993, PLANTA, V191, P23, DOI 10.1007/BF00240892; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; Nield J, 2000, NAT STRUCT BIOL, V7, P44; Ohta H, 2003, EUR J BIOCHEM, V270, P4156, DOI 10.1046/j.1432-1033.2003.03810.x; Perez-Bueno ML, 2004, PROTEOMICS, V4, P418, DOI 10.1002/pmic.200300655; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Pursiheimo S, 2001, PLANT J, V26, P317, DOI 10.1046/j.1365-313X.2001.01033.x; Rahoutei J, 2000, PHYSIOL PLANTARUM, V110, P286, DOI 10.1034/j.1399-3054.2000.110220.x; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; STOCKHAUS J, 1990, EMBO J, V9, P3013, DOI 10.1002/j.1460-2075.1990.tb07494.x; Summerfield TC, 2005, BIOCHEMISTRY-US, V44, P805, DOI 10.1021/bi048394k; Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Yamamoto Y, 2001, PLANT CELL PHYSIOL, V42, P121, DOI 10.1093/pcp/pce022	43	95	99	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					145	150		10.1074/jbc.M510600200	http://dx.doi.org/10.1074/jbc.M510600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16282331	hybrid			2022-12-25	WOS:000234307200021
J	Vainio, S; Jansen, M; Koivusalo, M; Rog, T; Karttunen, M; Vattulainen, I; Ikonen, E				Vainio, S; Jansen, M; Koivusalo, M; Rog, T; Karttunen, M; Vattulainen, I; Ikonen, E			Significance of sterol structural specificity - Desmosterol cannot replace cholesterol in lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; GPI-ANCHORED PROTEINS; NEWLY SYNTHESIZED CHOLESTEROL; PHOSPHATIDYLCHOLINE BILAYER; LATERAL DIFFUSION; INSULIN-RECEPTOR; DOMAINS; MEMBRANES; CELLS; TRANSPORT	Desmosterol is an immediate precursor of cholesterol in the Bloch pathway of sterol synthesis and an abundant membrane lipid in specific cell types. The significance of the difference between the two sterols, an additional double bond at position C24 in the tail of desmosterol, is not known. Here, we provide evidence that the biophysical and functional characteristics of the two sterols differ and that this is because the double bond at C24 significantly weakens the sterol ordering potential. In model membranes, desmosterol was significantly weaker than cholesterol in promoting the formation or stability of ordered domains, and in mammalian cell membranes, desmosterol associated less avidly than cholesterol with detergent-resistant membranes. Atomic scale molecular dynamics simulations showed that the double bond gives rise to additional stress in the tail, creating a rigid structure between C24 and C27 and favoring tilting of desmosterol distinct from cholesterol. Functional effects of desmosterol in cell membranes were assessed upon acutely exchanging similar to 70% of cholesterol to desmosterol. This led to impaired raft-dependent signaling via the insulin receptor, whereas non-raft-dependent protein secretion was not affected. We suggest that the choice of cholesterol synthesis route may provide a physiological mechanism to modulate raft-dependent functions in cells.	Univ Helsinki, Inst Biomed Anat, Haartmaninkatu 8, FI-00014 Helsinki, Finland; Aalto Univ, Biophys & Stat Mech Grp, Lab Computat Engn, FI-02015 Helsinki, Finland; Aalto Univ, Phys Lab, FI-02015 Helsinki, Finland; Aalto Univ, Helsinki Univ Technol, Helsinki Inst Phys, FI-02015 Helsinki, Finland; Jagiellonian Univ, Dept Biophys, PL-31007 Krakow, Poland; Univ So Denmark, MEMPHYS Ctr Biomembrane Phys, DK-5230 Odense M, Denmark	University of Helsinki; Aalto University; Aalto University; Aalto University; Helsinki Institute of Physics; Jagiellonian University; University of Southern Denmark	Ikonen, E (corresponding author), Univ Helsinki, Inst Biomed Anat, Haartmaninkatu 8, FI-00014 Helsinki, Finland.		Karttunen, Mikko/G-4531-2010; Rog, Tomasz/ABE-3044-2020; Vattulainen, Ilpo T/G-4224-2014	Karttunen, Mikko/0000-0002-8626-3033; Rog, Tomasz/0000-0001-6765-7013; Vattulainen, Ilpo/0000-0001-7408-3214; Ikonen, Elina/0000-0001-8382-1135				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; Bacia K, 2005, P NATL ACAD SCI USA, V102, P3272, DOI 10.1073/pnas.0408215102; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Berendsen H., 1981, INTERMOLECULAR FORCE, DOI DOI 10.1007/978-94-015-7658-1_21; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Falck E, 2004, J CHEM PHYS, V121, P12676, DOI 10.1063/1.1824033; Falck E, 2004, BIOPHYS J, V87, P1076, DOI 10.1529/biophysj.104.041368; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Grimmer S, 2005, TRAFFIC, V6, P144, DOI 10.1111/j.1600-0854.2005.00258.x; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Holtje M, 2001, BBA-BIOMEMBRANES, V1511, P156, DOI 10.1016/S0005-2736(01)00270-X; Huster D, 2005, BIOPHYS J, V88, P1838, DOI 10.1529/biophysj.104.048926; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G; LIN DS, 1993, J LIPID RES, V34, P491; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Mutka AL, 2004, J BIOL CHEM, V279, P48654, DOI 10.1074/jbc.M405345200; Ohvo-Rekila H, 2000, CHEM PHYS LIPIDS, V105, P167, DOI 10.1016/S0009-3084(00)00122-5; Patra M, 2003, BIOPHYS J, V84, P3636, DOI 10.1016/S0006-3495(03)75094-2; Phillips JE, 1998, J LIPID RES, V39, P2459; Repakova J, 2005, BIOPHYS J, V88, P3398, DOI 10.1529/biophysj.104.055533; Rog T, 2004, J LIPID RES, V45, P326, DOI 10.1194/jlr.M300187-JLR200; Rog T, 2004, BIOPHYS CHEM, V107, P151, DOI 10.1016/j.bpc.2003.09.002; Rog T, 2003, BIOPHYS J, V84, P1818, DOI 10.1016/S0006-3495(03)74989-3; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; Scheidt HA, 2005, BIOPHYS J, V89, P2504, DOI 10.1529/biophysj.105.062018; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; Stuven E, 2003, J BIOL CHEM, V278, P53112, DOI 10.1074/jbc.M300402200; Tieleman DP, 1996, J CHEM PHYS, V105, P4871, DOI 10.1063/1.472323; Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y; Waterham HR, 2001, AM J HUM GENET, V69, P685, DOI 10.1086/323473; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Wenz JJ, 2003, BIOCHEMISTRY-US, V42, P14267, DOI 10.1021/bi035759c; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zuckermann MJ, 2004, METHOD ENZYMOL, V383, P198	53	114	118	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					348	355		10.1074/jbc.M509530200	http://dx.doi.org/10.1074/jbc.M509530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249181	hybrid			2022-12-25	WOS:000234307200044
J	Ahmad, A; Uversky, VN; Hong, D; Fink, AL				Ahmad, A; Uversky, VN; Hong, D; Fink, AL			Early events in the fibrillation of monomeric insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; STRUCTURAL TRANSFORMATIONS; CONFORMATIONAL STABILITY; AMYLOID FIBRILLATION; PROTEIN; FIBRILS; CHAIN; MECHANISM; INTERMEDIATE; SPECTROSCOPY	Insulin has a largely alpha-helical structure and exists as amixture of hexameric, dimeric, and monomeric states in solution, depending on the conditions: the protein is monomeric in 20% acetic acid. Insulin forms amyloid-like fibrils under a variety of conditions, especially at low pH. In this study we investigated the fibrillation of monomeric human insulin by monitoring changes in CD, attenuated total reflectance-Fourier transform infrared spectroscopy, 8-anilinonaphthalenesulfonic acid fluorescence, thioflavin T fluorescence, dynamic light scattering, and H/D exchange during the initial stages of the fibrillation process to provide insight into early events involving the monomer. The results demonstrate the existence of structural changes occurring before the onset of fibril formation, which are detectable by multiple probes. The data indicate at least two major populations of oligomeric intermediates between the native monomer and fibrils. Both have significantly non-native conformations, and indicate that fibrillation occurs from a betarich structure significantly distinct from the native fold.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Ahmad, Atta/0000-0002-6968-192X				Ahmad A, 2004, J BIOL CHEM, V279, P14999, DOI 10.1074/jbc.M313134200; Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Bellotti V, 1999, CELL MOL LIFE SCI, V55, P977, DOI 10.1007/s000180050348; Brange J, 1997, J PHARM SCI, V86, P517, DOI 10.1021/js960297s; Brange J, 1997, PROTEINS, V27, P507, DOI 10.1002/(SICI)1097-0134(199704)27:4<507::AID-PROT4>3.3.CO;2-H; Buijs J, 1999, ANAL CHEM, V71, P3219, DOI 10.1021/ac9809433; BURKE MJ, 1972, BIOCHEMISTRY-US, V11, P2435, DOI 10.1021/bi00763a008; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; DISCHE FE, 1988, DIABETOLOGIA, V31, P158, DOI 10.1007/BF00276849; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; FINK AL, 1999, ENCY MOL BIOL, P140; FINK AL, 1999, INFRARED ANAL PEPTID, P132; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kuznetsova IM, 2004, J PROTEOME RES, V3, P485, DOI 10.1021/pr034094y; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Munishkina LA, 2004, BIOCHEMISTRY-US, V43, P3289, DOI 10.1021/bi034938r; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Nielsen L, 2001, J PHARM SCI-US, V90, P29, DOI 10.1002/1520-6017(200101)90:1<29::AID-JPS4>3.0.CO;2-4; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; Ramanathan R, 1997, ANAL CHEM, V69, P5142, DOI 10.1021/ac970290a; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Souillac PO, 2003, BIOCHEMISTRY-US, V42, P8094, DOI 10.1021/bi034652m; Souillac PO, 2002, J BIOL CHEM, V277, P12657, DOI 10.1074/jbc.M109230200; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tito P, 2000, J MOL BIOL, V303, P267, DOI 10.1006/jmbi.2000.4142; Uversky V.N., 1999, MED SCI MONITOR, V5, P1001; Uversky V.N., 1999, MED SCI MONITOR, V5, P1238; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Vecchio G, 1996, INT J PEPT PROT RES, V48, P113; WAUGH DF, 1946, J AM CHEM SOC, V68, P247, DOI 10.1021/ja01206a030; WEI J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P69, DOI 10.1016/0167-4838(92)90425-D; Whittingham JL, 2002, J MOL BIOL, V318, P479, DOI 10.1016/S0022-2836(02)00021-9; Yao ZP, 1999, ACTA CRYSTALLOGR D, V55, P1524, DOI 10.1107/S0907444999008562	48	207	209	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42669	42675		10.1074/jbc.M504298200	http://dx.doi.org/10.1074/jbc.M504298200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16246845	hybrid, Green Submitted			2022-12-25	WOS:000234200800024
J	Pathak, SK; Basu, S; Bhattacharyya, A; Pathak, S; Kundu, M; Basu, J				Pathak, SK; Basu, S; Bhattacharyya, A; Pathak, S; Kundu, M; Basu, J			Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLE CALMETTE-GUERIN; NF-KAPPA-B; IL-12 PRODUCTION; DENDRITIC CELLS; MANNOSE RECEPTOR; KINASE; ACTIVATION; EXPRESSION; CYTOKINES; REQUIREMENT	Mannose-capped lipoarabinomannans (Man-LAMs) are members of the repertoire of Mycobacterium tuberculosis modulins that the bacillus uses to subvert the host innate immune response. Interleukin-12 (IL-12) production is critical for mounting an effective immune response by the host against M. tuberculosis. We demonstrate that Man-LAM inhibits IL-12 p40 production mediated by subsequent challenge with lipopolysaccharide (LPS). Man-LAM inhibits LPS-induced IL-12 p40 expression in an IL-10-independent manner. It attenuates LPS-induced NF-kappa B-driven luciferase gene expression, suggesting that its effects are likely directly related to inhibition of NF-kappa B. This is probably because of dampening of the Toll-like receptor signaling. Man-LAM inhibits IL-1 receptor-associated kinase (IRAK)-TRAF6 interaction as well as I kappa B-alpha phosphorylation. It directly attenuates nuclear translocation and DNA binding of c-Rel and p50. Man-LAM exerts these effects by inducing the expression of Irak-M, a negative regulator of TLR signaling. Knockdown of Irak-M expression by RNA interference reinstates LPS-induced IL-12 production in Man-LAM-pretreated cells. The fact that Irak-M expression could be elicited by yeast mannan suggested that ligation of the mannose receptor by the mannooligosaccharide caps of LAM was the probable trigger for IRAK-M induction.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 APC Rd, Kolkata 700009, W Bengal, India.	joyoti@vsnl.com	Bhattacharyya, Asima/J-7423-2012; PATHAK, SHRESH/I-6938-2012	Bhattacharyya, Asima/0000-0001-7292-6644; PATHAK, SHRESH/0000-0001-5275-1816				Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Anderson A F, 2000, Am J Knee Surg, V13, P19; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004; de Jong R, 1998, SCIENCE, V280, P1435; Fernandez N, 2005, J IMMUNOL, V174, P8154, DOI 10.4049/jimmunol.174.12.8154; Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Gilleron M, 1997, J BIOL CHEM, V272, P117; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Heinonen JE, 2002, FEBS LETT, V527, P274, DOI 10.1016/S0014-5793(02)03206-4; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KOLLET JI, 2005, IN PRESS MOL IMMUNOL; Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Ma XJ, 1997, J BIOL CHEM, V272, P10389; MACDA N, 2003, J BIOL CHEM, V278, P5513; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Means TK, 1999, J IMMUNOL, V163, P6748; Medema RH, 2004, BIOCHEM J, V380, P593, DOI 10.1042/BJ20040260; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; Rojas M, 2000, J INFECT DIS, V182, P240, DOI 10.1086/315676; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Wakeham J, 1998, J IMMUNOL, V160, P6101; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	59	91	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42794	42800		10.1074/jbc.M506471200	http://dx.doi.org/10.1074/jbc.M506471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263713	hybrid			2022-12-25	WOS:000234200800040
J	Jin, K; Lim, S; Mercer, SE; Friedman, E				Jin, K; Lim, S; Mercer, SE; Friedman, E			The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOMA-CELLS; MIRK PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; MEDIATES SURVIVAL; BREAST-CANCER; RAC; GTPASES; TIAM1; APOPTOSIS; PATHWAY	The serine/threonine kinase Mirk/dyrk1B is activated in several solid tumors where it mediates cell survival, but the mechanism by which Mirk is activated in tumors is unknown. We now demonstrate that Mirk is activated as a kinase by signaling from Rac1 to the mitogen-activated protein kinase kinase MKK3. Rac is a Ras superfamily GTPase that, when activated, functions downstream of Ras oncoproteins to promote cell survival, transformation, and membrane ruffling. The constitutively active mutant Rac1QL activated Mirk in several cell types through MKK3, which in turn activated Mirk by phosphorylation. Dominant negative Rac1, dominant negative MKK3, and knockdown of MKK3 by RNA interference inhibited the kinase activity of co-expressed Mirk. E-cadherin ligation in confluent Madin-Darby canine kidney ( MDCK) epithelial cells is known to transiently activate Rac1. Mirk was activated by endogenous Rac1 following E-cadherin ligation in confluent MDCK epithelial cells, whereas treatment of confluent MDCK cells with an Rac1 inhibitor decreased Mirk activity. Disruption of cadherin ligation by EGTA or prevention of cadherin ligation by maintenance of cells at subconfluent density blocked activation of Mirk. Engagement of cadherin molecules on subconfluent cells by an E-cadherin/Fc chimeric molecule transiently activated both Rac1 and Mirk with a similar time course. Rac activity is up-regulated in many human tumors and mediates survival signals, which enable tumor cells to evade apoptosis. This study characterizes a new anti-apoptotic signaling pathway that connects Rac1 with a novel downstream effector, Mirk kinase, which has recently been demonstrated to mediate survival in human tumors.	SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), SUNY Upstate Med Univ, Dept Pathol, 2305 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu		Lim, Seunghwan/0000-0001-8920-0890	NCI NIH HHS [R01-CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lee K, 2000, CANCER RES, V60, P3631; Lee K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P273; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; Zhang BL, 2004, MOL CELL BIOL, V24, P6205, DOI 10.1128/MCB.24.14.6205-6214.2004; Zhang BL, 2003, MOL CELL BIOL, V23, P5716, DOI 10.1128/MCB.23.16.5716-5725.2003	28	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42097	42105		10.1074/jbc.M507301200	http://dx.doi.org/10.1074/jbc.M507301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257974	hybrid			2022-12-25	WOS:000233992700036
J	Yokoyama, N; Lougheed, J; Miller, WT				Yokoyama, N; Lougheed, J; Miller, WT			Phosphorylation of WASP by the Cdc42-associated kinase ACK1 - Dual hydroxyamino acid specificity in a tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; GROWTH-FACTOR STIMULATION; CRYSTAL-STRUCTURE; ARP2/3 COMPLEX; SUBSTRATE-SPECIFICITY; ACTIN POLYMERIZATION; PEPTIDE SUBSTRATE; RECEPTOR KINASE; HUMAN GENOME; N-WASP	ACK1 is a nonreceptor tyrosine kinase that associates specifically with Cdc42. Relatively few ACK1 substrates and interacting proteins have been identified. In this study, we demonstrated that ACK1 phosphorylates the Wiskott-Aldrich syndrome protein (WASP), a Cdc42 effector that plays an important role in the formation of new actin filaments. ACK1 and WASP interact in intact cells, and overexpression of ACK1 promotes WASP phosphorylation. Phosphorylation of WASP in vitro was enhanced by the addition of Cdc42 or phosphatidylinositol 4,5-biphosphate, presumably due to release of the autoinhibitory interactions in WASP. Surprisingly, when we mapped the sites of WASP phosphorylation, we found that ACK1 possesses significant serine kinase activity toward WASP (directed at Ser-242), as well as tyrosine kinase activity directed at Tyr-256. A serine peptide derived from the Ser-242 WASP phosphorylation site is also a substrate for ACK1. ACK1 expressed in bacteria retained its serine kinase activity, eliminating the possibility of contamination with a copurifying kinase. Serine phosphorylation of WASP enhanced the ability of WASP to stimulate actin polymerization in mammalian cell lysates. Thus, the tyrosine kinase ACK1 acts as a dual specificity kinase toward this substrate. In contrast to other dual specificity kinases that more closely resemble Ser/Thr kinases, ACK1 is a tyrosine kinase with an active site that can accommodate both types of hydroxyamino acids in substrates.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Exelixis Inc, San Francisco, CA 94083 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Exelixis, Inc.	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T 6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu						Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Coon M, 2002, J CELL BIOCHEM, V84, P655, DOI 10.1002/jcb.10078; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kato-Stankiewicz J, 2001, BIOCHEM BIOPH RES CO, V284, P470, DOI 10.1006/bbrc.2001.5004; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lougheed JC, 2004, J BIOL CHEM, V279, P44039, DOI 10.1074/jbc.M406703200; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh N, 1999, TRENDS CELL BIOL, V9, P15, DOI 10.1016/S0962-8924(98)01411-1; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200	45	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42219	42226		10.1074/jbc.M506996200	http://dx.doi.org/10.1074/jbc.M506996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257963	hybrid			2022-12-25	WOS:000233992700050
J	Vandebrouck, A; Ducret, T; Basset, O; Sebille, S; Raymond, G; Ruegg, U; Gailly, P; Cognard, C; Constantin, B				Vandebrouck, A; Ducret, T; Basset, O; Sebille, S; Raymond, G; Ruegg, U; Gailly, P; Cognard, C; Constantin, B			Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes	FASEB JOURNAL			English	Article						mitochondria; skeletal muscle cells; Duchenne muscular dystrophy	SKELETAL-MUSCLE FIBERS; DYSTROPHIN GENE-TRANSFER; CONTRACTING IN-VITRO; MDX MYOTUBES; SARCOPLASMIC-RETICULUM; LEAK CHANNEL; CELLS; CA2+; INFLUX; LOCALIZATION	Defective expression of dystrophin in muscle cells is the primary feature of Duchenne muscular dystrophy (DMD), which is accompanied by fiber necrosis and intracellular calcium mishandling. These features led to the hypothesis that dystrophin could control calcium movements. Calcium mishandling in human DMD myotubes is dependent on contraction and/or calcium release activity, suggesting the involvement of channels being activated during these processes. Forced expression of minidystrophin at the plasma membrane of dystrophin-deficient Sol8 myotubes reactivates appropriate sarcolemmal expression of dystrophin-associated proteins and results in normal calcium homeostasis. In active dystrophic myotubes, store-operated calcium channels could be responsible for a sustained calcium influx in muscle cells. We show here that depletion of calcium stores ( sarcoplasmic reticulum) by repetitive activation of calcium release and blockade of SERCA leads to a calcium influx. In myotubes expressing recombinant minidystrophin, these store-dependent influxes were reduced to a level similar to that observed in myotubes expressing native dystrophin. High store-dependent calcium influxes in dystrophin-deficient myotubes were associated with sustained cytosolic calcium transients and high intramitochondrial entries, while lower store-dependent calcium influx in myotubes expressing minidystrophin resulted in shorter calcium transients and reduced calcium uptake into mitochondria. We propose that minidystrophin negatively regulates sarcolemmal store-dependent calcium channels, which reduces store-dependent calcium influx, as well as its mitochondrial uptake. Forced expression of minidystrophin in dystrophic cells might restore the regulation of sarcolemmal store-dependent channels, which could protect against calcium mishandling.	Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France; Univ Geneva, Pharmacol Lab, Geneva, Switzerland; Univ Catholique Louvain, Dept Physiol, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; University of Geneva; Universite Catholique Louvain	Constantin, B (corresponding author), Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	bruno.constantin@univ-poitiers.fr	COGNARD, Christian/P-5305-2016; Sebille, Stéphane/P-7959-2016; Constantin, Bruno/AAH-6463-2021	Ducret, Thomas/0000-0002-5146-6869; RUEGG, Urs/0000-0001-6078-8280; Constantin, Bruno/0000-0003-1668-581X				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; BLINKS JR, 1978, J PHYSIOL-LONDON, V277, P291, DOI 10.1113/jphysiol.1978.sp012273; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; COGNARD C, 1993, CELL CALCIUM, V14, P333, DOI 10.1016/0143-4160(93)90054-A; CONSTANTIN B, 1993, CELL CALCIUM, V14, P135, DOI 10.1016/0143-4160(93)90083-I; DACOSTA AG, 1986, ARCH BIOCHEM BIOPHYS, V249, P199, DOI 10.1016/0003-9861(86)90575-8; Decrouy A, 1997, GENE THER, V4, P401, DOI 10.1038/sj.gt.3300407; Decrouy A, 1998, GENE THER, V5, P59, DOI 10.1038/sj.gt.3300553; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Imbert N, 1996, NEUROMUSCULAR DISORD, V6, P351, DOI 10.1016/0960-8966(96)00351-3; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Marchand E, 2004, EXP CELL RES, V297, P363, DOI 10.1016/j.yexcr.2004.02.032; Marchand E, 2001, CELL CALCIUM, V29, P85, DOI 10.1054/ceca.2000.0159; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MASUDA T, 1992, J CELL BIOL, V119, P543, DOI 10.1083/jcb.119.3.543; McCarter GC, 1997, GENE THER, V4, P483, DOI 10.1038/sj.gt.3300405; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; STRAUB V, 1992, J CELL BIOL, V119, P1183, DOI 10.1083/jcb.119.5.1183; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vandebrouck C, 2001, NEUROMUSCULAR DISORD, V11, P72, DOI 10.1016/S0960-8966(00)00153-X; WAKAYAMA Y, 1993, ACTA NEUROPATHOL, V86, P567, DOI 10.1007/BF00294294; WILLIAMS JH, 1990, MUSCLE NERVE, V13, P1118, DOI 10.1002/mus.880131206	37	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					136	+		10.1096/fj.04-3633fje	http://dx.doi.org/10.1096/fj.04-3633fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16254044	Green Published			2022-12-25	WOS:000232991100004
J	Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L				Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L			Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression	ONCOGENE			English	Article						ELF; Smad4; spectrin; gastrointestinal cancer; E-cadherin	CELL-CELL ADHESION; GASTRIC-CANCER; MESENCHYMAL TRANSITION; LIVER DEVELOPMENT; IN-VITRO; SPECTRIN; CARCINOMA; MEMBRANE; PROTEIN; MICE	Inactivation of the transforming growth factor-beta (TGF-beta) pathway occurs often in malignancies of the gastrointestinal (GI) system. However, only a fraction of sporadic GI tumors exhibit inactivating mutations in early stages of cancer formation, suggesting that other mechanisms play a critical role in the inactivation of this pathway. Here, we show a wide range of GI tumors, including those of the stomach, liver and colon in elf(+/-) and elf(+/-)/Smad4(+/-) mutant mice. We found that embryonic liver fodrin ( ELF), a beta-Spectrin originally identified in endodermal stem/progenitor cells committed to foregut lineage, possesses potent antioncogenic activity and is frequently inactivated in GI cancers. Specifically, E-cadherin accumulation at cell-cell contacts and E-cadherin-beta-catenin-dependent epithelial cell-cell adhesion is disrupted in elf(+/-)/Smad4(+)/(-) mutant gastric epithelial cells, and could be rescued by ectopic expression of full-length elf, but not Smad3 or Smad4. Subcellular fractionation revealed that E-cadherin is expressed mainly at the cell membrane after TGF-beta stimulation. In contrast, elf(+/-)/Smad4(+/-) mutant tissues showed abnormal distribution of E-cadherin that could be rescued by overexpression of ELF but not Smad3 or Smad4. Our results identify a group of common lethal malignancies in which inactivation of TGF-beta signaling, which is essential for tumor suppression, is disrupted by inactivation of the ELF adaptor protein.	Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Surg, Washington, DC USA; Dept Vet Affairs, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, B (corresponding author), Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Med Dent Bldg NW 210-212,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	bm72@georgetown.edu; lopamishra@yahoo.com	Reddy, E. Premkumar/F-6233-2011; deng, chuxia/N-6713-2016	Mishra, Lopa/0000-0002-6850-0808	NCI NIH HHS [R01 CA106614A, R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111, R01 DK056111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111, Z01DK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hadzija MP, 2004, MUTAT RES-FUND MOL M, V548, P61, DOI 10.1016/j.mrfmmm.2003.12.018; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, CANCER RES, V59, P4506; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; ROBERTS AB, 1990, TRANSFORMING GROWTH; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Scartozzi M, 2004, CANCER TREAT REV, V30, P451, DOI 10.1016/j.ctrv.2004.01.001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sormunen RT, 1999, J PATHOL, V187, P416; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	35	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1871	1886		10.1038/sj.onc.1209211	http://dx.doi.org/10.1038/sj.onc.1209211			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288220	Green Accepted			2022-12-25	WOS:000236224800004
J	Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C				Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C			DNA copy number gains in head and neck squamous cell carcinoma	ONCOGENE			English	Article						amplification; HNSCC; RLGS	COMPARATIVE-GENOMIC-HYBRIDIZATION; GENE AMPLIFICATION; CANDIDATE ONCOGENE; 3Q GAIN; C-MYC; CANCER; IDENTIFICATION; SEQUENCES; REGIONS; OVARIAN	Gene amplification, a common mechanism for oncogene activation in cancer, has been used as a tag for the identification of novel oncogenes. DNA amplification is frequently observed in head and neck squamous cell carcinoma (HNSCC) and potential oncogenes have already been reported. We applied restriction landmark genome scanning (RLGS) to study gene amplifications and low-level copy number changes in HNSCC in order to locate previously uncharacterized regions with copy number gains in primary tumor samples. A total of 63 enhanced RLGS fragments, indicative of DNA copy number changes, including gains of single alleles, were scored. Enhanced sequences were identified from 33 different chromosomal regions including those previously reported (e.g. 3q26.3 and 11q13.3) as well as novel regions (e.g. 3q29, 8q13.1, 8q22.3, 9q32, 10q24.32, 14q32.32, 17q25.1 and 20q13.33). Furthermore, our data suggest that amplicons 11q13.3 and 3q26.3-q29 may be divided into possibly two and three independent amplicons, respectively, an observation supported by published microarray expression data.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; Roswell Pk Canc Inst, Dept Canc Genet & Comprehens Canc Ctr, Buffalo, NY USA; Ohio State Univ, Comp Informat Sci Dept, Columbus, OH USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Roswell Park Cancer Institute; University System of Ohio; Ohio State University	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, 420 W 12th Ave,Room 464A, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	Reever, Larson/H-9685-2019; Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Reever, Larson/0000-0002-5692-4793; Smiraglia, Dominic/0000-0001-8852-1510; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13123-02] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arai H, 2003, CANCER GENET CYTOGEN, V146, P16, DOI 10.1016/S0165-4608(03)00106-7; Bitzer M, 2003, ANTICANCER RES, V23, P1489; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Costello JF, 1997, CANCER RES, V57, P1250; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Du Plessis L, 1999, CANCER RES, V59, P1877; Estilo CL, 2003, CLIN CANCER RES, V9, P2300; Fan CS, 2000, HUM PATHOL, V31, P169, DOI 10.1016/S0046-8177(00)80216-6; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermsen M, 2001, J PATHOL, V194, P177; HIROTSUNE S, 1992, CANCER RES, V52, P3642; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Knuutila S, 1998, AM J PATHOL, V152, P1107; Komiyama T, 1997, JPN J CANCER RES, V88, P476, DOI 10.1111/j.1349-7006.1997.tb00406.x; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lukasova E, 2004, CHROMOSOMA, V112, P221, DOI 10.1007/s00412-003-0263-3; Lyons SK, 1997, BRIT MED BULL, V53, P554; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Matsumura K, 2000, GENE CHROMOSOME CANC, V29, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1032>3.0.CO;2-U; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Oga A, 2001, CANCER GENET CYTOGEN, V127, P24, DOI 10.1016/S0165-4608(00)00430-1; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Rao PH, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-5; Redon R, 2002, CANCER RES, V62, P6211; Riazimand SH, 2002, ONCOLOGY-BASEL, V63, P385, DOI 10.1159/000066220; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHIMKE RT, 1990, CANCER CELL-MON REV, V2, P149; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh B, 2001, CANCER RES, V61, P4506; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SPEICHER MR, 1995, CANCER RES, V55, P1010; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tang TCM, 2002, CANCER RES, V62, P7157; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Wu R, 2003, AM J PATHOL, V162, P1603, DOI 10.1016/S0002-9440(10)64294-0	45	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1424	1433		10.1038/sj.onc.1209166	http://dx.doi.org/10.1038/sj.onc.1209166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247453				2022-12-25	WOS:000235708200017
J	Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH				Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH			RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells	ONCOGENE			English	Article						RelB; radiation; MnSOD	NF-KAPPA-B; NF-KAPPA-B2 P100; INDUCTION; TRANSCRIPTION; SPECIFICITY; RESPONSES; ASSAY	The relationship between NF-kappa B and resistance to radiation treatment in many tumor cell types has been generally well recognized. However, which members of the NF-kappa B family contribute to radiation resistance is unclear. In the present study, we demonstrate that RelB plays an important radioprotective role in aggressive prostate cancer cells, in part by the induction of antioxidant and antiapoptotic manganese superoxide dismutase (MnSOD) gene. RelB is both constitutively present and is inducible by radiation in aggressive prostate cancer cells. Using ectopically expressed dominant negative inhibitor, p100 mutant, and the siRNA approach, we demonstrate that selective inhibition of RelB significantly decreases the levels of MnSOD resulting in a significant increase in the sensitivity of prostate cancer cells to radiation treatment. These results demonstrate that RelB plays an important role in redox regulation of the cell and protects aggressive prostate cancer cells against radiation-induced cell death. Thus, inhibition of RelB could be a novel mechanism to radiosensitize prostate cancer.	Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, WH (corresponding author), Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, 800 Rose St N-10, Lexington, KY 40536 USA.	stclair@uky.edu			NATIONAL CANCER INSTITUTE [R01CA049797, R29CA049797] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA049797, R01 CA049797-14, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LESSARD L, 2005, P AM ASSOC CANC RES, V46, P3160; Murley JS, 2004, RADIAT RES, V162, P536, DOI 10.1667/RR3256; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401	19	72	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1554	1559		10.1038/sj.onc.1209186	http://dx.doi.org/10.1038/sj.onc.1209186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261162	Green Accepted			2022-12-25	WOS:000235890400012
J	Lee, SN; Hwang, JR; Lindberg, I				Lee, SN; Hwang, JR; Lindberg, I			Neuroendocrine protein 7B2 can be inactivated by phosphorylation within the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; LACTATING MAMMARY-GLAND; APPARATUS CASEIN KINASE; BOVINE ADRENAL-MEDULLA; GOLGI-APPARATUS; BINDING-PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; SELECTIVE INHIBITOR; GASTRIN PRECURSOR; GRP94 ENDOPLASMIN	The prohormone convertases play important roles in the maturation of neuropeptides and peptide hormone precursors. Prohormone convertase-2 (PC2) is the only convertase that requires the expression of another neuroendocrine protein, 7B2, for expression of enzyme activity. In this study, we determined that 7B2 can be phosphorylated in Rin cells (a rat insulinoma cell line) and cultured chromaffin cells, but not in AtT-20 cells (derived from mouse anterior pituitary). Phosphoamino acid analysis of Rin cell 7B2 indicated the presence of phosphorylated serine and threonine. Phosphorylation of Ser(115) (located within the minimally active 36-residue peptide) was confirmed by mutagenesis, although Ser(115) did not represent the sole residue phosphorylated. Two independent assays were used to investigate the effect of phosphorylated 7B2 on PC2 activation: the ability of 7B2 to bind to pro-PC2 was assessed by co-immunoprecipitation, and activation of pro-PC2 was assessed in a cell-free assay. Phosphorylated 7B2 was unable to bind pro-PC2, and the phosphorylated 7B2 peptide (residues 86-121, known to be the minimally active peptide for pro-PC2 activation) was impaired in its ability to facilitate the generation of PC2 activity in membrane fractions containing pro-PC2. In vitro phosphorylation experiments using Golgi membrane fractions showed that 7B2 could be phosphorylated by endogenous Golgi kinases. Golgi kinase activity was strongly inhibited by the broad-range kinase inhibitor staurosporine and partially inhibited by the protein kinase C inhibitor bisindolylmaleimide I, but not by the other protein kinase A, Ca2+/calmodulin-dependent kinase II, myosin light chain kinase, and protein kinase G inhibitors tested. We conclude that phosphorylation of 7B2 functionally inactivates this protein and suggest that this may be analogous to the phosphorylating inactivation of BiP, which impairs its ability to bind substrate.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsuhsc.edu	Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49703, R01 DK049703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENNETT HPJ, 1983, J BIOL CHEM, V258, P8108; BENNETT HPJ, 1981, P NATL ACAD SCI-BIOL, V78, P4713, DOI 10.1073/pnas.78.8.4713; BINGHAM EW, 1979, J BIOL CHEM, V254, P4510; BINGHAM EW, 1972, J BIOL CHEM, V247, P8193; BINGHAM EW, 1974, J BIOL CHEM, V249, P3647; Bishop L, 1998, GASTROENTEROLOGY, V115, P1154, DOI 10.1016/S0016-5085(98)70086-1; BLOCH KD, 1987, J BIOL CHEM, V262, P9956; Braks JAM, 1996, EUR J BIOCHEM, V238, P505, DOI 10.1111/j.1432-1033.1996.0505z.x; Brunati AM, 2000, BIOCHEM J, V351, P765, DOI 10.1042/0264-6021:3510765; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DRAY A, 1988, NEUROSCI LETT, V91, P301, DOI 10.1016/0304-3940(88)90697-0; Drzymala L, 2000, BIOCHEMISTRY-US, V39, P2023, DOI 10.1021/bi9924213; DSOUZA NB, 1988, J BIOL CHEM, V263, P2548; Duncan JS, 2000, BIOCHEM J, V350, P463, DOI 10.1042/0264-6021:3500463; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; Fekete C, 2000, J NEUROSCI, V20, P1550; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Gaut JR, 1997, CELL STRESS CHAPERON, V2, P252, DOI 10.1379/1466-1268(1997)002<0252:IVTPOI>2.3.CO;2; Giorgianni F, 2004, PROTEOMICS, V4, P587, DOI 10.1002/pmic.200300584; GLASS DB, 1983, BIOCHEM J, V213, P159, DOI 10.1042/bj2130159; GOTTLIEB TA, 1981, J BIOL CHEM, V256, P4116; GRIZZUTI K, 1973, BIOCHEMISTRY-US, V12, P4399, DOI 10.1021/bi00746a016; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hwang JR, 2000, J BIOL CHEM, V275, P17886, DOI 10.1074/jbc.M000032200; Imam A, 2001, FASEB J, V15, P28; Johanning K, 1996, J NEUROCHEM, V66, P898; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; KERR JM, 1991, GENE, V108, P237, DOI 10.1016/0378-1119(91)90439-I; Krarup T, 1998, AM J PHYSIOL-CELL PH, V275, pC239, DOI 10.1152/ajpcell.1998.275.1.C239; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; LINDBERG I, 1992, J NEUROCHEM, V58, P448, DOI 10.1111/j.1471-4159.1992.tb09742.x; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; MAINS RE, 1983, ENDOCRINOLOGY, V112, P1986, DOI 10.1210/endo-112-6-1986; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MERCIER JC, 1981, BIOCHIMIE, V63, P1, DOI 10.1016/S0300-9084(81)80141-1; MILGRAM SL, 1994, J CELL SCI, V107, P737; Muller L, 1999, J BIOL CHEM, V274, P21471, DOI 10.1074/jbc.274.30.21471; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PAQUET L, 1994, J BIOL CHEM, V269, P19279; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAKO T, 1988, CANCER RES, V48, P4646; Schultz A, 2004, J BIOL CHEM, V279, P31750, DOI 10.1074/jbc.M313017200; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SIGAFOOS J, 1993, CELL MOL NEUROBIOL, V13, P271, DOI 10.1007/BF00733755; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VARRO A, 1988, BIOCHEM J, V256, P951, DOI 10.1042/bj2560951; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WANG SY, 1982, J BIOL CHEM, V257, P3837; WATKINSON A, 1989, REGUL PEPTIDES, V26, P313, DOI 10.1016/0167-0115(89)90199-7; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WEST DW, 1986, J DAIRY RES, V53, P333, DOI 10.1017/S0022029900024948; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	75	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3312	3320		10.1074/jbc.M506635200	http://dx.doi.org/10.1074/jbc.M506635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16286464	hybrid			2022-12-25	WOS:000235128200038
J	Matsumoto, Y; Murai, M; Fujita, D; Sakamoto, K; Miyoshi, H; Yoshida, M; Mogi, T				Matsumoto, Y; Murai, M; Fujita, D; Sakamoto, K; Miyoshi, H; Yoshida, M; Mogi, T			Mass spectrometric analysis of the ubiquinol-binding site in cytochrome bd from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL OXIDASE COMPLEX; AEROBIC RESPIRATORY-CHAIN; QUINOL OXIDASE; ELECTRON-TRANSFER; AZOTOBACTER-VINELANDII; SUBUNIT-I; LIGAND-BINDING; AXIAL LIGANDS; IDENTIFICATION; PURIFICATION	Cytochrome bd is a heterodimeric terminal ubiquinol oxidase in the aerobic respiratory chain of Escherichia coli. For understanding the unique catalytic mechanism of the quinol oxidation, mass spectrometry was used to identify amino acid residue(s) that can be labeled with a reduced form of 2-azido-3-methoxy-5-methyl-6-geranyl-1,4- benzoquinone or 2-methoxy-3-azido-5-methyl-6-geranyl-1,4- benzoquinone. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry demonstrated that the photo inactivation of ubiquinol-1 oxidase activity was accompanied by the labeling of subunit I with both azidoquinols. The cross-linked domain was identified by reverse-phase high performance liquid chromatography of subunit I peptides produced by in-gel double digestion with lysyl endopeptidase and endoproteinase Asp-N. Electrospray ionization quadrupole time-of-flight mass spectrometry determined the amino acid sequence of the peptide (m/z 1047.5) to be Glu(278)-Lys(283), where a photoproduct of azido-Q(2) was linked to the carboxylic side chain of I-Glu(280). This study demonstrated directly that the N-terminal region of periplasmic loop VI/VII (Q-loop) is a part of the quinol oxidation site and indicates that the 2- and 3-methoxy groups of the quinone ring are in the close vicinity of I-Glu(280).	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Univ Tokyo, Grad Sch Med, Dept Biomed Chem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Org, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo Institute of Technology; Kyoto University; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Mogi, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	tmogi@res.titech.ac.jp	Sakamoto, Kimitoshi/G-4539-2014	Murai, Masatoshi/0000-0001-6601-2854				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; FANG H, 1989, J BIOL CHEM, V264, P8026; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Gilmour R, 1997, J BACTERIOL, V179, P863, DOI 10.1128/jb.179.3.863-870.1997; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; GREEN GN, 1984, J BIOL CHEM, V259, P7994; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HILL BC, 1994, BIOCHEMISTRY-US, V33, P15110, DOI 10.1021/bi00254a021; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; Hirota S, 1995, BIOSPECTROSCOPY, V1, P305, DOI 10.1002/bspy.350010502; Hori H, 1996, J BIOL CHEM, V271, P9254, DOI 10.1074/jbc.271.16.9254; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; Ito M, 1997, COMPUT APPL BIOSCI, V13, P415; Jasaitis A, 2000, BIOCHEMISTRY-US, V39, P13800, DOI 10.1021/bi001165n; Junemann S, 1997, BIOCHEMISTRY-US, V36, P9323, DOI 10.1021/bi970055m; JUNEMANN S, 1994, FEBS LETT, V345, P198, DOI 10.1016/0014-5793(94)00372-6; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; KITA K, 1984, J BIOL CHEM, V259, P3375; Kobayashi K, 1999, BIOCHEMISTRY-US, V38, P5913, DOI 10.1021/bi982088n; KOLONAY JF, 1994, J BACTERIOL, V176, P4177, DOI 10.1128/JB.176.13.4177-4181.1994; KONISHI K, 1986, J BIOCHEM, V99, P1227, DOI 10.1093/oxfordjournals.jbchem.a135586; KRANZ RG, 1984, J BIOL CHEM, V259, P7998; Kusumoto K, 2000, ARCH MICROBIOL, V173, P390, DOI 10.1007/s002030000161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LEYVA E, 1989, J ORG CHEM, V54, P5938, DOI 10.1021/jo00286a028; LORENCE RM, 1988, J BIOL CHEM, V263, P5271; LORENCE RM, 1984, BIOCHIM BIOPHYS ACTA, V790, P148, DOI 10.1016/0167-4838(84)90218-8; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P1076, DOI 10.1021/bi00003a044; MILLER MJ, 1985, J BIOL CHEM, V260, P4003; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; MILLER MJ, 1988, J BIOL CHEM, V263, P5235; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MOGI T, 2005, SEIKAGAKU, V77, P808; Osborne JP, 1999, BBA-BIOENERGETICS, V1410, P32, DOI 10.1016/S0005-2728(98)00171-6; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; POOLE RK, 1987, FEBS LETT, V217, P49, DOI 10.1016/0014-5793(87)81240-1; Sakamoto J, 1999, BBA-BIOENERGETICS, V1411, P147, DOI 10.1016/S0005-2728(99)00012-2; Sakamoto K, 1996, J BIOL CHEM, V271, P29897, DOI 10.1074/jbc.271.47.29897; Sakamoto K, 2002, J PESTIC SCI, V27, P147; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SMITH A, 1990, J GEN MICROBIOL, V136, P171, DOI 10.1099/00221287-136-1-171; Sturr MG, 1996, J BACTERIOL, V178, P1742, DOI 10.1128/jb.178.6.1742-1749.1996; Sun J, 1996, BIOCHEMISTRY-US, V35, P2403, DOI 10.1021/bi9518252; Tsatsos PH, 1998, BIOCHEMISTRY-US, V37, P9884, DOI 10.1021/bi9809270; Tsubaki M, 2000, J INORG BIOCHEM, V82, P19, DOI 10.1016/S0162-0134(00)00140-9; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; Venter H, 2002, BIOCHEM J, V363, P243, DOI 10.1042/0264-6021:3630243; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; WELTER R, 1994, J BIOL CHEM, V269, P28834; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; YANG FD, 1986, J BIOL CHEM, V261, P4987; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1985, J BIOL CHEM, V260, P963; Zhang J, 2004, FEBS LETT, V561, P58, DOI 10.1016/S0014-5793(04)00125-5; Zhang J, 2001, BIOCHEMISTRY-US, V40, P8548, DOI 10.1021/bi010469m	63	34	34	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1905	1912		10.1074/jbc.M508206200	http://dx.doi.org/10.1074/jbc.M508206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16299377	hybrid			2022-12-25	WOS:000234760400008
J	Weichart, D; Gobom, J; Klopfleisch, S; Hasler, R; Gustavsson, N; Billmann, S; Lehrach, H; Seegert, D; Schreiber, S; Rosenstiel, P				Weichart, D; Gobom, J; Klopfleisch, S; Hasler, R; Gustavsson, N; Billmann, S; Lehrach, H; Seegert, D; Schreiber, S; Rosenstiel, P			Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; CROHNS-DISEASE; TNF-ALPHA; 2-DIMENSIONAL ELECTROPHORESIS; INDUCED APOPTOSIS; INTERFERON-GAMMA; BINDING-PROTEIN; NOD2; GENE; EXPRESSION	NOD2, a cytosolic receptor for the bacterial proteoglycan fragment muramyl dipeptide (MDP), plays an important role in the recognition of intracellular pathogens. Variants in the bacterial sensor domain of NOD2 are genetically associated with an increased risk for the development of Crohn disease, a human chronic inflammatory bowel disease. In the present study, global protein expression changes after MDP stimulation were analyzed by two-dimensional PAGE of total protein extracts of human cultured cells stably transfected with expression constructs encoding for wild type NOD2 (NOD2(WT)) or the disease-associated NOD2 L1007fsinsC (NOD2(SNP13)) variant. Differentially regulated proteins were identified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) peptide mass fingerprinting and MALDI MS/MS. The limited overlap in the responses of the NOD2-overexpressing cell lines to MDP included a down-regulation of heat shock 70-kDa protein 4. A complex pro-inflammatory program regulated by NOD2WT that encompasses a regulation of key genes involved in protein folding, DNA repair, cellular redox homeostasis, and metabolism was observed both under normal growth conditions and after stimulation with MDP. By using the comparison of NOD2WT and disease-associated NOD2SNP13 variant, we have identified a proteomic signature pattern that may further our understanding of the influence of genetic variations in the NOD2 gene in the pathophysiology of chronic inflammatory bowel disease.	Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, D-24105 Kiel, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Conaris Res Inst AG, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; Max Planck Society	Schreiber, S (corresponding author), Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Rosenstiel, Philip/A-5137-2009; Häsler, Robert/A-4908-2009; Seegert, Dirk/B-8826-2011; Gustavsson, Niklas/D-5712-2011	Rosenstiel, Philip/0000-0002-9692-8828; Häsler, Robert/0000-0003-4174-8229; 				Ceulemans H, 1999, EUR J BIOCHEM, V262, P36, DOI 10.1046/j.1432-1327.1999.00344.x; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chen DQ, 2005, J BIOL CHEM, V280, P22425, DOI 10.1074/jbc.M413380200; Chen DQ, 2004, BIOCHEMISTRY-US, V43, P11796, DOI 10.1021/bi0490789; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; DZIARSKI R, 1988, CELL IMMUNOL, V111, P10, DOI 10.1016/0008-8749(88)90047-0; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Gadgil HS, 2003, PROTEOMICS, V3, P1767, DOI 10.1002/pmic.200300532; Geiben-Lynn R, 2003, J BIOL CHEM, V278, P1569, DOI 10.1074/jbc.M209964200; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gobom J, 2002, ANAL CHEM, V74, P3915, DOI 10.1021/ac011203o; Gobom J, 2001, ANAL CHEM, V73, P434, DOI 10.1021/ac001241s; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hocke M, 1999, HEPATO-GASTROENTEROL, V46, P2333; Homer C, 2005, ONCOGENE, V24, P8314, DOI 10.1038/sj.onc.1208998; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Issa JPJ, 2001, CANCER RES, V61, P3573; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kald B, 1996, DIGESTION, V57, P472, DOI 10.1159/000201376; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Lekmine F, 2002, BIOCHEM BIOPH RES CO, V291, P744, DOI 10.1006/bbrc.2002.6516; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Liu XW, 2004, WORLD J GASTROENTERO, V10, P2701, DOI 10.3748/wjg.v10.i18.2701; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Mannick EE, 2004, CLIN IMMUNOL, V112, P247, DOI 10.1016/j.clim.2004.03.014; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; MORAS ML, 1985, INT J IMMUNOPHARMACO, V7, P515; NAGAO S, 1984, CELL IMMUNOL, V89, P427, DOI 10.1016/0008-8749(84)90344-7; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; Nordhoff E, 2001, ELECTROPHORESIS, V22, P2844, DOI 10.1002/1522-2683(200108)22:14<2844::AID-ELPS2844>3.3.CO;2-Z; ODA T, 1994, J BIOL CHEM, V269, P22925; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Olsson I, 2002, PROTEOMICS, V2, P1630, DOI 10.1002/1615-9861(200211)2:11<1630::AID-PROT1630>3.0.CO;2-N; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Schreiber S, 2005, NAT REV GENET, V6, P376, DOI 10.1038/nrg1607; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; Shau HY, 1997, FREE RADICAL BIO MED, V22, P497, DOI 10.1016/S0891-5849(96)00372-3; SHAU HY, 1993, CELL IMMUNOL, V147, P1, DOI 10.1006/cimm.1993.1043; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Till A, 2005, J BIOL CHEM, V280, P5994, DOI 10.1074/jbc.M411541200; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; WOOD DD, 1981, INT J IMMUNOPHARMACO, V3, P31, DOI 10.1016/0192-0561(81)90043-6; Yokota S, 2001, CELL STRESS CHAPERON, V6, P345, DOI 10.1379/1466-1268(2001)006<0345:IEOCCC>2.0.CO;2; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	68	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2380	2389		10.1074/jbc.M505986200	http://dx.doi.org/10.1074/jbc.M505986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16257953	Green Published, hybrid			2022-12-25	WOS:000234760400063
J	Buscaglia, CA; Penesetti, D; Tao, MY; Nussenzweig, V				Buscaglia, CA; Penesetti, D; Tao, MY; Nussenzweig, V			Characterization of an aldolase-binding site in the Wiskott-Aldrich syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; F-ACTIN; ERYTHROCYTE-MEMBRANE; N-WASP; IDENTIFICATION; LOCALIZATION; PLASMODIUM; ENZYMES; LAMELLIPODIA; ACTIVATION	The thrombospondin-related anonymous protein (TRAP) is an essential transmembrane molecule in Plasmodium sporozoites. TRAP displays adhesive motifs on the extracellular portion, whereas its cytoplasmic tail connects to actin via aldolase, thus driving parasite motility and host cell invasion. The minimal requirements for the TRAP binding to aldolase were scanned here and found to be shared by different human proteins, including the Wiskott-Aldrich syndrome protein (WASp) family members. In vitro and in vivo binding of WASp members to aldolase was characterized by biochemical, deletion mapping, mutagenesis, and co-immunoprecipitation studies. As in the case of TRAP, the binding of WASp to aldolase is competitively inhibited by the enzyme substrate/products. Furthermore, TRAP and WASp, but not other unrelated aldolase binders, compete for the binding to the enzyme in vitro. Together, our results define a conserved aldolase binding motif in the WASp family members and suggest that aldolase modulates the motility and actin dynamics of mammalian cells. These findings along with the presence of similar aldolase binding motifs in additional human proteins, some of which indeed interact with aldolase in pull-down assays, suggest supplementary, non-glycolytic roles for this enzyme.	NYU, Sch Med, Michael Heidelberger Div Immunol, Dept Pathol, New York, NY 10016 USA	New York University	Buscaglia, CA (corresponding author), NYU, Sch Med, Michael Heidelberger Div Immunol, Dept Pathol, MSB 131,550 1st Ave, New York, NY 10016 USA.	buscac01@med.nyu.edu		Buscaglia, Carlos/0000-0001-6466-4138				Alvarez P, 2004, J BIOL CHEM, V279, P3375, DOI 10.1074/jbc.M311356200; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; CARR D, 1993, BIOCHEM BIOPH RES CO, V195, P289, DOI 10.1006/bbrc.1993.2043; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Dziewulska-Szwajkowska D, 2004, COMP BIOCHEM PHYS B, V137, P115, DOI 10.1016/j.cbpc.2003.10.010; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; Hatakeyama T, 2004, EUR J BIOCHEM, V271, P3765, DOI 10.1111/j.1432-1033.2004.04318.x; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hufner K, 2002, FEBS LETT, V514, P168, DOI 10.1016/S0014-5793(02)02358-X; Ishida A, 2005, ARCH BIOCHEM BIOPHYS, V435, P134, DOI 10.1016/j.abb.2004.11.022; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kappe SHI, 2004, ANNU REV CELL DEV BI, V20, P29, DOI 10.1146/annurev.cellbio.20.011603.150935; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Lundmark R, 2004, J BIOL CHEM, V279, P42694, DOI 10.1074/jbc.M407430200; Navarro-Lerida I, 2004, PROTEOMICS, V4, P339, DOI 10.1002/pmic.200300528; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; Otsuki M, 2003, J BIOL CHEM, V278, P6461, DOI 10.1074/jbc.M207433200; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Reddy VA, 2004, MICROB PATHOGENESIS, V36, P67, DOI 10.1016/j.micpath.2003.09.005; Schindler R, 2001, BIOCHEM CELL BIOL, V79, P719, DOI 10.1139/bcb-79-6-719; Schneider ML, 1995, BIOCHEMISTRY-US, V34, P16574, DOI 10.1021/bi00051a005; STRAPAZON E, 1977, BIOCHEMISTRY-US, V16, P2966, DOI 10.1021/bi00632a025; Sukumvanich P, 2004, CELL MOTIL CYTOSKEL, V59, P141, DOI 10.1002/cm.20030; Vertessy BG, 1997, J BIOL CHEM, V272, P25542, DOI 10.1074/jbc.272.41.25542; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Zhang DC, 2000, BLOOD, V96, P2925	34	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1324	1331		10.1074/jbc.M506346200	http://dx.doi.org/10.1074/jbc.M506346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16278221	hybrid			2022-12-25	WOS:000234652000006
J	Reinhold, MI; Kapadia, RM; Liao, ZX; Naski, MC				Reinhold, MI; Kapadia, RM; Liao, ZX; Naski, MC			The Wnt-inducible transcription factor Twist1 inhibits chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-3 GENE; BETA-CATENIN; SIGNALING PATHWAY; BINDING PROTEIN; EXPRESSION; DIFFERENTIATION; OSTEOBLAST; PLAYS; SOX9; MORPHOGENESIS	Wnt signaling is essential for many developmental processes, including skeletogenesis. To investigate the effects of Wnt signaling during skeletogenesis we studied the effects of Wnt on cultured chondrocytic cells and differentiating limb-bud mesenchyme. We showed that Wnt3a strongly repressed chondrogenesis and chondrocyte gene expression. Canonical Wnt signaling was responsible for the repression of differentiation, as evidenced by results showing that inhibition of glycogen synthase kinase 3 or expression of beta-catenin caused similar repression of differentiation. Significantly, we showed that the transcription repressor Twist1 is induced by canonical Wnt signaling. Expression of Twist1 strongly inhibited chondrocyte gene expression and short hairpin RNA knockdown of Twist1 transcript levels caused increased expression of the chondrocyte-specific genes aggrecan and type II collagen. Interestingly, Twist1 interfered with BMP2-induced expression of aggrecan and type II collagen expression and knockdown of Twist1 augmented BMP2-induced aggrecan and type II collagen expression. These data support the conclusions that Twist1 contributes to the repression of chondrogenesis and chondrocyte gene expression resulting from canonical Wnt signaling and that Twist1 interferes with BMP-dependent signaling.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Naski, MC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	naski@uthscsa.edu			NIAMS NIH HHS [AR47070, AR050024] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050024, R01AR047070] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Chimal-Monroy J, 2002, DEV DYNAM, V224, P314, DOI 10.1002/dvdy.10110; Chimal-Monroy J, 2003, DEV BIOL, V257, P292, DOI 10.1016/S0012-1606(03)00066-6; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; ElGhouzzi V, 1997, NAT GENET, V15, P42; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Howe LR, 2003, CANCER RES, V63, P1906; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Ishii M, 2003, DEVELOPMENT, V130, P6131, DOI 10.1242/dev.00793; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawakami Y, 2001, CELL, V104, P891, DOI 10.1016/S0092-8674(01)00285-9; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lyu J, 2005, J BIOL CHEM, V280, P21653, DOI 10.1074/jbc.m500374200; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730; Ota MS, 2004, DEV DYNAM, V230, P216, DOI 10.1002/dvdy.20047; Peifer M, 2002, CELL, V109, P271, DOI 10.1016/S0092-8674(02)00739-0; Reinhold MI, 2004, MOL ENDOCRINOL, V18, P241, DOI 10.1210/me.2003-0312; Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Tomita M, 2002, J BIOL CHEM, V277, P42214, DOI 10.1074/jbc.C200504200; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102	59	125	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1381	1388		10.1074/jbc.M504875200	http://dx.doi.org/10.1074/jbc.M504875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293629	hybrid			2022-12-25	WOS:000234652000013
J	Swain, JF; Schulz, EG; Gierasch, LM				Swain, JF; Schulz, EG; Gierasch, LM			Direct comparison of a stable isolated Hsp70 substrate-binding domain in the empty and substrate-bound states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; INDUCED CONFORMATIONAL-CHANGES; ATPASE DOMAIN; MECHANISM; PEPTIDES	The Hsp70 family of molecular chaperones acts to prevent protein misfolding, import proteins into organelles, unravel protein aggregates, and enhance cell survival under stress conditions. These activities are all mediated by recognition of diverse hydrophobic sequences via a C-terminal substrate-binding domain. ATP-binding/hydrolysis by the N-terminal ATPase domain regulates the interconversion of the substrate-binding domain between low and high affinity conformations. The empty state of the substrate-binding domain has been difficult to study because of its propensity to bind nearly any available protein chain, even if only modestly hydrophobic. We have generated a new stable construct of the substrate-binding domain from the Escherichia coli Hsp70, DnaK, which has enabled us to compare the empty and peptide-bound conformations using NMR chemical shift analysis and hydrogen-deuterium exchange. We have determined that the empty state is, overall, quite similar to the peptide-bound state, contrary to a previous report. Peptide binding leads to a subtle alteration in the packing of the alpha-helical lid relative to the beta-subdomain. Significantly, we have shown that the chemical shifts of the substrate-binding domain and the ATPase domain do not change when they are placed together in a two-domain construct, whether or not peptide is bound, suggesting that, in the absence of nucleotide, the two domains of E. coli DnaK do not interact. We conclude that the isolated substrate-binding domain exists in a stable high affinity state in the absence of influence from a nucleotide-bound ATPase domain.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, 913G LGRT,710 N Pleasant St, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NIGMS NIH HHS [GM27616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P411; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2004, J BIOL CHEM, V279, P19600, DOI 10.1074/jbc.M400921200; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; NG V, 2004, THESIS U MELBOURNE M; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; Revington M, 2005, J MOL BIOL, V349, P163, DOI 10.1016/j.jmb.2005.03.033; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Slepenkov SV, 2003, BIOCHEMISTRY-US, V42, P5867, DOI 10.1021/bi034126v; Slepenkov SV, 2003, FEBS LETT, V539, P100, DOI 10.1016/S0014-5793(03)00207-2; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Swain JF, 2001, BIOCHEM SOC SYMP, V68, P69; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Zhang YB, 2004, P NATL ACAD SCI USA, V101, P10272, DOI 10.1073/pnas.0401313101; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	37	61	61	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1605	1611		10.1074/jbc.M509356200	http://dx.doi.org/10.1074/jbc.M509356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16275641	hybrid			2022-12-25	WOS:000234652000039
J	Symersky, J; Perederina, A; Vassylyeva, MN; Svetlov, V; Artsimovitch, I; Vassylyev, DG				Symersky, J; Perederina, A; Vassylyeva, MN; Svetlov, V; Artsimovitch, I; Vassylyev, DG			Regulation through the RNA polymerase secondary channel - Structural and functional variability of the coiled-coil transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; CLEAVAGE FACTORS; ACTIVE-CENTER; MICROCIN J25; MECHANISM; PPGPP; GREB; INHIBITION; DKSA	Gre factors enhance the intrinsic endonucleolytic activity of RNA polymerase to rescue arrested transcription complexes and are thought to confer the high fidelity and processivity of RNA synthesis. The Gre factors insert the extended alpha-helical coiled-coil domains into the RNA polymerase secondary channel to position two invariant acidic residues at the coiled-coil tip near the active site to stabilize the catalytic metal ion. Gfh1, a GreA homolog from Thermus thermophilus, inhibits rather than activates RNA cleavage. Here we report the structure of the T. thermophilus Gfh1 at 2.4 angstrom resolution revealing a two-domain architecture closely resembling that of GreA. However, the interdomain orientation is strikingly distinct (similar to 162 rotation) between the two proteins. In contrast to GreA, which has two acidic residues on a well fixed self-stabilized alpha-turn, the tip of the Gfh1 coiled-coil is flexible and contains four acidic residues. This difference is likely the key to the Gre functional diversity, while Gfh1 inhibits exo- and endonucleolytic cleavage, RNA synthesis, and pyrophosphorolysis, GreA enhances only the endonucleolytic cleavage. We propose that Gfh1 acidic residues stabilize the RNA polymerase active center in a catalytically inactive configuration through Mg2+-mediated interactions. The excess of the acidic residues and inherent flexibility of the coiled-coil tip might allow Gfh1 to adjust its activity to structurally distinct substrates, thereby inhibiting diverse catalytic reactions of RNA polymerase.	Univ Alabama, Sch Med & Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University	Vassylyev, DG (corresponding author), Univ Alabama, Sch Med & Dent, Dept Biochem & Mol Genet, 402B Kaul Genet Bldg,720 20th St S, Birmingham, AL 35294 USA.	dmitry@uab.edu	Artsimovitch, Irina/L-3467-2019; Vassylyev, Dmitry/A-9005-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067153, R01GM074252, R01GM074840] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067153, R01 GM074840, GM67153, R01 GM074252, GM74840, GM74252] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2004, MOL CELL, V14, P753, DOI 10.1016/j.molcel.2004.05.017; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Hogan BP, 2002, J BIOL CHEM, V277, P967, DOI 10.1074/jbc.M108737200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; LAMOUR V, 2005, IN PRESS J MOL BIOL; Laptenko O, 2003, METHOD ENZYMOL, V371, P219; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Mukhopadhyay J, 2004, MOL CELL, V14, P739, DOI 10.1016/j.molcel.2004.06.010; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; Perederina A, 2004, CELL, V118, P297, DOI 10.1016/j.cell.2004.06.030; PEREDERINA A, 2005, IN PRESS ACTA CRYS F; ROZOVSKAYA T A, 1981, Molekulyarnaya Biologiya (Moscow), V15, P636; Sosunov V, 2005, NUCLEIC ACIDS RES, V33, P4202, DOI 10.1093/nar/gki688; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Vassylyev DG, 2005, NAT STRUCT MOL BIOL, V12, P1086, DOI 10.1038/nsmb1015	25	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1309	1312		10.1074/jbc.C500405200	http://dx.doi.org/10.1074/jbc.C500405200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16298991	Green Accepted, hybrid			2022-12-25	WOS:000234652000003
J	Gueguen, Y; Herpin, A; Aumelas, A; Garnier, J; Fievet, J; Escoubas, JM; Bulet, P; Gonzalez, M; Lelong, C; Favrel, P; Bachere, E				Gueguen, Y; Herpin, A; Aumelas, A; Garnier, J; Fievet, J; Escoubas, JM; Bulet, P; Gonzalez, M; Lelong, C; Favrel, P; Bachere, E			Characterization of a defensin from the oyster Crassostrea gigas - Recombinant production, folding, solution structure, antimicrobial activities, and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSSEL DEFENSIN; ALPHA-DEFENSINS; INNATE IMMUNITY; MYTILUS-EDULIS; BETA-DEFENSIN; PEPTIDES; INVERTEBRATES; NMR; SPECTROSCOPY; DEAMIDATION	In invertebrates, defensins were found in arthropods and in the mussels. Here, we report for the first time the identification and characterization of a defensin (Cg-Def) from an oyster. Cg-def mRNA was isolated from Crassostrea gigas mantle using an expressed sequence tag approach. To gain insight into potential roles of Cg-Def in oyster immunity, we produced the recombinant peptide in Escherichia coli, characterized its antimicrobial activities, determined its solution structure by NMR spectroscopy, and quantified its gene expression in vivo following bacterial challenge of oysters. Recombinant Cg-Def was active in vitro against Gram-positive bacteria but showed no or limited activities against Gram-negative bacteria and fungi. The activity of Cg-Def was retained in vitro at a salt concentration similar to that of seawater. The Cg-Def structure shares the so-called cystine-stabilized alpha-beta motif (CS-alpha beta) with arthropod defensins but is characterized by the presence of an additional disulfide bond, as previously observed in the mussel defensin (MGD-1). Nevertheless, despite a similar global fold, the Cg-Def and MGD-1 structures mainly differ by the size of their loops and by the presence of two aspartic residues in Cg-Def. Distribution of Cg-def mRNA in various oyster tissues revealed that Cg-def is mainly expressed in mantle edge where it was detected by mass spectrometry analyses. Furthermore, we observed that the Cg-def messenger concentration was unchanged after bacterial challenge. Our results suggest that Cg-def gene is continuously expressed in the mantle and would play a key role in oyster by providing a first line of defense against pathogen colonization.	Univ Montpellier 2, IFREMER, CNRS, UMR 5171, F-34095 Montpellier 5, France; Univ Caen, UMR 100 Ifremer, Inst Biol Fondamentale & Appl, Lab Biol & Biotechnol Marines, F-14032 Caen, France; Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR 5048,INSERM U554, F-34090 Montpellier, France; Atheris Labs, CH-1233 Geneva, Switzerland; SARS Int Care Marine Mol Biol, Ctr High Technol, N-5008 Bergen, Norway	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Ifremer; Universite de Caen Normandie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Gueguen, Y (corresponding author), Univ Montpellier 2, IFREMER, CNRS, UMR 5171, 2 Pl E Bataillon,CC80, F-34095 Montpellier 5, France.	ygueguen@ifremer.fr	Bachere, Evelyne/O-6117-2014; Herpin, Amaury/B-8950-2011; ESCOUBAS, Jean-Michel/G-4027-2010; Gueguen, Yannick/O-3248-2014; González, Marcelo/ABF-1450-2020; BULET, Philippe/C-8557-2014	Herpin, Amaury/0000-0002-0630-4027; ESCOUBAS, Jean-Michel/0000-0002-6138-1148; Gueguen, Yannick/0000-0002-8749-9582; BULET, Philippe/0000-0001-9016-265X; Favrel, Pascal/0000-0002-2504-9957; Gonzalez, Marcelo/0000-0001-9986-9504				Aarbiou J, 2002, ANN MED, V34, P96, DOI 10.1080/07853890252953482; Anderson RS, 2001, AQUAT LIVING RESOUR, V14, P343, DOI 10.1016/S0990-7440(01)01143-3; Bachere E, 2004, IMMUNOL REV, V198, P149, DOI 10.1111/j.0105-2896.2004.00115.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Boulanger N, 2004, INFECT IMMUN, V72, P7140, DOI 10.1128/IAI.72.12.7140-7146.2004; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Da Silva P, 2003, PROTEIN SCI, V12, P438, DOI 10.1110/ps.0228303; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Guijarro JI, 2003, PROTEIN SCI, V12, P1844, DOI 10.1110/ps.03186703; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hetru C, 1997, Methods Mol Biol, V78, P35; Imler Jean-Luc, 2005, V86, P1, DOI 10.1159/000086648; Izadpanah A, 2005, J AM ACAD DERMATOL, V52, P381, DOI 10.1016/j.jaad.2004.08.026; Landon C, 2004, J BIOL CHEM, V279, P30433, DOI 10.1074/jbc.M401338200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Li B, 2005, J PHARM SCI-US, V94, P666, DOI 10.1002/jps.20263; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Mitta G, 2000, DEV COMP IMMUNOL, V24, P381, DOI 10.1016/S0145-305X(99)00084-1; Mitta G, 2000, FEBS LETT, V486, P185, DOI 10.1016/S0014-5793(00)02192-X; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Romestand B, 2003, EUR J BIOCHEM, V270, P2805, DOI 10.1046/j.1432-1033.2003.03657.x; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Savarin P, 1999, PROTEIN SCI, V8, P2672; Sima P, 2003, FOLIA MICROBIOL, V48, P123, DOI 10.1007/BF02930945; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yang YS, 2000, BIOCHEMISTRY-US, V39, P14436, DOI 10.1021/bi0011835; Zaballos A, 2004, J BIOL CHEM, V279, P12421, DOI 10.1074/jbc.M307697200	50	166	178	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					313	323		10.1074/jbc.M510850200	http://dx.doi.org/10.1074/jbc.M510850200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16246846	Green Published, hybrid			2022-12-25	WOS:000234307200040
J	Mitchell, DC; Abdelrahim, M; Weng, JS; Stafford, LJ; Safe, S; Bar-Eli, M; Liu, MY				Mitchell, DC; Abdelrahim, M; Weng, JS; Stafford, LJ; Safe, S; Bar-Eli, M; Liu, MY			Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2 alpha and specificity protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; COUPLED RECEPTOR GPR54; FACTOR AP-2; DOWN-REGULATION; BLADDER-CANCER; GASTRIC-CANCER; HUMAN-MELANOMA; TUMOR-GROWTH; DNA-BINDING; FACTOR SP1	KiSS- 1 has been shown to function as a tumor metastasis suppressor gene and reduce the number of metastases in different cancers. The expression of KiSS- 1 or KiSS1, like other tumor suppressor, is commonly reduced or completely ablated in a variety of cancers via an unknown mechanism. Here we show that the loss of KiSS- 1 expression in highly metastatic breast cancer cell lines correlates directly with the expression levels of two transcription factors, activator protein- 2 alpha( AP- 2 alpha) and specificity protein 1 ( Sp1), which synergistically activate the transcriptional regulation of KiSS- 1 in breast cancer cells. Although the KiSS- 1 promoter contains multiple AP- 2 alpha binding elements, AP- 2 alpha- mediated regulation occurs indirectly through Sp1 sites, as determined by deletion and mutation analysis. Overexpression of AP- 2 alpha into highly metastatic breast cell lines did not alter KiSS- 1 promoter- driven luciferase gene activity. However, co- transfection of AP- 2 alpha wild- type or the dominant negative form of AP- 2 lacking its C- terminal DNA-binding domain, AP- 2B, together with Sp1, increased KiSS- 1 promoter activity dramatically, suggesting that AP- 2 alpha regulation of KiSS- 1 transcription does not require direct binding to the KiSS- 1 promoter. Furthermore, we demonstrated that AP- 2 alpha directly interacted with Sp1 to form transcription complexes at two tandem Sp1- binding sites of the promoter to activate KiSS- 1 transcription. Together, our results indicate that AP- 2 alpha and Sp1 are strong transcriptional regulators of KiSS- 1 and that loss or decreased expression of AP- 2 alpha in breast cancer may account for the loss of tumor metastasis suppressor KiSS- 1 expression and thus increased cancer metastasis.	Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Liu, Mingyao/0000-0001-7339-5048	NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Clements MK, 2001, BIOCHEM BIOPH RES CO, V284, P1189, DOI 10.1006/bbrc.2001.5098; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; Finkenzeller Gunter, 2004, Angiogenesis, V7, P59, DOI 10.1023/B:AGEN.0000037332.66411.f0; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Li QJ, 2004, J BIOL CHEM, V279, P45669, DOI 10.1074/jbc.M405025200; Liang HY, 2004, INT J ONCOL, V24, P1057; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smith ND, 2003, J UROLOGY, V169, P1219, DOI 10.1097/01.ju.0000056085.58221.80; Stafford LJ, 2002, CANCER RES, V62, P5399; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Turner BC, 1998, CANCER RES, V58, P5466; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	41	59	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					51	58		10.1074/jbc.M506245200	http://dx.doi.org/10.1074/jbc.M506245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260418	hybrid			2022-12-25	WOS:000234307200010
J	Khalil, N; Xu, YD; O'Connor, R; Duronio, V				Khalil, N; Xu, YD; O'Connor, R; Duronio, V			Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta 1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MUSCLE-CELL-PROLIFERATION; SMOOTH-MUSCLE; FACTOR-BETA; FACTOR-BETA-1-INDUCED ACTIVATION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LUNG FIBROBLASTS; EXPRESSION; MATRIX	Idiopathic pulmonary fibrosis (IPF; a progressive lung disease) is characterized by parenchymal remodeling with enlarged air spaces called honeycomb cysts and palisades of fibroblasts called fibroblast foci. In IPF, lung epithelial cells covering honeycomb cysts and fibroblast foci aberrantly express the active conformation of the potent fibrogenic cytokine transforming growth factor-beta 1 (TGF-beta 1). Using explanted rat lung slices, we transfected alveolar epithelial cells with the retrovirus pMX containing a site-directed mutation in which Cys(223) and Cys(225) were substituted with serines, resulting in release of biologically active TGF-beta 1 and fibroblast proliferation and remodeling that resembled IPF. Fibroblasts obtained from transfected explants and in culture for 6 weeks incorporated 6.59 +/- 1.55-fold more [H-3] thymidine compared with control fibroblasts without transfection or fibroblasts obtained from transfected explants cultured with antibody to fibroblast growth factor-2 (FGF-2). Primary lung fibroblasts obtained from normal rat lungs cultured with TGF-beta 1 expressed increased levels of phosphorylated p38 MAPK and JNK, but not ERK1/2. The presence of TGF-beta 1 caused an immediate release of extracellular FGF-2 from primary pulmonary fibroblasts; and in the presence of anti-FGF-2 antibody, phosphorylated p38 MAPK and JNK were abrogated. TGF-beta inhibits cell proliferation by suppression of c-Myc and induction of p15(INK46), p21(CIP1), or p27(KIP). Fibroblasts cultured with TGF-beta 1 showed no regulation of c-Myc or induction of p15INK46, p21CIP1, or p27KIP. These findings suggest that pulmonary fibroblasts may not respond to the anti-proliferative effects of TGF-beta 1, but proliferate in response to TGF-beta 1 indirectly by the release of FGF-2, which induces phosphorylation of p38 MAPK and JNK.	Univ British Columbia, Div Resp, Dept Med, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; British Columbia Cancer Agency	Khalil, N (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	nkhalil@interchange.ubc.ca						*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; Chen G, 2003, AM J PHYSIOL-LUNG C, V284, pL548, DOI 10.1152/ajplung.00091.2002; Chen G, 2002, RESP PHYSIOL NEUROBI, V132, P341, DOI 10.1016/S1569-9048(02)00111-8; Cohen MD, 1997, AM J RESP CELL MOL, V16, P85, DOI 10.1165/ajrcmb.16.1.8998083; Cohen P, 2000, AM J PHYSIOL-LUNG C, V278, pL545, DOI 10.1152/ajplung.2000.278.3.L545; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Czuwara-Ladykowska J, 2001, BRIT J DERMATOL, V145, P569, DOI 10.1046/j.1365-2133.2001.04443.x; Daian T, 2003, J INVEST DERMATOL, V120, P956, DOI 10.1046/j.1523-1747.2003.12143.x; Daniels JT, 2003, AM J PATHOL, V163, P2043, DOI 10.1016/S0002-9440(10)63562-6; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Dinbergs ID, 1996, J BIOL CHEM, V271, P29822, DOI 10.1074/jbc.271.47.29822; DORR W, 1994, CELL PROLIFERAT, V27, P321, DOI 10.1111/j.1365-2184.1994.tb01429.x; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Flaherty KR, 2003, AM J RESP CRIT CARE, V167, P1410, DOI 10.1164/rccm.200204-373OC; Flaherty KR, 2003, THORAX, V58, P143, DOI 10.1136/thorax.58.2.143; Hansell A, 1999, THORAX, V54, P413, DOI 10.1136/thx.54.5.413; Hoffmann G, 1995, BIOCHEM BIOPH RES CO, V217, P575, DOI 10.1006/bbrc.1995.2814; Jones SG, 1999, KIDNEY INT, V56, P83, DOI 10.1046/j.1523-1755.1999.00517.x; Jones SM, 2001, CHEM REV, V101, P2413, DOI 10.1021/cr000101f; Katzenstein ALA, 2002, AM J SURG PATHOL, V26, P1567, DOI 10.1097/00000478-200212000-00004; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; Khalil N, 2001, THORAX, V56, P907, DOI 10.1136/thorax.56.12.907; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Molloy T, 2003, SPORTS MED, V33, P381, DOI 10.2165/00007256-200333050-00004; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Murakami-Mori K, 1998, J IMMUNOL, V161, P1694; Myler HA, 2002, J BIOCHEM, V131, P913, DOI 10.1093/oxfordjournals.jbchem.a003182; Ramont L, 2003, EXP CELL RES, V291, P1, DOI 10.1016/S0014-4827(03)00336-7; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sakamoto Ryoichi, 2002, Medical Electron Microscopy, V35, P248, DOI 10.1007/s007950200029; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Selman M, 2001, RESP RES, V3, DOI 10.1186/rr175; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Stouffer GA, 1998, SEMIN THROMB HEMOST, V24, P145, DOI 10.1055/s-2007-995833; Sudhir K, 2001, AM J HYPERTENS, V14, P1128, DOI 10.1016/S0895-7061(01)02189-6; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Wang G, 1999, J GENE MED, V1, P22, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<22::AID-JGM1>3.3.CO;2-O; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xu YD, 2003, AM J PHYSIOL-LUNG C, V285, pL527, DOI 10.1152/ajplung.00298.2002; Yu JC, 2001, J CRANIOFAC SURG, V12, P391, DOI 10.1097/00001665-200107000-00018; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhou LM, 2003, RESP PHYSIOL NEUROBI, V137, P295, DOI 10.1016/S1569-9048(03)00154-X	60	126	145	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43000	43009		10.1074/jbc.M510441200	http://dx.doi.org/10.1074/jbc.M510441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16246848	hybrid			2022-12-25	WOS:000234200800064
J	Zhou, J; Huang, L; Hachey, DL; Chen, CH; Aiken, C				Zhou, J; Huang, L; Hachey, DL; Chen, CH; Aiken, C			Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROBETULINIC ACID-DERIVATIVES; ANTI-AIDS AGENTS; BETULINIC ACID; VIRION MATURATION; MATRIX PROTEIN; CELLS; CLEAVAGE; STEP; GP41	The small molecule 3-O-(3', 3'-dimethylsuccinyl)-betulinic acid ( DSB) potently inhibits human immunodeficiency virus, type 1 ( HIV-1) replication by interfering with proteolytic cleavage of the viral Gag protein at a specific site. Here we have demonstrated that the antiviral mechanism involves the association of DSB with Gag at a 1: 1 stoichiometry within immature HIV-1 particles. The binding was specific, as mutations in Gag that confer resistance to DSB inhibited the association, which could be competed by DSB but not by the inactive compound betulinic acid. The addition of DSB to purified immature viral cores inhibited the cleavage of Gag at the CA-SP1 junction in vitro, thus reproducing the effect of the drug when present during maturation of HIV-1 particles. Based on these findings, we propose a model in which a trimer of DSB associates with the CA-SP1 junction of adjacent subunits within the Gag polymer. The model may explain the ability of highly similar compounds to specifically target the seemingly unrelated steps of HIV-1 maturation and virus entry.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Duke Univ, Med Ctr, Dept Surg, Surg Oncol Res Facil, Durham, NC 27710 USA	Vanderbilt University; Vanderbilt University; Duke University	Aiken, C (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A-5301 Med Ctr N, Nashville, TN 37232 USA.	chris.aiken@vanderbilt.edu	Aiken, Christopher/Y-9252-2019	Huang, Li/0000-0001-5659-4053	NIAID NIH HHS [R01 AI062452] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiken C, 2005, TRENDS MOL MED, V11, P31, DOI 10.1016/j.molmed.2004.11.001; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dong XH, 2005, CELL, V120, P663, DOI 10.1016/j.cell.2004.12.023; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FUJIOKA T, 1994, J NAT PROD, V57, P243, DOI 10.1021/np50104a008; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GRANT RA, 1994, CURR BIOL, V4, P784, DOI 10.1016/S0960-9822(00)00176-7; Hashimoto F, 1997, BIOORGAN MED CHEM, V5, P2133, DOI 10.1016/S0968-0896(97)00158-2; Kanamoto T, 2001, ANTIMICROB AGENTS CH, V45, P1225, DOI 10.1128/AAC.45.4.1225-1230.2001; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; Kashiwada Y, 1996, J MED CHEM, V39, P1016, DOI 10.1021/jm950922q; Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; Tang C, 2004, P NATL ACAD SCI USA, V101, P517, DOI 10.1073/pnas.0305665101; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481; Wiegers K, 1998, J VIROL, V72, P2846, DOI 10.1128/JVI.72.4.2846-2854.1998; Wyma DJ, 2000, J VIROL, V74, P9381, DOI 10.1128/JVI.74.20.9381-9387.2000; Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004; Zhou J, 2004, J VIROL, V78, P922, DOI 10.1128/JVI.78.2.922-929.2004; Zhou Jing, 2004, Retrovirology, V1, P15, DOI 10.1186/1742-4690-1-15	24	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42149	42155		10.1074/jbc.M508951200	http://dx.doi.org/10.1074/jbc.M508951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251182	hybrid			2022-12-25	WOS:000233992700042
J	Haqqani, AS; Nesic, M; Preston, E; Baumann, E; Kelly, J; Stanimirovic, D				Haqqani, AS; Nesic, M; Preston, E; Baumann, E; Kelly, J; Stanimirovic, D			Characterization of vascular protein expression patterns in cerebral ischemia/reperfusion using laser capture microdissection and ICAT-nanoLC-MS/MS	FASEB JOURNAL			English	Article						blood-brain barrier; protein extraction; peptides	BLOOD-BRAIN-BARRIER; ENDOTHELIAL GROWTH-FACTOR; CODED AFFINITY TAG; GENE-EXPRESSION; QUANTITATIVE-ANALYSIS; FOREBRAIN ISCHEMIA; PROTEOMIC ANALYSIS; TEMPORAL PROFILE; IN-VITRO; MATRIX-METALLOPROTEINASE-9	Cerebral ischemia rapidly initiates structural and functional changes in brain vessels, including blood-brain barrier disruption, inflammation, and angiogenesis. Molecular events that accompany these changes were investigated in brain microvessels extracted using laser-capture microdissection (LCM) from Sprague-Dawley rats subjected to a 20 min transient global cerebral ischemia followed by 1, 6, or 24 h reperfusion. Proteins extracted from similar to 300 LCM captured microvessels (20-100 mu m) were ICAT-labeled and analyzed by nanoLC-MS. In-house software was used to identify paired ICAT peaks, which were then sequenced by nanoLC-MS/MS. Pattern analyses using k-means clustering method classified 57 differentially expressed proteins in 7 distinct dynamic patterns. Protein function was assigned using Panther Classification system. Early reperfusion ( 1 h) was characterized by down-regulation of ion pumps, nutrient transporters, and cell structure/motility proteins, and up-regulation of transcription factors, signal transduction molecules and proteins involved in carbohydrate metabolism. The up-regulation of inflammatory cytokines and proteins involved in the extracellular matrix remodeling and anti-oxidative defense was observed in late reperfusion (6-24 h). The up-regulation of IL-1 beta and TGF-1 beta in ischemic brain vessels was confirmed by ELISA, quantitative PCR, and/or immunohistochemistry. A biphasic postischemic ( 1 and 24 h) BBB opening for H-3-sucrose was evident in the same model. Differentially expressed proteins identified in brain vessels during reperfusion are likely involved in orchestrating functional vascular responses to ischemia, including the observed BBB disruption.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, D (corresponding author), Natl Res Council Canada, Inst Biol Sci, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	stanimirovic@nrc-cnrc.gc.ca						Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Aldred S, 2004, CLIN BIOCHEM, V37, P943, DOI 10.1016/j.clinbiochem.2004.09.002; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Bickel DR, 2004, BIOINFORMATICS, V20, P682, DOI 10.1093/bioinformatics/btg468; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Dirnagl U, 1997, ADV EXP MED BIOL, V413, P155; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; Fukuda S, 2004, STROKE, V35, P998, DOI 10.1161/01.STR.0000119383.76447.05; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; Goldsmith AP, 2004, J NEUROSCI RES, V78, P647, DOI 10.1002/jnr.20320; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; HIROSAWA M, 1993, COMPUT APPL BIOSCI, V9, P161; Ishikawa M, 2004, FRONT BIOSCI-LANDMRK, V9, P1339, DOI 10.2741/1330; Kahlina K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Li C, 2004, MOL CELL PROTEOMICS, V3, P399, DOI 10.1074/mcp.M300133-MCP200; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Methy D, 2004, BRAIN RES, V1003, P151, DOI 10.1016/j.brainres.2003.12.031; Mojsilovic-Petrovic J, 2004, J NEUROSCI METH, V133, P39, DOI 10.1016/j.jneumeth.2003.09.026; Mori K, 2002, J NEUROTRAUM, V19, P1261, DOI 10.1089/08977150260338047; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Novoradovskaya N, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-20; Ohtaki H, 2003, NEUROSCI RES, V45, P313, DOI 10.1016/S0168-0102(02)00238-9; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Pomfy M, 1992, Funct Dev Morphol, V2, P253; Preston E, 2004, ACTA NEUROPATHOL, V108, P406, DOI 10.1007/s00401-004-0905-4; Preston E, 2002, ACTA NEUROPATHOL, V103, P237, DOI 10.1007/s004010100458; PRESTON E, 1983, J NEUROSCI METH, V9, P45, DOI 10.1016/0165-0270(83)90108-5; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Schaller B, 2004, J CEREBR BLOOD F MET, V24, P351, DOI 10.1097/00004647-200404000-00001; Shekouh AR, 2003, PROTEOMICS, V3, P1988, DOI 10.1002/pmic.200300466; Singh R, 2005, AM J PHYSIOL-CELL PH, V288, pC1179, DOI 10.1152/ajpcell.00258.2004; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Smolka MB, 2001, ANAL BIOCHEM, V297, P25, DOI 10.1006/abio.2001.5318; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stanimirovic DB, 2001, PROG INFLAM RES, P101; Yamashita K, 1999, BRAIN RES, V836, P139, DOI 10.1016/S0006-8993(99)01626-1; Zang L, 2004, J PROTEOME RES, V3, P604, DOI 10.1021/pr034131l; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	52	96	103	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1809	1821		10.1096/fj.05-3793com	http://dx.doi.org/10.1096/fj.05-3793com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260651				2022-12-25	WOS:000234053100033
J	Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT				Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT			The N-terminus of rodent and human MAD1 confers species-specific stringency to spindle assembly checkpoint	ONCOGENE			English	Article						aneuploidy; spindle assembly checkpoint; cellular transformation; chromosomal instability; mitotic arrest	VIRUS TYPE-I; MITOTIC CHECKPOINT; SACCHAROMYCES-CEREVISIAE; CELLULAR-TRANSFORMATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; RAT FIBROBLASTS; TAX PROTEIN; LEUKEMIA; CANCER	The spindle assembly checkpoint (SAC) guards against chromosomal mis-segregation and the emergence of aneuploidy. SAC in higher eukaryotes includes at least 10 proteins including MAD1-3, BUB1-3, and Msp1. A long-standing observation has been that rodent cells are more tolerant of microtubule toxins than primate cells indicating that SAC function is more relaxed in the former than the latter. Here, we report on an unexpected functional difference between the rodent and human MAD1 component of the respective SAC. Ectopic expression of human MAD1 in mouse and hamster cells corrected a relaxed SAC to a more stringent form. Our findings posit MAD1 as a species-specific determinant which influences the stringency of cellular response to microtubule depolymerization and spindle damage.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Jeang, Kuan-Teh/A-2424-2008; Chi, Ya-Hui/B-1080-2010	Chi, Ya-Hui/0000-0002-9216-0938; Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI001023, ZIAAI000547, Z01AI001023] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Azran Inbal, 2004, Retrovirology, V1, P20; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gallardo MH, 2003, J EVOLUTION BIOL, V16, P163, DOI 10.1046/j.1420-9101.2003.00507.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lee MS, 2004, P NATL ACAD SCI USA, V101, P10655, DOI 10.1073/pnas.0404102101; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIDGLEY AR, 1959, SCIENCE, V130, P40, DOI 10.1126/science.130.3366.40; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861	59	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2137	2147		10.1038/sj.onc.1209259	http://dx.doi.org/10.1038/sj.onc.1209259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288203	Bronze			2022-12-25	WOS:000236581200001
J	Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G				Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G			Physical interaction of apoptosis-inducing factor with DNA and RNA	ONCOGENE			English	Article						apoptosis; chromatin condensation; mitochondria	CELL-DEATH; REGULATES APOPTOSIS; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; CANCER-CELLS; AIF; CASPASE; PROTEIN; DEGRADATION; PATHWAYS	Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein, which upon apoptosis induction translocates to the nucleus where it interacts with DNA by virtue of positive charges clustered on the AIF surface. Here we show that the AIF interactome, as determined by mass spectroscopy, contains a large panel of ribonucleoproteins, which apparently bind to AIF through the RNA moiety. However, AIF is devoid of any detectable RNAse activity both in vitro and in vivo. Recombinant AIF can directly bind to DNA as well as to RNA. This binding can be visualized by electron microscopy, revealing that AIF can condense DNA, showing a preferential binding to single-stranded over double-stranded DNA. AIF also binds and aggregates single-stranded and structured RNA in vitro. Single-stranded poly A, poly G and poly C, as well double-stranded A/T and G/C RNA competed with DNA for AIF binding with a similar efficiency, thus corroborating a computer-calculated molecular model in which the binding site within AIF is the same for distinct nucleic acid species, without a clear sequence specificity. Among the preferred electron donors and acceptors of AIF, nicotine adenine dinucleotide phosphate (NADP) was particularly efficient in enhancing the generation of higher-order AIF/DNA and AIF/RNA complexes. Altogether, these data support a model in which a direct interaction of AIF contributes to the compaction of nucleic acids within apoptotic cells.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Lab Microscopie Mol & Cellulaire, UMR 8126,IGR,UPS, F-94805 Villejuif, France; AstraZeneca R&D, Molndal, Sweden; Sanofi Aventis, Ctr Rech VA, Vitry Sur Seine, France; Karl Franzens Univ Graz, IMB, A-8010 Graz, Austria	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; AstraZeneca; Sanofi-Aventis; Sanofi France; University of Graz	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Giordanetto, Fabrizio/E-2811-2012; Herker, Eva/AAQ-1944-2021; Herker, Eva/B-9699-2014; Dupaigne, Pauline/C-6873-2019; MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	Herker, Eva/0000-0001-9644-2484; KROEMER, Guido/0000-0002-9334-4405; Madeo, Frank/0000-0002-5070-1329; Dupaigne, Pauline/0000-0001-7033-4055; MODJTAHEDI, NAZANINE/0000-0002-1832-0710; Le cam, Eric/0000-0002-6832-6117				Asselbergs FAM, 2003, ANAL BIOCHEM, V318, P221, DOI 10.1016/S0003-2697(03)00218-5; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Delain E, 1995, VISUALIZATION NUCL A, P35; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Giordanetto F, 2004, J CHEM INF COMP SCI, V44, P882, DOI 10.1021/ci0499626; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Halicka HD, 2000, EXP CELL RES, V260, P248, DOI 10.1006/excr.2000.5027; Hameau L, 2001, J VIROL, V75, P3301, DOI 10.1128/JVI.75.7.3301-3313.2001; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Le Cam E, 1998, BIOPOLYMERS, V45, P217, DOI 10.1002/(SICI)1097-0282(199803)45:3&lt;217::AID-BIP4&gt;3.0.CO;2-U; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rutjes SK, 1999, J BIOL CHEM, V274, P24799, DOI 10.1074/jbc.274.35.24799; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	49	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1763	1774		10.1038/sj.onc.1209206	http://dx.doi.org/10.1038/sj.onc.1209206			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278674				2022-12-25	WOS:000236013700008
J	Grove, DE; Bryant, FR				Grove, DE; Bryant, FR			Effect of Mg2+ on the DNA binding modes of the Streptococcus pneumoniae SsbA and SsbB proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; PURIFICATION; MICROARRAYS; GENES	The effect of Mg2+ on the binding of the Streptococcus pneumoniae single-stranded DNA binding (SSB) proteins, SsbA and SsbB, to various dT(n) oligomers was examined by polyacrylamide gel electrophoresis. The results were then compared with those that were obtained with the well characterized SSB protein from Escherichia coli, SsbEc. In the absence of Mg2+, the results indicated that the SsbEc protein was able to bind to the dT(n) oligomers in the SSB35 mode, with only two of the four subunits of the tetramer interacting with the dT(n) oligomers. In the presence of Mg2+, however, the results indicated that the SsbEc protein was bound to the dT(n) oligomers in the SSB65 mode, with all four subunits of the tetramer interacting with the dT(n) oligomers. The SsbA protein behaved similarly to the SsbEc protein under all conditions, indicating that it undergoes Mg2+-dependent changes in its DNA binding modes that are analogous to those of the SsbEc protein. The SsbB protein, in contrast, appeared to bind to the dT(n) oligomers in an SSB65-like mode in either the presence or the absence of Mg2+, suggesting that it may not exhibit the pronounced negative intrasubunit cooperativity in the absence of Mg2+ that is required for the formation of the SSB35 mode. Additional experiments with a chimeric SsbA/B protein indicated that the structural determinants that govern the transitions between the different DNA binding modes may be contained within the N-terminal domains of the SSB proteins.	Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bryant, FR (corresponding author), Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	fbryant@jhsph.edu			NIEHS NIH HHS [ES 07141] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Grove DE, 2005, J BIOL CHEM, V280, P11067, DOI 10.1074/jbc.M414057200; Hedayati MA, 2005, PROTEIN EXPRES PURIF, V43, P133, DOI 10.1016/j.pep.2005.03.034; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lindner C, 2004, J BACTERIOL, V186, P1097, DOI 10.1128/JB.186.4.1097-1105.2004; LOHMAN TM, 1988, BIOCHEMISTRY-US, V27, P2260, DOI 10.1021/bi00407a002; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Peterson S, 2000, J BACTERIOL, V182, P6192, DOI 10.1128/JB.182.21.6192-6202.2000; Peterson SN, 2004, MOL MICROBIOL, V51, P1051, DOI 10.1046/j.1365-2958.2003.03907.x; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286	9	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2087	2094		10.1074/jbc.M510884200	http://dx.doi.org/10.1074/jbc.M510884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16298996	hybrid			2022-12-25	WOS:000234760400030
J	Sabirov, RZ; Sheiko, T; Liu, HT; Deng, DF; Okada, Y; Craigen, WJ				Sabirov, RZ; Sheiko, T; Liu, HT; Deng, DF; Okada, Y; Craigen, WJ			Genetic demonstration that the plasma membrane maxianion channel and voltage-dependent anion channels are unrelated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; MAMMALIAN PORIN CHANNEL; XENOPUS-LAEVIS OOCYTES; INDUCED ATP RELEASE; HUMAN B-LYMPHOCYTES; PERMEABILITY TRANSITION; ARACHIDONIC-ACID; CELL-LINE; VDAC; APOPTOSIS	The maxianion channel is widely expressed in many cell types, where it fulfills a general physiological function as an ATP-conductive gate for cell-to-cell purinergic signaling. Establishing the molecular identity of this channel is crucial to understanding the mechanisms of regulated ATP release. Amitochondrial porin (voltagedependent anion channel (VDAC)) located in the plasma membrane has long been considered as the molecule underlying the maxianion channel activity, based upon similarities in the biophysical properties of these two channels and the purported presence of VDAC protein in the plasma membrane. We have deleted each of the three genes encoding the VDAC isoforms individually and collectively and demonstrate that maxianion channel (similar to 400 picosiemens) activity in VDAC-deficient mouse fibroblasts is unaltered. The channel activity is similar in VDAC1/VDAC3-double-deficient cells and in double-deficient cells with the VDAC2 protein depleted by RNA interference. VDAC deletion slightly down-regulated, but never abolished, the swelling-induced ATP release. The lack of correlation between VDAC protein expression and maxianion channel activity strongly argues against the long held hypothesis of plasmalemmal VDAC being the maxianion channel.	Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies SOKENDAI, Sch Life Sci, Dept Physiol Sci, Okazaki, Aichi 4448585, Japan; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Baylor College of Medicine	Sabirov, RZ (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan.	sabirov@nips.ac.jp	Sabirov, Ravshan/ABD-4896-2021	Sabirov, Ravshan/0000-0003-3512-0873; Tashmukhamedov, Bekjan/0000-0001-7383-1735				Anflous K, 1998, BBA-GENE STRUCT EXPR, V1399, P47, DOI 10.1016/S0167-4781(98)00088-8; Bahamonde MI, 2003, PFLUG ARCH EUR J PHY, V446, P309, DOI 10.1007/s00424-003-1054-7; Bahamonde MI, 2003, J BIOL CHEM, V278, P33284, DOI 10.1074/jbc.M302814200; Baker MA, 2004, J BIOL CHEM, V279, P4811, DOI 10.1074/jbc.M311020200; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Bathori G, 2000, J BIOENERG BIOMEMBR, V32, P79, DOI 10.1023/A:1005516513313; Bell PD, 2003, P NATL ACAD SCI USA, V100, P4322, DOI 10.1073/pnas.0736323100; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Boudreault F, 2002, AM J PHYSIOL-CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; Carneiro CMM, 2003, BBA-BIOMEMBRANES, V1612, P144, DOI 10.1016/S0005-2736(03)00113-5; Carneiro CMM, 1997, FEBS LETT, V416, P187, DOI 10.1016/S0014-5793(97)01198-8; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Colombini M., 1986, ION CHANNEL RECONSTI, P533; Decker WK, 2000, MOL GENET METAB, V70, P69, DOI 10.1006/mgme.2000.2987; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; Dutta AK, 2004, J PHYSIOL-LONDON, V559, P799, DOI 10.1113/jphysiol.2004.069245; Dutta AK, 2002, J PHYSIOL-LONDON, V542, P803, DOI 10.1113/jphysiol.2002.019802; Eben-Brunnen J, 1998, BIOL CHEM, V379, P1419, DOI 10.1515/bchm.1998.379.12.1419; Elinder F, 2005, CELL DEATH DIFFER, V12, P1134, DOI 10.1038/sj.cdd.4401646; Gincel D, 2000, J BIOENERG BIOMEMBR, V32, P571, DOI 10.1023/A:1005670527340; Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200; Graham BH, 2004, CURR TOP DEV BIOL, V59, P87, DOI 10.1016/S0070-2153(04)59004-X; HA HJ, 1993, J BIOL CHEM, V268, P12143; HALS GD, 1989, J GEN PHYSIOL, V93, P385, DOI 10.1085/jgp.93.3.385; JAKOB C, 1995, FEBS LETT, V368, P5, DOI 10.1016/0014-5793(95)00465-L; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Krasilnikov OV, 1996, BRAZ J MED BIOL RES, V29, P1691; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Moon JI, 1999, NEUROREPORT, V10, P443, DOI 10.1097/00001756-199902250-00001; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Okada SF, 2004, J GEN PHYSIOL, V124, P513, DOI 10.1085/jgp.200409154; Rahmani Z, 1998, EUR J HUM GENET, V6, P337, DOI 10.1038/sj.ejhg.5200198; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Rostovtseva TK, 2002, J MEMBRANE BIOL, V187, P147, DOI 10.1007/s00232-001-0159-1; Sabirov RZ, 2004, BIOPHYS J, V87, P1672, DOI 10.1529/biophysj.104.043174; Sabirov RZ, 2004, JPN J PHYSIOL, V54, P7, DOI 10.2170/jjphysiol.54.7; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; SABIROV RZ, 2005, IN PRESS PURINERG SI, V1; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; Sampson MJ, 1996, GENOMICS, V36, P192, DOI 10.1006/geno.1996.0445; Sampson MJ, 1998, J BIOL CHEM, V273, P30482, DOI 10.1074/jbc.273.46.30482; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; Schwarzer C, 2000, INT J BIOCHEM CELL B, V32, P1075, DOI 10.1016/S1357-2725(00)00047-9; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Steinacker P, 2000, INT J BIOCHEM CELL B, V32, P225, DOI 10.1016/S1357-2725(99)00124-7; STRANGE K, 1996, AM J PHYSIOL, V270, P711; Suzuki M, 2004, J BIOL CHEM, V279, P22461, DOI 10.1074/jbc.M313813200; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	62	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1897	1904		10.1074/jbc.M509482200	http://dx.doi.org/10.1074/jbc.M509482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16291750	hybrid			2022-12-25	WOS:000234760400007
J	Naik, MT; Suree, N; Ilangovan, U; Liew, CK; Thieu, W; Campbell, DO; Clemens, JJ; Jung, ME; Clubb, RT				Naik, MT; Suree, N; Ilangovan, U; Liew, CK; Thieu, W; Campbell, DO; Clemens, JJ; Jung, ME; Clubb, RT			Staphylococcus aureus Sortase A transpeptidase - Calcium promotes sorting signal binding by altering the mobility and structure of an active site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; IMIDAZOLIUM ION-PAIR; MODEL-FREE APPROACH; SURFACE-PROTEINS; CELL-WALL; BACKBONE DYNAMICS; LISTERIA-MONOCYTOGENES; CHEMICAL-EXCHANGE; NMR RELAXATION; TIME-SCALE	Many virulence factors in Gram-positive bacteria are covalently anchored to the cell-wall peptidoglycan by sortase enzymes, a group of widely distributed cysteine transpeptidases. The Staphylococcus aureus Sortase A protein (SrtA) is the archetypal member of the Sortase family and is activated by Ca2+, an adaptation that may facilitate host colonization as elevated concentrations of this ion are encountered in human tissue. Here we show that a single Ca2+ ion bound to an ordered pocket on SrtA allosterically activates catalysis by modulating both the structure and dynamics of a large active site loop. Detailed nitrogen-15 relaxation measurements indicate that Ca2+ may facilitate the adaptive recognition of the substrate by inducing slow micro- to millisecond time-scale dynamics in the active site. Interestingly, relaxation compensated Carr-Purcell-Meiboom- Gill experiments suggest that the time scale of these motions is directly correlated with ion binding. The results of site-directed mutagenesis indicate that this motional coupling is mediated by the side chain of Glu-171, which is positioned within the beta 6/beta 7 loop and shown to contribute to Ca2+ binding. The available structural and dynamics data are compatible with a loop closure model of Ca2+ activation, in which the beta 6/beta 7 loop fluctuates between a binding competent closed form that is stabilized by Ca2+, and an open, highly flexible state that removes key substrate contacting residues from the active site.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clubb, RT (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	rclubb@mbi.ucla.edu	Campbell, Dean/E-6905-2010; Liew, Chu Kong/H-1437-2011	Naik, Mandar/0000-0002-7016-572X	NIAID NIH HHS [AI52217, R01 AI052217] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052217] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Bruschweiler R, 2003, CURR OPIN STRUC BIOL, V13, P175, DOI 10.1016/S0959-440X(03)00036-8; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Comfort D, 2004, INFECT IMMUN, V72, P2710, DOI 10.1128/IAI.72.5.2710-2722.2004; Connolly KM, 2003, J BIOL CHEM, V278, P34061, DOI 10.1074/jbc.M305245200; Connolly KM, 2005, STRUCTURAL BIOLOGY OF BACTERIAL PATHOGENESIS, P101; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; Frankel BA, 2004, J AM CHEM SOC, V126, P3404, DOI 10.1021/ja0390294; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Goddard T., 2001, SPARKY 3 NMR SOFTWAR; Hu HT, 2004, J BIOL CHEM, V279, P50895, DOI 10.1074/jbc.M404233200; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; Huang XY, 2003, BIOCHEMISTRY-US, V42, P11307, DOI 10.1021/bi034391g; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Ishima R, 1999, J BIOMOL NMR, V14, P369, DOI 10.1023/A:1008324025406; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kneller JM, 2002, J AM CHEM SOC, V124, P1852, DOI 10.1021/ja017461k; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Liew CK, 2004, FEBS LETT, V571, P221, DOI 10.1016/j.febslet.2004.06.070; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mandel AM, 1996, BIOCHEMISTRY-US, V35, P16009, DOI 10.1021/bi962089k; Mao HY, 2004, J AM CHEM SOC, V126, P2670, DOI 10.1021/ja039915e; Marraffini LA, 2004, J BIOL CHEM, V279, P37763, DOI 10.1074/jbc.M405282200; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; McElheny D, 2005, P NATL ACAD SCI USA, V102, P5032, DOI 10.1073/pnas.0500699102; Millet O, 2002, FEBS LETT, V516, P93, DOI 10.1016/S0014-5793(02)02508-5; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Mueller GA, 2004, BIOCHEMISTRY-US, V43, P9332, DOI 10.1021/bi049555n; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Oh KB, 2004, J MED CHEM, V47, P2418, DOI 10.1021/jm0498708; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Paterson GK, 2004, TRENDS MICROBIOL, V12, P89, DOI 10.1016/j.tim.2003.12.007; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Rizo Josep, 2002, Methods Mol Biol, V172, P305; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Scott CJ, 2002, BIOCHEM J, V366, P953, DOI 10.1042/BJ20020602; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Steegborn C, 2005, NAT STRUCT MOL BIOL, V12, P32, DOI 10.1038/nsmb880; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Ton-That H, 2004, BBA-MOL CELL RES, V1694, P269, DOI 10.1016/j.bbamcr.2004.04.014; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Vogel Hans J, 2002, Methods Mol Biol, V172, P3; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wang LC, 2001, P NATL ACAD SCI USA, V98, P7684, DOI 10.1073/pnas.121069998; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200	68	80	83	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1817	1826		10.1074/jbc.M506123200	http://dx.doi.org/10.1074/jbc.M506123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16269411	hybrid			2022-12-25	WOS:000234652000063
J	He, YB; Zhou, H; Tang, HD; Luo, YZ				He, YB; Zhou, H; Tang, HD; Luo, YZ			Deficiency of disulfide bonds facilitating fibrillogenesis of endostatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRILS; SUPEROXIDE-DISMUTASE; FOLDING INTERMEDIATE; PROTEIN; MECHANISM; TRIFLUOROETHANOL; ANGIOGENESIS; REDUCTION; INHIBITOR; MUTANTS	Endostatin is an endogenous inhibitor of tumor angiogenesis and tumor growth. It has two pairs of disulfide bonds in a unique nested pattern, which play a key role in its native conformation, stability, and activity. Here, we constructed a disulfide-deficient variant of endostatin, endo-all-Ala, to examine the effects of the two disulfide bonds on fibrillogenesis of endostatin under nondenaturing conditions. Based on thioflavin T fluorescence, atomic force microscopy, far-UV circular dichroism, and Fourier transform infrared spectroscopy, we found that endo-all-Ala, which has a higher alpha-helical content compared with wild type, is prone to forming fibrils in a pH-dependent manner. Subsequently, more hydrophobic patches with a lower stability of endo-all-Ala were observed when compared with wild type, which possibly contributes to the propensity of amyloid formation of endo-all-Ala. To our surprise, the significant increase of the alpha-helical content in endostatin induced by trifluoroethanol can also facilitate fibril formation. In addition, the cytotoxicity of fibrillar aggregates of endo-all-Ala, which were generated at different stages of the fibril formation process, was evaluated by cell viability assay. The results indicate that the cytotoxicity is not due to the fibrils but rather due to the granular aggregates of endo-all-Ala. Moreover, endostatin was interestingly found to be reduced by glutathione at physiological concentrations. Our present work not only elucidates the correlation between the existence of disulfide bonds and the fibril formation of endostatin but also may provide some insights into the structural and functional basis of endostatin in Alzheimer disease brains.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Prot Chem Lab, Beijing 100084, Peoples R China	Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Prot Chem Lab, Beijing 100084, Peoples R China.	protein@tsinghua.edu.cn	He, Yingbo/G-1374-2012					ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bosques CJ, 2003, P NATL ACAD SCI USA, V100, P7593, DOI 10.1073/pnas.1232504100; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; COOPER EA, 1995, FOURIER TRANSFORM IN, P101; Deininger MH, 2002, J NEUROSCI, V22, P10621; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; He YB, 2005, FEBS LETT, V579, P1503, DOI 10.1016/j.febslet.2005.01.059; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; KOO EH, 1996, P NATL ACAD SCI USA, V96, P999; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li B, 2004, BIOCHEMISTRY-US, V43, P2550, DOI 10.1021/bi0357863; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PETERSON DA, 1994, BIOCHEM BIOPH RES CO, V200, P1586, DOI 10.1006/bbrc.1994.1632; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Sun Y, 2005, J CLIN ONCOL, V23, p654S; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Wu XY, 2004, BIOCHEM BIOPH RES CO, V320, P973, DOI 10.1016/j.bbrc.2004.06.047; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; Zhou H, 2005, J BIOL CHEM, V280, P11303, DOI 10.1074/jbc.M412072200; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	54	24	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1048	1057		10.1074/jbc.M507745200	http://dx.doi.org/10.1074/jbc.M507745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16269408	hybrid			2022-12-25	WOS:000234447200045
J	Mitchell, MS; Rao, VB				Mitchell, MS; Rao, VB			Functional analysis of the bacteriophage T4 DNA-packaging ATPase motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE SUBUNIT; IN-VITRO; PROTEIN GP17; TERMINASE; BINDING; SITE; DOMAINS; SYSTEM; PURIFICATION; EXPRESSION	Packaging of double-stranded DNA into bacteriophage capsids is driven by one of the most powerful force-generating motors reported to date. The phage T4 motor is constituted by gene product 16 (gp16) (18 kDa; small terminase), gp17 (70 kDa; large terminase), and gp20 (61 kDa; dodecameric portal). Extensive sequence alignments revealed that numerous phage and viral large terminases encode a common Walker-B motif in the N-terminal ATPase domain. The gp17 motif consists of a highly conserved aspartate (Asp(255)) preceded by four hydrophobic residues ((MIYI254)-M-251), which are predicted to form a beta-strand. Combinatorial mutagenesis demonstrated that mutations that compromised hydrophobicity, or integrity of the beta-strand, resulted in a null phenotype, whereas certain changes in hydrophobicity resulted in cs/ts phenotypes. No substitutions, including a highly conservative glutamate, are tolerated at the conserved aspartate. Biochemical analyses revealed that the Asp(255) mutants showed no detectable in vitro DNA packaging activity. The purified D255E, D255N, D255T, D255V, and D255E/E256D mutant proteins exhibited defective ATP binding and very low or no gp16-stimulated ATPase activity. The nuclease activity of gp17 is, however, retained, albeit at a greatly reduced level. These data define the N-terminal ATPase center in terminases and show for the first time that subtle defects in the ATP-Mg complex formation at this center lead to a profound loss of phage DNA packaging.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	Catholic University of America	Rao, VB (corresponding author), Catholic Univ Amer, Dept Biol, 103 McCort Ward Hall,620 Michigan Ave,NE, Washington, DC 20064 USA.	rao@cua.edu		Rao, Venigalla/0000-0002-0777-6587	NIAID NIH HHS [R01 AI081726, R01 AI011676, R01 AI011219, R56 AI081726] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson Dwight, 2005, P102; Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; Black Lindsay W., 1994, P218; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; Camacho AG, 2003, J BIOL CHEM, V278, P23251, DOI 10.1074/jbc.M301805200; CUE D, 1993, J MOL BIOL, V234, P594, DOI 10.1006/jmbi.1993.1614; DAVISON AJ, 1992, VIROLOGY, V186, P9, DOI 10.1016/0042-6822(92)90056-U; Dhar A, 2005, J MOL BIOL, V347, P71, DOI 10.1016/j.jmb.2004.12.041; Duffy C, 2002, J MOL BIOL, V316, P547, DOI 10.1006/jmbi.2001.5368; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; Franklin JL, 1996, GENE, V177, P179, DOI 10.1016/0378-1119(96)00299-5; Franklin JL, 1998, J MOL BIOL, V277, P541, DOI 10.1006/jmbi.1998.1619; Fujisawa H, 1997, GENES CELLS, V2, P537, DOI 10.1046/j.1365-2443.1997.1450343.x; Goetzinger KR, 2003, J MOL BIOL, V331, P139, DOI 10.1016/S0022-2836(03)00636-3; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HORTON RM, 1989, EMBO J, V11, P2643; Kanamaru S, 2004, J BIOL CHEM, V279, P40795, DOI 10.1074/jbc.M403647200; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; Kuebler D, 1998, J MOL BIOL, V281, P803, DOI 10.1006/jmbi.1998.1952; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Mezard C, 1997, J MOL BIOL, V271, P704, DOI 10.1006/jmbi.1997.1225; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; MORITA M, 1994, J MOL BIOL, V235, P248, DOI 10.1016/S0022-2836(05)80031-2; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; Rao VB, 2001, J MOL BIOL, V314, P401, DOI 10.1006/jmbi.2001.5169; RAO VB, 1992, GENE, V113, P25, DOI 10.1016/0378-1119(92)90666-D; Rao Venigalla B., 2005, P40; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; SHIBATA H, 1987, VIROLOGY, V159, P250, DOI 10.1016/0042-6822(87)90462-4; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480; Yang G, 2003, VIROLOGY, V305, P276, DOI 10.1006/viro.2002.1602; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	47	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					518	527		10.1074/jbc.M507719200	http://dx.doi.org/10.1074/jbc.M507719200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16258174	hybrid			2022-12-25	WOS:000234307200064
J	Vojnic, E; Simon, B; Strahl, BD; Sattler, M; Cramer, P				Vojnic, E; Simon, B; Strahl, BD; Sattler, M; Cramer, P			Structure and carboxyl-terminal domain (CTD) binding of the Set2 SRI domain that couples histone H3 Lys(36) methylation to transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MESSENGER-RNA; CAPPING ENZYME; PROTEIN STRUCTURES; H3K36 METHYLATION; PHOSPHORYLATION; NMR; ELONGATION; METHYLTRANSFERASE; RECOGNITION	During mRNA elongation, the SRI domain of the histone H3 methyltransferase Set2 binds to the phosphorylated carboxyl- terminal domain ( CTD) of RNA polymerase II. The solution structure of the yeast Set2 SRI domain reveals a novel CTD- binding fold consisting of a left- handed three- helix bundle. NMR titration shows that the SRI domain binds an Ser(2)/ Ser(5)- phosphorylated CTD peptide comprising two heptapeptide repeats and three flanking NH2- terminal residues, whereas a single CTD repeat is insufficient for binding. Residues that show strong chemical shift perturbations upon CTD binding cluster in two regions. Both CTD tyrosine side chains contact the SRI domain. One of the tyrosines binds in the region with the strongest chemical shift perturbations, formed by the two NH2- terminal helices. Unexpectedly, the SRI domain fold resembles the structure of an RNA polymerase- interacting domain in bacterial sigma factors ( domain sigma(2) in sigma(70)).	Univ Munich, Gene Ctr, Dept Chem & Biochem, D-81377 Munich, Germany; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Munich; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sattler, M (corresponding author), EMBL, D-69120 Heidelberg, Germany.	sattler@embl-heidelberg.de; cramer@LMB.uni-muenchen.de	Sattler, Michael/A-2407-2012; Sattler, Michael/C-1169-2010; Strahl, Brian/C-7601-2012	Sattler, Michael/0000-0002-1594-0527; Strahl, Brian/0000-0002-4947-6259; Simon, Bernd/0000-0003-0164-5516				Adhvaryu KK, 2005, EUKARYOT CELL, V4, P1455, DOI 10.1128/EC.4.8.1455-1464.2005; Allen M, 2002, J MOL BIOL, V323, P411, DOI 10.1016/S0022-2836(02)00968-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Morris SA, 2005, EUKARYOT CELL, V4, P1446, DOI 10.1128/EC.4.8.1446-1454.2005; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; OKHUMA Y, 1991, NATURE, V354, P398; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Phatnani HP, 2004, BIOCHEMISTRY-US, V43, P15702, DOI 10.1021/bi048364h; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	44	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					13	15		10.1074/jbc.C500423200	http://dx.doi.org/10.1074/jbc.C500423200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16286474	Green Published, hybrid			2022-12-25	WOS:000234307200004
J	Albert, A; Munoz-Espin, D; Jimenez, M; Asensio, JL; Hermoso, JA; Salas, M; Meijer, WJJ				Albert, A; Munoz-Espin, D; Jimenez, M; Asensio, JL; Hermoso, JA; Salas, M; Meijer, WJJ			Structural basis for membrane anchorage of viral phi 29 DNA during replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN P16.7; FUNCTIONAL DOMAIN; PROGRAM; CRYSTALLOGRAPHY; ORGANIZER; SUITE	Prokaryotic DNA replication is compartmentalized at the cellular membrane. Functional and biochemical studies showed that the Bacillus subtilis phage phi 29-encoded membrane protein p16.7 is directly involved in the organization of membrane-associated viral DNA replication. The structure of the functional domain of p16.7 in complex with DNA, presented here, reveals the multimerization mode of the protein and provides insights in the organization of the phage genome at the membrane of the infected cell.	CSIC, Grp Cristalog Macromol & Biol Estruct, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Autonoma Madrid, Inst Biol Mol Eladio Vinuela, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, Dept Quim Organ Biol, Inst Quim Organ, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)	Albert, A (corresponding author), CSIC, Grp Cristalog Macromol & Biol Estruct, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	xalbert@iqfr.csic.es; wmeijer@cbm.uam.es	Asensio, Juan L./J-1996-2015; Sarmiento, Mercedes Jimenez/K-2691-2014; Hermoso, Juan/J-3433-2012; Salas, Margarita/J-9873-2014; Albert, Armando/J-2373-2012	Asensio, Juan L./0000-0001-7536-5221; Hermoso, Juan/0000-0002-1862-8950; Salas, Margarita/0000-0001-5939-3441; Albert, Armando/0000-0002-0026-6816; Meijer, Wilfried/0000-0003-1842-0049				Asensio JL, 2005, J BIOL CHEM, V280, P20730, DOI 10.1074/jbc.M501687200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bravo A, 2005, FEMS MICROBIOL REV, V29, P25, DOI 10.1016/j.femsre.2004.06.003; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Meijer WJJ, 2000, EMBO J, V19, P4182, DOI 10.1093/emboj/19.15.4182; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Munoz-Espin D, 2004, J BIOL CHEM, V279, P50437, DOI 10.1074/jbc.M403297200; Murphy FV, 2000, STRUCT FOLD DES, V8, pR83, DOI 10.1016/S0969-2126(00)00126-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Salas M, 1999, GENET ENG P, V21, P159; Serna-Rico A, 2003, EMBO J, V22, P2297, DOI 10.1093/emboj/cdg221; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	23	9	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42486	42488		10.1074/jbc.C500429200	http://dx.doi.org/10.1074/jbc.C500429200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16275651	hybrid			2022-12-25	WOS:000234200800003
J	Xu, YR; Tan, LJ; Grachtchouk, V; Voorhees, JJ; Fisher, GJ				Xu, YR; Tan, LJ; Grachtchouk, V; Voorhees, JJ; Fisher, GJ			Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; HUMAN KERATINOCYTES; ACTIVATION; PROLIFERATION; ENDOCYTOSIS; EXPRESSION; SUBSTRATE; CYTOKINE; TARGET; LAR	Epidermal growth factor receptor (EGFR), the prototypic receptor protein tyrosine kinase, is a major regulator of growth and survival for many epithelial cell types. We report here that receptor-type protein-tyrosine phosphatase-kappa (RPTP-kappa) dephosphorylates EGFR and thereby regulates its function in human keratinocytes. Protein-tyrosine phosphatase (PTP) inhibitors induced EGFR tyrosine phosphorylation in intact primary human keratinocytes and cell-free membrane preparations. Five highly expressed RPTPs (RPTP-beta, delta, kappa, mu, and xi) were functionally analyzed in a Chinese hamster ovary (CHO) cell-based expression system. Full-length human EGFR expressed in CHO cells, which lack endogenous EGFR, displayed high basal (i.e. in the absence of ligand) tyrosine phosphorylation. Co-expression of RPTP-kappa, but not other RPTPs, specifically reduced basal EGFR tyrosine phosphorylation. RPTP-kappa also reduced epidermal growth factor-dependent EGFR tyrosine phosphorylation in CHO cells. Purified RPTP-kappa preferentially dephosphorylated EGFR tyrosines 1068 and 1173 in vitro. Overexpression of wild-type or catalytically inactive RPTP-kappa reduced or enhanced, respectively, basal and EGF-induced EGFR tyrosine phosphorylation in human keratinocytes. Furthermore, siRNA-mediated knockdown of RPTP-kappa increased basal and EGF-stimulated EGFR tyrosine phosphorylation and augmented downstream Erk activation in human keratinocytes. RPTP-kappa levels increased in keratinocytes as cells reached confluency, and overexpression of RPTP-kappa in subconfluent keratinocytes reduced keratinocyte proliferation. Taken together, the above data indicate that RPTP-kappa is a key regulator of EGFR tyrosine phosphorylation and function in human keratinocytes.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, Rm 6447,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dianemch@umich.edu	Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang ZQ, 2002, J BIOL CHEM, V277, P19470, DOI 10.1074/jbc.M201097200; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Yang Y, 1996, BIOCHEM BIOPH RES CO, V228, P807, DOI 10.1006/bbrc.1996.1736	38	90	96	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42694	42700		10.1074/jbc.M507722200	http://dx.doi.org/10.1074/jbc.M507722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263724	hybrid			2022-12-25	WOS:000234200800027
J	Bohman, S; Matsumoto, T; Suh, K; Dimberg, A; Jakobsson, L; Yuspa, S; Welsh, LC				Bohman, S; Matsumoto, T; Suh, K; Dimberg, A; Jakobsson, L; Yuspa, S; Welsh, LC			Proteomic analysis of vascular endothelial growth factor-induced endothelial cell differentiation reveals a role for chloride intracellular channel 4 (CLIC4) in tubular morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANGIOGENESIS INHIBITORS; COLLAGEN MATRICES; FACTOR RECEPTOR-2; TUBE FORMATION; BLOOD-VESSELS; ANION CHANNEL; PROTEIN; P64H1; FAMILY	Formation of new vessels from pre-existing capillaries demands extensive reprogramming of endothelial cells through transcriptional and post-transcriptional events. We show that 120 protein spots in a two-dimensional isoelectric focusing/electrophoretic analysis were affected during vascular endothelial growth factor-A-induced endothelial cell tubular morphogenesis in vitro, as a result of changes in charge or expression level of the corresponding proteins. For about 22% of the spots, the protein products could be identified, of which several previously have been implicated in cytoskeletal reorganization and angiogenesis. One such protein was heat shock protein 27, a chaperone involved in beta-actin rearrangement that was identified as regulated in degree of serine phosphorylation. We also identified regulation of chloride intracellular channel 4 (CLIC4), the expression of which decreased during tubular morphogenesis. CLIC4 was expressed at high levels in resting vessels, whereas expression was modulated during pathological angiogenesis such as in tumor vessels. The subcellular localization of CLIC4 in endothelial cells was dependent on whether cells were engaged in proliferation or tube formation. Antisense- and small interfering RNA-mediated suppression of CLIC4 expression led to arrest in tubular morphogenesis. Our data implicate CLIC4 in formation of a vessel lumen.	Uppsala Univ, Dept Genet & Pathol, S-75185 Uppsala, Sweden; NCI, Ctr Canc Res, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Welsh, LC (corresponding author), Uppsala Univ, Dept Genet & Pathol, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.	Lena.Welsh@genpat.uu.se	Jakobsson, Lars/B-4200-2011	Jakobsson, Lars/0000-0001-7956-587X; Claesson-Welsh, Lena/0000-0003-4275-2000; Dimberg, Anna/0000-0003-4422-9125				Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Bell SE, 2001, J CELL SCI, V114, P2755; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Egginton S, 2003, MICROCIRCULATION, V10, P45, DOI 10.1038/sj.mn.7800174; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Keezer SM, 2003, CANCER RES, V63, P6405; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Magnusson P, 2004, J CELL SCI, V117, P1513, DOI 10.1242/jcs.00999; Magnusson PU, 2005, ARTERIOSCL THROM VAS, V25, P944, DOI 10.1161/01.ATV.0000163182.73190.f9; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Proutski I, 2002, BIOCHEM BIOPH RES CO, V297, P317, DOI 10.1016/S0006-291X(02)02199-X; Qi J H, 1999, Angiogenesis, V3, P371, DOI 10.1023/A:1026565908445; Ribatti D, 2001, MECH DEVELOP, V100, P157, DOI 10.1016/S0925-4773(00)00522-0; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Scheurer SB, 2004, PROTEOMICS, V4, P1737, DOI 10.1002/pmic.200300689; SENGER DR, 1986, CANCER RES, V46, P5629; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Suh KS, 2005, CANCER RES, V65, P562; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Tuszynski GP, 2002, MICROVASC RES, V64, P448, DOI 10.1006/mvre.2002.2444; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Yang SY, 2001, ARTERIOSCL THROM VAS, V21, P1934, DOI 10.1161/hq1201.099432; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	44	80	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42397	42404		10.1074/jbc.M506724200	http://dx.doi.org/10.1074/jbc.M506724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239224	hybrid			2022-12-25	WOS:000233992700070
J	Lepidi, S; Abatangelo, G; Vindigni, V; Deriu, GP; Zavan, B; Tonello, C; Cortivo, R				Lepidi, S; Abatangelo, G; Vindigni, V; Deriu, GP; Zavan, B; Tonello, C; Cortivo, R			In vivo regeneration of small-diameter (2 mm) arteries using a polymer scaffold	FASEB JOURNAL			English	Article						vascular prosthesis; tissue engineering; remodeling; surgery	ENDOTHELIAL PROGENITOR CELLS; SAPHENOUS-VEIN; BLOOD-VESSEL; GRAFTS; MUSCLE; BYPASS; PERITONEAL; CONDUITS; VITRO	The difficulty of obtaining significant long-term patency and good wall mechanical strength in vivo has been a significant obstacle in achieving small-diameter vascular prostheses. The aim of the present study was to develop a prosthetic graft that could perform as a small-diameter vascular conduit. Tubular structures of hyaluronan (HYAFF-11 tubules, 2 mm diameter, 1 cm length) were grafted in the abdominal aorta of 30 rats as temporary absorbable guides to promote regeneration of vascular structures. Performance was assessed by histology, immunohistochemistry, and ultra-structural analysis. These experiments resulted in three novel findings: 1) complete endothelialization of the tube's luminal surface occurred; 2) sequential regeneration of vascular components led to complete vascular wall regeneration 15 days after surgery; and 3) the biomaterial used created the ideal environment for the delicate regeneration process during the critical initial phases, yet its biodegradability allowed for complete degradation of the construct four months after implantation, at which time, a new artery remained to connect the artery stumps. This study assesses the feasibility to create a completely biodegradable vascular regeneration guide in vivo, able to sequentially orchestrate vascular regeneration events needed for very small artery reconstruction.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy; Univ Padua, Clin Vasc Surg, I-35100 Padua, Italy; Univ Padua, Clin Plast Surg, I-35100 Padua, Italy	University of Padua; University of Padua; University of Padua	Abatangelo, G (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via G Colombo 3, I-35100 Padua, Italy.	g.abatangelo@unipd.it	Vindigni, Vincenzo/K-5059-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Lepidi, Sandro/0000-0003-2201-6081				Arts CHP, 2002, EUR J VASC ENDOVASC, V23, P404, DOI 10.1053/ejvs.2002.1604; Bujan J, 2004, BIOTECHNOL APPL BIOC, V39, P17, DOI 10.1042/BA20030111; Campbell JH, 1999, CIRC RES, V85, P1173; Cho SW, 2005, ANN SURG, V241, P506, DOI 10.1097/01.sla.0000154268.12239.ed; Chue WL, 2004, J VASC SURG, V39, P859, DOI 10.1016/j.jvs.2003.03.003; DallaLibera L, 1997, J MUSCLE RES CELL M, V18, P295; Daly CD, 2004, FRONT BIOSCI, V9, P1915, DOI 10.2741/1384; De Lorenzi F, 2002, PLAST RECONSTR SURG, V109, P2023, DOI 10.1097/00006534-200205000-00037; Gleason RL, 2004, FRONT BIOSCI-LANDMRK, V9, P2045, DOI 10.2741/1387; Hsu SH, 2003, ARTIF ORGANS, V27, P1068, DOI 10.1111/j.1525-1594.2003.07141.x; Kakisis JD, 2005, J VASC SURG, V41, P349, DOI 10.1016/j.jvs.2004.12.026; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Khot UN, 2004, CIRCULATION, V109, P2086, DOI 10.1161/01.CIR.0000127570.20508.5C; Kidane AG, 2004, BIOMACROMOLECULES, V5, P798, DOI 10.1021/bm0344553; Klinkert P, 2004, EUR J VASC ENDOVASC, V27, P357, DOI 10.1016/j.ejvs.2003.12.027; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Kurotobi K, 2003, ARTIF ORGANS, V27, P582, DOI 10.1046/j.1525-1594.2003.07016.x; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Leon Luis, 2003, Expert Rev Cardiovasc Ther, V1, P581; Matsuda T, 2004, ARTIF ORGANS, V28, P64, DOI 10.1111/j.1525-1594.2004.07324.x; McFetridge PS, 2004, ASAIO J, V50, P591, DOI 10.1097/01.MAT.0000144365.22025.9B; Mitchell SL, 2003, CARDIOVASC PATHOL, V12, P59, DOI 10.1016/S1054-8807(02)00183-7; Nanobashvili J, 2004, EUR SURG RES, V36, P74, DOI 10.1159/000076646; Nerem RM, 2003, BIORHEOLOGY, V40, P281; Pawlowski KJ, 2004, FRONT BIOSCI-LANDMRK, V9, P1412, DOI 10.2741/1302; Rashid ST, 2004, CELL PROLIFERAT, V37, P351, DOI 10.1111/j.1365-2184.2004.00318.x; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; Remy-Zolghadri M, 2004, J VASC SURG, V39, P613, DOI 10.1016/j.jvs.2003.08.007; Schaner PJ, 2004, J VASC SURG, V40, P146, DOI 10.1016/j.jvs.2004.03.033; Schmidt D, 2004, ANN THORAC SURG, V78, P2094, DOI 10.1016/j.athoracsur.2004.06.052; Thomas AC, 2003, CARDIOVASC PATHOL, V12, P271, DOI 10.1016/S1054-8807(03)00086-3; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; Vorp DA, 2005, FRONT BIOSCI-LANDMRK, V10, P768, DOI 10.2741/1571; Wang H, 2005, ARTERIOSCL THROM VAS, V25, P1817, DOI 10.1161/01.ATV.0000175840.90510.a8; Williams C, 2004, TISSUE ENG, V10, P930, DOI 10.1089/1076327041348536; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Zhang Z, 2004, BIOMATERIALS, V25, P177, DOI 10.1016/S0142-9612(03)00478-2; [No title captured]	40	38	40	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					103	+		10.1096/fj.05-4802fje	http://dx.doi.org/10.1096/fj.05-4802fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16291641				2022-12-25	WOS:000234053100010
J	Coolen, MW; van Loo, KMJ; van Bakel, NNHM; Ellenbroek, BA; Cools, AR; Martens, GJM				Coolen, MW; van Loo, KMJ; van Bakel, NNHM; Ellenbroek, BA; Cools, AR; Martens, GJM			Reduced Aph-1b expression causes tissue- and substrate-specific changes in gamma-secretase activity in rats with a complex phenotype	FASEB JOURNAL			English	Article						gamma-secretase complex composition; APO-SUS rat model; complex (neuro) developmental phenotype; amyloid-beta precursor protein	AMYLOID PRECURSOR PROTEIN; BETA-APP; ALZHEIMERS-DISEASE; ANIMAL-MODELS; MICE LACKING; MUTANT MICE; PRESENILIN; NICASTRIN; NOTCH; TRAFFICKING	The gamma-secretase enzyme complex displays intramembrane catalytic activity toward many type I transmembrane proteins, including the Alzheimer-linked amyloid-beta-protein precursor (APP) and the neuregulin receptor ErbB4. Active gamma-secretase is a tetrameric protein complex consisting of presenilin-1 ( or -2), nicastrin, PEN-2, and Aph-1a ( or -1b). We have recently discovered that pharmacogenetically bred apomorphine-susceptible Wistar rats ( APO-SUS) have only one or two copies of the Aph-1b gene ( termed I/I and II/II rats, respectively), whereas their phenotypic counterparts ( APO-UNSUS) have three copies ( III/III). As a result, APO-SUS rats display reduced Aph-1b expression and a complex phenotype reminiscent of neurodevelopmental disorders. Here we determined in the I/I and III/III rats the gamma-secretase cleavage activity toward the three APP superfamily members, p75 neurotrophin receptor, ErbB4, and neuregulin-2, and found that the cleavage of only a subset of the substrates was changed. Furthermore, the observed differences were restricted to tissues that normally express relatively high Aph-1b compared with Aph-1a levels. Thus, we provide in vivo evidence that subtle alterations in gamma-secretase subunit composition may lead to a variety of affected ( neuro) developmental signaling pathways and, consequently, a complex phenotype.	Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, NL-6525 GA Nijmegen, Netherlands; Radboud Univ Nijmegen, Inst Neurosci, NL-6525 GA Nijmegen, Netherlands; UMC St Radboud, Dept Psychoneuropharmacol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Martens, GJM (corresponding author), Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, Geert Grootepl Zuid 28, NL-6525 GA Nijmegen, Netherlands.	g.martens@ncmls.ru.nl	van Bakel, Nick/A-3187-2013; Ellenbroek, Bart/C-4570-2012; Martens, Gerard JM/D-1925-2010	Ellenbroek, Bart/0000-0003-1996-4873; Coolen, Marcel/0000-0002-8188-8480; Martens, Gerard/0000-0003-1761-4570				Berezovska O, 2003, J NEUROSCI, V23, P4560; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; COENDERS CJH, 1992, PHYSIOL BEHAV, V52, P321, DOI 10.1016/0031-9384(92)90278-A; Coolen MW, 2005, NEURON, V45, P497, DOI 10.1016/j.neuron.2004.12.054; COOLS AR, 1990, BRAIN RES BULL, V24, P49, DOI 10.1016/0361-9230(90)90288-B; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DHooge R, 1996, NEUROREPORT, V7, P2807, DOI 10.1097/00001756-199611040-00080; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ELLENBROEK BA, 1995, J NEUROSCI, V15, P7604; Ellenbroek BA, 2002, BEHAV GENET, V32, P349, DOI 10.1023/A:1020214322065; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gerlai R, 2000, BEHAV BRAIN RES, V109, P219, DOI 10.1016/S0166-4328(99)00175-8; Hawkes C, 2003, MOVEMENT DISORD, V18, P364, DOI 10.1002/mds.10379; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herrick C. J., 1899, ARCH NEUROLOGY PSYCH, V2, P1; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Lalonde R, 2002, EXP GERONTOL, V37, P1401, DOI 10.1016/S0531-5565(02)00123-7; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Li T, 2003, J NEUROSCI, V23, P3272; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Moberg Paul J, 2003, Curr Psychiatry Rep, V5, P311, DOI 10.1007/s11920-003-0061-x; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Page K, 1996, P NATL ACAD SCI USA, V93, P14020, DOI 10.1073/pnas.93.24.14020; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; ROTS NY, 1995, J NEUROENDOCRINOL, V7, P153, DOI 10.1111/j.1365-2826.1995.tb00678.x; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Sester M, 2000, J BIOL CHEM, V275, P3645, DOI 10.1074/jbc.275.5.3645; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; Tisay KT, 2000, J COMP NEUROL, V428, P656, DOI 10.1002/1096-9861(20001225)428:4<656::AID-CNE6>3.0.CO;2-7; Yan XX, 2004, J NEUROSCI, V24, P2942, DOI 10.1523/JNEUROSCI.0092-04.2004; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	45	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					175	+		10.1096/fj.05-4337fje	http://dx.doi.org/10.1096/fj.05-4337fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16249316				2022-12-25	WOS:000232991100006
J	Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R				Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R			Smad4 haploinsufficiency in mouse models for intestinal cancer	ONCOGENE			English	Article						Smad4; Apc; haploinsufficiency; TGF-beta signaling; LOH; Wnt signaling; gastrointestinal cancer	STEM-CELL DIFFERENTIATION; COLORECTAL CANCERS; JUVENILE POLYPOSIS; BETA-CATENIN; GENE; APC; TUMORIGENESIS; PATHWAY; TUMORS; MUTATIONS	The Smad4(+/E6sad) mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type Smad4 allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies Smad4-driven tumor initiation in the GI tract. As both the Apc and Smad4 tumor suppressor genes map to mouse chromosome 18, we have bred Smad4(+/E6sad) with the Apc(+/1638N) model to generate two distinct compound heterozygous lines carrying both mutations either in cis ( CAS) or in trans ( TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5-6 weeks of age. Phenotypic and molecular analyses indicate that Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances Apc-driven tumor formation.	ErasmusMC, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, Amsterdam, Netherlands; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; University of Edinburgh	Fodde, R (corresponding author), ErasmusMC, Dept Pathol, Josephine Nefkens Inst, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.fodde@erasmusmc.nl	Fodde, Riccardo/AAW-9394-2021; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; de Pater, Emma/0000-0002-7195-6769; Hohenstein, Peter/0000-0001-8548-4734				Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gaspar C, 2004, INT J DEV BIOL, V48, P377, DOI 10.1387/ijdb.041807cg; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hohenstein P, 2003, GENE CHROMOSOME CANC, V36, P273, DOI 10.1002/gcc.10169; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jass JR, 2001, J PATHOL, V193, P283, DOI 10.1002/1096-9896(200103)193:3<283::AID-PATH799>3.0.CO;2-9; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Satterwhite DJ, 2004, CELL CYCLE, V3, P1069; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504	33	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1841	1851		10.1038/sj.onc.1209226	http://dx.doi.org/10.1038/sj.onc.1209226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288217				2022-12-25	WOS:000236224800001
J	Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH				Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH			MCM7 amplification and overexpression are associated with prostate cancer progression	ONCOGENE			English	Article						MCM7; metastasis; prostate cancer; amplification	COMPARATIVE GENOMIC HYBRIDIZATION; MINICHROMOSOME-MAINTENANCE PROTEIN-7; DNA-REPLICATION; TUMOR-GROWTH; S-PHASE; COMPLEX; EXPRESSION; IDENTIFICATION; LOCALIZATION; MICROARRAYS	The genomic DNA profiles of prostate cancers with aggressive features were compared to the profiles of matched normal DNA to identify genes that are selectively amplified in the cancer cells. One of the identified genes, MCM7, which is a component of the DNA replication licensing complex, has been studied extensively both at the DNA and protein levels in human prostate tissues. Approximately half of the prostate cancer specimens studied showed MCM7 gene amplification, and 60% of the aggressive prostate cancer specimens had increased MCM7 protein expression. Amplification or overexpression of MCM7 was significantly associated with relapse, local invasion and a worse tumor grade. Constitutive expression of MCM7 in a human prostate cancer cell line, DU145, resulted in markedly increased DNA synthesis and cell proliferation compared to vector-only controls, and an increased cell invasion in vitro. Indeed, MCM7 overexpression produced primary tumors 12 times larger than vector-only controls and resulted in a rapid demise of mice bearing those tumors. These studies implicate MCM7, and the DNA replication licensing gene family, in prostate cancer progression, growth and invasion.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Scaife Hall A-725,3550 Terrace St, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu	Yu, Yan/GYV-4514-2022		NATIONAL CANCER INSTITUTE [U01CA088110, R01CA098249] Funding Source: NIH RePORTER; NCI NIH HHS [1 UO1CA88110-01, R01 CA098249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brake T, 2003, CANCER RES, V63, P8173; Clark J, 2003, ONCOGENE, V22, P1247, DOI 10.1038/sj.onc.1206247; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Lu ZH, 1999, MOL BIOL CELL, V10, P4091, DOI 10.1091/mbc.10.12.4091; LUO JH, 2003, EXPERT REV MOL MED, P1; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Wolter H, 2002, EUR UROL, V41, P328, DOI 10.1016/S0302-2838(02)00035-0; Xue WC, 2003, HISTOPATHOLOGY, V43, P485, DOI 10.1046/j.1365-2559.2003.01728.x; Yoshida K, 2003, FEBS LETT, V553, P213, DOI 10.1016/S0014-5793(03)01018-4	25	144	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1090	1098		10.1038/sj.onc.1209134	http://dx.doi.org/10.1038/sj.onc.1209134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247466				2022-12-25	WOS:000235361000013
J	Smyth, DJ; Glanfield, A; McManus, DP; Hacker, E; Blair, D; Anderson, GJ; Jones, MK				Smyth, DJ; Glanfield, A; McManus, DP; Hacker, E; Blair, D; Anderson, GJ; Jones, MK			Two isoforms of a divalent metal transporter (DMT1) in Schistosoma mansoni suggest a surface-associated pathway for iron absorption in schistosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; SEQUENCE ALIGNMENT; ADULT WORMS; EXPRESSION; LOCALIZATION; JAPONICUM; NRAMP2; FERRITIN; PROTEIN; EVOLUTIONARY	We describe two homologues of the mammalian divalent metal transporter (DMT1) for Schistosoma mansoni, a pathogenic intravascular parasite of humans. Schistosomes have a high nutritional and metabolic demand for iron. Nucleotide sequences of the parasite homologues, designated SmDMT1A and -B, are identical in all but the 5'-regions. The predicted amino acid sequences share at least 60% identity with DMT1 (= Nramp2) of humans, mice, and rats, and at least 55% identity with Nramp1 from mice, humans and Caenorhabditis elegans. SmDMT1A is expressed in differentiating eggs, miracidia, cercariae, schistosomula, and adults, whereas SmDMT1B is expressed in all but the miracidium and occurs at lower levels than SmDMT1A in differentiating eggs and cercariae. An iron-responsive element, present at the 3'-untranslated region of many DMT1 molecules, is not present in schistosome mRNAs studied here. A Western blot analysis of adult worm preparations using a homologous rabbit serum raised against a schistosome DMT1peptide and a heterologous serum raised against mammalian DMT1, revealed a band approximating 115 kDa. By immunofluorescence microscopy, the schistosome DMT1s localize primarily to the tegument. Iron uptake assays demonstrated that SmDMT1s were able to rescue yeast growth in ferrous iron- transport deficient yeast (fet3fet4). The results suggest that schistosomes express molecules for ferrous iron transport in their tegument, suggesting trans-tegumental transport as one means of iron acquisition for these parasites.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Sch Populat Hlth, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia; James Cook Univ N Queensland, Sch Trop Biol, Townsville, Qld 4811, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; James Cook University	Jones, MK (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp,300 Herston Rd, Brisbane, Qld 4029, Australia.	malcolm.jones@qimr.edu.au	McManus, Don/AAC-5394-2020; Blair, David/O-2786-2019; Anderson, Gregory J/G-4148-2013; Blair, David/G-6052-2011; McManus, Donald P./G-2678-2013; Hacker, Elke/J-1265-2012; Jones, Malcolm K/A-1097-2009	McManus, Don/0000-0001-6443-1449; Blair, David/0000-0002-4658-3251; Anderson, Gregory J/0000-0002-8814-5866; Blair, David/0000-0002-4658-3251; Hacker, Elke/0000-0003-2759-8244; Jones, Malcolm K/0000-0002-0035-6141; Smyth, Danielle/0000-0001-6080-2679	Wellcome Trust [071657] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Bengert P, 2003, NUCLEIC ACIDS RES, V31, P3441, DOI 10.1093/nar/gkg568; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CLEMENS LE, 1989, J PARASITOL, V75, P417, DOI 10.2307/3282599; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; Cumming J N, 1997, Adv Pharmacol, V37, P253; Dalton JP, 1997, PARASITOLOGY, V115, P29, DOI 10.1017/S0031182097001091; DIETZEL J, 1992, MOL BIOCHEM PARASIT, V50, P245, DOI 10.1016/0166-6851(92)90221-5; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J BIOL CHEM, V267, P20774; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; Frazer D M, 2001, Hematology, V6, P193, DOI 10.1080/10245332.2001.11746572; Gobert GN, 2003, INT J PARASITOL, V33, P1561, DOI 10.1016/S0020-7519(03)00255-8; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; Hooker CW, 1996, MOL BIOCHEM PARASIT, V82, P265, DOI 10.1016/0166-6851(96)02748-X; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Hubert N, 2002, P NATL ACAD SCI USA, V99, P12345, DOI 10.1073/pnas.192423399; Jones MK, 2004, BIOESSAYS, V26, P752, DOI 10.1002/bies.20058; Kaiser BN, 2003, PLANT J, V35, P295, DOI 10.1046/j.1365-313X.2003.01802.x; KASSCHAU MR, 1986, EXP PARASITOL, V61, P201, DOI 10.1016/0014-4894(86)90153-0; Kishi F, 1997, MOL IMMUNOL, V34, P839, DOI 10.1016/S0161-5890(97)00110-7; KLOETZEL K, 1966, AM J TROP MED HYG, V15, P28, DOI 10.4269/ajtmh.1966.15.28; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LAWRENCE JD, 1973, J PARASITOL, V59, P60, DOI 10.2307/3278572; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Li W, 2005, PLOS GENET, V1, P329, DOI 10.1371/journal.pgen.0010036; Liu Wen-qi, 2001, Chinese Journal of Parasitology and Parasitic Diseases, V19, P84; McCord JM, 1998, SEMIN HEMATOL, V35, P5; Meshnick S R, 1998, Med Trop (Mars), V58, P13; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; Mims MP, 2005, HEMATOLOGY, V10, P339, DOI 10.1080/10245330500093419; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Robijn MLM, 2005, PARASITOLOGY, V130, P67, DOI 10.1017/S0031182004006390; Robledo JAF, 2004, J PARASITOL, V90, P1004, DOI 10.1645/GE-240R; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; Roth JA, 2000, J NEUROSCI, V20, P7595; SAMOKYSZYN VM, 1988, DRUG METAB REV, V19, P283, DOI 10.3109/03602538808994137; SCHUSSLER P, 1995, MOL REPROD DEV, V41, P325, DOI 10.1002/mrd.1080410307; SMITH AM, 1994, MOL BIOCHEM PARASIT, V67, P11, DOI 10.1016/0166-6851(94)90091-4; Smyth J.D., 1983, PHYSL TREMATODES; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thors C, 2003, J HISTOCHEM CYTOCHEM, V51, P1367, DOI 10.1177/002215540305101013; Trinder D, 2000, GUT, V46, P270, DOI 10.1136/gut.46.2.270; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; WOLDEMUSSIE E, 1982, J PARASITOL, V68, P48, DOI 10.2307/3281324; Xiao SH, 2000, J PARASITOL, V86, P1125, DOI 10.1645/0022-3395(2000)086[1125:TCIASM]2.0.CO;2	50	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2242	2248		10.1074/jbc.M511148200	http://dx.doi.org/10.1074/jbc.M511148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16267047	hybrid, Green Accepted			2022-12-25	WOS:000234760400048
J	Li, Q; Engelhardt, JF				Li, Q; Engelhardt, JF			Interleukin-1 beta induction of NF kappa B is partially regulated by H2O2-mediated activation of NF kappa b-inducing kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR CHONDROCYTES; TERMINAL KINASE; IKK-ALPHA; IRAK; FAMILY; IL-1; COMPLEX; INVOLVEMENT; EXPRESSION; APOPTOSIS	Reactive oxygen species (ROS) have been demonstrated to act as second messengers in a number of signal transduction pathways, including NF kappa B. However, the mechanism(s) by which ROS regulate NF kappa B remain unclear and controversial. In the present report, we describe a mechanism whereby interleukin-1 beta(IL-1 beta) stimulation of NF kappa B is partially regulated by H2O2-mediated activation of NIK and subsequent NIK-mediated phosphorylation of IKK alpha. IL-1 beta induced H2O2 production in MCF-7 cells and clearance of this ROS through the expression of GPx-1 reduced NF kappa B transcriptional activation by inhibiting NIK-mediated phosphorylation of IKK alpha. Although IKK alpha and IKK alpha were both involved in IL-1 beta-mediated activation of NF kappa B, only the IKK alpha-dependent component was modulated by changes in H2O2 levels. Interestingly, in vitro reconstitution experiments demonstrated that NIK was activated by a very narrow range of H2O2 (1-10 mu M), whereas higher concentrations (100 mu M to 1 mM) inhibited NIK activity. Treatment of cells with the general Ser/Thr phosphatase inhibitor (okadaic acid) lead to activation of NF kappa B and enhanced NIK activity as a IKK alpha kinase, suggesting that ROS may directly regulate NIK through the inhibition of phosphatases. Recruitment of NIK to TRAF6 following IL-1 beta stimulation was inhibited by H2O2 clearance and Rac1 siRNA, suggesting that Rac-dependent NADPH oxidase may be a source of ROS required for NIK activation. In summary, our studies have demonstrated that redox regulation of NIK by H2O2 is mechanistically important in IL-1 beta induction of NF kappa B activation.	Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy Cyst Fibrosis & Other Genet Dis, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, Rm 1-111 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	john-engelhardt@uiowa.edu			NIDDK NIH HHS [P30 DK54759, R01-DK067928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759, R01DK067928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anasagasti MJ, 1996, J CELL PHYSIOL, V167, P314, DOI 10.1002/(SICI)1097-4652(199605)167:2<314::AID-JCP16>3.0.CO;2-7; Bol GF, 2003, BIOL CHEM, V384, P609, DOI 10.1515/BC.2003.068; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Brigelius-Flohe R, 2004, ARCH BIOCHEM BIOPHYS, V423, P66, DOI 10.1016/j.abb.2003.12.008; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Engelsing K, 2001, MECH TIME-DEPEND MAT, V5, P27, DOI 10.1023/A:1009858702188; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; Fitzgerald KA, 2000, MICROBES INFECT, V2, P933, DOI 10.1016/S1286-4579(00)00396-8; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gu Y, 2003, J BIOL CHEM, V278, P17210, DOI 10.1074/jbc.M210314200; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Je JH, 2004, FEBS LETT, V566, P183, DOI 10.1016/j.febslet.2004.04.037; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lo YYC, 1998, J CELL BIOCHEM, V69, P19, DOI 10.1002/(SICI)1097-4644(19980401)69:1<19::AID-JCB3>3.0.CO;2-Y; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marangolo M, 2001, NEUROTOX RES, V3, P397, DOI 10.1007/BF03033200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mendes AF, 2003, CELL BIOL TOXICOL, V19, P203; Mendes AF, 2001, MEDIAT INFLAMM, V10, P209, DOI 10.1080/09629350120080401; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Pantschenko AG, 2003, INT J ONCOL, V23, P269; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rhee S G, 2000, Sci STKE, V2000, ppe1; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Uekawa N, 2004, FEBS LETT, V575, P30, DOI 10.1016/j.febslet.2004.08.033; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Valacchi G, 2005, ANTIOXID REDOX SIGN, V7, P25, DOI 10.1089/ars.2005.7.25; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walley ER, 1996, INFECT IMMUN, V64, P4733, DOI 10.1128/IAI.64.11.4733-4738.1996; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Xiong SG, 2003, ALCOHOL, V30, P107, DOI 10.1016/S0741-8329(03)00100-9; Xiong SG, 2003, J BIOL CHEM, V278, P17646, DOI 10.1074/jbc.M210905200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang J, 2001, ANTIOXID REDOX SIGN, V3, P493, DOI 10.1089/15230860152409121	67	55	56	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1495	1505		10.1074/jbc.M511153200	http://dx.doi.org/10.1074/jbc.M511153200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16286467	hybrid			2022-12-25	WOS:000234652000027
J	Brummer, T; Schramek, D; Hayes, VM; Bennett, HL; Caldon, CE; Musgrove, EA; Daly, RJ				Brummer, T; Schramek, D; Hayes, VM; Bennett, HL; Caldon, CE; Musgrove, EA; Daly, RJ			Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; BASEMENT-MEMBRANE CULTURES; RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION; GLAND DEVELOPMENT; C-MET; ACTIVATION; SHP2; RECRUITMENT; MORPHOGENESIS	The docking protein Gab2 is a proto-oncogene product that is overexpressed in primary breast cancers. To determine the functional consequences of Gab2 overexpression, we utilized the immortalized human mammary epithelial cell line MCF-10A. In monolayer culture, expression of Gab2 at levels comparable with those detected in human breast cancer cells accelerated epidermal growth factor (EGF)-induced cell cycle progression and was associated with increased basal Stat5 tyrosine phosphorylation and enhanced and/or more sustained EGF-induced Erk and Akt activation. Three-dimensional Matrigel culture of MCF-10A cells resulted in the formation of polarized, growth-arrested acini with hollow lumina. Under these conditions, Gab2 increased cell proliferation during morphogenesis, leading to significantly larger acini, an effect dependent on Gab2 binding to Grb2 and Shp2 and enhanced by recruitment of the p85 subunit of phosphatidylinositol 3-kinase. Pharmacological inhibition of MEK revealed that, in addition to direct activation of phosphatidylinositol 3-kinase, increased Erk signaling also contributed to Gab2-mediated enhancement of acinar size. In addition, Gab2 overcame the proliferative suppression that normally occurs in late stage cultures and conferred independence of the morphogenetic program from exogenous EGF. Finally, higher levels of Gab2 expression led to the formation of large disorganized structures with defective luminal clearance. These findings support a role for Gab2 in mammary tumorigenesis.	Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research	Daly, RJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	r.daly@garvan.org.au	Brummer, Tilman/B-6218-2016; Schramek, Daniel/J-5792-2014; Hayes, Vanessa M/GPP-2807-2022; Brummer, Tilman/AAA-9428-2020; Hayes, Vanessa/W-3728-2019; Schramek, Daniel/AAL-1470-2020; Caldon, Liz/C-1559-2009; Daly, Roger J/C-8179-2009	Brummer, Tilman/0000-0003-4387-7905; Hayes, Vanessa M/0000-0002-4524-7280; Brummer, Tilman/0000-0003-4387-7905; Schramek, Daniel/0000-0001-9977-2104; Caldon, Liz/0000-0003-1392-3472; Daly, Roger/0000-0002-5739-8027				Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Brummer Tilman, 2004, Methods Mol Biol, V271, P189; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hayes V M, 1999, Nucleic Acids Res, V27, pe29, DOI 10.1093/nar/27.20.e29; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; JANES PW, 1994, ONCOGENE, V9, P3601; Kairouz R, 2000, BREAST CANCER RES, V2, P197, DOI 10.1186/bcr54; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; SOULE HD, 1990, CANCER RES, V50, P6075; Troyer KL, 2001, J MAMMARY GLAND BIOL, V6, P7, DOI 10.1023/A:1009560330359; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Wu Y, 1998, NUCLEIC ACIDS RES, V26, P5432, DOI 10.1093/nar/26.23.5432; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	51	89	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					626	637		10.1074/jbc.M509567200	http://dx.doi.org/10.1074/jbc.M509567200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16253990	hybrid			2022-12-25	WOS:000234307200075
J	Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY				Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY			Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells	ONCOGENE			English	Article						microarray; radiation; p53R2; TK6	NF-KAPPA-B; RIBONUCLEOTIDE REDUCTASE GENE; NUCLEOTIDE EXCISION-REPAIR; THYMIDINE KINASE LOCUS; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; CANCER CELLS; APOPTOSIS	The p53 protein has been implicated in multiple cellular responses related to DNA damage. Alterations in any of these cellular responses could be related to increased genomic instability. Our previous study has shown that mutations in p53 lead to hypermutability to ionizing radiation. To investigate further how p53 is involved in regulating mutational processes, we used 8K cDNA microarrays to compare the patterns of gene expression among three closely related human cell lines with different p53 status including TK6 (wild-type p53), NH32 (p53null), and WTK1 (mutant p53). Total RNA samples were collected at 1, 3, 6, 9, and 24 h after 10 Gy gamma-irradiation. Template-based clustering analysis of the gene expression over the time course showed that 464 genes are either up or downregulated by at least twofold following radiation treatment. In addition, cluster analyses of gene expression profiles among these three cell lines revealed distinct patterns. In TK6, 165 genes were upregulated, while 36 genes were downregulated. In contrast, in WTK1 75 genes were upregulated and 12 genes were downregulated. In NH32, only 54 genes were upregulated. Furthermore, we found several genes associated with DNA repair namely p53R2, DDB2, XPC, PCNA, BTG2, and MSH2 that were highly induced in TK6 compared to WTK1 and NH32. p53R2, which is regulated by the tumor suppressor p53, is a small subunit of ribonucleotide reductase. To determine whether it is involved in radiation-induced mutagenesis, p53R2 protein was inhibited by siRNA in TK6 cells and followed by 2Gy radiation. The background mutation frequencies at the TK locus of siRNA-transfected TK6 cells were about three times higher than those seen in TK6 cells. The mutation frequencies of siRNA-transfected TK6 cells after 2 Gy radiation were significantly higher than the irradiated TK6 cells without p53R2 knock down. These results indicate that p53R2 was induced by p53 protein and is involved in protecting against radiation-induced mutagenesis.	NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Oncol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA; Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; Natl Taiwan Univ, Dept Elect Engn, Taipei 10764, Taiwan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Rochester; Colorado State University; National Taiwan University	Chuang, EY (corresponding author), NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bldg 10,Room B3-B69, Bethesda, MD 20892 USA.	chuange@mail.nih.gov		TSAI, MONG-HSUN/0000-0001-8777-5818				Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Backlund MG, 2001, CANCER RES, V61, P6577; BARCELLOS CK, 1994, BRAZ J MED BIOL RES, V27, P1111; BENJAMIN MB, 1991, P NATL ACAD SCI USA, V88, P6652, DOI 10.1073/pnas.88.15.6652; Chen XF, 2002, CANCER RES, V62, P1213; Chuang YYE, 1999, CANCER RES, V59, P3073; Chuang YYE, 2002, CANCER RES, V62, P6246; Coelho D, 2002, RADIAT RES, V157, P446, DOI 10.1667/0033-7587(2002)157[0446:IOTIAI]2.0.CO;2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Ewan KB, 2002, CANCER RES, V62, P5627; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Geffrotin C, 1998, RADIAT RES, V149, P472, DOI 10.2307/3579787; Gong BD, 2000, CANCER RES, V60, P5754; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Holbrook N J, 1996, EXS, V77, P273; Kawai H, 1999, CANCER RES, V59, P6038; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Peng YL, 2002, CANCER RES, V62, P6400; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; XIA F, 1995, CANCER RES, V55, P12; Xue LJ, 2003, CANCER RES, V63, P980; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; Yu YJ, 1998, CANCER RES, V58, P4277; Zhao WL, 2001, CANCER RES, V61, P5537	48	34	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					622	632		10.1038/sj.onc.1209082	http://dx.doi.org/10.1038/sj.onc.1209082			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247478	Green Submitted			2022-12-25	WOS:000234897400013
J	Seo, NS; Hocking, AM; Hook, M; McQuillan, DJ				Seo, NS; Hocking, AM; Hook, M; McQuillan, DJ			Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; CHONDROITIN SULFATE PROTEOGLYCAN; SITE-DIRECTED MUTAGENESIS; HYBRID EXPRESSION SYSTEM; HAMSTER OVARY CELLS; TERMINAL G3 DOMAIN; DISULFIDE-ISOMERASE; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS	Expression of decorin using the vaccinia virus/T7 expression system resulted in secretion of two distinct glycoforms: a proteoglycan substituted with a single chondroitin sulfate chain and N-linked oligosaccharides and a core protein glycoform substituted with N-linked glycans but without a glycosaminoglycan chain. In this report, we have addressed two distinct questions. What is the rate-limiting step in glycosaminoglycan synthesis? Is glycosylation with either N-linked oligosaccharides or glycosaminoglycan required for secretion of decorin? N-terminal sequencing of the core protein glycoform, the addition of benzyl-beta-D-xyloside, and a UDP-xylose: core protein beta-D-xylosyltransferase activity assay show that xylosylation is a rate-limiting step in chondroitin sulfate biosynthesis. Decorin can be efficiently secreted with N-linked oligosaccharides alone or with a single chondroitin sulfate chain alone; however, there is severely impaired secretion of core protein devoid of any glycosylation. A decorin core protein mutant devoid of N-linked oligosaccharide attachment sites will not be secreted by Chinese hamster ovary cells deficient in xylosyltransferase or by parental Chinese hamster ovary wild type cells if the xylosyltransferase recognition sequence is disrupted. This finding suggests that quality control mechanisms sensitive to an absence of N-linked oligosaccharides can be abrogated by interaction of the core protein with the glycosaminoglycan synthetic machinery. We propose a model of regulation of decorin secretion that has several components, including appropriate substitution with N-linked oligosaccharides and factors involved in glycosaminoglycan synthesis.	Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; LifeCell Corp, Branchburg, NJ 08876 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Washington; University of Washington Seattle	Seo, NS (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.	nsseo@ibt.tamhsc.edu		Hocking, Anne/0000-0003-2130-3732	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826, P01AR042919] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR042919, AR042826] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; CAMPBELL P, 1984, ANAL BIOCHEM, V137, P505, DOI 10.1016/0003-2697(84)90119-2; CAMPBELL SC, 1990, BIOCHEMISTRY-US, V29, P907, DOI 10.1021/bi00456a009; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; COUDRON C, 1980, BIOCHEM BIOPH RES CO, V92, P618, DOI 10.1016/0006-291X(80)90378-2; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Gotting C, 2002, MOL HUM REPROD, V8, P1079, DOI 10.1093/molehr/8.12.1079; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; Kolset SO, 1999, J CELL SCI, V112, P1797; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MANN DM, 1990, J BIOL CHEM, V265, P5317; McQuillan D J, 2001, Methods Mol Biol, V171, P201; MCQUILLAN DJ, 1984, BIOCHEM J, V224, P977, DOI 10.1042/bj2240977; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; MORRISS FH, 1985, PEDIATR RES, V19, P1240, DOI 10.1203/00006450-198512000-00003; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OLSON CA, 1985, ANAL BIOCHEM, V146, P232, DOI 10.1016/0003-2697(85)90420-8; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARODI AJ, 1983, J BIOL CHEM, V258, P5589; Pfeil U, 2000, GLYCOBIOLOGY, V10, P803, DOI 10.1093/glycob/10.8.803; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; RamseyEwing A, 1996, J BIOL CHEM, V271, P16962, DOI 10.1074/jbc.271.28.16962; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON JA, 1984, BIOCHEM INT, V9, P501; RODEN L, 1985, FED PROC, V44, P373; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SCHWARTZ NB, 1975, FEBS LETT, V49, P342, DOI 10.1016/0014-5793(75)80781-2; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TAJIRI K, 1980, J BIOL CHEM, V255, P6036; Wang CC, 1998, ANN NY ACAD SCI, V864, P9, DOI 10.1111/j.1749-6632.1998.tb10283.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Weilke C, 1997, CLIN CHEM, V43, P45; WONGPALMS S, 1995, ARCH BIOCHEM BIOPHYS, V319, P383, DOI 10.1006/abbi.1995.1308; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	64	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42774	42784		10.1074/jbc.M511531200	http://dx.doi.org/10.1074/jbc.M511531200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16258169	hybrid			2022-12-25	WOS:000234200800038
J	Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A				Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A			Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas	ONCOGENE			English	Article						BMCC1; neuroblastoma; apoptosis; BNIP2; Cdc42GAP; BCH domain	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; RHO-FAMILY GTPASES; SIGNALING PATHWAY; INDUCED APOPTOSIS; SYMPATHETIC NEURONS; BCL-2 PROTEINS; GENOMIC DNA; JUN KINASE	Differential screening of the genes obtained from cDNA libraries of primary neuroblastomas ( NBLs) between the favorable and unfavorable subsets has identified a novel gene BCH motif-containing molecule at the carboxyl terminal region 1 (BMCC1). Its 350 kDa protein product possessed a Bcl2-/adenovirus E1B nineteen kDa-interacting protein 2 (BNIP2) and Cdc42GAP homology domain in the COOH-terminus in addition to P-loop and a coiled-coil region near the NH2-terminus. High levels of BMCC1 expression were detected in the human nervous system as well as spinal cord, brain and dorsal root ganglion in mouse embryo. The immunohistochemical study revealed that BMCC1 was positively stained in the cytoplasm of favorable NBL cells but not in unfavorable ones with MYCN amplification. The quantitative real-time reverse transcription-PCR using 98 primary NBLs showed that high expression of BMCC1 was a significant indicator of favorable NBL. In primary culture of newborn mice superior cervical ganglion ( SCG) neurons, mBMCC1 expression was downregulated after nerve growth factor (NGF)-induced differentiation, and upregulated during the NGF-depletion-induced apoptosis. Furthermore, the proapoptotic function of BMCC1 was also suggested by increased expression in CHP134 NBL cells undergoing apoptosis after treatment with retinoic acid, and by an enhanced apoptosis after depletion of NGF in the SCG neurons obtained from newborn mice transgenic with BMCC1 in primary culture. Thus, BMCC1 is a new member of prognostic factors for NBL and may play an important role in regulating differentiation, survival and aggressiveness of the tumor cells.	Childrens Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390, Japan; Gunma Univ, Sch Med, Dept Pathol, Maebashi, Gumma 371, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo, Japan	Shinshu University; Gunma University; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Childrens Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Fujimori, Maiko/N-2883-2019					BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; FAVROT MC, 1993, NEW ENGL J MED, V329, P1965, DOI 10.1056/NEJM199312233292615; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Garnier M, 1997, J NEUROSCI, V17, P4591; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; LEE VM, 1980, NEUROSCIENCE, V5, P2239, DOI 10.1016/0306-4522(80)90140-2; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Nagai M, 2000, INT J ONCOL, V16, P907; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 1998, BIOCHEM BIOPH RES CO, V243, P722, DOI 10.1006/bbrc.1998.8112; Ohira M, 2003, CANCER LETT, V197, P63, DOI 10.1016/S0304-3835(03)00085-5; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OLTVAI ZN, 1993, CELL, V74, P619; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Solovyev VV, 1999, NUCLEIC ACIDS RES, V27, P248, DOI 10.1093/nar/27.1.248; Subramanian T, 1995, ONCOGENE, V11, P2403; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Vegeto E, 1999, FASEB J, V13, P793, DOI 10.1096/fasebj.13.8.793; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	48	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1931	1942		10.1038/sj.onc.1209225	http://dx.doi.org/10.1038/sj.onc.1209225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288218				2022-12-25	WOS:000236224800010
J	Holcomb, M; Rufini, A; Barila, D; Klemke, RL				Holcomb, M; Rufini, A; Barila, D; Klemke, RL			Deregulation of proteasome function induces Abl-mediated cell death by uncoupling p130(CAS) and c-CrkII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; OXIDATIVE STRESS; DNA-DAMAGE; EXTRACELLULAR-MATRIX; APOPTOTIC RESPONSE; CAS/CRK SCAFFOLD; ACTIVATION; MIGRATION; PROTEIN; DEGRADATION	Cell migration and survival are coordinately regulated through activation of c-Abl (Abl) family tyrosine kinases. Activated Abl phosphorylates tyrosine 221 of c-CrkII (Crk; Crk-Y221-P), which prevents Crk from binding to the docking protein p130(CAS) (CAS). Disruption of CAS-Crk binding blocks downstream effectors of the actin cytoskeleton and focal adhesion assembly, inhibits cell migration, and disrupts survival signals leading to apoptosis. Here we show that inhibition of the 26 S proteasome and ubiquitination facilitates Abl-mediated Crk-Y221-P, leading to disassembly of CAS-Crk complexes in cells. Surprisingly, inhibition of these molecular interactions does not perturb cell migration but rather specifically induces apoptosis. Furthermore, we demonstrate that attachment to an extracellular matrix plays a key role in regulating the apoptotic machinery through caspase-mediated cleavage of Abl and Crk-Y221-P. Our findings indicate that regulated protein degradation by the proteasome specifically controls cell death through regulation of Abl-mediated Crk Tyr(221) phosphorylation and assembly of the CAS-Crk signaling scaffold.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Roma Tor Vergata, Dulbecco Telethon Inst, I-00133 Rome, Italy; Univ Roma Tor Vergata, Lab Immunol & Signal Transduct, I-00133 Rome, Italy; Univ Roma Tor Vergata, Lab Immunol & Signal Transduct, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	Scripps Research Institute; Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, SP231,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	klemke@scripps.edu	Rufini, Alessandra/J-2995-2012; Rufini, Alessandra/Q-9256-2019; Barilà, Daniela/K-8506-2016	Rufini, Alessandra/0000-0001-5654-9615; Barilà, Daniela/0000-0002-6192-1562	NCI NIH HHS [CA097022] Funding Source: Medline; NIGMS NIH HHS [GM068487] Funding Source: Medline; Telethon [TCP00061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Cao C, 2005, ONCOGENE, V24, P2433, DOI 10.1038/sj.onc.1208454; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Didier C, 2003, MOL CELL BIOL, V23, P5331, DOI 10.1128/MCB.23.15.5331-5345.2003; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Frisch SM, 2000, METHOD ENZYMOL, V322, P472; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gong JG, 1999, NATURE, V399, P806; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Marks PA, 2001, CLIN CANCER RES, V7, P759; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	42	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2430	2440		10.1074/jbc.M508454200	http://dx.doi.org/10.1074/jbc.M508454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16267043	hybrid, Green Published			2022-12-25	WOS:000234931800005
J	Kamiya, N; Watanabe, H; Habuchi, H; Takagi, H; Shinomura, T; Shimizu, K; Kimata, K				Kamiya, N; Watanabe, H; Habuchi, H; Takagi, H; Shinomura, T; Shimizu, K; Kimata, K			Versican/PG-M regulates chondrogenesis as an extracellular matrix molecule crucial for mesenchymal condensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-LINE ATDC5; CHICK-EMBRYO CARTILAGE; GROWTH-FACTOR-BETA; FACTOR-LIKE MOTIFS; PG-M VERSICAN; N-CADHERIN; LIMB BUDS; TGF-BETA; IN-VITRO	Mesenchymal cell condensation is an essential step for cartilage development. Versican/PG-M, a large chondroitin sulfate proteoglycan, is one of the major molecules expressed in the extracellular matrix during condensation. However, its role, especially as an environment for cells being condensed, has not been elucidated. Here we showed several lines of evidence for essential roles of versican/PG- M in chondrogenic condensation using a new chondrocytic cell line, N1511. Chondrogenic stimuli (treatment with parathyroid hormone, dexamethasone, 10% serum) induced a marked increase in the transcription and protein synthesis of versican/PG-M. Stable antisense clones for versican/PG-M, depending on suppression of the expression of versican/PG- M, showed different capacities for chondrogenesis, as indicated by the expression and deposition of aggrecan, a major chondrocytic cell product. The cells in the early stages of the culture only expressed V0 and V1 forms, having more chondroitin sulfate chains among the four variants of versican/PG-M, and treatment of those cells with chondroitinase ABC suppressed subsequent chondrogenesis. Furthermore, treatment with beta-xyloside, an artificial chain initiator of chondroitin sulfate synthesis to consequently inhibit the synthesis on the core proteins, suppressed chondrogenesis. In addition, forced expression of the variant V3, which has no chondroitin sulfate chain, disrupted the deposition and organization of native versican/PG-M (V0/V1) and other extracellular matrix molecules known to be expressed during the mesenchymal condensation and resulted in the inhibition of subsequent chondrogenesis. These results suggest that versican/PG-M is involved in positively regulating the formation of the mesenchymal matrix and the onset of chondrocyte differentiation through the attached chondroitin sulfate chains.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Gifu Univ, Dept Orthopaed Surg, Gifu 5008705, Japan	Aichi Medical University; Gifu University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp		Watanabe, Hideto/0000-0001-5291-0696				AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Chimal-Monroy J, 1999, INT J DEV BIOL, V43, P59; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Fell HB, 1925, J MORPHOL PHYSIOL, V40, P417, DOI 10.1002/jmor.1050400302; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GIBSON KD, 1977, BIOCHEM J, V162, P217, DOI 10.1042/bj1620217; Goltzman D, 1999, J BONE MINER RES, V14, P173, DOI 10.1359/jbmr.1999.14.2.173; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; Isogai Z, 1996, CANCER RES, V56, P3902; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; JURAND A, 1965, PROC R SOC SER B-BIO, V162, P387, DOI 10.1098/rspb.1965.0045; Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832; KATO Y, 1978, J BIOL CHEM, V253, P2784; KIMATA K, 1986, J BIOL CHEM, V261, P3517; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lemire JM, 2002, J CELL PHYSIOL, V190, P38, DOI 10.1002/jcp.10043; LEONARD CM, 1991, DEV BIOL, V145, P99, DOI 10.1016/0012-1606(91)90216-P; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; Shibata S, 2003, J ANAT, V203, P425, DOI 10.1046/j.1469-7580.2003.00226.x; SHINOMURA T, 1995, J BIOL CHEM, V270, P10328, DOI 10.1074/jbc.270.17.10328; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1991, ARTICULAR CARTILAGE, P35; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SOBUE M, 1989, HISTOCHEM J, V21, P455, DOI 10.1007/BF01845795; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SOLURSH M, 1984, DEV BIOL, V105, P451, DOI 10.1016/0012-1606(84)90302-6; Steer DL, 2004, DEV BIOL, V272, P310, DOI 10.1016/j.ydbio.2004.04.029; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Takagi H, 2002, J CELL SCI, V115, P3309; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; UJITA M, 1994, J BIOL CHEM, V269, P27603; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1994, J CELL SCI, V107, P2581; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	61	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2390	2400		10.1074/jbc.M509341200	http://dx.doi.org/10.1074/jbc.M509341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16257955	hybrid			2022-12-25	WOS:000234760400064
J	Mercado, A; Broumand, V; Zandi-Nejad, K; Enck, AH; Mount, DB				Mercado, A; Broumand, V; Zandi-Nejad, K; Enck, AH; Mount, DB			A C-terminal domain in KCC2 confers constitutive K+-Cl- cotransport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE TYPE-1; NEURONAL-SPECIFIC ISOFORM; RAT MIDBRAIN NEURONS; GABA(A) RECEPTOR; FUNCTIONAL-CHARACTERIZATION; CELL-VOLUME; MOLECULAR CHARACTERIZATION; INTRACELLULAR CHLORIDE; NA-K-2CL COTRANSPORTER; CORTICAL-NEURONS	The neuron-specific K+-Cl- cotransporter KCC2 plays a crucial role in determining intracellular chloride activity and thus the neuronal response to gamma-aminobutyric acid and glycine. Of the four KCCs, KCC2 is unique in mediating constitutive K+-Cl- cotransport under isotonic conditions; the other three KCCs are exclusively swelling-activated, with no isotonic activity. We have utilized a series of chimeric cDNAs to localize the determinant of isotonic transport in KCC2. Two generations of chimeric KCC4-KCC2 cDNAs initially localized this characteristic to within a KCC2-specific expansion of the cytoplasmic C terminus, between residues 929 and 1043. This region of KCC2 is rich in prolines, serines, and charged residues and encompasses two predicted PEST sequences. Substitution of this region in KCC2 with the equivalent sequence of KCC4 resulted in a chimeric KCC that was devoid of isotonic activity, with intact swelling-activated transport. A third generation of chimeras demonstrated that a domain just distal to the PEST sequences confers isotonic transport on KCC4. Mutagenesis of this region revealed that residues 1021-1035 of KCC2 are sufficient for isotonic transport. Swelling-activated K+-Cl- cotransport is abrogated by calyculin A, whereas isotonic transport mediated by KCC chimeras and KCC2 is completely resistant to this serine-threonine phosphatase inhibitor. In summary, a 15-residue C-terminal domain in KCC2 is both necessary and sufficient for constitutive K+-Cl- cotransport under isotonic conditions. Furthermore, unlike swelling-activated transport, constitutive K+-Cl- cotransport mediated by KCC2 is completely independent of serine-threonine phosphatase activity, suggesting that these two modes of transport are activated by distinct mechanisms.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Inst Med,Renal Div, Boston, MA 02115 USA; Harvard Univ, Vet Affairs Boston Healthcare Syst, Sch Med, Div Gen Internal Med, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Mount, DB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Inst Med,Renal Div, Rm 542,4 Blackfan Circle, Boston, MA 02115 USA.	dmount@rics.bwh.harvard.edu	Mercado, Adriana/AAR-6143-2021	Mercado, Adriana/0000-0002-6881-0160	NIDDK NIH HHS [R01 DK57708] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057708] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baliova M, 2004, J NEUROCHEM, V88, P227, DOI 10.1046/j.1471-4159.2003.02192.x; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boettger T, 2003, EMBO J, V22, P5422, DOI 10.1093/emboj/cdg519; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Chudotvorova I, 2005, J PHYSIOL-LONDON, V566, P671, DOI 10.1113/jphysiol.2005.089821; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Crable SC, 2005, EXP HEMATOL, V33, P624, DOI 10.1016/j.exphem.2005.02.006; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; DeFazio RA, 2000, J NEUROSCI, V20, P8069; Denton J, 2005, J GEN PHYSIOL, V125, P113, DOI 10.1085/jgp.200409215; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; DUNHAM PB, 1981, J PHYSIOL-LONDON, V318, P511; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; GAGNON KB, 2006, AM J PHYSL; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; GEORGE JN, 1989, J MEMBRANE BIOL, V112, P51, DOI 10.1007/BF01871163; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Grunnet M, 2002, PFLUG ARCH EUR J PHY, V444, P167, DOI 10.1007/s00424-002-0782-4; Gulyas AI, 2001, EUR J NEUROSCI, V13, P2205, DOI 10.1046/j.0953-816x.2001.01600.x; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Howard HC, 2002, NAT GENET, V32, P384, DOI 10.1038/ng1002; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Jarolimek W, 1999, J NEUROSCI, V19, P4695; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; JIN X, 2002, J NEUROPHYSIOL, V93, P2117; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kakazu Y, 2000, J NEUROPHYSIOL, V84, P281, DOI 10.1152/jn.2000.84.1.281; Karadsheh MF, 2004, NEUROSCIENCE, V123, P381, DOI 10.1016/j.neuroscience.2003.10.004; Khirug S, 2005, EUR J NEUROSCI, V21, P899, DOI 10.1111/j.1460-9568.2005.03886.x; Lauf PK, 2001, COMP BIOCHEM PHYS A, V130, P499, DOI 10.1016/S1095-6433(01)00421-4; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; LAUF PK, 1987, BIOCHEM BIOPH RES CO, V144, P849, DOI 10.1016/S0006-291X(87)80042-6; LAUF PK, 1980, BIOCHEM BIOPH RES CO, V92, P1422, DOI 10.1016/0006-291X(80)90445-3; Lee H, 2005, EUR J NEUROSCI, V21, P2593, DOI 10.1111/j.1460-9568.2005.04084.x; Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.0.CO;2-5; Ludwig A, 2003, EUR J NEUROSCI, V18, P3199, DOI 10.1111/j.1460-9568.2003.03069.x; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC1002, DOI 10.1152/ajpcell.1998.274.4.C1002; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; Matskevich L, 2005, BBA-BIOMEMBRANES, V1714, P25, DOI 10.1016/j.bbamem.2005.06.001; Mercado A, 2005, AM J PHYSIOL-RENAL, V289, pF1246, DOI 10.1152/ajprenal.00464.2004; Mercado A, 2001, AM J PHYSIOL-CELL PH, V281, pC670, DOI 10.1152/ajpcell.2001.281.2.C670; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Miles R, 1999, NATURE, V397, P215, DOI 10.1038/16604; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Schomberg SL, 2003, J NEUROPHYSIOL, V89, P159, DOI 10.1152/jn.00229.2002; Simard CF, 2004, J BIOL CHEM, V279, P40769, DOI 10.1074/jbc.M406458200; Song LY, 2002, MOL BRAIN RES, V103, P91, DOI 10.1016/S0169-328X(02)00190-0; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Su WF, 1999, AM J PHYSIOL-CELL PH, V277, pC899, DOI 10.1152/ajpcell.1999.277.5.C899; Sung KW, 2000, J NEUROSCI, V20, P7531; Titz S, 2003, J PHYSIOL-LONDON, V550, P719, DOI 10.1113/jphysiol.2003.041863; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656; Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014; Zhu L, 2005, J NEUROPHYSIOL, V93, P1557, DOI 10.1152/jn.00616.2004	76	73	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1016	1026		10.1074/jbc.M509972200	http://dx.doi.org/10.1074/jbc.M509972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16291749	hybrid			2022-12-25	WOS:000234447200042
J	Dimitrov, JD; Ivanovska, ND; Lacroix-Desmazes, S; Doltchinkova, VR; Kaveri, SV; Vassilev, TL				Dimitrov, JD; Ivanovska, ND; Lacroix-Desmazes, S; Doltchinkova, VR; Kaveri, SV; Vassilev, TL			Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-OXIDATION PATHWAY; FREE-RADICAL OXIDATIONS; AMINO-ACID-RESIDUES; SUPEROXIDE ANION; OZONE FORMATION; IRON RELEASE; PEPTIDE-MHC; RECOGNITION; EVOLUTION; POLYREACTIVITY	Polyspecific antibodies represent a first line of defense against infection and regulate inflammation, properties hypothesized to rely on their ability to interact with multiple antigens. We demonstrated that IgG exposure to pro-oxidative ferrous ions or to reactive oxygen species enhances paratope flexibility and hydrophobicity, leading to expansion of the spectrum of recognized antigens, regulation of cell proliferation, and protection in experimental sepsis. We propose that ferrous ions, released from transferrin and ferritin at sites of inflammation, synergize with reactive oxygen species to modify the immunoglobulins present in the surrounding microenvironment, thus quenching pro-inflammatory signals, while facilitating neutralization of pathogens.	Bulgarian Acad Sci, Stefan Angeloff Inst Microbiol, Dept Immunol, BU-1113 Sofia, Bulgaria; Univ Paris 06, INSERM, U681, F-75006 Paris, France; St Kliment Ohridski Univ, Dept Biophys & Radiobiol, Sofia 1164, Bulgaria	Bulgarian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Bulgarian Academy of Sciences; Medical University Sofia; University of Sofia	Vassilev, TL (corresponding author), Bulgarian Acad Sci, Stefan Angeloff Inst Microbiol, Dept Immunol, Acad G Bonchev St,Block 26, BU-1113 Sofia, Bulgaria.	vassilev@microbio.bas.bg	Doltchinkova, Virjinia/AAK-2672-2020; Dimitrov, Jordan/N-2141-2014	Lacroix-Desmazes, Sebastien/0000-0001-5625-8447; Dimitrov, Jordan/0000-0001-8536-8995; Doltchinkova, Virjinia/0000-0003-3096-7311				AMICI A, 1989, J BIOL CHEM, V264, P3341; Amzel LM, 2000, METHOD ENZYMOL, V323, P167; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; Babior BM, 2003, P NATL ACAD SCI USA, V100, P3031, DOI 10.1073/pnas.0530251100; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; Bouvet JP, 2001, J AUTOIMMUN, V16, P163, DOI 10.1006/jaut.2000.0472; BRIELAND JK, 1991, ARCH BIOCHEM BIOPHYS, V284, P78, DOI 10.1016/0003-9861(91)90266-L; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dean RT, 1997, BIOCHEM J, V324, P1; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; FAZEKAS G, 1990, EUR J IMMUNOL, V20, P2719, DOI 10.1002/eji.1830201229; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, PROTEIN SCI, V12, P2183, DOI 10.1110/ps.03172703; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; MASKOS Z, 1992, ARCH BIOCHEM BIOPHYS, V296, P514, DOI 10.1016/0003-9861(92)90605-V; McMahon MJ, 2000, J IMMUNOL METHODS, V241, P1, DOI 10.1016/S0022-1759(00)00196-4; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MORRIS CJ, 1995, INT J BIOCHEM CELL B, V27, P109, DOI 10.1016/1357-2725(94)00084-O; Nguyen HP, 2003, NAT STRUCT BIOL, V10, P1019, DOI 10.1038/nsb1014; Nieva J, 2004, TRENDS BIOCHEM SCI, V29, P274, DOI 10.1016/j.tibs.2004.03.009; Notkins AL, 2004, TRENDS IMMUNOL, V25, P174, DOI 10.1016/j.it.2004.02.004; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pierre JL, 1999, BIOMETALS, V12, P195, DOI 10.1023/A:1009252919854; PRYOR WA, 1993, J BIOL CHEM, V268, P3120; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Schafer FQ, 2000, CELL MOL BIOL, V46, P657; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Schuermann JP, 2005, J MOL BIOL, V347, P965, DOI 10.1016/j.jmb.2005.02.008; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; VANSCHAIK IN, 1992, J CLIN IMMUNOL, V12, P325, DOI 10.1007/BF00920789; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Zhu XY, 2004, P NATL ACAD SCI USA, V101, P2247, DOI 10.1073/pnas.0307311101	53	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					439	446		10.1074/jbc.M509190200	http://dx.doi.org/10.1074/jbc.M509190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16246843	hybrid			2022-12-25	WOS:000234307200054
J	Takagi, Y; Kornberg, RD				Takagi, Y; Kornberg, RD			Mediator as a general transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; MAMMALIAN MEDIATOR; IN-VIVO; DEPENDENT TRANSCRIPTION; PREINITIATION COMPLEX; ACTIVATOR PROTEINS; SRB MEDIATOR; HOLOENZYME; YEAST	Others have shown that yeast strains bearing a ts mutation in the Srb4 subunit of Mediator cease transcription of all mRNA at the restrictive temperature, in a manner virtually indistinguishable from a strain bearing a ts mutation in the largest subunit of RNA polymerase II. We find that srb4ts Mediator is defective for the stimulation of basal RNA polymerase II transcription at the restrictive temperature in vitro. Taken together, these findings lead to the suggestion that Mediator is required for basal RNA polymerase II transcription in vivo. On this basis, Mediator is identified as a general transcription factor, comparable in importance to RNA polymerase II and other general factors for the initiation of transcription. The possibility that Mediator serves as an anti- inhibitor, opposing the effects of global negative regulators, is largely excluded.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu			NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 2004, CURR OPIN STRUC BIOL, V14, P121, DOI 10.1016/j.sbi.2004.03.007; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chadick JZ, 2005, TRENDS BIOCHEM SCI, V30, P264, DOI 10.1016/j.tibs.2005.03.001; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Johnson KM, 2003, CURR BIOL, V13, P772, DOI 10.1016/S0960-9822(03)00283-5; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kim YJ, 2005, TRENDS BIOCHEM SCI, V30, P245, DOI 10.1016/j.tibs.2005.03.010; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Qiu HF, 2005, MOL CELL BIOL, V25, P3461, DOI 10.1128/MCB.25.9.3461-3474.2005; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Takagi Y, 2003, J BIOL CHEM, V278, P43897, DOI 10.1074/jbc.C300417200; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	45	119	143	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					80	89		10.1074/jbc.M508253200	http://dx.doi.org/10.1074/jbc.M508253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263706	hybrid			2022-12-25	WOS:000234307200013
J	Zhang, YM; Rock, CO; Jackowski, S				Zhang, YM; Rock, CO; Jackowski, S			Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALLERVORDEN-SPATZ-SYNDROME; COENZYME-A; FEEDBACK-REGULATION; IRON ACCUMULATION; ESCHERICHIA-COLI; CELL-CYCLE; PANK2; LOCALIZATION; ENCODES; ACTIN	The PANK2 gene encodes the human pantothenate kinase 2 protein isoforms, and PANK2 mutations are linked to pantothenate kinase- associated neurodegeneration. Two PanK2 protein forms are proteolytically processed to form a mitochondrially localized, mature PanK2. Another isoform arose from a proposed initiation at a leucine codon and was not processed further. The fifth isoform was postulated to arise from an alternative splicing event and was found to encode an inactive protein. Fourteen mutant PanK2 proteins with single amino acid substitutions, associated with either early or late onset disease, were evaluated for activity. The PanK2( G521R), the most frequent mutation in pantothenate kinase- associated neurodegeneration, was devoid of activity and did not fold properly. However, nine of the mutant proteins associated with disease possessed catalytic activities that were indistinguishable from wild type, including the frequently encountered PanK2( T528M) missense mutation. PanK2 was extremely sensitive to feedback inhibition by CoA thioesters ( IC50 values between 250 and 500 nM), and the regulation of the active PanK2 mutants was comparable with that of the wild- type protein. Coexpression of the PanK2( G521R) and wild- type PanK2 did not interfere with wildtype enzyme activity, arguing against a dominant negative effect of the PanK2( G521R) mutation in heterozygous patients. These data described the unique biochemical features of the PanK2 isoforms and suggested that catalytic defects may not be the sole cause for the neurodegenerative phenotype.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062896] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM62896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afshar K, 2001, GENETICS, V157, P1267; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ching KHL, 2002, NEUROLOGY, V58, P1673, DOI 10.1212/WNL.58.11.1673; Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Hayflick SJ, 2003, J NEUROL SCI, V207, P106, DOI 10.1016/S0022-510X(02)00433-1; Hortnagel K, 2003, HUM MOL GENET, V12, P321, DOI 10.1093/hmg/ddg026; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson MA, 2004, ANN NY ACAD SCI, V1012, P282, DOI 10.1196/annals.1306.023; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kotzbauer PT, 2005, J NEUROSCI, V25, P689, DOI 10.1523/JNEUROSCI.4265-04.2005; Kuo YM, 2005, HUM MOL GENET, V14, P49, DOI 10.1093/hmg/ddi005; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Ramaswamy G, 2004, J LIPID RES, V45, P17, DOI 10.1194/jlr.M300279-JLR200; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SONG WJ, 1994, J BIOL CHEM, V269, P27051; Thomas M, 2004, MOVEMENT DISORD, V19, P36, DOI 10.1002/mds.10650; VALENTINO P, 2005, IN PRESS MOVEMENT DI; Williamson J R, 1979, Methods Enzymol, V55, P200; Zhang YM, 2005, J BIOL CHEM, V280, P32594, DOI 10.1074/jbc.M506275200; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572; Zhyvoloup A, 2003, J BIOL CHEM, V278, P50316, DOI 10.1074/jbc.M307763200	29	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					107	114		10.1074/jbc.M508825200	http://dx.doi.org/10.1074/jbc.M508825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16272150	hybrid			2022-12-25	WOS:000234307200016
J	Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P				Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P			Cation of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development	ONCOGENE			English	Article						multistage carcinogenesis; papilloma; squamous cell carcinoma; gene expression profiling; self-organizing maps	MALIGNANCY-ASSOCIATED REGIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; DNA MICROARRAYS; CARCINOMA ESCC; HUMAN PROSTATE; CDNA; IDENTIFICATION; PROGRESSION; PROFILE	Chemically induced mouse skin carcinogenesis represents the most extensively utilized animal model to unravel the multistage nature of tumour development and to design novel therapeutic concepts of human epithelial neoplasia. We combined this tumour model with comprehensive gene expression analysis and could identify a large set of novel tumour-associated genes that have not been associated with epith elial skin cancer development yet. Expression data of selected genes were con. firmed by semiquantitative and quantitative RT-PCR as well as in situ hybridization and immuno. fluorescence analysis on mouse tumour sections. Enhanced expression of genes identified in our screen was also demonstrated in mouse keratinocyte cell lines that form tumours in vivo. Self-organizing map clustering was performed to identify different kinetics of gene expression and coregulation during skin cancer progression. Detailed analysis of differential expressed genes according to their functional annotation confirmed the involvement of several biological processes, such as regulation of cell cycle, apoptosis, extracellular proteolysis and cell adhesion, during skin malignancy. Finally, we detected high transcript levels of ANXA1, LCN2 and S100A8 as well as reduced levels for NDR2 protein in human skin tumour specimens demonstrating that tumour associated genes identified in the chemically induced tumour model might be of great relevance for the understanding of human epithelial malignancies as well.	Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-6900 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Biochem Tissue Specif Regulat, D-6900 Heidelberg, Germany; Univ Cologne, Dept Dermatol & Venerol, D-5000 Cologne 41, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de	Piris, Miguel A/AAP-1445-2020; Hess, Jochen/ABE-1144-2021	Piris, Miguel A/0000-0001-5839-3634; Hess, Jochen/0000-0003-3493-1711; Kokocinski, Felix/0000-0002-8472-9207				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chen Y, 2003, CANCER RES, V63, P1927; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diehl F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e38; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Glinsky GV, 2003, CANCER LETT, V201, P67, DOI 10.1016/S0304-3835(03)00419-1; Glinsky GV, 2003, NEOPLASIA, V5, P218, DOI 10.1016/S1476-5586(03)80054-4; Gogali A, 2004, EXP ONCOL, V26, P106; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hu YC, 2001, CLIN CANCER RES, V7, P3519; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Ishikawa N, 2004, CLIN CANCER RES, V10, P8363, DOI 10.1158/1078-0432.CCR-04-1436; Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Ko MSH, 2000, DEVELOPMENT, V127, P1737; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nair KS, 2005, J CLIN PATHOL, V58, P343, DOI 10.1136/jcp.2004.018036; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.0.CO;2-3; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Stern MC, 1997, MOL CARCINOGEN, V20, P137, DOI 10.1002/(SICI)1098-2744(199709)20:1<137::AID-MC15>3.0.CO;2-2; STRICKLAND JE, 1988, CANCER RES, V48, P165; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tsai WC, 2004, ORAL ONCOL, V40, P418, DOI 10.1016/j.oraloncology.2003.09.015; Wrobel G, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng067; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	52	62	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					111	121		10.1038/sj.onc.1209016	http://dx.doi.org/10.1038/sj.onc.1209016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247483				2022-12-25	WOS:000234406400012
J	Haendeler, J; Popp, R; Goy, C; Tischler, V; Zeiher, AM; Dimmeler, S				Haendeler, J; Popp, R; Goy, C; Tischler, V; Zeiher, AM; Dimmeler, S			Cathepsin D and H2O2 stimulate degradation of thioredoxin-1 - Implication for endothelial cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; REACTIVE OXYGEN; POTENTIAL ROLE; LYSOSOMES; DISRUPTION; ACTIVATION; EXPRESSION; PROTEASES	Cathepsin D (CatD) is a lysosomal aspartic proteinase and plays an important role in the degradation of proteins and in apoptotic processes induced by oxidative stress, cytokines, and aging. All of these stimuli are potent inducers of endothelial cell apoptosis. Therefore, we investigated the role of CatD in endothelial cell apoptosis and determined the underlying mechanisms. Incubation with 100-500 mu M H2O2 for 12 h induced apoptosis in endothelial cells. To determine a role for CatD, we co-incubated endothelial cells with the CatD inhibitor pepstatin A. Pepstatin A as well as genetic knock down of CatD abolished H2O2-induced apoptosis. In contrast, overexpression of CatD wild type but not a catalytically inactive mutant of CatD (CatDD295N) induced apoptosis under basal conditions. To gain insights into the underlying mechanisms, we investigated the effect of CatD on reactive oxygen species (ROS) formation. Indeed, knocking down CatD expression reduced H2O2 induced ROS formation and apoptosis. The major redox regulator in endothelial cells is thioredoxin-1 (Trx), which plays a crucial role in apoptosis inhibition. Thus, we hypothesized that CatD may alter Trx protein levels and thereby promote formation of ROS and apoptosis. Incubation with 100 mu M H2O2 for 6 h decreased Trx protein levels, whereas Trx mRNA was not altered. H2O2-induced Trx degradation was inhibited by pepstatin A and genetic knock down of CatD but not by other protease inhibitors. Incubation of unstimulated cell lysates with recombinant CatD significantly reduced Trx protein levels in vitro, which was completely blocked by pepstatin A pre-incubation. Overexpression of CatD reduced Trx protein in cells. Moreover, H2O2 incubation led to a translocation of Trx to the lysosomes prior to the induction of apoptosis. Taken together, CatD induces apoptosis via degradation of Trx protein, which is an essential anti-apoptotic and reactive oxygen species scavenging protein in endothelial cells.	Goethe Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Haendeler, J (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	j.haendeler@em.uni-frankfurt.de	Tischler, Verena/Q-7263-2017	Tischler, Verena/0000-0002-6673-8329; Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Barrett AJ, 2004, CURR OPIN DRUG DISC, V7, P334; Choi SH, 2002, FREE RADICAL BIO MED, V32, P394, DOI 10.1016/S0891-5849(01)00819-X; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1997, CIRCULATION, V95, P1760; Fujii J, 1999, FREE RADICAL RES, V31, P301, DOI 10.1080/10715769900300861; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Haendeler J, 2004, FEBS LETT, V577, P427, DOI 10.1016/j.febslet.2004.10.041; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Inoue M, 2004, REDOX REP, V9, P237, DOI 10.1179/135100004225006010; Jaattela M, 2004, CELL DEATH DIFFER, V11, P135, DOI 10.1038/sj.cdd.4401333; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Neuzil J, 2002, BIOCHEM J, V362, P709, DOI 10.1042/0264-6021:3620709; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Raymond MA, 2003, FASEB J, V17, P515, DOI 10.1096/fj.02-0500fje; REID WA, 1986, J CLIN PATHOL, V39, P1323, DOI 10.1136/jcp.39.12.1323; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Salvesen GS, 2001, J CLIN INVEST, V107, P21, DOI 10.1172/JCI11829; Shioji K, 2002, CIRCULATION, V106, P1403, DOI 10.1161/01.CIR.0000027817.55925.B4; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; Tardy C, 2003, CELL DEATH DIFFER, V10, P1090, DOI 10.1038/sj.cdd.4401272; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	38	64	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42945	42951		10.1074/jbc.M506985200	http://dx.doi.org/10.1074/jbc.M506985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263712	hybrid			2022-12-25	WOS:000234200800057
J	Rety, S; Salamitou, S; Garcia-Verdugo, I; Hulmes, DJS; Le Hegarat, F; Chaby, R; Lewit-Bentley, A				Rety, S; Salamitou, S; Garcia-Verdugo, I; Hulmes, DJS; Le Hegarat, F; Chaby, R; Lewit-Bentley, A			The crystal structure of the Bacillus anthracis spore surface protein BclA shows remarkable similarity to mammalian proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE REGION; PULMONARY SURFACTANT; EXOSPORIUM; IDENTIFICATION; GLYCOPROTEIN; C1Q; STABILITY; COMPONENT; BACTERIAL; DOMAIN	The lethal disease anthrax is propagated by spores of Bacillus anthracis, which can penetrate into the mammalian host by inhalation, causing a rapid progression of the disease and a mostly fatal outcome. We have solved the three-dimensional structure of the major surface protein BclA on B. anthracis spores. Surprisingly, the structure resembles C1q, the first component of complement, despite there being no sequence homology. Although most assays for C1q-like activity, including binding to C1q receptors, suggest that BclA does not mimic C1q, we show that BclA, as well as C1q, interacts with components of the lung alveolar surfactant layer. Thus, to better recognize and invade its hosts, this pathogenic soil bacterium may have evolved a surface protein whose structure is strikingly close to a mammalian protein.	CNRS, Lab Biotechnol & Pharmacol Genet Appl, UMR 8113, Ecole Normale Super, F-94235 Cachan, France; Univ Paris 11, CNRS, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France; Univ Paris 11, Equipe Endotoxines, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, F-91405 Orsay, France; CNRS, Inst Biol & Chim Prot, UMR 5086, F-69367 Lyon 7, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Lewit-Bentley, A (corresponding author), CNRS, Lab Biotechnol & Pharmacol Genet Appl, UMR 8113, Ecole Normale Super, 61 Ave President Wilson, F-94235 Cachan, France.	anita.bentley@lbpa.ens-cachan.fr	Garcia-Verdugo, Ignacio/J-3584-2017; Rety, Stephane/L-9870-2019	Garcia-Verdugo, Ignacio/0000-0003-4535-8316; Rety, Stephane/0000-0002-2089-6727; Hulmes, David/0000-0002-0651-1317				Augusto LA, 2003, AM J RESP CRIT CARE, V168, P335, DOI 10.1164/rccm.200212-1440OC; Augusto LA, 2002, J BIOL CHEM, V277, P23484, DOI 10.1074/jbc.M111925200; Baeyens KJ, 1999, ACTA CRYSTALLOGR D, V55, P772, DOI 10.1107/S0907444998018435; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Boydston JA, 2005, J BACTERIOL, V187, P5310, DOI 10.1128/JB.187.15.5310-5317.2005; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Cote CK, 2004, MICROB PATHOGENESIS, V37, P169, DOI 10.1016/j.micpath.2004.06.013; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; Daubenspeck JM, 2004, J BIOL CHEM, V279, P30945, DOI 10.1074/jbc.M401613200; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Donadini R, 2004, STRUCTURE, V12, P145, DOI 10.1016/j.str.2003.12.002; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; GERHARDT P, 1964, J BACTERIOL, V88, P1774, DOI 10.1128/JB.88.6.1774-1789.1964; Ghebrehiwet B, 2004, MOL IMMUNOL, V41, P173, DOI 10.1016/j.molimm.2004.03.014; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kvansakul M, 2003, MATRIX BIOL, V22, P145, DOI 10.1016/S0945-053X(02)00119-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Merckel MC, 2005, MOL CELL, V18, P161, DOI 10.1016/j.molcel.2005.03.019; Pepper IL, 2002, SOIL SCI, V167, P627, DOI 10.1097/00010694-200210000-00001; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Redmond C, 2004, MICROBIOL-SGM, V150, P355, DOI 10.1099/mic.0.26681-0; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Salamitou S, 2005, ACTA CRYSTALLOGR D, V61, P344, DOI 10.1107/S090744490403416X; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Stetefeld J, 2003, STRUCTURE, V11, P339, DOI 10.1016/S0969-2126(03)00025-X; Sylvestre P, 2003, J BACTERIOL, V185, P1555, DOI 10.1128/JB.185.5.1555-1563.2003; Sylvestre P, 2002, MOL MICROBIOL, V45, P169, DOI 10.1046/j.1365-2958.2000.03000.x; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; Todd SJ, 2003, J BACTERIOL, V185, P3373, DOI 10.1128/JB.185.11.3373-3378.2003	50	47	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43073	43078		10.1074/jbc.M510087200	http://dx.doi.org/10.1074/jbc.M510087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16249180	hybrid, Green Published			2022-12-25	WOS:000234200800073
J	Tanaka, T; Izawa, S; Inoue, Y				Tanaka, T; Izawa, S; Inoue, Y			GPX2, encoding a phospholipid hydroperoxide glutathione peroxidase homologue, codes for an atypical 2-Cys peroxiredoxin in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE STRESS; MEMBRANE PERMEABILIZATION; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR; INORGANIC-PHOSPHATE; CA2+ IONS; PROTEIN; GENE; ANTIOXIDANT	We have previously reported that Saccharomyces cerevisiae has three glutathione peroxidase homologues ( GPX1, GPX2, and GPX3) ( Inoue, Y., Matsuda, T., Sugiyama, K., Izawa, S., and Kimura, A. ( 1999) J. Biol. Chem. 274, 27002 - 27009). Of these, the GPX2 gene product ( Gpx2) shows the greatest similarity to phospholipid hydroperoxide glutathione peroxidase. Here we show that GPX2 encodes an atypical 2-Cys peroxiredoxin which uses thioredoxin as an electron donor. Gpx2 was essentially in a reduced form even in mutants defective in glutathione reductase or glutaredoxin under oxidative stressed conditions. On the other hand, Gpx2 was partially oxidized in a mutant defective in cytosolic thioredoxin ( trx1 Delta trx2 Delta) under non-stressed conditions and completely oxidized in tert-butyl hydroperoxide-treated cells of trx1 Delta trx2 Delta and thioredoxin reductase-deficient mutant cells. Alanine scanning of cysteine residues of Gpx2 revealed that an intramolecular disulfide bond was formed between Cys37 and Cys83 in vivo. Gpx2 was purified to determine whether it functions as a peroxidase that uses thioredoxin as an electron donor in vitro. Gpx2 reduced H2O2 and tert-butyl hydroperoxide in the presence of thioredoxin, thioredoxin reductase, and NADPH ( for H2O2, K-m = 20 mu M, k(cat) = 9.57 x 10(2) s(-1); for tert-butyl hydroperoxide, K-m = 62.5 mu M, k(cat) = 3.68 x 10(2) s(-1)); however, it showed remarkably less activity toward these peroxides in the presence of glutathione, glutathione reductase, and NADPH. The sensitivity of yeast cells to tert-butyl hydroperoxide was found to be exacerbated by the co-existence of Ca2+, a tendency that was most obvious in gpx2 Delta cells. Although the redox state of Gpx2 was not affected by Ca2+, the Gpx2 level was markedly increased in the presence of both tert- butyl hydroperoxide and Ca2+. Gpx2 is likely to play an important role in the protection of cells from oxidative stress in the presence of Ca2+.	Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Uji, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Uji, Kyoto 6110011, Japan.	y_inoue@kais.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450				Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; GAN ZR, 1991, J BIOL CHEM, V266, P1692; Herbette S, 2002, EUR J BIOCHEM, V269, P2414, DOI 10.1046/j.1432-1033.2002.02905.x; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLLAND D, 1993, PLANT MOL BIOL, V21, P923, DOI 10.1007/BF00027124; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Izawa S, 1998, BIOCHEM J, V330, P811, DOI 10.1042/bj3300811; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jung BG, 2002, J BIOL CHEM, V277, P12572, DOI 10.1074/jbc.M110791200; Kowaltowski AJ, 2000, FEBS LETT, V473, P177, DOI 10.1016/S0014-5793(00)01526-X; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Monje-Casas F, 2004, BIOCHEM J, V383, P139, DOI 10.1042/BJ20040851; Moye-Rowley WS, 2003, EUKARYOT CELL, V2, P381, DOI 10.1128/EC.2.3.381-389.2003; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; Trivelli X, 2003, BIOCHEMISTRY-US, V42, P14139, DOI 10.1021/bi035551r; Tsuzi D, 2004, FEBS LETT, V569, P301, DOI 10.1016/j.febslet.2004.05.077; Tsuzi D, 2004, FEBS LETT, V565, P148, DOI 10.1016/j.febslet.2004.03.091; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; Vernet P, 1996, BIOCHEM CELL BIOL, V74, P125, DOI 10.1139/o96-014; Yamada K, 1999, YEAST, V15, P1125, DOI 10.1002/(SICI)1097-0061(199908)15:11<1125::AID-YEA442>3.0.CO;2-Z	41	77	81	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42078	42087		10.1074/jbc.M508622200	http://dx.doi.org/10.1074/jbc.M508622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16251189	hybrid			2022-12-25	WOS:000233992700034
J	Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY				Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY			Stabilization of prolactin receptor in breast cancer cells	ONCOGENE			English	Article						prolactin; receptor; beta-TrCP; ubiquitin; E3 ligase; breast cancer	E3 UBIQUITIN LIGASE; MAMMARY-CARCINOMA; TRANSGENIC MICE; GROWTH-HORMONE; ACTIVATION; EXPRESSION; INDUCTION; TUMORS; RISK; GENE	The role of the hormone prolactin (PRL) in the pathogenesis of breast cancer is mediated by its cognate receptor (PRLr). Ubiquitin-dependent degradation of the PRLr that negatively regulates PRL signaling is triggered by PRL-mediated phosphorylation of PRLr on Ser349 followed by the recruitment of the beta-transducin repeats-containing protein ( beta-TrCP) ubiquitin-protein isopeptide ligase. We report here for the first time that interaction between PRLr and beta-TrCP is less efficient in human breast cancer cells than in non-tumorigenic human mammary epithelial cells. Furthermore, we demonstrate that both PRLr degradation and PRLr phosphorylation on Ser349 are impaired in breast tumor cells and tissues, an observation that directly correlates with enhanced expression of the PRLr in malignant breast epithelium. These findings represent a novel mechanism through which altered PRLr stability may directly influence the pathogenesis of breast cancer.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Wisconsin, Dept Dermatol, Madison, WI USA	University of Pennsylvania; Northwestern University; University of Pennsylvania; University of Wisconsin System; University of Wisconsin Madison	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu		Spiegelman, Vladimir S/0000-0003-4847-155X; Minkovsky, Natalie/0000-0002-2707-0506	NCI NIH HHS [CA069294, R01 CA115281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115281, R01CA069294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Canbay E, 2004, CURR MED RES OPIN, V20, P533, DOI 10.1185/030079904125003232; CARTUN RW, 1989, J HISTOTECHNOL, V12, P273; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Glasow A, 2001, J CLIN ENDOCR METAB, V86, P3826, DOI 10.1210/jc.86.8.3826; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Harvey PW, 2005, J APPL TOXICOL, V25, P179, DOI 10.1002/jat.1063; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kline JB, 2002, MOL ENDOCRINOL, V16, P2310, DOI 10.1210/me.2001-0033; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Perks CC, 2004, BRIT J CANCER, V91, P305, DOI 10.1038/sj.bjc.6601947; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	24	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1896	1902		10.1038/sj.onc.1209214	http://dx.doi.org/10.1038/sj.onc.1209214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278670				2022-12-25	WOS:000236224800006
J	Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F				Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F			Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene	ONCOGENE			English	Article						phosphatidylinositol phosphatase; erythroleukemia; erythropoietin; transcriptional regulation	INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; TRANSCRIPTION FACTOR PU.1; PHOSPHOINOSITIDE 3-KINASE; PROLIFERATION; INTERLEUKIN-3; SURVIVAL; RECEPTOR; PROTEIN; KINASE; FAMILY	The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistep process. At disease onset, preleukemic cells are arrested in differentiation at the proerythroblast stage (HS1 stage) and their survival and growth are under the tight control of erythropoietin (Epo). During disease progression, malignant proerythroblasts characterized by Epo autonomous growth and in vivo tumorigenicity can be isolated (HS2 stage). During analysis of transcriptional pro. ling representive of discrete stages of leukemic progression, we found that the phosphatidylinositol 4-phosphatase type II gene was turned off in malignant cells. PI-4-phosphatase II is an enzyme that hydrolyses the 4-phosphate position of phosphatidylinositol-3-4-bisphosphate (PtdIns(3,4) P-2) to form PtdIns (3) P. Using malignant cells engineered to stably express PI-4-phosphatase II, we showed that PI-4-phosphatase II reduced Akt activation level. Moreover, stimulation of malignant cells with Epo-induced PI-4-phosphatase II transcription pointing this gene as an Epo-responsive gene. This study provides first insight for a physiological role of PI-4-phosphatase II in the proerythroblast by controlling Epo responsiveness through a negative regulation of the PI3K/Akt pathway.	INSERM, Inst Curie, U528, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), INSERM, Inst Curie, U528, 26 Rue Ulm, Paris, France.	framoreau@curie.fr		KOSMIDER, olivier/0000-0002-6021-4057				Barnache S, 2001, BLOOD, V98, P2372, DOI 10.1182/blood.V98.8.2372; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; KOMATSU N, 1991, CANCER RES, V51, P341; Liang P, 1997, Methods Mol Biol, V85, P3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Munday AD, 1999, P NATL ACAD SCI USA, V96, P3640, DOI 10.1073/pnas.96.7.3640; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Tilbrook PA, 1999, INT J BIOCHEM CELL B, V31, P1001, DOI 10.1016/S1357-2725(99)00071-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	22	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1420	1423		10.1038/sj.onc.1209187	http://dx.doi.org/10.1038/sj.onc.1209187			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247441				2022-12-25	WOS:000235708200016
J	Speidel, D; Helmbold, H; Deppert, W				Speidel, D; Helmbold, H; Deppert, W			Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress	ONCOGENE			English	Article						p53; Bax; non-transcriptional apoptosis; transcription; senescence; fibroblasts	TUMOR-SUPPRESSOR P53; DNA-BINDING; IN-VIVO; APOPTOSIS; CELLS; PROTEIN; BAX; TRANSACTIVATION; MITOCHONDRIA; ACTIVATION	Following genotoxic stress, p53 either rescues a damaged cell or promotes its elimination. The parameters determining a specific outcome of the p53 response are largely unknown. In mouse. broblasts treated with different irradiation schemes, we monitored transcriptional and non-transcriptional p53 activities and identifi. ed determinants that initiate an anti- or a pro-apoptotic p53 response within the context of p53-independent stress signaling. The primary, transcription-mediated p53 response in these cells is anti-apoptotic, while induction of p53-dependent apoptosis requires an additional, transcription-independent p53 activity, provided by high intracellular levels of activated p53. High intracellular levels of p53 were selectively generated after apoptosis-inducing high-dose UV-irradiation, and correlated with a strongly delayed upregulation of Mdm2. Following high-dose UV-irradiation, p53 accumulated in the cytoplasm and led to activation of the pro-apoptotic protein Bax. As p53-dependent Bax-activation is transcription-independent, we postulated that certain transcription-deficient mutant p53 proteins might also exert this activity. Indeed we found an endogenous, transcription-inactive mutant p53 that upon genotoxic stress induced Bax-activation in vivo. Our results demonstrate the impact and in vivo relevance of non-transcriptional mechanisms for wild- type and mutant p53-mediated apoptosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de	Speidel, Daniel/I-4244-2012					Chen X, 2002, CELL RES, V12, P229, DOI 10.1038/sj.cr.7290129; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERMEKING H, 2003, NAT REV CANCER, V2, P594; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Roninson IB, 2003, CANCER RES, V63, P2705; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZIEGLER C, 1998, THESIS U HAMBURG HAM	33	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					940	953		10.1038/sj.onc.1209126	http://dx.doi.org/10.1038/sj.onc.1209126			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247471				2022-12-25	WOS:000235212700013
J	Kurschat, CE; Shmukler, BE; Jiang, LW; Wilhelm, S; Kim, EH; Chernova, MN; Kinne, RKH; Stewart, AK; Alper, SL				Kurschat, CE; Shmukler, BE; Jiang, LW; Wilhelm, S; Kim, EH; Chernova, MN; Kinne, RKH; Stewart, AK; Alper, SL			Alkaline-shifted pH(o) sensitivity of AE2c1-mediated anion exchange reveals novel regulatory determinants in the AE2 N-terminal cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; CL-/HCO3-EXCHANGER; MESSENGER-RNAS; MICROVASCULAR ARCHITECTURE; MOLECULAR-CLONING; GENE FAMILY; RAT-KIDNEY; CELL-LINE; PH; MOUSE	The mouse anion exchanger AE2/SLC4A2Cl(-)/HCO3(-) exchanger is essential to post-weaning life. AE2 polypeptides regulate pH(i), chloride concentration, cell volume, and transepithelial ion transport in many tissues. Although the AE2a isoform has been extensively studied, the function and regulation of the other AE2 N-terminal variant mRNAs of mouse (AE2b1, AE2b2, AE2c1, and AE2c2) have not been examined. We now present an extended analysis of AE2 variant mRNA tissue distribution and function. We show in Xenopus oocytes that all AE2 variant polypeptides except AE2c2 mediated Cl- transport are subject to inhibition by acidic pH(i) and to activation by hypertonicity and NH4+. However, AE2c1 differs from AE2a, AE2b1, and AE2b2 in its alkaline-shifted pH(o(50)) (7.70 +/- 0.11 versus 6.80 +/- 0.05), suggesting the presence of a novel AE2a pH-sensitive regulatory site between amino acids 99 and 198. Initial N-terminal deletion mutagenesis restricted this site to the region between amino acids 120 and 150. Further analysis identified AE2a residues 127-129, 130-134, and 145-149 as jointly responsible for the difference in pHo( 50) between AE2c1 and the longer AE2a, AE2b1, and AE2b2 polypeptides. Thus, AE2c1 exhibits a unique pHo sensitivity among the murine AE2 variant polypeptides, in addition to a unique tissue distribution. Physiological coexpression of AE2c1 with other AE2 variant polypeptides in the same cell should extend the range over which changing pHo can regulate AE2 transport activity.	Beth Israel Deaconess Med Ctr, Mol & Vasc Med Renal Units, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Max Planck Society	Alper, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol & Vasc Med Renal Units, E-RW763,330 Brookline Ave, Boston, MA 02215 USA.	salper@bidmc.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043495, R01DK043495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; Alper SL, 2002, J NEPHROL, V15, pS41; Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Alper SL, 1997, AM J PHYSIOL-RENAL, V273, pF601, DOI 10.1152/ajprenal.1997.273.4.F601; ALPER SL, 1989, ANION TRANSPORT PROT, P153; Chernova MN, 2005, J BIOL CHEM, V280, P8564, DOI 10.1074/jbc.M411703200; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; DOMINGUEZ L, 1995, P NATL ACAD SCI USA, V92, P8498; Frische S, 2004, AM J PHYSIOL-RENAL, V286, pF1163, DOI 10.1152/ajprenal.00409.2003; GANNON B, 1982, J ANAT, V135, P667; GANNON B, 1984, GASTROENTEROLOGY, V86, P866; Gawenis LR, 2004, J BIOL CHEM, V279, P30531, DOI 10.1074/jbc.M403779200; Humphreys BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1232, DOI 10.1152/ajpcell.1997.272.4.C1232; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V268, pC201, DOI 10.1152/ajpcell.1995.268.1.C201; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; Lecanda J, 2000, BIOCHEM BIOPH RES CO, V276, P117, DOI 10.1006/bbrc.2000.3439; LEE BS, 1991, J BIOL CHEM, V266, P11448; Medina JF, 2003, P NATL ACAD SCI USA, V100, P15847, DOI 10.1073/pnas.2536127100; Medina JF, 1997, GENOMICS, V39, P74, DOI 10.1006/geno.1996.4467; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Pal P, 2005, BIOCHEMISTRY-US, V44, P13638, DOI 10.1021/bi0506831; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Rossmann H, 2000, ANN NY ACAD SCI, V915, P81; STEHBERGER PA, 2004, J AM SOC NEPHROL, V15, pA70; Stewart AK, 2004, J BIOL CHEM, V279, P52664, DOI 10.1074/jbc.M408108200; Stewart AK, 2002, J GEN PHYSIOL, V120, P707, DOI 10.1085/jgp.20028641; Stewart AK, 2001, AM J PHYSIOL-CELL PH, V281, pC1344, DOI 10.1152/ajpcell.2001.281.4.C1344; Stuart-Tilley AK, 1998, J AM SOC NEPHROL, V9, P946; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Zhang DC, 2000, BLOOD, V96, P2925; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741	35	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1885	1896		10.1074/jbc.M509734200	http://dx.doi.org/10.1074/jbc.M509734200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16286476	hybrid			2022-12-25	WOS:000234760400006
J	Batra-Safferling, R; Abarca-Heidemann, K; Korschen, HG; Tziatzios, C; Stoldt, M; Budyak, I; Willbold, D; Schwalbe, H; Klein-Seetharaman, J; Kaupp, UB				Batra-Safferling, R; Abarca-Heidemann, K; Korschen, HG; Tziatzios, C; Stoldt, M; Budyak, I; Willbold, D; Schwalbe, H; Klein-Seetharaman, J; Kaupp, UB			Glutamic acid-rich proteins of rod photoreceptors are natively unfolded	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNEL; CIRCULAR-DICHROISM SPECTRA; SECONDARY STRUCTURE; BETA-SUBUNIT; MOLECULAR-CLONING; MEMBRANE-PROTEIN; CATION CHANNEL; DISK MEMBRANES; ROM-1; LOCALIZATION	The outer segment of vertebrate photoreceptors is a specialized compartment that hosts all the signaling components required for visual transduction. Specific to rod photoreceptors is an unusual set of three glutamic acid-rich proteins (GARPs) as follows: two soluble forms, GARP1 and GARP2, and the N-terminal cytoplasmic domain (GARP' part) of the B1 subunit of the cyclic GMP-gated channel. GARPs have been shown to interact with proteins at the rim of the disc membrane. Here we characterized native GARP1 and GARP2 purified from bovine rod photoreceptors. Amino acid sequence analysis of GARPs revealed structural features typical of "natively unfolded" proteins. By using biophysical techniques, including size-exclusion chromatography, dynamic light scattering, NMR spectroscopy, and circular dichroism, we showed that GARPs indeed exhibit a large degree of intrinsic disorder. Analytical ultracentrifugation and chemical cross-linking showed that GARPs exist in amonomer/multimer equilibrium. The results suggested that the function of GARP proteins is linked to their structural disorder. They may provide flexible spacers or linkers tethering the cyclic GMP-gated channel in the plasma membrane to peripherin at the disc rim to produce a stack of rings of these protein complexes along the long axis of the outer segment. GARP proteins could then provide the environment needed for protein interactions in the rim region of discs.	Inst Biol Informat Verarbeitung 1, D-52425 Julich, Germany; Forschungszentrum Julich, Inst Biol Informat Verarbeitung 2, D-52425 Julich, Germany; Univ Dusseldorf, Inst Biol Phys, D-40225 Dusseldorf, Germany; JW Goethe Univ Frankfurt, Zentrum Biol Magnet Resonanz, Inst Organ Chem & Biochem, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany	Helmholtz Association; Research Center Julich; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; Goethe University Frankfurt	Kaupp, UB (corresponding author), Inst Biol Informat Verarbeitung 1, FZJ-IBI-1, D-52425 Julich, Germany.	a.eckert@fz-juelich.de	Willbold, Dieter/A-6280-2013; Schwalbe, Harald/AAB-3143-2020; Batra-Safferling, Renu/G-2918-2013; Schwalbe, Harald J/F-9023-2010; Stoldt, Matthias/G-5738-2013	Willbold, Dieter/0000-0002-0065-7366; Schwalbe, Harald/0000-0001-5693-7909; Batra-Safferling, Renu/0000-0002-8597-4335; Schwalbe, Harald J/0000-0001-5693-7909; Stoldt, Matthias/0000-0002-5060-4844				ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; Ardell MD, 2000, GENE, V245, P311, DOI 10.1016/S0378-1119(00)00023-8; Ardell MD, 1996, FEBS LETT, V389, P213, DOI 10.1016/0014-5793(96)00588-1; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; Bonigk W, 1999, J NEUROSCI, V19, P5332; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; DUNKER AK, 2002, PROTEIN-STRUCT FUNCT, V41, P6573; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Gerstner A, 2000, J NEUROSCI, V20, P1324; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Higgins MK, 2002, EMBO J, V21, P2087, DOI 10.1093/emboj/21.9.2087; Huttl S, 2005, J NEUROSCI, V25, P130, DOI 10.1523/JNEUROSCI.3764-04.2005; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 2004, TRANDUCTION CHANNELS, P209; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 2000, MOL MECH VISUAL TRAN, P143; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; MUSCO G, 1995, BIOCHEMISTRY-US, V34, P553, DOI 10.1021/bi00002a021; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Palczewski K, 2004, BIOCHEM BIOPH RES CO, V322, P1123, DOI 10.1016/j.bbrc.2004.07.122; PENNINGTON MW, 1994, PEPTIDE SYNTHESIS PR, V35; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Romero P, 1997, 1997 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS, VOLS 1-4, P90, DOI 10.1109/ICNN.1997.611643; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; SCHNETKAMP PPM, 1982, METHOD ENZYMOL, V81, P110; SCHUBERT D, 1991, PROG COLL POL SCI S, V86, P12, DOI 10.1007/BFb0115002; Schubert D, 1999, CHEM-EUR J, V5, P1377, DOI 10.1002/(SICI)1521-3765(19990503)5:5<1377::AID-CHEM1377>3.0.CO;2-H; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUCK P, 1994, PROG COLL POL SCI S, V94, P1; SCHUCK P, 1995, EUR J BIOCHEM, V230, P806; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tziatzios C, 2004, PROG COLL POL SCI S, V127, P48, DOI 10.1007/b98012; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	72	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1449	1460		10.1074/jbc.M505012200	http://dx.doi.org/10.1074/jbc.M505012200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16280326	hybrid, Green Published			2022-12-25	WOS:000234652000022
J	Conner, AC; Simms, J; Howitt, SG; Wheatley, M; Poyner, DR				Conner, AC; Simms, J; Howitt, SG; Wheatley, M; Poyner, DR			The second intracellular loop of the calcitonin gene-related peptide receptor provides molecular determinants for signal transduction and cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGHT-DEPENDENT CHANGES; CYTOPLASMIC END; AMINO-ACIDS; KEY ROLE; RHODOPSIN; ADRENOMEDULLIN; ACTIVATION; PREDICTION; DISTANCE	The calcitonin gene-related peptide ( CGRP) receptor is a heterodimer of a family B G-protein-coupled receptor, calcitonin receptor-like receptor (CLR), and the accessory protein receptor activity modifying protein 1. It couples to G(s), but it is not known which intracellular loops mediate this. We have identified the boundaries of this loop based on the relative position and length of the juxtamembrane transmembrane regions 3 and 4. The loop has been analyzed by systematic mutagenesis of all residues to alanine, measuring cAMP accumulation, CGRP affinity, and receptor expression. Unlike rhodopsin, ICL2 of the CGRP receptor plays a part in the conformational switch after agonist interaction. His-216 and Lys-227 were essential for a functional CGRP-induced cAMP response. The effect of (H216A) CLR is due to a disruption to the cell surface transport or surface stability of the mutant receptor. In contrast, (K227A) CLR had wild-type expression and agonist affinity, suggesting a direct disruption to the downstream signal transduction mechanism of the CGRP receptor. Modeling suggests that the loop undergoes a significant shift in position during receptor activation, exposing a potential G-protein binding pocket. Lys-227 changes position to point into the pocket, potentially allowing it to interact with bound G-proteins. His-216 occupies a position similar to that of Tyr-136 in bovine rhodopsin, part of the DRY motif of the latter receptor. This is the first comprehensive analysis of an entire intracellular loop within the calcitonin family of G-protein-coupled receptor. These data help to define the structural and functional characteristics of the CGRP-receptor and of family B G-protein-coupled receptors in general.	Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Aston University; University of Birmingham	Poyner, DR (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	D.R.Poyner@aston.ac.uk		Poyner, David R/0000-0003-1590-112X; Simms, John/0000-0002-4675-0902; Wheatley, Mark/0000-0001-6261-5682	Biotechnology and Biological Sciences Research Council [C20091, C20090] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; Conner AC, 2005, MOL PHARMACOL, V67, P20, DOI 10.1124/mol.67.1.20; Conner AC, 2004, BIOCHEM SOC T, V32, P843, DOI 10.1042/BST0320843; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; Crozier PS, 2003, J MOL BIOL, V333, P493, DOI 10.1016/j.jmb.2003.08.045; de Bakker PIW, 2003, PROTEINS, V51, P21, DOI 10.1002/prot.10235; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; Gouldson PR, 2004, PROTEINS, V56, P67, DOI 10.1002/prot.20108; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Kalatskaya I, 2004, J BIOL CHEM, V279, P31268, DOI 10.1074/jbc.M401796200; Kang HT, 2005, BIOCHEM BIOPH RES CO, V329, P684, DOI 10.1016/j.bbrc.2005.02.040; Koller D, 2002, FEBS LETT, V531, P464, DOI 10.1016/S0014-5793(02)03585-8; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LOISEAU SC, 2004, NEUROPEPTIDES, V38, P6; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pappu RV, 1999, NAT STRUCT BIOL, V6, P50; POYNER DR, 1992, BRIT J PHARMACOL, V105, P441, DOI 10.1111/j.1476-5381.1992.tb14272.x; Samudrala R, 1998, J MOL BIOL, V275, P895, DOI 10.1006/jmbi.1997.1479; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; Sugimoto Y, 2004, J BIOL CHEM, V279, P11016, DOI 10.1074/jbc.M307404200; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Urizar E, 2005, J BIOL CHEM, V280, P17135, DOI 10.1074/jbc.M414678200; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	37	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1644	1651		10.1074/jbc.M510064200	http://dx.doi.org/10.1074/jbc.M510064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293613	Green Accepted, hybrid			2022-12-25	WOS:000234652000044
J	Galvez, AS; Brunskill, EW; Marreez, Y; Benner, BJ; Regula, KM; Kirschenbaum, LA; Dorn, GW				Galvez, AS; Brunskill, EW; Marreez, Y; Benner, BJ; Regula, KM; Kirschenbaum, LA; Dorn, GW			Distinct pathways regulate proapoptotic Nix and BNip3 in cardiac stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ESTER-RESPONSIVE ELEMENT; HEAVY-CHAIN PROMOTER; ENHANCER FACTOR-I; HEART-FAILURE; BCL-2 FAMILY; MYOCARDIAL-INFARCTION; MITOCHONDRIAL DEFECTS; VENTRICULAR MYOCYTES; INDUCIBLE EXPRESSION	Up-regulation of myocardial Nix and BNip3 is associated with apoptosis in cardiac hypertrophy and ischemia, respectively. To identify mechanisms of gene regulation for these critical cardiac apoptosis effectors, the determinants of Nix and BNip3 promoter activation were elucidated by luciferase reporter gene expression in neonatal rat cardiac myocytes. BNip3 transcription was increased by hypoxia but not by phenylephrine (10 mu M), angiotensin II (100 nM), or isoproterenol (10 mu M). In contrast, Nix transcription was increased by phenylephrine but not by isoproterenol, angiotensin II, or hypoxia. Since phenylephrine stimulates cardiomyocyte hypertrophy via protein kinase C (PKC), the effects of phorbol myristate acetate (PMA, 10 nM for 24 h) and adenoviral PKC expression were assessed. PMA and PKC alpha, but not PKC is an element of or dominant negative PKC alpha, increased Nix transcription. Multiple Nix promoter GC boxes bound transcription factor Sp-1, and basal and PMA- or PKC alpha-stimulated Nix promoter activity was suppressed by mithramycin inhibition of Sp1-DNA interactions. In vivo determinants of Nix expression were evaluated in Nix promoter-luciferase (NixP) transgenic mice that underwent ischemia-reperfusion (1h/24h), transverse aortic coarctation (TAC), or cross-breeding with the G(q) overexpression model of hypertrophy. Luciferase activity increased in G alpha(q)-NixP hearts 3.2 +/- 0.4-fold and in TAC hearts 2.8 +/- 0.4-fold but did not increase with infarction-reperfusion. NixP activity was proportional to the extent of TAC hypertrophy and was inhibited by mithramycin. These studies revealed distinct mechanisms of transcriptional regulation for cardiac Nix and BNip3. BNip3 is hypoxiainducible, whereas Nix expression was induced by G alpha(q)-mediated hypertrophic stimuli. PKC alpha, a Gq effector, transduced Nix transcriptional induction via Sp1.	Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Manitoba, St Boniface Gen Hosp Res Ctr, Fac Med, Inst Cardiovasc Sci,Dept Physiol, Winnipeg, MB R2H 2A6, Canada	University System of Ohio; University of Cincinnati; University of Manitoba; Children's Hospital Research Institute of Manitoba	Dorn, GW (corresponding author), Univ Cincinnati, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	dorngw@ucmail.uc.edu	Kirshenbaum, Lorrie A./F-5742-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059888, R01HL058010, T32HL007382] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07382, HL59888, HL58010] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aerbajinai W, 2003, BLOOD, V102, P712, DOI 10.1182/blood-2002-11-3324; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chou SF, 2003, EUR J BIOCHEM, V270, P1855, DOI 10.1046/j.1432-1033.2003.03551.x; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Crow MT, 2002, CIRC RES, V91, P183, DOI 10.1161/01.RES.0000030195.38795.CF; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hahn HS, 2003, CIRC RES, V93, P1111, DOI 10.1161/01.RES.0000105087.79373.17; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kim E, 2004, J BIOL CHEM, V279, P11188, DOI 10.1074/jbc.M313291200; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Marin-Garcia J, 2002, J CARD FAIL, V8, P347, DOI 10.1054/jcaf.2002.127774; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Sakamoto S, 2001, J BIOL CHEM, V276, P37237, DOI 10.1074/jbc.M105543200; Sowter HM, 2001, CANCER RES, V61, P6669; Syed FM, 2005, CIRC RES, V96, P1103, DOI 10.1161/01.RES.0000166925.45995.ed; Tanaka T, 2000, ARTERIOSCL THROM VAS, V20, P392, DOI 10.1161/01.ATV.20.2.392; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Yasuda M, 1999, CANCER RES, V59, P533; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang HM, 2003, APOPTOSIS, V8, P229, DOI 10.1023/A:1023616620970; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	36	105	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1442	1448		10.1074/jbc.M509056200	http://dx.doi.org/10.1074/jbc.M509056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291751	hybrid			2022-12-25	WOS:000234652000021
J	Han, W; Kim, KH; Jo, MJ; Lee, JH; Yang, J; Doctor, RB; Moe, OW; Lee, J; Kim, E; Lee, MG				Han, W; Kim, KH; Jo, MJ; Lee, JH; Yang, J; Doctor, RB; Moe, OW; Lee, J; Kim, E; Lee, MG			Shank2 associates with and regulates Na+/H+ exchanger 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PROTEIN-KINASE-A; RENAL PROXIMAL TUBULE; PDZ DOMAIN PROTEINS; APICAL MEMBRANE; POSTSYNAPTIC DENSITY; EPITHELIAL-CELLS; PANCREATIC-DUCT; HCO3-SALVAGE; H+ EXCHANGER	Na+/H+ exchanger 3 (NHE3) plays a pivotal role in transepithelial Na+ and HCO3(+) absorption across a wide range of epithelia in the digestive and renal-genitourinary systems. Accumulating evidence suggests that PDZ-based adaptor proteins play an important role in regulating the trafficking and activity of NHE3. A search for NHE3-binding modular proteins using yeast two-hybrid assays led us to the PDZ-based adaptor Shank2. The interaction between Shank2 and NHE3 was further confirmed by immunoprecipitation and surface plasmon resonance studies. When expressed in PS120/NHE3 cells, Shank2 increased the membrane expression and basal activity of NHE3 and attenuated the cAMP-dependent inhibition of NHE3 activity. Furthermore, knock-down of native Shank2 expression in Caco-2 epithelial cells by RNA interference decreased NHE3 protein expression as well as activity but amplified the inhibitory effect of cAMP on NHE3. These results indicate that Shank2 is a novel NHE3 interacting protein that is involved in the fine regulation of transepithelial salt and water transport through affecting NHE3 expression and activity.	Yonsei Univ, Coll Med, Dept Pharmacol,Inst Gastroenterol, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Korea Adv Inst Sci & Technol, Creat Res Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80439 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Pochun CHA Univ, Coll Med, Dept Pharmacol, Sungnam 463836, South Korea	Yonsei University; Yonsei University Health System; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pochon Cha University	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol,Inst Gastroenterol, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012; Kim, Eunjoon/C-1566-2011	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Yang, Jinhee/0000-0002-2888-7657				Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Bacic D, 2003, KIDNEY INT, V64, P2133, DOI 10.1046/j.1523-1755.2003.00308.x; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bookstein C, 1997, AM J PHYSIOL-CELL PH, V273, pC1496, DOI 10.1152/ajpcell.1997.273.5.C1496; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P3, DOI 10.1113/jphysiol.2005.090399; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Hecht G, 2004, AM J PHYSIOL-GASTR L, V287, pG370, DOI 10.1152/ajpgi.00432.2003; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Janecki AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG292, DOI 10.1152/ajpgi.1999.277.2.G292; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim JY, 2004, J BIOL CHEM, V279, P10389, DOI 10.1074/jbc.M312871200; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 2000, J CLIN INVEST, V105, P1651, DOI 10.1172/JCI9207; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; McWilliams RR, 2005, AM J PHYSIOL-CELL PH, V289, pC1042, DOI 10.1152/ajpcell.00568.2004; McWilliams RR, 2004, BIOCHEM J, V380, P181, DOI 10.1042/BJ20031577; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; Robertson MA, 1997, J BIOL CHEM, V272, P287; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Sheng M, 2000, J CELL SCI, V113, P1851; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Weinman EJ, 2005, PFLUG ARCH EUR J PHY, V450, P137, DOI 10.1007/s00424-005-1384-8; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	41	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1461	1469		10.1074/jbc.M509786200	http://dx.doi.org/10.1074/jbc.M509786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293618	hybrid			2022-12-25	WOS:000234652000023
J	Gatanaga, H; Das, D; Suzuki, Y; Yeh, DD; Hussain, KA; Ghosh, AK; Mitsuya, H				Gatanaga, H; Das, D; Suzuki, Y; Yeh, DD; Hussain, KA; Ghosh, AK; Mitsuya, H			Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VARIANTS RESISTANT; POSTENTRY RESTRICTION; DRUG-RESISTANCE; CLEAVAGE SITES; CAPSID PROTEIN; SIMIAN CELLS; REPLICATION; INHIBITORS; GENE	HIV-1 Gag protein interaction with cyclophilin A (CypA) is critical for viral fitness. Among the amino acid substitutions identified in Gag noncleavage sites in HIV-1 variants resistant to protease inhibitors, H219Q (Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M. F., Nagashima, K., Gorelick, R. J., Mardy, S., Tang, C., Summers, M. F., and Mitsuya, H. (2002) J. Biol. Chem. 277, 5952 5961) and H219P substitutions in the viral CypA binding loop confer the greatest replication advantage to HIV-1. These substitutions represent polymorphic amino acid residues. We found that the replication advantage conferred by these substitutions was far greater in CypA-rich MT-2 and H9 cells than in Jurkat cells and peripheral blood mononuclear cells (PBM), both of which contained less CypA. High intracellular CypA content in H9 and MT-2 cells, resulting in excessive CypA levels in virions, limited wild-type HIV-1 (HIV-1(WT)) replication and H219Q introduction into HIV-1 (HIV-1(H219Q)), reduced CypA incorporation of HIV-1, and potentiated viral replication. H219Q introduction also restored the otherwise compromised replication of HIV-1(P222A) in PBM, although the CypA content in HIV-1(H219Q/P222A) was comparable with that in HIV-1(P222A), suggesting that H219Q affected the conformation of the CypA-binding motif, rendering HIV-1 replicative in a low CypA environment. Structural modeling analyses revealed that although hydrogen bonds are lost with H219Q and H219P substitutions, no significant distortion of the CypA binding loop of Gag occurred. The loop conformation of HIV-1(P222A) was found highly distorted, although H219Q introduction to HIV-1(P222A) restored the conformation of the loop close to that of HIV-1WT. The present data suggested that the effect of CypA on HIV-1 replicative ability is bimodal (both high and low CypA content limits HIV-1 replication), that the conformation of the CypA binding region of Gag is important for viral fitness, and that the function of CypA is to maintain the conformation.	NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Infect Dis, Kumamoto 860, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Kumamoto University; Kumamoto University	Mitsuya, H (corresponding author), NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bldg 10,Rm 5A11,9000 Rockville Pike, Bethesda, MD 20892 USA.	hmitsuya@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01SC006738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053386, R37GM053386] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerson B, 1998, J VIROL, V72, P303, DOI 10.1128/JVI.72.1.303-308.1998; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004; Cornelissen M, 1997, J VIROL, V71, P6348, DOI 10.1128/JVI.71.9.6348-6358.1997; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gatanaga H, 2002, J BIOL CHEM, V277, P5952, DOI 10.1074/jbc.M108005200; Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; KAGEYAMA S, 1993, ANTIMICROB AGENTS CH, V37, P810, DOI 10.1128/AAC.37.4.810; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; Kavlick MF, 2001, ANTIRETROVIRAL THERAPY, P279; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; KUIKEN C, 2000, HUMAN RETROVIRUSES A, P201; Li Q, 2000, J MED CHEM, V43, P1770, DOI 10.1021/jm9903139; MIMOTO T, 1992, CHEM PHARM BULL, V40, P2251; Mitsuya H, 1999, TXB AIDS MED, P751; Owens CA, 2003, J VIROL, V77, P726, DOI 10.1128/JVI.77.1.726-731.2003; Owens CM, 2004, J VIROL, V78, P5423, DOI 10.1128/JVI.78.10.5423-5437.2004; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Tamiya S, 2004, J VIROL, V78, P12030, DOI 10.1128/JVI.78.21.12030-12040.2004; Tanaka M, 1997, ANTIMICROB AGENTS CH, V41, P1313, DOI 10.1128/AAC.41.6.1313; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; Yin L, 1998, J VIROL, V72, P6430, DOI 10.1128/JVI.72.8.6430-6436.1998; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Yoshimura K, 1999, P NATL ACAD SCI USA, V96, P8675, DOI 10.1073/pnas.96.15.8675; Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1358.2002	36	41	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1241	1250		10.1074/jbc.M505920200	http://dx.doi.org/10.1074/jbc.M505920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16275650	hybrid			2022-12-25	WOS:000234447200067
J	Samuel, T; Welsh, K; Lober, T; Togo, SH; Zapata, JM; Reed, JC				Samuel, T; Welsh, K; Lober, T; Togo, SH; Zapata, JM; Reed, JC			Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELLULAR INHIBITOR; STRUCTURAL BASIS; MALT LYMPHOMA; SWISS-MODEL; APOPTOSIS; PROTEINS; COMPLEX; FAMILY; C-IAP1	Inhibitor of apoptosis proteins (IAPs) regulate apoptosis primarily by inhibiting caspase-family proteases. However, many IAPs also possess E3 ligase (ubiquitin-protein isopeptide ligase) activities implicated in both caspase-dependent and -independent functions of these proteins. Here, we compared the structural features of cIAP1 responsible for its interactions with two known target proteins, TRAF2 and SMAC. The N-terminal (BIR1) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and SMAC, respectively. Mutational analysis of the BIR1 and BIR3 domains identified critical residues required for TRAF2 and SMAC binding. Using these mutants, cIAP1-mediated ubiquitination of TRAF2 and SMAC in vitro was determined to be correspondingly dependent on intact binding sites on BIR1 and BIR3. Because TRAF2 regulates NF-kappa B activation, the effects of cIAP1 on TRAF2-mediated induction of NF-kappa B transcriptional activity were studied using reporter gene assays. Expression of a fragment of cIAP1 encompassing the three BIR domains (but not full-length cIAP1) greatly enhanced TRAF2-induced increases in NF-kappa B activity, providing a convenient assay for monitoring BIR-dependent effects of cIAP1 on TRAF2 in cells. BIR1 mutants of the BIR1-3 fragment of cIAP1 that failed to bind TRAF2 lost the ability to modulate NF-kappa B activity, demonstrating a requirement for BIR1-mediated interactions with TRAF2. Altogether, these findings demonstrate the modularity and diversification of BIR domains, showing that a single cIAP can direct its E3 ligase activity toward different substrates and can alter the cellular functions of different protein targets in accordance with differences in the specificity of individual BIR domains.	Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER; NIA NIH HHS [AG15402] Funding Source: Medline; NIDDK NIH HHS [DK067515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Kipp RA, 2002, BIOCHEMISTRY-US, V41, P7344, DOI 10.1021/bi0121454; Laine Aaron, 2005, Sci STKE, V2005, pre5, DOI 10.1126/stke.2812005re5; Leo E, 1999, EUR J IMMUNOL, V29, P3908, DOI 10.1002/(SICI)1521-4141(199912)29:12<3908::AID-IMMU3908>3.0.CO;2-E; Li CL, 2003, J BIOL CHEM, V278, P50523, DOI 10.1074/jbc.M309381200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Morgan JA, 1999, CANCER RES, V59, P6205; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2005, CANCER RES, V65, P210; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012	31	119	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1080	1090		10.1074/jbc.M509381200	http://dx.doi.org/10.1074/jbc.M509381200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282325	hybrid			2022-12-25	WOS:000234447200049
J	Dobreva, I; Waeber, G; James, RW; Widmann, C				Dobreva, I; Waeber, G; James, RW; Widmann, C			Interleukin-8 secretion by fibroblasts induced by low density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADVENTITIAL FIBROBLASTS; LDL; MYOFIBROBLASTS; EXPRESSION; MITOGEN; ORIGIN; IL-8	We have previously reported (Dobreva, I., Waeber, G., Mooser, V., James, R. W., and Widmann, C. (2003) J. Lipid Res. 44, 2382 2390) that low density lipoproteins (LDLs) induce activation of the p38 MAPK pathway, resulting in fibroblast spreading and lamellipodia formation. Here, we show that LDL-stimulated fibroblast spreading and wound sealing are due to secretion of a soluble factor. Using an antibody-based human protein array, interleukin- 8 (IL-8) was identified as the main cytokine whose concentration was increased in supernatants from LDL-stimulated cells. Incubation of supernatants from LDL-treated cells with an anti-IL-8 blocking antibody completely abolished their ability to induce cell spreading and mediate wound closure. In addition, fibroblasts treated with recombinant IL-8 spread to the same extent as cells incubated with LDL or supernatants from LDL-treated cells. The ability of LDL and IL-8 to induce fibroblast spreading was mediated by the IL-8 receptor type II (CXCR-2). Furthermore, LDL-induced IL-8 production and subsequent wound closure required the activation of the p38 MAPK pathway, because both processes were abrogated by a specific p38 inhibitor. Therefore, the capacity of LDLs to induce fibroblast spreading and accelerate wound closure relies on their ability to stimulate IL-8 secretion in a p38 MAPK-dependent manner. Regulation of fibroblast shape and migration by lipoproteins may be relevant to atherosclerosis that is characterized by increased LDL cholesterol levels, IL-8 production, and extensive remodeling of the vessel wall.	Univ Lausanne, Dept Cellular Biol & Morphol, Biol & Med Fac, CH-1005 Lausanne, Switzerland; Univ Lausanne Hosp, CHU Vaudois, Dept Med Interne, CH-1011 Lausanne, Switzerland; Univ Hosp Geneva, Lipid Lab, Clin Diabet Unit, CH-1211 Geneva 14, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Widmann, C (corresponding author), Univ Lausanne, Dept Cellular Biol & Morphol, Biol & Med Fac, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Waeber, Gerard/0000-0003-4193-788X				De Castellarnau C, 2000, ARTERIOSCL THROM VAS, V20, P2281; DeSanctis JB, 1997, IMMUNOLOGY, V90, P526, DOI 10.1046/j.1365-2567.1997.00174.x; Dobreva I, 2005, BIOL CHEM, V386, P909, DOI 10.1515/BC.2005.106; Dobreva I, 2003, J LIPID RES, V44, P2382, DOI 10.1194/jlr.M300266-JLR200; Gouni-Berthold I, 2002, FASEB J, V16, P1477, DOI 10.1096/fj.02-0260rev; Gouni-Berthold I, 2001, EXP CLIN ENDOCR DIAB, V109, P203, DOI 10.1055/s-2001-15107; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAMES RW, 1990, DIABETES, V39, P1158, DOI 10.2337/diabetes.39.10.1158; Klouche M, 2000, CIRCULATION, V101, P1799, DOI 10.1161/01.CIR.101.15.1799; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kwon HM, 1998, J CLIN INVEST, V101, P1551, DOI 10.1172/JCI1568; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Miller FJ, 2001, ARTERIOSCL THROM VAS, V21, P722, DOI 10.1161/01.ATV.21.5.722; Ohashi N, 2000, ARTERIOSCL THROM VAS, V20, P2521, DOI 10.1161/01.ATV.20.12.2521; Porreca E, 1999, ATHEROSCLEROSIS, V146, P345, DOI 10.1016/S0021-9150(99)00160-4; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rus HG, 1996, ATHEROSCLEROSIS, V127, P263, DOI 10.1016/S0021-9150(96)05968-0; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Shi Y, 1997, CIRCULATION, V95, P997; Stenmark KR, 2002, CHEST, V122, p326S, DOI 10.1378/chest.122.6_suppl.326S; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; Zalewski A, 2002, CIRC RES, V91, P652, DOI 10.1161/01.RES.0000038996.97287.9A; Zhu Y, 1999, BBA-MOL CELL BIOL L, V1436, P557, DOI 10.1016/S0005-2760(98)00167-2	29	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					199	205		10.1074/jbc.M508857200	http://dx.doi.org/10.1074/jbc.M508857200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16251188	hybrid			2022-12-25	WOS:000234307200027
J	Flamand, N; Lefebvre, J; Surette, ME; Picard, S; Borgeat, P				Flamand, N; Lefebvre, J; Surette, ME; Picard, S; Borgeat, P			Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ACTIVATING-FACTOR BIOSYNTHESIS; LEUKOTRIENE SYNTHESIS; HUMAN-LEUKOCYTES; BINDS CALCIUM; MAP KINASE; CYCLIC-AMP; PROTEIN; PHOSPHORYLATION; DOMAIN	Elevation of the intracellular cAMP concentration in agonist- activated human neutrophils ( PMN) leads to the concomitant inhibitions of arachidonic acid ( AA) release, 5- lipoxygenase ( 5- LO) translocation, and leukotriene ( LT) biosynthesis. We report herein that exogenous AA completely prevents cAMP- dependent inhibition of 5- LO translocation and LT biosynthesis in agonist- activated PMN. Moreover, the group IVA phospholipase A(2) inhibitor pyrrophenone and the MEK inhibitor U- 0126 inhibited AA release and 5- LO translocation in activated PMN, and these effects were also prevented by exogenous AA, demonstrating a functional link between AA release and 5- LO translocation. Polyunsaturated fatty acids of the C18 and C20 series containing at least three double bonds located from carbon 9 ( or closer to the carboxyl group) were equally effective as AA in restoring 5- LO translocation in pyrrophenone- treated agonist- activated PMN. Importantly, experiments with the 5- LO- activating protein inhibitor MK- 0591 and the intracellular Ca2+ chelator BAPTA- AM demonstrated that the AA- regulated 5- LO translocation is FLAP- and Ca2+ dependent. Finally, the redox and competitive 5- LO inhibitors L- 685,015, L- 739,010, and L- 702,539 ( but not cyclooxygenase inhibitors) efficiently substituted for AA to reverse the pyrrophenone inhibition of 5-LO translocation, indicating that the site of regulation of 5- LO translocation by AA is at or in the vicinity of the catalytic site. This report demonstrates that AA regulates the translocation of 5- LO in human PMN and unravels a novel mechanism of the cAMP- mediated inhibition of LT biosynthesis.	CHUQ, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; Univ Moncton, Dept Chim & Biochim, Moncton, NB E1A 3E9, Canada	Laval University; Laval University; University of Moncton	Borgeat, P (corresponding author), CHUQ, Ctr Rech, Ctr Rech Rhumatol & Immunol, Off T1-49,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	Pierre.Borgeat@crchul.ulaval.ca	Flamand, Nicolas/H-5823-2019; Surette, Marc/AAW-1078-2021	Flamand, Nicolas/0000-0001-5944-7200; 	Canadian Institutes of Health Research [46187-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Chang LC, 2000, J PHARM PHARMACOL, V52, P539, DOI 10.1211/0022357001774336; CHARLESON S, 1994, EUR J PHARM-MOLEC PH, V267, P275, DOI 10.1016/0922-4106(94)90151-1; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; COFFEY M, 1992, J BIOL CHEM, V267, P570; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Evans JH, 2004, J BIOL CHEM, V279, P6005, DOI 10.1074/jbc.M311246200; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; FALGUEYRET JP, 1995, BIOCHEMISTRY-US, V34, P13603, DOI 10.1021/bi00041a040; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Flamand N, 2000, AM J RESP CRIT CARE, V161, pS88, DOI 10.1164/ajrccm.161.supplement_1.ltta-18; FLAMAND N, 2004, BRIT J PHARMACOL, V22, P1234; FONTEH AN, 1993, J IMMUNOL, V151, P339; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Grenier S, 2003, J LEUKOCYTE BIOL, V73, P530, DOI 10.1189/jlb.0702371; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HICHAMI A, 1995, EUR J PHARM-MOLEC PH, V291, P91, DOI 10.1016/0014-2999(95)90083-7; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 1999, ADV EXP MED BIOL, V469, P365; HUTCHINSON JH, 1995, J MED CHEM, V38, P4538, DOI 10.1021/jm00022a020; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; REID GK, 1990, J BIOL CHEM, V265, P19818; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	54	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					129	136		10.1074/jbc.M506513200	http://dx.doi.org/10.1074/jbc.M506513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16275640	hybrid			2022-12-25	WOS:000234307200019
J	Hashimoto, K; Cohen, RN; Yamada, M; Markan, KR; Monden, T; Satoh, T; Mori, M; Wondisford, FE				Hashimoto, K; Cohen, RN; Yamada, M; Markan, KR; Monden, T; Satoh, T; Mori, M; Wondisford, FE			Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-ALPHA-HYDROXYLASE MESSENGER-RNA; BETA-DEFICIENT MICE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; BILE-ACID; NUCLEAR RECEPTORS; GENERALIZED RESISTANCE; HYPOPHYSECTOMIZED RATS; DIETARY-CHOLESTEROL; LDL RECEPTOR; LXR-ALPHA	Hypercholesterolemia is found in patients with hypothyroidism and resistance to thyroid hormone. In this study, we examined cholesterol metabolism in a thyroid hormone receptor beta ( TR-beta) mutant mouse model of resistance to thyroid hormone. Whereas studies of cholesterol metabolism have been reported in TR-beta knock-out mice, generalized expression of a non-ligand binding TR-beta protein in this knock-in model more fully recapitulates the hypothyroid state, because the hypothyroid effect of TRs is mediated by the unliganded receptor. In the hypothyroid state, a high cholesterol diet increased serum cholesterol levels in wild-type animals (WT) but either did not change or reduced levels in mutant (MUT) mice relative to hypothyroidism alone. 7 alpha-Hydroxylase (CYP7A1) is the rate-limiting enzyme in cholesterol metabolism and mRNA levels were undetectable in the hypothyroid state in all animals. triiodothyronine replacement restored CYP7A1 mRNA levels in WT mice but had minimal effect in MUT mice. In contrast, a high cholesterol diet markedly induced CYP7A1 levels in MUT but not WT mice in the hypothyroid state. Elevation of CYP7A1 mRNA levels and reduced hepatic cholesterol content in MUT animals are likely because of cross-talk between TR-beta and liver X receptor alpha(LXR-alpha), which both bind to a direct repeat +4 ( DR+4) element in the CYP7A1 promoter. In transfection studies, WT but not MUT TR-beta antagonized induction of this promoter by LXR-alpha. Electromobility shift analysis revealed that LXR/RXR heterodimers bound to the DR+4 element in the presence of MUT but not WT TR-beta. A mechanism for cross-talk, and potential antagonism, between TR-beta and LXR-alpha is proposed.	Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 3718511, Japan; Univ Chicago, Endocrinol Sect, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	Gunma University; University of Chicago; University of Chicago	Wondisford, FE (corresponding author), Johns Hopkins Med Inst, Dept Pediat & Med, Div Metab, 600 N Wolfe St,Pk 211, Baltimore, MD 21287 USA.	fwondisford@jhmi.edu		Markan, Kathleen/0000-0002-3732-5525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, R01DK053036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49126, DK 53036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Bakker O, 1998, BIOCHEM BIOPH RES CO, V249, P517, DOI 10.1006/bbrc.1998.9174; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen JY, 2002, J BIOL CHEM, V277, P42588, DOI 10.1074/jbc.M205117200; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Cohen RN, 2003, J CLIN ENDOCR METAB, V88, P4832, DOI 10.1210/jc.2002-021868; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; Ferber D, 2000, SCIENCE, V289, P1446, DOI 10.1126/science.289.5484.1446; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Gullberg H, 2002, MOL ENDOCRINOL, V16, P1767, DOI 10.1210/me.2002-0009; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kawai K, 2004, ENDOCRINOLOGY, V145, P5515, DOI 10.1210/en.2004-0382; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li Y, 2002, MOL ENDOCRINOL, V16, P506, DOI 10.1210/me.16.3.506; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MYANT NB, 1977, J LIPID RES, V18, P135; NESS GC, 1994, BBA-LIPID LIPID MET, V1214, P229, DOI 10.1016/0005-2760(94)90068-X; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; NESS GC, 1995, ARCH BIOCHEM BIOPHYS, V323, P404, DOI 10.1006/abbi.1995.0061; Ness GC, 2000, P SOC EXP BIOL MED, V224, P8, DOI 10.1046/j.1525-1373.2000.22359.x; Noel-Suberville C, 1998, METABOLISM, V47, P301, DOI 10.1016/S0026-0495(98)90261-X; OBRIEN T, 1993, MAYO CLIN PROC, V68, P860, DOI 10.1016/S0025-6196(12)60694-6; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; Theodossiou C, 1999, CANCER, V86, P1596, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1596::AID-CNCR30>3.0.CO;2-C; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; UNDERWOOD AH, 1986, NATURE, V324, P425, DOI 10.1038/324425a0; USALA SJ, 1991, MOL ENDOCRINOL, V5, P327, DOI 10.1210/mend-5-3-327; Weetman A., 2000, WERNER INGBARS THYRO; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; WOLF B, 1984, ENDOCRINOLOGY, V114, P1334, DOI 10.1210/endo-114-4-1334; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zhou XY, 2004, NAT MED, V10, P633, DOI 10.1038/nm1050	40	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					295	302		10.1074/jbc.M507877200	http://dx.doi.org/10.1074/jbc.M507877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16260782	hybrid			2022-12-25	WOS:000234307200038
J	Kim, DJ; Kim, SH; Lim, CS; Choi, KY; Park, CS; Sung, BH; Yeo, MG; Chang, SH; Kim, JK; Song, WK				Kim, DJ; Kim, SH; Lim, CS; Choi, KY; Park, CS; Sung, BH; Yeo, MG; Chang, SH; Kim, JK; Song, WK			Interaction of SPIN90 with the Arp2/3 complex mediates lamellipodia and actin comet tail formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERPROLIN HOMOLOGY DOMAINS; CLATHRIN-COATED PITS; PROTEIN N-WASP; BINDING-PROTEIN; WASP/SCAR PROTEINS; POLYMERIZATION; ACTIVATION; ENDOSOMES; MOTILITY; CYTOSKELETON	The appropriate regulation of the actin cytoskeleton is essential for cell movement, changes in cell shape, and formation of membrane protrusions like lamellipodia and filopodia. Moreover, several regulatory proteins affecting actin dynamics have been identified in the motile regions of cells. Here, we provide evidence for the involvement of SPIN90 in the regulation of actin cytoskeleton and actin comet tail formation. SPIN90 was distributed throughout the cytoplasm in COS-7 cells, but exposing the cells to platelet-derived growth factor (PDGF) caused a redistribution of SPIN90 to the cell cortex and the formation of lamellipodia (or membrane ruffles), both of which were dramatically inhibited in SPIN90-knockdown cells. In addition, the binding of the C terminus of SPIN90 with both the Arp2/3 complex (actin-related proteins Arp 2 and Arp 3) and G-actin activates the former, leading to actin polymerization in vitro. And when coexpressed with phosphatidylinositol 4-phosphate 5 kinase, SPIN90 was observed within actin comet tails. Taken these findings suggest that SPIN90 participates in reorganization of the actin cytoskeleton and in actin-based cell motility.	GIST, Dept Life Sci, Kwangju 500712, South Korea; GIST, Mol Dis Res Ctr, Kwangju 500712, South Korea; Biosci Ctr, Hanwha Chem Res & Dev Ctr, Taejon 305345, South Korea; Changwon Natl Univ, Dept Microbiol, Chang Won 641773, South Korea	Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST); Changwon National University	Song, WK (corresponding author), GIST, Dept Life Sci, 1 Oryung Dong, Kwangju 500712, South Korea.	wksong@gist.ac.kr	Chang, Sunghoe/J-2784-2012	Park, Chun Shik/0000-0002-4329-3953; Yeo, Myeong Gu/0000-0001-8744-8403				Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chang FS, 2003, CURR BIOL, V13, P455, DOI 10.1016/S0960-9822(03)00131-3; de Bernard M, 2000, EMBO J, V19, P48, DOI 10.1093/emboj/19.1.48; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; HAYAKAWA A, 2004, GENE CHROMOSOME CANC, V30, P364; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Kaksonen M, 2000, J CELL SCI, V113, P4421; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lim CS, 2003, J BIOL CHEM, V278, P52116, DOI 10.1074/jbc.M310974200; Lim CS, 2001, J BIOL CHEM, V276, P12871, DOI 10.1074/jbc.M009411200; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miller KG, 2002, J CELL BIOL, V156, P591, DOI 10.1083/jcb.200201107; Nakagawa H, 2001, J CELL SCI, V114, P1555; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schwarz K, 1996, IMMUNOL TODAY, V17, P496, DOI 10.1016/0167-5699(96)30061-3; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Suetsugu S, 2001, J BIOL CHEM, V276, P33175, DOI 10.1074/jbc.M102866200; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamaguchi H, 2002, BIOCHEM BIOPH RES CO, V297, P214, DOI 10.1016/S0006-291X(02)02137-X	42	36	37	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					617	625		10.1074/jbc.M504450200	http://dx.doi.org/10.1074/jbc.M504450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16253999	hybrid			2022-12-25	WOS:000234307200074
J	Nair, AK; Menon, KMJ				Nair, AK; Menon, KMJ			Regulation of luteinizing hormone receptor expression - Evidence of translational suppression in vitro by a hormonally regulated mRNA-binding protein and its endogenous association with luteinizing hormone receptor mRNA in the ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; INDUCED DOWN-REGULATION; THYMIDYLATE SYNTHASE; RIBONUCLEIC-ACID; CHORIOGONADOTROPIN RECEPTOR; IDENTIFICATION; STABILIZATION; STABILITY; SEQUENCES; KINASE	Our previous studies have identified a luteinizing hormone receptor (LHR) mRNA-binding protein ( LRBP) that binds to the coding region (LBS) of rat LHR mRNA. The identity of LRBP was later established as mevalonate kinase (MVK). The present study examined if LRBP binding to LHR mRNA impairs translation. A full-length FLAG-tagged rat LHR mRNA was synthesized and translated in vitro. The translation product was immunoprecipitated and analyzed on SDS-PAGE. The addition of LRBP inhibited LHR mRNA translation. This inhibitory effect was reversed by an excess of wild type (wt) LBS. To determine whether this reversal of the inhibitory effect of LRBP was indeed due to the sequestration of LRBP by the wtLBS, a translation reaction was performed in the presence of mutated LBS in which all the cytidine in the wtLBS was mutated to uridine. This mutation of LBS has been shown to render it incapable of interacting with LRBP. Unlike wtLBS, the mutated LBS was unable to reverse the inhibitory effect of LRBP on LHR mRNA translation. The addition of mevalonate, which has been shown to compete for LHR mRNA binding to LRBP, also reduced the extent of translation inhibition by LRBP. Endogenous association of LHR mRNA with MVK was assessed by immunoprecipitation of the ribonucleoprotein complex with MVK antibody followed by reverse transcription-PCR of the RNA associated with the immune complex. Amplification of LHR mRNA, if any, associated with the immunoprecipitate obtained from ovarian ribonucleoprotein complex with gene-specific primers confirmed the association of LHR mRNA with MVK. Collectively, the present data support the novel function of LRBP as a translational inhibitor of LHR mRNA in the ovary.	Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Menon, KMJ (corresponding author), 6428 Med Sci 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	kmjmenon@umich.edu			NICHD NIH HHS [HD-06656] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD006656] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006656] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BERNARDI A, 1972, P NATL ACAD SCI USA, V69, P3033, DOI 10.1073/pnas.69.10.3033; BLUME JE, 1989, NUCLEIC ACIDS RES, V17, P9003, DOI 10.1093/nar/17.22.9003; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu E, 1999, METH MOL B, V118, P265; CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179; CHU E, 1994, MOL CELL BIOL, V14, P207, DOI 10.1128/MCB.14.1.207; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Chu E, 1999, MOL CELL BIOL, V19, P1582; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FRITZ DT, 2000, SCI STKE, pRE1; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOFFMAN YM, 1991, ENDOCRINOLOGY, V128, P388, DOI 10.1210/endo-128-1-388; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kash JC, 1998, J BIOL CHEM, V273, P10658, DOI 10.1074/jbc.273.17.10658; Kash JC, 1999, BIOCHEMISTRY-US, V38, P16889, DOI 10.1021/bi9915770; KEINANEN KP, 1988, BIOCHEM J, V256, P719, DOI 10.1042/bj2560719; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAPOLT PS, 1990, ENDOCRINOLOGY, V126, P3277, DOI 10.1210/endo-126-6-3277; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LU DL, 1993, ENDOCRINOLOGY, V132, P235, DOI 10.1210/en.132.1.235; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MENON KMJ, 1974, FERTIL STERIL, V25, P732; Nair AK, 2004, J BIOL CHEM, V279, P14937, DOI 10.1074/jbc.M309484200; Nair AK, 2002, J BIOL CHEM, V277, P21468, DOI 10.1074/jbc.M111653200; PATCHER JS, 1987, CELL, V51, P283; PEEGEL H, 1994, ENDOCRINOLOGY, V135, P1044, DOI 10.1210/en.135.3.1044; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; Wang L, 2005, ENDOCRINOLOGY, V146, P423, DOI 10.1210/en.2004-0805; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Xu YH, 2000, MOL GENET METAB, V70, P106, DOI 10.1006/mgme.2000.3010; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	42	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42809	42816		10.1074/jbc.M503154200	http://dx.doi.org/10.1074/jbc.M503154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263716	hybrid			2022-12-25	WOS:000234200800042
J	Jakopitsch, C; Droghetti, E; Schmuckenschlager, F; Furtmuller, PG; Smulevich, G; Obinger, C				Jakopitsch, C; Droghetti, E; Schmuckenschlager, F; Furtmuller, PG; Smulevich, G; Obinger, C			Role of the main access channel of catalase-peroxidase in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS KATG; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HEME CAVITY; WILD-TYPE; MUTANTS; RESISTANCE; MYOGLOBIN; VARIANTS; KINETICS	Catalase-peroxidases (KatG) are bifunctional heme peroxidases with an overwhelming catalatic activity. The structures show that the buried heme b is connected to the exterior of the enzyme by a main channel built up by KatG-specific loops named large loop LL1 and LL2, the former containing the highly conserved sequence Met-Gly- Leu-Ile-Tyr-Val-Asn-Pro-Glu-Gly. LL1 residues Ile(248), Asn(251), Pro(252), and Glu(253) of KatG from Synechocystis are the focus of this study because of their exposure to the solute matrix of the access channel. In particular, the I248F, N251L, P252A, E253Q, and E253D mutants have been analyzed by UV-visible and resonance Raman spectroscopies in combination with steady-state and presteady-state kinetic analyses. Exchange of these residues did not alter the kinetics of cyanide binding or the overall peroxidase activity. Moreover, the kinetics of compound I formation and reduction by one-electron donors was similar in the variants and the wild-type enzyme. However, the turnover numbers of the catalase activity of I248F, N251L, E253Q, and E253D were only 12.3, 32.6, 25, and 42% of the wild-type activity, respectively. These findings demonstrate that the oxidation reaction of hydrogen peroxide (not its reduction) was affected by these mutations. The altered kinetics allowed us to monitor the spectral features of the dominating redox intermediate of E253Q in the catalase cycle. Resonance Raman data and structural analysis demonstrated the existence of a very rigid and ordered structure built up by the interactions of these residues with distal side and also (via LL1) proximal side amino acids, with the heme itself, and with the solute matrix in the channel. The role of Glu253 and the other investigated channel residues in maintaining an ordered matrix of oriented water dipoles, which guides hydrogen peroxide to its site of oxidation, is discussed.	BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, A-1190 Vienna, Austria; Univ Florence, Dipartimento Chim, I-50019 Sesto Fiorentino, Italy	University of Natural Resources & Life Sciences, Vienna; University of Florence	Smulevich, G (corresponding author), BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, A-1190 Vienna, Austria.	giulietta.smulevich@unifi.it; christian.obinger@boku.ac.at	Obinger, Christian/AAV-3173-2021; smulevich, giulietta/A-6510-2008; Furtmüller, Paul G./Y-5819-2018	Furtmüller, Paul G./0000-0002-1199-2469; Jakopitsch, Christa/0000-0002-5855-2057; Smulevich, Giulietta/0000-0003-3021-8919; Obinger, Christian/0000-0002-7133-3430				Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chelikani P, 2003, J BIOL CHEM, V278, P31290, DOI 10.1074/jbc.M304076200; Dunford H. B., 1999, HEME PEROXIDASES, P58; Ghiladi RA, 2005, J AM CHEM SOC, V127, P13428, DOI 10.1021/ja054366t; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Jakopitsch C, 2005, J BIOL CHEM, V280, P9037, DOI 10.1074/jbc.M413317200; Jakopitsch C, 2003, BIOCHEMISTRY-US, V42, P5292, DOI 10.1021/bi026944d; Jakopitsch C, 2002, J INORG BIOCHEM, V91, P78, DOI 10.1016/S0162-0134(02)00374-4; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; Jakopitsch C, 2004, J BIOL CHEM, V279, P46082, DOI 10.1074/jbc.M408399200; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Kato S, 2004, J BIOL CHEM, V279, P52376, DOI 10.1074/jbc.M403532200; Marzocchi MP, 2003, J RAMAN SPECTROSC, V34, P725, DOI 10.1002/jrs.1037; Mate MJ, 1999, J BIOL CHEM, V274, P27717, DOI 10.1074/jbc.274.39.27717; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; Santoni E, 2004, BIOCHEMISTRY-US, V43, P5792, DOI 10.1021/bi035835b; Smulevich G, 2005, ACCOUNTS CHEM RES, V38, P433, DOI 10.1021/ar020112q; Wada K, 2002, ACTA CRYSTALLOGR D, V58, P157, DOI 10.1107/S0907444901017735; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wengenack NL, 2004, PROTEIN EXPRES PURIF, V36, P232, DOI 10.1016/j.pep.2004.04.018; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2003, J BIOL CHEM, V278, P14769, DOI 10.1074/jbc.M300326200	30	37	37	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42411	42422		10.1074/jbc.M508009200	http://dx.doi.org/10.1074/jbc.M508009200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16244360	hybrid			2022-12-25	WOS:000233992700072
J	Molina, DM; Grewal, S; Bardwell, L				Molina, DM; Grewal, S; Bardwell, L			Characterization of an ERK-binding domain in microphthalmia-associated transcription factor and differential inhibition of ERK2-mediated substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HIGH-AFFINITY INTERACTION; SIGNAL-REGULATED KINASE; MAP-KINASE; DOCKING-SITE; IN-VIVO; C-JUN; CELL-PROLIFERATION; PEPTIDE INHIBITOR; TIETZ-SYNDROME	Efficient and specific signaling by mitogen-activated protein kinases ( MAPKs) is enhanced by docking sites found on many MAPK substrates and regulators. Here we show that the MAPKs ERK1 and ERK2 form a stable complex ( K-d similar to 6 mu M) with their substrate the microphthalmia-associated transcription factor ( MITF). Complex formation requires a domain of MITF of similar to 100 residues that is nearby, but C-terminal to, the MAPK phosphorylation site at Ser(73). MITF derivatives lacking this ERK-binding domain do not bind ERK2 and are phosphorylated less efficiently by ERK2. The ERK-binding domain of MITF bears no obvious resemblance to previously characterized MAPK docking motifs; in particular, it does not contain a consensus D-site. Consistent with this, ERK2-MITF binding does not require the integrity of the CD/sevenmaker region of ERK2. Furthermore, D-site peptides, which are able to potently inhibit ERK2-mediated phosphorylation of the Elk-1 transcription factor ( IC50 = 3 mu M), are relatively poor inhibitors of ERK2-mediated phosphorylation of MITF, exhibiting >15-fold selectivity for inhibition of Elk-1 versus MITF. These observations demonstrate substrate-selective kinase inhibition: the possibility that small molecules that target docking interactions may be used to selectively inhibit the phosphorylation of a subset of the substrates of a kinase.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Bardwell, L (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	bardwell@uci.edu	Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363; Grewal, Seema/0000-0001-6372-8590	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060366] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060366, R01 GM060366-06, GM60366] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bismuth K, 2005, PIGM CELL RES, V18, P349, DOI 10.1111/j.1600-0749.2005.00249.x; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Caffrey DR, 1999, J MOL EVOL, V49, P567, DOI 10.1007/PL00006578; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Davidson W, 2004, BIOCHEMISTRY-US, V43, P11658, DOI 10.1021/bi0495073; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; EPSTEIN CJ, 2004, INBORN ERRORS DEV MO, V49; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Goding CR, 2000, GENE DEV, V14, P1712; Grewal S, 2006, CELL SIGNAL, V18, P123, DOI 10.1016/j.cellsig.2005.04.001; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; McInnes Campbell, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P57, DOI 10.2174/1568011033353506; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Parang K, 2004, CURR OPIN DRUG DISC, V7, P617; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Steingrimsson E, 2005, CELL, V121, P9, DOI 10.1016/j.cell.2005.03.021; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Vachtenheim J, 2004, PIGM CELL RES, V17, P43, DOI 10.1046/j.1600-0749.2003.00108.x; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu M, 2000, GENE DEV, V14, P301; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x	80	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42051	42060		10.1074/jbc.M510590200	http://dx.doi.org/10.1074/jbc.M510590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16246839	Green Accepted, hybrid			2022-12-25	WOS:000233992700031
J	Testa, JR; Tsichlis, PN				Testa, JR; Tsichlis, PN			AKT signaling in normal and malignant cells	ONCOGENE			English	Article						AKT/ PKB pathway; tumor suppressor genes	MOLECULAR-CLONING; PROTEIN-KINASE; ONCOGENE	AKT/protein kinase B (PKB) is a cardinal node in diverse signaling cascades important in both normal cellular physiology and various disease states. AKT signaling regulates cell proliferation and survival, cell growth ( size), glucose metabolism, cell motility and angiogenesis. Aberrant regulation of these processes result in cellular perturbations considered hallmarks of cancer, and numerous studies testify to the frequent hyperactivation of AKT signaling in many human cancers. Various oncoproteins and tumor suppressors intersect the AKT signal transduction pathway and are activated or inactivated, respectively, in cancer. This issue of Oncogene Reviews includes a collection of perspectives on the normal cellular functions of various components of the AKT pathway, as well as biological consequences of alterations of these proteins as related to tumorigenesis. Two reviews focus on AKT regulation, one of which addresses various aspects of phosphoinositide metabolism, while the other emphasizes the role of AKT-interacting proteins in AKT activation. Several reviews highlight the role of major AKT substrates involved in cellular metabolism, transcription and translation; another focuses on the role of AKT signaling in epithelial-mesenchymal transition. Also included are articles on the involvement of AKT pathway deregulation in human cancer and certain hereditary cancer syndromes, as well as in murine models of cancer based on AKT pathway activation. Additional articles discuss current approaches to identify selective inhibitors of the AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Fox Chase Cancer Center; Tufts Medical Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NCI NIH HHS [CA06927, CA57436, CA77429, CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, P50CA083638, R01CA057436, R01CA077429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, ONCOGENE REV, V24, P7482; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065	10	215	226	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7391	7393		10.1038/sj.onc.1209100	http://dx.doi.org/10.1038/sj.onc.1209100			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288285				2022-12-25	WOS:000233201900001
J	Eul, B; Rose, F; Krick, S; Savai, R; Goyal, P; Klepetko, W; Grimminger, F; Weissmann, N; Seeger, W; Hanze, J				Eul, B; Rose, F; Krick, S; Savai, R; Goyal, P; Klepetko, W; Grimminger, F; Weissmann, N; Seeger, W; Hanze, J			Impact of HIF-1 alpha and HIF-2 alpha on proliferation and migration of human pulmonary artery fibroblasts in hypoxia	FASEB JOURNAL			English	Article						adventitia; alpha-smooth-muscle actin; remodeling; RNA interference	SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; CELLULAR PROLIFERATION; INDUCIBLE FACTOR-1-ALPHA; ADVENTITIAL FIBROBLASTS; MOLECULAR-MECHANISMS; RNA INTERFERENCE; FACTOR-I; LUNG; HYPERTENSION	Proliferation of adventitial fibroblasts of small intrapulmonary arteries ( FBPA) has been disclosed as an early event in the development of pulmonary hypertension and cor pulmonale in response to hypoxia. We investigated the role of hypoxia-inducible transcription factors (HIF) in human FBPA exposed to hypoxia. Primary cultures of FBPA displayed a strong mitogenic response to 24 h hypoxia, whereas the rate of apoptosis was significantly suppressed. In addition, the migration of FBPA was strongly increased under hypoxic conditions but not the expression of alpha-smooth muscle actin. Hypoxia induced a marked up-regulation ( protein level) of both HIF-1 alpha and HIF-2 alpha, alongside with nuclear translocation of these transcription factors. Specific inhibition of either HIF-1 alpha or HIF-2 alpha was achieved by RNA interference technology, as proven by HIF-1 alpha and HIF-2 alpha mRNA and protein analysis and expression analysis of HIF downstream target genes. With the use of this approach, the hypoxia-induced proliferative response of the FBPA was found to be solely HIF-2 alpha dependent, whereas the migratory response was significantly reduced by both HIF-1 alpha and HIF-2 alpha interference. In conclusion, HIF up-regulation is essential for hypoxic cellular responses in human pulmonary artery adventitial fibroblasts such as proliferation and migration, mimicking the pulmonary hypertensive phenotype in vivo. Differential HIF subtype dependency was noted, with HIF-2 alpha playing a predominant role, which may offer future intervention strategies.	Univ Giessen, Med Clin 2, Lung Ctr, D-35392 Giessen, Germany; Univ Hosp Vienna, A-1220 Vienna, Austria	Justus Liebig University Giessen; University Hospital Vienna	Hanze, J (corresponding author), Univ Giessen, Med Clin 2, Lung Ctr, Klinikstr 36, D-35392 Giessen, Germany.	joerg.haenze@uglc.de	Goyal, Parag/ABH-1136-2021	Goyal, Parag/0000-0002-5678-8592; Savai, Rajkumar/0000-0003-1538-2091; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Weissmann, Norbert/0000-0003-2675-3871				Berg JT, 1998, AM J RESP CRIT CARE, V158, P1920, DOI 10.1164/ajrccm.158.6.9804076; Brusselmans K, 2003, J CLIN INVEST, V111, P1519, DOI 10.1172/JCI200315496; Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Das M, 2000, AM J RESP CELL MOL, V22, P15, DOI 10.1165/ajrcmb.22.1.3536; Das M, 2002, AM J PHYSIOL-LUNG C, V282, pL976, DOI 10.1152/ajplung.00382.2001; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Iida T, 2002, GENES CELLS, V7, P143, DOI 10.1046/j.1356-9597.2001.00512.x; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Krick S, 2005, FASEB J, V19, P857, DOI 10.1096/fj.04-2890fje; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; MIN BH, 1990, J BIOL CHEM, V265, P16667; MURPHY JD, 1991, J PEDIAT, V98, P962; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; PERKETT EA, 1992, AM J RESP CELL MOL, V6, P82, DOI 10.1165/ajrcmb/6.1.82; Pfeifer M, 1998, RESP PHYSIOL, V111, P201, DOI 10.1016/S0034-5687(97)00102-3; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; Short M, 2004, AM J PHYSIOL-CELL PH, V286, pC416, DOI 10.1152/ajpcell.00169.2003; Sowter HM, 2003, CANCER RES, V63, P8562; Stenmark KR, 2000, PHYSIOL RES, V49, P503; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; SUI GJ, 1988, J PATHOL, V155, P161, DOI 10.1002/path.1711550213; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wort SJ, 2001, AM J RESP CELL MOL, V25, P104, DOI 10.1165/ajrcmb.25.1.4331; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	39	46	53	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					163	+		10.1096/fj.05-4104fje	http://dx.doi.org/10.1096/fj.05-4104fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263938				2022-12-25	WOS:000234053100023
J	Yu, LCH; Flynn, AN; Turner, JR; Buret, AG				Yu, LCH; Flynn, AN; Turner, JR; Buret, AG			SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism?	FASEB JOURNAL			English	Article						enterocytes apoptosis; paracellular permeability; LPS; SGLT-1; glucose	MITOCHONDRIAL PERMEABILITY TRANSITION; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; BAX TRANSLOCATION; DOWN-REGULATION; BCL-2 FAMILY; IN-VIVO; EXPRESSION; INHIBITION; MYOSIN	Excessive apoptosis induced by enteric microbes leads to epithelial barrier defects. This mechanism has been implicated in the pathogenesis of inflammatory bowel diseases (IBD) and bacterial enteritis. The sodium-dependent glucose cotransporter (SGLT-1) is responsible for active glucose uptake in enterocytes. The aim was to investigate the effects of SGLT-1 glucose uptake on enterocyte apoptosis and barrier defects induced by bacterial lipopolysaccharide (LPS). SGLT-1-transfected Caco-2 cells were treated with LPS ( 50 mu g/mL) in low ( 5 mM) or high ( 25 mM) glucose media. LPS in low glucose induced caspase-3 cleavage, DNA fragmentation, and increased paracellular permeability to dextran in epithelial cells. These phenomena were significantly attenuated in high glucose. LPS increased SGLT-1 activity in high, but not low glucose media. Addition of phloridzin, which competitively binds to SGLT-1, inhibited the cytoprotection mediated by high glucose. Western blot showed that LPS in high glucose increased the levels of anti-apoptotic Bcl-2 and Bcl-XL, and did not change proapoptotic Bax. Differential extraction of membranous vs. cytosolic cell components demonstrated that high glucose inhibits mitochondrial cytochrome c translocation to cytosol. Collectively, SGLT-1-mediated glucose uptake increases anti-apoptotic proteins, and protects enterocytes from LPS-induced apoptosis and barrier defects. The understanding of this novel glucose-mediated rescue mechanism may lead to therapeutic interventions for various enteric diseases.	Univ Calgary, Mucosal Inflammat Res Grp, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Calgary; University of Chicago	Buret, AG (corresponding author), Univ Calgary, Mucosal Inflammat Res Grp, Dept Biol Sci, BI 117,2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	aburet@ucalgary.ca	Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455; Yu, Linda Chia-Hui/0000-0003-1461-3249				Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Antonelli A, 2001, BLOOD CELL MOL DIS, V27, P978, DOI 10.1006/bcmd.2001.0470; Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1; Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Bocker U, 2000, J BIOL CHEM, V275, P12207, DOI 10.1074/jbc.275.16.12207; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chin AC, 2003, P NATL ACAD SCI USA, V100, P11104, DOI 10.1073/pnas.1831452100; Chin AC, 2002, INFECT IMMUN, V70, P3673, DOI 10.1128/IAI.70.7.3673-3680.2002; Courtois F, 2003, AM J CLIN NUTR, V77, P744, DOI 10.1093/ajcn/77.3.744; Darfeuille-Michaud A, 1998, GASTROENTEROLOGY, V115, P1405, DOI 10.1016/S0016-5085(98)70019-8; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; Drewe J, 2001, EUR J CLIN INVEST, V31, P138, DOI 10.1046/j.1365-2362.2001.00792.x; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Eguchi Y, 1997, CANCER RES, V57, P1835; Eipel C, 2004, AM J PHYSIOL-GASTR L, V286, pG769, DOI 10.1152/ajpgi.00275.2003; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; Giovannini C, 2003, FEBS LETT, V540, P117, DOI 10.1016/S0014-5793(03)00236-9; Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Imaeda H, 2002, HISTOCHEM CELL BIOL, V118, P381, DOI 10.1007/s00418-002-0458-3; Jones GB, 2000, ORG LETT, V2, P811, DOI 10.1021/ol0055566; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; KIMMICH GA, 1981, AM J PHYSIOL, V241, pC227, DOI 10.1152/ajpcell.1981.241.5.C227; KIMMICH GA, 1984, AM J PHYSIOL, V247, pC74, DOI 10.1152/ajpcell.1984.247.1.C74; Le'Negrate G, 2001, INFECT IMMUN, V69, P5001, DOI 10.1128/IAI.69.8.5001-5009.2001; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; MADARA JL, 1987, AM J PHYSIOL, V253, pC854, DOI 10.1152/ajpcell.1987.253.6.C854; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; Merger M, 2002, GUT, V51, P155, DOI 10.1136/gut.51.2.155; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nazli A, 2004, AM J PATHOL, V164, P947, DOI 10.1016/S0002-9440(10)63182-3; Neut C, 2002, AM J GASTROENTEROL, V97, P939, DOI 10.1111/j.1572-0241.2002.05613.x; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Paesold G, 2002, CELL MICROBIOL, V4, P771, DOI 10.1046/j.1462-5822.2002.00233.x; Pollman MJ, 1999, CIRC RES, V84, P113; Power C, 2001, J SURG RES, V101, P138, DOI 10.1006/jsre.2001.6270; Ramachandran A, 2000, J GASTROEN HEPATOL, V15, P109, DOI 10.1046/j.1440-1746.2000.02059.x; Rao JN, 2003, AM J PHYSIOL-CELL PH, V284, pC848, DOI 10.1152/ajpcell.00371.2002; REGOLI DC, 1981, EUR J PHARMACOL, V71, P105, DOI 10.1016/0014-2999(81)90391-5; Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5; Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689; Schaffer SW, 2000, AM J PHYSIOL-HEART C, V278, pH1948; Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364; SCHILDBERG FA, 2005, CELL TISSUE RES; Scott KGE, 2002, GASTROENTEROLOGY, V123, P1179, DOI 10.1053/gast.2002.36002; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; THAKKAR NS, 1993, CANCER RES, V53, P2057; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; Unno N, 1997, GASTROENTEROLOGY, V113, P1246, DOI 10.1053/gast.1997.v113.pm9322519; Yagi Seiji, 2002, Fukuoka Igaku Zasshi, V93, P38; Yamada T, 2003, AM J PHYSIOL-GASTR L, V284, pG782, DOI 10.1152/ajpgi.00376.2002; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	69	112	116	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1822	1835		10.1096/fj.05-4226com	http://dx.doi.org/10.1096/fj.05-4226com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260652				2022-12-25	WOS:000234053100034
J	Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK				Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK			Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; apoptosis; soluble guanylyl cyclase; cGMP; p53	X-LINKED INHIBITOR; INSULIN-RECEPTOR SUBSTRATE-1; CISPLATIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; ENDOGENOUS NITRIC-OXIDE; CYCLIC-GMP; DNA-DAMAGE; PC12 CELLS; GUANOSINE-MONOPHOSPHATE; NATRIURETIC PEPTIDES	Dysregulated apoptosis plays a critical role in the development of a number of aberrant cellular processes, including tumorigenesis and chemoresistance. However, the mechanisms that govern the normal apoptotic program are not completely understood. Soluble guanylyl cyclase (sGC) and cyclic guanosine monophosphate ( cGMP) promote mammalian cell viability via an unknown mechanism and p53 status is a key determinant of cell fate in human ovarian cancer cells. Whether an interaction exists between these two determinants of cell fate is unknown. We hypothesized that basal sGC activity reduces p53 content and attenuates p53-dependent apoptosis in human ovarian cancer cells. Suppression of sGC activity with the specific inhibitor 1H-[1,2,4] oxadiazolo[ 4,3-a] quinoxalin-1-one (ODQ) lowered cGMP content, and increased p53 protein content and induced apoptosis in three ovarian cancer cell lines, effects which were attenuated by the cGMP analog 8-Br-cGMP and by Atrial Natriuretic Factor, an activator of particulate guanylyl cyclase, which circumvent the inhibition of sGC. ODQ prolonged p53 half-life, induced phosphorylation of p53 on Ser15, and upregulated the p53- dependent gene products p21, murine double minute-2, and the proapoptotic, p53- responsive gene product Bax. ODQ activated caspase-3, and ODQ-induced apoptosis was inhibited by overexpression of X-linked inhibitor of apoptosis Protein. Pretreatment with the specific p53 inhibitor pifithrin or downregulation of p53 using a specific small inhibitory RNA significantly attenuated ODQ-induced apoptosis. Moreover, ODQ-induced upregulation of p21 and Bax and ODQ-induced apoptosis were significantly reduced in a p53 mutant cell line relative to the wild-type parental cell line. Thus, the current study establishes that basal sGC/cGMP activity regulates p53 protein stability, content, and function, possibly by altering p53 phosphorylation and stabilization, and promotes cell survival in part through regulation of caspase-3 and p53.	Univ Ottawa, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Obstet & Gynecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Biol, Ottawa, ON, Canada; Ottawa Hosp, Hlth Res Inst, Hormones Growth & Dev Program, Ottawa, ON, Canada; Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Gerontol & Geriatr, Shatin, Hong Kong, Peoples R China	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Chinese University of Hong Kong; Chinese University of Hong Kong	Tsang, BK (corresponding author), Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Asselin E, 2001, CANCER RES, V61, P1862; Chan SL, 2003, MOL HUM REPROD, V9, P775, DOI 10.1093/molehr/gag094; Chen HW, 2001, FERTIL STERIL, V75, P1163, DOI 10.1016/S0015-0282(01)01780-0; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Estevez AG, 1998, PROG BRAIN RES, V118, P269; Falcone S, 2002, BIOCHEM J, V366, P165, DOI 10.1042/bj20020017; Fiscus RR, 2002, J CARDIAC SURG, V17, P336; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Fiscus RR, 2001, NEUROREPORT, V12, P185, DOI 10.1097/00001756-200102120-00003; Flamigni F, 2001, BIOCHEM PHARMACOL, V62, P319, DOI 10.1016/S0006-2952(01)00646-3; Fraser M, 2003, CANCER RES, V63, P7081; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Jadeski LC, 2003, INT J CANCER, V106, P496, DOI 10.1002/ijc.11268; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; LEVINE EL, 1995, RADIOTHER ONCOL, V37, P1, DOI 10.1016/0167-8140(95)01622-N; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUESLEY DM, 1987, BRIT J OBSTET GYNAEC, V94, P461, DOI 10.1111/j.1471-0528.1987.tb03126.x; LUESLEY DM, 1986, BRIT J OBSTET GYNAEC, V93, P380; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2; Panahian N, 2001, J NEUROCHEM, V76, P539, DOI 10.1046/j.1471-4159.2001.00023.x; Panahian N, 1999, J NEUROCHEM, V72, P1187; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REAP EA, 1995, J IMMUNOL, V154, P936; Sasaki H, 2000, CANCER RES, V60, P5659; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Sheets EE, 1997, ANN MED, V29, P121, DOI 10.3109/07853899709113697; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Suenobu N, 1999, ARTERIOSCL THROM VAS, V19, P140, DOI 10.1161/01.ATV.19.1.140; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Tejedo JR, 2004, ENDOCRINOLOGY, V145, P2319, DOI 10.1210/en.2003-1489; TURNER GA, 1982, BRIT J OBSTET GYNAEC, V89, P760, DOI 10.1111/j.1471-0528.1982.tb05105.x; TURNER GA, 1982, J CLIN PATHOL, V35, P800, DOI 10.1136/jcp.35.8.800; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	55	65	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2203	2212		10.1038/sj.onc.1209251	http://dx.doi.org/10.1038/sj.onc.1209251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288207				2022-12-25	WOS:000236581200007
J	Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS				Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS			The E5 protein of BPV-4 interacts with the heavy chain of MHC class I and irreversibly retains the MHC complex in the Golgi apparatus	ONCOGENE			English	Article						BPV-4; E5; MHC class I; heavy chain; interaction; immunoevasion	BOVINE PAPILLOMAVIRUS TYPE-4; FACTOR-BETA RECEPTOR; GROWTH-FACTOR; CELL-TRANSFORMATION; DOWN-REGULATION; INTERCELLULAR COMMUNICATION; IMMUNE EVASION; E8 PROTEIN; ONCOPROTEIN; EXPRESSION	BPV-4 E5 inhibits transcription of the bovine MHC class I heavy chain (HC) gene, increases degradation of HC and downregulates surface expression of MHC class I by retaining the complex in the Golgi apparatus (GA). Here we report that transcription inhibition can be alleviated by interferon treatment and the degradation of HC can be reversed by treatment with inhibitors of proteasomes and lysosomes. However, the inhibition of transport of MHC class I to the cell surface is irreversible. We show that E5 is capable of physically interacting with HC. Together with the inhibition of the vacuolar ATPase ( due to the interaction between E5 and 16k subunit c), the interaction between E5 and HC is likely to be responsible for retention of MHC class I in the GA. C-terminus deletion mutants of E5 are incapable of either downregulating surface MHC class I or interacting with HC, establishing that the C-terminus domain of E5 is important in the inhibition of MHC class I.	Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland; Inst Anim Hlth, Immunol & Pathol Div, Compton, Berks, England	University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Campo, MS (corresponding author), Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk		Ashrafi, G. Hossein/0000-0002-4516-5111				Agrawal S, 2000, J HEMATOTH STEM CELL, V9, P795, DOI 10.1089/152581600750062237; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Araibi EH, 2004, J GEN VIROL, V85, P2809, DOI 10.1099/vir.0.80128-0; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2005, INT J CANCER, V113, P276, DOI 10.1002/ijc.20558; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; BENSAID A, 1989, ANIM GENET, V20, P241; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Ellis SA, 1996, IMMUNOGENETICS, V43, P156, DOI 10.1007/BF00176677; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Gaddum RM, 1996, IMMUNOGENETICS, V43, P238, DOI 10.1007/BF00587307; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Grindlay GJ, 2005, VIRUS RES, V108, P29, DOI 10.1016/j.virusres.2004.07.010; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Marchetti B, 2002, ONCOGENE, V21, P7808, DOI 10.1038/sj.onc.1205885; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 2001, J BIOL CHEM, V276, P33861, DOI 10.1074/jbc.M100958200; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Pichowski JS, 1996, IMMUNOGENETICS, V43, P253, DOI 10.1007/BF00587314; Piguet V, 2005, CURR TOP MICROBIOL, V285, P199; Sawhney SMS, 1996, GENE, V171, P281, DOI 10.1016/0378-1119(96)00096-0; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Tirabassi RS, 2002, J VIROL, V76, P6832, DOI 10.1128/JVI.76.13.6832-6835.2002; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Williams M, 2005, J VIROL, V79, P632, DOI 10.1128/JVI.79.1.632-636.2005; Williams M, 2002, J VIROL, V76, P12173, DOI 10.1128/JVI.76.23.12173-12184.2002; Zago M, 2004, J GEN VIROL, V85, P3585, DOI 10.1099/vir.0.80313-0	46	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2254	2263		10.1038/sj.onc.1209245	http://dx.doi.org/10.1038/sj.onc.1209245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288210	Green Accepted			2022-12-25	WOS:000236581200012
J	Pettigrew, DM; Williams, DT; Kerrigan, D; Evans, DJ; Lea, SM; Bhella, D				Pettigrew, DM; Williams, DT; Kerrigan, D; Evans, DJ; Lea, SM; Bhella, D			Structural and functional insights into the interaction of echoviruses and decay-accelerating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR RECEPTOR; FACTOR CD55; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; COXSACKIEVIRUS A21; BINDING DOMAINS; FACTOR DAF; POLIOVIRUS; VIRUS; RESOLUTION	Many enteroviruses bind to the complement control protein decay-accelerating factor (DAF) to facilitate cell entry. We present here a structure for echovirus (EV) type 12 bound to DAF using cryo-negative stain transmission electron microscopy and three-dimensional image reconstruction to 16-angstrom resolution, which we interpreted using the atomic structures of EV11 and DAF. DAF binds to a hypervariable region of the capsid close to the 2-fold symmetry axes in an interaction that involves mostly the short consensus repeat 3 domain of DAF and the capsid protein VP2. A bulge in the density for the short consensus repeat 3 domain suggests that a loop at residues 174-180 rearranges to prevent steric collision between closely packed molecules at the 2-fold symmetry axes. Detailed analysis of receptor interactions between a variety of echo-viruses and DAF using surface plasmon resonance and comparison of this structure (and our previous work; Bhella, D., Goodfellow, I. G., Roversi, P., Pettigrew, D., Chaudhry, Y., Evans, D. J., and Lea, S. M. (2004) J. Biol. Chem. 279, 8325-8332) with reconstructions published for EV7 bound to DAF support major differences in receptor recognition among these viruses. However, comparison of the electron density for the two virus receptor complexes (rather than comparisons of the pseudo-atomic models derived from fitting the coordinates into these densities) suggests that the dramatic differences in interaction affinities/specificities may arise from relatively subtle structural differences rather than from large-scale repositioning of the receptor with respect to the virus surface.	Univ Glasgow, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G11 5JR, Lanark, Scotland; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	University of Glasgow; University of Glasgow; University of Oxford	Bhella, D (corresponding author), Univ Glasgow, MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	d.bhella@vir.gla.ac.uk	Evans, David/C-7553-2012; Bhella, David/J-8514-2012; Williams, David T/H-6750-2013; Lea, Susan M/B-7678-2009	Bhella, David/0000-0003-2096-8310; Williams, David T/0000-0002-7169-149X; Lea, Susan M/0000-0001-9287-8053; Evans, David J./0000-0002-1315-4258	MRC [MC_U130115834] Funding Source: UKRI; Medical Research Council [MC_U130115834] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; Bhella D, 2004, J BIOL CHEM, V279, P8325, DOI 10.1074/jbc.M311334200; Bubeck D, 2005, J VIROL, V79, P7745, DOI 10.1128/JVI.79.12.7745-7755.2005; Bubeck D, 2005, NAT STRUCT MOL BIOL, V12, P615, DOI 10.1038/nsmb955; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; FENWICK ML, 1962, VIROLOGY, V18, P212, DOI 10.1016/0042-6822(62)90007-7; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; GUTTMAN N, 1977, VIROLOGY, V82, P25, DOI 10.1016/0042-6822(77)90029-0; He YN, 2003, J VIROL, V77, P4827, DOI 10.1128/JVI.77.8.4827-4835.2003; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Karnauchow TM, 1996, J VIROL, V70, P5143, DOI 10.1128/JVI.70.8.5143-5152.1996; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEA S, 1995, STRUCTURE, V3, P571, DOI 10.1016/S0969-2126(01)00191-5; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Powell RM, 1999, J GEN VIROL, V80, P3145, DOI 10.1099/0022-1317-80-12-3145; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Powell RM, 1998, J GEN VIROL, V79, P1707, DOI 10.1099/0022-1317-79-7-1707; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; RUSSELL RJ, 2005, IN PRESS GLYCOCONJ J; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Stuart AD, 2002, J VIROL, V76, P7694, DOI 10.1128/JVI.76.15.7694-7704.2002; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604; Williams DT, 2004, J GEN VIROL, V85, P731, DOI 10.1099/vir.0.19674-0; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200; Xiao C, 2001, J VIROL, V75, P2444, DOI 10.1128/JVI.75.5.2444-2451.2001	41	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5169	5177		10.1074/jbc.M510362200	http://dx.doi.org/10.1074/jbc.M510362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16272562	hybrid			2022-12-25	WOS:000235426200071
J	Segatori, L; Murphy, L; Arredondo, S; Kadokura, H; Gilbert, H; Beckwith, J; Georgiou, G				Segatori, L; Murphy, L; Arredondo, S; Kadokura, H; Gilbert, H; Beckwith, J; Georgiou, G			Conserved role of the linker alpha-helix of the bacterial disulfide isomerase DsbC in the avoidance of misoxidation by DsbB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOND-FORMATION; CRYSTAL-STRUCTURE; THIOREDOXIN; OXIDOREDUCTASE; EXPRESSION; PROTEINS; PATHWAY; OXIDANT	In the bacterial periplasm the co-existence of a catalyst of disulfide bond formation (DsbA) that is maintained in an oxidized state and of a reduced enzyme that catalyzes the rearrangement of mispaired cysteine residues (DsbC) is important for the folding of proteins containing multiple disulfide bonds. The kinetic partitioning of the DsbA/DsbB and DsbC/DsbD pathways partly depends on the ability of DsbB to oxidize DsbA at rates > 1000 times greater than DsbC. We show that the resistance of DsbC to oxidation by DsbB is abolished by deletions of one or more amino acids within the alpha-helix that connects the N-terminal dimerization domain with the C-terminal thioredoxin domain. As a result, mutant DsbC carrying alpha-helix deletions could catalyze disulfide bond formation and complemented the phenotypes of dsbA cells. Examination of DsbC homologues from Haemophilus influenzae, Pseudomonas aeruginosa, Erwinia chrysanthemi, Yersinia pseudotuberculosis, Vibrio cholerae (30-70% sequence identity with the Escherichia coli enzyme) revealed that the mechanism responsible for avoiding oxidation by DsbB is a general property of DsbC family enzymes. In addition we found that deletions in the linker region reduced, but did not abolish, the ability of DsbC to assist the formation of active vtPA and phytase in vivo, in a DsbD-dependent manner, revealing that interactions between DsbD and DsbC are also conserved.	Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Harvard University; Harvard Medical School; Baylor College of Medicine	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.	gg@che.uteas.edu	Kadokura, Hiroshi/AAE-1645-2019	Kadokura, Hiroshi/0000-0001-7308-7141	NIGMS NIH HHS [GM55090] Funding Source: Medline; PHS HHS [41883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; Berkmen M, 2005, J BIOL CHEM, V280, P11387, DOI 10.1074/jbc.M411774200; Bessette PH, 2001, J BACTERIOL, V183, P980, DOI 10.1128/JB.183.3.980-988.2001; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; CALHOUN DH, 1985, J BACTERIOL, V161, P128, DOI 10.1128/JB.161.1.128-132.1985; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Debarbieux L, 2000, J BACTERIOL, V182, P723, DOI 10.1128/JB.182.3.723-727.2000; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haebel PW, 2002, EMBO J, V21, P4774, DOI 10.1093/emboj/cdf489; Heras B, 2004, P NATL ACAD SCI USA, V101, P8876, DOI 10.1073/pnas.0402769101; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTINEZGALISTEO E, 1995, COMP BIOCHEM PHYS B, V111, P17, DOI 10.1016/0305-0491(94)00235-M; Masip L, 2004, SCIENCE, V303, P1185, DOI 10.1126/science.1092612; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; Philipps B, 2002, J BIOL CHEM, V277, P43050, DOI 10.1074/jbc.M207638200; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Segatori L, 2004, P NATL ACAD SCI USA, V101, P10018, DOI 10.1073/pnas.0403003101; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zhang M, 2004, ACTA CRYSTALLOGR D, V60, P1512, DOI 10.1107/S0907444904014S93	32	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4911	4919		10.1074/jbc.M505453200	http://dx.doi.org/10.1074/jbc.M505453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16280324	hybrid			2022-12-25	WOS:000235426200042
J	Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F				Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F			AML1 deletion in adult mice causes splenomegaly and lymphomas	ONCOGENE			English	Article						AML1; conditional allele; hematopoiesis; splenomegaly; lymphoma	ACUTE MYELOID-LEUKEMIA; CORE-BINDING FACTOR; N-RAS ONCOGENE; MYELODYSPLASTIC SYNDROME; DEFINITIVE HEMATOPOIESIS; POINT MUTATIONS; RUNT DOMAIN; AML1/PEBP2-ALPHA-B GENE; ACQUIRED TRISOMY-21; EMBRYONIC LETHALITY	AML1 (RUNX1) encodes a DNA- binding subunit of the CBF transcription factor family and is required for the establishment of defi. nitive hematopoiesis. AML1 is one of the most frequently mutated genes associated with human acute leukemia, suggesting that genetic alterations of the gene contribute to leukemogenesis. Here, we report the analysis of mice e carrying conditional AML1 knockout alleles that were inactivated using the Cre/loxP system. AML1 was deleted in adult mice by inducing Cre activity to replicate AML1 deletions found in human MDS, familial platelet disorder and rare de novo human AML. At a latency of 2 months after induction, the thymus was reduced in size and frequently populated by immature double negative thymocytes, indicating defective T-lymphocyte maturation, resulting in lymphatic diseases with 50% penetrance, including atypical hyperplasia and thymic lymphoma. Metastatic lymphomas to the liver and the meninges were observed. Mice also developed splenomegaly with an expansion of the myeloid compartment. Increased Howell-Jolly body counts indicated splenic hypofunction. Thrombocytopenia occurred due to immaturity of mini-megakaryocytes in the bone marrow. Together with mild lymphocytopenia in the peripheral blood and increased fractions of immature cells in the bone marrow, AML1 deficient mice display features of a myelodysplastic syndrome, suggesting a preleukemic state.	Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; Tech Univ Dresden, Klin & Polklin Strahlentherapie & Radioonkol, Expt Zentrum, Med Fak Carl Gustav Carus, D-8027 Dresden, Germany	Max Planck Society; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Buchholz, F (corresponding author), Pfotenhauer Str 108, D-01037 Dresden, Germany.	buchholz@mpi-cbg.de	Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344				Bourgeois E, 2001, LEUKEMIA, V15, P950, DOI 10.1038/sj.leu.2402129; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Dunnick JK, 1997, TOXICOL PATHOL, V25, P533, DOI 10.1177/019262339702500601; Fredrickson TN, 2000, ATLAS MOUSE HEMATOPA; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HIRAI H, 1988, BLOOD, V71, P256; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; Morohashi K, 1999, BLOOD, V93, P1586; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Rhoades KL, 2000, BLOOD, V96, P2108; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schiering A, 1999, ATHEROSCLEROSIS, V144, P73, DOI 10.1016/S0021-9150(99)00045-3; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Steensma DP, 2005, EUR J HAEMATOL, V74, P47, DOI 10.1111/j.1600-0609.2004.00363.x; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	41	97	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					929	939		10.1038/sj.onc.1209136	http://dx.doi.org/10.1038/sj.onc.1209136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247465				2022-12-25	WOS:000235212700012
J	Breen, EP; Gouin, SG; Murphy, AF; Haines, LR; Jackson, AM; Pearson, TW; Murphy, PV; Richard, KP				Breen, EP; Gouin, SG; Murphy, AF; Haines, LR; Jackson, AM; Pearson, TW; Murphy, PV; Richard, KP			On the mechanism of mitochondrial uncoupling protein 1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; FATTY-ACID INTERACTION; UCP1; MEMBRANE; CONDUCTANCE; TRANSPORT	Native uncoupling protein 1 (UCP 1) was purified from rat mitochondria by hydroxyapatite chromatography and identified by peptide mass mapping and tandem mass spectrometry. Native and expressed UCP1 were reconstituted into liposomes, and proton flux through UCP 1 was shown to be fatty acid-dependent and GDP-sensitive. To investigate the mechanism of action of UCP 1, we determined whether hydrophilic modification of the omega-carbon of palmitate effected its transport function. We show that proton flux was greater through native UCP 1-containing proteoliposomes when facilitated by less hydrophilically modified palmitate (palmitate > omega-methoxypalmitate > omega-hydroxypalmitate with little or no proton flux due to glucose-O-omega-palmitate or undecanesulfonate). We show that non-proton-dependent charge transfer was greater when facilitated by less hydrophilically modified palmitate (palmitate/undecanesulfonate > omega-methoxypalmitate > omega-hydroxypalmitate, with no non-proton-dependent charge transfer flux due to glucose-O-omega-palmitate). We show that the GDP-inhibitable oxygen consumption rate in brown adipose tissue mitochondria was reversed by palmitate (as expected) but not by glucose-O-omega-palmitate. Our data are consistent with the model that UCP 1 flips long-chain fatty acid anions and contradict the "cofactor" model of UCP 1 function.	Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland; Univ Coll Dublin, Ctr Synth & Chem Biol, Dublin 4, Ireland; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	Trinity College Dublin; University College Dublin; University of Victoria	Richard, KP (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Coll Green, Dublin 2, Ireland.	rkporter@tcd.ie	Murphy, Paul V/F-7655-2010; Haines, Lee/K-9264-2017	Haines, Lee/0000-0001-8821-6479; Murphy, Paul/0000-0002-1529-6540; Porter, Richard/0000-0001-9854-5161; Jackson, Angela/0000-0002-0943-6287; gouin, sebastien/0000-0002-0985-1165				Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carroll AM, 2005, J BIOL CHEM, V280, P15534, DOI 10.1074/jbc.M413315200; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Cunningham O, 2003, BBA-BIOENERGETICS, V1604, P170, DOI 10.1016/S0005-2728(03)00057-4; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; Gouin SG, 2005, CARBOHYD RES, V340, P1547, DOI 10.1016/j.carres.2005.04.004; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1999, J BIOENERG BIOMEMBR, V31, P457, DOI 10.1023/A:1005496306893; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 1999, J BIOENERG BIOMEMBR, V31, P399, DOI 10.1023/A:1005436121005; NICHOLLS DG, 2004, BIOCHEM SOC T, V29, P751; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1986, BROWN ADIPOSE TISSUE, P86; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P	27	30	33	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2114	2119		10.1074/jbc.M511575200	http://dx.doi.org/10.1074/jbc.M511575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16291746	hybrid			2022-12-25	WOS:000234760400033
J	Oddo, S; Caccamo, A; Tran, L; Lambert, MP; Glabe, CG; Klein, WL; LaFerla, FM				Oddo, S; Caccamo, A; Tran, L; Lambert, MP; Glabe, CG; Klein, WL; LaFerla, FM			Temporal profile of amyloid-beta (A beta) oligomerization in an in vivo model of Alzheimer disease - A link between A beta and tau pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; TRANSGENIC MICE; PROTEIN; BRAIN; FIBRILLOGENESIS; ACCUMULATION; A-BETA(1-42); AGGREGATION; NEUROTOXINS; GENERATION	Accumulation of amyloid-beta(A beta) is one of the earliest molecular events in Alzheimer disease (AD), whereas tau pathology is thought to be a later downstream event. It is now well established that A beta exists as monomers, oligomers, and fibrils. To study the temporal profile of A beta oligomer formation in vivo and to determine their interaction with tau pathology, we used the 3xTg-AD mice, which develop a progressive accumulation of plaques and tangles and cognitive impairments. We show that SDS-resistant A beta oligomers accumulate in an age- dependent fashion, and we present evidence to show that oligomerization of A beta appears to first occur intraneuronally. Finally, we show that a single intrahippocampal injection of a specific oligomeric antibody is sufficient to clear A beta pathology, and more importantly, tau pathology. Therefore, A beta oligomers may play a role in the induction of tau pathology, making the interference of A beta oligomerization a valid therapeutic target.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Northwestern University	LaFerla, FM (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, 1109 Gillespie Neurosci Bldg, Irvine, CA 92697 USA.	laferla@uci.edu		Oddo, Salvatore/0000-0001-7304-7430	NATIONAL INSTITUTE ON AGING [R01AG018877, R37AG011385, R01AG022547, R01AG011385] Funding Source: NIH RePORTER; NIA NIH HHS [AG0212982, AG00538, AG 18877, AG 11385, AG 22547] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Chang L, 2003, J MOL NEUROSCI, V20, P305, DOI 10.1385/JMN:20:3:305; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2005, P NATL ACAD SCI USA, V102, P3046, DOI 10.1073/pnas.0408500102; ODDO S, 2006, IN PRESS AM J PATHOL; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Souillac PO, 2003, BIOCHEMISTRY-US, V42, P8094, DOI 10.1021/bi034652m; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tseng Bertrand P., 2004, Current Alzheimer Research, V1, P231, DOI 10.2174/1567205043332045; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	42	345	373	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1599	1604		10.1074/jbc.M507892200	http://dx.doi.org/10.1074/jbc.M507892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16282321	hybrid			2022-12-25	WOS:000234652000038
J	Noton, EA; Colnaghi, R; Tate, S; Starck, C; Carvalho, A; Ferrigno, PK; Wheatley, SP				Noton, EA; Colnaghi, R; Tate, S; Starck, C; Carvalho, A; Ferrigno, PK; Wheatley, SP			Molecular analysis of survivin isoforms - Evidence that alternatively spliced variants do not play a role in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; LOCALIZATION; INCENP; IDENTIFICATION; REVEALS; SPINDLE; BINDING	Survivin is a protein with proposed roles in cell division and apoptosis. Transcripts encoding splice variants of human survivin have been described and their expression correlated with cancer progression. As survivin forms homodimers in vitro, it has been suggested that these isoforms could interfere with wild type function by forming heterodimers. Here we show that survivin-2 beta and survivin-delta Ex3 can interact with wild type survivin but have reduced affinity for the partner protein of survivin, borealin, and thus do not localize with the chromosomal passenger complex in vivo. Furthermore, we demonstrate that overexpression of survivin-2 beta-green fluorescent protein (GFP) or survivin-delta Ex3-GFP does not impede cell cycle progression. We also report that wild type survivin, but not survivin-2 beta-GFP or survivin-delta Ex3-GFP, can rescue cell proliferation inhibited by small interfering RNA-mediated survivin depletion. These data suggest that, despite their ability to interact with wild type survivin, neither of these isoforms acts as its competitor during mitosis nor has an essential function.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Hutchison Med Res Council Res Ctr, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, San Diego, CA 92103 USA	University of Sussex; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Wheatley, SP (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	s.p.wheatley@sussex.ac.uk	Carvalho, Ana/J-4788-2013	Carvalho, Ana/0000-0002-2256-7134; Ko Ferrigno, Paul/0000-0002-5922-4100	Medical Research Council [MC_U105359876] Funding Source: Medline; MRC [MC_U105359876] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Caldas H, 2005, ONCOGENE, V24, P1994, DOI 10.1038/sj.onc.1208350; Caldas H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-11; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li F, 2005, BRIT J CANCER, V92, P212, DOI 10.1038/sj.bjc.6602340; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Meng H, 2004, CANCER LETT, V216, P147, DOI 10.1016/j.canlet.2003.12.020; Romano A, 2003, J CELL BIOL, V161, P229, DOI 10.1083/jcb.200207117; Song ZY, 2005, ONCOGENE, V24, P2723, DOI 10.1038/sj.onc.1208097; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	20	69	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1286	1295		10.1074/jbc.M508773200	http://dx.doi.org/10.1074/jbc.M508773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16291752	hybrid			2022-12-25	WOS:000234447200071
J	Robinson, F; Smith, CWJ				Robinson, F; Smith, CWJ			A splicing repressor domain in polypyrimidine tract-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE 3'-SPLICE-SITE SELECTION; EXON DEFINITION; RNA-BINDING; IN-VIVO; PTB; TRANSLATION; INHIBITION; MUTATIONS; NONSENSE; LIGAND	Polypyrimidine tract-binding protein (PTB) is an hnRNP with four RRM type domains. It plays roles as a repressive alternative splicing regulator of multilple target genes, as well as being involved in pre-mRNA3' end processing, mRNA localization, stability, and internal ribosome entry site-mediated translation. Here we have used a tethered function assay, in which a fusion protein of PTB and the bacteriophage MS2 coat protein is recruited to a splicing regulatory site by binding to an artificially inserted MS2 binding site. Deletion mutations of PTB in this system allowed us to identify RRM2 and the following inter-RRM linker region as the minimal region of PTB that can act as splicing repressor domain when recruited to RNA. Splicing repression by the minimal repressor domain remained cell type-specific and dependent upon other defined regulatory elements in the alpha-tropomyosin test minigene. Our results highlight the fact that splicing repression by PTB can be uncoupled from the mode by which it binds to RNA.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Smith, CWJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	cwjs1@cam.ac.uk						Amir-Ahmady B, 2005, RNA, V11, P699, DOI 10.1261/rna.2250405; Ashiya M, 1997, RNA, V3, P996; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; GATTOKONCZAK F, 1999, MOL CELL BIOL, V19, P251; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Gromak N, 2002, NUCLEIC ACIDS RES, V30, P3548, DOI 10.1093/nar/gkf480; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; Huttelmaier S, 2001, J CELL BIOL, V155, P775, DOI 10.1083/jcb.200105044; Izquierdo JM, 2005, MOL CELL, V19, P475, DOI 10.1016/j.molcel.2005.06.015; Kaminski A, 1995, RNA, V1, P924; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; LIN CH, 1995, RNA, V1, P234; Liu HY, 2002, RNA, V8, P137, DOI 10.1017/S1355838202015029; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Mitchell SA, 2005, GENE DEV, V19, P1556, DOI 10.1101/gad.339105; Oberstrass FC, 2005, SCIENCE, V309, P2054, DOI 10.1126/science.1114066; Oh YL, 1998, BIOCHEM J, V331, P169, DOI 10.1042/bj3310169; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perez I, 1997, RNA, V3, P764; Sharma S, 2005, MOL CELL, V19, P485, DOI 10.1016/j.molcel.2005.07.014; Shen HH, 2004, RNA, V10, P787, DOI 10.1261/rna.5229704; Simpson PJ, 2004, STRUCTURE, V12, P1631, DOI 10.1016/j.str.2004.07.008; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					800	806		10.1074/jbc.M510578200	http://dx.doi.org/10.1074/jbc.M510578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16282332	hybrid			2022-12-25	WOS:000234447200017
J	Sekine, M; Taya, C; Shitara, H; Kikkawa, Y; Akamatsu, N; Kotani, M; Miyazaki, M; Suzuki, A; Yonekawa, H				Sekine, M; Taya, C; Shitara, H; Kikkawa, Y; Akamatsu, N; Kotani, M; Miyazaki, M; Suzuki, A; Yonekawa, H			The cis-regulatory element Gsl5 is indispensable for proximal straight tubule cell-specific transcription of core 2 beta-1,6-N-acetylglucosaminyltransferase in the mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; GLCNAC TRANSFERASE; MOLECULAR-CLONING; EXPRESSION; GENE; REGION; OLIGOSACCHARIDES; IDENTIFICATION; RECOMBINATION; CHROMOSOME	Gsl5 regulates the expression of a glycolipid and glycoproteins that contain the Le(X) epitope in the mouse kidney through tissue-specific transcriptional regulation of the core 2 beta-1,6-N-acetylglucosaminyltransferase (core 2 GnT) gene. The core 2 GnT gene has six exons and produces three alternatively spliced transcripts. Gsl5 regulates only the expression of the kidney-type mRNA, which is transcribed from the most 5'-upstream exon. By introducing a 159-kb bacterial artificial chromosome (BAC) clone that carries the mouse core 2GnT gene and its 5'-upstream region into DBA/2 mice that carry a defective Gsl5 allele, we were able to rescue the deficient phenotype. The BAC clone was subsequently engineered to replace the core 2 GnT gene with the sequence of enhanced green fluorescent protein (EGFP) as a reporter by an inducible homologous recombination system in Escherichia coli. The transgenic mice derived from the modified BAC clone expressed EGFP in the kidney, which suggests that the candidate Gsl5 is in the 5'-upstream region of the core 2GnT gene. Sequence analysis of the 5'-upstream regions of the BAC clone and DBA/2 genomic DNA revealed a candidate sequence for Gsl5 at about 5.5 kb upstream of exon 1. This sequence consisted of eight repeats of two GT-rich units in the wildtype mice, whereas it consisted of only one pair of GT-rich units with a minor modification in the DBA/2 mice. Transgenic mice produced with the EGFP reporter gene construct that included this candidate sequence expressed EGFP exclusively in the proximal straight tubular cells of the kidney. These results indicated that this unique repeat is indeed the Gsl5, and it is a cis-regulatory element responsible for proximal straight tubule cell-specific transcriptional regulation.	RIKEN, Frontier Res Syst, Sphingolipid Express Lab, Wako, Saitama 3510198, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Clin Genet, Tokyo 1138613, Japan	RIKEN; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Suzuki, A (corresponding author), RIKEN, Frontier Res Syst, Sphingolipid Express Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	aksuzuki@riken.jp	Kikkawa, Yoshiaki/AAI-7229-2020	Kikkawa, Yoshiaki/0000-0001-8859-4998				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Charron M, 1999, MOL CELL BIOL, V19, P5823; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Falkenberg VR, 2003, GLYCOBIOLOGY, V13, P411, DOI 10.1093/glycob/cwg039; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hamamoto H, 2000, APPL ENVIRON MICROB, V66, P3421, DOI 10.1128/AEM.66.8.3421-3426.2000; Jockusch H, 2003, J HISTOCHEM CYTOCHEM, V51, P401, DOI 10.1177/002215540305100315; Kikuchi J, 2005, GLYCOBIOLOGY, V15, P271, DOI 10.1093/glycob/cwi005; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; ORFORD M, 2000, NUCLEIC ACIDS RES, V28, P84; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; Rubera I, 2004, J AM SOC NEPHROL, V15, P2050, DOI 10.1097/01.ASN.0000133023.89251.01; Sambrook J., 1989, MOL CLONING, pA1; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SEKINE M, 1994, J BIOL CHEM, V269, P31143; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; SEKINE M, 1989, J BIOCHEM-TOKYO, V105, P680, DOI 10.1093/oxfordjournals.jbchem.a122726; Sekine M, 2002, J BIOCHEM, V132, P387, DOI 10.1093/oxfordjournals.jbchem.a003234; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; Sekine M, 2001, EUR J BIOCHEM, V268, P1129, DOI 10.1046/j.1432-1327.2001.01980.x; Sepulveda AR, 1997, J BIOL CHEM, V272, P11959, DOI 10.1074/jbc.272.18.11959; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yoshida T, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013885.23734.CA; Yu YA, 2003, LUMINESCENCE, V18, P1, DOI 10.1002/bio.701; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200	33	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1008	1015		10.1074/jbc.M509307200	http://dx.doi.org/10.1074/jbc.M509307200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278214	hybrid			2022-12-25	WOS:000234447200041
J	Erwin, PA; Mitchell, DA; Sartoretto, J; Marletta, MA; Michel, T				Erwin, PA; Mitchell, DA; Sartoretto, J; Marletta, MA; Michel, T			Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; RECEPTOR; PALMITOYLATION; NITROSOTHIOLS; NITROSATION; INHIBITION; STABILITY; ENZYME; DOMAIN; SIGNAL	Endothelial nitric-oxide synthase (eNOS) undergoes a complex pattern of post-translational modifications that regulate its activity. We have recently reported that eNOS is constitutively S-nitrosylated in endothelial cells and that agonists promote eNOS denitrosylation concomitant with enzyme activation (Erwin, P. A., Lin, A. J., Golan, D. E., and Michel, T. (2005), J. Biol. Chem. 280, 19888 - 19894). In the present studies, we use mass spectrometry to confirm that the zinc-tetrathiolate cysteines of eNOS are S-nitrosylated. eNOS targeting to the plasma membrane is necessary for enzyme S-nitrosylation, and we report that translocation between cellular compartments is necessary for dynamic eNOS S-nitrosylation. We transfected cells with cDNA encoding wildtype eNOS, which is membrane-targeted, or with acylation-deficient mutant eNOS (Myr(-)), which is expressed solely in the cytosol. While wild-type eNOS is robustly S-nitrosylated, we found that S-nitrosylation of the Myr(-) eNOS mutant is nearly abolished. When we transfected cells with a fusion protein in which Myr(-) eNOS is ligated to the CD8-transmembrane domain (CD8-Myr(-)), we found that CD8-Myr(-) eNOS, which does not undergo dynamic subcellular translocation, is hypernitrosylated relative to wild-type eNOS. Furthermore, we found that when endothelial cells transfected with wild-type or CD8-Myr(-) eNOS are stimulated with eNOS agonist, only wild-type eNOS is denitrosylated; CD8-Myr(-) eNOSS-nitrosylation is unchanged. These findings indicate that subcellular targeting is a critical determinant of eNOS S-nitrosylation. Finally, we show that eNOS S-nitrosylation can be detected in intact arterial preparations from mouse and that eNOS S-nitrosylation is a dynamic agonist-modulated process in intact blood vessels. These studies suggest that receptor-regulated eNOSS-nitrosylation may represent an important determinant of NO-dependent signaling in the vascular wall.	Harvard Univ, Div Cardiovasc, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Phys Biosci, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Div Cardiovasc, Sch Med, Brigham & Womens Hosp, Thorn Bldg,1210A,75 Francis St, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu	Mitchell, Douglas/C-4400-2011; Mitchell, Doug/B-6349-2012	Mitchell, Doug/0000-0002-9564-0953; sartoretto, juliano/0000-0002-0355-5541	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48743, HL46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lancaster JR, 2004, AM J PHYSIOL-LUNG C, V287, pL465, DOI 10.1152/ajplung.00151.2004; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mitchell DA, 2005, NAT CHEM BIOL, V1, P154, DOI 10.1038/nchembio720; Mitchell DA, 2005, BIOCHEMISTRY-US, V44, P4636, DOI 10.1021/bi0474463; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAVICHANDRAN LV, 1995, AM J PHYSIOL-HEART C, V268, pH2216, DOI 10.1152/ajpheart.1995.268.6.H2216; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SLISLOVIC I, 2005, J BIOL CHEM, V283, P8733; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; Zhang YH, 2004, AM J PHYSIOL-LUNG C, V287, pL467, DOI 10.1152/ajplung.00350.2003	38	90	95	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					151	157		10.1074/jbc.M510421200	http://dx.doi.org/10.1074/jbc.M510421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16286475	hybrid			2022-12-25	WOS:000234307200022
J	Johnson, AA; Santos, W; Pais, GCG; Marchand, C; Amin, R; Burke, TR; Verdine, G; Pommier, Y				Johnson, AA; Santos, W; Pais, GCG; Marchand, C; Amin, R; Burke, TR; Verdine, G; Pommier, Y			Integration requires a specific interaction of the donor DNA terminal 5 '-cytosine with glutamine 148 of the HIV-1 integrase flexible loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-DIKETO ACIDS; ACTIVE-SITE; VIRAL-DNA; CATALYTIC DOMAIN; I INTEGRASE; CRYSTAL-STRUCTURE; STRAND TRANSFER; METAL-BINDING; CORE DOMAIN	Integration is essential for retroviral replication and gene therapy using retroviral vectors. Human immunodeficiency virus, type 1 (HIV-1), integrase specifically recognizes the terminal sequences of each long terminal repeat ( LTR) and cleaves the 3'-end terminal dinucleotide 5'-GT. The exposed 3'-hydroxyl is then positioned for nucleophilic attack and subsequent strand transfer into another DNAduplex (target or chromosomal DNA). We report that both the terminal cytosine at the protruding 5'-end of the long terminal repeats (5'-C) and the integrase residue Gln-148 are critical for strand transfer. Proximity of the 5'-C and Gln-148 was demonstrated by disulfide cross-linking. Cross- linking is inhibited by the inhibitor 5CITEP 1-( 5- chloroindol- 3- yl)- 3- hydroxy- 3-(2H-tetrazol-5- yl)- propenone. We propose that strand transfer requires a conformational change of the integrase-viral (donor) DNA-complex with formation of an H-bond between the N-3 of the 5'-C and the amine group of Gln-148. These findings have implications for the molecular mechanisms coupling 3'-processing and strand transfer as well as for the molecular pharmacology of integrase inhibitors.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Burke, Terrence R/N-2601-2014; Marchand, Christophe/D-8559-2016	Burke, Terrence/0000-0001-9925-8586; Santos, Webster/0000-0002-4731-8548	NATIONAL CANCER INSTITUTE [Z01BC007363, Z01BC007333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, F32GM067380] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [R01 GM044853, F32 GM067380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7; BUSHMAN FD, 1992, P NATL ACAD SCI USA, V89, P3458, DOI 10.1073/pnas.89.8.3458; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FERENTZ AE, 1991, J AM CHEM SOC, V113, P4000, DOI 10.1021/ja00010a057; Gao K, 2004, J VIROL, V78, P6715, DOI 10.1128/JVI.78.13.6715-6722.2004; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gerton JL, 1998, J VIROL, V72, P5046, DOI 10.1128/JVI.72.6.5046-5055.1998; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632; Johnson AA, 2004, CURR TOP MED CHEM, V4, P1059, DOI 10.2174/1568026043388394; Johnson AA, 2004, J BIOL CHEM, V279, P7947, DOI 10.1074/jbc.M311263200; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Lu R, 2005, J VIROL, V79, P2493, DOI 10.1128/JVI.79.4.2493-2505.2005; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600; Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200; Martin R.B., 1990, MET IONS BIOL SYST, P1; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Neamati N, 2002, EXPERT OPIN THER PAT, V12, P709, DOI 10.1517/13543776.12.5.709; Neamati N, 1997, MOL PHARMACOL, V52, P1041, DOI 10.1124/mol.52.6.1041; Pais GCG, 2002, J MED CHEM, V45, P3184, DOI 10.1021/jm020037p; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; Renisio JG, 2005, NUCLEIC ACIDS RES, V33, P1970, DOI 10.1093/nar/gki346; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Sotriffer CA, 2000, J MED CHEM, V43, P4109, DOI 10.1021/jm000194t; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; WOLFE SA, 1995, CHEM BIOL, V2, P213, DOI 10.1016/1074-5521(95)90271-6; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n	45	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					461	467		10.1074/jbc.M511348200	http://dx.doi.org/10.1074/jbc.M511348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16257967	hybrid, Green Submitted			2022-12-25	WOS:000234307200057
J	Qian, SB; Princiotta, MF; Bennink, JR; Yewdell, JW				Qian, SB; Princiotta, MF; Bennink, JR; Yewdell, JW			Characterization of rapidly degraded polypeptides in mammalian cells reveals a novel layer of nascent protein quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; NEWLY SYNTHESIZED PROTEINS; OXIDIZED PROTEINS; PROTEOLYTIC PATHWAY; 26S PROTEASOME; DEGRADATION; LOCALIZATION; CONJUGATION	Approximately 30% of polypeptides synthesized by mammalian cells are degraded with a half-life of < 10 min by proteasomes. These rapidly degraded polypeptides ( RDPs) constitute the bulk of proteasome substrates and are the principal source of viral and self- peptide ligands for major histocompatibility complex class I molecules. Here we provide evidence that similar to 75% of RDPs are degraded by the standard ubiquitin 26 S proteasome system and that their degradation is regulated by modulating Hsc70 activity in cells. Surprisingly, the remaining similar to 25% of RDPs are degraded without ubiquitylation by 20 S proteasomes independently of 19 S regulators and in a manner that is largely unaffected by modulating Hsc70 activity. This latter pathway is utilized for generating an antigenic peptide from viral-defective ribosomal products. The dichotomy in the behavior of RDPs points to a novel quality control level for nascent proteins that is independent of the well established Hsc70-ubiquitin 26 S proteasome pathway.	NIAID, Lab Viral Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Yewdell, JW (corresponding author), Rm 211,Bldg 4,4 Ctr Dr, Bethesda, MD 20892 USA.	jyewdell@nih.gov	yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000653, ZIAAI000653] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; COX JH, 1995, J IMMUNOL, V154, P511; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Inai Y, 2002, ARCH BIOCHEM BIOPHYS, V404, P279, DOI 10.1016/S0003-9861(02)00336-3; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; POOLE B, 1973, J BIOL CHEM, V248, P6221; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Qian SB, 2002, J BIOL CHEM, V277, P38818, DOI 10.1074/jbc.M205547200; Qian Shu-Bing, 2005, V301, P271; REITS EA, 2000, SCIENCE, V404, P774; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; WHEATLEY DN, 1982, J THEOR BIOL, V98, P283, DOI 10.1016/0022-5193(82)90265-X; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Yewdell JW, 2005, IMMUNOL REV, V207, P8; Yewdell JW, 2001, J CELL SCI, V114, P845	35	100	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					392	400		10.1074/jbc.M509126200	http://dx.doi.org/10.1074/jbc.M509126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263705	hybrid			2022-12-25	WOS:000234307200049
J	Rubio, MAT; Ragone, FL; Gaston, KW; Ibba, M; Alfonzo, JD				Rubio, MAT; Ragone, FL; Gaston, KW; Ibba, M; Alfonzo, JD			C to U editing stimulates A to I editing in the anticodon loop of a cytoplasmic threonyl tRNA in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; LEISHMANIA-TARENTOLAE; ENZYMATIC CONVERSION; ADENOSINE-DEAMINASE; UNWINDING ACTIVITY; INOSINE; CODON; MITOCHONDRIA; MARSUPIALS; EVOLUTION	Editing of tRNAs is widespread in nature and either changes the decoding properties or restores the folding of a tRNA. Unlike the phylogenetically disperse adenosine ( A) to inosine ( I) editing, cytosine ( C) to uridine ( U) editing has only been previously described in organellar tRNAs. We have shown that cytoplasmic tRNA(Thr)( AGU) undergoes two distinct editing events in the anticodon loop: C to U and A to I. In vivo, every inosine- containing tRNA(Thr) is also C to U edited at position 32. In vitro, C to U editing stimulates conversion of A to I at the wobble base. Although the in vivo and in vitro requirements differ, in both cases, the C to U change plays a key role in A to I editing. Due to an unusual abundance of A34- containing tRNAs, our results also suggest that the unedited and edited tRNAs are functional, each dedicated to decoding a specific threonine codon. C to U editing of cytoplasmic tRNA expands the editing repertoire in eukaryotic cells, and when coupled to A to I changes, leads to an interrelation between editing sites.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biohem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Alfonzo, JD (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	alfonzo.1@osu.edu						Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185; AGRIS PF, 1995, NUCL ACIDS S SER, V254; Alfonzo JD, 1999, EMBO J, V18, P7056, DOI 10.1093/emboj/18.24.7056; ANDACHI Y, 1987, P NATL ACAD SCI USA, V84, P7398, DOI 10.1073/pnas.84.21.7398; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Borner GV, 1996, EMBO J, V15, P5949, DOI 10.1002/j.1460-2075.1996.tb00981.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; ESBERG B, 1995, J BACTERIOL, V177, P1967, DOI 10.1128/jb.177.8.1967-1975.1995; Fahlman RP, 2004, MOL CELL, V16, P799, DOI 10.1016/j.molcel.2004.10.030; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Grosjean H, 2004, TRENDS BIOCHEM SCI, V29, P165, DOI 10.1016/j.tibs.2004.02.009; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Grosjean H, 1996, BIOCHIMIE, V78, P488, DOI 10.1016/0300-9084(96)84755-9; Grosjean Henri, 2004, Methods Mol Biol, V265, P357; JANKE A, 1994, GENETICS, V137, P243; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; Kapushoc ST, 2000, J BIOL CHEM, V275, P37907, DOI 10.1074/jbc.M007838200; MORL M, 1995, NUCLEIC ACIDS RES, V23, P3380, DOI 10.1093/nar/23.17.3380; NELSON JA, 1967, BIOCHIM BIOPHYS ACTA, V149, P590, DOI 10.1016/0005-2787(67)90188-8; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; Rubio MAT, 2005, TOP CURR GENET, V12, P71, DOI 10.1007/b106363; Senger B, 1997, BIOCHEMISTRY-US, V36, P8269, DOI 10.1021/bi970206l; Simpson L, 2000, P NATL ACAD SCI USA, V97, P6986, DOI 10.1073/pnas.97.13.6986; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENNYSON GE, 1989, NUCLEIC ACIDS RES, V17, P691, DOI 10.1093/nar/17.2.691; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; Wolf J, 2002, EMBO J, V21, P3841, DOI 10.1093/emboj/cdf362	34	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					115	120		10.1074/jbc.M510136200	http://dx.doi.org/10.1074/jbc.M510136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16269406	hybrid, Green Published			2022-12-25	WOS:000234307200017
J	Stahelin, RV; Hwang, JH; Kim, JH; Park, ZY; Johnson, KR; Obeid, LM; Cho, WH				Stahelin, RV; Hwang, JH; Kim, JH; Park, ZY; Johnson, KR; Obeid, LM; Cho, WH			The mechanism of membrane targeting of human sphingosine kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; SURFACE-PLASMON RESONANCE; CYTOSOLIC PHOSPHOLIPASE A(2); SPHINGOSINE KINASE; PROTEIN INTERACTIONS; FUNCTIONAL-CHARACTERIZATION; DIFFERENTIAL ROLES; MOLECULAR-CLONING; ACTIVATION; SPHINGOSINE-1-PHOSPHATE	Sphingosine 1-phosphate is a bioactive sphingolipid that regulates cell growth and suppresses programmed cell death. The biosynthesis of sphingosine 1-phosphate is catalyzed by sphingosine kinase (SK) but the mechanism by which the subcellular localization and activity of SK is regulated in response to various stimuli is not fully understood. To elucidate the origin and structural determinant of the specific subcellular localization of SK, we performed biophysical and cell studies of human SK1 (hSK1) and selected mutants. In vitro measurements showed that hSK1 selectively bound phosphatidylserine over other anionic phospholipids and strongly preferred the plasma membrane-mimicking membrane to other cellular membrane mimetics. Mutational analysis indicates that conserved Thr(54) and Asn(89) in the putative membrane-binding surface are essential for lipid selectivity and membrane targeting both in vitro and in the cell. Also, phosphorylation of Ser(225) enhances the membrane affinity and plasma membrane selectivity of hSK1, presumably by modulating the interaction of Thr(54) and Asn(89) with the membrane. Collectively, these studies suggest that the specific plasma membrane localization and activation of SK1 is mediated largely by specific lipid-protein interactions.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Med Univ S Carolina, Dept Med Biochem & Mol Biol, Charleston, SC 29425 USA; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina; Gwangju Institute of Science & Technology (GIST)	Cho, WH (corresponding author), M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863; obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598, R01GM062887, R01GM068849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM68849, GM062887, GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Edsall LC, 1997, J NEUROSCI, V17, P6952; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Lapko VN, 2002, BIOCHEMISTRY-US, V41, P8638, DOI 10.1021/bi015924t; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Olivera A, 1998, Methods Mol Biol, V105, P233; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	47	117	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43030	43038		10.1074/jbc.M507574200	http://dx.doi.org/10.1074/jbc.M507574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16243846	hybrid, Green Submitted			2022-12-25	WOS:000234200800068
J	Tammenkoski, M; Benini, S; Magretova, NN; Baykov, AA; Lahti, R				Tammenkoski, M; Benini, S; Magretova, NN; Baykov, AA; Lahti, R			An unusual, His-dependent family I pyrophosphatase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; METAL-ION; PROTEIN; SITE; THERMOSTABILITY; REQUIREMENT; MANGANESE	Soluble inorganic pyrophosphatases (PPases) comprise two evolutionarily unrelated families (I and II). These two families have different specificities for metal cofactors, which is thought to be because of the fact that family II PPases have three active site histidines, whereas family I PPases have none. Here, we report the structural and functional characterization of a unique family I PPase from Mycobacterium tuberculosis (mtPPase) that has two His residues (His(21) and His(86)) in the active site. The 1.3-angstrom three-dimensional structure of mtPPase shows that His86 directly interacts with bound sulfate, which mimics the product phosphate. Otherwise, mtPPase is structurally very similar to the well studied family I hexameric PPase from Escherichia coli, although mtPPase lacks the intersubunit metal binding site found in E. coli PPase. The cofactor specificity of mtPPase resembles that of E. coli PPase in that it has high activity in the presence of Mg2+, but it differs from the E. coli enzyme and family II PPases because it has much lower activity in the presence of Mn2+ or Zn2+. Replacements of His21 and His86 in mtPPase with the residues found in the corresponding positions of E. coli PPase had either no effect on the Mg2+- and Mn2+-supported reactions (H86K) or reduced Mg2+-supported activity (H21K). However, both replacements markedly increased the Zn2+-supported activity of mtPPase (up to 11-fold). In the double mutant, Zn2+ was a 2.5-fold better cofactor than Mg2+. These results show that the His residues in mtPPase are not essential for catalysis, although they determine cofactor specificity.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Phys Chem Biol, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ York, Heslington YO10 5YW, England	Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; University of York - UK	Lahti, R (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Phys Chem Biol, Moscow 119899, Russia.	reijo.lahti@utu.fi	Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021; Benini, Stefano/C-2598-2009	Benini, Stefano/0000-0001-6299-888X; Baykov, Alexander/0000-0002-2495-8200				Ahn S, 2001, J MOL BIOL, V313, P797, DOI 10.1006/jmbi.2001.5070; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Avaeva S, 1997, FEBS LETT, V410, P502, DOI 10.1016/S0014-5793(97)00650-9; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; BORSHCHIK I B, 1986, Biokhimiya, V51, P1484; CHERVENKA CH, 1972, METHODS ANAL ULTRACE, P23; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Efimova IS, 1999, J BIOL CHEM, V274, P3294, DOI 10.1074/jbc.274.6.3294; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabrichniy IP, 2004, BIOCHEMISTRY-US, V43, P14403, DOI 10.1021/bi0484973; Halonen P, 2005, BIOCHEMISTRY-US, V44, P4004, DOI 10.1021/bi047926u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; Kornberg A., 1962, HORIZONS BIOCH, P251; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leppanen VM, 1999, PROTEIN SCI, V8, P1218, DOI 10.1110/ps.8.6.1218; Liu BB, 2004, BIOPHYS J, V86, P420, DOI 10.1016/S0006-3495(04)74118-1; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Morris RJ, 2004, J SYNCHROTRON RADIAT, V11, P56, DOI 10.1107/S090904950302394X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parfenyev AN, 2001, J BIOL CHEM, V276, P24511, DOI 10.1074/jbc.M101829200; Pohjanjoki P, 1998, BIOCHEMISTRY-US, V37, P1754, DOI 10.1021/bi971771r; Salminen A, 1999, J BIOL CHEM, V274, P33898, DOI 10.1074/jbc.274.48.33898; Salminen T, 1996, PROTEIN SCI, V5, P1014; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; Sambrook J, 2001, MOL CLONING LAB MANU; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563; Zyryanov AB, 2004, BIOCHEMISTRY-US, V43, P14395, DOI 10.1021/bi048470j; Zyryanov AB, 2004, BIOCHEMISTRY-US, V43, P1065, DOI 10.1021/bi0357513	42	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41819	41826		10.1074/jbc.M509489200	http://dx.doi.org/10.1074/jbc.M509489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239227	hybrid			2022-12-25	WOS:000233992700007
J	Hill, DA; Peterson, CL; Imbalzano, AN				Hill, DA; Peterson, CL; Imbalzano, AN			Effects of HMGN1 on chromatin structure and SWI/SNF-mediated chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS HMG-14; MOBILITY GROUP PROTEIN-14; NUCLEOSOME CORE PARTICLE; HIGHER-ORDER STRUCTURE; LINKER HISTONE H1; NASCENT CHROMATIN; ACTIVATOR BINDING; GENE ACTIVATION; IN-VIVO; COMPLEX	The dynamic modulation of chromatin structure is determined by many factors, including enzymes that modify the core histone proteins, enzymes that remodel the structure of chromatin, and factors that bind to genomic DNA to affect its structure. Previous work indicates that the nucleosome binding family of high mobility group proteins (HMGN) facilitates the formation of a chromatin structure that is more conducive for transcription. SWI/SNF complexes are ATP-dependent chromatin remodeling enzymes that alter nucleosome structure to facilitate the binding of various regulatory proteins to chromatin. Here we examine the structural consequences of reconstituting chromatin with HMGN1 and the resulting effects on hSWI/SNF function. We demonstrate that HMGN1 decreases the sedimentation velocity of nucleosomal arrays in low ionic strength buffers but has little effect on the structure of more highly folded arrays. We further demonstrate that HMGN1 does not affect SWI/SNF-dependent chromatin remodeling on either mononucleosomes or nucleosomal arrays, indicating that SWI/SNF functions independently of HMGN1.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Hill, DA (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S3-209,55 Lake Ave N, Worcester, MA 01655 USA.	david.hill@umassmed.edu			NATIONAL CANCER INSTITUTE [P01CA082834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM049650] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA82834] Funding Source: Medline; NIGMS NIH HHS [R37 GM049650, R01 GM049650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; Birger Y, 2001, DNA CELL BIOL, V20, P257; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GONZALEZ PJ, 1990, J BIOL CHEM, V265, P8225; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LINDSEY GG, 1989, BIOCHIM BIOPHYS ACTA, V1009, P257, DOI 10.1016/0167-4781(89)90111-5; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma ZD, 2004, J BIOL CHEM, V279, P46326, DOI 10.1074/jbc.M405438200; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; MCGHEE JD, 1982, NUCLEIC ACIDS RES, V10, P2007, DOI 10.1093/nar/10.6.2007; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; PATON AE, 1983, J BIOL CHEM, V258, P3221; Ramachandran A, 2003, J BIOL CHEM, V278, P48590, DOI 10.1074/jbc.M309033200; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Schalch T, 2005, NATURE, V436, P138, DOI 10.1038/nature03686; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; Shirakawa H, 2000, J BIOL CHEM, V275, P37937, DOI 10.1074/jbc.M000989200; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Weigmann N, 1997, DNA CELL BIOL, V16, P1207, DOI 10.1089/dna.1997.16.1207; WEISBROD ST, 1982, NUCLEIC ACIDS RES, V10, P2017, DOI 10.1093/nar/10.6.2017	69	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41777	41783		10.1074/jbc.M509637200	http://dx.doi.org/10.1074/jbc.M509637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16253989	hybrid			2022-12-25	WOS:000233866900080
J	Dekanty, A; Sauane, M; Cadenas, B; Coluccio, F; Barrio, M; Casala, J; Paciencia, M; Rogers, F; Coso, OA; Piwien-Pilipuk, G; Rudland, PS; de Asua, LJ				Dekanty, A; Sauane, M; Cadenas, B; Coluccio, F; Barrio, M; Casala, J; Paciencia, M; Rogers, F; Coso, OA; Piwien-Pilipuk, G; Rudland, PS; de Asua, LJ			Leukemia inhibitory factor induces DNA synthesis in swiss mouse 3T3 cells independently of cyclin D-1 expression through a mechanism involving MEK/ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; PROTEIN-KINASE KINASE; ONCOSTATIN-M; MYELOID-LEUKEMIA; HUMAN INTERLEUKIN; DA-CELLS; RETINOBLASTOMA PROTEIN; REGULATE INITIATION; SIGNALING PATHWAYS; DEPENDENT KINASE	Leukemia inhibitory factor (LIF) and oncostatin M (OSM) induce DNA synthesis in Swiss 3T3 cells through common signaling mechanism(s), whereas other related cytokines such as interleukin-6 and ciliary neurotrophic factor do not cause this response. Induction of DNA replication by LIF or prostaglandin F-2 alpha (PGF(2 alpha)) occurs, in part, through different signaling events. LIF and OSM specifically trigger STAT1 cytoplasmic to nuclear translocation, whereas PGF(2 alpha) fails to do so. However, LIF and PGF(2 alpha) can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF(2 alpha) treatment. PGF(2 alpha) induces cyclin D expression and full phosphorylation of retinoblastoma protein. In contrast, LIF fails to promote increases in cyclin D mRNA/protein levels; consequently, LIF induces DNA synthesis without promoting full phosphorylation of retinoblastoma protein (Rb). However, both LIF and PGF(2 alpha) increase cyclin E expression. Furthermore, LIF mitogenic action does not involve protein kinase C (PKC) activation, because a PKC inhibitor does not block this effect. In contrast, PKC activity is required for PGF(2 alpha) mitogenic action. More importantly, the synergistic effect between LIF and PGF(2 alpha) to promote S phase entry is independent of PKC activation. These results show fundamental differences between LIF- and PGF(2 alpha)-dependent mechanism(s) that induce cellular entry into S phase. These findings are critical in understanding how LIF and other related cytokine-regulated events participate in normal cell cycle control and may also provide clues to unravel crucial processes underlying cancerous cell division.	Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Fisiol & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; Univ Liverpool, Sch Biol Sci, Mol Med Grp, Liverpool L69 3BX, Merseyside, England	Leloir Institute; University of Buenos Aires; University of Liverpool	de Asua, LJ (corresponding author), Fdn Inst Leloir, Av Patricias Argentinas 435,C1405BWE, RA-1405 Buenos Aires, DF, Argentina.	Ljimeneza@leloir.org.ar	Dekanty, Andres/C-3925-2018	Dekanty, Andres/0000-0002-0587-0449				Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dazai S, 2000, J CRANIOFAC SURG, V11, P513, DOI 10.1097/00001665-200011060-00002; DEALZAGA MG, 1994, FEBS LETT, V356, P21, DOI 10.1016/0014-5793(94)01223-7; DEASUA LJ, 1981, P NATL ACAD SCI-BIOL, V78, P1004; DEASUA LJ, 1992, FEBS LETT, V299, P235, DOI 10.1016/0014-5793(92)80122-W; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GASCAN H, 1990, J IMMUNOL, V144, P2592; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GROUNDS MD, 1991, PATHOL RES PRACT, V187, P1; GROUNDS MD, 1993, MOL CELL BIOL MUSCUL, P120; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Levy CS, 1997, BIOCHEM BIOPH RES CO, V236, P814, DOI 10.1006/bbrc.1997.7055; LEVY CS, 2003, EXP CELL RES, V282, P35; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; OTTO AM, 1982, P NATL ACAD SCI-BIOL, V79, P4992, DOI 10.1073/pnas.79.16.4992; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PINES J, 1997, ONCOGENES TUMOUR SUP, P189; PINES J, 1995, CELL CYCLE CONTROL, P144; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sauane M, 2004, BIOCHEM BIOPH RES CO, V313, P926, DOI 10.1016/j.bbrc.2003.11.182; Sauane M, 2000, BIOCHEM BIOPH RES CO, V270, P11, DOI 10.1006/bbrc.2000.2383; Savatier P, 1996, ONCOGENE, V12, P309; Schiemann WP, 1998, ONCOGENE, V16, P2671, DOI 10.1038/sj.onc.1201800; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YIN TG, 1994, J BIOL CHEM, V269, P3731; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	62	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6136	6143		10.1074/jbc.M505839200	http://dx.doi.org/10.1074/jbc.M505839200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16291739	Green Published, hybrid			2022-12-25	WOS:000236030800005
J	Galliano, MF; Toulza, E; Gallinaro, H; Jonca, N; Ishida-Yamamoto, A; Serre, G; Guerrin, M				Galliano, MF; Toulza, E; Gallinaro, H; Jonca, N; Ishida-Yamamoto, A; Serre, G; Guerrin, M			A novel protease inhibitor of the alpha(2)-macroglobulin family expressed in the human epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; GROWTH-FACTOR-BETA; PROTEINASE COMPLEX-FORMATION; MULTIPLE SEQUENCE ALIGNMENT; HUMAN SERINE PROTEINASE; ALPHA-MACROGLOBULIN; HUMAN ALPHA-2-MACROGLOBULIN; HUMAN KERATINOCYTES; NETHERTON-SYNDROME; RECEPTOR-BINDING	In the course of a large scale analysis of late- expressed genes in the human epidermis, we identified a new member of the alpha(2)- macroglobulin (alpha 2M) protease inhibitor family, A2ML1 ( for alpha(2)- macroglobulin-like 1). Like A2M and PZP, A2ML1 is located on chromosome 12p13.31. A2ML1 encodes a protein of 1454 amino acids, which fits the characteristics of alpha 2Ms: 1) strong conservation in amino acid sequence including most of cysteine positions with alpha 2M; 2) a putative central bait domain; 3) a typical thiol ester sequence. Northern blot and reverse transcriptase- PCR studies revealed a single 5- kb A2ML1 mRNA, mainly in the epidermis granular keratinocytes. A2ML1 is also transcribed in placenta, thymus, and testis. By Western blot analysis, alpha 2ML1 is detected as a monomeric, similar to 180- kDa protein in human epidermis. In vitro keratinocyte differentiation is associated with increased expression levels. By immunohistochemistry, alpha 2ML1 was detected within keratinosomes in the granular layer of the epidermis, and as a secreted product in the extracellular space between the uppermost granular layer and the cornified layer. Recombinant alpha 2ML1 displayed inhibitory activity toward chymotrypsin, papain, thermolysin, subtilisin A, and to a lesser extent, elastase but not trypsin. Incubation with chymotrypsin and the chymotrypsin- like kallikrein 7 protease indicated that alpha 2ML1 binds covalently to these proteases, a feature shared with other members of the family. Therefore, alpha 2ML1 is the first alpha 2M family member detected in the epidermis. It may play an important role during desquamation by inhibiting extracellular proteases.	Toulouse III Univ CHU, CNRS, INSERM, UMR 5165, F-31073 Toulouse, France; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Asahikawa Medical College	Guerrin, M (corresponding author), UDEAR, UMR 5165, 37 Allees J Guesde, F-31073 Toulouse, France.	mweber@udear.cnrs.fr	Jonca, Nathalie/AAX-3870-2020; Toulza, Eve/A-9919-2012	Jonca, Nathalie/0000-0003-3602-0102; Toulza, Eve/0000-0003-2049-2279				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; Birkenmeier G, 1998, ARCH DERMATOL RES, V290, P561, DOI 10.1007/s004030050352; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; FELDMAN SR, 1992, ACTA DERM-VENEREOL, V72, P331; Gallinaro H, 2004, J INVEST DERMATOL, V122, P730, DOI 10.1111/j.0022-202X.2004.22306.x; GANROT PO, 1966, CLIN CHIM ACTA, V14, P493, DOI 10.1016/0009-8981(66)90037-4; Gold LI, 2000, J PATHOL, V190, P579, DOI 10.1002/(SICI)1096-9896(200004)190:5<579::AID-PATH548>3.0.CO;2-I; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hashimoto K, 2000, J DERMATOL SCI, V24, pS46, DOI 10.1016/S0923-1811(00)00141-9; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Ishida-Yamamoto A, 2004, J INVEST DERMATOL, V122, P1137, DOI 10.1111/j.0022-202X.2004.22515.x; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; Krimbou L, 1998, J LIPID RES, V39, P2373; LAMARRE J, 1991, LAB INVEST, V65, P3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Mettenburg JM, 2002, J BIOL CHEM, V277, P13338, DOI 10.1074/jbc.M106792200; Neto ED, 1997, GENE, V186, P135, DOI 10.1016/S0378-1119(96)00699-3; OVERBERGH L, 1994, GENOMICS, V22, P530, DOI 10.1006/geno.1994.1426; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rozen S, 2000, Methods Mol Biol, V132, P365; RUBENSTEIN DS, 1993, BIOCHEM J, V290, P85, DOI 10.1042/bj2900085; SAITO A, 1985, J BIOL CHEM, V260, P775; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STARKEY PM, 1982, BIOCHEM J, V205, P91, DOI 10.1042/bj2050091; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toulza E, 2006, J INVEST DERMATOL, V126, P503, DOI 10.1038/sj.jid.5700033; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; Wu SM, 1998, J IMMUNOL, V161, P4356; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867	56	60	61	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5780	5789		10.1074/jbc.M508017200	http://dx.doi.org/10.1074/jbc.M508017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16298998	hybrid			2022-12-25	WOS:000235568900056
J	Sher, I; Zisman-Rozen, S; Eliahu, L; Whitelock, JM; Maas-Szabowski, N; Yamada, Y; Breitkreutz, D; Fusenig, NE; Arikawa-Hirasawa, E; Iozzo, RV; Bergman, R; Ron, D				Sher, I; Zisman-Rozen, S; Eliahu, L; Whitelock, JM; Maas-Szabowski, N; Yamada, Y; Breitkreutz, D; Fusenig, NE; Arikawa-Hirasawa, E; Iozzo, RV; Bergman, R; Ron, D			Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANE FORMATION; CULTURED HUMAN KERATINOCYTES; ORGANOTYPIC SKIN CULTURE; GENE-EXPRESSION; PROTEIN CORE; EXTRACELLULAR-MATRIX; BIOLOGICAL-ACTIVITY; RECEPTOR-BINDING	Heparin-binding growth factors are crucial for the formation of human epidermis, but little is known about the role of heparan sulfate proteoglycans in this process. Here we investigated the role of the heparan sulfate proteoglycan, perlecan, in the formation of human epidermis, by utilizing in vitro engineered human skin. By disrupting perlecan expression either in the dermis or the epidermis, we found that epidermally derived perlecan is essential for epidermal formation. Perlecan-deficient keratinocytes formed a strikingly thin and poorly organized epidermis because of premature apoptosis and failure to complete their stratification program. Exogenous perlecan fully restored epidermal formation. Perlecan deposition in the basement membrane zone correlated with formation of multilayered epidermis. Perlecan deficiency, however, had no effect on the lining and deposition of major basement membrane components as was evident by a continuous linear staining of laminin and collagen IV. Similarly, perlecan deficiency did not affect the distribution of beta 1 integrin. Addition of the perlecan ligand, fibroblast growth factor 7, protected perlecan-deficient keratinocytes from cell death and improved the thickness of the epidermis. Taken together, our results revealed novel roles for perlecan in epidermal formation. Perlecan regulates both the survival and terminal differentiation steps of keratinocytes. Our results suggested a model whereby perlecan regulates these processes via controlling the bioavailability of perlecan-binding soluble factors involved in epidermal morphogenesis.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; CSIRO, N Ryde, NSW 2113, Australia; DKFZ, Div Differentiat & Carcinogenesis, D-69120 Heidelberg, Germany; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA; Rambam Med Ctr, Dept Dermatol, IL-31096 Haifa, Israel; Rambam Med Ctr, Lab Mol Dermatol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Jefferson University; Jefferson University; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@tx.technion.ac.il	Iozzo, Renato/AAS-1980-2020	Whitelock, John/0000-0003-1835-802X; Iozzo, Renato/0000-0002-5908-5112				ALECK KA, 1987, AM J MED GENET, V27, P295, DOI 10.1002/ajmg.1320270208; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bernard FX, 2002, EXP DERMATOL, V11, P59, DOI 10.1034/j.1600-0625.2002.110107.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; Breitkreutz D, 2004, J CELL SCI, V117, P2611, DOI 10.1242/jcs.01127; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Fleischmajer R, 1998, ANN NY ACAD SCI, V857, P212, DOI 10.1111/j.1749-6632.1998.tb10118.x; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; FUSENIG NE, 1992, CULTURE EPITHELIAL C, P25; Gamady A, 2003, J CELL BIOCHEM, V89, P440, DOI 10.1002/jcb.10508; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Ghiselli G, 2001, BIOCHEM J, V359, P153, DOI 10.1042/0264-6021:3590153; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Harding KG, 2002, BRIT MED J, V324, P160, DOI 10.1136/bmj.324.7330.160; Henry MD, 2001, J CELL SCI, V114, P1137; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Jeschke MG, 2002, GENE THER, V9, P1065, DOI 10.1038/sj.gt.3301732; Jiang XN, 2003, J HISTOCHEM CYTOCHEM, V51, P1393, DOI 10.1177/002215540305101101; KLEIN G, 1995, MATRIX BIOL, V14, P457, DOI 10.1016/0945-053X(95)90003-9; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Maas-Szabowski N, 2000, J INVEST DERMATOL, V114, P1075, DOI 10.1046/j.1523-1747.2000.00987.x; Mathiak M, 1997, CANCER RES, V57, P2130; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; NEWBOLD RF, 1997, CIBA F SYMP, V211, P177; NOLTE CJM, 1993, ARCH DERMATOL RES, V285, P466, DOI 10.1007/BF00376819; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; O'Toole EA, 2001, CLIN EXP DERMATOL, V26, P525, DOI 10.1046/j.1365-2230.2001.00891.x; Olsen BR, 1999, J CELL BIOL, V147, P909, DOI 10.1083/jcb.147.5.909; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARENTEAU NL, 1991, J CELL BIOCHEM, V45, P245, DOI 10.1002/jcb.240450304; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; Raymond MA, 2004, FASEB J, V18, P705, DOI 10.1096/fj.03-0573fje; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RON D, 1993, J BIOL CHEM, V268, P2984; Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Turksen K, 1998, BIOCHEM CELL BIOL, V76, P889, DOI 10.1139/bcb-76-6-889; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; Yamane YO, 1996, J INVEST DERMATOL, V106, P531, DOI 10.1111/1523-1747.ep12343940; Zhou ZJ, 2004, CANCER RES, V64, P4699, DOI 10.1158/0008-5472.CAN-04-0810	76	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5178	5187		10.1074/jbc.M509500200	http://dx.doi.org/10.1074/jbc.M509500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16269412	hybrid			2022-12-25	WOS:000235426200072
J	Galetto, R; Giacomoni, VR; Veron, M; Negroni, M				Galetto, R; Giacomoni, VR; Veron, M; Negroni, M			Dissection of a circumscribed recombination hot spot in HIV-1 after a single infectious cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOCAPSID PROTEIN NCP7; TRANSCRIPTASE RNASE-H; MINUS-STRAND TRANSFER; REVERSE-TRANSCRIPTASE; IN-VIVO; RETROVIRAL RECOMBINATION; DESTABILIZING ACTIVITY; LENTIVIRAL VECTOR; INTERNAL REGIONS	Recombination is a major source of genetic heterogeneity in the human immunodeficiency virus type 1 (HIV-1) population. The main mechanism responsible for the generation of recombinant viruses is a process of copy choice between the two copies of genomic RNA during reverse transcription. We previously identified, after a single cycle of infection of cells in culture, a recombination hot spot within the gp120 gene, corresponding to the top portion of a RNA hairpin. Here, we determine that the hot region is circumscribed to 18 nucleotides located in the descending strand of the stem, following the sense of reverse transcription. Three factors appeared to be important, albeit at different extents, for the high rate of recombination observed in this region. The position of the hot sequence in the context of the RNA structure appears crucial, because changing its location within this structure triggered differences in recombination up to 20-fold. Another pivotal factor is the presence of a perfectly identical sequence between donor and acceptor RNA in the region of transfer, because single or double nucleotide differences in the hot spot were sufficient to almost completely abolish recombination in the region. Last, the primary structure of the hot region also influenced recombination, although with effects only in the 2-3-fold range. Altogether, these results provide the first molecular dissection of a hot spot in infected cells and indicate that several factors contribute to the generation of a site of preferential copy choice.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS, URA 2185, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Negroni, M (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS, URA 2185, 25 Rue Dr Roux, F-75724 Paris, France.	matteo@pasteur.fr		Negroni, Matteo/0000-0003-3005-8871				An Wenfeng, 2002, AIDS Reviews, V4, P195; Anderson JA, 1998, J VIROL, V72, P1195, DOI 10.1128/JVI.72.2.1195-1202.1998; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019; Beltz H, 2003, J MOL BIOL, V328, P95, DOI 10.1016/S0022-2836(03)00244-4; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Chen Y, 2005, J BIOL CHEM, V280, P14443, DOI 10.1074/jbc.M412190200; Chohan B, 2005, J VIROL, V79, P10701, DOI 10.1128/JVI.79.16.10701-10708.2005; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; DeStefano JJ, 2000, VIROLOGY, V276, P7, DOI 10.1006/viro.2000.0533; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Fang GW, 2004, AIDS, V18, P153, DOI 10.1097/00002030-200401230-00003; Galetto R, 2005, AIDS REV, V7, P92; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Mansky LM, 1997, TRENDS GENET, V13, P134, DOI 10.1016/S0168-9525(97)01062-7; McKinney SA, 2005, P NATL ACAD SCI USA, V102, P5715, DOI 10.1073/pnas.0409328102; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246; Ramos A, 2002, J VIROL, V76, P7444, DOI 10.1128/JVI.76.15.7444-7452.2002; Rhodes TD, 2005, J VIROL, V79, P1666, DOI 10.1128/JVI.79.3.1666-1677.2005; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; Telesnitsky A., 1997, P121; Vogt V. M., 1997, P27; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	54	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2711	2720		10.1074/jbc.M505457200	http://dx.doi.org/10.1074/jbc.M505457200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16291743	hybrid			2022-12-25	WOS:000234931800037
J	Anderson, PJ; Kokame, K; Sadler, JE				Anderson, PJ; Kokame, K; Sadler, JE			Zinc and calcium ions cooperatively modulate ADAMTS13 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; HUMAN VONWILLEBRAND-FACTOR; PLATELET GLYCOPROTEIN IB; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; MATRIX METALLOPROTEINASES; PARTIAL-PURIFICATION; HUMAN STROMELYSIN-1	ADAMTS13 is a metalloproteinase that cleaves von Willebrand factor (VWF) multimers. The metal ion dependence of ADAMTS13 activity was examined with multimeric VWF and a fluorescent peptide substrate based on Asp(1596)-Arg(1668) of the VWF A2 domain, FRETS-VWF73. ADAMTS13 activity in citrate-anticoagulated plasma was enhanced similar to 2-fold by zinc ions, similar to 3-fold by calcium ions, and similar to 6-fold by both ions, suggesting cooperative activation. Cleavage of VWF by recombinant ADAMTS13 was activated up to similar to 200-fold by zinc ions (K-D (app) similar to 0.5 similar to M), calcium ions (K-D (app) similar to 4.8 similar to M), and barium ions (K-D (app) similar to 1.7 mM). Barium ions stimulated ADAMTS13 activity in citrated plasma but not in citrate-free plasma. Therefore, the stimulation by barium ions of ADAMTS13 in citrated plasma appears to reflect the release of chelated calcium and zinc ions from complexes with citrate. At optimal zinc and calcium concentrations, ADAMTS13 cleaved VWF with a Km app of 3.7 +/- 1.4 mu/ml (similar to 15 nM for VWF subunits), which is comparable with the plasma VWF concentration of 5-10 mu g/ml. ADAMTS13 could cleave similar to 14% of VWF pretreated with guanidine HCl, suggesting that this substrate is heterogeneous in susceptibility to proteolysis. ADAMTS13 cleaved FRETS-VWF73 with a K-m (app) of 3.2 +/- 1.1 mu M, consistent with an 200-fold decrease in affinity compared with VWF. ADAMTS13 cleaved VWF and FRETS-VWF73 with roughly comparable catalytic efficiency of 55 mu M-1 min(-1) and 18 mu M-1 min(-1), respectively. The striking preference of ADAMTS13 for VWF suggests that substrate recognition depends on structural features or exosites on multimeric VWF that are missing from FRETS-VWF73.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Natl Cardiovasc Ctr, Inst Res, Osaka 5658565, Japan	Howard Hughes Medical Institute; Washington University (WUSTL); National Cerebral & Cardiovascular Center - Japan	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl.edu	Sadler, Evan/D-8556-2011	Kokame, Koichi/0000-0002-9654-6299; Sadler, J. Evan/0000-0001-5705-469X	NHLBI NIH HHS [HL72917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AULD DS, 1995, METHOD ENZYMOL, V248, P228; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cha J, 1998, J BIOL INORG CHEM, V3, P353, DOI 10.1007/s007750050244; Cha JH, 1996, BIOCHEMISTRY-US, V35, P15831, DOI 10.1021/bi962085f; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; De Cristofaro R, 2005, J BIOL CHEM, V280, P23295, DOI 10.1074/jbc.M501143200; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; HOJIMA Y, 1994, MATRIX BIOL, V14, P113, DOI 10.1016/0945-053X(94)90001-9; Inouye K, 1996, BIOCHEM J, V315, P133, DOI 10.1042/bj3150133; Jenkins PV, 1998, BLOOD, V91, P2032, DOI 10.1182/blood.V91.6.2032.2032_2032_2044; Kokame K, 2005, BRIT J HAEMATOL, V129, P93, DOI 10.1111/j.1365-2141.2005.05420.x; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Maldonado S, 2002, PROTEIN SCI, V11, P1260, DOI 10.1110/ps.2980102; Moake JL, 2004, SEMIN HEMATOL, V41, P4, DOI 10.1053/j.seminhematol.2003.10.003; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Rock G, 2000, HAEMATOLOGICA, V85, P410; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; Sadler J Evan, 2004, Hematology Am Soc Hematol Educ Program, P407; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SEGEL IH, 1975, ENZYME KINETICS BEHA, P39; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; STOCKER W, 1995, PROTEIN SCI, V4, P823; Sutherland JJ, 2004, J MOL MODEL, V10, P259, DOI 10.1007/s00894-004-0194-9; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tsai HM, 1997, BLOOD, V89, P1954, DOI 10.1182/blood.V89.6.1954; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; YAO M, 1995, BIOCHEMISTRY-US, V34, P3771, DOI 10.1021/bi00011a035; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2004, BLOOD, V103, P4043, DOI 10.1182/blood-2003-11-4035; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	56	70	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					850	857		10.1074/jbc.M504540200	http://dx.doi.org/10.1074/jbc.M504540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286459	hybrid			2022-12-25	WOS:000234447200023
J	Koike-Takeshita, A; Shimamura, T; Yokoyama, K; Yoshida, M; Taguchi, H				Koike-Takeshita, A; Shimamura, T; Yokoyama, K; Yoshida, M; Taguchi, H			Leu(309) plays a critical role in the encapsulation of substrate protein into the internal cavity of GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CRYSTAL-STRUCTURE; IN-VIVO; POLYPEPTIDE BINDING; COMPLEX; ATP; 2.8-ANGSTROM; MECHANISM; RESIDUES; RELEASE	In the crystal structure of the native GroEL center dot GroES center dot substrate protein complex from Thermus thermophilus, one GroEL subunit makes contact with two GroES subunits. One contact is through the H-I helices, and the other is through a novel GXXLE region. The side chain of Leu, in the GXXLE region, forms a hydrophobic cluster with residues of the H helix (Shimamura, T., Koike-Takeshita, A., Yokoyama, K., Masui, R., Murai, N., Yoshida, M., Taguchi, H., and Iwata, S. (2004) Structure (Camb.) 12, 1471-1480). Here, we investigated the functional role of Leu in the GXXLE region, using Escherichia coli GroEL. The results are as follows: (i) cross-linking between introduced cysteines confirmed that the GXXLE region in the E. coli GroEL center dot GroES complex is also in contact with GroES; (ii) when Leu was replaced by Lys (GroEL(L309K)) or other charged residues, chaperone activity was largely lost; (iii) the GroEL(L309K)center dot substrate complex failed to bind GroES to produce a stable GroEL(L309K)center dot GroES center dot substrate complex, whereas free GroEL( L309K) bound GroES normally; (iv) the GroEL(L309K)center dot GroES center dot substrate complex was stabilized with BeFx, but the substrate protein in the complex was readily digested by protease, indicating that it was not properly encapsulated into the internal cavity of the complex. Thus, conformational communication between the two GroES contact sites, the H helix and the GXXLE region (through Leu(309)), appears to play a critical role in encapsulation of the substrate.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Japan Sci & Technol Corp, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2778562, Japan; RIKEN, Harima Inst, Struct Biophys Lab, Mikaziku, Hyogo 6795148, Japan	Tokyo Institute of Technology; Imperial College London; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Yokoyama, Ken/AAJ-3582-2020; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Yokoyama, Ken/0000-0002-6813-1096; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; McLennan N, 1998, NATURE, V392, P139, DOI 10.1038/32317; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Shimamura T, 2004, STRUCTURE, V12, P1471, DOI 10.1016/j.str.2004.05.020; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; Taguchi H, 2004, J BIOL CHEM, V279, P45737, DOI 10.1074/jbc.M406795200; Taguchi H, 2001, NAT BIOTECHNOL, V19, P861, DOI 10.1038/nbt0901-861; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; VIITANEN PV, 1992, PROTEIN SCI, V1, P361; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	28	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					962	967		10.1074/jbc.M506298200	http://dx.doi.org/10.1074/jbc.M506298200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16239229	hybrid			2022-12-25	WOS:000234447200035
J	Youn, H; Kerby, RL; Conrad, M; Roberts, GP				Youn, H; Kerby, RL; Conrad, M; Roberts, GP			Study of highly constitutively active mutants suggests how cAMP activates cAMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-SUBUNIT; C-TERMINAL DOMAIN; ESCHERICHIA-COLI; TRANSCRIPTION ACTIVATION; CYCLIC-NUCLEOTIDE; DNA-BINDING; CONFORMATIONAL CHANGE; DEPENDENT PROMOTERS; HINGE REORIENTATION; ALLOSTERIC CHANGES	The cAMP receptor protein (CRP) of Escherichia coli undergoes a conformational change in response to cAMP binding that allows it to bind specific DNA sequences. Using an in vivo screening method following the simultaneous randomization of the codons at positions 127 and 128 (two C-helix residues of the protein interacting with cAMP), we have isolated a series of novel constitutively active CRP variants. Sequence analysis showed that this group of variants commonly possesses leucine or methionine at position 127 with a beta-branched amino acid at position 128. One specific variant, T127L/S128I CRP, showed extremely high cAMP-independent DNA binding affinity comparable with that of cAMP-bound wildtype CRP. Further biochemical analysis of this variant and others revealed that Leu(127) and Ile(128) have different roles in stabilizing the active conformation of CRP in the absence of cAMP. Leu(127) contributes to an improved leucine zipper at the dimer interface, leading to an altered intersubunit interaction in the C-helix region. In contrast, Ile(128) stabilizes the proper position of the beta 4/beta 5 loop by functionally communicating with Leu(61). By analogy, the results suggest two direct local effects of cAMP binding in the course of activating wild-type CRP: (i) C-helix repositioning through direct interaction with Thr(127) and Ser(128) and (ii) the concomitant reorientation of the beta 4/beta 5 loop. Finally, we also report that elevated expression of T127L/S128I CRP markedly perturbed E. coli growth even in the absence of cAMP, which suggests why comparably active variants have not been described previously.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, 420 Henry Mall, Madison, WI 53706 USA.	groberts@bact.wisc.edu			NIGMS NIH HHS [R01 GM053228, GM53228, R01 GM053228-11] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; Baichoo N, 1999, PROTEIN SCI, V8, P518; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Brown CT, 2004, P NATL ACAD SCI USA, V101, P2404, DOI 10.1073/pnas.0308628100; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHENG XD, 1994, J BIOL CHEM, V269, P30781; Chiang L W, 1993, PCR Methods Appl, V2, P210; Chu SY, 2001, J BIOL CHEM, V276, P11230, DOI 10.1074/jbc.M010428200; Dai JY, 2004, BIOCHEMISTRY-US, V43, P8901, DOI 10.1021/bi0499359; Eiting M, 2005, MOL MICROBIOL, V56, P433, DOI 10.1111/j.1365-2958.2005.04561.x; EMMER M, 1970, P NATL ACAD SCI USA, V66, P480, DOI 10.1073/pnas.66.2.480; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lawson CL, 2004, CURR OPIN STRUC BIOL, V14, P10, DOI 10.1016/j.sbi.2004.01.012; LEE BJ, 1991, BIOCHEMISTRY-US, V30, P9047, DOI 10.1021/bi00101a020; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Leu SF, 1999, BIOCHEMISTRY-US, V38, P6222, DOI 10.1021/bi982938z; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; Moore LJ, 2001, J BIOL CHEM, V276, P45744, DOI 10.1074/jbc.M106569200; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Polit A, 2003, J BIOL CHEM, V278, P43020, DOI 10.1074/jbc.M306398200; Rhodius VA, 2000, J MOL BIOL, V299, P311, DOI 10.1006/jmbi.2000.3737; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savery NJ, 1998, EMBO J, V17, P3439, DOI 10.1093/emboj/17.12.3439; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shi Y, 2000, BIOCHEMISTRY-US, V39, P7300, DOI 10.1021/bi000225m; Shi Y, 1999, J BIOL CHEM, V274, P6946, DOI 10.1074/jbc.274.11.6946; TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096; Tomlinson SR, 2003, BIOCHEMISTRY-US, V42, P3759, DOI 10.1021/bi027126o; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Youn H, 2004, J BIOL CHEM, V279, P45744, DOI 10.1074/jbc.M404336200; ZUBAY G, 1970, P NATL ACAD SCI USA, V66, P104, DOI 10.1073/pnas.66.1.104	46	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1119	1127		10.1074/jbc.M509421200	http://dx.doi.org/10.1074/jbc.M509421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16260780	Green Accepted, hybrid			2022-12-25	WOS:000234447200053
J	Herzog, B; Cardenas, J; Hall, RK; Villena, JA; Budge, PJ; Giguere, V; Granner, DK; Kralli, A				Herzog, B; Cardenas, J; Hall, RK; Villena, JA; Budge, PJ; Giguere, V; Granner, DK; Kralli, A			Estrogen-related receptor alpha is a repressor of phosphoenolpyruvate carboxykinase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; GAMMA COACTIVATOR-1-ALPHA PGC-1-ALPHA; ERR-ALPHA; HEPATIC GLUCONEOGENESIS; NUCLEAR RECEPTORS; ENERGY-METABOLISM; GLUCOCORTICOID-RECEPTOR; RESPONSE ELEMENT; BINDING PROTEIN; SKELETAL-MUSCLE	The orphan nuclear receptor estrogen- related receptor ( ERR) alpha is a downstream effector of the transcriptional coactivator PGC- 1 alpha in the regulation of genes important for mitochondrial oxidative capacity. PGC- 1 alpha is also a potent activator of the transcriptional program required for hepatic gluconeogenesis, and in particular of the key gluconeogenic enzyme phosphoenolpyruvate carboxykinase ( PEPCK). We report here that the regulatory sequences of the PEPCK gene harbor a functional ERR alpha binding site. However, in contrast to the co- stimulating effects ofERR alpha and PGC- 1 alpha on mitochondrial gene expression, ERR alpha acts as a transcriptional repressor of the PEPCK gene. Suppression of ERR alpha expression by small interfering RNA leads to reduced binding of ERR alpha to the endogenous PEPCK gene, and an increase in promoter occupancy by PGC- 1 alpha, suggesting that part of the ERR alpha function at this gene is to antagonize the action of PGC- 1 alpha. In agreement with the in vitro studies, animals that lack ERR alpha show increased expression of gluconeogenic genes, including PEPCK and glycerol kinase, but decreased expression of mitochondrial genes, such as ATP synthase subunit beta and cytochrome c- 1. Our findings suggest that ERR alpha has opposing effects on genes important for mitochondrial oxidative capacity and gluconeogenesis. The different functions of ERR alpha in the regulation of these pathways suggest that enhancing ERR alpha activity could have beneficial effects on glucose metabolism in diabetic subjects by two distinct mechanisms: increasing mitochondrial oxidative capacity in peripheral tissues and liver, and suppressing hepatic glucose production.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Imperial College London; Scripps Research Institute; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; McGill University	Kralli, A (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kralli@scripps.edu	Villena, Josep A/H-1597-2015; Budge, Philip/ABE-6458-2020	Villena, Josep A/0000-0002-2200-2985; Giguere, Vincent/0000-0001-9567-3694; Budge, Philip/0000-0002-0069-2372	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK064951, K01DK002887, R37DK035107, R01DK035107, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK20593, DK064951, DK02887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Busch BB, 2004, J MED CHEM, V47, P5593, DOI 10.1021/jm049334f; Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Glass CK, 2004, MOL CELL, V13, P459, DOI 10.1016/S1097-2765(04)00093-0; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Herzog B, 2004, MOL ENDOCRINOL, V18, P807, DOI 10.1210/mg.2003-0384; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; IMAI E, 1993, J BIOL CHEM, V268, P5353; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Opherk C, 2004, MOL ENDOCRINOL, V18, P1346, DOI 10.1210/me.2003-0283; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Waltner-Law M, 2003, J BIOL CHEM, V278, P10427, DOI 10.1074/jbc.M211846200; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yu DD, 2005, BIOORG MED CHEM LETT, V15, P1311, DOI 10.1016/j.bmcl.2005.01.025; Zuercher WJ, 2005, J MED CHEM, V48, P3107, DOI 10.1021/jm050161j	58	73	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					99	106		10.1074/jbc.M509276200	http://dx.doi.org/10.1074/jbc.M509276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267049	hybrid			2022-12-25	WOS:000234307200015
J	Maeda, M; Shintani, Y; Wheelock, MJ; Johnson, KR				Maeda, M; Shintani, Y; Wheelock, MJ; Johnson, KR			Src activation is not necessary for transforming growth factor (TGF)-beta- mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells - PP1 directly inhibits TGF-beta receptors I AND II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; E-CADHERIN; C-SRC; FAMILY KINASES; V-SRC; ACTIN CYTOSKELETON; CATALYTIC-ACTIVITY	Epithelial to mesenchymal transitions ( EMTs) are key events during embryonic development and cancer progression. It has been proposed that Src plays amajor role in some EMT models, as shown by the overexpression of viral Src ( v- Src) in epithelial cells. It is clear that Src family kinases can regulate the integrity of both adherens junctions and focal adhesions; however, their significance in EMT, especially in the physiological context, remains to be elucidated. Here we showed that Src is activated in transforming growth factor-beta 1 ( TGF- beta 1)- mediated EMT in mammary epithelial cells and that the Src family kinase inhibitor, PP1, prevents EMT. However, neither a more specific Src family kinase inhibitor, SU6656, nor a dominant- negative Src inhibited TGF- beta 1- mediated EMT, leading us to speculate that Src activation is not an essential component of TGF- beta 1- mediated EMT. Unexpectedly, PP1 prevented Smad2/ 3 activation by TGF- beta 1, whereas SU6656 did not. Most interestingly, an in vitro kinase assay showed that PP1 strongly inhibited the TGF- beta receptor type I, and to a lesser extent, the TGF- beta receptor type II. Taken together, our data indicated that PP1 interferes with TGF- beta 1- mediated EMT not by inhibiting Src family kinases but by inhibiting the Smad pathway via a direct inhibition of TGF- beta receptor kinase activity.	Univ Nebraska, Med Ctr, Dept Oral Biol, Coll Dent,Nebraska Med Ctr 987696, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Oral Biol, Coll Dent, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, Coll Dent,Nebraska Med Ctr 987696, 600 S 42nd St, Omaha, NE 68198 USA.	mwheelock@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; Carlomagno F, 2002, CANCER RES, V62, P1077; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fincham VJ, 1999, J CELL SCI, V112, P947; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hayashi K, 1999, J CELL SCI, V112, P1149; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jayanthi S, 2002, MOL PHARMACOL, V61, P1124, DOI 10.1124/mol.61.5.1124; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; Lee YI, 2004, BIOCHEM BIOPH RES CO, V316, P997, DOI 10.1016/j.bbrc.2004.02.150; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Park SS, 2004, ONCOGENE, V23, P6272, DOI 10.1038/sj.onc.1207856; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Piek E, 1999, J CELL SCI, V112, P4557; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Saika S, 2004, LAB INVEST, V84, P1259, DOI 10.1038/labinvest.3700151; Sato M, 2005, ARTERIOSCL THROM VAS, V25, P341, DOI 10.1161/01.ATV.0000152608.29351.8f; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03-07-0478; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Waltenberger J, 1999, CIRC RES, V85, P12; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	76	36	38	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					59	68		10.1074/jbc.M503304200	http://dx.doi.org/10.1074/jbc.M503304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16267045	hybrid			2022-12-25	WOS:000234307200011
J	Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H				Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H			Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability	ONCOGENE			English	Article						epigenetics; colorectal carcinoma; microsatellite instability; AXIN2; MLH1	ISLAND METHYLATOR PHENOTYPE; ADENOMATOUS-POLYPOSIS-COLI; BETA-CATENIN; MISMATCH REPAIR; HMLH1 PROMOTER; DNA METHYLATION; CELL-LINES; CANCER; MUTATIONS; HOMOLOG	Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs). However, little is yet known of genes that directly contribute to tumor formation in such cancers. To characterize MSI-dependent changes in gene expression, we have now compared transcriptomes between fresh CRC specimens positive or negative for MSI (n= 10 for each) with the use of high-density oligonucleotide microarrays harboring > 44 000 probe sets. Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed that the transcriptome of MSI+ CRCs is clearly distinct from that of MSI- CRCs. Such MSI-associated genes included that for AXIN2, an important component of the WNT signaling pathway. AXIN2 was silenced, apparen tly as a result of extensive methylation of its promoter region, specifi. cally in MSI+ CRC specimens. Forced expression of AXIN2, either by treatment with 50 '-azacytidine or by transfection with AXIN2 cDNA, resul ted in rapid cell death in an MSI+ CRC cell line. These data indicate that epigenetic silencing of AXIN2 is specifically associated with carcinogenesis in MSI+ CRCs.	Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Minami Kawachi, Tochigi 3290498, Japan; Mayo Clin & Mayo Grad Sch Med, Div Expt Pathol, Rochester, MN USA	Jichi Medical University; Jichi Medical University; Mayo Clinic	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Fujiwara, Shin-ichiro/ABH-2030-2020	Fujiwara, Shin-ichiro/0000-0002-4523-2994; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cunningham JM, 1998, CANCER RES, V58, P3455; Esteller M, 2000, CANCER RES, V60, P4366; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Ohki-Kaneda R, 2004, BIOCHEM BIOPH RES CO, V320, P1328, DOI 10.1016/j.bbrc.2004.06.090; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wu R, 2001, CANCER RES, V61, P8247; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Zysman M, 2002, CANCER RES, V62, P3663	34	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					139	146		10.1038/sj.onc.1209009	http://dx.doi.org/10.1038/sj.onc.1209009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247484				2022-12-25	WOS:000234406400015
J	Carter, RS; Pennington, KN; Arrate, P; Oltz, EM; Ballard, DW				Carter, RS; Pennington, KN; Arrate, P; Oltz, EM; Ballard, DW			Site-specific monoubiquitination of I kappa B kinase IKK beta regulates its phosphorylation and persistent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAX TRANSFORMING PROTEIN; SIGNALING PATHWAYS; NEMO/IKK-GAMMA; UBIQUITIN; COMPLEX; SUBUNIT; INNATE; JNK	Transcription factor NF-kappa B governs the expression of multiple genes involved in cell growth, immunity, and inflammation. Nuclear translocation of NF-kappa B is regulated from the cytoplasm by I kappa B kinase-beta (IKK beta), which earmarks inhibitors of NF-kappa B for polyubiquination and proteasome-mediated degradation. Activation of IKK beta is contingent upon signal-induced phosphorylation of its T loop at Ser-177/Ser-181. T loop phosphorylation also renders IKK beta a substrate for monoubiquitination in cells exposed to chronic activating cues, such as the Tax oncoprotein or sustained signaling through proinflammatory cytokine receptors. Here we provide evidence that the T loop-proximal residue Lys-163 in IKK beta serves as a major site for signal-induced monoubiquitination with significant regulatory potential. Conservative replacement of Lys-163 with Arg yielded a monoubiquitination-defective mutant of IKK beta that retains kinase activity in Tax-expressing cells but is impaired for activation mediated by chronic signaling from the type 1 receptor for tumor necrosis factor-alpha. Phosphopeptide mapping experiments revealed that the Lys-163 3 Arg mutation also interferes with proper in vivo but not in vitro phosphorylation of cytokine-responsive serine residues located in the distal C-terminal region of IKK beta. Taken together, these data indicate that chronic phosphorylation of IKK beta at Ser-177/Ser-181 leads to monoubiquitin attachment at nearby Lys-163, which in turn modulates the phosphorylation status of IKK beta at select C-terminal serines. This mechanism for post-translational cross-talk may play an important role in the control of IKK beta signaling during chronic inflammation.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N,1161 21st Ave, Nashville, TN 37232 USA.	dean.ballard@vanderbilt.edu			NCI NIH HHS [CA082556] Funding Source: Medline; NHLBI NIH HHS [HL069452, T32 HL069765, HL068744] Funding Source: Medline; NIAID NIH HHS [AI052379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082556] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069765, R01HL069452, P01HL068744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Burns KA, 2004, CURR BIOL, V14, pR1040, DOI 10.1016/j.cub.2004.11.040; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	32	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43272	43279		10.1074/jbc.M508656200	http://dx.doi.org/10.1074/jbc.M508656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16267042	hybrid			2022-12-25	WOS:000234200800094
J	Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A				Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A			Mitochondrial DNA determines androgen dependence in prostate cancer cell lines	ONCOGENE			English	Article						mitochondrial DNA; prostate cancer; hormone dependence	FACTOR-KAPPA-B; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; SACCHAROMYCES-CEREVISIAE; MULTIPLE DELETIONS; MUTATOR PHENOTYPE; POINT MUTATIONS; MTDNA; ACTIVATION; EXPRESSION; CARCINOMA	Prostate cancer progresses from an androgen-dependent to androgen-independent stage after androgen ablation therapy. Mitochondrial DNA plays a role in cell death and metastatic competence. Further, heteroplasmic large-deletion mitochondrial DNA is very common in prostate cancer. To investigate the role of mitochondrial DNA in androgen dependence of prostate cancers, we tested the changes of normal and deleted mitochondrial DNA in accordance with the progression of prostate cancer. We demonstrated that the androgen-independent cell line C4-2, established by inoculation of the androgen-dependent LNCaP cell line into castrated mice, has a greatly reduced amount of normal mitochondrial DNA and an accumulation of large-deletion DNA. Strikingly, the depletion of mitochondrial DNA from androgen-dependent LNCaP resulted in a loss of androgen dependence. Reconstitution of normal mitochondrial DNA to the mitochondrial DNA-depleted clone restored androgen dependence. These results indicate that mitochondrial DNA determines androgen dependence of prostate cancer cell lines. Further, mitochondrial DNA-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not. The accumulation of large deletion and depletion of mitochondrial DNA may thus play a role in the development of androgen independence, leading to progression of prostate cancers.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; VA Med Ctr, Houston, TX USA; Dept Neurol, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Kobe Univ, Sch Med, Dept Radiol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Clin Genet, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Urol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Int Ctr Med Res, Chuo Ku, Kobe, Hyogo 657, Japan; Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Baylor College of Medicine; Kobe University; Kobe University; Kobe University; Kobe University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Suzuki, Seigo/G-5378-2012	Shirakawa, Toshiro/0000-0003-3925-8730	NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100846-06, R01 CA100846-03, R01 CA100846-02, R01 CA100846-01A1, R01 CA100846-04, R01 CA100846, R01 CA100846-05, CA100846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen JJZ, 2002, CANCER RES, V62, P6470; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Higuchi M, 2002, ANTIOXID REDOX SIGN, V4, P945, DOI 10.1089/152308602762197489; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kawarada Y, 1998, J BIOCHEM-TOKYO, V123, P492; Kimura K, 2001, CANCER RES, V61, P5611; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Loeb LA, 2001, CANCER RES, V61, P3230; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Sommer A, 2003, CURR OPIN DRUG DISC, V6, P702; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	44	64	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1437	1445		10.1038/sj.onc.1209190	http://dx.doi.org/10.1038/sj.onc.1209190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278679	Green Accepted			2022-12-25	WOS:000235890400001
J	Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K				Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K			Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners	ONCOGENE			English	Article						cell cycle; E2F; target gene; p27(Kip1); growth stimulation	S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F; DNA-REPLICATION; CHECKPOINT RESPONSE; MICROARRAY ANALYSIS; TUMOR-SUPPRESSOR; IN-VIVO; EXPRESSION; APOPTOSIS; GROWTH	The transcription factor E2F mediates cell cycle-dependent expression of genes important for cell proliferation in response to growth stimulation. To further understand the role of E2F, we utilized a sensitive subtraction method to explore new E2F1 targets, which are expressed at low levels and might have been unrecognized in previous studies. We identified 33 new E2F1-inducible genes, including checkpoint genes Claspin and Rad51ap1, and four genes with unknown function required for cell cycle progression. Moreover, we found three groups of E2F1-inducible genes that were not induced by growth stimulation. At least, two groups of genes were directly induced by E2F1, indicating that E2F1 can regulate expression of genes not induced during the cell cycle. One included Neogenin, WASF1 and SGEF genes, which may have a role in differentiation or development. The other was the cyclin-dependent kinase inhibitor p27(Kip1), which was involved in suppression of inappropriate cell cycle progression induced by deregulated E2F. E2F1-responsive regions of these genes were located more upstream than those of typical E2F targets and did not have typical E2F sites. These results indicate that there are groups of E2F1 targets, which are regulated in a distinct manner from that of typical E2F targets.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 158, Japan; Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Lab Microbiol & Immunol, Bunkyo Ku, Tokyo, Japan; Tohoku Univ, Grad Sch Med, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis,Aoba Ku, Sendai, Miyagi 980, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Health Sciences - Japan; Tokyo Medical & Dental University (TMDU); Tohoku University; Kyushu University	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BALZER HJ, 1994, NUCLEIC ACIDS RES, V22, P2853, DOI 10.1093/nar/22.14.2853; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, GENE, V228, P93, DOI 10.1016/S0378-1119(99)00022-0; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Qi H, 2003, ENDOCRINOLOGY, V144, P1742, DOI 10.1210/en.2002-220984; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shieh SY, 2000, GENE DEV, V14, P289; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	34	50	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1786	1798		10.1038/sj.onc.1209210	http://dx.doi.org/10.1038/sj.onc.1209210			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288221				2022-12-25	WOS:000236013700010
J	Langenfeld, EM; Kong, Y; Langenfeld, J				Langenfeld, EM; Kong, Y; Langenfeld, J			Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5	ONCOGENE			English	Article						BMP-2; lung cancer; Smad-1/5; proliferation; Id-1; metastasis	CANCER CELL-PROLIFERATION; OSTEOBLAST-LIKE CELLS; GENE-EXPRESSION; TOOTH DEVELOPMENT; ACTIVITY GRADIENT; A549 CELLS; DIFFERENTIATION; TRANSFORMATION; INDUCTION; ID-1	Morphogenetic protein 2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in approximately 98% of lung carcinomas, however, its role in regulating tumor growth is poorly understood. We show that BMP-2 induces Id-1 expression in lung cancer cell lines through its activation of Smad-1/ 5, which is dependent on cell culture conditions. A549 cells in DMEM/5% FCS BMP-2 activated S mad-1/5 and caused a transient increase in proliferation. In serum-free medium, BMP-2 induced significantly less Smad-1/ 5 activation and Id-1 expression, and produced significant growth inhibition. The affect of BMP-2 on tumor growth in vivo was substantially more significant. Recombinant BMP-2 coinjected with A549 cells, into nude mice increased proliferation and produced an increase in Id-1 expression. Forced expression of BMP-2 in A549 cells significantly enhanced tumor growth in the lungs following intravenous injection but not of subcutaneous tumors. Tumors in the lung were found to have an activatedSmad 1/5 and expressed Id-1. Subcutaneous tumors expressed less activated Smad-1/5 and Id-1 than that of controls. Human lung carcinomas were also found to express an activated Smad-1/5 and Id-1. We provide evidence that BMP-2 promotes tumor growth. This paper highlights that cell culture experiments may not reveal the full biological affects of BMP-2, and its activity varies depending of the local environment.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Surg Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Langenfeld, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, MEB 536,1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.	langenje@umdnj.edu			NCI NIH HHS [K22 CA91919-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA091919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Clement JH, 2000, J CANCER RES CLIN, V126, P271, DOI 10.1007/s004320050342; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Han MJ, 2003, DEVELOPMENT, V130, P5123, DOI 10.1242/dev.00710; Ide H, 1997, CANCER RES, V57, P5022; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Kameda T, 1999, GENES CELLS, V4, P175, DOI 10.1046/j.1365-2443.1999.00250.x; LANGENFELD E, 2005, IN PRESS ANN THORACI; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lee TKW, 2003, CARCINOGENESIS, V24, P1729, DOI 10.1093/carcin/bgg145; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Myers DC, 2002, DEV BIOL, V243, P81, DOI 10.1006/dbio.2001.0523; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pizette S, 2001, DEVELOPMENT, V128, P4463; Pouliot F, 2003, CANCER RES, V63, P277; Rothhammer T, 2005, CANCER RES, V65, P448; Souza CJH, 2002, REPRODUCTION, V123, P363, DOI 10.1530/rep.0.1230363; Sutherland DJ, 2003, DEVELOPMENT, V130, P5705, DOI 10.1242/dev.00801; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tada A, 1998, ONCOL REP, V5, P1137; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tucker AS, 1998, SCIENCE, V282, P1136, DOI 10.1126/science.282.5391.1136; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Weaver M, 1999, DEVELOPMENT, V126, P4005; Willette RN, 1999, J VASC RES, V36, P120, DOI 10.1159/000025634; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7	48	107	123	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					685	692		10.1038/sj.onc.1209110	http://dx.doi.org/10.1038/sj.onc.1209110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247476				2022-12-25	WOS:000235068800004
J	Mitsuuchi, Y; Powell, DR; Gallo, JM				Mitsuuchi, Y; Powell, DR; Gallo, JM			Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor	ONCOGENE			English	Article						endothelial cells; drug delivery; adenovirus; VEGF; apoptosis	ANGIOGENESIS; MECHANISMS; VEHICLES; PROTEIN; CANCER; DELIVERY; RECEPTOR; SYSTEM; DRUGS; GENE	A second generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced drug delivery (AIDD), was developed using endothelial cells (ECs) that undergo apoptosis upon binding of vascular endothelial growth factor (VEGF) to a Flk-1: Fas fusion protein (FF). This new AIDD was redesigned using mouse brain derived ECs, bEnd3cells, and an adenovirus vector in order to enhance and control the expression of FF. The FF was tagged with a HA epitope (FFHA) and designed to be coexpressed with green. fluorescence protein (GFP) by the regulation of cytomegalovirus promoters in the adenovirus vector. bEnd3 ce lls showed favorable coexpression of FFHA and GFP consistent with the multiplicity of infection of the adenovirus. Immunofluorescence analysis demonstrated that FFHA was localized at the plasma membrane, whereas GFP was predominantly located in the cytoplasm of ECs. Cell death was induced by VEGF, but not by platelet derived growth factor or. fibroblast growth factor in a dose-dependent manner (range 2 - 20 ng/ml), and revealed caspase-dependent apoptotic profiles. The FFHA expressing bEnd3cells underwent apoptosis when cocultured with a glioma cell (SF188V +) line able to overexpress VEGF. The combined data indicated that the FFHA adenovirus system can induce apoptotic signaling in ECs in response to VEGF, and thus, is an instrumental modi. cation to the development of AIDD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Gallo, JM (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 333 Cottham Ave, Philadelphia, PA 19111 USA.	jmgallo@temple.edu			NATIONAL CANCER INSTITUTE [R01CA085577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 085577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carpenito C, 2002, INT J RADIAT ONCOL, V54, P1473, DOI 10.1016/S0360-3016(02)03921-4; CHINNAIYAN AM, 1995, CELL, V81, P512; Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Hallmann R, 2000, ENDOTHELIUM-J ENDOTH, V7, P135, DOI 10.3109/10623320009072208; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; ITOH N, 1993, J BIOL CHEM, V268, P10932; Le Ricousse-Roussanne S, 2004, CARDIOVASC RES, V62, P176, DOI 10.1016/j.cardiores.2004.01.017; Ma J, 1998, APOPTOSIS, V3, P195, DOI 10.1023/A:1009603023214; Ma JG, 1998, CLIN EXP METASTAS, V16, P559, DOI 10.1023/A:1006598419541; Ma JG, 2002, CANCER RES, V62, P1382; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pereboeva L, 2003, STEM CELLS, V21, P389, DOI 10.1634/stemcells.21-4-389; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Quinn TP, 2001, CANCER RES, V61, P8629; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200	22	4	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					954	958		10.1038/sj.onc.1209142	http://dx.doi.org/10.1038/sj.onc.1209142			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247462				2022-12-25	WOS:000235212700014
J	Niiya, F; Tatsumoto, T; Lee, KS; Miki, T				Niiya, F; Tatsumoto, T; Lee, KS; Miki, T			Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA	ONCOGENE			English	Article						protooncogene; Rho GTPase; exchange factor; polo-box domain; interacting protein	POLO-BOX DOMAIN; CELL-DIVISION; EXCHANGE FACTOR; FAMILY GTPASES; SPINDLE; EXPRESSION; PROTEINS; SRF	The epithelial cell transforming gene 2 (ECT2) proto-oncogene encodes a Rho exchange factor, and regulates cytokinesis. ECT2 is phosphorylated in G2/M phases, but its role in the biological function is not known. Here we show that two mitotic kinases, Cdk1 and polo-like kinase 1 (Plk1), phosphorylate ECT2 in vitro. We identified an in vitro Cdk1 phosphorylation site (T412) in ECT2, which comprises a consensus phosphospecific-binding module for the Plk1 polo-box domain (PBD). Endogenous ECT2 in mitotic cells strongly associated with Plk1 PBD, and this binding was inhibited by phosphatase treatment. A phosphorylation-deficient mutant form of ECT2, T412A, did not exhibit strong association with Plk1 PBD compared with wild-type (WT) ECT2. Moreover, ECT2 T412A, but not phosphomimic T412D, displayed a diminished accumulation of GTP-bound RhoA compared with WT ECT2, suggesting that phosphorylation of Thr-412 is critical for the catalytic activity of ECT2. Moreover, while overexpression of WT ECT2 or the T412D mutant caused cortical hyperactivity in U2OS cells during cell division, this activity was not observed in cells expressing ECT2 T412A. These results suggest that ECT2 is regulated by Cdk1 and Plk1 in concert.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bldg 37 Rm 2144,37 Convent Dr, Bethesda, MD 20892 USA.	toru@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Reiter NJ, 2002, BIOCHEMISTRY-US, V41, P1051, DOI 10.1021/bi011577b; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Seong YS, 2003, CANCER RES, V63, P7384; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	29	91	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					827	837		10.1038/sj.onc.1209124	http://dx.doi.org/10.1038/sj.onc.1209124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247472				2022-12-25	WOS:000235212700002
J	Jung, Y; Lippard, SJ				Jung, Y; Lippard, SJ			RNA polymerase II blockage by cisplatin-damaged DNA - Stability and polyubiquitylation of stalled polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE SUBUNIT; INDUCED UBIQUITINATION; TRANSCRIPTION INITIATION; PROTEIN; DEGRADATION; PHOSPHORYLATION; RECOGNITION; PATHWAY; CHAINS; DIMER	The consequences of human RNA polymerase II (pol II) arrest at the site of DNA damaged by cisplatin were studied in whole cells and cell extracts, with a particular focus on the stability of stalled pol II and its subsequent ubiquitylation. Site-specifically platinated DNA templates immobilized on a solid support were used to perform in vitro transcription in HeLa nuclear extracts. RNA elongation was completely blocked by a cisplatin intrastrand cross-link. The stalled polymerase was quite stable, remaining on the DNA template in nuclear extracts. The stability of pol II stalled at the site of cisplatin damage was also observed in live cells. A cell fractionation experiment using cisplatin-treated HeLa cells revealed an increased level of chromatin-associated pol II proteins following DNA damage. The stalled polymerase was transcriptionally active and capable of elongating the transcript following chemical removal of platinum from the template. Transcription inhibition by alpha-amanitin in vitro enhanced pol II ubiquitylation at ubiquitin residues Lys-6, Lys-48, and Lys-63. In live cells expressing epitopetagged ubiquitin mutants, several ubiquitin lysines also participated in pol II ubiquitylation following DNA damage. Cisplatin treatment triggered ubiquitylation-mediated pol II degradation in HeLa cells, which could be prevented by the proteasomal inhibitor MG132. Fractionation of pol II from cells co-treated with MG132 and cisplatin indicated that the undegraded ubiquitylated polymerase was mostly unbound or only loosely associated with chromatin. These data are consistent with a model in which only a fraction of pol II, ubiquitylated in response to cisplatin damage of DNA, dissociates from the sites of platination. This altered polymerase is rapidly destroyed by proteasomes.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Rm 18-498,77 Massachusetts Ave, Cambridge, MA 02139 USA.	lippard@mit.edu	Jung, Yongwon/G-7634-2012		NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Cline SD, 2003, NAT REV MOL CELL BIO, V4, P361, DOI 10.1038/nrm1101; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jung YW, 2003, J BIOL CHEM, V278, P52084, DOI 10.1074/jbc.M310120200; Kimura H, 1999, MOL CELL BIOL, V19, P5383; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lee KB, 2004, BIOCHEMISTRY-US, V43, P15223, DOI 10.1021/bi048719x; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tornaletti S, 2003, J BIOL CHEM, V278, P35791, DOI 10.1074/jbc.M305394200; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tremeau-Bravard A, 2004, J BIOL CHEM, V279, P7751, DOI 10.1074/jbc.M309853200; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; WARREN SL, 1992, J CELL SCI, V103, P381; Wei M, 2001, J BIOL CHEM, V276, P38774, DOI 10.1074/jbc.M106374200; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yang LY, 2003, ONCOL REP, V10, P1489; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	35	51	59	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1361	1370		10.1074/jbc.M509688200	http://dx.doi.org/10.1074/jbc.M509688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16275646	hybrid			2022-12-25	WOS:000234652000011
J	Rosenfeld, Y; Papo, N; Shai, Y				Rosenfeld, Y; Papo, N; Shai, Y			Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides - Peptide properties and plausible modes of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; LPS BINDING-PROTEIN; MACROPHAGE ACTIVATION; SEPTIC SHOCK; KAPPA-B; CD14; SEPSIS; ALPHA; CELLS; DIASTEREOMERS	Binding of lipopolysaccharide (LPS) to macrophages results in proinflammatory cytokine secretion. In extreme cases it leads to endotoxic shock. A few innate immunity antimicrobial peptides (AMPs) neutralize LPS activity. However, the underlying mechanism and properties of the peptides are not yet clear. Toward meeting this goal we investigated four AMPs and their fluorescently labeled analogs. These AMPs varied in composition, length, structure, and selectivity toward cells. The list included human LL-37 (37-mer), magainin (24- mer), a 15-mer amphipathic alpha-helix, and its D, L-amino acid structurally altered analog. The peptides were investigated for their ability to inhibit LPS-mediated cytokine release from RAW264.7 and bone marrow-derived primary macrophages, to bind LPS in solution, and when LPS is already bound to macrophages (fluorescence spectroscopy and confocal microscopy), to compete with LPS for its binding site on the CD14 receptor (flow cytometry) and affect LPS oligomerization. We conclude that a strong binding of a peptide to LPS aggregates accompanied by aggregate dissociation prevents LPS from binding to the carrier protein lipopolysaccharide-binding protein, or alternatively to its receptor, and hence inhibits cytokine secretion.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Papo, Niv/R-3946-2017					Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Andra J, 2004, ANTIMICROB AGENTS CH, V48, P1593, DOI 10.1128/AAC.48.5.1593-1599.2004; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; David SA, 2001, J MOL RECOGNIT, V14, P370, DOI 10.1002/jmr.549; David SA, 2000, J ENDOTOXIN RES, V6, P249, DOI 10.1177/09680519000060030601; de Haas CJC, 2000, J IMMUNOL METHODS, V242, P79, DOI 10.1016/S0022-1759(00)00207-6; Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; Giacometti A, 2002, ANTIMICROB AGENTS CH, V46, P2132, DOI 10.1128/AAC.46.7.2132-2136.2002; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hardaway RM, 2000, AM SURGEON, V66, P22; Hirata M, 1995, Prog Clin Biol Res, V392, P317; HOPKIN DAB, 1978, LANCET, V2, P211; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Manocha S, 2002, EXPERT OPIN INV DRUG, V11, P1795, DOI 10.1517/13543784.11.12.1795; Nagaoka I, 2002, CLIN DIAGN LAB IMMUN, V9, P972, DOI 10.1128/CDLI.9.5.972-982.2002; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Scott MG, 1999, INFECT IMMUN, V67, P2005; Stover AG, 2004, J BIOL CHEM, V279, P4440, DOI 10.1074/jbc.M310760200; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Wang PY, 1996, J INFLAMM, V47, P126; Woltmann A, 1998, LANGENBECK ARCH SURG, V383, P2, DOI 10.1007/s004230050085; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	44	309	320	4	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1636	1643		10.1074/jbc.M504327200	http://dx.doi.org/10.1074/jbc.M504327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293630	hybrid			2022-12-25	WOS:000234652000043
J	Park, S; Dong, XC; Fisher, TL; Dunn, S; Omer, AK; Weir, G; White, MF				Park, S; Dong, XC; Fisher, TL; Dunn, S; Omer, AK; Weir, G; White, MF			Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; INSULIN-RECEPTOR SUBSTRATE-2; PROTEIN-KINASE; DIABETES-MELLITUS; EXENATIDE EXENDIN-4; GLYCEMIC CONTROL; KNOCKOUT MICE; GLP-1 ACTION; TYPE-2; APOPTOSIS	The insulin receptor substrate 2 (Irs2) branch of the insulin/insulin-like growth factor-signaling cascade prevents diabetes in mice because it promotes beta cell replication, function, and survival, especially during metabolic stress. Because exendin-4 (Ex4), a long acting glucagon-like peptide 1 receptor agonist, has similar effects upon beta cells in rodents and humans, we investigated whether Irs2 signaling was required for Ex4 action in isolated beta cells and in Irs2(-/-) mice. Ex4 increased cAMP levels in human islets and Min6 cells, which promoted Irs2 expression and stimulated Akt phosphorylation. In wild type mice Ex4 administered continuously for 28 days increased beta cell mass 2-fold. By contrast, Ex4 failed to arrest the progressive beta cell loss in Irs2(-/-) mice, which culminated in fatal diabetes; however, Ex4 delayed the progression of diabetes by 3 weeks by promoting insulin secretion from the remaining islets. We conclude that some short term therapeutic effects of glucagon-like peptide 1 receptor agonists can be independent of Irs2, but its long term effects upon beta cell growth and survival are mediated by the Irs2 branch of the insulin/insulin-like growth factor signaling cascade.	Harvard Univ, Sch Med, Childrens Hosp Boston, Howard Hughes Med Inst,Div Endocrinol,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	White, MF (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Howard Hughes Med Inst,Div Endocrinol,Dept Med, Karp Res Bldg,300 Longwood Ave, Boston, MA 02115 USA.	morris.white@childrens.harvard.edu			NIDDK NIH HHS [DK55326] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055326] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Anini Y, 2003, DIABETES, V52, P252, DOI 10.2337/diabetes.52.2.252; Aziz A, 2003, J NUTR, V133, P2326, DOI 10.1093/jn/133.7.2326; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210/en.2004-0015; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2004, DIABETOLOGIA, V47, P806, DOI 10.1007/s00125-004-1379-6; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; Chang Q, 2002, CANCER RES, V62, P6035; Chepurny OG, 2002, ENDOCRINOLOGY, V143, P2303, DOI 10.1210/en.143.6.2303; De Leon DD, 2003, DIABETES, V52, P365, DOI 10.2337/diabetes.52.2.365; DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092; DEFRONZO RA, 2001, ENDOCRINOLOGY, P737; Doyle ME, 2001, RECENT PROG HORM RES, V56, P377, DOI 10.1210/rp.56.1.377; Drucker DJ, 2003, DIABETES CARE, V26, P2929, DOI 10.2337/diacare.26.10.2929; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Drucker DJ, 2002, GASTROENTEROLOGY, V122, P531, DOI 10.1053/gast.2002.31068; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Egan JM, 2002, J CLIN ENDOCR METAB, V87, P3768, DOI 10.1210/jc.87.8.3768; EGAN JM, 1994, ENDOCRINOLOGY, V135, P2070, DOI 10.1210/en.135.5.2070; Giannoukakis Nick, 2003, Curr Opin Investig Drugs, V4, P459; HABENER JF, 2004, DIABETES MELLITUS FU, P99; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Holst Jens Juul, 2004, Expert Opin Emerg Drugs, V9, P155, DOI 10.1517/14728214.9.1.155; Holst JJ, 2002, DIABETES-METAB RES, V18, P430, DOI 10.1002/dmrr.328; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Hui HX, 2003, ENDOCRINOLOGY, V144, P1444, DOI 10.1210/en.2002-220897; Idris I, 2002, BIOCHEM PHARMACOL, V63, P993, DOI 10.1016/S0006-2952(01)00924-8; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kjems LL, 2003, DIABETES, V52, P380, DOI 10.2337/diabetes.52.2.380; Kolterman OG, 2003, J CLIN ENDOCR METAB, V88, P3082, DOI 10.1210/jc.2002-021545; Kushner JA, 2004, DIABETES, V53, P61, DOI 10.2337/diabetes.53.1.61; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Meneilly GS, 2003, DIABETES CARE, V26, P2835, DOI 10.2337/diacare.26.10.2835; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Reaven G, 2003, J AM COLL CARDIOL, V41, P1044, DOI 10.1016/S0735-1097(02)02982-0; Redondo A, 2003, MOL CELL ENDOCRINOL, V204, P43, DOI 10.1016/S0303-7207(03)00146-1; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Silvestre RA, 2003, EUR J PHARMACOL, V469, P195, DOI 10.1016/S0014-2999(03)01692-3; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Suzuki R, 2003, J BIOL CHEM, V278, P43691, DOI 10.1074/jbc.M307004200; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; TRAN H, 2003, SCI STKE 2003; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	65	160	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1159	1168		10.1074/jbc.M508307200	http://dx.doi.org/10.1074/jbc.M508307200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272563	hybrid			2022-12-25	WOS:000234447200058
J	Wang, XZ; Khaleque, MA; Zhao, MJ; Zhong, R; Gaestel, M; Calderwood, SK				Wang, XZ; Khaleque, MA; Zhao, MJ; Zhong, R; Gaestel, M; Calderwood, SK			Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits transcriptional activity and promotes HSP90 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DNA-BINDING; FACTOR-I; SUBSTRATE-SPECIFICITY; GENE-TRANSCRIPTION; PROTEIN-KINASE; C-FOS	Heat shock transcription factor 1 (HSF1) monitors the structural integrity of intracellular proteins and its regulation is essential for the health and longevity of eukaryotic organisms. HSF1 also plays a role in the acute inflammatory response in the negative regulation of cytokine gene transcription. Here we show, for the first time, that HSF1 is regulated by the proinflammatory protein kinase MAPKAP kinase 2 (MK2). We have shown that MK2 directly phosphorylates HSF1 and inhibits activity by decreasing its ability to bind the heat shock elements (HSE) found in the promoters of target genes encoding the HSP molecular chaperones and cytokine genes. We show that activation of HSF1 to bind HSE in hsp promoters is inhibited through the phosphorylation of a specific residue, serine 121 by MK2. A potential mechanism for MK2- induced HSF1 inactivation is suggested by the findings that phosphorylation of serine 121 enhances HSF1 binding to HSP90, a major repressor of HSF1. Dephosphorylation of serine 121 in cells exposed to non-steroidal anti-inflammatory drugs leads to HSP90 dissociation from HSF1, which then forms active DNA binding trimers. These experiments indicate a novel mechanism for the regulation of HSF1 by proinflammatory signaling and may permit HSF1 to respond rapidly to extracellular events, permitting optimal physiological regulation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiat Oncol, Boston, MA 02215 USA; Harvard Univ, Dana Farber Canc Inst, Sch Med, Dept Radiat Oncol, Boston, MA 02215 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Hannover Medical School	Calderwood, SK (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiat Oncol, 21-27 Burlington Ave,Room 553B, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [P01CA031303, R01CA047407, R01CA050642] Funding Source: NIH RePORTER; NCI NIH HHS [CA47407, CA50642, CA31303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; BORNE RF, 1995, PRINCIPLES MED CHEM, P535; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Calderwood SK, 2005, METHODS, V35, P139, DOI 10.1016/j.ymeth.2004.08.004; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Citri A, 2004, CELL CYCLE, V3, P51; Cornford PA, 2000, CANCER RES, V60, P7099; Degousee N, 2001, J BIOL CHEM, V276, P43842, DOI 10.1074/jbc.M101516200; Gewert K, 1999, CELL SIGNAL, V11, P665, DOI 10.1016/S0898-6568(99)00014-5; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Gutsmann-Conrad A, 1998, EXP CELL RES, V241, P404, DOI 10.1006/excr.1998.4069; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; Heydari AR, 2000, EXP CELL RES, V256, P83, DOI 10.1006/excr.2000.4808; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Huang TM, 2002, J BIOL CHEM, V277, P37798, DOI 10.1074/jbc.M204786200; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Nollen EAA, 2002, J CELL SCI, V115, P2809; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Stevenson MA, 1999, J IMMUNOL, V163, P5608; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang XZ, 2000, CELL STRESS CHAPERON, V5, P432, DOI 10.1379/1466-1268(2000)005<0432:RRHADH>2.0.CO;2; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	59	95	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					782	791		10.1074/jbc.M505822200	http://dx.doi.org/10.1074/jbc.M505822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278218	hybrid			2022-12-25	WOS:000234447200015
J	Xu, J; Keeton, AB; Franklin, JL; Li, X; Venable, DY; Frank, SJ; Messina, JL				Xu, J; Keeton, AB; Franklin, JL; Li, X; Venable, DY; Frank, SJ; Messina, JL			Insulin enhances growth hormone induction of the MEK/ERK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEPENDENT DIABETES-MELLITUS; TYROSINE PHOSPHORYLATION; MESSENGER-RNA; EGF RECEPTOR; IN-VIVO; RAS; IDENTIFICATION; JAK2; RAF-1	Growth hormone (GH) plays an important role in growth and metabolism by signaling via at least three major pathways, including STATs, ERK1/2, and phosphatidylinositol 3-kinase/Akt. Physiological concentrations of insulin promote growth probably by modulating liver GH receptor (GHR) levels in vivo, but the possible effects of insulin on GH-induced post-GHR signaling have yet to be studied. We hypothesized that short-term insulin, similar to the fluctuations that occur following feeding, affects GH-induced post-GHR signaling. Our present studies suggest that, in rat H4IIE hepatoma cells, insulin ( 4 h or less) selectively enhanced GH-induced phosphorylation of MEK1/2 and ERK1/2, but not GH-induced activation of STAT5 and Akt. Although insulin pretreatment altered GH-induced formation of Shc center dot Grb2 center dot SOS complex, it did not significantly affect GH-induced activation of other signaling intermediates upstream of MEK/ERK, including JAK2, Ras, and Raf-1. Immunofluorescent staining indicated that insulin pretreatment facilitated GH-induced cell membrane translocation of MEK1/2. Insulin pretreatment also increased the amount of MEK association with its scaffolding protein, KSR. In summary, short-term insulin treatment of cultured, liver-derived cells selectively sensitized GH-induced MEK/ERK phosphorylation independent of JAK2, Ras, and Raf-1, but likely resulted from increased cell membrane translocation of MEK1/2. These findings suggest that insulin may be necessary for sensitization of cells to GH-induced ERK1/2 activation and provides a potential cellular mechanism by which insulin promotes growth.	Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Diabet Endocrinol & Metab, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Messina, JL (corresponding author), Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,Go19,1670 Univ Blvd, Birmingham, AL 35294 USA.	messina@path.uab.edu			NIDDK NIH HHS [DK62071, DK46395, DK40456] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R01DK062071, R29DK046395, R01DK040456, R01DK046395] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Cerasi E, 1970, Horm Metab Res, V2, P302; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Chiarelli F, 2004, EUR J ENDOCRINOL, V151, pU109, DOI 10.1530/eje.0.151U109; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Donaghue KC, 2003, ARCH DIS CHILD, V88, P151, DOI 10.1136/adc.88.2.151; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GUEST GM, 1953, DIABETES, V2, P415, DOI 10.2337/diab.2.5.415; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Ho Ken K. Y., 1996, Endocrine Journal, V43, pS57; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003-0418; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; Ji SN, 2002, J BIOL CHEM, V277, P28384, DOI 10.1074/jbc.M111723200; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; Lewis MD, 2004, J CLIN ENDOCR METAB, V89, P1068, DOI 10.1210/jc.2003-030652; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Maassen JA, 1997, FRONT HORM RES, V22, P201; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MENON RK, 1992, J CLIN ENDOCR METAB, V74, P934, DOI 10.1210/jc.74.4.934; MENON RK, 1994, J ENDOCRINOL, V142, P453, DOI 10.1677/joe.0.1420453; Metherell Louise A., 2001, American Journal of Human Genetics, V69, P641, DOI 10.1086/323266; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Nakae J, 1999, J PEDIATR ENDOCR MET, V12, P721; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Sadowski CL, 2001, J BIOL CHEM, V276, P20703, DOI 10.1074/jbc.M101014200; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; Styne DM, 2003, HORM RES, V60, P22, DOI 10.1159/000071222; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Verma AS, 2005, MOL PHARMACOL, V67, P891, DOI 10.1124/mol.104.005454; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Wei YR, 2004, J NUTR, V134, P545, DOI 10.1093/jn/134.3.545; WHITE MF, 1994, J BIOL CHEM, V269, P1; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	64	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					982	992		10.1074/jbc.M505484200	http://dx.doi.org/10.1074/jbc.M505484200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272159	hybrid			2022-12-25	WOS:000234447200038
J	Bates, S; Hughes, HB; Munro, CA; Thomas, WPH; MacCallum, DM; Bertram, G; Atrih, A; Ferguson, MAJ; Brown, AJP; Odds, FC; Gow, NAR				Bates, S; Hughes, HB; Munro, CA; Thomas, WPH; MacCallum, DM; Bertram, G; Atrih, A; Ferguson, MAJ; Brown, AJP; Odds, FC; Gow, NAR			Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SABOURAUD LIQUID-MEDIUM; BRANCHED SIDE-CHAINS; SEROTYPE-A STRAIN; SACCHAROMYCES-CEREVISIAE; LINKED GLYCOSYLATION; PICHIA-PASTORIS; PROTEIN MANNOSYLTRANSFERASE; ANTIFUNGAL RESISTANCE; ANTIGENIC FACTOR-4; GOLGI-APPARATUS	The outer layer of the Candida albicans cell wall is enriched in highly glycosylated mannoproteins that are the immediate point of contact with the host and strongly influence the host- fungal interaction. N- Glycans are the major form of mannoprotein modification and consist of a core structure, common to all eukaryotes, that is further elaborated in the Golgi to form the highly branched outer chain that is characteristic of fungi. In yeasts, outer chain branching is initiated by the action of the alpha 1,6- mannosyltransferase Och1p; therefore, we disrupted the C. albicans OCH1 homolog to determine the importance of outer chain N- glycans on the host- fungal interaction. Loss of CaOCH1 resulted in a temperature- sensitive growth defect and cellular aggregation. Outer chain elongation of N- glycans was absent in the null mutant, demonstrated by the lack of the alpha 1,6- linked polymannose backbone and the underglycosylation of N- acetylglucosaminidase. A null mutant lacking OCH1 was hypersensitive to a range of cell wall perturbing agents and had a constitutively activated cell wall integrity pathway. These mutants had near normal growth rates in vitro but were attenuated in virulence in a murine model of systemic infection. However, tissue burdens for the Caoch1 Delta null mutant were similar to control strains with normal N- glycosylation, suggesting the host- fungal interaction was altered such that high burdens were tolerated. This demonstrates the importance of N- glycan outer chain epitopes to the host- fungal interaction and virulence.	Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 4NH, Scotland	University of Aberdeen; University of Dundee	Gow, NAR (corresponding author), Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	n.gow@abdn.ac.uk	MacCallum, Donna M./D-7897-2011; Munro, Carol A/A-5175-2011; Brown, Alistair J.P./B-6627-2014; GOW, Neil/AAS-5323-2021; Ferguson, Michael A. J./F-7829-2010	MacCallum, Donna M./0000-0003-4833-0378; GOW, Neil/0000-0002-2776-5850; Ferguson, Michael A. J./0000-0003-1321-8714; Brown, Alistair JP/0000-0003-1406-4251; Bates, Steven/0000-0003-0489-5705; Munro, Carol/0000-0003-0761-1755	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Atrih A, 2005, J BIOL CHEM, V280, P865, DOI 10.1074/jbc.M411061200; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Bates S, 2005, J BIOL CHEM, V280, P23408, DOI 10.1074/jbc.M502162200; Brand A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Calderone RA., 2002, CANDIDA CANDIDIASIS; Calderone Richard, 2002, P67; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; CANNON RD, 1994, J BACTERIOL, V176, P2640, DOI 10.1128/JB.176.9.2640-2647.1994; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; CHUHAN N, 2002, CANDIDA CANDIDIASIS, P159; Csank C, 1998, INFECT IMMUN, V66, P2713, DOI 10.1128/IAI.66.6.2713-2721.1998; Cullen PJ, 2000, GENETICS, V155, P1005; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; de Groot PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FONZI WA, 1993, GENETICS, V134, P717; Fukazawa Y, 1997, J MED VET MYCOL, V35, P87; Herrero AB, 2002, EUKARYOT CELL, V1, P420, DOI 10.1128/EC.1.3.420-431.2002; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; Hobson RP, 2004, J BIOL CHEM, V279, P39628, DOI 10.1074/jbc.M405003200; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KOBAYASHI H, 1992, PHYTOCHEMISTRY, V31, P1147, DOI 10.1016/0031-9422(92)80250-I; Kobayashi H, 1997, FEMS MICROBIOL LETT, V152, P235, DOI 10.1111/j.1574-6968.1997.tb10433.x; Kumamoto CA, 2005, P NATL ACAD SCI USA, V102, P5576, DOI 10.1073/pnas.0407097102; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; LEHLE L, 1995, FEBS LETT, V370, P41, DOI 10.1016/0014-5793(95)00789-C; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; MOLLOY C, 1994, MICROBIOL-SGM, V140, P1543, DOI 10.1099/13500872-140-7-1543; Munro CA, 2005, J BIOL CHEM, V280, P1051, DOI 10.1074/jbc.M411413200; Munro CA, 2003, FUNGAL GENET BIOL, V40, P146, DOI 10.1016/S1087-1845(03)00083-5; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; Nakayama H, 2000, INFECT IMMUN, V68, P6712, DOI 10.1128/IAI.68.12.6712-6719.2000; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Nakayama K, 1997, FEBS LETT, V412, P547, DOI 10.1016/S0014-5793(97)00634-0; Navarro-Garcia F, 2005, MICROBIOL-SGM, V151, P2737, DOI 10.1099/mic.0.28038-0; Niimi K, 1997, ARCH MICROBIOL, V168, P464, DOI 10.1007/s002030050523; Nishikawa A, 2002, J BACTERIOL, V184, P29, DOI 10.1128/JB.184.1.29-42.2002; Odds FC., 1988, CANDIDA CANDIDOSIS; OKAWA Y, 1994, FEBS LETT, V345, P167, DOI 10.1016/0014-5793(94)00434-X; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906; Prill SKH, 2005, MOL MICROBIOL, V55, P546, DOI 10.1111/j.1365-2958.2004.04401.x; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; Romani Luigina, 2002, P223; Rouabhia M, 2005, INFECT IMMUN, V73, P4571, DOI 10.1128/IAI.73.8.4571-4580.2005; Sandven Per, 2000, Revista Iberoamericana de Micologia, V17, P73; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Thomson LM, 2000, J BIOL CHEM, V275, P18933, DOI 10.1074/jbc.M909699199; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; Vervecken W, 2004, APPL ENVIRON MICROB, V70, P2639, DOI 10.1128/AEM.70.5.2639-2646.2004; Wang YY, 1998, INFECT IMMUN, V66, P1384, DOI 10.1128/IAI.66.4.1384-1391.1998; Warit S, 2000, MOL MICROBIOL, V36, P1156, DOI 10.1046/j.1365-2958.2000.01944.x; Wilson RB, 2000, YEAST, V16, P65, DOI 10.1002/(SICI)1097-0061(20000115)16:1&lt;65::AID-YEA508&gt;3.0.CO;2-M; Yoko-o T, 2001, FEBS LETT, V489, P75, DOI 10.1016/S0014-5793(01)02082-8	66	178	184	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					90	98		10.1074/jbc.M510360200	http://dx.doi.org/10.1074/jbc.M510360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16263704	hybrid			2022-12-25	WOS:000234307200014
J	Ji, YS; Gu, JJ; Makhov, AM; Griffith, JD; Mitchell, BS				Ji, YS; Gu, JJ; Makhov, AM; Griffith, JD; Mitchell, BS			Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE ACTIVATION; IMP-DEHYDROGENASE; LIGAND-BINDING; IN-VITRO; 5'-MONOPHOSPHATE DEHYDROGENASE; LEUKEMIC-CELLS; MOFETIL; INHIBITION; IDENTIFICATION; PROLIFERATION	Inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme in the de novo synthesis of guanine nucleotides, is a major therapeutic target. A prototypic uncompetitive inhibitor of IMPDH, mycophenolic acid (MPA), is the active form of mycophenolate mofeteil (CellCept (R)), a widely used immunosuppressive drug. We have found that MPA interacts with intracellular IMPDH in vivo to alter its mobility on SDS-polyacrylamide gels. MPA also induces a striking conformational change in IMPDH protein in intact cells, resulting in the formation of annular aggregates of protein with concomitant inhibition of IMPDH activity. These aggregates are not associated with any known intracellular organelles and are reversible by incubating cells with guanosine, which repletes intracellular GTP, or with GTP gamma S. GTP also restores IMPDH activity. Treatment of highly purified IMPDH with MPA also results in the formation of large aggregates of protein, a process that is both prevented and reversed by the addition of GTP. Finally, GTP binds to IMPDH at physiologic concentrations, induces the formation of linear arrays of tetrameric protein, and prevents the aggregation of protein induced by MPA. We conclude that intracellular GTP acts as an antagonist to MPA by directly binding to IMPDH and reversing the conformational changes in the protein.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Immunol Microbiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mitchell, BS (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	mitchell@med.unc.edu			NATIONAL CANCER INSTITUTE [R01CA064192, P30CA016086] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA64192, CA16086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aherne A, 2004, HUM MOL GENET, V13, P641, DOI 10.1093/hmg/ddh061; ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0; Behrend M, 1996, CLIN NEPHROL, V45, P336; Colby TD, 1999, P NATL ACAD SCI USA, V96, P3531, DOI 10.1073/pnas.96.7.3531; DAYTON JS, 1994, J IMMUNOL, V152, P984; Franchetti P, 1999, CURR MED CHEM, V6, P599; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; Gu JJ, 1997, J BIOL CHEM, V272, P4458, DOI 10.1074/jbc.272.7.4458; Gu JJ, 2003, BLOOD, V101, P4958, DOI 10.1182/blood-2002-08-2547; Ishikawa H, 1999, CURR MED CHEM, V6, P575; Jonsson CA, 2001, CLIN EXP IMMUNOL, V124, P486, DOI 10.1046/j.1365-2249.2001.01545.x; Kaur R, 2005, AIDS RES HUM RETROV, V21, P116, DOI 10.1089/aid.2005.21.116; Kerr KM, 1997, BIOCHEMISTRY-US, V36, P13365, DOI 10.1021/bi9714161; Kohler GA, 2005, J BIOL CHEM, V280, P11295, DOI 10.1074/jbc.M409847200; Li W, 1998, LIFE SCI, V63, P1975, DOI 10.1016/S0024-3205(98)00475-5; McLean JE, 2004, BIOCHEM J, V379, P243, DOI 10.1042/BJ20031585; McPhillips CC, 2004, P NATL ACAD SCI USA, V101, P12171, DOI 10.1073/pnas.0403341101; Mehling A, 2000, J IMMUNOL, V165, P2374, DOI 10.4049/jimmunol.165.5.2374; Messina E, 2004, NUCLEOS NUCLEOT NUCL, V23, P1545, DOI 10.1081/NCN-200027770; NAGAI M, 1992, CANCER RES, V52, P258; Nimmesgern E, 1996, J BIOL CHEM, V271, P19421, DOI 10.1074/jbc.271.32.19421; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Pankiewicz KW, 2004, CURR MED CHEM, V11, P887, DOI 10.2174/0929867043455648; Picard N, 2005, DRUG METAB DISPOS, V33, P139, DOI 10.1124/dmd.104.001651; Picardi A, 2004, CURR PHARM DESIGN, V10, P2081, DOI 10.2174/1381612043384330; Robertson CM, 2004, ANTIVIR RES, V64, P55, DOI 10.1016/j.antiviral.2004.05.004; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Srinivas TR, 2003, EXPERT OPIN PHARMACO, V4, P2325, DOI 10.1517/14656566.4.12.2325; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; Wright DG, 2004, LEUKEMIA RES, V28, P1137, DOI 10.1016/j.leukres.2004.03.004; Zhou SF, 2003, VIROLOGY, V310, P333, DOI 10.1016/S0042-6822(03)00152-1; Zimmermann A, 1996, ADV ENZYME REGUL, V36, P75, DOI 10.1016/0065-2571(95)00012-7; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	35	83	87	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					206	212		10.1074/jbc.M507056200	http://dx.doi.org/10.1074/jbc.M507056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16243838	hybrid, Green Published			2022-12-25	WOS:000234307200028
J	Park, E; Han, J; Son, GH; Lee, MS; Chung, S; Park, SH; Park, K; Lee, KH; Choi, S; Seong, JY; Kim, K				Park, E; Han, J; Son, GH; Lee, MS; Chung, S; Park, SH; Park, K; Lee, KH; Choi, S; Seong, JY; Kim, K			Cooperative actions of Tra2 alpha with 9G8 and SRp30c in the RNA splicing of the gonadotropin-releasing hormone gene transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MOTOR-NEURON SMN; SR-PROTEINS; 1ST INTRON; POLYPYRIMIDINE TRACT; REGULATORY ELEMENTS; ENHANCER FUNCTION; EXON-7 INCLUSION; FACTOR U2AF(35); RICH DOMAINS	In earlier studies, we demonstrated that excision of the first intron ( intron A) from the gonadotropin-releasing hormone ( GnRH) transcript is highly cell type- and developmental stage-specific. The removal of GnRH intron A requires exonic splicing enhancers on exons 3 and 4 (ESE3 and ESE4, respectively). Tra2 alpha, a serine/arginine- rich (SR)- like protein, specifically binds to ESE4, although it requires additional nuclear co-factors for efficient removal of this intron. In the present study, we demonstrate the cooperative action of multiple SR proteins in the regulation of GnRH pre-mRNA splicing. SRp30c specifically binds to both ESE3 and ESE4, whereas 9G8 binds to an element in exon 3 and strongly enhances the excision of GnRH intron A in the presence of minimal amount of other nuclear components. Interestingly, Tra2 alpha can interact with either 9G8 or SRp30c, whereas no interaction between 9G8 and SRp30c is observed. Tra2 alpha has an additive effect on the RNA binding of these proteins. Overexpression or knock-down of these three proteins in cultured cells further suggests their essential role in intron A excision activities, and their presence in GnRH neurons of the mouse preoptic area further strengthens this possibility. Together, these results indicate that interaction of Tra2 alpha with 9G8 and SRp30c appears to be crucial for ESE-dependent GnRH pre-mRNA splicing, allowing efficient generation of mature mRNA in GnRH- producing cells.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Korea Univ, Coll Med, Grad Sch Med, Seoul 136705, South Korea	Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine)	Kim, K (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	kyungjin@snu.ac.kr	Seong, Jae Young/A-5794-2012	Seong, Jae Young/0000-0002-3312-6924				ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; BOND CT, 1989, MOL ENDOCRINOL, V3, P1257, DOI 10.1210/mend-3-8-1257; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Expert-Bezancon A, 2004, J BIOL CHEM, V279, P38249, DOI 10.1074/jbc.M405377200; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Guth S, 1999, MOL CELL BIOL, V19, P8263; Han J, 2001, MOL CELL ENDOCRINOL, V173, P157, DOI 10.1016/S0303-7207(00)00409-3; Hoffman BE, 2000, MOL CELL BIOL, V20, P181, DOI 10.1128/MCB.20.1.181-186.2000; Hofmann Y, 2002, HUM MOL GENET, V11, P2037, DOI 10.1093/hmg/11.17.2037; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; Kim MS, 2002, J BIOL CHEM, V277, P36863, DOI 10.1074/jbc.M206443200; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; Li Y, 1999, J BIOL CHEM, V274, P35074, DOI 10.1074/jbc.274.49.35074; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; PENG XB, 1995, MOL CELL BIOL, V15, P6273; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; Seong JY, 1999, MOL ENDOCRINOL, V13, P1882, DOI 10.1210/me.13.11.1882; Seong JY, 2002, MOL ENDOCRINOL, V16, P2426, DOI 10.1210/me.2001-0297; Seong JY, 2001, ENDOCRINOLOGY, V142, P4454, DOI 10.1210/en.142.10.4454; Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5; Son GH, 2003, J BIOL CHEM, V278, P18037, DOI 10.1074/jbc.M209850200; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Wang YZ, 2005, J BIOL CHEM, V280, P14230, DOI 10.1074/jbc.M413846200; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	43	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					401	409		10.1074/jbc.M505814200	http://dx.doi.org/10.1074/jbc.M505814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16249178	Green Published, hybrid			2022-12-25	WOS:000234307200050
J	Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM				Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM			Overexpression of CEBP beta correlates with decreased TFF1 in gastric cancer	ONCOGENE			English	Article						gastric cancer; c/EBP beta overexpression; TFF1	BINDING-PROTEIN-BETA; C/EBP-BETA; GENE-EXPRESSION; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; BREAST-CANCER; MICE LACKING; ACTIVATION; INVASIVENESS; ENHANCER	CCAAT element binding protein beta (C/EBP beta) is an important regulator of cell growth, differentiation and in promoting tumor invasiveness. C/EBP beta is located on chromosome 20q, which is amplified in many solid tumors including gastric cancers ( GC). We sought to characterize the status of C/EBP beta expression in GCs, which was recently found to repres TFF1 gene. Microarray analysis revealed overexpression of C/EBP beta in 25 of 27 (93%) GC when compared to 12 normal gastric tissue samples. RT-PCR analysis confirmed the overexpression of C/EBP beta b transcripts in 54 of 59 (91%) GC. In total, 15 of 18 gastric tumors exhibited at least fivefold higher C/EBPb transcript levels compared to their corresponding adjacent normal gastric tissue samples. Moreover, immunohistochemistry analysis demonstrated increased nuclear staining of C/EBP beta in 10 of 13 GC and at least fourfold overexpression of C/EBP beta in three primary GC compared to adjacent normal gastric tissue. Furthermore, a striking correlation of decreased TFF1 expression with increased C/EBP beta was observed in the gastric tumors studied. Microarray analysis demonstrated a loss of TFF1 expression in all 27 GC cases examined, of which 25 exhibited high C/EBP beta expression compared to normal gastric tissue. RT-PCR analysis revealed loss of TFF1 expression in 56 of 59 gastric tumors in which 54 of these tumors exhibited overexpression of C/EBP beta. Immunohistochemical analysis revealed overexpression of C/EBP beta in 10 of 13 gastric tumors that exhibited low expression of TFF1 at the protein level. Thus, overexpression of the transcription factor C/EBP beta in the majority of GCs is a novel finding.	Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Novartis Res Fdn, Genom Inst, San Diego, CA USA	University of Virginia; University of Virginia; Novartis	Powell, SM (corresponding author), Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, POB 800708, Charlottesville, VA 22908 USA.	powell@virginia.edu			NATIONAL CANCER INSTITUTE [R29CA067900, R01CA067900] Funding Source: NIH RePORTER; NCI NIH HHS [CA67900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beckler AD, 2003, CANCER, V98, P2184, DOI 10.1002/cncr.11789; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Dossinger V, 2002, CELL PHYSIOL BIOCHEM, V12, P197, DOI 10.1159/000066279; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hasegawa S, 2002, CANCER RES, V62, P7012; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kagan BL, 2003, CANCER RES, V63, P1696; Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53; Kintscher J, 2004, ONCOGENE, V23, P5807, DOI 10.1038/sj.onc.1207722; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Oya M, 2003, CLIN CANCER RES, V9, P1021; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887	23	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					643	649		10.1038/sj.onc.1209081	http://dx.doi.org/10.1038/sj.onc.1209081			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247479				2022-12-25	WOS:000234897400015
J	Choi, S; Lee, E; Kwon, S; Park, H; Yi, JY; Kim, S; Han, IO; Yun, Y; Oh, ES				Choi, S; Lee, E; Kwon, S; Park, H; Yi, JY; Kim, S; Han, IO; Yun, Y; Oh, ES			Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; PROTEOGLYCAN; ASSOCIATION; SYNTENIN; FAMILY	The syndecans are known to form homologous oligomers that may be important for their functions. We have therefore determined the role of oligomerization of syndecan-2 and syndecan-4. A series of glutathione S-transferase- syndecan-2 and syndecan-4 chimeric proteins showed that all syndecan constructs containing the transmembrane domain formed SDS-resistant dimers, but not those lacking it. SDS-resistant dimer formation was hardly seen in the syndecan chimeras where each transmembrane domain was substituted with that of platelet-derived growth factor receptor (PDGFR). Increased MAPK activity was detected in HEK293T cells transfected with syndecan/PDGFR chimeras in a syndecan transmembrane domain-dependent fashion. The chimera-induced MAPK activation was independent of both ligand and extracellular domain, implying that the transmembrane domain is sufficient to induce dimerization/oligomerization in vivo. Furthermore, the syndecan chimeras were defective in syndecan-4-mediated focal adhesion formation and protein kinase C alpha activation or in syndecan-2-mediated cell migration. Taken together, these data suggest that the transmembrane domains are sufficient for inducing dimerization and that transmembrane domain-induced oligomerization is crucial for syndecan- 2 and syndecan- 4 functions.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Coll Med, Dept Physiol & Biophys, Inchon 402751, South Korea	Ewha Womans University; Ewha Womans University; Inha University	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Daehyun Dong, Seoul 120750, South Korea.	OhES@ewha.ac.kr						ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1997, BIOCHEM J, V327, P1; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Greene DK, 2003, J BIOL CHEM, V278, P7617, DOI 10.1074/jbc.M207123200; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Longley RL, 1999, J CELL SCI, V112, P3421; Oh ES, 2004, MOL CELLS, V17, P181; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Schlesinger TK, 1999, BIOCHEM J, V344, P519, DOI 10.1042/0264-6021:3440519; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Wonerow P, 2001, ONCOGENE, V20, P6273, DOI 10.1038/sj.onc.1204770; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Zimmermann P, 1999, FASEB J, V13, pS91	28	89	90	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42573	42579		10.1074/jbc.M509238200	http://dx.doi.org/10.1074/jbc.M509238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16253987	hybrid			2022-12-25	WOS:000234200800014
J	Chen, YH; Kocherginskaya, SA; Lin, YY; Sriratana, B; Lagunas, AM; Robbins, JB; Mackie, RI; Cann, IKO				Chen, YH; Kocherginskaya, SA; Lin, YY; Sriratana, B; Lagunas, AM; Robbins, JB; Mackie, RI; Cann, IKO			Biochemical and mutational analyses of a unique clamp loader complex in the archaeon Methanosarcina acetivorans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; DNA-POLYMERASE; PYROCOCCUS-ABYSSI; EURYARCHAEOTA; GENOME; PROTEINS; GENE	Clamp loaders orchestrate the switch from distributive to processive DNA synthesis. Their importance in cellular processes is underscored by their conservation across all forms of life. Here, we describe a new form of clamp loader from the archaeon Methanosarcina acetivorans. Unlike previously described archaeal clamp loaders, which are composed of one small subunit and one large subunit, the M. acetivorans clamp loader comprises two similar small subunits (M. acetivorans replication factor C small subunit (MacRFCS)) and one large subunit (MacRFCL). The relatedness of the archaeal and eukaryotic clamp loaders (which are made up of four similar small subunits and one large subunit) suggests that the M. acetivorans clamp loader may be an intermediate form in the archaeal/eukaryotic sister lineages. The clamp loader complex reconstituted from the three subunits MacRFCS1, MacRFCS2, and MacRFCL stimulated DNA synthesis by a cognate DNA polymerase in the presence of its sliding clamp. We used site-directed mutagenesis in the Walker A and SRC motifs to examine the contribution of each subunit to the function of the M. acetivorans clamp loader. Although mutations in MacRFCL and MacRFCS2 did not impair clamp loading activity, any mutant clamp loader harboring a mutation in MacRFCS1 was devoid of the clamp loading property. MacRFCS1 is therefore critical to the clamp loading activity of the M. acetivorans clamp loader. It is our anticipation that the discovery of this unique replication factor C homolog will lead to critical insights into the evolution of more complex clamp loaders from simpler ones as more complex organisms evolved in the archaeal/eukaryotic sister lineages.	Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Inst Gen Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cann, IKO (corresponding author), Univ Illinois, Dept Anim Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	icann@uiuc.edu						Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Henneke G, 2005, J MOL BIOL, V350, P53, DOI 10.1016/j.jmb.2005.04.042; Henneke G, 2002, J MOL BIOL, V323, P795, DOI 10.1016/S0022-2836(02)01028-8; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Macario AJL, 2001, FRONT BIOSCI-LANDMRK, V6, pD262, DOI 10.2741/Macario; Metcalf WW, 1996, J BACTERIOL, V178, P5797, DOI 10.1128/jb.178.19.5797-5802.1996; Miyata T, 2004, NAT STRUCT MOL BIOL, V11, P632, DOI 10.1038/nsmb788; Neuwald AF, 1999, GENOME RES, V9, P27; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Robbins JB, 2005, J BIOL CHEM, V280, P15325, DOI 10.1074/jbc.M412870200; Robbins JB, 2004, J BIOL CHEM, V279, P6315, DOI 10.1074/jbc.M304491200; Seybert A, 2002, NUCLEIC ACIDS RES, V30, P4329, DOI 10.1093/nar/gkf584; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	28	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41852	41863		10.1074/jbc.M508684200	http://dx.doi.org/10.1074/jbc.M508684200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16257971	hybrid			2022-12-25	WOS:000233992700011
J	Yamamoto, T; Nakahata, Y; Tanaka, M; Yoshida, M; Soma, H; Shinohara, K; Yasuda, A; Mamine, T; Takumi, T				Yamamoto, T; Nakahata, Y; Tanaka, M; Yoshida, M; Soma, H; Shinohara, K; Yasuda, A; Mamine, T; Takumi, T			Acute physical stress elevates mouse Period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; LIGHT; MPER1; RHYTHMS; RAT; TRANSCRIPTION; ORGANIZATION; OSCILLATORS	In mammals, the circadian and stress systems ( both centers of which are located in the hypothalamus) are involved in adaptation to predictable and unpredictable environmental stimuli, respectively. Although the interaction and relationship between these two systems are intriguing and have been studied in different ways since the "pre-clock gene" era, the molecular interaction between them remains largely unknown. Here, we show by systematic molecular biological analysis that acute physical stress elevated only Period1 ( Per1) mRNA expression in mouse peripheral organs. Although behavioral rhythms in vivo and peripheral molecular clocks are rather stable against acute restraint stress, the results of a series of promoter analyses, including chromatin immunoprecipitation assays, indicate that a glucocorticoid-responsive element in the Per1 promoter is indispensable for induction of this mRNA both in vitro and in vivo. These results suggest that Per1 can be a potential stress marker and that a third pathway of Per1 transcriptional control may exist in addition to the clock-regulated CLOCK-BMAL1/E-box and light-responsive cAMP-responsive element-binding protein/cAMP-responsive element pathways.	Osaka Biosci Inst, Suita, Osaka 5650874, Japan; Sony Corp, Life Sci Lab, Mat Labs, Tokyo 1440001, Japan; Osaka City Univ, Grad Sch Med, Osaka 5458585, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan; Nagasaki Univ, Grad Sch Med, Dept Physiol, Nagasaki 8528523, Japan	Sony Corporation; Osaka Metropolitan University; Kyoto University; Kyoto University; Nagasaki University	Takumi, T (corresponding author), Osaka Biosci Inst, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	takumi@obi.or.jp		Nakahata, Yasukazu/0000-0003-3814-5822				Akashi M, 2000, GENE DEV, V14, P645; Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Connor TJ, 1997, PHARMACOL BIOCHEM BE, V58, P961, DOI 10.1016/S0091-3057(97)00028-2; DUIJS RM, 2001, NAT REV NEUROSCI, V2, P521; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; FLESHNER M, 1995, ENDOCRINOLOGY, V136, P5336, DOI 10.1210/en.136.12.5336; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hastings MH, 2004, J BIOL RHYTHM, V19, P400, DOI 10.1177/0748730404268786; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; HORSEMAN ND, 1982, AM J PHYSIOL, V243, pR373, DOI 10.1152/ajpregu.1982.243.3.R373; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; KATZ P, 2000, CECIL TXB MED, P111; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Maywood ES, 1999, P NATL ACAD SCI USA, V96, P15211, DOI 10.1073/pnas.96.26.15211; Meerlo P, 2002, STRESS, V5, P15, DOI 10.1080/102538902900012323; Meerlo P, 1996, PHYSIOL BEHAV, V59, P735, DOI 10.1016/0031-9384(95)02182-5; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sakakida Y, 2005, J BIOL CHEM, V280, P13272, DOI 10.1074/jbc.M413236200; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahashi S, 2001, ENDOCRINOLOGY, V142, P4910, DOI 10.1210/en.142.11.4910; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tischkau SA, 2003, J BIOL CHEM, V278, P718, DOI 10.1074/jbc.M209241200; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Wang GK, 2002, CURR OPIN NEUROBIOL, V12, P331, DOI 10.1016/S0959-4388(02)00324-0; Weibel L, 2002, J BIOL RHYTHM, V17, P438, DOI 10.1177/074873002237138; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	44	205	207	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42036	42043		10.1074/jbc.M509600200	http://dx.doi.org/10.1074/jbc.M509600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16249183	hybrid			2022-12-25	WOS:000233992700029
J	Bangham, AD				Bangham, AD			Liposomes and the physico-chemical basis of unconsciousness	FASEB JOURNAL			English	Editorial Material							ANESTHETICS				Bangham, AD (corresponding author), 17 High Green, Cambridge CB2 5EG, England.	alecbangham@wwr.co.uk						Bangham A, 2000, BRIT J ANAESTH, V84, P820; BANGHAM AD, 1980, ANESTHESIOLOGY, V53, P135, DOI 10.1097/00000542-198008000-00007; BENNETT P. B., 1967, LIFE SCI, V6, P2527, DOI 10.1016/0024-3205(67)90317-7; BRYSON BA, 2003, SHORT HIST NEARLY EV, P102; HILL MW, 1981, J COMP PHYSIOL, V142, P61, DOI 10.1007/BF00605476; JOHNSON SM, 1969, BIOCHIM BIOPHYS ACTA, V193, P92, DOI 10.1016/0005-2736(69)90062-5; JOHNSON SM, 1970, NATURE, V288, P75; MILLER KW, 1983, LIPOSOME LETT, P251; NICHOLS JW, 1980, BIOCHIM BIOPHYS ACTA, V596, P393; WHITTAKER VP, 1965, J NEUROCHEM, V12, P363, DOI 10.1111/j.1471-4159.1965.tb04237.x	10	3	3	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1766	1768		10.1096/fj.05-1103ufm	http://dx.doi.org/10.1096/fj.05-1103ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260644				2022-12-25	WOS:000234053100027
J	Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q				Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q			Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation	ONCOGENE			English	Article						Protocadherin; tumor suppressor gene; methylation; epigenetic; promoter; carcinoma	REPRESENTATIONAL DIFFERENCE ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; E-CADHERIN; ABERRANT METHYLATION; ADHESION MOLECULE; GASTRIC-CANCER; CELL-ADHESION; CO-REPRESSOR; HUMAN BREAST; H-CADHERIN	Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumorspecific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3-a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2'-deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Natl Univ Singapore Hosp, Dept Pathol, Singapore 117548, Singapore; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	Chinese University of Hong Kong; Wellcome Trust Sanger Institute; University of Hong Kong; University of Hong Kong; National University of Singapore; Cancer Research UK; University of Birmingham	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Tsao, George/C-4422-2009	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; 				Angst BD, 2001, J CELL SCI, V114, P629; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185; DI PF, 2001, NAT GENET, V27, P103; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Hirano S, 1999, J NEUROSCI, V19, P995; Hukku B, 1997, CANCER GENET CYTOGEN, V93, P125, DOI 10.1016/S0165-4608(96)00210-5; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakao S, 2005, MOL BRAIN RES, V134, P294, DOI 10.1016/j.molbrainres.2004.11.017; Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Wolverton T, 2001, GENOMICS, V76, P66, DOI 10.1006/geno.2001.6592; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Yagi T, 2000, GENE DEV, V14, P1169; YING J, 2005, IN PRESS CLIN CANC R; Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	52	225	245	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1070	1080		10.1038/sj.onc.1209154	http://dx.doi.org/10.1038/sj.onc.1209154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247458				2022-12-25	WOS:000235361000011
J	McFadden, DC; De Jesus, M; Casadevall, A				McFadden, DC; De Jesus, M; Casadevall, A			The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SEROTYPE-A; MONOCLONAL-ANTIBODIES; PROTECTIVE ANTIBODIES; O-ACETYLATION; IN-VIVO; GLUCURONOXYLOMANNAN; INFECTION; ARCHITECTURE; VARIANT	The most distinctive feature of the human pathogenic fungus is a polysaccharide capsule that is essential for virulence and is composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM). GXM mediates multiple deleterious effects on host immune function, yet relatively little is known about its physical properties. The average mass of Cryptococcus neoformans GXM from four antigenically different strains ranged from 1.7 to 7 x 10(6) daltons as calculated from Zimm plots of light-scattering data. GalXM was significantly smaller than GXM, with an average mass of 1 x 10(5) daltons. These molecular masses imply that GalXM is the most numerous polysaccharide in the capsule on a molar basis. The radius of gyration of the capsular polysaccharides ranged between 68 and 208 nm. Viscosity measurements suggest that neither polysaccharide altered fluid dynamics during infection since GXM behaved in solution as a polyelectrolyte and GalXM did not increase solution viscosity. Immunoblot analysis indicated heterogeneity within GXM. In agreement with this, scanning transmission electron microscopy of GXM preparations revealed a tangled network of two different types of molecules. Mass per length measurements from light scattering and scanning transmission electron microscopy were consistent and suggested GXM molecules self-associate. A mechanism for capsule growth is proposed based on the extracellular release and entanglement of GXM molecules.	Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	McFadden, DC (corresponding author), Albert Einstein Coll Med, Dept Med, Div Infect Dis, 1300 Morris Pk Ave,Golding 701, Bronx, NY 10461 USA.	casadeva@aecom.yu.edu			NCI NIH HHS [2T32 CA 009173-31] Funding Source: Medline; NHLBI NIH HHS [HL 59842-01] Funding Source: Medline; NIAID NIH HHS [AI 33774, AI 33142] Funding Source: Medline; NIBIB NIH HHS [5P41 EB 2181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033142, R01AI033774, R37AI033142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Arend SM, 2004, EUR J CLIN MICROBIOL, V23, P638, DOI 10.1007/s10096-004-1185-6; Bryan RA, 2005, EUKARYOT CELL, V4, P465, DOI 10.1128/EC.4.2.465-475.2005; CASADEVALL A, 1992, J IMMUNOL METHODS, V154, P27, DOI 10.1016/0022-1759(92)90209-C; CASADEVALL A, 1991, J EXP MED, V174, P151, DOI 10.1084/jem.174.1.151; CASADEVALL A, 1992, J INFECT DIS, V165, P1086, DOI 10.1093/infdis/165.6.1086; Charlier C, 2005, AM J PATHOL, V166, P421, DOI 10.1016/S0002-9440(10)62265-1; Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146; CHERNIAK R, 1988, CARBOHYD RES, V172, P113, DOI 10.1016/S0008-6215(00)90846-2; CHERNIAK R, 1982, CARBOHYD RES, V103, P239, DOI 10.1016/S0008-6215(00)80686-2; CLEARE W, 1994, CLIN DIAGN LAB IMMUN, V1, P737, DOI 10.1128/CDLI.1.6.737-740.1994; Cleare W, 1999, INFECT IMMUN, V67, P3096, DOI 10.1128/IAI.67.6.3096-3107.1999; De Hoog GS, 2000, ATLAS CLIN FUNGI, p[130, 156, 164]; DEVI SJN, 1991, INFECT IMMUN, V59, P3700, DOI 10.1128/IAI.59.10.3700-3707.1991; DROMER F, 1987, INFECT IMMUN, V55, P749, DOI 10.1128/IAI.55.3.749-752.1987; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ellerbroek PM, 2004, J IMMUNOL, V173, P7513, DOI 10.4049/jimmunol.173.12.7513; Feldmesser M, 2001, MICROBIOL-SGM, V147, P2355, DOI 10.1099/00221287-147-8-2355; Feldmesser M, 1997, J IMMUNOL, V158, P790; FELDMESSER M, 1998, FRONT BIOSCI, V3, P136; Fries BC, 2005, INFECT IMMUN, V73, P1779, DOI 10.1128/IAI.73.3.1779-1787.2005; Fries BC, 1999, INFECT IMMUN, V67, P6076, DOI 10.1128/IAI.67.11.6076-6083.1999; Fries BC, 2001, J CLIN INVEST, V108, P1639, DOI 10.1172/JCI13407; GADEBUSCH HH, 1964, J INFECT DIS, V114, P95, DOI 10.1093/infdis/114.1.95; Garcia-Rivera J, 2004, EUKARYOT CELL, V3, P385, DOI 10.1128/EC.3.2.385-392.2004; Gates MA, 2004, MOL MICROBIOL, V52, P13, DOI 10.1111/j.1365-2958.2003.03957.x; Goldman DL, 1998, P NATL ACAD SCI USA, V95, P14967, DOI 10.1073/pnas.95.25.14967; Hage CA, 2003, CHEST, V124, P2395, DOI 10.1378/chest.124.6.2395; JACOBSON ES, 1989, MYCOSES, V32, P14, DOI 10.1111/j.1439-0507.1989.tb02163.x; JAMES PG, 1992, INFECT IMMUN, V60, P1084, DOI 10.1128/IAI.60.3.1084-1088.1992; Janbon G, 2004, FEMS YEAST RES, V4, P765, DOI 10.1016/j.femsyr.2004.04.003; Janbon G, 2001, MOL MICROBIOL, V42, P453, DOI 10.1046/j.1365-2958.2001.02651.x; KOZEL TR, 1971, INFECT IMMUN, V3, P287, DOI 10.1128/IAI.3.2.287-294.1971; KOZEL TR, 1977, INFECT IMMUN, V16, P99, DOI 10.1128/IAI.16.1.99-106.1977; KOZEL TR, 1984, INFECT IMMUN, V43, P879, DOI 10.1128/IAI.43.3.879-886.1984; KRATOCHVIL P, 1989, PURE APPL CHEM, V61, P211, DOI 10.1351/pac198961020211; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lendvai N, 1998, J INFECT DIS, V177, P1647, DOI 10.1086/515329; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; McFadden DC, 2004, J IMMUNOL, V172, P3670, DOI 10.4049/jimmunol.172.6.3670; McIntosh M, 2005, APPL MICROBIOL BIOT, V68, P163, DOI 10.1007/s00253-005-1959-5; Monari C, 2005, J IMMUNOL, V174, P3461, DOI 10.4049/jimmunol.174.6.3461; Monari C, 2005, J INFECT DIS, V191, P127, DOI 10.1086/426511; MUKHERJEE J, 1993, J EXP MED, V177, P1105, DOI 10.1084/jem.177.4.1105; MUKHERJEE S, 1994, INFECT IMMUN, V62, P1079, DOI 10.1128/IAI.62.3.1079-1088.1994; MURPHY JW, 1979, INFECT IMMUN, V25, P284, DOI 10.1128/IAI.25.1.284-292.1979; MURPHY JW, 1988, INFECT IMMUN, V56, P424, DOI 10.1128/IAI.56.2.424-431.1988; Nussbaum G, 1997, J EXP MED, V185, P685, DOI 10.1084/jem.185.4.685; OGAWA K, 1986, CARBOHYD RES, V148, P115, DOI 10.1016/0008-6215(86)80042-8; Perfect JR, 2002, INFECT DIS CLIN N AM, V16, P837, DOI 10.1016/S0891-5520(02)00064-8; Pierini LM, 2001, MOL MICROBIOL, V41, P105, DOI 10.1046/j.1365-2958.2001.02504.x; Pirofski LA, 2001, TRENDS MICROBIOL, V9, P445, DOI 10.1016/S0966-842X(01)02134-5; Rivera J, 1998, INFECT IMMUN, V66, P5027, DOI 10.1128/IAI.66.10.5027-5030.1998; SAKAGUCHI N, 1993, VIRCHOWS ARCH B, V64, P57, DOI 10.1007/BF02915096; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Shrestha Rabin K, 2004, Respir Care, V49, P606; Sist P, 2003, CARBOHYD RES, V338, P1861, DOI 10.1016/S0008-6215(03)00306-9; Taborda CP, 2001, J IMMUNOL, V166, P2100, DOI 10.4049/jimmunol.166.3.2100; THOMAS D, 1994, BIOL CELL, V80, P181, DOI 10.1016/0248-4900(94)90041-8; Tissi L, 2004, INFECT IMMUN, V72, P6367, DOI 10.1128/IAI.72.11.6367-6372.2004; TURNER SH, 1991, CARBOHYD RES, V211, P103, DOI 10.1016/0008-6215(91)84149-9; Vaishnav VV, 1998, CARBOHYD RES, V306, P315, DOI 10.1016/S0008-6215(97)10058-1; VARTIVARIAN SE, 1989, J BACTERIOL, V171, P6850, DOI 10.1128/jb.171.12.6850-6852.1989; Vecchiarelli A, 2003, J LEUKOCYTE BIOL, V74, P370, DOI 10.1189/jlb.1002476; VECCHIARELLI A, 1995, INFECT IMMUN, V63, P2919, DOI 10.1128/IAI.63.8.2919-2923.1995; Vincken JP, 2003, PLANT PHYSIOL, V132, P1781, DOI 10.1104/pp.103.022350; ZIMM BH, 1948, J CHEM PHYS, V16, P1093, DOI 10.1063/1.1746738	66	103	108	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1868	1875		10.1074/jbc.M509465200	http://dx.doi.org/10.1074/jbc.M509465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16278213				2022-12-25	WOS:000234760400004
J	Kawaguchi, Y; Ito, A; Appella, E; Yao, TP				Kawaguchi, Y; Ito, A; Appella, E; Yao, TP			Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; TETRAMERIZATION DOMAIN; TUMOR-SUPPRESSOR; ACETYLATION; MDM2; EXPORT; PHOSPHORYLATION; UBIQUITINATION; DEACETYLATION; LOCALIZATION	The basal level of the tumor suppressor p53 is regulated by MDM2-mediated ubiquitination at specific lysines, which leads to p53 nuclear export and degradation. Upon p53 activation, however, these lysines become acetylated by p300/CREB-binding protein. Here we have reported an unexpected finding that p300-mediated acetylation also regulates p53 subcellular localization and can promote cytoplasmic localization of p53. This activity is independent of MDM2 but requires a p53 nuclear export signal and acetylation of multiple lysines by p300. Mechanistically, we showed that conversion of a minimal four of these lysines to alanines but not arginines mimics p300-mediated p53 nuclear export, and these lysine-neutralizing mutations effectively prevent p53 tetramerization, thus exposing the oligomerization-regulated nuclear export signal. Our study suggested a threshold mechanism whereby the degree of acetylation regulates p53 nucleus-cytoplasm trafficking by neutralizing a lysine-dependent charge patch, which in turn, controls oligomerization-dependent p53 nuclear export.	Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yao, TP (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, C327,LSRC, Durham, NC 27710 USA.	yao00001@mc.duke.edu	Ito, Akihiro/A-6100-2015		NCI NIH HHS [CA85676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085676, Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; McMasters KM, 1996, ONCOGENE, V13, P1731; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	23	52	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1394	1400		10.1074/jbc.M505772200	http://dx.doi.org/10.1074/jbc.M505772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16291740	hybrid			2022-12-25	WOS:000234652000015
J	O'Connell, CM; Ionova, IA; Quayle, AJ; Visintin, A; Ingalls, RR				O'Connell, CM; Ionova, IA; Quayle, AJ; Visintin, A; Ingalls, RR			Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions - Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; INNATE IMMUNE-RESPONSE; DOUBLE-STRANDED-RNA; CUTTING EDGE; LYMPHOGRANULOMA-VENEREUM; EPITHELIAL-CELLS; LIPOPOLYSACCHARIDE EPITOPE; MICROBIAL LIPOPROTEINS; NEISSERIA-GONORRHOEAE	Chlamydia trachomatis is an obligate intracellular Gram-negative pathogen and the etiologic agent of significant ocular and genital tract diseases. Chlamydiae primarily infect epithelial cells, and the inflammatory response of these cells to the infection directs both the innate and adaptive immune response. This study focused on determining the cellular immune receptors involved in the early events following infection with the L2 serovar of C. trachomatis. We found that dominant negative MyD88 inhibited interleukin-8 (IL-8) secretion during a productive infection with chlamydia. Furthermore, expression of Toll-like receptor (TLR)-2 was required for IL-8 secretion from infected cells, whereas the effect of TLR4/MD-2 expression was minimal. Cell activation was dependent on infection with live, replicating bacteria, because infection with UV-irradiated bacteria and treatment of infected cells with chloramphenicol, but not ampicillin, abrogated the induction of IL-8 secretion. Finally, we show that both TLR2 and MyD88 co-localize with the intracellular chlamydial inclusion, suggesting that TLR2 is actively engaged in signaling from this intracellular location. These data support the role of TLR2 in the host response to infection with C. trachomatis. Our data further demonstrate that TLR2 and the adaptor MyD88 are specifically recruited to the bacterial or inclusion membrane during a productive infection with chlamydia and provide the first evidence that intracellular TLR2 is responsible for signal transduction during infection with an intracellular bacterium.	Univ Arkansas Med Sci, Dept Immunol Microbiol, Little Rock, AR 72205 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Infect Dis, Boston, MA 02118 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; Univ Massachusetts, Sch Med, Dept Infect Dis, Worcester, MA 01655 USA	University of Arkansas System; University of Arkansas Medical Sciences; Boston Medical Center; Boston University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Massachusetts System; University of Massachusetts Worcester	Ingalls, RR (corresponding author), Evans Biomed Res Ctr, 650 Albany St, Boston, MA 02118 USA.	ringalls@bu.edu		Ingalls, Robin/0000-0003-2197-7198; O'Connell, Catherine/0000-0002-8229-684X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064749, R01AI046613, U19AI061972] Funding Source: NIH RePORTER; NIAID NIH HHS [AI064749, AI46613, AI061972] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Anderson DJ, 1998, AIDS RES HUM RETROV, V14, pS43; BANKS J, 1970, Infection and Immunity, V1, P259; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Beagley KW, 2000, J REPROD IMMUNOL, V48, P47, DOI 10.1016/S0165-0378(00)00069-3; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; BRADE L, 1986, INFECT IMMUN, V54, P568, DOI 10.1128/IAI.54.2.568-574.1986; BRADE L, 1990, INFECT IMMUN, V58, P205, DOI 10.1128/IAI.58.1.205-213.1990; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; *CDCP, 2004, SEX TRANSM DIS SURV, P4; Chopra I, 1998, MICROBIOL-UK, V144, P2673, DOI 10.1099/00221287-144-10-2673; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Darville T, 2003, J IMMUNOL, V171, P6187, DOI 10.4049/jimmunol.171.11.6187; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fichorova RN, 1999, BIOL REPROD, V60, P508, DOI 10.1095/biolreprod60.2.508; Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047; Fichorova RN, 2002, J IMMUNOL, V168, P2424, DOI 10.4049/jimmunol.168.5.2424; Fisette PL, 2003, J BIOL CHEM, V278, P46252, DOI 10.1074/jbc.M306587200; Galdiero M, 2004, INFECT IMMUN, V72, P1204, DOI 10.1128/IAI.72.2.1204-1209.2004; Gotz H M, 2004, Ned Tijdschr Geneeskd, V148, P441; Hackstadt T, 1997, TRENDS MICROBIOL, V5, P288, DOI 10.1016/S0966-842X(97)01061-5; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heine H, 2003, EUR J BIOCHEM, V270, P440, DOI 10.1046/j.1432-1033.2003.03392.x; Heinzen RA, 1996, INFECT IMMUN, V64, P796, DOI 10.1128/IAI.64.3.796-809.1996; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; Hoshino K, 1999, J IMMUNOL, V162, P3749; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Manthey CL, 1994, J ENDOTOXIN RES, V1, P84; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; Means TK, 1999, J IMMUNOL, V163, P6748; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nagarajan UM, 2005, J IMMUNOL, V175, P450, DOI 10.4049/jimmunol.175.1.450; Nieuwenhuis RF, 2004, CLIN INFECT DIS, V39, P996, DOI 10.1086/423966; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Ossewaarde JM, 1996, APPL ENVIRON MICROB, V62, P328, DOI 10.1128/AEM.62.2.328-331.1996; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Prebeck S, 2003, MICROBES INFECT, V5, P463, DOI 10.1016/S1286-4579(03)00063-7; Prebeck S, 2001, J IMMUNOL, V167, P3316, DOI 10.4049/jimmunol.167.6.3316; Qureshi N, 1997, J BIOL CHEM, V272, P10594; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; SCHACHTE.J, 1969, J INFECT DIS, V120, P372, DOI 10.1093/infdis/120.3.372; SCHACHTER J, 1969, J BACTERIOL, V99, P636, DOI 10.1128/JB.99.3.636-638.1969; SCHACHTER J, 1999, SEXUALLY TRANSMITTED, P391; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Storey C, 2001, ANTIMICROB AGENTS CH, V45, P303, DOI 10.1128/AAC.45.1.303-305.2001; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wang RF, 1998, CANCER RES, V58, P3519; Wylie JL, 1997, J BACTERIOL, V179, P7233, DOI 10.1128/jb.179.23.7233-7242.1997; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125	71	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1652	1659		10.1074/jbc.M510182200	http://dx.doi.org/10.1074/jbc.M510182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293622	hybrid			2022-12-25	WOS:000234652000045
J	Albrecht, A; Felk, A; Pichova, I; Naglik, JR; Schaller, M; de Groot, P; MacCallum, D; Odds, FC; Schafer, W; Klis, F; Monod, M; Hube, B				Albrecht, A; Felk, A; Pichova, I; Naglik, JR; Schaller, M; de Groot, P; MacCallum, D; Odds, FC; Schafer, W; Klis, F; Monod, M; Hube, B			Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SECRETED ASPARTYL PROTEINASE; SCHIZOSACCHAROMYCES-POMBE; HYPHAL FORMATION; ACID PROTEINASE; KEX2 PROTEASE; GPI PROTEINS; GENOME-WIDE; IN-VIVO; GENE	Intracellular and secreted proteases fulfill multiple functions in microorganisms. In pathogenic microorganisms extracellular proteases may be adapted to interactions with host cells. Here we describe two cell surface-associated aspartic proteases, Sap9 and Sap10, which have structural similarities to yapsins of Saccharomyces cerevisiae and are produced by the human pathogenic yeast Candida albicans. Sap9 and Sap10 are glycosylphosphatidylinositol-anchored and located in the cell membrane or the cell wall. Both proteases are glycosylated, cleave at dibasic or basic processing sites similar to yapsins and Kex2-like proteases, and have functions in cell surface integrity and cell separation during budding. Overexpression of SAP9 in mutants lacking KEX2 or SAP10, or of SAP10 in mutants lacking KEX2 or SAP9, only partially restored these phenotypes, suggesting distinct target proteins of fungal origin for each of the three proteases. In addition, deletion of SAP9 and SAP10 modified the adhesion properties of C. albicans to epithelial cells and caused attenuated epithelial cell damage during experimental oral infection suggesting a unique role for these proteases in both cellular processes and host-pathogen interactions.	Robert Koch Inst, D-13353 Berlin, Germany; Univ Hamburg, D-22609 Hamburg, Germany; Acad Sci Czech Republic, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic; Kings Coll London, Dept Oral Med & Pathol, London SE1 9RT, England; Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; Univ Amsterdam, NL-1018 WV Amsterdam, Netherlands; Univ Aberdeen, Sch Med Sci, Aberdeen Fungal Grp, Aberdeen AB25 2ZD, Scotland; CHU Vaudois, CH-1011 Lausanne, Switzerland	Robert Koch Institute; University of Hamburg; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; University of London; King's College London; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Amsterdam; University of Aberdeen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hube, B (corresponding author), Robert Koch Inst, D-13353 Berlin, Germany.	HubeB@rki.de	De Groot, Piet/L-7737-2014; Pichova, Iva/G-7917-2014; Klis, Frans M/B-9085-2008; MacCallum, Donna M./D-7897-2011	De Groot, Piet/0000-0002-3112-6947; Klis, Frans M/0000-0003-0079-9492; MacCallum, Donna M./0000-0003-4833-0378; Hube, Bernhard/0000-0002-6028-0425; Naglik, Julian/0000-0002-8072-7917				Barelle CJ, 2004, YEAST, V21, P333, DOI 10.1002/yea.1099; BORG M, 1988, INFECT IMMUN, V56, P626, DOI 10.1128/IAI.56.3.626-631.1988; Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7; Carruthers VB, 2005, MOL MICROBIOL, V55, P1617, DOI 10.1111/j.1365-2958.2005.04483.x; Cawley NX, 2003, J BIOL CHEM, V278, P5523, DOI 10.1074/jbc.M207230200; d'Enfert C, 2005, NUCLEIC ACIDS RES, V33, pD353, DOI 10.1093/nar/gki124; DAVEY J, 1994, EMBO J, V13, P5910, DOI 10.1002/j.1460-2075.1994.tb06936.x; de Groot PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004; de Groot PWJ, 2003, YEAST, V20, P781, DOI 10.1002/yea.1007; De Groot PWJ, 2005, FUNGAL GENET BIOL, V42, P657, DOI 10.1016/j.fgb.2005.04.002; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; Eisenhaber B, 2004, J MOL BIOL, V337, P243, DOI 10.1016/j.jmb.2004.01.025; Felk A, 2002, INFECT IMMUN, V70, P3689, DOI 10.1128/IAI.70.7.3689-3700.2002; FONZI WA, 1993, GENETICS, V134, P717; Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; Granger BL, 2005, MICROBIOL-SGM, V151, P1631, DOI 10.1099/mic.0.27663-0; Herrero AB, 2004, EUKARYOT CELL, V3, P1423, DOI 10.1128/EC.3.6.1423-1432.2004; HUBE B, 1994, MOL MICROBIOL, V14, P87, DOI 10.1111/j.1365-2958.1994.tb01269.x; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kelly MT, 2004, MOL MICROBIOL, V53, P969, DOI 10.1111/j.1365-2958.2004.04185.x; KINAL H, 1995, PLANT CELL, V7, P677, DOI 10.1105/tpc.7.6.677; Komano H, 1999, J BIOL CHEM, V274, P24431, DOI 10.1074/jbc.274.34.24431; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; Li F, 2003, EUKARYOT CELL, V2, P1266, DOI 10.1128/EC.2.6.1266-1273.2003; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Munro CA, 2001, MOL MICROBIOL, V39, P1414, DOI 10.1046/j.1365-2958.2001.02347.x; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003; Naglik JR, 1999, INFECT IMMUN, V67, P2482, DOI 10.1128/IAI.67.5.2482-2490.1999; Naglik JR, 2003, J INFECT DIS, V188, P469, DOI 10.1086/376536; Newport G, 1997, J BIOL CHEM, V272, P28954, DOI 10.1074/jbc.272.46.28954; Newport G, 2003, J BIOL CHEM, V278, P1713, DOI 10.1074/jbc.M209713200; OLLERT MW, 1993, INFECT IMMUN, V61, P4560, DOI 10.1128/IAI.61.11.4560-4568.1993; Olsen V, 1998, BIOCHEMISTRY-US, V37, P2768, DOI 10.1021/bi9724826; Olsen V, 1999, BIOCHEM J, V339, P407, DOI 10.1042/0264-6021:3390407; Pardo M, 2004, MICROBIOL-SGM, V150, P4157, DOI 10.1099/mic.0.26924-0; PARK CM, 1994, MOL MICROBIOL, V11, P155, DOI 10.1111/j.1365-2958.1994.tb00297.x; RAY TL, 1988, INFECT IMMUN, V56, P1942, DOI 10.1128/IAI.56.8.1942-1949.1988; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Richard M, 2002, MICROBIOL-SGM, V148, P2125, DOI 10.1099/00221287-148-7-2125; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Schaller M, 1999, MOL MICROBIOL, V34, P169, DOI 10.1046/j.1365-2958.1999.01590.x; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; Weig M, 2004, MICROBIOL-SGM, V150, P3129, DOI 10.1099/mic.0.27256-0; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; Yabe T, 1996, J BACTERIOL, V178, P477, DOI 10.1128/jb.178.2.477-483.1996; Zhao XM, 2004, MICROBIOL-SGM, V150, P2415, DOI 10.1099/mic.0.26943-0	51	193	212	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					688	694		10.1074/jbc.M509297200	http://dx.doi.org/10.1074/jbc.M509297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16269404	hybrid			2022-12-25	WOS:000234447200004
J	Ashida, H; Maeda, Y; Kinoshita, T				Ashida, H; Maeda, Y; Kinoshita, T			DPM1, the catalytic subunit of dolichol-phosphate mannose synthase, is tethered to and stabilized on the endoplasmic reticulum membrane by DPM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDE; SUBCELLULAR-LOCALIZATION; CONGENITAL DISORDER; MAMMALIAN-CELLS; E3 LIGASE; PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; GLYCOSYLTRANSFERASES; ENZYME; YEAST	Dolichol-phosphate mannose (DPM) synthase is required for synthesis of the glycosylphosphatidylinositol (GPI) anchor, N-glycan precursor, protein O-mannose, and C-mannose. We previously identified DPM3, the third component of this enzyme, which was co-purified with DPM1 and DPM2. Here, we have established mutant Chinese hamster ovary (CHO) 2.38 cells that were defective in DPM3. CHO2.38 cells were negative for GPI-anchored proteins, and microsomes from these cells showed no detectable DPM synthase activity, indicating that DPM3 is an essential component of this enzyme. A coiled-coil domain near the C terminus of DPM3 was important for tethering DPM1, the catalytic subunit of the enzyme, to the endoplasmic reticulum membrane and, therefore, was critical for enzyme activity. On the other hand, two transmembrane regions in the N-terminal portion of DPM3 showed no specific functions. DPM1 was rapidly degraded by the proteasome in the absence of DPM3. Free DPM1 was strongly associated with the C terminus of Hsc70-interacting protein (CHIP), a chaperone-dependent E3 ubiquitin ligase, suggesting that DPM1 is ubiquitinated, at least in part, by CHIP.	Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Ashida, Hisashi/HCI-0293-2022; Kinoshita, Taroh/C-7353-2009	Ashida, Hisashi/0000-0001-5844-4075				Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Ashida H, 2005, MOL BIOL CELL, V16, P1439, DOI 10.1091/mbc.E04-09-0802; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Banerjee DK, 2004, GLYCOCONJUGATE J, V21, P479, DOI 10.1007/s10719-004-5538-2; BANERJEE DK, 1987, P NATL ACAD SCI USA, V84, P6389, DOI 10.1073/pnas.84.18.6389; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Colussi PA, 1997, P NATL ACAD SCI USA, V94, P7873, DOI 10.1073/pnas.94.15.7873; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; Ermonval M, 1997, J CELL SCI, V110, P323; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kang JY, 2005, J BIOL CHEM, V280, P9489, DOI 10.1074/jbc.M413867200; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Pottekat A, 2004, J BIOL CHEM, V279, P15743, DOI 10.1074/jbc.M313537200; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Taron BW, 2004, J BIOL CHEM, V279, P36083, DOI 10.1074/jbc.M405081200; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tomita S, 1998, J BIOL CHEM, V273, P9249, DOI 10.1074/jbc.273.15.9249; Watanabe R, 2000, EMBO J, V19, P4402, DOI 10.1093/emboj/19.16.4402	33	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					896	904		10.1074/jbc.M511311200	http://dx.doi.org/10.1074/jbc.M511311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16280320	hybrid			2022-12-25	WOS:000234447200028
J	Fernandez, Y; Miller, TP; Denoyelle, C; Esteban, JA; Tang, WH; Bengston, AL; Soengas, MS				Fernandez, Y; Miller, TP; Denoyelle, C; Esteban, JA; Tang, WH; Bengston, AL; Soengas, MS			Chemical blockage of the proteasome inhibitory function of bortezomib - Impact on tumor cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL DYSFUNCTION; MOLECULAR-MECHANISMS; SKIN RECONSTRUCTS; MULTIPLE-MYELOMA; IN-VITRO; APOPTOSIS; MELANOMA; UBIQUITIN; PS-341; STRESS	The proteasome inhibitor bortezomib is emerging as a potent anti-cancer agent. Still, recent clinical trials have revealed a significant secondary toxicity of bortezomib. Consequently, there is much interest in dissecting the mechanism of action of this compound to rationally improve its therapeutic index. The cytotoxic effect of bortezomib is frequently characterized by interfering with downstream events derived from the accumulation of proteasomal targets. Here we identify the first chemical agent able to act upstream of the proteasome to prevent cell killing by bortezomib. Specifically, we show that the polyhydroxyl compound Tiron can function as a competitive inhibitor of bortezomib. This effect of Tiron was surprising, since it is a classical radical spin trap and was expected to scavenge reactive oxygen species produced as a consequence of bortezomib action. The inhibitory effect of Tiron against bortezomib was selective, since it was not shared by other antioxidants, such as vitamin E, MnTBAP, L-N-acetyl-cysteine, and FK-506. Comparative analyses with nonboronated proteasome inhibitors (i.e. MG132) revealed a specificity of Tiron for bortezomib. We exploited this novel feature of Tiron to define the "point of no return" of proteasome inhibition in melanoma cells and to block cell death in a three-dimensional model of human skin. Cells from T-cell lymphoma, breast carcinoma, and non-small cell lung cancer were also responsive to Tiron, suggesting a broad impact of this agent as a bortezomib blocker. These results may have important implications for the analysis of bortezomib in vivo and for the design of drug mixtures containing proteasome inhibitors.	Univ Michigan, Ctr Comprehens Canc, Melanoma Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Soengas, MS (corresponding author), Univ Michigan, Ctr Comprehens Canc, Melanoma Program, 4217 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	soengas@umich.edu	Esteban, Jose/L-4944-2014; Soengas, Maria S/H-6455-2015; DENOYELLE, Christophe CD/K-6205-2015	Esteban, Jose/0000-0002-3759-3300; Soengas, Maria S/0000-0003-0612-6299; DENOYELLE, Christophe CD/0000-0001-7153-8826	NATIONAL CANCER INSTITUTE [R01CA107237] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2004, CLIN CANCER RES, V10, P3853, DOI 10.1158/1078-0432.CCR-03-0806; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Agterof MJ, 2005, NEW ENGL J MED, V352, P2534, DOI 10.1056/NEJMicm041166; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Blatt NB, 2002, J CLIN INVEST, V110, P1123, DOI 10.1172/JCI200216029; Boitano A, 2003, CANCER RES, V63, P6870; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; Ceolotto G, 2004, DIABETES, V53, P1344, DOI 10.2337/diabetes.53.5.1344; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Claycombe KJ, 2001, MUTAT RES-FUND MOL M, V475, P37, DOI 10.1016/S0027-5107(01)00077-X; Colson Kathleen, 2004, Clin J Oncol Nurs, V8, P473, DOI 10.1188/04.CJON.473-480; Dy GK, 2005, CLIN CANCER RES, V11, P3410, DOI 10.1158/1078-0432.CCR-04-2068; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; ISHIHARA K, 1991, INORG CHEM, V30, P2356, DOI 10.1021/ic00010a025; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kajstura J, 2001, DIABETES, V50, P1414, DOI 10.2337/diabetes.50.6.1414; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lightcap ES, 2000, CLIN CHEM, V46, P673; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; MacKenzie A, 1998, BRIT J PHARMACOL, V124, P719, DOI 10.1038/sj.bjp.0701899; Malassagne B, 2001, GASTROENTEROLOGY, V121, P1451, DOI 10.1053/gast.2001.29590; Markovic SN, 2005, CANCER-AM CANCER SOC, V103, P2584, DOI 10.1002/cncr.21108; McCurrach ME, 2001, METHOD CELL BIOL, V66, P197; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Melov S, 2002, ANN NY ACAD SCI, V959, P330, DOI 10.1111/j.1749-6632.2002.tb02104.x; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Miyajima A, 1999, JPN J CANCER RES, V90, P565, DOI 10.1111/j.1349-7006.1999.tb00784.x; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Novalija E, 2003, ANESTHESIOLOGY, V98, P1155, DOI 10.1097/00000542-200305000-00018; PALMER BS, 2004, AM J PHYSIOL, V287, pH1264; Park DJ, 2004, ANN MED, V36, P296, DOI 10.1080/07853890410029031; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Richardson P, 2003, CANCER TREAT REV, V29, P33, DOI 10.1016/S0305-7372(03)00080-X; Satyamoorthy K, 1999, CANCER METAST REV, V18, P401, DOI 10.1023/A:1006333627271; Schwartz Rowena, 2004, Oncology (Williston Park), V18, P14; Shao CY, 2002, ANALYST, V127, P1614, DOI 10.1039/b207869d; Shen SC, 2004, TOXICOL APPL PHARM, V197, P84, DOI 10.1016/j.taap.2004.02.002; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Suzuki TM, 1999, J CHEM SOC DALTON, P1639, DOI 10.1039/a900618d; Takahashi Y, 2003, J CARDIOVASC PHARM, V41, P162, DOI 10.1097/00005344-200302000-00003; Theron AJ, 2004, FREE RADICAL BIO MED, V36, P1408, DOI 10.1016/j.freeradbiomed.2004.02.064; Uttamsingh V, 2005, DRUG METAB DISPOS, V33, P1723, DOI 10.1124/dmd.105.005710; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Yamada J, 2003, NEUROSCI RES, V45, P1, DOI 10.1016/S0168-0102(02)00196-7; Yoshimura, 2001, ANAL SCI           S, V17, pI1475, DOI 10.14891/analscisp.17icas.0.i1475.0; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zhou XM, 2004, KIDNEY INT, V65, P139, DOI 10.1111/j.1523-1755.2004.00380.x; Zini R, 1998, LIFE SCI, V63, P357, DOI 10.1016/S0024-3205(98)00284-7	66	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1107	1118		10.1074/jbc.M511607200	http://dx.doi.org/10.1074/jbc.M511607200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278210	hybrid			2022-12-25	WOS:000234447200052
J	Liang, WC; Wu, XM; Peale, FV; Lee, CV; Meng, G; Gutierrez, J; Fu, L; Malik, AK; Gerber, HP; Ferrara, N; Fuh, G				Liang, WC; Wu, XM; Peale, FV; Lee, CV; Meng, G; Gutierrez, J; Fu, L; Malik, AK; Gerber, HP; Ferrara, N; Fuh, G			Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE; ANGIOGENIC SWITCH; ANGSTROM RESOLUTION; PROMOTER ACTIVITY; BEVACIZUMAB; COMPLEX; FAB; EXPRESSION; LETHALITY	To fully assess the role of VEGF-A in tumor angiogenesis, antibodies that can block all sources of vascular endothelial growth factor (VEGF) are desired. Selectively targeting tumor-derived VEGF overlooks the contribution of host stromal VEGF. Other strategies, such as targeting VEGF receptors directly or using receptor decoys, result in inhibiting not only VEGF-A but also VEGF homologues (e.g. placental growth factor, VEGF-B, and VEGF-C), which may play a role in angiogenesis. Here we report the identification of novel anti-VEGF antibodies, B20 and G6, from synthetic antibody phage libraries, which block both human and murine VEGF action in vitro. Their affinity-improved variants completely inhibit three human tumor xenografts in mice of skeletal muscle, colorectal, and pancreatic origins (A673, HM-7, and HPAC). Avastin, which only inhibits the tumor-derived human VEGF, is similar to 90% effective at inhibiting HM-7 and A673 growth but is < 50% effective at inhibiting HPAC growth. Indeed, HPAC tumors contain more host stroma invasion and stroma-derived VEGF than other tumors. Thus, the functional contribution of stromal VEGF varies greatly among tumors, and systemic blockade of both tumor and stroma-derived VEGF is sufficient for inhibiting the growth of tumor xenografts.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay & Automat Technol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Fuh, G (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	nf@gene.com; gml@gene.com		MALIK, AJAY/0000-0002-4831-3597				Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Barbera-Guillem E, 2002, CANCER RES, V62, P7042; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 2005, CANCER RES, V65, P671; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; HLATKY L, 1994, CANCER RES, V54, P6083; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kishimoto J, 2000, AM J PATHOL, V157, P103, DOI 10.1016/S0002-9440(10)64522-1; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; Presta LG, 1997, CANCER RES, V57, P4593; Rodriguez CR, 1998, J IMMUNOL METHODS, V219, P45, DOI 10.1016/S0022-1759(98)00131-8; Samson M, 2004, J CLIN ENDOCR METAB, V89, P4078, DOI 10.1210/jc.2003-032024; Shi YP, 1999, BIOCHEM BIOPH RES CO, V254, P480, DOI 10.1006/bbrc.1998.9966; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Viloria-Petit A, 2003, EMBO J, V22, P4091, DOI 10.1093/emboj/cdg408; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	44	285	365	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					951	961		10.1074/jbc.M508199200	http://dx.doi.org/10.1074/jbc.M508199200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278208	hybrid			2022-12-25	WOS:000234447200034
J	Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K				Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K			Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53	ONCOGENE			English	Article						Cdt1; genomic instability; p53; cancer	DNA-REPLICATION; CELL-CYCLE; CANCER; GEMININ; GENE; EXPRESSION; REREPLICATION; INHIBITION; PROTEIN; MARKER	The exact duplication of chromosomal DNA during each cell cycle ensures the correct inheritance of genetic material from mother to daughter cells. In eukaryotic cells, DNA replication can occur only when the origin of DNA replication is accurately marked by a group of proteins termed licensing proteins. One such protein is Cdt1, which is recruited first to the origin of DNA replication followed by cell division cycle 6 (Cdc6) and mini-chromosome maintenance proteins (Mcms). We previously reported that NIH3T3 cells overexpressing Cdt1 readily formed tumors in mice. To further investigate its oncogenic mechanism, we generated transgenic mice expressing Cdt1 in thymocytes. Our studies demonstrated that T-cell-directed Cdt1 transgenic mice showed normal T-cell development. However, such transgenic mice developed thymic lymphoblastic lymphoma when crossed with p53 null mice. Furthermore, tumor cells derived from NIH3T3 cells overexpressing Cdt1 displayed numerical and structural chromosomal aberrations in the form of ploidy, double minutes, translocation, inversion, chromosome end-to-end fusion and robertsonian mutation. Collectively, our studies suggest that Cdt1 overexpression most likely contributes to tumorigenecity by causing genomic instability.	Washington Univ, Sch Med, Dept Pathol & Immunol, Suwon, South Korea; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea; Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA	Ajou University; Washington University (WUSTL)	Choi, K (corresponding author), Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu	Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA10445] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Bond L, 2002, ARCH PATHOL LAB MED, V126, P1163; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJITA M, 1999, FRONT BIOSCI, V4, P816; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; KAMB A, 1994, SCIENCE, V264, P440; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; MOIR D, 1982, GENETICS, V100, P547; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohta S, 2001, ONCOL REP, V8, P1063; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; Saxena S, 2003, CELL CYCLE, V2, P283, DOI 10.4161/cc.2.4.443; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shreeram S, 2003, Prog Cell Cycle Res, V5, P287; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Whittaker AJ, 2000, GENE DEV, V14, P1765; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8176	8186		10.1038/sj.onc.1208881	http://dx.doi.org/10.1038/sj.onc.1208881			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16261166				2022-12-25	WOS:000233809400009
J	Yang, SC; Levine, H; Onuchic, JN; Cox, DL				Yang, SC; Levine, H; Onuchic, JN; Cox, DL			Structure of infectious prions: stabilization by domain swapping	FASEB JOURNAL			English	Article						prion; domain swapping; beta-helix; amyloid	MOLECULAR-DYNAMICS; PROTEIN; MECHANISM; SIMULATIONS; OLIGOMER; FIBERS; CORE	A candidate structure for the minimal prion infectious unit is a recently discovered protein oligomer modeled as a beta-helical prion trimer (BPT); BPTs can stack to form cross-beta fibrils and may provide insight into protein aggregates of other amyloid diseases. However, the BPT lacks a clear intermonomer binding mechanism. Here we propose an alternative domain-swapped trimeric prion (DSTP) model and show with molecular dynamics (MD) that the DSTP has more favorable intermonomer hydrogen bonding and proline dihedral strain energy than the BPT. This new structural proposal may be tested by lysine and N terminus fluorescent resonance energy transfer (FRET) either directly on recombinant prion protein amyloid aggregates or on synthetic constructs that contain the proline/lysine-rich hinge region critical for domains to swap. In addition, the domain swapping may provide 1) intrinsic entanglement, which can contribute to the remarkable temperature stability of the infectious prion structure and help explain the absence of PrPSc monomers, 2) insight into why specific prolines are potentially relevant to three inherited forms of prion disease, and 3) a simple explanation of prion strains assuming the strain is encoded in the monomer number of the oligomers.	Univ Calif San Diego, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA; Univ Calif Davis, Dept Phys, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California Davis	Cox, DL (corresponding author), Univ Calif San Diego, Ctr Theoret Biol Phys, MC 0374,9500 Gilman Dr, La Jolla, CA 92093 USA.	cox@physics.ucdavis.edu	Levine, Herbert/C-1704-2008; Yang, Sichun/B-1608-2008	Levine, Herbert/0000-0002-8819-9055; Yang, Sichun/0000-0002-1726-0576				BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; May BCH, 2004, TRENDS BIOCHEM SCI, V29, P162, DOI 10.1016/j.tibs.2004.02.008; Mobley DL, 2003, BIOPHYS J, V85, P2213, DOI 10.1016/S0006-3495(03)74647-5; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Prusiner SB, 2004, PRION BIOL DIS; Pye VE, 2004, J BIOL CHEM, V279, P40729, DOI 10.1074/jbc.M403751200; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Sinha N, 2001, PROTEIN ENG, V14, P93, DOI 10.1093/protein/14.2.93; Stork M, 2005, BIOPHYS J, V88, P2442, DOI 10.1529/biophysj.104.052415; Sugimoto T, 2003, CHEM ENG TECHNOL, V26, P313, DOI 10.1002/ceat.200390048; Welker E, 2002, J BIOL CHEM, V277, P33477, DOI 10.1074/jbc.M204273200; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Yang SC, 2004, P NATL ACAD SCI USA, V101, P13786, DOI 10.1073/pnas.0403724101	28	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1778	1782		10.1096/fj.05-4067hyp	http://dx.doi.org/10.1096/fj.05-4067hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260647				2022-12-25	WOS:000234053100029
J	Paruch, S; El-Benna, J; Djerdjouri, B; Marullo, S; Perianin, A				Paruch, S; El-Benna, J; Djerdjouri, B; Marullo, S; Perianin, A			A role of p44/42 mitogen-activated protein kinases in formyl-peptide receptor-mediated phospholipase D activity and oxidant production	FASEB JOURNAL			English	Article						MAP kinases; phosphorylation; chemoattractant; superoxide	NEUTROPHIL RESPIRATORY BURST; STIMULATED HUMAN NEUTROPHILS; PHOSPHATIDIC-ACID PRODUCTION; PHORBOL-MYRISTATE ACETATE; SMOOTH-MUSCLE-CELLS; MET-LEU-PHE; MAP KINASE; NADPH OXIDASE; COMPONENT P47(PHOX); NEURITE OUTGROWTH	Phosphatidylcholine-specific phospholipase D (PLD) is a major cellular source of phosphatidic acid and choline, which regulate various physiopathological processes. PLD activation mediated by chemoattractants involves protein phosphorylation. This study provides pharmacological and biochemical evidence of a major role of p44/42 MAP kinases (ERK1/2) in PLD activation induced by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine ( fMLP). ERK1/ 2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity. Conversely, a constitutively activated MEK1 mutant expressed in HEK 293T cells potentiated fMLP-induced PLD activity. Expression of inactive PLD mutants showed that PLD2, but not PLD1, contributed to fMLP-mediated PLD activity. PLD2 co-immunoprecipitated with ERK1/ 2 and became phosphorylated on MAP kinase consensus sites in fMLP-stimulated cells. In cell-free systems, ERK2 gave rise to strong ATP-dependent PLD activity and directly phosphorylated PLD2 that generated two phosphopeptides only after tryptic digestion. Finally, pharmacological inhibition of ERK activation and the inhibition of PLD expression by antisense oligonucleotides in HL-60 cells suggest that the ERK/PLD2 pathway contributes to fMLP-mediated oxidant production. In conclusion, the fMLP-mediated PLD activity is regulated by ERK1/ 2, involving a predominant contribution of PLD2. The ERK/PLD2 coupling may provide potential pharmacological targets to control PLD-associated cellular dysfunctions.	CNRS, UMR 8104, Dept Biol Cellulaire, Inst Cochin,INSERM U567, F-75018 Paris, France; Univ Paris 05, F-75018 Paris, France; INSERM U683, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Perianin, A (corresponding author), Hop Cochin, Dept Biol Cellulaire, Pavillon G Roussy 5eme Etage,27,Rue Faubourt St J, F-75014 Paris, France.	perianin@cochin.inserm.fr	Djerdjouri, Bahia/I-2533-2019; Marullo, Stefano/C-6142-2008	Marullo, Stefano/0000-0001-9604-9973				BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; Downey GP, 1998, J IMMUNOL, V160, P434; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El Marjou M, 2000, LEUKEMIA, V14, P2118; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li F, 2005, J PHARMACOL EXP THER, V312, P1043, DOI 10.1124/jpet.104.076588; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LU DJ, 1993, BLOOD CELLS, V19, P343; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; Nakashima S, 1998, BBA-LIPID LIPID MET, V1389, P173, DOI 10.1016/S0005-2760(97)00153-7; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; PAI JK, 1988, J BIOL CHEM, V263, P12472; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; Pedruzzi E, 1998, CELL SIGNAL, V10, P481, DOI 10.1016/S0898-6568(97)00174-5; PERIANIN A, 1994, FEBS LETT, V342, P135, DOI 10.1016/0014-5793(94)80487-7; Rais S, 1998, CELL SIGNAL, V10, P121, DOI 10.1016/S0898-6568(97)00116-2; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Watanabe H, 2004, J BIOL CHEM, V279, P37870, DOI 10.1074/jbc.M402610200; Watanabe H, 2004, J NEUROCHEM, V89, P142, DOI 10.1111/j.1471-4159.2004.02308.x; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	51	24	25	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					142	+		10.1096/fj.05-3881fje	http://dx.doi.org/10.1096/fj.05-3881fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16253958				2022-12-25	WOS:000232991100005
J	He, B; Mirza, M; Weber, GF				He, B; Mirza, M; Weber, GF			An osteopontin splice variant induces anchorage independence in human breast cancer cells	ONCOGENE			English	Article						breast cancer; alternative splicing; cell adhesion; metastasis; soft agar	FALSE DISCOVERY RATE; METASTATIC PHENOTYPE; SIGNALING PATHWAY; MOUSE OSTEOPONTIN; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; GENE; ACTIVATION; LIGAND	In malignant tumors, metastasis genes are typically deregulated by aberrant expression or splicing. Osteopontin is expressed at high levels by various cancers and contributes importantly to their invasive potential. In contrast, osteopontin derived from host cells induces cellular immunity and could bolster antitumor protection by cytotoxic T lymphocytes. Here we show that breast cancer cells express multiple splice variants of osteopontin. According to RT-PCR analysis of human breast tissue specimens, the splice variant osteopontin-c is a highly specific marker for transformed cells, which is not expressed in their surrounding normal tissue. The full-length form of osteopontin aggregates in the presence of physiologic amounts of calcium and, in this state, leads to enhanced cell adhesion. Ostensibly, this effect is inhibitory for tumor cell dissemination. The shortest splice variant, osteopontin-c, does not aggregate in the presence of calcium and enhances clone formation in soft agar. According to microarray analysis, osteopontin-c induces the expression of oxidoreductases, consistent with protection from anoikis during anchorage-independent growth. These studies de. ne a third functional domain of osteopontin, beside the C-terminal CD44-binding site and the central integrin-binding site. They also provide evidence for a bifunctional character of osteopontin, with the soluble form supporting invasiveness and the aggregated form promoting adhesion.	Univ Cincinnati, Med Ctr, Coll Pharm, Cincinnati, OH 45267 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA USA	University System of Ohio; University of Cincinnati; Tufts Medical Center	Weber, GF (corresponding author), Univ Cincinnati, Med Ctr, Coll Pharm, 3225 Eden Ave, Cincinnati, OH 45267 USA.	georg.weber@uc.edu			NCI NIH HHS [CA76176] Funding Source: Medline; NCRR NIH HHS [M01 RR 08084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adler B, 2001, CELL IMMUNOL, V210, P30, DOI 10.1006/cimm.2001.1800; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Barraclough R, 1998, BIOCHEM SOC SYMP, P273; Bayless KJ, 1998, J CELL SCI, V111, P1165; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Chen PW, 1996, ANN NY ACAD SCI, V795, P325, DOI 10.1111/j.1749-6632.1996.tb52683.x; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2001, ONCOGENE, V20, P1793, DOI 10.1038/sj.onc.1204358; Goldsmith HL, 2002, ANN BIOMED ENG, V30, P840, DOI 10.1114/1.1497383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HWANG S, 1994, J BIOL CHEM, V269, P711; KARYALA S, 2003, CARDIOVASC TOXICOL, V4, P47; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; Kon S, 2000, J CELL BIOCHEM, V77, P487; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; O'Regan AW, 2000, J LEUKOCYTE BIOL, V68, P495; Oates AJ, 1996, ONCOGENE, V13, P97; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Rudland PS, 2002, CANCER RES, V62, P3417; SAITOH Y, 1995, LAB INVEST, V72, P55; Sartor M, 2004, BIOTECHNIQUES, V36, P790, DOI 10.2144/04365ST02; Seraj MJ, 2000, CANCER RES, V60, P2764; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; TANABE KK, 1995, ANN SURG, V222, P493; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Weber GF, 2000, J MOL MED-JMM, V78, P404, DOI 10.1007/s001090000138; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; Weber GF, 2000, BRAIN RES BULL, V53, P421, DOI 10.1016/S0361-9230(00)00379-8; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEBER GF, 1999, INFLAMMATORY CELLS M, P97; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x	48	138	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2192	2202		10.1038/sj.onc.1209248	http://dx.doi.org/10.1038/sj.onc.1209248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288209				2022-12-25	WOS:000236581200006
J	Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC				Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC			Redundancy of DNA helicases in p53-mediated apoptosis	ONCOGENE			English	Article						helicases; apoptosis; microinjection	BLOOMS-SYNDROME PROTEIN; WERNERS-SYNDROME GENES; SACCHAROMYCES-CEREVISIAE; GENOMIC INSTABILITY; XERODERMA-PIGMENTOSUM; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; RECQ HELICASES; SYNDROME CELLS; SGS1 MUTANT	A subset of DNA helicases, the RecQ family, has been found to be associated with the p53-mediated apoptotic pathway and is involved in maintaining genomic integrity. This family contains the BLM and WRN helicases, in which germline mutations are responsible for Bloom and Werner syndromes, respectively. TFIIH DNA helicases, XPB and XPD, are also components in this apoptotic pathway. We hypothesized that there may be some redundancy between helicases in their ability to complement the attenuated p53-mediated apoptotic levels seen in cells from individuals with diseases associated with these defective helicase genes. The attenuated apoptotic phenotype in Bloom syndrome cells was rescued not only by ectopic expression of BLM, but also by WRN or XPB, both 30-50 helicases, but not expression of the 50-30 helicase XPD. Overexpression of Sgs1, a WRN/BLM yeast homolog, corrected the reduction in BS cells only, which is consistent with Sgs1 being evolutionarily most homologous to BLM. A restoration of apoptotic levels in cells from WS, XPB or XPD patients was attained only by overexpression of the specific helicase. Our data suggest a limited redundancy in the pathways of these RecQ helicases in p53-induced apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, DHHS, NIH, Baltimore, MD USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Hickson, Ian/0000-0002-0583-566X; von Kobbe, Cayetano/0000-0003-3895-3790	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 BC005795-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajima J, 2002, MUTAT RES-FUND MOL M, V504, P157, DOI 10.1016/S0027-5107(02)00089-1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Lane D, 2004, CARCINOGENESIS, V25, P1077, DOI 10.1093/carcin/bgh186; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lillard-Wetherell K, 2005, CANCER RES, V65, P5520, DOI 10.1158/0008-5472.CAN-05-0632; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Robles AI, 2001, ACTA ONCOL, V40, P696; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sanz MM, 2000, AM J HUM GENET, V67, P89; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Watt PM, 1996, GENETICS, V144, P935; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	40	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2119	2123		10.1038/sj.onc.1209242	http://dx.doi.org/10.1038/sj.onc.1209242			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288211	Green Accepted			2022-12-25	WOS:000236359700015
J	Seigneurin-Berny, D; Gravot, A; Auroy, P; Mazard, C; Kraut, A; Finazzi, G; Grunwald, D; Rappaport, F; Vavasseur, A; Joyard, J; Richaud, P; Rolland, N				Seigneurin-Berny, D; Gravot, A; Auroy, P; Mazard, C; Kraut, A; Finazzi, G; Grunwald, D; Rappaport, F; Vavasseur, A; Joyard, J; Richaud, P; Rolland, N			HMA1, a new Cu-ATPase of the chloroplast envelope, is essential for growth under adverse light conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL TRANSPORT; P-TYPE ATPASE; SUPEROXIDE-DISMUTASE; P-1B-TYPE ATPASE; ARABIDOPSIS; MEMBRANE; IDENTIFICATION; ATHMA4; PROTEINS; DATABASE	Although ions play important roles in the cell and chloroplast metabolism, little is known about ion transport across the chloroplast envelope. Using a proteomic approach specifically targeted to the Arabidopsis chloroplast envelope, we have identified HMA1, which belongs to the metal-transporting P-1B-type ATPases family. HMA1 is mainly expressed in green tissues, and we validated its chloroplast envelope localization. Yeast expression experiments demonstrated that HMA1 is involved in copper homeostasis and that deletion of its N-terminal His-domain partially affects the metal transport. Characterization of hma1 Arabidopsis mutants revealed a lower chloroplast copper content and a diminution of the total chloroplast superoxide dismutase activity. No effect was observed on the plastocyanin content in these lines. The hma1 insertional mutants grew like WT plants in standard condition but presented a photosensitivity phenotype under high light. Finally, direct biochemical ATPase assays performed on purified chloroplast envelope membranes showed that the ATPase activity of HMA1 is specifically stimulated by copper. Our results demonstrate that HMA1 offers an additional way to the previously characterized chloroplast envelope Cu-ATPase PAA1 to import copper in the chloroplast.	Univ Grenoble 1, INRA, Physiol Cellulaire Vegetale Lab, CNRS,UMR 5168,CEA,Dept Reponse & Dynam Cellulaire, F-38054 Grenoble 9, France; Univ Grenoble 1, INSERM, Lab Canaux Ion Fonct & Pathol, EMI 9931,CEA,DRDC, F-38054 Grenoble 9, France; Univ Paris 06, CNRS, UMR 7141, Inst Biol Physicochim, F-75005 Paris, France; Univ Aix Marseille 2, CEA Cadarache, CNRS,Dept Ecophysiol Vegetale & Microbiol, Lab Echanges Membranaires & Signalisat,UMR 6191, F-13108 St Paul Les Durance, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Seigneurin-Berny, D (corresponding author), Univ Grenoble 1, INRA, Physiol Cellulaire Vegetale Lab, CNRS,UMR 5168,CEA,Dept Reponse & Dynam Cellulaire, 17 Rue Martyrs, F-38054 Grenoble 9, France.	daphne.berny@cea.fr; nrolland@cea.fr	ROLLAND, Norbert/B-4405-2012; SEIGNEURIN-BERNY, Daphne/C-8412-2017	ROLLAND, Norbert/0000-0003-1959-6636; SEIGNEURIN-BERNY, Daphne/0000-0002-7436-9885; Rappaport, Fabrice/0000-0001-9377-4934; Gravot, Antoine/0000-0001-9125-1494				Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Baxter I, 2003, PLANT PHYSIOL, V132, P618, DOI 10.1104/pp.103.021923; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLUMWALD E, 1985, P NATL ACAD SCI USA, V82, P3683, DOI 10.1073/pnas.82.11.3683; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugiere S, 2004, PHYTOCHEMISTRY, V65, P1693, DOI 10.1016/j.phytochem.2004.03.028; BRUINSMA J, 1961, BIOCHIM BIOPHYS ACTA, V52, P576, DOI 10.1016/0006-3002(61)90418-8; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Fox TC, 1998, ANNU REV PLANT PHYS, V49, P669, DOI 10.1146/annurev.arplant.49.1.669; Gravot A, 2004, FEBS LETT, V561, P22, DOI 10.1016/S0014-5793(04)00072-9; Hanikenne M, 2005, PLANT PHYSIOL, V137, P428, DOI 10.1104/pp.104.054189; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Hussain D, 2004, PLANT CELL, V16, P1327, DOI 10.1105/tpc.020487; Joliot P, 2005, P NATL ACAD SCI USA, V102, P4913, DOI 10.1073/pnas.0501268102; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561; Levine A., 1999, PLANT RESPONSES ENV, P247, DOI 10.1201/9780203743157-11; Mana-Capelli S, 2003, J BIOL CHEM, V278, P40534, DOI 10.1074/jbc.M306907200; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Marmagne A, 2004, MOL CELL PROTEOMICS, V3, P675, DOI 10.1074/mcp.M400001-MCP200; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mills RF, 2005, FEBS LETT, V579, P783, DOI 10.1016/j.febslet.2004.12.040; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Rizhsky L, 2003, J BIOL CHEM, V278, P38921, DOI 10.1074/jbc.M304987200; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Ruzsa SM, 2003, BIOCHEMISTRY-US, V42, P1508, DOI 10.1021/bi020551x; Samson F, 2002, NUCLEIC ACIDS RES, V30, P94, DOI 10.1093/nar/30.1.94; Schwacke R, 2003, PLANT PHYSIOL, V131, P16, DOI 10.1104/pp.011577; SENGUPTA A, 1993, PLANT PHYSIOL, V103, P1067, DOI 10.1104/pp.103.4.1067; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Teyssier E, 1996, PLANT J, V10, P903, DOI 10.1046/j.1365-313X.1996.10050903.x; Tong L, 2002, J BACTERIOL, V184, P5027, DOI 10.1128/JB.184.18.5027-5035.2002; Verret F, 2004, FEBS LETT, V576, P306, DOI 10.1016/j.febslet.2004.09.023; Verret F, 2005, FEBS LETT, V579, P1515, DOI 10.1016/j.febslet.2005.01.065; Werhahn W, 2001, PLANT PHYSIOL, V125, P943, DOI 10.1104/pp.125.2.943; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4; Williams LE, 2005, TRENDS PLANT SCI, V10, P491, DOI 10.1016/j.tplants.2005.08.008	51	145	163	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2882	2892		10.1074/jbc.M508333200	http://dx.doi.org/10.1074/jbc.M508333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16282320	Green Submitted, hybrid			2022-12-25	WOS:000234931800057
J	Martin, V; Groenendyk, J; Steiner, SS; Guo, L; Dabrowska, M; Parker, JMR; Muller-Esterl, W; Opas, M; Michalak, M				Martin, V; Groenendyk, J; Steiner, SS; Guo, L; Dabrowska, M; Parker, JMR; Muller-Esterl, W; Opas, M; Michalak, M			Identification by mutational analysis of amino acid residues essential in the chaperone function of calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; P-DOMAIN; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; CALNEXIN; PROTEIN; BINDING; ERP57	Calreticulin is a Ca2+-binding chaperone that resides in the lumen of the endoplasmic reticulum and is involved in the regulation of intra-cellular Ca2+ homeostasis and in the folding of newly synthesized gly-coproteins. In this study, we have used site-specific mutagenesis to map amino acid residues that are critical in calreticulin function. We have focused on two cysteine residues (Cys(88) and Cys(120)), which from a disulfide bridge in the N-terminal domain of calreticulin, on a tryptophan residue located in the carbohydrate binding site (Trp(302)), and on certain residues located at the tip of the "hairpin-like" P-domain of the protein (Glu(238), Glu(239), Asp(241), Glu(243), and Trp(244)). Calreticulin mutants were expressed in crt(-/-) fibroblasts, and bradykinin-dependent Ca2+ release was measured as a marker of calreticulin function. Bradykinin-dependent Ca2+ release from the endoplasmic reticulum was rescued by wild-type calreticulin and by the Glu(238), Glu(239), Asp(241), and Glu(243) mutants. The Cys(88) and Cys(120) mutants rescued the calreticulin-deficient phenotype only partially (similar to 40%), and the Trp(244) and Trp(302) mutants did not rescue it at all. We identified four amino acid residues (Glu(239), Asp(241), Glu(243), and Trp(244)) at the hairpin tip of the P-domain that are critical in the formation of a complex between ERp57 and calreticulin. Although the Glu(239), Asp(241), and Glu(243) mutants did not bind ERp57 efficiently, they fully restored bradykinin-dependent Ca2+ release in crt(-/-) cells. This indicates that binding of ERp57 to calreticulin may not be critical for the chaperone function of calreticulin with respect to the bradykinin receptor.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Membrance Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Hosp Frankfurt, Inst Biochem, D-60590 Frankfurt, Germany; Univ Toronto, Dept Pathol & Lab Med, Toronto, ON M5S 1A8, Canada	University of Alberta; University of Alberta; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Toronto	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	Marek.Michalak@ualberta.ca	Guo, Lei/E-9232-2011	guo, lei/0000-0002-0402-4152				Andrin C, 2000, PROTEIN EXPRES PURIF, V20, P207, DOI 10.1006/prep.2000.1291; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2002, J MOL BIOL, V322, P773, DOI 10.1016/S0022-2836(02)00812-4; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Guo L, 2003, J BIOL CHEM, V278, P50645, DOI 10.1074/jbc.M309497200; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kapoor M, 2004, BIOCHEMISTRY-US, V43, P97, DOI 10.1021/bi0355286; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	32	57	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2338	2346		10.1074/jbc.M508302200	http://dx.doi.org/10.1074/jbc.M508302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16291754	hybrid			2022-12-25	WOS:000234760400059
J	Xu, LM; Harada, H; Yokohama-Tamaki, T; Matsumoto, S; Tanaka, J; Taniguchi, A				Xu, LM; Harada, H; Yokohama-Tamaki, T; Matsumoto, S; Tanaka, J; Taniguchi, A			Reuptake of extracellular amelogenin by dental epithelial cells results in increased levels of amelogenin mRNA through enhanced mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN ALPHA; RECOMBINANT AMELOGENIN; GENE-EXPRESSION; GROWTH; CDNA; IDENTIFICATION; CRYSTALS; MOLECULE; SEQUENCE; APATITE	Amelogenin is an extracellular matrix protein secreted by ameloblasts and is a major component of enamel matrix. Recently, in addition to their role in enamel formation, the biological activity of enamel proteins in the process of cell differentiation has recently become widely appreciated. In this study, we examined the biological activity of amelogenin on ameloblast differentiation. Recombinant mouse amelogenin (rm-amelogenin) enhanced the expression of endogenous amelogenin mRNA in a cultured dental epithelial cell line (HAT-7), despite a lack of increased amelogenin promoter activity. To solve this discrepancy, we analyzed the effects of rm-amelogenin on the stability of amelogenin mRNA. The half-life of amelogenin mRNA is extremely short, but in the presence of rm-amelogenin its half-life was extended three times longer than the control. Furthermore, we showed the entry of exogenous fluorescein isothiocyanate-conjugated rm-amelogenin into the cytoplasm of HAT-7 cells. It follows from our results that exogenous amelogenin increases amelogenin mRNA levels through stabilization of mRNA in the cytoplasm of HAT-7 cells. Here we speculated that during differentiation, dental epithelial cells utilize a unique mechanism for increasing the production of amelogenin, the reuptake of secreted amelogenin.	Osaka Univ, Grad Sch Dent, Dept Oral Anat & Dev Biol, Suita, Osaka 5650871, Japan; Natl Inst Mat Sci, Biomat Ctr, Tsukuba, Ibaraki 3050044, Japan; Sekisui Chem Co Ltd, New Business Off Dev Ctr Res & Dev & Technol Ctr, Shimamoto, Osaka 6188589, Japan	Osaka University; National Institute for Materials Science; Sekisui Chemical Co Ltd	Harada, H (corresponding author), Osaka Univ, Grad Sch Dent, Dept Oral Anat & Dev Biol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	hide-h@dent.osaka-u.ac.jp; TANIGUCHI.Akiyoshi@nims.go.jp	Wada, Ken-Ichi/GVS-5955-2022; TANIGUCHI, Akiyoshi/H-2896-2011; Harada, Hidemitsu/P-5692-2017	Wada, Ken-Ichi/0000-0001-5144-905X; Harada, Hidemitsu/0000-0002-9724-8568				Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Boabaid F, 2004, J PERIODONTOL, V75, P1126, DOI 10.1902/jop.2004.75.8.1126; BONASS WA, 1994, BBA-GENE STRUCT EXPR, V1219, P690, DOI 10.1016/0167-4781(94)90228-3; Bouropoulos N, 2003, CALCIFIED TISSUE INT, V72, P599, DOI 10.1007/s00223-002-1099-1; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; Coin R, 1999, EUR J ORAL SCI, V107, P487, DOI 10.1046/j.0909-8836.1999.eos107611.x; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Goldberg M, 2003, AM J DENT, V16, P66; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; Hu CC, 1996, J DENT RES, V75, P1735, DOI 10.1177/00220345960750100501; Hunter GK, 1999, CALCIFIED TISSUE INT, V65, P226, DOI 10.1007/s002239900688; Iijima M, 2002, J DENT RES, V81, P69, DOI 10.1177/154405910208100115; INAI T, 1991, ANAT REC, V229, P259, DOI 10.1002/ar.1092290213; Kawano S, 2002, CONNECT TISSUE RES, V43, P409, DOI 10.1080/03008200290000637; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; Li R, 1995, J DENT RES, V74, P1880, DOI 10.1177/00220345950740121101; Moradian-Oldak J, 1998, BIOPOLYMERS, V46, P225, DOI 10.1002/(SICI)1097-0282(19981005)46:4<225::AID-BIP4>3.0.CO;2-R; MoradianOldak J, 1996, BIOCHEM J, V318, P1015, DOI 10.1042/bj3181015; NAKAMURA M, 1994, ANAT RECORD, V238, P383, DOI 10.1002/ar.1092380313; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Nowak W, 2002, AM J PHYSIOL-CELL PH, V282, pC1322, DOI 10.1152/ajpcell.00561.2001; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; Simmer JP, 1995, CONNECT TISSUE RES, V32, P131, DOI 10.3109/03008209509013715; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; Taguchi T, 2005, BIOMATERIALS, V26, P1247, DOI 10.1016/j.biomaterials.2004.04.029; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; Veis A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200; Viswanathan HL, 2003, J PERIODONTOL, V74, P1423, DOI 10.1902/jop.2003.74.10.1423; Wang HJ, 2005, J BONE MINER RES, V20, P1032, DOI 10.1359/JBMR.050111; Wen HB, 1999, BIOMATERIALS, V20, P1717, DOI 10.1016/S0142-9612(99)00085-X; Wen HB, 2000, J BIOMED MATER RES, V52, P762, DOI 10.1002/1097-4636(20001215)52:4<762::AID-JBM22>3.3.CO;2-N; Xu LM, 2003, BIOCHEM BIOPH RES CO, V307, P1070, DOI 10.1016/S0006-291X(03)01314-7; ZEICHNERDAVID M, 1995, INT J DEV BIOL, V39, P69; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273	37	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2257	2262		10.1074/jbc.M507695200	http://dx.doi.org/10.1074/jbc.M507695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16293627	hybrid			2022-12-25	WOS:000234760400050
J	Kwon, ES; Jeong, JH; Roe, JH				Kwon, ES; Jeong, JH; Roe, JH			Inactivation of homocitrate synthase causes lysine auxotrophy in copper/zinc-containing superoxide dismutase-deficient yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID BIOSYNTHESIS; CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; PENICILLIUM-CHRYSOGENUM; REGULATORY MECHANISM; OXIDATIVE DAMAGE; GENE; PROTEIN; MUTATIONS; ENZYMES	The fission yeast Schizosaccharomyces pombe lacking copper/zinc-containing superoxide dismutase ( CuZn-SOD) is auxotrophic for lysine and sulfurous amino acids under aerobic growth conditions. A multicopy suppressor gene (phx1(+)) that restored the growth of CuZn-SOD-deficient cells on minimal medium was isolated. It encodes a putative DNA-binding protein with a conserved homeobox domain. Overproduction of Phx1 increased the amount of several proteins, and one of those turned out to be a putative homocitrate synthase (HCS) encoded by the lys4(+) gene in S. pombe as judged by mass spectrometric analysis. Consistent with this observation, overexpression of the lys4(+) gene increased HCS enzyme activity and was sufficient to suppress the lysine requirement of the CuZn-SOD-deficient cells. Enzyme activity and Western blot analyses revealed that the activity and protein level of HCS were dramatically reduced upon depletion of CuZn-SOD. Treatment of exponentially growing S. pombe cells with paraquat, a superoxide generator, caused a decrease in the amount of Lys4 protein as expected. These results led us to conclude that HCS, the first enzyme in the alpha-aminoadipate-mediated pathway for lysine synthesis common in fungi and some bacteria, is a labile target of oxidative stress caused by CuZn-SOD depletion and that its synthesis is positively regulated by the putative transcriptional regulator Phx1.	Seoul Natl Univ, Sch Biol Sci, Mol Microbiol Lab, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Roe, JH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Mol Microbiol Lab, Bldg 18,Rm 308, Seoul 151742, South Korea.	jhroe@snu.ac.kr						Alfa C, 1993, EXPT FISSION YEAST L; Andi B, 2005, J BIOL CHEM, V280, P31624, DOI 10.1074/jbc.M502846200; Banuelos O, 2002, MOL GENET GENOMICS, V266, P711, DOI 10.1007/s00438-001-0591-z; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; Chen SP, 1997, J BIOL CHEM, V272, P10839; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; Feller A, 1999, EUR J BIOCHEM, V261, P163, DOI 10.1046/j.1432-1327.1999.00262.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRAY GS, 1976, CAN J MICROBIOL, V22, P1664, DOI 10.1139/m76-246; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Irvin SD, 1998, J MOL EVOL, V46, P401, DOI 10.1007/PL00006319; JAKLITSCH WM, 1990, BIOCHEM J, V269, P247, DOI 10.1042/bj2690247; Jensen LT, 2004, J BIOL CHEM, V279, P29938, DOI 10.1074/jbc.M402795200; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lee J, 2002, BIOCHEM BIOPH RES CO, V297, P854, DOI 10.1016/S0006-291X(02)02290-8; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mutoh N, 2002, CURR GENET, V41, P82, DOI 10.1007/s00294-002-0288-9; Nishida H, 1999, GENOME RES, V9, P1175, DOI 10.1101/gr.9.12.1175; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TRACY JW, 1975, P NATL ACAD SCI USA, V72, P1802, DOI 10.1073/pnas.72.5.1802; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; Wallace MA, 2004, J BIOL CHEM, V279, P32055, DOI 10.1074/jbc.M403590200; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; Wuerges J, 2004, P NATL ACAD SCI USA, V101, P8569, DOI 10.1073/pnas.0308514101; Wulandari AP, 2002, FEBS LETT, V522, P35, DOI 10.1016/S0014-5793(02)02877-6; YE ZH, 1988, J BACTERIOL, V170, P5968, DOI 10.1128/jb.170.12.5968-5970.1988; YURA T, 1957, BIOCHIM BIOPHYS ACTA, V24, P648, DOI 10.1016/0006-3002(57)90266-4	42	9	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1345	1351		10.1074/jbc.M506611200	http://dx.doi.org/10.1074/jbc.M506611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16299000	hybrid			2022-12-25	WOS:000234652000009
J	Melnyk, RA; Hewitt, KM; Lacy, DB; Lin, HC; Gessner, CR; Li, S; Woods, VL; Collier, RJ				Melnyk, RA; Hewitt, KM; Lacy, DB; Lin, HC; Gessner, CR; Li, S; Woods, VL; Collier, RJ			Structural determinants for the binding of anthrax lethal factor to oligomeric protective antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE MASS-SPECTROMETRY; AMIDE HYDROGEN/DEUTERIUM EXCHANGE; HYDROGEN-DEUTERIUM EXCHANGE; TERMINAL SRC KINASE; PROTEIN-KINASE; EDEMA FACTOR; BACILLUS-ANTHRACIS; ESCHERICHIA-COLI; TOXIN; DXMS	Anthrax lethal toxin assembles at the surface of mammalian cells when the lethal factor (LF) binds via its amino-terminal domain, LFN, to oligomeric forms of activated protective antigen (PA). LF(.)PA complexes are then trafficked to acidified endosomes, where PA forms heptameric pores in the bounding membrane and LF translocates through these pores to the cytosol. We used enhanced peptide amide hydrogen/deuterium exchange mass spectrometry and directed mutagenesis to define the surface on LFN that interacts with PA. A continuous surface encompassing one face of LFN became protected from deuterium exchange when LFN was bound to a PA dimer. Directed mutational analysis demonstrated that residues within this surface on LFN interact with Lys-197 on two PA subunits simultaneously, thereby showing that LFN spans the PA subunit: subunit interface and explaining why heptameric PA binds a maximum of three LFN molecules. Our results elucidate the structural basis for anthrax lethal toxin assembly and may be useful in developing drugs to block toxin action.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Harvard Medical School	Woods, VL (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	vwoods@ucsd.edu; jcollier@hms.harvard.edu	Melnyk, Roman/GQA-9908-2022; Lacy, D. Borden/AFQ-2203-2022	Collier, R John/0000-0002-2427-4239; Lacy, Borden/0000-0003-2273-8121	NATIONAL CANCER INSTITUTE [R21CA099835, R01CA105347, R33CA099835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021] Funding Source: NIH RePORTER; NCI NIH HHS [CA105347, CA099835] Funding Source: Medline; NIAID NIH HHS [AI22021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Burns-Hamuro LL, 2005, PROTEIN SCI, V14, P2982, DOI 10.1110/ps.051687305; Chauhan V, 2001, BIOCHEM BIOPH RES CO, V283, P308, DOI 10.1006/bbrc.2001.4777; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Derunes C, 2005, BIOCHEM BIOPH RES CO, V333, P925, DOI 10.1016/j.bbrc.2005.05.190; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; Englander JJ, 2003, P NATL ACAD SCI USA, V100, P7057, DOI 10.1073/pnas.1232301100; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Garcia RA, 2005, MOL PHARMACOL, V67, P1128, DOI 10.1124/mol.104.006346; Gupta P, 2001, BIOCHEM BIOPH RES CO, V280, P158, DOI 10.1006/bbrc.2000.4099; Hamuro Y, 2002, J MOL BIOL, V323, P871, DOI 10.1016/S0022-2836(02)01003-3; Hamuro Y, 2004, J MOL BIOL, V340, P1185, DOI 10.1016/j.jmb.2004.05.042; Hamuro Y, 2003, J MOL BIOL, V327, P1065, DOI 10.1016/S0022-2836(03)00234-1; Hamuro Y, 2002, J MOL BIOL, V321, P703, DOI 10.1016/S0022-2836(02)00419-9; Hoofnagle AN, 2003, ANNU REV BIOPH BIOM, V32, P1, DOI 10.1146/annurev.biophys.32.110601.142417; Iyer GH, 2005, J MOL BIOL, V351, P1110, DOI 10.1016/j.jmb.2005.06.011; Krantz BA, 2004, J MOL BIOL, V344, P739, DOI 10.1016/j.jmb.2004.09.067; Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380; Kumar P, 2001, INFECT IMMUN, V69, P6532, DOI 10.1128/IAI.69.10.6532-6536.2001; Lacy DB, 2005, P NATL ACAD SCI USA, V102, P16409, DOI 10.1073/pnas.0508259102; Lacy DB, 2002, J BIOL CHEM, V277, P3006, DOI 10.1074/jbc.M109997200; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Pantazatos D, 2004, P NATL ACAD SCI USA, V101, P751, DOI 10.1073/pnas.0307204101; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; QUINN CP, 1991, J BIOL CHEM, V266, P20124; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Singh A, 2002, FEMS MICROBIOL LETT, V212, P183, DOI 10.1111/j.1574-6968.2002.tb11264.x; Spraggon G, 2004, PROTEIN SCI, V13, P3187, DOI 10.1110/ps.04939904; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Wong L, 2004, J MOL BIOL, V341, P93, DOI 10.1016/j.jmb.2004.05.060; Woods VL, 2001, J CELL BIOCHEM, V84, P89, DOI 10.1002/jcb.10069; Yang J, 2005, J MOL BIOL, V346, P191, DOI 10.1016/j.jmb.2004.11.030; Zawadzki KM, 2003, PROTEIN SCI, V12, P1980, DOI 10.1110/ps.03166903; Zhang S, 2004, P NATL ACAD SCI USA, V101, P16756, DOI 10.1073/pnas.0405754101; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	46	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1630	1635		10.1074/jbc.M511164200	http://dx.doi.org/10.1074/jbc.M511164200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16293620	hybrid			2022-12-25	WOS:000234652000042
J	Baekgaard, L; Luoni, L; De Michelis, MI; Palmgren, MG				Baekgaard, L; Luoni, L; De Michelis, MI; Palmgren, MG			The plant plasma membrane Ca2+ pump ACA8 contains overlapping as well as physically separated autoinhibitory and calmodulin-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM-PUMP; TARGET RECOGNITION; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; STRUCTURAL BASIS; H+-ATPASE; CA2+-ATPASE; COMPLEX	In plant Ca2+ pumps belonging to the P-2B subfamily of P-type ATPases, the N-terminal cytoplasmic domain is responsible for pump autoinhibition. Binding of calmodulin (CaM) to this region results in pump activation but the structural basis for CaM activation is still not clear. All residues in a putative CaM-binding domain (Arg(43) to Lys(68)) were mutagenized and the resulting recombinant proteins were studied with respect to CaM binding and the activation state. The results demonstrate that (i) the binding site for CaM is overlapping with the autoinhibitory region and (ii) the autoinhibitory region comprises significantly fewer residues than the CaM-binding region. In a helical wheel projection of the CaM-binding domain, residues involved in autoinhibition cluster on one side of the helix, which is proposed to interact with an intramolecular receptor site in the pump. Residues influencing CaM negatively are situated on the other face of the helix, likely to face the cytosol, whereas residues controlling CaM binding positively are scattered throughout. We propose that early CaM recognition is mediated by the cytosolic face and that CaM subsequently competes with the intramolecular autoinhibitor in binding to the other face of the helix.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Univ Milan, CNR, Inst Biofis, Dipartimento Biol L Gorini,Sez Milano, I-20133 Milan, Italy	University of Copenhagen; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	palmgren@kvl.dk	Palmgren, Michael/A-9808-2013; De Michelis, Maria/A-7151-2011	Palmgren, Michael/0000-0002-9982-6114; De Michelis, Maria/0000-0001-7684-9252; Luoni, Laura/0000-0002-6485-5417				Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Bonza MC, 2000, PLANT PHYSIOL, V123, P1495, DOI 10.1104/pp.123.4.1495; Bonza MC, 2004, PLANTA, V218, P814, DOI 10.1007/s00425-003-1160-y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 2002, BIOCHEMISTRY-US, V41, P14001, DOI 10.1021/bi025640o; Chung WS, 2000, PLANT CELL, V12, P1393, DOI 10.1105/tpc.12.8.1393; Clapperton JA, 2002, BIOCHEMISTRY-US, V41, P14669, DOI 10.1021/bi026660t; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Geisler M, 2000, PLANT PHYSIOL, V124, P1814, DOI 10.1104/pp.124.4.1814; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; Hwang I, 2000, PLANT PHYSIOL, V122, P157, DOI 10.1104/pp.122.1.157; Hwang I, 2000, P NATL ACAD SCI USA, V97, P6224, DOI 10.1073/pnas.97.11.6224; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; Johnson CK, 2004, BIOPHYS J, V86, p181A; Luoni L, 2004, FEBS LETT, V574, P20, DOI 10.1016/j.febslet.2004.08.003; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Padanyi R, 2003, J BIOL CHEM, V278, P35798, DOI 10.1074/jbc.M305794200; Paszty K, 2002, J BIOL CHEM, V277, P36146, DOI 10.1074/jbc.M205457200; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Penheiter AR, 2005, BIOCHEMISTRY-US, V44, P2009, DOI 10.1021/bi0488552; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Schiott M, 2005, PHYSIOL PLANTARUM, V124, P278, DOI 10.1111/j.1399-3054.2005.00512.x; Schiott M, 2004, P NATL ACAD SCI USA, V101, P9502, DOI 10.1073/pnas.0401542101; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Yamniuk AP, 2004, J BIOL CHEM, V279, P7698, DOI 10.1074/jbc.M310763200; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	50	46	48	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1058	1065		10.1074/jbc.M508299200	http://dx.doi.org/10.1074/jbc.M508299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16267044	hybrid			2022-12-25	WOS:000234447200046
J	Mashek, DG; McKenzie, MA; Van Horn, CG; Coleman, RA				Mashek, DG; McKenzie, MA; Van Horn, CG; Coleman, RA			Rat long chain acyl-CoA synthetase 5 increases fatty acid uptake and partitioning to cellular triacylglycerol in McArdle-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; TRIACSIN-C; LIVER; EXPRESSION; MEMBRANE; CHOLESTEROL; METABOLISM; TRANSPORT; MODELS; ALPHA	Long chain acyl-CoA synthetase (ACSL) catalyzes the initial step in long chain fatty acid metabolism. Of the five mammalian ACSL isoforms cloned and characterized, ACSL5 is the only isoform found to be located, in part, on mitochondria and thus was hypothesized to be involved in fatty acid oxidation. To elucidate the specific roles of ACSL5 in fatty acid metabolism, we used adenoviral-mediated overexpression of ACSL5 (Ad-ACSL5) in rat hepatoma McArdle-RH7777 cells. Confocal microscopy revealed that Ad-ACSL5 colocalized to both mitochondria and endoplasmic reticulum. When compared with cells infected with Ad-GFP, Ad-ACSL5-infected cells at 24 h after infection had 2-fold higher acyl-CoA synthetase activities and 30% higher rates of fatty acid uptake when incubated with 500 mu M [1-C-14] oleic acid. Metabolism of [1-C-14]oleic acid to cellular triacylglycerol (TAG) increased 42% in Ad-ACSL5-infected cells, but when compared with control cells, metabolism to acid-soluble metabolites, phospholipids, and medium TAG did not differ substantially. The incorporation of [1-C-14]oleate and [1,2,3-H-3] glycerol into TAG was similar in Ad-ACSL5-infected cells, thus indicating that Ad-ACSL5 increased TAG synthesis through both de novo and reacylation pathways. However, [1-C-14] acetic acid incorporation into cellular lipids showed that, when compared with control cells, Ad-ACSL5-infected cells did not increase the metabolism of fatty acids that were derived from de novo synthesis. These results suggest that uptake of fatty acids into cells is regulated by metabolism and that overexpressed ACSL5 partitions exogenously derived fatty acids toward TAG synthesis and storage.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Core, Vector/CAF-4832-2022; Mashek, Douglas/ABD-6844-2021; Ariel, Pablo/AGJ-4118-2022	Mashek, Douglas/0000-0001-7033-3386	NIDDK NIH HHS [DK68993, DK61190] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061190, F32DK068993] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORTZ WM, 1973, BIOCHIM BIOPHYS ACTA, V306, P85, DOI 10.1016/0005-2760(73)90212-9; DARNLEY AC, 1988, BIOCHEM J, V253, P351, DOI 10.1042/bj2530351; Dieck HT, 2005, J NUTR, V135, P199, DOI 10.1093/jn/135.2.199; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FULLER RW, 1970, METABOLIS, V19, P226, DOI 10.1016/0026-0495(70)90056-9; Hansson PK, 2004, BBA-MOL CELL BIOL L, V1684, P54, DOI 10.1016/j.bbalip.2004.06.005; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; Pei ZT, 2004, J BIOL CHEM, V279, P54454, DOI 10.1074/jbc.M410091200; Pownall HJ, 2003, ACTA PHYSIOL SCAND, V178, P357, DOI 10.1046/j.1365-201X.2003.01154.x; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TROTTER PJ, 1991, J LIPID RES, V32, P293; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi047721l; Yu XX, 2002, FASEB J, V16, P155, DOI 10.1096/fj.01-0568com	30	99	103	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					945	950		10.1074/jbc.M507646200	http://dx.doi.org/10.1074/jbc.M507646200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16263710	hybrid, Green Published			2022-12-25	WOS:000234447200033
J	Neidlinger, NA; Larkin, SK; Bhagat, A; Victorino, GP; Kuypers, FA				Neidlinger, NA; Larkin, SK; Bhagat, A; Victorino, GP; Kuypers, FA			Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A(2) generates lysophosphatidic acid and results in vascular dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE CHEST SYNDROME; TYROSINE PHOSPHORIC-ACIDS; MULTIPLE-ORGAN FAILURE; N-PALMITOYL-SERINE; HUMAN ERYTHROCYTES; ENDOTHELIAL-CELLS; APOPTOTIC CELLS; LIPID MEDIATOR; RECEPTORS	Secretory phospholipase A(2) (sPLA(2)) type IIa, elevated in inflammation, breaks down membrane phospholipids and generates arachidonic acid. We hypothesized that sPLA(2) will hydrolyze red blood cells that expose phosphatidylserine ( PS) and generate lysophosphatidic acid (LPA) from phosphatidic acid that is elevated in PS-exposing red blood cells. In turn, LPA, a powerful lipid mediator, could affect vascular endothelial cell function. Although normal red blood cells were not affected by sPLA2, at levels of sPLA2 observed under inflammatory conditions (100 ng/ml) PS-exposing red blood cells hemolyzed and generated LPA (1.2 nM/10(8) RBC). When endothelial cell monolayers were incubated in vitro with LPA, a loss of confluence was noted. Moreover, a dose-dependent increase in hydraulic conductivity was identified in rat mesenteric venules in vivo with 5 mu M LPA, and the combination of PS-exposing red blood cells with PLA(2) caused a similar increase in permeability. In the presence of N-palmitoyl L-serine phosphoric acid, a competitive inhibitor for the endothelial LPA receptor, loss of confluence in vitro and the hydraulic permeability caused by 5 mu M LPA in vivo were abolished. The present study demonstrates that increased sPLA(2) activity in inflammation in the presence of cells that have lost their membrane phospholipid asymmetry can lead to LPA-mediated endothelial dysfunction and loss of vascular integrity.	Univ Calif San Francisco, Dept Surg, Oakland, CA 94602 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Neidlinger, NA (corresponding author), Rm 1114,5700 Martin Luther King,Jr Way, Oakland, CA 94609 USA.	NeidlingerN@surgery.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066355, U54HL070583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070583, HL66355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bittman R, 1996, J LIPID RES, V37, P391; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bursten SL, 1996, CRIT CARE MED, V24, P1129, DOI 10.1097/00003246-199607000-00011; BUTIKOFER P, 1993, EUR J BIOCHEM, V213, P367, DOI 10.1111/j.1432-1033.1993.tb17770.x; Curry FE, 1983, CARDIOVASCULAR PHY P, P1; de Jong K, 2001, BLOOD, V98, P860, DOI 10.1182/blood.V98.3.860; Eder AM, 2000, CLIN CANCER RES, V6, P2482; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; He P, 2000, AM J PHYSIOL-HEART C, V278, pH1124, DOI 10.1152/ajpheart.2000.278.4.H1124; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; JALINK K, 1990, J BIOL CHEM, V265, P12232; KIM DK, 1995, AM J PHYSIOL, V269, P109; Kuypers FA, 2004, CELL MOL BIOL, V50, P87; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Le Balle F, 1999, ADV ENZYME REGUL, V39, P275, DOI 10.1016/S0065-2571(98)00024-7; Liliom K, 1996, MOL PHARMACOL, V50, P616; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; MICHEL CC, 1974, Q J EXP PHYSIOL CMS, V59, P283, DOI 10.1113/expphysiol.1974.sp002275; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Neidlinger NA, 2005, J AM COLL SURGEONS, V200, P173, DOI 10.1016/j.jamcollsurg.2004.10.010; NIEWOEHNER DE, 1989, J APPL PHYSIOL, V66, P261, DOI 10.1152/jappl.1989.66.1.261; Partrick DA, 2001, CRIT CARE MED, V29, P989, DOI 10.1097/00003246-200105000-00020; Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003; Quinlan GJ, 1996, CRIT CARE MED, V24, P241, DOI 10.1097/00003246-199602000-00010; ROMASCHIN AD, 1992, CLIN BIOCHEM, V25, P55, DOI 10.1016/0009-9120(92)80046-J; ROSE HG, 1965, J LIPID RES, V6, P428; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Styles LA, 2000, BLOOD, V96, P3276; Styles LA, 1996, BLOOD, V87, P2573, DOI 10.1182/blood.V87.6.2573.bloodjournal8762573; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Touqui L, 1999, MOL MED TODAY, V5, P244, DOI 10.1016/S1357-4310(99)01470-7; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Victorino GP, 2002, J SURG RES, V104, P77, DOI 10.1006/jsre.2002.6412; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; Wu GX, 1997, BLOOD, V90, P2660, DOI 10.1182/blood.V90.7.2660.2660_2660_2669; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	55	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					775	781		10.1074/jbc.M505790200	http://dx.doi.org/10.1074/jbc.M505790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16278219	hybrid			2022-12-25	WOS:000234447200014
J	Fu, AG; Park, S; Rodermel, S				Fu, AG; Park, S; Rodermel, S			Sequences required for the activity of PTOX (IMMUTANS), a plastid terminal oxidase - In vitro and in planta mutagenesis of iron-binding sites and a conserved sequence that corresponds to exon 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEOTIDE REDUCTASE; CYANIDE-RESISTANT OXIDASE; ALTERNATIVE OXIDASE; ARABIDOPSIS-THALIANA; ELECTRON-TRANSPORT; PROTEIN R2; MITOCHONDRIA; VARIEGATION; MUTANT; GENE	The thylakoid membranes of most photosynthetic organisms contain a terminal oxidase (PTOX, the product of the Arabidopsis IMMUTANS gene) that functions in the oxidation of the plastoquinone pool. PTOX and AOX are diiron carboxylate proteins, and based on crystal structures of other members of this protein class, a structural model of PTOX has been proposed in which the ligation sphere of the diiron center is composed of six conserved histidine and glutamate residues. We tested the functional significance of these residues by site-directed mutagenesis of PTOX in vitro and in planta, taking advantage null immutans alleles for the latter studies. These experiments showed that the six iron-binding sites do not tolerate change, even conservative ones. We also examined the significance of a conserved sequence in (or near) the PTOX active site that corresponds precisely to Exon 8 of the IM gene. In vitro and in planta mutagenesis revealed that conserved amino acids within this domain can be altered but that deletion of all or part of the domain abolishes activity. Because protein accumulates normally in the deletion mutants, the data suggest that the conformation of the Exon 8 sequence is important for PTOX activity. An allele of immutans (designated 3639) was identified that lacks the Exon 8 sequence; it does not accumulate PTOX protein. Chloroplast import assays revealed that mutant enzymes lacking Exon 8 have enhanced turnover. We conclude that the Exon 8 domain is required not only for PTOX activity but also for its stability.	Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA	Iowa State University	Rodermel, S (corresponding author), Iowa State Univ, Dept Genet Dev & Cell Biol, 253 Bessey Hall, Ames, IA 50011 USA.	rodermel@iastate.edu						Affourtit C, 2002, FEBS LETT, V510, P121, DOI 10.1016/S0014-5793(01)03261-6; Ajayi WU, 2002, J BIOL CHEM, V277, P8187, DOI 10.1074/jbc.M111477200; Albury MS, 1998, J BIOL CHEM, V273, P30301, DOI 10.1074/jbc.273.46.30301; Albury MS, 2002, J BIOL CHEM, V277, P1190, DOI 10.1074/jbc.M109853200; Aluru MR, 2001, PLANT PHYSIOL, V127, P67, DOI 10.1104/pp.127.1.67; Andersson ME, 1999, FEBS LETT, V449, P17, DOI 10.1016/S0014-5793(99)00376-2; Baerr JN, 2005, PHYSIOL PLANTARUM, V124, P390, DOI 10.1111/j.1399-3054.2005.00506.x; Barr J, 2004, PLANT CELL ENVIRON, V27, P840, DOI 10.1111/j.1365-3040.2004.01190.x; Berthold DA, 2000, BBA-BIOENERGETICS, V1460, P241, DOI 10.1016/S0005-2728(00)00149-3; Berthold DA, 2003, ANNU REV PLANT BIOL, V54, P497, DOI 10.1146/annurev.arplant.54.031902.134915; Carol P, 1999, PLANT CELL, V11, P57, DOI 10.1105/tpc.11.1.57; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Chen M, 2000, PLANT J, V22, P303, DOI 10.1046/j.1365-313x.2000.00738.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cournac L, 2000, PHILOS T ROY SOC B, V355, P1447, DOI 10.1098/rstb.2000.0705; Joet T, 2002, J BIOL CHEM, V277, P31623, DOI 10.1074/jbc.M203538200; Josse EM, 2000, PLANT PHYSIOL, V123, P1427, DOI 10.1104/pp.123.4.1427; Josse EM, 2003, EUR J BIOCHEM, V270, P3787, DOI 10.1046/j.1432-1033.2003.03766.x; Kong J, 2003, THEOR APPL GENET, V107, P326, DOI 10.1007/s00122-003-1250-z; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; Niyogi KK, 2000, CURR OPIN PLANT BIOL, V3, P455, DOI 10.1016/S1369-5266(00)00113-8; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; Peltier G, 2002, ANNU REV PLANT BIOL, V53, P523, DOI 10.1146/annurev.arplant.53.100301.135242; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; Purvis AC, 1997, HORTSCIENCE, V32, P1165, DOI 10.21273/HORTSCI.32.7.1165; PURVIS AC, 1993, PHYSIOL PLANTARUM, V88, P712, DOI 10.1111/j.1399-3054.1993.tb01393.x; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Rhoads DM, 1998, J BIOL CHEM, V273, P30750, DOI 10.1074/jbc.273.46.30750; Rizhsky L, 2002, PLANT J, V32, P329, DOI 10.1046/j.1365-313X.2002.01427.x; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; Siedow JN, 2000, BBA-BIOENERGETICS, V1459, P432, DOI 10.1016/S0005-2728(00)00181-X; Umbach AL, 2000, ARCH BIOCHEM BIOPHYS, V378, P234, DOI 10.1006/abbi.2000.1834; Vanlerberghe GC, 1998, PLANT CELL, V10, P1551, DOI 10.1105/tpc.10.9.1551; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; WETZEL CM, 1994, PLANT J, V6, P161, DOI 10.1046/j.1365-313X.1994.6020161.x; Wu DY, 1999, PLANT CELL, V11, P43, DOI 10.1105/tpc.11.1.43; Yip JYH, 2001, PHYSIOL PLANTARUM, V112, P327, DOI 10.1034/j.1399-3054.2001.1120305.x	39	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42489	42496		10.1074/jbc.M508940200	http://dx.doi.org/10.1074/jbc.M508940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16249174	hybrid			2022-12-25	WOS:000234200800004
J	Wu, ZB; Li, XQ; de Leeuw, E; Ericksen, B; Lu, WY				Wu, ZB; Li, XQ; de Leeuw, E; Ericksen, B; Lu, WY			Why is the Arg(5)-Glu(13) salt bridge conserved in mammalian alpha-defensins?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL DEFENSINS; NATIVE CHEMICAL LIGATION; PHASE PEPTIDE-SYNTHESIS; ANTIMICROBIAL PEPTIDES; HOST-DEFENSE; MEMBRANOLYTIC SELECTIVITY; SERINE PROTEINASES; MOUSE CRYPTDIN-4; DENDRITIC CELLS; PANETH CELLS	Mammalian alpha-defensins, expressed primarily in leukocytes and epithelia, kill a broad range of microbes, constituting one of the first lines of innate immune defense against infection. Nine amino acid residues, including six cysteines, one glycine, and a pair of oppositely charged residues Arg/Glu, are conserved in the otherwise diverse sequences of all known mammalian alpha-defensins. Structural analysis indicates that the two charged residues form a salt bridge, likely stabilizing a protruding loop in the molecule. To investigate the structural and functional roles of the conserved Arg(5)-Glu(13) salt bridge in alpha-defensins, we chemically prepared human neutrophil alpha-defensin 2 ( HNP2) and five HNP2 analogs, R5E/E13R, E13Q, E13R, R5T/E13Y, and R14A. In contrast to HNP2 and R14A-HNP2, none of the four salt bridge analogs was capable of folding into a native conformation in the context of isolated defensin domains. However, when covalently attached to the 45-residue pro-HNP2 propeptide, the salt bridge analogs of HNP2 in their pro-forms all folded productively, suggesting that the Arg(5)-Glu(13) salt bridge is not required for correct pro-alpha-defensin folding. When assayed against both Escherichia coli and Staphylococcus aureus, the six alpha-defensins showed bactericidal activity that correlated with the number of net positive charges carried by individual molecules in the panel, irrespective of whether or not the Arg(5)-Glu(13) salt bridge was decimated, suggesting that Arg(5) and Glu(13) are not functionally conserved. Proteolytic resistance analysis with human neutrophil elastase, one major protease contained in azurophils with HNPs, revealed that destabilization of the salt bridge dramatically accelerated defensin degradation by the enzyme. Thus, we propose that the Arg(5)-Glu(13) salt bridge found in most mammalian alpha-defensins is conserved for defensin in vivo stability.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, WY (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA.	luw@umbi.umd.edu	Ericksen, Bryan/F-9047-2012; Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017	Lu, Wuyuan/0000-0003-1318-9968; Ericksen, Bryan/0000-0002-8016-8289	NIAID NIH HHS [AI061482, AI056264] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061482, R21AI056264] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Blondelle SE, 1999, BBA-BIOMEMBRANES, V1462, P89, DOI 10.1016/S0005-2736(99)00202-3; Campopiano DJ, 2004, J BIOL CHEM, V279, P48671, DOI 10.1074/jbc.M404690200; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; DeSamblanx GW, 1997, J BIOL CHEM, V272, P1171, DOI 10.1074/jbc.272.2.1171; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Ericksen B, 2005, ANTIMICROB AGENTS CH, V49, P269, DOI 10.1128/AAC.49.1.269-275.2005; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; Kim C, 2005, P NATL ACAD SCI USA, V102, P4830, DOI 10.1073/pnas.0500508102; Kluver E, 2005, BIOCHEMISTRY-US, V44, P9804, DOI 10.1021/bi050272k; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; Lu SM, 2001, P NATL ACAD SCI USA, V98, P1410, DOI 10.1073/pnas.031581398; Lu WY, 1996, J AM CHEM SOC, V118, P8518, DOI 10.1021/ja960812o; Lu WY, 2000, BIOCHEMISTRY-US, V39, P3575, DOI 10.1021/bi992292q; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; Maemoto A, 2004, J BIOL CHEM, V279, P44188, DOI 10.1074/jbc.M406154200; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Polanowska J, 1998, BBA-PROTEIN STRUCT M, V1386, P189, DOI 10.1016/S0167-4838(98)00085-5; Raj PA, 2000, BIOCHEM J, V347, P633, DOI 10.1042/0264-6021:3470633; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; Tam JP, 2000, BIOCHEMISTRY-US, V39, P7159, DOI 10.1021/bi0003487; Tam JP, 2000, BIOCHEM BIOPH RES CO, V267, P783, DOI 10.1006/bbrc.1999.2035; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; VALORE EV, 1992, BLOOD, V79, P1538; WILDE CG, 1989, J BIOL CHEM, V264, P11200; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wu Z, 2004, J PEPT RES, V64, P118, DOI 10.1111/j.1399-3011.2004.00179.x; Wu Z, 2003, J PEPT RES, V62, P53, DOI 10.1034/j.1399-3011.2003.00068.x; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Xie C, 2005, J BIOL CHEM, V280, P32921, DOI 10.1074/jbc.M503084200; XIE C, 2005, IN PRESS PEPTIDES; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yu QT, 2000, J BIOL CHEM, V275, P3943, DOI 10.1074/jbc.275.6.3943; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	59	44	44	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43039	43047		10.1074/jbc.M510562200	http://dx.doi.org/10.1074/jbc.M510562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16246847	hybrid			2022-12-25	WOS:000234200800069
J	Zhou, ZC; Song, XM; Gong, WM				Zhou, ZC; Song, XM; Gong, WM			Novel conformational states of peptide deformylase from pathogenic bacterium Leptospira interrogans - Implications for population shift	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR; MOTIONS; DESIGN; TARGET	Peptide deformylase is an attractive target for developing novel antibiotics. Previous studies at pH 3.0 showed peptide deformylase from Leptospira interrogans (LiPDF) exists as a dimer in which one monomer is in a closed form and the other is in an open form, with different conformations of the CD-loop controlling the entrance to the active pocket. Here we present structures of LiPDF at its active pH range. LiPDF forms a similar dimer at pH values 6.5-8.0 as it does at pH 3.0. Interestingly, both of the monomers are almost in the same closed form as that observed at pH 3.0. However, when the enzyme is complexed with the natural inhibitor actinotin, the conformation of the CD-loop is half-open. Two pairs of Arg(109)-mediated cation-pi interactions, as well as hydrogen bonds, have been identified to stabilize the different CD-loop conformations. These results indicate that LiPDF may be found in different structural states, a feature that has never before been observed in the peptide deformylase family. Based on our results, a novel substrate binding model, featured by an equilibrium between the closed and the open forms, is proposed. Our results present crystallographic evidence supporting population shift theory, which is distinguished from the conventional lock-and-key or induced-fit models. These results not only facilitate the development of peptide deformylase-targeted drugs but also provide structural insights into the mechanism of an unusual type of protein binding event.	Chinese Acad Sci, Inst Biophys, Natl Key Lab Biomacromol, Beijing 100101, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Anhua 230026, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gong, WM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Key Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	wgong@sun5.ibp.ac.cn						ADAMS JM, 1966, P NATL ACAD SCI USA, V55, P147, DOI 10.1073/pnas.55.1.147; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan MK, 1997, BIOCHEMISTRY-US, V36, P13904, DOI 10.1021/bi9711543; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; Fritsche TR, 2005, ANTIMICROB AGENTS CH, V49, P1468, DOI 10.1128/AAC.49.4.1468-1476.2005; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; Guilloteau JP, 2002, J MOL BIOL, V320, P951, DOI 10.1016/S0022-2836(02)00549-1; Hao B, 1999, BIOCHEMISTRY-US, V38, P4712, DOI 10.1021/bi982594c; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 2003, J MOL BIOL, V330, P309, DOI 10.1016/S0022-2836(03)00596-5; Lee MD, 2004, J CLIN INVEST, V114, P1107, DOI 10.1172/JCI200422269; Li YK, 2002, BIOCHEM BIOPH RES CO, V295, P884, DOI 10.1016/S0006-291X(02)00777-5; Li YK, 2002, ACTA CRYSTALLOGR D, V58, P846, DOI 10.1107/S0907444902003736; LIVINGSTON DM, 1969, BIOCHEMISTRY-US, V8, P435, DOI 10.1021/bi00829a059; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; TAKEDA M, 1968, P NATL ACAD SCI USA, V60, P1487, DOI 10.1073/pnas.60.4.1487; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Zhou ZC, 2004, J MOL BIOL, V339, P207, DOI 10.1016/j.jmb.2004.03.045; Zhou ZC, 2004, ACTA CRYSTALLOGR D, V60, P137, DOI 10.1107/S0907444903022480	29	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42391	42396		10.1074/jbc.M506370200	http://dx.doi.org/10.1074/jbc.M506370200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239225	hybrid			2022-12-25	WOS:000233992700069
J	Lin, TM; Tang, N; Ostap, EM				Lin, TM; Tang, N; Ostap, EM			Biochemical and motile properties of Myo1b splice isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MYOSIN-I; LIGHT-CHAIN; CALMODULIN DISSOCIATION; ACTIN; CALCIUM; BINDING; PROTEIN; LOCALIZATION; ACANTHAMOEBA; FILAMENTS	Myo1b is a widely expressed myosin-I isoform that concentrates on endosomal and ruffling membranes and is thought to play roles in membrane trafficking and dynamics. Myo1b is alternatively spliced within the regulatory domain of the molecule, yielding isoforms with six (myo1ba), five (myo1bb), or four (myo1bc) non-identical IQ motifs. The calmodulin binding properties of the myo1b IQ motifs have not been investigated, and the mechanical and cell biological consequences of alternative splicing are not known. Therefore, we expressed the alternatively spliced myo1b isoforms truncated after the final IQ motif and included a sequence at their C termini that is a substrate for bacterial biotin ligase. Site-specific biotinylation allows us to specifically attach the myosin to motility surfaces via a biotin-streptavidin linkage. We measured the ATPase and motile properties of the recombinant myo1b splice isoforms, and we correlated these properties with calmodulin binding. We confirmed that calcium-dependent changes in the ATPase activity are due to calcium binding to the calmodulin closest to the motor. We found that calmodulin binds tightly to some of the IQ motifs (K-d < 0.2 mu M) and very weakly to the others (K-d > 5 mu M), suggesting that a subset of the IQ motifs are not calmodulin bound under physiological conditions. Finally, we found the in vitro motility rate to be dependent on the myo1b isoform and the calmodulin concentration and that the myo1b regulatory domain acts as a rigid lever arm upon calmodulin binding to the high affinity and low affinity IQ motifs.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ostap, EM (corresponding author), Univ Penn, Sch Med, Dept Physiol, B400 Richards, Philadelphia, PA 19104 USA.	ostap@mail.med.upenn.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR051174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057247] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR051174] Funding Source: Medline; NIGMS NIH HHS [GM 57247] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; Cyr JL, 2002, J NEUROSCI, V22, P2487, DOI 10.1523/JNEUROSCI.22-07-02487.2002; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Perreault-Micale C, 2000, J BIOL CHEM, V275, P21618, DOI 10.1074/jbc.M000363200; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; RUPPERT C, 1995, J CELL SCI, V108, P3775; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; Tyska MJ, 2005, MOL BIOL CELL, V16, P2443, DOI 10.1091/mbc.e04-12-1116; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; WATANABE M, 2005, MOL BIOL CELL; Whittaker M, 1997, J MOL BIOL, V269, P548, DOI 10.1006/jmbi.1997.1058; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	36	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41562	41567		10.1074/jbc.M508653200	http://dx.doi.org/10.1074/jbc.M508653200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16254000	hybrid			2022-12-25	WOS:000233866900056
J	Haraguchi, K; Hayashi, T; Jimbo, T; Yamamoto, T; Akiyama, T				Haraguchi, K; Hayashi, T; Jimbo, T; Yamamoto, T; Akiyama, T			Role of the kinesin-2 family protein, KIF3, during mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; SEA-URCHIN EMBRYOS; CHROMOSOME ALIGNMENT; SUPERFAMILY PROTEIN; MITOTIC SPINDLE; MOTOR PROTEIN; CELL-CYCLE; GENE; PHOSPHORYLATION; EXPRESSION	During mitosis, kinesin and dynein motor proteins play critical roles in the equal segregation of chromosomes between two daughter cells. Kinesin-2 is composed of two microtubule-based motor subunits, KIF3A/3B, and a kinesin-associated protein known as KAP3, which links KIF3A/3B to cargo that is carried to cellular organelles along microtubules in interphase cells. We have shown here that the kinesin-2 complex is localized with components of the mitotic apparatus such as spindle microtubules and centrosomes. Furthermore, we found that expression of amutant KIF3B, which is able to associate with KIF3A but not KAP3 in NIH3T3 cells, caused chromosomal aneuploidy and abnormal spindle formation. Our data suggested that the kinesin-2 complex plays an important role not only in interphase but also in mitosis.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp						Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; COLE DG, 1992, J CELL SCI, V101, P291; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HENSON JH, 1995, DEV BIOL, V171, P182, DOI 10.1006/dbio.1995.1270; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Kurasawa Y, 2004, EMBO J, V23, P3237, DOI 10.1038/sj.emboj.7600347; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Miller MS, 2005, MOL BIOL CELL, V16, P3810, DOI 10.1091/mbc.E05-05-0404; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; Mountain V, 2000, ANAT REC, V261, P14, DOI 10.1002/(SICI)1097-0185(20000215)261:1<14::AID-AR5>3.0.CO;2-E; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Ohsugi M, 2003, EMBO J, V22, P2091, DOI 10.1093/emboj/cdg208; Onishi M, 1996, EXP HEMATOL, V24, P324; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tuma MC, 1998, J CELL BIOL, V143, P1547, DOI 10.1083/jcb.143.6.1547; Vashishtha M, 1996, J CELL SCI, V109, P541; Wedaman KP, 1996, J CELL BIOL, V132, P371, DOI 10.1083/jcb.132.3.371; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387	32	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4094	4099		10.1074/jbc.M507028200	http://dx.doi.org/10.1074/jbc.M507028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16298999	hybrid			2022-12-25	WOS:000235275300039
J	English, EP; Chumanov, RS; Gellman, SH; Compton, T				English, EP; Chumanov, RS; Gellman, SH; Compton, T			Rational development of beta-peptide inhibitors of human cytomegalovirus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; DE-NOVO DESIGN; MEMBRANE-FUSION; GLYCOPROTEIN-B; COILED-COIL; ALPHA-HELIX; TYPE-1 GP41; INFECTION; FOLDAMERS; RESIDUES	Human cytomegalovirus (HCMV) is a pervasive and significant pathogen. At present, there is no HCMV vaccine, and the available drugs target only replication events. Thus, new therapeutic strategies are needed. HCMV fusion appears to require interactions of alpha-helical regions in viral surface glycoproteins gB and gH. Oligomers of beta-amino acids ("beta-peptides") are attractive unnatural scaffolds for mimicry of specific protein surfaces, because beta-peptides adopt predictable helical conformations and resist proteolysis. Here, we report the development of beta-peptides designed to mimic the gB heptad repeat and block HCMV entry. The most potent beta-peptide inhibits HCMV infection in a cell based-assay with an IC50 of similar to 30 mu M. Consistent with our structure-based design strategy, inhibition is highly specific for HCMV relative to other related viruses. Mechanistic studies indicate that inhibitory beta-peptides act by disrupting membrane fusion. Our findings raise the possibility that beta-peptides may provide a general platform for development of a new class of antiviral agents and that inhibitory beta-peptides will constitute new tools for elucidating viral entry mechanisms.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gellman, SH (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.	gellman@chem.wisc.edu; tcompton@wisc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056414] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI34998] Funding Source: Medline; NIGMS NIH HHS [R01-GM56414] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER SP, 1990, PROG MED VIROL, V37, P136; ALFORD CA, 1988, J INFECT DIS, V158, P917, DOI 10.1093/infdis/158.5.917; Appella DH, 1997, NATURE, V387, P381, DOI 10.1038/387381a0; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Cheng RP, 2001, CHEM REV, V101, P3219, DOI 10.1021/cr000045i; Cobbs CS, 2002, CANCER RES, V62, P3347; COMPTON T, 1993, J VIROL, V67, P3644, DOI 10.1128/JVI.67.6.3644-3648.1993; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Frackenpohl J, 2001, CHEMBIOCHEM, V2, P445, DOI 10.1002/1439-7633(20010601)2:6<445::AID-CBIC445>3.3.CO;2-I; Gademann K, 1999, ANGEW CHEM INT EDIT, V38, P1223, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1223::AID-ANIE1223>3.0.CO;2-A; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; Gelman MA, 2003, ORG LETT, V5, P3563, DOI 10.1021/ol034977v; Gianni T, 2005, J VIROL, V79, P7042, DOI 10.1128/JVI.79.11.7042-7049.2005; Gianni T, 2005, J VIROL, V79, P2931, DOI 10.1128/JVI.79.5.2931-2940.2005; Hamuro Y, 1999, J AM CHEM SOC, V121, P12200, DOI 10.1021/ja992728p; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Hill DJ, 2001, CHEM REV, V101, P3893, DOI 10.1021/cr990120t; Huber MT, 1999, J VIROL, V73, P3886, DOI 10.1128/JVI.73.5.3886-3892.1999; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kritzer JA, 2004, J AM CHEM SOC, V126, P9468, DOI 10.1021/ja031625a; Lee HS, 2001, J AM CHEM SOC, V123, P7721, DOI 10.1021/ja010734r; LePlae PR, 2002, J AM CHEM SOC, V124, P6820, DOI 10.1021/ja017869h; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Lopper M, 2004, J VIROL, V78, P8333, DOI 10.1128/jvi.78.15.8333-8341.2004; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Milne RSB, 2003, J VIROL, V77, P8962, DOI 10.1128/JVI.77.16.8962-8972.2003; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Murray JK, 2005, J AM CHEM SOC, V127, P13271, DOI 10.1021/ja052733v; Park JS, 2003, J AM CHEM SOC, V125, P8539, DOI 10.1021/ja034180z; Porter EA, 2000, NATURE, V404, P565, DOI 10.1038/35007145; RICH JD, 1992, CLIN INFECT DIS, V15, P609, DOI 10.1093/clind/15.4.609; Sanchez V, 2002, J VIROL, V76, P2973, DOI 10.1128/JVI.76.6.2973-2989.2002; Schmitt MA, 2004, J AM CHEM SOC, V126, P6848, DOI 10.1021/ja048546z; Schoppel K, 1996, VIROLOGY, V216, P133, DOI 10.1006/viro.1996.0040; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Werder M, 1999, HELV CHIM ACTA, V82, P1774; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	42	91	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2661	2667		10.1074/jbc.M508485200	http://dx.doi.org/10.1074/jbc.M508485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16275647	hybrid			2022-12-25	WOS:000234931800031
J	Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW				Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW			Reactivity of apolipoprotein E4 and amyloid beta peptide - Lysosomal stability and neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; ONSET ALZHEIMER-DISEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; PRECURSOR PROTEIN; CELL-DEATH; E GENOTYPE; ENDOCYTIC PATHWAY; TRANSPORT PROTEIN	We previously demonstrated that apolipoprotein E4 (apoE4) potentiates lysosomal leakage and apoptosis induced by amyloid beta (A beta) peptide in cultured Neuro-2a cells and hypothesized that the low pH of lysosomes accentuates the conversion of apoE4 to a molten globule, inducing reactive intermediates capable of destabilizing cellular membranes. Here we report that neutralizing lysosomal pH with bafilomycin or NH4Cl abolished the apoE4 potentiation of A beta-induced lysosomal leakage and apoptosis in Neuro-2a cells. Consistent with these results, apoE4 at acidic pH bound more avidly to phospholipid vesicles and disrupted them to a greater extent than at pH 7.4. Comparison of "Arctic" mutant A beta, which forms multimers, and GM6 mutant A beta, which remains primarily monomeric, showed that aggregation is essential for apoE4 to potentiate A beta-induced lysosomal leakage and apoptosis. Both apoE4 and A beta 1-42 had to be internalized to exert these effects. Blocking the low density lipoprotein receptor-related protein with small interfering RNA abolished the enhanced effects of apoE4 and A beta on lysosomes and apoptosis. In cultured Neuro-2a cells, A beta 1-42 increased lysosome formation to a greater extent in apoE3- or apoE4-transfected cells than in Neo-transfected cells, as shown by immunostaining for lysosome-associated membrane protein 1. Similarly, in transgenic mice expressing apoE and amyloid precursor protein, hippocampal neurons displayed increased numbers of lysosomes. Thus, apoE4 and A beta 1-42 may work in concert in neurons to increase lysosome formation while increasing the susceptibility of lysosomal membranes to disruption, release of lysosomal enzymes into the cytosol, and neuronal degeneration.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	rmahley@gladstone.ucsf.edu			NCRR NIH HHS [C06 RR18928] Funding Source: Medline; NIA NIH HHS [P01 AG022074] Funding Source: Medline; NINDS NIH HHS [R21 NS046465] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022074] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arelin K, 2002, MOL BRAIN RES, V104, P38, DOI 10.1016/S0169-328X(02)00203-6; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 1999, J NEUROSCI, V19, P4867; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Demattos RB, 2004, J MOL NEUROSCI, V23, P255, DOI 10.1385/JMN:23:3:255; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Irizarry MC, 2004, J NEUROCHEM, V90, P1132, DOI 10.1111/j.1471-4159.2004.02581.x; Ji Y, 2003, NEUROSCIENCE, V122, P305, DOI 10.1016/j.neuroscience.2003.08.007; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jordan J, 1998, J NEUROSCI, V18, P195; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; Kane MD, 1999, J NEUROCHEM, V72, P1939, DOI 10.1046/j.1471-4159.1999.0721939.x; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lacomblez L, 2002, NEUROLOGY, V58, P1112, DOI 10.1212/WNL.58.7.1112; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nacmias B, 2004, NEUROSCI LETT, V367, P379, DOI 10.1016/j.neulet.2004.06.039; Narita M, 1997, J NEUROCHEM, V69, P1904; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Nilsson LNG, 2004, NEUROBIOL AGING, V25, P1153, DOI 10.1016/j.neurobiolaging.2003.12.011; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; Panas M, 1999, J NEUROL, V246, P574, DOI 10.1007/s004150050406; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Permanne B, 1997, BIOCHEM BIOPH RES CO, V240, P715, DOI 10.1006/bbrc.1997.7727; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Stenh C, 2002, NEUROREPORT, V13, P1857, DOI 10.1097/00001756-200210280-00005; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Su Y, 2001, BRAIN RES, V893, P287, DOI 10.1016/S0006-8993(00)03322-9; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Tsuang DW, 2002, ARCH NEUROL-CHICAGO, V59, P1622, DOI 10.1001/archneur.59.10.1622; Van Everbroeck B, 2001, NEUROSCI LETT, V313, P69, DOI 10.1016/S0304-3940(01)02264-9; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wurth C, 2002, J MOL BIOL, V319, P1279, DOI 10.1016/S0022-2836(02)00399-6; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Ye CP, 2003, NEUROBIOL DIS, V13, P177, DOI 10.1016/S0969-9961(03)00068-8; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6	77	105	106	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2683	2692		10.1074/jbc.M506646200	http://dx.doi.org/10.1074/jbc.M506646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16298992	hybrid			2022-12-25	WOS:000234931800034
J	Odom, EW; Vasta, GR				Odom, EW; Vasta, GR			Characterization of a binary tandem domain F-type lectin from striped bass (Morone saxatilis)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNICATE DIDEMNUM-CANDIDUM; GALACTOSYL-BINDING LECTINS; C-TYPE LECTIN; CRYSTAL-STRUCTURE; AFFINITY-CHROMATOGRAPHY; EEL SERUM; SEQUENCE; PROTEIN; FUCOSE; RECOGNITION	Among other functions, lectins play an important role in the innate immune response of vertebrates and invertebrates by recognizing exposed glycans on the surface of potential pathogens. Despite the typically weak interaction of lectin domains with their carbohydrate ligands, they usually achieve high avidity through oligomeric structures or by the presence of tandem carbohydrate-binding domains along the polypeptide. The recently described structure of the fucose-binding European eel agglutinin revealed a novel lectin fold (the "F-type" fold), which is shared with other carbohydrate-binding proteins and apparently unrelated proteins from prokaryotes to vertebrates, and a unique fucose-binding sequence motif. Here we described the biochemical and molecular characterization of a unique fucose-binding lectin (MsaFBP32) isolated from serum of the striped bass (Morone saxatilis), composed of two tandem domains that exhibit the eel carbohydrate recognition sequence motif, which we designate F-type. We also described a novel lectin family ("F-type") constituted by a large number of proteins exhibiting greater multiples of the F-type motif, either tandemly arrayed or in mosaic combinations with other domains, including a putative transmembrane receptor, that suggests an extensive functional diversification of this lectin family. Among the tandem lectins, MsaFBP32 and other tandem binary homologues appear unique in that although their N-terminal domain shows close similarity to the fucose recognition domain of the eel agglutinin, their C-terminal domain exhibits changes that potentially could confer a distinct specificity for fucosylated ligands. In contrast with the amniotes, in which the F-type lectins appear conspicuously absent, the widespread gene duplication in the teleost fish suggests these F-type lectins acquired increasing evolutionary value within this taxon.	Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Baltimore, MD 21202 USA	University System of Maryland; University of Maryland Baltimore	Vasta, GR (corresponding author), Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, 701 E Pratt St, Baltimore, MD 21202 USA.	vasta@umbi.umd.edu						Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; AGRAWAL A, 1993, ACUTE PHASE PROTEINS, P79; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Borson N D, 1992, PCR Methods Appl, V2, P144; Chan PF, 2003, J BACTERIOL, V185, P2051, DOI 10.1128/JB.185.6.2051-2058.2003; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COLTEN HR, 1993, ACUTE PHASE PROTEINS, P207; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DARCY SM, 1989, BIOCHEM J, V260, P389, DOI 10.1042/bj2600389; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; Ensor LA, 1999, J IND MICROBIOL BIOT, V23, P123, DOI 10.1038/sj.jim.2900696; Fujiki K, 2001, FISH SHELLFISH IMMUN, V11, P275, DOI 10.1006/fsim.2000.0331; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; GERCKEN J, 1994, COMP BIOCHEM PHYS B, V108, P449, DOI 10.1016/0305-0491(94)90098-1; Gilges D, 2000, BIOCHEM J, V352, P49, DOI 10.1042/0264-6021:3520049; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harlow E., 1988, ANTIBODIES LAB MANUA; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; HELFMAN GS, 1997, DIVERSITY FISHES, P224; HERMANSON GT, 1992, IMMOBILIZED AFFINITY, P164; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Honda S, 2000, J BIOL CHEM, V275, P33151, DOI 10.1074/jbc.M002337200; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P299, DOI 10.1016/0304-4165(78)90358-6; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Jensen LE, 1997, J IMMUNOL, V158, P384; KELLY C, 1984, BIOCHEM J, V220, P221, DOI 10.1042/bj2200221; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; Leulliot N, 2004, J BIOL CHEM, V279, P23447, DOI 10.1074/jbc.M401336200; Lund V, 1999, DEV COMP IMMUNOL, V23, P61, DOI 10.1016/S0145-305X(98)00038-X; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masse K, 2004, INT J DEV BIOL, V48, P1119, DOI 10.1387/ijdb.041892km; MATSUMOTO I, 1974, BIOCHEMISTRY-US, V13, P582, DOI 10.1021/bi00700a028; McGreal EP, 2004, MOL IMMUNOL, V41, P1109, DOI 10.1016/j.molimm.2004.06.013; Multerer KA, 2004, IMMUNOGENETICS, V56, P89, DOI 10.1007/s00251-004-0665-2; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODA Y, 1993, J BIOL CHEM, V268, P5929; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Peterson JD, 2001, NUCLEIC ACIDS RES, V29, P123, DOI 10.1093/nar/29.1.123; Pilstrom L, 1996, FISH SHELLFISH IMMUN, V6, P243, DOI 10.1006/fsim.1996.0026; PLOEGH HL, 2000, CURRENT PROTOCOLS PR; Pohl J, 1994, Methods Mol Biol, V36, P107; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER G, 1993, ACUTE PHASE PROTEINS, P39; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SLOMIANY BL, 1973, J BIOL CHEM, V248, P2290; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tort L, 1996, VET IMMUNOL IMMUNOP, V51, P179, DOI 10.1016/0165-2427(95)05502-9; UHLENBRUCK G, 1982, IMMUNOBIOLOGY, V163, P36, DOI 10.1016/S0171-2985(82)80104-6; Vasta GR, 2004, CURR OPIN STRUC BIOL, V14, P617, DOI 10.1016/j.sbi.2004.09.008; VASTA GR, 1986, J BIOL CHEM, V261, P9174; VASTA GR, 1986, J BIOL CHEM, V261, P9182; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7	81	64	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1698	1713		10.1074/jbc.M507652200	http://dx.doi.org/10.1074/jbc.M507652200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16251191	hybrid			2022-12-25	WOS:000234652000050
J	Mandard, S; Zandbergen, F; van Straten, E; Wahli, W; Kuipers, F; Muller, M; Kersten, S				Mandard, S; Zandbergen, F; van Straten, E; Wahli, W; Kuipers, F; Muller, M; Kersten, S			The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-4; HIGH-DENSITY-LIPOPROTEIN; ACYLATION STIMULATING PROTEIN; SEVERE HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE CLEARANCE; ENDOTHELIAL LIPASE; INSULIN-RESISTANCE; TRANSGENIC MICE; TARGET GENE; EXPRESSION	Proteins secreted from adipose tissue are increasingly recognized to play an important role in the regulation of glucose metabolism. However, muchless is known about their effect on lipid metabolism. The fasting-induced adipose factor (FIAF/angiopoietin-like protein 4/peroxisome proliferator-activated receptor gamma angiopoietin-related protein) was previously identified as a target of hypolipidemic fibrate drugs and insulin-sensitizing thiazolidinediones. Using transgenic mice that mildly overexpress FIAF in peripheral tissues we show that FIAF is an extremely powerful regulator of lipid metabolism and adiposity. FIAF overexpression caused a 50% reduction in adipose tissue weight, partly by stimulating fatty acid oxidation and uncoupling in fat. In addition, FIAF overexpression increased plasma levels of triglycerides, free fatty acids, glycerol, total cholesterol, and high density lipoprotein (HDL)-cholesterol. Functional tests indicated that FIAF overexpression severely impaired plasma triglyceride clearance but had no effect on very low density lipoprotein production. The effects of FIAF overexpression were amplified by a high fat diet, resulting in markedly elevated plasma and liver triglycerides, plasma free fatty acids, and plasma glycerol levels, and impaired glucose tolerance in FIAF transgenic mice fed a high fat diet. Remarkably, in mice the full-length form of FIAF was physically associated with HDL, whereas truncated FIAF was associated with low density lipoprotein. In human both full-length and truncated FIAF were associated with HDL. The composite data suggest that via physical association with plasma lipoproteins, FIAF acts as a powerful signal from fat and other tissues to prevent fat storage and stimulate fat mobilization. Our data indicate that disturbances in FIAF signaling might be involved in dyslipidemia.	Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, NL-6700 EV Wageningen, Netherlands; Univ Groningen, Med Ctr, Dept Pediat, Ctr Liver Digest & Metab Dis, NL-9700 RB Groningen, Netherlands; Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland	Wageningen University & Research; University of Groningen; University of Lausanne	Kersten, S (corresponding author), Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@wur.nl	Muller, Michael/B-5795-2008; Mandard, Stéphane/J-4800-2019; Kersten, Sander/A-1116-2011; Muller, Michael/M-5724-2019; Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Muller, Michael/0000-0002-5930-9905; Mandard, Stéphane/0000-0002-7298-821X; Kersten, Sander/0000-0003-4488-7734; Muller, Michael/0000-0002-5930-9905; Wahli, Walter/0000-0002-5966-9089; Kuipers, Folkert/0000-0003-2518-737X				Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Berbee JFP, 2005, J LIPID RES, V46, P297, DOI 10.1194/jlr.M400301-JLR200; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200; Goudriaan JR, 2005, J LIPID RES, V46, P2175, DOI 10.1194/jlr.M500112-JLR200; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu CC, 2004, OBES RES, V12, P1264, DOI 10.1038/oby.2004.160; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Ito Y, 2003, CANCER RES, V63, P6651; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Koster A, 2005, ENDOCRINOLOGY, V146, P4943, DOI 10.1210/en.2005-0476; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Le Lay S, 2001, BIOCHEM BIOPH RES CO, V289, P564, DOI 10.1006/bbrc.2001.6015; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; Murray I, 1999, AM J PHYSIOL-ENDOC M, V277, pE474, DOI 10.1152/ajpendo.1999.277.3.E474; Murray I, 1999, J BIOL CHEM, V274, P36219, DOI 10.1074/jbc.274.51.36219; Oike Y, 2005, NAT MED, V11, P400, DOI 10.1038/nm1214; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Trujillo ME, 2005, J INTERN MED, V257, P167, DOI 10.1111/j.1365-2796.2004.01426.x; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Xu AM, 2005, P NATL ACAD SCI USA, V102, P6086, DOI 10.1073/pnas.0408452102; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200; Yu XX, 2005, P NATL ACAD SCI USA, V102, P1767, DOI 10.1073/pnas.0409564102; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	39	333	357	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					934	944		10.1074/jbc.M506519200	http://dx.doi.org/10.1074/jbc.M506519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16272564	hybrid			2022-12-25	WOS:000234447200032
J	Meyer, RD; Mohammadi, M; Rahimi, N				Meyer, RD; Mohammadi, M; Rahimi, N			A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CRYSTAL-STRUCTURE; DOMAIN; FLT-1; VEGF; MUTATIONS; KDR; AUTOPHOSPHORYLATION; PROLIFERATION	VEGFR-1 is a kinase-defective receptor tyrosine kinase (RTK) and negatively modulates angiogenesis by acting as a decoy receptor. The decoy characteristic of VEGFR-1 is required for normal development and angiogenesis. To date, there is no molecular explanation for this unusual characteristic of VEGFR-1. Here we show that the molecular mechanisms underlying the decoy characteristic of VEGFR-1 is linked to the replacement of a highly conserved amino acid residue in the activation loop. This amino acid is highly conserved among all the type III RTKs and corresponds to aspartic acid, but in VEGFR-1 it is substituted to asparagine. Mutation of asparagine (Asn1050) within the activation loop to aspartic acid promoted enhanced ligand-dependent tyrosine autophosphorylation and kinase activation in vivo and in vitro. The mutant VEGFR-1 (Asp1050) promoted endothelial cell proliferation but not tubulogenesis. It also displayed an oncogenic phenotype as its expression in fibroblast cells elicited transformation and colony growth. Furthermore, mutation of the invariable aspartic acid to asparagine in VEGFR-2 lowered the autophosphorylation of activation loop tyrosines 1052 and 1057. We propose that the conserved aspartic acid in the activation loop favors the transphosphorylation of the activation loop tyrosines, and its absence renders RTK to a less potent enzyme by disfavoring transphosphorylation of activation loop tyrosines.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Boston University; Boston University; New York University	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Rm 921L, Boston, MA 02118 USA.	nrahimi@bu.edu	Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Rahimi, Nader/0000-0002-6745-1725	NEI NIH HHS [R01 EY012997, EY012997, EY0137061, R03 EY013706] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY013706, R01EY012997] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS S, 1999, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; LI SW, 1994, J BIOL CHEM, V269, P32558; LONGATI P, 1994, ONCOGENE, V9, P49; Maru Y, 1998, ONCOGENE, V16, P2585, DOI 10.1038/sj.onc.1201786; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meyer RD, 2004, ONCOGENE, V23, P5523, DOI 10.1038/sj.onc.1207712; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MOSSIE K, 1995, ONCOGENE, V11, P2179; Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7; Pawson T, 2002, FEBS LETT, V513, P2, DOI 10.1016/S0014-5793(01)03292-6; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749; Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	44	60	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					867	875		10.1074/jbc.M506454200	http://dx.doi.org/10.1074/jbc.M506454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286478	Green Accepted, hybrid			2022-12-25	WOS:000234447200025
J	Zhang, BL; Cao, HQ; Rao, GN				Zhang, BL; Cao, HQ; Rao, GN			Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; CELL-SURVIVAL; SRC KINASES; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; AKT; EXPRESSION; PHOSPHORYLATION; CANCER	To determine the efficacy of cytochrome P450 2C9 metabolites of arachidonic acid, viz. 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), in inducing angiogenesis, we have studied their effects on human dermal microvascular endothelial cell (HDMVEC) tube formation and migration. All four EETs stimulated HDMVEC tube formation and migration in a dose-dependent manner. Because 14,15-EET was found to be slightly more efficacious than 5,6-, 8,9-, and 11,12-EETs in stimulating HDMVEC tube formation and migration, we next focused on elucidation of the signaling mechanisms underlying its angiogenic activity. 14,15-EET stimulated Akt and S6K1 phosphorylation in Src- and phosphatidylinositol 3-kinase (PI3K)-dependent manner in HDMVECs. Inhibition of Src and PI3K-Akt-mTOR signaling by both pharmacological and dominant-negative mutant approaches suppressed 14,15-EET-induced HDMVEC tube formation and migration in vitro and Matrigel plug angiogenesis in vivo. In addition, 14,15-EET induced the expression of fibroblast growth factor-2 (FGF-2) in Src- and PI3K-Akt-dependent and mTOR-independent manner in HDMVECs. Neutralizing anti-FGF-2 antibodies completely suppressed 14,15-EET-induced HDMVEC tube formation and migration in vitro and Matrigel plug angiogenesis in vivo. Together, these results show for the first time that Src and PI3K-Akt signaling via targeting in parallel with FGF-2 expression and mTOR-S6K1 activation plays an indispensable role in 14,15-EET-induced angiogenesis.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL74860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badawi AF, 2004, CANCER RES, V64, P1181, DOI 10.1158/0008-5472.CAN-03-2556; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JR, 2000, J BIOL CHEM, V275, P13789, DOI 10.1074/jbc.275.18.13789; CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; delPeso L, 1997, SCIENCE, V278, P687; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Fukuda R, 2003, CANCER RES, V63, P2330; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Medhora M, 2003, AM J PHYSIOL-HEART C, V284, pH215, DOI 10.1152/ajpheart.01118.2001; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nie D, 1998, CANCER RES, V58, P4047; Nijhuis E, 2002, J LEUKOCYTE BIOL, V71, P115; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Pidgeon GP, 2002, CANCER RES, V62, P2721; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; POSTOAK D, 1990, AM J PHYSIOL, V259, pC849, DOI 10.1152/ajpcell.1990.259.6.C849; Potente M, 2003, J BIOL CHEM, V278, P29619, DOI 10.1074/jbc.M305385200; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shappell SB, 2003, CANCER RES, V63, P2256; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; Teshima-Kondo S, 2004, FASEB J, V18, P1583, DOI 10.1096/fj.03-1118fje; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Xie ZJ, 2005, MOL BIOL CELL, V16, P3236, DOI 10.1091/mbc.E05-02-0109; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200; Zhang BL, 2005, CANCER RES, V65, P7283, DOI 10.1158/0008-5472.CAN-05-0633	57	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					905	914		10.1074/jbc.M503945200	http://dx.doi.org/10.1074/jbc.M503945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16286479				2022-12-25	WOS:000234447200029
J	Tomasinsig, L; Skerlavaj, B; Papo, N; Giabbai, B; Shai, Y; Zanetti, M				Tomasinsig, L; Skerlavaj, B; Papo, N; Giabbai, B; Shai, Y; Zanetti, M			Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; ALPHA-HELICAL PEPTIDE; ANTIBACTERIAL PEPTIDE; PHOSPHOLIPID-MEMBRANES; CATHELICIDIN PEPTIDES; PENETRATING PEPTIDES; SEQUENCE ALTERATION; SECONDARY STRUCTURE; EPITHELIAL-CELLS; INNATE IMMUNITY	Mammalian antimicrobial peptides provide rapid defense against infection by inactivating pathogens and by influencing the functions of cells involved in defense responses. Although the direct antibacterial properties of these peptides have been widely characterized, their multiple effects on host cells are only beginning to surface. Here we investigated the mechanistic and functional aspects of the interaction of the proline- rich antimicrobial peptide Bac7( 1 - 35) with mammalian cells, as compared with a truncated analog, Bac7( 5 - 35), lacking four critical N- terminal residues ( RRIR) of the Bac7( 1 - 35) sequence. By using confocal microscopy and flow cytometry, we showed that although the truncated analog Bac7( 5 - 35) remains on the cell surface, Bac7( 1 - 35) is rapidly taken up into 3T3 and U937 cells through a nontoxic energy- and temperature dependent process. Cell biology-based assays using selective endocytosis inhibitors and spectroscopic and surface plasmon resonance studies of the interaction of Bac7( 1 - 35) with phosphatidyl-choline/ cholesterol model membranes collectively suggest the concurrent contribution of macropinocytosis and direct membrane translocation. Structural studies with model membranes indicated that membrane-bound Bac7( 5 - 35) is significantly more aggregated than Bac7( 1 - 35) due to the absence of the N- terminal cationic cluster, thus providing an explanation for hampered cellular internalization of the truncated form. Further investigations aimed to reveal functional implications of intracellular uptake of Bac7( 1 - 35) demonstrated that it correlates with enhanced S phase entry of 3T3 cells, indicating a novel function for this proline- rich peptide.	Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy; Natl Lab Interuniv Consortium Biotechnol, I-34012 Trieste, Italy; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of Udine; Weizmann Institute of Science	Zanetti, M (corresponding author), Univ Udine, Dept Biomed Sci & Technol, P Kolbe 4, I-33100 Udine, Italy.	zanetti@icgeb.trieste.it	Papo, Niv/R-3946-2017; Giabbai, Barbara/AAB-5759-2020	Giabbai, Barbara/0000-0002-3345-8064; SKERLAVAJ, Barbara/0000-0003-0437-802X				Benincasa M, 2004, PEPTIDES, V25, P2055, DOI 10.1016/j.peptides.2004.08.004; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAMERON DG, 1980, BIOCHIM BIOPHYS ACTA, V596, P463, DOI 10.1016/0005-2736(80)90135-2; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Gao YH, 2000, J CLIN INVEST, V106, P439, DOI 10.1172/JCI9826; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Gennaro R, 2002, CURR PHARM DESIGN, V8, P763, DOI 10.2174/1381612023395394; Ghiselli R, 2003, SHOCK, V19, P577, DOI 10.1097/01.shk.0000055236.26446.c9; Giacometti A, 2003, J ANTIMICROB CHEMOTH, V51, P843, DOI 10.1093/jac/dkg149; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; HARRICK NJ, 1967, INT REFLECTION SPECT; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; Huang HJ, 1997, J LEUKOCYTE BIOL, V61, P624, DOI 10.1002/jlb.61.5.624; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Kobayashi S, 2004, BIOCHEMISTRY-US, V43, P15610, DOI 10.1021/bi048206q; Lau YE, 2005, INFECT IMMUN, V73, P583, DOI 10.1128/IAI.73.1.583-591.2005; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; LECLERC M, 1967, ANN BIOL CLIN-PARIS, V25, P469; Levy O, 2004, J LEUKOCYTE BIOL, V76, P909, DOI 10.1189/jlb.0604320; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Oren Z, 1999, EUR J BIOCHEM, V259, P360, DOI 10.1046/j.1432-1327.1999.00047.x; Papo N, 2004, BIOCHEMISTRY-US, V43, P6393, DOI 10.1021/bi049944h; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; PEZOLET M, 1992, FEBS LETT, V299, P247, DOI 10.1016/0014-5793(92)80125-Z; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; Tomasinsig L, 2004, ANTIMICROB AGENTS CH, V48, P3260, DOI 10.1128/AAC.48.9.3260-3267.2004; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; van Wetering S, 2005, J LEUKOCYTE BIOL, V77, P444, DOI 10.1189/jlb.0604367; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Wu JP, 2004, CIRCULATION, V109, P1660, DOI 10.1161/01.CIR.0000124067.35915.E0; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zanetti M, 2002, CURR PHARM DESIGN, V8, P779, DOI 10.2174/1381612023395457; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zaro JL, 2005, EXP CELL RES, V307, P164, DOI 10.1016/j.yexcr.2005.02.024	61	53	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					383	391		10.1074/jbc.M510354200	http://dx.doi.org/10.1074/jbc.M510354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16257969	hybrid			2022-12-25	WOS:000234307200048
J	Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD				Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD			Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1	ONCOGENE			English	Article						3D culture; endothelial cells; angiogenesis inhibitors; collagens	GROWTH-FACTOR-BETA; ENDOTHELIAL-CELL RESPONSES; TUMOR-GROWTH; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CAPILLARY MORPHOGENESIS; ACTIVATION; VIVO; MECHANISMS; APOPTOSIS	Three-dimensional explant cultures of muscle tissue were used to characterize secreted proteins regulated by endogenous levels of the angiogenesis modulator thrombospondin (TSP)-1. Explants from TSP1 null mice exhibit enhanced neovascularization associated with increased endothelial outgrowth but decreased outgrowth of perivascular smooth muscle cells. The absence of endogenous TSP1 did not diminish activation of latent transforming growth factor-beta and moderately decreased matrix metal-loproteinase levels. However, significant changes in other secreted proteins were observed. Endogenous TSP1 decreased mRNA levels for collagens I alpha 1, I alpha 2, and III alpha 1 and laminin alpha 4 and increased collagen IV alpha 1 mRNA expression. Endogenous TSP1 also decreased the level of type I collagen protein produced by the vascular out-growths. Collagens Ia1, Ia2, and IIIa1 are known tumor endothelial markers, suggesting that TSP1 coordinately regulates a set of extracellular matrix genes that reverse the angiogenic switch. Suppression of collagen Ia1 or Ia2 mRNAs using antisense morpholinos inhibited outgrowth in TSP1 null explants and proliferation of TSP1 null endothelial cells, indicating that type I collagen synthesis is limiting for this neovascularization response.	NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bldg 10,Room 2A33,10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC009172, Z01SC009172] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelouahed M, 2000, J BIOL CHEM, V275, P17933, DOI 10.1074/jbc.275.24.17933; Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; ALBINI A, 1987, CANCER RES, V47, P3239; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bell SE, 2001, J CELL SCI, V114, P2755; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen DH, 1999, AM J PHYSIOL-HEART C, V277, pH1100, DOI 10.1152/ajpheart.1999.277.3.H1100; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; de Fraipont F, 2004, ONCOGENE, V23, P3642, DOI 10.1038/sj.onc.1207438; DeHahn KC, 2004, EXP CELL RES, V294, P281, DOI 10.1016/j.yexcr.2003.11.006; Donnini S, 2004, LIFE SCI, V74, P2975, DOI 10.1016/j.lfs.2003.09.075; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; FOUSER L, 1991, J BIOL CHEM, V266, P18345; GONZALEZ AM, 2002, P NATL ACAD SCI USA, V26, P26; Guo NH, 1997, J PEPT RES, V50, P210; Guo NH, 1997, CANCER RES, V57, P1735; Hamano Y, 2004, CANCER RES, V64, P1570, DOI 10.1158/0008-5472.CAN-03-3126; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Keezer SM, 2003, CANCER RES, V63, P6405; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Maeda K, 2001, ONCOL REP, V8, P763; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; Mazzanti CM, 2004, GENOME RES, V14, P1585, DOI 10.1101/gr.2552804; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; St Croix B, 2000, SCIENCE, V289, P1197; Streit M, 2002, CANCER RES, V62, P2004; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Westphal JR, 2004, CURR OPIN MOL THER, V6, P451; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	66	30	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					536	545		10.1038/sj.onc.1209069	http://dx.doi.org/10.1038/sj.onc.1209069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247480				2022-12-25	WOS:000234897400005
J	Hoshino, K; Momiyama, E; Yoshida, K; Nishimura, K; Sakai, S; Toida, T; Kashiwagi, K; Igarashi, K				Hoshino, K; Momiyama, E; Yoshida, K; Nishimura, K; Sakai, S; Toida, T; Kashiwagi, K; Igarashi, K			Polyamine transport by mammalian cells and mitochondria - Role of antizyme and glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE; PERMEABILITY TRANSITION; VACUOLAR MEMBRANE; PUTRESCINE; PROTEIN; IDENTIFICATION; SPERMIDINE; EXCRETION; GENE; DEGRADATION	The role of antizyme (AZ) and glycosaminoglycans in polyamine uptake by mammalian cells and mitochondria was examined using NIH3T3 and FM3A cells and rat liver mitochondria. AZ is synthesized as two isoforms (29 and 24.5 kDa) due to the existence of two initiation codon AUGs in the AZ mRNA. Most AZ existed as the 24.5-kDa form translatable from the second AUG, but a portion of the 29-kDa AZ from the first AUG was associated with mitochondria because of the presence of a mitochondrial targeting signal between the first and the second methionine. The predominance of the 24.5-kDa isoform was mainly due to the presence of spermidine and a favorable sequence context (Kozak sequence) at the second initiation codon AUG. Spermine uptake by NIH3T3 cells was inhibited by both 29- and 24.5-kDa AZs, but uptake by rat liver mitochondria was not influenced by either form of AZ. Because spermine uptake by mitochondria caused a release of cytochrome c, an enhancer of apoptosis, we looked for inhibitors of mitochondrial spermine uptake other than AZ. Cations such as Na+, K+, and Mg2+ were inhibitors of the mitochondrial uptake. It has been reported that heparan sulfate on glypican-1 plays important roles in spermine uptake by human embryonic lung fibroblasts. Heparin, but not heparan sulfate, slightly inhibited spermine uptake by FM3A cells in the absence of Mg2+ and Ca2+ but had no effect under physiological conditions in the presence of Mg2+ and Ca2+.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187; Nishimura, Kazuhiro/0000-0002-6209-5522				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Aouida M, 2005, J BIOL CHEM, V280, P24267, DOI 10.1074/jbc.M503071200; BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; Gandre S, 2003, MITOCHONDRION, V2, P245, DOI 10.1016/S1567-7249(02)00105-8; Hasne MP, 2005, J BIOL CHEM, V280, P15188, DOI 10.1074/jbc.M411331200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Homma R, 2005, INT J BIOCHEM CELL B, V37, P1911, DOI 10.1016/j.biocel.2005.04.014; IGARASHI K, 1989, J BIOCHEM-TOKYO, V106, P294, DOI 10.1093/oxfordjournals.jbchem.a122847; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAKINUMA Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P171, DOI 10.1016/0003-9861(87)90483-8; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V855, P201, DOI 10.1016/0005-2736(86)90166-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; Mitchell JLA, 1998, BIOCHEM J, V329, P453; Mitchell JLA, 1998, BIOCHEM SOC T, V26, P591, DOI 10.1042/bst0260591; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; Rustenbeck I, 1998, BIOCHEM PHARMACOL, V56, P987, DOI 10.1016/S0006-2952(98)00233-0; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Soulet D, 2004, J BIOL CHEM, V279, P49355, DOI 10.1074/jbc.M401287200; Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875; Sudo M, 2001, ANAL BIOCHEM, V297, P42, DOI 10.1006/abio.2001.5296; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; SUZUKI T, 1993, EUR J BIOCHEM, V215, P247, DOI 10.1111/j.1432-1033.1993.tb18029.x; Tachihara K, 2005, J BIOL CHEM, V280, P12637, DOI 10.1074/jbc.M410778200; Tassani V, 1996, BIOCHEM BIOPH RES CO, V226, P850, DOI 10.1006/bbrc.1996.1439; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; TONINELLO A, 1988, J BIOL CHEM, V263, P19407; TONINELLO A, 1992, J BIOL CHEM, V267, P18393; TONINELLO A, 1985, BIOCHIM BIOPHYS ACTA, V815, P399, DOI 10.1016/0005-2736(85)90366-9; Toyoda H, 1999, J CHROMATOGR A, V830, P197, DOI 10.1016/S0021-9673(98)00854-1; Uemura T, 2005, J BIOL CHEM, V280, P9646, DOI 10.1074/jbc.M410274200; Uemura T, 2005, BIOCHEM BIOPH RES CO, V328, P1028, DOI 10.1016/j.bbrc.2005.01.064; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; WATANABE S, 1991, J BIOL CHEM, V266, P20803	56	42	48	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42801	42808		10.1074/jbc.M505445200	http://dx.doi.org/10.1074/jbc.M505445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263714	hybrid			2022-12-25	WOS:000234200800041
J	Moriguchi, T; Urushiyama, S; Hisamoto, N; Iemura, SI; Uchida, S; Natsume, T; Matsumoto, K; Shibuya, H				Moriguchi, T; Urushiyama, S; Hisamoto, N; Iemura, SI; Uchida, S; Natsume, T; Matsumoto, K; Shibuya, H			WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; PROTEIN-KINASE; ACTIVATES SGK1; MUTANT WNK4; HYPERTENSION; PERMEABILITY; PHYSIOLOGY; EPITHELIA; MECHANISM; SUBFAMILY	The WNK1 and WNK4 genes have been found to be mutated in some patients with hyperkalemia and hypertension caused by pseudohypoaldosteronism type II. The clue to the pathophysiology of pseudohypoaldosteronism type II was its striking therapeutic response to thiazide diuretics, which are known to block the sodium chloride cotransporter (NCC). Although this suggests a role for WNK1 in hypertension, the precise molecular mechanisms are largely unknown. Here we have shown that WNK1 phosphorylates and regulates the STE20-related kinases, Ste20-related proline-alanine- rich kinase (SPAK) and oxidative stress response 1 (OSR1). WNK1 was observed to phosphorylate the evolutionary conserved serine residue located outside the kinase domains of SPAK and OSR1, and mutation of the OSR1 serine residue caused enhanced OSR1 kinase activity. In addition, hypotonic stress was shown to activate SPAK and OSR1 and induce phosphorylation of the conserved OSR1 serine residue, suggesting that WNK1 may be an activator of the SPAK and OSR1 kinases. Moreover, SPAK and OSR1 were found to directly phosphorylate the N-terminal regulatory regions of cation-chloride-coupled cotransporters including NKCC1, NKCC2, and NCC. Phosphorylation of NCC was induced by hypotonic stress in cells. These results suggested that WNK1 and SPAK/OSR1 mediate the hypotonic stress signaling pathway to the transporters and may provide insights into the mechanisms by which WNK1 regulates ion balance.	Tokyo Med & Dent Univ, Dept Mol Cell Biol, Med Res Inst, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1010062, Japan; JST, CREST, Tokyo 1010062, Japan; Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1010062, Japan; Nagoya Univ, Dept Mol Biol, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; JST, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Adv Ind Sci & Technol, JBIRC, Kohoku Ku, Tokyo 1350064, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Nephrol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Nagoya University; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Medical & Dental University (TMDU)	Shibuya, H (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cell Biol, Med Res Inst, Tokyo 1010062, Japan.	shibuya.mcb@mri.tmd.ac.jp	Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chen W, 2004, J BIOL CHEM, V279, P11129, DOI 10.1074/jbc.M313562200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; GAGNON KB, 2005, IN PRESS AM J PHYSL; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; James P, 1996, GENETICS, V144, P1425; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P14877, DOI 10.1073/pnas.0406172101; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Li YQ, 2004, EMBO J, V23, P1112, DOI 10.1038/sj.emboj.7600125; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Waldegger S, 1998, PFLUG ARCH EUR J PHY, V436, P575, DOI 10.1007/s004240050674; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2005, J BIOL CHEM, V280, P34218, DOI 10.1074/jbc.M505735200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Yang SS, 2005, BIOCHEM BIOPH RES CO, V330, P410, DOI 10.1016/j.bbrc.2005.02.172; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100	36	149	150	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42685	42693		10.1074/jbc.M510042200	http://dx.doi.org/10.1074/jbc.M510042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16263722	hybrid			2022-12-25	WOS:000234200800026
J	Schaefer, M; Konrad, S; Thalmann, J; Rheinheimer, C; Johswich, K; Sohns, B; Klos, A				Schaefer, M; Konrad, S; Thalmann, J; Rheinheimer, C; Johswich, K; Sohns, B; Klos, A			The transcription factors AP-1 and Ets are regulators of C3a receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ANAPHYLATOXIN C3A; HUMAN MAST-CELLS; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; MULTIPLE-SCLEROSIS; T-LYMPHOCYTES; C5A RECEPTORS; CUTTING EDGE; MURINE MODEL; U937 CELLS	The anaphylatoxin C3a is a proinflammatory mediator generated during complement activation. The tight control of C3a receptor ( C3aR) expression is crucial for the regulation of anaphylatoxin-mediated effects. Key factors regulating constitutive expression of the C3aR in the mast cell line HMC-1 and receptor induction by dibutyryl-cAMP in monomyeloblastic U937 cells were determined by functional characterization of the C3aR promoter. Nucleotides -18 to -285 upstream of the translational start site proved to be critical for promoter activity in HMC-1 cells. Binding sites for the transcription factors AP-1 and Ets could be located. Overexpressed c-Jun/c-Fos ( AP-1) and Ets-1 led synergistically to increased promoter activity that was substantially reduced by site-directed mutagenesis of the corresponding elements within the C3aR promoter. In HMC-1 cells, Ets interacted directly with the predicted binding motif of the C3aR promoter as determined by electromobility shift assays. AP-1 binding to the C3aR promoter was augmented during C3aR induction in U937 cells. A retroviral gene transfer system was used to express a dominant negative mutant of Ets-1 in these cells. The resulting cells failed to up-regulate the C3aR after stimulation with dibutyryl-cAMP and showed decreased AP-1 binding, suggesting that Ets acts here indirectly. Thus, it was established that Ets and the AP-1 element mediates dibutyrylc-AMP induction of C3aR promoter activity, hence providing a mechanistic explanation of dibutyryl-cAMP-dependent up-regulation of C3aR expression. In conclusion, this study demonstrates an important role of AP-1 and a member of the Ets family in the transcriptional regulation of C3aR expression, a prerequisite for the ability of C3a to participate in immunomodulation and inflammation.	Hannover Med Sch, Dept Med Microbiol, D-30625 Hannover, Germany; LEBAO, D-30659 Hannover, Germany	Hannover Medical School	Klos, A (corresponding author), Hannover Med Sch, Dept Med Microbiol, Carl Neubergstr 1, D-30625 Hannover, Germany.	Klos.Andreas@mh-hannover.de		Martin, Myriam/0000-0003-1526-8678				Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Burg M, 1996, J IMMUNOL, V157, P5574; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fischer WH, 1997, J IMMUNOL, V159, P4279; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Hollmann TJ, 1998, MOL IMMUNOL, V35, P137, DOI 10.1016/S0161-5890(98)00021-2; Jagels MA, 2000, IMMUNOPHARMACOLOGY, V46, P209, DOI 10.1016/S0162-3109(99)00178-2; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; Lee SH, 1997, DNA CELL BIOL, V16, P1267, DOI 10.1089/dna.1997.16.1267; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Markiewski MM, 2004, J IMMUNOL, V173, P747, DOI 10.4049/jimmunol.173.2.747; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McKinlay LH, 1998, J IMMUNOL, V161, P4098; Monsinjon T, 2001, FEBS LETT, V487, P339, DOI 10.1016/S0014-5793(00)02320-6; Nilsson G, 1996, J IMMUNOL, V157, P1693; Paral D, 1998, EUR J IMMUNOL, V28, P2417, DOI 10.1002/(SICI)1521-4141(199808)28:08<2417::AID-IMMU2417>3.0.CO;2-B; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Settmacher B, 1999, J IMMUNOL, V162, P7409; Settmacher B, 2003, EUR J IMMUNOL, V33, P920, DOI 10.1002/eji.200323293; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Takabayashi T, 1996, J IMMUNOL, V156, P3455; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Werfel T, 2000, J IMMUNOL, V165, P6599, DOI 10.4049/jimmunol.165.11.6599; Wernert N, 2002, J MOL MED-JMM, V80, P258, DOI 10.1007/s00109-001-0316-0; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zwirner J, 1998, SCAND J IMMUNOL, V47, P19; Zwirner J, 1999, IMMUNOLOGY, V97, P166	53	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42113	42123		10.1074/jbc.M508146200	http://dx.doi.org/10.1074/jbc.M508146200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16253992	hybrid			2022-12-25	WOS:000233992700038
J	Thelin, WR; Kesimer, M; Tarran, R; Kreda, SM; Grubb, BR; Sheehan, JK; Stutts, MJ; Milgram, SL				Thelin, WR; Kesimer, M; Tarran, R; Kreda, SM; Grubb, BR; Sheehan, JK; Stutts, MJ; Milgram, SL			The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; KINASE-A; PERICILIARY LIQUID; AIRWAY EPITHELIA; APICAL MEMBRANE; CL CONDUCTANCE; TUMOR-ANTIGENS; LUNG-DISEASE; IN-VIVO; PHOSPHORYLATION	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-activated chloride channel expressed at the apical surface of epithelia. Although the regulation of CFTR by protein kinases is well documented, channel deactivation by phosphatases is not well understood. We find that the serine/threonine phosphatase PP2A can physically associate with the CFTR COOH terminus. PP2A is a heterotrimeric phosphatase composed of a catalytic subunit and two divergent regulatory subunits (A and B). The cellular localization and substrate specificity of PP2A is determined by the unique combination of A and B regulatory subunits, which can give rise to at least 75 different enzymes. By mass spectrometry, we identified the exact PP2A regulatory subunits associated with CFTR as A alpha and B'epsilon and find that the B'epsilon subunit binds CFTR directly. PP2A subunits localize to the apical surface of airway epithelia and PP2A phosphatase activity co-purifies with CFTR in Calu-3 cells. In functional assays, inhibitors of PP2A block rundown of basal CFTR currents and increase channel activity in excised patches of airway epithelia and in intact mouse jejunum. Moreover, PP2A inhibition in well differentiated human bronchial epithelial cells results in a CFTR-dependent increase in the airway surface liquid. Our data demonstrate that PP2A is a relevant CFTR phosphatase in epithelial tissues. Our results may help reconcile differences in phosphatase-mediated channel regulation observed for different tissues and cells. Furthermore, PP2A may be a clinically relevant drug target for CF, which should be considered in future studies.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 506 Taylor Hall, Chapel Hill, NC 27599 USA.	milg@med.unc.edu			NHLBI NIH HHS [HL34422, HL074158] Funding Source: Medline; NIDDK NIH HHS [DK065988] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034422, R01HL074158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK065988] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen NA, 2003, AM J PHYSIOL-CELL PH, V284, pC429, DOI 10.1152/ajpcell.00261.2002; Barnes AP, 2005, J BIOL CHEM, V280, P7997, DOI 10.1074/jbc.M407521200; BECKER W, 1994, J BIOL CHEM, V269, P22586; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Fischer H, 1998, PFLUG ARCH EUR J PHY, V436, P175, DOI 10.1007/s004240050620; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; Grubb Barbara R, 2002, Methods Mol Med, V70, P525; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; Guggino WB, 2001, NAT MED, V7, P888, DOI 10.1038/90914; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Ostedgaard LS, 2003, P NATL ACAD SCI USA, V100, P1937, DOI 10.1073/pnas.2627982100; Reddy MM, 1996, AM J PHYSIOL-CELL PH, V270, pC474, DOI 10.1152/ajpcell.1996.270.2.C474; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tarran R, 2002, J GEN PHYSIOL, V120, P407, DOI 10.1085/jgp.20028599; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Vastiau A, 2005, FEBS LETT, V579, P3392, DOI 10.1016/j.febslet.2005.04.079; Verkman AS, 2001, AM J PHYSIOL-LUNG C, V281, pL306, DOI 10.1152/ajplung.2001.281.2.L306; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	56	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41512	41520		10.1074/jbc.M507308200	http://dx.doi.org/10.1074/jbc.M507308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16239222	hybrid, Green Published			2022-12-25	WOS:000233866900050
J	Fu, JD; Li, J; Tweedie, D; Yu, HM; Chen, L; Wang, R; Riordon, DR; Brugh, SA; Wang, SQ; Boheler, KR; Yang, HT				Fu, JD; Li, J; Tweedie, D; Yu, HM; Chen, L; Wang, R; Riordon, DR; Brugh, SA; Wang, SQ; Boheler, KR; Yang, HT			Crucial role of the sarcoplasmic reticulum in the developmental regulation of Ca2+ transients and contraction in cardiomyocytes derived from embryonic stem cells	FASEB JOURNAL			English	Article						cardiomyocyte differentiation; calcium transients; type 2 ryanodine receptor	BETA-ADRENERGIC STIMULATION; CARDIAC MYOCYTES; RYANODINE RECEPTOR; INTRACELLULAR CALCIUM; CHAMBER MYOCARDIUM; MOUSE HEART; RAT; RELEASE; DIFFERENTIATION; CHANNELS	In adult myocardium, excitation-contraction coupling is critically regulated by sarcoplasmic reticulum (SR) Ca2+ release via type 2 ryanodine receptor (RyR2), but generally, it is believed that SR-function is rudimentary in the fetal heart and in embryonic stem (ES) cell-derived cardiomyocytes (ESCMs), a possible source for cell replacement therapies. This study used wild-type (RyR2(+/+)) and RyR2 null ( RyR2(-/-)) ESCMs as an in vitro model of cardiomyogenesis, together with pharmacological approaches and expression profiles of genes relevant for SR function, to elucidate the functional importance of RyR2 and SR on the regulation of Ca2+ transients and contraction during early cardiomyocyte development. During differentiation of RyR2(+/+) ESCMs, SR function developed progressively with increased basal cytosolic free Ca2+ concentration ([ Ca2+] (i)), enhanced frequency and amplitude, and decreased duration of Ca2+ transients that were inhibited by ryanodine and thapsigargin. These functional traits correlated with SR Ca2+ load and the expression of RyR2, SERCA2a, and phospholamban. RyR2-/- ESCMs, comparatively, demonstrated a significantly prolonged time-to-peak and reduced frequency of Ca2+ transients and contractions. beta-adrenergic stimulation of RyR2(+/+) ESCMs increased the frequency and amplitude of Ca2+ transients with differentiation but was much weaker in RyR2(-/-)ESCMs. We conclude that functional SR and control of RyR2-mediated SR Ca2+ release directly contribute to the spontaneous and beta-adrenergic receptor-stimulated contraction of ESCMs, even at very immature stages of development.	Chinese Acad Sci, Mol Cardiol Lab, Inst Hlth Sci, SIBS, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Chinese Acad Sci, Key Lab Stem Cell Biol, SIBS, Shanghai 200025, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200025, Peoples R China; NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA; Peking Univ, Coll Life Sci, Natl Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University	Yang, HT (corresponding author), Chinese Acad Sci, Mol Cardiol Lab, Inst Hlth Sci, SIBS, 225 Chong Qing Nan Rd,1 Bulg, Shanghai 200025, Peoples R China.	htyang@sibs.ac.cn	Fu, Jidong/E-8173-2012	Wang, Shi-Qiang/0000-0001-7784-4461; Fu, Jidong/0000-0003-2797-5193	NATIONAL INSTITUTE ON AGING [ZIAAG000849, Z01AG000849] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; Bers DM, 2002, FRONT BIOSCI, V7, pD1697, DOI 10.2741/bers; Beutner G, 2001, J BIOL CHEM, V276, P21482, DOI 10.1074/jbc.M101486200; Bogdanov KY, 2001, CIRC RES, V88, P1254, DOI 10.1161/hh1201.092095; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Boheler KR, 1999, CELLS TISSUES ORGANS, V165, P237, DOI 10.1159/000016684; Cribbs LL, 2001, CIRC RES, V88, P403; Fabiato A, 1978, Ann N Y Acad Sci, V307, P491, DOI 10.1111/j.1749-6632.1978.tb41979.x; Fijnvandraat AC, 2003, J MOL CELL CARDIOL, V35, P1461, DOI 10.1016/j.yjmcc.2003.09.011; Fijnvandraat AC, 2003, CARDIOVASC RES, V58, P399, DOI 10.1016/S0008-6363(03)00282-7; Freestone NS, 2000, PFLUG ARCH EUR J PHY, V441, P78, DOI 10.1007/s004240000397; Gorza L, 1997, J MOL CELL CARDIOL, V29, P1023, DOI 10.1006/jmcc.1996.0346; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huser J, 2000, J PHYSIOL-LONDON, V524, P415, DOI 10.1111/j.1469-7793.2000.00415.x; JANCZEWSKI AM, 1995, AM J PHYSIOL-HEART C, V268, pH916, DOI 10.1152/ajpheart.1995.268.2.H916; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; Liu WR, 2002, LIFE SCI, V71, P1279, DOI 10.1016/S0024-3205(02)01826-X; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; Mery A, 2005, MOL BIOL CELL, V16, P2414, DOI 10.1091/mbc.E04-10-0883; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; Moorman AFM, 2000, DEV BIOL, V223, P279, DOI 10.1006/dbio.2000.9752; NAKANISHI T, 1988, EXPERIENTIA, V44, P936, DOI 10.1007/BF01939887; PEGG W, 1987, AM J PHYSIOL, V252, pH22, DOI 10.1152/ajpheart.1987.252.1.H22; Sauer H, 2001, AM J PHYSIOL-HEART C, V281, pH411, DOI 10.1152/ajpheart.2001.281.1.H411; Seki S, 2003, CARDIOVASC RES, V58, P535, DOI 10.1016/S0008-6363(03)00255-4; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Song LS, 2001, CIRC RES, V88, P794, DOI 10.1161/hh0801.090461; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; Terentyev D, 2003, P NATL ACAD SCI USA, V100, P11759, DOI 10.1073/pnas.1932318100; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Wobus A M, 2002, Methods Mol Biol, V185, P127; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; Zhang YM, 2003, AM J PHYSIOL-HEART C, V285, pH2770, DOI 10.1152/ajpheart.01114.2002	38	53	63	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					181	+		10.1096/fj.05-4501fje	http://dx.doi.org/10.1096/fj.05-4501fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16249315				2022-12-25	WOS:000232991100007
J	Nunes, AF; Saraiva, MJ; Sousa, MM				Nunes, AF; Saraiva, MJ; Sousa, MM			Transthyretin knockouts are a new mouse model for increased neuropeptide Y	FASEB JOURNAL			English	Article						lipoprotein lipase; peptidylglycine alpha-amidating monooxygenase; peripheral nerve; depression	VASOACTIVE INTESTINAL POLYPEPTIDE; DORSAL-ROOT GANGLIA; MESSENGER-RNA; LIPOPROTEIN-LIPASE; EXPRESSION; PEPTIDE; CELLS; MONOOXYGENASE; RECEPTOR; BEHAVIOR	Transthyretin (TTR) has access to the brain and nerve through the blood and cerebrospinal fluid. To investigate TTR function in nervous system homeostasis, differential gene expression in wild-type (WT) and TTR knockout ( KO) mice was assessed. Peptidylglycine alpha-amidating monooxygenase (PAM), the rate-limiting enzyme in neuropeptide maturation, is overexpressed in the peripheral (PNS) and central nervous system (CNS) of TTR KOs that, consequently, display increased neuropeptide Y (NPY) levels. NPY acts on energy homeostasis by increasing white adipose tissue lipoprotein lipase (LPL) and decreasing thermogenesis; accordingly, we show increased LPL expression and activity in white adipose tissue, PNS, and CNS as well as decreased body temperature in TTR KOs. Associated to increased NPY levels, TTR KOs display increased carbohydrate consumption and preference. In neuronal cells, absence of TTR is related to increased PAM activity, NPY levels and LPL expression, reinforcing that TTR is involved in neuropeptide maturation and that increased NPY correlates with LPL overexpression in the nervous system. Furthermore, we provide molecular insights to the reduced depressive behavior of TTR KOs, as NPY is anti-depressant. Our findings demonstrate that TTR KOs are a model for increased NPY and that TTR plays a role in nervous system physiology.	Inst Mol & Cellular Biol, Mol Neurobiol Grp, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa, MM (corresponding author), Inst Mol & Cellular Biol, Mol Neurobiol Grp, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	msousa@ibmc.up.pt	Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899				BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; Cougnon-Aptel N, 1999, NEUROSCI LETT, V259, P45, DOI 10.1016/S0304-3940(98)00900-8; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; ESTEBAN J, 1989, LIFE SCI, V45, P2395, DOI 10.1016/0024-3205(89)90002-7; FORD TA, 1993, J MOL NEUROSCI, V4, P97, DOI 10.1007/BF02782122; Fraboulet S, 1996, ENDOCRINOLOGY, V137, P5493, DOI 10.1210/en.137.12.5493; Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002; HEILIG M, 1988, EUR J PHARMACOL, V147, P465, DOI 10.1016/0014-2999(88)90182-3; Herzog H, 2003, EUR J PHARMACOL, V480, P21, DOI 10.1016/j.ejphar.2003.08.089; Hiruma H, 2000, BRAIN RES, V883, P184, DOI 10.1016/S0006-8993(00)02892-4; Huey PU, 2002, J LIPID RES, V43, P19; Huey PU, 1998, J LIPID RES, V39, P2135; Inui A, 1998, P ASSOC AM PHYSICIAN, V110, P171; Kohno K, 1997, AM J PATHOL, V150, P1497; Liz MA, 2004, J BIOL CHEM, V279, P21431, DOI 10.1074/jbc.M402212200; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PULFORD D, 2002, SOC NEUR 32 ANN M WA; RAZ A, 1969, J BIOL CHEM, V244, P3230; Redrobe JP, 2002, NEUROPSYCHOPHARMACOL, V26, P615, DOI 10.1016/S0893-133X(01)00403-1; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Saegusa T, 2003, J VET MED SCI, V65, P1365, DOI 10.1292/jvms.65.1365; Serot JM, 1997, J NEUROL NEUROSUR PS, V63, P506, DOI 10.1136/jnnp.63.4.506; Shi TJS, 1999, NEUROSCIENCE, V93, P741; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Sousa MM, 2003, PROG NEUROBIOL, V71, P385, DOI 10.1016/j.pneurobio.2003.11.002; Sousa MM, 2000, J LIPID RES, V41, P58; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; STENFORS C, 1989, J NEUROSCI RES, V24, P445, DOI 10.1002/jnr.490240315; Stogner KA, 2000, EUR J PHARMACOL, V387, pR9, DOI 10.1016/S0014-2999(99)00800-6; Sunman JA, 2004, MOL CARCINOGEN, V41, P231, DOI 10.1002/mc.20060; THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Valenzuela RF, 2000, J NEUROL SCI, V173, P140, DOI 10.1016/S0022-510X(99)00316-0; Vasquez PAJ, 2000, BEHAV BRAIN RES, V111, P115, DOI 10.1016/S0166-4328(00)00142-X; White DM, 1996, NEUROSCIENCE, V73, P881, DOI 10.1016/0306-4522(96)00055-3; WIDDOWSON PS, 1992, J NEUROCHEM, V59, P73, DOI 10.1111/j.1471-4159.1992.tb08877.x; WIDERLOV E, 1988, J PSYCHIATR RES, V22, P69, DOI 10.1016/0022-3956(88)90030-1; ZACHRISSON O, 1995, NEUROSCI LETT, V194, P89, DOI 10.1016/0304-3940(95)11735-F	45	64	70	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					166	+		10.1096/fj.05-4106fje	http://dx.doi.org/10.1096/fj.05-4106fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263939				2022-12-25	WOS:000234053100022
